and,job 1.0 0.000143348623853 0 1 -1
ht3,antagonists 0.0 0.0 1 1 0
controlled,and 1.0 0.000143348623853 0 1 -1
of,percentage 0.5 0.000286697247706 3 1 2
with,food 0.2 0.000143348623853 3 2 1
atromid-s,may 1.0 0.000143348623853 1 0 1
a,cyp2c19 1.0 0.000143348623853 1 0 1
been,assessed 1.0 0.000143348623853 0 1 -1
to,cardiac 1.0 0.000286697247706 0 2 -2
when,has 1.0 0.000143348623853 1 0 1
neurontin,mg 1.0 0.000143348623853 1 0 1
not,indicate 1.0 0.000286697247706 2 0 2
of,concentrations 0.333333333333 0.000143348623853 1 2 -1
and,mononuclear 1.0 0.000143348623853 0 1 -1
renal,secretion 1.0 0.000143348623853 0 1 -1
by,use 1.0 0.000143348623853 0 1 -1
effects,toward 1.0 0.000143348623853 0 1 -1
your,b12 1.0 0.000143348623853 0 1 -1
and,brevibloc 1.0 0.000286697247706 2 0 2
think,you 1.0 0.000143348623853 0 1 -1
or,nephrotoxic 1.0 0.000143348623853 0 1 -1
administered,tagamet 1.0 0.000143348623853 0 1 -1
were,of 1.0 0.000286697247706 0 2 -2
inhibitors,the 0.333333333333 0.000143348623853 2 1 1
thereby,delaying 1.0 0.000286697247706 2 0 2
were,on 0.333333333333 0.000143348623853 1 2 -1
time,but 1.0 0.000143348623853 0 1 -1
been,occasional 1.0 0.000143348623853 1 0 1
enzymes,cyp1a2 1.0 0.000143348623853 0 1 -1
minimal,experimental 1.0 0.000143348623853 0 1 -1
by,cerulein--an 1.0 0.000143348623853 0 1 -1
additive,interaction 1.0 0.000143348623853 1 0 1
barrier,form 1.0 0.000143348623853 0 1 -1
contrary,and 1.0 0.000143348623853 1 0 1
midamor,may 1.0 0.000143348623853 1 0 1
intravenous,adenocard 1.0 0.000143348623853 0 1 -1
livers,of 1.0 0.000143348623853 0 1 -1
reports,the 1.0 0.000143348623853 0 1 -1
an,interleukin-1 1.0 0.000286697247706 2 0 2
inhibitor,produced 1.0 0.000143348623853 1 0 1
of,arachidonic 1.0 0.000143348623853 0 1 -1
between,blood 1.0 0.000143348623853 0 1 -1
bio-rad,laboratories 1.0 0.000286697247706 0 2 -2
this,pharmacological 1.0 0.000143348623853 1 0 1
the,change 1.0 0.000143348623853 0 1 -1
lower,serum 1.0 0.000286697247706 2 0 2
monkeys,the 1.0 0.000143348623853 1 0 1
developed,rash 1.0 0.000143348623853 1 0 1
reversal,of 0.0 0.0 1 1 0
excessive,fecal 1.0 0.000143348623853 0 1 -1
oral,placebo 1.0 0.000143348623853 0 1 -1
rare,instances 0.333333333333 0.000143348623853 2 1 1
medicated,or 1.0 0.000143348623853 0 1 -1
in,mean 0.8 0.00114678899083 9 1 8
then,allowed 1.0 0.000143348623853 0 1 -1
vasopressors,thyroxine 1.0 0.000143348623853 1 0 1
may,contribute 0.0 0.0 1 1 0
one-third,to 0.0 0.0 1 1 0
fi,and 0.333333333333 0.000143348623853 1 2 -1
if,given 1.0 0.000143348623853 0 1 -1
by,see 1.0 0.000143348623853 1 0 1
since,bacteriostatic 1.0 0.000286697247706 2 0 2
hypertension,was 1.0 0.000143348623853 1 0 1
neuropsychiatric,confusion 1.0 0.000143348623853 0 1 -1
with,any 0.25 0.000573394495413 6 10 -4
cadmium,mixtures 1.0 0.00043004587156 0 3 -3
and,placebo 1.0 0.000286697247706 0 2 -2
on,known 1.0 0.000143348623853 0 1 -1
of,nor 1.0 0.000286697247706 0 2 -2
conditions,such 1.0 0.000143348623853 0 1 -1
may,depress 1.0 0.000143348623853 1 0 1
of,not 1.0 0.000143348623853 0 1 -1
another,botulinum 1.0 0.000143348623853 1 0 1
were,experienced 0.0 0.0 1 1 0
of,non 1.0 0.000143348623853 0 1 -1
of,didanosine-placebo 1.0 0.000143348623853 1 0 1
vitro,from 1.0 0.000143348623853 1 0 1
assess,the 0.5 0.000286697247706 1 3 -2
progesterone,preparations 1.0 0.000143348623853 1 0 1
although,trough 1.0 0.000143348623853 1 0 1
evaluating,plasma 1.0 0.000143348623853 0 1 -1
other,monoamines 1.0 0.000286697247706 0 2 -2
ii,may 1.0 0.000143348623853 1 0 1
durations,of 0.0 0.0 1 1 0
epidemics,of 1.0 0.000143348623853 0 1 -1
because,a 0.333333333333 0.000143348623853 1 2 -1
p450,isoen-zymes 1.0 0.000143348623853 0 1 -1
the,intensity 1.0 0.000143348623853 0 1 -1
yeast,and 1.0 0.000143348623853 0 1 -1
hydrochloride,on 1.0 0.000143348623853 1 0 1
thalidomide,co-administration 1.0 0.000143348623853 0 1 -1
containing,multivalent 1.0 0.000143348623853 1 0 1
noted,at 1.0 0.000143348623853 0 1 -1
serotonin,ht2a 1.0 0.000143348623853 0 1 -1
samples,for 1.0 0.000286697247706 0 2 -2
tests,vital 1.0 0.000286697247706 0 2 -2
a,g 1.0 0.000286697247706 0 2 -2
a,d 1.0 0.000143348623853 0 1 -1
a,c 1.0 0.000573394495413 4 0 4
certain,or 1.0 0.000143348623853 1 0 1
maalox,reduced 1.0 0.000143348623853 1 0 1
nonpredisposed,strain 1.0 0.000143348623853 0 1 -1
drugs,substances 1.0 0.000143348623853 0 1 -1
glutathione-s,transferase 1.0 0.000143348623853 0 1 -1
urine,allow 1.0 0.000143348623853 0 1 -1
parts,of 1.0 0.000143348623853 1 0 1
ototoxicity,and 1.0 0.000143348623853 0 1 -1
induce,cyp3a4 0.2 0.000286697247706 4 6 -2
patients,already 0.2 0.000143348623853 2 3 -1
alternate,sequence 1.0 0.000143348623853 1 0 1
a,four-day 1.0 0.000143348623853 1 0 1
to,play 1.0 0.000143348623853 0 1 -1
hypotension,and 0.2 0.000286697247706 6 4 2
containing,or 0.833333333333 0.00143348623853 11 1 10
as,poor 1.0 0.000286697247706 0 2 -2
older,ask 1.0 0.000143348623853 0 1 -1
be,concomitantly 1.0 0.000143348623853 0 1 -1
systolic,diastolic 1.0 0.000143348623853 1 0 1
kits,such 1.0 0.000143348623853 0 1 -1
been,a 1.0 0.000286697247706 2 0 2
into,question 1.0 0.000143348623853 0 1 -1
the,serum 0.0 0.0 12 12 0
and,traumatic 1.0 0.000143348623853 1 0 1
interventions,each 1.0 0.000143348623853 0 1 -1
exogenous,co-factors 1.0 0.000143348623853 0 1 -1
albumin,bound 1.0 0.000143348623853 0 1 -1
hydrochloride,has 1.0 0.00043004587156 3 0 3
as,these 0.333333333333 0.000143348623853 2 1 1
by,hours 0.333333333333 0.000143348623853 2 1 1
citrate,tablets 1.0 0.000143348623853 0 1 -1
erection-supporting,medication 1.0 0.000143348623853 0 1 -1
variations,of 1.0 0.000143348623853 0 1 -1
with,nitrous 1.0 0.000143348623853 1 0 1
their,dosages 1.0 0.000143348623853 0 1 -1
qd,for 0.0 0.0 1 1 0
stress,may 1.0 0.000143348623853 0 1 -1
the,long 0.666666666667 0.000573394495413 1 5 -4
and,n-acetyl 1.0 0.000143348623853 0 1 -1
imuran,the 1.0 0.000143348623853 1 0 1
following,elspar 1.0 0.000143348623853 1 0 1
and,limited 1.0 0.000143348623853 0 1 -1
produce,ventricular 1.0 0.000143348623853 0 1 -1
with,treatment 1.0 0.000143348623853 0 1 -1
individuals,discontinuing 1.0 0.000143348623853 0 1 -1
the,leukopenic 1.0 0.000143348623853 1 0 1
synthesis,of 0.0 0.0 2 2 0
comparative,study 1.0 0.000143348623853 0 1 -1
pressure,beyond 1.0 0.000143348623853 0 1 -1
the,greatest 1.0 0.000143348623853 0 1 -1
synthesis,or 1.0 0.000143348623853 0 1 -1
relaxants,nondepolarizing 1.0 0.00043004587156 0 3 -3
if,other 1.0 0.00043004587156 0 3 -3
sporanox,lipitor 1.0 0.000143348623853 1 0 1
pharmacodynamics,prothrombin 1.0 0.000143348623853 0 1 -1
nonlethal,dose 0.0 0.0 1 1 0
or,bind 1.0 0.000143348623853 1 0 1
feso4,or 1.0 0.000143348623853 1 0 1
hcl,with 1.0 0.000143348623853 1 0 1
traumatic,edemas 1.0 0.000143348623853 1 0 1
several,but 1.0 0.000143348623853 0 1 -1
fluoride,and 1.0 0.000143348623853 1 0 1
hallucinations,have 1.0 0.000143348623853 1 0 1
bsa,during 1.0 0.000143348623853 0 1 -1
either,initiated 1.0 0.000143348623853 0 1 -1
on,rare 1.0 0.000286697247706 2 0 2
antagonized,the 1.0 0.000286697247706 2 0 2
thereby,increasing 0.5 0.000286697247706 3 1 2
next,chapter 1.0 0.000286697247706 0 2 -2
activity--such,as 1.0 0.000143348623853 1 0 1
coadministration,whereas 1.0 0.000143348623853 1 0 1
of,drug-drug 1.0 0.000143348623853 0 1 -1
the,daily 0.0 0.0 2 2 0
and,maximum 0.0 0.0 1 1 0
and,essentially 1.0 0.000143348623853 0 1 -1
primidone,population 1.0 0.000143348623853 1 0 1
organisms,and 1.0 0.000143348623853 0 1 -1
the,fed 1.0 0.000143348623853 1 0 1
assay,result 1.0 0.000143348623853 0 1 -1
nonlinear,regression 1.0 0.000143348623853 0 1 -1
post-implantation,loss 1.0 0.000143348623853 0 1 -1
nnrti,based 1.0 0.000143348623853 0 1 -1
affecting,myelopoesis 1.0 0.000143348623853 0 1 -1
of,per 0.333333333333 0.000286697247706 2 4 -2
with,noted 1.0 0.000143348623853 0 1 -1
maximal,to 1.0 0.000143348623853 1 0 1
all,muscle 1.0 0.000143348623853 1 0 1
these,have 0.333333333333 0.000143348623853 2 1 1
this,patients 1.0 0.000143348623853 0 1 -1
an,adverse 1.0 0.000143348623853 0 1 -1
skin,that 1.0 0.000143348623853 0 1 -1
containing,microgram 1.0 0.000143348623853 0 1 -1
lies,in 1.0 0.000143348623853 0 1 -1
but,should 0.5 0.000286697247706 3 1 2
typhoid,attenuation 1.0 0.000143348623853 1 0 1
protein,synthesis 1.0 0.000143348623853 0 1 -1
as,toxic 1.0 0.000143348623853 0 1 -1
are,started 1.0 0.000143348623853 1 0 1
adrenergic,agents 1.0 0.000143348623853 1 0 1
increase,plasma 0.454545454545 0.000716743119266 8 3 5
amino,acids 1.0 0.000143348623853 0 1 -1
pre-sacral,vertebrae 1.0 0.000143348623853 0 1 -1
can,affect 1.0 0.00043004587156 0 3 -3
with,coumarin-derivative 1.0 0.000143348623853 1 0 1
has,had 1.0 0.000143348623853 1 0 1
auc,ci 1.0 0.000143348623853 0 1 -1
for,cyp1a2 1.0 0.000143348623853 0 1 -1
of,onto 1.0 0.000143348623853 1 0 1
and,cold 0.0 0.0 1 1 0
two,hour 1.0 0.000143348623853 0 1 -1
midamor,and 1.0 0.000143348623853 1 0 1
estrogen,increased 1.0 0.000143348623853 0 1 -1
studied,systematically 1.0 0.000143348623853 0 1 -1
symptoms,have 1.0 0.000143348623853 1 0 1
ophthalmic,solution 0.0 0.0 1 1 0
that,toradol 1.0 0.000143348623853 0 1 -1
benefit,from 1.0 0.000143348623853 1 0 1
state,serum 1.0 0.000143348623853 0 1 -1
ketoconazole,phenytoin 1.0 0.000143348623853 0 1 -1
valid,in 1.0 0.000143348623853 0 1 -1
corticotropin,may 1.0 0.000286697247706 2 0 2
system,though 1.0 0.000143348623853 1 0 1
of,daily 0.0 0.0 1 1 0
of,because 0.5 0.000286697247706 3 1 2
neurobiological,alterations 1.0 0.000286697247706 0 2 -2
these,effects 0.666666666667 0.00172018348624 3 15 -12
cytochrome,p4502d6 1.0 0.000143348623853 0 1 -1
inr,was 0.0 0.0 1 1 0
theophylline,serum 1.0 0.000143348623853 1 0 1
mediating,stimulus-induced 1.0 0.000143348623853 0 1 -1
an,enhancement 1.0 0.000286697247706 2 0 2
also,produce 1.0 0.000143348623853 0 1 -1
given,once 1.0 0.000286697247706 2 0 2
aminoglutethimide,may 1.0 0.000286697247706 2 0 2
therefore,coagulation 1.0 0.000286697247706 0 2 -2
healthy,white 1.0 0.000143348623853 0 1 -1
mg,were 1.0 0.000286697247706 0 2 -2
used,when 0.166666666667 0.000286697247706 7 5 2
metabolite,concentrations 0.0 0.0 1 1 0
one,hour 0.0 0.0 3 3 0
patients,there 0.333333333333 0.000143348623853 1 2 -1
responding,in 0.333333333333 0.000143348623853 1 2 -1
increased,prothrombin 0.5 0.000573394495413 6 2 4
mechanism,underlying 1.0 0.000143348623853 0 1 -1
kg,body 0.666666666667 0.000573394495413 1 5 -4
when,trisenox 1.0 0.000143348623853 1 0 1
sh,fa 1.0 0.000143348623853 0 1 -1
subsequent,treatment 1.0 0.000143348623853 1 0 1
effectiveness,of 0.294117647059 0.000716743119266 6 11 -5
functions,to 1.0 0.000143348623853 0 1 -1
possible,toxicity 1.0 0.000143348623853 0 1 -1
p-type,channel 1.0 0.000143348623853 0 1 -1
induce,inhibit 1.0 0.000143348623853 1 0 1
combination,should 1.0 0.000143348623853 0 1 -1
clinicians,have 1.0 0.000143348623853 0 1 -1
exposure,to 0.222222222222 0.000573394495413 7 11 -4
closely,when 1.0 0.00043004587156 3 0 3
a,cyp 0.6 0.00043004587156 1 4 -3
however,and 1.0 0.000286697247706 0 2 -2
peripheral,vasospasm 0.2 0.000143348623853 2 3 -1
general,local 1.0 0.000143348623853 0 1 -1
with,tenormin 1.0 0.000143348623853 0 1 -1
decision,to 1.0 0.000143348623853 0 1 -1
those,who 1.0 0.000143348623853 0 1 -1
whenever,increased 1.0 0.000143348623853 0 1 -1
molt-4,cells 1.0 0.000143348623853 1 0 1
additive,inotropic 1.0 0.000143348623853 0 1 -1
interaction,appears 1.0 0.000286697247706 0 2 -2
may,potentially 1.0 0.00043004587156 0 3 -3
acetaminophen,had 1.0 0.000143348623853 0 1 -1
initiates,or 1.0 0.000143348623853 1 0 1
bone,scintigraphy 1.0 0.000143348623853 0 1 -1
was,hypercholesterolemia 1.0 0.000143348623853 0 1 -1
dexfenfluramine,should 1.0 0.000143348623853 1 0 1
treatment-experienced,patients 1.0 0.000286697247706 0 2 -2
male,animals 1.0 0.000143348623853 0 1 -1
dexamethasone,steady-state 1.0 0.000143348623853 1 0 1
transitory,changes 1.0 0.000143348623853 0 1 -1
procedures,during 1.0 0.000143348623853 1 0 1
increased,intracranial 1.0 0.000143348623853 1 0 1
sole,indication 1.0 0.000143348623853 0 1 -1
given,i 1.0 0.000143348623853 0 1 -1
also,inhibits 1.0 0.000143348623853 0 1 -1
antiepileptic,aeds 1.0 0.000143348623853 1 0 1
proposed,methodology 1.0 0.000143348623853 0 1 -1
free,will 1.0 0.000143348623853 0 1 -1
of,alternate-day 1.0 0.000143348623853 1 0 1
lipids,should 1.0 0.000143348623853 0 1 -1
relief,of 1.0 0.000143348623853 0 1 -1
class,not 1.0 0.000143348623853 0 1 -1
is,eliminated 0.333333333333 0.000143348623853 1 2 -1
and,l-methionine 1.0 0.000143348623853 1 0 1
helpful,means 1.0 0.000143348623853 0 1 -1
mediated,transport 1.0 0.000143348623853 0 1 -1
of,nonsedating 1.0 0.000143348623853 1 0 1
induced,hypokalemia 1.0 0.000143348623853 1 0 1
even,experienced 1.0 0.000143348623853 1 0 1
routine,dosage 1.0 0.000143348623853 0 1 -1
on,potential 1.0 0.000143348623853 0 1 -1
early,and 1.0 0.000143348623853 0 1 -1
is,ordinarily 1.0 0.000143348623853 0 1 -1
conjugated,system 1.0 0.000143348623853 0 1 -1
information,assists 1.0 0.000143348623853 0 1 -1
hyperplasia,polymorphic 1.0 0.000143348623853 0 1 -1
nitrofurantoin,interferes 1.0 0.000143348623853 1 0 1
of,induced 1.0 0.000286697247706 0 2 -2
to,plasma 0.846153846154 0.00157683486239 1 12 -11
known,inhibitor 1.0 0.00043004587156 3 0 3
when,grown 1.0 0.000143348623853 0 1 -1
sensitive,and 1.0 0.000143348623853 0 1 -1
groups,developed 1.0 0.000143348623853 0 1 -1
be,required 0.5 0.000860091743119 3 9 -6
each,year 1.0 0.000143348623853 0 1 -1
findings,of 1.0 0.000143348623853 0 1 -1
treated,animals 1.0 0.000143348623853 0 1 -1
and,reliable 1.0 0.000143348623853 0 1 -1
s,determined 1.0 0.000143348623853 1 0 1
the,have 0.5 0.000286697247706 3 1 2
over,indinavir-based 1.0 0.000143348623853 0 1 -1
increases,about 1.0 0.000143348623853 1 0 1
inotropic,effects 1.0 0.000286697247706 2 0 2
dog,whelk 1.0 0.000143348623853 0 1 -1
reaction,while 1.0 0.00043004587156 0 3 -3
competition,for 0.5 0.000286697247706 1 3 -2
behavioral,or 1.0 0.000143348623853 0 1 -1
nevertheless,caution 0.142857142857 0.000143348623853 4 3 1
normally,to 1.0 0.000143348623853 0 1 -1
geriatric,population 1.0 0.000286697247706 0 2 -2
aerosol,and 1.0 0.000143348623853 0 1 -1
also,fulfils 1.0 0.000143348623853 0 1 -1
pulse,arterial 1.0 0.000143348623853 0 1 -1
suggested,the 1.0 0.000143348623853 0 1 -1
the,amplitude 1.0 0.000286697247706 0 2 -2
with,coly-mycin 0.0 0.0 1 1 0
device,and 1.0 0.000143348623853 0 1 -1
gene,which 1.0 0.000143348623853 0 1 -1
occurred,significantly 1.0 0.000143348623853 0 1 -1
should,if 0.0 0.0 1 1 0
in,standing 1.0 0.000143348623853 1 0 1
gi,tract 1.0 0.000143348623853 1 0 1
should,it 1.0 0.000143348623853 1 0 1
periodic,measurement 1.0 0.000143348623853 0 1 -1
the,ec50 1.0 0.000143348623853 0 1 -1
often,applied 1.0 0.000143348623853 0 1 -1
enzyme,ace 1.0 0.000286697247706 0 2 -2
calcium-channel,blockers 1.0 0.00043004587156 0 3 -3
but,nearly 1.0 0.000143348623853 0 1 -1
results,in 0.1 0.000286697247706 11 9 2
if,replacement 1.0 0.000143348623853 0 1 -1
asa,and 1.0 0.000143348623853 0 1 -1
by,explain 1.0 0.000143348623853 1 0 1
experiences,have 1.0 0.000143348623853 0 1 -1
may,develop 0.5 0.000286697247706 3 1 2
v,remains 1.0 0.000143348623853 0 1 -1
mathematical,functions 1.0 0.000143348623853 0 1 -1
species,of 0.5 0.000286697247706 3 1 2
or,either 1.0 0.000143348623853 1 0 1
of,macrolide 1.0 0.000143348623853 1 0 1
n,were 0.0 0.0 1 1 0
review,is 1.0 0.000143348623853 0 1 -1
review,in 1.0 0.000143348623853 0 1 -1
adsorption,of 1.0 0.000143348623853 1 0 1
and,serial 1.0 0.000143348623853 1 0 1
two,isoenzymes 1.0 0.000143348623853 0 1 -1
female,cynomolgus 1.0 0.000143348623853 0 1 -1
for,using 1.0 0.000143348623853 0 1 -1
its,clinical 1.0 0.000143348623853 0 1 -1
affect,pharmacokinetics 1.0 0.000143348623853 1 0 1
adequate,dosage 1.0 0.000143348623853 0 1 -1
wort,because 1.0 0.000143348623853 0 1 -1
cyclic,in 1.0 0.000143348623853 0 1 -1
coadministered,with 0.111111111111 0.000716743119266 25 20 5
isozyme,including 0.0 0.0 1 1 0
with,foscavir 1.0 0.000143348623853 1 0 1
min,following 1.0 0.000143348623853 0 1 -1
they,have 1.0 0.000286697247706 0 2 -2
reported,as 1.0 0.000143348623853 1 0 1
careful,observation 0.0 0.0 1 1 0
with,anaesthesia 1.0 0.000143348623853 0 1 -1
changed,the 0.0 0.0 1 1 0
in,ethinyl 1.0 0.000143348623853 1 0 1
secreted,via 1.0 0.000143348623853 1 0 1
levels,shown 1.0 0.000143348623853 0 1 -1
the,steadystate 0.0 0.0 1 1 0
management,of 0.555555555556 0.000716743119266 2 7 -5
haart,treatment 1.0 0.000143348623853 0 1 -1
ketamine,when 1.0 0.000143348623853 1 0 1
the,full 1.0 0.000143348623853 0 1 -1
has,elapsed 1.0 0.000143348623853 0 1 -1
time,zero 1.0 0.000143348623853 0 1 -1
series,of 1.0 0.000286697247706 0 2 -2
sequence,initiation 1.0 0.000143348623853 0 1 -1
outward,rectification 1.0 0.000143348623853 0 1 -1
hiv-related,systemic 1.0 0.000143348623853 0 1 -1
the,one-stage 1.0 0.000143348623853 0 1 -1
research,center 1.0 0.000143348623853 0 1 -1
variability,of 1.0 0.00043004587156 0 3 -3
multicenter,randomized 1.0 0.000143348623853 0 1 -1
good,inhibition 1.0 0.000143348623853 0 1 -1
and,add 1.0 0.000860091743119 6 0 6
of,relapses 1.0 0.000143348623853 0 1 -1
concentration,due 1.0 0.000143348623853 1 0 1
formal,laboratory 1.0 0.000143348623853 0 1 -1
qd,by 1.0 0.000143348623853 1 0 1
sodium,succinate 1.0 0.000143348623853 0 1 -1
phenytoin,causes 1.0 0.000143348623853 1 0 1
delayed,adverse 1.0 0.000143348623853 1 0 1
subjects,demonstrated 1.0 0.000143348623853 1 0 1
antagonist,with 1.0 0.000143348623853 1 0 1
to,exhibit 1.0 0.000573394495413 0 4 -4
table,summary 1.0 0.000143348623853 0 1 -1
the,volume 1.0 0.000143348623853 0 1 -1
characterized,a 1.0 0.000143348623853 1 0 1
the,adverse 0.5 0.000573394495413 2 6 -4
prophylactic,and 1.0 0.000143348623853 1 0 1
against,gram 1.0 0.000143348623853 0 1 -1
collected,through 1.0 0.000143348623853 0 1 -1
or,reduced 1.0 0.000286697247706 2 0 2
enterococci,were 1.0 0.000143348623853 0 1 -1
and,received 1.0 0.000143348623853 0 1 -1
in,any 0.5 0.000573394495413 2 6 -4
in,and 0.555555555556 0.000716743119266 2 7 -5
as,measured 0.714285714286 0.000716743119266 1 6 -5
either,pharmacokinetics 1.0 0.000143348623853 0 1 -1
comments,about 1.0 0.000143348623853 0 1 -1
continued,admistration 1.0 0.000143348623853 0 1 -1
second,day 1.0 0.000143348623853 1 0 1
interactions,as 1.0 0.000573394495413 0 4 -4
with,alphagan 1.0 0.000286697247706 2 0 2
potentially,significant 0.0 0.0 1 1 0
the,side 0.142857142857 0.000143348623853 4 3 1
of,cns 1.0 0.000143348623853 1 0 1
enhancing,heparin 1.0 0.000143348623853 0 1 -1
oxidative,metabolites 1.0 0.000143348623853 0 1 -1
microscopy,were 1.0 0.000143348623853 0 1 -1
as,high 1.0 0.00043004587156 0 3 -3
measurements,and 1.0 0.000286697247706 0 2 -2
threshold,should 1.0 0.000143348623853 1 0 1
presumably,by 1.0 0.000143348623853 1 0 1
that,ingestion 1.0 0.000143348623853 1 0 1
no,dosage 1.0 0.000716743119266 0 5 -5
acid,a-blockers 1.0 0.000143348623853 0 1 -1
general,caution 1.0 0.000143348623853 0 1 -1
diuretic,agents 1.0 0.00043004587156 3 0 3
chronic,therapy 0.0 0.0 1 1 0
be,metabolized 0.0 0.0 1 1 0
mediated,by 0.555555555556 0.000716743119266 2 7 -5
and,older 1.0 0.000143348623853 0 1 -1
twofold,from 1.0 0.000143348623853 1 0 1
thereby,providing 1.0 0.000143348623853 0 1 -1
small,quantities 1.0 0.000143348623853 0 1 -1
before,resulted 1.0 0.000143348623853 1 0 1
gm,daily 1.0 0.000143348623853 1 0 1
cyp2d6,increase 1.0 0.000143348623853 0 1 -1
studies,showed 0.333333333333 0.000143348623853 2 1 1
these,are 0.875 0.00200688073394 1 15 -14
noted,that 0.333333333333 0.000286697247706 2 4 -2
accumulation,of 0.6 0.00043004587156 1 4 -3
developed,regarding 1.0 0.000143348623853 0 1 -1
anti-anxiety,used 1.0 0.000143348623853 0 1 -1
a,literature 0.0 0.0 1 1 0
state,conditions 1.0 0.000286697247706 0 2 -2
on,thiazide 1.0 0.000286697247706 2 0 2
achieving,a 1.0 0.000143348623853 0 1 -1
other,having 1.0 0.000143348623853 1 0 1
as,reinforcing 1.0 0.000143348623853 0 1 -1
tikosyn,or 1.0 0.000143348623853 0 1 -1
following,completion 1.0 0.000143348623853 0 1 -1
bodyweight,gain 1.0 0.000286697247706 0 2 -2
decongestant,allergy 1.0 0.000143348623853 1 0 1
piperacillin,sodium 1.0 0.000143348623853 1 0 1
and,degree 1.0 0.000143348623853 0 1 -1
on,concentration 1.0 0.000143348623853 0 1 -1
platelets,by 1.0 0.000143348623853 1 0 1
of,isoform 1.0 0.000143348623853 0 1 -1
produces,psychotomimetic 1.0 0.000143348623853 0 1 -1
dosage,levels 1.0 0.000143348623853 1 0 1
reports,are 1.0 0.000143348623853 0 1 -1
free,had 1.0 0.000143348623853 0 1 -1
myocardium,in 1.0 0.000143348623853 0 1 -1
platelet,effects 1.0 0.000286697247706 0 2 -2
sc,or 1.0 0.000143348623853 0 1 -1
was,carried 1.0 0.000286697247706 0 2 -2
or,basic 1.0 0.000143348623853 1 0 1
microsomal,fraction 1.0 0.00043004587156 0 3 -3
fewer,extrapyramidal 1.0 0.000143348623853 0 1 -1
is,group 1.0 0.000143348623853 0 1 -1
as,not 1.0 0.000143348623853 1 0 1
different,routes 1.0 0.000143348623853 1 0 1
eg,implants 1.0 0.000143348623853 0 1 -1
ulcerans,was 1.0 0.000286697247706 0 2 -2
or,cyp-mediated 1.0 0.000143348623853 0 1 -1
respiratory,depression 0.2 0.000143348623853 3 2 1
human,growth 1.0 0.000143348623853 1 0 1
a,facilitates 1.0 0.000143348623853 0 1 -1
study,male 1.0 0.000143348623853 0 1 -1
betaseron,on 1.0 0.000143348623853 1 0 1
but,are 1.0 0.00043004587156 0 3 -3
if,it 0.0 0.0 1 1 0
if,is 0.368421052632 0.00100344036697 13 6 7
s,nor 1.0 0.000143348623853 0 1 -1
was,higher 1.0 0.00043004587156 3 0 3
schedule,was 1.0 0.000143348623853 1 0 1
c,should 1.0 0.000286697247706 2 0 2
in,a-chloralose 1.0 0.000143348623853 0 1 -1
test,could 1.0 0.000143348623853 0 1 -1
strong,central 1.0 0.000143348623853 0 1 -1
significant,lengthening 1.0 0.000143348623853 0 1 -1
basal,small 1.0 0.000143348623853 0 1 -1
dietary-obese,rats 1.0 0.000573394495413 0 4 -4
or,overlapping 1.0 0.000143348623853 0 1 -1
particularly,if 0.333333333333 0.000143348623853 1 2 -1
detected,after 1.0 0.000143348623853 0 1 -1
days,decreased 1.0 0.000143348623853 1 0 1
to,administer 1.0 0.000143348623853 1 0 1
pqq,based 1.0 0.000143348623853 0 1 -1
proleukin,and 1.0 0.000286697247706 2 0 2
increased,possibility 0.333333333333 0.000143348623853 2 1 1
of,coma 1.0 0.000143348623853 1 0 1
with,multivalent 1.0 0.000143348623853 1 0 1
populations,prostate 1.0 0.000143348623853 0 1 -1
toxic,metabolites 1.0 0.000143348623853 0 1 -1
produce,inhibition 1.0 0.000143348623853 0 1 -1
can,lead 0.2 0.000143348623853 3 2 1
inhibited,insp 1.0 0.000286697247706 2 0 2
had,treatment-emergent 1.0 0.000143348623853 0 1 -1
automated,equipment 1.0 0.000143348623853 0 1 -1
of,innovar 0.0 0.0 1 1 0
derivatives,niacin 1.0 0.000143348623853 0 1 -1
k,the 1.0 0.000143348623853 1 0 1
cmax,of 0.333333333333 0.000716743119266 10 5 5
if,resumed 1.0 0.000143348623853 0 1 -1
that,occur 1.0 0.000143348623853 0 1 -1
none,of 1.0 0.000143348623853 0 1 -1
excluded,from 1.0 0.000143348623853 0 1 -1
derivatives,nicotinic 1.0 0.000143348623853 0 1 -1
glucocorticoid-induced,mouse 1.0 0.000143348623853 0 1 -1
for,medications 1.0 0.000143348623853 0 1 -1
of,permits 1.0 0.000143348623853 1 0 1
by,approximately 0.5 0.00114678899083 12 4 8
a,a 1.0 0.000143348623853 1 0 1
mobilization,of 1.0 0.000143348623853 0 1 -1
solutions,blood 1.0 0.000143348623853 0 1 -1
aspirin,animal 1.0 0.000143348623853 1 0 1
is,being 1.0 0.000143348623853 0 1 -1
tbpa,is 1.0 0.000143348623853 0 1 -1
pharmacokinetic,results 1.0 0.000143348623853 1 0 1
achieve,exposures 1.0 0.000286697247706 2 0 2
were,randomized 1.0 0.000286697247706 0 2 -2
therapeutic,efficacy 0.0 0.0 2 2 0
transferase,level 1.0 0.000143348623853 0 1 -1
of,especially 1.0 0.000286697247706 2 0 2
and,resulted 0.846153846154 0.00157683486239 12 1 11
smallest,effective 1.0 0.000143348623853 0 1 -1
filtration,may 1.0 0.000143348623853 0 1 -1
contractile,responses 0.0 0.0 1 1 0
inhibitors,for 1.0 0.000143348623853 0 1 -1
mild,but 1.0 0.000143348623853 0 1 -1
arterial,thrombus 1.0 0.000143348623853 1 0 1
the,placebo-controlled 1.0 0.000143348623853 0 1 -1
a,u 1.0 0.000143348623853 0 1 -1
is,dealt 1.0 0.000143348623853 0 1 -1
bind,significantly 1.0 0.000143348623853 0 1 -1
indicated,and 1.0 0.000143348623853 1 0 1
blocking,properties 1.0 0.000286697247706 2 0 2
bleeding,with 1.0 0.000143348623853 0 1 -1
resistant,mcf-7 1.0 0.000143348623853 0 1 -1
test,or 1.0 0.000143348623853 0 1 -1
value,abstract 1.0 0.000143348623853 0 1 -1
metabolite,are 1.0 0.000143348623853 0 1 -1
longer,term 1.0 0.000143348623853 0 1 -1
celebrex,concomitantly 1.0 0.000143348623853 1 0 1
condition,in 0.0 0.0 1 1 0
altretamines,half-life 1.0 0.000143348623853 1 0 1
maintain,concentrations 1.0 0.000143348623853 0 1 -1
and,raise 1.0 0.000143348623853 1 0 1
as,immediate-early 1.0 0.000143348623853 0 1 -1
and,frequently 1.0 0.000286697247706 2 0 2
their,main 1.0 0.000143348623853 0 1 -1
hours,concurrently 1.0 0.000143348623853 0 1 -1
and,discontinuing 1.0 0.000573394495413 4 0 4
of,iopidine 1.0 0.000143348623853 1 0 1
the,cardiotoxicity 1.0 0.000143348623853 0 1 -1
from,controlled 1.0 0.000143348623853 0 1 -1
rats,did 1.0 0.000286697247706 0 2 -2
evidence,suggesting 1.0 0.000143348623853 0 1 -1
not,known 0.555555555556 0.0021502293578 6 21 -15
by,in 0.333333333333 0.000286697247706 4 2 2
but,also 0.714285714286 0.000716743119266 1 6 -5
the,direction 1.0 0.000286697247706 0 2 -2
included,seven 1.0 0.000143348623853 0 1 -1
of,fatal 1.0 0.000143348623853 0 1 -1
preclinical,or 1.0 0.000143348623853 0 1 -1
individual,simulect 1.0 0.000143348623853 0 1 -1
especially,neglect 1.0 0.000143348623853 0 1 -1
or,potentiation 1.0 0.000286697247706 0 2 -2
not,differ 1.0 0.000286697247706 0 2 -2
interest,in 1.0 0.000143348623853 0 1 -1
because,is 0.428571428571 0.000860091743119 4 10 -6
animals,indicate 1.0 0.000143348623853 1 0 1
immunodeficiency,virus 1.0 0.000143348623853 0 1 -1
requiring,angioedema 1.0 0.000143348623853 0 1 -1
and,inhibit 1.0 0.000860091743119 0 6 -6
following,protease 1.0 0.000143348623853 0 1 -1
demonstrated,a 0.0 0.0 2 2 0
known,hence 1.0 0.000143348623853 1 0 1
cocaine-treated,animals 1.0 0.000143348623853 0 1 -1
to,sensitize 0.333333333333 0.000143348623853 1 2 -1
effort,to 1.0 0.000143348623853 0 1 -1
reducing,hunger 1.0 0.000143348623853 0 1 -1
level,should 1.0 0.000143348623853 1 0 1
hypercholesterolemic,noninsulin 1.0 0.000143348623853 0 1 -1
c,eg 1.0 0.000143348623853 1 0 1
of,equetrotm 0.0 0.0 3 3 0
could,contribute 1.0 0.000286697247706 0 2 -2
to,influence 0.0 0.0 2 2 0
using,effective 1.0 0.000286697247706 0 2 -2
only,of 1.0 0.000143348623853 0 1 -1
four-day,regimen 1.0 0.000143348623853 1 0 1
values,similar 1.0 0.000143348623853 0 1 -1
of,n-desmethyldiazepam 1.0 0.000143348623853 0 1 -1
glyburide,in 1.0 0.000143348623853 0 1 -1
sodium,plasma 1.0 0.000286697247706 2 0 2
on,bar-press 1.0 0.000143348623853 0 1 -1
remain,to 1.0 0.000143348623853 0 1 -1
the,simultaneous 0.2 0.000143348623853 2 3 -1
subjects,taking 1.0 0.000143348623853 0 1 -1
interaction,data 1.0 0.000573394495413 0 4 -4
glyburide,is 1.0 0.000143348623853 0 1 -1
n,ingestion 1.0 0.000143348623853 1 0 1
valdecoxib,steady 1.0 0.000143348623853 0 1 -1
metabolic,enzymes 1.0 0.000286697247706 0 2 -2
of,edetate 1.0 0.000143348623853 1 0 1
on,treatment 1.0 0.000143348623853 1 0 1
clear,whether 1.0 0.000286697247706 0 2 -2
eight,of 1.0 0.000143348623853 1 0 1
a,non-steroidal 1.0 0.00043004587156 3 0 3
tests,performed 1.0 0.000143348623853 0 1 -1
neoplastic,disease 1.0 0.000143348623853 1 0 1
effective,contraception 1.0 0.000286697247706 0 2 -2
purification,of 1.0 0.000143348623853 0 1 -1
volunteers,did 1.0 0.00043004587156 0 3 -3
inhibited,at 1.0 0.000143348623853 0 1 -1
guide,to 1.0 0.000143348623853 1 0 1
population,with 1.0 0.000143348623853 0 1 -1
engaging,in 1.0 0.000143348623853 0 1 -1
milk,products 1.0 0.000143348623853 1 0 1
sudden,extrusion 1.0 0.000143348623853 0 1 -1
selective,mao 1.0 0.000143348623853 1 0 1
gastrointestinal,disturbances 1.0 0.000143348623853 0 1 -1
effective,than 1.0 0.000143348623853 0 1 -1
i-labelled,antigen 1.0 0.000286697247706 0 2 -2
among,fifteen 1.0 0.000143348623853 0 1 -1
administered,but 1.0 0.000143348623853 0 1 -1
a,theoretical 0.6 0.00043004587156 4 1 3
valproate,available 1.0 0.000143348623853 0 1 -1
relevant,interactions 1.0 0.000286697247706 0 2 -2
excretion,is 0.0 0.0 2 2 0
area,basis 1.0 0.000143348623853 0 1 -1
or,proton 1.0 0.00043004587156 3 0 3
lactic,acidosis 1.0 0.000143348623853 0 1 -1
aprepitant,may 1.0 0.000143348623853 1 0 1
deviation,to 1.0 0.000143348623853 1 0 1
situations,in 1.0 0.000143348623853 0 1 -1
hydrodiuril,diuril 1.0 0.000143348623853 0 1 -1
excretion,in 1.0 0.000286697247706 2 0 2
recommended,daily 0.333333333333 0.000143348623853 1 2 -1
elevations,less 1.0 0.000143348623853 1 0 1
at,of 1.0 0.000143348623853 0 1 -1
by,millions 1.0 0.000143348623853 0 1 -1
which,require 1.0 0.000143348623853 1 0 1
mac,was 0.0 0.0 1 1 0
a,group 1.0 0.000716743119266 0 5 -5
reduced,kidney 1.0 0.000143348623853 0 1 -1
striking,and 1.0 0.000286697247706 2 0 2
flurbiprofen,like 1.0 0.000143348623853 1 0 1
racemic,was 1.0 0.000143348623853 0 1 -1
the,positive 0.0 0.0 1 1 0
thiazide,use 1.0 0.000143348623853 1 0 1
studies,other 1.0 0.000143348623853 0 1 -1
tricyclic,which 1.0 0.000143348623853 0 1 -1
be,gradual 1.0 0.000143348623853 1 0 1
regression,model 1.0 0.000143348623853 0 1 -1
active,monohydroxy 1.0 0.000143348623853 0 1 -1
probe,study 1.0 0.000286697247706 0 2 -2
rabbit,kidney 1.0 0.000143348623853 0 1 -1
insurances,and 1.0 0.000143348623853 0 1 -1
strategies,during 1.0 0.000143348623853 0 1 -1
syncope,or 0.2 0.000143348623853 2 3 -1
because,many 1.0 0.000286697247706 0 2 -2
of,grams 1.0 0.000143348623853 1 0 1
dietary,salt 1.0 0.000143348623853 1 0 1
erythromycin,azole 1.0 0.000143348623853 0 1 -1
switched,from 1.0 0.000143348623853 0 1 -1
hydroxylation,during 1.0 0.000143348623853 0 1 -1
anticoagulants,potentiation 1.0 0.000143348623853 0 1 -1
had,no 0.764705882353 0.00745412844037 8 60 -52
ingesting,the 0.5 0.000286697247706 1 3 -2
not,approved 1.0 0.000286697247706 0 2 -2
a,because 1.0 0.000143348623853 1 0 1
or,concomitant 0.333333333333 0.000143348623853 1 2 -1
ecg,of 1.0 0.000143348623853 0 1 -1
shortened,elimination 1.0 0.000143348623853 1 0 1
without,co-administered 1.0 0.000143348623853 0 1 -1
primary,metabolite 1.0 0.000143348623853 0 1 -1
few,data 1.0 0.000286697247706 0 2 -2
be,deferred 1.0 0.000143348623853 1 0 1
however,there 0.2 0.000143348623853 2 3 -1
number,of 0.5 0.00200688073394 7 21 -14
hctz,hydrodiuril 1.0 0.000143348623853 0 1 -1
no,potentiation 1.0 0.000143348623853 0 1 -1
to,this 0.0 0.0 3 3 0
not,ordinarily 1.0 0.000286697247706 2 0 2
will,need 1.0 0.000143348623853 1 0 1
receiving,may 1.0 0.000143348623853 1 0 1
uptake,inhibitors 1.0 0.000143348623853 1 0 1
racemic,combined 0.0 0.0 1 1 0
inhibitors,nnrtis 1.0 0.000143348623853 1 0 1
msec,was 1.0 0.000143348623853 1 0 1
subgroup,of 1.0 0.000143348623853 0 1 -1
presynaptic,defect 1.0 0.000143348623853 0 1 -1
coadministered,medicinal 0.333333333333 0.000143348623853 1 2 -1
produce,any 0.0 0.0 1 1 0
the,tablets 1.0 0.000143348623853 1 0 1
aerosolized,has 1.0 0.000143348623853 0 1 -1
feels,better 1.0 0.000143348623853 0 1 -1
weekly,or 1.0 0.000573394495413 0 4 -4
about,when 1.0 0.000573394495413 4 0 4
it,might 1.0 0.000143348623853 0 1 -1
data,suggesting 1.0 0.000143348623853 1 0 1
to,treat 0.75 0.00172018348624 2 14 -12
and,bone 0.0 0.0 1 1 0
serum,plasma 1.0 0.000143348623853 0 1 -1
mp,aza 1.0 0.000143348623853 0 1 -1
air,passages 1.0 0.000143348623853 1 0 1
especially,cyclic 1.0 0.000143348623853 1 0 1
itraconazole,with 1.0 0.000286697247706 2 0 2
indicate,only 1.0 0.000143348623853 1 0 1
with,labetalol 1.0 0.000143348623853 1 0 1
after,weeks 1.0 0.000573394495413 0 4 -4
ameliorate,increased 1.0 0.000143348623853 1 0 1
of,cadmium 1.0 0.000716743119266 0 5 -5
eprosartan,has 1.0 0.000143348623853 0 1 -1
range,mg 1.0 0.000143348623853 1 0 1
overall,exposure 1.0 0.000143348623853 1 0 1
been,titrated 0.333333333333 0.000286697247706 2 4 -2
preliminary,animal 1.0 0.000143348623853 0 1 -1
uninfected,volunteers 1.0 0.000143348623853 1 0 1
of,aranesp 1.0 0.000143348623853 0 1 -1
anti-infectives,without 1.0 0.000143348623853 0 1 -1
without,clinically 1.0 0.000143348623853 0 1 -1
to,acth 1.0 0.000143348623853 0 1 -1
fulvestrant-treated,lactating 1.0 0.000143348623853 0 1 -1
and,dpcpx-induced 1.0 0.000143348623853 1 0 1
or,recovery 1.0 0.000143348623853 1 0 1
however,is 0.666666666667 0.000573394495413 1 5 -4
similar,increases 1.0 0.000143348623853 0 1 -1
daily,activities 1.0 0.000143348623853 0 1 -1
receiving,vioxx 1.0 0.000143348623853 1 0 1
however,if 1.0 0.000286697247706 0 2 -2
absolute,in 1.0 0.000143348623853 0 1 -1
produced,significant 1.0 0.000143348623853 1 0 1
rats,suggest 1.0 0.000143348623853 1 0 1
regularly,during 1.0 0.000143348623853 0 1 -1
however,in 0.384615384615 0.000716743119266 4 9 -5
of,chop-haart 1.0 0.000143348623853 0 1 -1
were,carried 1.0 0.00043004587156 0 3 -3
alone,because 1.0 0.000143348623853 1 0 1
efflux,transporter 1.0 0.000143348623853 0 1 -1
which,was 0.0909090909091 0.000143348623853 6 5 1
mean,plasma 0.333333333333 0.000143348623853 2 1 1
some,increase 1.0 0.000143348623853 1 0 1
other,specific 1.0 0.000143348623853 0 1 -1
regarding,the 0.714285714286 0.000716743119266 1 6 -5
retention,was 1.0 0.000143348623853 0 1 -1
antipsychotic,with 1.0 0.000143348623853 0 1 -1
bioavailability,studies 1.0 0.000286697247706 0 2 -2
careful,monitoring 0.0909090909091 0.000143348623853 6 5 1
large,increases 1.0 0.000143348623853 0 1 -1
conclusion,cisapride 1.0 0.000143348623853 0 1 -1
epirubicin,is 1.0 0.000143348623853 0 1 -1
personality,characteristics 1.0 0.000143348623853 0 1 -1
mental,status 0.0 0.0 1 1 0
events,reported 1.0 0.000143348623853 0 1 -1
kill,even 1.0 0.000143348623853 1 0 1
nanm,nanm 1.0 0.000143348623853 0 1 -1
body,surface 1.0 0.00043004587156 0 3 -3
pharmacist,of 1.0 0.000143348623853 0 1 -1
we,describe 1.0 0.000143348623853 0 1 -1
or,potassium-containing 0.0 0.0 1 1 0
indocin,relafen 1.0 0.000143348623853 0 1 -1
when,xigris 1.0 0.000143348623853 0 1 -1
possibly,increasing 1.0 0.000286697247706 2 0 2
not,exceed 0.6 0.00043004587156 4 1 3
any,oral 1.0 0.000143348623853 1 0 1
positive,reaction 1.0 0.00043004587156 0 3 -3
cmax,was 1.0 0.000143348623853 0 1 -1
risks,of 0.142857142857 0.000143348623853 4 3 1
observations,which 1.0 0.000143348623853 0 1 -1
compromised,uptake-1 1.0 0.000143348623853 0 1 -1
drug,toxicity 1.0 0.000143348623853 0 1 -1
compounds,and 1.0 0.000143348623853 1 0 1
food,one 1.0 0.000143348623853 1 0 1
thiazide,for 1.0 0.000143348623853 0 1 -1
adverse,interaction 1.0 0.000143348623853 0 1 -1
body,occurs 1.0 0.000143348623853 0 1 -1
a,day 0.5 0.00114678899083 4 12 -8
with,potentially 0.0 0.0 1 1 0
i,expression 1.0 0.000143348623853 0 1 -1
nondepolarizing,used 1.0 0.000143348623853 0 1 -1
with,continuation 1.0 0.000286697247706 0 2 -2
bar-press,conditioning 1.0 0.000143348623853 0 1 -1
pt,such 1.0 0.000143348623853 0 1 -1
withdrawn,from 0.727272727273 0.00229357798165 3 19 -16
as,post-marketing 1.0 0.00043004587156 3 0 3
in,livers 1.0 0.000143348623853 0 1 -1
bronchodilator,may 1.0 0.000143348623853 0 1 -1
not,recovered 1.0 0.000143348623853 0 1 -1
and,antiparkinsonian 1.0 0.000143348623853 1 0 1
on,high 1.0 0.000143348623853 0 1 -1
contribution,to 1.0 0.000143348623853 0 1 -1
maintained,between 1.0 0.000143348623853 1 0 1
these,birth 1.0 0.000143348623853 0 1 -1
levothyroxine,sodium 1.0 0.000143348623853 1 0 1
respectively,suggesting 1.0 0.000286697247706 2 0 2
dose,proleukin 1.0 0.000143348623853 1 0 1
lotensin,has 1.0 0.000143348623853 0 1 -1
considerable,segment 1.0 0.000143348623853 0 1 -1
nsaids,have 1.0 0.000716743119266 5 0 5
l,did 1.0 0.000143348623853 0 1 -1
major,serum 1.0 0.000143348623853 0 1 -1
fully,evaluating 1.0 0.000143348623853 0 1 -1
mhd,have 1.0 0.000143348623853 0 1 -1
opposite,way 1.0 0.000143348623853 1 0 1
generation,in 1.0 0.000143348623853 0 1 -1
vitro,displacement 1.0 0.000143348623853 0 1 -1
colistimethate,salts 1.0 0.000143348623853 1 0 1
approximately,was 1.0 0.000143348623853 1 0 1
such,it 1.0 0.00043004587156 0 3 -3
it,has 0.04 0.000143348623853 13 12 1
s,disease 1.0 0.000573394495413 0 4 -4
of,stadol 0.0 0.0 2 2 0
a,gas 1.0 0.000143348623853 0 1 -1
following,precautions 1.0 0.000143348623853 1 0 1
alternating,therapy 1.0 0.000143348623853 0 1 -1
cautious,initiation 1.0 0.000143348623853 1 0 1
another,study 0.5 0.000286697247706 1 3 -2
similar,personality 1.0 0.000143348623853 0 1 -1
with,reports 1.0 0.000143348623853 0 1 -1
levels,considerably 1.0 0.000286697247706 2 0 2
isoforms,a2 1.0 0.000143348623853 0 1 -1
isoforms,a4 1.0 0.000143348623853 0 1 -1
and,sustained 0.333333333333 0.000143348623853 2 1 1
tcas,when 1.0 0.000716743119266 0 5 -5
although,administered 1.0 0.000143348623853 0 1 -1
occurred,more 1.0 0.000143348623853 0 1 -1
oral,estrogens 1.0 0.000143348623853 1 0 1
the,evidence 1.0 0.000286697247706 0 2 -2
indicate,important 1.0 0.000143348623853 0 1 -1
volunteers,under 1.0 0.000286697247706 0 2 -2
adp-induced,increases 1.0 0.000143348623853 0 1 -1
for,signs 0.230769230769 0.00043004587156 8 5 3
includes,both 1.0 0.000143348623853 1 0 1
any,intentional 1.0 0.000143348623853 1 0 1
after,was 1.0 0.000143348623853 0 1 -1
of,albendazole 1.0 0.000143348623853 1 0 1
following,antibiotics 1.0 0.000143348623853 0 1 -1
average,of 1.0 0.000716743119266 5 0 5
the,week 0.0 0.0 1 1 0
effect,compared 1.0 0.000143348623853 0 1 -1
provided,a 1.0 0.000143348623853 0 1 -1
a,variety 1.0 0.0021502293578 0 15 -15
and,retinyl 1.0 0.000286697247706 2 0 2
an,experimental 1.0 0.000143348623853 1 0 1
therefore,can 1.0 0.000143348623853 0 1 -1
pharmacology,studies 1.0 0.00043004587156 0 3 -3
scales,and 1.0 0.000143348623853 0 1 -1
until,it 1.0 0.000286697247706 0 2 -2
antinociception,was 1.0 0.000143348623853 0 1 -1
hepatic,lipid 1.0 0.000143348623853 1 0 1
enzyme,group 1.0 0.000143348623853 0 1 -1
cns-active,drugs 1.0 0.000286697247706 2 0 2
to,carbodiimide 1.0 0.000143348623853 0 1 -1
blockade,produced 1.0 0.000286697247706 2 0 2
to,exclude 1.0 0.000143348623853 0 1 -1
experienced,users 1.0 0.000143348623853 1 0 1
in,bile 1.0 0.000143348623853 1 0 1
period,mg 1.0 0.000286697247706 0 2 -2
that,require 1.0 0.000143348623853 0 1 -1
bromocriptine,mesylate 1.0 0.00043004587156 3 0 3
c9,have 1.0 0.000143348623853 0 1 -1
of,antagonists 1.0 0.000286697247706 0 2 -2
micrograms,caused 1.0 0.000143348623853 1 0 1
worsened,glucose 1.0 0.000143348623853 0 1 -1
drugs,aliskiren 1.0 0.000143348623853 0 1 -1
and,dietary-induced 1.0 0.000143348623853 0 1 -1
the,kd 1.0 0.000286697247706 0 2 -2
divalproex,sodium 1.0 0.000143348623853 1 0 1
some,angiotensin 1.0 0.000143348623853 1 0 1
their,plasma 0.0 0.0 1 1 0
before,receiving 1.0 0.000143348623853 0 1 -1
acute,intake 1.0 0.000143348623853 1 0 1
perspiration,weight 1.0 0.000143348623853 0 1 -1
of,nizoral 0.0 0.0 1 1 0
not,available 1.0 0.000143348623853 0 1 -1
of,cholesterol 1.0 0.000143348623853 1 0 1
tissues,induced 1.0 0.000143348623853 1 0 1
and,disadvantages 1.0 0.000143348623853 0 1 -1
mg,capsules 1.0 0.00043004587156 3 0 3
disorder,or 1.0 0.000143348623853 1 0 1
protects,against 1.0 0.000143348623853 1 0 1
carboxymethylcellulose,nacmc 1.0 0.000143348623853 0 1 -1
increase,in 0.420689655172 0.00874426605505 103 42 61
induces,apoptosis 1.0 0.000286697247706 0 2 -2
varying,durations 1.0 0.000143348623853 0 1 -1
grouped,as 1.0 0.000143348623853 0 1 -1
in,difluoro-2 1.0 0.000143348623853 1 0 1
increase,is 0.333333333333 0.000143348623853 1 2 -1
derivative,is 1.0 0.000143348623853 0 1 -1
for,women 1.0 0.000286697247706 0 2 -2
inducers,eg 1.0 0.000143348623853 0 1 -1
both,the 0.0909090909091 0.000143348623853 5 6 -1
peak,and 1.0 0.000143348623853 0 1 -1
interval,must 1.0 0.000143348623853 1 0 1
resistant,to 0.6 0.00043004587156 1 4 -3
be,administered 0.310344827586 0.00258027522936 38 20 18
study,had 1.0 0.000143348623853 0 1 -1
practices,in 1.0 0.000143348623853 0 1 -1
no,doubt 1.0 0.000143348623853 0 1 -1
a,hot 1.0 0.000143348623853 0 1 -1
in,this 0.826086956522 0.00272362385321 2 21 -19
study,has 0.333333333333 0.000143348623853 2 1 1
comparison,to 0.333333333333 0.000143348623853 1 2 -1
tablets,reduces 1.0 0.000143348623853 1 0 1
to,difluoroacetone 0.333333333333 0.000143348623853 1 2 -1
were,generated 1.0 0.000143348623853 0 1 -1
for,each 1.0 0.000143348623853 0 1 -1
remedies,and 1.0 0.000143348623853 1 0 1
has,no 0.888888888889 0.00229357798165 1 17 -16
however,patients 0.2 0.000143348623853 2 3 -1
underlie,its 1.0 0.000143348623853 0 1 -1
premenopausal,women 1.0 0.000143348623853 0 1 -1
the,scale 1.0 0.000143348623853 0 1 -1
auc,increased 1.0 0.000573394495413 4 0 4
peroxidation,which 1.0 0.000143348623853 1 0 1
proven,efficacy 1.0 0.000143348623853 0 1 -1
hmg-coa,reductase 0.25 0.000573394495413 10 6 4
preliminary,investigations 1.0 0.000143348623853 0 1 -1
capsule,within 1.0 0.000143348623853 1 0 1
other,highly 0.666666666667 0.000573394495413 1 5 -4
step,in 1.0 0.000286697247706 0 2 -2
on,valproic 1.0 0.000143348623853 1 0 1
replacement,is 1.0 0.000143348623853 0 1 -1
not,likely 0.6 0.00043004587156 1 4 -3
be,highly 1.0 0.000286697247706 0 2 -2
acid,monoamine 1.0 0.000143348623853 1 0 1
for,those 1.0 0.000143348623853 0 1 -1
from,this 1.0 0.000286697247706 0 2 -2
pregnancy,test 1.0 0.00043004587156 0 3 -3
individual,case 1.0 0.000143348623853 0 1 -1
meth,has 1.0 0.000143348623853 0 1 -1
of,mmol 1.0 0.000143348623853 0 1 -1
have,focused 1.0 0.000143348623853 0 1 -1
change,to 1.0 0.000143348623853 1 0 1
hypercholesterolemia,was 1.0 0.000143348623853 0 1 -1
pharmacodynamic,interactions 0.2 0.000143348623853 3 2 1
addition,several 0.0 0.0 1 1 0
with,erectile 1.0 0.000143348623853 0 1 -1
subjects,had 1.0 0.000143348623853 0 1 -1
upon,beginning 1.0 0.000143348623853 1 0 1
rats,the 1.0 0.000143348623853 0 1 -1
acid,binding 1.0 0.00043004587156 3 0 3
dosages,or 1.0 0.000143348623853 1 0 1
previously,received 0.333333333333 0.000143348623853 2 1 1
ingestion,of 0.6 0.00043004587156 4 1 3
and,subsequently 1.0 0.000143348623853 1 0 1
system,mainly 1.0 0.000143348623853 1 0 1
be,involved 1.0 0.00043004587156 0 3 -3
dosages,of 1.0 0.000143348623853 0 1 -1
been,attributed 0.833333333333 0.00143348623853 1 11 -10
long,and 1.0 0.000143348623853 0 1 -1
on,long-term 1.0 0.000143348623853 1 0 1
depressant,effects 0.2 0.000286697247706 6 4 2
flupenthixol,and 1.0 0.000143348623853 1 0 1
preliminary,clinical 1.0 0.000143348623853 1 0 1
increased,initially 1.0 0.000143348623853 0 1 -1
antagonism,in 0.0 0.0 1 1 0
aerosol,of 1.0 0.000143348623853 0 1 -1
doses,have 1.0 0.000143348623853 0 1 -1
nerally,classified 1.0 0.000143348623853 0 1 -1
patient,must 1.0 0.000143348623853 0 1 -1
slow-release,mg 1.0 0.000143348623853 0 1 -1
weak,b6 1.0 0.000143348623853 0 1 -1
gastric,acidity 1.0 0.000143348623853 0 1 -1
cortisone-like,medicine 1.0 0.000143348623853 1 0 1
patient,during 1.0 0.000143348623853 0 1 -1
with,pcp 1.0 0.000143348623853 0 1 -1
from,time 1.0 0.000143348623853 0 1 -1
few,patients 0.333333333333 0.000143348623853 2 1 1
the,basis 0.4 0.000573394495413 3 7 -4
b12,diagnostic 1.0 0.000143348623853 0 1 -1
and,when 0.6 0.00043004587156 4 1 3
electrophysiologic,interactions 1.0 0.000143348623853 0 1 -1
fluothane,as 1.0 0.000143348623853 1 0 1
day,ig 1.0 0.000143348623853 1 0 1
dogs,unchanged 1.0 0.000143348623853 0 1 -1
of,relative 0.0 0.0 1 1 0
routes,a 1.0 0.000143348623853 1 0 1
relevant,elevation 1.0 0.000143348623853 1 0 1
day,in 0.25 0.000286697247706 3 5 -2
day,im 1.0 0.000286697247706 0 2 -2
its,toxicity 1.0 0.000143348623853 1 0 1
iii,decreased 1.0 0.000286697247706 0 2 -2
day,is 1.0 0.000143348623853 0 1 -1
ca,currents 1.0 0.000286697247706 0 2 -2
system,inhibitors 1.0 0.000143348623853 0 1 -1
medication,must 1.0 0.000143348623853 1 0 1
enhance,the 0.672727272727 0.00530389908257 46 9 37
d,inhibited 1.0 0.000143348623853 1 0 1
not,after 1.0 0.000143348623853 1 0 1
active,s-isomer 1.0 0.000143348623853 0 1 -1
with,cefamandole 1.0 0.000143348623853 0 1 -1
concentrations,at 1.0 0.000143348623853 0 1 -1
inhibitors,as 0.0 0.0 1 1 0
n,pretreatment 1.0 0.000143348623853 1 0 1
from,twitch 1.0 0.000143348623853 1 0 1
bezalip,retard 1.0 0.00043004587156 3 0 3
population,pharmacokinetic 0.333333333333 0.000286697247706 4 2 2
equetrotm,due 1.0 0.000143348623853 1 0 1
are,the 0.6 0.00043004587156 4 1 3
eg,or 1.0 0.00043004587156 3 0 3
also,increase 1.0 0.000716743119266 0 5 -5
mm,and 1.0 0.000143348623853 0 1 -1
phenothiazines,tindal 1.0 0.000143348623853 0 1 -1
to,progression 1.0 0.000143348623853 0 1 -1
variable,effects 1.0 0.000143348623853 1 0 1
tdm,of 1.0 0.000143348623853 0 1 -1
myelosuppressive,agents 1.0 0.000143348623853 0 1 -1
increase,gastrointestinal 1.0 0.000143348623853 0 1 -1
str,may 1.0 0.000143348623853 0 1 -1
of,dietary 1.0 0.000143348623853 0 1 -1
metabolized,the 1.0 0.000143348623853 0 1 -1
cyp3a,to 1.0 0.000143348623853 0 1 -1
clearance,leading 1.0 0.000286697247706 0 2 -2
abnormality,in 1.0 0.000143348623853 0 1 -1
liquid,impinger 1.0 0.000143348623853 0 1 -1
allows,the 1.0 0.000143348623853 0 1 -1
and,diuretics 1.0 0.000143348623853 1 0 1
whenever,an 1.0 0.000143348623853 0 1 -1
population,who 1.0 0.000143348623853 0 1 -1
tablet,formulation 1.0 0.00043004587156 3 0 3
injection,use 1.0 0.000143348623853 0 1 -1
reports,describe 1.0 0.000143348623853 1 0 1
and,resulting 1.0 0.000143348623853 1 0 1
of,progestin-only 0.0 0.0 1 1 0
injection,usp 0.6 0.00043004587156 4 1 3
animals,studies 1.0 0.000143348623853 0 1 -1
association,functional 1.0 0.000143348623853 0 1 -1
allergy,cold 1.0 0.000143348623853 1 0 1
pediatric,use 1.0 0.000286697247706 0 2 -2
chick,embryos 0.0 0.0 1 1 0
of,hypoglycemia 0.333333333333 0.000143348623853 1 2 -1
of,hypoglycemic 1.0 0.000286697247706 2 0 2
comedication,particularly 1.0 0.000143348623853 1 0 1
a,precursor 1.0 0.000143348623853 0 1 -1
producing,medications 1.0 0.000286697247706 0 2 -2
fortovase,may 1.0 0.000143348623853 0 1 -1
for,hypertension 1.0 0.000143348623853 0 1 -1
with,renal 0.111111111111 0.000143348623853 4 5 -1
risk,factor 1.0 0.000143348623853 0 1 -1
achieve,mac 1.0 0.000143348623853 1 0 1
reduced,and 0.333333333333 0.000143348623853 1 2 -1
observe,the 1.0 0.000143348623853 0 1 -1
possibility,and 1.0 0.000143348623853 0 1 -1
warrant,alteration 1.0 0.000143348623853 0 1 -1
extent,auc 1.0 0.000143348623853 1 0 1
days,results 1.0 0.000143348623853 1 0 1
the,sympathetic 1.0 0.00043004587156 0 3 -3
nsaids,without 1.0 0.000143348623853 0 1 -1
curve,was 1.0 0.000143348623853 0 1 -1
sulfoxide,plasma 1.0 0.000143348623853 0 1 -1
intracellular,exposure 1.0 0.000143348623853 1 0 1
may,experience 0.2 0.000143348623853 3 2 1
oral,product 1.0 0.000143348623853 0 1 -1
meal,as 1.0 0.000143348623853 1 0 1
very,weak 1.0 0.000143348623853 1 0 1
cases,the 1.0 0.000286697247706 0 2 -2
three-,to 1.0 0.000143348623853 0 1 -1
amphotericin,b 0.384615384615 0.000716743119266 9 4 5
amoxicillin,an 1.0 0.000143348623853 1 0 1
the,nueronal 1.0 0.000143348623853 0 1 -1
fentanyl,is 1.0 0.000143348623853 0 1 -1
mind,that 1.0 0.000143348623853 1 0 1
produce,a 0.538461538462 0.00100344036697 3 10 -7
with,nephrotoxic 0.0 0.0 1 1 0
indinavir,and 1.0 0.000143348623853 1 0 1
no,systematic 1.0 0.000143348623853 0 1 -1
lethality,in 1.0 0.000143348623853 0 1 -1
however,higher 1.0 0.000143348623853 0 1 -1
fr,schedule 1.0 0.000143348623853 0 1 -1
systems,inhibition 1.0 0.000143348623853 0 1 -1
oral,live 1.0 0.000143348623853 1 0 1
must,receive 1.0 0.000143348623853 0 1 -1
extracellular,ca 1.0 0.000143348623853 0 1 -1
concomitantly,should 0.333333333333 0.000143348623853 1 2 -1
primarily,a 1.0 0.000143348623853 0 1 -1
opioid,decreased 1.0 0.000143348623853 0 1 -1
that,pulmozyme 1.0 0.000143348623853 0 1 -1
interaction,were 1.0 0.000286697247706 0 2 -2
substrate,given 1.0 0.000143348623853 0 1 -1
negative,result 1.0 0.000143348623853 0 1 -1
of,nonsteroial 1.0 0.000143348623853 1 0 1
not,demonstrate 1.0 0.000286697247706 0 2 -2
of,walking 1.0 0.000143348623853 0 1 -1
significant,impact 0.0 0.0 1 1 0
in,transfusion 1.0 0.000143348623853 0 1 -1
chop,chemotherapy 1.0 0.000143348623853 0 1 -1
rhythm,followed 1.0 0.000143348623853 0 1 -1
significant,oxidative 1.0 0.000143348623853 0 1 -1
myocardial,infarction 0.5 0.000573394495413 2 6 -4
distribution,effect 1.0 0.000143348623853 0 1 -1
transplants,malignancy 1.0 0.000143348623853 0 1 -1
lesions,resulting 1.0 0.000143348623853 0 1 -1
volunteers,who 0.0 0.0 1 1 0
dependence,of 1.0 0.000143348623853 0 1 -1
m,markedly 1.0 0.000143348623853 1 0 1
occurring,in 1.0 0.000143348623853 0 1 -1
also,dyslipidemia 1.0 0.000143348623853 0 1 -1
dependence,on 1.0 0.000143348623853 0 1 -1
acid,when 1.0 0.000143348623853 0 1 -1
when,you 1.0 0.000143348623853 1 0 1
no,drug 1.0 0.000860091743119 0 6 -6
similar,changes 1.0 0.00043004587156 0 3 -3
any,hypokalemic 1.0 0.000143348623853 1 0 1
maleate,or 1.0 0.000143348623853 1 0 1
in,angina 1.0 0.000143348623853 0 1 -1
infarction,patients 1.0 0.000143348623853 0 1 -1
digoxin,did 1.0 0.000143348623853 0 1 -1
antipsychotic,agent 1.0 0.000143348623853 0 1 -1
muscle,cell 1.0 0.000143348623853 0 1 -1
profile,prothrombin 1.0 0.000143348623853 0 1 -1
oxytocic,may 0.0 0.0 2 2 0
have,received 0.333333333333 0.000286697247706 2 4 -2
virologic,response 1.0 0.000573394495413 0 4 -4
of,plendil 1.0 0.000143348623853 0 1 -1
of,agents 0.428571428571 0.000860091743119 4 10 -6
warfarin,anticoagulant 1.0 0.000143348623853 1 0 1
of,individual 1.0 0.00043004587156 0 3 -3
function,accompanied 1.0 0.000143348623853 1 0 1
clinical,study 0.2 0.000143348623853 3 2 1
over,in 1.0 0.000143348623853 0 1 -1
mothers,it 1.0 0.000143348623853 0 1 -1
to,concurrent 1.0 0.000143348623853 1 0 1
are,years 1.0 0.000143348623853 0 1 -1
and,active 0.333333333333 0.000286697247706 2 4 -2
azithromycin,had 0.0 0.0 1 1 0
latent,lcv 1.0 0.000143348623853 0 1 -1
dihydropyridine,derivative 1.0 0.000143348623853 0 1 -1
a,positive 0.75 0.000860091743119 1 7 -6
increased,responsiveness 1.0 0.000286697247706 0 2 -2
pcp,produced 1.0 0.000286697247706 0 2 -2
against,two 1.0 0.000143348623853 0 1 -1
cardiac,conduction 0.0 0.0 1 1 0
users,develop 1.0 0.000143348623853 0 1 -1
pcp,produces 1.0 0.000143348623853 0 1 -1
relevant,effects 1.0 0.000143348623853 0 1 -1
in,december 1.0 0.000143348623853 0 1 -1
with,formulations 1.0 0.000143348623853 1 0 1
additional,including 1.0 0.000143348623853 1 0 1
sedatives,hypnotics 0.0 0.0 1 1 0
laboratory,results 1.0 0.000143348623853 0 1 -1
for,more 1.0 0.000143348623853 0 1 -1
this,sample 1.0 0.000143348623853 0 1 -1
enzyme,function 1.0 0.000143348623853 0 1 -1
of,succinylcholine-induced 1.0 0.000143348623853 0 1 -1
patient,being 0.6 0.00043004587156 1 4 -3
the,large 1.0 0.000143348623853 0 1 -1
subjects,to 1.0 0.00043004587156 0 3 -3
nephropathies,and 1.0 0.000143348623853 0 1 -1
from,given 0.6 0.00043004587156 1 4 -3
d6,and 1.0 0.00043004587156 0 3 -3
apparent,increase 1.0 0.000143348623853 0 1 -1
during,both 1.0 0.000143348623853 0 1 -1
indicated,dosing 1.0 0.000143348623853 0 1 -1
normalizing,the 1.0 0.000143348623853 0 1 -1
data,including 1.0 0.000143348623853 0 1 -1
can,produce 1.0 0.000286697247706 2 0 2
nonsteroidal,that 1.0 0.000143348623853 1 0 1
intravenous,mg 1.0 0.00043004587156 0 3 -3
anticoagulants,should 1.0 0.000143348623853 0 1 -1
the,smallest 1.0 0.000143348623853 0 1 -1
third,group 1.0 0.000143348623853 0 1 -1
behavioral,inhibition 1.0 0.000143348623853 0 1 -1
or,substances 0.0 0.0 1 1 0
slowly,from 1.0 0.000143348623853 0 1 -1
renal,clearance 0.25 0.000860091743119 15 9 6
virus,also 1.0 0.000143348623853 0 1 -1
by,to 0.2 0.000143348623853 2 3 -1
antifungal,agents 0.333333333333 0.000143348623853 2 1 1
at,a 0.545454545455 0.00172018348624 5 17 -12
within,weeks 0.5 0.000286697247706 1 3 -2
amevive,on 1.0 0.000143348623853 0 1 -1
tmax,was 1.0 0.000143348623853 0 1 -1
terfenadine,in 1.0 0.000143348623853 0 1 -1
in,learning 1.0 0.000143348623853 0 1 -1
have,either 1.0 0.000143348623853 0 1 -1
mc,has 1.0 0.000286697247706 0 2 -2
predictable,and 1.0 0.000143348623853 0 1 -1
potassium-sparing,diuretics 1.0 0.000286697247706 2 0 2
and,progestogen 1.0 0.000143348623853 0 1 -1
that,causative 1.0 0.000143348623853 0 1 -1
ulceration,and 1.0 0.000286697247706 2 0 2
hematopoietic,system 1.0 0.000143348623853 0 1 -1
concurrently,subjects 1.0 0.000573394495413 4 0 4
these,cyp 1.0 0.000143348623853 0 1 -1
concomitantly,showed 1.0 0.000143348623853 0 1 -1
a,rabbit 1.0 0.000143348623853 0 1 -1
v,did 1.0 0.000143348623853 0 1 -1
achieved,indicating 1.0 0.000143348623853 0 1 -1
nimbex,in 1.0 0.000143348623853 1 0 1
precaution,should 1.0 0.00043004587156 0 3 -3
either,of 1.0 0.000286697247706 0 2 -2
aeds,do 1.0 0.000143348623853 0 1 -1
integration,the 1.0 0.000143348623853 0 1 -1
of,hydroxylated 1.0 0.000143348623853 1 0 1
botox,and 1.0 0.000143348623853 1 0 1
locomotion,and 1.0 0.000143348623853 0 1 -1
arterial,pressure 0.0 0.0 1 1 0
develop,higher 1.0 0.000143348623853 0 1 -1
develop,a 1.0 0.000143348623853 1 0 1
valproate,keppra 1.0 0.000143348623853 0 1 -1
system,depression 0.0 0.0 1 1 0
not,primarily 1.0 0.000143348623853 1 0 1
cyp3a4,ingestion 1.0 0.000143348623853 0 1 -1
vioxx,may 1.0 0.000143348623853 1 0 1
lowers,serum 1.0 0.000143348623853 0 1 -1
axert,within 1.0 0.000143348623853 1 0 1
regimen,includes 1.0 0.000143348623853 1 0 1
normal,dogs 1.0 0.000143348623853 0 1 -1
post,marketing 1.0 0.000143348623853 1 0 1
intercourse,with 1.0 0.000143348623853 0 1 -1
based,regimens 1.0 0.000143348623853 0 1 -1
skin,medicines 1.0 0.000143348623853 0 1 -1
that,histaminergic 1.0 0.000143348623853 0 1 -1
carotid,cannulation 1.0 0.000143348623853 0 1 -1
cardiac,transplant 1.0 0.000143348623853 1 0 1
two,combined 1.0 0.000143348623853 0 1 -1
valproate,a 1.0 0.000143348623853 1 0 1
peganone,is 1.0 0.000143348623853 1 0 1
are,unlikely 1.0 0.00043004587156 0 3 -3
p,although 1.0 0.000143348623853 0 1 -1
seven,experiments 1.0 0.000143348623853 0 1 -1
the,cases 1.0 0.000143348623853 0 1 -1
conjunction,with 0.166666666667 0.000286697247706 5 7 -2
seen,are 1.0 0.000143348623853 0 1 -1
peripheral,anitagonism 1.0 0.000143348623853 1 0 1
of,endogenous 1.0 0.000286697247706 2 0 2
mmol,day 1.0 0.000143348623853 0 1 -1
of,clonazepam 1.0 0.000286697247706 0 2 -2
trial,has 1.0 0.000143348623853 1 0 1
didanosine,it 1.0 0.000143348623853 0 1 -1
of,bronchodilator 1.0 0.000143348623853 0 1 -1
normetanephrine,and 1.0 0.000143348623853 0 1 -1
approach,in 1.0 0.000143348623853 0 1 -1
treat,a 1.0 0.000143348623853 0 1 -1
approach,is 1.0 0.000143348623853 0 1 -1
data,described 1.0 0.00043004587156 0 3 -3
of,correlation 1.0 0.000143348623853 0 1 -1
triiodothyronine,levels 1.0 0.000143348623853 0 1 -1
cases,two 1.0 0.000286697247706 0 2 -2
or,cns 0.0 0.0 1 1 0
low,to 1.0 0.000143348623853 0 1 -1
of,cerubidine 0.0 0.0 1 1 0
in,ontario 1.0 0.000286697247706 0 2 -2
the,extent 0.571428571429 0.00229357798165 6 22 -16
with,hemodynamic 1.0 0.000143348623853 1 0 1
with,potential 1.0 0.000143348623853 0 1 -1
nodal,conduction 1.0 0.000286697247706 2 0 2
declining,to 1.0 0.000143348623853 0 1 -1
produce,scintigraphic 1.0 0.000143348623853 0 1 -1
previously,been 1.0 0.000143348623853 0 1 -1
of,fetal 1.0 0.00043004587156 0 3 -3
propranolol,attenuated 1.0 0.000143348623853 1 0 1
isoniazid,should 1.0 0.000143348623853 0 1 -1
made,carefully 1.0 0.000143348623853 0 1 -1
oxidase,from 1.0 0.000143348623853 0 1 -1
certain,antagonists 1.0 0.000143348623853 1 0 1
ritonavir,significantly 1.0 0.000143348623853 1 0 1
decrease,thyroidal 1.0 0.000143348623853 1 0 1
dipotassium,prolongs 1.0 0.000143348623853 1 0 1
to,oral 1.0 0.000286697247706 0 2 -2
flavoridin,alone 1.0 0.000143348623853 1 0 1
colestipol-concomitant,intake 1.0 0.000143348623853 1 0 1
use,resulted 1.0 0.000143348623853 0 1 -1
augment,the 1.0 0.000573394495413 4 0 4
i131,a 1.0 0.000143348623853 1 0 1
the,same 0.655172413793 0.00272362385321 5 24 -19
others,orudis 1.0 0.000143348623853 0 1 -1
fluothane,augments 1.0 0.000143348623853 1 0 1
hit,may 1.0 0.000143348623853 0 1 -1
regimen,containing 1.0 0.000143348623853 0 1 -1
metabolism,and 0.5 0.00114678899083 4 12 -8
fa,were 1.0 0.000143348623853 0 1 -1
high,intraluminal 1.0 0.000143348623853 0 1 -1
mg,per 0.0 0.0 2 2 0
barbiturates,or 1.0 0.000143348623853 1 0 1
other,affected 1.0 0.000143348623853 0 1 -1
while,under 1.0 0.000143348623853 1 0 1
lactulose-induced,drop 1.0 0.000143348623853 1 0 1
augmentin,xr 0.333333333333 0.000143348623853 1 2 -1
anticholinesterases,concomitant 1.0 0.000143348623853 1 0 1
clearance,ml 1.0 0.000143348623853 0 1 -1
cassette,fully 1.0 0.000143348623853 0 1 -1
morphine-induced,tail-flick 1.0 0.000143348623853 0 1 -1
probenecid,or 1.0 0.000143348623853 1 0 1
experiencing,breakthrough 1.0 0.000143348623853 0 1 -1
check,your 1.0 0.000143348623853 0 1 -1
costs,despite 1.0 0.000143348623853 0 1 -1
reduced,cmax 1.0 0.000286697247706 2 0 2
p-glycoprotein,in 1.0 0.000143348623853 1 0 1
a,sensitive 1.0 0.000143348623853 1 0 1
receiving,taxotere 1.0 0.000143348623853 0 1 -1
interactions,amphetamines 0.0 0.0 1 1 0
closely,for 0.5 0.00114678899083 4 12 -8
xii,vii-x 1.0 0.000286697247706 0 2 -2
and,thus 0.230769230769 0.00043004587156 8 5 3
monitored,frequently 0.5 0.000286697247706 3 1 2
control,group 1.0 0.000143348623853 0 1 -1
cerebyx,with 1.0 0.000143348623853 0 1 -1
with,caution 0.0833333333333 0.000573394495413 26 22 4
adl,and 1.0 0.000143348623853 0 1 -1
thiazides,are 1.0 0.00043004587156 0 3 -3
district,of 1.0 0.000143348623853 0 1 -1
oxide,with 1.0 0.000143348623853 0 1 -1
at,therapeutic 0.5 0.000286697247706 1 3 -2
phase,days 1.0 0.00043004587156 0 3 -3
therapy,a 0.333333333333 0.000286697247706 4 2 2
plasma,exposure 0.666666666667 0.000573394495413 5 1 4
potentiated,resulting 1.0 0.000143348623853 1 0 1
successive,generation 1.0 0.000143348623853 0 1 -1
broth,dilution 1.0 0.000143348623853 0 1 -1
of,desethylzaleplon 1.0 0.000143348623853 0 1 -1
support,was 1.0 0.000143348623853 0 1 -1
and,copegus 1.0 0.000286697247706 0 2 -2
for,dandruff 1.0 0.000143348623853 0 1 -1
accelerated,prothrombin 1.0 0.000286697247706 0 2 -2
on,acth 1.0 0.000143348623853 0 1 -1
rbc,mice 1.0 0.000286697247706 0 2 -2
combined,therapy 0.111111111111 0.000143348623853 4 5 -1
are,begun 1.0 0.000143348623853 1 0 1
a,controlled 0.0 0.0 1 1 0
replaced,by 1.0 0.000143348623853 0 1 -1
oral,twice 1.0 0.000143348623853 1 0 1
strattera,may 1.0 0.000143348623853 1 0 1
receiving,comedication 1.0 0.000143348623853 1 0 1
reports,in 1.0 0.000286697247706 2 0 2
neutrophil,count 1.0 0.000143348623853 0 1 -1
and,infrequent 1.0 0.000143348623853 0 1 -1
listed,agents 1.0 0.000143348623853 0 1 -1
weekly,subcutaneous 1.0 0.000143348623853 0 1 -1
of,include 1.0 0.000143348623853 0 1 -1
creatinine,level 1.0 0.000143348623853 1 0 1
of,hyperkalemia 1.0 0.000286697247706 2 0 2
other,may 0.142857142857 0.000143348623853 4 3 1
antidepressant,single 1.0 0.000143348623853 1 0 1
study,evaluated 1.0 0.000143348623853 0 1 -1
inhibitors,studies 1.0 0.000143348623853 1 0 1
potential,increased 1.0 0.000143348623853 0 1 -1
inter-patient,variation 1.0 0.000143348623853 1 0 1
mefloquine,and 1.0 0.000143348623853 1 0 1
tinnitus,slurred 1.0 0.000143348623853 0 1 -1
with,chirocaine 1.0 0.000143348623853 0 1 -1
aprepitant,increased 1.0 0.000286697247706 2 0 2
agents,eg 1.0 0.000143348623853 1 0 1
cns-depressant,effects 1.0 0.000143348623853 1 0 1
cancidas,is 1.0 0.000143348623853 1 0 1
ability,to 0.5 0.000286697247706 1 3 -2
dose,ranges 1.0 0.000143348623853 0 1 -1
pretreatment,and 1.0 0.00043004587156 0 3 -3
case,report 1.0 0.000286697247706 2 0 2
the,organic 1.0 0.000143348623853 0 1 -1
values,for 0.333333333333 0.00043004587156 3 6 -3
doses,above 1.0 0.000143348623853 1 0 1
macrolide,or 1.0 0.000143348623853 0 1 -1
if,this 1.0 0.00043004587156 0 3 -3
fertility,no 1.0 0.000143348623853 0 1 -1
inhibitors,intravenous 1.0 0.000143348623853 0 1 -1
when,these 0.565217391304 0.00186353211009 5 18 -13
is,inhibited 1.0 0.00043004587156 3 0 3
either,was 0.0 0.0 2 2 0
of,reduction 1.0 0.000143348623853 0 1 -1
lithium,diclofenac 1.0 0.000143348623853 1 0 1
dextromethorphan,dextromethorphan 1.0 0.000143348623853 0 1 -1
effects,on 0.647058823529 0.00473050458716 9 42 -33
together,as 1.0 0.000143348623853 0 1 -1
perforatum,may 1.0 0.000143348623853 0 1 -1
with,produces 1.0 0.000143348623853 1 0 1
effects,of 0.0727272727273 0.00229357798165 102 118 -16
omeprazole,no 1.0 0.000143348623853 0 1 -1
cholinergic,crisis 1.0 0.000143348623853 0 1 -1
filtrated,to 1.0 0.000143348623853 1 0 1
with,produced 1.0 0.000143348623853 0 1 -1
effects,or 1.0 0.000143348623853 0 1 -1
important,interaction 1.0 0.000143348623853 0 1 -1
counts,were 1.0 0.000143348623853 0 1 -1
of,norpace 1.0 0.000143348623853 1 0 1
coadministered,and 1.0 0.000286697247706 0 2 -2
red-orange,which 1.0 0.000143348623853 0 1 -1
therapy,patients 1.0 0.00043004587156 3 0 3
finally,it 1.0 0.000143348623853 0 1 -1
the,ld50 1.0 0.000143348623853 1 0 1
during,can 1.0 0.000143348623853 1 0 1
that,nonabsorbable 1.0 0.000143348623853 1 0 1
at,total 1.0 0.000143348623853 0 1 -1
with,alfenta 1.0 0.000143348623853 1 0 1
whose,hypertension 1.0 0.000143348623853 1 0 1
least,four 1.0 0.000143348623853 0 1 -1
cimetidines,known 1.0 0.000143348623853 1 0 1
taking,lexapro 1.0 0.000143348623853 1 0 1
k,aquamephyton 1.0 0.000143348623853 0 1 -1
for,nevirapine-associated 1.0 0.000143348623853 0 1 -1
swine,has 1.0 0.000143348623853 0 1 -1
receiving,velcade 0.0 0.0 1 1 0
by,general 1.0 0.000143348623853 0 1 -1
acute,renal 1.0 0.000143348623853 1 0 1
activase,may 1.0 0.000143348623853 0 1 -1
clozapine,may 1.0 0.000143348623853 1 0 1
alcohol,alcohol 1.0 0.000143348623853 0 1 -1
severe,structural 1.0 0.000143348623853 0 1 -1
term,therapy 0.0 0.0 1 1 0
mm,hg 0.333333333333 0.000143348623853 2 1 1
cime-tidine,therapy 1.0 0.000143348623853 1 0 1
bextra,concomitantly 1.0 0.000143348623853 1 0 1
receive,low-molecular 1.0 0.000143348623853 0 1 -1
on,such 1.0 0.000143348623853 1 0 1
with,administered 1.0 0.000143348623853 1 0 1
mg,five 1.0 0.000143348623853 0 1 -1
were,identified 0.333333333333 0.000143348623853 1 2 -1
albendazole,sulfoxide 0.0 0.0 1 1 0
antiresistance,determinant 1.0 0.000143348623853 0 1 -1
synergism,was 1.0 0.000143348623853 1 0 1
weight,loss 1.0 0.000143348623853 1 0 1
trilafon,compazine 1.0 0.000143348623853 0 1 -1
significant,interaction 0.666666666667 0.000573394495413 1 5 -4
dsst,symbol 1.0 0.000143348623853 1 0 1
and,area-under 1.0 0.000143348623853 1 0 1
agents,affecting 1.0 0.000573394495413 0 4 -4
or,human 1.0 0.000143348623853 0 1 -1
known,as 1.0 0.000143348623853 0 1 -1
and,monoamine 0.2 0.000143348623853 3 2 1
year-old,african-american 1.0 0.000143348623853 0 1 -1
alprazolam,when 1.0 0.000143348623853 1 0 1
been,conducted 0.75 0.00258027522936 3 21 -18
agents,zyvox 1.0 0.000143348623853 1 0 1
decreased,an 1.0 0.000286697247706 2 0 2
high-estradiol,rats 1.0 0.000143348623853 1 0 1
substudy,in 1.0 0.000143348623853 1 0 1
and,disorder 1.0 0.000143348623853 0 1 -1
oral,supplementation 1.0 0.000286697247706 0 2 -2
ejection,by 1.0 0.000286697247706 0 2 -2
beta-adrenergic,stimulating 1.0 0.000143348623853 0 1 -1
less,pronounced 1.0 0.000143348623853 1 0 1
markedly,inhibit 0.5 0.000286697247706 3 1 2
also,prolonged 1.0 0.000143348623853 0 1 -1
using,higher 1.0 0.000143348623853 1 0 1
cyp2d6,cyp2c9 1.0 0.000143348623853 0 1 -1
administering,with 1.0 0.000143348623853 1 0 1
substances,the 0.0 0.0 1 1 0
factors,ii 1.0 0.000286697247706 0 2 -2
the,digitalized 1.0 0.000143348623853 0 1 -1
or,orthostatic 1.0 0.000143348623853 1 0 1
by,some 1.0 0.000143348623853 0 1 -1
medications,that 0.25 0.000286697247706 3 5 -2
cimetidine,treatment 1.0 0.000143348623853 1 0 1
anti,platelet 1.0 0.000143348623853 0 1 -1
one-third,as 1.0 0.000143348623853 1 0 1
of,atropinization 1.0 0.000143348623853 1 0 1
experience,to 0.0 0.0 1 1 0
dyskinesia,side 1.0 0.000143348623853 1 0 1
but,that 1.0 0.000143348623853 0 1 -1
in,plasma 0.428571428571 0.00258027522936 30 12 18
formed,often 1.0 0.000143348623853 0 1 -1
metabolic,activation 1.0 0.000143348623853 0 1 -1
doses,were 1.0 0.000143348623853 0 1 -1
in,future 1.0 0.000143348623853 0 1 -1
of,oxypurines 0.0 0.0 1 1 0
p-450,isoenzymes 0.0 0.0 1 1 0
systemic,are 1.0 0.000143348623853 0 1 -1
hypertensive,reactions 1.0 0.000143348623853 1 0 1
healthy,volunteers 0.128205128205 0.000716743119266 17 22 -5
as,antineoplastic 1.0 0.000143348623853 1 0 1
same,effects 1.0 0.000143348623853 0 1 -1
with,fatal 1.0 0.000286697247706 2 0 2
these,above 1.0 0.000143348623853 0 1 -1
with,systemic 1.0 0.000143348623853 0 1 -1
vitro,has 0.0 0.0 1 1 0
analyses,of 0.0 0.0 1 1 0
an,levonorgestrol 1.0 0.000143348623853 0 1 -1
indicated,reduction 1.0 0.000143348623853 1 0 1
with,anticoagulation 1.0 0.000143348623853 1 0 1
cyp3a4,patients 1.0 0.000143348623853 0 1 -1
as,judged 1.0 0.000286697247706 0 2 -2
oral,did 1.0 0.000143348623853 0 1 -1
even,ileus 1.0 0.000143348623853 1 0 1
the,subjective 1.0 0.000286697247706 0 2 -2
studies,also 0.5 0.000286697247706 1 3 -2
c,the 1.0 0.000143348623853 0 1 -1
in,genetically 1.0 0.000143348623853 0 1 -1
used,such 1.0 0.000143348623853 0 1 -1
resulted,in 0.521739130435 0.00688073394495 70 22 48
extravasation,reactions 1.0 0.000143348623853 0 1 -1
requires,an 1.0 0.000143348623853 0 1 -1
cholestyramine-concomitant,intake 1.0 0.000143348623853 1 0 1
to,competitive 1.0 0.000143348623853 0 1 -1
hydroxides,and 1.0 0.000143348623853 0 1 -1
agents,some 1.0 0.00043004587156 3 0 3
reduces,the 0.777777777778 0.00100344036697 8 1 7
by,antihypertensive 1.0 0.000286697247706 2 0 2
significantly,higher 0.2 0.000143348623853 2 3 -1
show,subnormal 1.0 0.000143348623853 0 1 -1
noted,above 1.0 0.000143348623853 0 1 -1
responsiveness,of 1.0 0.000143348623853 1 0 1
be,expressed 1.0 0.000143348623853 0 1 -1
us,a 1.0 0.000143348623853 0 1 -1
including,immune 1.0 0.000143348623853 0 1 -1
with,full 1.0 0.000143348623853 0 1 -1
reduce,proleukin-induced 1.0 0.000143348623853 1 0 1
avoided,by 0.0 0.0 1 1 0
resulted,when 1.0 0.000143348623853 1 0 1
treatment,period 1.0 0.000143348623853 0 1 -1
production,elevation 1.0 0.000143348623853 0 1 -1
following,anti-anxiety 1.0 0.000143348623853 0 1 -1
resin,or 1.0 0.000143348623853 0 1 -1
rats,followed 1.0 0.000143348623853 0 1 -1
dialyzable,may 1.0 0.000143348623853 0 1 -1
and,dietary-obese 1.0 0.000143348623853 0 1 -1
a,vanh 1.0 0.000143348623853 0 1 -1
a,vana 1.0 0.000143348623853 0 1 -1
p450,enzyme-inducer 1.0 0.000143348623853 1 0 1
the,alkaline 1.0 0.000143348623853 0 1 -1
one-half,the 0.333333333333 0.000143348623853 1 2 -1
as,are 1.0 0.000573394495413 4 0 4
is,suggested 0.25 0.000286697247706 5 3 2
type,strains 1.0 0.000143348623853 0 1 -1
anafranil,to 1.0 0.000143348623853 1 0 1
eg,for 1.0 0.000143348623853 1 0 1
daily,and 0.0 0.0 2 2 0
later,time 1.0 0.000143348623853 0 1 -1
rifampicin,in 1.0 0.000143348623853 1 0 1
dopamine-induced,ventricular 1.0 0.000143348623853 1 0 1
mg,of 0.128205128205 0.000716743119266 22 17 5
patient,who 0.333333333333 0.000143348623853 2 1 1
in,volume 1.0 0.000143348623853 1 0 1
excluded,patients 1.0 0.000286697247706 0 2 -2
mg,on 0.0 0.0 4 4 0
anabolic,hormones 0.0 0.0 1 1 0
mg,or 0.5 0.000573394495413 2 6 -4
exposures,to 1.0 0.000143348623853 1 0 1
excessive,increase 1.0 0.000143348623853 0 1 -1
herbs,do 1.0 0.000143348623853 0 1 -1
intestinal,mucosa 0.333333333333 0.000143348623853 1 2 -1
pointes,and 1.0 0.000143348623853 0 1 -1
ssri-tcainteractions,may 1.0 0.000143348623853 1 0 1
mean,minimum 1.0 0.00043004587156 0 3 -3
similarly,in 1.0 0.000143348623853 0 1 -1
altering,concentrations 1.0 0.000143348623853 0 1 -1
but,were 1.0 0.000143348623853 0 1 -1
may,influence 1.0 0.000286697247706 0 2 -2
in,situ 0.333333333333 0.000143348623853 1 2 -1
include,fever 1.0 0.000143348623853 0 1 -1
effective,treatment 1.0 0.000143348623853 0 1 -1
study,adverse 1.0 0.000143348623853 1 0 1
or,hypokalemia 1.0 0.000143348623853 1 0 1
healthcare,prescribers 1.0 0.000143348623853 0 1 -1
the,or 0.272727272727 0.00043004587156 7 4 3
diclofenac,is 1.0 0.000143348623853 0 1 -1
supported,by 1.0 0.000143348623853 0 1 -1
noted,even 1.0 0.000143348623853 1 0 1
in,systemic 1.0 0.00043004587156 3 0 3
however,modification 1.0 0.000143348623853 0 1 -1
is,acidified 1.0 0.000143348623853 0 1 -1
reported,in 0.291666666667 0.00200688073394 31 17 14
key,pharmaceuticals 1.0 0.000143348623853 1 0 1
ergotamine,or 1.0 0.000143348623853 0 1 -1
parkinsons,disease 0.0 0.0 1 1 0
is,presented 1.0 0.000143348623853 0 1 -1
and,ergot-type 0.0 0.0 1 1 0
of,augmentin 1.0 0.000143348623853 0 1 -1
sodium,does 1.0 0.000286697247706 0 2 -2
agents,available 1.0 0.000143348623853 0 1 -1
reactions,including 0.0 0.0 2 2 0
in,temperature 1.0 0.000143348623853 0 1 -1
by,subsequent 1.0 0.000143348623853 1 0 1
case,study 1.0 0.000143348623853 1 0 1
rapidly,hydrolyzed 1.0 0.000143348623853 0 1 -1
receiving,antihypertensive 1.0 0.000143348623853 1 0 1
jacalin,an 1.0 0.000143348623853 0 1 -1
amiodarone,taken 1.0 0.00043004587156 0 3 -3
is,added 0.555555555556 0.000716743119266 7 2 5
atorvastatin,increases 1.0 0.000143348623853 1 0 1
tyrosine,phosphorylation 0.6 0.00043004587156 1 4 -3
ethyol,in 1.0 0.000143348623853 1 0 1
and,return 1.0 0.000143348623853 0 1 -1
intracellular,phosphorylation 0.0 0.0 2 2 0
supplemental,folic 1.0 0.000143348623853 0 1 -1
underlying,many 1.0 0.000143348623853 0 1 -1
given,by 1.0 0.000143348623853 0 1 -1
when,lotensin 1.0 0.000143348623853 0 1 -1
cautiously,coadministered 1.0 0.000143348623853 1 0 1
reactions,from 1.0 0.000286697247706 0 2 -2
or,prolongation 0.333333333333 0.000143348623853 1 2 -1
treat,aggressively 1.0 0.000143348623853 0 1 -1
intravenous,pentamidine 1.0 0.000143348623853 0 1 -1
intercurrent,illnesses 1.0 0.000143348623853 0 1 -1
creams,ointments 1.0 0.000143348623853 0 1 -1
benedict,s 1.0 0.000716743119266 0 5 -5
administered,minutes 0.0 0.0 1 1 0
although,neither 1.0 0.000143348623853 1 0 1
influence,recovery 1.0 0.000143348623853 0 1 -1
mechanism,involved 1.0 0.000143348623853 0 1 -1
taking,other 0.0 0.0 2 2 0
taking,concomitantly 1.0 0.000286697247706 2 0 2
urine,after 1.0 0.000143348623853 0 1 -1
soon,after 1.0 0.000143348623853 1 0 1
interactions,in 1.0 0.000573394495413 0 4 -4
of,vasoconstricting 1.0 0.000143348623853 1 0 1
the,data 1.0 0.000860091743119 0 6 -6
interactions,it 1.0 0.000143348623853 0 1 -1
erythromycin,in 1.0 0.000286697247706 2 0 2
in,steady-state 1.0 0.000573394495413 4 0 4
bid,with 1.0 0.00043004587156 3 0 3
interactions,exists 1.0 0.000143348623853 0 1 -1
a,bar-press 1.0 0.000143348623853 0 1 -1
the,approved 1.0 0.000143348623853 0 1 -1
therefore,based 1.0 0.000143348623853 0 1 -1
electrolyte,disturbances 0.0 0.0 1 1 0
of,l-ccg 1.0 0.000143348623853 0 1 -1
reliable,estimates 1.0 0.000716743119266 0 5 -5
alter,glucose 1.0 0.000143348623853 0 1 -1
antithrombin,iii 0.333333333333 0.000143348623853 1 2 -1
to,groups 0.0 0.0 1 1 0
metabolite,ucb 1.0 0.000143348623853 0 1 -1
inhibitors,that 1.0 0.00043004587156 3 0 3
minor,symptoms 1.0 0.000143348623853 0 1 -1
hyperprolactinaemia,as 1.0 0.000143348623853 0 1 -1
useof,a 1.0 0.000143348623853 1 0 1
pertechnetate,tc99m 1.0 0.000143348623853 0 1 -1
twice,those 1.0 0.000143348623853 1 0 1
could,prolong 1.0 0.000143348623853 1 0 1
similarly,as 1.0 0.000143348623853 0 1 -1
measures,should 1.0 0.000143348623853 0 1 -1
may,occasionally 1.0 0.000716743119266 5 0 5
or,might 1.0 0.000143348623853 0 1 -1
undergoing,treatment 0.5 0.000286697247706 3 1 2
that,include 1.0 0.000143348623853 1 0 1
cells,treated 1.0 0.000143348623853 0 1 -1
p-450,the 0.0 0.0 1 1 0
not,measured 1.0 0.000143348623853 0 1 -1
testing,and 1.0 0.000143348623853 1 0 1
breast,irradiation 1.0 0.000143348623853 0 1 -1
depletion,related 1.0 0.000143348623853 0 1 -1
acid,for 1.0 0.000143348623853 0 1 -1
in,comparative 1.0 0.000143348623853 0 1 -1
inhibit,and 1.0 0.000143348623853 1 0 1
that,alter 0.333333333333 0.000143348623853 2 1 1
role,for 1.0 0.000143348623853 0 1 -1
l-histidine,via 1.0 0.000143348623853 1 0 1
demonstrated,superior 1.0 0.000143348623853 0 1 -1
migraine,therapy 1.0 0.000143348623853 1 0 1
the,regimen 0.0 0.0 1 1 0
marketing,observations 1.0 0.000143348623853 1 0 1
cause,peripheral 1.0 0.000143348623853 0 1 -1
anorectic,and 1.0 0.000143348623853 1 0 1
mice,after 1.0 0.000286697247706 0 2 -2
these,reasons 1.0 0.000143348623853 1 0 1
possibly,nicotinic 1.0 0.000143348623853 0 1 -1
and,toxicity 1.0 0.000286697247706 2 0 2
administered,together 0.5 0.000286697247706 1 3 -2
blood,level 1.0 0.000573394495413 0 4 -4
used,with 0.0526315789474 0.000286697247706 20 18 2
a,short-acting 0.0 0.0 1 1 0
symptom,onset 1.0 0.000143348623853 0 1 -1
following,the 0.428571428571 0.000860091743119 4 10 -6
with,glutathione 0.0 0.0 1 1 0
related,have 1.0 0.000143348623853 1 0 1
with,does 1.0 0.000143348623853 0 1 -1
affect,disease 1.0 0.000143348623853 1 0 1
resolved,with 1.0 0.000286697247706 0 2 -2
antiglobulin,coombs 1.0 0.000143348623853 0 1 -1
elucidating,the 1.0 0.000143348623853 0 1 -1
or,concentrations 1.0 0.000143348623853 0 1 -1
in,proof 1.0 0.000143348623853 0 1 -1
feasible,and 1.0 0.000143348623853 0 1 -1
fold,range 1.0 0.000143348623853 0 1 -1
measure,over 1.0 0.000143348623853 0 1 -1
maintained,patients 1.0 0.000143348623853 1 0 1
presumably,a 1.0 0.000143348623853 0 1 -1
of,ethyol 1.0 0.000143348623853 1 0 1
of,those 0.333333333333 0.000143348623853 1 2 -1
ecg,changes 0.0 0.0 1 1 0
and,non-ossification 1.0 0.000143348623853 0 1 -1
to,trace 1.0 0.000143348623853 0 1 -1
open,air 1.0 0.000143348623853 1 0 1
decreased,with 1.0 0.00043004587156 3 0 3
factor,in 1.0 0.000143348623853 0 1 -1
factor,ii 1.0 0.000143348623853 0 1 -1
were,below 1.0 0.000143348623853 0 1 -1
etc,is 1.0 0.000143348623853 1 0 1
of,factors 1.0 0.000143348623853 0 1 -1
vasoconstriction,after 1.0 0.000143348623853 1 0 1
clearance,secondary 1.0 0.000143348623853 1 0 1
lymphocytes,either 1.0 0.000143348623853 0 1 -1
histamine-induced,gastric 1.0 0.000143348623853 0 1 -1
etc,in 1.0 0.000143348623853 1 0 1
therapy,lies 1.0 0.000143348623853 0 1 -1
lotions,or 1.0 0.000143348623853 0 1 -1
other,significantly 1.0 0.000143348623853 1 0 1
denudation,indicating 1.0 0.000143348623853 0 1 -1
particularly,at 1.0 0.000143348623853 1 0 1
suitable,anticoagulation 1.0 0.000143348623853 1 0 1
a,blockade 1.0 0.000143348623853 1 0 1
on,exjade 1.0 0.000143348623853 0 1 -1
inhibit,prostaglandin 0.0 0.0 1 1 0
activity,of 0.454545454545 0.00286697247706 12 32 -20
of,their 0.2 0.000143348623853 3 2 1
ecg,heart 1.0 0.000143348623853 0 1 -1
sinus,bradycardia 1.0 0.000143348623853 0 1 -1
medical,literature 1.0 0.000143348623853 0 1 -1
statistically,significant 0.333333333333 0.000573394495413 4 8 -4
effector,immediate-early 1.0 0.000143348623853 0 1 -1
given,situation 1.0 0.000143348623853 0 1 -1
long,acting 0.0 0.0 1 1 0
noradrenaline,storage 1.0 0.000143348623853 0 1 -1
acid,temporarily 1.0 0.000143348623853 1 0 1
toxicity,but 1.0 0.000143348623853 0 1 -1
frequently,to 1.0 0.000143348623853 0 1 -1
tumor,types 1.0 0.000143348623853 0 1 -1
is,displaced 1.0 0.000286697247706 2 0 2
zone,in 1.0 0.000143348623853 0 1 -1
specific,sulfosalicylic 1.0 0.000143348623853 0 1 -1
increasing,gastric 1.0 0.000143348623853 1 0 1
the,potassium-depleted 1.0 0.000143348623853 0 1 -1
control,values 1.0 0.000143348623853 0 1 -1
insufficiency,are 1.0 0.000143348623853 0 1 -1
data,lower 1.0 0.000143348623853 1 0 1
infusion,rates 1.0 0.000143348623853 1 0 1
only,additive 1.0 0.000143348623853 1 0 1
significant,difference 1.0 0.00100344036697 0 7 -7
whether,the 0.333333333333 0.00043004587156 3 6 -3
cyp3a4,inducers 0.5 0.000573394495413 2 6 -4
we,compared 1.0 0.000143348623853 0 1 -1
or,stop 1.0 0.000143348623853 0 1 -1
on,repeated 1.0 0.000143348623853 0 1 -1
coma,and 1.0 0.000143348623853 1 0 1
show,whether 1.0 0.000143348623853 0 1 -1
trecator,has 1.0 0.000143348623853 1 0 1
conclusions,are 1.0 0.000143348623853 0 1 -1
anticholinesterase,effect 1.0 0.000143348623853 1 0 1
in,nucleoside-experienced 1.0 0.000143348623853 0 1 -1
identical,and 1.0 0.000143348623853 0 1 -1
changed,in 1.0 0.000143348623853 1 0 1
of,injection 0.333333333333 0.000143348623853 1 2 -1
decrease,the 0.428571428571 0.00301032110092 35 14 21
sodium,approximately 1.0 0.000286697247706 2 0 2
max,by 0.0 0.0 1 1 0
no,pharmacokinetic 1.0 0.00129013761468 0 9 -9
findings,on 1.0 0.000143348623853 0 1 -1
n6-cyclopentyladenosine,cpa 1.0 0.000143348623853 1 0 1
the,year 1.0 0.000286697247706 0 2 -2
zebeta,may 1.0 0.000143348623853 1 0 1
an,antiparkinsonian 1.0 0.000143348623853 1 0 1
includes,longer 1.0 0.000143348623853 0 1 -1
be,inactivated 1.0 0.000143348623853 0 1 -1
the,macrolide 1.0 0.000143348623853 1 0 1
aluminum-,or 1.0 0.000143348623853 1 0 1
and,antineoplastic 1.0 0.000143348623853 1 0 1
whether,these 0.333333333333 0.000143348623853 1 2 -1
differential,effect 1.0 0.000143348623853 0 1 -1
a,safe 1.0 0.000143348623853 1 0 1
reported,to 0.506172839506 0.00587729357798 61 20 41
must,have 1.0 0.000286697247706 0 2 -2
microsomes,cyp1a2 1.0 0.000143348623853 0 1 -1
clearances,by 1.0 0.000143348623853 1 0 1
stools,in 1.0 0.000143348623853 0 1 -1
decrease,first 1.0 0.000143348623853 0 1 -1
several,species 1.0 0.000143348623853 0 1 -1
particular,sulphydryl-containing 1.0 0.000143348623853 0 1 -1
and,special 1.0 0.000143348623853 1 0 1
their,serum 1.0 0.000143348623853 0 1 -1
all,that 1.0 0.000143348623853 0 1 -1
intravenously,over 1.0 0.000143348623853 0 1 -1
not,change 1.0 0.000573394495413 0 4 -4
interindividual,pharmacokinetic 1.0 0.000143348623853 0 1 -1
pose,clinical 1.0 0.000716743119266 5 0 5
temporarily,suspending 1.0 0.000143348623853 1 0 1
enhance,in 1.0 0.000143348623853 1 0 1
substrates,has 1.0 0.000143348623853 0 1 -1
the,single-dose 1.0 0.000143348623853 0 1 -1
although,theophylline-induced 1.0 0.000143348623853 0 1 -1
triglyceride,and 1.0 0.000286697247706 0 2 -2
or,toxicologic 1.0 0.000143348623853 0 1 -1
the,exposure 0.333333333333 0.000143348623853 2 1 1
other,hormonalmethods 1.0 0.000143348623853 1 0 1
administering,insp 1.0 0.000143348623853 1 0 1
pharmacology,coadministration 1.0 0.000143348623853 1 0 1
other,substances 0.333333333333 0.000143348623853 1 2 -1
of,nucleolin 1.0 0.000143348623853 0 1 -1
of,videx 0.333333333333 0.000143348623853 2 1 1
ligated,duodenal 1.0 0.000143348623853 0 1 -1
differ,from 1.0 0.000143348623853 0 1 -1
very,unlikely 1.0 0.000143348623853 0 1 -1
therapeutic,effect 0.5 0.000286697247706 1 3 -2
in,greater 1.0 0.000143348623853 1 0 1
doses,are 1.0 0.000143348623853 0 1 -1
cause,tumors 1.0 0.000143348623853 1 0 1
the,standard 1.0 0.000143348623853 1 0 1
initial,doses 0.2 0.000143348623853 2 3 -1
with,enbrel 1.0 0.000143348623853 1 0 1
chronic,indications 1.0 0.000143348623853 0 1 -1
advisable,to 0.428571428571 0.00043004587156 5 2 3
ca,concentration 0.0 0.0 1 1 0
you,may 0.0 0.0 2 2 0
duodenal,absorption 1.0 0.000143348623853 1 0 1
potassium-sparing,supplements 1.0 0.000143348623853 0 1 -1
anticipated,with 1.0 0.000286697247706 2 0 2
myopathy,and 1.0 0.000286697247706 0 2 -2
these,who 1.0 0.000143348623853 0 1 -1
of,post-ganglionic 1.0 0.000143348623853 0 1 -1
study,received 1.0 0.000143348623853 0 1 -1
hypoglycemia,has 1.0 0.000860091743119 6 0 6
disoproxil,fumarate 1.0 0.000143348623853 0 1 -1
altered,before 1.0 0.000143348623853 0 1 -1
enough,to 1.0 0.000143348623853 0 1 -1
is,probably 0.333333333333 0.000143348623853 1 2 -1
spinal,naloxone-sensitive 1.0 0.000143348623853 0 1 -1
that,itraconazole 1.0 0.000143348623853 1 0 1
and,antidepressant 1.0 0.000143348623853 0 1 -1
toward,other 1.0 0.000143348623853 0 1 -1
capsule,was 1.0 0.000143348623853 1 0 1
and,with 0.384615384615 0.000716743119266 4 9 -5
taxol,may 1.0 0.000143348623853 0 1 -1
reduce,pulse 0.0 0.0 1 1 0
pi,classified 1.0 0.000143348623853 0 1 -1
unchanged,in 1.0 0.000143348623853 0 1 -1
pharmacodynamic,consequences 1.0 0.000143348623853 0 1 -1
incisive,by 1.0 0.000143348623853 0 1 -1
be,artifactually 1.0 0.000143348623853 0 1 -1
channel,antagonists 1.0 0.00043004587156 0 3 -3
inhaled,such 1.0 0.000143348623853 0 1 -1
the,literature 0.333333333333 0.000286697247706 2 4 -2
with,are 1.0 0.00043004587156 0 3 -3
reasonable,to 0.2 0.000143348623853 2 3 -1
fungal,infections 1.0 0.000143348623853 0 1 -1
are,made 1.0 0.000143348623853 0 1 -1
problem,has 1.0 0.000143348623853 0 1 -1
in,unbound 1.0 0.000143348623853 1 0 1
sectral,lopressor 1.0 0.000143348623853 0 1 -1
of,healthy 0.142857142857 0.000143348623853 3 4 -1
per,ml 1.0 0.000143348623853 0 1 -1
inhibited,in 1.0 0.000286697247706 0 2 -2
supplements,are 1.0 0.000143348623853 1 0 1
of,monitoring 1.0 0.000143348623853 0 1 -1
magnitude,and 0.2 0.000143348623853 2 3 -1
survanta,also 1.0 0.000143348623853 0 1 -1
v,concentration 1.0 0.000143348623853 0 1 -1
aucasian,population 1.0 0.000143348623853 0 1 -1
to,reduced 1.0 0.000860091743119 0 6 -6
by,monoamine 0.5 0.000286697247706 3 1 2
and,together 1.0 0.000143348623853 1 0 1
affinities,for 1.0 0.000143348623853 0 1 -1
show,clinically 1.0 0.000143348623853 0 1 -1
of,distribution 0.428571428571 0.00043004587156 2 5 -3
very,potent 1.0 0.000143348623853 1 0 1
binds,bile 1.0 0.000143348623853 0 1 -1
impairment,of 0.714285714286 0.000716743119266 1 6 -5
and,lunch 1.0 0.000143348623853 0 1 -1
understood,and 1.0 0.000143348623853 0 1 -1
significant,in 1.0 0.000143348623853 1 0 1
kg,once 1.0 0.000286697247706 0 2 -2
below,are 1.0 0.000286697247706 0 2 -2
is,of 1.0 0.000573394495413 0 4 -4
reduces,urinary 1.0 0.000143348623853 1 0 1
mg,appears 1.0 0.000143348623853 1 0 1
of,metabolism 0.142857142857 0.000143348623853 4 3 1
daily,mg 1.0 0.000143348623853 0 1 -1
compounds,have 1.0 0.00043004587156 0 3 -3
received,either 1.0 0.000143348623853 0 1 -1
intravenous,administration 1.0 0.00043004587156 0 3 -3
a,nasal 1.0 0.000143348623853 0 1 -1
of,valproic 1.0 0.000143348623853 0 1 -1
standard,clinical 1.0 0.000143348623853 0 1 -1
gabapentin,pharmacokinetic 1.0 0.000143348623853 0 1 -1
plasma,tca 1.0 0.000143348623853 1 0 1
and,hepatitis 1.0 0.000143348623853 0 1 -1
doxil,be 1.0 0.000143348623853 0 1 -1
and,general 1.0 0.000143348623853 1 0 1
pharmacology,drug 1.0 0.000143348623853 1 0 1
an,interval 0.666666666667 0.000573394495413 1 5 -4
saw,palmetto 1.0 0.000143348623853 0 1 -1
damage,as 0.0 0.0 1 1 0
sensitive,to 1.0 0.000716743119266 0 5 -5
a,total 1.0 0.000286697247706 0 2 -2
deleterious,effects 1.0 0.000143348623853 0 1 -1
usp,is 1.0 0.000143348623853 1 0 1
if,stadol 1.0 0.000143348623853 1 0 1
intermediate,doses 0.0 0.0 1 1 0
nutrition,or 1.0 0.000143348623853 0 1 -1
sodium,valproic 1.0 0.000143348623853 1 0 1
homocysteine,following 1.0 0.000143348623853 0 1 -1
net,change 0.5 0.000286697247706 3 1 2
is,receiving 0.5 0.000286697247706 3 1 2
guardians,of 1.0 0.000143348623853 0 1 -1
man,and 1.0 0.000286697247706 0 2 -2
probenecid,pretreatment 1.0 0.000143348623853 1 0 1
increases,substantially 1.0 0.000143348623853 1 0 1
were,submitted 1.0 0.000286697247706 0 2 -2
or,cerebroactive 1.0 0.000143348623853 0 1 -1
mellitus,is 1.0 0.000143348623853 0 1 -1
equetrotm,to 1.0 0.000143348623853 0 1 -1
symptomatic,pharmaceutical 1.0 0.000143348623853 0 1 -1
depressants,including 1.0 0.000860091743119 6 0 6
additive,vasodilator 1.0 0.000143348623853 0 1 -1
cationic,secretion 1.0 0.000143348623853 0 1 -1
other,pressor 1.0 0.000143348623853 0 1 -1
of,sublingual 1.0 0.000143348623853 1 0 1
another,known 1.0 0.000573394495413 0 4 -4
apparently,through 1.0 0.000143348623853 1 0 1
nateglinide,is 1.0 0.000143348623853 0 1 -1
the,glucose 1.0 0.00043004587156 0 3 -3
other,antihypertensive 1.0 0.000143348623853 0 1 -1
take,this 1.0 0.000286697247706 0 2 -2
displacing,the 1.0 0.000143348623853 1 0 1
pathways,and 1.0 0.000143348623853 0 1 -1
suggest,no 1.0 0.000143348623853 0 1 -1
after,exposure 1.0 0.000286697247706 0 2 -2
enflurane,than 1.0 0.000143348623853 0 1 -1
and,pharmacotherapy 1.0 0.000143348623853 0 1 -1
impairment,the 1.0 0.000143348623853 1 0 1
patients,does 1.0 0.000143348623853 0 1 -1
a,slower 1.0 0.00043004587156 3 0 3
taking,with 1.0 0.00043004587156 3 0 3
other,cns-depressant 1.0 0.000143348623853 1 0 1
primary,and 0.0 0.0 1 1 0
same,pharmacological 1.0 0.000143348623853 0 1 -1
tacrolimus,felodipine 1.0 0.000143348623853 0 1 -1
a-v,node 1.0 0.000143348623853 1 0 1
or,medications 1.0 0.000143348623853 1 0 1
or,clotting 1.0 0.000143348623853 0 1 -1
either,simultaneously 1.0 0.000143348623853 1 0 1
enzymes,involved 1.0 0.000143348623853 0 1 -1
overdosage,cns 1.0 0.000286697247706 2 0 2
defects,occur 1.0 0.000143348623853 0 1 -1
after,m-tco 1.0 0.000143348623853 1 0 1
is,begun 1.0 0.000143348623853 0 1 -1
of,drug-metabolizing 1.0 0.000143348623853 0 1 -1
conjugated,dienes 1.0 0.000143348623853 0 1 -1
time,kill 1.0 0.000143348623853 1 0 1
xanthine,and 1.0 0.000286697247706 2 0 2
twofold,greater 1.0 0.000143348623853 0 1 -1
celebrex,should 1.0 0.000143348623853 1 0 1
even,though 1.0 0.000573394495413 0 4 -4
species,was 1.0 0.000143348623853 0 1 -1
responded,to 1.0 0.000143348623853 0 1 -1
volunteers,significantly 1.0 0.000143348623853 1 0 1
american,coffee 1.0 0.000143348623853 0 1 -1
tca5,with 1.0 0.000143348623853 0 1 -1
and,triazole 1.0 0.000143348623853 0 1 -1
prevent,symptoms 1.0 0.000143348623853 1 0 1
not,require 1.0 0.000573394495413 0 4 -4
may,occur 0.0 0.0 17 17 0
in,aortic 1.0 0.000143348623853 0 1 -1
other,complications 0.333333333333 0.000143348623853 2 1 1
and,especially 1.0 0.00043004587156 3 0 3
minimal,essential 1.0 0.000143348623853 0 1 -1
microsomal,monooxygenase 1.0 0.000143348623853 0 1 -1
inhibited,phosphorylation 1.0 0.000286697247706 2 0 2
once-monthly,with 1.0 0.000143348623853 0 1 -1
use,is 0.333333333333 0.000143348623853 1 2 -1
several,medicinal 1.0 0.000143348623853 1 0 1
tests,may 1.0 0.000286697247706 0 2 -2
of,tmp 1.0 0.000286697247706 0 2 -2
folate,utilization 1.0 0.000143348623853 1 0 1
creatinine,clearance 0.5 0.000286697247706 3 1 2
severe,cardiovascular 1.0 0.000143348623853 1 0 1
medicines,although 1.0 0.000143348623853 0 1 -1
of,tml 1.0 0.000143348623853 0 1 -1
when,bleeding 1.0 0.000143348623853 0 1 -1
treatment,occurred 1.0 0.000143348623853 0 1 -1
this,isozyme 0.5 0.000573394495413 2 6 -4
ischemia,of 1.0 0.000286697247706 0 2 -2
failure,of 1.0 0.000143348623853 0 1 -1
dependent,upon 1.0 0.000286697247706 0 2 -2
a,are 1.0 0.000286697247706 0 2 -2
potential,interactions 0.777777777778 0.00100344036697 1 8 -7
interactions,serum 1.0 0.000143348623853 0 1 -1
the,cyp 1.0 0.00043004587156 0 3 -3
thus,may 0.2 0.000143348623853 2 3 -1
functional,classes 1.0 0.000286697247706 0 2 -2
adverse,cardiovascular 1.0 0.000143348623853 0 1 -1
and,sustain 1.0 0.000143348623853 0 1 -1
minor,metabolizing 1.0 0.000143348623853 0 1 -1
including,central 1.0 0.000143348623853 0 1 -1
mptp,administration 1.0 0.000143348623853 0 1 -1
combination,of 0.0 0.0 10 10 0
pectoris,additional 1.0 0.000143348623853 1 0 1
trivalent,cations 0.0 0.0 2 2 0
in,humans 0.529411764706 0.00129013761468 4 13 -9
in,prolongation 1.0 0.000716743119266 5 0 5
groups,treated 1.0 0.000143348623853 1 0 1
ki,values 1.0 0.000143348623853 0 1 -1
the,bound 1.0 0.000143348623853 0 1 -1
compounds,such 1.0 0.000143348623853 1 0 1
important,effects 1.0 0.00043004587156 0 3 -3
effects,may 0.272727272727 0.000860091743119 8 14 -6
and,alone 1.0 0.000143348623853 0 1 -1
the,stadol 1.0 0.000143348623853 1 0 1
cause,prolonged 1.0 0.00043004587156 0 3 -3
the,nonfailing 1.0 0.000143348623853 0 1 -1
buffer,should 1.0 0.000143348623853 1 0 1
cisapride,should 1.0 0.000143348623853 1 0 1
to,mechanisms 1.0 0.000143348623853 1 0 1
various,containing 1.0 0.000143348623853 1 0 1
individual,patient 1.0 0.000143348623853 0 1 -1
for,day 1.0 0.000143348623853 0 1 -1
given,at 0.333333333333 0.000143348623853 1 2 -1
especially,so 1.0 0.000143348623853 0 1 -1
to,overlap 1.0 0.000143348623853 0 1 -1
products,and 1.0 0.00043004587156 3 0 3
prinivil,with 1.0 0.000143348623853 1 0 1
pills,sleeping 1.0 0.000143348623853 0 1 -1
additional,therapy 1.0 0.000143348623853 0 1 -1
equivalent,in 1.0 0.000143348623853 0 1 -1
patient,for 1.0 0.000286697247706 0 2 -2
topical,dose 1.0 0.000143348623853 0 1 -1
of,corticosteroid-binding 1.0 0.000143348623853 0 1 -1
ssris,and 0.0909090909091 0.000143348623853 5 6 -1
because,unexpected 1.0 0.000143348623853 0 1 -1
replacement,indicates 1.0 0.000143348623853 0 1 -1
of,some 0.111111111111 0.000143348623853 4 5 -1
in,glomerular 1.0 0.000143348623853 0 1 -1
unless,necessary 1.0 0.000143348623853 0 1 -1
patients,predisposing 1.0 0.000143348623853 1 0 1
beta-receptor,blockers 1.0 0.000286697247706 0 2 -2
of,rhabdomyolysis 1.0 0.000573394495413 0 4 -4
in,kidney 1.0 0.000143348623853 0 1 -1
discontinuation,ordinarily 1.0 0.000143348623853 0 1 -1
relative,risk 1.0 0.000286697247706 0 2 -2
pulse,and 0.333333333333 0.000143348623853 1 2 -1
pseudomonas,aeruginosa 1.0 0.00043004587156 0 3 -3
patient,with 0.0 0.0 2 2 0
lansoprazole,is 1.0 0.000143348623853 0 1 -1
fertility,pegasys 1.0 0.000143348623853 0 1 -1
with,increasing 0.333333333333 0.000143348623853 1 2 -1
exposure,were 1.0 0.000286697247706 0 2 -2
ketoconazole,tablets 1.0 0.000286697247706 2 0 2
reduced,requirements 1.0 0.000143348623853 0 1 -1
eg,channel 1.0 0.000143348623853 1 0 1
disorders,plasmacytic 1.0 0.000143348623853 0 1 -1
any,added 1.0 0.000143348623853 0 1 -1
increased,central 1.0 0.000143348623853 1 0 1
rhabdomyolysis,appear 1.0 0.000143348623853 1 0 1
clinitest,benedict 1.0 0.000286697247706 0 2 -2
citrate,may 1.0 0.000143348623853 1 0 1
iatrogenic,alterations 1.0 0.000143348623853 1 0 1
beta-adrenergic,antagonists 1.0 0.000286697247706 2 0 2
maximum,recommended 0.6 0.00043004587156 1 4 -3
interaction,for 1.0 0.000143348623853 1 0 1
glycosides,inducers 1.0 0.000143348623853 0 1 -1
by,different 1.0 0.000143348623853 1 0 1
zebeta,be 1.0 0.000143348623853 1 0 1
certain,thereby 1.0 0.000143348623853 1 0 1
reflected,in 0.0 0.0 1 1 0
dose-limiting,toxicities 1.0 0.000143348623853 0 1 -1
studied,and 0.5 0.000286697247706 1 3 -2
tsh,levels 1.0 0.000143348623853 0 1 -1
general,antianxiety 1.0 0.000143348623853 0 1 -1
enoxacin,may 1.0 0.000143348623853 1 0 1
bextra,mg 1.0 0.000143348623853 0 1 -1
involvement,of 0.333333333333 0.000143348623853 2 1 1
such,concurrent 1.0 0.000143348623853 0 1 -1
week,period 1.0 0.000143348623853 1 0 1
wort,theo-dur 1.0 0.000143348623853 1 0 1
intervals,or 0.0 0.0 1 1 0
undergoing,concurrent 1.0 0.000143348623853 1 0 1
of,vital 1.0 0.000143348623853 1 0 1
serosal,surfaces 1.0 0.000143348623853 0 1 -1
that,coadministration 0.333333333333 0.000286697247706 4 2 2
and,involve 1.0 0.000143348623853 0 1 -1
serotype,o11 1.0 0.000573394495413 0 4 -4
other,antipsychotic 1.0 0.000143348623853 1 0 1
to,reach 1.0 0.000286697247706 0 2 -2
a,sudden 0.0 0.0 1 1 0
have,entirely 1.0 0.000143348623853 0 1 -1
parameters,for 1.0 0.000143348623853 0 1 -1
used,by 1.0 0.000143348623853 0 1 -1
not,undergo 1.0 0.000286697247706 0 2 -2
from,neuromuscular 1.0 0.000143348623853 0 1 -1
block,the 1.0 0.00043004587156 3 0 3
stimulus,response 1.0 0.000143348623853 0 1 -1
transmission,curare-like 1.0 0.000286697247706 2 0 2
administered,alone 0.0 0.0 3 3 0
younger,patients 1.0 0.000286697247706 0 2 -2
of,ect 1.0 0.000143348623853 0 1 -1
resistance,to 0.333333333333 0.000286697247706 2 4 -2
certain,inhibit 1.0 0.000716743119266 0 5 -5
direct,causal 1.0 0.000143348623853 1 0 1
rate,constant 1.0 0.000286697247706 0 2 -2
known,side 1.0 0.000143348623853 1 0 1
insertion,of 1.0 0.000143348623853 0 1 -1
coadministration,may 1.0 0.000143348623853 0 1 -1
use,to 1.0 0.000143348623853 0 1 -1
continued,need 1.0 0.000143348623853 0 1 -1
aminoglutethimide,diminishes 1.0 0.000143348623853 1 0 1
like,due 1.0 0.000143348623853 1 0 1
main,meal 1.0 0.000143348623853 0 1 -1
for,abilify 1.0 0.000143348623853 0 1 -1
both,possibly 1.0 0.000143348623853 0 1 -1
substrate,trough 1.0 0.000143348623853 1 0 1
kerlone,and 1.0 0.000143348623853 0 1 -1
of,bromocriptine 1.0 0.000143348623853 1 0 1
reactions,include 1.0 0.000143348623853 0 1 -1
cognitive,function 1.0 0.000143348623853 0 1 -1
coagulant,activity 1.0 0.000286697247706 0 2 -2
to,select 1.0 0.000143348623853 0 1 -1
of,antiaddictive 1.0 0.000143348623853 0 1 -1
as,initial 1.0 0.000143348623853 0 1 -1
of,preparations 0.2 0.000143348623853 3 2 1
in,that 1.0 0.000143348623853 0 1 -1
injections,in 1.0 0.000143348623853 0 1 -1
tested,the 1.0 0.000143348623853 0 1 -1
show,that 0.636363636364 0.00100344036697 2 9 -7
class,of 0.5 0.000860091743119 3 9 -6
containing,alone 1.0 0.000143348623853 1 0 1
this,dose 1.0 0.000143348623853 0 1 -1
close,collaboration 1.0 0.000143348623853 0 1 -1
usp,has 1.0 0.000143348623853 0 1 -1
in,long 1.0 0.000143348623853 1 0 1
where,survival 1.0 0.000143348623853 0 1 -1
intravenous,and 0.333333333333 0.000286697247706 4 2 2
in,horses 1.0 0.000143348623853 0 1 -1
fluoxetine,a 1.0 0.000143348623853 0 1 -1
a4,or 1.0 0.000143348623853 1 0 1
d,analogues 0.333333333333 0.00043004587156 6 3 3
promoted,the 1.0 0.000143348623853 0 1 -1
antagonists,when 1.0 0.000143348623853 1 0 1
the,period 0.428571428571 0.00043004587156 2 5 -3
sudden,death 1.0 0.000143348623853 1 0 1
non-selective,mao 1.0 0.000286697247706 2 0 2
about,three-fold 1.0 0.000143348623853 0 1 -1
man,in 1.0 0.000143348623853 0 1 -1
of,synthetic 1.0 0.000286697247706 2 0 2
open,randomized 1.0 0.000143348623853 0 1 -1
of,overdosage 1.0 0.000286697247706 2 0 2
the,p-glycoprotein 1.0 0.000143348623853 0 1 -1
vasodilator,and 1.0 0.000143348623853 0 1 -1
reduce,lithiums 1.0 0.000143348623853 1 0 1
overdose,recognized 1.0 0.000143348623853 0 1 -1
flexeril,may 1.0 0.000286697247706 2 0 2
however,initial 1.0 0.000143348623853 0 1 -1
the,sixth 1.0 0.000143348623853 1 0 1
promoted,significant 1.0 0.000143348623853 0 1 -1
avoid,iatrogenic 1.0 0.000143348623853 1 0 1
diminish,the 1.0 0.00114678899083 8 0 8
however,other 1.0 0.000143348623853 1 0 1
a,moderate 1.0 0.000860091743119 0 6 -6
increased,thioether 1.0 0.000143348623853 0 1 -1
of,ergomar 1.0 0.000286697247706 2 0 2
concentrations,peak 1.0 0.000143348623853 1 0 1
mean,estimates 1.0 0.000143348623853 0 1 -1
involving,adult 1.0 0.000143348623853 0 1 -1
receptors,thus 1.0 0.000286697247706 2 0 2
of,has 0.333333333333 0.000573394495413 4 8 -4
myopathy,by 1.0 0.000143348623853 0 1 -1
inserted,between 1.0 0.000143348623853 0 1 -1
well,concurent 1.0 0.000143348623853 1 0 1
examples,of 0.777777777778 0.00100344036697 1 8 -7
axert,and 1.0 0.000143348623853 1 0 1
corresponding,increase 1.0 0.000286697247706 2 0 2
insulin,or 0.0 0.0 1 1 0
reuptake,of 1.0 0.000143348623853 0 1 -1
mania,whereas 1.0 0.000143348623853 0 1 -1
or,collagen-stimulated 1.0 0.000143348623853 0 1 -1
therefore,these 1.0 0.000143348623853 0 1 -1
kg,injected 1.0 0.000143348623853 1 0 1
strong,drying 1.0 0.000143348623853 0 1 -1
additive,toxicity 1.0 0.000143348623853 0 1 -1
other,similarly 1.0 0.000143348623853 0 1 -1
hyperlipidemia,or 1.0 0.000143348623853 1 0 1
with,previous 1.0 0.000143348623853 0 1 -1
elevations,in 0.142857142857 0.000143348623853 4 3 1
therefore,agents 1.0 0.000143348623853 0 1 -1
fbs,followed 1.0 0.000143348623853 1 0 1
treatment,did 1.0 0.000286697247706 0 2 -2
isomer,of 1.0 0.000143348623853 1 0 1
extraneals,effects 1.0 0.000143348623853 0 1 -1
colestld,tablets 1.0 0.000143348623853 0 1 -1
of,further 1.0 0.000143348623853 1 0 1
no,trials 1.0 0.000143348623853 0 1 -1
on,one 0.333333333333 0.000143348623853 1 2 -1
no,known 1.0 0.00100344036697 0 7 -7
ascertain,when 1.0 0.000143348623853 0 1 -1
cyp3a4,can 1.0 0.000143348623853 0 1 -1
including,derivatives 1.0 0.000143348623853 1 0 1
subjects,already 1.0 0.000143348623853 1 0 1
with,sustiva 0.666666666667 0.000573394495413 1 5 -4
consume,greater 1.0 0.000143348623853 0 1 -1
the,question 1.0 0.000143348623853 0 1 -1
hcl,cream 1.0 0.000143348623853 0 1 -1
other,and 0.5 0.000860091743119 3 9 -6
same,dose 1.0 0.000286697247706 2 0 2
containing,membranes 1.0 0.000143348623853 0 1 -1
a2,c8 1.0 0.000143348623853 0 1 -1
digestion,and 1.0 0.000143348623853 0 1 -1
a,randomized 0.5 0.000286697247706 1 3 -2
to,approximately 0.142857142857 0.000143348623853 3 4 -1
itching,mouth 1.0 0.000143348623853 0 1 -1
oral,bioavailability 0.333333333333 0.000143348623853 2 1 1
colchicine,may 1.0 0.000143348623853 1 0 1
more,rapid 1.0 0.000143348623853 0 1 -1
typical,side 1.0 0.000143348623853 0 1 -1
thorazine,prolixin 1.0 0.000286697247706 0 2 -2
vertigo,syncope 0.142857142857 0.000143348623853 3 4 -1
prevents,gastrointestinal 1.0 0.000143348623853 1 0 1
be,falsely 1.0 0.000143348623853 0 1 -1
reported,these 1.0 0.000143348623853 0 1 -1
gallate,also 1.0 0.000143348623853 0 1 -1
also,although 1.0 0.000143348623853 0 1 -1
therefore,close 0.333333333333 0.000143348623853 2 1 1
infections,an 1.0 0.000143348623853 1 0 1
and,chapter 1.0 0.000143348623853 0 1 -1
increasing,plasma 1.0 0.000143348623853 1 0 1
bombesin,significantly 1.0 0.000143348623853 0 1 -1
antibiotics,and 0.333333333333 0.000143348623853 2 1 1
therapeutic,concentration 1.0 0.000143348623853 1 0 1
in,hippocampal 1.0 0.000143348623853 0 1 -1
inhalation,device 1.0 0.000143348623853 0 1 -1
products,including 1.0 0.000143348623853 1 0 1
of,active 1.0 0.000286697247706 2 0 2
be,precipitated 1.0 0.000143348623853 0 1 -1
unknown,neither 1.0 0.000143348623853 1 0 1
small,but 1.0 0.000143348623853 1 0 1
hind,paw 1.0 0.000143348623853 0 1 -1
the,differential 1.0 0.000143348623853 0 1 -1
the,atac 1.0 0.000143348623853 1 0 1
endemic,primate 1.0 0.000143348623853 0 1 -1
twice-daily,with 1.0 0.000143348623853 1 0 1
ingesting,these 1.0 0.000143348623853 1 0 1
paresthesia,and 1.0 0.000143348623853 0 1 -1
reduced,as 1.0 0.000143348623853 0 1 -1
with,salts 1.0 0.000143348623853 0 1 -1
in,elderly 0.0 0.0 1 1 0
aluminum-containing,antacid 1.0 0.000143348623853 0 1 -1
inh,isoniazid 1.0 0.000143348623853 1 0 1
breakdown,products 1.0 0.000143348623853 1 0 1
possibly,due 0.5 0.000286697247706 3 1 2
combine,to 1.0 0.000143348623853 1 0 1
affect,hepatic 0.0 0.0 1 1 0
selectively,bred 1.0 0.000143348623853 0 1 -1
and,female 0.0 0.0 1 1 0
of,both 0.0833333333333 0.000286697247706 11 13 -2
animal,source 1.0 0.000143348623853 0 1 -1
intravenously,as 1.0 0.000143348623853 1 0 1
from,alterations 1.0 0.000143348623853 0 1 -1
was,to 1.0 0.00100344036697 0 7 -7
or,enzyme 1.0 0.000143348623853 0 1 -1
brevibloc,should 1.0 0.000286697247706 2 0 2
hiv-infected,subjects 1.0 0.000143348623853 0 1 -1
and,tmax 1.0 0.000143348623853 0 1 -1
flare,were 1.0 0.000143348623853 0 1 -1
another,agent 1.0 0.000143348623853 0 1 -1
human,hour 1.0 0.000143348623853 0 1 -1
the,disulfiram-ethanol 1.0 0.000286697247706 0 2 -2
romazicon,is 1.0 0.000143348623853 0 1 -1
non-specific,cyp-450 1.0 0.000143348623853 0 1 -1
concentration,by 1.0 0.000286697247706 0 2 -2
inhibitors,mg 1.0 0.000143348623853 1 0 1
to,diethylnitrosamine 1.0 0.000143348623853 0 1 -1
videx,was 1.0 0.000143348623853 1 0 1
referred,to 1.0 0.00043004587156 0 3 -3
the,initiation 0.0 0.0 3 3 0
replication,of 1.0 0.000143348623853 1 0 1
of,abnormal 1.0 0.000143348623853 0 1 -1
iodometric,titration 1.0 0.000143348623853 0 1 -1
fulminant,pancreatitis 1.0 0.000143348623853 1 0 1
maintain,twitch 1.0 0.000143348623853 0 1 -1
induction,by 1.0 0.000143348623853 0 1 -1
consider,xanax 1.0 0.000143348623853 1 0 1
was,possible 1.0 0.000143348623853 0 1 -1
hours,is 1.0 0.000143348623853 1 0 1
as,antiemetic 0.0 0.0 1 1 0
certain,weak 1.0 0.000143348623853 1 0 1
other,oral 0.5 0.000286697247706 3 1 2
sem,to 1.0 0.000143348623853 0 1 -1
which,enbrel 1.0 0.000143348623853 1 0 1
if,high 1.0 0.000143348623853 1 0 1
injectable,produces 1.0 0.000143348623853 1 0 1
not,predispose 1.0 0.000143348623853 0 1 -1
systemic,administration 0.0 0.0 1 1 0
tablets,not 1.0 0.000143348623853 1 0 1
interactive,effect 1.0 0.00043004587156 0 3 -3
agents,coadministration 1.0 0.000286697247706 0 2 -2
dosed,subjects 1.0 0.000143348623853 0 1 -1
against,gram-negative 1.0 0.000143348623853 0 1 -1
chemotherapy,concomitantly 1.0 0.000143348623853 0 1 -1
some,potential 1.0 0.000143348623853 1 0 1
two,strains 1.0 0.000143348623853 0 1 -1
state,therefore 1.0 0.000143348623853 0 1 -1
its,cellular 1.0 0.000143348623853 1 0 1
blockers,of 1.0 0.000143348623853 1 0 1
or,marked 0.0 0.0 3 3 0
or,did 0.5 0.000286697247706 1 3 -2
resistance,of 1.0 0.000143348623853 0 1 -1
blockers,on 1.0 0.000286697247706 0 2 -2
and,therapeutic 0.333333333333 0.000143348623853 2 1 1
resistance,or 1.0 0.00043004587156 0 3 -3
blockers,or 1.0 0.000716743119266 5 0 5
biodistribution,may 1.0 0.000143348623853 0 1 -1
association,between 0.0 0.0 1 1 0
as,adverse 1.0 0.000143348623853 0 1 -1
the,vehicle-controlled 1.0 0.000143348623853 0 1 -1
oral,combination 1.0 0.000143348623853 1 0 1
a,premedication 1.0 0.000143348623853 0 1 -1
and,mc 0.5 0.000286697247706 1 3 -2
some,disorders 1.0 0.000143348623853 0 1 -1
cardiac,arrests 1.0 0.000143348623853 0 1 -1
and,mg 0.0 0.0 31 31 0
and,mm 1.0 0.000286697247706 0 2 -2
basis,for 0.333333333333 0.000143348623853 1 2 -1
and,loop 1.0 0.000143348623853 0 1 -1
agents,reduce 1.0 0.000286697247706 2 0 2
known,relationships 1.0 0.000143348623853 0 1 -1
and,mu 1.0 0.000143348623853 0 1 -1
color,reverses 1.0 0.000143348623853 0 1 -1
receiving,revia 1.0 0.000143348623853 1 0 1
clinically,effective 0.333333333333 0.000143348623853 2 1 1
miracidia,was 1.0 0.000143348623853 0 1 -1
release,by 1.0 0.000286697247706 0 2 -2
cautious,titration 1.0 0.000143348623853 1 0 1
m2,pegasys 1.0 0.000143348623853 0 1 -1
be,avoided 0.0 0.0 13 13 0
unusual,and 1.0 0.000143348623853 0 1 -1
prescribed,daily 1.0 0.000143348623853 0 1 -1
microsomal,enzymes 0.333333333333 0.000143348623853 1 2 -1
amevive,before 1.0 0.000143348623853 0 1 -1
of,novolog 1.0 0.000286697247706 0 2 -2
reassess,the 1.0 0.000143348623853 0 1 -1
response,seen 1.0 0.000143348623853 1 0 1
nuromax,before 1.0 0.000143348623853 0 1 -1
the,duloxetine 1.0 0.000143348623853 0 1 -1
these,usually 1.0 0.000143348623853 0 1 -1
with,enteric 1.0 0.000143348623853 1 0 1
the,insulin-sensitizing 1.0 0.000143348623853 0 1 -1
interval,for 1.0 0.000286697247706 0 2 -2
captopril,s 1.0 0.000143348623853 1 0 1
pointe,particularly 1.0 0.000143348623853 0 1 -1
have,varied 1.0 0.000143348623853 0 1 -1
of,cefotan 1.0 0.000143348623853 0 1 -1
addition,other 1.0 0.000143348623853 1 0 1
results,showed 1.0 0.000143348623853 0 1 -1
of,deep-seated 1.0 0.000143348623853 0 1 -1
potentiation,the 1.0 0.000143348623853 0 1 -1
emerge,with 1.0 0.000143348623853 1 0 1
effects,caution 1.0 0.000286697247706 0 2 -2
antiepileptic,effect 1.0 0.000143348623853 1 0 1
serum,slightly 1.0 0.000143348623853 1 0 1
a,catecholamine 1.0 0.00043004587156 0 3 -3
cause,decreased 1.0 0.000143348623853 1 0 1
of,aeds 1.0 0.000143348623853 1 0 1
the,surface 1.0 0.000143348623853 1 0 1
further,doses 1.0 0.000143348623853 0 1 -1
the,risks 0.0 0.0 3 3 0
change,in 0.411764705882 0.00100344036697 5 12 -7
water,for 1.0 0.000143348623853 0 1 -1
erpf,and 1.0 0.000143348623853 1 0 1
began,within 1.0 0.000286697247706 0 2 -2
helpful,when 1.0 0.000143348623853 0 1 -1
system,fentanyl 1.0 0.000143348623853 0 1 -1
with,muscle 1.0 0.000143348623853 0 1 -1
and,corticotropin 1.0 0.000143348623853 1 0 1
arimidex,and 1.0 0.000143348623853 0 1 -1
ten,patients 1.0 0.000143348623853 0 1 -1
to,decrease 0.217391304348 0.000716743119266 14 9 5
response,has 1.0 0.000860091743119 0 6 -6
and,triglyceride 1.0 0.000143348623853 0 1 -1
observed,hours 1.0 0.000143348623853 0 1 -1
of,migraine 1.0 0.000143348623853 0 1 -1
against,hepatic 1.0 0.000143348623853 0 1 -1
dilation,associated 1.0 0.000143348623853 1 0 1
provides,considerable 1.0 0.000143348623853 0 1 -1
decreased,significantly 1.0 0.000143348623853 0 1 -1
three,concentrations 1.0 0.000286697247706 0 2 -2
impacted,by 1.0 0.000143348623853 0 1 -1
recording,technique 1.0 0.000143348623853 0 1 -1
derive,from 1.0 0.000143348623853 1 0 1
carefully,and 0.0 0.0 1 1 0
steroidal,antiinflammatory 1.0 0.000143348623853 1 0 1
not,mc 1.0 0.000143348623853 0 1 -1
utilization,of 1.0 0.000143348623853 0 1 -1
pharmacodynamic,interaction 0.666666666667 0.000573394495413 1 5 -4
interaction,began 1.0 0.000143348623853 0 1 -1
accutane,use 0.0 0.0 1 1 0
post-transplant,year 1.0 0.000143348623853 0 1 -1
d2,binding 1.0 0.000143348623853 0 1 -1
detected,although 1.0 0.000143348623853 0 1 -1
risk,that 1.0 0.000143348623853 1 0 1
if,prosom 1.0 0.000143348623853 0 1 -1
be,withdrawn 1.0 0.00043004587156 3 0 3
that,prolongs 1.0 0.000143348623853 1 0 1
appear,in 1.0 0.000143348623853 0 1 -1
risk,than 1.0 0.000143348623853 0 1 -1
mac,or 1.0 0.000143348623853 0 1 -1
and,complications 1.0 0.000143348623853 1 0 1
this,indicates 1.0 0.000286697247706 0 2 -2
perhexiline,hydrogen 1.0 0.000143348623853 1 0 1
transdermal,and 1.0 0.000286697247706 2 0 2
or,carbidopa-levodopa 1.0 0.000286697247706 0 2 -2
other,chelator 1.0 0.000143348623853 0 1 -1
prudent,evaluation 1.0 0.000143348623853 0 1 -1
bone,and 1.0 0.000143348623853 1 0 1
methylglutaryl,coenzyme 1.0 0.000143348623853 0 1 -1
contrast,reactions 1.0 0.000143348623853 0 1 -1
controls,was 1.0 0.000143348623853 0 1 -1
nimbex,at 1.0 0.000143348623853 1 0 1
medrol,others 1.0 0.000143348623853 0 1 -1
after,initiating 0.333333333333 0.000143348623853 2 1 1
resedation,at 1.0 0.000143348623853 0 1 -1
p-450,inducers 1.0 0.000143348623853 1 0 1
the,apoptosis 1.0 0.000143348623853 0 1 -1
additive,hypotensive 1.0 0.000143348623853 1 0 1
ganciclovir,administration 1.0 0.000143348623853 1 0 1
second,pregnancy 1.0 0.000143348623853 0 1 -1
half-lives,to 1.0 0.000143348623853 0 1 -1
month,prior 1.0 0.000143348623853 0 1 -1
wthionamide,trecator-sc 1.0 0.000143348623853 0 1 -1
of,nnrtis 1.0 0.000143348623853 0 1 -1
indinavir,may 1.0 0.000143348623853 1 0 1
conversion,of 0.6 0.00043004587156 1 4 -3
its,closely 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,has 1.0 0.000286697247706 2 0 2
slightly,shorter 1.0 0.000143348623853 1 0 1
the,contents 1.0 0.000286697247706 0 2 -2
starting,and 1.0 0.000143348623853 1 0 1
treatment,regimen 0.0 0.0 1 1 0
with,plus 0.0 0.0 1 1 0
modified,given 1.0 0.000143348623853 0 1 -1
auc,but 1.0 0.000143348623853 1 0 1
particularly,those 1.0 0.000286697247706 0 2 -2
experience,there 0.0 0.0 2 2 0
that,oral 0.25 0.000286697247706 5 3 2
with,mixed 1.0 0.000143348623853 1 0 1
cognitive,and 1.0 0.000143348623853 1 0 1
reduce,and 1.0 0.000143348623853 0 1 -1
aczone,gel 1.0 0.000143348623853 0 1 -1
therapeutic,response 1.0 0.000143348623853 0 1 -1
about,fold 0.0 0.0 2 2 0
to,established 1.0 0.000143348623853 0 1 -1
pregnancy,when 1.0 0.000143348623853 0 1 -1
were,dose 1.0 0.000143348623853 0 1 -1
including,vitamin 1.0 0.000143348623853 1 0 1
acetate,similarly 1.0 0.000143348623853 1 0 1
that,there 0.555555555556 0.000716743119266 2 7 -5
with,long-term 0.0 0.0 1 1 0
h,also 1.0 0.000143348623853 0 1 -1
embryos,was 1.0 0.000143348623853 0 1 -1
of,importance 1.0 0.000143348623853 0 1 -1
increases,hydralazines 1.0 0.000143348623853 1 0 1
binding-globulinemias,have 1.0 0.000143348623853 0 1 -1
half-life,multiple-dose 1.0 0.000143348623853 0 1 -1
termed,serotonin 1.0 0.000143348623853 1 0 1
g,of 1.0 0.000143348623853 1 0 1
autoinduction,has 1.0 0.000143348623853 0 1 -1
as,deltasone 1.0 0.000143348623853 0 1 -1
death,potentially 1.0 0.000143348623853 1 0 1
comparable,to 0.142857142857 0.000143348623853 3 4 -1
may,suppress 1.0 0.000286697247706 0 2 -2
estradiol,substrate 1.0 0.000143348623853 0 1 -1
intraluminally,was 1.0 0.000143348623853 0 1 -1
additional,effect 1.0 0.000286697247706 2 0 2
igg,or 1.0 0.000143348623853 0 1 -1
does,it 1.0 0.000286697247706 0 2 -2
indicated,that 0.8 0.00114678899083 1 9 -8
hearing,have 1.0 0.000143348623853 1 0 1
also,across 1.0 0.000143348623853 0 1 -1
produce,additive 0.333333333333 0.000143348623853 2 1 1
a,dose 0.290322580645 0.00129013761468 20 11 9
metabolized,nor 1.0 0.000143348623853 0 1 -1
excessive,perspiration 1.0 0.000143348623853 0 1 -1
therapy,can 1.0 0.000286697247706 0 2 -2
vivo,animal 1.0 0.000143348623853 1 0 1
receiving,purinethol 1.0 0.000143348623853 1 0 1
before,conducting 1.0 0.000143348623853 1 0 1
serial,use 1.0 0.000286697247706 0 2 -2
which,ssri-tca 1.0 0.000573394495413 4 0 4
logs,of 1.0 0.000143348623853 0 1 -1
during,clinical 1.0 0.000573394495413 0 4 -4
to,function 1.0 0.000286697247706 0 2 -2
cyclosporine-induced,toxicity 1.0 0.000286697247706 2 0 2
reduced,protein 1.0 0.000143348623853 1 0 1
might,occur 1.0 0.000143348623853 0 1 -1
the,undesirable 1.0 0.000143348623853 1 0 1
sensitization,to 1.0 0.000143348623853 0 1 -1
a,toxic 1.0 0.000143348623853 1 0 1
induce,toxicity 1.0 0.000143348623853 0 1 -1
reductions,in 0.555555555556 0.000716743119266 2 7 -5
not,display 1.0 0.000143348623853 0 1 -1
nih-3t3,or 1.0 0.000143348623853 0 1 -1
and,crixivan 1.0 0.000143348623853 1 0 1
vehicle-controlled,studies 1.0 0.000143348623853 0 1 -1
diarrhea,was 1.0 0.000143348623853 0 1 -1
between,intake 1.0 0.000286697247706 0 2 -2
those,changes 1.0 0.000143348623853 0 1 -1
by,simply 1.0 0.000143348623853 0 1 -1
causal,mechanism 1.0 0.000143348623853 1 0 1
acarbose,did 1.0 0.000143348623853 0 1 -1
of,autoimmune 1.0 0.000143348623853 1 0 1
involving,concomitant 1.0 0.000143348623853 0 1 -1
aspirin,in 1.0 0.000143348623853 1 0 1
mao,inhibitor 0.428571428571 0.00043004587156 5 2 3
for,metabolism 1.0 0.000143348623853 0 1 -1
aspirin,is 1.0 0.000143348623853 1 0 1
enzymes,was 1.0 0.000143348623853 1 0 1
and,heavy 1.0 0.000143348623853 1 0 1
renal,clearances 1.0 0.000143348623853 1 0 1
mean,drug 1.0 0.000143348623853 0 1 -1
included,with 1.0 0.000143348623853 0 1 -1
exogenous,enhancement 1.0 0.000143348623853 0 1 -1
acquisition,of 1.0 0.000286697247706 0 2 -2
aldosterone,excretion 1.0 0.000143348623853 0 1 -1
subjects,should 1.0 0.000573394495413 4 0 4
or,corrected 1.0 0.000143348623853 0 1 -1
is,unaffected 1.0 0.000286697247706 0 2 -2
angiomax,with 1.0 0.000143348623853 1 0 1
the,impairment 1.0 0.000143348623853 0 1 -1
be,prescribed 1.0 0.000143348623853 1 0 1
n,compared 1.0 0.00043004587156 3 0 3
induced,diarrhea 0.333333333333 0.000143348623853 1 2 -1
effect,for 0.0 0.0 1 1 0
level,of 0.473684210526 0.00129013761468 5 14 -9
with,transient 1.0 0.000286697247706 2 0 2
be,notified 1.0 0.000143348623853 0 1 -1
males,and 1.0 0.000143348623853 1 0 1
with,cyp2d6 1.0 0.000143348623853 1 0 1
hcl,ascorbic 1.0 0.000143348623853 1 0 1
affinity,chromatography 1.0 0.000143348623853 0 1 -1
of,alkalinization 1.0 0.000143348623853 0 1 -1
adenocarcinomas,which 1.0 0.000143348623853 1 0 1
years,total 1.0 0.000143348623853 0 1 -1
cardiac,arrhythmias 0.333333333333 0.000143348623853 1 2 -1
the,chosen 1.0 0.000143348623853 0 1 -1
amphotericin,b-induced 1.0 0.000286697247706 2 0 2
clonidine,concomitant 1.0 0.000143348623853 1 0 1
digoxin,when 0.333333333333 0.000143348623853 1 2 -1
hypotension,could 1.0 0.000143348623853 0 1 -1
of,elixir 1.0 0.000143348623853 0 1 -1
effects,have 0.5 0.000860091743119 3 9 -6
that,be 0.0 0.0 1 1 0
highly,bound 0.818181818182 0.00129013761468 1 10 -9
agents,concomitant 1.0 0.000143348623853 1 0 1
patients,developed 1.0 0.000143348623853 0 1 -1
block,induced 1.0 0.000286697247706 2 0 2
function,may 1.0 0.000286697247706 0 2 -2
antiinflammatory,agent 1.0 0.000143348623853 1 0 1
effect,after 1.0 0.000143348623853 0 1 -1
using,red 1.0 0.000143348623853 0 1 -1
to,date 1.0 0.000860091743119 0 6 -6
of,people 1.0 0.000143348623853 1 0 1
maintain,trough 1.0 0.000143348623853 1 0 1
treatment,the 1.0 0.000143348623853 0 1 -1
excretion,was 1.0 0.00043004587156 0 3 -3
adenocard,has 1.0 0.000143348623853 0 1 -1
except,leukemia 1.0 0.000143348623853 1 0 1
a,spinal 1.0 0.000143348623853 0 1 -1
nmda,and 1.0 0.000143348623853 0 1 -1
recalcitrant,nodular 1.0 0.000143348623853 0 1 -1
including,robust 1.0 0.000143348623853 0 1 -1
sodium,perchlorate 1.0 0.000143348623853 0 1 -1
since,some 1.0 0.000286697247706 0 2 -2
growth,in 1.0 0.000143348623853 1 0 1
or,cyp3a4 1.0 0.000143348623853 0 1 -1
immediately,following 1.0 0.000286697247706 2 0 2
characteristic,of 1.0 0.000143348623853 0 1 -1
of,immunoreactive 1.0 0.000143348623853 0 1 -1
combined,moieties 1.0 0.000143348623853 0 1 -1
additive,potentiation 1.0 0.000143348623853 0 1 -1
bioavailability,or 1.0 0.000143348623853 0 1 -1
more,highly 1.0 0.000143348623853 0 1 -1
medium,blocked 1.0 0.000143348623853 0 1 -1
ms,contin 1.0 0.000143348623853 1 0 1
resveratrol,has 1.0 0.000143348623853 0 1 -1
interaction,between 0.230769230769 0.00172018348624 20 32 -12
solution,the 0.0 0.0 1 1 0
comparison,with 0.0 0.0 1 1 0
of,blood 0.111111111111 0.000286697247706 8 10 -2
using,human 1.0 0.000143348623853 0 1 -1
with,cyp2c19 1.0 0.000143348623853 0 1 -1
when,plasma 1.0 0.000286697247706 2 0 2
antithrombotic,agent 1.0 0.000143348623853 1 0 1
a,type 0.333333333333 0.000143348623853 1 2 -1
for,include 1.0 0.000143348623853 1 0 1
dosing,and 1.0 0.00043004587156 0 3 -3
coagulation,alterations 1.0 0.000143348623853 0 1 -1
either,due 1.0 0.000143348623853 0 1 -1
fo,these 1.0 0.000143348623853 0 1 -1
cyp2d6,the 1.0 0.000143348623853 0 1 -1
an,and 1.0 0.00043004587156 3 0 3
age,sex 1.0 0.000143348623853 0 1 -1
specific,molecular 1.0 0.000143348623853 0 1 -1
were,receiving 1.0 0.000286697247706 0 2 -2
anticoagulants,ten 1.0 0.000143348623853 0 1 -1
mg,elemental 1.0 0.000143348623853 0 1 -1
or,nitrous 1.0 0.000143348623853 0 1 -1
mylotarg,is 1.0 0.000143348623853 0 1 -1
agent,administered 1.0 0.000286697247706 0 2 -2
was,analyzed 1.0 0.000286697247706 0 2 -2
may,antagonize 1.0 0.00143348623853 10 0 10
the,metabolizing 1.0 0.000573394495413 0 4 -4
probenecid,is 0.0 0.0 1 1 0
with,more 0.0 0.0 1 1 0
isoflurane,potentiates 1.0 0.000143348623853 1 0 1
changes,that 0.0 0.0 1 1 0
older,who 1.0 0.000143348623853 0 1 -1
mg,both 1.0 0.000143348623853 0 1 -1
of,channel 1.0 0.000143348623853 0 1 -1
randomly,bred 1.0 0.000143348623853 0 1 -1
and,test 1.0 0.000143348623853 0 1 -1
compounds,taken 1.0 0.000143348623853 1 0 1
itraconazole,macrolides 1.0 0.000143348623853 0 1 -1
anemia,grade 1.0 0.000143348623853 0 1 -1
phenytoin,tiagabine 1.0 0.000143348623853 0 1 -1
and,frequent 1.0 0.00043004587156 0 3 -3
status,and 1.0 0.000286697247706 0 2 -2
had,achieved 1.0 0.000143348623853 0 1 -1
levulan,kerastick 0.0 0.0 1 1 0
evaluate,potential 1.0 0.000143348623853 0 1 -1
because,may 1.0 0.000573394495413 4 0 4
loss,were 1.0 0.000143348623853 0 1 -1
would,seem 1.0 0.000143348623853 1 0 1
is,expected 0.2 0.000143348623853 2 3 -1
salts,and 1.0 0.000286697247706 2 0 2
monitoring,is 0.0 0.0 1 1 0
decrease,conduction 1.0 0.000143348623853 1 0 1
monitoring,if 1.0 0.000143348623853 0 1 -1
ache,activity 1.0 0.000143348623853 1 0 1
consequences,for 1.0 0.000143348623853 1 0 1
therapy,urinary 1.0 0.000286697247706 2 0 2
include,regular 1.0 0.000143348623853 0 1 -1
and,potassium-depleting 1.0 0.000143348623853 1 0 1
coordination,disorder 1.0 0.000143348623853 0 1 -1
inflammatory,arthritis 1.0 0.000143348623853 1 0 1
reciprocal,interactions 1.0 0.000143348623853 1 0 1
race,intercurrent 1.0 0.000143348623853 0 1 -1
lithium,nsaids 1.0 0.00043004587156 3 0 3
steroidal,anti- 1.0 0.000143348623853 1 0 1
auc,ss 1.0 0.000286697247706 2 0 2
normal,rates 1.0 0.000143348623853 0 1 -1
which,also 0.333333333333 0.000143348623853 1 2 -1
smaller,alfenta 1.0 0.000143348623853 0 1 -1
be,reduced 0.0625 0.000286697247706 15 17 -2
before,or 0.125 0.000286697247706 7 9 -2
analogue,scales 1.0 0.000143348623853 0 1 -1
an,interacting 1.0 0.000143348623853 0 1 -1
infarction,or 1.0 0.000143348623853 0 1 -1
with,be 1.0 0.000143348623853 0 1 -1
on,performance 1.0 0.000143348623853 0 1 -1
with,by 1.0 0.000143348623853 0 1 -1
primarily,to 1.0 0.000143348623853 1 0 1
of,assistance 1.0 0.000143348623853 0 1 -1
severe,short 1.0 0.000143348623853 1 0 1
multiple,occupational 1.0 0.000143348623853 0 1 -1
realization,of 1.0 0.000143348623853 0 1 -1
affecting,hepatic 1.0 0.000143348623853 0 1 -1
reactive,species 1.0 0.000143348623853 0 1 -1
will,become 1.0 0.000143348623853 0 1 -1
of,antithrombotics 1.0 0.000143348623853 0 1 -1
symptoms,appear 1.0 0.000143348623853 0 1 -1
were,added 0.333333333333 0.000143348623853 1 2 -1
of,rash 1.0 0.000143348623853 0 1 -1
utilizing,a 1.0 0.000143348623853 0 1 -1
ephesus,patients 1.0 0.000143348623853 0 1 -1
hydrobromide,may 1.0 0.000143348623853 1 0 1
magnitude,lower 1.0 0.000143348623853 0 1 -1
the,rat 0.333333333333 0.000143348623853 1 2 -1
peganone,to 1.0 0.000143348623853 1 0 1
patients,lacking 1.0 0.000143348623853 0 1 -1
are,more 1.0 0.000286697247706 0 2 -2
other,interactions 1.0 0.000573394495413 0 4 -4
reviewed,in 1.0 0.000143348623853 1 0 1
paresthesia,muscle 1.0 0.000143348623853 0 1 -1
for,assessing 1.0 0.000143348623853 0 1 -1
ethacrynic,acid 0.6 0.00043004587156 4 1 3
avoid,giving 1.0 0.000143348623853 1 0 1
decreased,in 0.428571428571 0.00043004587156 2 5 -3
orencia,has 1.0 0.000143348623853 1 0 1
with,concurrently 1.0 0.000143348623853 1 0 1
several,days 0.428571428571 0.00043004587156 5 2 3
cell-independent,activator 1.0 0.000143348623853 0 1 -1
demonstrated,any 1.0 0.000286697247706 0 2 -2
the,nonlinear 1.0 0.000143348623853 0 1 -1
mean,value 1.0 0.000143348623853 0 1 -1
reversible,acute 1.0 0.000143348623853 1 0 1
low,as 1.0 0.00043004587156 0 3 -3
the,analgesic 1.0 0.000286697247706 2 0 2
taxol,at 1.0 0.000286697247706 0 2 -2
n2,and 1.0 0.000143348623853 0 1 -1
bisphosphonates,are 1.0 0.000143348623853 0 1 -1
significant,when 1.0 0.000143348623853 0 1 -1
of,hyperlipidemia 1.0 0.000143348623853 1 0 1
and,behavioral 0.6 0.00043004587156 1 4 -3
placed,in 1.0 0.000143348623853 0 1 -1
dosage,on 0.0 0.0 2 2 0
similar,effects 1.0 0.000860091743119 0 6 -6
possible,deleterious 1.0 0.000143348623853 0 1 -1
subsequent,courses 1.0 0.000143348623853 0 1 -1
an,week 1.0 0.000286697247706 0 2 -2
by,reducing 0.0 0.0 1 1 0
so,as 1.0 0.000286697247706 0 2 -2
pronestyl,sulfa 1.0 0.000143348623853 1 0 1
myopathy,underlying 1.0 0.000143348623853 0 1 -1
cleavable,complex 1.0 0.000143348623853 0 1 -1
im,has 1.0 0.000143348623853 0 1 -1
acid,calcium 1.0 0.000143348623853 0 1 -1
monitor,the 1.0 0.00043004587156 0 3 -3
increase,toxicity 0.0 0.0 1 1 0
induce,cytochrome 0.6 0.00043004587156 1 4 -3
injection,who 1.0 0.000143348623853 0 1 -1
infinity,auc 1.0 0.000143348623853 0 1 -1
pronounced,intersubject 1.0 0.000143348623853 1 0 1
reports,indicates 1.0 0.000143348623853 0 1 -1
capsule,formulation 0.5 0.000286697247706 3 1 2
vioxx,should 1.0 0.000143348623853 0 1 -1
concomitantly,indicate 1.0 0.000143348623853 1 0 1
but,this 1.0 0.000286697247706 2 0 2
and,get 1.0 0.000143348623853 0 1 -1
to,fulminant 1.0 0.000143348623853 1 0 1
demonstrated,efficacy 1.0 0.000286697247706 0 2 -2
by,when 0.333333333333 0.000143348623853 2 1 1
levels,using 1.0 0.000143348623853 0 1 -1
ca,store 1.0 0.000143348623853 0 1 -1
serum,sex 1.0 0.000143348623853 1 0 1
as,can 1.0 0.000143348623853 1 0 1
these,isozymes 1.0 0.000143348623853 0 1 -1
two,controlled 1.0 0.000143348623853 0 1 -1
following,cisplatin 1.0 0.000143348623853 1 0 1
subtle,cell 1.0 0.000143348623853 0 1 -1
trials,mean 1.0 0.000143348623853 0 1 -1
nonbenzodiazepine,agonists 1.0 0.000143348623853 1 0 1
allow,sufficient 1.0 0.000143348623853 0 1 -1
interactions,a 1.0 0.000716743119266 0 5 -5
or,suspected 1.0 0.000286697247706 0 2 -2
or,related 1.0 0.000143348623853 0 1 -1
patients,want 1.0 0.000143348623853 0 1 -1
muscle,pains 1.0 0.000143348623853 0 1 -1
confirmed,these 1.0 0.000143348623853 0 1 -1
antagonists,increased 1.0 0.000143348623853 1 0 1
been,too 1.0 0.000143348623853 0 1 -1
cause,hypothyroidism 1.0 0.000143348623853 0 1 -1
science,and 1.0 0.000143348623853 0 1 -1
hypo-thyroxine,binding-globulinemias 1.0 0.000143348623853 0 1 -1
and,prevent 1.0 0.000143348623853 0 1 -1
involving,inhibition 1.0 0.000143348623853 1 0 1
acute,ischemic 1.0 0.000143348623853 0 1 -1
or,delay 1.0 0.000143348623853 0 1 -1
adverse,consequences 1.0 0.000143348623853 0 1 -1
disturbances,have 0.0 0.0 1 1 0
compounds,rather 1.0 0.000143348623853 0 1 -1
modify,the 0.6 0.00043004587156 1 4 -3
indinavir,mg 1.0 0.000143348623853 1 0 1
predominantly,cyp 1.0 0.000143348623853 0 1 -1
may,counteract 1.0 0.000716743119266 5 0 5
cardiovascular,collapse 1.0 0.000286697247706 0 2 -2
as,flushing 1.0 0.000143348623853 0 1 -1
regarding,potential 1.0 0.000143348623853 0 1 -1
absorbed,into 1.0 0.000286697247706 2 0 2
corticosteroids,methylxanthines 1.0 0.000143348623853 1 0 1
lower,seizure 1.0 0.000143348623853 1 0 1
were,separated 1.0 0.000143348623853 0 1 -1
d-ala2,metenkephalinamide 1.0 0.000143348623853 0 1 -1
agents,there 1.0 0.000286697247706 2 0 2
complex,anions 1.0 0.000143348623853 0 1 -1
a,do 1.0 0.000143348623853 1 0 1
in,terms 1.0 0.00043004587156 0 3 -3
but,changes 1.0 0.000143348623853 0 1 -1
of,genetic 1.0 0.000143348623853 0 1 -1
on,phenytoin 1.0 0.000143348623853 1 0 1
possible,resistance 1.0 0.00043004587156 0 3 -3
reported,activity 1.0 0.000143348623853 0 1 -1
enoxacin,interferes 1.0 0.000143348623853 1 0 1
robinul,injection 1.0 0.000286697247706 2 0 2
trileptal,the 1.0 0.000143348623853 1 0 1
hand,the 1.0 0.000286697247706 0 2 -2
activity,level 1.0 0.000143348623853 0 1 -1
glucose,oxidase 1.0 0.00114678899083 0 8 -8
increase,awareness 1.0 0.000143348623853 1 0 1
neurological,effects 1.0 0.000143348623853 0 1 -1
with,indirect 1.0 0.000143348623853 0 1 -1
hydroxytamoxifen,tam 1.0 0.000143348623853 0 1 -1
electrocardiographic,abnormalities 1.0 0.000143348623853 1 0 1
or,bezalip 1.0 0.00043004587156 3 0 3
phase,and 1.0 0.000143348623853 0 1 -1
indocin,with 1.0 0.000143348623853 1 0 1
a,basic 1.0 0.000143348623853 0 1 -1
insulin,requirements 1.0 0.000143348623853 0 1 -1
oxidase,enzyme 1.0 0.000286697247706 0 2 -2
electrolytes,and 1.0 0.000143348623853 0 1 -1
aspirin,celebrex 1.0 0.000143348623853 1 0 1
components,p1 0.333333333333 0.000143348623853 1 2 -1
slight,degree 1.0 0.000143348623853 0 1 -1
components,p2 1.0 0.000143348623853 1 0 1
single,weekly 1.0 0.000143348623853 0 1 -1
delay,premature 1.0 0.000143348623853 0 1 -1
no,statistically 1.0 0.000286697247706 0 2 -2
antihypertensives,amphetamines 1.0 0.000286697247706 2 0 2
from,treatment 0.0 0.0 1 1 0
aliskiren,does 1.0 0.000143348623853 0 1 -1
with,many 1.0 0.000143348623853 0 1 -1
in,uptake 1.0 0.000143348623853 1 0 1
is,further 1.0 0.000143348623853 0 1 -1
cimetidine,reduces 1.0 0.000143348623853 1 0 1
positive,coombs 1.0 0.00043004587156 0 3 -3
abolishes,the 1.0 0.000143348623853 0 1 -1
toxicity,possibly 1.0 0.000286697247706 2 0 2
washed,out 1.0 0.000143348623853 0 1 -1
doses,besides 1.0 0.000143348623853 0 1 -1
liquid,chromatographic 1.0 0.000143348623853 0 1 -1
diabetics,with 1.0 0.000143348623853 1 0 1
the,nitrobluetetrazolium 1.0 0.000143348623853 0 1 -1
necessary,the 0.0 0.0 1 1 0
these,factors 1.0 0.000143348623853 0 1 -1
cancer,cells 0.333333333333 0.000143348623853 1 2 -1
to,dose 1.0 0.000143348623853 0 1 -1
of,selective 0.333333333333 0.000143348623853 2 1 1
either,healthy 1.0 0.000143348623853 0 1 -1
is,advised 0.363636363636 0.00114678899083 7 15 -8
tarceva,should 1.0 0.000143348623853 0 1 -1
to,administration 1.0 0.000860091743119 0 6 -6
a,dose-related 1.0 0.000286697247706 2 0 2
fat,including 1.0 0.000143348623853 0 1 -1
baseline,values 1.0 0.000143348623853 1 0 1
primary,focus 1.0 0.000143348623853 0 1 -1
is,therefore 0.6 0.00043004587156 4 1 3
using,their 1.0 0.000143348623853 0 1 -1
of,r-warfarin 0.333333333333 0.000143348623853 2 1 1
and,must 1.0 0.000143348623853 0 1 -1
of,exjade 1.0 0.00043004587156 0 3 -3
several,months 1.0 0.000286697247706 0 2 -2
hepatic,metabolism 0.636363636364 0.00100344036697 9 2 7
jacalin,is 1.0 0.000143348623853 0 1 -1
ptx,caused 1.0 0.000143348623853 0 1 -1
volunteer,received 1.0 0.000143348623853 0 1 -1
which,induce 1.0 0.000286697247706 2 0 2
before,after 1.0 0.000143348623853 0 1 -1
general,or 1.0 0.000286697247706 2 0 2
reactions,atg 1.0 0.000143348623853 0 1 -1
great,interest 1.0 0.000143348623853 0 1 -1
been,studied 0.368421052632 0.00100344036697 6 13 -7
significantly,affect 0.8 0.00114678899083 1 9 -8
of,antistress 1.0 0.000143348623853 0 1 -1
the,drug 0.6 0.00043004587156 1 4 -3
containing,to 1.0 0.000143348623853 1 0 1
orange,and 1.0 0.000143348623853 0 1 -1
exfoliation,necrosis 1.0 0.000143348623853 0 1 -1
administered,did 1.0 0.000143348623853 0 1 -1
those,produced 1.0 0.000143348623853 1 0 1
allowed,to 1.0 0.000286697247706 0 2 -2
meth,administration 1.0 0.000143348623853 0 1 -1
increase,respectively 1.0 0.000143348623853 1 0 1
a,well-known 1.0 0.000143348623853 0 1 -1
activity-regulated,cytoskeleton-associated 1.0 0.000143348623853 0 1 -1
days,systemic 1.0 0.000286697247706 2 0 2
other,hivid-associated 1.0 0.000143348623853 1 0 1
receiving,both 0.0 0.0 4 4 0
system,by 1.0 0.000143348623853 0 1 -1
multiple,forms 1.0 0.000286697247706 0 2 -2
i,roegnik 1.0 0.000143348623853 0 1 -1
vital,sign 1.0 0.000143348623853 0 1 -1
possible,dose 1.0 0.000143348623853 1 0 1
increased,the 0.675675675676 0.00358371559633 31 6 25
levels,mcg 1.0 0.000143348623853 1 0 1
on,other 0.666666666667 0.000573394495413 1 5 -4
and,mycophenolate 1.0 0.000143348623853 1 0 1
t3,in 1.0 0.000143348623853 1 0 1
they,reduce 1.0 0.000573394495413 4 0 4
behaviors,most 1.0 0.000143348623853 0 1 -1
may,mimic 1.0 0.000143348623853 0 1 -1
antizol,by 1.0 0.000143348623853 1 0 1
either,protein 1.0 0.000143348623853 0 1 -1
while,the 0.142857142857 0.000143348623853 3 4 -1
glutathione,or 1.0 0.000143348623853 0 1 -1
produce,clinically 1.0 0.000286697247706 2 0 2
cyps,a1 1.0 0.000143348623853 0 1 -1
cyps,a2 1.0 0.000143348623853 0 1 -1
of,cyp3a4-eplerenone 1.0 0.000143348623853 0 1 -1
acarbose,in 1.0 0.000143348623853 0 1 -1
morphine-induced,and 1.0 0.000143348623853 1 0 1
men,levels 1.0 0.000143348623853 0 1 -1
applicable,across 1.0 0.000143348623853 0 1 -1
by,activation 1.0 0.000143348623853 0 1 -1
treated,subjects 1.0 0.000286697247706 0 2 -2
auc0-12,of 0.0 0.0 1 1 0
combination,was 1.0 0.000143348623853 0 1 -1
resulting,in 0.584905660377 0.00444380733945 42 11 31
and,protease 1.0 0.000143348623853 0 1 -1
heart,can 1.0 0.000143348623853 0 1 -1
control,of 1.0 0.000573394495413 0 4 -4
than,two-fold 1.0 0.000286697247706 2 0 2
and,manageable 1.0 0.000143348623853 0 1 -1
tests,with 1.0 0.000286697247706 0 2 -2
and,bowel 1.0 0.000143348623853 0 1 -1
of,chloride-induced 1.0 0.000143348623853 1 0 1
oral,are 1.0 0.000143348623853 0 1 -1
acid,secretion 0.2 0.000143348623853 2 3 -1
plasma,has 1.0 0.000143348623853 1 0 1
an,uncontrolled 1.0 0.000143348623853 0 1 -1
state,mg 1.0 0.000143348623853 1 0 1
the,management 0.8 0.00114678899083 1 9 -8
with,nevirapine- 1.0 0.000143348623853 0 1 -1
is,coadministered 0.555555555556 0.000716743119266 7 2 5
affect,distribution 1.0 0.000143348623853 0 1 -1
ml,throughout 1.0 0.000143348623853 0 1 -1
exposure,tonevirapine 1.0 0.000143348623853 0 1 -1
be,displaced 1.0 0.000143348623853 1 0 1
mg,before 1.0 0.000143348623853 0 1 -1
basis,appears 1.0 0.000143348623853 1 0 1
antagonists,histamine 1.0 0.000143348623853 0 1 -1
and,returned 1.0 0.000286697247706 0 2 -2
in,rodent 1.0 0.000286697247706 0 2 -2
mg,sustained-release 1.0 0.000143348623853 0 1 -1
sodium,enhances 1.0 0.000143348623853 1 0 1
experience,an 0.6 0.00043004587156 4 1 3
effect,increased 1.0 0.000286697247706 0 2 -2
c-cholesteryl,oleate 1.0 0.000143348623853 0 1 -1
epilepsy,ingesting 1.0 0.00043004587156 0 3 -3
agents,must 1.0 0.000573394495413 0 4 -4
activity,because 1.0 0.000143348623853 0 1 -1
exacerbated,by 1.0 0.000286697247706 2 0 2
by,cyp2c19 1.0 0.000143348623853 0 1 -1
a,change 0.333333333333 0.000143348623853 1 2 -1
cmin,were 1.0 0.000573394495413 4 0 4
single,agent 1.0 0.000143348623853 0 1 -1
for,estimation 1.0 0.000143348623853 0 1 -1
but,caused 1.0 0.000143348623853 0 1 -1
experience,as 1.0 0.000143348623853 0 1 -1
hot,weather 1.0 0.000143348623853 1 0 1
estradiol,by 1.0 0.00043004587156 3 0 3
obesity,as 1.0 0.000143348623853 0 1 -1
implantable,forms 1.0 0.000143348623853 1 0 1
haca,titers 1.0 0.000143348623853 0 1 -1
chemotherapy,plus 1.0 0.00043004587156 0 3 -3
patients,treated 0.030303030303 0.000143348623853 16 17 -1
displacement,studies 1.0 0.000143348623853 0 1 -1
with,ethacrynic 1.0 0.000143348623853 1 0 1
may,play 1.0 0.000143348623853 0 1 -1
produce,cns-depressant 1.0 0.000143348623853 1 0 1
any,signs 1.0 0.000143348623853 1 0 1
isocarboxazid,and 0.0 0.0 1 1 0
or,hypersensitivity 1.0 0.000143348623853 0 1 -1
contained,in 1.0 0.000286697247706 2 0 2
increased,plasminogen 1.0 0.000286697247706 0 2 -2
against,micrococcus 1.0 0.000143348623853 0 1 -1
of,were 0.310344827586 0.00129013761468 10 19 -9
following,acetaminophen 1.0 0.000286697247706 2 0 2
might,increase 0.5 0.000286697247706 3 1 2
tests,the 1.0 0.000143348623853 1 0 1
suggest,any 1.0 0.000143348623853 0 1 -1
had,less 1.0 0.000143348623853 1 0 1
collapse,in 1.0 0.000286697247706 0 2 -2
more,convenient 1.0 0.000143348623853 0 1 -1
it,significantly 0.0 0.0 1 1 0
failure,in 1.0 0.000143348623853 1 0 1
perivascular,spaces 1.0 0.000143348623853 0 1 -1
the,mesenteric 1.0 0.000143348623853 0 1 -1
biochemical,toxicology 1.0 0.000143348623853 0 1 -1
the,breadth 1.0 0.000143348623853 0 1 -1
males,the 1.0 0.000143348623853 0 1 -1
have,noted 1.0 0.000143348623853 0 1 -1
that,are 0.402597402597 0.00444380733945 23 54 -31
kg,or 1.0 0.000716743119266 0 5 -5
however,have 1.0 0.000143348623853 0 1 -1
polystyrene,sulfonate 1.0 0.000143348623853 1 0 1
a,fixed 1.0 0.000143348623853 0 1 -1
warranted,in 0.333333333333 0.000143348623853 1 2 -1
cardiac,enlargement 1.0 0.000143348623853 1 0 1
were,usually 1.0 0.000143348623853 0 1 -1
kg,on 0.333333333333 0.000143348623853 2 1 1
its,prevention 1.0 0.000143348623853 0 1 -1
strength,from 1.0 0.000143348623853 0 1 -1
kg,of 1.0 0.00043004587156 0 3 -3
in,young 1.0 0.000143348623853 0 1 -1
stable,for 1.0 0.000143348623853 0 1 -1
therapeutic,point 1.0 0.000143348623853 0 1 -1
ileus,may 1.0 0.000143348623853 1 0 1
operating,dangerous 1.0 0.000143348623853 0 1 -1
mild,to 0.333333333333 0.000143348623853 2 1 1
the,promotion 1.0 0.000143348623853 0 1 -1
block,caution 1.0 0.000143348623853 1 0 1
have,developed 1.0 0.000143348623853 0 1 -1
were,nonsteroidal 1.0 0.000143348623853 0 1 -1
reduced,when 0.333333333333 0.000143348623853 2 1 1
be,additive 0.777777777778 0.00100344036697 8 1 7
than,might 1.0 0.000143348623853 1 0 1
is,greatest 1.0 0.000286697247706 0 2 -2
of,strattera 1.0 0.000143348623853 1 0 1
these,medicinal 1.0 0.000286697247706 2 0 2
lowering,the 1.0 0.000286697247706 2 0 2
no,chemical 1.0 0.000143348623853 0 1 -1
of,elimination 0.0 0.0 3 3 0
cyp2a6,cyp2b6 1.0 0.000143348623853 0 1 -1
vasculature,without 1.0 0.000143348623853 0 1 -1
be,provided 1.0 0.000286697247706 0 2 -2
receiving,prinivil 1.0 0.000143348623853 1 0 1
acute,dosing 1.0 0.000286697247706 0 2 -2
food,and 1.0 0.000143348623853 0 1 -1
of,profound 1.0 0.000143348623853 1 0 1
causing,bone 1.0 0.000143348623853 1 0 1
intraindividual,interoccasion 1.0 0.000143348623853 0 1 -1
agents,monoamine 1.0 0.000143348623853 1 0 1
changed,as 1.0 0.000143348623853 0 1 -1
thiazides,may 1.0 0.000143348623853 1 0 1
that,mcf-7 1.0 0.000143348623853 0 1 -1
patients,steady-state 1.0 0.000143348623853 1 0 1
effective,due 0.0 0.0 1 1 0
inhaler,take 1.0 0.000143348623853 1 0 1
retinogeniculate,fibers 1.0 0.000143348623853 0 1 -1
complex,and 0.5 0.000286697247706 1 3 -2
novolog,but 1.0 0.000143348623853 0 1 -1
three-period,randomized 1.0 0.000143348623853 0 1 -1
homopolyribonucleotides,and 1.0 0.000143348623853 0 1 -1
ill,and 1.0 0.000143348623853 0 1 -1
contraindication,to 1.0 0.000143348623853 0 1 -1
performance,of 1.0 0.000143348623853 0 1 -1
control,with 1.0 0.000143348623853 0 1 -1
were,determined 1.0 0.000573394495413 0 4 -4
or,extent 1.0 0.00043004587156 0 3 -3
enzyme,eg 1.0 0.000143348623853 1 0 1
mc,enhance 1.0 0.000143348623853 0 1 -1
indication,for 1.0 0.000143348623853 0 1 -1
however,this 1.0 0.000143348623853 0 1 -1
tubular,atrophy 1.0 0.000143348623853 0 1 -1
chewable,dispersible 1.0 0.000286697247706 2 0 2
concentrations,showing 1.0 0.000143348623853 0 1 -1
bmax,in 1.0 0.000286697247706 0 2 -2
unknown,at 1.0 0.000143348623853 0 1 -1
day,against 1.0 0.000143348623853 0 1 -1
in,exposure 0.0 0.0 2 2 0
the,fourth 1.0 0.000143348623853 0 1 -1
future,trends 1.0 0.000143348623853 0 1 -1
careful,adjustment 0.0 0.0 3 3 0
beta-adrenergic,blockers 1.0 0.000286697247706 2 0 2
fold,by 1.0 0.000143348623853 1 0 1
laboratory,testing 1.0 0.000143348623853 1 0 1
medicine,you 1.0 0.000143348623853 1 0 1
with,humira 1.0 0.000143348623853 0 1 -1
seriraline,and 1.0 0.000143348623853 0 1 -1
trileptal,with 1.0 0.000286697247706 2 0 2
tricor,there 1.0 0.000143348623853 1 0 1
amitriptyline,hcl 0.0 0.0 1 1 0
of,peptide 1.0 0.000143348623853 0 1 -1
were,observed 0.862068965517 0.00358371559633 2 27 -25
the,anti-glaucoma 0.0 0.0 1 1 0
in,eight 0.5 0.000286697247706 3 1 2
and,mechanisms 1.0 0.000143348623853 0 1 -1
angiotensln,converting 1.0 0.000143348623853 1 0 1
were,short-lasting 1.0 0.000143348623853 0 1 -1
qtc,values 1.0 0.000143348623853 1 0 1
and,hydroxide-containing 1.0 0.000143348623853 0 1 -1
inhibitory,concentrations 1.0 0.000286697247706 0 2 -2
end,of 0.5 0.000286697247706 1 3 -2
dose,to 0.333333333333 0.00043004587156 6 3 3
family,in 1.0 0.000143348623853 1 0 1
elevated,levels 0.2 0.000143348623853 3 2 1
hepatic,or 1.0 0.000143348623853 0 1 -1
be,individualized 1.0 0.000143348623853 0 1 -1
warfarin,co- 1.0 0.000143348623853 0 1 -1
increased,deet 1.0 0.000143348623853 0 1 -1
recurrence,relative 1.0 0.000143348623853 0 1 -1
structural,similarity 1.0 0.000143348623853 1 0 1
we,investigated 1.0 0.000716743119266 0 5 -5
with,cefizox 1.0 0.000143348623853 1 0 1
paperhanging,playing 1.0 0.000143348623853 0 1 -1
administration,attenuates 1.0 0.000143348623853 1 0 1
data,suggest 0.157894736842 0.00043004587156 8 11 -3
clinician,to 1.0 0.000143348623853 0 1 -1
any,agent 1.0 0.000573394495413 0 4 -4
zaleplons,maximal 1.0 0.000143348623853 1 0 1
phosphate-binding,agents 1.0 0.00043004587156 0 3 -3
c,up 1.0 0.000143348623853 0 1 -1
conclusions,olanzapine 1.0 0.000143348623853 0 1 -1
treatment,plans 1.0 0.000143348623853 0 1 -1
and,low-dose 1.0 0.000143348623853 1 0 1
with,changes 1.0 0.000143348623853 0 1 -1
cyp450s,cyp1a2 1.0 0.000143348623853 0 1 -1
interactions,among 1.0 0.000143348623853 0 1 -1
to,triple-immunosuppression 1.0 0.000143348623853 0 1 -1
and,collected 1.0 0.000143348623853 0 1 -1
hypotension,cimetidine 1.0 0.000143348623853 1 0 1
subject,n 1.0 0.000143348623853 0 1 -1
gaba-ergic,system 1.0 0.000143348623853 1 0 1
interferon,induction 1.0 0.000143348623853 0 1 -1
arise,in 1.0 0.000143348623853 0 1 -1
unaltered,by 1.0 0.000143348623853 0 1 -1
cephalothin,sodium 1.0 0.000143348623853 0 1 -1
antihypertensive,therapy 1.0 0.000143348623853 1 0 1
and,hoof 1.0 0.000143348623853 0 1 -1
particularly,in 0.25 0.000286697247706 3 5 -2
could,pose 0.0 0.0 1 1 0
and,might 1.0 0.000286697247706 2 0 2
and,increases 0.25 0.000286697247706 5 3 2
copper,sulfate 1.0 0.000143348623853 0 1 -1
volunteers,either 1.0 0.000143348623853 1 0 1
ensure,that 0.0 0.0 1 1 0
carbamazepine,overdose 1.0 0.000143348623853 0 1 -1
to,potential 1.0 0.00143348623853 0 10 -10
actually,produced 1.0 0.000143348623853 0 1 -1
positive,readings 1.0 0.000143348623853 0 1 -1
when,cefotan 1.0 0.000143348623853 0 1 -1
clozapine,plasma 1.0 0.000143348623853 1 0 1
and,increased 0.111111111111 0.000286697247706 8 10 -2
effects,reported 1.0 0.000143348623853 0 1 -1
between,cerebral 1.0 0.000143348623853 0 1 -1
collected,by 1.0 0.000143348623853 0 1 -1
narcotic,may 1.0 0.000143348623853 1 0 1
a4,should 1.0 0.000143348623853 0 1 -1
t,a 1.0 0.000143348623853 1 0 1
placebo,coadministered 1.0 0.000143348623853 0 1 -1
t,i 1.0 0.00043004587156 3 0 3
thus,decrease 1.0 0.000143348623853 1 0 1
the,residual 1.0 0.000143348623853 1 0 1
both,therapies 1.0 0.000143348623853 0 1 -1
phenotype,were 1.0 0.000143348623853 0 1 -1
each,found 1.0 0.000143348623853 0 1 -1
a,partially 1.0 0.000143348623853 0 1 -1
a,continuing 1.0 0.000143348623853 0 1 -1
have,essentially 1.0 0.000143348623853 0 1 -1
be,augmented 1.0 0.000143348623853 1 0 1
by,cyp 1.0 0.000860091743119 0 6 -6
with,concurrent 0.333333333333 0.000286697247706 4 2 2
ra,were 1.0 0.000286697247706 2 0 2
phenyl-1,tetrahydropyridine 1.0 0.000143348623853 0 1 -1
and,vitamin 0.0 0.0 2 2 0
few,systemic 1.0 0.000143348623853 0 1 -1
to,micrograms 0.25 0.000286697247706 3 5 -2
effects,administered 1.0 0.000143348623853 0 1 -1
vaginal,preparations 1.0 0.00043004587156 0 3 -3
activity,predominantly 1.0 0.000143348623853 0 1 -1
plus,to 1.0 0.000143348623853 0 1 -1
in,older 1.0 0.000143348623853 0 1 -1
due,to 0.232876712329 0.0024369266055 28 45 -17
or,pgp 1.0 0.000143348623853 0 1 -1
been,definitively 1.0 0.000143348623853 1 0 1
interactions,the 0.666666666667 0.00114678899083 2 10 -8
reactions,consisted 1.0 0.000143348623853 0 1 -1
required,for 1.0 0.000860091743119 0 6 -6
hydroxy-corticosteroids,by 1.0 0.000143348623853 0 1 -1
increase,over 1.0 0.000286697247706 0 2 -2
either,tagamet 1.0 0.000143348623853 1 0 1
interactions,listed 1.0 0.000143348623853 0 1 -1
of,b6 1.0 0.000143348623853 0 1 -1
emptying,by 1.0 0.000143348623853 0 1 -1
has,also 0.714285714286 0.000716743119266 1 6 -5
stimulants,are 1.0 0.000143348623853 0 1 -1
enzyme,inducer 0.333333333333 0.000143348623853 2 1 1
assay,system 1.0 0.000143348623853 0 1 -1
and,fermented 1.0 0.000143348623853 0 1 -1
increases,auc 1.0 0.000143348623853 1 0 1
makes,the 1.0 0.000143348623853 0 1 -1
vitro,upon 1.0 0.000143348623853 1 0 1
of,be 1.0 0.000286697247706 2 0 2
of,by 0.777777777778 0.00401376146789 32 4 28
however,usually 1.0 0.000143348623853 0 1 -1
bacteria,should 1.0 0.000143348623853 0 1 -1
from,lean 1.0 0.000143348623853 0 1 -1
until,a 1.0 0.000143348623853 1 0 1
depressive,effects 1.0 0.000143348623853 1 0 1
of,low-dose 0.333333333333 0.000143348623853 2 1 1
as,with 0.217391304348 0.000716743119266 14 9 5
useful,to 1.0 0.000143348623853 0 1 -1
interaction,as 1.0 0.000143348623853 0 1 -1
from,minutes 1.0 0.000143348623853 1 0 1
regulation,of 1.0 0.00114678899083 0 8 -8
coat-core,formulation 1.0 0.000143348623853 1 0 1
two,other 1.0 0.000143348623853 1 0 1
although,these 0.0 0.0 1 1 0
interaction,at 0.333333333333 0.000143348623853 1 2 -1
a,lectin 1.0 0.000143348623853 0 1 -1
i,trial 0.0 0.0 1 1 0
inhibits,o-glucuronidation 1.0 0.000143348623853 0 1 -1
receiving,no 1.0 0.000143348623853 0 1 -1
single,subject 1.0 0.000143348623853 1 0 1
and,demonstrates 1.0 0.000143348623853 0 1 -1
metabolite,concentrationswere 1.0 0.000143348623853 0 1 -1
prothrombin,level 1.0 0.000143348623853 0 1 -1
camptosar,than 1.0 0.000143348623853 1 0 1
systemic,may 1.0 0.000143348623853 0 1 -1
respond,differently 1.0 0.000143348623853 0 1 -1
increased,synaptic 1.0 0.000143348623853 0 1 -1
and,demonstrated 1.0 0.000143348623853 0 1 -1
continuous,cardiac 1.0 0.000143348623853 0 1 -1
ethanolysis,of 1.0 0.000143348623853 1 0 1
include,adrenocortical 1.0 0.000143348623853 1 0 1
and,avastin 1.0 0.000143348623853 0 1 -1
died,compared 1.0 0.000143348623853 0 1 -1
contributed,to 1.0 0.000286697247706 0 2 -2
on,sodium 1.0 0.000143348623853 1 0 1
xigris,is 1.0 0.000143348623853 0 1 -1
in,ems 1.0 0.000143348623853 0 1 -1
microsomal,enzyme 0.2 0.000143348623853 3 2 1
controlled,clinical 0.714285714286 0.000716743119266 1 6 -5
been,proposed 0.333333333333 0.000143348623853 1 2 -1
with,coenzyme 1.0 0.000143348623853 0 1 -1
slightly,from 1.0 0.000143348623853 1 0 1
of,breast 0.0 0.0 1 1 0
psychiatric,rating 1.0 0.000143348623853 1 0 1
to,benefits 1.0 0.000143348623853 0 1 -1
erectile,dysfunction 1.0 0.00043004587156 0 3 -3
cmax,by 0.6 0.00043004587156 4 1 3
prolonging,atrioventricular 1.0 0.000143348623853 1 0 1
of,tikosyn 1.0 0.000143348623853 1 0 1
from,spontaneous 1.0 0.000143348623853 0 1 -1
all,were 1.0 0.000143348623853 0 1 -1
volunteers,treatment 0.0 0.0 1 1 0
generally,be 1.0 0.000143348623853 0 1 -1
particular,caution 0.6 0.00043004587156 4 1 3
rodent,pups 1.0 0.000143348623853 0 1 -1
have,confirmed 1.0 0.000143348623853 0 1 -1
generally,by 1.0 0.000143348623853 0 1 -1
neuromuscular,blockers 1.0 0.000143348623853 0 1 -1
for,multiple 1.0 0.000143348623853 0 1 -1
concentrations,have 1.0 0.000573394495413 0 4 -4
mg,initial 1.0 0.000143348623853 1 0 1
and,nose 1.0 0.000143348623853 1 0 1
time,response 0.333333333333 0.000143348623853 2 1 1
cyp2c19,substrate 1.0 0.000143348623853 1 0 1
synthetic,galloyl 1.0 0.000143348623853 0 1 -1
efficacy,has 1.0 0.000286697247706 0 2 -2
including,humira 1.0 0.000143348623853 1 0 1
recognition,and 1.0 0.000143348623853 0 1 -1
absorbed,is 1.0 0.000143348623853 0 1 -1
be,demonstrated 1.0 0.000143348623853 0 1 -1
no,inhibitory 1.0 0.000143348623853 0 1 -1
rats,results 1.0 0.000143348623853 1 0 1
hormone,binding 1.0 0.000143348623853 0 1 -1
cardiovascular,risk 1.0 0.000143348623853 0 1 -1
formation,in 1.0 0.000143348623853 1 0 1
sub-therapeutic,concentrations 1.0 0.000143348623853 1 0 1
profound,hypotensive 1.0 0.000143348623853 1 0 1
evaluating,men 1.0 0.000143348623853 0 1 -1
concomitant,therapy 0.25 0.000573394495413 6 10 -4
identity,of 1.0 0.000143348623853 0 1 -1
oxidation,of 1.0 0.000143348623853 1 0 1
when,k 1.0 0.000143348623853 1 0 1
the,alveoli 1.0 0.000143348623853 0 1 -1
metabotropic,glutamate 1.0 0.000143348623853 0 1 -1
trisenox,is 1.0 0.000143348623853 1 0 1
when,a 0.2 0.00043004587156 9 6 3
objective,of 1.0 0.000143348623853 0 1 -1
a,antidepressant 1.0 0.000143348623853 1 0 1
new,acute 1.0 0.000143348623853 0 1 -1
duloxetine,unprotected 1.0 0.000143348623853 0 1 -1
rash,diarrhea 1.0 0.000143348623853 0 1 -1
authorization,cards 1.0 0.000143348623853 0 1 -1
bradycardia,vertigo 1.0 0.000143348623853 0 1 -1
for,information 1.0 0.000143348623853 0 1 -1
possible,to 1.0 0.000286697247706 0 2 -2
a,euthyroid 1.0 0.000143348623853 0 1 -1
at,nacmc 1.0 0.000143348623853 0 1 -1
area-under,the-curve 0.0 0.0 1 1 0
employed,for 1.0 0.000143348623853 0 1 -1
treatment-naive,patients 1.0 0.000143348623853 0 1 -1
out,tests 1.0 0.000286697247706 0 2 -2
mechanisms,similar 1.0 0.000143348623853 0 1 -1
and,hypertension 1.0 0.000143348623853 0 1 -1
an,omega-agatoxin 1.0 0.000143348623853 0 1 -1
oral,hypoglycemics 0.5 0.000286697247706 1 3 -2
agents,including 0.333333333333 0.000286697247706 4 2 2
celebrex,with 1.0 0.000143348623853 1 0 1
tagamet,is 1.0 0.000143348623853 1 0 1
agonists,because 1.0 0.000143348623853 1 0 1
sustained,increases 0.333333333333 0.000143348623853 2 1 1
tablets,in 1.0 0.000286697247706 2 0 2
given,lodine 1.0 0.000143348623853 0 1 -1
decreased,when 0.142857142857 0.000143348623853 4 3 1
was,only 0.333333333333 0.000143348623853 1 2 -1
play,an 1.0 0.000286697247706 2 0 2
when,addiction 1.0 0.000143348623853 0 1 -1
tablets,is 1.0 0.000143348623853 1 0 1
of,multiple 0.333333333333 0.000143348623853 1 2 -1
metabolized,triazolo-benzodiazepines 1.0 0.000143348623853 1 0 1
when,are 0.428571428571 0.00043004587156 5 2 3
renal,effects 1.0 0.000143348623853 0 1 -1
intestinal,first 1.0 0.000143348623853 0 1 -1
several,instances 1.0 0.000143348623853 0 1 -1
rifabutin,did 1.0 0.000143348623853 0 1 -1
an,ssri 1.0 0.000573394495413 4 0 4
lower,blood 0.5 0.000286697247706 1 3 -2
other,medical 1.0 0.000143348623853 0 1 -1
to,start 1.0 0.000143348623853 0 1 -1
certain,endocrine 1.0 0.000286697247706 0 2 -2
via,cytochrome 1.0 0.00043004587156 0 3 -3
reduced,ldl 1.0 0.000286697247706 0 2 -2
unexpectedly,high 1.0 0.000143348623853 0 1 -1
was,bioequivalent 1.0 0.000286697247706 0 2 -2
intravenous,is 1.0 0.000143348623853 1 0 1
studies,including 1.0 0.000286697247706 0 2 -2
tmax,at 1.0 0.000143348623853 0 1 -1
within,h 1.0 0.000143348623853 0 1 -1
furthermore,it 1.0 0.000143348623853 1 0 1
within,a 0.333333333333 0.000143348623853 1 2 -1
l,and 0.0 0.0 1 1 0
bleeding,has 0.6 0.00043004587156 4 1 3
cycles,and 1.0 0.000286697247706 0 2 -2
cancer,increases 1.0 0.000143348623853 0 1 -1
that,prolong 1.0 0.000143348623853 0 1 -1
strong,inhibitor 0.333333333333 0.000143348623853 1 2 -1
nonsteroidal,agents 0.4 0.000573394495413 7 3 4
of,labetalol 1.0 0.000143348623853 0 1 -1
a,clinical 0.333333333333 0.000573394495413 4 8 -4
be,noted 0.0 0.0 2 2 0
of,proteus 1.0 0.000143348623853 0 1 -1
tremor,hemiballismus 1.0 0.000143348623853 0 1 -1
titrated,with 1.0 0.000143348623853 1 0 1
shortened,in 1.0 0.000143348623853 1 0 1
the,cardiac 1.0 0.000143348623853 0 1 -1
decrease,hepatic 0.0 0.0 1 1 0
problem,associated 1.0 0.000143348623853 1 0 1
of,total 0.5 0.000286697247706 1 3 -2
antagonists,congestive 1.0 0.000143348623853 0 1 -1
and,fertility 1.0 0.000143348623853 0 1 -1
sensitivity,and 0.0 0.0 1 1 0
day,washout 1.0 0.000143348623853 0 1 -1
that,conclusively 1.0 0.000143348623853 0 1 -1
when,any 0.0 0.0 1 1 0
renal,blood 1.0 0.000143348623853 0 1 -1
probably,related 1.0 0.000143348623853 0 1 -1
hemabate,may 1.0 0.000143348623853 1 0 1
reaction,in 1.0 0.000143348623853 0 1 -1
parturition,it 1.0 0.000143348623853 0 1 -1
used,together 0.2 0.000143348623853 3 2 1
five,normal 1.0 0.000143348623853 1 0 1
effective,as 1.0 0.000143348623853 0 1 -1
suspension,results 1.0 0.000143348623853 1 0 1
increased,mean 1.0 0.000573394495413 4 0 4
oral,such 1.0 0.000143348623853 1 0 1
ritonavir,mg 1.0 0.000143348623853 1 0 1
other,taken 1.0 0.000143348623853 1 0 1
clinical,dose 1.0 0.000143348623853 0 1 -1
total,peak 1.0 0.000143348623853 0 1 -1
analogues,vitamin 1.0 0.00043004587156 3 0 3
by,both 1.0 0.000143348623853 0 1 -1
march,citrate 1.0 0.000143348623853 0 1 -1
in,several 1.0 0.000573394495413 0 4 -4
of,flucoxacillin 1.0 0.000143348623853 0 1 -1
may,ameliorate 1.0 0.000143348623853 1 0 1
immunodeficiency-associated,lymphocyte 1.0 0.000143348623853 0 1 -1
dilution,method 1.0 0.000143348623853 0 1 -1
anticipated,due 1.0 0.000143348623853 0 1 -1
oral,should 1.0 0.000143348623853 0 1 -1
an,altered 0.0 0.0 1 1 0
were,explored 1.0 0.000143348623853 0 1 -1
their,concomitant 1.0 0.000143348623853 0 1 -1
circulating,after 1.0 0.000143348623853 0 1 -1
h1-blocking,agents 1.0 0.000143348623853 1 0 1
many,angiotensin-converting 1.0 0.000143348623853 1 0 1
task,induced 1.0 0.000143348623853 0 1 -1
when,therapeutic 1.0 0.000143348623853 0 1 -1
oral,products 1.0 0.000143348623853 0 1 -1
s,diet 1.0 0.000143348623853 0 1 -1
critical,for 1.0 0.000143348623853 0 1 -1
beta-glucuronidase,are 1.0 0.000143348623853 0 1 -1
to,reduce 0.846153846154 0.00157683486239 12 1 11
passages,increasing 1.0 0.000143348623853 1 0 1
plasma,area-under 1.0 0.000143348623853 0 1 -1
considered,in 0.75 0.000860091743119 1 7 -6
concurrent,ingestion 1.0 0.000143348623853 1 0 1
considered,if 0.333333333333 0.000143348623853 1 2 -1
several,factors 1.0 0.000143348623853 0 1 -1
of,phenytoin 1.0 0.000143348623853 0 1 -1
pressure,lowering 1.0 0.000143348623853 1 0 1
methaemoglobinaemia,particularly 1.0 0.000143348623853 0 1 -1
cohort,then 1.0 0.000143348623853 0 1 -1
microsomes,showed 1.0 0.000143348623853 0 1 -1
problems,and 1.0 0.000143348623853 0 1 -1
been,rarely 1.0 0.000286697247706 2 0 2
suggested,when 1.0 0.000143348623853 1 0 1
n-cetyl,gallate 1.0 0.000143348623853 0 1 -1
can,speed-up 1.0 0.000143348623853 0 1 -1
each,administered 1.0 0.000143348623853 1 0 1
both,with 1.0 0.000143348623853 0 1 -1
the,utilization 1.0 0.000143348623853 0 1 -1
for,all 1.0 0.000143348623853 0 1 -1
or,substituted 1.0 0.000143348623853 0 1 -1
peak,plasma 0.636363636364 0.00100344036697 9 2 7
g,h 1.0 0.000143348623853 1 0 1
nsaids,suggests 1.0 0.000143348623853 1 0 1
the,antimuscarinic 1.0 0.000143348623853 1 0 1
alternative,hypoglycemic 1.0 0.000143348623853 1 0 1
studies,where 1.0 0.000143348623853 0 1 -1
approx,because 1.0 0.000143348623853 1 0 1
with,gram 1.0 0.000143348623853 1 0 1
depress,the 1.0 0.000143348623853 1 0 1
obtained,before 1.0 0.000143348623853 0 1 -1
also,important 1.0 0.000143348623853 0 1 -1
unbound,by 1.0 0.000143348623853 1 0 1
take,other 1.0 0.000286697247706 0 2 -2
precaution,is 1.0 0.000286697247706 0 2 -2
cancer,indicated 1.0 0.000143348623853 1 0 1
antitumour,activity 0.333333333333 0.000143348623853 1 2 -1
confusion,extrapyramidal 1.0 0.000143348623853 1 0 1
operating,machinery 1.0 0.000143348623853 0 1 -1
homocysteine,may 1.0 0.000143348623853 0 1 -1
consideration,when 1.0 0.000143348623853 1 0 1
most,effective 1.0 0.000143348623853 0 1 -1
is,believed 1.0 0.000143348623853 1 0 1
inhibit,drug 1.0 0.000143348623853 0 1 -1
urate,uricosuric 1.0 0.000143348623853 1 0 1
rd,th 1.0 0.000143348623853 0 1 -1
completely,depressed 1.0 0.000143348623853 1 0 1
to,alert 1.0 0.000143348623853 1 0 1
patients,stabilized 1.0 0.000143348623853 1 0 1
who,successfully 1.0 0.000143348623853 0 1 -1
feasible,as 1.0 0.000143348623853 0 1 -1
be,the 0.333333333333 0.000286697247706 2 4 -2
acetate,and 0.0 0.0 1 1 0
in,postmenopausal 1.0 0.000143348623853 1 0 1
caused,by 0.176470588235 0.00043004587156 7 10 -3
dependent,oxidation 0.0 0.0 1 1 0
separately,by 1.0 0.000143348623853 1 0 1
a,conservative 1.0 0.000143348623853 0 1 -1
m2,basis 0.333333333333 0.000143348623853 1 2 -1
with,imidazole 1.0 0.000143348623853 1 0 1
the,enhanced 1.0 0.000143348623853 0 1 -1
period,when 1.0 0.000573394495413 4 0 4
be,greater 0.333333333333 0.000143348623853 2 1 1
importance,in 1.0 0.000143348623853 0 1 -1
different,in 1.0 0.000143348623853 0 1 -1
range,reported 1.0 0.000143348623853 0 1 -1
suitable,for 1.0 0.000286697247706 0 2 -2
refer,to 0.0 0.0 2 2 0
certain,nonsteroidal 1.0 0.000143348623853 1 0 1
potent,iiia4 1.0 0.000143348623853 1 0 1
doubling,times 1.0 0.000143348623853 0 1 -1
factor,vii 1.0 0.000143348623853 0 1 -1
conclusion,that 1.0 0.000143348623853 1 0 1
the,nonpredisposed 1.0 0.000143348623853 0 1 -1
abciximab,has 1.0 0.000143348623853 0 1 -1
individuals,with 1.0 0.000143348623853 0 1 -1
antacids,containing 1.0 0.000286697247706 2 0 2
eg,valproic 1.0 0.000143348623853 1 0 1
by,xanthine 1.0 0.000286697247706 0 2 -2
therapy,but 1.0 0.000143348623853 0 1 -1
between,january 1.0 0.000143348623853 0 1 -1
however,retinyl 1.0 0.000143348623853 1 0 1
to,x 1.0 0.000143348623853 0 1 -1
and,b-cell 1.0 0.000143348623853 0 1 -1
oral,antidiabetes 1.0 0.000143348623853 0 1 -1
this,represents 1.0 0.000143348623853 0 1 -1
had,an 0.0 0.0 1 1 0
approved,for 1.0 0.000143348623853 0 1 -1
to,h 1.0 0.000143348623853 0 1 -1
to,m 0.333333333333 0.000143348623853 2 1 1
to,l 1.0 0.000143348623853 1 0 1
to,c 1.0 0.000143348623853 0 1 -1
to,a 0.26582278481 0.00301032110092 29 50 -21
to,g 1.0 0.000143348623853 0 1 -1
agents,such 0.0588235294118 0.000143348623853 9 8 1
not,morphine-induced 1.0 0.000143348623853 0 1 -1
we,conclude 0.333333333333 0.000143348623853 2 1 1
of,co 1.0 0.000143348623853 0 1 -1
tool,with 1.0 0.000143348623853 0 1 -1
coffee,was 1.0 0.000143348623853 0 1 -1
compensatory,increases 1.0 0.000143348623853 0 1 -1
can,inhibit 0.0909090909091 0.000143348623853 5 6 -1
when,macrolide 1.0 0.000143348623853 0 1 -1
and,optic 1.0 0.000143348623853 0 1 -1
nmda,receptors 1.0 0.000143348623853 0 1 -1
additionally,higher 1.0 0.000143348623853 1 0 1
and,their 0.25 0.000286697247706 3 5 -2
substances,of 1.0 0.000143348623853 0 1 -1
on,pharmacokinetics 0.714285714286 0.000716743119266 1 6 -5
showed,that 0.666666666667 0.00114678899083 2 10 -8
currently,do 1.0 0.000143348623853 0 1 -1
accelerated,when 1.0 0.000143348623853 1 0 1
dysfunction,eg 1.0 0.000143348623853 0 1 -1
c9,in 1.0 0.000143348623853 0 1 -1
interactions,could 1.0 0.000143348623853 0 1 -1
auc,for 0.333333333333 0.000143348623853 1 2 -1
side-effects,in 1.0 0.000143348623853 1 0 1
mg,considered 1.0 0.000143348623853 0 1 -1
terfenadine,and 1.0 0.000143348623853 1 0 1
or,and 0.555555555556 0.000716743119266 7 2 5
warfarin,meclofenamate 1.0 0.000143348623853 1 0 1
pimozide,and 1.0 0.000143348623853 1 0 1
when,mg 0.142857142857 0.000143348623853 4 3 1
second,contraction 1.0 0.000286697247706 0 2 -2
or,any 0.6 0.00043004587156 4 1 3
vertebra,at 1.0 0.000143348623853 0 1 -1
and,new 1.0 0.000143348623853 0 1 -1
any,of 0.51724137931 0.0021502293578 7 22 -15
cyp3a4,did 1.0 0.000143348623853 0 1 -1
as,stable 1.0 0.000143348623853 0 1 -1
approximately,peak 1.0 0.000143348623853 1 0 1
any,on 1.0 0.000143348623853 0 1 -1
the,average 1.0 0.00043004587156 0 3 -3
cisapride,was 1.0 0.000143348623853 0 1 -1
cyp2c9,cyp2c19 1.0 0.00129013761468 0 9 -9
reduced,if 0.0 0.0 1 1 0
of,enhanced 1.0 0.000143348623853 1 0 1
cause,adrenal 1.0 0.000143348623853 1 0 1
dmpge2,given 1.0 0.000143348623853 0 1 -1
reduced,in 1.0 0.00129013761468 0 9 -9
c8,and 1.0 0.000143348623853 0 1 -1
usually,does 1.0 0.000143348623853 1 0 1
in,no 1.0 0.000716743119266 0 5 -5
reduced,it 1.0 0.000143348623853 0 1 -1
mc,potentiates 1.0 0.000143348623853 1 0 1
use,both 1.0 0.000143348623853 0 1 -1
accumulation,during 1.0 0.000143348623853 0 1 -1
retention,of 0.0 0.0 1 1 0
to,triple 1.0 0.000143348623853 0 1 -1
this,protein 1.0 0.000143348623853 1 0 1
spermatozoa,from 1.0 0.000143348623853 0 1 -1
m,parenteral 0.0 0.0 1 1 0
carcinogenesis,mutagenesis 1.0 0.000573394495413 0 4 -4
examine,some 1.0 0.000143348623853 0 1 -1
altered,by 0.555555555556 0.000716743119266 2 7 -5
reached,after 0.0 0.0 1 1 0
metabolism,were 1.0 0.000143348623853 0 1 -1
the,net 0.0 0.0 1 1 0
however,be 1.0 0.000143348623853 0 1 -1
promotion,of 1.0 0.000143348623853 0 1 -1
may,indicate 0.0 0.0 1 1 0
gained,may 1.0 0.000143348623853 0 1 -1
the,availability 0.333333333333 0.000143348623853 1 2 -1
oa,patients 1.0 0.000143348623853 0 1 -1
intestinal,carcinogenesis 1.0 0.000143348623853 0 1 -1
minimally,elevated 1.0 0.000143348623853 0 1 -1
the,case 0.333333333333 0.000286697247706 2 4 -2
v,vii 1.0 0.000143348623853 0 1 -1
wellbutrin,on 1.0 0.000143348623853 0 1 -1
have,carried 1.0 0.000143348623853 0 1 -1
hypermagnesaemia,high 1.0 0.000143348623853 0 1 -1
intravenous,prodrug 1.0 0.000286697247706 0 2 -2
anhydrous,and 1.0 0.000143348623853 1 0 1
evoked,hind 1.0 0.000143348623853 0 1 -1
study,the 0.8 0.00114678899083 1 9 -8
haemodynamic,effects 1.0 0.000143348623853 0 1 -1
levodopa,is 1.0 0.000143348623853 0 1 -1
large,initial 1.0 0.000143348623853 0 1 -1
signs,and 0.142857142857 0.000143348623853 4 3 1
be,blunted 1.0 0.000286697247706 2 0 2
amevive,who 1.0 0.000143348623853 0 1 -1
and,foods 1.0 0.000143348623853 1 0 1
and,liver 0.6 0.00043004587156 1 4 -3
i,these 1.0 0.000143348623853 0 1 -1
intrinsic,effect 1.0 0.000143348623853 1 0 1
pharmacological,effect 1.0 0.000143348623853 1 0 1
where,or 1.0 0.000143348623853 0 1 -1
captopril-digoxin,interaction 1.0 0.000143348623853 0 1 -1
average,by 1.0 0.000143348623853 1 0 1
started,on 1.0 0.000286697247706 0 2 -2
setting,cardioselective 1.0 0.000143348623853 0 1 -1
may,predispose 1.0 0.000143348623853 1 0 1
of,difluoroacetone 1.0 0.00043004587156 0 3 -3
time,reported 1.0 0.000143348623853 1 0 1
with,intravascular 1.0 0.000143348623853 1 0 1
such,medicinal 1.0 0.000143348623853 1 0 1
a,statistically 0.2 0.000143348623853 2 3 -1
if,hormonal 1.0 0.000143348623853 0 1 -1
etc,lower 1.0 0.000143348623853 1 0 1
tested,by 1.0 0.000143348623853 0 1 -1
started,or 1.0 0.000143348623853 1 0 1
between,mealtime 1.0 0.000143348623853 0 1 -1
peripheral,mononuclear 1.0 0.000143348623853 0 1 -1
observation,must 1.0 0.000143348623853 0 1 -1
thin-layer,chromatographic 1.0 0.000143348623853 0 1 -1
kinetics,and 1.0 0.000286697247706 2 0 2
dangerous,because 1.0 0.000143348623853 0 1 -1
hour,then 1.0 0.000143348623853 0 1 -1
general,conditions 1.0 0.000143348623853 0 1 -1
a,medicine 1.0 0.000143348623853 0 1 -1
diphenhydramine,is 1.0 0.000143348623853 0 1 -1
have,led 1.0 0.000143348623853 0 1 -1
days,after 0.333333333333 0.000573394495413 8 4 4
prolonged,use 1.0 0.000143348623853 0 1 -1
toxicity,with 1.0 0.000286697247706 2 0 2
from,their 0.2 0.000143348623853 2 3 -1
when,amitriptyline 0.0 0.0 1 1 0
not,detect 1.0 0.000143348623853 0 1 -1
together,during 1.0 0.000143348623853 1 0 1
diminished,binding 1.0 0.000143348623853 1 0 1
by,nonbarbiturate 1.0 0.000143348623853 1 0 1
need,expensive 1.0 0.000143348623853 0 1 -1
historicalcontrol,group 1.0 0.000143348623853 1 0 1
food,isrecommended 1.0 0.000143348623853 1 0 1
cigarettes,and 1.0 0.000143348623853 0 1 -1
is,defined 1.0 0.000143348623853 0 1 -1
vision,and 1.0 0.000286697247706 2 0 2
curariform,effect 1.0 0.000143348623853 1 0 1
additive,depressant 1.0 0.000143348623853 0 1 -1
inhibits,the 0.555555555556 0.00143348623853 14 4 10
drugs,based 1.0 0.000143348623853 0 1 -1
interference,by 1.0 0.000143348623853 0 1 -1
failure,where 1.0 0.000143348623853 0 1 -1
proper,interpretation 1.0 0.000143348623853 0 1 -1
duloxetine,has 1.0 0.000143348623853 0 1 -1
hyper-,or 1.0 0.000143348623853 0 1 -1
after,treatment 1.0 0.00043004587156 0 3 -3
ten-subject,study 1.0 0.000143348623853 1 0 1
the,interference 0.0 0.0 1 1 0
relevant,inhibition 1.0 0.000143348623853 0 1 -1
human,lymphocytes 1.0 0.00043004587156 0 3 -3
with,overdosage 1.0 0.000143348623853 1 0 1
synergistically,to 1.0 0.000143348623853 0 1 -1
aripiprazole,dose 1.0 0.000143348623853 1 0 1
cells,either 1.0 0.000143348623853 0 1 -1
methyl-4,phenyl-1 1.0 0.000143348623853 0 1 -1
study,cocaine-induced 1.0 0.000143348623853 0 1 -1
comparison,of 0.6 0.00043004587156 1 4 -3
small,differences 1.0 0.000143348623853 0 1 -1
avoid,administration 1.0 0.000143348623853 0 1 -1
dosing,recommendations 1.0 0.000143348623853 0 1 -1
a,synergistic 0.2 0.000143348623853 2 3 -1
metabolism,via 0.333333333333 0.000143348623853 1 2 -1
after,days 0.6 0.00043004587156 1 4 -3
release,or 1.0 0.000143348623853 0 1 -1
fluctuate,significantly 1.0 0.000143348623853 1 0 1
to,cross 1.0 0.000143348623853 1 0 1
release,of 0.8 0.00114678899083 1 9 -8
concentrations,following 1.0 0.000286697247706 0 2 -2
with,erythromycin 1.0 0.000143348623853 0 1 -1
population,has 1.0 0.000286697247706 0 2 -2
male,rats 0.666666666667 0.000573394495413 1 5 -4
from,adrenergic 1.0 0.000143348623853 0 1 -1
defined,physical 1.0 0.000143348623853 0 1 -1
should,discuss 1.0 0.000143348623853 0 1 -1
reduction,at 1.0 0.000286697247706 0 2 -2
mean,standard 1.0 0.000143348623853 1 0 1
with,inomax 1.0 0.000143348623853 1 0 1
obtained,with 0.0 0.0 1 1 0
the,geriatric 1.0 0.000286697247706 0 2 -2
the,acute 0.2 0.000143348623853 2 3 -1
products,sharing 0.0 0.0 1 1 0
way,the 1.0 0.000143348623853 1 0 1
to,ng 0.0 0.0 1 1 0
select,and 1.0 0.000143348623853 0 1 -1
deaths,have 1.0 0.000143348623853 1 0 1
d2,antagonists 1.0 0.000143348623853 1 0 1
of,but 0.25 0.000286697247706 5 3 2
including,has 1.0 0.000143348623853 1 0 1
taking,amyl 1.0 0.000143348623853 1 0 1
gut,motility 1.0 0.000143348623853 1 0 1
that,produced 1.0 0.000286697247706 0 2 -2
anticipated,and 1.0 0.000143348623853 1 0 1
fraction,containing 1.0 0.000143348623853 0 1 -1
azole,antifungals 0.5 0.000286697247706 1 3 -2
cyp2d6,sensipar 1.0 0.000143348623853 0 1 -1
these,when 1.0 0.000143348623853 0 1 -1
elspar,therapy 1.0 0.000143348623853 1 0 1
delayed,at 1.0 0.000143348623853 0 1 -1
or,interruption 1.0 0.000143348623853 0 1 -1
phase,was 1.0 0.000143348623853 0 1 -1
days,following 0.333333333333 0.000143348623853 2 1 1
pulmonary,emboli 1.0 0.000143348623853 0 1 -1
the,muscle 0.6 0.00043004587156 4 1 3
a,nitrosamine 1.0 0.000143348623853 1 0 1
bioavailability,area 1.0 0.000143348623853 0 1 -1
oral,inhibits 1.0 0.000286697247706 2 0 2
of,c 0.2 0.000143348623853 2 3 -1
active,hydroxy 1.0 0.000143348623853 1 0 1
levels,induced 1.0 0.000143348623853 0 1 -1
higher,plasma 1.0 0.000143348623853 0 1 -1
two-hour,period 1.0 0.000143348623853 0 1 -1
reduced,efficacy 1.0 0.00043004587156 0 3 -3
bosentan,is 0.0 0.0 2 2 0
second,experiment 1.0 0.000143348623853 0 1 -1
significantly,prolonged 1.0 0.000143348623853 1 0 1
rifampicin,racemic 1.0 0.000143348623853 1 0 1
including,oral 0.5 0.000286697247706 3 1 2
most,genotoxic 1.0 0.000143348623853 0 1 -1
are,expected 0.333333333333 0.000286697247706 4 2 2
potent,in 1.0 0.000143348623853 0 1 -1
baseline,to 1.0 0.000143348623853 0 1 -1
inventory,the 1.0 0.000143348623853 0 1 -1
rofecoxib,did 1.0 0.00043004587156 0 3 -3
rates,and 1.0 0.000286697247706 0 2 -2
vary,by 1.0 0.000143348623853 0 1 -1
be,ineffective 1.0 0.000143348623853 1 0 1
as,postmarketing 1.0 0.000143348623853 1 0 1
in,caution 1.0 0.000143348623853 0 1 -1
abnormal,renal 1.0 0.000143348623853 1 0 1
having,vasodilator 0.0 0.0 1 1 0
identical,whether 1.0 0.000143348623853 0 1 -1
although,not 0.142857142857 0.000143348623853 4 3 1
not,correct 1.0 0.000143348623853 0 1 -1
healthy,individuals 1.0 0.000143348623853 1 0 1
antiepileptic,periodic 1.0 0.000143348623853 1 0 1
of,s 1.0 0.000143348623853 1 0 1
i,d 0.384615384615 0.000716743119266 9 4 5
count,is 1.0 0.000143348623853 0 1 -1
preparations,in 0.0 0.0 1 1 0
diabetics,die 1.0 0.000143348623853 0 1 -1
i,n 1.0 0.000143348623853 1 0 1
effects,conditioning 1.0 0.000143348623853 0 1 -1
about,a 1.0 0.00043004587156 3 0 3
i,v 1.0 0.000143348623853 0 1 -1
co-administered,antiepilepsy 1.0 0.000143348623853 0 1 -1
about,x 1.0 0.000143348623853 1 0 1
i,p 1.0 0.000143348623853 0 1 -1
short-acting,has 1.0 0.000143348623853 0 1 -1
concentration,mean 1.0 0.000286697247706 0 2 -2
septic,shock 1.0 0.000143348623853 0 1 -1
agonist-antagonist,effects 1.0 0.000143348623853 0 1 -1
drugs,which 0.166666666667 0.000286697247706 7 5 2
endoscopy,study 1.0 0.000143348623853 0 1 -1
major,cyp 1.0 0.000143348623853 0 1 -1
azoles,were 1.0 0.000143348623853 0 1 -1
on,glycemic 1.0 0.000143348623853 0 1 -1
the,concentration 0.230769230769 0.00043004587156 8 5 3
cleared,primarily 1.0 0.000143348623853 0 1 -1
may,temporarily 1.0 0.000143348623853 1 0 1
how,age 1.0 0.000143348623853 0 1 -1
or,agents 1.0 0.000286697247706 2 0 2
warning,coadministration 1.0 0.000143348623853 0 1 -1
the,mptp-induced 1.0 0.000143348623853 1 0 1
laceration,especially 1.0 0.000143348623853 1 0 1
by,cholinergic 1.0 0.000143348623853 0 1 -1
be,employed 0.6 0.00043004587156 1 4 -3
p450,isoforms 1.0 0.00043004587156 0 3 -3
therapy,did 1.0 0.000286697247706 0 2 -2
because,both 0.5 0.000286697247706 3 1 2
which,promote 1.0 0.00043004587156 3 0 3
adenocard,in 1.0 0.000143348623853 1 0 1
to,your 1.0 0.000716743119266 0 5 -5
least,squares 1.0 0.000143348623853 0 1 -1
selective,ca 1.0 0.000143348623853 0 1 -1
exposure,the 1.0 0.000143348623853 0 1 -1
system,may 0.428571428571 0.00043004587156 2 5 -3
routine,administration 1.0 0.000143348623853 1 0 1
nuromax,and 1.0 0.000143348623853 0 1 -1
increased,anticoagulation 1.0 0.000286697247706 0 2 -2
cancer,patients 1.0 0.000143348623853 1 0 1
anionic-binding,has 1.0 0.000143348623853 1 0 1
cyp2c19,cyp2d6 1.0 0.000573394495413 0 4 -4
with,haca 1.0 0.000143348623853 0 1 -1
as,risk 1.0 0.000286697247706 0 2 -2
viracept,and 0.5 0.000286697247706 1 3 -2
proportions,in 1.0 0.000143348623853 0 1 -1
of,newborns 1.0 0.000143348623853 0 1 -1
breadth,of 1.0 0.000143348623853 0 1 -1
appropriate,adjustment 0.333333333333 0.000143348623853 1 2 -1
viii,antigen 1.0 0.000286697247706 0 2 -2
intravenously,to 1.0 0.000143348623853 1 0 1
opioids,co-administration 1.0 0.000143348623853 1 0 1
of,nephrotoxic 1.0 0.000143348623853 0 1 -1
exposures,of 0.6 0.00043004587156 4 1 3
prescription,dose 1.0 0.000286697247706 2 0 2
the,broadening 1.0 0.000143348623853 0 1 -1
doses,that 1.0 0.000143348623853 0 1 -1
anti-inflammatory,have 1.0 0.000143348623853 1 0 1
therefore,advisable 1.0 0.000143348623853 1 0 1
enzymes,are 0.0 0.0 1 1 0
schizophrenia,schizoaffective 1.0 0.000143348623853 1 0 1
dinitrate,chloride 1.0 0.000143348623853 0 1 -1
indicates,that 0.25 0.000286697247706 3 5 -2
significant,accuracy 1.0 0.000143348623853 1 0 1
histologic,type 1.0 0.000143348623853 0 1 -1
enzyme,would 1.0 0.000143348623853 0 1 -1
contain,any 1.0 0.000143348623853 1 0 1
itraconazole,co-administration 1.0 0.000143348623853 0 1 -1
amiodarone-treated,patients 1.0 0.000143348623853 0 1 -1
a,bioequivalence 1.0 0.000143348623853 0 1 -1
and,synthetic 1.0 0.000286697247706 0 2 -2
sodium,may 0.333333333333 0.000143348623853 2 1 1
accordingly,when 1.0 0.000143348623853 1 0 1
decreased,respectively 1.0 0.000143348623853 1 0 1
exceeded,when 1.0 0.000143348623853 1 0 1
and,coly-mycin 1.0 0.000143348623853 1 0 1
hand,promoted 1.0 0.000143348623853 0 1 -1
thyroxine,increases 1.0 0.000143348623853 1 0 1
levels,could 1.0 0.00043004587156 0 3 -3
using,concomitant 1.0 0.000143348623853 0 1 -1
prolonged,prothrombin 1.0 0.000286697247706 2 0 2
additive,sedative 1.0 0.000143348623853 1 0 1
consequent,possible 1.0 0.000143348623853 1 0 1
selective,peripheral 1.0 0.000143348623853 1 0 1
human,cytochrome 1.0 0.000286697247706 0 2 -2
some,molecular 1.0 0.000143348623853 0 1 -1
common,comorbidity 1.0 0.000143348623853 0 1 -1
alone,when 1.0 0.000143348623853 0 1 -1
vascular,lesions 1.0 0.000143348623853 0 1 -1
given,intravenously 1.0 0.000143348623853 0 1 -1
if,you 0.4 0.000573394495413 3 7 -4
aeruginosa,were 1.0 0.000143348623853 0 1 -1
the,cautious 1.0 0.000143348623853 1 0 1
especially,conduction 1.0 0.000143348623853 0 1 -1
acromegaly,and 1.0 0.000143348623853 0 1 -1
theoretically,it 1.0 0.000143348623853 0 1 -1
fifteen,to 1.0 0.000143348623853 0 1 -1
oral,during 1.0 0.000143348623853 1 0 1
inadequate,to 1.0 0.000143348623853 0 1 -1
from,midcycle 1.0 0.000143348623853 0 1 -1
experience,enhanced 1.0 0.000143348623853 1 0 1
a,mammalian 1.0 0.000143348623853 0 1 -1
metabolism,mediated 1.0 0.000286697247706 0 2 -2
of,tablets 0.6 0.00043004587156 4 1 3
endothelial,dysfunction 1.0 0.000286697247706 0 2 -2
though,reversible 1.0 0.000143348623853 1 0 1
c9,substrates 1.0 0.000143348623853 0 1 -1
paper,we 1.0 0.000143348623853 0 1 -1
as,inderal 1.0 0.000143348623853 0 1 -1
since,does 1.0 0.000143348623853 0 1 -1
analyses,were 1.0 0.000143348623853 0 1 -1
endogenous,steroid 1.0 0.000143348623853 1 0 1
cardiac,autonomic 1.0 0.000143348623853 1 0 1
concentration,c12hr 1.0 0.000143348623853 1 0 1
instruct,the 1.0 0.000143348623853 0 1 -1
undertaken,only 1.0 0.000143348623853 1 0 1
following,initial 1.0 0.000143348623853 0 1 -1
have,generally 1.0 0.000143348623853 0 1 -1
hydroxydesloratadine,pharmacokinetics 1.0 0.000143348623853 0 1 -1
concurrently,patient 1.0 0.000143348623853 0 1 -1
ranged,from 1.0 0.000143348623853 0 1 -1
formal,drug 1.0 0.000573394495413 0 4 -4
taking,mg 0.2 0.000143348623853 3 2 1
aerosol,particles 1.0 0.000860091743119 0 6 -6
and,achieve 1.0 0.000143348623853 1 0 1
effective,there 1.0 0.000143348623853 0 1 -1
hypotension,developed 1.0 0.000143348623853 1 0 1
agent,and 0.0 0.0 1 1 0
withdrawal,methadone 1.0 0.000143348623853 1 0 1
occur,following 1.0 0.000143348623853 0 1 -1
cold,remedies 1.0 0.000143348623853 1 0 1
segment,of 1.0 0.000286697247706 0 2 -2
renal,impairment 0.0 0.0 3 3 0
or,mycophenolate 1.0 0.000143348623853 0 1 -1
its,rate 1.0 0.000143348623853 0 1 -1
the,pharmacology-related 1.0 0.000143348623853 0 1 -1
the,chronically 1.0 0.000143348623853 0 1 -1
provide,close 0.0 0.0 1 1 0
delayed,until 1.0 0.000286697247706 0 2 -2
are,commonly 1.0 0.000143348623853 0 1 -1
and,leading 0.0 0.0 1 1 0
produce,hyperglycemia 1.0 0.000573394495413 0 4 -4
p,a 0.5 0.000286697247706 1 3 -2
reportedly,are 1.0 0.000143348623853 1 0 1
p,o 0.333333333333 0.000143348623853 2 1 1
release,the 1.0 0.000143348623853 1 0 1
the,a-blocking 1.0 0.000143348623853 0 1 -1
free,hormone 1.0 0.00043004587156 0 3 -3
patients,experiencing 0.0 0.0 1 1 0
additional,method 1.0 0.000143348623853 0 1 -1
taking,should 0.333333333333 0.000143348623853 1 2 -1
non-depolarising,muscle 1.0 0.000143348623853 1 0 1
classes,ii 1.0 0.000286697247706 0 2 -2
diarrhea,or 1.0 0.000143348623853 0 1 -1
and,discontinuation 0.333333333333 0.000143348623853 2 1 1
of,alone 0.666666666667 0.000573394495413 1 5 -4
difference,in 1.0 0.000716743119266 0 5 -5
olanzapine,is 1.0 0.000143348623853 0 1 -1
evidence,suggests 0.0 0.0 1 1 0
indicate,cyp3a4 1.0 0.000143348623853 0 1 -1
with,resultant 1.0 0.000143348623853 0 1 -1
obtained,evidence 1.0 0.000143348623853 0 1 -1
phenyltheophylline,and 1.0 0.000143348623853 0 1 -1
with,reduce 1.0 0.000143348623853 1 0 1
revia,and 0.333333333333 0.000143348623853 1 2 -1
peak,concentrations 1.0 0.000286697247706 0 2 -2
prostatic,epithelium 0.0 0.0 1 1 0
compounds,was 1.0 0.000143348623853 0 1 -1
isoenzyme,family 1.0 0.000143348623853 0 1 -1
false-negative,result 1.0 0.000286697247706 0 2 -2
aspirin,as 1.0 0.000143348623853 1 0 1
thus,impairing 1.0 0.000143348623853 1 0 1
benefit,when 1.0 0.000143348623853 0 1 -1
trisilicate,when 1.0 0.000143348623853 1 0 1
when,or 0.333333333333 0.000143348623853 1 2 -1
interaction,occurs 1.0 0.000143348623853 0 1 -1
artifactually,low 1.0 0.000143348623853 0 1 -1
will,depend 1.0 0.000716743119266 5 0 5
or,products 1.0 0.000143348623853 1 0 1
of,arrhythmias 1.0 0.000286697247706 0 2 -2
following,concurrent 1.0 0.000143348623853 1 0 1
absorption,by 1.0 0.000143348623853 1 0 1
of,diffusible 1.0 0.000143348623853 0 1 -1
complications,careful 1.0 0.000143348623853 0 1 -1
serial,broth 1.0 0.000143348623853 0 1 -1
disease,medications 1.0 0.000143348623853 0 1 -1
mouth,use 1.0 0.000143348623853 1 0 1
number,induced 1.0 0.000143348623853 1 0 1
omega-conotoxin,gvia-sensitive 1.0 0.000143348623853 0 1 -1
steady-state,pharmacokinetics 1.0 0.000716743119266 0 5 -5
isis-2,currently 1.0 0.000143348623853 0 1 -1
an,action 1.0 0.000286697247706 0 2 -2
of,coadministration 0.428571428571 0.00043004587156 2 5 -3
use,products 1.0 0.000143348623853 1 0 1
therefore,potentiate 1.0 0.000143348623853 0 1 -1
count,ria 1.0 0.000143348623853 0 1 -1
subset,of 1.0 0.00114678899083 0 8 -8
orasone,others 1.0 0.000143348623853 0 1 -1
dactinomycin,may 1.0 0.000143348623853 0 1 -1
the,urinary 0.2 0.000143348623853 2 3 -1
stable,as 1.0 0.000286697247706 0 2 -2
and,maintenance 1.0 0.000143348623853 1 0 1
gene,cassette 1.0 0.000143348623853 0 1 -1
or,teratogenic 1.0 0.000143348623853 0 1 -1
gonadotropin,levels 1.0 0.000286697247706 0 2 -2
exposure,presumably 1.0 0.000143348623853 1 0 1
normalized,ratio 0.5 0.000286697247706 3 1 2
and,l-ccg 1.0 0.00043004587156 0 3 -3
atrovent,inhalation 0.333333333333 0.000143348623853 1 2 -1
p450iid6,cyp2d6 1.0 0.000143348623853 0 1 -1
to,enhance 1.0 0.000860091743119 6 0 6
of,theophylline-related 0.5 0.000286697247706 3 1 2
no,effect 0.653333333333 0.00702408256881 13 62 -49
effects,resulting 1.0 0.000143348623853 1 0 1
when,deet 1.0 0.000143348623853 0 1 -1
pure,powders 1.0 0.000143348623853 1 0 1
that,starlix 1.0 0.000143348623853 0 1 -1
to,years 0.5 0.000286697247706 1 3 -2
anaesthesia,for 1.0 0.000143348623853 0 1 -1
or,infusions 1.0 0.000143348623853 0 1 -1
in,chronic 0.0 0.0 1 1 0
ccnu,was 1.0 0.000143348623853 0 1 -1
activity,persists 1.0 0.000143348623853 1 0 1
time,spent 0.0 0.0 1 1 0
the,neutrophil 1.0 0.000143348623853 0 1 -1
specific,information 1.0 0.000143348623853 0 1 -1
administering,compounds 1.0 0.000143348623853 0 1 -1
analogues,which 1.0 0.00043004587156 3 0 3
interactions,see 1.0 0.000143348623853 0 1 -1
in,bioavailability 0.333333333333 0.000143348623853 1 2 -1
men,with 1.0 0.000286697247706 0 2 -2
the,decreased 1.0 0.000286697247706 0 2 -2
examined,the 1.0 0.00043004587156 0 3 -3
when,meclofenamate 1.0 0.000143348623853 1 0 1
acid,will 1.0 0.000143348623853 0 1 -1
clearance,from 0.0 0.0 1 1 0
the,activity 0.4 0.00114678899083 6 14 -8
its,ability 1.0 0.000143348623853 1 0 1
innovar,or 1.0 0.000143348623853 1 0 1
bred,for 1.0 0.000143348623853 0 1 -1
either,singly 1.0 0.000143348623853 0 1 -1
chlorpropamides,plasma 1.0 0.000143348623853 1 0 1
p450-based,metabolic 1.0 0.000143348623853 0 1 -1
juice,with 1.0 0.000286697247706 0 2 -2
enhance,cardiovascular 1.0 0.000143348623853 0 1 -1
of,rural 1.0 0.000143348623853 0 1 -1
and,note 1.0 0.000143348623853 0 1 -1
are,consistent 1.0 0.000143348623853 0 1 -1
reached,by 1.0 0.000143348623853 0 1 -1
foods,fortified 1.0 0.000143348623853 1 0 1
several,aed 1.0 0.000143348623853 1 0 1
procedure,is 1.0 0.000143348623853 0 1 -1
however,high 1.0 0.000143348623853 1 0 1
concentrations,did 1.0 0.000143348623853 0 1 -1
steady-state,in 1.0 0.000143348623853 0 1 -1
non-specialist,hospitals 1.0 0.000143348623853 0 1 -1
s-ast,and 1.0 0.000143348623853 0 1 -1
solvents,this 1.0 0.000143348623853 0 1 -1
preparations,has 1.0 0.000143348623853 0 1 -1
also,on 1.0 0.000143348623853 0 1 -1
and,mesenteric 0.0 0.0 1 1 0
molecule,naflu 1.0 0.000143348623853 0 1 -1
prediction,of 1.0 0.000143348623853 0 1 -1
auc,infinity 1.0 0.000143348623853 0 1 -1
myelotoxic,chemotherapy 1.0 0.000143348623853 1 0 1
irritability,and 1.0 0.000143348623853 1 0 1
interresponse,times 1.0 0.000143348623853 0 1 -1
subject,themselves 1.0 0.000143348623853 0 1 -1
and,initiation 1.0 0.000286697247706 2 0 2
well,as 0.105263157895 0.000573394495413 17 21 -4
and,platelet 0.5 0.000286697247706 1 3 -2
curve,after 1.0 0.000143348623853 1 0 1
interactions,albuterol 1.0 0.000143348623853 1 0 1
clearance,resulting 1.0 0.000143348623853 0 1 -1
transmission,should 1.0 0.000143348623853 0 1 -1
these,may 0.0 0.0 1 1 0
one,report 0.6 0.00043004587156 4 1 3
physician,or 1.0 0.000143348623853 1 0 1
cyp1a2,which 0.0 0.0 1 1 0
pentamidine,may 1.0 0.000286697247706 0 2 -2
esophageal,motility 1.0 0.000143348623853 0 1 -1
and,coronary 1.0 0.000143348623853 0 1 -1
the,likelihood 0.2 0.000143348623853 3 2 1
each,dose 0.0 0.0 1 1 0
increased,clearance 1.0 0.000143348623853 0 1 -1
be,drawn 1.0 0.00043004587156 0 3 -3
concomitant,at 1.0 0.000286697247706 0 2 -2
biweekly,intervals 1.0 0.000286697247706 0 2 -2
de,pointes 0.333333333333 0.000143348623853 1 2 -1
sparing,pharmacological 1.0 0.000143348623853 0 1 -1
psychomotor,performance 0.5 0.000286697247706 3 1 2
its,plasma 0.0 0.0 1 1 0
may,not 0.272727272727 0.00043004587156 4 7 -3
benzodiazepines,metabolized 1.0 0.000143348623853 1 0 1
mg,result 1.0 0.000143348623853 0 1 -1
when,used 0.0833333333333 0.000286697247706 13 11 2
dmpge2,were 1.0 0.000143348623853 0 1 -1
during,transfer 1.0 0.000143348623853 0 1 -1
antiepileptic,potential 1.0 0.000143348623853 0 1 -1
comparable,cognitive 1.0 0.000143348623853 0 1 -1
pharmacokinetic,parameter 1.0 0.000143348623853 0 1 -1
storage,vesicles 1.0 0.000143348623853 0 1 -1
reported,when 1.0 0.00114678899083 8 0 8
or,therapy 1.0 0.000143348623853 1 0 1
the,testes 1.0 0.000143348623853 0 1 -1
i,mg 1.0 0.000143348623853 1 0 1
arthritis,concomitant 1.0 0.000143348623853 0 1 -1
were,treated 0.25 0.000286697247706 3 5 -2
beverages,in 1.0 0.000143348623853 0 1 -1
prospective,study 1.0 0.000143348623853 0 1 -1
in,gastrointestinal 1.0 0.000143348623853 1 0 1
the,goal 1.0 0.000286697247706 0 2 -2
defined,as 1.0 0.000143348623853 0 1 -1
kg,infused 1.0 0.000143348623853 0 1 -1
who,developed 1.0 0.000143348623853 1 0 1
at,or 1.0 0.000143348623853 1 0 1
where,the 1.0 0.000286697247706 0 2 -2
serum,constituent 1.0 0.000143348623853 0 1 -1
coma,have 1.0 0.000143348623853 1 0 1
morning,doses 1.0 0.000143348623853 0 1 -1
when,nsaids 1.0 0.00043004587156 3 0 3
malignant,hyperthermia 1.0 0.000143348623853 1 0 1
before,taking 0.333333333333 0.000143348623853 1 2 -1
was,inappropriate 1.0 0.000143348623853 0 1 -1
concentrations,cyp3a4 1.0 0.000286697247706 0 2 -2
of,sprycel 1.0 0.000286697247706 2 0 2
simvastatin,and 1.0 0.000143348623853 1 0 1
microsomal,metabolizing 1.0 0.000143348623853 0 1 -1
gout,and 1.0 0.000143348623853 0 1 -1
if,withdrawn 1.0 0.000143348623853 0 1 -1
study,did 0.333333333333 0.000143348623853 1 2 -1
life,of 1.0 0.000143348623853 1 0 1
longer,than 1.0 0.000143348623853 1 0 1
certain,conditions 1.0 0.000143348623853 0 1 -1
increases,serum 1.0 0.000143348623853 0 1 -1
meals,was 1.0 0.000286697247706 0 2 -2
the,existence 1.0 0.000143348623853 0 1 -1
altered,renal 1.0 0.000143348623853 0 1 -1
acetate,with 1.0 0.000143348623853 1 0 1
corticosteroids,a 1.0 0.00043004587156 3 0 3
serum,i 1.0 0.000286697247706 0 2 -2
hormone,replacement 1.0 0.000143348623853 0 1 -1
interactions,would 1.0 0.000286697247706 0 2 -2
circulates,largely 1.0 0.000143348623853 0 1 -1
urine,which 1.0 0.000143348623853 0 1 -1
to,worsen 1.0 0.000143348623853 0 1 -1
lithium,reversible 1.0 0.000143348623853 1 0 1
is,approximately 1.0 0.000286697247706 2 0 2
sustiva,is 0.5 0.000286697247706 1 3 -2
type-specific,differences 1.0 0.000143348623853 0 1 -1
mixing,novolog 1.0 0.000286697247706 0 2 -2
seven,cerebrovascular 1.0 0.000143348623853 0 1 -1
had,returned 1.0 0.000143348623853 1 0 1
antimigraine,derivatives 1.0 0.000143348623853 1 0 1
derivatives,in 0.0 0.0 1 1 0
activity,thus 1.0 0.000143348623853 1 0 1
difficult,to 1.0 0.000286697247706 0 2 -2
alone,mg 1.0 0.000143348623853 0 1 -1
its,congeners 1.0 0.000143348623853 0 1 -1
akathisia,however 1.0 0.000143348623853 0 1 -1
sublingual,mg 1.0 0.000143348623853 1 0 1
uganda,since 1.0 0.000143348623853 0 1 -1
relationship,and 1.0 0.000143348623853 1 0 1
alosetron,also 1.0 0.000143348623853 0 1 -1
colorectal,cancer 1.0 0.000143348623853 0 1 -1
infants,a 1.0 0.000286697247706 0 2 -2
enzymes,capable 1.0 0.000143348623853 0 1 -1
substrates,inhibitors 1.0 0.00043004587156 0 3 -3
thus,inhibiting 1.0 0.000573394495413 4 0 4
slows,the 1.0 0.000143348623853 0 1 -1
manifestation,of 1.0 0.000143348623853 1 0 1
emboli,rises 1.0 0.000143348623853 0 1 -1
of,allergic 0.0 0.0 1 1 0
a,rebound 1.0 0.000143348623853 1 0 1
that,same 1.0 0.000143348623853 0 1 -1
from,containing 1.0 0.000143348623853 1 0 1
of,vasodilator 1.0 0.000143348623853 0 1 -1
improve,sensitivity 1.0 0.000143348623853 0 1 -1
ketoconazole,may 1.0 0.00043004587156 3 0 3
readings,were 1.0 0.000143348623853 0 1 -1
more,in 1.0 0.000143348623853 1 0 1
is,reduced 0.0769230769231 0.000143348623853 6 7 -1
has,proven 1.0 0.000143348623853 0 1 -1
and,genetically 1.0 0.000143348623853 0 1 -1
for,migraine 1.0 0.000143348623853 1 0 1
heart,block 0.333333333333 0.000143348623853 1 2 -1
to,report 1.0 0.000143348623853 0 1 -1
interactions,flupenthixol 1.0 0.000143348623853 1 0 1
pre-treatment,with 1.0 0.000143348623853 1 0 1
the,blood 0.0526315789474 0.000143348623853 9 10 -1
mechanism,under 1.0 0.000143348623853 1 0 1
following,similar 1.0 0.000286697247706 0 2 -2
with,antagonists 1.0 0.000286697247706 2 0 2
drugs,associated 1.0 0.000286697247706 0 2 -2
children,has 1.0 0.000143348623853 0 1 -1
a,systemic 1.0 0.000143348623853 0 1 -1
loss,compared 1.0 0.000143348623853 1 0 1
against,of 1.0 0.000143348623853 0 1 -1
esomeprazole,is 1.0 0.000143348623853 0 1 -1
p4502d6,in 1.0 0.000143348623853 0 1 -1
of,pharmacokinetics 1.0 0.000143348623853 0 1 -1
no,first-pass 1.0 0.000143348623853 0 1 -1
type,diabetes 0.6 0.00043004587156 1 4 -3
for,loss 0.8 0.00114678899083 1 9 -8
occur,physicians 1.0 0.000143348623853 1 0 1
on,sgpt 1.0 0.000143348623853 1 0 1
have,long 1.0 0.000143348623853 0 1 -1
felbatol,at 0.333333333333 0.000143348623853 2 1 1
inhalational,such 1.0 0.000143348623853 1 0 1
clinical,significance 0.771428571429 0.00387041284404 4 31 -27
a,week 0.5 0.000573394495413 2 6 -4
conclusions,to 1.0 0.000143348623853 0 1 -1
pronounced,when 1.0 0.000143348623853 1 0 1
kg,min 1.0 0.000286697247706 0 2 -2
displaced,from 1.0 0.00043004587156 3 0 3
fashion,from 1.0 0.000143348623853 0 1 -1
similar,study 0.0 0.0 1 1 0
of,observed 1.0 0.000143348623853 0 1 -1
of,welchol 1.0 0.000143348623853 0 1 -1
strength,mg 1.0 0.000143348623853 0 1 -1
trough,serum 1.0 0.000286697247706 0 2 -2
isoenzyme,system 1.0 0.000143348623853 0 1 -1
if,tranxene 1.0 0.000286697247706 0 2 -2
than,dose 1.0 0.000143348623853 0 1 -1
hematology,taxol 1.0 0.000143348623853 0 1 -1
maalox,decreased 1.0 0.000143348623853 1 0 1
cyp-2c19,by 1.0 0.000143348623853 0 1 -1
preclude,effectiveness 1.0 0.000286697247706 0 2 -2
day,resulted 1.0 0.000143348623853 1 0 1
indocin,resulted 1.0 0.000143348623853 1 0 1
to,delirium 1.0 0.000143348623853 1 0 1
the,supraventricular 1.0 0.000143348623853 1 0 1
agents,no 1.0 0.000286697247706 0 2 -2
in,common 1.0 0.000143348623853 1 0 1
binding,in 0.333333333333 0.000143348623853 2 1 1
r,b 1.0 0.000143348623853 0 1 -1
dose,studies 1.0 0.000143348623853 1 0 1
such,considerations 1.0 0.000143348623853 0 1 -1
c,pegasys 1.0 0.000143348623853 0 1 -1
dose-response,curves 0.0 0.0 1 1 0
r,p 1.0 0.000143348623853 0 1 -1
of,mhd 1.0 0.000143348623853 0 1 -1
potentiation,synergistic 1.0 0.000143348623853 0 1 -1
cause,synergistic 1.0 0.000143348623853 1 0 1
hydrochloride,does 1.0 0.000143348623853 0 1 -1
in,treatment-experienced 1.0 0.000286697247706 0 2 -2
activity,potentiates 1.0 0.000143348623853 1 0 1
fda,have 1.0 0.000143348623853 0 1 -1
as,an 0.666666666667 0.000573394495413 1 5 -4
min,p 0.0 0.0 1 1 0
the,mean 0.1875 0.000860091743119 13 19 -6
phenytoin,levels 1.0 0.000143348623853 0 1 -1
diabetic,nsaids 1.0 0.000143348623853 1 0 1
sucralfate,and 0.0 0.0 1 1 0
protein,mna 1.0 0.000143348623853 0 1 -1
to,either 0.0 0.0 1 1 0
of,thiazide 1.0 0.000286697247706 2 0 2
following,enzymes 1.0 0.000143348623853 0 1 -1
appears,to 0.428571428571 0.000860091743119 4 10 -6
dissolution,rate 1.0 0.000286697247706 0 2 -2
drawn,into 1.0 0.000143348623853 0 1 -1
recovery,in 1.0 0.000143348623853 0 1 -1
vitamin,d 0.0967741935484 0.00043004587156 17 14 3
the,pharmacodynamics 1.0 0.00129013761468 0 9 -9
this,situation 1.0 0.000143348623853 0 1 -1
of,ras-3t3 1.0 0.000143348623853 0 1 -1
through,cyp3a4 1.0 0.000143348623853 0 1 -1
require,that 1.0 0.000143348623853 1 0 1
giving,in 1.0 0.000143348623853 1 0 1
affect,cyp3a4 1.0 0.000143348623853 0 1 -1
the,divided 1.0 0.000143348623853 1 0 1
absorption,has 1.0 0.000143348623853 0 1 -1
or,tubular 1.0 0.000143348623853 0 1 -1
advanced,or 1.0 0.000143348623853 1 0 1
opioid-antagonist,and 1.0 0.000143348623853 0 1 -1
unclear,patients 1.0 0.000143348623853 0 1 -1
or,micrograms 1.0 0.000143348623853 0 1 -1
blockers,beta 1.0 0.000143348623853 0 1 -1
indinavir,steady-state 1.0 0.000143348623853 1 0 1
cyclosporine,diclofenac 1.0 0.000143348623853 0 1 -1
be,stopped 0.0 0.0 1 1 0
during,videx 1.0 0.000143348623853 0 1 -1
indications,use 1.0 0.000143348623853 0 1 -1
and,live-attenuated 1.0 0.000143348623853 1 0 1
of,what 1.0 0.000143348623853 0 1 -1
involving,nizoral 1.0 0.000143348623853 1 0 1
tachycardia,do 1.0 0.000143348623853 0 1 -1
compatibility,of 1.0 0.000143348623853 0 1 -1
drug,to 1.0 0.000286697247706 0 2 -2
of,camptosar 0.0 0.0 1 1 0
to,lower 1.0 0.000286697247706 0 2 -2
according,to 0.6 0.00043004587156 1 4 -3
and,respectively 0.529411764706 0.00129013761468 13 4 9
naloxone-sensitive,endorphinergic 1.0 0.000143348623853 0 1 -1
report,describes 0.333333333333 0.000143348623853 2 1 1
lower,meclofenamate 1.0 0.000143348623853 1 0 1
some,urinary 1.0 0.000143348623853 0 1 -1
chronically,had 0.0 0.0 1 1 0
basic,as 1.0 0.000143348623853 1 0 1
one,or 0.75 0.00172018348624 2 14 -12
glucose,when 1.0 0.000143348623853 0 1 -1
administering,other 1.0 0.000286697247706 0 2 -2
were,to 0.6 0.00043004587156 1 4 -3
following,doses 0.0 0.0 1 1 0
elevation,in 0.2 0.000143348623853 3 2 1
observations,now 1.0 0.000143348623853 0 1 -1
the,histidine 1.0 0.000143348623853 0 1 -1
an,an 1.0 0.000143348623853 0 1 -1
received,tended 1.0 0.000143348623853 0 1 -1
experiences,are 1.0 0.000143348623853 0 1 -1
for,comprehensive 1.0 0.000143348623853 0 1 -1
conversely,may 1.0 0.000143348623853 1 0 1
five,men 1.0 0.000143348623853 0 1 -1
epinephrine,also 1.0 0.000143348623853 1 0 1
predisposition,for 1.0 0.000143348623853 0 1 -1
effects,specifically 1.0 0.000143348623853 0 1 -1
p-450iie1,a 1.0 0.000143348623853 0 1 -1
circulating,and 1.0 0.000286697247706 0 2 -2
by,multiple-dose 1.0 0.000143348623853 0 1 -1
for,to 0.0 0.0 2 2 0
nicotinic,receptors 1.0 0.000143348623853 0 1 -1
n,and 1.0 0.000286697247706 2 0 2
ibandronate,should 1.0 0.000143348623853 1 0 1
in,nursing 1.0 0.00043004587156 0 3 -3
sh,ea 1.0 0.000143348623853 0 1 -1
levels,up 1.0 0.000143348623853 0 1 -1
products,absorption 1.0 0.000143348623853 0 1 -1
amphetamines,may 0.75 0.00172018348624 14 2 12
modest,increases 1.0 0.000286697247706 2 0 2
of,racemic 0.428571428571 0.00043004587156 2 5 -3
hormones,appear 1.0 0.000143348623853 0 1 -1
greater,fecal 1.0 0.000143348623853 0 1 -1
when,considering 1.0 0.000143348623853 1 0 1
and,terminal 1.0 0.000143348623853 1 0 1
theoretical,potential 0.0 0.0 1 1 0
sickness,medications 1.0 0.000143348623853 0 1 -1
are,typically 1.0 0.000143348623853 0 1 -1
administered,parenterally 1.0 0.000286697247706 0 2 -2
that,given 0.0 0.0 1 1 0
antagonists,angiotensin 1.0 0.000143348623853 0 1 -1
liver,alt 1.0 0.000143348623853 1 0 1
relevant,concentrations 1.0 0.000143348623853 0 1 -1
on,hormone 1.0 0.000286697247706 0 2 -2
theoretically,the 1.0 0.000143348623853 0 1 -1
and,developed 1.0 0.000286697247706 2 0 2
administered,prior 1.0 0.000286697247706 2 0 2
respiratory,and 0.0 0.0 1 1 0
medications,may 0.6 0.00043004587156 1 4 -3
studies,studies 1.0 0.000143348623853 0 1 -1
that,after 1.0 0.000286697247706 0 2 -2
premedline,and 1.0 0.000143348623853 0 1 -1
scanning,electron 1.0 0.000143348623853 0 1 -1
epithelium,in 1.0 0.000143348623853 1 0 1
or,dihydroxyflavone 1.0 0.000286697247706 0 2 -2
experience,in 0.0 0.0 1 1 0
of,natrecor 1.0 0.000143348623853 0 1 -1
serum,by 1.0 0.000143348623853 1 0 1
convulsions,in 0.0 0.0 1 1 0
of,thiobarbituric 1.0 0.000143348623853 0 1 -1
added,in 1.0 0.000286697247706 0 2 -2
the,bioavailabillty 1.0 0.000143348623853 1 0 1
ultimately,atherosclerotic 1.0 0.000143348623853 0 1 -1
experienced,elevated 1.0 0.000143348623853 0 1 -1
a1,c9 1.0 0.000143348623853 0 1 -1
of,precedex 0.333333333333 0.000143348623853 2 1 1
general,skeletal 1.0 0.000286697247706 2 0 2
eg,other 1.0 0.000143348623853 1 0 1
with,dosage 1.0 0.000286697247706 0 2 -2
bid,resulted 1.0 0.000143348623853 1 0 1
denileukin,diftitox 1.0 0.000143348623853 0 1 -1
are,to 0.142857142857 0.000143348623853 4 3 1
either,dose 1.0 0.000143348623853 0 1 -1
transient,elevations 0.333333333333 0.000143348623853 2 1 1
without,changes 1.0 0.000143348623853 0 1 -1
metabolites,n-desmethylclozapine 1.0 0.000143348623853 0 1 -1
this,may 0.789473684211 0.0021502293578 2 17 -15
more,commonly 1.0 0.000286697247706 2 0 2
herbal,therapy 1.0 0.000143348623853 0 1 -1
patients,response 1.0 0.000143348623853 0 1 -1
common,phenotypic 1.0 0.000143348623853 0 1 -1
old,participated 1.0 0.000143348623853 0 1 -1
small,n 1.0 0.000143348623853 1 0 1
on,positive 1.0 0.000143348623853 0 1 -1
with,breast 1.0 0.000143348623853 1 0 1
evidence,indicating 1.0 0.000143348623853 0 1 -1
carbonate,mg 1.0 0.000143348623853 0 1 -1
circulating,total 1.0 0.00043004587156 0 3 -3
lesser,degree 1.0 0.000143348623853 0 1 -1
escalating,use 1.0 0.000143348623853 0 1 -1
intestinal,adenocarcinomas 0.0 0.0 1 1 0
inhibit,aldehyde 1.0 0.000143348623853 0 1 -1
cns,vascular 1.0 0.000143348623853 0 1 -1
ect,there 1.0 0.000143348623853 0 1 -1
cimetidine,can 1.0 0.000143348623853 1 0 1
and,mhd 1.0 0.00043004587156 0 3 -3
without,doctor 1.0 0.000143348623853 0 1 -1
should,therefore 0.111111111111 0.000143348623853 5 4 1
tab,ria 1.0 0.000143348623853 0 1 -1
or,decrease 0.0 0.0 2 2 0
sodation,of 1.0 0.000143348623853 1 0 1
aldomet,use 1.0 0.000143348623853 1 0 1
being,converted 1.0 0.000143348623853 1 0 1
an,hmg-coa 1.0 0.000143348623853 1 0 1
before,each 1.0 0.000143348623853 0 1 -1
and,some 0.0 0.0 4 4 0
sustained-release,with 1.0 0.000143348623853 0 1 -1
the,tyrosine 1.0 0.000143348623853 0 1 -1
potentiate,renal 1.0 0.000143348623853 1 0 1
direct,treatment 1.0 0.000143348623853 0 1 -1
administration,twice 1.0 0.000143348623853 0 1 -1
and,reduce 0.0 0.0 1 1 0
in,situations 1.0 0.00043004587156 0 3 -3
vitamin,b12 0.333333333333 0.000143348623853 2 1 1
starting,or 1.0 0.000286697247706 0 2 -2
recovery,time 0.0 0.0 1 1 0
carbohydrate,metabolism 1.0 0.000143348623853 0 1 -1
exceed,mg 1.0 0.000143348623853 1 0 1
study,denileukin 1.0 0.000143348623853 0 1 -1
interferences,between 1.0 0.000143348623853 0 1 -1
keppra,on 1.0 0.000143348623853 0 1 -1
have,indicated 1.0 0.000286697247706 0 2 -2
these,or 0.333333333333 0.000143348623853 1 2 -1
to,hours 0.25 0.000286697247706 5 3 2
with,fortovase 1.0 0.000143348623853 0 1 -1
its,adverse 1.0 0.000143348623853 0 1 -1
mg,dl 0.333333333333 0.000143348623853 1 2 -1
romazicon,exerts 1.0 0.000143348623853 1 0 1
acute,asthma 1.0 0.000143348623853 0 1 -1
to,competitively 1.0 0.000143348623853 1 0 1
capsules,twice 1.0 0.000143348623853 0 1 -1
acetate,affected 1.0 0.000143348623853 1 0 1
potentially,fatal 0.0 0.0 1 1 0
each,treatment 1.0 0.000143348623853 0 1 -1
of,n-allylnormetazocine 1.0 0.000286697247706 0 2 -2
active,in 1.0 0.000143348623853 1 0 1
cell,cultures 1.0 0.000286697247706 0 2 -2
day,to 1.0 0.000860091743119 0 6 -6
diabetics,dosage 1.0 0.000143348623853 1 0 1
bone,marrow 0.428571428571 0.00043004587156 2 5 -3
are,warranted 1.0 0.000143348623853 0 1 -1
many,are 1.0 0.000143348623853 0 1 -1
between,a 0.0 0.0 1 1 0
subjects,decreases 1.0 0.000143348623853 0 1 -1
on,mean 1.0 0.000143348623853 0 1 -1
prevent,the 0.6 0.00043004587156 4 1 3
theophylline-related,side 1.0 0.000286697247706 2 0 2
failure,as 0.6 0.00043004587156 1 4 -3
major,cause 1.0 0.000286697247706 0 2 -2
yields,a 1.0 0.000143348623853 1 0 1
compounds,requiring 1.0 0.000143348623853 0 1 -1
first,pass 1.0 0.000286697247706 0 2 -2
a,tca 0.6 0.00043004587156 1 4 -3
oral,upon 1.0 0.000143348623853 1 0 1
hypertension,hypercoagulation 1.0 0.000143348623853 0 1 -1
explained,by 0.0 0.0 1 1 0
including,or 0.5 0.000286697247706 1 3 -2
maintenance,schedule 1.0 0.000143348623853 1 0 1
these,recommendations 1.0 0.000143348623853 0 1 -1
antifungals,grapefruit 1.0 0.000143348623853 1 0 1
when,norpace 1.0 0.000143348623853 0 1 -1
solvents,can 1.0 0.000143348623853 0 1 -1
also,reduced 1.0 0.000286697247706 0 2 -2
to,has 1.0 0.000143348623853 1 0 1
relationship,physicians 1.0 0.000143348623853 1 0 1
the,other 0.857142857143 0.00172018348624 1 13 -12
antinonciceptive,effect 1.0 0.000143348623853 0 1 -1
precedex,on 1.0 0.000143348623853 1 0 1
of,class 0.0 0.0 1 1 0
potentiated,when 0.333333333333 0.000286697247706 2 4 -2
cyp1a2,c8 1.0 0.000143348623853 0 1 -1
at,higher 0.0 0.0 1 1 0
failure,were 1.0 0.000143348623853 0 1 -1
a,method 1.0 0.00043004587156 0 3 -3
caspase-3,and 1.0 0.000143348623853 0 1 -1
by,similar 1.0 0.000286697247706 0 2 -2
gram,negative 1.0 0.000143348623853 0 1 -1
either,toxicities 1.0 0.000143348623853 0 1 -1
initiated,and 1.0 0.000143348623853 0 1 -1
substitutes,may 0.0 0.0 1 1 0
and,higher 1.0 0.000286697247706 2 0 2
be,potential 1.0 0.000143348623853 0 1 -1
and,mean 0.333333333333 0.000286697247706 4 2 2
second,generation 1.0 0.000143348623853 0 1 -1
cyp2d6,i 1.0 0.000143348623853 1 0 1
for,dose 1.0 0.000286697247706 0 2 -2
dna-damaging,agents 1.0 0.000143348623853 0 1 -1
pharmacokinetics,have 1.0 0.000143348623853 0 1 -1
capsule,n 1.0 0.000143348623853 1 0 1
isocarboxazid,should 1.0 0.000143348623853 1 0 1
other,monoamine 1.0 0.000143348623853 1 0 1
concurrently,should 0.333333333333 0.000143348623853 1 2 -1
kg,for 0.333333333333 0.000143348623853 2 1 1
blocks,receptors 1.0 0.000143348623853 1 0 1
noted,a 1.0 0.000143348623853 0 1 -1
novolog,and 1.0 0.000143348623853 0 1 -1
daily,acquisition 1.0 0.000143348623853 0 1 -1
require,dose 1.0 0.00043004587156 0 3 -3
that,obtained 1.0 0.000143348623853 1 0 1
manifested,significantly 1.0 0.000143348623853 0 1 -1
and,apoptosis 1.0 0.000143348623853 0 1 -1
being,a 1.0 0.000143348623853 0 1 -1
therapy,or 1.0 0.000143348623853 0 1 -1
concurrently,it 1.0 0.000143348623853 0 1 -1
nine,patients 1.0 0.000143348623853 1 0 1
therapy,on 1.0 0.000143348623853 1 0 1
weaker,inhibitors 1.0 0.000143348623853 0 1 -1
microg,kg 0.333333333333 0.000143348623853 1 2 -1
therapy,of 0.333333333333 0.000143348623853 2 1 1
again,allowed 1.0 0.000143348623853 0 1 -1
be,acutely 1.0 0.000143348623853 1 0 1
continuing,surveillance 1.0 0.000143348623853 0 1 -1
our,data 1.0 0.000143348623853 1 0 1
general,population 1.0 0.00043004587156 0 3 -3
with,first-episode 1.0 0.000143348623853 0 1 -1
long,as 1.0 0.000143348623853 1 0 1
unknown,in 1.0 0.000143348623853 0 1 -1
not,experience 1.0 0.000143348623853 0 1 -1
two,type 1.0 0.000143348623853 0 1 -1
or,hepatic 0.333333333333 0.000143348623853 1 2 -1
elevations,seen 1.0 0.000143348623853 1 0 1
peripheral,wasting 1.0 0.000143348623853 0 1 -1
adl,mg 1.0 0.000286697247706 0 2 -2
femara,and 1.0 0.000143348623853 1 0 1
dose,will 1.0 0.000143348623853 1 0 1
agents,into 1.0 0.000143348623853 0 1 -1
larger,when 1.0 0.000143348623853 0 1 -1
hydroxy,acid 1.0 0.000143348623853 1 0 1
nimbex,before 1.0 0.000143348623853 0 1 -1
with,these 0.454545454545 0.000716743119266 3 8 -5
with,than 0.0 0.0 1 1 0
unchanged,and 1.0 0.000143348623853 0 1 -1
to,chemotherapy 1.0 0.000143348623853 0 1 -1
ssri-tca,interactions 1.0 0.000573394495413 4 0 4
as,hctz 1.0 0.000143348623853 0 1 -1
rarely,enuresis 1.0 0.000143348623853 0 1 -1
in,laboratory 1.0 0.000286697247706 0 2 -2
out,of 1.0 0.000286697247706 0 2 -2
from,mean 1.0 0.000143348623853 0 1 -1
with,that 0.5625 0.00258027522936 7 25 -18
qd,mg 1.0 0.000143348623853 1 0 1
to,obstetric 0.0 0.0 1 1 0
significantly,reduced 0.333333333333 0.000286697247706 4 2 2
towards,cyp1a2 0.0 0.0 1 1 0
frequent,doses 1.0 0.000143348623853 0 1 -1
including,continuous 1.0 0.000143348623853 0 1 -1
effects,celebrex 1.0 0.000143348623853 0 1 -1
compounds,attenuate 1.0 0.000143348623853 0 1 -1
and,levo-dromoran 1.0 0.000143348623853 1 0 1
significantly,reduces 1.0 0.000143348623853 1 0 1
density,bmax 1.0 0.000143348623853 0 1 -1
conjugation,through 1.0 0.000143348623853 0 1 -1
physostigmine,pretreatment 1.0 0.000143348623853 1 0 1
benzthiazide,may 1.0 0.000143348623853 1 0 1
may,or 1.0 0.000143348623853 0 1 -1
assists,in 1.0 0.000143348623853 0 1 -1
disease,patients 1.0 0.000143348623853 0 1 -1
dose-proportionality,and 1.0 0.000143348623853 0 1 -1
well,controlled 0.0 0.0 1 1 0
in,more 1.0 0.000143348623853 0 1 -1
hypertriglyceridemia,is 1.0 0.000143348623853 0 1 -1
p450,inhibitors 1.0 0.000286697247706 0 2 -2
as,narcotics 1.0 0.000143348623853 1 0 1
a,course 0.142857142857 0.000143348623853 3 4 -1
diminish,adrenal 1.0 0.000143348623853 1 0 1
cimetidine,and 0.0 0.0 1 1 0
a,sub- 1.0 0.000143348623853 0 1 -1
and,non-steroidal 1.0 0.000573394495413 4 0 4
in,sheep 1.0 0.000143348623853 0 1 -1
cyp3a4,mediated 1.0 0.000143348623853 0 1 -1
c9,ic50 1.0 0.000143348623853 0 1 -1
stomach,acidity 1.0 0.000143348623853 0 1 -1
and,didanosine-placebo 1.0 0.000143348623853 1 0 1
cordarone,i 1.0 0.000143348623853 0 1 -1
metabolite,at 0.666666666667 0.000573394495413 1 5 -4
nc1,decrease 1.0 0.00043004587156 0 3 -3
would,therefore 1.0 0.000143348623853 0 1 -1
max,decreased 1.0 0.000143348623853 1 0 1
on,diastolic 1.0 0.000143348623853 0 1 -1
the,response 0.4 0.000573394495413 3 7 -4
test,should 0.142857142857 0.000143348623853 3 4 -1
aeds,affects 1.0 0.000143348623853 1 0 1
benzylpenicillin,and 1.0 0.000143348623853 0 1 -1
use,with 0.310344827586 0.00129013761468 10 19 -9
severe,dietary 1.0 0.000143348623853 1 0 1
potentiating,effects 1.0 0.000143348623853 1 0 1
medicine,certain 1.0 0.000143348623853 0 1 -1
particles,and 1.0 0.000143348623853 0 1 -1
in,epileptic 0.0 0.0 2 2 0
as,ophthalmic 0.0 0.0 1 1 0
drinks,may 1.0 0.000143348623853 0 1 -1
were,reduced 0.333333333333 0.000286697247706 4 2 2
potential,benefits 0.333333333333 0.000143348623853 2 1 1
and,studies 1.0 0.000143348623853 0 1 -1
cations,likely 1.0 0.000143348623853 1 0 1
hydrolase,or 1.0 0.000143348623853 0 1 -1
male,fertility 1.0 0.000286697247706 0 2 -2
place,at 1.0 0.000143348623853 0 1 -1
simplest,inference 1.0 0.000143348623853 0 1 -1
those,listed 1.0 0.000143348623853 0 1 -1
of,ions 1.0 0.000143348623853 0 1 -1
cellulitis,induration 1.0 0.000143348623853 0 1 -1
it,had 0.0 0.0 1 1 0
and,plus 1.0 0.000143348623853 1 0 1
which,sensitize 1.0 0.000143348623853 1 0 1
to,ptx 0.333333333333 0.000143348623853 1 2 -1
was,a 0.166666666667 0.000286697247706 5 7 -2
everolimus,dose-proportionality 1.0 0.000143348623853 0 1 -1
agent,with 1.0 0.000143348623853 1 0 1
a4,macrolide 1.0 0.000143348623853 1 0 1
may,displace 0.2 0.000143348623853 2 3 -1
flavonoids,alone 1.0 0.000143348623853 0 1 -1
goal,of 1.0 0.000286697247706 0 2 -2
weeks,has 1.0 0.000143348623853 1 0 1
a2,are 1.0 0.000143348623853 0 1 -1
the,steady-state 0.153846153846 0.000573394495413 11 15 -4
electrically,stimulated 1.0 0.000143348623853 0 1 -1
and,cause 0.5 0.000286697247706 1 3 -2
high-dose,may 1.0 0.000143348623853 0 1 -1
enzymes,a2 1.0 0.000286697247706 0 2 -2
convulsions,and 1.0 0.000143348623853 1 0 1
transport,pathway 1.0 0.000143348623853 0 1 -1
protein-bound,from 1.0 0.000143348623853 0 1 -1
dogs,but 1.0 0.000143348623853 1 0 1
primary,enzymes 1.0 0.000143348623853 0 1 -1
but,only 1.0 0.00043004587156 0 3 -3
as,nausea 1.0 0.000143348623853 0 1 -1
that,undergo 0.0 0.0 1 1 0
until,neutrophils 1.0 0.000143348623853 0 1 -1
assay,appears 1.0 0.000143348623853 0 1 -1
of,depletion 1.0 0.000143348623853 0 1 -1
last,subcutaneous 1.0 0.000143348623853 1 0 1
clinical,conditions 1.0 0.000143348623853 1 0 1
abnormalities,in 1.0 0.000286697247706 0 2 -2
following,adverse 1.0 0.000143348623853 1 0 1
im,was 1.0 0.000143348623853 0 1 -1
karst,was 1.0 0.000143348623853 0 1 -1
to,toxoids 1.0 0.000143348623853 1 0 1
reported,resulting 1.0 0.000143348623853 1 0 1
ssris,weakness 1.0 0.000143348623853 1 0 1
sprycel,is 1.0 0.000143348623853 1 0 1
sprycel,in 1.0 0.000286697247706 0 2 -2
per,day 0.166666666667 0.000286697247706 5 7 -2
to,one 0.5 0.000286697247706 1 3 -2
hcl,phenytoin 1.0 0.000286697247706 2 0 2
inhibitors,aminosalicylic 1.0 0.000143348623853 1 0 1
frequent,monitoring 1.0 0.000860091743119 0 6 -6
that,krm-1648 1.0 0.000143348623853 0 1 -1
that,small 1.0 0.000143348623853 0 1 -1
gel,should 1.0 0.000143348623853 1 0 1
oliguria,tachycardia 1.0 0.000143348623853 0 1 -1
been,suggested 0.6 0.00043004587156 1 4 -3
taking,concurrent 1.0 0.000143348623853 1 0 1
pharmacokinetic,profiles 1.0 0.000143348623853 0 1 -1
was,gathered 1.0 0.000143348623853 0 1 -1
greater,gastrointestinal 1.0 0.000143348623853 1 0 1
p450,substrates 1.0 0.000143348623853 0 1 -1
hepatic,cyp 1.0 0.000143348623853 0 1 -1
fluconazole,fluoxetine 1.0 0.000143348623853 0 1 -1
no,difference 1.0 0.000286697247706 0 2 -2
bioavailability,was 1.0 0.000286697247706 2 0 2
special,precautions 1.0 0.000143348623853 0 1 -1
analysis,of 0.75 0.000860091743119 1 7 -6
additional,adrenergic 1.0 0.000143348623853 1 0 1
rifabutin,rifampin 1.0 0.000143348623853 0 1 -1
and,dmpge2-induced 1.0 0.000143348623853 0 1 -1
to,outweigh 1.0 0.000143348623853 1 0 1
in,luteinizing 1.0 0.000143348623853 0 1 -1
of,extraneal 1.0 0.000143348623853 0 1 -1
maintenance,of 1.0 0.000286697247706 0 2 -2
accompanied,by 0.5 0.000573394495413 2 6 -4
be,above 1.0 0.000143348623853 0 1 -1
twitch,gradually 1.0 0.000143348623853 0 1 -1
ketoconazole,increased 1.0 0.000143348623853 1 0 1
oral,includes 1.0 0.000143348623853 0 1 -1
member,of 1.0 0.000143348623853 1 0 1
levels,by 0.428571428571 0.00043004587156 2 5 -3
tablets,as 1.0 0.000143348623853 1 0 1
an,nsaid 0.0 0.0 1 1 0
of,altered 1.0 0.000286697247706 0 2 -2
valid,prothrombin 1.0 0.000143348623853 1 0 1
ischemic,stroke 1.0 0.000143348623853 0 1 -1
enterococcus,faecium 1.0 0.000143348623853 0 1 -1
colistemethate,salts 1.0 0.000143348623853 1 0 1
including,protease 1.0 0.000143348623853 0 1 -1
levels,be 1.0 0.000860091743119 6 0 6
tablets,an 1.0 0.000143348623853 1 0 1
nonlinear,in 1.0 0.000143348623853 0 1 -1
selegiline,l-phenylalanine 1.0 0.000143348623853 1 0 1
m-dinitrobenzene,used 1.0 0.000143348623853 0 1 -1
p450-mediated,interactions 1.0 0.000143348623853 0 1 -1
cordarone,administration 1.0 0.000143348623853 0 1 -1
microtubules,in 1.0 0.000286697247706 0 2 -2
drugs,can 1.0 0.000143348623853 1 0 1
seen,with 0.333333333333 0.00043004587156 3 6 -3
epidural,may 1.0 0.000143348623853 1 0 1
of,anticoagulation 1.0 0.000286697247706 0 2 -2
secretion,distribution 1.0 0.000286697247706 0 2 -2
taxol,to 1.0 0.000143348623853 0 1 -1
cyclosporine,cyp3a4 1.0 0.000143348623853 0 1 -1
after,than 0.0 0.0 1 1 0
general,have 1.0 0.000143348623853 1 0 1
poor,patient 1.0 0.000143348623853 0 1 -1
from,ml 0.333333333333 0.000143348623853 2 1 1
of,see 0.0 0.0 1 1 0
steady-state,conditions 1.0 0.000286697247706 0 2 -2
two,studies 0.0 0.0 1 1 0
and,caused 1.0 0.000143348623853 0 1 -1
diagnostic,challenge 1.0 0.000143348623853 0 1 -1
from,mg 1.0 0.000286697247706 2 0 2
tumors,and 0.333333333333 0.000143348623853 1 2 -1
volunteers,hydrochloride 1.0 0.000143348623853 1 0 1
phenobarbital,it 1.0 0.000143348623853 1 0 1
these,resulting 1.0 0.000143348623853 1 0 1
with,prostatectomy 1.0 0.000143348623853 0 1 -1
examined,whether 1.0 0.000143348623853 0 1 -1
low,levels 1.0 0.000143348623853 0 1 -1
lower,total 1.0 0.000143348623853 0 1 -1
each,may 1.0 0.000143348623853 0 1 -1
through,a 1.0 0.000143348623853 0 1 -1
neurological,complications 1.0 0.000143348623853 0 1 -1
t,cell-independent 1.0 0.000143348623853 0 1 -1
studies,one 1.0 0.000143348623853 1 0 1
studies,which 1.0 0.000143348623853 0 1 -1
exposure,levels 1.0 0.000143348623853 0 1 -1
had,minimal 1.0 0.000143348623853 0 1 -1
calcium,supplements 1.0 0.00043004587156 0 3 -3
diabectics,than 1.0 0.000143348623853 0 1 -1
protein,kinase 1.0 0.000143348623853 0 1 -1
with,stable 1.0 0.000286697247706 0 2 -2
and,stimulate 1.0 0.000143348623853 1 0 1
or,fehling 1.0 0.000286697247706 0 2 -2
cells,that 0.333333333333 0.000143348623853 1 2 -1
renin,release 1.0 0.000286697247706 2 0 2
when,patients 0.5 0.000286697247706 1 3 -2
are,negatively 1.0 0.000143348623853 0 1 -1
inhibited,by 0.0 0.0 6 6 0
behavior,has 1.0 0.000143348623853 1 0 1
or,pharmacodynamic 1.0 0.000716743119266 0 5 -5
interaction,involving 1.0 0.000143348623853 1 0 1
but,definite 1.0 0.000143348623853 0 1 -1
participated,in 1.0 0.000143348623853 0 1 -1
effective,in 0.333333333333 0.000143348623853 2 1 1
and,confusion 1.0 0.000143348623853 1 0 1
functional,consequences 1.0 0.000286697247706 0 2 -2
interval,prolongation 0.0 0.0 1 1 0
to,weeks 1.0 0.000286697247706 2 0 2
the,cold 1.0 0.000143348623853 0 1 -1
cyp3a4,metabolism 1.0 0.000143348623853 0 1 -1
is,to 0.0909090909091 0.000143348623853 6 5 1
taken,hour 1.0 0.000143348623853 0 1 -1
or,glatiramer 1.0 0.000143348623853 0 1 -1
bleeding,associated 1.0 0.000143348623853 1 0 1
isoenzymes,cyp1a2 1.0 0.000143348623853 0 1 -1
another,is 1.0 0.000143348623853 0 1 -1
proteus,rettgeri 1.0 0.000143348623853 0 1 -1
as,demonstrated 1.0 0.000143348623853 0 1 -1
of,anticholinesterase 0.333333333333 0.000143348623853 2 1 1
well,matched 1.0 0.000143348623853 0 1 -1
drug,levels 1.0 0.000143348623853 0 1 -1
urine,was 1.0 0.000143348623853 0 1 -1
that,also 1.0 0.000143348623853 1 0 1
period,followed 1.0 0.000143348623853 0 1 -1
the,ionized 1.0 0.000286697247706 2 0 2
isoforms,epoxide 1.0 0.000143348623853 0 1 -1
or,near 1.0 0.000143348623853 1 0 1
microm,increased 1.0 0.000143348623853 0 1 -1
binding,studies 1.0 0.000143348623853 0 1 -1
basis,to 1.0 0.000143348623853 1 0 1
to,several 1.0 0.000143348623853 0 1 -1
and,cyp3a3 1.0 0.000143348623853 0 1 -1
of,parenterally 1.0 0.000143348623853 1 0 1
arrhythmias,during 1.0 0.000143348623853 1 0 1
patients,undergoing 0.25 0.000286697247706 5 3 2
an,agent 0.6 0.00043004587156 1 4 -3
and,cyp3a4 0.6 0.00043004587156 1 4 -3
cardiovascular,agents 1.0 0.000143348623853 0 1 -1
addition,neuromuscular 1.0 0.000143348623853 0 1 -1
clarithromycin,exposure 1.0 0.000143348623853 1 0 1
and,suppressed 1.0 0.000143348623853 0 1 -1
tardive,dyskinesia 1.0 0.000143348623853 1 0 1
nephrotoxicity,of 1.0 0.000143348623853 1 0 1
possibility,of 0.0967741935484 0.00043004587156 14 17 -3
requires,a 1.0 0.000143348623853 0 1 -1
will,aid 1.0 0.000143348623853 0 1 -1
considered,as 1.0 0.000143348623853 0 1 -1
acids,may 1.0 0.000143348623853 0 1 -1
populations,such 1.0 0.000143348623853 0 1 -1
or,outpatient 1.0 0.000143348623853 0 1 -1
casodex,can 1.0 0.000143348623853 1 0 1
zarontin,may 1.0 0.000143348623853 1 0 1
ocs,macrolide 1.0 0.000143348623853 0 1 -1
them,and 1.0 0.000143348623853 0 1 -1
mucosal,cells 1.0 0.000143348623853 0 1 -1
nonsteroidal,anti-inflammatory 0.538461538462 0.00100344036697 10 3 7
binding,and 0.333333333333 0.000143348623853 1 2 -1
as,certain 1.0 0.000143348623853 1 0 1
conjugated,with 1.0 0.000143348623853 0 1 -1
the,potentiating 1.0 0.000143348623853 1 0 1
liver,function 0.8 0.00114678899083 1 9 -8
inhibitors,serotonin 1.0 0.000143348623853 1 0 1
elimination,half-life 0.333333333333 0.000286697247706 4 2 2
to,help 1.0 0.000143348623853 0 1 -1
disease,have 1.0 0.000143348623853 1 0 1
facilitated,by 1.0 0.000143348623853 0 1 -1
no,or 1.0 0.000143348623853 0 1 -1
reactions,after 1.0 0.000143348623853 0 1 -1
of,affected 1.0 0.000286697247706 0 2 -2
schizophrenia,and 1.0 0.000286697247706 0 2 -2
chemotherapy,or 1.0 0.000286697247706 0 2 -2
chirocaine,should 1.0 0.000143348623853 1 0 1
even,so 1.0 0.000143348623853 1 0 1
not,potentiate 0.333333333333 0.000143348623853 1 2 -1
fraction,of 1.0 0.00129013761468 0 9 -9
endogenous,vitamin 1.0 0.00043004587156 0 3 -3
to,gibaldi 1.0 0.000143348623853 0 1 -1
prone,to 1.0 0.000143348623853 0 1 -1
sodium,colistemethate 1.0 0.000143348623853 1 0 1
less,frequent 1.0 0.000143348623853 1 0 1
when,changing 1.0 0.000143348623853 0 1 -1
before,these 1.0 0.000143348623853 0 1 -1
sodium,can 1.0 0.000143348623853 1 0 1
highly,effective 1.0 0.000143348623853 0 1 -1
or,nucleus 1.0 0.000143348623853 0 1 -1
hypoparathyroid,patients 1.0 0.000286697247706 2 0 2
in,t24 0.0 0.0 1 1 0
type,strain 1.0 0.000143348623853 0 1 -1
high,concentrations 0.777777777778 0.00100344036697 1 8 -7
required,or 1.0 0.000143348623853 1 0 1
discontinued,and 1.0 0.000286697247706 0 2 -2
chloride,sodium 1.0 0.000286697247706 2 0 2
levels,levodopa 1.0 0.000143348623853 0 1 -1
choroidal,blood 1.0 0.000143348623853 0 1 -1
that,potentiate 1.0 0.000143348623853 0 1 -1
we,evaluated 1.0 0.000143348623853 0 1 -1
antiparkinsonism,agents 1.0 0.000143348623853 0 1 -1
starting,therapy 1.0 0.000143348623853 0 1 -1
unaltered,impaired 1.0 0.000143348623853 0 1 -1
hallucinations,paresthesia 1.0 0.000143348623853 0 1 -1
injectable,implantable 1.0 0.000143348623853 0 1 -1
low,intrinsic 1.0 0.000143348623853 0 1 -1
establish,strategies 1.0 0.000143348623853 0 1 -1
the,cyp2c9 1.0 0.000286697247706 2 0 2
prolixin,permitil 1.0 0.000143348623853 0 1 -1
when,central 1.0 0.000143348623853 1 0 1
when,edecrin 1.0 0.000143348623853 1 0 1
hypothesis,that 1.0 0.000143348623853 0 1 -1
p450,with 1.0 0.000143348623853 0 1 -1
modification,had 1.0 0.000143348623853 0 1 -1
about,bound 1.0 0.000143348623853 0 1 -1
conducting,an 1.0 0.000143348623853 1 0 1
with,kerlone 1.0 0.000143348623853 0 1 -1
requirement,of 1.0 0.000143348623853 1 0 1
and,high-estradiol 1.0 0.000143348623853 1 0 1
was,estimated 1.0 0.000143348623853 0 1 -1
j,chromatogr 1.0 0.000143348623853 0 1 -1
neutralized,the 1.0 0.000286697247706 0 2 -2
frequent,dosing 1.0 0.000143348623853 0 1 -1
is,derived 1.0 0.000143348623853 1 0 1
methotrexate,there 1.0 0.000286697247706 2 0 2
decreases,gastrointestinal 1.0 0.000143348623853 1 0 1
amicar,may 1.0 0.000143348623853 0 1 -1
antidiabetic,agents 0.0 0.0 1 1 0
alfenta,doses 1.0 0.000143348623853 0 1 -1
isoenzymes,a4 1.0 0.000143348623853 0 1 -1
established,on 1.0 0.000143348623853 0 1 -1
gait,or 1.0 0.000143348623853 1 0 1
iva,p-type 1.0 0.000143348623853 0 1 -1
and,multifaceted 1.0 0.000143348623853 0 1 -1
rare,defect 1.0 0.000143348623853 0 1 -1
are,necessary 1.0 0.000286697247706 0 2 -2
all,prescription 1.0 0.000143348623853 0 1 -1
usual,daily 1.0 0.000143348623853 1 0 1
and,therefore 0.428571428571 0.000860091743119 4 10 -6
equipotent,inducers 1.0 0.000143348623853 0 1 -1
pretreatment,attenuated 1.0 0.000143348623853 1 0 1
indanyl,sodium 1.0 0.000143348623853 1 0 1
epoxide,metabolite 1.0 0.000143348623853 0 1 -1
oral,regimen 1.0 0.000143348623853 0 1 -1
neuropathy,is 1.0 0.000143348623853 0 1 -1
rash,has 1.0 0.000143348623853 1 0 1
sulfa-based,such 1.0 0.000143348623853 0 1 -1
substrates,dasatinib 1.0 0.000143348623853 0 1 -1
or,drug 1.0 0.000143348623853 0 1 -1
yet,statistically 1.0 0.000143348623853 0 1 -1
therapeutic,margin 1.0 0.000143348623853 0 1 -1
present,clearly 1.0 0.000143348623853 0 1 -1
antagonism,of 1.0 0.000143348623853 1 0 1
any,dose 1.0 0.000143348623853 0 1 -1
underwent,trans-placental 1.0 0.000143348623853 0 1 -1
stimulating,the 1.0 0.000143348623853 0 1 -1
considered,clinically 1.0 0.000143348623853 0 1 -1
the,sst 1.0 0.00043004587156 0 3 -3
situation,when 1.0 0.000143348623853 1 0 1
approximately,one-hundredth 1.0 0.000286697247706 0 2 -2
the,dextrorotatory 1.0 0.000143348623853 0 1 -1
significantly,elevating 1.0 0.000143348623853 1 0 1
damage,has 1.0 0.000143348623853 1 0 1
patients,or 1.0 0.00043004587156 0 3 -3
of,pocs 1.0 0.000143348623853 0 1 -1
unless,otherwise 1.0 0.000286697247706 0 2 -2
cerubidine,may 0.0 0.0 1 1 0
patients,of 1.0 0.000143348623853 0 1 -1
patient,requires 1.0 0.000143348623853 1 0 1
efficacy,compared 1.0 0.000143348623853 0 1 -1
the,intestinal 0.666666666667 0.000573394495413 1 5 -4
patients,on 0.463414634146 0.00272362385321 30 11 19
spontaneous,action 1.0 0.000143348623853 0 1 -1
results,indicate 1.0 0.00100344036697 0 7 -7
or,initiating 1.0 0.000143348623853 1 0 1
function,studies 1.0 0.000143348623853 0 1 -1
and,understanding 1.0 0.000143348623853 0 1 -1
responses,associated 1.0 0.000143348623853 0 1 -1
from,a 0.52380952381 0.00157683486239 5 16 -11
and,xenobiotic 1.0 0.000143348623853 0 1 -1
inhibiting,parts 1.0 0.000143348623853 1 0 1
the,requirements 1.0 0.000143348623853 1 0 1
local,solutions 1.0 0.00043004587156 3 0 3
from,l 1.0 0.000143348623853 1 0 1
from,m 1.0 0.000143348623853 0 1 -1
the,third 1.0 0.000143348623853 0 1 -1
when,beginning 1.0 0.000143348623853 1 0 1
ganoderma,lucidum 1.0 0.000286697247706 0 2 -2
pain,medication 1.0 0.000143348623853 0 1 -1
antacids,increase 1.0 0.000143348623853 1 0 1
acid,itself 1.0 0.000143348623853 0 1 -1
ras-transformed,ras-3t3 1.0 0.000143348623853 0 1 -1
tdp,in 1.0 0.000143348623853 0 1 -1
d6,include 1.0 0.000716743119266 0 5 -5
hour,and 0.0 0.0 1 1 0
carbamazepine,concomitant 1.0 0.000143348623853 1 0 1
nrtis,other 1.0 0.000143348623853 0 1 -1
effect,should 0.0 0.0 2 2 0
women,receiving 1.0 0.000143348623853 0 1 -1
a,substantial 0.0 0.0 1 1 0
pharmacokinetics,has 1.0 0.000143348623853 0 1 -1
chosen,method 1.0 0.000143348623853 0 1 -1
sclerosis,patients 1.0 0.000143348623853 0 1 -1
of,against 1.0 0.000143348623853 0 1 -1
patients,although 1.0 0.000143348623853 0 1 -1
should,elapse 0.6 0.00043004587156 4 1 3
pressure,may 0.0 0.0 1 1 0
m,resulted 1.0 0.000143348623853 0 1 -1
neoplasia,are 1.0 0.000143348623853 0 1 -1
treatments,corrective 1.0 0.000143348623853 0 1 -1
patient,s 0.333333333333 0.000143348623853 1 2 -1
toxic,reactions 1.0 0.000143348623853 0 1 -1
study,regardless 1.0 0.000143348623853 0 1 -1
meaningful,reductions 1.0 0.000143348623853 1 0 1
and,trivalent 1.0 0.000286697247706 2 0 2
primary,cns 0.0 0.0 3 3 0
relative,to 0.555555555556 0.000716743119266 2 7 -5
levonorgestrol,oral 1.0 0.000143348623853 0 1 -1
broad,range 1.0 0.000143348623853 0 1 -1
were,about 0.0 0.0 1 1 0
and,membrane 1.0 0.000143348623853 0 1 -1
is,prevented 1.0 0.000143348623853 1 0 1
tnf,antagonist 1.0 0.000143348623853 1 0 1
in,absorption 0.0 0.0 1 1 0
relationship,of 1.0 0.000573394495413 4 0 4
example,sparing 1.0 0.000143348623853 0 1 -1
agents,used 0.0 0.0 2 2 0
monitoring,during 1.0 0.000143348623853 0 1 -1
mg,mcg 1.0 0.000143348623853 0 1 -1
nanm,in 1.0 0.000143348623853 0 1 -1
or,not 0.0 0.0 1 1 0
or,nor 1.0 0.000143348623853 0 1 -1
nonetheless,their 1.0 0.000143348623853 0 1 -1
hydroxylation,catalyzed 1.0 0.000143348623853 0 1 -1
plasma,asparagine 1.0 0.000286697247706 2 0 2
still,valid 1.0 0.000143348623853 0 1 -1
all,inclusive 1.0 0.000143348623853 0 1 -1
than,thrombin 1.0 0.000143348623853 0 1 -1
been,extensively 1.0 0.000286697247706 0 2 -2
orally,disintegrating 1.0 0.000143348623853 1 0 1
and,anxiety 1.0 0.000286697247706 0 2 -2
positive,inotropic 1.0 0.000143348623853 1 0 1
settings,commonly 1.0 0.000143348623853 0 1 -1
ordinarily,recommended 1.0 0.000143348623853 1 0 1
didrex,should 1.0 0.000143348623853 1 0 1
acellular,live 1.0 0.000143348623853 1 0 1
to,recover 1.0 0.000143348623853 0 1 -1
decreased,protein 1.0 0.000143348623853 1 0 1
known,clinically 1.0 0.000143348623853 0 1 -1
also,chronically 1.0 0.000143348623853 0 1 -1
of,activated 1.0 0.000143348623853 0 1 -1
mptp-induced,neuronal 1.0 0.000143348623853 1 0 1
by,causing 1.0 0.000143348623853 1 0 1
all,nsaids 1.0 0.000143348623853 1 0 1
coadministration,can 1.0 0.000143348623853 1 0 1
quinidine,at 1.0 0.000143348623853 1 0 1
feasibility,and 1.0 0.000143348623853 0 1 -1
coadministered,on 1.0 0.000143348623853 1 0 1
s,serum 1.0 0.000143348623853 0 1 -1
cells,including 1.0 0.000143348623853 0 1 -1
interfere,with 0.121951219512 0.00143348623853 36 46 -10
in,altered 1.0 0.000286697247706 0 2 -2
concentrations,ic50 1.0 0.000143348623853 0 1 -1
in,cervical 1.0 0.000143348623853 0 1 -1
have,involved 1.0 0.000143348623853 0 1 -1
with,bezalip 1.0 0.000286697247706 2 0 2
with,greater 1.0 0.000143348623853 0 1 -1
occasional,susceptible 1.0 0.000143348623853 0 1 -1
meal,resulted 1.0 0.000143348623853 1 0 1
one-hundredth,of 1.0 0.000286697247706 0 2 -2
levels,following 1.0 0.000143348623853 0 1 -1
problems,that 1.0 0.000143348623853 0 1 -1
strong,and 1.0 0.000143348623853 1 0 1
serious,and 0.846153846154 0.00157683486239 1 12 -11
doses,increased 1.0 0.000143348623853 1 0 1
little,progression 1.0 0.000143348623853 0 1 -1
undergoing,strenuous 1.0 0.000143348623853 0 1 -1
behavioral,changes 1.0 0.000716743119266 0 5 -5
needed,following 1.0 0.000143348623853 1 0 1
either,stereoisomer 1.0 0.000143348623853 1 0 1
specific,method 1.0 0.000143348623853 0 1 -1
in,coma 1.0 0.000143348623853 1 0 1
week,placebo 1.0 0.000143348623853 0 1 -1
creatinine,by 1.0 0.000143348623853 0 1 -1
occurred,between 1.0 0.000143348623853 0 1 -1
rise,resulting 1.0 0.000143348623853 0 1 -1
warfarin,co-administration 1.0 0.000143348623853 1 0 1
any,time 1.0 0.000143348623853 0 1 -1
discussed,especially 1.0 0.000143348623853 0 1 -1
following,infusions 1.0 0.000143348623853 0 1 -1
rats,are 1.0 0.000143348623853 0 1 -1
psychiatric,disorder 1.0 0.000143348623853 1 0 1
strength,of 1.0 0.000143348623853 1 0 1
b,however 1.0 0.000143348623853 0 1 -1
dimethyl-4,hydroxyphenyl 1.0 0.000143348623853 1 0 1
with,restricted 1.0 0.000143348623853 0 1 -1
inhibitors,during 1.0 0.000286697247706 2 0 2
by,cardiac 1.0 0.000143348623853 1 0 1
least,days 0.5 0.000286697247706 1 3 -2
allergic,or 1.0 0.000286697247706 0 2 -2
fall,in 0.333333333333 0.000143348623853 1 2 -1
relaxants,amphotericin 1.0 0.000143348623853 1 0 1
phenothiazines,and 1.0 0.000286697247706 2 0 2
also,see 0.0 0.0 1 1 0
of,saline 1.0 0.000143348623853 0 1 -1
ketoconazole,coadministration 1.0 0.000286697247706 2 0 2
of,acidity 1.0 0.000143348623853 1 0 1
reduction,is 1.0 0.000143348623853 1 0 1
therefore,precaution 1.0 0.00043004587156 0 3 -3
other,products 0.5 0.000286697247706 1 3 -2
patients,whose 0.333333333333 0.000143348623853 1 2 -1
cases,approximately 1.0 0.000143348623853 0 1 -1
reduction,in 0.222222222222 0.00114678899083 22 14 8
dose,have 1.0 0.000143348623853 0 1 -1
injury,including 1.0 0.000143348623853 1 0 1
anticoagulants,while 1.0 0.000143348623853 1 0 1
or,dosing 1.0 0.000143348623853 0 1 -1
lowers,the 1.0 0.000143348623853 1 0 1
gabapentin,is 1.0 0.000143348623853 0 1 -1
myopathy,rhabdomyolysis 1.0 0.00043004587156 3 0 3
careful,supervision 1.0 0.000143348623853 0 1 -1
used,successfully 1.0 0.000286697247706 0 2 -2
some,of 0.818181818182 0.00129013761468 1 10 -9
systematic,experience 1.0 0.000143348623853 0 1 -1
deferred,until 1.0 0.000143348623853 1 0 1
antidiabetic,requirements 1.0 0.000143348623853 0 1 -1
not,the 0.0 0.0 2 2 0
particular,has 1.0 0.00043004587156 0 3 -3
myopathy,is 1.0 0.000143348623853 0 1 -1
selective,toxicity 1.0 0.000143348623853 0 1 -1
compulsion,loss 1.0 0.000143348623853 0 1 -1
potent,a4 1.0 0.000143348623853 1 0 1
biological,levels 1.0 0.000143348623853 0 1 -1
carbamazepine,elevated 1.0 0.000143348623853 1 0 1
myopathy,in 1.0 0.000143348623853 0 1 -1
location,histologic 1.0 0.000143348623853 0 1 -1
elixir,was 1.0 0.000143348623853 0 1 -1
kg,x 1.0 0.000143348623853 1 0 1
vardenafil,mg 0.384615384615 0.000716743119266 9 4 5
kg,w 1.0 0.000143348623853 1 0 1
of,known 0.333333333333 0.000143348623853 1 2 -1
nimbex,include 1.0 0.000143348623853 1 0 1
package,inserts 1.0 0.000143348623853 0 1 -1
kg,p 0.0 0.0 1 1 0
avoid,this 1.0 0.000143348623853 1 0 1
variable,degrees 1.0 0.000143348623853 0 1 -1
kg,h 1.0 0.000143348623853 1 0 1
measure,plasma 1.0 0.000143348623853 0 1 -1
the,aqueous 1.0 0.000143348623853 0 1 -1
theoretical,risk 1.0 0.000143348623853 1 0 1
in,addressing 1.0 0.000143348623853 0 1 -1
interactions,implications 1.0 0.000143348623853 0 1 -1
arrest,torsades 1.0 0.000143348623853 0 1 -1
and,hydroxy-1 1.0 0.000143348623853 1 0 1
irritation,caution 1.0 0.000143348623853 1 0 1
observed,but 1.0 0.000286697247706 0 2 -2
pharmacological,action 1.0 0.000143348623853 0 1 -1
intact,subjects 1.0 0.000143348623853 0 1 -1
greater,proportion 1.0 0.000143348623853 1 0 1
in,tambocor 1.0 0.000143348623853 0 1 -1
lodine,treatment 1.0 0.000143348623853 0 1 -1
determinant,of 0.333333333333 0.000143348623853 2 1 1
that,your 1.0 0.000143348623853 1 0 1
probably,responsible 1.0 0.000143348623853 0 1 -1
of,miracidia 1.0 0.000286697247706 0 2 -2
the,following 0.428571428571 0.0043004587156 20 50 -30
with,serotonin 0.0 0.0 1 1 0
digestive,enzyme 1.0 0.000143348623853 1 0 1
were,common 1.0 0.000143348623853 0 1 -1
seen,but 1.0 0.000143348623853 1 0 1
makes,use 1.0 0.000143348623853 0 1 -1
as,should 1.0 0.00043004587156 0 3 -3
or,salt 1.0 0.000286697247706 0 2 -2
might,arise 1.0 0.000143348623853 0 1 -1
the,diuretic 1.0 0.000143348623853 1 0 1
inhibit,proliferation 1.0 0.000143348623853 1 0 1
infusion,site 1.0 0.000143348623853 0 1 -1
reaction,for 1.0 0.00229357798165 0 16 -16
enhanced,as 1.0 0.000143348623853 1 0 1
is,about 0.333333333333 0.000143348623853 1 2 -1
the,frequency 0.111111111111 0.000143348623853 5 4 1
acetazolamide,increases 1.0 0.000143348623853 1 0 1
female,and 1.0 0.000143348623853 0 1 -1
l-glutamine,at 1.0 0.000286697247706 2 0 2
the,antimicrobial 0.5 0.000286697247706 1 3 -2
other,general 1.0 0.000573394495413 4 0 4
of,ergot-type 1.0 0.000143348623853 0 1 -1
a,simple 1.0 0.000143348623853 0 1 -1
hour,period 0.75 0.000860091743119 7 1 6
the,anti-inflammatory 1.0 0.000143348623853 1 0 1
at,about 1.0 0.000143348623853 1 0 1
the,rats 1.0 0.00043004587156 0 3 -3
was,in 1.0 0.000143348623853 0 1 -1
be,approximately 1.0 0.000143348623853 0 1 -1
by,containing 1.0 0.000143348623853 1 0 1
maintained,in 1.0 0.000143348623853 0 1 -1
the,rate 0.25 0.000860091743119 9 15 -6
of,asthma 1.0 0.000143348623853 0 1 -1
physician,the 1.0 0.000143348623853 1 0 1
although,clinical 0.0 0.0 2 2 0
endogenous,and 1.0 0.000143348623853 0 1 -1
except,with 1.0 0.000143348623853 0 1 -1
solution,should 0.333333333333 0.000143348623853 2 1 1
and,activated 1.0 0.000143348623853 0 1 -1
or,higher 1.0 0.000143348623853 0 1 -1
pk,and 1.0 0.000143348623853 0 1 -1
in,susceptible 0.333333333333 0.000143348623853 2 1 1
age,the 1.0 0.000143348623853 0 1 -1
coagulation,test 0.333333333333 0.000143348623853 2 1 1
and,volunteers 1.0 0.000143348623853 1 0 1
added,cholesterol 1.0 0.000143348623853 0 1 -1
or,regimen 1.0 0.000286697247706 0 2 -2
be,anticipated 0.6 0.00043004587156 4 1 3
substance,to 1.0 0.000143348623853 1 0 1
robust,induction 1.0 0.000143348623853 0 1 -1
intravenous,self-administration 0.0 0.0 1 1 0
either,striatum 1.0 0.000143348623853 0 1 -1
proportions,as 1.0 0.000143348623853 0 1 -1
low,uptakes 1.0 0.000143348623853 0 1 -1
abdominal,symptoms 1.0 0.000143348623853 0 1 -1
diphen-hydramine,and 1.0 0.000143348623853 0 1 -1
unchanged,alkaloids 1.0 0.000143348623853 1 0 1
uptake-1,in 1.0 0.000286697247706 0 2 -2
pneumonia,vs 1.0 0.000143348623853 1 0 1
the,microtubules 1.0 0.000143348623853 0 1 -1
x,kg 1.0 0.000143348623853 0 1 -1
together,may 1.0 0.000286697247706 2 0 2
properties,if 1.0 0.000143348623853 1 0 1
changes,were 1.0 0.000716743119266 0 5 -5
may,necessitate 1.0 0.000143348623853 1 0 1
block,angiotensin 1.0 0.000143348623853 0 1 -1
prolonged,daily 1.0 0.000143348623853 0 1 -1
pharmacologic,effect 1.0 0.000143348623853 1 0 1
concentrations,above 1.0 0.000143348623853 1 0 1
dose,co-administered 1.0 0.000286697247706 2 0 2
intake,prior 1.0 0.000573394495413 4 0 4
limit,adverse 1.0 0.000143348623853 1 0 1
retention,dysuria 1.0 0.000143348623853 0 1 -1
lst,short 1.0 0.000143348623853 0 1 -1
not,substantially 1.0 0.000143348623853 1 0 1
of,tracrium 1.0 0.000143348623853 1 0 1
extraneal,on 1.0 0.000143348623853 0 1 -1
active,organic 1.0 0.000143348623853 0 1 -1
how,safe 1.0 0.000143348623853 0 1 -1
clotibrate,and 1.0 0.000143348623853 0 1 -1
likely,to 0.0909090909091 0.000286697247706 10 12 -2
in,metabolite 1.0 0.000143348623853 0 1 -1
drug,transport 1.0 0.000286697247706 0 2 -2
tissues,either 1.0 0.000143348623853 0 1 -1
common,transport 1.0 0.000143348623853 0 1 -1
coly-mycin,m 0.0 0.0 1 1 0
rodent,studies 1.0 0.000143348623853 0 1 -1
drug,drug 1.0 0.000143348623853 0 1 -1
serious,cardiac 1.0 0.000143348623853 1 0 1
enhanced,possibility 1.0 0.000143348623853 0 1 -1
mask,or 1.0 0.000143348623853 0 1 -1
fertility,carcinogenesis 1.0 0.000143348623853 0 1 -1
the,development 0.733333333333 0.00157683486239 2 13 -11
the,cause 1.0 0.000286697247706 0 2 -2
isomers,of 1.0 0.000143348623853 0 1 -1
analysing,the 1.0 0.000143348623853 0 1 -1
opioid-induced,gastrointestinal 1.0 0.000143348623853 1 0 1
particular,importance 0.6 0.00043004587156 1 4 -3
and,cannot 1.0 0.000143348623853 0 1 -1
impairing,absorption 1.0 0.000143348623853 1 0 1
when,encountered 1.0 0.000143348623853 0 1 -1
and,fold 0.2 0.000143348623853 2 3 -1
days,received 1.0 0.000143348623853 0 1 -1
concentrations,be 1.0 0.000143348623853 1 0 1
concentrations,by 1.0 0.000143348623853 1 0 1
patients,must 1.0 0.000143348623853 0 1 -1
of,intrathecal 1.0 0.000143348623853 0 1 -1
specific,compatibility 1.0 0.000143348623853 0 1 -1
ph,in 1.0 0.000143348623853 0 1 -1
similarly,the 0.0 0.0 1 1 0
by,jaffe 1.0 0.000143348623853 0 1 -1
used,at 1.0 0.000286697247706 2 0 2
since,they 1.0 0.000143348623853 0 1 -1
pretreatment,on 1.0 0.000143348623853 0 1 -1
the,us 1.0 0.000286697247706 0 2 -2
ph,is 1.0 0.000286697247706 2 0 2
pretreatment,of 1.0 0.00043004587156 3 0 3
some,would 1.0 0.000143348623853 0 1 -1
may,each 1.0 0.000143348623853 1 0 1
restlessness,loss 1.0 0.000143348623853 0 1 -1
would,be 0.238095238095 0.000716743119266 8 13 -5
plasticity,ieg 1.0 0.000143348623853 0 1 -1
palmetto,red 1.0 0.000143348623853 0 1 -1
following,symptoms 1.0 0.000143348623853 0 1 -1
between,doses 1.0 0.000143348623853 1 0 1
the,urine 0.913043478261 0.00301032110092 1 22 -21
first,hour 0.0 0.0 1 1 0
thiazide,substrates 1.0 0.000143348623853 0 1 -1
of,upon 1.0 0.000286697247706 0 2 -2
vardenafil,dose 1.0 0.000573394495413 4 0 4
cancidas,should 1.0 0.000143348623853 1 0 1
extravasation,following 1.0 0.000143348623853 0 1 -1
several,hours 0.333333333333 0.000143348623853 1 2 -1
cyp-450,inhibitor 1.0 0.000143348623853 0 1 -1
v,patients 1.0 0.000143348623853 0 1 -1
long,lasting 0.0 0.0 1 1 0
this,alteration 1.0 0.000143348623853 0 1 -1
many,cyp 1.0 0.000143348623853 0 1 -1
f2alpha,and 0.0 0.0 1 1 0
acid,derivatives 1.0 0.000286697247706 0 2 -2
hormonal,birth 1.0 0.000143348623853 0 1 -1
the,blood-glucose 0.333333333333 0.000286697247706 2 4 -2
oxidase,the 1.0 0.000143348623853 0 1 -1
all,species 1.0 0.000143348623853 0 1 -1
of,control 0.0 0.0 1 1 0
ix,x 1.0 0.000286697247706 0 2 -2
with,crohns 1.0 0.000143348623853 1 0 1
n,or 1.0 0.000286697247706 0 2 -2
that,rr 1.0 0.000143348623853 0 1 -1
tiagabine,has 1.0 0.000143348623853 0 1 -1
and,live 1.0 0.000143348623853 1 0 1
n,of 1.0 0.000143348623853 1 0 1
olanzapine,an 1.0 0.000143348623853 0 1 -1
other,thyroid 1.0 0.000143348623853 0 1 -1
was,again 1.0 0.000286697247706 0 2 -2
cyp3a4,but 1.0 0.000143348623853 0 1 -1
l-type,omega-conotoxin 1.0 0.000143348623853 0 1 -1
significant,protection 1.0 0.000143348623853 1 0 1
they,do 0.333333333333 0.000143348623853 1 2 -1
wide,interindividual 1.0 0.000143348623853 1 0 1
therefore,caution 0.714285714286 0.000716743119266 1 6 -5
normal,volunteers 0.304347826087 0.00100344036697 15 8 7
effect,caution 1.0 0.000143348623853 1 0 1
grade,diarrhea 1.0 0.000143348623853 0 1 -1
long-,and 1.0 0.000143348623853 0 1 -1
the,unbound 0.333333333333 0.000143348623853 1 2 -1
urgently,to 1.0 0.000143348623853 0 1 -1
serotonin,release 1.0 0.000143348623853 0 1 -1
and,n3 1.0 0.000143348623853 0 1 -1
cause,transient 1.0 0.000143348623853 0 1 -1
precautions,should 1.0 0.000143348623853 1 0 1
cerebrovascular,accidents 1.0 0.000143348623853 0 1 -1
that,plasma 1.0 0.000286697247706 2 0 2
mildly,reduced 1.0 0.000143348623853 1 0 1
with,co-administered 0.0 0.0 1 1 0
diltiazem,in 1.0 0.000143348623853 1 0 1
doctor,may 1.0 0.000143348623853 0 1 -1
interaction,after 1.0 0.000143348623853 0 1 -1
states,but 1.0 0.000143348623853 0 1 -1
mg,to 0.0 0.0 2 2 0
system,specifically 1.0 0.000143348623853 0 1 -1
ras,nucleophosmin 1.0 0.000143348623853 0 1 -1
inducers,cyp3a4 1.0 0.000143348623853 0 1 -1
absorbed,when 1.0 0.000143348623853 0 1 -1
response,of 0.6 0.00043004587156 1 4 -3
syndrome,has 1.0 0.000143348623853 1 0 1
the,functional 1.0 0.000143348623853 0 1 -1
activase,for 1.0 0.000143348623853 0 1 -1
known,that 0.333333333333 0.000143348623853 2 1 1
phenytoin,altered 1.0 0.000143348623853 1 0 1
acidified,in 1.0 0.000143348623853 0 1 -1
male,adult 1.0 0.000143348623853 0 1 -1
the,antihypertensive 0.833333333333 0.00143348623853 11 1 10
mg,neurontin 0.0 0.0 1 1 0
open,three-period 1.0 0.000143348623853 0 1 -1
in,subcortical 1.0 0.000143348623853 0 1 -1
patients,some 1.0 0.000143348623853 0 1 -1
and,serotonergic 0.0 0.0 1 1 0
phase,ii 1.0 0.000143348623853 1 0 1
days,and 0.333333333333 0.000860091743119 6 12 -6
doses,there 1.0 0.000143348623853 0 1 -1
phase,in 1.0 0.000143348623853 0 1 -1
relatively,little 1.0 0.000143348623853 0 1 -1
has,resulted 0.2 0.000143348623853 2 3 -1
levels,of 0.133333333333 0.00172018348624 51 39 12
the,start 1.0 0.000286697247706 2 0 2
other,populations 1.0 0.000716743119266 0 5 -5
epsilon,and 1.0 0.000143348623853 0 1 -1
host,of 1.0 0.000143348623853 0 1 -1
discontinuing,treatment 1.0 0.000143348623853 1 0 1
additional,caution 1.0 0.000143348623853 0 1 -1
reveal,an 1.0 0.000143348623853 0 1 -1
the,exact 1.0 0.000286697247706 0 2 -2
be,indicated 1.0 0.000143348623853 0 1 -1
of,excreted 1.0 0.000143348623853 0 1 -1
menstrual,cycle 1.0 0.000143348623853 0 1 -1
oral,potently 1.0 0.000286697247706 2 0 2
once,daily 0.0833333333333 0.000286697247706 11 13 -2
mechanism,of 0.692307692308 0.00129013761468 2 11 -9
clinical,toxicity 1.0 0.000143348623853 0 1 -1
approximately,minutes 1.0 0.000143348623853 1 0 1
in,another 0.0 0.0 3 3 0
this,reduction 1.0 0.000143348623853 1 0 1
placebo,or 1.0 0.000143348623853 0 1 -1
by,consulting 1.0 0.000143348623853 0 1 -1
decrease,about 1.0 0.000143348623853 1 0 1
study,tambocor 1.0 0.000143348623853 0 1 -1
established,current 1.0 0.000143348623853 1 0 1
residues,may 1.0 0.000143348623853 0 1 -1
moderate,activity 1.0 0.000143348623853 0 1 -1
as,impulsivity 1.0 0.000143348623853 0 1 -1
of,bar-press 1.0 0.000143348623853 0 1 -1
doubly,labeled 1.0 0.000143348623853 0 1 -1
natrecor,were 1.0 0.000143348623853 0 1 -1
female,patients 1.0 0.000143348623853 0 1 -1
oral,clearance 0.5 0.000286697247706 3 1 2
identified,potentially 1.0 0.000143348623853 1 0 1
or,elimination 1.0 0.000286697247706 0 2 -2
when,gl 1.0 0.000143348623853 1 0 1
on,voltage-dependent 1.0 0.000143348623853 0 1 -1
exercised,with 1.0 0.000286697247706 0 2 -2
coadminstered,with 1.0 0.000143348623853 1 0 1
on,white 1.0 0.000143348623853 0 1 -1
of,nimbex 0.333333333333 0.000286697247706 4 2 2
nursing,or 1.0 0.000286697247706 0 2 -2
differential,actions 1.0 0.000143348623853 0 1 -1
observations,on 0.0 0.0 1 1 0
to,adenylyl 1.0 0.000143348623853 0 1 -1
amines,possible 1.0 0.000286697247706 0 2 -2
transport-related,effects 1.0 0.000143348623853 1 0 1
anion,because 1.0 0.000143348623853 0 1 -1
qid,did 1.0 0.000143348623853 0 1 -1
an,apparently 1.0 0.000143348623853 0 1 -1
are,identical 1.0 0.000143348623853 0 1 -1
contraceptive,agents 1.0 0.000143348623853 0 1 -1
increasing,salt 1.0 0.000143348623853 1 0 1
with,rr 1.0 0.000143348623853 1 0 1
slightly,reduced 1.0 0.000143348623853 1 0 1
arteries,from 1.0 0.000860091743119 0 6 -6
as,amphotericin 1.0 0.000143348623853 1 0 1
concurrently,resulting 1.0 0.000143348623853 1 0 1
blood,mononuclear 1.0 0.000286697247706 2 0 2
with,only 1.0 0.000286697247706 0 2 -2
likewise,pharmacokinetics 1.0 0.000143348623853 0 1 -1
the,benzodiazepine 1.0 0.000143348623853 1 0 1
the,genotypes 1.0 0.000143348623853 0 1 -1
the,retention 0.0 0.0 1 1 0
mild,decrease 1.0 0.000143348623853 1 0 1
while,left 1.0 0.000143348623853 0 1 -1
tablets,with 0.5 0.000286697247706 3 1 2
lymphoma,on 1.0 0.000143348623853 0 1 -1
bsa,for 1.0 0.000143348623853 0 1 -1
cholinesterase,activity 1.0 0.000143348623853 1 0 1
concomitant,in 1.0 0.000143348623853 0 1 -1
are,unchanged 1.0 0.000143348623853 0 1 -1
sprycel,should 1.0 0.000286697247706 0 2 -2
and,concerns 1.0 0.000143348623853 0 1 -1
with,nsaids 0.0 0.0 1 1 0
dizziness,during 1.0 0.000143348623853 0 1 -1
antimycobacterial,agents 0.0 0.0 1 1 0
was,conducted 1.0 0.000286697247706 0 2 -2
wait,about 1.0 0.000143348623853 1 0 1
the,pituitary-gonadal 1.0 0.000143348623853 0 1 -1
oral,treatment 1.0 0.000143348623853 1 0 1
with,did 1.0 0.000286697247706 0 2 -2
other,agents 0.333333333333 0.00100344036697 7 14 -7
in,volunteers 1.0 0.000143348623853 0 1 -1
was,abolished 1.0 0.000143348623853 1 0 1
anxiogenic,effects 0.0 0.0 2 2 0
given,together 1.0 0.000286697247706 0 2 -2
experiences,in 0.333333333333 0.000143348623853 1 2 -1
relevant,alterations 1.0 0.000143348623853 0 1 -1
metabolites,or 1.0 0.000143348623853 0 1 -1
preservation,of 1.0 0.000286697247706 0 2 -2
only,clinically 1.0 0.000143348623853 1 0 1
monitored,during 1.0 0.000143348623853 1 0 1
pgf2alpha,upon 1.0 0.000143348623853 1 0 1
as,palpitations 1.0 0.000143348623853 0 1 -1
severe,toxicity 1.0 0.000286697247706 2 0 2
dogs,have 1.0 0.000143348623853 0 1 -1
doxil,may 1.0 0.000143348623853 0 1 -1
follow-up,measurements 1.0 0.000143348623853 0 1 -1
and,tam 1.0 0.000143348623853 1 0 1
should,also 0.25 0.000286697247706 3 5 -2
thyroid-stimulating,hormone 1.0 0.000143348623853 0 1 -1
of,additive 1.0 0.000143348623853 1 0 1
suppression,test 1.0 0.000286697247706 0 2 -2
in,march 1.0 0.000143348623853 0 1 -1
judged,by 1.0 0.000143348623853 0 1 -1
at,but 1.0 0.000143348623853 0 1 -1
major,bleeding 1.0 0.000143348623853 1 0 1
arthritis,or 1.0 0.000143348623853 0 1 -1
to,produce 0.263157894737 0.000716743119266 7 12 -5
positive,for 1.0 0.000143348623853 0 1 -1
unclear,how 1.0 0.000143348623853 1 0 1
to,humans 0.333333333333 0.000143348623853 1 2 -1
is,unknown 0.777777777778 0.00100344036697 1 8 -7
these,strategies 1.0 0.000143348623853 0 1 -1
system,notably 1.0 0.000143348623853 1 0 1
iv,myocardium 1.0 0.000143348623853 0 1 -1
in,prolonged 1.0 0.000143348623853 0 1 -1
conversion,to 1.0 0.000143348623853 0 1 -1
contra-indication,overt 1.0 0.000143348623853 0 1 -1
dose,administered 1.0 0.000143348623853 0 1 -1
of,mesenteric 1.0 0.000143348623853 0 1 -1
itraconazole,decreases 1.0 0.000143348623853 1 0 1
not,statistically 1.0 0.000143348623853 1 0 1
inadequate,method 1.0 0.000143348623853 1 0 1
cbg,sex 1.0 0.000286697247706 0 2 -2
blurred,vision 0.6 0.00043004587156 4 1 3
aminocaproic,acid 1.0 0.000143348623853 0 1 -1
agonists,on 1.0 0.000143348623853 1 0 1
stereotypic,effects 1.0 0.000143348623853 0 1 -1
separated,by 0.0 0.0 2 2 0
approximately,case 1.0 0.000143348623853 0 1 -1
anticoagulants,coagulation 1.0 0.000143348623853 0 1 -1
have,a 0.5 0.00229357798165 8 24 -16
cross-reactions,with 1.0 0.000143348623853 0 1 -1
adequate,respiratory 1.0 0.000143348623853 0 1 -1
gi,ulceration 1.0 0.00043004587156 3 0 3
in,concurrent 1.0 0.000286697247706 0 2 -2
b,was 1.0 0.000143348623853 0 1 -1
watery,stool 1.0 0.00043004587156 0 3 -3
prolonged,hot 1.0 0.000143348623853 1 0 1
evaluated,using 1.0 0.000143348623853 0 1 -1
damage,when 1.0 0.000143348623853 0 1 -1
additional,benefit 1.0 0.000286697247706 2 0 2
not,with 1.0 0.00100344036697 0 7 -7
precipitous,reduction 1.0 0.000143348623853 1 0 1
some,limited 0.0 0.0 1 1 0
blood,liver 1.0 0.000143348623853 0 1 -1
adjusted,in 0.6 0.00043004587156 1 4 -3
steroids,chloral 1.0 0.000286697247706 2 0 2
carbenicillin,indanyl 1.0 0.000143348623853 1 0 1
potentially,increased 1.0 0.000143348623853 0 1 -1
non-infection,unwanted 1.0 0.000143348623853 0 1 -1
with,platelet 1.0 0.00043004587156 0 3 -3
proportion,of 0.2 0.000143348623853 2 3 -1
or,impairing 1.0 0.000143348623853 1 0 1
disorientation,anxiety 1.0 0.000143348623853 0 1 -1
gallocatechins,epigallocatechin-3 1.0 0.000143348623853 0 1 -1
of,transdermal 1.0 0.000143348623853 1 0 1
glucose,and 0.333333333333 0.000286697247706 2 4 -2
antipyrine,because 1.0 0.000143348623853 0 1 -1
a,to 1.0 0.000573394495413 4 0 4
pharmacodynamic,effects 0.5 0.000286697247706 1 3 -2
that,mc 1.0 0.000143348623853 0 1 -1
that,mg 1.0 0.000143348623853 1 0 1
of,barrier 0.0 0.0 1 1 0
high,threshold 1.0 0.00043004587156 0 3 -3
volunteers,n 0.2 0.000143348623853 2 3 -1
mhd,did 1.0 0.000143348623853 0 1 -1
a,half-life 1.0 0.000143348623853 0 1 -1
instances,synergism 1.0 0.000143348623853 1 0 1
predominant,sterol 1.0 0.000143348623853 0 1 -1
enzyme,induction 0.0 0.0 2 2 0
bioavailability,low 1.0 0.000143348623853 0 1 -1
to,maintain 0.777777777778 0.00200688073394 2 16 -14
increased,sgot 1.0 0.000143348623853 0 1 -1
uncontrolled,intake 1.0 0.00043004587156 0 3 -3
wort,based 1.0 0.000143348623853 0 1 -1
patient,monitoring 0.5 0.000286697247706 1 3 -2
by,mao 1.0 0.000143348623853 1 0 1
condition,after 1.0 0.000143348623853 0 1 -1
aerolizertm,inhalation 1.0 0.000143348623853 0 1 -1
test,strips 1.0 0.000143348623853 0 1 -1
in,reversing 1.0 0.000143348623853 0 1 -1
using,cardiovascular 1.0 0.000143348623853 0 1 -1
or,inhibit 0.5 0.000286697247706 1 3 -2
bleeding,from 1.0 0.000143348623853 0 1 -1
cmin,increased 1.0 0.000286697247706 0 2 -2
hydroxy-iso,by 1.0 0.000143348623853 1 0 1
make,up 1.0 0.000143348623853 0 1 -1
renal,transplant 0.0 0.0 1 1 0
certain,such 0.333333333333 0.000143348623853 1 2 -1
opioids,are 1.0 0.000143348623853 0 1 -1
the,preservation 1.0 0.000143348623853 0 1 -1
not,proliferation-dependent 1.0 0.000143348623853 0 1 -1
oral,concomitant 1.0 0.000143348623853 1 0 1
and,aftercare 1.0 0.000143348623853 0 1 -1
of,sustiva 1.0 0.000143348623853 0 1 -1
discontinued,several 1.0 0.000143348623853 0 1 -1
liver,gallbladder 1.0 0.000143348623853 0 1 -1
for,cigarette 1.0 0.000143348623853 0 1 -1
hiv-infected,patients 1.0 0.000143348623853 1 0 1
plasma,expanders 1.0 0.000143348623853 0 1 -1
following,may 0.333333333333 0.000286697247706 2 4 -2
action,data 1.0 0.000143348623853 0 1 -1
of,ganglionic 1.0 0.000143348623853 1 0 1
experienced,tremor 1.0 0.000143348623853 1 0 1
hazards,of 1.0 0.000143348623853 0 1 -1
population,is 1.0 0.000286697247706 0 2 -2
and,second 0.0 0.0 1 1 0
normal,menstrual 1.0 0.000143348623853 0 1 -1
for,longer 1.0 0.000143348623853 1 0 1
acid,doses 1.0 0.000143348623853 1 0 1
and,greater 0.333333333333 0.000143348623853 1 2 -1
system,probably 1.0 0.000143348623853 0 1 -1
supervision,and 0.2 0.000143348623853 2 3 -1
an,regimen 1.0 0.000143348623853 0 1 -1
between,brevibloc 1.0 0.000143348623853 0 1 -1
extreme,caution 0.333333333333 0.000286697247706 4 2 2
including,combined 1.0 0.000143348623853 0 1 -1
levels,whenever 1.0 0.000716743119266 0 5 -5
administered,alternately 1.0 0.000286697247706 0 2 -2
simultaneously,at 1.0 0.000143348623853 0 1 -1
as,is 1.0 0.00043004587156 0 3 -3
as,it 1.0 0.000143348623853 0 1 -1
was,evident 1.0 0.00043004587156 0 3 -3
binds,both 1.0 0.000143348623853 1 0 1
a,complication 1.0 0.000143348623853 0 1 -1
density,of 1.0 0.000143348623853 0 1 -1
the,action 0.727272727273 0.00229357798165 19 3 16
with,without 1.0 0.000286697247706 0 2 -2
zone,and 1.0 0.000143348623853 1 0 1
treat,strongyloidiasis 1.0 0.000143348623853 1 0 1
ecg,taken 1.0 0.000143348623853 0 1 -1
gliftor,difluoro-2 1.0 0.000143348623853 0 1 -1
require,downward 1.0 0.000286697247706 2 0 2
nucleoside-experienced,patients 1.0 0.000143348623853 0 1 -1
drawn,regarding 1.0 0.000143348623853 0 1 -1
green,as 1.0 0.000143348623853 0 1 -1
assays,resulting 1.0 0.000143348623853 0 1 -1
of,glucocorticoid-induced 1.0 0.000143348623853 0 1 -1
norpace,cr 1.0 0.000143348623853 1 0 1
mouth,bodyweight 1.0 0.000143348623853 0 1 -1
the,inhibition 0.6 0.00043004587156 4 1 3
skin,rash 0.0 0.0 1 1 0
which,contain 1.0 0.000143348623853 1 0 1
reference,to 1.0 0.000143348623853 0 1 -1
oxidase,inhibitor 1.0 0.000143348623853 0 1 -1
by,selective 1.0 0.000143348623853 0 1 -1
mean,scores 1.0 0.000143348623853 1 0 1
older,and 1.0 0.000143348623853 0 1 -1
other,psychotropic 0.666666666667 0.000573394495413 5 1 4
for,pancreatic 1.0 0.000143348623853 0 1 -1
in,individualizing 1.0 0.000143348623853 0 1 -1
loss,between 1.0 0.000286697247706 0 2 -2
of,peripheral 1.0 0.000143348623853 0 1 -1
qd,resulted 1.0 0.00043004587156 3 0 3
that,dopamine-induced 1.0 0.000143348623853 1 0 1
still,be 1.0 0.000143348623853 0 1 -1
magnesium-containing,meq 1.0 0.000143348623853 0 1 -1
those,for 1.0 0.000143348623853 0 1 -1
neurological,toxic 1.0 0.000143348623853 0 1 -1
conjugated,and 1.0 0.000143348623853 0 1 -1
were,assessed 1.0 0.000716743119266 0 5 -5
total,concentrations 0.333333333333 0.000143348623853 1 2 -1
pupil,size 1.0 0.000143348623853 1 0 1
received,cephalosporin 1.0 0.000143348623853 0 1 -1
duration,or 1.0 0.000143348623853 0 1 -1
pregnancy,category 1.0 0.000286697247706 0 2 -2
as,bradycardia 1.0 0.000143348623853 1 0 1
out,with 1.0 0.000143348623853 0 1 -1
the,prior 1.0 0.000143348623853 1 0 1
of,using 0.2 0.000286697247706 4 6 -2
duration,of 0.263157894737 0.000716743119266 7 12 -5
with,on 0.0 0.0 1 1 0
joint,action 1.0 0.000286697247706 0 2 -2
and,digestive 1.0 0.000143348623853 1 0 1
with,oh 1.0 0.000143348623853 1 0 1
with,of 0.142857142857 0.000143348623853 3 4 -1
when,measured 1.0 0.000143348623853 0 1 -1
oxytocin,or 1.0 0.000143348623853 1 0 1
which,adds 1.0 0.000143348623853 0 1 -1
increase,following 1.0 0.000143348623853 1 0 1
with,or 0.345454545455 0.00272362385321 37 18 19
specific,objectives 1.0 0.000143348623853 0 1 -1
that,accompany 1.0 0.000143348623853 1 0 1
the,class 0.5 0.000286697247706 1 3 -2
or,ergot-type 1.0 0.00043004587156 3 0 3
nephrotoxicity,has 1.0 0.000860091743119 6 0 6
urinary,homocysteine 1.0 0.000143348623853 0 1 -1
stress,of 1.0 0.000143348623853 0 1 -1
generally,good 1.0 0.000143348623853 0 1 -1
of,newly 1.0 0.000143348623853 0 1 -1
prolonged,the 1.0 0.000286697247706 2 0 2
oral,antagonist 1.0 0.000143348623853 1 0 1
exercised,when 0.130434782609 0.00043004587156 10 13 -3
no,alterations 1.0 0.000143348623853 0 1 -1
a,thienobenzodiazepine 1.0 0.000143348623853 0 1 -1
monitoring,tdm 1.0 0.000143348623853 0 1 -1
objectives,of 1.0 0.000143348623853 0 1 -1
given,only 1.0 0.000143348623853 0 1 -1
decreased,fi 1.0 0.000286697247706 0 2 -2
agonists,hepatic 1.0 0.000143348623853 0 1 -1
vary,from 1.0 0.000143348623853 0 1 -1
metabolite,averaged 1.0 0.000143348623853 0 1 -1
pressure,below 1.0 0.00043004587156 3 0 3
other,ergot 1.0 0.000143348623853 1 0 1
amiodarone,is 0.333333333333 0.000143348623853 1 2 -1
or,than 1.0 0.000143348623853 1 0 1
theophylline,twelve 1.0 0.000143348623853 0 1 -1
or,that 1.0 0.000286697247706 2 0 2
the,increase 0.692307692308 0.00129013761468 2 11 -9
with,hereditary 1.0 0.000143348623853 1 0 1
conducted,on 1.0 0.000286697247706 0 2 -2
and,half 1.0 0.000143348623853 0 1 -1
any,enzyme 1.0 0.000143348623853 0 1 -1
upon,discontinuation 1.0 0.00043004587156 3 0 3
in,insulin-dependent 1.0 0.000143348623853 0 1 -1
prolongation,has 1.0 0.000143348623853 0 1 -1
attempt,to 1.0 0.000143348623853 1 0 1
is,primarily 1.0 0.00114678899083 0 8 -8
high,intraperitoneal 1.0 0.000143348623853 1 0 1
dual,effect 1.0 0.000143348623853 0 1 -1
vs,serious 1.0 0.000143348623853 1 0 1
beyond,those 1.0 0.000143348623853 0 1 -1
known,cyp3a4 1.0 0.00043004587156 3 0 3
guardians,should 1.0 0.000143348623853 0 1 -1
reported,case 1.0 0.000143348623853 1 0 1
terminal,half-life 1.0 0.00043004587156 3 0 3
any,form 1.0 0.000143348623853 0 1 -1
flupenthixol,increases 1.0 0.000143348623853 1 0 1
secretion,and 0.0 0.0 1 1 0
by,bezalip 1.0 0.000143348623853 1 0 1
macrolide,and 0.0 0.0 2 2 0
of,there 0.0 0.0 1 1 0
in,bleeding 1.0 0.000143348623853 0 1 -1
have,similar 1.0 0.000573394495413 0 4 -4
culture,the 1.0 0.000143348623853 1 0 1
and,carbonate 1.0 0.000143348623853 1 0 1
link,between 1.0 0.000143348623853 0 1 -1
important,also 1.0 0.000143348623853 0 1 -1
of,insp 1.0 0.000143348623853 0 1 -1
during,simultaneous 1.0 0.000143348623853 0 1 -1
alternative,agents 1.0 0.000143348623853 0 1 -1
the,proportion 1.0 0.000143348623853 0 1 -1
clinical,evaluation 1.0 0.000143348623853 0 1 -1
renally,eliminated 1.0 0.000143348623853 0 1 -1
p-450,a4 1.0 0.000143348623853 0 1 -1
hydroxides,be 1.0 0.000143348623853 1 0 1
with,four 0.0 0.0 1 1 0
also,affected 1.0 0.000143348623853 0 1 -1
cyp3a4,metabolized 1.0 0.000286697247706 2 0 2
prolonged,survival 1.0 0.000143348623853 0 1 -1
are,suggested 0.0 0.0 1 1 0
teratogenic,effects 1.0 0.000286697247706 0 2 -2
avoided,serum 1.0 0.000143348623853 0 1 -1
from,co-administration 1.0 0.000143348623853 1 0 1
the,enzymatic 1.0 0.000143348623853 1 0 1
cause,are 1.0 0.000143348623853 0 1 -1
mimicked,by 1.0 0.000143348623853 0 1 -1
insure,that 1.0 0.000143348623853 1 0 1
administration,with 0.333333333333 0.000286697247706 4 2 2
increased,breakthrough 1.0 0.000143348623853 0 1 -1
if,tykerb 1.0 0.000286697247706 0 2 -2
of,unbound 1.0 0.000286697247706 0 2 -2
subjects,who 0.4 0.000573394495413 3 7 -4
pressure,than 1.0 0.000143348623853 1 0 1
as,much 0.6 0.00043004587156 1 4 -3
marker,of 1.0 0.000143348623853 1 0 1
efficacious,a 1.0 0.000143348623853 0 1 -1
a,liquid 1.0 0.000143348623853 0 1 -1
the,ames 1.0 0.00043004587156 0 3 -3
to,find 1.0 0.000143348623853 0 1 -1
cgi,generic3 1.0 0.000143348623853 0 1 -1
pi,with 1.0 0.000143348623853 0 1 -1
of,incompatibility 1.0 0.000286697247706 0 2 -2
clearance,rate 0.0 0.0 1 1 0
attenuate,morphine-induced 1.0 0.000143348623853 0 1 -1
distinct,from 1.0 0.000143348623853 0 1 -1
adjunctive,therapy 1.0 0.000143348623853 1 0 1
therapies,are 1.0 0.000143348623853 0 1 -1
if,combination 0.333333333333 0.000143348623853 1 2 -1
exposure,or 1.0 0.000286697247706 0 2 -2
the,tnf 1.0 0.000143348623853 1 0 1
the,mortality 1.0 0.000143348623853 0 1 -1
administering,disulfiram 1.0 0.000143348623853 1 0 1
indicated,when 1.0 0.000143348623853 0 1 -1
to,first-pass 1.0 0.000143348623853 0 1 -1
uptake-1,was 1.0 0.000143348623853 0 1 -1
some,preliminary 1.0 0.000143348623853 0 1 -1
activation,factor 1.0 0.000143348623853 0 1 -1
medications,the 1.0 0.000143348623853 1 0 1
respond,normally 1.0 0.000143348623853 0 1 -1
point,in 1.0 0.000143348623853 0 1 -1
added,as 1.0 0.000143348623853 0 1 -1
was,taken 0.0 0.0 2 2 0
hydrochloride,including 1.0 0.000143348623853 0 1 -1
cytadren,accelerates 1.0 0.000143348623853 1 0 1
drug,should 1.0 0.000286697247706 0 2 -2
and,specific 1.0 0.000143348623853 0 1 -1
individual,levels 1.0 0.000143348623853 0 1 -1
caused,identical 1.0 0.000143348623853 0 1 -1
treat,achlorhydria 1.0 0.000143348623853 0 1 -1
and,nonrenal 1.0 0.000143348623853 0 1 -1
respectively,resulted 1.0 0.000143348623853 1 0 1
be,prolonged 1.0 0.00043004587156 3 0 3
and,kappa-selective 1.0 0.000143348623853 0 1 -1
nafazodone,consider 1.0 0.000143348623853 1 0 1
in,failing 1.0 0.000143348623853 0 1 -1
or,or 0.0 0.0 5 5 0
taxol,infusion 1.0 0.000143348623853 0 1 -1
humans,demonstrated 1.0 0.000143348623853 0 1 -1
amiodarone,therapy 1.0 0.000143348623853 0 1 -1
virus-positive,patients 1.0 0.000143348623853 0 1 -1
caffeine,theobromine 1.0 0.000143348623853 1 0 1
addition,steady 1.0 0.000143348623853 0 1 -1
or,of 1.0 0.000286697247706 0 2 -2
are,reviewed 1.0 0.000143348623853 0 1 -1
or,on 0.666666666667 0.000573394495413 1 5 -4
receiving,another 1.0 0.000143348623853 1 0 1
the,decrease 1.0 0.000286697247706 0 2 -2
the,proposed 1.0 0.00043004587156 0 3 -3
method,to 1.0 0.00043004587156 0 3 -3
appearance,have 1.0 0.000143348623853 0 1 -1
by,serial 1.0 0.000143348623853 0 1 -1
gabitril,carbamazepine 1.0 0.000143348623853 1 0 1
be,warranted 1.0 0.000286697247706 0 2 -2
grams,daily 1.0 0.000143348623853 0 1 -1
primarily,iron-fortified 1.0 0.000143348623853 0 1 -1
human,response 1.0 0.000143348623853 0 1 -1
bioequivalent,when 1.0 0.000143348623853 0 1 -1
inhibit,cyp2c19 1.0 0.000143348623853 0 1 -1
amiodarone,amiodarone 1.0 0.000143348623853 0 1 -1
liver,and 0.142857142857 0.000143348623853 4 3 1
excreted,by 1.0 0.000143348623853 0 1 -1
fistulas,were 1.0 0.000143348623853 0 1 -1
vitro,on 1.0 0.000143348623853 0 1 -1
ranges,of 1.0 0.000143348623853 0 1 -1
activity,induced 1.0 0.000143348623853 0 1 -1
alteration,in 0.714285714286 0.000716743119266 1 6 -5
addition,interfere 1.0 0.000143348623853 1 0 1
lesions,have 1.0 0.000143348623853 0 1 -1
e2-induced,diarrhea 1.0 0.000143348623853 0 1 -1
absence,of 0.636363636364 0.00100344036697 2 9 -7
millions,of 1.0 0.000143348623853 0 1 -1
deaths,three 1.0 0.000143348623853 0 1 -1
decreased,free 1.0 0.000143348623853 0 1 -1
induce,abnormalities 1.0 0.000143348623853 0 1 -1
are,specific 1.0 0.000143348623853 0 1 -1
into,three 0.0 0.0 1 1 0
is,necessary 0.5 0.000573394495413 2 6 -4
known,strong 1.0 0.000286697247706 0 2 -2
and,half-life 0.333333333333 0.000143348623853 2 1 1
the,conjugates 1.0 0.000143348623853 0 1 -1
ml,egf 1.0 0.000143348623853 0 1 -1
etodolac-treated,patients 1.0 0.000143348623853 1 0 1
diet,resulted 1.0 0.000143348623853 1 0 1
in,half-life 1.0 0.000143348623853 0 1 -1
test,a 1.0 0.000143348623853 0 1 -1
methods,that 1.0 0.000143348623853 0 1 -1
increased,auc 0.333333333333 0.000143348623853 1 2 -1
it,does 1.0 0.000143348623853 0 1 -1
agents,decrease 1.0 0.000143348623853 1 0 1
the,antitumor 0.0 0.0 1 1 0
recent,better 1.0 0.000143348623853 0 1 -1
vitro,human 1.0 0.000143348623853 0 1 -1
compared,directly 1.0 0.000143348623853 0 1 -1
co,administered 0.0 0.0 1 1 0
for,anions 1.0 0.000143348623853 0 1 -1
identified,and 1.0 0.000143348623853 0 1 -1
physiological,behavioral 1.0 0.000143348623853 0 1 -1
gallic,acid 1.0 0.000143348623853 0 1 -1
components,ee 1.0 0.000143348623853 1 0 1
symptoms,may 1.0 0.000286697247706 0 2 -2
same,in 1.0 0.00043004587156 0 3 -3
of,ssri-associated 1.0 0.000143348623853 0 1 -1
lithium,serum 1.0 0.000143348623853 1 0 1
carcinogen,can 1.0 0.000143348623853 0 1 -1
concentration,cmax 0.333333333333 0.000143348623853 1 2 -1
concomitantly,taking 1.0 0.000143348623853 0 1 -1
the,strength 1.0 0.000143348623853 1 0 1
sensory,and 1.0 0.000143348623853 1 0 1
vs,cmax 1.0 0.000143348623853 0 1 -1
doxepin,is 1.0 0.000143348623853 0 1 -1
levels,suggesting 1.0 0.000143348623853 1 0 1
compensate,for 1.0 0.000286697247706 2 0 2
background,the 1.0 0.00043004587156 0 3 -3
hump,peripheral 1.0 0.000143348623853 0 1 -1
da,levels 1.0 0.000143348623853 0 1 -1
quality,of 1.0 0.000143348623853 0 1 -1
higher,as 1.0 0.000143348623853 1 0 1
at,many 1.0 0.000143348623853 0 1 -1
hormonal,who 1.0 0.000286697247706 0 2 -2
dose,unfractionated 1.0 0.000143348623853 0 1 -1
with,wshow 1.0 0.000143348623853 0 1 -1
fatal,interactions 1.0 0.000143348623853 0 1 -1
this,kind 1.0 0.000143348623853 1 0 1
oruvail,voltaren 1.0 0.000143348623853 0 1 -1
pressure,carotid 1.0 0.000143348623853 0 1 -1
chemotherapy,cardiotoxic 1.0 0.000143348623853 1 0 1
standard,cystic 1.0 0.000143348623853 0 1 -1
in,incomplete 1.0 0.000143348623853 0 1 -1
vasodilating,effects 0.5 0.000286697247706 3 1 2
embryos,similarly 1.0 0.000143348623853 0 1 -1
total,cholesterol 1.0 0.00043004587156 0 3 -3
isozymes,evaluated 1.0 0.000143348623853 0 1 -1
greater,extent 1.0 0.000286697247706 0 2 -2
and,dehydration 1.0 0.000143348623853 1 0 1
mg,for 0.333333333333 0.000143348623853 1 2 -1
relaxants,sleeping 1.0 0.000143348623853 0 1 -1
less,of 1.0 0.000286697247706 0 2 -2
resistance,was 1.0 0.000143348623853 0 1 -1
anabolic,anabolin 1.0 0.000143348623853 0 1 -1
when,hydrochlorothiazide 1.0 0.000143348623853 1 0 1
citrate,theoretically 1.0 0.000143348623853 1 0 1
alcohol,has 1.0 0.000143348623853 1 0 1
acth,may 1.0 0.000143348623853 1 0 1
showed,behavioral 1.0 0.000143348623853 0 1 -1
any,conclusions 1.0 0.000143348623853 0 1 -1
this,table 1.0 0.000286697247706 0 2 -2
infarction,liver 1.0 0.000143348623853 0 1 -1
cholesterol,mg 1.0 0.000143348623853 0 1 -1
insert,labeling 1.0 0.000143348623853 0 1 -1
cardiovascular,system 0.5 0.000286697247706 3 1 2
statins,co-administration 1.0 0.000143348623853 1 0 1
difluoroacetone,by 1.0 0.000143348623853 0 1 -1
containing,are 1.0 0.000143348623853 0 1 -1
pancreases,of 1.0 0.000143348623853 0 1 -1
and,recurred 1.0 0.000143348623853 0 1 -1
thyroidal,uptake 1.0 0.000143348623853 1 0 1
with,this 1.0 0.00043004587156 0 3 -3
by,severe 0.333333333333 0.000143348623853 2 1 1
higher,virologic 1.0 0.000143348623853 0 1 -1
forevidence,of 1.0 0.000143348623853 1 0 1
volunteers,the 0.333333333333 0.000286697247706 4 2 2
therapeutic,concentrations 0.666666666667 0.000573394495413 1 5 -4
pulmozyme,can 1.0 0.000143348623853 0 1 -1
the,levels 0.428571428571 0.00043004587156 2 5 -3
solubility,of 1.0 0.000143348623853 0 1 -1
as,may 0.333333333333 0.000143348623853 2 1 1
eagles,minimal 1.0 0.000143348623853 0 1 -1
hours,competes 1.0 0.000143348623853 1 0 1
and,ketoconazole 1.0 0.000286697247706 0 2 -2
found,but 1.0 0.000143348623853 0 1 -1
given,mg 0.0 0.0 1 1 0
any,deficit 1.0 0.000143348623853 0 1 -1
exhibit,characteristic 1.0 0.000143348623853 0 1 -1
rats,treated 0.5 0.000286697247706 1 3 -2
volunteers,resulted 0.5 0.000286697247706 3 1 2
their,additive 1.0 0.000143348623853 1 0 1
fenfluramine,may 1.0 0.000143348623853 1 0 1
achieve,and 1.0 0.000143348623853 0 1 -1
contraction,and 1.0 0.000143348623853 0 1 -1
hydrochloride,either 1.0 0.000143348623853 1 0 1
high-dose,with 1.0 0.000143348623853 1 0 1
be,placed 1.0 0.000143348623853 0 1 -1
theophylline,vioxx 1.0 0.000143348623853 1 0 1
modulatory,effect 1.0 0.000143348623853 0 1 -1
produced,an 0.714285714286 0.000716743119266 6 1 5
dose-dependent,fashion 0.0 0.0 1 1 0
d,redistributed 1.0 0.000143348623853 0 1 -1
also,contribute 0.0 0.0 1 1 0
ascertained,between 1.0 0.000143348623853 0 1 -1
of,rr 1.0 0.000286697247706 0 2 -2
neither,inhibitors 1.0 0.000143348623853 0 1 -1
metabolite,is 1.0 0.000143348623853 0 1 -1
metabolite,in 1.0 0.000143348623853 0 1 -1
are,at 0.142857142857 0.000143348623853 3 4 -1
was,delayed 0.5 0.000286697247706 1 3 -2
receiving,other 1.0 0.00043004587156 3 0 3
another,serotonin 1.0 0.000143348623853 1 0 1
decreases,of 0.333333333333 0.000143348623853 2 1 1
colestipol,plasma 1.0 0.000143348623853 1 0 1
tindal,thorazine 1.0 0.000143348623853 0 1 -1
sirolimus,works 1.0 0.000143348623853 0 1 -1
suggested,that 0.111111111111 0.000143348623853 5 4 1
closely,after 1.0 0.000143348623853 1 0 1
initially,and 1.0 0.000143348623853 0 1 -1
available,and 1.0 0.000286697247706 0 2 -2
of,nsaids 0.0 0.0 1 1 0
of,that 0.111111111111 0.000143348623853 5 4 1
following,use 1.0 0.000286697247706 2 0 2
relafen,daypro 1.0 0.000143348623853 0 1 -1
tricyclic,antidepressants 0.333333333333 0.000143348623853 2 1 1
in,elimination 1.0 0.000143348623853 1 0 1
ototoxic,potential 1.0 0.00043004587156 3 0 3
of,r- 1.0 0.000143348623853 0 1 -1
pretreatment,did 1.0 0.000143348623853 0 1 -1
of,than 1.0 0.000143348623853 1 0 1
pharmacokinetics,data 1.0 0.000286697247706 2 0 2
could,facilitate 1.0 0.000143348623853 0 1 -1
identified,in 1.0 0.000143348623853 1 0 1
or,nsaid 1.0 0.000143348623853 0 1 -1
penthrane,has 1.0 0.000143348623853 1 0 1
similar,metabolism 1.0 0.000143348623853 0 1 -1
of,taking 1.0 0.000143348623853 1 0 1
the,mouth 1.0 0.000143348623853 1 0 1
about,compared 1.0 0.000143348623853 1 0 1
with,propranolols 1.0 0.000143348623853 1 0 1
enzymes,is 0.0 0.0 1 1 0
t24,human 1.0 0.000143348623853 0 1 -1
reproducible,pattern 1.0 0.000143348623853 0 1 -1
diabetes,longitudinal 1.0 0.000143348623853 0 1 -1
to,co-administration 1.0 0.000143348623853 0 1 -1
biological,half-lives 1.0 0.000143348623853 0 1 -1
enzymes,in 1.0 0.000143348623853 0 1 -1
effects,for 1.0 0.000143348623853 0 1 -1
limited,inhibitory 0.0 0.0 1 1 0
of,within 1.0 0.000143348623853 0 1 -1
drug,exposure 1.0 0.000143348623853 0 1 -1
cyp2d6,activity 1.0 0.000286697247706 0 2 -2
be,performed 0.333333333333 0.00043004587156 3 6 -3
increased,thyroid-binding 1.0 0.00043004587156 0 3 -3
abilify,is 1.0 0.000143348623853 1 0 1
enhanced,effects 1.0 0.000143348623853 0 1 -1
that,significantly 0.0 0.0 2 2 0
sodium,it 1.0 0.000143348623853 1 0 1
sodium,is 0.2 0.000143348623853 3 2 1
beta-blockers,in 1.0 0.000143348623853 0 1 -1
clearance,measurements 1.0 0.000143348623853 1 0 1
and,hepatic 0.0 0.0 2 2 0
agents,now 1.0 0.000143348623853 0 1 -1
affinity,for 0.666666666667 0.000573394495413 1 5 -4
interactions,toxicity 1.0 0.000143348623853 1 0 1
the,curve 0.5 0.000286697247706 3 1 2
impaired,when 1.0 0.000143348623853 0 1 -1
increases,anion 1.0 0.000143348623853 1 0 1
metabolized,similarly 1.0 0.000143348623853 1 0 1
levels,comparable 1.0 0.000143348623853 0 1 -1
releaser,and 1.0 0.000143348623853 1 0 1
hours,are 1.0 0.000143348623853 1 0 1
parnate,using 1.0 0.000143348623853 0 1 -1
in,normovolemic 1.0 0.000143348623853 1 0 1
and,profound 0.0 0.0 1 1 0
systemic,medications 1.0 0.000143348623853 1 0 1
interaction,including 1.0 0.000143348623853 0 1 -1
of,phosphate-binding 1.0 0.00043004587156 0 3 -3
significantly,potentiates 1.0 0.000143348623853 1 0 1
other,bronchodilators 1.0 0.000143348623853 1 0 1
significantly,potentiated 1.0 0.000143348623853 0 1 -1
bacillus,subtilis 1.0 0.000143348623853 1 0 1
to,b-cell 1.0 0.000143348623853 0 1 -1
frequent,clinical 1.0 0.000143348623853 0 1 -1
h,by 1.0 0.000286697247706 0 2 -2
min,in 1.0 0.000143348623853 1 0 1
eg,should 1.0 0.000143348623853 1 0 1
fell,by 1.0 0.000143348623853 1 0 1
potential,benefit 1.0 0.000143348623853 0 1 -1
following,lipid-lowering 1.0 0.000143348623853 0 1 -1
receiving,daily 1.0 0.000143348623853 0 1 -1
lipolysis,and 1.0 0.000143348623853 0 1 -1
generation,atypical 1.0 0.000143348623853 0 1 -1
beta-blocking,agents 1.0 0.000286697247706 0 2 -2
a,two-year 1.0 0.000143348623853 0 1 -1
pharmacology,and 1.0 0.000143348623853 0 1 -1
the,bile-acidsequestering 1.0 0.000143348623853 0 1 -1
formation,the 1.0 0.000143348623853 0 1 -1
of,aerosol 1.0 0.000286697247706 0 2 -2
restoration,of 1.0 0.000286697247706 0 2 -2
produced,significantly 1.0 0.000143348623853 1 0 1
cyp1a2,isoform 1.0 0.000143348623853 0 1 -1
are,mediated 1.0 0.000143348623853 0 1 -1
healthy,women 1.0 0.000143348623853 0 1 -1
antagonists,of 1.0 0.000143348623853 1 0 1
dose,or 0.4 0.000573394495413 3 7 -4
related,changes 1.0 0.000143348623853 0 1 -1
pressure,their 1.0 0.000143348623853 1 0 1
administration,the 1.0 0.000143348623853 0 1 -1
action,including 1.0 0.000143348623853 0 1 -1
hypo-prothrombinemic,effect 1.0 0.000143348623853 0 1 -1
prolonged,administration 1.0 0.00043004587156 0 3 -3
sumatriptan,sumatriptan 1.0 0.000143348623853 1 0 1
decreasing,heparin 1.0 0.000143348623853 1 0 1
dialyzed,were 1.0 0.000143348623853 0 1 -1
and,elimination 1.0 0.000143348623853 0 1 -1
affinities,than 1.0 0.000143348623853 0 1 -1
few,spontaneous 1.0 0.000143348623853 1 0 1
discoloration,or 1.0 0.000143348623853 0 1 -1
package,insert 0.0 0.0 2 2 0
since,bile 1.0 0.000143348623853 1 0 1
correlation,between 1.0 0.000143348623853 0 1 -1
benzodiazepines,benzodiazepines 1.0 0.000143348623853 1 0 1
by,while 1.0 0.000143348623853 1 0 1
dark,test 1.0 0.00043004587156 0 3 -3
and,bioavailability 1.0 0.000143348623853 1 0 1
tca,may 0.6 0.00043004587156 1 4 -3
of,adrenocortical 1.0 0.000143348623853 1 0 1
above,listed 1.0 0.000143348623853 0 1 -1
vecuronium,when 1.0 0.000143348623853 1 0 1
or,predicted 1.0 0.000143348623853 0 1 -1
the,administration 0.0384615384615 0.000286697247706 27 25 2
adrenocortical,steroids 1.0 0.000143348623853 1 0 1
and,cmc-cys 1.0 0.000143348623853 0 1 -1
low,for 1.0 0.000143348623853 0 1 -1
leukopenia,was 1.0 0.000143348623853 0 1 -1
addicts,in 1.0 0.000143348623853 0 1 -1
antagonists,based 1.0 0.000143348623853 1 0 1
exert,direct 1.0 0.000143348623853 0 1 -1
sedation,if 1.0 0.000143348623853 1 0 1
low-levels,of 1.0 0.000143348623853 0 1 -1
relevant,as 1.0 0.000143348623853 0 1 -1
sst,mice 1.0 0.000143348623853 0 1 -1
of,other 0.159420289855 0.00157683486239 29 40 -11
be,usedas 1.0 0.000143348623853 1 0 1
dentistry,cannot 1.0 0.000143348623853 0 1 -1
cyp3a4,increased 1.0 0.000143348623853 1 0 1
would,play 1.0 0.000143348623853 0 1 -1
d,respectively 1.0 0.000143348623853 1 0 1
apparent,effect 1.0 0.000143348623853 0 1 -1
free,t3 1.0 0.00043004587156 0 3 -3
carcinogenesis,by 1.0 0.000143348623853 0 1 -1
including,concomitantly 1.0 0.000286697247706 2 0 2
free,t4 1.0 0.000573394495413 0 4 -4
warfarin,concomitant 1.0 0.000143348623853 0 1 -1
commercially,available 1.0 0.000286697247706 0 2 -2
tablets,inhibit 1.0 0.000143348623853 1 0 1
result,from 0.5 0.000573394495413 2 6 -4
multivitamins,quinolones 1.0 0.000143348623853 0 1 -1
test,do 1.0 0.000143348623853 0 1 -1
or,inhibition 1.0 0.000286697247706 0 2 -2
c129h223n3o54,isolated 1.0 0.000143348623853 0 1 -1
clostridium,difficile 1.0 0.000143348623853 0 1 -1
brevibloc,concentrations 1.0 0.000143348623853 1 0 1
a,bacteriostatic 1.0 0.000286697247706 2 0 2
mothers,received 1.0 0.000143348623853 0 1 -1
as,assessed 1.0 0.00043004587156 0 3 -3
with,qt-interval 1.0 0.000143348623853 0 1 -1
binding,displacement 1.0 0.000143348623853 0 1 -1
of,fade 1.0 0.000143348623853 1 0 1
choice,for 1.0 0.000143348623853 0 1 -1
affecting,cytochrome 1.0 0.000143348623853 0 1 -1
plasma,level 1.0 0.000286697247706 2 0 2
external,subcutaneous 1.0 0.000143348623853 0 1 -1
to,regimens 1.0 0.000143348623853 0 1 -1
rash,particularly 1.0 0.000143348623853 0 1 -1
be,potentiated 0.3 0.000860091743119 13 7 6
partial,thromboplastin 1.0 0.000573394495413 0 4 -4
ganciclovir,the 1.0 0.000143348623853 0 1 -1
changing,therapy 1.0 0.000143348623853 1 0 1
an,inhibitor 0.6 0.00172018348624 4 16 -12
observed,training-induced 1.0 0.000143348623853 0 1 -1
biopsy,revealed 1.0 0.000143348623853 0 1 -1
it,creates 1.0 0.000143348623853 0 1 -1
glutathione,total 1.0 0.000143348623853 0 1 -1
arrythmias,ventricular 1.0 0.000143348623853 1 0 1
remedies,may 1.0 0.000143348623853 0 1 -1
neuromuscular,blocking 0.636363636364 0.00100344036697 9 2 7
of,liver 0.5 0.000286697247706 1 3 -2
higher,dosage 1.0 0.000143348623853 0 1 -1
produced,mean 1.0 0.000143348623853 1 0 1
erythromycin,clarithromycin 1.0 0.000143348623853 0 1 -1
in,general 1.0 0.00114678899083 0 8 -8
miotic,actions 1.0 0.000143348623853 0 1 -1
encephalopathic,syndrome 1.0 0.000143348623853 1 0 1
this,combination 0.714285714286 0.00143348623853 2 12 -10
and,hyperinsulinaemia 1.0 0.000143348623853 0 1 -1
current,study 1.0 0.000143348623853 0 1 -1
celexa,in 1.0 0.000143348623853 1 0 1
sucralfate,should 1.0 0.000143348623853 1 0 1
that,discontinuation 1.0 0.000143348623853 1 0 1
by,observations 1.0 0.000143348623853 0 1 -1
modify,exposed 1.0 0.000143348623853 0 1 -1
can,cause 0.6 0.000860091743119 2 8 -6
the,high 1.0 0.000286697247706 0 2 -2
argatroban,with 0.0 0.0 1 1 0
an,effect 0.428571428571 0.000860091743119 4 10 -6
hydrophobic,side 1.0 0.000143348623853 0 1 -1
chylomicron,lipolysis 1.0 0.000143348623853 0 1 -1
a,tarceva 1.0 0.000143348623853 0 1 -1
inhibit,pgp 1.0 0.000143348623853 0 1 -1
conditions,produce 1.0 0.000143348623853 0 1 -1
or,ergot 1.0 0.000143348623853 1 0 1
concomitantly,used 1.0 0.000143348623853 0 1 -1
inr,determinations 1.0 0.000143348623853 0 1 -1
other,amphotericin 1.0 0.000143348623853 1 0 1
increases,and 1.0 0.000143348623853 1 0 1
with,iron 1.0 0.000143348623853 1 0 1
utero,exposure 1.0 0.000143348623853 0 1 -1
these,also 1.0 0.000143348623853 0 1 -1
may,cause 0.2 0.00100344036697 21 14 7
if,leustatin 1.0 0.000143348623853 0 1 -1
clostridium,three 1.0 0.000143348623853 0 1 -1
therefore,you 1.0 0.000143348623853 1 0 1
the,dog 1.0 0.000143348623853 0 1 -1
like,mptp 1.0 0.000143348623853 1 0 1
presumably,to 1.0 0.000143348623853 0 1 -1
from,protein 1.0 0.000286697247706 2 0 2
excessive,ingestion 1.0 0.000143348623853 0 1 -1
high-estradiol,treated 1.0 0.000143348623853 1 0 1
and,caution 1.0 0.000716743119266 0 5 -5
workers,involved 1.0 0.000143348623853 0 1 -1
cells,this 1.0 0.000143348623853 1 0 1
with,hemostasis 1.0 0.000143348623853 0 1 -1
ecg,intervals 1.0 0.000143348623853 0 1 -1
alcohol,in 0.5 0.000286697247706 1 3 -2
buffered,tablets 1.0 0.00114678899083 8 0 8
patients,requiring 1.0 0.000143348623853 0 1 -1
to,might 1.0 0.000143348623853 1 0 1
of,isocarboxazid 0.0 0.0 1 1 0
course,of 0.130434782609 0.00043004587156 10 13 -3
histamine,h2 1.0 0.000143348623853 1 0 1
constituent,precipitated 1.0 0.000143348623853 0 1 -1
alcohol,it 1.0 0.000143348623853 1 0 1
may,become 0.714285714286 0.000716743119266 1 6 -5
is,mildly 1.0 0.000143348623853 1 0 1
functional,class 0.333333333333 0.000143348623853 1 2 -1
optimal,pulmonary 1.0 0.000143348623853 0 1 -1
iiia,inhibitors 1.0 0.000143348623853 1 0 1
of,concurrent 1.0 0.000143348623853 1 0 1
potential,must 0.0 0.0 1 1 0
table,is 1.0 0.000286697247706 0 2 -2
phase,extraction 1.0 0.000143348623853 0 1 -1
avoid,possible 1.0 0.00043004587156 3 0 3
cross,toxicity 1.0 0.000143348623853 1 0 1
accumulation,that 1.0 0.000143348623853 0 1 -1
drugs,cimetidine 1.0 0.000143348623853 0 1 -1
risk,and 1.0 0.000143348623853 0 1 -1
because,higher 1.0 0.000143348623853 0 1 -1
taken,on 0.0 0.0 1 1 0
bradycardia,sinus 1.0 0.000143348623853 0 1 -1
reduce,its 0.333333333333 0.000286697247706 4 2 2
myocardial,depressants 1.0 0.000143348623853 1 0 1
qt-interval,prolongation 1.0 0.000143348623853 0 1 -1
precipitate,is 1.0 0.000143348623853 0 1 -1
and,administered 1.0 0.000143348623853 0 1 -1
marked,interference 1.0 0.000143348623853 1 0 1
via,this 1.0 0.000143348623853 1 0 1
fold,accumulation 1.0 0.000143348623853 0 1 -1
interactions,dofetilide 1.0 0.000143348623853 0 1 -1
when,patient 1.0 0.000143348623853 0 1 -1
results,for 0.0 0.0 1 1 0
risk,of 0.139784946237 0.00186353211009 40 53 -13
careful,consideration 0.5 0.000286697247706 1 3 -2
volunteers,concomitant 1.0 0.00043004587156 3 0 3
initial,therapy 1.0 0.000143348623853 0 1 -1
or,camp-stimulated 1.0 0.000143348623853 1 0 1
potentiated,by 0.733333333333 0.00157683486239 13 2 11
individuals,were 1.0 0.000143348623853 0 1 -1
administered,separately 1.0 0.000143348623853 1 0 1
by,cyp2d6 0.5 0.000573394495413 2 6 -4
asian,african 1.0 0.000716743119266 0 5 -5
of,measured 1.0 0.000143348623853 0 1 -1
hydrochloride,before 1.0 0.000143348623853 0 1 -1
of,the 0.295315682281 0.0207855504587 173 318 -145
was,strongly 1.0 0.000143348623853 0 1 -1
such,without 1.0 0.000143348623853 0 1 -1
small,intestinal 1.0 0.000286697247706 0 2 -2
taking,can 1.0 0.000286697247706 0 2 -2
phenytoin,felbatol 1.0 0.000143348623853 1 0 1
between,cecectomized 1.0 0.000143348623853 0 1 -1
to,one-half 0.5 0.000286697247706 3 1 2
cigarette,smokers 1.0 0.000143348623853 0 1 -1
a,increase 0.916666666667 0.00315366972477 23 1 22
of,diethyl 1.0 0.000143348623853 0 1 -1
red,on 1.0 0.000143348623853 0 1 -1
concentrates,or 1.0 0.000143348623853 0 1 -1
two,drugs 1.0 0.000143348623853 1 0 1
control,hyperuricemia 1.0 0.000143348623853 0 1 -1
for,l-glutamine 1.0 0.000143348623853 0 1 -1
counts,be 1.0 0.000143348623853 0 1 -1
african-american,man 1.0 0.000143348623853 0 1 -1
serum,with 1.0 0.000143348623853 0 1 -1
of,products 1.0 0.000143348623853 1 0 1
experiments,reactions 1.0 0.000143348623853 0 1 -1
noted,with 0.333333333333 0.000143348623853 1 2 -1
hypokalemia,or 1.0 0.000143348623853 0 1 -1
all,central 1.0 0.000143348623853 1 0 1
only,block 1.0 0.000143348623853 1 0 1
by,cimetidines 1.0 0.000143348623853 1 0 1
the,homodimeric 1.0 0.000286697247706 0 2 -2
cyclosporine,increased 1.0 0.000143348623853 1 0 1
coumarin,anticoagulants 0.5 0.000286697247706 3 1 2
decreasing,its 1.0 0.000143348623853 1 0 1
labelled,and 1.0 0.000143348623853 0 1 -1
higher,increases 1.0 0.000143348623853 1 0 1
article,reviews 1.0 0.000143348623853 0 1 -1
elc,should 1.0 0.000143348623853 1 0 1
made,they 1.0 0.000143348623853 0 1 -1
clozapine,and 1.0 0.000286697247706 2 0 2
hormone,fsh 1.0 0.000143348623853 0 1 -1
tablets,to 0.0 0.0 1 1 0
an,aluminum 1.0 0.000143348623853 0 1 -1
have,suggested 1.0 0.000143348623853 0 1 -1
via,the 1.0 0.00114678899083 0 8 -8
garlic,allium 1.0 0.000143348623853 1 0 1
are,predominantly 0.0 0.0 2 2 0
antagonism,was 1.0 0.000143348623853 0 1 -1
fluorouracil,is 1.0 0.000143348623853 1 0 1
when,other 1.0 0.000286697247706 2 0 2
both,cyp2d6 1.0 0.000143348623853 0 1 -1
cmax,up 1.0 0.000143348623853 1 0 1
this,particular 1.0 0.000143348623853 0 1 -1
promptly,if 1.0 0.000143348623853 0 1 -1
safety,is 1.0 0.000143348623853 0 1 -1
and,observations 1.0 0.000143348623853 0 1 -1
establishing,the 1.0 0.000143348623853 0 1 -1
regimens,may 1.0 0.000143348623853 0 1 -1
see,clinical 0.142857142857 0.000143348623853 3 4 -1
and,cns-active 1.0 0.000143348623853 0 1 -1
including,such 1.0 0.000286697247706 2 0 2
enzymatic,oxidation 1.0 0.000143348623853 1 0 1
atcc,showed 1.0 0.000143348623853 0 1 -1
diet,and 1.0 0.000143348623853 0 1 -1
criteria,for 1.0 0.000143348623853 0 1 -1
or,acute 1.0 0.000143348623853 0 1 -1
in,central 1.0 0.000143348623853 1 0 1
levels,during 1.0 0.000143348623853 1 0 1
not,suggest 1.0 0.000286697247706 0 2 -2
guided,by 1.0 0.000143348623853 0 1 -1
acid,may 0.666666666667 0.000573394495413 5 1 4
secretion,in 1.0 0.000143348623853 0 1 -1
n,resulted 1.0 0.000143348623853 1 0 1
of,thio 1.0 0.000143348623853 0 1 -1
that,inhibits 0.333333333333 0.000286697247706 2 4 -2
rises,in 1.0 0.000143348623853 1 0 1
on,gabitril 1.0 0.000143348623853 1 0 1
transient,cardiac 1.0 0.000143348623853 1 0 1
slow,alterations 1.0 0.000143348623853 0 1 -1
rashes,itching 1.0 0.000143348623853 0 1 -1
specific,interactions 0.0 0.0 1 1 0
foradil,other 1.0 0.000143348623853 0 1 -1
december,the 1.0 0.000143348623853 0 1 -1
only,take 1.0 0.000143348623853 0 1 -1
edema,excessive 1.0 0.000143348623853 0 1 -1
tachycardia,induced 1.0 0.000143348623853 1 0 1
sampling,were 1.0 0.000143348623853 0 1 -1
oral,carbonic 1.0 0.000286697247706 2 0 2
observed,with 0.555555555556 0.00143348623853 4 14 -10
during,therapy 0.333333333333 0.00043004587156 6 3 3
pharmacokinetic,variability 1.0 0.000143348623853 0 1 -1
or,organophosphate 1.0 0.000143348623853 1 0 1
neonatally,to 1.0 0.000143348623853 0 1 -1
theophylline,ethinyl 1.0 0.000143348623853 1 0 1
concentrations,as 1.0 0.000143348623853 0 1 -1
dynacirc,and 1.0 0.000286697247706 0 2 -2
displaces,from 1.0 0.000143348623853 1 0 1
lithium,lithium 1.0 0.00043004587156 3 0 3
shifts,in 1.0 0.000143348623853 0 1 -1
clinical,basis 1.0 0.000143348623853 0 1 -1
and,males 1.0 0.000143348623853 0 1 -1
of,therapeutic 1.0 0.000716743119266 0 5 -5
published,reports 1.0 0.000143348623853 1 0 1
upon,a 1.0 0.000143348623853 0 1 -1
at,intervals 1.0 0.000143348623853 0 1 -1
from,smoking 1.0 0.000143348623853 0 1 -1
any,occasion 1.0 0.000143348623853 0 1 -1
gastrointestinal,and 1.0 0.000143348623853 0 1 -1
equetrotm,are 1.0 0.000286697247706 2 0 2
mean,serum 1.0 0.000286697247706 2 0 2
ataxia,dysarthria 1.0 0.000143348623853 0 1 -1
circulating,concentrations 1.0 0.000143348623853 0 1 -1
in,auc0-12 1.0 0.000143348623853 1 0 1
or,severity 0.333333333333 0.000143348623853 2 1 1
these,with 1.0 0.00043004587156 0 3 -3
desmopressin,tablets 1.0 0.000143348623853 0 1 -1
needed,to 0.0 0.0 1 1 0
theobromine,grepafloxacin 1.0 0.000143348623853 1 0 1
prevent,absorption 1.0 0.000143348623853 0 1 -1
inhibitors,administered 1.0 0.000143348623853 1 0 1
sensitize,tissues 1.0 0.000143348623853 0 1 -1
equivocally,higher 1.0 0.000143348623853 1 0 1
against,cryptosporidium 1.0 0.000143348623853 0 1 -1
oral,antagonists 1.0 0.000143348623853 1 0 1
week,until 1.0 0.000143348623853 0 1 -1
of,administration 1.0 0.000716743119266 0 5 -5
reactions,the 1.0 0.000143348623853 1 0 1
isoenzyme,including 0.333333333333 0.000143348623853 2 1 1
synergistic,or 1.0 0.000143348623853 0 1 -1
erythrocyte,acetylcholinesterase 1.0 0.000143348623853 1 0 1
thought,to 1.0 0.00043004587156 0 3 -3
therefore,inhibitors 1.0 0.000143348623853 0 1 -1
severe,abdominal 1.0 0.000143348623853 0 1 -1
can,potentiate 1.0 0.000143348623853 1 0 1
by,measuring 1.0 0.000286697247706 0 2 -2
or,over 1.0 0.000143348623853 0 1 -1
this,sequence 1.0 0.000286697247706 0 2 -2
bring,latent 1.0 0.000143348623853 0 1 -1
the,agent 1.0 0.000286697247706 0 2 -2
metabolizers,have 1.0 0.000716743119266 0 5 -5
with,itraconazole 1.0 0.000143348623853 1 0 1
without,consulting 1.0 0.000143348623853 0 1 -1
deaths,in 0.333333333333 0.000143348623853 1 2 -1
chemotherapy,interrupted 1.0 0.000143348623853 0 1 -1
has,previously 1.0 0.000143348623853 1 0 1
direct,action 0.0 0.0 1 1 0
temporarily,mask 1.0 0.000143348623853 1 0 1
of,trypanosomiasis 1.0 0.000143348623853 0 1 -1
deaths,is 1.0 0.000143348623853 0 1 -1
abstinence,is 1.0 0.000143348623853 0 1 -1
obtained,in 1.0 0.000286697247706 0 2 -2
a,two-fold 1.0 0.000143348623853 1 0 1
or,potentially 0.0 0.0 1 1 0
described,as 1.0 0.000143348623853 0 1 -1
and,monomeric 1.0 0.000143348623853 0 1 -1
depressant,should 1.0 0.000286697247706 2 0 2
the,brain 1.0 0.000286697247706 0 2 -2
further,metabolized 1.0 0.000143348623853 0 1 -1
p,administration 1.0 0.000143348623853 0 1 -1
deet,n 1.0 0.000143348623853 1 0 1
increases,should 0.333333333333 0.000143348623853 1 2 -1
and,exacerbation 1.0 0.000143348623853 0 1 -1
the,implication 1.0 0.000143348623853 1 0 1
agents,has 0.2 0.000143348623853 2 3 -1
more,efficiently 1.0 0.000143348623853 0 1 -1
cyp1a2,cyp2a6 1.0 0.000716743119266 0 5 -5
n-demethylated,metabolite 1.0 0.000143348623853 0 1 -1
cholino-,and 1.0 0.000143348623853 0 1 -1
center,inventory 1.0 0.000143348623853 0 1 -1
growth,hormone 1.0 0.000143348623853 1 0 1
falsely,identify 1.0 0.000143348623853 0 1 -1
also,not 0.333333333333 0.000143348623853 1 2 -1
outcomes,in 1.0 0.000143348623853 0 1 -1
newborns,whose 1.0 0.000143348623853 0 1 -1
detrimental,effects 1.0 0.000286697247706 0 2 -2
do,if 1.0 0.000143348623853 0 1 -1
increased,phenytoin 1.0 0.000143348623853 0 1 -1
oral,erection-supporting 1.0 0.000143348623853 0 1 -1
attenuated,live 1.0 0.000143348623853 0 1 -1
hcl,in 1.0 0.000286697247706 2 0 2
epoxide,steady-state 1.0 0.000143348623853 0 1 -1
sonata,mg 0.142857142857 0.000143348623853 4 3 1
rate,of 0.0526315789474 0.000143348623853 10 9 1
natrecor,in 1.0 0.000143348623853 0 1 -1
for,hydroxy-iso 1.0 0.000143348623853 1 0 1
assume,that 1.0 0.000143348623853 0 1 -1
novo,kidney 1.0 0.000143348623853 0 1 -1
rate,or 1.0 0.000716743119266 0 5 -5
doubling,the 1.0 0.000143348623853 0 1 -1
hcl,is 0.6 0.00043004587156 4 1 3
populations,are 1.0 0.000716743119266 0 5 -5
been,cases 1.0 0.000143348623853 1 0 1
no,teratogenic 1.0 0.000143348623853 0 1 -1
increase,with 0.0 0.0 1 1 0
not,significant 1.0 0.000143348623853 0 1 -1
expected,than 1.0 0.000143348623853 1 0 1
dose,baseline 1.0 0.000143348623853 0 1 -1
following,blood 1.0 0.000143348623853 0 1 -1
unfortunately,folic 1.0 0.000143348623853 0 1 -1
qid,n 1.0 0.000143348623853 1 0 1
compared,retrospectively 1.0 0.000143348623853 0 1 -1
than,reduction 1.0 0.000143348623853 1 0 1
establishing,interactions 1.0 0.000143348623853 0 1 -1
palythoa,tuberculosa 1.0 0.000143348623853 0 1 -1
as,great 1.0 0.000143348623853 0 1 -1
hypertensive,crises 1.0 0.000286697247706 2 0 2
cyp,a 0.333333333333 0.000143348623853 2 1 1
myopathy,secondary 1.0 0.000143348623853 0 1 -1
agent,additional 1.0 0.000143348623853 0 1 -1
compounds--can,be 1.0 0.000143348623853 0 1 -1
antizol,and 1.0 0.000143348623853 1 0 1
of,initial 0.333333333333 0.000143348623853 1 2 -1
significant,and 1.0 0.000286697247706 0 2 -2
subjects,clearance 1.0 0.000143348623853 0 1 -1
drugs,given 1.0 0.00043004587156 0 3 -3
metabolite,was 1.0 0.000143348623853 0 1 -1
months,after 1.0 0.000143348623853 0 1 -1
coadministered,orally 1.0 0.000143348623853 1 0 1
microsomes,indicate 1.0 0.00043004587156 0 3 -3
since,in 1.0 0.000143348623853 1 0 1
normal,and 1.0 0.000286697247706 0 2 -2
the,spleen 1.0 0.000286697247706 0 2 -2
when,combined 0.333333333333 0.000143348623853 2 1 1
antihypertensive,effects 1.0 0.000716743119266 5 0 5
increase,fi 1.0 0.000143348623853 0 1 -1
red,rr 1.0 0.000143348623853 0 1 -1
treatment,arm 1.0 0.000143348623853 0 1 -1
of,extravasation 1.0 0.000143348623853 0 1 -1
daily,had 1.0 0.000286697247706 0 2 -2
cmax,tmax 1.0 0.000143348623853 0 1 -1
higher,was 1.0 0.000143348623853 0 1 -1
been,as 1.0 0.000143348623853 0 1 -1
be,reported 1.0 0.000143348623853 0 1 -1
inhibition,while 1.0 0.000143348623853 0 1 -1
daily,has 1.0 0.000143348623853 0 1 -1
of,actions 1.0 0.000143348623853 0 1 -1
analgesic,actions 1.0 0.000143348623853 0 1 -1
decreased,psychomotor 1.0 0.000143348623853 0 1 -1
isoform,mediate 1.0 0.000143348623853 0 1 -1
enhanced,if 1.0 0.000143348623853 1 0 1
treated,for 0.333333333333 0.000143348623853 2 1 1
disturbances,were 1.0 0.000143348623853 1 0 1
recovered,weeks 1.0 0.000143348623853 0 1 -1
with,lodosyn 1.0 0.000286697247706 0 2 -2
double-blind,placebo-controlled 1.0 0.000143348623853 0 1 -1
showed,increased 1.0 0.000143348623853 0 1 -1
by,lesions 1.0 0.000143348623853 0 1 -1
require,increases 1.0 0.000143348623853 1 0 1
and,addicts 1.0 0.000143348623853 1 0 1
aprepitant,has 1.0 0.000143348623853 1 0 1
prinivil,has 1.0 0.000143348623853 0 1 -1
function,were 1.0 0.000143348623853 0 1 -1
lipids,were 1.0 0.000143348623853 0 1 -1
trimethoprim,alone 1.0 0.000143348623853 0 1 -1
indinavir,concentrations 1.0 0.000143348623853 1 0 1
p,endothelial 1.0 0.000143348623853 0 1 -1
hypothyroid,patient 0.0 0.0 1 1 0
blockers,have 1.0 0.000143348623853 0 1 -1
occasion,in 1.0 0.000143348623853 0 1 -1
events,such 1.0 0.000286697247706 0 2 -2
maintained,at 1.0 0.000286697247706 0 2 -2
and,suggest 0.0 0.0 1 1 0
either,before 1.0 0.000143348623853 0 1 -1
to,prevent 0.2 0.000286697247706 4 6 -2
produced,less 1.0 0.000143348623853 0 1 -1
rectification,were 1.0 0.000143348623853 0 1 -1
tegretol,tagamet 1.0 0.000143348623853 0 1 -1
study,one 1.0 0.000143348623853 0 1 -1
central,syndrome 1.0 0.000143348623853 1 0 1
including,most 1.0 0.000143348623853 0 1 -1
during,photic 1.0 0.000143348623853 0 1 -1
known,enzyme 1.0 0.00043004587156 3 0 3
higher,when 1.0 0.000716743119266 5 0 5
retard,and 1.0 0.000143348623853 1 0 1
between,trisenox 1.0 0.000143348623853 0 1 -1
monitoring,and 0.0 0.0 1 1 0
reduced,by 0.290322580645 0.00129013761468 20 11 9
closely,and 0.0 0.0 1 1 0
a,substantially 1.0 0.000143348623853 0 1 -1
the,objective 1.0 0.000143348623853 0 1 -1
mean,percentage 1.0 0.000143348623853 1 0 1
increasing,from 1.0 0.000143348623853 0 1 -1
for,every 1.0 0.000143348623853 0 1 -1
in-creased,circulating 1.0 0.000143348623853 0 1 -1
or,older 1.0 0.000143348623853 0 1 -1
average,increase 1.0 0.000143348623853 1 0 1
the,analysis 1.0 0.000143348623853 0 1 -1
determine,if 0.272727272727 0.00043004587156 7 4 3
of,n-acetyltransferase 1.0 0.000143348623853 1 0 1
day,during 1.0 0.000143348623853 1 0 1
have,specifically 1.0 0.000143348623853 0 1 -1
are,adequate 1.0 0.000143348623853 0 1 -1
aspects,that 1.0 0.000143348623853 0 1 -1
and,invalidate 1.0 0.000143348623853 0 1 -1
casodex,is 1.0 0.000143348623853 1 0 1
interact,synergistically 1.0 0.000143348623853 0 1 -1
interactions,allows 1.0 0.000143348623853 0 1 -1
therefore,appropriate 1.0 0.000143348623853 0 1 -1
cellular,basis 1.0 0.000143348623853 0 1 -1
two,mg 0.333333333333 0.000143348623853 1 2 -1
homocysteine,in 1.0 0.000143348623853 0 1 -1
class,resulting 1.0 0.000143348623853 1 0 1
diminish,its 1.0 0.000143348623853 1 0 1
the,apparent 0.0 0.0 1 1 0
greater,for 1.0 0.000286697247706 0 2 -2
the,patients 0.714285714286 0.00143348623853 2 12 -10
these,hormones 1.0 0.000143348623853 0 1 -1
transport,in 1.0 0.00043004587156 0 3 -3
on,cycle 1.0 0.000143348623853 0 1 -1
an,nad 1.0 0.000143348623853 0 1 -1
true,in 1.0 0.000143348623853 0 1 -1
and,stress 1.0 0.000143348623853 0 1 -1
characteristics,related 1.0 0.000143348623853 0 1 -1
or,unintentional 1.0 0.000143348623853 1 0 1
white,female 1.0 0.000143348623853 0 1 -1
a4,substrate 1.0 0.000143348623853 0 1 -1
alphagan,p 0.333333333333 0.000143348623853 2 1 1
inhibitor,talk 1.0 0.000143348623853 0 1 -1
with,depression 1.0 0.000143348623853 0 1 -1
tested,up 1.0 0.000143348623853 0 1 -1
hypercoagulation,vasculopathy 1.0 0.000143348623853 0 1 -1
ellence,after 1.0 0.000143348623853 0 1 -1
significantly,larger 1.0 0.000143348623853 0 1 -1
by,cyp3a 1.0 0.000286697247706 0 2 -2
particular,convulsions 1.0 0.000143348623853 1 0 1
who,discontinue 1.0 0.000143348623853 1 0 1
most,notably 1.0 0.000143348623853 1 0 1
is,theoretically 0.0 0.0 1 1 0
eye,drops 1.0 0.000286697247706 0 2 -2
pharmacokinetic-related,interactions 1.0 0.000143348623853 0 1 -1
tcatreatment,in 1.0 0.000143348623853 1 0 1
migraine,has 1.0 0.000143348623853 0 1 -1
need,for 0.5 0.000573394495413 2 6 -4
n-desmethyldiazepam,to 1.0 0.000143348623853 0 1 -1
cause,elimination 1.0 0.000286697247706 2 0 2
received,or 1.0 0.000143348623853 1 0 1
tasks,that 1.0 0.000143348623853 0 1 -1
or,induces 1.0 0.000143348623853 0 1 -1
antidepressants,or 1.0 0.000143348623853 0 1 -1
efficacy,on 1.0 0.000143348623853 0 1 -1
discontinuing,to 1.0 0.000286697247706 2 0 2
delay,or 0.0 0.0 1 1 0
efficacy,of 0.1 0.000286697247706 9 11 -2
this,observed 1.0 0.000143348623853 1 0 1
the,are 1.0 0.00114678899083 0 8 -8
and,define 1.0 0.000143348623853 0 1 -1
for,protein 1.0 0.000716743119266 0 5 -5
added,were 1.0 0.000143348623853 1 0 1
however,it 0.428571428571 0.00043004587156 2 5 -3
atropine-like,effects 1.0 0.000143348623853 0 1 -1
help,to 1.0 0.00043004587156 0 3 -3
the,thioxanthene 1.0 0.000143348623853 1 0 1
ns,were 1.0 0.000286697247706 0 2 -2
flow,were 1.0 0.000143348623853 0 1 -1
with,agonists 1.0 0.000143348623853 1 0 1
respectively,were 1.0 0.000143348623853 1 0 1
target,of 1.0 0.000143348623853 0 1 -1
serious,cardiovascular 0.0 0.0 1 1 0
with,respectto 1.0 0.000143348623853 0 1 -1
cyp2b6,cyp2c8 1.0 0.000143348623853 0 1 -1
interaction,has 0.2 0.000143348623853 2 3 -1
abased,on 1.0 0.000143348623853 1 0 1
contraction,of 1.0 0.000143348623853 0 1 -1
highly,protein 0.25 0.000286697247706 3 5 -2
concentration,mm 1.0 0.000143348623853 0 1 -1
taking,coumarin-derivative 1.0 0.000143348623853 1 0 1
strains,and 0.0 0.0 1 1 0
extracellular,application 1.0 0.000143348623853 0 1 -1
for,detoxification 1.0 0.000143348623853 1 0 1
function,testing 1.0 0.000143348623853 0 1 -1
administered,on 0.0 0.0 4 4 0
if,a 0.238095238095 0.000716743119266 13 8 5
acth,induced 1.0 0.000286697247706 0 2 -2
digoxin,methotrexate 0.0 0.0 1 1 0
bilateral,ovariectomy 1.0 0.000143348623853 0 1 -1
has,emerged 1.0 0.000143348623853 0 1 -1
dysrhythmias,torsades 1.0 0.000143348623853 0 1 -1
potent,parental 1.0 0.000143348623853 1 0 1
including,for 1.0 0.000143348623853 1 0 1
tissues,from 1.0 0.000143348623853 1 0 1
receive,large 1.0 0.000143348623853 0 1 -1
the,cross-reactivity 1.0 0.000143348623853 1 0 1
including,hyperthermia 1.0 0.000143348623853 1 0 1
clinical,vancomycin-resistant 1.0 0.000143348623853 0 1 -1
substrate,in 1.0 0.000286697247706 0 2 -2
toradol,therapy 1.0 0.000143348623853 1 0 1
was,associated 0.454545454545 0.000716743119266 8 3 5
plus,vioxx 1.0 0.000143348623853 0 1 -1
pain,without 1.0 0.000143348623853 0 1 -1
incoordination,following 1.0 0.000143348623853 1 0 1
developed,b-cell 1.0 0.000143348623853 0 1 -1
sleeping,time 1.0 0.000143348623853 1 0 1
adjustments,are 1.0 0.000143348623853 0 1 -1
and,isolated 1.0 0.000143348623853 0 1 -1
antifungals,the 1.0 0.000143348623853 0 1 -1
by,p450 1.0 0.00157683486239 0 11 -11
most,are 1.0 0.000143348623853 1 0 1
not,altered 1.0 0.00129013761468 0 9 -9
great,an 1.0 0.000143348623853 0 1 -1
that,modulates 1.0 0.000143348623853 1 0 1
decins,sans 1.0 0.000143348623853 0 1 -1
systems,for 1.0 0.000143348623853 0 1 -1
the,design 1.0 0.000143348623853 0 1 -1
reduced,risk 1.0 0.000143348623853 0 1 -1
long-term,administration 1.0 0.000143348623853 0 1 -1
between,vitamin 1.0 0.00043004587156 3 0 3
between,viracept 1.0 0.000143348623853 0 1 -1
relevant,significant 1.0 0.000143348623853 0 1 -1
elapse,between 1.0 0.00043004587156 3 0 3
substantially,decrease 0.0 0.0 1 1 0
contributing,factor 1.0 0.000143348623853 1 0 1
evidence,that 1.0 0.00100344036697 0 7 -7
of,adverse 0.666666666667 0.00114678899083 2 10 -8
both,studies 1.0 0.000143348623853 0 1 -1
with,xanthine 1.0 0.000143348623853 1 0 1
selecting,an 1.0 0.000286697247706 2 0 2
arterial,hypertension 1.0 0.000143348623853 0 1 -1
properties,can 1.0 0.000143348623853 0 1 -1
parameters,pt 1.0 0.000143348623853 1 0 1
acquainted,with 1.0 0.000143348623853 0 1 -1
of,radiation 1.0 0.000143348623853 0 1 -1
rare,cases 1.0 0.000573394495413 0 4 -4
abilify,aripiprazole 1.0 0.000143348623853 0 1 -1
ketoconazole,when 0.0 0.0 1 1 0
fertility,a 1.0 0.000143348623853 0 1 -1
concentration,monitoring 1.0 0.000143348623853 1 0 1
vivo,resulting 1.0 0.000143348623853 1 0 1
and,brovana 1.0 0.000143348623853 1 0 1
small,magnitude 1.0 0.000143348623853 0 1 -1
eliminated,by 0.5 0.000286697247706 1 3 -2
inactivated,by 1.0 0.000143348623853 0 1 -1
male,n 1.0 0.000143348623853 0 1 -1
triglycerides,mg 1.0 0.000143348623853 0 1 -1
ligand,binding 1.0 0.000143348623853 0 1 -1
respectively,which 1.0 0.000143348623853 0 1 -1
didanosine,chewable 1.0 0.000286697247706 2 0 2
understand,how 1.0 0.000143348623853 0 1 -1
several,beta-adrenergic 1.0 0.000143348623853 0 1 -1
effects,caused 0.0 0.0 1 1 0
a,basis 1.0 0.000143348623853 0 1 -1
when,tagamet 1.0 0.000143348623853 1 0 1
concentrations,substances 1.0 0.000143348623853 0 1 -1
no,apparent 1.0 0.000860091743119 0 6 -6
reduced,relative 1.0 0.000143348623853 0 1 -1
shows,no 1.0 0.000143348623853 0 1 -1
in,special 1.0 0.000143348623853 0 1 -1
compounds,which 1.0 0.000143348623853 0 1 -1
and,superiority 1.0 0.000143348623853 0 1 -1
a,pulmonary 1.0 0.000143348623853 0 1 -1
norpace,was 1.0 0.000143348623853 0 1 -1
the,auc0-120hr 1.0 0.000143348623853 1 0 1
diabetic,chinese 1.0 0.00043004587156 0 3 -3
pharmacokinetic-pharmacodynamic,relationship 1.0 0.000143348623853 0 1 -1
of,life 1.0 0.000143348623853 0 1 -1
cleared,from 1.0 0.000143348623853 0 1 -1
vitro,interferes 1.0 0.000143348623853 1 0 1
to,insulin-induced 1.0 0.000143348623853 0 1 -1
a,genetically 1.0 0.000143348623853 0 1 -1
with,normal 0.6 0.00043004587156 1 4 -3
aspirin,concomitant 1.0 0.000573394495413 4 0 4
methods,all 1.0 0.000143348623853 0 1 -1
anafranil,should 1.0 0.000143348623853 1 0 1
nodular,acne 1.0 0.000143348623853 0 1 -1
bid,as 1.0 0.000143348623853 1 0 1
no,relevant 1.0 0.00043004587156 0 3 -3
when,possible 0.0 0.0 1 1 0
concentration,altered 0.0 0.0 1 1 0
as,proof 1.0 0.000143348623853 0 1 -1
or,increase 1.0 0.000143348623853 1 0 1
patients,mean 1.0 0.000143348623853 0 1 -1
qhs,after 1.0 0.000143348623853 0 1 -1
bind,the 1.0 0.000143348623853 1 0 1
of,where 1.0 0.000286697247706 2 0 2
intestinal,tumors 1.0 0.000143348623853 0 1 -1
route,than 1.0 0.000143348623853 0 1 -1
auranofin,should 1.0 0.000286697247706 2 0 2
randomized,double-blind 1.0 0.000143348623853 0 1 -1
or,those 0.0 0.0 1 1 0
affect,renal 1.0 0.000716743119266 0 5 -5
p450iid6,a 1.0 0.000143348623853 0 1 -1
or,absence 1.0 0.000143348623853 0 1 -1
loop,potassium- 1.0 0.000143348623853 1 0 1
anakinra,concurrent 1.0 0.000143348623853 1 0 1
literature,showing 1.0 0.000143348623853 0 1 -1
a,therapeutic 0.0 0.0 1 1 0
toxic,neurological 1.0 0.000143348623853 0 1 -1
potentially,serious 0.0 0.0 1 1 0
when,starting 1.0 0.000286697247706 0 2 -2
up,smoking 1.0 0.000143348623853 0 1 -1
being,observed 1.0 0.000143348623853 0 1 -1
warranted,appropriate 1.0 0.000573394495413 4 0 4
done,extremely 1.0 0.000143348623853 1 0 1
of,hypotensive 1.0 0.000716743119266 5 0 5
in,hazardous 1.0 0.000143348623853 0 1 -1
and,cyp4a11 1.0 0.000143348623853 0 1 -1
substantial,intercurrent 1.0 0.000143348623853 0 1 -1
fourth,group 1.0 0.000143348623853 0 1 -1
glucosyl,transferase 1.0 0.000143348623853 0 1 -1
combinations,should 1.0 0.00043004587156 0 3 -3
adequate,evidence 1.0 0.000143348623853 0 1 -1
the,requirement 1.0 0.000143348623853 1 0 1
much,higher 1.0 0.000143348623853 0 1 -1
beta-adrenergic,receptor 1.0 0.000143348623853 0 1 -1
cyp2d6,are 1.0 0.000286697247706 0 2 -2
results,blood 1.0 0.000143348623853 0 1 -1
by,beta-adrenergic 1.0 0.000143348623853 1 0 1
hydroxide,cerivastatin 1.0 0.000143348623853 0 1 -1
adverse,experience 1.0 0.000143348623853 0 1 -1
on,steady-state 1.0 0.000143348623853 0 1 -1
with,amprenavir 1.0 0.000143348623853 1 0 1
as,but 1.0 0.000143348623853 1 0 1
para-aminobenzoic,acid 0.0 0.0 1 1 0
effect,could 1.0 0.000286697247706 2 0 2
require,empiric 1.0 0.000143348623853 0 1 -1
drug,metabolism 1.0 0.000143348623853 1 0 1
daily,should 1.0 0.000143348623853 0 1 -1
agents,only 1.0 0.000143348623853 0 1 -1
when,duloxetine 1.0 0.000143348623853 0 1 -1
modification,is 1.0 0.000286697247706 0 2 -2
elimination,was 1.0 0.000143348623853 0 1 -1
lengthened,and 1.0 0.000143348623853 1 0 1
should,generally 0.428571428571 0.00043004587156 2 5 -3
affect,either 1.0 0.000143348623853 0 1 -1
probability,distribution 1.0 0.000143348623853 0 1 -1
as,this 1.0 0.000573394495413 0 4 -4
potentiates,a 1.0 0.000143348623853 0 1 -1
been,performed 0.764705882353 0.00186353211009 2 15 -13
cases,it 1.0 0.000143348623853 0 1 -1
similar,conditions 1.0 0.000143348623853 0 1 -1
significance,these 1.0 0.000143348623853 0 1 -1
additional,effects 1.0 0.000143348623853 1 0 1
hydrochloride,may 1.0 0.000286697247706 2 0 2
greater,affinity 1.0 0.000143348623853 0 1 -1
ie,recall 1.0 0.000143348623853 0 1 -1
either,one 1.0 0.000143348623853 1 0 1
considers,the 1.0 0.000143348623853 0 1 -1
d3,calcitriol 1.0 0.00043004587156 3 0 3
and,six 1.0 0.000143348623853 0 1 -1
fentanyl,in 1.0 0.000143348623853 1 0 1
probenecid,probenecid 0.0 0.0 3 3 0
data,are 1.0 0.00172018348624 0 12 -12
where,patients 1.0 0.000143348623853 0 1 -1
as,required 1.0 0.000143348623853 0 1 -1
p,app 1.0 0.000143348623853 0 1 -1
h-triglyceride,fractional 1.0 0.000143348623853 1 0 1
bacteriostatic,antibiotics 1.0 0.000143348623853 1 0 1
besides,mtx 1.0 0.000143348623853 0 1 -1
severe,reactions 1.0 0.000143348623853 0 1 -1
rats,hydrochloride 1.0 0.000143348623853 1 0 1
separating,the 1.0 0.000143348623853 1 0 1
neurotoxic,effect 1.0 0.000143348623853 1 0 1
activity,they 1.0 0.000143348623853 0 1 -1
microg,ml 1.0 0.000286697247706 0 2 -2
apparent,oral 1.0 0.00043004587156 3 0 3
by,resecting 1.0 0.000143348623853 0 1 -1
the,new 1.0 0.000143348623853 0 1 -1
tbg,concentration 1.0 0.000143348623853 0 1 -1
hydrogen-3,revealed 1.0 0.000143348623853 0 1 -1
medications,agents 1.0 0.000143348623853 0 1 -1
related,to 0.619047619048 0.00186353211009 4 17 -13
interaction,fosinopril 1.0 0.000143348623853 0 1 -1
caution,especially 1.0 0.000143348623853 0 1 -1
arthritic,patients 1.0 0.000143348623853 0 1 -1
a,dopa 1.0 0.000143348623853 0 1 -1
short-term,pharmacokinetic 1.0 0.000143348623853 1 0 1
studies,beta-receptor 1.0 0.000143348623853 0 1 -1
decrease,by 0.0 0.0 1 1 0
str,was 1.0 0.000143348623853 0 1 -1
metabolites,have 1.0 0.000143348623853 0 1 -1
while,may 1.0 0.000143348623853 1 0 1
by,such 0.5 0.000286697247706 1 3 -2
estradiol,following 1.0 0.000143348623853 0 1 -1
decreasing,gut 1.0 0.000143348623853 1 0 1
induce,metabolic 1.0 0.000143348623853 0 1 -1
the,observed 1.0 0.000143348623853 0 1 -1
absorption,resulting 1.0 0.00043004587156 3 0 3
with,hours 1.0 0.000143348623853 1 0 1
of,retinogeniculate 1.0 0.000143348623853 0 1 -1
capsules,there 1.0 0.000143348623853 1 0 1
before,parturition 1.0 0.000143348623853 0 1 -1
in,almost 1.0 0.000143348623853 0 1 -1
and,markedly 1.0 0.000286697247706 2 0 2
are,added 1.0 0.000143348623853 0 1 -1
antidepressant,or 1.0 0.00043004587156 0 3 -3
gastric,secretion 1.0 0.000143348623853 0 1 -1
r,and 1.0 0.000143348623853 0 1 -1
in,a 0.00440528634361 0.000143348623853 113 114 -1
pcp,were 0.0 0.0 1 1 0
physicians,should 0.333333333333 0.000286697247706 4 2 2
may,significantly 0.0 0.0 1 1 0
with,sodium 0.333333333333 0.000143348623853 2 1 1
or,cimetidine 1.0 0.000143348623853 1 0 1
daily,dosage 1.0 0.000286697247706 0 2 -2
cyclosporine,a 1.0 0.000143348623853 0 1 -1
be,kept 0.5 0.000286697247706 1 3 -2
metabolism,increased 1.0 0.000143348623853 1 0 1
to,toxic 1.0 0.000143348623853 1 0 1
pelvic,girdle 1.0 0.000143348623853 0 1 -1
zevalin,therapeutic 1.0 0.000143348623853 0 1 -1
affect,any 1.0 0.000143348623853 0 1 -1
antidepressant,agent 1.0 0.000286697247706 0 2 -2
should,either 1.0 0.000143348623853 1 0 1
depletions,of 1.0 0.000286697247706 2 0 2
and,magnesium-containing 1.0 0.000143348623853 0 1 -1
displacing,effect 1.0 0.000143348623853 0 1 -1
these,conclusions 1.0 0.000143348623853 0 1 -1
and,appears 1.0 0.000143348623853 0 1 -1
or,urinary 1.0 0.000143348623853 0 1 -1
the,horses 1.0 0.000143348623853 0 1 -1
was,coadministered 0.0769230769231 0.000143348623853 6 7 -1
orange,juice 1.0 0.000143348623853 0 1 -1
to,inhibition 0.666666666667 0.00114678899083 2 10 -8
polyene,showed 1.0 0.000143348623853 0 1 -1
occurred,with 0.333333333333 0.000143348623853 1 2 -1
receiving,maintenance 1.0 0.000143348623853 0 1 -1
acidifying,agents 1.0 0.000860091743119 6 0 6
exaggerated,hypertensive 1.0 0.000143348623853 1 0 1
significantly,affected 1.0 0.000573394495413 0 4 -4
rather,than 1.0 0.000286697247706 0 2 -2
that,demonstrate 1.0 0.000143348623853 0 1 -1
used,concurrently 0.142857142857 0.000286697247706 6 8 -2
analyses,revealed 1.0 0.000143348623853 0 1 -1
and,beta-adrenergic 1.0 0.000143348623853 1 0 1
adjust,dosage 1.0 0.00043004587156 0 3 -3
pancreatic,alpha 1.0 0.000143348623853 0 1 -1
moieties,significantly 1.0 0.000143348623853 0 1 -1
consisting,of 0.0 0.0 1 1 0
sufficient,time 0.666666666667 0.000573394495413 1 5 -4
employed,clinical 1.0 0.00043004587156 0 3 -3
resveratrol-induced,vasorelaxation 1.0 0.000286697247706 0 2 -2
dose,for 1.0 0.000860091743119 0 6 -6
negative,and 1.0 0.000286697247706 0 2 -2
by,but 0.5 0.000286697247706 3 1 2
were,compared 1.0 0.000286697247706 0 2 -2
fibrosis,therapies 1.0 0.000143348623853 0 1 -1
increase,decrease 1.0 0.000143348623853 0 1 -1
and,reaction 1.0 0.000143348623853 1 0 1
dipropylxanthine,dpcpx 1.0 0.000143348623853 0 1 -1
indomethacin,was 1.0 0.000143348623853 0 1 -1
in,insufficient 1.0 0.000143348623853 1 0 1
for,individual 1.0 0.000143348623853 0 1 -1
of,theo-dur 1.0 0.000143348623853 1 0 1
ellence,when 1.0 0.000143348623853 0 1 -1
potentially,lead 1.0 0.000143348623853 0 1 -1
considerable,evidence 1.0 0.000286697247706 0 2 -2
potential,terfenadine 1.0 0.000143348623853 0 1 -1
conducted,concomitant 1.0 0.000143348623853 1 0 1
tissues,metabolism 1.0 0.000143348623853 0 1 -1
taking,are 1.0 0.000143348623853 0 1 -1
the,pressor 0.111111111111 0.000143348623853 5 4 1
specific,blockade 1.0 0.000143348623853 0 1 -1
levo-dromoran,reported 1.0 0.000143348623853 0 1 -1
not,expected 0.833333333333 0.00143348623853 1 11 -10
of,proleukin 0.0 0.0 1 1 0
simultaneously,it 1.0 0.000143348623853 0 1 -1
of,before 1.0 0.000143348623853 1 0 1
suggest,a 1.0 0.000573394495413 4 0 4
new,class 1.0 0.000143348623853 0 1 -1
too,high 1.0 0.000143348623853 0 1 -1
weakness,lethargy 0.0 0.0 1 1 0
of,chronic 0.2 0.000143348623853 2 3 -1
fat,and 1.0 0.000143348623853 0 1 -1
maintain,optimum 1.0 0.000286697247706 0 2 -2
hen,f1 1.0 0.000143348623853 0 1 -1
reactions,all 1.0 0.000143348623853 0 1 -1
lesions,in 1.0 0.000143348623853 1 0 1
orally,because 1.0 0.000143348623853 1 0 1
of,multipledose 1.0 0.000143348623853 0 1 -1
duration,suggesting 1.0 0.000143348623853 1 0 1
growth,to 1.0 0.000143348623853 0 1 -1
additional,methods 1.0 0.000143348623853 0 1 -1
one,of 0.809523809524 0.0024369266055 2 19 -17
be,similar 1.0 0.000143348623853 0 1 -1
be,predictive 1.0 0.000143348623853 0 1 -1
any,change 1.0 0.000143348623853 0 1 -1
hypoglycemics,agents 1.0 0.000143348623853 1 0 1
deet,was 1.0 0.000143348623853 0 1 -1
maalox,tc 0.333333333333 0.000143348623853 2 1 1
not,take 1.0 0.00043004587156 0 3 -3
are,provided 0.0 0.0 1 1 0
the,continued 1.0 0.000143348623853 0 1 -1
pregnancy,from 1.0 0.000143348623853 0 1 -1
diets,no 1.0 0.000143348623853 0 1 -1
interference,has 1.0 0.000286697247706 0 2 -2
organisms,contained 1.0 0.000143348623853 1 0 1
to,whom 1.0 0.000286697247706 2 0 2
hiv,disease 1.0 0.000143348623853 0 1 -1
of,warfarin-type 0.0 0.0 1 1 0
supplementation,mg 1.0 0.000143348623853 0 1 -1
decrease,range 1.0 0.000143348623853 1 0 1
activity,while 0.0 0.0 1 1 0
aggressively,is 1.0 0.000143348623853 0 1 -1
curves,with 1.0 0.000143348623853 1 0 1
the,prevalence 1.0 0.000716743119266 0 5 -5
were,drawn 1.0 0.000286697247706 0 2 -2
parameters,including 1.0 0.000143348623853 0 1 -1
dexamethasone,is 1.0 0.000143348623853 0 1 -1
sular,tablets 1.0 0.000143348623853 1 0 1
stered,orally 1.0 0.000143348623853 1 0 1
studies,as 0.714285714286 0.000716743119266 6 1 5
correlate,with 1.0 0.000143348623853 0 1 -1
carefully,monitored 0.333333333333 0.00043004587156 6 3 3
deprivation,in 1.0 0.000143348623853 0 1 -1
between,betaseron 1.0 0.000143348623853 0 1 -1
known,substrates 1.0 0.000143348623853 0 1 -1
containing,may 0.333333333333 0.000143348623853 2 1 1
in,anti-apoptotic 1.0 0.000143348623853 0 1 -1
chronic,or 1.0 0.000143348623853 1 0 1
it,reduced 1.0 0.000143348623853 0 1 -1
except,for 1.0 0.000716743119266 0 5 -5
expression,that 1.0 0.000143348623853 0 1 -1
elevated,with 1.0 0.000286697247706 0 2 -2
compounds,caution 1.0 0.000143348623853 0 1 -1
tolerated,and 1.0 0.000143348623853 1 0 1
of,hexalen 1.0 0.000286697247706 2 0 2
potentials,in 1.0 0.000143348623853 0 1 -1
quinidine,coadministration 1.0 0.000143348623853 1 0 1
might,reflect 1.0 0.000143348623853 0 1 -1
wort,should 1.0 0.000143348623853 0 1 -1
vessels,to 1.0 0.000143348623853 1 0 1
with,tylenol 1.0 0.000143348623853 1 0 1
has,little 1.0 0.000143348623853 1 0 1
is,contraindicated 0.2 0.000143348623853 3 2 1
is,advisable 0.2 0.000143348623853 2 3 -1
depression,than 1.0 0.000143348623853 0 1 -1
outbreaks,of 1.0 0.000143348623853 0 1 -1
any,serious 1.0 0.000143348623853 0 1 -1
organic,were 1.0 0.000286697247706 2 0 2
currently,receiving 1.0 0.00043004587156 3 0 3
days,mg 1.0 0.000573394495413 0 4 -4
formed,after 1.0 0.000143348623853 0 1 -1
physicians,and 1.0 0.000143348623853 0 1 -1
hypothyroid,patients 1.0 0.000573394495413 0 4 -4
therapeutic,hypermagnesaemia 1.0 0.000143348623853 0 1 -1
in,area 1.0 0.000143348623853 1 0 1
by,coadministration 0.333333333333 0.000286697247706 2 4 -2
adrenal,insufficiency 1.0 0.000143348623853 1 0 1
should,not 0.16814159292 0.00272362385321 66 47 19
secretion,chronic 1.0 0.000143348623853 0 1 -1
bleeding,shortly 1.0 0.000143348623853 0 1 -1
increased,nephrotoxicity 1.0 0.000286697247706 2 0 2
glucose,including 1.0 0.000143348623853 1 0 1
this,small 1.0 0.000143348623853 1 0 1
reduce,endogenous 0.333333333333 0.000143348623853 2 1 1
or,evidence 1.0 0.000143348623853 0 1 -1
each,month 1.0 0.000286697247706 0 2 -2
auc0-30,days 1.0 0.000286697247706 0 2 -2
omega-agatoxin,iva-sensitive 1.0 0.000143348623853 0 1 -1
auc,vs 1.0 0.000143348623853 0 1 -1
precautions,may 1.0 0.000143348623853 0 1 -1
low-dose,combination 1.0 0.000143348623853 0 1 -1
exert,additive 1.0 0.000286697247706 0 2 -2
similarly,patients 1.0 0.000143348623853 0 1 -1
de,novo 1.0 0.000286697247706 0 2 -2
phosphatase,activity 1.0 0.000143348623853 0 1 -1
with,occurs 1.0 0.000143348623853 1 0 1
kg,was 0.0 0.0 1 1 0
both,cyp1a2 1.0 0.000286697247706 0 2 -2
taking,amevive 1.0 0.000286697247706 0 2 -2
only,for 1.0 0.000143348623853 0 1 -1
three,well-controlled 1.0 0.000143348623853 0 1 -1
facilitates,acquisition 1.0 0.000143348623853 0 1 -1
oxidation,responsible 1.0 0.000143348623853 1 0 1
be,explained 0.333333333333 0.000143348623853 1 2 -1
offers,advantages 1.0 0.000143348623853 0 1 -1
potential,to 0.411764705882 0.00100344036697 5 12 -7
in,severe 1.0 0.000143348623853 1 0 1
receiving,either 0.333333333333 0.000143348623853 2 1 1
enhanced,when 0.0 0.0 1 1 0
two,cases 1.0 0.000143348623853 1 0 1
of,rat 1.0 0.000573394495413 0 4 -4
against,multidrug-resistant 1.0 0.000143348623853 0 1 -1
local,factor 1.0 0.000143348623853 0 1 -1
of,ras 1.0 0.000286697247706 0 2 -2
vioxx,mg 0.333333333333 0.000143348623853 1 2 -1
with,one 0.0 0.0 2 2 0
mmol,mmol 1.0 0.000143348623853 0 1 -1
effects,lower 1.0 0.000143348623853 0 1 -1
liver,injury 1.0 0.000143348623853 0 1 -1
p-450,is 1.0 0.000143348623853 0 1 -1
further,kidney 1.0 0.000143348623853 0 1 -1
altered,mental 1.0 0.000143348623853 0 1 -1
toxic,medications 1.0 0.000143348623853 0 1 -1
with,were 0.0 0.0 1 1 0
of,pointer 1.0 0.000143348623853 0 1 -1
cardiovascular,and 1.0 0.000143348623853 0 1 -1
or,prothrombin 1.0 0.000286697247706 0 2 -2
mg,was 0.0 0.0 4 4 0
significant,additional 1.0 0.000143348623853 1 0 1
commonly,showed 1.0 0.000143348623853 0 1 -1
shown,no 1.0 0.000573394495413 0 4 -4
efficacy,benefit 1.0 0.000143348623853 0 1 -1
animal,reproduction 1.0 0.000143348623853 0 1 -1
p450,cyp 1.0 0.000716743119266 0 5 -5
d6,metabolizers 1.0 0.000143348623853 0 1 -1
decision,is 1.0 0.000143348623853 0 1 -1
vii,and 1.0 0.000143348623853 0 1 -1
was,and 1.0 0.000573394495413 0 4 -4
orally,administered 0.333333333333 0.000143348623853 1 2 -1
a,kg 1.0 0.000286697247706 0 2 -2
with,depen 1.0 0.000143348623853 1 0 1
a,ki 1.0 0.000143348623853 0 1 -1
morbidity,from 1.0 0.000143348623853 0 1 -1
thyroid,hormone 1.0 0.000143348623853 0 1 -1
after,bilateral 1.0 0.000143348623853 0 1 -1
reduction,for 1.0 0.000143348623853 0 1 -1
coagulation,diclofenac 1.0 0.000143348623853 0 1 -1
e2,dmpge2 1.0 0.000143348623853 0 1 -1
acetazolamide,and 1.0 0.000143348623853 1 0 1
was,prolonged 0.0 0.0 1 1 0
presently,not 1.0 0.000143348623853 0 1 -1
oral,injectable 1.0 0.000286697247706 2 0 2
mg,daily 0.0526315789474 0.000143348623853 9 10 -1
hormone,and 1.0 0.000286697247706 0 2 -2
the,median 0.333333333333 0.000143348623853 1 2 -1
of,akathisia 0.0 0.0 1 1 0
or,systolic 1.0 0.000143348623853 0 1 -1
masking,symptoms 1.0 0.000143348623853 0 1 -1
arava,levels 1.0 0.000143348623853 1 0 1
available,on 1.0 0.000286697247706 0 2 -2
labeling,index 1.0 0.000286697247706 0 2 -2
then,careful 1.0 0.000143348623853 1 0 1
alone,significantly 1.0 0.000143348623853 0 1 -1
dose,pharmacokinetic 1.0 0.000143348623853 0 1 -1
myopathy,during 1.0 0.000143348623853 0 1 -1
in,adults 0.2 0.000143348623853 2 3 -1
mammalian,liver 1.0 0.000143348623853 0 1 -1
potential,hepatotoxic 1.0 0.000143348623853 0 1 -1
blockers,did 1.0 0.000143348623853 0 1 -1
as,hypercalcemia 1.0 0.00043004587156 3 0 3
was,admini 1.0 0.000143348623853 1 0 1
carpophores,of 1.0 0.000143348623853 0 1 -1
subjects,unless 1.0 0.000143348623853 0 1 -1
phenylbutazone,causes 1.0 0.000143348623853 1 0 1
and,aspecific 1.0 0.000143348623853 0 1 -1
temporal,patterns 1.0 0.000143348623853 0 1 -1
below,have 1.0 0.000143348623853 0 1 -1
and,rarely 1.0 0.00043004587156 0 3 -3
avoid,concurrent 1.0 0.000143348623853 1 0 1
establish,a 1.0 0.000143348623853 1 0 1
migraines,such 1.0 0.000143348623853 0 1 -1
elevate,serum 1.0 0.000143348623853 1 0 1
i,sodium 1.0 0.000143348623853 0 1 -1
chloromycetin,local 1.0 0.000143348623853 1 0 1
sole,method 1.0 0.000143348623853 1 0 1
after,at 1.0 0.000143348623853 0 1 -1
exists,for 0.6 0.00043004587156 1 4 -3
very,low 1.0 0.000286697247706 0 2 -2
concentration,has 0.0 0.0 1 1 0
a,marked 0.333333333333 0.000143348623853 2 1 1
alter,behaviors 1.0 0.000143348623853 0 1 -1
biologic,half-life 1.0 0.000143348623853 1 0 1
serum,exposure 1.0 0.000143348623853 1 0 1
transferase,it 1.0 0.000143348623853 0 1 -1
also,interact 1.0 0.000286697247706 0 2 -2
prolong,bleeding 1.0 0.000143348623853 0 1 -1
reaction,has 1.0 0.000143348623853 0 1 -1
subsequent,synthesis 1.0 0.000143348623853 0 1 -1
is,mediated 0.333333333333 0.000143348623853 1 2 -1
a,one 1.0 0.000143348623853 1 0 1
reaction,had 1.0 0.000143348623853 0 1 -1
were,fasted 1.0 0.000286697247706 0 2 -2
warfarin,multiple 1.0 0.000143348623853 0 1 -1
exacerbate,rebound 1.0 0.000143348623853 1 0 1
dysrhythmias,some 1.0 0.000143348623853 1 0 1
on,prolonging 1.0 0.000143348623853 1 0 1
pharmacodynamic,with 1.0 0.000286697247706 0 2 -2
taking,tell 1.0 0.000143348623853 1 0 1
bombesin-enhanced,peritoneal 1.0 0.000143348623853 1 0 1
with,phenurone 1.0 0.000143348623853 1 0 1
this,observation 1.0 0.000286697247706 0 2 -2
less,suppression 1.0 0.000143348623853 0 1 -1
a,hour 1.0 0.00100344036697 7 0 7
alter,platelet 1.0 0.000143348623853 1 0 1
the,infusion 1.0 0.000143348623853 0 1 -1
response,suggest 1.0 0.000143348623853 0 1 -1
interactions,corticosteroids 1.0 0.000143348623853 0 1 -1
enzyme,and 1.0 0.000143348623853 0 1 -1
certain,actions 1.0 0.000143348623853 0 1 -1
be,formed 0.0 0.0 1 1 0
modifying,factors 1.0 0.000143348623853 1 0 1
however,current 1.0 0.000143348623853 0 1 -1
failed,to 0.75 0.000860091743119 1 7 -6
day,was 0.666666666667 0.000573394495413 1 5 -4
secretion,may 0.333333333333 0.000143348623853 1 2 -1
increase,cmax 1.0 0.000143348623853 1 0 1
cecectomized,and 1.0 0.000573394495413 0 4 -4
a,containing 1.0 0.000143348623853 0 1 -1
dicumarol,and 1.0 0.000286697247706 0 2 -2
effects,if 1.0 0.000143348623853 0 1 -1
acute,ergot 1.0 0.000143348623853 0 1 -1
the,udp-glucuronyl 1.0 0.000143348623853 0 1 -1
premedicated,with 1.0 0.000143348623853 0 1 -1
lipid,levels 0.0 0.0 1 1 0
higher,in 0.0 0.0 2 2 0
between,patients 1.0 0.000143348623853 0 1 -1
parameters,auc 1.0 0.000143348623853 1 0 1
interactions,to 1.0 0.000143348623853 0 1 -1
for,either 1.0 0.00114678899083 0 8 -8
bicarbonate,etc 1.0 0.000143348623853 1 0 1
serum-deprived,ras-transformed 1.0 0.000143348623853 0 1 -1
concentration,reached 1.0 0.000143348623853 0 1 -1
with,low 1.0 0.000143348623853 1 0 1
give,false 1.0 0.000143348623853 1 0 1
there,have 0.2 0.00129013761468 27 18 9
juices,compared 1.0 0.000143348623853 0 1 -1
if,therapy 0.714285714286 0.000716743119266 6 1 5
of,approximately 0.4 0.000573394495413 7 3 4
pharmacodynamic,effect 1.0 0.000716743119266 0 5 -5
clinical,interest 1.0 0.000143348623853 0 1 -1
a,potent 0.0714285714286 0.000286697247706 13 15 -2
cause,hypermagnesemia 1.0 0.00043004587156 3 0 3
a,severe 1.0 0.000143348623853 1 0 1
can,only 1.0 0.000143348623853 0 1 -1
fetal,immune 1.0 0.000143348623853 0 1 -1
not,depend 1.0 0.000143348623853 0 1 -1
status,which 1.0 0.000143348623853 0 1 -1
metabolized,via 0.333333333333 0.000143348623853 1 2 -1
to,normal 0.636363636364 0.00100344036697 2 9 -7
depen,cuprimine 1.0 0.000143348623853 1 0 1
irradiation,was 1.0 0.000143348623853 0 1 -1
group,therapy 1.0 0.000143348623853 0 1 -1
nor,its 1.0 0.000286697247706 0 2 -2
basic,science 1.0 0.000143348623853 0 1 -1
sst,and 1.0 0.00043004587156 0 3 -3
amenorrhea,were 1.0 0.000143348623853 0 1 -1
or,fasting 1.0 0.000143348623853 0 1 -1
recommended,levetiracetam 1.0 0.000143348623853 0 1 -1
our,understanding 1.0 0.000143348623853 0 1 -1
treatment,measures 1.0 0.000143348623853 0 1 -1
cells,or 1.0 0.000143348623853 1 0 1
enzyme,activity 0.0 0.0 1 1 0
pegasys,did 1.0 0.000143348623853 0 1 -1
muscle,cells 1.0 0.000143348623853 0 1 -1
molecule,thereby 1.0 0.00043004587156 3 0 3
jackfruit,contain 1.0 0.000143348623853 0 1 -1
inducers,that 1.0 0.000143348623853 1 0 1
similar,agents 1.0 0.000286697247706 2 0 2
demonstrate,very 1.0 0.000143348623853 0 1 -1
mixtures,at 1.0 0.000286697247706 0 2 -2
micrograms,had 1.0 0.000143348623853 1 0 1
often,administered 1.0 0.000143348623853 0 1 -1
type,inositol 1.0 0.000143348623853 0 1 -1
volunteers,it 1.0 0.000143348623853 1 0 1
evaluation,and 1.0 0.000143348623853 0 1 -1
be,detected 1.0 0.000143348623853 0 1 -1
of,peritoneal 1.0 0.000143348623853 0 1 -1
and,life-threatening 1.0 0.000143348623853 0 1 -1
of,conduction 1.0 0.000143348623853 1 0 1
frequently,administered 1.0 0.000143348623853 0 1 -1
adverse,experiences 0.2 0.000143348623853 2 3 -1
cervical,mucus 1.0 0.000143348623853 0 1 -1
volunteers,in 0.333333333333 0.000143348623853 1 2 -1
ureidopenicillins,including 1.0 0.000143348623853 1 0 1
best,choice 1.0 0.000143348623853 0 1 -1
admissions,for 1.0 0.000143348623853 0 1 -1
demonstrates,some 0.0 0.0 1 1 0
received,angiomax 1.0 0.000143348623853 0 1 -1
of,dosing 0.0 0.0 1 1 0
milk,secretion 1.0 0.000143348623853 0 1 -1
fluvastatin,is 1.0 0.000143348623853 0 1 -1
of,prescribed 1.0 0.000143348623853 0 1 -1
it,combines 1.0 0.000143348623853 0 1 -1
potential,only 1.0 0.000143348623853 0 1 -1
were,recorded 1.0 0.00043004587156 0 3 -3
plasma,protein-bound 1.0 0.000143348623853 1 0 1
handling,of 1.0 0.000143348623853 0 1 -1
mg,causing 1.0 0.000143348623853 0 1 -1
ecg,and 1.0 0.000143348623853 1 0 1
about,minutes 1.0 0.000143348623853 1 0 1
with,glucuronidation 1.0 0.000143348623853 0 1 -1
conductivity,and 1.0 0.000143348623853 1 0 1
with,very 1.0 0.000143348623853 0 1 -1
usually,a 1.0 0.000143348623853 1 0 1
induced,arc 1.0 0.000143348623853 0 1 -1
strong,likelihood 1.0 0.000143348623853 1 0 1
studies,conducted 1.0 0.000143348623853 0 1 -1
hormone,levels 1.0 0.000716743119266 0 5 -5
co-therapy,an 1.0 0.000573394495413 0 4 -4
are,used 0.142857142857 0.000573394495413 16 12 4
cyp1a2,weak 1.0 0.000143348623853 0 1 -1
a,complete 1.0 0.000143348623853 1 0 1
cpk,elevations 1.0 0.000143348623853 0 1 -1
in,dosage 0.2 0.000143348623853 2 3 -1
pharmacologic,doses 1.0 0.000143348623853 0 1 -1
of,this 0.809523809524 0.00731077981651 6 57 -51
mac,minimum 1.0 0.000286697247706 2 0 2
cause,pancreatitis 1.0 0.000286697247706 0 2 -2
significance,on 1.0 0.000143348623853 1 0 1
i,mac 1.0 0.000143348623853 1 0 1
cardiopulmonary,arrest 1.0 0.000143348623853 0 1 -1
recipients,during 1.0 0.000143348623853 0 1 -1
no,separate 1.0 0.000143348623853 0 1 -1
and,hmg-coa 1.0 0.000143348623853 1 0 1
p450,isozymes 1.0 0.000573394495413 0 4 -4
association,though 1.0 0.000286697247706 0 2 -2
and,only 1.0 0.000143348623853 0 1 -1
pegasys,equivalent 1.0 0.000143348623853 0 1 -1
orally,imidazole 1.0 0.000143348623853 1 0 1
pharmacokinetics,except 1.0 0.000143348623853 1 0 1
potentiation,occurs 1.0 0.000286697247706 0 2 -2
patients,receiving 0.048275862069 0.00100344036697 76 69 7
and,arachidonic 1.0 0.00043004587156 0 3 -3
caucasian,population 1.0 0.000573394495413 0 4 -4
standard,in 1.0 0.000143348623853 0 1 -1
initiated,as 1.0 0.000143348623853 1 0 1
replication,etc 1.0 0.000143348623853 0 1 -1
wellbutrin,and 1.0 0.000286697247706 2 0 2
initiated,at 0.0 0.0 1 1 0
whole-cell,recording 1.0 0.000286697247706 0 2 -2
beginning,therapy 1.0 0.000143348623853 1 0 1
both,are 1.0 0.000286697247706 2 0 2
the,embryogenesis 1.0 0.000143348623853 0 1 -1
acute,pretreatment 1.0 0.000143348623853 0 1 -1
by,users 1.0 0.000286697247706 0 2 -2
cns,and 1.0 0.000286697247706 0 2 -2
toxicodynamic,interference 1.0 0.000143348623853 0 1 -1
to,see 1.0 0.000286697247706 2 0 2
sodium,an 1.0 0.000143348623853 0 1 -1
norfloxacin,in 1.0 0.000143348623853 1 0 1
atropine,either 1.0 0.000143348623853 0 1 -1
access,distribution 1.0 0.000143348623853 0 1 -1
further,designs 1.0 0.000143348623853 0 1 -1
anticoagulant,inhibition 1.0 0.000143348623853 0 1 -1
system,such 1.0 0.000143348623853 0 1 -1
with,proton 1.0 0.000143348623853 1 0 1
treatments,lacking 1.0 0.000143348623853 0 1 -1
anhydrase,inhibitors 0.5 0.000286697247706 3 1 2
tcas,with 1.0 0.00043004587156 3 0 3
demonstrated,less 1.0 0.000143348623853 1 0 1
development,essential 1.0 0.000143348623853 0 1 -1
max,of 1.0 0.000143348623853 1 0 1
absorption,can 1.0 0.000143348623853 1 0 1
to,allow 1.0 0.000143348623853 0 1 -1
beta2,agonists 1.0 0.000143348623853 1 0 1
actions,via 1.0 0.000143348623853 0 1 -1
colestid,tablets 0.333333333333 0.000143348623853 1 2 -1
max,or 1.0 0.000286697247706 0 2 -2
information,for 1.0 0.000573394495413 0 4 -4
decreased,antithrombin 1.0 0.000286697247706 0 2 -2
of,general 1.0 0.000143348623853 0 1 -1
eliminated,from 1.0 0.000143348623853 1 0 1
lodine,or 1.0 0.000143348623853 0 1 -1
apparently,t 1.0 0.000143348623853 0 1 -1
carbamazepine,coadministration 1.0 0.000143348623853 1 0 1
analgesics,was 1.0 0.000143348623853 0 1 -1
and,carbonic 1.0 0.000143348623853 1 0 1
therapy,ect 1.0 0.000143348623853 0 1 -1
s-warfarin,with 1.0 0.000143348623853 0 1 -1
attenuation,in 1.0 0.000143348623853 0 1 -1
study,were 1.0 0.000286697247706 0 2 -2
given,simultaneously 1.0 0.000286697247706 2 0 2
hatching,of 1.0 0.000143348623853 0 1 -1
transcriptional,activator 1.0 0.000143348623853 0 1 -1
effect,would 1.0 0.000143348623853 0 1 -1
in,animal 1.0 0.000286697247706 0 2 -2
enzymes,interactions 1.0 0.000143348623853 0 1 -1
large,fold 1.0 0.000716743119266 0 5 -5
morphine,combination 1.0 0.000143348623853 1 0 1
live,bacteria 1.0 0.000143348623853 0 1 -1
actively,secreted 1.0 0.000143348623853 1 0 1
have,frequently 1.0 0.000143348623853 0 1 -1
drug,interaction 0.769230769231 0.00286697247706 3 23 -20
vision,nystagmus 1.0 0.000143348623853 0 1 -1
all,should 1.0 0.000143348623853 1 0 1
h2antagonists,reduced 1.0 0.000143348623853 1 0 1
and,anti-depressants 1.0 0.000143348623853 1 0 1
hiv-infected,individuals 1.0 0.000286697247706 0 2 -2
and,sudden 1.0 0.000143348623853 1 0 1
with,elemental 1.0 0.000143348623853 0 1 -1
for,management 0.0 0.0 1 1 0
reaction,at 1.0 0.000286697247706 0 2 -2
ie,from 1.0 0.000143348623853 0 1 -1
studies,fully 1.0 0.000143348623853 0 1 -1
of,beta-receptor 1.0 0.000143348623853 0 1 -1
qualification,of 1.0 0.000143348623853 0 1 -1
undergo,tyrosine 1.0 0.000143348623853 0 1 -1
like,mg 1.0 0.000143348623853 0 1 -1
barrier,contraception 1.0 0.000143348623853 1 0 1
like,mc 1.0 0.000143348623853 0 1 -1
on,endometrial 1.0 0.000143348623853 0 1 -1
nsaids,has 1.0 0.000286697247706 2 0 2
administration,regimens 1.0 0.000143348623853 0 1 -1
circulating,catecholamines 1.0 0.000143348623853 0 1 -1
hormone,should 1.0 0.000143348623853 0 1 -1
to,minimize 1.0 0.000143348623853 0 1 -1
simulect,was 1.0 0.000143348623853 1 0 1
to,nonopioid 1.0 0.000143348623853 0 1 -1
drying,effect 1.0 0.000143348623853 0 1 -1
that,physicians 1.0 0.000143348623853 0 1 -1
with,further 1.0 0.000143348623853 0 1 -1
selection,and 1.0 0.000143348623853 0 1 -1
octapeptide,is 1.0 0.000143348623853 0 1 -1
gl,the 1.0 0.000143348623853 0 1 -1
effect,one 1.0 0.000143348623853 1 0 1
quantitative,approach 1.0 0.000143348623853 0 1 -1
their,possible 1.0 0.000143348623853 0 1 -1
barton,braunberg 1.0 0.000143348623853 0 1 -1
substrate,are 1.0 0.000143348623853 0 1 -1
specific,treatment 1.0 0.000143348623853 0 1 -1
increased,dosage 1.0 0.000143348623853 1 0 1
ethosuximide,amphetamines 1.0 0.000286697247706 2 0 2
m,min 1.0 0.000143348623853 1 0 1
discontinues,therapy 1.0 0.000143348623853 1 0 1
overload,of 1.0 0.000143348623853 0 1 -1
cell,lines 1.0 0.000143348623853 1 0 1
intrathecal,on 1.0 0.000286697247706 0 2 -2
dna,damage 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,some 1.0 0.000143348623853 0 1 -1
separate,controlled 1.0 0.000143348623853 0 1 -1
to,block 1.0 0.000143348623853 1 0 1
further,antihypertensive 1.0 0.000143348623853 1 0 1
pediatric,patients 0.5 0.000286697247706 1 3 -2
receiving,narrow 1.0 0.000143348623853 0 1 -1
receiving,similar 1.0 0.000143348623853 0 1 -1
becoming,increasingly 1.0 0.000143348623853 0 1 -1
oral,administration 0.5 0.000573394495413 2 6 -4
between,oral 1.0 0.00043004587156 3 0 3
recall,has 1.0 0.000143348623853 0 1 -1
dilantin,use 1.0 0.000143348623853 1 0 1
six,volunteers 1.0 0.000143348623853 0 1 -1
despite,reduction 1.0 0.000143348623853 0 1 -1
or,herbs 1.0 0.000143348623853 0 1 -1
norethindrone,coadministration 1.0 0.000143348623853 1 0 1
growth,factor 1.0 0.000143348623853 0 1 -1
circulation,there 1.0 0.000143348623853 1 0 1
systemic,data 1.0 0.000143348623853 0 1 -1
antiplatelet,agents 1.0 0.000286697247706 2 0 2
digital,extensor 1.0 0.000143348623853 0 1 -1
closely,observed 0.75 0.000860091743119 1 7 -6
taken,for 1.0 0.000143348623853 0 1 -1
however,plasma 1.0 0.000143348623853 0 1 -1
oral,contraception 1.0 0.000143348623853 0 1 -1
mmol,l 1.0 0.000716743119266 0 5 -5
be,maximal 1.0 0.000143348623853 1 0 1
of,used 1.0 0.00100344036697 0 7 -7
reduced,serum 0.333333333333 0.000143348623853 1 2 -1
synthesis,to 1.0 0.000143348623853 0 1 -1
with,depressed 1.0 0.000143348623853 1 0 1
mg,bid 0.185185185185 0.000716743119266 16 11 5
several,advantages 1.0 0.000143348623853 0 1 -1
convenient,administration 1.0 0.000143348623853 0 1 -1
than,mug 1.0 0.000143348623853 0 1 -1
inhibitor,the 1.0 0.000286697247706 2 0 2
animals,than 1.0 0.000143348623853 0 1 -1
to,discontinue 0.5 0.000286697247706 1 3 -2
correspond,to 1.0 0.000286697247706 0 2 -2
blockers,antagonists 1.0 0.000143348623853 0 1 -1
when,romazicon 1.0 0.000143348623853 0 1 -1
ergomar,may 1.0 0.000143348623853 1 0 1
xigris,have 1.0 0.000286697247706 0 2 -2
paranoid,symptoms 1.0 0.000143348623853 1 0 1
lipid-lowering,that 1.0 0.000286697247706 0 2 -2
in,arthritic 1.0 0.000143348623853 0 1 -1
for,three 1.0 0.000143348623853 0 1 -1
hydroxide-,and 1.0 0.000143348623853 0 1 -1
that,allegra 1.0 0.000143348623853 0 1 -1
elemental,oz 1.0 0.000143348623853 0 1 -1
maximum,block 1.0 0.000143348623853 1 0 1
dopaminergic,renal 1.0 0.000143348623853 1 0 1
interfering,with 1.0 0.00043004587156 3 0 3
test,female 1.0 0.000143348623853 0 1 -1
cmin,plasma 1.0 0.000286697247706 0 2 -2
triglycerides,sgot 1.0 0.000143348623853 1 0 1
also,used 0.2 0.000143348623853 2 3 -1
cells,mm3 1.0 0.000286697247706 0 2 -2
advocated,on 1.0 0.000143348623853 0 1 -1
cholestytamine,and 1.0 0.000143348623853 1 0 1
s,that 1.0 0.000143348623853 1 0 1
times,can 1.0 0.000143348623853 0 1 -1
examine,interactions 1.0 0.000143348623853 0 1 -1
was,ineffective 1.0 0.000286697247706 0 2 -2
after,chemotherapy 1.0 0.000143348623853 0 1 -1
of,ee 1.0 0.000143348623853 0 1 -1
strong,cyp 1.0 0.000143348623853 0 1 -1
antifibrinolytic,therapies 1.0 0.000143348623853 0 1 -1
of,er 1.0 0.000143348623853 0 1 -1
injection,with 1.0 0.000286697247706 2 0 2
is,narrow 1.0 0.000143348623853 0 1 -1
to,severe 1.0 0.000573394495413 4 0 4
agonists,have 1.0 0.000143348623853 1 0 1
currently,taking 1.0 0.000143348623853 0 1 -1
percentage,increase 0.6 0.00043004587156 4 1 3
potential,twofold 1.0 0.000143348623853 1 0 1
alterations,might 1.0 0.000143348623853 0 1 -1
mean,eight-fold 1.0 0.000286697247706 2 0 2
restored,susceptibility 1.0 0.000143348623853 0 1 -1
clarithromycin,is 1.0 0.000143348623853 1 0 1
main,indications 1.0 0.000143348623853 0 1 -1
of,cholinesterase 1.0 0.000286697247706 2 0 2
b23,in 1.0 0.00043004587156 0 3 -3
hypertensive,nephropathy 1.0 0.000143348623853 0 1 -1
at,their 1.0 0.000143348623853 0 1 -1
were,almost 1.0 0.000143348623853 1 0 1
dosage,will 1.0 0.000143348623853 0 1 -1
of,positive 1.0 0.000286697247706 0 2 -2
two,hepatic 1.0 0.000143348623853 0 1 -1
mechanism,for 0.2 0.000143348623853 2 3 -1
metabolic,rate 1.0 0.000143348623853 0 1 -1
prolonged,sodation 1.0 0.000143348623853 1 0 1
basis,that 1.0 0.000286697247706 2 0 2
l,mmol 1.0 0.000143348623853 0 1 -1
other,metabolized 0.714285714286 0.00143348623853 2 12 -10
mouse,tumour 1.0 0.000143348623853 1 0 1
also,conducted 1.0 0.000143348623853 0 1 -1
concomitant,medication 1.0 0.000286697247706 0 2 -2
mononitrate,may 1.0 0.000143348623853 1 0 1
ergot,derivatives 1.0 0.000143348623853 0 1 -1
ng,x 1.0 0.000143348623853 1 0 1
and,creatinine 1.0 0.000286697247706 2 0 2
prepared,to 1.0 0.000143348623853 0 1 -1
sympatholytic,medicinal 1.0 0.000286697247706 0 2 -2
and,ortho-novum 1.0 0.000143348623853 1 0 1
might,also 0.0 0.0 1 1 0
with,regard 1.0 0.000573394495413 0 4 -4
currently,exist 1.0 0.000143348623853 0 1 -1
nearly,normal 1.0 0.000143348623853 0 1 -1
mean,sodium 1.0 0.000143348623853 1 0 1
laboratory,test-interactions 1.0 0.000143348623853 0 1 -1
m,the 1.0 0.000143348623853 0 1 -1
fluoxetine,and 1.0 0.000286697247706 0 2 -2
where,gastric 1.0 0.000286697247706 2 0 2
caspase-3,activity 1.0 0.000143348623853 0 1 -1
involves,depression 1.0 0.000143348623853 0 1 -1
of,foscavir 1.0 0.000286697247706 2 0 2
currents,discriminates 1.0 0.000143348623853 0 1 -1
system,responsible 1.0 0.000286697247706 2 0 2
at,dosages 1.0 0.000143348623853 0 1 -1
although,ipratropium 1.0 0.000143348623853 1 0 1
compromised,in 1.0 0.000143348623853 1 0 1
between,theraputic 1.0 0.000143348623853 0 1 -1
from,displacement 1.0 0.000143348623853 0 1 -1
of,supplementary 1.0 0.000143348623853 0 1 -1
initiate,therapy 1.0 0.000143348623853 1 0 1
diminished,the 1.0 0.000143348623853 1 0 1
formulations,containing 1.0 0.00043004587156 3 0 3
more,or 1.0 0.000143348623853 0 1 -1
naflu,compared 1.0 0.000143348623853 0 1 -1
furosemide,has 1.0 0.000143348623853 1 0 1
hormonal,evidence 1.0 0.000143348623853 0 1 -1
diclofenac,and 1.0 0.000143348623853 1 0 1
of,repeated 1.0 0.000143348623853 0 1 -1
completely,inhibited 1.0 0.000143348623853 1 0 1
may,turn 1.0 0.000143348623853 0 1 -1
and,toxic 1.0 0.000143348623853 0 1 -1
antihypertensive,and 1.0 0.000143348623853 1 0 1
safely,with 1.0 0.000143348623853 0 1 -1
in,determining 1.0 0.000286697247706 0 2 -2
daily,produced 1.0 0.000143348623853 1 0 1
tablets,the 1.0 0.00043004587156 3 0 3
anti-inflammatory,concomitantly 1.0 0.000143348623853 1 0 1
prolonged,hypotension 1.0 0.000143348623853 1 0 1
macrolide,have 1.0 0.000143348623853 1 0 1
with,mao 1.0 0.000573394495413 4 0 4
b23,was 1.0 0.000143348623853 0 1 -1
in,vitamin 0.0 0.0 1 1 0
proton,pump 0.5 0.000573394495413 6 2 4
ieg,arc 1.0 0.000143348623853 0 1 -1
ml,or 1.0 0.00043004587156 0 3 -3
naproxen,and 1.0 0.000143348623853 1 0 1
with,may 0.333333333333 0.00143348623853 20 10 10
depressant,and 0.0 0.0 1 1 0
years,have 1.0 0.000143348623853 0 1 -1
ml,of 1.0 0.000286697247706 0 2 -2
oxaloacetate,and 1.0 0.000143348623853 0 1 -1
salt,restriction 1.0 0.000143348623853 1 0 1
organism,and 1.0 0.000143348623853 0 1 -1
a,segment 1.0 0.000143348623853 0 1 -1
pancreatitis,and 1.0 0.000143348623853 0 1 -1
supplements,may 0.0 0.0 1 1 0
soft-gelatin,capsule 1.0 0.000143348623853 1 0 1
diamox,modifies 1.0 0.000143348623853 1 0 1
temporarily,discontinued 0.0 0.0 1 1 0
inflammatory,agents 1.0 0.000143348623853 1 0 1
although,in 1.0 0.000143348623853 1 0 1
metabolic,interactions 1.0 0.00043004587156 0 3 -3
possible,interaction 0.0 0.0 3 3 0
side,effects 0.0714285714286 0.000286697247706 13 15 -2
that,concomitan 1.0 0.000143348623853 1 0 1
doses,is 0.333333333333 0.000143348623853 1 2 -1
trileptal,doses 1.0 0.000143348623853 1 0 1
doses,in 1.0 0.000143348623853 1 0 1
therefore,signs 1.0 0.000143348623853 0 1 -1
mg,q24h 1.0 0.000286697247706 0 2 -2
patients,reveiving 1.0 0.000143348623853 1 0 1
combinations,has 1.0 0.000143348623853 0 1 -1
although,is 1.0 0.000143348623853 0 1 -1
intracellular,ca 0.333333333333 0.000143348623853 1 2 -1
although,it 0.333333333333 0.000286697247706 4 2 2
extensively,bound 1.0 0.000286697247706 0 2 -2
nsaids,including 0.0 0.0 1 1 0
particularly,carefully 1.0 0.000143348623853 0 1 -1
inhibitors,dasatinib 1.0 0.000143348623853 0 1 -1
caused,a 0.111111111111 0.000143348623853 5 4 1
tablets,have 1.0 0.000286697247706 0 2 -2
pressor,response 1.0 0.000143348623853 1 0 1
analgesia,must 1.0 0.000143348623853 1 0 1
acid,anabolic 1.0 0.000143348623853 1 0 1
into,account 0.666666666667 0.000573394495413 1 5 -4
tablets,but 1.0 0.000573394495413 0 4 -4
a,non-selective 1.0 0.000143348623853 1 0 1
thiobarbituric,acid 1.0 0.000143348623853 0 1 -1
psychiatric,patients 1.0 0.000143348623853 1 0 1
are,weak 1.0 0.000143348623853 0 1 -1
high,or 1.0 0.000143348623853 0 1 -1
tca,treatment 1.0 0.000573394495413 0 4 -4
other,commonly 1.0 0.000143348623853 0 1 -1
he,was 1.0 0.000143348623853 0 1 -1
or,altered 1.0 0.000143348623853 0 1 -1
may,sterilize 1.0 0.000143348623853 0 1 -1
fibroblast,y1 1.0 0.000143348623853 0 1 -1
levels,is 0.333333333333 0.000143348623853 2 1 1
rest,were 1.0 0.000143348623853 0 1 -1
levels,it 1.0 0.000286697247706 2 0 2
of,similar 1.0 0.000573394495413 4 0 4
levels,in 0.125 0.000286697247706 7 9 -2
is,essential 1.0 0.000573394495413 0 4 -4
administering,concurrently 1.0 0.000143348623853 1 0 1
were,sacrificed 1.0 0.000143348623853 0 1 -1
of,circulating 1.0 0.000716743119266 0 5 -5
are,minimally 1.0 0.000143348623853 0 1 -1
was,responsible 1.0 0.000143348623853 1 0 1
of,artocarpus 1.0 0.000143348623853 0 1 -1
bid,the 1.0 0.000286697247706 2 0 2
other,niacin 1.0 0.000143348623853 0 1 -1
http,www 1.0 0.000143348623853 0 1 -1
in,enhancing 1.0 0.000143348623853 0 1 -1
therefore,the 0.238095238095 0.000716743119266 8 13 -5
half-life,the 1.0 0.000143348623853 1 0 1
human,cyp 1.0 0.000143348623853 0 1 -1
during,which 1.0 0.000143348623853 0 1 -1
either,or 0.466666666667 0.00100344036697 4 11 -7
inhibitor,because 1.0 0.000143348623853 0 1 -1
by,protein-bound 1.0 0.000286697247706 0 2 -2
the,factrel 1.0 0.000143348623853 0 1 -1
qd,and 1.0 0.000286697247706 2 0 2
auc,from 1.0 0.000143348623853 1 0 1
trace,pathways 1.0 0.000143348623853 0 1 -1
therophylline,a 1.0 0.000143348623853 1 0 1
manic-depressive,illness 1.0 0.000143348623853 1 0 1
that,gets 1.0 0.000143348623853 1 0 1
vasoconstrictors,d 1.0 0.000143348623853 1 0 1
frova,within 1.0 0.000143348623853 1 0 1
sexological,psychological 1.0 0.000143348623853 0 1 -1
either,on 1.0 0.000143348623853 0 1 -1
theoretically,coadministration 1.0 0.000143348623853 1 0 1
how,the 1.0 0.000143348623853 0 1 -1
interleukin-1,antagonist 1.0 0.000286697247706 2 0 2
curve,from 1.0 0.000143348623853 0 1 -1
and,how 1.0 0.000143348623853 0 1 -1
urinary,retention 0.333333333333 0.000143348623853 2 1 1
used,for 0.6 0.00043004587156 1 4 -3
ie,timi-ii 1.0 0.000143348623853 0 1 -1
strong,in 1.0 0.000143348623853 0 1 -1
plasma,half-life 0.0 0.0 2 2 0
or,large 1.0 0.000143348623853 0 1 -1
the,pesticide 1.0 0.000286697247706 0 2 -2
reviews,recent 1.0 0.000286697247706 0 2 -2
corticosteroids,dexamethasone 1.0 0.000143348623853 1 0 1
anti-hiv,protease 1.0 0.000143348623853 0 1 -1
bioavailability,eg 1.0 0.000143348623853 1 0 1
other,with 1.0 0.000143348623853 1 0 1
nanm,but 1.0 0.000286697247706 2 0 2
with,amphotericin 1.0 0.000286697247706 2 0 2
those,obtained 1.0 0.00043004587156 3 0 3
or,inr 1.0 0.000143348623853 1 0 1
sn38,the 1.0 0.000143348623853 0 1 -1
concentration,profile 1.0 0.000143348623853 0 1 -1
for,worsening 1.0 0.000143348623853 0 1 -1
hyperglycaemic,clamps 1.0 0.000143348623853 0 1 -1
possible,or 1.0 0.000143348623853 0 1 -1
in,dose 0.4 0.000573394495413 3 7 -4
patients,optimal 1.0 0.000143348623853 0 1 -1
and,nicotine-induced 1.0 0.000143348623853 1 0 1
of,observation 1.0 0.000143348623853 0 1 -1
cation,transport 1.0 0.000143348623853 0 1 -1
nph,human 1.0 0.000286697247706 0 2 -2
of,morning 1.0 0.000143348623853 0 1 -1
level,determinations 1.0 0.000143348623853 1 0 1
have,shown 0.277777777778 0.00143348623853 13 23 -10
a,placebo-controlled 0.333333333333 0.000143348623853 2 1 1
receiving,monoamine 0.6 0.00043004587156 4 1 3
and,facilitate 1.0 0.000143348623853 0 1 -1
however,did 1.0 0.000143348623853 0 1 -1
not,sufficient 0.75 0.000860091743119 1 7 -6
acidic,conditions 0.0 0.0 1 1 0
diarrhea-inducing,effects 1.0 0.000143348623853 0 1 -1
beyond,the 1.0 0.000143348623853 1 0 1
mesylate,injection 0.6 0.00043004587156 4 1 3
multipledose,treatment 1.0 0.000143348623853 0 1 -1
modified,histidine 1.0 0.000143348623853 0 1 -1
diabetics,or 1.0 0.000143348623853 1 0 1
advised,against 0.333333333333 0.000143348623853 2 1 1
or,consider 1.0 0.000143348623853 1 0 1
placebo-controlled,phase 1.0 0.000143348623853 0 1 -1
initial,dose 0.555555555556 0.000716743119266 2 7 -5
transporter,as 1.0 0.000143348623853 0 1 -1
is,involved 1.0 0.000716743119266 0 5 -5
modest,dysphoria 1.0 0.000143348623853 0 1 -1
significant,drug 1.0 0.000286697247706 0 2 -2
active,when 1.0 0.000143348623853 0 1 -1
neuromuscular,block 0.5 0.000286697247706 3 1 2
nacmc,m 1.0 0.000286697247706 0 2 -2
drug,laboratorytest 1.0 0.000143348623853 0 1 -1
among,or 1.0 0.000143348623853 0 1 -1
or,resistance 1.0 0.000143348623853 0 1 -1
study,maximum 1.0 0.000143348623853 1 0 1
femara,with 1.0 0.000143348623853 0 1 -1
proleukin,in 1.0 0.000143348623853 0 1 -1
acid,higher 1.0 0.000143348623853 1 0 1
or,amenorrhea 1.0 0.000143348623853 0 1 -1
animal,in 1.0 0.000143348623853 0 1 -1
presyncope,or 1.0 0.000143348623853 1 0 1
corticosteroid-binding,globulin 1.0 0.000143348623853 0 1 -1
transient,thrombocytopenia 1.0 0.000143348623853 0 1 -1
liver,via 1.0 0.000143348623853 0 1 -1
the,brief 1.0 0.000143348623853 1 0 1
systems,may 1.0 0.000143348623853 0 1 -1
a,mcg 1.0 0.000143348623853 0 1 -1
mice,on 1.0 0.000143348623853 0 1 -1
this,included 1.0 0.000143348623853 0 1 -1
experimental,toxic 1.0 0.000143348623853 1 0 1
romazicon,blocks 1.0 0.000143348623853 1 0 1
exposure,may 1.0 0.000143348623853 0 1 -1
n-acetyl,by 1.0 0.000143348623853 0 1 -1
substrate,of 1.0 0.000716743119266 0 5 -5
sufficient,numbers 1.0 0.000143348623853 0 1 -1
who,may 0.5 0.000286697247706 1 3 -2
disturbing,the 1.0 0.000143348623853 0 1 -1
microm,also 1.0 0.000143348623853 1 0 1
pathway,suggesting 1.0 0.000143348623853 0 1 -1
drugs,ethanol 1.0 0.000286697247706 2 0 2
manner,when 1.0 0.000143348623853 1 0 1
dietary,deficiencies 1.0 0.000143348623853 1 0 1
the,escalating 1.0 0.000143348623853 0 1 -1
of,given 0.0 0.0 2 2 0
follow,dosing 1.0 0.000143348623853 0 1 -1
congeners,and 1.0 0.000143348623853 0 1 -1
dose,that 1.0 0.000286697247706 0 2 -2
liver,by 1.0 0.00043004587156 0 3 -3
and,metacercariae 1.0 0.000143348623853 0 1 -1
and,increase 0.125 0.000286697247706 9 7 2
class,produced 1.0 0.000143348623853 0 1 -1
disorder,attention 1.0 0.000143348623853 0 1 -1
mg2,converted 1.0 0.000143348623853 0 1 -1
retention,and 1.0 0.000143348623853 1 0 1
warfarin,quinolones 1.0 0.00043004587156 3 0 3
notably,nondepolarizing 1.0 0.000143348623853 1 0 1
as,peripheral 1.0 0.000143348623853 0 1 -1
gallate,showed 1.0 0.000143348623853 0 1 -1
ophthalmic,and 0.0 0.0 1 1 0
certain,neurologic 1.0 0.000143348623853 0 1 -1
believed,that 1.0 0.000143348623853 1 0 1
test,monitoring 1.0 0.000143348623853 0 1 -1
prolongation,in 0.5 0.000286697247706 1 3 -2
cryptosporidium,parvum 0.0 0.0 1 1 0
be,worsened 1.0 0.000143348623853 0 1 -1
longitudinal,assessment 1.0 0.000143348623853 0 1 -1
succinylcholine-induced,neuromuscular 1.0 0.000143348623853 0 1 -1
the,identification 1.0 0.000286697247706 0 2 -2
after,concomitant 0.0 0.0 1 1 0
abolished,the 1.0 0.000143348623853 0 1 -1
of,atp 1.0 0.000143348623853 0 1 -1
n,there 1.0 0.000143348623853 0 1 -1
over,those 1.0 0.000143348623853 1 0 1
an,indication 1.0 0.000143348623853 0 1 -1
reducing,effect 1.0 0.000143348623853 1 0 1
at,similar 1.0 0.000286697247706 0 2 -2
could,observe 1.0 0.000143348623853 0 1 -1
exposure,compared 0.0 0.0 1 1 0
chloride,folic 1.0 0.000143348623853 0 1 -1
fondaparinux,the 1.0 0.000143348623853 0 1 -1
common,pathogens 1.0 0.000143348623853 0 1 -1
systemic,vascular 1.0 0.000143348623853 1 0 1
without,to 1.0 0.000143348623853 1 0 1
that,anion 1.0 0.000143348623853 0 1 -1
thinners,decongestant 1.0 0.000143348623853 1 0 1
fi,responding 0.333333333333 0.000143348623853 1 2 -1
or,hctz 1.0 0.000143348623853 0 1 -1
performed,with 0.428571428571 0.00043004587156 2 5 -3
alfa-2a,for 1.0 0.000143348623853 0 1 -1
for,human 1.0 0.000143348623853 0 1 -1
the,joint 1.0 0.000143348623853 0 1 -1
maoi,there 1.0 0.000143348623853 1 0 1
virus,vaccine 1.0 0.000143348623853 1 0 1
values,it 1.0 0.000143348623853 0 1 -1
brain,levels 1.0 0.000143348623853 0 1 -1
intrinsic,value 1.0 0.000143348623853 0 1 -1
values,in 0.333333333333 0.000143348623853 1 2 -1
d6,debrisoquin 1.0 0.000143348623853 0 1 -1
maximum,concentration 0.714285714286 0.000716743119266 1 6 -5
regimen,as 1.0 0.000143348623853 0 1 -1
addition,patients 1.0 0.000143348623853 0 1 -1
these,monkeys 1.0 0.000143348623853 0 1 -1
or,bone 1.0 0.000143348623853 0 1 -1
or,acth 1.0 0.000143348623853 0 1 -1
two,doses 1.0 0.000143348623853 0 1 -1
qrs,complex 0.0 0.0 1 1 0
showing,that 1.0 0.000143348623853 0 1 -1
an,increasing 1.0 0.000143348623853 0 1 -1
exposure,with 1.0 0.000143348623853 1 0 1
using,clozapine 1.0 0.000143348623853 0 1 -1
teratogenic,and 1.0 0.000143348623853 0 1 -1
ns,was 1.0 0.000286697247706 2 0 2
can,diminish 1.0 0.000143348623853 1 0 1
be,manifested 1.0 0.000143348623853 0 1 -1
i,coadministration 1.0 0.000143348623853 1 0 1
about,higher 1.0 0.000143348623853 1 0 1
on,accutane 1.0 0.000143348623853 0 1 -1
hepatoxicity,of 1.0 0.000143348623853 1 0 1
expected,lasma 1.0 0.000143348623853 0 1 -1
between,coadministered 1.0 0.000143348623853 0 1 -1
a4,by 1.0 0.000143348623853 0 1 -1
limited,sampling 1.0 0.000143348623853 0 1 -1
attenuated,by 1.0 0.000143348623853 0 1 -1
nitroglycerin,dynacirc 1.0 0.000143348623853 0 1 -1
dysfunction,by 1.0 0.000143348623853 1 0 1
of,crohn 1.0 0.000143348623853 0 1 -1
nsaid,such 1.0 0.000143348623853 0 1 -1
products,or 1.0 0.000143348623853 0 1 -1
units,with 1.0 0.000143348623853 0 1 -1
synthetase,inhibitors 1.0 0.000143348623853 0 1 -1
ssris,seriraline 1.0 0.000143348623853 0 1 -1
currently,it 1.0 0.000143348623853 0 1 -1
streptozotocin-induced,diabetic 1.0 0.000143348623853 0 1 -1
high,to 1.0 0.000143348623853 1 0 1
type,revealed 1.0 0.000143348623853 0 1 -1
tambocor,unless 1.0 0.000143348623853 1 0 1
characterised,by 1.0 0.000143348623853 0 1 -1
metabolite,mhd 1.0 0.000143348623853 0 1 -1
if,argatroban 1.0 0.000143348623853 0 1 -1
although,concomitant 1.0 0.000143348623853 1 0 1
diminished,effect 1.0 0.000143348623853 0 1 -1
pituitary-gonadal,axis 1.0 0.000143348623853 0 1 -1
sudden,withdrawal 1.0 0.000143348623853 1 0 1
listed,below 0.333333333333 0.000143348623853 1 2 -1
least,hours 0.375 0.000860091743119 11 5 6
inhibitor,therapy 1.0 0.000143348623853 1 0 1
potent,of 1.0 0.000143348623853 0 1 -1
other,isozymes 1.0 0.000143348623853 0 1 -1
either,mask 1.0 0.000143348623853 0 1 -1
both,free 1.0 0.000143348623853 1 0 1
local,breast 1.0 0.000143348623853 0 1 -1
with,hcl 0.333333333333 0.000143348623853 1 2 -1
can,directly 1.0 0.000143348623853 1 0 1
discriminate,between 1.0 0.000143348623853 0 1 -1
d,dosage 1.0 0.000573394495413 4 0 4
physiological,changes 1.0 0.000143348623853 0 1 -1
the,rabbit 1.0 0.000143348623853 0 1 -1
or,clastogenic 1.0 0.000143348623853 0 1 -1
in,ms 0.0 0.0 1 1 0
adjustments,made 1.0 0.00043004587156 0 3 -3
in,mm 1.0 0.000143348623853 0 1 -1
time,beyond 1.0 0.000143348623853 1 0 1
regard,to 1.0 0.000716743119266 0 5 -5
aed,s 1.0 0.000143348623853 1 0 1
nonsteroidal,has 1.0 0.000143348623853 1 0 1
that,nsaids 1.0 0.00157683486239 11 0 11
hypokalemia,that 1.0 0.000143348623853 1 0 1
a,possible 0.230769230769 0.00043004587156 8 5 3
underlying,renal 1.0 0.000143348623853 0 1 -1
copd,should 1.0 0.000143348623853 0 1 -1
considering,that 1.0 0.000143348623853 0 1 -1
hours,subsequent 1.0 0.000143348623853 0 1 -1
use,was 1.0 0.000143348623853 0 1 -1
adjusting,or 1.0 0.000143348623853 1 0 1
with,colorectal 1.0 0.000143348623853 0 1 -1
cause,significant 0.0 0.0 1 1 0
that,reached 1.0 0.000143348623853 0 1 -1
are,being 0.2 0.000143348623853 2 3 -1
with,known 0.5 0.000286697247706 1 3 -2
time,ratio 1.0 0.000143348623853 0 1 -1
displace,less 1.0 0.000143348623853 1 0 1
estradiol,the 1.0 0.000143348623853 0 1 -1
exposure,from 1.0 0.000143348623853 0 1 -1
potassium,supplements 1.0 0.000286697247706 2 0 2
an,attempt 1.0 0.000143348623853 1 0 1
reuptake,thus 1.0 0.000286697247706 2 0 2
and,dopa 1.0 0.000143348623853 0 1 -1
confusion,and 1.0 0.000143348623853 1 0 1
higher,concentrations 0.0 0.0 2 2 0
somnolence,dizziness 1.0 0.000143348623853 0 1 -1
be,fatal 1.0 0.000143348623853 1 0 1
lower,affinities 1.0 0.000143348623853 0 1 -1
a,nonabsorbable 1.0 0.000143348623853 1 0 1
finasteride,does 1.0 0.000143348623853 0 1 -1
anesthetized,with 1.0 0.000143348623853 1 0 1
the,flavonoids 1.0 0.000143348623853 0 1 -1
disease,are 1.0 0.000143348623853 0 1 -1
influence,limbic 1.0 0.000143348623853 0 1 -1
administered,once 0.0 0.0 2 2 0
powder,for 1.0 0.00100344036697 7 0 7
tbg,leading 1.0 0.00043004587156 0 3 -3
while,studies 1.0 0.000143348623853 1 0 1
time,following 1.0 0.000286697247706 0 2 -2
toxicity,associated 0.0 0.0 2 2 0
concomitant,and 0.0 0.0 2 2 0
aberration,assay 1.0 0.000143348623853 0 1 -1
episodes,may 1.0 0.000143348623853 1 0 1
and,gram 1.0 0.000143348623853 0 1 -1
the,amount 0.333333333333 0.000286697247706 4 2 2
comparison,study 1.0 0.000143348623853 0 1 -1
stomach,may 1.0 0.000143348623853 1 0 1
observed,when 0.111111111111 0.000286697247706 10 8 2
potentially,result 1.0 0.000143348623853 1 0 1
type,caution 1.0 0.000143348623853 1 0 1
if,the 0.103448275862 0.00043004587156 13 16 -3
h,exposures 1.0 0.000143348623853 0 1 -1
species,including 1.0 0.000143348623853 0 1 -1
currently,available 1.0 0.000286697247706 0 2 -2
in,anti-inflammatory 1.0 0.000143348623853 1 0 1
and,cell 1.0 0.000143348623853 0 1 -1
of,carbimazole 1.0 0.000143348623853 1 0 1
total,bioavailability 1.0 0.000143348623853 0 1 -1
could,theoretically 0.0 0.0 2 2 0
perhaps,at 1.0 0.000143348623853 0 1 -1
and,depend 1.0 0.000143348623853 0 1 -1
n,under 1.0 0.000143348623853 0 1 -1
aucs,m 1.0 0.000143348623853 1 0 1
greater,after 1.0 0.000143348623853 0 1 -1
combined,data 1.0 0.000143348623853 0 1 -1
four,patients 1.0 0.000143348623853 1 0 1
for,cytochrome 1.0 0.000286697247706 0 2 -2
or,two 0.0 0.0 1 1 0
dosage,or 1.0 0.000143348623853 0 1 -1
in,development 1.0 0.000143348623853 0 1 -1
individualizing,it 1.0 0.000143348623853 0 1 -1
dose,ranging 1.0 0.000143348623853 1 0 1
supplements,containing 1.0 0.000143348623853 1 0 1
evaluated,to 1.0 0.000143348623853 0 1 -1
inr,days 1.0 0.000143348623853 1 0 1
alert,for 1.0 0.000286697247706 0 2 -2
oral,form 1.0 0.000143348623853 1 0 1
prolonged,thrombocytopenia 1.0 0.000143348623853 0 1 -1
should,consider 0.0 0.0 2 2 0
treatments,with 1.0 0.000286697247706 0 2 -2
receiving,chronic 1.0 0.000143348623853 0 1 -1
prodrug,are 1.0 0.000143348623853 0 1 -1
aluminum-containing,administered 1.0 0.000143348623853 1 0 1
other,significant 1.0 0.000143348623853 0 1 -1
p,dmpge2 1.0 0.000143348623853 0 1 -1
in,advanced 1.0 0.000143348623853 1 0 1
bretylium,tosylate 1.0 0.000143348623853 0 1 -1
vitro,sodium 1.0 0.000143348623853 0 1 -1
least,balanced 1.0 0.000143348623853 0 1 -1
orally,as 1.0 0.000286697247706 2 0 2
blocker,on 1.0 0.000143348623853 0 1 -1
cyp3a4,therefore 1.0 0.000143348623853 0 1 -1
gallates,is 1.0 0.000143348623853 0 1 -1
blocker,of 1.0 0.000143348623853 0 1 -1
angiotensin,ii 0.333333333333 0.000143348623853 1 2 -1
and,h2 0.0 0.0 1 1 0
after,one 1.0 0.000143348623853 0 1 -1
and,charcoal 1.0 0.000143348623853 1 0 1
appreciably,metabolized 1.0 0.000143348623853 0 1 -1
minimizing,the 1.0 0.000143348623853 0 1 -1
the,orally 1.0 0.000143348623853 1 0 1
unknown,but 1.0 0.00043004587156 0 3 -3
when,hydrochloride 0.2 0.000143348623853 2 3 -1
coadministration,of 0.00709219858156 0.000143348623853 71 70 1
initial,and 1.0 0.000143348623853 1 0 1
with,n 1.0 0.000286697247706 0 2 -2
with,m 1.0 0.000143348623853 0 1 -1
with,c 1.0 0.000143348623853 0 1 -1
with,a 0.186813186813 0.0024369266055 37 54 -17
antacid,when 1.0 0.000143348623853 1 0 1
with,g 1.0 0.000143348623853 0 1 -1
with,d 1.0 0.000143348623853 1 0 1
or,red 1.0 0.000143348623853 0 1 -1
decreases,effectiveness 1.0 0.000143348623853 1 0 1
mucocutaneous,and 1.0 0.000143348623853 0 1 -1
isocarboxazid,may 1.0 0.000143348623853 0 1 -1
is,nevertheless 1.0 0.000143348623853 0 1 -1
and,azoles 1.0 0.000143348623853 0 1 -1
the,light 0.333333333333 0.000143348623853 1 2 -1
very,high 0.333333333333 0.000143348623853 1 2 -1
the,next 1.0 0.000286697247706 0 2 -2
crossover,studies 1.0 0.000143348623853 0 1 -1
certain,including 1.0 0.000860091743119 6 0 6
they,modify 1.0 0.000143348623853 1 0 1
increase,metabolism 1.0 0.000143348623853 0 1 -1
varapamil,and 1.0 0.000143348623853 0 1 -1
short-acting,adrenergic 1.0 0.000143348623853 0 1 -1
about,and 0.5 0.000286697247706 3 1 2
ontario,the 1.0 0.000143348623853 0 1 -1
potentially,toxic 0.5 0.000286697247706 1 3 -2
central,obesity 1.0 0.000143348623853 0 1 -1
drugs,are 1.0 0.000573394495413 0 4 -4
the,skin 1.0 0.000143348623853 0 1 -1
subsequently,treated 1.0 0.000143348623853 1 0 1
hcl,to 1.0 0.000143348623853 1 0 1
both,in 1.0 0.000573394495413 0 4 -4
on,multiple 1.0 0.000143348623853 0 1 -1
relationships,among 1.0 0.000143348623853 0 1 -1
antitumor,effectiveness 1.0 0.000143348623853 1 0 1
cause,hypercalcemia 1.0 0.000143348623853 1 0 1
hematemesis,hematuria 1.0 0.000143348623853 0 1 -1
cyp3a4,mg 1.0 0.000143348623853 1 0 1
closely,monitored 0.384615384615 0.000716743119266 9 4 5
reported,association 1.0 0.000143348623853 0 1 -1
concomitantly,renal 1.0 0.000143348623853 1 0 1
post-myocardial,infarction 1.0 0.000143348623853 0 1 -1
to,direct 1.0 0.000143348623853 0 1 -1
to,fluctuate 1.0 0.000143348623853 1 0 1
in,pharmacodynamic 1.0 0.000143348623853 0 1 -1
broad-spectrum,augmentin 1.0 0.000143348623853 1 0 1
inhibitors,felodipine 1.0 0.000143348623853 0 1 -1
a,together 1.0 0.000143348623853 1 0 1
during,multiple-dose 1.0 0.000143348623853 0 1 -1
the,hypotensive 0.882352941176 0.0021502293578 16 1 15
of,actinic 1.0 0.000143348623853 1 0 1
out,during 1.0 0.000143348623853 0 1 -1
the,receptor-binding 1.0 0.000143348623853 0 1 -1
previously,effective 1.0 0.000143348623853 1 0 1
of,any 1.0 0.00157683486239 0 11 -11
affected,the 1.0 0.000143348623853 1 0 1
microdosed,progestin-containing 1.0 0.000143348623853 1 0 1
hazardous,activities 1.0 0.000143348623853 0 1 -1
rifampin,reduced 1.0 0.000143348623853 1 0 1
single,mg 0.0 0.0 15 15 0
alternatively,provide 1.0 0.000143348623853 0 1 -1
or,administered 1.0 0.000143348623853 1 0 1
activity,at 1.0 0.000286697247706 0 2 -2
be,cautiously 1.0 0.000143348623853 1 0 1
people,are 1.0 0.000143348623853 0 1 -1
of,tricor 1.0 0.000143348623853 1 0 1
treated,patients 1.0 0.000143348623853 0 1 -1
may,slow 1.0 0.000143348623853 0 1 -1
affect,behaviors 1.0 0.000143348623853 0 1 -1
were,additive 1.0 0.000143348623853 0 1 -1
a4,were 1.0 0.000286697247706 0 2 -2
of,however 0.0 0.0 1 1 0
spectrum,of 1.0 0.000286697247706 0 2 -2
tid,no 1.0 0.000143348623853 0 1 -1
either,by 1.0 0.000573394495413 0 4 -4
a,multiple-dose 0.0 0.0 1 1 0
with,life-threatening 1.0 0.000143348623853 0 1 -1
acid,with 1.0 0.000143348623853 1 0 1
demonstrates,that 1.0 0.000143348623853 1 0 1
antiretroviral,drugs 1.0 0.000143348623853 1 0 1
may,still 0.0 0.0 1 1 0
possibly,other 1.0 0.000573394495413 4 0 4
rates,in 1.0 0.000143348623853 0 1 -1
either,be 1.0 0.000143348623853 1 0 1
show,elevations 1.0 0.000143348623853 1 0 1
lithium,valdecoxib 1.0 0.000143348623853 1 0 1
interaction,which 1.0 0.000143348623853 1 0 1
symptoms,suggestive 1.0 0.000143348623853 1 0 1
with,mefloquine 0.0 0.0 1 1 0
bleeding,and 0.2 0.000143348623853 2 3 -1
possible,that 0.428571428571 0.00043004587156 5 2 3
not,metabolize 1.0 0.000143348623853 0 1 -1
benign,prostatic 1.0 0.000143348623853 0 1 -1
metabolism,produced 1.0 0.000143348623853 1 0 1
sensitivity,to 0.666666666667 0.000573394495413 1 5 -4
are,limited 1.0 0.000143348623853 1 0 1
max,although 1.0 0.000143348623853 0 1 -1
a,predisposition 1.0 0.000143348623853 0 1 -1
sequential,high 1.0 0.000143348623853 1 0 1
coronary,artery 0.333333333333 0.000143348623853 1 2 -1
naproxen,coadministration 1.0 0.000143348623853 1 0 1
among,subjects 1.0 0.000143348623853 0 1 -1
can,also 1.0 0.000143348623853 1 0 1
leukocytes,and 1.0 0.000143348623853 0 1 -1
lymphoma,hiv-nhl 1.0 0.000143348623853 0 1 -1
limited,therefore 1.0 0.000143348623853 1 0 1
to,interfere 0.176470588235 0.00043004587156 7 10 -3
steadystate,trough 1.0 0.000143348623853 0 1 -1
delayed,by 1.0 0.000143348623853 0 1 -1
tc,had 1.0 0.000143348623853 0 1 -1
on,replacement 0.333333333333 0.000143348623853 1 2 -1
infants,from 1.0 0.000143348623853 0 1 -1
weakness,their 1.0 0.000143348623853 0 1 -1
inducer,mg 1.0 0.000143348623853 1 0 1
an,emergency 1.0 0.000143348623853 1 0 1
juice,have 1.0 0.000143348623853 0 1 -1
approximately,in 0.142857142857 0.000143348623853 3 4 -1
on,that 1.0 0.000143348623853 0 1 -1
vigorous,physical 1.0 0.000143348623853 0 1 -1
of,isosorbide 1.0 0.000286697247706 2 0 2
taxol,until 1.0 0.000143348623853 0 1 -1
a,previously 1.0 0.00043004587156 3 0 3
ss,of 1.0 0.000286697247706 2 0 2
this,report 0.333333333333 0.000143348623853 2 1 1
corticosteroids,systemic 1.0 0.000143348623853 0 1 -1
guidelines,are 1.0 0.000143348623853 0 1 -1
inhibitor,pi 1.0 0.000143348623853 0 1 -1
electrolyte,depletion 1.0 0.000286697247706 0 2 -2
concentrations,greater 1.0 0.000143348623853 0 1 -1
hyperplasia,of 1.0 0.000143348623853 0 1 -1
including,anafranil 1.0 0.000143348623853 0 1 -1
is,susceptible 1.0 0.000143348623853 0 1 -1
racemic,celexa 1.0 0.000143348623853 1 0 1
mononuclear,cells 0.333333333333 0.000143348623853 2 1 1
primarily,by 1.0 0.00043004587156 0 3 -3
while,avoiding 1.0 0.000143348623853 0 1 -1
clearance,by 0.666666666667 0.000573394495413 5 1 4
that,necessitated 1.0 0.000143348623853 1 0 1
at,recovery 1.0 0.000143348623853 1 0 1
a,pronounced 1.0 0.000143348623853 1 0 1
sodium,are 1.0 0.000143348623853 0 1 -1
urine,levels 1.0 0.000143348623853 1 0 1
to,slow 1.0 0.000143348623853 1 0 1
was,changed 1.0 0.000143348623853 0 1 -1
of,infection 0.0 0.0 1 1 0
anti-inflammatory,agent 1.0 0.000286697247706 2 0 2
where,appropriate 1.0 0.000143348623853 0 1 -1
in,coombs 1.0 0.000143348623853 0 1 -1
is,mmol 1.0 0.000143348623853 0 1 -1
prolonged,in 1.0 0.000143348623853 1 0 1
estradiol,concentrations 1.0 0.000143348623853 0 1 -1
actions,certain 1.0 0.000143348623853 1 0 1
by,equilibrium 1.0 0.000143348623853 0 1 -1
any,antineoplastic 1.0 0.000143348623853 0 1 -1
persisted,even 1.0 0.000143348623853 0 1 -1
another,class 1.0 0.000143348623853 1 0 1
time,must 0.6 0.00043004587156 1 4 -3
to,avoid 0.0434782608696 0.000143348623853 12 11 1
agents,medicine 1.0 0.000143348623853 0 1 -1
an,effective 1.0 0.000143348623853 0 1 -1
as,that 1.0 0.000143348623853 0 1 -1
which,directly 1.0 0.000143348623853 0 1 -1
including,ether 1.0 0.000143348623853 1 0 1
is,decreasing 1.0 0.000143348623853 0 1 -1
serum,antidepressant 1.0 0.000143348623853 1 0 1
is,currently 1.0 0.000286697247706 0 2 -2
may,diminish 1.0 0.00143348623853 10 0 10
organisation,m 1.0 0.000143348623853 0 1 -1
both,together 1.0 0.000286697247706 2 0 2
with,quantitative 1.0 0.000143348623853 0 1 -1
production,of 0.2 0.000143348623853 2 3 -1
locomotor,activity 1.0 0.00043004587156 0 3 -3
that,raise 1.0 0.000143348623853 0 1 -1
blunting,of 0.333333333333 0.000143348623853 2 1 1
level,cells 1.0 0.000143348623853 0 1 -1
tissues,to 1.0 0.000143348623853 0 1 -1
activity,towards 0.0 0.0 1 1 0
cyp2c9,substrate 1.0 0.00043004587156 3 0 3
daily,doses 0.2 0.000143348623853 2 3 -1
salicylate,and 1.0 0.000143348623853 1 0 1
spinal,endorphinergic 1.0 0.000143348623853 0 1 -1
early,as 1.0 0.000143348623853 1 0 1
prolonged,diarrhea 1.0 0.000143348623853 0 1 -1
by,acidifying 1.0 0.000286697247706 2 0 2
potentially,leading 1.0 0.000143348623853 1 0 1
unchanged,the 1.0 0.000143348623853 0 1 -1
the,pituitary 1.0 0.000143348623853 0 1 -1
low,dietary 1.0 0.000143348623853 0 1 -1
psychoactive,or 1.0 0.000143348623853 1 0 1
grams,three 1.0 0.000143348623853 1 0 1
permeability,and 1.0 0.000143348623853 0 1 -1
decreased,even 1.0 0.000143348623853 1 0 1
activity,and 0.428571428571 0.00043004587156 2 5 -3
to,protein 1.0 0.000143348623853 1 0 1
marrow,toxicity 1.0 0.000143348623853 0 1 -1
oral,diabetes 1.0 0.000143348623853 1 0 1
and,volume 1.0 0.000143348623853 1 0 1
that,inhibit 0.625 0.00286697247706 6 26 -20
relevant,drug-drug 1.0 0.000143348623853 0 1 -1
avoided,except 1.0 0.000143348623853 1 0 1
well,tolerated 0.5 0.000286697247706 1 3 -2
hypotension,induced 1.0 0.000143348623853 1 0 1
in,safety 1.0 0.000143348623853 0 1 -1
and,like 1.0 0.000143348623853 0 1 -1
pregnancy,tests 1.0 0.000143348623853 0 1 -1
of,faslodex 1.0 0.000143348623853 0 1 -1
that,alcoholic 1.0 0.000143348623853 0 1 -1
high-density,lipoproteins 1.0 0.000143348623853 0 1 -1
tests,using 1.0 0.000286697247706 0 2 -2
ethyl,mao 1.0 0.000143348623853 1 0 1
progressing,to 1.0 0.000143348623853 1 0 1
fludara,for 1.0 0.000143348623853 1 0 1
humira,has 1.0 0.000286697247706 0 2 -2
patient,had 1.0 0.000286697247706 0 2 -2
of,have 0.111111111111 0.000286697247706 8 10 -2
serum,activity 1.0 0.000143348623853 0 1 -1
were,dry 1.0 0.000143348623853 0 1 -1
inositol,trisphosphate 1.0 0.000286697247706 0 2 -2
discernible,changes 1.0 0.000143348623853 0 1 -1
from,trials 1.0 0.000143348623853 0 1 -1
all,when 1.0 0.000143348623853 1 0 1
of,female 1.0 0.000286697247706 0 2 -2
spermine,promotes 1.0 0.000143348623853 0 1 -1
neonates,with 1.0 0.000143348623853 0 1 -1
resulting,increase 1.0 0.000286697247706 0 2 -2
manufacturer,or 1.0 0.000143348623853 0 1 -1
of,ptx 1.0 0.000143348623853 0 1 -1
indications,are 1.0 0.000143348623853 0 1 -1
effects,although 1.0 0.000143348623853 0 1 -1
wishing,to 1.0 0.000143348623853 0 1 -1
by,single 0.0 0.0 1 1 0
cns-depressive,effects 1.0 0.000143348623853 1 0 1
brovana,has 1.0 0.000143348623853 0 1 -1
and,intracellular 1.0 0.000143348623853 0 1 -1
temperature,and 1.0 0.000143348623853 1 0 1
might,induce 1.0 0.000143348623853 0 1 -1
combined,use 0.8 0.00114678899083 9 1 8
limbic,system 1.0 0.000286697247706 0 2 -2
whole-cell,tight 1.0 0.000286697247706 0 2 -2
pathways,which 1.0 0.000143348623853 0 1 -1
most,automated 1.0 0.000143348623853 0 1 -1
increased,from 0.333333333333 0.000143348623853 1 2 -1
fortovase,as 1.0 0.000143348623853 0 1 -1
accidents,six 1.0 0.000143348623853 0 1 -1
male,partners 1.0 0.000143348623853 0 1 -1
tests,interactions 1.0 0.000573394495413 0 4 -4
the,dosing 1.0 0.000143348623853 1 0 1
not,so 1.0 0.000143348623853 0 1 -1
clinical,laboratory 1.0 0.000716743119266 0 5 -5
r-value,of 1.0 0.000286697247706 0 2 -2
of,ast 1.0 0.000143348623853 0 1 -1
pharmacological,actions 1.0 0.000143348623853 0 1 -1
when,they 0.2 0.000143348623853 3 2 1
separate,studies 1.0 0.000286697247706 0 2 -2
inhibition,inhibition 1.0 0.000143348623853 0 1 -1
in,tarceva 1.0 0.000143348623853 0 1 -1
all,of 1.0 0.000143348623853 0 1 -1
of,soriatane 1.0 0.000143348623853 0 1 -1
non-aspergillus,polysaccharides 1.0 0.000143348623853 0 1 -1
recently,instituted 1.0 0.000573394495413 4 0 4
double,strength 1.0 0.000143348623853 0 1 -1
potassium-depleted,solution 1.0 0.000143348623853 0 1 -1
zebeta,resulting 1.0 0.000143348623853 1 0 1
aids-related,kaposi 1.0 0.000143348623853 0 1 -1
a,decrease 0.515151515152 0.0024369266055 25 8 17
and,mixed--pharmacological 1.0 0.000143348623853 0 1 -1
rr,had 1.0 0.000143348623853 0 1 -1
complications,have 1.0 0.000143348623853 0 1 -1
notably,systemic 1.0 0.000143348623853 0 1 -1
which,suggests 1.0 0.000143348623853 1 0 1
displacement,between 1.0 0.000143348623853 0 1 -1
predisposed,mice 1.0 0.000286697247706 0 2 -2
weekly,for 0.333333333333 0.000143348623853 1 2 -1
novolog,should 1.0 0.00043004587156 0 3 -3
indinavir,coadministration 1.0 0.000143348623853 1 0 1
maoi,such 1.0 0.000143348623853 0 1 -1
those,aspects 1.0 0.000143348623853 0 1 -1
of,rheumatoid 1.0 0.000143348623853 0 1 -1
events,are 1.0 0.000286697247706 0 2 -2
are,advisable 1.0 0.00043004587156 0 3 -3
racemic,mg 0.2 0.000143348623853 2 3 -1
in,those 0.142857142857 0.000143348623853 4 3 1
be,free 1.0 0.000143348623853 0 1 -1
of,agranulocytosis 1.0 0.000143348623853 0 1 -1
in,erythro-fluorocitrate 1.0 0.000143348623853 0 1 -1
synergistic,activity 1.0 0.000286697247706 2 0 2
interaction,of 0.333333333333 0.00114678899083 8 16 -8
trials,and 1.0 0.00043004587156 0 3 -3
bid,decreased 1.0 0.000143348623853 1 0 1
interaction,on 0.333333333333 0.000143348623853 1 2 -1
inducers,may 1.0 0.000143348623853 0 1 -1
children,who 1.0 0.000143348623853 0 1 -1
secretory,effect 1.0 0.000143348623853 1 0 1
sprycel,dose 1.0 0.000143348623853 0 1 -1
cns-depressant,should 1.0 0.000143348623853 1 0 1
in,rabbits 1.0 0.000286697247706 0 2 -2
acid,depakene 1.0 0.000143348623853 0 1 -1
those,that 1.0 0.000143348623853 0 1 -1
be,more 0.6 0.000860091743119 2 8 -6
days,with 0.0 0.0 4 4 0
higher,absolute 1.0 0.000143348623853 0 1 -1
regimens,consisted 1.0 0.000143348623853 0 1 -1
therapeutic,index 0.2 0.000143348623853 2 3 -1
require,careful 1.0 0.000143348623853 0 1 -1
report,suggesting 1.0 0.000143348623853 1 0 1
naltrexone,trexan 1.0 0.000143348623853 0 1 -1
following,a 0.4 0.000573394495413 3 7 -4
gleevec,inhibits 1.0 0.000286697247706 0 2 -2
on,plasma 0.866666666667 0.00186353211009 1 14 -13
cgs,nor 1.0 0.000143348623853 1 0 1
the,duodenum 1.0 0.000143348623853 0 1 -1
concurrently,did 1.0 0.000143348623853 0 1 -1
long-sedation,time 1.0 0.000143348623853 0 1 -1
after,discontinuation 1.0 0.000143348623853 0 1 -1
mice,did 1.0 0.000286697247706 0 2 -2
of,rats 0.0 0.0 2 2 0
x,ed95 1.0 0.000143348623853 1 0 1
a,number 0.0 0.0 5 5 0
inhibitor,mg 1.0 0.000286697247706 2 0 2
important,factors 1.0 0.000143348623853 0 1 -1
in,functional 0.6 0.00043004587156 1 4 -3
capsules,is 1.0 0.000143348623853 1 0 1
be,lowered 1.0 0.000143348623853 0 1 -1
although,beta-adrenergic 1.0 0.000143348623853 1 0 1
from,prefrontal 1.0 0.000143348623853 0 1 -1
resting,membrane 1.0 0.000143348623853 0 1 -1
measurement,must 1.0 0.000143348623853 0 1 -1
rats,prepared 1.0 0.000143348623853 0 1 -1
fr,responding 0.0 0.0 1 1 0
subnormal,pancreatic 1.0 0.000143348623853 0 1 -1
was,discussed 1.0 0.000143348623853 0 1 -1
several,with 1.0 0.000143348623853 0 1 -1
human,ventricular 1.0 0.000143348623853 0 1 -1
but,serious 1.0 0.000143348623853 1 0 1
of,pancreatitis 1.0 0.000143348623853 0 1 -1
equipment,for 1.0 0.000143348623853 0 1 -1
or,glycosides 1.0 0.000143348623853 0 1 -1
albendazole,mg 1.0 0.000143348623853 1 0 1
the,analyte 1.0 0.000143348623853 0 1 -1
embryo,fetal 1.0 0.000143348623853 0 1 -1
a,hypothyroid 1.0 0.000143348623853 0 1 -1
aptt,such 1.0 0.000143348623853 0 1 -1
increases,both 1.0 0.000143348623853 1 0 1
adjustment,of 0.155555555556 0.00100344036697 19 26 -7
of,flushing 1.0 0.000143348623853 0 1 -1
after,stopping 1.0 0.00043004587156 3 0 3
that,cyp1a2 1.0 0.000143348623853 1 0 1
enbrel,and 1.0 0.000286697247706 2 0 2
kidney,which 1.0 0.000143348623853 0 1 -1
but,presumably 1.0 0.000143348623853 0 1 -1
milk,milk 1.0 0.000143348623853 1 0 1
disorder,and 1.0 0.000143348623853 0 1 -1
the,liver 0.428571428571 0.000860091743119 4 10 -6
for,older 1.0 0.000286697247706 0 2 -2
both,therapeutic 1.0 0.00043004587156 0 3 -3
the,chop 1.0 0.000286697247706 0 2 -2
begins,a 0.2 0.000143348623853 2 3 -1
the,actions 0.5 0.000286697247706 1 3 -2
be,based 1.0 0.000143348623853 0 1 -1
aprepitant,was 0.2 0.000143348623853 2 3 -1
significant,inhibitory 1.0 0.000143348623853 0 1 -1
significant,inhibitors 1.0 0.000143348623853 0 1 -1
auc,values 0.0 0.0 4 4 0
clinical,drug-drug 1.0 0.000143348623853 0 1 -1
efficacy,although 1.0 0.000143348623853 0 1 -1
of,fluorescence 1.0 0.000143348623853 0 1 -1
of,safe 1.0 0.000143348623853 0 1 -1
of,hoof 1.0 0.000143348623853 1 0 1
days,was 1.0 0.000286697247706 2 0 2
maois,or 1.0 0.000143348623853 1 0 1
dexamethasone,at 1.0 0.000143348623853 1 0 1
serum,deprivation 1.0 0.000143348623853 0 1 -1
toxicity,than 1.0 0.000143348623853 1 0 1
deleterious,interactions 1.0 0.000143348623853 0 1 -1
dog,treated 1.0 0.000143348623853 0 1 -1
time,after 1.0 0.000143348623853 1 0 1
edema,it 1.0 0.000143348623853 1 0 1
in,eagles 1.0 0.000143348623853 0 1 -1
dose,reduction 0.0769230769231 0.000143348623853 6 7 -1
close,medical 0.0 0.0 1 1 0
ci,when 1.0 0.000143348623853 1 0 1
erythromycin,use 1.0 0.000143348623853 1 0 1
detrimental,for 1.0 0.000143348623853 0 1 -1
medicines,when 1.0 0.000143348623853 0 1 -1
plenaxis,should 1.0 0.000143348623853 0 1 -1
and,extracellular 1.0 0.000143348623853 0 1 -1
hcl,alternatives 1.0 0.000143348623853 1 0 1
was,continued 1.0 0.000143348623853 0 1 -1
is,discontinued 1.0 0.000143348623853 1 0 1
with,narrow 0.5 0.000286697247706 1 3 -2
the,electrocardiographic 1.0 0.000286697247706 0 2 -2
during,muscle 1.0 0.000143348623853 0 1 -1
and,contraindications 1.0 0.000143348623853 0 1 -1
inhibitors,amprenavir 1.0 0.000143348623853 1 0 1
nine,additional 1.0 0.000143348623853 0 1 -1
sgpt,alt 1.0 0.000286697247706 2 0 2
of,nmda-ergic 1.0 0.000143348623853 0 1 -1
assessed,using 1.0 0.000143348623853 1 0 1
concurrently,and 0.333333333333 0.000143348623853 1 2 -1
ephedrine,ephedrine 1.0 0.000143348623853 1 0 1
regimen,may 1.0 0.000286697247706 0 2 -2
alterations,in 0.578947368421 0.00157683486239 4 15 -11
has,undergone 1.0 0.000143348623853 0 1 -1
copegus,and 1.0 0.000143348623853 1 0 1
edemas,that 1.0 0.000143348623853 1 0 1
of,enterococcus 1.0 0.000286697247706 0 2 -2
of,exogenously 1.0 0.000143348623853 0 1 -1
the,hydrophilic 1.0 0.000143348623853 0 1 -1
mainly,via 1.0 0.000286697247706 0 2 -2
multiple-dose,administration 0.0 0.0 1 1 0
certain,that 0.333333333333 0.000143348623853 1 2 -1
infrequent,reports 1.0 0.000143348623853 0 1 -1
of,metabolic 1.0 0.000286697247706 0 2 -2
not,higher 1.0 0.000143348623853 0 1 -1
effector,ieg 1.0 0.000143348623853 0 1 -1
suggest,the 1.0 0.000286697247706 0 2 -2
hand,intrathecal 1.0 0.000143348623853 1 0 1
toxicity,brain 1.0 0.000143348623853 0 1 -1
unless,clinically 1.0 0.000143348623853 1 0 1
and,consisted 1.0 0.000143348623853 0 1 -1
basal,plasma 1.0 0.000286697247706 0 2 -2
induced,a 1.0 0.000286697247706 0 2 -2
by,one-half 1.0 0.000143348623853 0 1 -1
breakthrough,symptoms 1.0 0.000143348623853 0 1 -1
products,such 0.333333333333 0.000143348623853 1 2 -1
enzyme,prolongs 1.0 0.000143348623853 0 1 -1
with,would 0.0 0.0 1 1 0
accuracy,in 1.0 0.000143348623853 1 0 1
considered,when 0.0 0.0 7 7 0
a,watery 1.0 0.000286697247706 0 2 -2
cholinergic,blockade 1.0 0.000143348623853 1 0 1
intoxication,prior 1.0 0.000143348623853 1 0 1
mcg,im 0.0 0.0 1 1 0
an,interaction 0.333333333333 0.000716743119266 5 10 -5
require,close 1.0 0.000143348623853 1 0 1
in,etodolac-treated 1.0 0.000143348623853 1 0 1
previous,extravasation 1.0 0.000143348623853 0 1 -1
occurrence,has 1.0 0.000143348623853 1 0 1
immediate-early,gene 1.0 0.000143348623853 0 1 -1
swelling,at 1.0 0.000143348623853 0 1 -1
phenytoin,steady 1.0 0.000143348623853 1 0 1
short-acting,because 1.0 0.000143348623853 1 0 1
group,took 1.0 0.000143348623853 0 1 -1
placebo-controlled,crossover 1.0 0.000143348623853 1 0 1
were,transient 1.0 0.000143348623853 1 0 1
augmented,by 1.0 0.00043004587156 3 0 3
receiving,concurrent 0.0 0.0 2 2 0
intensive,monitoring 1.0 0.000143348623853 0 1 -1
control,and 0.6 0.00043004587156 1 4 -3
not,include 1.0 0.000143348623853 0 1 -1
ml,for 1.0 0.000286697247706 0 2 -2
exception,of 1.0 0.00043004587156 0 3 -3
secretion,was 1.0 0.000143348623853 0 1 -1
and,where 1.0 0.000143348623853 0 1 -1
by,alpha-adrenergic 1.0 0.000143348623853 1 0 1
d6,a4 1.0 0.00043004587156 0 3 -3
combined,administration 0.5 0.000573394495413 2 6 -4
the,homocysteine 1.0 0.000143348623853 0 1 -1
including,were 0.0 0.0 1 1 0
cautioned,regarding 1.0 0.000143348623853 0 1 -1
fully,formed 1.0 0.000143348623853 0 1 -1
of,sonata 0.142857142857 0.000143348623853 3 4 -1
all,with 1.0 0.000143348623853 1 0 1
ii,to 1.0 0.000286697247706 0 2 -2
in,average 1.0 0.000143348623853 1 0 1
bodies,in 1.0 0.000143348623853 0 1 -1
to,insure 1.0 0.000143348623853 1 0 1
b23,is 1.0 0.000143348623853 0 1 -1
c23,in 1.0 0.000143348623853 0 1 -1
ethyl,is 1.0 0.000143348623853 0 1 -1
of,deficit 1.0 0.000286697247706 0 2 -2
mg,dose 0.0 0.0 15 15 0
trypanosomiasis,in 1.0 0.000143348623853 0 1 -1
the,biliary 1.0 0.000143348623853 0 1 -1
his,own 1.0 0.000143348623853 0 1 -1
adefovir,dipivoxil 1.0 0.000143348623853 0 1 -1
metabolites,induce 1.0 0.000143348623853 0 1 -1
with,standard 1.0 0.00043004587156 0 3 -3
were,reported 0.5 0.000573394495413 2 6 -4
that,produce 1.0 0.00043004587156 3 0 3
other,nephrotoxic 1.0 0.000143348623853 0 1 -1
the,immune 1.0 0.000286697247706 0 2 -2
oral,physiological 1.0 0.000143348623853 0 1 -1
rats,with 0.333333333333 0.000143348623853 2 1 1
granulomata,subacute 1.0 0.000143348623853 0 1 -1
without,climbing 1.0 0.000143348623853 0 1 -1
who,inactivate 1.0 0.000143348623853 1 0 1
the,measurable 1.0 0.000143348623853 1 0 1
imipramine,and 1.0 0.000143348623853 0 1 -1
to,both 0.0 0.0 1 1 0
over,pi-based 1.0 0.000143348623853 0 1 -1
clinic,is 1.0 0.000143348623853 0 1 -1
is,likely 0.272727272727 0.00043004587156 7 4 3
affect,plasma 0.0 0.0 2 2 0
also,known 1.0 0.000286697247706 0 2 -2
acid,did 1.0 0.000143348623853 0 1 -1
synthetic,analogue 1.0 0.000143348623853 0 1 -1
or,the 0.135135135135 0.000716743119266 16 21 -5
to,one-fourth 1.0 0.000143348623853 1 0 1
sulfate,tests 1.0 0.000143348623853 0 1 -1
avoided,unless 1.0 0.000286697247706 2 0 2
and,cytoplasmic 1.0 0.000143348623853 0 1 -1
protein,the 1.0 0.000143348623853 1 0 1
events,was 1.0 0.000143348623853 0 1 -1
example,when 1.0 0.000143348623853 1 0 1
consuming,while 1.0 0.000143348623853 1 0 1
before,starting 0.2 0.000143348623853 3 2 1
aprepitant,with 0.0 0.0 4 4 0
unchanged,accounts 1.0 0.000143348623853 0 1 -1
for,these 0.0 0.0 1 1 0
agonist,can 1.0 0.000143348623853 1 0 1
take,by 1.0 0.000143348623853 1 0 1
cholesterol,concentration 1.0 0.000286697247706 0 2 -2
warrant,dosage 1.0 0.000143348623853 1 0 1
diminished,when 1.0 0.000143348623853 1 0 1
cells,resistant 1.0 0.000143348623853 0 1 -1
information,was 1.0 0.000286697247706 0 2 -2
whole,body 1.0 0.000143348623853 0 1 -1
also,appears 1.0 0.000143348623853 0 1 -1
gain,and 0.0 0.0 1 1 0
the,vascular 1.0 0.000143348623853 1 0 1
tysabri,clearance 1.0 0.000143348623853 1 0 1
significant,decrease 0.0 0.0 4 4 0
a,necessary 1.0 0.000143348623853 0 1 -1
celebrex,did 1.0 0.000143348623853 0 1 -1
as,three 1.0 0.000143348623853 1 0 1
on,prothrombin 1.0 0.00043004587156 0 3 -3
unlikely,for 1.0 0.000143348623853 0 1 -1
agonists,at 1.0 0.000143348623853 1 0 1
with,can 0.0 0.0 2 2 0
interval,has 1.0 0.000143348623853 0 1 -1
two-second,increase 1.0 0.000143348623853 1 0 1
redistribution,accumulation 1.0 0.000143348623853 0 1 -1
analyzed,in 1.0 0.000143348623853 0 1 -1
reduced,higher 1.0 0.00043004587156 0 3 -3
the,for 1.0 0.000143348623853 0 1 -1
was,not 0.846153846154 0.00315366972477 2 24 -22
cell,infiltration 1.0 0.000143348623853 0 1 -1
nimbex,are 1.0 0.000143348623853 1 0 1
supplements,can 1.0 0.00043004587156 0 3 -3
reversed,by 1.0 0.000143348623853 1 0 1
pseudotumor,cerebri 1.0 0.000143348623853 1 0 1
stopped,during 1.0 0.000143348623853 1 0 1
study,evaluating 1.0 0.000286697247706 2 0 2
serum,and 0.4 0.000573394495413 3 7 -4
neuronal,reuptake 1.0 0.000143348623853 0 1 -1
immediately,before 1.0 0.000143348623853 0 1 -1
primidone,no 1.0 0.000143348623853 0 1 -1
medications,like 1.0 0.00043004587156 3 0 3
specific,regulation 1.0 0.000143348623853 0 1 -1
decreased,urinary 1.0 0.000143348623853 0 1 -1
used,alone 1.0 0.000286697247706 2 0 2
literature,provides 1.0 0.000143348623853 0 1 -1
balance,were 1.0 0.000143348623853 0 1 -1
infections,caused 1.0 0.000143348623853 0 1 -1
blood,concentration-time 1.0 0.000143348623853 0 1 -1
alter,plasma 1.0 0.000143348623853 1 0 1
mac,with 1.0 0.000143348623853 0 1 -1
less,than 0.222222222222 0.000573394495413 7 11 -4
antipsychotic,such 1.0 0.000143348623853 0 1 -1
estrogens,including 1.0 0.000143348623853 1 0 1
clearance,were 1.0 0.000143348623853 0 1 -1
in,fat 1.0 0.000143348623853 0 1 -1
worsened,by 0.0 0.0 1 1 0
if,concomitant 0.272727272727 0.00043004587156 4 7 -3
g,per 1.0 0.000143348623853 0 1 -1
responsive,to 1.0 0.000143348623853 0 1 -1
study,concomitant 0.0 0.0 1 1 0
of,time 0.333333333333 0.000143348623853 1 2 -1
implications,for 1.0 0.00043004587156 0 3 -3
the,platelets 1.0 0.000143348623853 0 1 -1
in,qtc 1.0 0.000143348623853 1 0 1
will,affect 1.0 0.000143348623853 1 0 1
hyperglycemia,has 1.0 0.000143348623853 0 1 -1
an,individual 1.0 0.000860091743119 0 6 -6
to,elevate 1.0 0.000143348623853 1 0 1
ect,and 1.0 0.000143348623853 0 1 -1
not,outweigh 1.0 0.000143348623853 1 0 1
its,use 1.0 0.00043004587156 0 3 -3
which,in 1.0 0.000143348623853 1 0 1
large,well 1.0 0.000143348623853 0 1 -1
eg,commonly 1.0 0.000143348623853 1 0 1
tablets,administration 1.0 0.000143348623853 1 0 1
ventricular,arrhythmias 0.428571428571 0.00043004587156 2 5 -3
diminution,is 1.0 0.000286697247706 0 2 -2
sodium,injection 1.0 0.000143348623853 0 1 -1
sulfate,sulfate 0.0 0.0 1 1 0
endothelium,from 1.0 0.000143348623853 1 0 1
measures,have 1.0 0.000143348623853 0 1 -1
which,is 0.8 0.00114678899083 1 9 -8
dexamethasone,and 1.0 0.000143348623853 1 0 1
which,it 1.0 0.000286697247706 0 2 -2
evaluated,cyps 1.0 0.000143348623853 0 1 -1
anticoagulation,levels 0.0 0.0 1 1 0
with,orencia 0.333333333333 0.000143348623853 2 1 1
than,to 1.0 0.000143348623853 0 1 -1
valproate,the 1.0 0.000143348623853 1 0 1
as,early 1.0 0.000143348623853 1 0 1
arachidonate-,or 1.0 0.000143348623853 0 1 -1
turn,out 1.0 0.000143348623853 0 1 -1
injection,like 1.0 0.000143348623853 1 0 1
cautious,and 1.0 0.000143348623853 0 1 -1
mind,when 1.0 0.00043004587156 0 3 -3
undesirable,involving 1.0 0.000286697247706 0 2 -2
approximately,half 1.0 0.00043004587156 0 3 -3
placental,vessels 0.0 0.0 1 1 0
findings,and 1.0 0.000143348623853 0 1 -1
to,elucidate 1.0 0.000143348623853 0 1 -1
cat,inferior 1.0 0.000143348623853 0 1 -1
nephrotoxic,medications 1.0 0.000143348623853 0 1 -1
psychopathology,rating 1.0 0.000143348623853 0 1 -1
decreased,reflecting 1.0 0.000573394495413 0 4 -4
dose,with 1.0 0.000143348623853 0 1 -1
collagen-induced,platelet 1.0 0.000143348623853 0 1 -1
hospitals,resulting 1.0 0.000143348623853 0 1 -1
control,by 1.0 0.000286697247706 2 0 2
dst,should 1.0 0.000286697247706 0 2 -2
hydatid,cyst 1.0 0.000143348623853 1 0 1
the,sensitivity 1.0 0.000286697247706 0 2 -2
patients,where 1.0 0.000143348623853 0 1 -1
inhibit,alfenta 1.0 0.000143348623853 1 0 1
transient,hypotensive 1.0 0.000143348623853 0 1 -1
rifampin,significantly 1.0 0.000143348623853 1 0 1
study,healthy 1.0 0.000286697247706 0 2 -2
with,co-administration 0.142857142857 0.000143348623853 4 3 1
induced,agranulocytosis 1.0 0.000143348623853 0 1 -1
products,could 1.0 0.000143348623853 1 0 1
lipolytic,activity 1.0 0.000143348623853 1 0 1
initiated,in 1.0 0.000716743119266 5 0 5
were,neither 1.0 0.000143348623853 1 0 1
while,all 1.0 0.000716743119266 0 5 -5
grade,according 1.0 0.000143348623853 0 1 -1
parenteral,forms 1.0 0.000143348623853 0 1 -1
hydroxy-corticosteroid,measurements 1.0 0.000143348623853 0 1 -1
cimetidine,inhibits 1.0 0.000286697247706 2 0 2
mixed,agonist 0.0 0.0 1 1 0
lymphopenia,proper 1.0 0.000143348623853 0 1 -1
be,minimized 1.0 0.000860091743119 6 0 6
of,cleavable 1.0 0.000143348623853 0 1 -1
false-positive,direct 1.0 0.000286697247706 0 2 -2
fetal,development 1.0 0.00043004587156 0 3 -3
to,dictate 1.0 0.000143348623853 1 0 1
under,a 1.0 0.000143348623853 0 1 -1
disease,has 1.0 0.000143348623853 1 0 1
the,modulation 0.0 0.0 1 1 0
load,constitutes 1.0 0.000143348623853 0 1 -1
brevibloc,esmolol 1.0 0.000143348623853 0 1 -1
very,rarely 1.0 0.000143348623853 1 0 1
lymphoma,that 1.0 0.000143348623853 0 1 -1
in,blood 0.142857142857 0.000143348623853 4 3 1
molecular,level 1.0 0.000143348623853 0 1 -1
produced,transient 1.0 0.000143348623853 0 1 -1
and,produces 1.0 0.000143348623853 1 0 1
be,safely 1.0 0.00043004587156 0 3 -3
intervention,in 1.0 0.000143348623853 0 1 -1
determined,by 1.0 0.00100344036697 0 7 -7
with,conventional 1.0 0.000143348623853 0 1 -1
possible,rapid 1.0 0.000143348623853 1 0 1
a,shorter 1.0 0.000143348623853 0 1 -1
following,medicines 1.0 0.000143348623853 1 0 1
tests,to 1.0 0.000143348623853 0 1 -1
rate-decreasing,effects 1.0 0.000143348623853 1 0 1
axons,of 1.0 0.000143348623853 0 1 -1
bleeding,events 0.5 0.000286697247706 3 1 2
halved,for 1.0 0.000143348623853 1 0 1
a,multi-day 1.0 0.000143348623853 1 0 1
mediated,responses 1.0 0.000143348623853 0 1 -1
commonly,involved 1.0 0.000143348623853 0 1 -1
ssris,have 0.5 0.000286697247706 3 1 2
poc,in 1.0 0.000143348623853 0 1 -1
oral,dose 0.272727272727 0.00043004587156 4 7 -3
or,by 1.0 0.000860091743119 0 6 -6
with,reported 1.0 0.000143348623853 0 1 -1
and,formulations 1.0 0.000143348623853 1 0 1
or,be 1.0 0.000286697247706 0 2 -2
the,was 1.0 0.000286697247706 0 2 -2
hydroalcoholic,solutions 1.0 0.000286697247706 0 2 -2
be,monitored 0.127272727273 0.00100344036697 31 24 7
v,oral 1.0 0.000143348623853 1 0 1
instead,of 1.0 0.000143348623853 1 0 1
required,infusion 1.0 0.000143348623853 1 0 1
cerubidine,in 1.0 0.000143348623853 1 0 1
as,pure 1.0 0.000143348623853 1 0 1
therapy,compliance 1.0 0.000143348623853 0 1 -1
first,year 1.0 0.000143348623853 0 1 -1
with,similar 0.333333333333 0.000143348623853 1 2 -1
total,gsh 1.0 0.000143348623853 0 1 -1
caution,must 1.0 0.000143348623853 0 1 -1
including,nalidixic 1.0 0.000143348623853 1 0 1
multifaceted,and 1.0 0.000143348623853 0 1 -1
milk,and 1.0 0.000286697247706 0 2 -2
hg,higher 1.0 0.000143348623853 0 1 -1
cyp3a4,activity 0.230769230769 0.00043004587156 5 8 -3
additional,titration 1.0 0.000143348623853 1 0 1
cytochrome,p450-mediated 1.0 0.000286697247706 0 2 -2
in,combinations 1.0 0.000143348623853 0 1 -1
carcinogen,may 1.0 0.000143348623853 0 1 -1
significantly,smaller 1.0 0.000143348623853 0 1 -1
relevance,to 1.0 0.000143348623853 0 1 -1
cancidas,did 1.0 0.000143348623853 0 1 -1
since,a 1.0 0.000286697247706 0 2 -2
between,two 1.0 0.000143348623853 0 1 -1
oral,containing 0.0 0.0 2 2 0
is,structurally 1.0 0.000286697247706 0 2 -2
lesions,as 1.0 0.000143348623853 1 0 1
beta-lactam,including 1.0 0.000143348623853 1 0 1
hind,limb 1.0 0.000143348623853 0 1 -1
the,toxic 0.2 0.000143348623853 3 2 1
the,intervals 1.0 0.000143348623853 0 1 -1
being,the 1.0 0.000143348623853 0 1 -1
cyp3a,the 1.0 0.000143348623853 0 1 -1
herb,nutraceutical 1.0 0.000143348623853 0 1 -1
if,dosage 1.0 0.000143348623853 1 0 1
drowsiness,may 1.0 0.000143348623853 0 1 -1
doses,corresponding 1.0 0.000143348623853 0 1 -1
hydroxylation,of 1.0 0.000143348623853 1 0 1
serious,infections 1.0 0.000716743119266 5 0 5
the,ferricyanide 1.0 0.000286697247706 0 2 -2
patients,before 1.0 0.000143348623853 0 1 -1
results,of 0.5 0.00143348623853 5 15 -10
antidepressant,may 1.0 0.00043004587156 0 3 -3
areas,examines 1.0 0.000143348623853 0 1 -1
or,statistically 1.0 0.000143348623853 0 1 -1
have,secondary 1.0 0.000143348623853 1 0 1
used,because 1.0 0.000143348623853 1 0 1
a,subset 1.0 0.00114678899083 0 8 -8
mean,cmax 1.0 0.00114678899083 8 0 8
repeated,oral 1.0 0.000143348623853 0 1 -1
on,fertility 1.0 0.000143348623853 0 1 -1
taking,while 1.0 0.000286697247706 2 0 2
cardiopulmonary,stimulation 1.0 0.000143348623853 0 1 -1
bepridil,and 1.0 0.000143348623853 0 1 -1
the,permeation 1.0 0.000143348623853 0 1 -1
disease,treated 1.0 0.000143348623853 0 1 -1
suggested,with 1.0 0.00043004587156 0 3 -3
that,iressa 1.0 0.000143348623853 1 0 1
benzyl,has 1.0 0.000143348623853 0 1 -1
hyperglycemia,in 1.0 0.000143348623853 0 1 -1
increased,levels 0.0 0.0 3 3 0
the,medicines 1.0 0.000143348623853 0 1 -1
protein,eszopiclone 1.0 0.000143348623853 0 1 -1
b,were 1.0 0.000143348623853 0 1 -1
fixed,daily 1.0 0.000143348623853 0 1 -1
organophosphate,and 1.0 0.000143348623853 1 0 1
second,in 1.0 0.000143348623853 0 1 -1
models,are 1.0 0.000143348623853 0 1 -1
reversible,impairment 1.0 0.000143348623853 1 0 1
significantly,metabolized 1.0 0.000143348623853 0 1 -1
usually,only 1.0 0.000143348623853 0 1 -1
brief,psychiatric 1.0 0.000143348623853 1 0 1
all,the 1.0 0.00114678899083 0 8 -8
medicines,central 1.0 0.000143348623853 1 0 1
available,agents 1.0 0.000143348623853 0 1 -1
agonists,concomitant 1.0 0.000143348623853 1 0 1
a,tnf 1.0 0.000143348623853 1 0 1
what,would 1.0 0.000143348623853 0 1 -1
dyspnea,concomitant 1.0 0.000143348623853 1 0 1
by,fold 1.0 0.000860091743119 6 0 6
and,upon 1.0 0.000143348623853 1 0 1
whom,aminoglycoside 1.0 0.000143348623853 1 0 1
tumors,seen 1.0 0.000143348623853 0 1 -1
insulin-dependent,diabetic 1.0 0.000143348623853 0 1 -1
particularly,c-17 1.0 0.000143348623853 0 1 -1
congestive,heart 0.0 0.0 3 3 0
are,predictable 1.0 0.000143348623853 0 1 -1
absorption,but 1.0 0.000143348623853 0 1 -1
nevirapine,or 1.0 0.000143348623853 0 1 -1
hour,of 1.0 0.000143348623853 0 1 -1
x,xii 1.0 0.000286697247706 0 2 -2
using,pcp 1.0 0.000143348623853 0 1 -1
impairs,metabolism 1.0 0.000143348623853 0 1 -1
or,azoles 1.0 0.000143348623853 0 1 -1
those,seen 1.0 0.00043004587156 3 0 3
significantly,affects 1.0 0.000143348623853 0 1 -1
and,vanillylmandelic 1.0 0.000143348623853 0 1 -1
bexarotene,oxidative 1.0 0.000143348623853 0 1 -1
forms,of 1.0 0.000573394495413 0 4 -4
preterm,neonates 1.0 0.000143348623853 0 1 -1
the,weekly 1.0 0.000143348623853 1 0 1
designs,can 1.0 0.000286697247706 0 2 -2
androgens,may 1.0 0.000286697247706 0 2 -2
agents,pharmacokinetic 1.0 0.000143348623853 0 1 -1
thus,results 1.0 0.000286697247706 0 2 -2
agent,has 0.2 0.000143348623853 3 2 1
profound,sedation 0.0 0.0 1 1 0
preferably,the 1.0 0.000143348623853 0 1 -1
test,interactions 0.960784313725 0.00702408256881 1 50 -49
kidney,function 1.0 0.000286697247706 0 2 -2
rr,on 1.0 0.000143348623853 0 1 -1
progestin-only,oral 1.0 0.000286697247706 0 2 -2
may,be 0.221757322176 0.00759747706422 93 146 -53
others,or 1.0 0.000286697247706 0 2 -2
nor,other 1.0 0.000143348623853 0 1 -1
functional,or 1.0 0.000143348623853 0 1 -1
these,groups 1.0 0.000143348623853 0 1 -1
collected,for 1.0 0.000143348623853 0 1 -1
the,metabolite 1.0 0.000286697247706 0 2 -2
daily,treatment 1.0 0.000143348623853 0 1 -1
intraperitoneally,ip 1.0 0.000143348623853 1 0 1
on,renal 0.333333333333 0.000143348623853 2 1 1
hypothyroid,it 1.0 0.000143348623853 0 1 -1
unknown,and 1.0 0.000143348623853 1 0 1
additionally,brevibloc 1.0 0.000143348623853 1 0 1
digitalis,immediate 1.0 0.000143348623853 1 0 1
were,considerably 1.0 0.000143348623853 1 0 1
probable,benefits 1.0 0.000143348623853 1 0 1
or,volume 1.0 0.000143348623853 0 1 -1
enhance,s 1.0 0.000143348623853 0 1 -1
of,foscarnets 1.0 0.000143348623853 1 0 1
the,mode 1.0 0.000286697247706 0 2 -2
and,various 1.0 0.000143348623853 0 1 -1
cyp1a2,results 1.0 0.000143348623853 1 0 1
sexual,activity 1.0 0.000286697247706 0 2 -2
intracranial,hypertension 1.0 0.000143348623853 1 0 1
significant,increases 0.333333333333 0.00043004587156 3 6 -3
onset,of 0.25 0.000286697247706 3 5 -2
increase,catabolism 1.0 0.000143348623853 0 1 -1
plasma,concentration 0.0909090909091 0.00043004587156 15 18 -3
rats,decreased 1.0 0.000143348623853 1 0 1
of,mm 0.0 0.0 1 1 0
of,ml 1.0 0.000286697247706 0 2 -2
inhaled,and 0.5 0.000286697247706 1 3 -2
of,mg 0.00826446280992 0.000143348623853 61 60 1
vitro,anti-cryptosporidial 1.0 0.000143348623853 0 1 -1
neuropathy,should 1.0 0.000143348623853 0 1 -1
increase,absorption 1.0 0.000143348623853 1 0 1
effected,by 1.0 0.000143348623853 0 1 -1
long,half-life 0.6 0.00043004587156 1 4 -3
not,metabolized 1.0 0.00100344036697 0 7 -7
administered,highly 1.0 0.000143348623853 0 1 -1
primary,effect 1.0 0.000143348623853 1 0 1
caused,the 1.0 0.000143348623853 0 1 -1
of,m1 1.0 0.000143348623853 1 0 1
clostridium,were 1.0 0.000143348623853 0 1 -1
half-life,and 0.6 0.00043004587156 4 1 3
core,temperature 0.333333333333 0.000143348623853 1 2 -1
fluctuated,there 1.0 0.000143348623853 0 1 -1
octapeptide,was 1.0 0.000143348623853 0 1 -1
cautious,when 1.0 0.000286697247706 2 0 2
administration,impairs 1.0 0.000143348623853 0 1 -1
homozygous,for 1.0 0.000143348623853 0 1 -1
catecholamine-depleting,drugs 1.0 0.000143348623853 1 0 1
for,pharmacokinetic 1.0 0.000143348623853 0 1 -1
action,ija 1.0 0.000143348623853 0 1 -1
antiepileptic,and 1.0 0.000143348623853 1 0 1
reactions,catalyzed 1.0 0.000143348623853 0 1 -1
mild,uncomplicated 1.0 0.000143348623853 0 1 -1
concurrently,the 0.142857142857 0.000143348623853 3 4 -1
be,confirmed 1.0 0.000143348623853 0 1 -1
profound,effect 1.0 0.000143348623853 0 1 -1
classes,that 1.0 0.000143348623853 0 1 -1
the,variability 0.333333333333 0.000143348623853 1 2 -1
distribution,was 1.0 0.000143348623853 0 1 -1
coombs,testing 1.0 0.000143348623853 0 1 -1
medicine,may 1.0 0.000143348623853 1 0 1
whether,they 1.0 0.000143348623853 0 1 -1
or,supplemented 1.0 0.000143348623853 1 0 1
nonetheless,individual 1.0 0.000143348623853 1 0 1
inhibitors,dipyridamole 1.0 0.000143348623853 1 0 1
enzymes,carbamazepine 1.0 0.000143348623853 0 1 -1
b6,weak 1.0 0.000143348623853 0 1 -1
treatment,during 1.0 0.000143348623853 0 1 -1
content,after 1.0 0.000143348623853 0 1 -1
dogs,with 1.0 0.000143348623853 0 1 -1
subtype,in 1.0 0.000143348623853 0 1 -1
as,safety 1.0 0.000143348623853 0 1 -1
tests,elevations 1.0 0.000143348623853 0 1 -1
should,achieve 1.0 0.000143348623853 0 1 -1
picr,in 1.0 0.000143348623853 0 1 -1
nursing,mothers 1.0 0.000286697247706 0 2 -2
also,bleeding 1.0 0.000143348623853 1 0 1
with,parkinson 1.0 0.000143348623853 0 1 -1
documented,however 1.0 0.000143348623853 0 1 -1
transport,ratio 1.0 0.000143348623853 0 1 -1
with,abciximab 1.0 0.000143348623853 0 1 -1
etofibrate,elicited 1.0 0.000143348623853 1 0 1
adequate,and 1.0 0.000573394495413 0 4 -4
tests,of 1.0 0.000143348623853 0 1 -1
alveoli,of 1.0 0.000286697247706 0 2 -2
with,vaprisol 1.0 0.000143348623853 1 0 1
hypogastric,nerve 1.0 0.000143348623853 0 1 -1
or,withdrawn 0.333333333333 0.000143348623853 1 2 -1
cumulative,urinary 1.0 0.000143348623853 0 1 -1
the,pathway 1.0 0.000143348623853 0 1 -1
to,broadly 1.0 0.000143348623853 0 1 -1
s-warfarin,a 1.0 0.000143348623853 1 0 1
through,an 1.0 0.000143348623853 1 0 1
vitro,against 1.0 0.000286697247706 0 2 -2
but,a 1.0 0.000143348623853 0 1 -1
would,affect 1.0 0.000143348623853 0 1 -1
technique,in 1.0 0.000143348623853 0 1 -1
with,knowledge 1.0 0.000143348623853 0 1 -1
with,bleeding 1.0 0.000143348623853 0 1 -1
secretory,diarrhea 1.0 0.000286697247706 0 2 -2
combined,exposures 1.0 0.000143348623853 0 1 -1
of,dcg-iv 0.0 0.0 1 1 0
other,day 1.0 0.00043004587156 0 3 -3
including,dry 1.0 0.000143348623853 1 0 1
single,intravenous 1.0 0.000143348623853 0 1 -1
in,hemostasis 0.333333333333 0.000143348623853 2 1 1
technique,it 1.0 0.000143348623853 0 1 -1
antacids,sucralfate 1.0 0.000143348623853 0 1 -1
the,mammary 1.0 0.000286697247706 0 2 -2
and,postnatal 1.0 0.000143348623853 0 1 -1
amantadine,limited 1.0 0.000143348623853 1 0 1
increases,will 1.0 0.000143348623853 0 1 -1
involved,in 1.0 0.00229357798165 0 16 -16
demonstrated,similar 1.0 0.000143348623853 0 1 -1
cmax,differences 1.0 0.000143348623853 0 1 -1
doses,as 1.0 0.000143348623853 0 1 -1
periodic,monitoring 1.0 0.000143348623853 0 1 -1
on,anecdotal 1.0 0.000143348623853 1 0 1
bolus-ifl,alone 1.0 0.000143348623853 0 1 -1
drug-metabolizing,enzymes 1.0 0.000286697247706 0 2 -2
compatibility,data 1.0 0.000143348623853 0 1 -1
in,separate 1.0 0.000573394495413 0 4 -4
h,or 1.0 0.000143348623853 0 1 -1
substances,tbars 1.0 0.000143348623853 0 1 -1
propanol,to 0.0 0.0 1 1 0
to,fully 1.0 0.000286697247706 0 2 -2
with,cytochalasin 1.0 0.000143348623853 0 1 -1
arrest,and 1.0 0.000143348623853 0 1 -1
general,agents 1.0 0.000143348623853 0 1 -1
significant,elevation 0.0 0.0 1 1 0
with,inhibitors 0.5 0.000286697247706 3 1 2
of,colonic 1.0 0.000143348623853 0 1 -1
concurrent,kineret 1.0 0.000143348623853 1 0 1
a,mean 0.5 0.000573394495413 6 2 4
with,strenuous 1.0 0.000143348623853 0 1 -1
tagamet,to 1.0 0.000143348623853 0 1 -1
of,panretin 1.0 0.000286697247706 0 2 -2
therapeutic,and 1.0 0.000716743119266 0 5 -5
without,affecting 1.0 0.000143348623853 1 0 1
distribution,in 1.0 0.000143348623853 1 0 1
this,might 0.0 0.0 1 1 0
a,rare 1.0 0.000143348623853 1 0 1
levels,as 1.0 0.000286697247706 0 2 -2
necessary,receive 1.0 0.000143348623853 0 1 -1
levels,at 0.333333333333 0.000143348623853 1 2 -1
dosages,and 1.0 0.000143348623853 0 1 -1
aggression,and 1.0 0.000143348623853 0 1 -1
metabolizers,with 1.0 0.000286697247706 0 2 -2
maintenance,dosing 1.0 0.000143348623853 1 0 1
maois,may 1.0 0.000286697247706 2 0 2
were,several 1.0 0.000143348623853 0 1 -1
rats,of 1.0 0.000143348623853 0 1 -1
needed,agents 1.0 0.000143348623853 0 1 -1
increase,when 1.0 0.000573394495413 4 0 4
overall,direct 1.0 0.000143348623853 0 1 -1
chemical,i 1.0 0.000143348623853 0 1 -1
necessary,for 0.0 0.0 1 1 0
that,were 1.0 0.000143348623853 1 0 1
such,combined 0.333333333333 0.000286697247706 2 4 -2
methods,to 1.0 0.000143348623853 0 1 -1
when,arava 1.0 0.000286697247706 2 0 2
mg,all 1.0 0.000143348623853 0 1 -1
impairing,its 1.0 0.000143348623853 1 0 1
displaying,transient 1.0 0.000143348623853 0 1 -1
inhibitor,hydrogen-3 1.0 0.000143348623853 0 1 -1
tachycardia,produced 1.0 0.000143348623853 1 0 1
soluble,such 1.0 0.000143348623853 0 1 -1
skeletal-muscle,relaxants 1.0 0.000143348623853 0 1 -1
angina,attacks 1.0 0.000143348623853 0 1 -1
ergot-type,medications 1.0 0.00043004587156 3 0 3
myelotoxicity,of 1.0 0.000143348623853 0 1 -1
medications,can 0.333333333333 0.000143348623853 1 2 -1
monkeys,and 1.0 0.000143348623853 0 1 -1
when,trileptal 1.0 0.000143348623853 1 0 1
including,many 1.0 0.000286697247706 0 2 -2
non-human,primates 1.0 0.000143348623853 0 1 -1
ptx,was 1.0 0.000286697247706 0 2 -2
conducted,the 1.0 0.000143348623853 0 1 -1
oral,anticoagulents 1.0 0.000143348623853 0 1 -1
mg,orally 0.333333333333 0.000143348623853 1 2 -1
a,supine 1.0 0.000143348623853 0 1 -1
to,concomitant 1.0 0.000286697247706 0 2 -2
depression,and 1.0 0.000143348623853 0 1 -1
subpopulations,of 1.0 0.000143348623853 0 1 -1
symptoms,indicates 1.0 0.000143348623853 0 1 -1
test,in 1.0 0.00043004587156 0 3 -3
calcium,channel 0.333333333333 0.000286697247706 2 4 -2
of,proportionate 1.0 0.000143348623853 0 1 -1
and,treatment 1.0 0.000716743119266 0 5 -5
curariform,muscle 1.0 0.000143348623853 1 0 1
test,is 1.0 0.000286697247706 0 2 -2
supplement,that 1.0 0.000143348623853 0 1 -1
system,and 0.2 0.000143348623853 2 3 -1
information,to 0.333333333333 0.000143348623853 1 2 -1
concurrent,or 1.0 0.000286697247706 0 2 -2
geriatric,use 1.0 0.000286697247706 0 2 -2
in,his 1.0 0.000143348623853 0 1 -1
synergistic,relationship 1.0 0.000143348623853 1 0 1
premature,atherosclerotic 1.0 0.000143348623853 0 1 -1
contrast,to 1.0 0.000286697247706 0 2 -2
fluvoxamine,tablets 1.0 0.000716743119266 5 0 5
human,weekly 1.0 0.000143348623853 0 1 -1
be,helpful 1.0 0.000143348623853 0 1 -1
effect,measured 1.0 0.000143348623853 0 1 -1
about,equipotent 1.0 0.000143348623853 0 1 -1
a,nondrug 1.0 0.000143348623853 0 1 -1
with,microalbuminuria 1.0 0.000143348623853 1 0 1
nonsteroidal,nsaid 1.0 0.000143348623853 0 1 -1
described,in 1.0 0.000573394495413 0 4 -4
poisonings,of 1.0 0.000143348623853 0 1 -1
levels,leading 1.0 0.000143348623853 0 1 -1
increasing,concentration 1.0 0.000143348623853 0 1 -1
data,exist 1.0 0.000143348623853 0 1 -1
hydroxylamine,dha 1.0 0.000143348623853 0 1 -1
metal,mixture 1.0 0.000143348623853 0 1 -1
a4,enzyme 0.0 0.0 2 2 0
tmax,vs 1.0 0.000143348623853 0 1 -1
tolerated,in 1.0 0.00043004587156 0 3 -3
systematically,alter 1.0 0.000143348623853 0 1 -1
acute,effect 1.0 0.000143348623853 0 1 -1
the,effects 0.188679245283 0.00286697247706 43 63 -20
together,at 1.0 0.000143348623853 0 1 -1
critically,reviews 1.0 0.000143348623853 0 1 -1
of,receptors 1.0 0.000143348623853 0 1 -1
difference,p 1.0 0.000143348623853 0 1 -1
aeds,phenytoin 1.0 0.000286697247706 0 2 -2
higher,than 0.238095238095 0.000716743119266 8 13 -5
generated,to 1.0 0.000143348623853 0 1 -1
accutane,therapy 1.0 0.000286697247706 0 2 -2
to,explain 1.0 0.000143348623853 0 1 -1
control,symptoms 1.0 0.000143348623853 0 1 -1
median,fold 1.0 0.000143348623853 0 1 -1
the,myelotoxicity 1.0 0.000143348623853 0 1 -1
peak,as 1.0 0.000143348623853 0 1 -1
interactions,blood 1.0 0.000143348623853 0 1 -1
during,initiation 1.0 0.000143348623853 0 1 -1
with,creatinine 1.0 0.000143348623853 0 1 -1
not,systematically 0.0 0.0 1 1 0
at,concentrations 1.0 0.00143348623853 0 10 -10
dosage,adjustments 0.571428571429 0.00114678899083 3 11 -8
days,in 0.6 0.00043004587156 1 4 -3
and,histamine-induced 1.0 0.000143348623853 0 1 -1
during,concurrent 1.0 0.000143348623853 0 1 -1
require,adjustment 1.0 0.000143348623853 0 1 -1
pharmacodynamics,of 1.0 0.00100344036697 0 7 -7
which,impair 1.0 0.000143348623853 0 1 -1
and,qualitative 1.0 0.000143348623853 0 1 -1
shivering,pupillary 1.0 0.000143348623853 0 1 -1
cyp3a4,cyp3a4 1.0 0.000143348623853 0 1 -1
of,manic-depressive 1.0 0.000143348623853 0 1 -1
derivatives,hormones 1.0 0.000286697247706 0 2 -2
with,early-phase 1.0 0.000143348623853 0 1 -1
deoxy,to 1.0 0.000143348623853 0 1 -1
mind,in 1.0 0.000143348623853 1 0 1
efficacy,against 1.0 0.000143348623853 0 1 -1
plus,experienced 1.0 0.000143348623853 1 0 1
smoking,cessation 1.0 0.000143348623853 0 1 -1
approximate,doubling 1.0 0.000286697247706 2 0 2
doxylamine,may 1.0 0.000143348623853 1 0 1
beverages,are 1.0 0.000143348623853 0 1 -1
based,on 0.591836734694 0.00415711009174 10 39 -29
other,will 1.0 0.000143348623853 0 1 -1
considered,the 1.0 0.000143348623853 0 1 -1
daily,trough 1.0 0.000143348623853 0 1 -1
ingestion,should 1.0 0.000143348623853 0 1 -1
necessitating,a 1.0 0.000143348623853 1 0 1
potentiate,or 1.0 0.000286697247706 2 0 2
one,survey 1.0 0.000143348623853 1 0 1
excretion,of 0.384615384615 0.00143348623853 18 8 10
and,nonclinical 1.0 0.000143348623853 0 1 -1
interpreted,cautiously 1.0 0.000143348623853 0 1 -1
calcium-rich,foods 1.0 0.000143348623853 1 0 1
spite,of 1.0 0.00043004587156 0 3 -3
a,sign 1.0 0.000143348623853 0 1 -1
both,angiotensins 1.0 0.000143348623853 0 1 -1
given,exclusively 1.0 0.000143348623853 0 1 -1
iron-fortified,breakfast 1.0 0.000143348623853 0 1 -1
laboratory,evidence 1.0 0.000143348623853 0 1 -1
taken,orally 1.0 0.000143348623853 1 0 1
co,and 1.0 0.000143348623853 0 1 -1
when,both 1.0 0.000143348623853 1 0 1
of,immunization 1.0 0.000143348623853 1 0 1
bound,with 1.0 0.000143348623853 0 1 -1
exhibits,non-linear 1.0 0.000143348623853 1 0 1
objective,this 1.0 0.000143348623853 0 1 -1
rapid,while 1.0 0.000143348623853 0 1 -1
oculo-bulbar,myasthenia 1.0 0.000143348623853 1 0 1
twenty-four,h 1.0 0.000143348623853 0 1 -1
low,cardiac 1.0 0.000143348623853 0 1 -1
and,peak 1.0 0.000143348623853 1 0 1
treatments,and 1.0 0.000143348623853 0 1 -1
selective,survival 1.0 0.000143348623853 0 1 -1
resulting,interference 1.0 0.000143348623853 1 0 1
a,blocker 1.0 0.000143348623853 0 1 -1
inhibitors,also 1.0 0.000143348623853 0 1 -1
died,with 1.0 0.000143348623853 0 1 -1
in,diabetic 0.454545454545 0.000716743119266 3 8 -5
of,significantly 1.0 0.000143348623853 1 0 1
and,videx 1.0 0.000143348623853 1 0 1
of,palythoa 1.0 0.000143348623853 0 1 -1
demonstrated,that 0.222222222222 0.000573394495413 7 11 -4
globulin,shbg 1.0 0.000286697247706 0 2 -2
inhibits,cancer 1.0 0.000143348623853 0 1 -1
we,show 1.0 0.000286697247706 0 2 -2
sodium,bicarbonate 0.333333333333 0.000143348623853 2 1 1
toxic,levels 0.0 0.0 1 1 0
loads,treated 1.0 0.000143348623853 0 1 -1
ovarian,cervical 1.0 0.000143348623853 0 1 -1
the,release 1.0 0.00100344036697 0 7 -7
month,controlled 1.0 0.000143348623853 0 1 -1
therapeutic,regimen 1.0 0.00043004587156 0 3 -3
nonetheless,the 1.0 0.000286697247706 0 2 -2
sulfate,multivitamin 1.0 0.000143348623853 1 0 1
than,usually 1.0 0.00100344036697 0 7 -7
therapeutic,regimes 1.0 0.000143348623853 0 1 -1
hepatotoxic,drugs 1.0 0.000143348623853 0 1 -1
cmax,leading 1.0 0.000143348623853 1 0 1
also,indicated 1.0 0.000143348623853 0 1 -1
the,phase 1.0 0.000143348623853 0 1 -1
including,manic-depressive 1.0 0.000143348623853 1 0 1
at,recommended 1.0 0.000143348623853 1 0 1
populations,the 1.0 0.000143348623853 1 0 1
peripheral,because 1.0 0.000143348623853 1 0 1
emulsion,model 1.0 0.000143348623853 0 1 -1
effectiveness,may 1.0 0.000143348623853 0 1 -1
for,differential 1.0 0.000143348623853 0 1 -1
cycle,irregularities 1.0 0.000143348623853 0 1 -1
a,b-cell 1.0 0.000143348623853 0 1 -1
first,double-blind 1.0 0.000143348623853 0 1 -1
saline,was 1.0 0.000143348623853 0 1 -1
cause,arrhythmias 1.0 0.000143348623853 0 1 -1
particularly,serotype 1.0 0.000143348623853 0 1 -1
inducer,decreased 1.0 0.000143348623853 1 0 1
vivo,particularly 1.0 0.000143348623853 0 1 -1
rarely,toxicity 1.0 0.000143348623853 1 0 1
or,efficacy 1.0 0.000716743119266 0 5 -5
mean,neutrophil 1.0 0.000143348623853 1 0 1
in,enterococci 1.0 0.000143348623853 0 1 -1
vascular,or 1.0 0.000143348623853 0 1 -1
bolus,followed 1.0 0.000143348623853 0 1 -1
because,active 1.0 0.000143348623853 0 1 -1
to,active 1.0 0.000143348623853 0 1 -1
a,cyp3a4 0.333333333333 0.00043004587156 6 3 3
inhibit,elimination 1.0 0.000143348623853 1 0 1
t4,concentration 1.0 0.000286697247706 0 2 -2
descending,epsilon 1.0 0.000143348623853 0 1 -1
proleukin,including 1.0 0.000143348623853 1 0 1
using,escalating 1.0 0.000143348623853 1 0 1
lacking,kidney 1.0 0.000143348623853 0 1 -1
with,elevations 0.5 0.000286697247706 3 1 2
can,completely 1.0 0.000143348623853 1 0 1
with,intestinal 1.0 0.000143348623853 1 0 1
inhibitors,and 0.25 0.00114678899083 20 12 8
produce,excessive 1.0 0.000143348623853 1 0 1
microg,l 1.0 0.000716743119266 0 5 -5
respiration,was 1.0 0.000143348623853 0 1 -1
oral,regular 1.0 0.000143348623853 0 1 -1
alfa-2a,treatment 1.0 0.000143348623853 0 1 -1
carcinogenicity,or 1.0 0.000143348623853 0 1 -1
safety,however 1.0 0.000143348623853 0 1 -1
disruptive,effects 1.0 0.000143348623853 1 0 1
as,retention 1.0 0.000143348623853 0 1 -1
again,neutralized 1.0 0.000143348623853 0 1 -1
volunteers,hormone 1.0 0.000143348623853 0 1 -1
membranes,of 1.0 0.000143348623853 0 1 -1
desired,and 0.0 0.0 1 1 0
grapefruit,orange 1.0 0.000143348623853 0 1 -1
i,and 1.0 0.000573394495413 0 4 -4
anaesthetic,agents 1.0 0.000143348623853 0 1 -1
following,varying 1.0 0.000143348623853 0 1 -1
observations,i 1.0 0.000143348623853 0 1 -1
with,tablets 1.0 0.000573394495413 4 0 4
pharmacokinetic,captopril-digoxin 1.0 0.000143348623853 0 1 -1
and,non-opioid 1.0 0.000143348623853 0 1 -1
tagamet,prozac 1.0 0.000143348623853 0 1 -1
therefore,advised 1.0 0.000286697247706 2 0 2
repeat,testing 1.0 0.000143348623853 0 1 -1
diagnostic,interference 1.0 0.000143348623853 0 1 -1
usp,to 1.0 0.000143348623853 1 0 1
range,kg 1.0 0.000143348623853 0 1 -1
receiving,concurrently 1.0 0.000143348623853 1 0 1
maintain,an 1.0 0.000143348623853 0 1 -1
assay,of 1.0 0.000286697247706 0 2 -2
however,oh 1.0 0.000143348623853 0 1 -1
however,on 1.0 0.000143348623853 0 1 -1
highly,unstable 1.0 0.000143348623853 0 1 -1
the,renal 0.047619047619 0.000143348623853 11 10 1
secretion,by 0.333333333333 0.000143348623853 1 2 -1
generation,of 1.0 0.000286697247706 0 2 -2
ci,kg 1.0 0.000143348623853 0 1 -1
and,concomitant 0.2 0.000143348623853 2 3 -1
times,were 1.0 0.000573394495413 0 4 -4
altered,so 1.0 0.000143348623853 0 1 -1
both,parental 1.0 0.000143348623853 0 1 -1
little,or 0.0 0.0 3 3 0
wax,matrix 1.0 0.000143348623853 1 0 1
cephalosporins,including 1.0 0.000143348623853 0 1 -1
mixture,toxicity 1.0 0.000143348623853 0 1 -1
or,pharmacokinetics 1.0 0.000286697247706 0 2 -2
one,patient 0.0 0.0 1 1 0
edema,has 1.0 0.000143348623853 1 0 1
enzyme,should 1.0 0.000143348623853 1 0 1
arteries,of 1.0 0.000143348623853 0 1 -1
diazepam,the 1.0 0.000143348623853 1 0 1
for,diabetic 1.0 0.000143348623853 0 1 -1
of,caspase-3 1.0 0.000143348623853 0 1 -1
or,aluminum-containing 1.0 0.000143348623853 1 0 1
contrast,in 1.0 0.000286697247706 0 2 -2
taken,closely 1.0 0.000143348623853 1 0 1
subjects,concurrent 1.0 0.000143348623853 1 0 1
contrast,media 0.333333333333 0.000143348623853 1 2 -1
dilute,solutions 1.0 0.000143348623853 0 1 -1
long-term,therapy 1.0 0.000143348623853 1 0 1
that,intoxication 1.0 0.000286697247706 2 0 2
of,from 0.5 0.000573394495413 2 6 -4
nsaids,was 1.0 0.000143348623853 0 1 -1
tuberculosa,caused 1.0 0.000143348623853 0 1 -1
the,results 0.6 0.0021502293578 5 20 -15
key,to 1.0 0.000143348623853 0 1 -1
placebo-controlled,within-subject 1.0 0.000143348623853 0 1 -1
ingestion,may 1.0 0.000143348623853 1 0 1
inhibitors,to 0.0 0.0 1 1 0
currently,little 1.0 0.000143348623853 0 1 -1
because,elderly 1.0 0.000143348623853 0 1 -1
other,studies 1.0 0.000143348623853 0 1 -1
a,shortened 1.0 0.000143348623853 1 0 1
toxoids,should 1.0 0.000143348623853 1 0 1
little,published 1.0 0.000143348623853 0 1 -1
unchanged,when 1.0 0.000143348623853 0 1 -1
and,slight 1.0 0.000143348623853 1 0 1
lengthening,of 1.0 0.000143348623853 0 1 -1
toxicity,especially 1.0 0.000143348623853 0 1 -1
antihypertensives,amiodarone 1.0 0.000143348623853 0 1 -1
metabolism,may 0.666666666667 0.000573394495413 1 5 -4
later,changed 1.0 0.000143348623853 0 1 -1
impaired,by 0.5 0.000286697247706 3 1 2
pancreatic,effects 1.0 0.000143348623853 0 1 -1
from,other 1.0 0.000143348623853 0 1 -1
of,clostridium 1.0 0.00043004587156 0 3 -3
the,dose 0.09375 0.000860091743119 29 35 -6
ovulation,but 1.0 0.000143348623853 0 1 -1
in,em 1.0 0.000143348623853 1 0 1
in,desloratadine 1.0 0.000143348623853 0 1 -1
coadministration,leads 1.0 0.000286697247706 2 0 2
tricyclic,may 0.5 0.000286697247706 3 1 2
interference,of 1.0 0.00043004587156 0 3 -3
the,visual 1.0 0.000143348623853 0 1 -1
e1,and 1.0 0.00043004587156 0 3 -3
during,up-titration 1.0 0.000143348623853 0 1 -1
of,rashes 0.333333333333 0.000143348623853 2 1 1
activity,such 1.0 0.000286697247706 2 0 2
dysregulation,of 1.0 0.000143348623853 0 1 -1
surfaces,of 1.0 0.000143348623853 0 1 -1
increased,factors 1.0 0.000286697247706 0 2 -2
ventricular,function 1.0 0.000143348623853 0 1 -1
but,there 0.2 0.000143348623853 2 3 -1
to,doses 1.0 0.000143348623853 0 1 -1
as,inhibitors 1.0 0.000143348623853 0 1 -1
three,study 1.0 0.000143348623853 0 1 -1
frequent,involvement 1.0 0.000143348623853 1 0 1
species,nanm 1.0 0.000143348623853 1 0 1
concentration,times 1.0 0.000143348623853 0 1 -1
concomitantly,closely 1.0 0.000143348623853 0 1 -1
regimens,of 1.0 0.000143348623853 0 1 -1
or,since 1.0 0.000143348623853 0 1 -1
anxiety,agitation 1.0 0.000143348623853 0 1 -1
cerebyx,dosage 1.0 0.000143348623853 1 0 1
a-chloralose,anesthetized 1.0 0.000143348623853 0 1 -1
acid,or 1.0 0.000143348623853 1 0 1
in,phosphorylation 1.0 0.000143348623853 1 0 1
c-cholesterol,ester 1.0 0.000143348623853 0 1 -1
centrally,acting 1.0 0.000143348623853 0 1 -1
pharmacokinetics,therapeutic 1.0 0.000143348623853 0 1 -1
of,potentially 0.0 0.0 1 1 0
and,result 0.333333333333 0.000143348623853 2 1 1
indicated,in 0.0 0.0 4 4 0
n,did 1.0 0.000143348623853 0 1 -1
maoi,maoi 1.0 0.000143348623853 1 0 1
haart,was 1.0 0.000143348623853 0 1 -1
limited,comparative 1.0 0.000143348623853 0 1 -1
development,consistent 1.0 0.000143348623853 0 1 -1
usual,concentrations 1.0 0.000143348623853 0 1 -1
one-half,and 1.0 0.000143348623853 0 1 -1
zinecard,on 1.0 0.000143348623853 0 1 -1
recorded,from 1.0 0.000143348623853 0 1 -1
specified,time 1.0 0.000143348623853 0 1 -1
hydoxide,hydrochloride 1.0 0.000143348623853 1 0 1
of,prolongation 1.0 0.000143348623853 1 0 1
of,flolan 1.0 0.000143348623853 0 1 -1
differences,indicated 1.0 0.000143348623853 0 1 -1
in,peripheral 0.333333333333 0.000143348623853 2 1 1
higher-than,expected 1.0 0.000143348623853 1 0 1
to,in 0.666666666667 0.000573394495413 5 1 4
the,months 1.0 0.000143348623853 0 1 -1
including,ventricular 1.0 0.000143348623853 0 1 -1
to,which 0.75 0.000860091743119 7 1 6
known,microsomal 1.0 0.000143348623853 1 0 1
to,is 0.0 0.0 1 1 0
the,m1 1.0 0.000143348623853 0 1 -1
doses,nanm 1.0 0.000143348623853 0 1 -1
daily,a 1.0 0.000143348623853 1 0 1
p450,c9 0.333333333333 0.000286697247706 2 4 -2
a,lesser 0.666666666667 0.000573394495413 1 5 -4
be,repeated 1.0 0.000143348623853 0 1 -1
in,higher 0.0 0.0 1 1 0
diuretics,the 1.0 0.000143348623853 1 0 1
that,health 1.0 0.000143348623853 0 1 -1
pharmacokinetic-based,drug-drug 1.0 0.000143348623853 0 1 -1
of,starlix 0.333333333333 0.000143348623853 2 1 1
the,mg 0.2 0.000143348623853 2 3 -1
both,at 1.0 0.000143348623853 0 1 -1
have,effects 1.0 0.000143348623853 0 1 -1
occur,earlier 1.0 0.000143348623853 1 0 1
the,ethanolysis 1.0 0.000143348623853 1 0 1
with,fruit 1.0 0.000143348623853 0 1 -1
extreme,agitation 1.0 0.000143348623853 1 0 1
highly,lethal 1.0 0.000143348623853 0 1 -1
events,involving 1.0 0.000143348623853 0 1 -1
methods,clinical 1.0 0.000143348623853 0 1 -1
n,demonstrated 1.0 0.000286697247706 0 2 -2
the,coagulation 1.0 0.000143348623853 0 1 -1
balance,testing 1.0 0.000143348623853 1 0 1
within,hours 0.294117647059 0.000716743119266 11 6 5
their,potential 1.0 0.000143348623853 0 1 -1
shown,a 1.0 0.000716743119266 5 0 5
deficiency,and 1.0 0.000143348623853 0 1 -1
conclusions,single-dose 1.0 0.000143348623853 1 0 1
be,envisaged 1.0 0.000143348623853 0 1 -1
fixed-interval,fixed-ratio 1.0 0.000143348623853 0 1 -1
neuropathy,has 1.0 0.000143348623853 0 1 -1
of,carbamazepine 0.0 0.0 1 1 0
erythema,pruritus 1.0 0.000143348623853 0 1 -1
glycosides,may 1.0 0.000143348623853 0 1 -1
that,absorption 1.0 0.000143348623853 0 1 -1
saline,values 1.0 0.000143348623853 0 1 -1
using,such 1.0 0.000143348623853 1 0 1
protection,against 1.0 0.000143348623853 1 0 1
with,peripheral 0.333333333333 0.000143348623853 1 2 -1
since,animal 1.0 0.000143348623853 1 0 1
ml,before 1.0 0.000143348623853 0 1 -1
topical,glaucoma 1.0 0.000143348623853 1 0 1
in,each 1.0 0.00100344036697 0 7 -7
acquisition,after 1.0 0.000143348623853 0 1 -1
with,pegasys 0.0 0.0 1 1 0
of,growth 1.0 0.00043004587156 0 3 -3
activity,if 1.0 0.000143348623853 1 0 1
active,metabolites 1.0 0.000286697247706 0 2 -2
d1,antagonist 1.0 0.000143348623853 1 0 1
respect,to 1.0 0.00100344036697 0 7 -7
intravenous,route 1.0 0.000143348623853 0 1 -1
recipients,over 1.0 0.000143348623853 0 1 -1
activity,in 0.6 0.00043004587156 1 4 -3
mesylate,has 1.0 0.000286697247706 0 2 -2
alternatives,to 0.0 0.0 3 3 0
male,dogs 1.0 0.000143348623853 0 1 -1
by,means 0.5 0.000286697247706 1 3 -2
activity,is 1.0 0.00043004587156 0 3 -3
derivative,of 1.0 0.000143348623853 0 1 -1
activity,ix 1.0 0.000286697247706 0 2 -2
metabolism,with 1.0 0.000143348623853 1 0 1
patient,population 1.0 0.00043004587156 0 3 -3
osteoporosis,treatment 1.0 0.000286697247706 0 2 -2
and,chloride 1.0 0.000286697247706 2 0 2
literature,reports 0.2 0.000143348623853 3 2 1
concentration,greater 1.0 0.000143348623853 0 1 -1
advisable,not 1.0 0.000143348623853 0 1 -1
and,obesity 1.0 0.000143348623853 0 1 -1
genetically,predisposed 1.0 0.000286697247706 0 2 -2
oral,formulation 1.0 0.000143348623853 0 1 -1
ethanol,flupenthixol 1.0 0.000143348623853 1 0 1
activate,the 1.0 0.000143348623853 0 1 -1
achieved,in 1.0 0.000286697247706 0 2 -2
acid,vitamin 1.0 0.000143348623853 1 0 1
that,taking 1.0 0.000143348623853 0 1 -1
at,any 1.0 0.000286697247706 0 2 -2
have,investigated 1.0 0.000286697247706 0 2 -2
because,nafarelin 1.0 0.000143348623853 0 1 -1
heart,function 1.0 0.000143348623853 1 0 1
increasingly,those 1.0 0.000143348623853 0 1 -1
of,anafranil 0.0 0.0 1 1 0
aminoglycosides,drugs 1.0 0.000143348623853 1 0 1
zaleplon,is 1.0 0.000143348623853 0 1 -1
similar,properties 1.0 0.000143348623853 1 0 1
vet,or 1.0 0.000143348623853 1 0 1
and,cohort 0.0 0.0 1 1 0
these,functions 1.0 0.000143348623853 0 1 -1
most,potent 1.0 0.00043004587156 0 3 -3
antagonist,may 1.0 0.000143348623853 0 1 -1
evaluate,possible 1.0 0.000143348623853 0 1 -1
predominantly,in 0.0 0.0 1 1 0
baseline,use 1.0 0.000143348623853 0 1 -1
by,combination 1.0 0.000143348623853 1 0 1
didanosine,fluconazole 1.0 0.000143348623853 0 1 -1
will,require 1.0 0.000143348623853 1 0 1
expected,in 1.0 0.000143348623853 0 1 -1
the,coadministration 0.416666666667 0.00143348623853 7 17 -10
administering,cyp3a4 1.0 0.000143348623853 0 1 -1
deficiency,can 1.0 0.000143348623853 1 0 1
tranexamic,acid 1.0 0.000143348623853 0 1 -1
agents,the 0.25 0.000286697247706 3 5 -2
withdrawal,the 1.0 0.00043004587156 0 3 -3
receiving,treatment 1.0 0.000286697247706 0 2 -2
steroidal,agent 1.0 0.000143348623853 1 0 1
moreover,as 1.0 0.000143348623853 1 0 1
subjects,on 1.0 0.00043004587156 0 3 -3
drugs,phenytoin 1.0 0.000143348623853 1 0 1
subjects,or 1.0 0.000143348623853 0 1 -1
enterohepatic,elimination 1.0 0.000143348623853 0 1 -1
cohort,or 1.0 0.000143348623853 0 1 -1
affect,gastric 1.0 0.000143348623853 0 1 -1
its,derivatives 1.0 0.000716743119266 5 0 5
typhimurium,and 1.0 0.000143348623853 0 1 -1
which,clearance 0.0 0.0 1 1 0
d6,e1 1.0 0.000860091743119 0 6 -6
obtained,from 1.0 0.000860091743119 0 6 -6
both,thiazide-like 1.0 0.000143348623853 0 1 -1
bowel,and 1.0 0.000143348623853 0 1 -1
the,intravenous 0.6 0.000860091743119 2 8 -6
and,coreg 1.0 0.000143348623853 1 0 1
neuroleptic,drugs 1.0 0.000143348623853 1 0 1
administration,to 0.0 0.0 3 3 0
followed,for 1.0 0.000143348623853 0 1 -1
patient,initiates 1.0 0.000143348623853 1 0 1
by,or 0.5 0.000286697247706 1 3 -2
th,day 0.0 0.0 2 2 0
neuropathy,the 1.0 0.000143348623853 0 1 -1
intravenously,or 1.0 0.000143348623853 0 1 -1
both,hyperthyroidism 1.0 0.000143348623853 0 1 -1
by,of 0.0 0.0 2 2 0
by,oh 1.0 0.000143348623853 1 0 1
was,prepared 1.0 0.000143348623853 0 1 -1
by,on 1.0 0.000286697247706 2 0 2
is,enhanced 0.6 0.00043004587156 4 1 3
plus,haart 1.0 0.00043004587156 0 3 -3
other,cholinesterase 1.0 0.000143348623853 1 0 1
numerous,interactions 1.0 0.000143348623853 0 1 -1
the,ganglionic-blocking 1.0 0.000143348623853 1 0 1
regimens,and 1.0 0.000143348623853 0 1 -1
any,medicine 1.0 0.000143348623853 0 1 -1
somepatients,may 1.0 0.000143348623853 0 1 -1
cmin,to 1.0 0.000286697247706 2 0 2
on,malignant 1.0 0.000143348623853 1 0 1
regimen,consisting 1.0 0.000143348623853 1 0 1
and,vasoconstrictive 1.0 0.000143348623853 1 0 1
vioxx,with 1.0 0.000286697247706 2 0 2
nimbex,were 1.0 0.000143348623853 1 0 1
fluoride,accumulation 1.0 0.000143348623853 0 1 -1
a,significant 0.0434782608696 0.000143348623853 11 12 -1
those,resulting 1.0 0.000143348623853 0 1 -1
glycosides,in 1.0 0.000286697247706 0 2 -2
endometrial,ovarian 1.0 0.000143348623853 0 1 -1
triglyceride,plasma 1.0 0.000143348623853 0 1 -1
metabolites,are 1.0 0.000143348623853 0 1 -1
any,that 1.0 0.000143348623853 0 1 -1
preparations,by 1.0 0.000143348623853 1 0 1
prolixin,serentil 1.0 0.000143348623853 0 1 -1
therefore,that 1.0 0.000143348623853 0 1 -1
be,no 1.0 0.000286697247706 0 2 -2
systemic,circulation 1.0 0.000143348623853 1 0 1
enhanced,by 0.6 0.000860091743119 8 2 6
to,check 0.0 0.0 1 1 0
isoenzyme,cyp3a4 1.0 0.000286697247706 0 2 -2
about,absorption 1.0 0.000143348623853 0 1 -1
in,uptake-1 1.0 0.000286697247706 0 2 -2
antisense,gene 1.0 0.000143348623853 0 1 -1
of,sedation 0.333333333333 0.000143348623853 1 2 -1
seen,during 0.333333333333 0.000143348623853 2 1 1
when,baraclude 1.0 0.000143348623853 0 1 -1
unrecognized,interaction 1.0 0.000143348623853 1 0 1
non-steroidal,concomitantly 1.0 0.000143348623853 1 0 1
and,extended 1.0 0.000286697247706 2 0 2
other,tnf-blocking 1.0 0.000143348623853 1 0 1
dose,modifying 1.0 0.000143348623853 1 0 1
and,imitrex 1.0 0.000143348623853 0 1 -1
and,through 1.0 0.000143348623853 0 1 -1
concentrations,or 0.333333333333 0.000143348623853 1 2 -1
contractile,response 1.0 0.000143348623853 0 1 -1
us,food 1.0 0.000143348623853 0 1 -1
iron,concomitant 1.0 0.000143348623853 1 0 1
compelling,reasons 1.0 0.000143348623853 0 1 -1
concentrations,of 0.107692307692 0.00200688073394 58 72 -14
the,selection 1.0 0.000143348623853 0 1 -1
active,vomiting 1.0 0.000143348623853 1 0 1
mg,three 0.2 0.000143348623853 3 2 1
whom,cyp3a4 1.0 0.000143348623853 0 1 -1
iv,injection 1.0 0.000143348623853 1 0 1
commonly,results 1.0 0.000143348623853 1 0 1
strains,from 1.0 0.000286697247706 0 2 -2
than,fold 0.333333333333 0.000143348623853 1 2 -1
concentrates,has 1.0 0.000143348623853 0 1 -1
including,crescentic 1.0 0.000143348623853 1 0 1
invalidate,folic 1.0 0.000143348623853 0 1 -1
acetate,because 1.0 0.000143348623853 1 0 1
combined,with 0.272727272727 0.00043004587156 7 4 3
ketoconazole,at 1.0 0.000143348623853 1 0 1
salmonella,typhimurium 1.0 0.000143348623853 0 1 -1
containing,vitamin 1.0 0.000143348623853 1 0 1
also,produces 1.0 0.000143348623853 1 0 1
conduction,disturbances 0.0 0.0 2 2 0
administration,decreased 1.0 0.000143348623853 1 0 1
of,reduced 0.8 0.00114678899083 1 9 -8
potential,especially 1.0 0.000143348623853 1 0 1
increased,bun 1.0 0.000143348623853 1 0 1
hydrate,and 0.5 0.000286697247706 1 3 -2
underlying,mechanism 1.0 0.000143348623853 1 0 1
fischer-344,strain 1.0 0.000143348623853 0 1 -1
stopping,before 1.0 0.000143348623853 1 0 1
reported,both 1.0 0.000143348623853 1 0 1
comparable,in 1.0 0.000143348623853 0 1 -1
iib,iiia 1.0 0.000143348623853 1 0 1
edecrin,and 1.0 0.000143348623853 1 0 1
psychotic,disorders 1.0 0.000143348623853 1 0 1
studies,no 1.0 0.000143348623853 0 1 -1
paw,at 1.0 0.000143348623853 0 1 -1
subjects,mean 1.0 0.000143348623853 1 0 1
ci,by 1.0 0.000143348623853 0 1 -1
decreased,renal 0.333333333333 0.000143348623853 1 2 -1
pharmacokinetics,parameters 1.0 0.000143348623853 1 0 1
treated,concurrently 0.2 0.000143348623853 3 2 1
achlorhydria,and 1.0 0.000143348623853 0 1 -1
vectors,containing 1.0 0.000143348623853 0 1 -1
levels,after 1.0 0.000143348623853 0 1 -1
necessitate,reduction 1.0 0.000143348623853 0 1 -1
of,parorchis 1.0 0.000286697247706 0 2 -2
been,drawn 1.0 0.000143348623853 0 1 -1
mice,one 1.0 0.000143348623853 0 1 -1
where,definitely 1.0 0.000143348623853 1 0 1
to,half 1.0 0.000143348623853 1 0 1
but,would 1.0 0.000143348623853 0 1 -1
bid,for 0.333333333333 0.00043004587156 6 3 3
moderate,cyp1a2 1.0 0.000143348623853 1 0 1
rhabdomyolysis,resulting 1.0 0.000143348623853 0 1 -1
is,withdrawn 0.75 0.000860091743119 1 7 -6
falls,vs 1.0 0.000143348623853 1 0 1
prolongs,the 1.0 0.000286697247706 2 0 2
days,a 1.0 0.000286697247706 2 0 2
in,vertigo 1.0 0.000143348623853 0 1 -1
mutagenic,in 1.0 0.000143348623853 0 1 -1
transient,asymptomatic 1.0 0.000143348623853 0 1 -1
use,lowest 1.0 0.000143348623853 1 0 1
days,n 1.0 0.000143348623853 0 1 -1
sharing,that 0.0 0.0 1 1 0
female,n 1.0 0.000143348623853 0 1 -1
competing,for 1.0 0.000286697247706 2 0 2
and,decreased 0.5 0.000860091743119 9 3 6
vital,signs 0.5 0.000286697247706 1 3 -2
produces,an 1.0 0.000286697247706 2 0 2
target,tissues 1.0 0.000143348623853 0 1 -1
parenteral,enzyme 1.0 0.000143348623853 0 1 -1
another,tnf 1.0 0.000143348623853 1 0 1
it,affect 1.0 0.000143348623853 0 1 -1
that,use 0.333333333333 0.000143348623853 1 2 -1
other,medication 1.0 0.000143348623853 0 1 -1
vitro,metabolic 1.0 0.000143348623853 0 1 -1
models,for 1.0 0.000143348623853 0 1 -1
that,epa 1.0 0.000286697247706 0 2 -2
higher,among 1.0 0.000143348623853 0 1 -1
when,flolan 1.0 0.000143348623853 1 0 1
patients,but 1.0 0.000143348623853 0 1 -1
ventricular,fibrulation 1.0 0.000143348623853 1 0 1
cells,with 1.0 0.000286697247706 0 2 -2
significant,pharmacokinetic 1.0 0.000716743119266 0 5 -5
areas,in 1.0 0.000143348623853 0 1 -1
controlled,on 1.0 0.000143348623853 1 0 1
with,neuromuscular 0.333333333333 0.000143348623853 2 1 1
about,but 1.0 0.000143348623853 0 1 -1
of,events 1.0 0.000143348623853 0 1 -1
following,cyclosporine 1.0 0.000143348623853 0 1 -1
thyroxine-binding,prealbumin 1.0 0.000143348623853 0 1 -1
vs,myocardial 1.0 0.000143348623853 1 0 1
through,inhibition 1.0 0.000143348623853 1 0 1
h,receptor 1.0 0.000143348623853 1 0 1
tid,was 1.0 0.000143348623853 1 0 1
medicine,should 1.0 0.000286697247706 0 2 -2
which,plasma 1.0 0.000286697247706 0 2 -2
subfraction,concentrations 1.0 0.000286697247706 0 2 -2
taken,before 1.0 0.000143348623853 0 1 -1
felodipine,may 1.0 0.000143348623853 0 1 -1
hand,had 1.0 0.000143348623853 0 1 -1
isozymes,in 1.0 0.000286697247706 0 2 -2
receiving,accutane 1.0 0.000143348623853 0 1 -1
sequence,however 1.0 0.000143348623853 0 1 -1
oxidation,elc 1.0 0.000143348623853 1 0 1
reach,to10 1.0 0.000143348623853 1 0 1
dolasetron,has 1.0 0.000143348623853 0 1 -1
approximately,one 1.0 0.000143348623853 1 0 1
increased,toxicity 1.0 0.000143348623853 0 1 -1
reduced,clozapine 1.0 0.000143348623853 0 1 -1
determined,with 1.0 0.00043004587156 3 0 3
acid,concentrations 1.0 0.000143348623853 0 1 -1
or,urine 1.0 0.000143348623853 0 1 -1
require,reduction 1.0 0.000286697247706 0 2 -2
were,also 0.714285714286 0.000716743119266 1 6 -5
resumed,during 1.0 0.000143348623853 0 1 -1
axert,is 1.0 0.000143348623853 0 1 -1
and,sensitization 1.0 0.000143348623853 0 1 -1
plus,was 0.0 0.0 1 1 0
describe,a 1.0 0.000143348623853 0 1 -1
anastrozole,did 1.0 0.000286697247706 0 2 -2
site,ie 1.0 0.000143348623853 0 1 -1
videx,to 1.0 0.000143348623853 1 0 1
purpose,of 1.0 0.000286697247706 0 2 -2
the,dmpge2 1.0 0.000143348623853 1 0 1
possible,adverse 1.0 0.000286697247706 0 2 -2
triple-immunosuppression,regimens 1.0 0.000143348623853 0 1 -1
that,gaba-positive 1.0 0.000143348623853 0 1 -1
stopping,an 1.0 0.000143348623853 1 0 1
protein-binding,displacement 1.0 0.000143348623853 0 1 -1
reveiving,phenytoin 1.0 0.000143348623853 1 0 1
metabolizes,may 1.0 0.000143348623853 0 1 -1
treatment-emergent,positive 1.0 0.000143348623853 0 1 -1
the,carcinogenic 1.0 0.000286697247706 0 2 -2
proteins,interacting 1.0 0.000143348623853 0 1 -1
t,max 0.666666666667 0.000573394495413 1 5 -4
two,sequential 1.0 0.000143348623853 0 1 -1
urine,remained 1.0 0.000143348623853 0 1 -1
measurements,of 1.0 0.000143348623853 1 0 1
the,loss 1.0 0.000143348623853 1 0 1
bioavailability,by 1.0 0.000143348623853 0 1 -1
volunteers,received 1.0 0.000143348623853 0 1 -1
angiomax,exhibited 1.0 0.000143348623853 0 1 -1
in,moribund 1.0 0.000143348623853 0 1 -1
this,practice 1.0 0.000143348623853 0 1 -1
for,antipsychotic 1.0 0.000143348623853 0 1 -1
tumors,when 1.0 0.000143348623853 0 1 -1
unbound,was 1.0 0.000143348623853 0 1 -1
enhancing,efficacious 1.0 0.000143348623853 0 1 -1
of,enhancement 1.0 0.000143348623853 0 1 -1
after,therapy 1.0 0.000143348623853 0 1 -1
solution,one 1.0 0.000143348623853 1 0 1
assays,of 1.0 0.000143348623853 0 1 -1
cefotan,may 1.0 0.000143348623853 0 1 -1
long-term,safety 1.0 0.000143348623853 0 1 -1
ergot,toxicity 1.0 0.000143348623853 0 1 -1
in,males 0.0 0.0 1 1 0
d2,in 1.0 0.000286697247706 0 2 -2
capsules,at 1.0 0.000143348623853 0 1 -1
results,that 1.0 0.00043004587156 0 3 -3
as,methyltetrahydro-folate 1.0 0.000143348623853 0 1 -1
disorder,including 1.0 0.000143348623853 1 0 1
clinical,effects 0.333333333333 0.000143348623853 1 2 -1
order,of 1.0 0.000143348623853 0 1 -1
pressure,reductions 1.0 0.000143348623853 1 0 1
product,erythro-fluorocitrate 1.0 0.000143348623853 0 1 -1
galloyl,esters 1.0 0.000143348623853 0 1 -1
the,length 1.0 0.000143348623853 0 1 -1
in,significant 0.0 0.0 1 1 0
between,these 1.0 0.000286697247706 0 2 -2
clinical,bleeding 1.0 0.000286697247706 2 0 2
decreased,hearing 1.0 0.000143348623853 1 0 1
all,physciains 1.0 0.000143348623853 0 1 -1
concomitantly,being 1.0 0.000143348623853 0 1 -1
lower,and 1.0 0.000286697247706 2 0 2
you,need 1.0 0.000143348623853 1 0 1
solutions,containing 0.5 0.000286697247706 3 1 2
patient,receiving 0.555555555556 0.00143348623853 4 14 -10
with,ribavirin 1.0 0.000286697247706 0 2 -2
under,certain 1.0 0.000286697247706 0 2 -2
termed,the 1.0 0.000143348623853 0 1 -1
forms,may 1.0 0.000143348623853 1 0 1
a,bile 1.0 0.000286697247706 2 0 2
or,avoided 1.0 0.000143348623853 1 0 1
also,reported 0.0 0.0 1 1 0
tests,since 1.0 0.000143348623853 0 1 -1
if,regranex 1.0 0.000143348623853 0 1 -1
potassium-sparing,such 1.0 0.000143348623853 0 1 -1
given,weekly 1.0 0.000143348623853 0 1 -1
profile,total 1.0 0.000143348623853 0 1 -1
rbc,were 1.0 0.000143348623853 0 1 -1
tapering,of 1.0 0.000143348623853 0 1 -1
with,varapamil 1.0 0.000143348623853 0 1 -1
similar,serum 1.0 0.000143348623853 0 1 -1
via,dehydrogenase 1.0 0.000143348623853 1 0 1
hplc,peak 1.0 0.000143348623853 0 1 -1
paclitaxel,in 1.0 0.000143348623853 1 0 1
also,be 0.25 0.000286697247706 3 5 -2
possible,complications 1.0 0.000143348623853 1 0 1
the,excreted 1.0 0.000143348623853 0 1 -1
clinical,studies 0.423728813559 0.00358371559633 17 42 -25
immunoreactive,after 1.0 0.000143348623853 0 1 -1
other,related 1.0 0.000286697247706 2 0 2
systemically-administered,oral 1.0 0.000143348623853 1 0 1
elevated,creatinine 1.0 0.000143348623853 0 1 -1
other,monomeric 1.0 0.000143348623853 0 1 -1
the,limbic 1.0 0.000286697247706 0 2 -2
antiarrhythmics,other 1.0 0.000143348623853 0 1 -1
can,then 1.0 0.000143348623853 0 1 -1
qtc,interval 0.333333333333 0.000286697247706 2 4 -2
with,modest 1.0 0.000143348623853 1 0 1
either,alone 0.5 0.000286697247706 1 3 -2
enzyme,could 1.0 0.000143348623853 0 1 -1
the,minimum 1.0 0.000286697247706 0 2 -2
administered,orally 0.333333333333 0.000143348623853 1 2 -1
use,during 1.0 0.000143348623853 1 0 1
concomitant,useof 1.0 0.000143348623853 1 0 1
concomitant,intake 1.0 0.000143348623853 0 1 -1
when,hcl 1.0 0.000143348623853 1 0 1
as,random 1.0 0.000143348623853 1 0 1
system,can 1.0 0.000143348623853 1 0 1
with,channel 1.0 0.000143348623853 1 0 1
of,myobloc 1.0 0.000143348623853 1 0 1
but,had 0.333333333333 0.000143348623853 1 2 -1
indications,for 1.0 0.000143348623853 0 1 -1
an,expression 1.0 0.000143348623853 0 1 -1
vitamin,supplements 1.0 0.000143348623853 1 0 1
desired,level 1.0 0.000286697247706 0 2 -2
the,various 1.0 0.000286697247706 0 2 -2
but,has 1.0 0.000143348623853 0 1 -1
two,should 1.0 0.000286697247706 0 2 -2
were,mp 1.0 0.000143348623853 0 1 -1
also,compromise 1.0 0.000143348623853 0 1 -1
with,clinical 1.0 0.000286697247706 0 2 -2
patient,survival 1.0 0.000143348623853 0 1 -1
dependence,usually 1.0 0.000143348623853 0 1 -1
treatments,to 1.0 0.000143348623853 0 1 -1
appropriate,dose 0.333333333333 0.000143348623853 1 2 -1
dialysis,may 1.0 0.000143348623853 1 0 1
directly,on 1.0 0.000143348623853 1 0 1
be,capable 1.0 0.000143348623853 1 0 1
close,monitoring 0.166666666667 0.000286697247706 7 5 2
phenobarbital,tegretol 1.0 0.000143348623853 1 0 1
pharmacology-pharmacokinetics,drug-drug 1.0 0.000143348623853 0 1 -1
was,added 0.25 0.000286697247706 5 3 2
cimetidine,atorvastatin 1.0 0.000143348623853 0 1 -1
not,inhibited 1.0 0.000143348623853 0 1 -1
can,avoid 1.0 0.000143348623853 1 0 1
acid,levels 1.0 0.000143348623853 0 1 -1
as,triple 1.0 0.000143348623853 0 1 -1
concomitantly,with 0.224489795918 0.00315366972477 60 38 22
near,mg 1.0 0.000143348623853 1 0 1
antihypertensive,agents 1.0 0.00043004587156 3 0 3
concomitant,agents 1.0 0.000143348623853 0 1 -1
infusion,rate 0.333333333333 0.000143348623853 2 1 1
a,main 1.0 0.000143348623853 0 1 -1
p,this 1.0 0.000143348623853 1 0 1
effect,when 0.75 0.000860091743119 7 1 6
systematically,investigated 1.0 0.000143348623853 0 1 -1
extended,sodium 1.0 0.000143348623853 0 1 -1
inhibiting,their 1.0 0.000143348623853 1 0 1
on,measures 1.0 0.000143348623853 0 1 -1
an,analog 1.0 0.000143348623853 0 1 -1
isoform,selective 1.0 0.000143348623853 0 1 -1
demonstrated,to 1.0 0.00043004587156 3 0 3
cyp,drug-metabolizing 1.0 0.000143348623853 0 1 -1
increase,and 0.333333333333 0.000143348623853 2 1 1
importance,brevibloc 1.0 0.000143348623853 1 0 1
chronic,toxicity 1.0 0.000143348623853 0 1 -1
immediate,side 1.0 0.000143348623853 0 1 -1
factors,like 1.0 0.000143348623853 0 1 -1
at,various 1.0 0.000143348623853 0 1 -1
crisis,until 1.0 0.000143348623853 1 0 1
conclusions,it 1.0 0.000143348623853 0 1 -1
with,used 1.0 0.000143348623853 0 1 -1
bolus-ifl,plus 1.0 0.000143348623853 0 1 -1
conclusions,in 1.0 0.000143348623853 0 1 -1
receiving,concomitant 0.0 0.0 4 4 0
other,neurotoxic 1.0 0.000143348623853 0 1 -1
or,has 1.0 0.000716743119266 5 0 5
hydrochloride,mg 1.0 0.000286697247706 0 2 -2
dispersible,buffered 1.0 0.000143348623853 1 0 1
major,ingredient 1.0 0.000143348623853 0 1 -1
acid,sympathomimet-ics 1.0 0.000143348623853 0 1 -1
or,had 0.0 0.0 1 1 0
their,metabolites 1.0 0.000143348623853 0 1 -1
x-ray,diffraction 1.0 0.000143348623853 0 1 -1
vi,of 1.0 0.000143348623853 0 1 -1
parental,such 1.0 0.000143348623853 1 0 1
from,marketing 1.0 0.000143348623853 1 0 1
vana,glycopeptide-resistant 1.0 0.000143348623853 0 1 -1
be,evaluated 0.0 0.0 1 1 0
used,cautiously 0.454545454545 0.000716743119266 8 3 5
and,not 1.0 0.000573394495413 0 4 -4
data,from 0.230769230769 0.00043004587156 5 8 -3
using,four 1.0 0.000143348623853 0 1 -1
sex,number 1.0 0.000143348623853 0 1 -1
have,produced 1.0 0.00043004587156 3 0 3
a,see 1.0 0.000143348623853 0 1 -1
coumarin-like,should 1.0 0.000143348623853 1 0 1
norpace,and 1.0 0.000143348623853 1 0 1
transcriptase,inhibitor 1.0 0.000143348623853 0 1 -1
with,busulfex 1.0 0.000143348623853 1 0 1
and,host 1.0 0.000143348623853 0 1 -1
because,false 1.0 0.000143348623853 0 1 -1
on,both 1.0 0.000143348623853 0 1 -1
fr,karst 1.0 0.000143348623853 0 1 -1
patients,the 0.333333333333 0.000860091743119 12 6 6
maximal,plasma 1.0 0.00043004587156 3 0 3
cytostatic,agent 1.0 0.000143348623853 1 0 1
examining,the 1.0 0.000143348623853 0 1 -1
affect,glucose 1.0 0.000286697247706 0 2 -2
pressure,and 1.0 0.00043004587156 0 3 -3
costs,of 1.0 0.000143348623853 0 1 -1
acid-catalyzed,ethanol-drug 1.0 0.000143348623853 0 1 -1
the,mediated 1.0 0.000143348623853 0 1 -1
marrow,depression 0.0 0.0 1 1 0
drugs,l-phenylalanine 1.0 0.000143348623853 1 0 1
m,failed 1.0 0.000143348623853 1 0 1
the,complete 1.0 0.000143348623853 0 1 -1
modest,degree 1.0 0.000286697247706 0 2 -2
tam,which 1.0 0.000143348623853 0 1 -1
fatal,adverse 1.0 0.000143348623853 0 1 -1
concert,with 1.0 0.000143348623853 0 1 -1
viii,coagulant 1.0 0.000286697247706 0 2 -2
reverses,when 1.0 0.000143348623853 0 1 -1
of,metal 1.0 0.000143348623853 0 1 -1
a,site 1.0 0.000143348623853 0 1 -1
aranesp,have 1.0 0.000143348623853 0 1 -1
efficacy,ectopic 1.0 0.000143348623853 0 1 -1
fungal,resistance 1.0 0.000143348623853 1 0 1
that,users 1.0 0.000286697247706 2 0 2
to,blunt 1.0 0.000286697247706 2 0 2
lesions,characterized 1.0 0.000143348623853 0 1 -1
parvum,growth 1.0 0.000143348623853 1 0 1
and,clinical 0.333333333333 0.000143348623853 1 2 -1
persistently,elevated 1.0 0.000143348623853 0 1 -1
treatment,there 1.0 0.000143348623853 0 1 -1
cancidas,reduced 1.0 0.000143348623853 1 0 1
atorvastatin,had 1.0 0.000143348623853 0 1 -1
metabolizers,had 1.0 0.000143348623853 0 1 -1
are,neither 1.0 0.000286697247706 0 2 -2
transaminases,bilirubin 1.0 0.000143348623853 0 1 -1
with,resulted 0.333333333333 0.000286697247706 4 2 2
safety,contraindications 1.0 0.000143348623853 0 1 -1
h,period 1.0 0.000143348623853 0 1 -1
approximately,increase 1.0 0.000143348623853 1 0 1
medicine,blood 1.0 0.000143348623853 1 0 1
inhibitors,rare 1.0 0.000143348623853 1 0 1
a,luciferase 1.0 0.000143348623853 0 1 -1
on,has 1.0 0.000143348623853 1 0 1
known,it 0.0 0.0 1 1 0
slight,decreases 1.0 0.000143348623853 1 0 1
acid,should 1.0 0.000143348623853 0 1 -1
mg,co-administered 1.0 0.000143348623853 1 0 1
epithelium,by 1.0 0.000143348623853 1 0 1
elevated,international 1.0 0.000143348623853 0 1 -1
n,n-diethyl 1.0 0.000143348623853 1 0 1
completely,block 1.0 0.000143348623853 1 0 1
and,aortic 1.0 0.000143348623853 0 1 -1
of,transient 1.0 0.000143348623853 0 1 -1
window,is 1.0 0.000143348623853 1 0 1
oral,medication 1.0 0.000143348623853 1 0 1
neglect,of 1.0 0.000143348623853 0 1 -1
binding,to 0.25 0.000286697247706 3 5 -2
as,because 1.0 0.000573394495413 4 0 4
adjustment,and 1.0 0.000286697247706 0 2 -2
but,the 0.142857142857 0.000143348623853 3 4 -1
of,pgp 1.0 0.000143348623853 0 1 -1
carbonate,the 1.0 0.000286697247706 2 0 2
in,healthy 0.0588235294118 0.00043004587156 24 27 -3
of,men 1.0 0.000143348623853 0 1 -1
butyrophenone,classes 1.0 0.000143348623853 1 0 1
acute,delirium 1.0 0.000143348623853 1 0 1
digoxin,volume 1.0 0.000143348623853 0 1 -1
digoxin,concomitant 0.0 0.0 1 1 0
l,from 0.0 0.0 1 1 0
eg,esophageal 1.0 0.000143348623853 0 1 -1
in,over 1.0 0.000143348623853 1 0 1
phenytoin,is 1.0 0.000573394495413 0 4 -4
w,and 1.0 0.000143348623853 1 0 1
phenytoin,if 1.0 0.000143348623853 1 0 1
not,observed 0.333333333333 0.000143348623853 1 2 -1
a,relationship 1.0 0.00043004587156 3 0 3
phenytoin,in 0.0 0.0 1 1 0
vitro,evaluation 1.0 0.000143348623853 0 1 -1
imidazole,and 0.0 0.0 1 1 0
blood,sugar 0.0 0.0 2 2 0
co-factors,could 1.0 0.000143348623853 0 1 -1
contribute,to 0.2 0.000143348623853 2 3 -1
plasma,lipid 1.0 0.000143348623853 0 1 -1
experience,with 0.555555555556 0.000716743119266 2 7 -5
or,induction 1.0 0.000143348623853 0 1 -1
suffer,from 1.0 0.000143348623853 0 1 -1
lymphatic,invasion 1.0 0.000143348623853 1 0 1
administered,intraperitoneally 1.0 0.000143348623853 0 1 -1
may,sensitize 0.0 0.0 1 1 0
mice,induced 1.0 0.000286697247706 0 2 -2
care,as 1.0 0.000143348623853 1 0 1
antizol,mg 1.0 0.000143348623853 1 0 1
rats,probably 1.0 0.000143348623853 0 1 -1
serious,adverse 1.0 0.000716743119266 0 5 -5
water,pill 1.0 0.000143348623853 0 1 -1
undetectable,release 1.0 0.000143348623853 0 1 -1
raptiva,should 1.0 0.000143348623853 1 0 1
soluble,particularly 1.0 0.000143348623853 0 1 -1
bleeding,complications 1.0 0.000286697247706 0 2 -2
kineret,when 1.0 0.000143348623853 0 1 -1
rhythm,following 1.0 0.000143348623853 1 0 1
not,alter 0.916666666667 0.00315366972477 1 23 -22
as,complications 1.0 0.000143348623853 0 1 -1
nad,dependent 0.0 0.0 1 1 0
by,intrathecal 1.0 0.000143348623853 0 1 -1
not,concurrently 1.0 0.000143348623853 1 0 1
ranitidine,in 1.0 0.000143348623853 1 0 1
and,s-warfarin 1.0 0.000143348623853 1 0 1
prohibited,in 1.0 0.000143348623853 0 1 -1
is,prolonged 1.0 0.000143348623853 0 1 -1
be,observed 0.0 0.0 21 21 0
interactions,has 1.0 0.000143348623853 0 1 -1
progestin-only,pills 1.0 0.000143348623853 1 0 1
successive,application 0.0 0.0 1 1 0
patient,demographics 1.0 0.000143348623853 0 1 -1
and,polyfuranoses 1.0 0.000143348623853 0 1 -1
treatments,of 1.0 0.000143348623853 0 1 -1
since,and 1.0 0.000286697247706 2 0 2
alter,the 0.589743589744 0.00329701834862 8 31 -23
infections,and 0.333333333333 0.000143348623853 2 1 1
elevated,in 1.0 0.000286697247706 0 2 -2
also,lowers 1.0 0.000143348623853 0 1 -1
acth,treatment 1.0 0.000143348623853 0 1 -1
however,severe 1.0 0.000143348623853 0 1 -1
examining,potential 1.0 0.000143348623853 0 1 -1
precipitating,factor 1.0 0.000143348623853 0 1 -1
including,remicade 1.0 0.000143348623853 1 0 1
antianxiety,agents 1.0 0.000286697247706 2 0 2
points,after 1.0 0.000143348623853 0 1 -1
exhibit,monoamine 1.0 0.000143348623853 1 0 1
frequent,condition 1.0 0.000143348623853 0 1 -1
dose-related,blockade 1.0 0.000143348623853 1 0 1
to,higher 0.0 0.0 1 1 0
in,local 1.0 0.000143348623853 0 1 -1
hormonal,differ 1.0 0.000143348623853 0 1 -1
enhances,the 0.6 0.00043004587156 4 1 3
renal,toxicity 0.333333333333 0.000143348623853 2 1 1
the,pharmacologic 0.5 0.000286697247706 3 1 2
free,may 1.0 0.000143348623853 1 0 1
importance,sufficient 0.6 0.00043004587156 1 4 -3
primarily,being 1.0 0.000143348623853 0 1 -1
agents,interfering 1.0 0.000286697247706 2 0 2
twice-a,day 1.0 0.000143348623853 0 1 -1
the,introduction 1.0 0.000143348623853 1 0 1
whom,this 1.0 0.000143348623853 0 1 -1
with,dopa 1.0 0.000143348623853 0 1 -1
individuals,known 1.0 0.000143348623853 0 1 -1
lexapro,and 0.0 0.0 1 1 0
were,challenged 1.0 0.000143348623853 0 1 -1
differ,in 1.0 0.000143348623853 0 1 -1
cases,was 1.0 0.000143348623853 0 1 -1
intake,of 0.333333333333 0.000573394495413 4 8 -4
smokers,have 1.0 0.000143348623853 0 1 -1
adversely,affect 0.0 0.0 1 1 0
an,overactive 1.0 0.000143348623853 0 1 -1
example,the 1.0 0.000143348623853 0 1 -1
been,postmarketing 1.0 0.000143348623853 1 0 1
was,noted 0.6 0.00043004587156 1 4 -3
interactions,and 0.5 0.000286697247706 1 3 -2
received,ace 1.0 0.000143348623853 0 1 -1
medications,or 0.25 0.000286697247706 5 3 2
cisplatin,hcl 1.0 0.000143348623853 1 0 1
a,penicillin-type 1.0 0.000143348623853 1 0 1
inflammatory,disorders 1.0 0.000143348623853 1 0 1
active,ra 1.0 0.000286697247706 2 0 2
in,two 0.111111111111 0.000143348623853 4 5 -1
magnesium-,and 1.0 0.000286697247706 2 0 2
shown,consistent 1.0 0.000143348623853 0 1 -1
variables,for 1.0 0.000143348623853 0 1 -1
average,steady- 1.0 0.000143348623853 1 0 1
those,required 1.0 0.000143348623853 1 0 1
and,pulmonary 1.0 0.000143348623853 0 1 -1
of,adenocarcinomas 1.0 0.000143348623853 1 0 1
and,more 0.333333333333 0.000143348623853 1 2 -1
hcl,usually 1.0 0.000143348623853 1 0 1
induced,with 1.0 0.000143348623853 1 0 1
profiles,and 1.0 0.000143348623853 0 1 -1
through,udp-glucuronyl 1.0 0.000143348623853 0 1 -1
doses,vioxx 1.0 0.000143348623853 1 0 1
some,cases 1.0 0.00043004587156 0 3 -3
prospective,long-term 1.0 0.000143348623853 0 1 -1
gdh,pqq-based 1.0 0.000143348623853 0 1 -1
and,inhaled 1.0 0.000143348623853 0 1 -1
also,the 1.0 0.000143348623853 0 1 -1
drug,may 1.0 0.000143348623853 0 1 -1
becomes,metabolically 1.0 0.000143348623853 0 1 -1
the,neuronal 1.0 0.000143348623853 0 1 -1
pbi,t4 1.0 0.000573394495413 0 4 -4
liver,aminotransferases 1.0 0.000143348623853 0 1 -1
and,for 0.333333333333 0.000573394495413 4 8 -4
confirms,the 1.0 0.000143348623853 0 1 -1
which,are 0.333333333333 0.000716743119266 5 10 -5
provided,this 1.0 0.000143348623853 1 0 1
overdosage,since 1.0 0.000143348623853 1 0 1
xr,patients 1.0 0.000143348623853 0 1 -1
ois,in 1.0 0.000143348623853 0 1 -1
the,group 1.0 0.00043004587156 0 3 -3
total,glutathione 1.0 0.000143348623853 0 1 -1
reactions,compared 1.0 0.000143348623853 0 1 -1
tylenol,such 1.0 0.000143348623853 1 0 1
one,mechanism 1.0 0.000143348623853 0 1 -1
a,different 0.333333333333 0.000143348623853 1 2 -1
and,vasodilators 1.0 0.000143348623853 1 0 1
of,neurons 1.0 0.000573394495413 0 4 -4
and,abciximab 1.0 0.000143348623853 1 0 1
occult,blood 1.0 0.000143348623853 0 1 -1
when,inspra 1.0 0.000143348623853 1 0 1
in,seriously 1.0 0.000143348623853 0 1 -1
reported,rarely 0.5 0.000286697247706 3 1 2
including,based 1.0 0.000143348623853 1 0 1
bleeding,times 1.0 0.000143348623853 0 1 -1
a,release 1.0 0.000143348623853 0 1 -1
felbatol,gris-peg 1.0 0.000143348623853 1 0 1
either,agent 1.0 0.000286697247706 0 2 -2
b-cell,lymphomas 1.0 0.000286697247706 0 2 -2
effect,seen 1.0 0.000143348623853 0 1 -1
epoxide,concentrations 1.0 0.000143348623853 0 1 -1
diaphoresis,emesis 1.0 0.000143348623853 0 1 -1
mg,as 1.0 0.000286697247706 0 2 -2
well,correlated 1.0 0.000143348623853 0 1 -1
mice,with 1.0 0.000143348623853 0 1 -1
mainly,responsible 1.0 0.000143348623853 1 0 1
cyp2e1,and 1.0 0.000143348623853 0 1 -1
oral,route 1.0 0.000143348623853 0 1 -1
usual,dose 0.5 0.000286697247706 3 1 2
plasma,exposures 1.0 0.000143348623853 1 0 1
vision,have 1.0 0.000286697247706 2 0 2
supplied,aerolizertm 1.0 0.000143348623853 0 1 -1
system,regardless 1.0 0.000143348623853 1 0 1
of,thioethers 1.0 0.000143348623853 0 1 -1
or,increased 0.0 0.0 2 2 0
ames,bacterial 1.0 0.000143348623853 0 1 -1
of,schistosoma 1.0 0.000143348623853 0 1 -1
therapeutic,dose 0.333333333333 0.000143348623853 1 2 -1
which,had 1.0 0.000143348623853 0 1 -1
diastolic,blood 1.0 0.000143348623853 1 0 1
summary,of 1.0 0.000143348623853 0 1 -1
vaccinations,with 1.0 0.000143348623853 0 1 -1
expected,plasma 1.0 0.00100344036697 0 7 -7
however,can 1.0 0.000143348623853 0 1 -1
mg,followed 1.0 0.000143348623853 0 1 -1
inwomen,taking 1.0 0.000143348623853 1 0 1
caution,in 0.12 0.00043004587156 14 11 3
duloxetine,it 1.0 0.000143348623853 0 1 -1
hypertension,did 1.0 0.000143348623853 0 1 -1
caution,if 1.0 0.000143348623853 1 0 1
value,is 1.0 0.000143348623853 0 1 -1
presented,here 1.0 0.000143348623853 0 1 -1
duloxetine,in 1.0 0.000143348623853 0 1 -1
agents,negative 1.0 0.000143348623853 1 0 1
differences,may 1.0 0.000143348623853 0 1 -1
caution,is 0.117647058824 0.000573394495413 19 15 4
of,lanoxin 1.0 0.000143348623853 1 0 1
fecal,excretion 1.0 0.000143348623853 0 1 -1
this,combinational 1.0 0.000143348623853 0 1 -1
least,partially 1.0 0.000143348623853 1 0 1
received,both 1.0 0.000143348623853 0 1 -1
encodes,a 1.0 0.000143348623853 0 1 -1
multiple,dose 0.2 0.000143348623853 2 3 -1
nearly,times 1.0 0.000143348623853 0 1 -1
setting,rural 1.0 0.000143348623853 0 1 -1
of,keflex 1.0 0.000143348623853 0 1 -1
when,orudis 1.0 0.000143348623853 0 1 -1
unavailable,a 1.0 0.000143348623853 0 1 -1
agent,contraindicated 1.0 0.000143348623853 0 1 -1
cytochrome,p-450 0.0769230769231 0.000143348623853 7 6 1
sensipar,is 1.0 0.00043004587156 0 3 -3
a,threshold 1.0 0.000143348623853 0 1 -1
another,investigator 1.0 0.000286697247706 0 2 -2
subacute,hepatitis 1.0 0.000143348623853 0 1 -1
periodic,intervals 1.0 0.000143348623853 1 0 1
definitely,that 1.0 0.000143348623853 0 1 -1
which,has 0.333333333333 0.000143348623853 1 2 -1
meq,or 1.0 0.000143348623853 0 1 -1
fsh,or 1.0 0.000143348623853 0 1 -1
given,dose 1.0 0.000716743119266 0 5 -5
kinetic,characteristics 1.0 0.000143348623853 0 1 -1
may,under 1.0 0.000143348623853 0 1 -1
on,specific 1.0 0.000143348623853 0 1 -1
significantly,impaired 1.0 0.000143348623853 0 1 -1
of,negative 1.0 0.000286697247706 0 2 -2
m2,and 1.0 0.000143348623853 1 0 1
interactions,of 0.272727272727 0.00043004587156 4 7 -3
neurologic,disorders 1.0 0.000143348623853 0 1 -1
supplementary,oral 1.0 0.000143348623853 0 1 -1
potassium,prinivil 1.0 0.000143348623853 1 0 1
interactions,on 1.0 0.000143348623853 0 1 -1
cynomolgus,monkeys 1.0 0.000573394495413 0 4 -4
is,present 1.0 0.000286697247706 0 2 -2
the,manifestation 1.0 0.000143348623853 1 0 1
natural,and 1.0 0.000143348623853 0 1 -1
unless,absolute 1.0 0.000143348623853 0 1 -1
causing,increased 1.0 0.000143348623853 1 0 1
profound,and 1.0 0.000143348623853 0 1 -1
xanthine,oxidase 1.0 0.000143348623853 0 1 -1
little,change 1.0 0.000143348623853 1 0 1
precautions,appear 1.0 0.000143348623853 0 1 -1
blood,sampling 1.0 0.000143348623853 0 1 -1
the,chick 1.0 0.000143348623853 0 1 -1
agents,without 1.0 0.000143348623853 0 1 -1
usually,results 1.0 0.000143348623853 1 0 1
trial,using 1.0 0.000143348623853 1 0 1
in,mouse 1.0 0.000143348623853 0 1 -1
narcotic,general 1.0 0.000143348623853 1 0 1
seen,after 0.0 0.0 1 1 0
collaboration,with 1.0 0.000143348623853 0 1 -1
trial,there 1.0 0.000143348623853 0 1 -1
hydroxide-containing,maalox 1.0 0.000143348623853 0 1 -1
acid,combination 1.0 0.000286697247706 2 0 2
indomethacin,indomethacin 1.0 0.000143348623853 1 0 1
resulting,mixture 1.0 0.000143348623853 0 1 -1
wistar,rats 1.0 0.00043004587156 0 3 -3
brain,memory 1.0 0.000143348623853 0 1 -1
this,increase 0.6 0.00043004587156 1 4 -3
developing,rhabdomyolysis 1.0 0.000143348623853 0 1 -1
multiple-dose,study 0.0 0.0 1 1 0
provide,medical 1.0 0.000143348623853 0 1 -1
glycosides,concurrent 1.0 0.000143348623853 0 1 -1
accumulation,in 1.0 0.000143348623853 1 0 1
serotonin,releaser 1.0 0.000143348623853 1 0 1
tml,or 1.0 0.000143348623853 0 1 -1
has,orphan 1.0 0.000143348623853 0 1 -1
is,patient 1.0 0.000143348623853 0 1 -1
is,prone 1.0 0.000143348623853 0 1 -1
or,primidone 1.0 0.000143348623853 0 1 -1
nimbex,is 0.0 0.0 1 1 0
mild-to,moderate 1.0 0.000143348623853 0 1 -1
by,their 1.0 0.000143348623853 0 1 -1
given,hour 1.0 0.000143348623853 1 0 1
the,half-life 0.666666666667 0.000573394495413 5 1 4
time,points 1.0 0.000143348623853 0 1 -1
systematically,studied 1.0 0.000143348623853 1 0 1
after,dosing 1.0 0.000286697247706 0 2 -2
cyclosporine,modest 1.0 0.000143348623853 1 0 1
severe,weakness 1.0 0.000143348623853 1 0 1
this,was 0.6 0.00043004587156 1 4 -3
breast,feeding 1.0 0.000143348623853 0 1 -1
theophylline,the 1.0 0.000286697247706 0 2 -2
broadly,the 1.0 0.000143348623853 0 1 -1
cancers,it 1.0 0.000143348623853 0 1 -1
dosage,of 0.411764705882 0.00200688073394 10 24 -14
daily,alternating 1.0 0.000143348623853 0 1 -1
been,fully 1.0 0.000143348623853 1 0 1
six-healthy,male 1.0 0.000143348623853 0 1 -1
selective,agonists 1.0 0.000143348623853 0 1 -1
for,colazal 1.0 0.000143348623853 0 1 -1
systemic,anticholinesterase 1.0 0.000143348623853 0 1 -1
two,clinical 1.0 0.000143348623853 1 0 1
injectables,are 1.0 0.000143348623853 0 1 -1
useful,in 0.333333333333 0.000143348623853 1 2 -1
of,up 1.0 0.000286697247706 0 2 -2
nephrotoxicity,associated 1.0 0.000143348623853 0 1 -1
profiles,in 1.0 0.000143348623853 0 1 -1
life-threatening,situations 1.0 0.000143348623853 0 1 -1
metabolite,norfluoxe-tine 1.0 0.000143348623853 0 1 -1
filtration,rate 1.0 0.000143348623853 0 1 -1
about,three 1.0 0.000143348623853 0 1 -1
as,beta-adrenergic 1.0 0.000143348623853 0 1 -1
occur,within 1.0 0.000143348623853 0 1 -1
and,wide 1.0 0.000143348623853 0 1 -1
one,reported 1.0 0.000143348623853 1 0 1
of,um 1.0 0.000143348623853 0 1 -1
can,enhance 1.0 0.000143348623853 0 1 -1
pd,studies 1.0 0.000143348623853 0 1 -1
this,has 0.428571428571 0.00043004587156 2 5 -3
of,neuropathy 1.0 0.000143348623853 0 1 -1
equetrotm,it 0.333333333333 0.000143348623853 1 2 -1
equetrotm,is 1.0 0.000143348623853 1 0 1
are,conflicting 1.0 0.000143348623853 1 0 1
induce,or 1.0 0.000286697247706 0 2 -2
occasional,literature 1.0 0.000143348623853 1 0 1
enzymes,d6 1.0 0.000286697247706 0 2 -2
study,week 1.0 0.000143348623853 0 1 -1
the,presence 0.416666666667 0.00286697247706 14 34 -20
using,for 1.0 0.000286697247706 0 2 -2
etc,or 1.0 0.000143348623853 1 0 1
than,for 0.142857142857 0.000143348623853 3 4 -1
the,capsule 0.333333333333 0.000143348623853 2 1 1
increase,of 0.5 0.000860091743119 9 3 6
of,tambocor 0.0 0.0 2 2 0
increased,amounts 1.0 0.000143348623853 0 1 -1
or,prophylactic 1.0 0.000143348623853 0 1 -1
and,anti 1.0 0.000143348623853 0 1 -1
pulmonary,toxicity 1.0 0.000143348623853 1 0 1
damage,produced 1.0 0.000143348623853 1 0 1
decreases,the 0.5 0.000286697247706 3 1 2
non-selective,monoamine 1.0 0.000143348623853 0 1 -1
states,to 1.0 0.000143348623853 1 0 1
the,hyperuricemic 1.0 0.000286697247706 2 0 2
phase,i 0.0 0.0 1 1 0
minimal,alterations 1.0 0.000143348623853 0 1 -1
potassium-sparing,including 1.0 0.000143348623853 1 0 1
life-,threatening 1.0 0.000143348623853 1 0 1
antihypertensive,effect 0.818181818182 0.00129013761468 10 1 9
regarding,asthma 1.0 0.000143348623853 0 1 -1
tightly,bound 1.0 0.000143348623853 0 1 -1
lucidum,fr 1.0 0.000143348623853 0 1 -1
by,chloral 1.0 0.000143348623853 0 1 -1
to,compete 1.0 0.000143348623853 0 1 -1
to,compared 1.0 0.000143348623853 1 0 1
produce,adverse 1.0 0.000143348623853 0 1 -1
of,variability 1.0 0.000143348623853 0 1 -1
time,has 1.0 0.000286697247706 0 2 -2
significantly,lowering 1.0 0.000143348623853 0 1 -1
and,such 0.5 0.000286697247706 3 1 2
mephenytoin,mesantoin 1.0 0.000143348623853 0 1 -1
disorders,unrelated 1.0 0.000143348623853 0 1 -1
max,t 1.0 0.000143348623853 0 1 -1
maoi,as 1.0 0.000286697247706 2 0 2
max,c 1.0 0.000143348623853 0 1 -1
the,seizure 1.0 0.000143348623853 1 0 1
cercariae,exposed 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,is 1.0 0.000286697247706 2 0 2
ace,inhibitor 1.0 0.00043004587156 3 0 3
was,expressed 1.0 0.000143348623853 0 1 -1
fluid,transfers 1.0 0.000143348623853 0 1 -1
get,the 1.0 0.000143348623853 0 1 -1
even,in 1.0 0.000143348623853 1 0 1
physician,should 0.333333333333 0.000286697247706 2 4 -2
preliminary,results 1.0 0.000286697247706 0 2 -2
state,levels 1.0 0.000143348623853 0 1 -1
reactions,resemble 1.0 0.000143348623853 0 1 -1
bid,otc 1.0 0.000143348623853 1 0 1
with,crohn 1.0 0.000143348623853 0 1 -1
literature,suggests 1.0 0.000143348623853 0 1 -1
some,clinicians 1.0 0.000143348623853 0 1 -1
other,enzyme- 1.0 0.000286697247706 2 0 2
chain,is 1.0 0.000143348623853 0 1 -1
hyperuricemia,present 1.0 0.000143348623853 1 0 1
study,demonstrated 0.333333333333 0.000143348623853 2 1 1
increased,half-life 1.0 0.000143348623853 1 0 1
the,low 1.0 0.000143348623853 0 1 -1
with,citrate 1.0 0.000143348623853 1 0 1
has,shown 0.454545454545 0.000716743119266 8 3 5
approximate,reduction 1.0 0.000143348623853 1 0 1
of,strains 1.0 0.000143348623853 0 1 -1
ribavirin,can 1.0 0.000143348623853 1 0 1
that,precipitation 1.0 0.000143348623853 0 1 -1
may,have 0.0285714285714 0.000143348623853 18 17 1
pms,will 1.0 0.000143348623853 0 1 -1
may,depend 1.0 0.000286697247706 0 2 -2
intensify,electrolyte 1.0 0.000143348623853 0 1 -1
affect,protein 1.0 0.000143348623853 0 1 -1
intake,for 1.0 0.000143348623853 1 0 1
symptoms,leukocytosis 1.0 0.000143348623853 1 0 1
oral,solution 1.0 0.00114678899083 8 0 8
valium,is 1.0 0.000143348623853 0 1 -1
group,clinical 1.0 0.000143348623853 0 1 -1
are,impaired 1.0 0.000143348623853 0 1 -1
d,was 1.0 0.000143348623853 1 0 1
medication,on 1.0 0.000143348623853 0 1 -1
patient,only 1.0 0.000143348623853 1 0 1
relevant,inhibitory 1.0 0.000143348623853 0 1 -1
using,a 0.333333333333 0.000143348623853 1 2 -1
autoimmune,and 1.0 0.000143348623853 1 0 1
the,consumption 1.0 0.000143348623853 1 0 1
adjustment,when 1.0 0.000286697247706 0 2 -2
pyrroloquinolinequinone,gdh 1.0 0.000143348623853 0 1 -1
to,three 0.333333333333 0.000143348623853 2 1 1
a,beta 1.0 0.000143348623853 1 0 1
parameter,values 1.0 0.000143348623853 0 1 -1
hypermagnesemia,and 1.0 0.00043004587156 3 0 3
antibiotics,macrolide 1.0 0.000143348623853 1 0 1
too,much 0.0 0.0 1 1 0
regimens,prediction 1.0 0.000143348623853 0 1 -1
changing,from 1.0 0.000143348623853 0 1 -1
platelets,and 1.0 0.000143348623853 0 1 -1
concomitant,oral 1.0 0.000286697247706 2 0 2
not,bear 1.0 0.000143348623853 1 0 1
when,abilify 1.0 0.000143348623853 1 0 1
the,utility 1.0 0.000143348623853 0 1 -1
status,changes 1.0 0.000143348623853 1 0 1
for,tubular 1.0 0.000143348623853 1 0 1
with,skin 1.0 0.000143348623853 0 1 -1
and,acetylsalicylic 0.0 0.0 1 1 0
of,rejection 1.0 0.000143348623853 0 1 -1
k,oral 1.0 0.000143348623853 1 0 1
weight,heparins 1.0 0.000143348623853 0 1 -1
either,nanm 1.0 0.000143348623853 1 0 1
hypotension,edema 1.0 0.000143348623853 0 1 -1
nitrous,oxide 0.0 0.0 1 1 0
interactions,because 1.0 0.000286697247706 0 2 -2
potentially,interact 1.0 0.000143348623853 0 1 -1
papers,published 1.0 0.000143348623853 0 1 -1
dose,range 0.0 0.0 2 2 0
to,significantly 0.0 0.0 1 1 0
example,inhibitors 1.0 0.000143348623853 0 1 -1
corticosteroids,may 0.0 0.0 2 2 0
b-induced,hypokalemia 1.0 0.000286697247706 2 0 2
of,cmc-cys 1.0 0.000143348623853 0 1 -1
faecium,to 1.0 0.000143348623853 0 1 -1
responding,whereas 1.0 0.000143348623853 0 1 -1
editorials,concerning 1.0 0.000143348623853 0 1 -1
scores,on 1.0 0.000143348623853 1 0 1
calcium-containing,preparations 1.0 0.00043004587156 0 3 -3
addition,certain 1.0 0.00100344036697 0 7 -7
iegs,are 1.0 0.000143348623853 0 1 -1
factor,bacterial 1.0 0.000143348623853 0 1 -1
periods,were 1.0 0.000143348623853 0 1 -1
high,doses 0.25 0.000573394495413 10 6 4
changes,to 0.0 0.0 1 1 0
decreased,activity 1.0 0.000143348623853 0 1 -1
and,editorials 1.0 0.000143348623853 0 1 -1
presumably,through 1.0 0.000143348623853 1 0 1
fosinopril,sodium 1.0 0.000143348623853 1 0 1
pivoxil,resulted 1.0 0.000143348623853 1 0 1
one-fourth,of 1.0 0.000143348623853 1 0 1
vivo,the 1.0 0.000286697247706 2 0 2
provide,the 1.0 0.000143348623853 0 1 -1
medications,containing 1.0 0.000143348623853 1 0 1
strain,were 1.0 0.000143348623853 0 1 -1
serum,concentration 0.230769230769 0.00043004587156 8 5 3
in,opioid-dependent 1.0 0.000143348623853 0 1 -1
and,viracept 0.333333333333 0.000143348623853 2 1 1
also,decrease 1.0 0.00043004587156 3 0 3
significantly,underestimates 1.0 0.000143348623853 0 1 -1
to,model 1.0 0.000143348623853 0 1 -1
where,endothelial 1.0 0.000143348623853 0 1 -1
unchanged,or 1.0 0.000143348623853 0 1 -1
maalox,coadministration 1.0 0.000143348623853 0 1 -1
to,withhold 1.0 0.000143348623853 1 0 1
profile,seen 1.0 0.000143348623853 0 1 -1
sugar,some 1.0 0.000143348623853 0 1 -1
resins,an 1.0 0.000143348623853 1 0 1
chemical,or 1.0 0.000143348623853 0 1 -1
sixty,minutes 1.0 0.000143348623853 1 0 1
rats,showed 1.0 0.000143348623853 0 1 -1
after,nalidixic 1.0 0.000143348623853 0 1 -1
inhibition,and 0.428571428571 0.00043004587156 5 2 3
were,sampled 1.0 0.000143348623853 0 1 -1
of,one 0.636363636364 0.00100344036697 2 9 -7
from,regression 1.0 0.000143348623853 1 0 1
the,clinical 0.803921568627 0.00587729357798 5 46 -41
a,baseline 1.0 0.000143348623853 1 0 1
serum,triglyceride 1.0 0.000286697247706 0 2 -2
allows,to 1.0 0.000143348623853 1 0 1
other,eg 1.0 0.000143348623853 0 1 -1
other,added 1.0 0.000143348623853 0 1 -1
suggests,the 1.0 0.000143348623853 1 0 1
the,photosensitivity 1.0 0.000143348623853 1 0 1
sequence,ie 1.0 0.000143348623853 1 0 1
dosage,must 1.0 0.00043004587156 3 0 3
years,with 1.0 0.000143348623853 0 1 -1
griseofulvin,griseofulvin 1.0 0.000143348623853 1 0 1
inhibitor,has 1.0 0.000143348623853 1 0 1
aspirin,when 1.0 0.000143348623853 1 0 1
a,patients 1.0 0.000143348623853 1 0 1
omega-agatoxin,via-resistant 1.0 0.000143348623853 0 1 -1
bilirubin,levels 1.0 0.000143348623853 0 1 -1
of,gastrointestinal 1.0 0.000573394495413 4 0 4
two,inhibitors 1.0 0.000143348623853 0 1 -1
xr,was 1.0 0.000143348623853 0 1 -1
false-positive,findings 1.0 0.000143348623853 0 1 -1
patient,appeared 1.0 0.000143348623853 1 0 1
re-treated,with 1.0 0.000143348623853 0 1 -1
affect,platelet 0.0 0.0 1 1 0
chlorpromazine,chlorpromazine 1.0 0.000286697247706 2 0 2
worsen,side 1.0 0.000143348623853 1 0 1
and,oxo-desethylzaleplon 1.0 0.000143348623853 0 1 -1
desbutyl,levobupivacaine 1.0 0.000143348623853 0 1 -1
and,others 0.428571428571 0.00043004587156 2 5 -3
with,parasympathomimetic 1.0 0.000143348623853 0 1 -1
within,two 1.0 0.000143348623853 1 0 1
given,for 1.0 0.000286697247706 0 2 -2
in,clinically 0.666666666667 0.000573394495413 1 5 -4
dependent,hypertension 1.0 0.000143348623853 1 0 1
or,gonadal 1.0 0.000143348623853 0 1 -1
superior,antipsychotic 1.0 0.000143348623853 0 1 -1
mg,respectively 0.0 0.0 2 2 0
otc,dose 1.0 0.000143348623853 1 0 1
vivo,platelet 1.0 0.000143348623853 0 1 -1
effect,its 1.0 0.000143348623853 1 0 1
if,there 1.0 0.000573394495413 0 4 -4
cyp1a2,activity 1.0 0.000143348623853 0 1 -1
with,emphasis 1.0 0.000143348623853 0 1 -1
ovarian,cancer 1.0 0.000143348623853 1 0 1
by,p450iid6 1.0 0.000143348623853 0 1 -1
with,high 0.428571428571 0.00043004587156 2 5 -3
demonstrated,renal 1.0 0.000143348623853 0 1 -1
because,these 1.0 0.000143348623853 1 0 1
for,triacylglycerol 1.0 0.000143348623853 0 1 -1
theories,assume 1.0 0.000143348623853 0 1 -1
the,first 0.538461538462 0.00200688073394 6 20 -14
intravenous,misuse 1.0 0.000143348623853 1 0 1
myasthenic,weakness 1.0 0.000286697247706 0 2 -2
demonstrate,that 0.75 0.000860091743119 1 7 -6
when,pletal 1.0 0.000143348623853 1 0 1
membrane,and 1.0 0.000143348623853 0 1 -1
increase,certain 1.0 0.000143348623853 0 1 -1
on,concurrent 1.0 0.000143348623853 0 1 -1
class,to 0.6 0.00043004587156 4 1 3
triazolopyridazines,and 1.0 0.000143348623853 1 0 1
to,initiation 0.0909090909091 0.000143348623853 5 6 -1
other,given 1.0 0.000143348623853 1 0 1
sign,of 1.0 0.000143348623853 0 1 -1
arrhythmia,and 1.0 0.000143348623853 1 0 1
impaired,liver 1.0 0.000143348623853 0 1 -1
be,expected 0.2 0.000860091743119 12 18 -6
alkaloids,amphetamines 1.0 0.000286697247706 2 0 2
rare,but 1.0 0.000143348623853 1 0 1
with,few 1.0 0.000143348623853 0 1 -1
argatroban,g 1.0 0.000143348623853 0 1 -1
by,baseline 1.0 0.000143348623853 0 1 -1
contribute,in 1.0 0.000143348623853 0 1 -1
clinical,response 1.0 0.000143348623853 0 1 -1
at,mg 0.0 0.0 12 12 0
difluoro-2,propanol 0.0 0.0 2 2 0
presumably,acts 1.0 0.000143348623853 1 0 1
t4,by 1.0 0.000286697247706 0 2 -2
coadministered,the 1.0 0.000143348623853 1 0 1
the,course 0.714285714286 0.000716743119266 1 6 -5
into,mice 1.0 0.000143348623853 0 1 -1
enroll,patients 1.0 0.000143348623853 0 1 -1
ibuprofen,ibuprofen 1.0 0.000143348623853 0 1 -1
dose-dependently,increased 1.0 0.000143348623853 0 1 -1
vivo,data 1.0 0.00043004587156 3 0 3
several,proteins 1.0 0.000143348623853 0 1 -1
by,cyp2c9 0.0 0.0 2 2 0
slurred,speech 1.0 0.000143348623853 0 1 -1
from,vasodilating 1.0 0.000143348623853 0 1 -1
interactions,is 1.0 0.000286697247706 0 2 -2
balance,in 1.0 0.000143348623853 0 1 -1
cyp2d6,duloxetine 1.0 0.000143348623853 0 1 -1
in,treating 1.0 0.000143348623853 0 1 -1
since,its 1.0 0.000143348623853 0 1 -1
selected,patient 1.0 0.000143348623853 0 1 -1
long-,term 1.0 0.000143348623853 1 0 1
the,controlled 1.0 0.000143348623853 0 1 -1
general,may 1.0 0.000143348623853 0 1 -1
peptides,in 1.0 0.000143348623853 0 1 -1
and,bones 1.0 0.00043004587156 0 3 -3
sulfonylureas,requirements 1.0 0.000143348623853 0 1 -1
therapy,allow 1.0 0.000143348623853 0 1 -1
equetrotm,may 0.333333333333 0.000143348623853 1 2 -1
each,group 1.0 0.000143348623853 0 1 -1
total,mucosal 1.0 0.000143348623853 0 1 -1
the,negative 1.0 0.000286697247706 0 2 -2
derivatives,dihydroergotamine 1.0 0.000143348623853 0 1 -1
sodium,colistimethate 1.0 0.000143348623853 1 0 1
with,close 1.0 0.000143348623853 1 0 1
clinitest,tablets 1.0 0.000716743119266 0 5 -5
electrolyte,alterations 1.0 0.000143348623853 0 1 -1
large,size 1.0 0.000143348623853 0 1 -1
have,congenital 1.0 0.000143348623853 0 1 -1
frequency,and 1.0 0.000286697247706 2 0 2
taking,cyp3a4 1.0 0.000143348623853 0 1 -1
identified,through 1.0 0.000143348623853 0 1 -1
trial,showed 1.0 0.000143348623853 0 1 -1
immediate,medical 1.0 0.000143348623853 0 1 -1
changes,induced 1.0 0.000286697247706 0 2 -2
of,two 0.428571428571 0.00043004587156 2 5 -3
either,concomitant 1.0 0.000143348623853 0 1 -1
auc,approximately 1.0 0.000143348623853 1 0 1
and,severity 1.0 0.000143348623853 1 0 1
worse,and 1.0 0.000143348623853 0 1 -1
clinical,trial 0.142857142857 0.000143348623853 3 4 -1
sites,during 1.0 0.000286697247706 2 0 2
between,clozapine 1.0 0.000143348623853 1 0 1
mechanisms,with 1.0 0.000143348623853 0 1 -1
to,refrain 1.0 0.000143348623853 0 1 -1
amine,since 1.0 0.000143348623853 1 0 1
chirocaine,that 1.0 0.000143348623853 0 1 -1
haloperidol,blocks 1.0 0.000286697247706 2 0 2
should,then 0.333333333333 0.000143348623853 1 2 -1
upper,limit 1.0 0.000286697247706 0 2 -2
specifically,lipid 1.0 0.000143348623853 0 1 -1
pressure,after 1.0 0.000573394495413 4 0 4
was,depressed 1.0 0.000143348623853 1 0 1
and,one 0.666666666667 0.000573394495413 1 5 -4
which,they 1.0 0.000143348623853 0 1 -1
bentiromide,may 1.0 0.000143348623853 1 0 1
depresses,activity 1.0 0.000143348623853 1 0 1
the,has 0.5 0.000286697247706 3 1 2
as,mug 1.0 0.000143348623853 0 1 -1
a,atp 1.0 0.000143348623853 0 1 -1
of,various 0.0 0.0 2 2 0
a,sulfonamide 1.0 0.000143348623853 1 0 1
week,of 1.0 0.000286697247706 0 2 -2
diagnostic,treatment 1.0 0.000143348623853 0 1 -1
a,using 1.0 0.000143348623853 0 1 -1
mouse,lymphoma 1.0 0.000143348623853 0 1 -1
for,further 1.0 0.000143348623853 0 1 -1
and,depletion 1.0 0.000143348623853 0 1 -1
even,when 0.142857142857 0.000143348623853 3 4 -1
combination,is 0.0 0.0 1 1 0
s-isomer,and 1.0 0.000143348623853 0 1 -1
the,str 1.0 0.00043004587156 0 3 -3
titration,to 1.0 0.000143348623853 1 0 1
when,coadministering 0.0 0.0 1 1 0
hitherto,unrecognized 1.0 0.000143348623853 0 1 -1
therapy,any 1.0 0.000143348623853 0 1 -1
therapy,and 0.25 0.000286697247706 3 5 -2
asymptomatic,but 1.0 0.000143348623853 0 1 -1
decreased,prothrombin 1.0 0.000286697247706 0 2 -2
combination,in 1.0 0.000143348623853 0 1 -1
c19,the 1.0 0.000143348623853 0 1 -1
usp,have 1.0 0.000143348623853 0 1 -1
menstrual,irregularities 1.0 0.000286697247706 0 2 -2
rat,spinal 1.0 0.000286697247706 0 2 -2
concentrations,increased 0.2 0.000143348623853 3 2 1
non-steroidal,and 1.0 0.000143348623853 1 0 1
bronchodilator,effect 1.0 0.000143348623853 0 1 -1
enzyme,abnormalities 1.0 0.000143348623853 1 0 1
recommendations,for 1.0 0.000143348623853 0 1 -1
potential,differences 1.0 0.000143348623853 0 1 -1
decreasing,responding 1.0 0.000143348623853 0 1 -1
rate,which 1.0 0.000143348623853 0 1 -1
back-up,methods 1.0 0.000143348623853 1 0 1
infusion,pumps 1.0 0.000143348623853 0 1 -1
mouse,model 1.0 0.000143348623853 0 1 -1
of,gram 1.0 0.000143348623853 1 0 1
especially,if 1.0 0.000286697247706 0 2 -2
symptoms,occur 1.0 0.000143348623853 1 0 1
by,one-third 1.0 0.000286697247706 0 2 -2
especially,in 0.111111111111 0.000143348623853 5 4 1
medications,and 0.2 0.000143348623853 2 3 -1
when,sustiva 0.0 0.0 1 1 0
a,well-controlled 1.0 0.000286697247706 0 2 -2
carinii,pneumonia 1.0 0.000143348623853 1 0 1
and,discrete 1.0 0.000143348623853 0 1 -1
drug,classes 1.0 0.000143348623853 0 1 -1
haart,on 1.0 0.000143348623853 0 1 -1
objective,our 1.0 0.000286697247706 0 2 -2
a,talk 1.0 0.000143348623853 0 1 -1
possible,adjustment 1.0 0.000143348623853 0 1 -1
like,does 1.0 0.000143348623853 0 1 -1
cardiac,function 0.333333333333 0.000143348623853 1 2 -1
a,nonfunctioning 1.0 0.000143348623853 1 0 1
strenuous,physical 1.0 0.000143348623853 0 1 -1
problems,in 1.0 0.000143348623853 0 1 -1
discontinuing,in 1.0 0.000143348623853 0 1 -1
to,volunteers 1.0 0.000143348623853 0 1 -1
frova,treatment 1.0 0.000143348623853 0 1 -1
trials,have 0.6 0.00043004587156 1 4 -3
been,identified 0.0 0.0 1 1 0
all,subsequentcourses 1.0 0.000143348623853 0 1 -1
aspirin,nonsteroidal 1.0 0.000143348623853 0 1 -1
abdominal,pain 1.0 0.000143348623853 0 1 -1
different,medicines 1.0 0.000143348623853 0 1 -1
therapeutic,ratio 1.0 0.000286697247706 0 2 -2
effects,constipation 1.0 0.000143348623853 0 1 -1
not,indicated 1.0 0.000143348623853 0 1 -1
their,blood 0.0 0.0 1 1 0
studies,the 1.0 0.000286697247706 0 2 -2
certain,medicines 1.0 0.000143348623853 0 1 -1
studied,increased 1.0 0.000143348623853 1 0 1
for,arava 1.0 0.000143348623853 1 0 1
mics,of 1.0 0.000143348623853 0 1 -1
acth,intensified 1.0 0.000286697247706 0 2 -2
activity,however 1.0 0.000143348623853 0 1 -1
impinger,for 1.0 0.000143348623853 0 1 -1
inhibits,proliferation 1.0 0.000143348623853 1 0 1
disintegrin,was 1.0 0.000143348623853 0 1 -1
of,functional 1.0 0.00043004587156 3 0 3
mtx,have 1.0 0.000143348623853 0 1 -1
of,habituation 1.0 0.000143348623853 0 1 -1
substrate,by 1.0 0.000716743119266 5 0 5
better,designed 1.0 0.000143348623853 0 1 -1
and,ultimately 1.0 0.000143348623853 0 1 -1
important,drug 1.0 0.000143348623853 1 0 1
skin,exfoliation 1.0 0.000143348623853 0 1 -1
increase,may 1.0 0.000143348623853 0 1 -1
agents,include 1.0 0.000143348623853 0 1 -1
of,azole 1.0 0.000143348623853 1 0 1
thromboplastin,times 1.0 0.000143348623853 0 1 -1
proteins,the 1.0 0.000143348623853 1 0 1
desloratadine,and 1.0 0.000143348623853 0 1 -1
conjugates,so 1.0 0.000143348623853 0 1 -1
by,maximum 1.0 0.000286697247706 0 2 -2
to,as 0.6 0.00043004587156 1 4 -3
to,an 0.0769230769231 0.000143348623853 6 7 -1
a,urine 1.0 0.000143348623853 0 1 -1
checkerboard,assay 1.0 0.000143348623853 0 1 -1
start,therapy 1.0 0.000143348623853 0 1 -1
tests,occur 1.0 0.000143348623853 1 0 1
for,days 0.134328358209 0.00129013761468 29 38 -9
be,undertaken 1.0 0.00043004587156 3 0 3
no,capacity 1.0 0.000143348623853 0 1 -1
conditions,for 1.0 0.000143348623853 0 1 -1
agents,a 1.0 0.000286697247706 0 2 -2
made,whether 1.0 0.00043004587156 0 3 -3
the,injection 1.0 0.000286697247706 0 2 -2
and,pharmacodynamics 1.0 0.000143348623853 0 1 -1
contrast,the 1.0 0.000143348623853 0 1 -1
who,also 1.0 0.000286697247706 0 2 -2
manufacturers,have 1.0 0.000143348623853 0 1 -1
antagonized,evidently 1.0 0.000143348623853 1 0 1
than,additive 1.0 0.000143348623853 1 0 1
factors,may 1.0 0.00043004587156 0 3 -3
therefore,plasma 1.0 0.000143348623853 1 0 1
their,dose 0.0 0.0 3 3 0
involved,either 1.0 0.000143348623853 0 1 -1
of,biocytin 1.0 0.000286697247706 0 2 -2
hazardous,when 1.0 0.000143348623853 0 1 -1
based,upon 1.0 0.000143348623853 1 0 1
compliance,and 1.0 0.000143348623853 0 1 -1
specific,methods 1.0 0.000143348623853 0 1 -1
hyperthermia,shivering 1.0 0.000143348623853 0 1 -1
local,and 0.0 0.0 1 1 0
data,beyond 1.0 0.000143348623853 0 1 -1
injections,of 1.0 0.000716743119266 0 5 -5
novel,targets 1.0 0.000143348623853 0 1 -1
authors,compared 1.0 0.000143348623853 0 1 -1
drugs,demonstrated 1.0 0.000143348623853 1 0 1
levels,generally 1.0 0.000143348623853 0 1 -1
release,capsules 1.0 0.000286697247706 2 0 2
from,prospective 1.0 0.000143348623853 0 1 -1
disease,requires 1.0 0.000143348623853 0 1 -1
agents,simultaneous 1.0 0.000143348623853 1 0 1
theo-dur,key 1.0 0.000143348623853 1 0 1
excreted,levels 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,particularly 1.0 0.000143348623853 0 1 -1
characterized,to 1.0 0.000143348623853 0 1 -1
required,concentrations 1.0 0.000143348623853 1 0 1
bind,and 1.0 0.000143348623853 1 0 1
is,drawn 1.0 0.000143348623853 1 0 1
toxicokinetic,interferences 1.0 0.000143348623853 0 1 -1
to,beta-adrenergic 1.0 0.000143348623853 0 1 -1
indices,as 0.0 0.0 1 1 0
offer,patients 1.0 0.000143348623853 0 1 -1
when,taking 0.0 0.0 2 2 0
lincomycin,has 1.0 0.000143348623853 1 0 1
of,large 1.0 0.000286697247706 0 2 -2
medications,used 1.0 0.00043004587156 0 3 -3
of,hypotension 0.0 0.0 5 5 0
vitro,does 1.0 0.000143348623853 0 1 -1
its,metabolite 1.0 0.000286697247706 0 2 -2
needed,they 1.0 0.000143348623853 0 1 -1
latter,might 1.0 0.000143348623853 0 1 -1
were,less 1.0 0.000143348623853 1 0 1
parental,and 1.0 0.000143348623853 0 1 -1
low-density,lipoprotein 1.0 0.000143348623853 0 1 -1
longitudinal,stability 1.0 0.000143348623853 0 1 -1
day-old,chick 1.0 0.000143348623853 1 0 1
increased,about 0.5 0.000286697247706 3 1 2
the,parental 1.0 0.000143348623853 0 1 -1
symptoms,but 1.0 0.000143348623853 0 1 -1
glucose,was 1.0 0.000143348623853 0 1 -1
on,no 1.0 0.000143348623853 1 0 1
acute,and 1.0 0.000143348623853 0 1 -1
be,effectively 1.0 0.000143348623853 0 1 -1
step,of 0.0 0.0 1 1 0
study,tentatively 1.0 0.000143348623853 0 1 -1
aspirin,and 1.0 0.000143348623853 0 1 -1
concentrations,c 1.0 0.000143348623853 0 1 -1
of,mixed 1.0 0.000143348623853 1 0 1
edetate,disodium 1.0 0.000143348623853 1 0 1
taxol,but 1.0 0.000143348623853 0 1 -1
compazine,phenergan 1.0 0.000143348623853 0 1 -1
narrower,spectrum 1.0 0.000143348623853 0 1 -1
men,n 1.0 0.000143348623853 0 1 -1
inhibitors,has 0.333333333333 0.000143348623853 2 1 1
example,and 1.0 0.000143348623853 1 0 1
administered,twice 1.0 0.000143348623853 0 1 -1
proves,to 1.0 0.000143348623853 1 0 1
seizure,risk 1.0 0.000143348623853 1 0 1
from,decrease 1.0 0.000286697247706 2 0 2
during,and 0.5 0.000286697247706 3 1 2
other,hormonal 1.0 0.000143348623853 0 1 -1
by,movement 1.0 0.000143348623853 0 1 -1
of,between 1.0 0.000143348623853 0 1 -1
several,of 1.0 0.000143348623853 0 1 -1
during,any 1.0 0.000143348623853 0 1 -1
exhibit,an 1.0 0.000286697247706 2 0 2
phenotype,of 1.0 0.000143348623853 0 1 -1
general,logistic 1.0 0.000143348623853 0 1 -1
which,cause 1.0 0.00043004587156 3 0 3
cyp3a,results 1.0 0.000143348623853 0 1 -1
mepron,interferes 1.0 0.000143348623853 0 1 -1
selective,tumor 1.0 0.000143348623853 0 1 -1
i,with 1.0 0.000143348623853 0 1 -1
such,tumors 1.0 0.000143348623853 0 1 -1
when,healthy 1.0 0.000143348623853 0 1 -1
extend,the 1.0 0.000143348623853 1 0 1
alprazolam,caution 1.0 0.000143348623853 1 0 1
appear,to 0.7 0.00200688073394 3 17 -14
accutane,to 1.0 0.000143348623853 1 0 1
when,coadministration 1.0 0.00043004587156 0 3 -3
established,steady-state 1.0 0.000143348623853 1 0 1
minute,after 1.0 0.000143348623853 1 0 1
rule,out 1.0 0.000286697247706 0 2 -2
that,can 0.333333333333 0.000716743119266 5 10 -5
as,mhd 1.0 0.000143348623853 0 1 -1
benign,intracranial 1.0 0.000143348623853 1 0 1
controlled,study 0.6 0.00043004587156 1 4 -3
five,different 1.0 0.000143348623853 0 1 -1
the,cortex 1.0 0.000143348623853 0 1 -1
parameters,clinical 1.0 0.000143348623853 0 1 -1
of,concomitantly 0.333333333333 0.000143348623853 2 1 1
day,of 0.0 0.0 10 10 0
to,substances 1.0 0.000143348623853 0 1 -1
the,clearance 0.428571428571 0.0021502293578 25 10 15
urine,sampling 1.0 0.000143348623853 0 1 -1
day,on 0.0 0.0 3 3 0
day,or 1.0 0.000716743119266 0 5 -5
and,does 1.0 0.00043004587156 0 3 -3
tests,if 1.0 0.000143348623853 0 1 -1
research,is 1.0 0.000143348623853 0 1 -1
clearance,ranged 1.0 0.000143348623853 0 1 -1
groups,pd2 1.0 0.000143348623853 1 0 1
relaxants,in 1.0 0.000143348623853 0 1 -1
by,co-administration 1.0 0.000573394495413 0 4 -4
renal,dysfunction 1.0 0.000143348623853 1 0 1
sites,produced 1.0 0.000143348623853 0 1 -1
and,electrophysiologic 1.0 0.000143348623853 0 1 -1
or,taking 1.0 0.000143348623853 1 0 1
or,toxoids 1.0 0.000143348623853 1 0 1
a,metabolism 1.0 0.000143348623853 0 1 -1
certain,circumstances 1.0 0.000143348623853 0 1 -1
a,radioactive 1.0 0.000143348623853 0 1 -1
to,share 1.0 0.000143348623853 0 1 -1
relaxants,is 1.0 0.000143348623853 0 1 -1
be,flexible 1.0 0.000143348623853 0 1 -1
range,from 1.0 0.000286697247706 2 0 2
been,taking 1.0 0.000143348623853 0 1 -1
receiving,beta 1.0 0.000143348623853 0 1 -1
intestinal,adsorbents 1.0 0.000143348623853 1 0 1
in,case 0.0 0.0 1 1 0
deriving,experimental 1.0 0.000143348623853 0 1 -1
to,soriatane 1.0 0.000143348623853 0 1 -1
eight,target 1.0 0.000143348623853 0 1 -1
no,adjustment 1.0 0.00043004587156 0 3 -3
contribution,of 1.0 0.000286697247706 0 2 -2
creatinine,levels 1.0 0.00043004587156 0 3 -3
provoke,toxicity 1.0 0.000143348623853 0 1 -1
of,procrit 1.0 0.000143348623853 0 1 -1
usual,dosage 1.0 0.000143348623853 0 1 -1
failure,channel 1.0 0.000143348623853 1 0 1
co-administered,avonex 1.0 0.000143348623853 0 1 -1
but,by 1.0 0.000143348623853 1 0 1
the,non-myelinated 1.0 0.000286697247706 0 2 -2
minutes,from 1.0 0.000143348623853 0 1 -1
tysabri,associated 1.0 0.000143348623853 0 1 -1
cardiac,preparations 1.0 0.000143348623853 0 1 -1
compounds,because 1.0 0.000143348623853 0 1 -1
should,report 1.0 0.000143348623853 0 1 -1
mixed,agonist-antagonist 1.0 0.000143348623853 0 1 -1
sulfoxide,concentrations 1.0 0.000143348623853 1 0 1
rifampin,coadministration 1.0 0.000286697247706 2 0 2
been,implicated 0.0 0.0 1 1 0
monitoring,serum 1.0 0.000143348623853 0 1 -1
rats,that 1.0 0.000143348623853 0 1 -1
of,bone 1.0 0.000286697247706 0 2 -2
of,erythromycin 1.0 0.000143348623853 0 1 -1
augments,the 1.0 0.000143348623853 1 0 1
ieg,response 1.0 0.000143348623853 0 1 -1
type,c 0.6 0.00043004587156 4 1 3
to,inhibitory 1.0 0.000143348623853 0 1 -1
with,have 0.714285714286 0.000716743119266 1 6 -5
repeated,if 1.0 0.000143348623853 0 1 -1
tumor,phenotype 1.0 0.000143348623853 0 1 -1
other,similar 1.0 0.000143348623853 0 1 -1
study,caused 1.0 0.000143348623853 1 0 1
interact,pharmacologically 1.0 0.000143348623853 1 0 1
mellaril,stelazine 1.0 0.000143348623853 0 1 -1
estradiol,may 1.0 0.000286697247706 2 0 2
orally,to 1.0 0.000143348623853 0 1 -1
these,levels 1.0 0.000143348623853 0 1 -1
considered,prior 1.0 0.000143348623853 1 0 1
steps,include 1.0 0.000143348623853 0 1 -1
on,immune 1.0 0.000143348623853 0 1 -1
the,biotransformation 0.333333333333 0.000143348623853 2 1 1
maneuver,often 1.0 0.000143348623853 0 1 -1
the,above 0.666666666667 0.000573394495413 1 5 -4
extrapolated,to 1.0 0.000143348623853 0 1 -1
the,transcriptional 1.0 0.000143348623853 0 1 -1
the,currently 1.0 0.000143348623853 0 1 -1
safety,studies 1.0 0.000143348623853 0 1 -1
initiating,treatment 1.0 0.000143348623853 0 1 -1
everolimus,exhibited 1.0 0.000143348623853 0 1 -1
potentiate,vecuronium-induced 1.0 0.000143348623853 1 0 1
avastin,had 1.0 0.000143348623853 0 1 -1
within,five 1.0 0.000143348623853 0 1 -1
developing,renal 1.0 0.000143348623853 0 1 -1
consensus,reports 1.0 0.000143348623853 0 1 -1
can,modulate 1.0 0.000143348623853 0 1 -1
blocking,hepatic 1.0 0.000143348623853 1 0 1
with,beta-lactamtype 1.0 0.000143348623853 1 0 1
those,prior 1.0 0.000143348623853 0 1 -1
occur,which 1.0 0.000143348623853 0 1 -1
ml,when 0.6 0.00043004587156 1 4 -3
on,aspects 1.0 0.000143348623853 0 1 -1
abruptly,toxic 1.0 0.000716743119266 0 5 -5
sixth,day 1.0 0.000143348623853 1 0 1
of,toxic 0.5 0.000286697247706 1 3 -2
of,inhibitor 1.0 0.000143348623853 0 1 -1
increases,enterohepatic 1.0 0.000143348623853 0 1 -1
repeated,exposure 1.0 0.000143348623853 0 1 -1
inducers,iodinated 1.0 0.000143348623853 0 1 -1
the,bile 1.0 0.000143348623853 0 1 -1
showed,good 1.0 0.000143348623853 0 1 -1
some,concomitantly 1.0 0.000143348623853 0 1 -1
upper,gastrointestinal 0.6 0.00043004587156 1 4 -3
particularly,and 1.0 0.000143348623853 0 1 -1
isoenzymes,cyp2c8 1.0 0.000143348623853 0 1 -1
following,acetazolamide 1.0 0.000143348623853 1 0 1
the,pk 1.0 0.000143348623853 0 1 -1
causes,a 0.2 0.000143348623853 3 2 1
cerivastatin,plasma 1.0 0.00043004587156 0 3 -3
capsule,with 1.0 0.000143348623853 1 0 1
inhibit,p-glycoprotein 1.0 0.000143348623853 0 1 -1
events,associated 1.0 0.000143348623853 1 0 1
adds,to 1.0 0.000143348623853 0 1 -1
to,ascertain 1.0 0.000143348623853 0 1 -1
the,pr 1.0 0.000143348623853 1 0 1
with,zyvox 1.0 0.000143348623853 1 0 1
the,pt 1.0 0.000143348623853 0 1 -1
on,day 0.0666666666667 0.000143348623853 7 8 -1
food,cns 1.0 0.000143348623853 1 0 1
concentrations,resulted 1.0 0.000143348623853 0 1 -1
ketoconazole,in 1.0 0.000143348623853 1 0 1
including,decrease 1.0 0.000143348623853 1 0 1
ketoconazole,is 1.0 0.000286697247706 0 2 -2
bleeding,time 1.0 0.000860091743119 0 6 -6
of,ace 0.0 0.0 1 1 0
hepatic,tissues 0.0 0.0 1 1 0
the,hydroxylation 1.0 0.000143348623853 0 1 -1
lowering,their 1.0 0.000143348623853 0 1 -1
dose-related,increase 1.0 0.000143348623853 1 0 1
significantly,different 1.0 0.00043004587156 0 3 -3
or,kcl 1.0 0.000143348623853 0 1 -1
agents,disturbances 1.0 0.000143348623853 1 0 1
activity,to 1.0 0.000143348623853 0 1 -1
photosensitizing,agents 1.0 0.000143348623853 1 0 1
potent,cyp3a 1.0 0.000143348623853 1 0 1
medications,with 0.4 0.000573394495413 3 7 -4
vasoconstriction,caused 1.0 0.000143348623853 1 0 1
the,neuromuscular 0.8 0.00114678899083 9 1 8
hypotension,or 0.5 0.000286697247706 1 3 -2
of,hippocampal 1.0 0.000143348623853 0 1 -1
schizophrenia,were 1.0 0.000143348623853 0 1 -1
fully,define 1.0 0.000143348623853 0 1 -1
usp,should 1.0 0.000286697247706 2 0 2
usually,depresses 1.0 0.000143348623853 1 0 1
over,of 1.0 0.000143348623853 0 1 -1
immediate,discontinuation 1.0 0.000143348623853 0 1 -1
on,cas 1.0 0.000143348623853 1 0 1
some,normal 1.0 0.000143348623853 1 0 1
introduced,atypical 1.0 0.000143348623853 0 1 -1
article,review 1.0 0.000143348623853 0 1 -1
by,mtc-methylene 1.0 0.000143348623853 1 0 1
in,renally 1.0 0.000143348623853 0 1 -1
was,low 1.0 0.000143348623853 0 1 -1
and,showed 1.0 0.000286697247706 0 2 -2
their,guardians 1.0 0.000143348623853 0 1 -1
the,only 0.0 0.0 1 1 0
relaxants,could 1.0 0.000143348623853 1 0 1
nitrosamine,which 1.0 0.000143348623853 1 0 1
isozymes,a2 1.0 0.000143348623853 0 1 -1
isozymes,a1 1.0 0.000143348623853 0 1 -1
lipoproteins,high-density 1.0 0.000143348623853 0 1 -1
one-thousandth,of 1.0 0.000143348623853 0 1 -1
um,toward 1.0 0.000143348623853 0 1 -1
unlikely,to 1.0 0.0024369266055 0 17 -17
of,compared 0.333333333333 0.000143348623853 1 2 -1
tubular,excretion 1.0 0.000143348623853 1 0 1
lower,locomotor 1.0 0.000143348623853 0 1 -1
needed,should 1.0 0.000143348623853 0 1 -1
treatpatients,co-infected 1.0 0.000143348623853 0 1 -1
without,change 1.0 0.000143348623853 0 1 -1
impaired,fertility 1.0 0.000143348623853 0 1 -1
when,nimbex 1.0 0.000143348623853 0 1 -1
inconcomitant,administration 1.0 0.000143348623853 0 1 -1
show,a 1.0 0.000286697247706 0 2 -2
high,acquisition 1.0 0.000143348623853 0 1 -1
concentration,which 1.0 0.000143348623853 0 1 -1
may,worsen 1.0 0.000143348623853 1 0 1
of,seriously 1.0 0.000143348623853 0 1 -1
demonstrated,clinical 1.0 0.000143348623853 0 1 -1
receiving,multiple 1.0 0.000143348623853 1 0 1
arsenical,reactive 1.0 0.000143348623853 0 1 -1
response,by 1.0 0.000143348623853 1 0 1
velcade,and 1.0 0.000143348623853 0 1 -1
with,equal 1.0 0.000143348623853 0 1 -1
that,when 1.0 0.000286697247706 2 0 2
of,myasthenic 1.0 0.000143348623853 0 1 -1
changes,has 1.0 0.000143348623853 0 1 -1
the,nephrotoxicity 0.0 0.0 1 1 0
addition,most 1.0 0.000143348623853 1 0 1
uptake,of 0.6 0.00043004587156 1 4 -3
camptosar,such 1.0 0.000143348623853 1 0 1
could,likewise 1.0 0.000286697247706 0 2 -2
initiating,or 1.0 0.000286697247706 2 0 2
the,committed 1.0 0.000143348623853 1 0 1
can,exaggerate 1.0 0.000143348623853 0 1 -1
this,article 1.0 0.000573394495413 0 4 -4
introduction,of 1.0 0.000286697247706 2 0 2
ace,inhibitors 0.0 0.0 10 10 0
apoptotic,morphology 1.0 0.000143348623853 0 1 -1
occur,up 1.0 0.000143348623853 1 0 1
ee,were 1.0 0.000143348623853 0 1 -1
of,neuromuscular 0.6 0.00043004587156 4 1 3
spontaneous,reports 0.333333333333 0.000143348623853 2 1 1
bid,in 1.0 0.000143348623853 1 0 1
in,preclinical 1.0 0.000143348623853 0 1 -1
balanced,technique 1.0 0.000143348623853 0 1 -1
prevent,stomach 1.0 0.000143348623853 0 1 -1
be,treated 0.0 0.0 2 2 0
is,extensively 0.714285714286 0.000716743119266 1 6 -5
cause,renal 0.0 0.0 1 1 0
of,subpopulations 1.0 0.000143348623853 0 1 -1
progression,of 1.0 0.000143348623853 0 1 -1
incoordination,hyperthermia 1.0 0.000143348623853 0 1 -1
three,cases 1.0 0.000143348623853 0 1 -1
has,led 1.0 0.00043004587156 3 0 3
and,serotonin 1.0 0.000143348623853 0 1 -1
acutely,worsened 1.0 0.000143348623853 1 0 1
either,mg 1.0 0.00043004587156 0 3 -3
elderly,in 1.0 0.000143348623853 1 0 1
but,caspase-3 1.0 0.000143348623853 0 1 -1
on,microtubules 1.0 0.000143348623853 0 1 -1
an,endogenous 1.0 0.000143348623853 1 0 1
delayed,and 1.0 0.000143348623853 1 0 1
and,monitoring 1.0 0.000143348623853 1 0 1
including,biocytin 1.0 0.000143348623853 0 1 -1
was,evidence 1.0 0.000143348623853 0 1 -1
reductions,of 1.0 0.000143348623853 1 0 1
wheal,and 1.0 0.000143348623853 0 1 -1
activities,and 1.0 0.000143348623853 0 1 -1
dry,mouth 0.142857142857 0.000143348623853 4 3 1
mg,twice-daily 1.0 0.000143348623853 1 0 1
is,becoming 1.0 0.000143348623853 0 1 -1
since,falsely 1.0 0.000143348623853 0 1 -1
agonists,within 0.333333333333 0.000143348623853 2 1 1
hypersensitivity,reactions 0.2 0.000143348623853 2 3 -1
vitro,activity 1.0 0.000143348623853 0 1 -1
decreased,levels 1.0 0.00043004587156 0 3 -3
structurally,similar 1.0 0.000143348623853 0 1 -1
with,c-cholesteryl 1.0 0.000143348623853 0 1 -1
interferences,dicumarol 1.0 0.000143348623853 0 1 -1
most,components 1.0 0.000143348623853 0 1 -1
potassium-,sparing 1.0 0.000143348623853 1 0 1
increased,dramatically 1.0 0.000143348623853 0 1 -1
data,indicated 1.0 0.000143348623853 0 1 -1
with,neoplastic 1.0 0.000143348623853 1 0 1
affect,the 0.868852459016 0.00759747706422 4 57 -53
nsaid,while 1.0 0.000143348623853 1 0 1
health,if 0.0 0.0 1 1 0
with,solid 1.0 0.000143348623853 0 1 -1
treatments,given 1.0 0.000143348623853 0 1 -1
or,concomitantly 1.0 0.000286697247706 2 0 2
drugs,fibric 1.0 0.000143348623853 0 1 -1
concomitantly,within14 1.0 0.000143348623853 1 0 1
myasthenic,patient 1.0 0.000143348623853 1 0 1
drug,monitoring 1.0 0.000143348623853 0 1 -1
other,potent 0.5 0.000286697247706 3 1 2
cardiovascular,effects 0.6 0.00043004587156 1 4 -3
from,combined 1.0 0.000286697247706 2 0 2
known,cytochrome 1.0 0.000143348623853 0 1 -1
pth,and 1.0 0.000143348623853 1 0 1
reduction,depending 1.0 0.000143348623853 0 1 -1
maximum,cumulative 1.0 0.000143348623853 1 0 1
some,agents 1.0 0.000286697247706 0 2 -2
no,important 1.0 0.000143348623853 0 1 -1
decrease,of 1.0 0.000860091743119 0 6 -6
data,on 0.75 0.000860091743119 1 7 -6
or,moieties 1.0 0.000143348623853 0 1 -1
chlorpropamide,chlorpropamides 1.0 0.000143348623853 1 0 1
peak,levels 0.0 0.0 1 1 0
cholestyramine,binds 1.0 0.000143348623853 1 0 1
they,can 0.0 0.0 1 1 0
proquin,xr 1.0 0.00043004587156 0 3 -3
affecting,sympathetic 1.0 0.000286697247706 0 2 -2
identify,the 1.0 0.000286697247706 0 2 -2
clinical,relevance 1.0 0.00114678899083 0 8 -8
dual,therapy 1.0 0.000143348623853 0 1 -1
discontinued,increase 1.0 0.000143348623853 0 1 -1
frequently,co-administered 1.0 0.000143348623853 0 1 -1
strong,synergistic 1.0 0.000143348623853 1 0 1
inpatient,and 1.0 0.000143348623853 0 1 -1
of,metabolites 1.0 0.000143348623853 0 1 -1
peak,b 1.0 0.000143348623853 0 1 -1
diabetes,coagulation 1.0 0.000143348623853 0 1 -1
the,proteins 1.0 0.000143348623853 0 1 -1
elevations,returned 1.0 0.000143348623853 0 1 -1
but,colony 1.0 0.000143348623853 0 1 -1
n-desmethylclozapine,and 1.0 0.000143348623853 0 1 -1
receiving,there 1.0 0.000143348623853 1 0 1
that,protects 1.0 0.000143348623853 1 0 1
decrease,its 1.0 0.000143348623853 0 1 -1
via,cyp3a4 0.0 0.0 1 1 0
controlled,hypotensive 1.0 0.000143348623853 1 0 1
cause,cardio 1.0 0.000143348623853 0 1 -1
activities,requiring 1.0 0.000143348623853 0 1 -1
inference,is 1.0 0.000143348623853 0 1 -1
strongly,suppressed 1.0 0.000143348623853 0 1 -1
of,fluorouracil 1.0 0.000143348623853 1 0 1
from,albumin 1.0 0.000143348623853 0 1 -1
primarily,metabolized 0.818181818182 0.00129013761468 1 10 -9
of,pulmonary 1.0 0.000143348623853 1 0 1
and,c19 1.0 0.000286697247706 0 2 -2
endothelium,were 1.0 0.000143348623853 0 1 -1
blood,or 1.0 0.000143348623853 0 1 -1
progress,very 1.0 0.000143348623853 0 1 -1
double-blind,study 1.0 0.000143348623853 0 1 -1
unaffected,given 1.0 0.000143348623853 1 0 1
exert,particular 1.0 0.000143348623853 1 0 1
correct,changes 1.0 0.000143348623853 0 1 -1
required,may 1.0 0.000143348623853 1 0 1
was,lower 1.0 0.000286697247706 2 0 2
in,psoriatic 1.0 0.000143348623853 0 1 -1
patients,prone 1.0 0.000143348623853 1 0 1
recipients,suggest 1.0 0.000143348623853 0 1 -1
with,medications 0.333333333333 0.000143348623853 1 2 -1
endotoxin-induced,deaths 1.0 0.000143348623853 1 0 1
including,anti-arrhythmic 1.0 0.000143348623853 0 1 -1
a,satisfactory 0.0 0.0 1 1 0
need,similar 1.0 0.000143348623853 0 1 -1
necessary,when 0.2 0.000286697247706 4 6 -2
decrease,established 1.0 0.000143348623853 1 0 1
aqueous,extract 1.0 0.000143348623853 0 1 -1
these,concomitantly 1.0 0.000143348623853 0 1 -1
on,enzymatic 1.0 0.000860091743119 0 6 -6
oxidase,inhibition 1.0 0.000143348623853 0 1 -1
enzymes,would 1.0 0.00043004587156 0 3 -3
emerged,from 1.0 0.000143348623853 0 1 -1
the,tricyclic 0.5 0.000286697247706 1 3 -2
the,dietary 1.0 0.000143348623853 0 1 -1
th,generation 1.0 0.000143348623853 0 1 -1
two,elements 1.0 0.000143348623853 0 1 -1
agents,amphotericin 1.0 0.000143348623853 1 0 1
aid,sleep 1.0 0.000143348623853 0 1 -1
offset,by 1.0 0.000143348623853 0 1 -1
actions,are 1.0 0.000143348623853 0 1 -1
with,maxipime 1.0 0.000143348623853 1 0 1
unusual,taste 1.0 0.000143348623853 0 1 -1
or,crohn 1.0 0.000143348623853 0 1 -1
hormone,action 1.0 0.000143348623853 0 1 -1
this,loss 1.0 0.000143348623853 0 1 -1
min,compared 1.0 0.000143348623853 0 1 -1
or,omega-agatoxin 1.0 0.000143348623853 0 1 -1
review,discusses 1.0 0.000143348623853 0 1 -1
unknown,amevive 1.0 0.000143348623853 0 1 -1
prolong,and 0.4 0.000573394495413 7 3 4
the,augmentation 1.0 0.000143348623853 0 1 -1
pregnancy,could 1.0 0.000143348623853 0 1 -1
to,amide-type 1.0 0.000143348623853 1 0 1
renal,failure 0.25 0.000286697247706 3 5 -2
nalidixic,acid 1.0 0.000286697247706 2 0 2
mg,led 1.0 0.000143348623853 1 0 1
colorimetric,complexometric 1.0 0.000143348623853 0 1 -1
consider,monitoring 1.0 0.000143348623853 0 1 -1
stability,over 1.0 0.000143348623853 0 1 -1
factors,when 1.0 0.000143348623853 0 1 -1
st,johns 0.6 0.00043004587156 1 4 -3
receiving,high 1.0 0.000286697247706 2 0 2
using,cyp3a4 1.0 0.000143348623853 1 0 1
the,failing 1.0 0.000286697247706 0 2 -2
the,pharmacokinetic 0.538461538462 0.00100344036697 3 10 -7
baseline,for 1.0 0.000143348623853 0 1 -1
metabolized,by 0.68932038835 0.0101777522936 16 87 -71
escalating,doses 0.333333333333 0.000143348623853 1 2 -1
levobupivacaine,and 1.0 0.000143348623853 0 1 -1
interaction,to 1.0 0.000143348623853 0 1 -1
effect,oral 1.0 0.000143348623853 0 1 -1
may,delay 0.555555555556 0.000716743119266 7 2 5
and,hearing 1.0 0.000143348623853 1 0 1
cimetidine,has 1.0 0.00043004587156 3 0 3
zdv,has 1.0 0.000143348623853 0 1 -1
m,enhance 1.0 0.000143348623853 1 0 1
when,two 1.0 0.000143348623853 0 1 -1
of,new 1.0 0.000143348623853 0 1 -1
at,least 0.103448275862 0.000860091743119 26 32 -6
for,incombination 1.0 0.000143348623853 0 1 -1
microsomes,appears 1.0 0.000143348623853 0 1 -1
required,and 0.0 0.0 1 1 0
illustrated,by 1.0 0.000143348623853 0 1 -1
digoxin,interaction 1.0 0.000143348623853 0 1 -1
confidence,interval 0.333333333333 0.000143348623853 1 2 -1
adrenergic-blocking,agents 1.0 0.000143348623853 0 1 -1
rarely,dry 1.0 0.000143348623853 0 1 -1
body,increase 1.0 0.000143348623853 0 1 -1
dipyridamole,has 1.0 0.000143348623853 1 0 1
inhibiting,cryptosporidium 1.0 0.000143348623853 1 0 1
plus,catecholamine 1.0 0.000143348623853 1 0 1
for,both 1.0 0.000143348623853 0 1 -1
situation,has 1.0 0.000143348623853 0 1 -1
be,certain 1.0 0.000143348623853 1 0 1
first-line,option 1.0 0.000143348623853 0 1 -1
showed,higher 1.0 0.000143348623853 1 0 1
methotrexate,mexate 1.0 0.000143348623853 1 0 1
excessive,concurrent 1.0 0.000143348623853 0 1 -1
white,male 1.0 0.000143348623853 0 1 -1
or,frequency 1.0 0.000143348623853 1 0 1
evidence,of 0.894736842105 0.00487385321101 2 36 -34
female,patient 1.0 0.000143348623853 0 1 -1
interval,decrease 1.0 0.000143348623853 0 1 -1
g,and 1.0 0.000286697247706 2 0 2
amounts,may 0.0 0.0 1 1 0
however,serious 1.0 0.000143348623853 0 1 -1
of,displacement 1.0 0.000143348623853 0 1 -1
human,african 1.0 0.000143348623853 0 1 -1
concluded,that 0.0 0.0 3 3 0
inhibitors,agenerase 1.0 0.000143348623853 1 0 1
and,repeat 1.0 0.000143348623853 0 1 -1
therefore,omnicef 1.0 0.000143348623853 0 1 -1
interpretation,glucose 1.0 0.000143348623853 0 1 -1
being,given 0.0 0.0 1 1 0
interactions,given 1.0 0.000143348623853 1 0 1
el,eg 1.0 0.000143348623853 1 0 1
and,nonprescription 1.0 0.000143348623853 0 1 -1
progestational,eg 1.0 0.000143348623853 0 1 -1
interactions,acetaminophen 1.0 0.000143348623853 0 1 -1
tnfa-blocking,agents 1.0 0.000143348623853 1 0 1
despite,seemingly 1.0 0.000143348623853 0 1 -1
some,studies 1.0 0.000143348623853 1 0 1
consider,the 1.0 0.000143348623853 1 0 1
these,actions 1.0 0.000143348623853 1 0 1
receiving,or 0.555555555556 0.000716743119266 7 2 5
suggests,that 0.142857142857 0.000143348623853 3 4 -1
the,they 1.0 0.000143348623853 1 0 1
seven,cases 1.0 0.000143348623853 0 1 -1
ethanol,depressed 1.0 0.000143348623853 0 1 -1
made,with 1.0 0.000143348623853 1 0 1
infarction,in 1.0 0.000143348623853 0 1 -1
increased,dose 0.714285714286 0.000716743119266 1 6 -5
between,zdv 1.0 0.000143348623853 0 1 -1
salt,or 1.0 0.000143348623853 0 1 -1
concentration,curve 1.0 0.000143348623853 1 0 1
produce,significant 0.333333333333 0.000143348623853 1 2 -1
insulin-dependent,diabetes 1.0 0.000143348623853 0 1 -1
mix,toradol 1.0 0.000143348623853 0 1 -1
care,is 1.0 0.000143348623853 0 1 -1
care,in 0.5 0.000286697247706 3 1 2
the,dopaminergic 1.0 0.000143348623853 1 0 1
doses,has 1.0 0.000143348623853 1 0 1
includes,anafranil 1.0 0.000143348623853 0 1 -1
clinical,and 0.6 0.00043004587156 1 4 -3
cyp2d6,cyp1a2 1.0 0.000143348623853 0 1 -1
the,hydroalcoholic 1.0 0.000143348623853 0 1 -1
are,types 1.0 0.000143348623853 0 1 -1
week,plasma 1.0 0.000143348623853 1 0 1
doses,had 1.0 0.000143348623853 1 0 1
dipstick,test 1.0 0.000143348623853 0 1 -1
rates,over 1.0 0.000143348623853 0 1 -1
after,spontaneous 1.0 0.000143348623853 0 1 -1
phenytoin,phenobarbitol 1.0 0.000143348623853 0 1 -1
a,prostaglandin 1.0 0.000143348623853 0 1 -1
an,mao 0.333333333333 0.000143348623853 2 1 1
maintain,the 1.0 0.000716743119266 0 5 -5
with,possible 1.0 0.000143348623853 1 0 1
between,single 1.0 0.000143348623853 1 0 1
an,may 1.0 0.000143348623853 1 0 1
rats,given 1.0 0.000143348623853 1 0 1
coated,aspirin 1.0 0.000143348623853 1 0 1
attributed,to 0.818181818182 0.00129013761468 1 10 -9
and,torsades 0.0 0.0 1 1 0
previously,reported 1.0 0.000143348623853 0 1 -1
only,a 0.2 0.000143348623853 2 3 -1
taxol,a 1.0 0.000143348623853 0 1 -1
ija,models 1.0 0.000143348623853 0 1 -1
a,cause-and 1.0 0.000286697247706 2 0 2
their,effect 1.0 0.000286697247706 0 2 -2
severe,hypersensitivity 0.333333333333 0.000143348623853 1 2 -1
fluconazole,and 1.0 0.000286697247706 0 2 -2
because,can 1.0 0.000143348623853 1 0 1
asymptomatic,transitory 1.0 0.000143348623853 0 1 -1
pegasys,treatment 1.0 0.000143348623853 0 1 -1
mutagenicity,assay 1.0 0.000143348623853 0 1 -1
theoretically,may 1.0 0.000143348623853 1 0 1
hippocampus,and 1.0 0.000143348623853 0 1 -1
with,experienced 1.0 0.000143348623853 1 0 1
on,without 1.0 0.000143348623853 0 1 -1
as,tablets 1.0 0.000143348623853 0 1 -1
female,animals 1.0 0.000143348623853 0 1 -1
the,benefit 1.0 0.000143348623853 1 0 1
formal,pharmacokinetic 1.0 0.000143348623853 0 1 -1
asthma,decreased 1.0 0.000143348623853 0 1 -1
performed,both 1.0 0.000143348623853 0 1 -1
use,supplements 1.0 0.000286697247706 0 2 -2
samples,were 1.0 0.000286697247706 0 2 -2
population,of 1.0 0.000286697247706 0 2 -2
central,nervous 0.166666666667 0.000573394495413 14 10 4
clomipramine,hcl 1.0 0.000143348623853 1 0 1
acr,criteria 1.0 0.000143348623853 0 1 -1
aprepitant,mg 1.0 0.000143348623853 1 0 1
dha,was 1.0 0.000143348623853 0 1 -1
the,balance 1.0 0.000143348623853 0 1 -1
of,causes 1.0 0.000143348623853 1 0 1
also,with 1.0 0.000286697247706 0 2 -2
other,antiretroviral 0.0 0.0 1 1 0
exhibit,doubling 1.0 0.000143348623853 0 1 -1
low,molecular 1.0 0.000143348623853 0 1 -1
for,combined 1.0 0.000143348623853 0 1 -1
a-blockers,angiotensin-converting 1.0 0.000143348623853 0 1 -1
of,caused 0.0 0.0 2 2 0
m-tco,injection 1.0 0.000143348623853 1 0 1
pressor,activity 1.0 0.000286697247706 0 2 -2
systemic,eg 1.0 0.000143348623853 0 1 -1
delirium,associated 1.0 0.000143348623853 1 0 1
m2,before 1.0 0.000143348623853 0 1 -1
isoniazid,is 1.0 0.000286697247706 2 0 2
two-fold,increases 1.0 0.000143348623853 1 0 1
human,auc 1.0 0.000143348623853 0 1 -1
of,fludrocortisone 1.0 0.000143348623853 1 0 1
potential,in 1.0 0.000143348623853 0 1 -1
toxicity,cns 1.0 0.000143348623853 0 1 -1
demonstrated,in 0.2 0.000143348623853 2 3 -1
with,conditions 1.0 0.000286697247706 0 2 -2
certain,metabolizing 1.0 0.000286697247706 0 2 -2
co-administration,concomitant 1.0 0.000143348623853 1 0 1
different,concentrations 1.0 0.000143348623853 0 1 -1
median,gastric 1.0 0.000143348623853 1 0 1
cations,or 1.0 0.000143348623853 1 0 1
the,tysabri 1.0 0.000143348623853 0 1 -1
lower,tablet 1.0 0.000143348623853 0 1 -1
secondary,to 0.111111111111 0.000143348623853 4 5 -1
axons,has 1.0 0.000143348623853 0 1 -1
test,may 1.0 0.000286697247706 0 2 -2
related,with 1.0 0.000143348623853 0 1 -1
prescribing,a 1.0 0.000143348623853 0 1 -1
cautiously,with 0.333333333333 0.000143348623853 2 1 1
change,was 1.0 0.000143348623853 0 1 -1
given,one 0.666666666667 0.000573394495413 1 5 -4
in,controlled 0.6 0.00043004587156 1 4 -3
depression,cns 1.0 0.000143348623853 0 1 -1
the,hippocampus 1.0 0.00043004587156 0 3 -3
may,either 1.0 0.000573394495413 4 0 4
of,clearance 0.333333333333 0.000143348623853 2 1 1
shown,in 0.0 0.0 2 2 0
co-administered,particularly 1.0 0.000143348623853 1 0 1
prostigmin,may 1.0 0.000143348623853 0 1 -1
world,medical 1.0 0.000143348623853 0 1 -1
injectionsite,reaction 1.0 0.000143348623853 0 1 -1
protects,mouse 1.0 0.000143348623853 1 0 1
potential,for 0.529411764706 0.00516055045872 16 52 -36
m1,was 1.0 0.000286697247706 0 2 -2
are,pregnant 1.0 0.000143348623853 0 1 -1
exhibited,similar 1.0 0.000143348623853 0 1 -1
produced,modest 1.0 0.000143348623853 0 1 -1
whether,might 1.0 0.000143348623853 0 1 -1
volunteers,taking 1.0 0.000143348623853 1 0 1
warfarin,when 0.0 0.0 1 1 0
insp,mediated 1.0 0.000143348623853 0 1 -1
a,nd 1.0 0.000286697247706 0 2 -2
result,if 1.0 0.000143348623853 1 0 1
theoretically,affect 1.0 0.000143348623853 1 0 1
g,day 1.0 0.000143348623853 1 0 1
exposure,by 1.0 0.000143348623853 1 0 1
elevated,plasma 0.6 0.00129013761468 12 3 9
metabolite,beta-naltrexol 1.0 0.000143348623853 0 1 -1
taking,which 1.0 0.000286697247706 0 2 -2
prelone,st 1.0 0.000143348623853 1 0 1
another,tnf-blocking 1.0 0.000143348623853 1 0 1
or,reverse 1.0 0.000286697247706 2 0 2
i,potency 1.0 0.000143348623853 0 1 -1
value,prescribed 1.0 0.000143348623853 0 1 -1
already,accumulated 1.0 0.000143348623853 1 0 1
the,fetus 1.0 0.000143348623853 0 1 -1
indications,specific 1.0 0.000143348623853 0 1 -1
weekly,reduced 1.0 0.000143348623853 1 0 1
cyp2d6,substrate 1.0 0.000143348623853 1 0 1
histaminergic,and 1.0 0.000143348623853 0 1 -1
min,or 1.0 0.000143348623853 0 1 -1
mhd,to 1.0 0.000143348623853 0 1 -1
akathisia,in 1.0 0.000143348623853 1 0 1
dispersed,in 1.0 0.000143348623853 0 1 -1
mg,if 1.0 0.000143348623853 1 0 1
antimicrobial,is 1.0 0.000286697247706 2 0 2
mg,in 0.111111111111 0.000143348623853 5 4 1
or,other 0.174603174603 0.00157683486239 37 26 11
single,doses 0.142857142857 0.000143348623853 3 4 -1
concentrations,well 1.0 0.000143348623853 0 1 -1
prelone,pediapred 1.0 0.000143348623853 0 1 -1
of,side 0.111111111111 0.000143348623853 5 4 1
mg,iv 1.0 0.000143348623853 0 1 -1
alone,markedly 1.0 0.000143348623853 0 1 -1
profile,in 1.0 0.000143348623853 0 1 -1
in,men 1.0 0.00043004587156 0 3 -3
for,appropriate 1.0 0.000143348623853 0 1 -1
subtypes,using 1.0 0.000143348623853 0 1 -1
stopping,since 1.0 0.000143348623853 1 0 1
levonorgestrel-treated,rats 1.0 0.000143348623853 0 1 -1
into,a 1.0 0.000143348623853 0 1 -1
similarly,of 1.0 0.000143348623853 0 1 -1
fortovase,invirase 1.0 0.000143348623853 1 0 1
preclinical,researchers 1.0 0.000143348623853 0 1 -1
directed,and 1.0 0.000143348623853 0 1 -1
hypnotics,opioids 1.0 0.000143348623853 1 0 1
acid,hcl 1.0 0.000143348623853 1 0 1
variability,and 0.0 0.0 1 1 0
the,lipid 1.0 0.000286697247706 0 2 -2
maximum,plasma 1.0 0.000716743119266 5 0 5
performed,prior 1.0 0.000143348623853 0 1 -1
supporting,the 1.0 0.000143348623853 1 0 1
that,could 0.142857142857 0.000143348623853 3 4 -1
hormones,and 1.0 0.000143348623853 1 0 1
with,joint 1.0 0.000143348623853 0 1 -1
much,less 1.0 0.000143348623853 0 1 -1
catecholamine-depleting,eg 1.0 0.000143348623853 1 0 1
electrophilic,agents--a 1.0 0.000143348623853 0 1 -1
protein-bound,with 1.0 0.000143348623853 1 0 1
against,driving 1.0 0.000143348623853 0 1 -1
discontinue,pegasys 1.0 0.000143348623853 0 1 -1
avoided,see 1.0 0.000143348623853 1 0 1
user,such 1.0 0.000143348623853 0 1 -1
therefore,dose 1.0 0.000143348623853 0 1 -1
with,somatic 1.0 0.000143348623853 0 1 -1
sg,dipstick 1.0 0.000143348623853 0 1 -1
fumarate,did 1.0 0.000143348623853 0 1 -1
opioid-evoked,hyperpolarization 1.0 0.000143348623853 0 1 -1
however,cohort 1.0 0.000143348623853 0 1 -1
reaching,epidemic 1.0 0.000143348623853 0 1 -1
depressive,symptoms 1.0 0.00043004587156 0 3 -3
caution,as 1.0 0.000286697247706 2 0 2
interpreted,with 1.0 0.000286697247706 0 2 -2
thromboxane,a2 1.0 0.000143348623853 0 1 -1
medication,administered 1.0 0.000286697247706 0 2 -2
values,are 1.0 0.000143348623853 0 1 -1
have,yet 1.0 0.000143348623853 0 1 -1
effects,with 0.636363636364 0.00100344036697 9 2 7
acute,locomotor 1.0 0.000143348623853 1 0 1
hyperinsulinaemia,on 1.0 0.000143348623853 0 1 -1
other,potassium-sparing 1.0 0.000143348623853 1 0 1
strips,that 1.0 0.000143348623853 0 1 -1
crixivan,and 0.5 0.000286697247706 1 3 -2
clinician,in 1.0 0.000143348623853 0 1 -1
be,induced 1.0 0.000286697247706 0 2 -2
marked,has 1.0 0.000286697247706 0 2 -2
that,xanthine-derived 1.0 0.000143348623853 0 1 -1
period,will 1.0 0.000143348623853 1 0 1
second,study 0.333333333333 0.000143348623853 1 2 -1
at,three 1.0 0.000286697247706 0 2 -2
no,reports 1.0 0.000286697247706 0 2 -2
was,decrease 1.0 0.000143348623853 0 1 -1
be,done 0.666666666667 0.000573394495413 1 5 -4
levels,meq 1.0 0.000143348623853 0 1 -1
glucuronidation,being 1.0 0.000143348623853 0 1 -1
genomes,have 1.0 0.000143348623853 0 1 -1
as,mercapturic 1.0 0.000143348623853 0 1 -1
the,single 1.0 0.000143348623853 0 1 -1
with,heart 1.0 0.000573394495413 0 4 -4
not,however 1.0 0.000143348623853 0 1 -1
alter,tromethamine 1.0 0.000143348623853 0 1 -1
effects,kemstro 1.0 0.000143348623853 0 1 -1
clozapine,induced 1.0 0.000143348623853 0 1 -1
drug,concentrations 1.0 0.000143348623853 0 1 -1
anti-glaucoma,and 1.0 0.000143348623853 0 1 -1
low,therapeutic 1.0 0.00043004587156 0 3 -3
reduce,exposure 1.0 0.000143348623853 0 1 -1
unprotected,sexual 1.0 0.000143348623853 0 1 -1
may,effect 1.0 0.000143348623853 1 0 1
inhibitors,monoamine 1.0 0.000143348623853 0 1 -1
of,during 0.0 0.0 2 2 0
oral,response 1.0 0.000573394495413 4 0 4
adrenocorticoids,is 1.0 0.000143348623853 0 1 -1
had,received 0.0 0.0 1 1 0
could,lessen 1.0 0.000143348623853 0 1 -1
of,antizol 1.0 0.00043004587156 3 0 3
both,minimal 1.0 0.000143348623853 0 1 -1
were,decreased 0.333333333333 0.000286697247706 4 2 2
a,p53 1.0 0.000143348623853 0 1 -1
of,refludan 1.0 0.000143348623853 0 1 -1
insufficiency,hyperbilirubinemia 1.0 0.000143348623853 1 0 1
day,and 0.0526315789474 0.000143348623853 9 10 -1
neutropenia,anc 1.0 0.000286697247706 2 0 2
simulect,clearance 1.0 0.000143348623853 0 1 -1
serum,bilirubin 1.0 0.000143348623853 0 1 -1
which,significantly 1.0 0.000143348623853 1 0 1
less,alteration 1.0 0.000143348623853 1 0 1
always,seen 1.0 0.000143348623853 0 1 -1
bleeding,international 1.0 0.000143348623853 0 1 -1
higher,exposure 1.0 0.000143348623853 1 0 1
blockers,proton 1.0 0.000143348623853 1 0 1
as,belladonna 1.0 0.000143348623853 1 0 1
remainder,were 1.0 0.000143348623853 0 1 -1
difluoroacetone,mg 1.0 0.000286697247706 0 2 -2
using,doses 1.0 0.000143348623853 1 0 1
developed,increased 1.0 0.000143348623853 1 0 1
the,inhibitory 0.2 0.000143348623853 3 2 1
mixing,of 1.0 0.000286697247706 2 0 2
st,john 0.714285714286 0.000716743119266 1 6 -5
myocardium,p 1.0 0.000143348623853 1 0 1
placebo-controlled,osteoporosis 1.0 0.000143348623853 0 1 -1
c,inhibited 1.0 0.000143348623853 1 0 1
those,with 0.0 0.0 4 4 0
and,are 0.333333333333 0.00157683486239 22 11 11
their,capacity 1.0 0.000143348623853 0 1 -1
blood,which 1.0 0.000143348623853 1 0 1
induce,cyp 0.333333333333 0.000143348623853 1 2 -1
with,hiv-related 1.0 0.000143348623853 0 1 -1
those,in 0.0 0.0 4 4 0
first,days 1.0 0.000143348623853 0 1 -1
route,with 1.0 0.000143348623853 0 1 -1
of,av 1.0 0.000286697247706 2 0 2
potassium-sparing,may 1.0 0.000143348623853 0 1 -1
the,dermatologist 1.0 0.000143348623853 0 1 -1
on,exposure 1.0 0.000286697247706 0 2 -2
significantly,eliminated 1.0 0.000143348623853 1 0 1
the,provide 1.0 0.000143348623853 0 1 -1
activity,increase 1.0 0.000143348623853 0 1 -1
of,as 0.466666666667 0.00100344036697 4 11 -7
glucose,dehydrogenase 1.0 0.000143348623853 0 1 -1
the,changes 1.0 0.000716743119266 0 5 -5
with,glucose 1.0 0.000143348623853 0 1 -1
standard,therapy 1.0 0.000143348623853 0 1 -1
catabolic,enzymes 1.0 0.00043004587156 3 0 3
is,desired 1.0 0.000143348623853 0 1 -1
following,alfenta 1.0 0.000143348623853 1 0 1
or,accidental 1.0 0.000143348623853 0 1 -1
v,to 1.0 0.000143348623853 0 1 -1
weeks,was 1.0 0.000143348623853 1 0 1
related,compounds 1.0 0.000143348623853 1 0 1
garlic,capsules 1.0 0.000143348623853 0 1 -1
mefloquine,should 1.0 0.000143348623853 0 1 -1
and,will 1.0 0.000143348623853 0 1 -1
affect,absorption 1.0 0.000143348623853 0 1 -1
pharmacokinetics,after 1.0 0.000143348623853 0 1 -1
targets,and 1.0 0.000143348623853 0 1 -1
competes,for 1.0 0.000286697247706 2 0 2
maleate,its 1.0 0.000143348623853 1 0 1
the,anticoagulation 1.0 0.000143348623853 1 0 1
celexa,the 1.0 0.000143348623853 1 0 1
categories,result 1.0 0.000143348623853 1 0 1
employed,when 1.0 0.000143348623853 0 1 -1
study,alone 1.0 0.000143348623853 0 1 -1
constituents,of 1.0 0.000143348623853 0 1 -1
different,before 1.0 0.000143348623853 0 1 -1
protein,when 1.0 0.000143348623853 0 1 -1
significant,findings 1.0 0.000143348623853 0 1 -1
by,displacement 1.0 0.000143348623853 0 1 -1
titrated,according 1.0 0.000143348623853 1 0 1
toxicity,bronchospasm 1.0 0.000143348623853 1 0 1
to,use 0.25 0.000286697247706 3 5 -2
or,alter 1.0 0.000143348623853 1 0 1
from,women 1.0 0.000143348623853 0 1 -1
be,mediated 0.2 0.000143348623853 2 3 -1
and,depressive 1.0 0.000286697247706 0 2 -2
agonist,in 1.0 0.000143348623853 0 1 -1
concerns,regarding 1.0 0.000143348623853 0 1 -1
prothrombin,activity 1.0 0.000286697247706 2 0 2
cyp2d6,eg 1.0 0.000143348623853 1 0 1
with,extreme 0.5 0.000286697247706 3 1 2
agonist,it 1.0 0.000143348623853 1 0 1
and,small 0.0 0.0 1 1 0
is,truly 1.0 0.000143348623853 0 1 -1
antagonists,drugs 1.0 0.000143348623853 1 0 1
the,influence 1.0 0.000860091743119 0 6 -6
the,taking 1.0 0.000143348623853 0 1 -1
residues,abolishes 1.0 0.000143348623853 0 1 -1
its,dose 1.0 0.000143348623853 1 0 1
injection,clonidine 1.0 0.000143348623853 1 0 1
antacid,maalox 1.0 0.000143348623853 1 0 1
welchol,was 1.0 0.000143348623853 0 1 -1
organization,criteria 1.0 0.000143348623853 0 1 -1
beginning,depletion 1.0 0.000143348623853 1 0 1
and,clinically 1.0 0.000143348623853 0 1 -1
metabolites,hydroxytolbutamide 1.0 0.000143348623853 0 1 -1
function,have 1.0 0.000143348623853 0 1 -1
presumably,resulting 1.0 0.000143348623853 0 1 -1
this,organism 1.0 0.000143348623853 0 1 -1
significant,differences 1.0 0.00129013761468 0 9 -9
overlapping,administration 1.0 0.000143348623853 0 1 -1
intravenous,infusion 1.0 0.000573394495413 0 4 -4
of,resulting 0.818181818182 0.00258027522936 20 2 18
factor,support 1.0 0.000143348623853 0 1 -1
less,firmly 1.0 0.000143348623853 1 0 1
training,dose 1.0 0.000143348623853 0 1 -1
for,pseudomonas 1.0 0.000143348623853 0 1 -1
echistatin,alone 1.0 0.000143348623853 1 0 1
should,apply 1.0 0.000143348623853 0 1 -1
twice,daily 0.384615384615 0.00143348623853 8 18 -10
heparin,the 1.0 0.000143348623853 1 0 1
apart,so 1.0 0.000143348623853 0 1 -1
for,therapy 0.0 0.0 1 1 0
repeated,co-administration 1.0 0.000143348623853 1 0 1
of,buspirone 1.0 0.000286697247706 2 0 2
mean,fold 1.0 0.000143348623853 1 0 1
tromethamine,control 1.0 0.000143348623853 1 0 1
of,cases 1.0 0.000143348623853 1 0 1
chloride,excretion 1.0 0.000143348623853 1 0 1
of,xigris 1.0 0.000143348623853 0 1 -1
an,average 1.0 0.00100344036697 7 0 7
be,needed 0.0 0.0 1 1 0
either,erythro-fluorocitrate 1.0 0.000143348623853 0 1 -1
two,concomitantly 1.0 0.000143348623853 0 1 -1
as,most 1.0 0.000143348623853 0 1 -1
nondepolarizing,agents 1.0 0.000286697247706 2 0 2
focused,on 1.0 0.000286697247706 0 2 -2
tricyclic,with 1.0 0.000143348623853 0 1 -1
lifestyle,giving 1.0 0.000143348623853 0 1 -1
monohydroxy,metabolite 1.0 0.000143348623853 0 1 -1
relevant,plasma 1.0 0.000143348623853 0 1 -1
of,levo-dromoran 1.0 0.000143348623853 1 0 1
caffeine,two 1.0 0.000143348623853 0 1 -1
ace-inhibitors,reports 1.0 0.000286697247706 2 0 2
of,beginning 1.0 0.000143348623853 0 1 -1
amprenavir,is 1.0 0.000286697247706 0 2 -2
of,staphylococcus 0.0 0.0 1 1 0
arthralgia,adverse 1.0 0.000143348623853 1 0 1
than,months 1.0 0.000143348623853 0 1 -1
copegus,are 1.0 0.000143348623853 0 1 -1
this,isoenzyme 0.2 0.000143348623853 2 3 -1
has,recently 0.0 0.0 1 1 0
this,hit 1.0 0.000143348623853 0 1 -1
without,preventing 1.0 0.000143348623853 1 0 1
of,colestid 1.0 0.000143348623853 0 1 -1
received,under 1.0 0.000143348623853 0 1 -1
potentiate,a 1.0 0.000143348623853 1 0 1
gi,bleeding 0.333333333333 0.000143348623853 2 1 1
agonist,antagonist 0.0 0.0 1 1 0
a,precipitate 1.0 0.000143348623853 0 1 -1
to,affect 0.7 0.00200688073394 3 17 -14
fentanyl,anesthesia 1.0 0.000143348623853 1 0 1
interactions,general 1.0 0.000143348623853 0 1 -1
mutagenesis,impairment 1.0 0.00043004587156 0 3 -3
uricosuric,medication 1.0 0.000143348623853 1 0 1
take,lodine 1.0 0.000143348623853 0 1 -1
of,based 1.0 0.000143348623853 1 0 1
inhibitory,action 1.0 0.000286697247706 0 2 -2
for,bleeding 1.0 0.000143348623853 0 1 -1
either,discontinuing 1.0 0.000716743119266 5 0 5
man,significantly 1.0 0.000286697247706 2 0 2
a4,inhibitors 0.5 0.000286697247706 1 3 -2
cefditoren,pivoxil 0.0 0.0 2 2 0
principally,metabolized 1.0 0.000143348623853 0 1 -1
scotland,were 1.0 0.000143348623853 0 1 -1
markedly,with 1.0 0.000143348623853 1 0 1
p-450,a 1.0 0.000143348623853 1 0 1
i,corticosteroid 1.0 0.000143348623853 0 1 -1
taking,into 1.0 0.000286697247706 0 2 -2
including,an 1.0 0.000143348623853 0 1 -1
dosing,is 1.0 0.000143348623853 0 1 -1
alt,and 0.333333333333 0.000143348623853 1 2 -1
or,coagulation 1.0 0.000143348623853 0 1 -1
cyp450,enzyme 1.0 0.000286697247706 0 2 -2
through,actions 1.0 0.000143348623853 0 1 -1
dosages,exceeding 1.0 0.000143348623853 0 1 -1
avoidance,of 1.0 0.000143348623853 0 1 -1
derivatives,prothrombin 1.0 0.000143348623853 1 0 1
significant,qtc 1.0 0.000143348623853 0 1 -1
and,blurred 1.0 0.000143348623853 1 0 1
mentioned,above 1.0 0.000143348623853 0 1 -1
juice,co-administration 1.0 0.000143348623853 0 1 -1
determined,definitely 1.0 0.000143348623853 0 1 -1
sedation,hallucinations 1.0 0.000143348623853 1 0 1
and,k 1.0 0.00043004587156 3 0 3
and,i 1.0 0.000286697247706 0 2 -2
and,n 1.0 0.000143348623853 1 0 1
and,m 1.0 0.000286697247706 0 2 -2
and,b 1.0 0.000143348623853 0 1 -1
and,a 0.342857142857 0.00344036697248 47 23 24
and,g 1.0 0.000286697247706 2 0 2
and,d 0.0 0.0 1 1 0
and,s 0.333333333333 0.000143348623853 1 2 -1
newly,diagnosed 1.0 0.000143348623853 0 1 -1
maltose,interference 1.0 0.000143348623853 0 1 -1
reduce,plasma 0.6 0.00043004587156 4 1 3
antipsychotic,action 1.0 0.000143348623853 0 1 -1
survival,and 1.0 0.000143348623853 0 1 -1
to,supraspinal 1.0 0.000143348623853 0 1 -1
monitoring,levels 1.0 0.000143348623853 0 1 -1
was,greater 0.333333333333 0.000143348623853 2 1 1
subtilis,and 1.0 0.000143348623853 1 0 1
injection,q12h 1.0 0.000143348623853 0 1 -1
decrease,arterial 1.0 0.00043004587156 3 0 3
time,may 0.333333333333 0.000143348623853 1 2 -1
and,following 1.0 0.000716743119266 0 5 -5
heart,association 1.0 0.000143348623853 0 1 -1
thirst,weakness 1.0 0.000143348623853 0 1 -1
pregnancies,have 1.0 0.00043004587156 0 3 -3
one,contra-indication 1.0 0.000143348623853 0 1 -1
salicylic,acid 0.0 0.0 2 2 0
oxidative,stress 0.333333333333 0.000143348623853 1 2 -1
produced,optic 1.0 0.000143348623853 0 1 -1
binding,sites 0.230769230769 0.00043004587156 5 8 -3
treatment,dosage 1.0 0.000143348623853 1 0 1
were,dosed 1.0 0.000143348623853 0 1 -1
diazepam,diazepam 1.0 0.000143348623853 0 1 -1
therefore,unless 1.0 0.000286697247706 0 2 -2
grown,in 1.0 0.000143348623853 0 1 -1
but,given 1.0 0.000143348623853 0 1 -1
or,resulted 1.0 0.000143348623853 1 0 1
tested,here 1.0 0.000143348623853 0 1 -1
exhibiting,m 1.0 0.000143348623853 0 1 -1
however,numerous 1.0 0.000143348623853 0 1 -1
relevance,picr 1.0 0.000143348623853 0 1 -1
healthy,female 1.0 0.000286697247706 0 2 -2
survey,of 0.0 0.0 1 1 0
im,and 1.0 0.000143348623853 0 1 -1
necessary,while 1.0 0.000143348623853 0 1 -1
and,increasingly 1.0 0.000143348623853 0 1 -1
viracept,was 1.0 0.000143348623853 0 1 -1
both,lower 1.0 0.000143348623853 1 0 1
sustain,plasma 1.0 0.000143348623853 0 1 -1
however,caution 0.333333333333 0.000143348623853 2 1 1
leads,to 0.333333333333 0.000143348623853 2 1 1
form,or 1.0 0.000143348623853 1 0 1
cardiac,and 1.0 0.00043004587156 0 3 -3
acidity,in 1.0 0.000143348623853 1 0 1
combination,lies 1.0 0.000143348623853 0 1 -1
medication,should 1.0 0.00043004587156 0 3 -3
form,of 1.0 0.000716743119266 0 5 -5
or,uncomplicated 1.0 0.000143348623853 0 1 -1
evening,meal 0.333333333333 0.000143348623853 1 2 -1
with,dilaudid 1.0 0.000143348623853 1 0 1
d,with 1.0 0.000143348623853 1 0 1
regimen,did 1.0 0.000143348623853 1 0 1
induction,the 1.0 0.000143348623853 1 0 1
a,cytostatic 1.0 0.000143348623853 1 0 1
inspra,mg 1.0 0.000286697247706 2 0 2
and,fluoride 1.0 0.000143348623853 0 1 -1
chance,of 0.0 0.0 5 5 0
several,clinical 1.0 0.000143348623853 0 1 -1
is,in 1.0 0.000143348623853 0 1 -1
to10,m 1.0 0.000143348623853 1 0 1
cyp3a4,that 1.0 0.000143348623853 0 1 -1
mg,sular 1.0 0.000143348623853 1 0 1
ergotamine,concurrent 1.0 0.000143348623853 1 0 1
increased,inr 1.0 0.000143348623853 1 0 1
fulminant,rhabdomyolysis 1.0 0.000143348623853 1 0 1
antagonize,the 0.875 0.00200688073394 15 1 14
objective,responses 1.0 0.000143348623853 0 1 -1
v,in 1.0 0.000143348623853 0 1 -1
was,measured 1.0 0.000716743119266 0 5 -5
interpretation,of 1.0 0.000286697247706 0 2 -2
these,include 1.0 0.000573394495413 0 4 -4
general,most 1.0 0.000143348623853 0 1 -1
receiving,foradil 1.0 0.000143348623853 0 1 -1
occurrence,of 0.25 0.000286697247706 3 5 -2
theophylline,mg 1.0 0.000143348623853 0 1 -1
cefotaxime,sodium 1.0 0.000143348623853 0 1 -1
persistent,inhibition 1.0 0.000143348623853 1 0 1
and,estrogen-containing 0.0 0.0 1 1 0
ampicillin,in 1.0 0.000143348623853 1 0 1
aspirin,acetaminophen 1.0 0.000143348623853 0 1 -1
isoenzyme,macrolide 1.0 0.000143348623853 1 0 1
serious,pneumonia 1.0 0.000143348623853 1 0 1
with,benedict 1.0 0.000286697247706 0 2 -2
a,methotrexate 1.0 0.000143348623853 1 0 1
to,provoke 1.0 0.000143348623853 0 1 -1
a,time-dependent 1.0 0.000143348623853 0 1 -1
cancer,in 0.0 0.0 1 1 0
to,interactions 1.0 0.000286697247706 0 2 -2
effectively,administered 1.0 0.000143348623853 0 1 -1
from,fulvestrant-treated 1.0 0.000143348623853 0 1 -1
oxidases,and 1.0 0.000143348623853 0 1 -1
is,virtually 1.0 0.000143348623853 0 1 -1
induces,a 1.0 0.000143348623853 0 1 -1
either,levels 1.0 0.000143348623853 0 1 -1
be,small 1.0 0.000716743119266 0 5 -5
acids,proteins 1.0 0.000143348623853 0 1 -1
flow,glomerular 1.0 0.000143348623853 0 1 -1
adequately,evaluated 1.0 0.000143348623853 0 1 -1
the,intake 0.0 0.0 1 1 0
exchange,it 1.0 0.000143348623853 0 1 -1
flurbiprofen,pretreatment 1.0 0.000143348623853 1 0 1
bid,have 1.0 0.000143348623853 0 1 -1
i,alone 1.0 0.000143348623853 0 1 -1
diclofenac,decreases 1.0 0.000143348623853 1 0 1
time,and 1.0 0.000860091743119 0 6 -6
a,first 1.0 0.000286697247706 0 2 -2
same,procedures 1.0 0.000143348623853 0 1 -1
slight,reduction 1.0 0.000143348623853 1 0 1
any,excessive 1.0 0.000143348623853 1 0 1
toxicity,is 1.0 0.000143348623853 0 1 -1
during,dosing 1.0 0.000143348623853 1 0 1
interactions,measurement 1.0 0.000143348623853 0 1 -1
h,to 0.0 0.0 1 1 0
the,rest 1.0 0.000143348623853 0 1 -1
and,ethanol 1.0 0.000143348623853 1 0 1
states,at 1.0 0.000286697247706 0 2 -2
major,pathophysiologic 1.0 0.000143348623853 0 1 -1
hours,experienced 1.0 0.000143348623853 1 0 1
been,exploited 1.0 0.000143348623853 0 1 -1
the,applied 1.0 0.000143348623853 0 1 -1
failure,there 1.0 0.000143348623853 0 1 -1
of,antihypertensive 1.0 0.000143348623853 1 0 1
smaller,proportion 1.0 0.000143348623853 0 1 -1
steady-state,cmin 0.333333333333 0.000286697247706 2 4 -2
patient,has 0.111111111111 0.000143348623853 4 5 -1
d-penicillamine,or 1.0 0.000143348623853 0 1 -1
interaction,use 1.0 0.000143348623853 1 0 1
whether,abnormal 1.0 0.000143348623853 0 1 -1
the,significantly 1.0 0.000143348623853 0 1 -1
levels,to 1.0 0.000286697247706 2 0 2
h-spiroperidol,and 1.0 0.000286697247706 0 2 -2
avoid,intoxication 1.0 0.000286697247706 0 2 -2
close,observation 1.0 0.000286697247706 2 0 2
tablets,or 1.0 0.00114678899083 8 0 8
account,variations 1.0 0.000143348623853 0 1 -1
alter,renal 1.0 0.000143348623853 0 1 -1
additionally,is 1.0 0.000143348623853 0 1 -1
should,include 1.0 0.000143348623853 0 1 -1
to,days 0.0 0.0 3 3 0
other,suitable 0.25 0.000286697247706 3 5 -2
has,occurred 0.0 0.0 1 1 0
of,years 1.0 0.000143348623853 0 1 -1
the,principles 1.0 0.000286697247706 0 2 -2
catecholamines,after 1.0 0.000143348623853 0 1 -1
determine,therapy 1.0 0.000143348623853 0 1 -1
first,few 1.0 0.00043004587156 3 0 3
assessed,on 1.0 0.000143348623853 0 1 -1
diuretics,lotensin 1.0 0.000143348623853 1 0 1
stress,and 1.0 0.000286697247706 0 2 -2
nondepolarizing,possible 1.0 0.000286697247706 0 2 -2
refrain,from 1.0 0.000143348623853 0 1 -1
sumatriptan,and 1.0 0.000143348623853 1 0 1
bleeding,higher 1.0 0.000286697247706 2 0 2
investigate,the 1.0 0.000716743119266 0 5 -5
were,co-administered 1.0 0.000286697247706 2 0 2
intestine,so 1.0 0.000143348623853 1 0 1
major,metabolite 1.0 0.00043004587156 0 3 -3
mg,enteric 1.0 0.000143348623853 0 1 -1
almost,always 1.0 0.000143348623853 0 1 -1
efficacy,were 1.0 0.000143348623853 0 1 -1
higher,doses 0.230769230769 0.00043004587156 5 8 -3
possible,clinical 0.333333333333 0.000143348623853 1 2 -1
mm,declining 1.0 0.000143348623853 0 1 -1
health,care 0.333333333333 0.000143348623853 1 2 -1
concurrently,being 1.0 0.000286697247706 2 0 2
reinstate,psychostimulant 1.0 0.000143348623853 0 1 -1
with,there 1.0 0.000143348623853 1 0 1
as,decreasing 1.0 0.000143348623853 1 0 1
and,there 0.333333333333 0.000143348623853 1 2 -1
non-linear,pharmacokinetics 1.0 0.000143348623853 1 0 1
arteries,preconstricted 1.0 0.000143348623853 0 1 -1
midcycle,day 1.0 0.000143348623853 0 1 -1
dams,was 1.0 0.000143348623853 0 1 -1
of,allergens 1.0 0.000860091743119 0 6 -6
evidence,supporting 1.0 0.000143348623853 1 0 1
antithyroid,b-adrenergic 1.0 0.000143348623853 0 1 -1
have,some 1.0 0.000143348623853 0 1 -1
incubated,at 1.0 0.000143348623853 0 1 -1
d6,poor 1.0 0.000143348623853 1 0 1
ponstel,is 1.0 0.000143348623853 0 1 -1
vasodilators,the 1.0 0.000143348623853 1 0 1
or,epoxide 1.0 0.000286697247706 0 2 -2
such,a 0.6 0.00043004587156 1 4 -3
mortality,were 1.0 0.000143348623853 0 1 -1
this,adverse 1.0 0.000143348623853 0 1 -1
iodine-containing,products 1.0 0.000143348623853 0 1 -1
hepatic,blood 1.0 0.000143348623853 0 1 -1
because,cyp 1.0 0.000143348623853 0 1 -1
replacement,therapy 0.142857142857 0.000143348623853 3 4 -1
carbamazepine,causes 1.0 0.000143348623853 1 0 1
beneficial,effects 1.0 0.000286697247706 2 0 2
leakage,of 1.0 0.000143348623853 0 1 -1
receiving,micronase 1.0 0.000573394495413 0 4 -4
min,after 0.0 0.0 1 1 0
urine,were 1.0 0.000143348623853 0 1 -1
directly,affect 1.0 0.000286697247706 0 2 -2
thus,not 1.0 0.000143348623853 0 1 -1
are,using 0.0 0.0 1 1 0
an,inadequate 1.0 0.000143348623853 1 0 1
bile,caution 1.0 0.000143348623853 0 1 -1
and,time 0.0 0.0 1 1 0
fashion,and 1.0 0.000143348623853 0 1 -1
to,below 1.0 0.000143348623853 1 0 1
methotrexate,lodine 1.0 0.000143348623853 1 0 1
laser,interferometric 1.0 0.000143348623853 0 1 -1
possible,index 1.0 0.000143348623853 0 1 -1
placental,weight 1.0 0.000143348623853 0 1 -1
in,class 1.0 0.000143348623853 0 1 -1
psychoactive,drugs 1.0 0.000143348623853 1 0 1
since,these 1.0 0.000286697247706 2 0 2
patients,observed 1.0 0.000143348623853 0 1 -1
enzyme,based 1.0 0.000143348623853 0 1 -1
bicarbonate,used 1.0 0.000143348623853 1 0 1
benefit,justifies 1.0 0.000143348623853 0 1 -1
ratio,when 1.0 0.000143348623853 1 0 1
beta-blockers,not 1.0 0.000143348623853 1 0 1
exist,comparing 1.0 0.000143348623853 0 1 -1
hydrochlorothiazide,and 1.0 0.000143348623853 1 0 1
metabolic,reactions 1.0 0.000286697247706 0 2 -2
the,result 1.0 0.000286697247706 0 2 -2
special,care 0.333333333333 0.000143348623853 1 2 -1
was,recently 1.0 0.000573394495413 4 0 4
t3,concentrations 1.0 0.000286697247706 0 2 -2
when,coadminstered 1.0 0.000143348623853 1 0 1
then,the 1.0 0.000143348623853 0 1 -1
glyburide,an 1.0 0.000143348623853 0 1 -1
b,cells 1.0 0.000143348623853 0 1 -1
anabolic,steroids 1.0 0.000143348623853 1 0 1
probenecid,slows 1.0 0.000143348623853 0 1 -1
inducers,such 0.5 0.000286697247706 3 1 2
act,of 1.0 0.000143348623853 0 1 -1
h2-receptor,antagonists 0.333333333333 0.000143348623853 2 1 1
caution,using 1.0 0.000143348623853 1 0 1
reviewed,for 1.0 0.000143348623853 1 0 1
of,local 1.0 0.00043004587156 3 0 3
depressasnts,such 1.0 0.000143348623853 1 0 1
of,fat 0.333333333333 0.000143348623853 2 1 1
monitor,closely 1.0 0.000143348623853 0 1 -1
and,brain 1.0 0.000286697247706 2 0 2
were,negative 1.0 0.000143348623853 0 1 -1
dose,m 1.0 0.000143348623853 0 1 -1
re-results,in 1.0 0.000143348623853 0 1 -1
fasted,for 1.0 0.000143348623853 0 1 -1
by,evaluating 1.0 0.000143348623853 0 1 -1
with,beta 0.0 0.0 1 1 0
pump,inhibitors 0.714285714286 0.000716743119266 6 1 5
on,administration 1.0 0.000143348623853 1 0 1
breast,cancer 0.0 0.0 3 3 0
fatal,prolongation 1.0 0.000143348623853 1 0 1
consideration,of 1.0 0.000143348623853 0 1 -1
or,ugt 1.0 0.000143348623853 0 1 -1
with,iopidine 1.0 0.000143348623853 0 1 -1
was,initiated 1.0 0.000143348623853 1 0 1
ergot,alkaloids 1.0 0.000286697247706 2 0 2
other,instances 1.0 0.000143348623853 0 1 -1
inhibitors,have 1.0 0.000143348623853 1 0 1
dogs,treated 1.0 0.000143348623853 0 1 -1
the,review 1.0 0.000143348623853 0 1 -1
blockade,will 1.0 0.000143348623853 0 1 -1
cause,myopathy 1.0 0.00043004587156 0 3 -3
i,without 1.0 0.000143348623853 0 1 -1
phenomenon,was 1.0 0.000143348623853 0 1 -1
drugs,include 1.0 0.000143348623853 0 1 -1
of,lean 1.0 0.000143348623853 0 1 -1
cyp3a3,also 1.0 0.000143348623853 0 1 -1
anticholinergics,concurrent 1.0 0.000143348623853 1 0 1
little,work 1.0 0.000143348623853 0 1 -1
level,hyperlipidaemia 1.0 0.000143348623853 0 1 -1
and,p2 1.0 0.000143348623853 0 1 -1
oxidase,and 1.0 0.000143348623853 1 0 1
mixed--pharmacological,and 1.0 0.000143348623853 0 1 -1
hyperaminotransferasemia,significant 1.0 0.000143348623853 0 1 -1
with,nonsteroidal 1.0 0.00043004587156 3 0 3
additional,patients 1.0 0.000143348623853 0 1 -1
of,prior 1.0 0.000143348623853 1 0 1
treat,anxiety 1.0 0.000143348623853 0 1 -1
quite,large 1.0 0.000716743119266 0 5 -5
requirements,for 0.0 0.0 1 1 0
not,highly 1.0 0.00043004587156 0 3 -3
or,too 1.0 0.000286697247706 0 2 -2
gvia-sensitive,n-type 1.0 0.000143348623853 0 1 -1
of,each 0.142857142857 0.000286697247706 6 8 -2
with,metabolism 1.0 0.000143348623853 0 1 -1
insertable,hormonal 1.0 0.000143348623853 0 1 -1
mg,day 0.153846153846 0.00114678899083 22 30 -8
acid,using 1.0 0.000143348623853 1 0 1
hepatitis,c 1.0 0.000143348623853 0 1 -1
cereals,on 1.0 0.000143348623853 0 1 -1
mm,fractional 1.0 0.000143348623853 0 1 -1
propanol,derive 1.0 0.000143348623853 1 0 1
been,reviewed 1.0 0.000143348623853 1 0 1
without,additional 1.0 0.000143348623853 0 1 -1
subject,was 1.0 0.000143348623853 0 1 -1
patients,addition 1.0 0.000143348623853 0 1 -1
medicine,for 1.0 0.00043004587156 0 3 -3
compared,to 0.219512195122 0.00129013761468 25 16 9
of,natural 1.0 0.000143348623853 0 1 -1
the,manufacturer 1.0 0.000143348623853 0 1 -1
subjects,ages 1.0 0.000143348623853 1 0 1
toxicology,studies 0.333333333333 0.000143348623853 1 2 -1
inducers,of 0.473684210526 0.00129013761468 5 14 -9
this,to 1.0 0.000143348623853 0 1 -1
recommended,when 0.333333333333 0.000716743119266 10 5 5
and,effect 1.0 0.000143348623853 1 0 1
pharmacologically,predictable 1.0 0.000143348623853 1 0 1
agents,likely 1.0 0.000143348623853 0 1 -1
nsaids,and 0.142857142857 0.000143348623853 4 3 1
loop,diuretics 1.0 0.000143348623853 0 1 -1
peripheral,vascular 1.0 0.000143348623853 0 1 -1
class,ia 1.0 0.000143348623853 1 0 1
vertebrae,at 1.0 0.000143348623853 0 1 -1
with,non-aspergillus 1.0 0.000143348623853 0 1 -1
class,ii 1.0 0.000143348623853 0 1 -1
class,iv 1.0 0.000286697247706 0 2 -2
lines,showed 1.0 0.000143348623853 0 1 -1
class,is 1.0 0.000143348623853 0 1 -1
describe,the 1.0 0.000143348623853 0 1 -1
therapy,haart 1.0 0.000143348623853 0 1 -1
colostrum,iga 1.0 0.000143348623853 0 1 -1
nonlethal,mg 1.0 0.000143348623853 0 1 -1
monitored,carefully 1.0 0.000286697247706 2 0 2
histamine,h2-receptor 1.0 0.000143348623853 0 1 -1
diabetics,and 1.0 0.000143348623853 0 1 -1
included,beta-adrenergic 1.0 0.000143348623853 0 1 -1
known,or 1.0 0.000143348623853 0 1 -1
the,cecum 1.0 0.000286697247706 0 2 -2
excessive,bradycardia 1.0 0.000143348623853 0 1 -1
pregnancy,and 1.0 0.000286697247706 0 2 -2
not,considered 1.0 0.000286697247706 0 2 -2
followed,cessation 1.0 0.000143348623853 0 1 -1
statistical,work 1.0 0.000143348623853 0 1 -1
in,their 0.0 0.0 3 3 0
hyperthermia,crisis 1.0 0.000143348623853 1 0 1
crixivan,or 1.0 0.000286697247706 0 2 -2
prolong,adverse 1.0 0.000143348623853 1 0 1
msec,compared 1.0 0.000143348623853 1 0 1
copaxone,did 1.0 0.000143348623853 0 1 -1
population,pharmacokinetics 1.0 0.000143348623853 0 1 -1
including,chronic 1.0 0.000143348623853 0 1 -1
subjects,aged 0.0 0.0 1 1 0
blockers,presumably 1.0 0.000143348623853 1 0 1
illustrated,information 1.0 0.000143348623853 0 1 -1
p450,isoenzymes 1.0 0.000716743119266 0 5 -5
amevive,underwent 1.0 0.000143348623853 0 1 -1
for,reduction 0.0 0.0 1 1 0
updated,review 1.0 0.000143348623853 0 1 -1
reduce,renal 1.0 0.000143348623853 0 1 -1
phosphatase,activities 1.0 0.000143348623853 1 0 1
i,such 1.0 0.000143348623853 0 1 -1
clearance,does 1.0 0.000143348623853 0 1 -1
with,persantine 1.0 0.000143348623853 0 1 -1
on,antinociceptive 1.0 0.000143348623853 0 1 -1
for,that 0.333333333333 0.000143348623853 1 2 -1
that,did 1.0 0.000143348623853 0 1 -1
some,dysrhythmias 1.0 0.000143348623853 0 1 -1
have,pulse 1.0 0.000143348623853 0 1 -1
reduced,extent 1.0 0.000143348623853 1 0 1
various,combinations 1.0 0.000143348623853 0 1 -1
mesantoin,use 1.0 0.000143348623853 0 1 -1
antiarrhythmics,amiodarone 1.0 0.000143348623853 0 1 -1
flow,or 1.0 0.000143348623853 0 1 -1
mao,inhibitors 0.454545454545 0.0021502293578 24 9 15
osteoarthritis,when 1.0 0.000143348623853 0 1 -1
importance,of 1.0 0.000860091743119 0 6 -6
the,mentioned 1.0 0.000143348623853 0 1 -1
different,on 1.0 0.000143348623853 0 1 -1
the,similarity 1.0 0.000143348623853 0 1 -1
control,mechanisms 1.0 0.000143348623853 0 1 -1
potent,t 1.0 0.000143348623853 0 1 -1
similarly,dialyzed 1.0 0.000143348623853 0 1 -1
mg,oral 0.666666666667 0.000573394495413 1 5 -4
pancreatic,content 1.0 0.000143348623853 0 1 -1
or,skeletal-muscle 1.0 0.000143348623853 0 1 -1
for,than 1.0 0.000143348623853 1 0 1
extent,with 1.0 0.000143348623853 0 1 -1
increase,ci 1.0 0.000143348623853 0 1 -1
pharmacokinetics,over 1.0 0.000143348623853 1 0 1
produce,nephrotoxicity 1.0 0.000143348623853 1 0 1
iodide,potentiates 1.0 0.000143348623853 1 0 1
the,electrolyte 1.0 0.000286697247706 2 0 2
simultaneous,dosing 1.0 0.000286697247706 2 0 2
following,single 1.0 0.000143348623853 0 1 -1
some,pronestyl 1.0 0.000143348623853 1 0 1
even,be 1.0 0.000143348623853 1 0 1
t4,and 0.5 0.000286697247706 1 3 -2
of,alfenta 1.0 0.000143348623853 0 1 -1
thiosulfate,is 1.0 0.000143348623853 1 0 1
especially,those 1.0 0.000716743119266 5 0 5
clinical,effect 1.0 0.000143348623853 0 1 -1
necessary,careful 1.0 0.00043004587156 0 3 -3
however,currently 1.0 0.000143348623853 0 1 -1
with,serial 1.0 0.000143348623853 0 1 -1
or,does 1.0 0.000286697247706 0 2 -2
rehospitalisation,was 1.0 0.000143348623853 0 1 -1
beginning,of 1.0 0.000286697247706 0 2 -2
ml,h 0.333333333333 0.000143348623853 1 2 -1
interval,have 1.0 0.000143348623853 0 1 -1
humans,metabolism 1.0 0.000143348623853 0 1 -1
model,using 1.0 0.000143348623853 0 1 -1
who,require 1.0 0.00043004587156 0 3 -3
of,desmopressin 1.0 0.000143348623853 0 1 -1
from,infectious 1.0 0.000143348623853 0 1 -1
these,agents 0.473684210526 0.00258027522936 10 28 -18
is,encountered 1.0 0.000143348623853 0 1 -1
endocrine,and 1.0 0.000286697247706 0 2 -2
with,betagan 1.0 0.000143348623853 1 0 1
behavioral,responses 1.0 0.000143348623853 0 1 -1
oil,and 1.0 0.000143348623853 1 0 1
be,diminished 1.0 0.000143348623853 1 0 1
not,quantitatively 1.0 0.000143348623853 0 1 -1
the,best 1.0 0.000573394495413 0 4 -4
cause,hypoglycemia 1.0 0.000286697247706 0 2 -2
therapies,standard 1.0 0.000143348623853 0 1 -1
remedies,nephropathies 1.0 0.000143348623853 0 1 -1
experienced,more 1.0 0.000143348623853 1 0 1
are,treated 1.0 0.000143348623853 1 0 1
of,pharmacokinetic 1.0 0.000286697247706 0 2 -2
the,ht3 0.0 0.0 1 1 0
the,colonic 1.0 0.000143348623853 0 1 -1
nonopioid,tolerant 1.0 0.000143348623853 0 1 -1
self-administration,of 0.0 0.0 1 1 0
long,withdrawal 1.0 0.000143348623853 0 1 -1
and,o-desacetylrifabutin 1.0 0.000143348623853 1 0 1
and,streptozotocin-induced 1.0 0.000143348623853 0 1 -1
also,blocked 1.0 0.000143348623853 1 0 1
is,suitable 1.0 0.000286697247706 0 2 -2
redistribution,redistribution 1.0 0.000143348623853 0 1 -1
form,chelates 1.0 0.00043004587156 0 3 -3
not,have 1.0 0.00186353211009 0 13 -13
disturbances,of 1.0 0.000143348623853 1 0 1
impaired,in 1.0 0.000143348623853 1 0 1
reduced,or 1.0 0.00043004587156 3 0 3
nacmc,with 1.0 0.000143348623853 0 1 -1
combination,products 1.0 0.000143348623853 0 1 -1
blood,pressures 1.0 0.000143348623853 0 1 -1
time,profiles 1.0 0.000143348623853 0 1 -1
and,protein 1.0 0.000143348623853 0 1 -1
drugs,such 0.5 0.000573394495413 6 2 4
that,co-administration 0.333333333333 0.000143348623853 2 1 1
and,dosage 0.555555555556 0.000716743119266 2 7 -5
with,chemical 1.0 0.000143348623853 0 1 -1
hypotension,has 1.0 0.00043004587156 3 0 3
and,negative 1.0 0.00043004587156 0 3 -3
reviewed,after 1.0 0.000143348623853 0 1 -1
levels,caused 1.0 0.000143348623853 0 1 -1
be,reserved 1.0 0.000143348623853 0 1 -1
nsaids,should 1.0 0.000286697247706 2 0 2
chelates,with 1.0 0.00043004587156 0 3 -3
oral,therapy 1.0 0.000143348623853 0 1 -1
tested,cyp1a2 1.0 0.000143348623853 0 1 -1
media,experienced 1.0 0.000143348623853 1 0 1
are,tricky 1.0 0.000143348623853 0 1 -1
beta,adrenergic 1.0 0.000573394495413 4 0 4
eulexin,capsules 1.0 0.000143348623853 1 0 1
when,such 1.0 0.0024369266055 0 17 -17
rises,that 1.0 0.000143348623853 0 1 -1
or,their 1.0 0.000286697247706 0 2 -2
acid,by 1.0 0.000143348623853 1 0 1
between,administration 0.0 0.0 1 1 0
complexes,with 1.0 0.000143348623853 1 0 1
independent,joint 1.0 0.000143348623853 0 1 -1
previous,radiation 1.0 0.000143348623853 0 1 -1
severe,dry 1.0 0.000286697247706 2 0 2
other,members 0.333333333333 0.000143348623853 2 1 1
they,bring 1.0 0.000143348623853 0 1 -1
with,symptoms 1.0 0.000143348623853 0 1 -1
characteristics,in 1.0 0.000143348623853 0 1 -1
activity,should 0.333333333333 0.000143348623853 2 1 1
reductase,may 1.0 0.000143348623853 0 1 -1
be,carefully 0.5 0.000860091743119 9 3 6
extrusion,of 1.0 0.000143348623853 0 1 -1
representing,a 1.0 0.000143348623853 1 0 1
date,show 1.0 0.000143348623853 0 1 -1
ergomar,and 1.0 0.000143348623853 1 0 1
which,interfere 1.0 0.000143348623853 0 1 -1
ames,test 1.0 0.000143348623853 0 1 -1
inhibitor,can 1.0 0.000143348623853 1 0 1
consideration,to 1.0 0.000143348623853 0 1 -1
than,one-tenth 1.0 0.000143348623853 1 0 1
b,patients 1.0 0.000143348623853 1 0 1
solutions,but 1.0 0.000143348623853 0 1 -1
aeds,during 1.0 0.000143348623853 0 1 -1
zinecard,does 1.0 0.000143348623853 0 1 -1
amprenavir,significantly 1.0 0.000286697247706 2 0 2
when,levsin 1.0 0.000143348623853 1 0 1
shock,can 1.0 0.000143348623853 1 0 1
optimal,conditions 1.0 0.000143348623853 0 1 -1
coumarin-type,has 1.0 0.000143348623853 0 1 -1
inhibitory,interactions 1.0 0.000143348623853 0 1 -1
antiplatelet,and 1.0 0.000143348623853 1 0 1
similarly,had 1.0 0.000143348623853 0 1 -1
mg,every 0.0909090909091 0.000143348623853 6 5 1
juice,or 1.0 0.000143348623853 0 1 -1
species,during 1.0 0.000143348623853 1 0 1
in,symptoms 1.0 0.000143348623853 1 0 1
ng,ml 0.142857142857 0.000143348623853 3 4 -1
patient,slow 1.0 0.000143348623853 0 1 -1
decreased,auc 1.0 0.000286697247706 2 0 2
blockers,in 1.0 0.000286697247706 0 2 -2
of,astringents 1.0 0.000143348623853 0 1 -1
toradoliv,im 1.0 0.00043004587156 0 3 -3
acid,have 1.0 0.000143348623853 1 0 1
agents,and 0.166666666667 0.000573394495413 10 14 -4
of,cyp3a4 0.4 0.00172018348624 9 21 -12
by,glucuronidation 1.0 0.000143348623853 0 1 -1
for,glucose 1.0 0.00200688073394 0 14 -14
laboratory,abnormalities 1.0 0.000143348623853 0 1 -1
coat-a,count 1.0 0.000143348623853 0 1 -1
crixivan,fortovase 1.0 0.000143348623853 1 0 1
qd,did 1.0 0.000143348623853 0 1 -1
obstipation,even 1.0 0.000143348623853 1 0 1
on,placebo 1.0 0.000143348623853 0 1 -1
but,brevibloc 1.0 0.000143348623853 1 0 1
containing,containing 1.0 0.000143348623853 1 0 1
produced,in 0.0 0.0 1 1 0
corticosteroids,acth 1.0 0.000286697247706 0 2 -2
hypertension,or 0.333333333333 0.000143348623853 1 2 -1
and,endogenous 1.0 0.000143348623853 0 1 -1
respectively,by 1.0 0.000143348623853 1 0 1
inhibitors,psychotropic 1.0 0.000143348623853 1 0 1
anticoagulants,thyroid 1.0 0.000143348623853 0 1 -1
the,parenteral 1.0 0.000143348623853 0 1 -1
five,lacking 1.0 0.000143348623853 0 1 -1
pill,such 1.0 0.000143348623853 0 1 -1
anions,antithyroid 1.0 0.000143348623853 0 1 -1
be,antagonistic 1.0 0.000143348623853 1 0 1
maintain,pregnancy 1.0 0.000143348623853 0 1 -1
onset,were 1.0 0.000143348623853 0 1 -1
vasoconstrictor,thromboxane 1.0 0.000143348623853 0 1 -1
humans,taking 1.0 0.000143348623853 0 1 -1
or,maois 1.0 0.000143348623853 0 1 -1
cardiac,glycosides 0.428571428571 0.00043004587156 2 5 -3
messages,advise 1.0 0.000143348623853 0 1 -1
of,retinal 1.0 0.000143348623853 0 1 -1
administered,by 0.0 0.0 1 1 0
inactivate,by 1.0 0.000143348623853 1 0 1
patients,interaction 1.0 0.000143348623853 0 1 -1
sprycel,and 1.0 0.000143348623853 1 0 1
dilaudid,may 1.0 0.000143348623853 1 0 1
depression,tricyclic 1.0 0.000143348623853 1 0 1
anorexia,taste 1.0 0.000143348623853 0 1 -1
investigation,was 1.0 0.000143348623853 0 1 -1
contains,a 1.0 0.000143348623853 0 1 -1
l,kg 1.0 0.000143348623853 1 0 1
whenever,a 1.0 0.000573394495413 0 4 -4
alter,a 1.0 0.000143348623853 1 0 1
to,to 1.0 0.00043004587156 0 3 -3
august,were 1.0 0.000143348623853 0 1 -1
motion,sickness 1.0 0.000143348623853 0 1 -1
anitagonism,without 1.0 0.000143348623853 1 0 1
treatment-related,pattern 1.0 0.000143348623853 0 1 -1
altered,responsiveness 1.0 0.000143348623853 0 1 -1
by,increased 0.2 0.000143348623853 2 3 -1
to,attenuate 1.0 0.000286697247706 0 2 -2
by,since 1.0 0.000143348623853 1 0 1
activity,the 1.0 0.000143348623853 0 1 -1
generally,this 1.0 0.000143348623853 0 1 -1
other,cell 1.0 0.000143348623853 1 0 1
that,neither 1.0 0.000143348623853 0 1 -1
other,likely 1.0 0.000143348623853 0 1 -1
h,this 1.0 0.000143348623853 0 1 -1
h,was 1.0 0.000143348623853 0 1 -1
particularly,have 1.0 0.000143348623853 1 0 1
can,interact 1.0 0.00043004587156 3 0 3
injected,with 1.0 0.000143348623853 1 0 1
ii,showed 1.0 0.000143348623853 0 1 -1
treatment,should 0.2 0.000143348623853 3 2 1
fludrocortisone,acetate 1.0 0.000143348623853 1 0 1
contraception,a 1.0 0.000143348623853 0 1 -1
concomitantly,receiving 0.6 0.00043004587156 4 1 3
of,consciousness 0.0 0.0 1 1 0
together,have 1.0 0.000286697247706 2 0 2
receiving,without 1.0 0.000143348623853 0 1 -1
elevated,cerebral 1.0 0.000143348623853 1 0 1
skeletal,muscle 0.333333333333 0.000286697247706 4 2 2
for,single 1.0 0.000143348623853 0 1 -1
for,coadministration 1.0 0.000286697247706 0 2 -2
acute,atypical 1.0 0.000143348623853 1 0 1
activity,with 1.0 0.000143348623853 1 0 1
patients,used 1.0 0.000143348623853 0 1 -1
contortrostatin-induced,phosphorylation 1.0 0.000143348623853 1 0 1
encephalopathy,in 1.0 0.000143348623853 0 1 -1
on,receiving 1.0 0.000143348623853 1 0 1
pressure,strattera 1.0 0.000143348623853 0 1 -1
severe,or 1.0 0.000143348623853 0 1 -1
proleukin,may 0.333333333333 0.000143348623853 2 1 1
either,unchanged 1.0 0.000143348623853 0 1 -1
have,life-threatening 1.0 0.000143348623853 1 0 1
or,should 0.111111111111 0.000143348623853 5 4 1
between,wellbutrin 1.0 0.000143348623853 1 0 1
interaction,or 1.0 0.000143348623853 1 0 1
balance,patient 1.0 0.000143348623853 0 1 -1
gene,transfer 1.0 0.000143348623853 0 1 -1
this,metabolic 1.0 0.000143348623853 0 1 -1
if,inspra 1.0 0.000143348623853 1 0 1
for,nmda 1.0 0.000143348623853 0 1 -1
are,inducers 1.0 0.000286697247706 0 2 -2
was,times 1.0 0.000286697247706 0 2 -2
ergot-containing,have 1.0 0.000286697247706 0 2 -2
an,important 0.333333333333 0.000286697247706 4 2 2
major,membrane 1.0 0.000143348623853 0 1 -1
acid,level 1.0 0.000143348623853 1 0 1
which,have 0.333333333333 0.000143348623853 2 1 1
or,would 1.0 0.000143348623853 0 1 -1
systolic,blood 0.428571428571 0.00043004587156 5 2 3
with,frequent 1.0 0.00043004587156 0 3 -3
apart,was 1.0 0.000143348623853 1 0 1
normal,metab-olizers 1.0 0.000143348623853 0 1 -1
eliminated,or 1.0 0.000143348623853 0 1 -1
temporarily,reduced 1.0 0.000143348623853 1 0 1
test,dst 1.0 0.000286697247706 0 2 -2
preparations,of 1.0 0.00043004587156 0 3 -3
with,habituating 1.0 0.000143348623853 0 1 -1
rodent,study 1.0 0.000143348623853 0 1 -1
of,cortisol 1.0 0.000143348623853 0 1 -1
allium,sativum 1.0 0.000143348623853 1 0 1
addition,there 0.0 0.0 1 1 0
mixtures,of 1.0 0.000143348623853 0 1 -1
regimens,who 1.0 0.000143348623853 1 0 1
embryonic,survival 1.0 0.000143348623853 0 1 -1
confirm,that 1.0 0.00043004587156 0 3 -3
blocking,the 0.0 0.0 1 1 0
of,previous 1.0 0.000143348623853 0 1 -1
of,brevibloc 0.333333333333 0.000143348623853 1 2 -1
with,doses 1.0 0.000573394495413 0 4 -4
h2,receptor 1.0 0.000143348623853 1 0 1
sulfide,metabolite 1.0 0.000143348623853 1 0 1
trial,should 1.0 0.000143348623853 1 0 1
analogue,d-ala2 1.0 0.000143348623853 0 1 -1
indices,should 1.0 0.000286697247706 0 2 -2
is,true 1.0 0.000143348623853 0 1 -1
that,pretreatment 1.0 0.000143348623853 0 1 -1
prolonged,from 0.0 0.0 1 1 0
rural,primary 1.0 0.000143348623853 0 1 -1
commit,to 1.0 0.000143348623853 0 1 -1
possible,drug 1.0 0.00043004587156 3 0 3
other,signs 1.0 0.000286697247706 0 2 -2
hydrochloride,x 1.0 0.000143348623853 1 0 1
understanding,of 1.0 0.00043004587156 0 3 -3
clinical,experience 0.6 0.00043004587156 1 4 -3
however,because 0.0 0.0 3 3 0
molecular,mechanisms 1.0 0.000143348623853 0 1 -1
and,metabolite 1.0 0.000143348623853 1 0 1
its,active 0.4 0.000573394495413 7 3 4
hydrochloride,a 1.0 0.000143348623853 0 1 -1
glaucoma,or 1.0 0.000143348623853 1 0 1
are,concomitantly 1.0 0.000286697247706 0 2 -2
adult,data 1.0 0.000143348623853 1 0 1
various,antihypertensive 1.0 0.000143348623853 1 0 1
following,days 1.0 0.000143348623853 0 1 -1
with,d2-antagonists 1.0 0.000143348623853 1 0 1
glucose,measurement 1.0 0.000143348623853 0 1 -1
this,suggests 1.0 0.000286697247706 0 2 -2
via,its 1.0 0.000143348623853 1 0 1
creatinine,concentration 1.0 0.000143348623853 0 1 -1
and,multiple 0.333333333333 0.000143348623853 1 2 -1
with,activity 0.0 0.0 3 3 0
furosemide,should 1.0 0.000143348623853 1 0 1
concentrations,include 1.0 0.00043004587156 3 0 3
truly,hypothyroid 1.0 0.000143348623853 0 1 -1
the,iatrogenic 1.0 0.000143348623853 0 1 -1
neonates,whose 1.0 0.000143348623853 0 1 -1
these,interactions 1.0 0.000573394495413 0 4 -4
further,the 1.0 0.000143348623853 1 0 1
in,whom 0.111111111111 0.000143348623853 5 4 1
be,crucial 1.0 0.000143348623853 0 1 -1
g,ml 0.0 0.0 1 1 0
inhalation,aerosol 0.333333333333 0.000143348623853 1 2 -1
juices,studies 1.0 0.000143348623853 0 1 -1
sub-,for 1.0 0.000143348623853 0 1 -1
potassium,sparing 1.0 0.000286697247706 0 2 -2
absorbed,from 1.0 0.000143348623853 0 1 -1
without,a 0.333333333333 0.000143348623853 1 2 -1
endogenous,plasma 0.333333333333 0.000143348623853 2 1 1
as,alternatives 1.0 0.000143348623853 1 0 1
hypoglycemic,effect 1.0 0.000143348623853 1 0 1
g,m2 1.0 0.00043004587156 0 3 -3
been,coadministered 1.0 0.00043004587156 0 3 -3
also,higher 1.0 0.000143348623853 1 0 1
antagonists,phenyltheophylline 1.0 0.000143348623853 0 1 -1
with,micromol 1.0 0.000143348623853 0 1 -1
revealed,that 0.333333333333 0.000143348623853 2 1 1
inhibited,gastric 1.0 0.000143348623853 0 1 -1
after,cholestyramine 1.0 0.000143348623853 0 1 -1
ca,channels 1.0 0.000143348623853 0 1 -1
meals,for 1.0 0.000286697247706 0 2 -2
was,more 0.6 0.00043004587156 1 4 -3
elevations,resolved 1.0 0.000143348623853 0 1 -1
aldehyde,oxidase 0.333333333333 0.000143348623853 1 2 -1
a,facilitation 1.0 0.000143348623853 0 1 -1
the,medication 1.0 0.000286697247706 0 2 -2
the,caucasian 1.0 0.000573394495413 0 4 -4
cmax,when 1.0 0.000573394495413 4 0 4
decreased,antihypertensive 1.0 0.000143348623853 1 0 1
coumarin-type,the 1.0 0.000286697247706 2 0 2
the,nursing 1.0 0.000143348623853 0 1 -1
an,updated 1.0 0.000143348623853 0 1 -1
circulating,fluids 1.0 0.000286697247706 0 2 -2
another,drug 1.0 0.000286697247706 0 2 -2
received,such 1.0 0.000143348623853 0 1 -1
rt-pa,or 1.0 0.000143348623853 0 1 -1
thrombus,formation 1.0 0.000143348623853 1 0 1
treatment,may 0.0 0.0 1 1 0
monitored,regularly 0.5 0.000286697247706 1 3 -2
if,additional 1.0 0.000143348623853 1 0 1
nsaids,tnf 1.0 0.000143348623853 0 1 -1
relevant,effect 0.0 0.0 1 1 0
these,leading 1.0 0.000143348623853 1 0 1
phenytoin,phenytoin 1.0 0.000143348623853 1 0 1
extracellular,rr 1.0 0.000143348623853 1 0 1
and,industrial 1.0 0.000143348623853 0 1 -1
therapy,standard 1.0 0.000143348623853 0 1 -1
that,administration 0.333333333333 0.000143348623853 1 2 -1
was,thus 1.0 0.000143348623853 0 1 -1
desired,effect 0.555555555556 0.000716743119266 7 2 5
two,were 0.333333333333 0.000143348623853 1 2 -1
ketoconazole,cyp3a4 1.0 0.000143348623853 0 1 -1
insufficient,experience 1.0 0.000143348623853 1 0 1
during,with 1.0 0.000143348623853 1 0 1
long-term,suppression 1.0 0.000143348623853 1 0 1
antidepressants,concurrent 1.0 0.000143348623853 0 1 -1
study,toradoliv 1.0 0.000143348623853 0 1 -1
more,inhalations 1.0 0.000143348623853 0 1 -1
therefore,consideration 1.0 0.000143348623853 1 0 1
elimination,route 1.0 0.000143348623853 1 0 1
acetazolamide,may 0.5 0.000286697247706 3 1 2
to,show 1.0 0.000143348623853 0 1 -1
between,copaxone 1.0 0.000286697247706 0 2 -2
wedge,pressure 1.0 0.000143348623853 1 0 1
prostacyclin,which 1.0 0.000143348623853 0 1 -1
clearance,mechanism 1.0 0.000143348623853 0 1 -1
glucose,control 1.0 0.000143348623853 0 1 -1
that,occurred 1.0 0.000143348623853 0 1 -1
cations,including 1.0 0.000143348623853 1 0 1
hypotension,because 1.0 0.000143348623853 0 1 -1
with,antihypertensive 1.0 0.000143348623853 1 0 1
including,solganal 1.0 0.000143348623853 1 0 1
tbg,levels 1.0 0.000143348623853 0 1 -1
no,acceptable 1.0 0.000143348623853 0 1 -1
enzymes,may 0.5 0.000286697247706 1 3 -2
of,vehicle 1.0 0.000143348623853 0 1 -1
to,repeated 1.0 0.000716743119266 0 5 -5
not,impaired 1.0 0.000143348623853 0 1 -1
medicines,thiazide 1.0 0.000143348623853 1 0 1
hourly,diuresis 1.0 0.000143348623853 0 1 -1
confirmed,interactions 1.0 0.000143348623853 0 1 -1
individual,cases 1.0 0.000143348623853 0 1 -1
alone,was 1.0 0.000143348623853 1 0 1
therapy,although 1.0 0.00043004587156 0 3 -3
metabolism,is 1.0 0.000716743119266 0 5 -5
also,expected 1.0 0.000286697247706 2 0 2
until,stable 1.0 0.000143348623853 0 1 -1
metabolism,in 0.2 0.000143348623853 3 2 1
single,and 1.0 0.000143348623853 1 0 1
and,instructions 1.0 0.000143348623853 0 1 -1
carbamazepine,equetrotm 1.0 0.000143348623853 1 0 1
agents,benzodiazepines 1.0 0.000143348623853 1 0 1
significant,symptoms 1.0 0.000143348623853 0 1 -1
toxic,that 1.0 0.000143348623853 0 1 -1
b,non-steroidal 1.0 0.000143348623853 0 1 -1
blocked,the 0.333333333333 0.000143348623853 2 1 1
plasma,prothrombin 1.0 0.000286697247706 2 0 2
ipratropium,bromide 1.0 0.000143348623853 1 0 1
that,they 0.0 0.0 1 1 0
diarrhea,in 0.333333333333 0.000143348623853 1 2 -1
lithium,should 1.0 0.000143348623853 1 0 1
in,markedly 1.0 0.000143348623853 1 0 1
inhibiting,as 1.0 0.000716743119266 0 5 -5
non-significantly,reduced 1.0 0.000143348623853 0 1 -1
to,examine 1.0 0.00100344036697 0 7 -7
from,therapeutic 1.0 0.000143348623853 0 1 -1
a,comprehensive 1.0 0.000143348623853 0 1 -1
tc99m,uptake 1.0 0.000143348623853 0 1 -1
depress,plasma 1.0 0.000286697247706 2 0 2
despite,persistent 1.0 0.000143348623853 0 1 -1
to,relieve 1.0 0.000143348623853 0 1 -1
for,maintenance 1.0 0.000143348623853 0 1 -1
adenocard,should 1.0 0.000143348623853 0 1 -1
acid,and 0.466666666667 0.00100344036697 4 11 -7
with,but 0.333333333333 0.000143348623853 1 2 -1
of,hydroxy 1.0 0.000143348623853 0 1 -1
palpitation,chest 1.0 0.000143348623853 0 1 -1
reports,concerned 1.0 0.000143348623853 0 1 -1
lodosyn,carbidopa 1.0 0.000143348623853 0 1 -1
be,tested 1.0 0.000143348623853 0 1 -1
completely,evaluated 1.0 0.000143348623853 0 1 -1
in,large 0.333333333333 0.000143348623853 1 2 -1
inhibiting,cyp3a 1.0 0.000143348623853 0 1 -1
and,significant 1.0 0.00043004587156 3 0 3
that,hippocampal 1.0 0.000143348623853 0 1 -1
supplement,while 1.0 0.000143348623853 1 0 1
isoenzymes,caution 1.0 0.000143348623853 1 0 1
use,and 1.0 0.000143348623853 0 1 -1
pheochromocytoma,and 1.0 0.000143348623853 0 1 -1
convulsion,was 1.0 0.000143348623853 0 1 -1
analysed,using 1.0 0.000143348623853 0 1 -1
predict,the 1.0 0.00043004587156 0 3 -3
same,study 1.0 0.000286697247706 0 2 -2
when,vardenafil 0.333333333333 0.000143348623853 2 1 1
pathway,may 1.0 0.000143348623853 0 1 -1
side,chain 1.0 0.000143348623853 0 1 -1
equilibrium,and 1.0 0.000143348623853 0 1 -1
studies,demonstrated 1.0 0.000286697247706 0 2 -2
of,striatal 1.0 0.000286697247706 2 0 2
blockers,calcium 1.0 0.000143348623853 0 1 -1
containing,higher 1.0 0.000143348623853 0 1 -1
stomach,minutes 1.0 0.000143348623853 0 1 -1
prolongation,cardiac 0.0 0.0 1 1 0
ventricular,dysfunction 1.0 0.000143348623853 0 1 -1
n-acetyltransferase,may 1.0 0.000143348623853 1 0 1
when,intravenous 1.0 0.000143348623853 1 0 1
the,striatum 1.0 0.000143348623853 1 0 1
function,normally 1.0 0.000143348623853 0 1 -1
therapeutic,advantage 1.0 0.000143348623853 0 1 -1
rifampin,and 1.0 0.000143348623853 1 0 1
by,hippocampal 1.0 0.000143348623853 0 1 -1
endogenous,marker 1.0 0.000143348623853 1 0 1
lack,of 1.0 0.00157683486239 0 11 -11
potentiate,and 1.0 0.000286697247706 0 2 -2
fatty,acids 1.0 0.000143348623853 0 1 -1
undertaken,with 0.333333333333 0.000143348623853 2 1 1
ethanol,cause 1.0 0.000143348623853 1 0 1
potentiate,any 1.0 0.000143348623853 1 0 1
this,diminution 1.0 0.000286697247706 0 2 -2
pharmacokinetic,substudy 1.0 0.000143348623853 1 0 1
been,investigated 0.0 0.0 1 1 0
generally,not 0.2 0.000143348623853 2 3 -1
p450iiia4,isozyme 1.0 0.000143348623853 1 0 1
hydroxymethylglutaryl,coenzyme 1.0 0.000143348623853 1 0 1
when,their 1.0 0.000143348623853 0 1 -1
chemical,resemblance 1.0 0.000143348623853 1 0 1
cyp,d6 0.6 0.00043004587156 1 4 -3
monitoring,or 0.0 0.0 1 1 0
least,months 1.0 0.000286697247706 0 2 -2
on,body 1.0 0.000573394495413 0 4 -4
the,pronounced 1.0 0.000143348623853 1 0 1
impulsivity,and 1.0 0.000143348623853 0 1 -1
monitoring,of 0.268292682927 0.00157683486239 15 26 -11
system,derived 1.0 0.000143348623853 0 1 -1
of,containing 1.0 0.000143348623853 1 0 1
these,subjects 0.333333333333 0.000143348623853 1 2 -1
since,decreases 1.0 0.000143348623853 0 1 -1
and,dry 1.0 0.000143348623853 0 1 -1
minimize,risks 1.0 0.000143348623853 0 1 -1
mycophenolate,mofetil 0.333333333333 0.000143348623853 1 2 -1
exaggerate,the 0.333333333333 0.000143348623853 2 1 1
cimetidine,co-administration 0.333333333333 0.000143348623853 1 2 -1
allowed,in 1.0 0.000143348623853 0 1 -1
urine,may 1.0 0.00114678899083 0 8 -8
with,norpace 1.0 0.000143348623853 1 0 1
co-,administration 1.0 0.000143348623853 0 1 -1
effects,especially 1.0 0.000286697247706 0 2 -2
preparations,glyceryl 1.0 0.000143348623853 0 1 -1
its,nephrotoxicity 1.0 0.000143348623853 1 0 1
maximum,of 1.0 0.00043004587156 3 0 3
subsequent,recovery 1.0 0.000143348623853 0 1 -1
or,reproductive 1.0 0.000143348623853 0 1 -1
nicotine-induced,release 1.0 0.000143348623853 1 0 1
medium,rpmi1640 1.0 0.000143348623853 0 1 -1
drug,at 1.0 0.000143348623853 0 1 -1
vomiting,and 1.0 0.000143348623853 1 0 1
also,in 0.142857142857 0.000143348623853 4 3 1
results,using 1.0 0.000143348623853 0 1 -1
mean,confidence 1.0 0.000143348623853 1 0 1
itraconazole,ketoconazole 1.0 0.000143348623853 0 1 -1
of,hydrobromide 1.0 0.000143348623853 1 0 1
or,changing 1.0 0.00043004587156 3 0 3
inr,elevations 0.0 0.0 1 1 0
emulsion,doubly 1.0 0.000143348623853 0 1 -1
of,h-triglyceride 1.0 0.000143348623853 1 0 1
concentrations,similar 1.0 0.000143348623853 1 0 1
between,tumor 1.0 0.000143348623853 0 1 -1
medication,but 1.0 0.000143348623853 0 1 -1
with,indicate 1.0 0.000143348623853 1 0 1
b12,and 1.0 0.000143348623853 1 0 1
possible,anticholinesterase 1.0 0.000143348623853 1 0 1
accompany,high 1.0 0.000143348623853 1 0 1
prostaglandins,may 1.0 0.000143348623853 1 0 1
post-marketing,experience 0.666666666667 0.000573394495413 5 1 4
about,in 0.5 0.000286697247706 3 1 2
oxo-desethylzaleplon,and 1.0 0.000143348623853 0 1 -1
acid,sequestrants 0.0 0.0 1 1 0
higher,daily 1.0 0.000143348623853 0 1 -1
the,lower 1.0 0.00043004587156 3 0 3
grapefruit,or 1.0 0.000286697247706 0 2 -2
arthritis,n 1.0 0.000143348623853 0 1 -1
essentially,completely 1.0 0.000286697247706 0 2 -2
with,topical 1.0 0.000143348623853 1 0 1
locomotor,and 1.0 0.000143348623853 0 1 -1
practice,has 1.0 0.000143348623853 1 0 1
nimotop,was 1.0 0.000143348623853 1 0 1
event,profile 1.0 0.000143348623853 0 1 -1
insulin-induced,proliferation 1.0 0.000143348623853 1 0 1
multiple-dose,crossover 1.0 0.000143348623853 0 1 -1
nausea,paresthesia 1.0 0.000143348623853 0 1 -1
immunodepressant--the,sandimmune--on 1.0 0.000143348623853 0 1 -1
system,cns 0.0 0.0 1 1 0
conclusion,fluvoxamine 1.0 0.000143348623853 0 1 -1
patterns,of 1.0 0.000143348623853 0 1 -1
of,reaction 1.0 0.000143348623853 0 1 -1
pre-existing,cardiac 1.0 0.000143348623853 1 0 1
amiodarone,may 1.0 0.000143348623853 0 1 -1
higher,serum 1.0 0.000286697247706 2 0 2
were,extensive 1.0 0.000143348623853 1 0 1
those,elevations 1.0 0.000143348623853 0 1 -1
follow-up,of 1.0 0.000143348623853 0 1 -1
occurred,in 0.0 0.0 5 5 0
regarding,interactions 1.0 0.00043004587156 0 3 -3
increase,resulting 1.0 0.000143348623853 1 0 1
ataxia,blurred 1.0 0.000143348623853 0 1 -1
of,lexapro 1.0 0.000143348623853 0 1 -1
been,started 1.0 0.000143348623853 0 1 -1
pharmacokinetics,exposure 1.0 0.000143348623853 0 1 -1
fatal,reactions 1.0 0.000143348623853 1 0 1
placed,on 1.0 0.000143348623853 0 1 -1
with,neurontin 1.0 0.000143348623853 1 0 1
and,azole 1.0 0.000143348623853 0 1 -1
tail-flick,inhibition 0.0 0.0 3 3 0
perchlorate,in 1.0 0.000143348623853 0 1 -1
estazolam,interaction 1.0 0.000286697247706 0 2 -2
microvascular,complications 1.0 0.000143348623853 0 1 -1
of,linear 1.0 0.000143348623853 0 1 -1
hand,surprisingly 1.0 0.000143348623853 0 1 -1
may,require 0.416666666667 0.00143348623853 7 17 -10
attempts,to 1.0 0.000143348623853 0 1 -1
detoxification,of 1.0 0.000143348623853 1 0 1
and,from 1.0 0.00043004587156 0 3 -3
existence,of 1.0 0.000143348623853 0 1 -1
an,impairment 1.0 0.000143348623853 0 1 -1
titration,are 1.0 0.000143348623853 0 1 -1
regularly,results 1.0 0.000143348623853 0 1 -1
continued,use 1.0 0.000286697247706 0 2 -2
identifies,clinically 1.0 0.000143348623853 0 1 -1
established,drug 1.0 0.000286697247706 0 2 -2
antiinflammatory,agents 1.0 0.000286697247706 2 0 2
patients,and 0.111111111111 0.000143348623853 4 5 -1
who,must 1.0 0.000143348623853 0 1 -1
lithium,coadministration 1.0 0.000143348623853 0 1 -1
warfarin-type,certain 1.0 0.000143348623853 1 0 1
the,channel 1.0 0.000143348623853 0 1 -1
alkaloid,class 1.0 0.000143348623853 1 0 1
inhibitors,should 0.714285714286 0.000716743119266 6 1 5
demonstrated,an 1.0 0.000143348623853 1 0 1
oxcarbazepine,can 1.0 0.000143348623853 0 1 -1
rare,postmarketing 0.0 0.0 1 1 0
mode,of 1.0 0.000286697247706 0 2 -2
inhibitors,serious 1.0 0.000143348623853 0 1 -1
activity,against 1.0 0.00043004587156 0 3 -3
authors,examined 1.0 0.000143348623853 0 1 -1
or,insulin-induced 1.0 0.000143348623853 1 0 1
of,alcohol-related 1.0 0.000143348623853 0 1 -1
be,transiently 1.0 0.000143348623853 0 1 -1
study,periods 1.0 0.000143348623853 0 1 -1
with,cerubidine 1.0 0.000143348623853 1 0 1
that,impact 1.0 0.000143348623853 0 1 -1
excretion,rate 1.0 0.000143348623853 0 1 -1
there,any 1.0 0.000143348623853 0 1 -1
sedation,times 1.0 0.000143348623853 0 1 -1
kg,results 1.0 0.000143348623853 0 1 -1
changing,vioxx 1.0 0.000143348623853 1 0 1
preparations,such 1.0 0.000143348623853 1 0 1
diuretics,concomitant 1.0 0.000143348623853 1 0 1
receiving,sprycel 1.0 0.000143348623853 0 1 -1
on,adult 1.0 0.000143348623853 1 0 1
the,outset 1.0 0.000143348623853 0 1 -1
therefore,simultaneous 1.0 0.000143348623853 0 1 -1
supine,position 1.0 0.000143348623853 0 1 -1
fully,restored 1.0 0.000143348623853 0 1 -1
diuretics,patients 1.0 0.000286697247706 2 0 2
bacteria,by 1.0 0.000143348623853 0 1 -1
methylthiadiazole,can 1.0 0.000143348623853 0 1 -1
that,has 0.5 0.000286697247706 1 3 -2
treatment,study 1.0 0.000143348623853 0 1 -1
all,animal 1.0 0.000143348623853 0 1 -1
which,could 0.428571428571 0.00043004587156 2 5 -3
that,had 1.0 0.000286697247706 0 2 -2
psoriatic,arthritis 1.0 0.000143348623853 0 1 -1
im,twice 1.0 0.000143348623853 0 1 -1
infusion,requirements 1.0 0.000143348623853 1 0 1
effects,concerning 1.0 0.000143348623853 1 0 1
metabolizers,resemble 1.0 0.000860091743119 0 6 -6
miracidia,of 1.0 0.000143348623853 0 1 -1
more,of 1.0 0.00043004587156 0 3 -3
similar,between 1.0 0.000286697247706 0 2 -2
been,tested 1.0 0.00043004587156 0 3 -3
the,therapeutic 0.157894736842 0.00043004587156 8 11 -3
are,relatively 1.0 0.000143348623853 0 1 -1
of,stimulation 1.0 0.000143348623853 0 1 -1
been,formally 1.0 0.000143348623853 0 1 -1
dehydrogenase,pyrroloquinolinequinone 1.0 0.000143348623853 0 1 -1
result,at 1.0 0.000143348623853 0 1 -1
without,significantly 1.0 0.000143348623853 0 1 -1
may,show 0.0 0.0 1 1 0
of,primary 1.0 0.000143348623853 0 1 -1
against,an 1.0 0.000143348623853 1 0 1
ie,decreased 1.0 0.000286697247706 2 0 2
phenytoin,therapy 1.0 0.000143348623853 1 0 1
with,m-dinitrobenzene 1.0 0.000143348623853 0 1 -1
received,days 0.0 0.0 1 1 0
and,hyperreninemia 1.0 0.000143348623853 1 0 1
the,early 1.0 0.000143348623853 1 0 1
kg,week 1.0 0.000143348623853 0 1 -1
lime,should 1.0 0.000143348623853 0 1 -1
decreased,approximately 1.0 0.000286697247706 2 0 2
not,recommended 0.428571428571 0.00129013761468 15 6 9
this,class 1.0 0.00043004587156 0 3 -3
of,l-tyrosine 1.0 0.000143348623853 1 0 1
minor,adverse 1.0 0.000143348623853 0 1 -1
was,especially 1.0 0.000143348623853 0 1 -1
deplete,and 1.0 0.000143348623853 1 0 1
fibrillation,and 1.0 0.000143348623853 0 1 -1
that,renal 1.0 0.000143348623853 1 0 1
the,fertility 1.0 0.00043004587156 0 3 -3
on,warfarin-type 1.0 0.000143348623853 1 0 1
antagonists,appear 1.0 0.000143348623853 0 1 -1
and,bezalip 1.0 0.000143348623853 1 0 1
almost,complete 1.0 0.000143348623853 0 1 -1
the,rate-limiting 1.0 0.000143348623853 0 1 -1
cyp3a4,have 1.0 0.000143348623853 0 1 -1
receiving,should 0.5 0.000286697247706 1 3 -2
one-week,course 1.0 0.000143348623853 1 0 1
doses,will 1.0 0.000143348623853 0 1 -1
until,after 1.0 0.000143348623853 0 1 -1
plasmaconcentration,of 1.0 0.000143348623853 1 0 1
mg,qd 0.0 0.0 8 8 0
of,either 0.5 0.00229357798165 8 24 -16
psychostimulant,effects 1.0 0.000143348623853 0 1 -1
and,commit 1.0 0.000143348623853 0 1 -1
are,bodyweight 1.0 0.000143348623853 0 1 -1
potential,pharmacokinetic 1.0 0.000286697247706 0 2 -2
the,estimated 1.0 0.000143348623853 0 1 -1
inhibitors,such 0.555555555556 0.000716743119266 7 2 5
with,male 1.0 0.000143348623853 1 0 1
therapeutic,benefit 1.0 0.000143348623853 0 1 -1
of,worsened 1.0 0.000143348623853 0 1 -1
to,within 1.0 0.000143348623853 0 1 -1
activity,among 1.0 0.000716743119266 0 5 -5
prolong,further 1.0 0.000143348623853 1 0 1
blockers,could 1.0 0.000143348623853 1 0 1
medicines,such 1.0 0.000143348623853 1 0 1
for,hour 1.0 0.000143348623853 1 0 1
fold,greater 0.333333333333 0.000143348623853 1 2 -1
limited,to 0.0 0.0 2 2 0
achieve,or 1.0 0.000143348623853 0 1 -1
the,copegus 1.0 0.000143348623853 0 1 -1
with,angiotensln 1.0 0.000143348623853 1 0 1
general,clinical 1.0 0.000143348623853 1 0 1
activity,pra 1.0 0.000143348623853 0 1 -1
were,variable 1.0 0.000143348623853 0 1 -1
the,concomitant 0.357142857143 0.0043004587156 57 27 30
binding,of 0.25 0.000860091743119 9 15 -6
as,marplan 1.0 0.000286697247706 0 2 -2
low-dose,microg 1.0 0.000143348623853 1 0 1
that,doxil 1.0 0.000143348623853 0 1 -1
and,uroxatral 1.0 0.000143348623853 1 0 1
as,plasma 0.0 0.0 1 1 0
describes,two 1.0 0.000143348623853 1 0 1
that,of 0.142857142857 0.000143348623853 3 4 -1
differences,among 1.0 0.000143348623853 0 1 -1
antagonists,the 0.0 0.0 1 1 0
conditions,kinetics 1.0 0.000143348623853 0 1 -1
decreased,increased 1.0 0.000143348623853 1 0 1
to,assess 0.666666666667 0.000573394495413 1 5 -4
of,mna 1.0 0.000143348623853 0 1 -1
and,cerebyx 0.0 0.0 1 1 0
the,distribution 1.0 0.000143348623853 0 1 -1
hormonal,ortho-novum 1.0 0.000143348623853 1 0 1
produce,or 1.0 0.000143348623853 0 1 -1
mics,and 1.0 0.000143348623853 0 1 -1
in,lower 1.0 0.000860091743119 6 0 6
of,specific 1.0 0.000143348623853 0 1 -1
shorter,withdrawal 1.0 0.000143348623853 0 1 -1
general,if 1.0 0.000143348623853 0 1 -1
by,c 1.0 0.000286697247706 0 2 -2
by,a 0.142857142857 0.000716743119266 15 20 -5
highly,plasma 0.333333333333 0.000143348623853 1 2 -1
choose,particular 1.0 0.000143348623853 0 1 -1
by,m 1.0 0.000143348623853 1 0 1
general,in 1.0 0.000286697247706 0 2 -2
including,herbal 1.0 0.000143348623853 0 1 -1
elderly,basic 1.0 0.000143348623853 0 1 -1
in,fdf 0.5 0.000286697247706 3 1 2
proteins,and 0.333333333333 0.000143348623853 1 2 -1
furosemide-stimulated,diuresis 1.0 0.000143348623853 0 1 -1
available,assay 1.0 0.000143348623853 0 1 -1
prolong,its 1.0 0.000143348623853 0 1 -1
complete,and 1.0 0.000143348623853 1 0 1
atherosclerotic,risk 1.0 0.000143348623853 0 1 -1
phenytoin,should 1.0 0.000143348623853 0 1 -1
fluothane,may 1.0 0.000143348623853 1 0 1
pharmacology,clinical 1.0 0.000143348623853 1 0 1
not,show 1.0 0.000860091743119 0 6 -6
frequently,been 1.0 0.000143348623853 0 1 -1
manifested,by 1.0 0.000286697247706 0 2 -2
contractility,when 1.0 0.000143348623853 1 0 1
certain,drugs 1.0 0.000143348623853 0 1 -1
trough,concentration 1.0 0.000143348623853 1 0 1
inhibitors,result 1.0 0.000143348623853 1 0 1
for,optimal 1.0 0.000143348623853 0 1 -1
serum,valproic 1.0 0.000143348623853 0 1 -1
of,orthostatic 1.0 0.000143348623853 0 1 -1
subsequent,cycles 1.0 0.000143348623853 0 1 -1
gram-negative,organisms 1.0 0.000143348623853 0 1 -1
micro-dosed,preparations 1.0 0.000143348623853 1 0 1
much,lower 1.0 0.000143348623853 0 1 -1
alone,suggesting 1.0 0.000143348623853 1 0 1
isoform,also 1.0 0.000143348623853 1 0 1
but,available 1.0 0.000143348623853 0 1 -1
metastasis,to 1.0 0.000143348623853 0 1 -1
consequently,it 1.0 0.000286697247706 2 0 2
abnormalities,also 1.0 0.000143348623853 0 1 -1
a,inhibitors 1.0 0.000286697247706 2 0 2
hormonal,and 1.0 0.000143348623853 0 1 -1
resistance,reversal 1.0 0.000143348623853 0 1 -1
was,inserted 1.0 0.000143348623853 0 1 -1
other,psychoactive 1.0 0.000143348623853 1 0 1
metenkephalinamide,or 1.0 0.000143348623853 0 1 -1
attributed,at 1.0 0.000143348623853 1 0 1
the,leakage 1.0 0.000143348623853 0 1 -1
app,control 1.0 0.000143348623853 0 1 -1
taken,if 0.0 0.0 1 1 0
calculated,by 1.0 0.000143348623853 0 1 -1
the,introductory 1.0 0.000143348623853 0 1 -1
daily,increases 1.0 0.000143348623853 1 0 1
the,pathophysiologic 1.0 0.000143348623853 0 1 -1
reported,upon 1.0 0.000143348623853 1 0 1
brovana,treated 1.0 0.000286697247706 0 2 -2
daily,increased 1.0 0.000143348623853 1 0 1
out,to 1.0 0.000286697247706 0 2 -2
significantly,influence 1.0 0.000143348623853 0 1 -1
first,test 1.0 0.000143348623853 0 1 -1
kg,increased 1.0 0.000143348623853 1 0 1
tegretol,trileptal 1.0 0.000143348623853 1 0 1
cells,rr 1.0 0.000143348623853 0 1 -1
patients,have 0.75 0.000860091743119 1 7 -6
to,wshow 1.0 0.000286697247706 0 2 -2
the,upper 1.0 0.000286697247706 0 2 -2
at,hr 1.0 0.000143348623853 0 1 -1
a4,have 1.0 0.000143348623853 0 1 -1
limited,renal 1.0 0.000143348623853 0 1 -1
inflammatory,recall 1.0 0.000143348623853 0 1 -1
short-acting,such 1.0 0.000143348623853 0 1 -1
including,certain 1.0 0.000286697247706 2 0 2
liver,are 1.0 0.000143348623853 0 1 -1
safety,profile 1.0 0.00043004587156 0 3 -3
of,most 0.0 0.0 2 2 0
the,treatments 1.0 0.000143348623853 0 1 -1
affect,leukocyte 1.0 0.000143348623853 0 1 -1
was,investigated 1.0 0.000573394495413 0 4 -4
of,fully 1.0 0.000143348623853 0 1 -1
somatrem,somatropin 1.0 0.000143348623853 0 1 -1
some,physicians 1.0 0.000143348623853 0 1 -1
phase,study 1.0 0.000143348623853 0 1 -1
included,post 1.0 0.000143348623853 0 1 -1
hypotensive,including 1.0 0.000143348623853 1 0 1
local,including 1.0 0.000143348623853 1 0 1
non-opioid,analgesics 1.0 0.000143348623853 0 1 -1
the,nrtis 1.0 0.000143348623853 0 1 -1
indocin,are 1.0 0.000143348623853 0 1 -1
neurons,recorded 1.0 0.000286697247706 0 2 -2
other,pharmacokinetics 1.0 0.000143348623853 1 0 1
solution,fehlings 1.0 0.000286697247706 0 2 -2
remedies,is 1.0 0.000143348623853 0 1 -1
the,recommendation 1.0 0.000143348623853 0 1 -1
the,tail-flick 0.25 0.000286697247706 5 3 2
fifteen,species 1.0 0.000143348623853 0 1 -1
prescription,or 1.0 0.000143348623853 0 1 -1
single-dose,pharmacokinetic 1.0 0.000143348623853 0 1 -1
iv,cannot 1.0 0.000143348623853 0 1 -1
could,have 1.0 0.000573394495413 0 4 -4
prescription,of 1.0 0.000143348623853 1 0 1
in,gene 1.0 0.000143348623853 0 1 -1
trisenox,and 1.0 0.000143348623853 0 1 -1
glomerulonephritis,oculo-bulbar 1.0 0.000143348623853 1 0 1
involving,metabolized 1.0 0.000143348623853 1 0 1
not,possible 1.0 0.000286697247706 0 2 -2
continued,these 1.0 0.000143348623853 0 1 -1
and,tricyclic 1.0 0.000143348623853 1 0 1
on,oral 0.6 0.00043004587156 4 1 3
of,an 0.0344827586207 0.000143348623853 14 15 -1
overall,improvements 1.0 0.000143348623853 0 1 -1
type,may 1.0 0.000143348623853 0 1 -1
interactions,clozapine 1.0 0.000143348623853 0 1 -1
decreased,binding 1.0 0.000143348623853 1 0 1
of,possible 0.0 0.0 5 5 0
haloperidol,reduced 1.0 0.000143348623853 1 0 1
kg,mc 1.0 0.000143348623853 0 1 -1
kg,mg 1.0 0.00043004587156 0 3 -3
prostate-specific,antigen 1.0 0.000143348623853 0 1 -1
kg,ml 1.0 0.000143348623853 0 1 -1
and,transition 1.0 0.000143348623853 0 1 -1
co-administration,with 0.333333333333 0.000286697247706 2 4 -2
by,peptidase 1.0 0.000143348623853 0 1 -1
acid-catalyzed,ethanolysis 0.0 0.0 1 1 0
sedative,effects 1.0 0.000286697247706 2 0 2
three,mg 1.0 0.000143348623853 1 0 1
temporary,decrease 1.0 0.000143348623853 0 1 -1
psychotropic,or 1.0 0.000143348623853 0 1 -1
zofran,and 1.0 0.000143348623853 0 1 -1
whereas,it 1.0 0.000143348623853 1 0 1
depression,anxiety 1.0 0.000143348623853 0 1 -1
the,community 1.0 0.000143348623853 0 1 -1
postoperative,respiratory 1.0 0.000143348623853 0 1 -1
other,cyp3a4 0.2 0.000143348623853 3 2 1
dysrhythmias,of 1.0 0.000143348623853 1 0 1
these,observations 1.0 0.000716743119266 0 5 -5
striatum,and 1.0 0.000143348623853 1 0 1
homogenates,supplemented 1.0 0.000143348623853 0 1 -1
other,treatment 1.0 0.000143348623853 0 1 -1
secondary,prevention 1.0 0.000143348623853 0 1 -1
in,occasional 1.0 0.000143348623853 0 1 -1
administration,but 1.0 0.000143348623853 0 1 -1
of,had 0.75 0.000860091743119 1 7 -6
unwanted,effects 1.0 0.000143348623853 0 1 -1
such,are 1.0 0.0021502293578 0 15 -15
choice,of 1.0 0.000143348623853 0 1 -1
oral,markedly 1.0 0.000286697247706 2 0 2
digoxin,some 1.0 0.000143348623853 1 0 1
diffuse,muscle 1.0 0.000143348623853 0 1 -1
pharmacokinetic,changes 0.333333333333 0.000143348623853 1 2 -1
too,low 1.0 0.000286697247706 0 2 -2
essential,to 1.0 0.000286697247706 0 2 -2
multivalent,cation-containing 1.0 0.000143348623853 1 0 1
and,use 0.0 0.0 1 1 0
genes,iegs 1.0 0.000143348623853 0 1 -1
quantity,and 1.0 0.000143348623853 0 1 -1
or,follow 1.0 0.000143348623853 0 1 -1
sulfate,sodium 1.0 0.000143348623853 1 0 1
to,maximizing 1.0 0.000286697247706 0 2 -2
kinds,of 1.0 0.000143348623853 0 1 -1
control,hypertension 1.0 0.000143348623853 1 0 1
other,the 0.0 0.0 1 1 0
after,starting 1.0 0.000286697247706 0 2 -2
while,corresponding 1.0 0.000143348623853 0 1 -1
adversely,influence 1.0 0.000143348623853 1 0 1
and,fluvoxamine 1.0 0.000143348623853 1 0 1
adsorbents,and 1.0 0.000143348623853 1 0 1
iron,salts 1.0 0.000143348623853 1 0 1
hypothermia,as 1.0 0.000143348623853 0 1 -1
similarly,metabolized 1.0 0.000143348623853 0 1 -1
function,induced 1.0 0.000143348623853 0 1 -1
phenytoin,serum 1.0 0.000286697247706 2 0 2
intoxication,appropriate 1.0 0.000143348623853 0 1 -1
the,central 0.428571428571 0.000860091743119 10 4 6
had,not 1.0 0.000143348623853 0 1 -1
histidines,on 1.0 0.000143348623853 0 1 -1
in,tbg 1.0 0.000286697247706 0 2 -2
not,influence 1.0 0.00143348623853 0 10 -10
similarly,might 1.0 0.000143348623853 0 1 -1
thus,this 1.0 0.000143348623853 0 1 -1
healthy,males 1.0 0.000286697247706 0 2 -2
medications,to 1.0 0.000286697247706 0 2 -2
with,recordings 1.0 0.000143348623853 0 1 -1
for,four 1.0 0.000286697247706 0 2 -2
hippocampus,would 1.0 0.000143348623853 0 1 -1
alterations,is 1.0 0.000143348623853 0 1 -1
disadvantages,of 1.0 0.000143348623853 0 1 -1
weeks,plasma 1.0 0.000143348623853 1 0 1
parenteral,may 1.0 0.000143348623853 1 0 1
cyp3a5,responsible 1.0 0.000143348623853 0 1 -1
studies,oral 1.0 0.000143348623853 0 1 -1
counts,and 1.0 0.000143348623853 0 1 -1
immediately,preceding 1.0 0.000143348623853 0 1 -1
pancreatic,acinar 1.0 0.000143348623853 0 1 -1
and,b12 1.0 0.000143348623853 0 1 -1
reports,suggest 0.777777777778 0.00100344036697 8 1 7
of,months 1.0 0.000143348623853 0 1 -1
dosing,at 1.0 0.000143348623853 0 1 -1
substrate,administered 1.0 0.000143348623853 0 1 -1
significantly,improve 1.0 0.000143348623853 0 1 -1
fentanyl,cyp3a4 1.0 0.000143348623853 0 1 -1
caution,to 1.0 0.000860091743119 6 0 6
the,serotype 1.0 0.000143348623853 0 1 -1
were,resistant 1.0 0.000143348623853 0 1 -1
of,co-administration 1.0 0.000286697247706 0 2 -2
three,months 1.0 0.000143348623853 0 1 -1
three,different 1.0 0.000143348623853 0 1 -1
beyond,days 1.0 0.000143348623853 0 1 -1
for,total 1.0 0.000143348623853 0 1 -1
anesthesiologist,should 1.0 0.000286697247706 0 2 -2
no,depressant 1.0 0.000143348623853 0 1 -1
undergoing,systemic 1.0 0.000143348623853 0 1 -1
time,concomitant 1.0 0.000143348623853 0 1 -1
with,iron-fortified 1.0 0.000143348623853 0 1 -1
two,times 1.0 0.000143348623853 0 1 -1
most,evoked 1.0 0.000143348623853 0 1 -1
release,was 1.0 0.000143348623853 0 1 -1
by,through 1.0 0.000143348623853 0 1 -1
renal,prostaglandins 0.0 0.0 1 1 0
relationship,measurement 1.0 0.000143348623853 0 1 -1
be,determined 0.25 0.000286697247706 5 3 2
an,inhibition 0.333333333333 0.000143348623853 2 1 1
at,other 1.0 0.000286697247706 0 2 -2
be,susceptible 1.0 0.000143348623853 0 1 -1
the,myocardium 0.6 0.00043004587156 4 1 3
monoamine,oxidase 0.384615384615 0.0021502293578 27 12 15
immunodeficiency,virus-related 1.0 0.000143348623853 0 1 -1
pathogenic,species 1.0 0.000143348623853 0 1 -1
synthetic,hydroxy-3 1.0 0.000143348623853 0 1 -1
prevents,morphine-induced 1.0 0.000143348623853 1 0 1
observed,after 1.0 0.000286697247706 0 2 -2
indocin,mg 1.0 0.000143348623853 1 0 1
of,hyperpyrexia 1.0 0.000143348623853 0 1 -1
systemic,corticosteroids 1.0 0.000143348623853 0 1 -1
also,received 1.0 0.000143348623853 0 1 -1
of,type 1.0 0.000143348623853 0 1 -1
the,reddish 1.0 0.000143348623853 1 0 1
effects,addiction 1.0 0.000143348623853 0 1 -1
be,subject 1.0 0.000286697247706 0 2 -2
of,sleep 1.0 0.000286697247706 0 2 -2
four,diets 1.0 0.000143348623853 0 1 -1
nsaids,concomitant 1.0 0.00043004587156 3 0 3
synthetase,inhibitor 1.0 0.000143348623853 0 1 -1
bismuth,bismuth 1.0 0.000143348623853 1 0 1
kg,weekly 1.0 0.000143348623853 0 1 -1
the,non-ionized 1.0 0.000143348623853 1 0 1
and,catabolic 1.0 0.00043004587156 3 0 3
hydroxylamine,a 1.0 0.000143348623853 0 1 -1
doctor,before 1.0 0.000286697247706 0 2 -2
necessary,if 1.0 0.00043004587156 0 3 -3
while,levels 1.0 0.000143348623853 1 0 1
taking,either 1.0 0.000143348623853 1 0 1
nevertheless,associated 1.0 0.000143348623853 0 1 -1
necessary,in 1.0 0.000143348623853 0 1 -1
results,have 1.0 0.000286697247706 0 2 -2
an,acceptable 1.0 0.000143348623853 0 1 -1
previous,studies 1.0 0.000143348623853 1 0 1
excessive,neuromuscular 1.0 0.000143348623853 1 0 1
lithium,increased 1.0 0.00043004587156 3 0 3
reflecting,the 1.0 0.000716743119266 0 5 -5
out,in 1.0 0.000286697247706 0 2 -2
with,tambocor 1.0 0.000143348623853 1 0 1
an,adequate 1.0 0.000573394495413 0 4 -4
fluoxetine,does 1.0 0.000143348623853 0 1 -1
the,anemia 1.0 0.000143348623853 0 1 -1
from,normal 1.0 0.000286697247706 0 2 -2
and,sgpt 0.0 0.0 1 1 0
who,consume 0.0 0.0 1 1 0
digoxin,a 1.0 0.000143348623853 0 1 -1
model,possibly 1.0 0.000143348623853 1 0 1
ht1b,d 0.0 0.0 1 1 0
hyperreflexia,ataxia 1.0 0.000143348623853 0 1 -1
a,relatively 1.0 0.000286697247706 0 2 -2
dihydroergotamine,contraindicated 1.0 0.000143348623853 0 1 -1
is,an 0.666666666667 0.00172018348624 3 15 -12
outside,the 1.0 0.000143348623853 0 1 -1
ratio,or 0.5 0.000286697247706 1 3 -2
normal,range 1.0 0.000143348623853 0 1 -1
micrograms,g 1.0 0.000143348623853 0 1 -1
either,added 1.0 0.000286697247706 2 0 2
glucose,some 1.0 0.000143348623853 0 1 -1
mg,once 0.25 0.000573394495413 6 10 -4
or,hexokinase 1.0 0.000286697247706 0 2 -2
brovana,dose 1.0 0.000143348623853 0 1 -1
frequently,with 1.0 0.000286697247706 0 2 -2
and,associated 1.0 0.000143348623853 1 0 1
tenderness,skin 1.0 0.000143348623853 0 1 -1
v,as 1.0 0.000143348623853 0 1 -1
fever,renal 1.0 0.000143348623853 1 0 1
center,italy 1.0 0.000143348623853 0 1 -1
in,decreased 0.333333333333 0.00043004587156 6 3 3
the,polymorphic 1.0 0.000143348623853 0 1 -1
pcp-induced,behavioral 1.0 0.000143348623853 0 1 -1
placebo-controlled,study 1.0 0.000143348623853 0 1 -1
in,decreases 0.0 0.0 1 1 0
ec50,values 1.0 0.000143348623853 0 1 -1
demonstrate,any 1.0 0.000286697247706 0 2 -2
admistration,of 1.0 0.000143348623853 0 1 -1
limited,evidence 1.0 0.000143348623853 0 1 -1
pcp,or 1.0 0.000143348623853 1 0 1
occurred,within 1.0 0.000286697247706 0 2 -2
pointer,dogs 1.0 0.000143348623853 0 1 -1
levels,aldosterone 1.0 0.000143348623853 0 1 -1
permeation,of 1.0 0.000286697247706 0 2 -2
on,glucose 1.0 0.000143348623853 0 1 -1
supplements,uncontrolled 1.0 0.00043004587156 0 3 -3
nefazodone,cyclosporine 1.0 0.000143348623853 0 1 -1
of,adrenergic 1.0 0.000143348623853 1 0 1
furosemide,toradol 1.0 0.000143348623853 1 0 1
an,inflammatory 1.0 0.000143348623853 0 1 -1
unique,biopharmaceutical 1.0 0.000143348623853 0 1 -1
liver,but 1.0 0.000143348623853 0 1 -1
particularly,during 0.0 0.0 2 2 0
hypoglycemia,secondary 1.0 0.000143348623853 1 0 1
and,similar 1.0 0.000143348623853 0 1 -1
that,decreases 1.0 0.000143348623853 0 1 -1
amino,acid 1.0 0.000143348623853 0 1 -1
may,blunt 1.0 0.000143348623853 0 1 -1
in,symptomatic 1.0 0.000143348623853 0 1 -1
potent,than 1.0 0.000286697247706 0 2 -2
potential,bleeding 1.0 0.000143348623853 0 1 -1
steady-state,cmax 1.0 0.00043004587156 3 0 3
however,these 1.0 0.000143348623853 0 1 -1
the,antiedematous 1.0 0.000143348623853 1 0 1
and,effectiveness 1.0 0.000573394495413 0 4 -4
interval,as 1.0 0.000143348623853 0 1 -1
cyp1a2,inhibitors 0.0 0.0 1 1 0
substantially,interfere 1.0 0.000573394495413 4 0 4
dicumarol,it 1.0 0.000143348623853 1 0 1
fulfils,the 1.0 0.000143348623853 0 1 -1
elimination,or 1.0 0.000143348623853 0 1 -1
from,addicts 1.0 0.000286697247706 0 2 -2
than,atiii 1.0 0.000143348623853 0 1 -1
an,oral 0.333333333333 0.000573394495413 8 4 4
a,smaller 0.0 0.0 1 1 0
were,there 1.0 0.000143348623853 0 1 -1
urine,volume 1.0 0.000286697247706 2 0 2
c,human 1.0 0.000143348623853 0 1 -1
they,cause 1.0 0.000143348623853 0 1 -1
including,eye 1.0 0.000143348623853 0 1 -1
azopt,ophthalmic 1.0 0.000143348623853 0 1 -1
to,cause 0.285714285714 0.00114678899083 10 18 -8
measurements,porter-silber 1.0 0.000143348623853 0 1 -1
your,doctor 0.8 0.00114678899083 1 9 -8
with,pivoxil 1.0 0.000143348623853 1 0 1
to,efficacy 1.0 0.000716743119266 0 5 -5
these,products 0.714285714286 0.000716743119266 1 6 -5
blood,flow 1.0 0.000716743119266 0 5 -5
acting,primarily 1.0 0.000143348623853 1 0 1
molecular,basis 0.0 0.0 1 1 0
the,behaviour 1.0 0.000286697247706 0 2 -2
inomax,has 1.0 0.000143348623853 0 1 -1
individual,patients 1.0 0.000143348623853 1 0 1
ether,and 1.0 0.000143348623853 1 0 1
two,appear 1.0 0.000143348623853 1 0 1
when,compared 0.0 0.0 4 4 0
prolonged,long 1.0 0.000143348623853 1 0 1
as,or 0.25 0.000860091743119 15 9 6
significantly,bound 1.0 0.000143348623853 0 1 -1
myelosuppression,was 1.0 0.000143348623853 1 0 1
downward,adjustment 1.0 0.000286697247706 2 0 2
production,including 1.0 0.000143348623853 0 1 -1
r,or 0.333333333333 0.000143348623853 1 2 -1
achieved,steady-state 1.0 0.000143348623853 0 1 -1
evaluating,the 0.5 0.000573394495413 2 6 -4
caution,since 1.0 0.000143348623853 0 1 -1
interactions,under 1.0 0.000143348623853 0 1 -1
hydrocarbon,general 1.0 0.000143348623853 1 0 1
severe,high 1.0 0.000143348623853 1 0 1
c19,are 1.0 0.000143348623853 0 1 -1
to,adult 1.0 0.000143348623853 0 1 -1
sites,other 1.0 0.000286697247706 0 2 -2
in,comparison 0.2 0.000143348623853 2 3 -1
juice,given 1.0 0.000143348623853 0 1 -1
abciximab,may 1.0 0.000143348623853 1 0 1
kidney,damage 1.0 0.000143348623853 0 1 -1
occasionally,induce 1.0 0.00043004587156 0 3 -3
in,patients 0.0131578947368 0.000573394495413 150 154 -4
anti-factor,xa 1.0 0.000286697247706 0 2 -2
may,elevate 1.0 0.000143348623853 1 0 1
of,in 0.353846153846 0.00329701834862 21 44 -23
juices,etc 1.0 0.000143348623853 1 0 1
the,short-acting 1.0 0.000143348623853 0 1 -1
anecdotal,reports 1.0 0.000143348623853 1 0 1
from,one 0.333333333333 0.000286697247706 4 2 2
selected,for 1.0 0.000143348623853 0 1 -1
glucose,alone 1.0 0.000143348623853 0 1 -1
large,placebo-controlled 1.0 0.000143348623853 0 1 -1
decreased,have 1.0 0.000143348623853 1 0 1
oxidation,is 1.0 0.000143348623853 0 1 -1
o-desacetyl,metabolites 1.0 0.000143348623853 0 1 -1
period,has 1.0 0.000143348623853 1 0 1
the,safety 0.75 0.00172018348624 2 14 -12
immunosuppressive,drugs 1.0 0.000143348623853 0 1 -1
been,concern 1.0 0.000143348623853 1 0 1
subsalicylate,given 1.0 0.000143348623853 1 0 1
these,data 0.777777777778 0.00100344036697 1 8 -7
fe,instead 1.0 0.000143348623853 1 0 1
reduced,approximately 0.0 0.0 1 1 0
trans-placental,passage 1.0 0.000143348623853 0 1 -1
ci,increase 1.0 0.000143348623853 0 1 -1
also,occurs 1.0 0.000573394495413 0 4 -4
study,examining 1.0 0.000143348623853 1 0 1
doses,than 1.0 0.00100344036697 0 7 -7
are,administered 0.2 0.000860091743119 12 18 -6
to,desbutyl 1.0 0.000143348623853 0 1 -1
of,higher 1.0 0.000143348623853 0 1 -1
a,hydroalcoholic 1.0 0.000143348623853 0 1 -1
the,onset 0.2 0.000143348623853 2 3 -1
occur,the 1.0 0.000143348623853 0 1 -1
manner,the 1.0 0.000143348623853 1 0 1
generally,do 1.0 0.000143348623853 0 1 -1
nursing,infants 1.0 0.00043004587156 0 3 -3
in,neonates 1.0 0.00043004587156 0 3 -3
pooled,human 1.0 0.000143348623853 0 1 -1
included,as 1.0 0.000143348623853 0 1 -1
dosing,with 0.2 0.000143348623853 2 3 -1
often,appear 1.0 0.000143348623853 0 1 -1
by,acute 1.0 0.000143348623853 0 1 -1
in,noradrenaline-precontracted 1.0 0.000143348623853 0 1 -1
effective,dose 0.0 0.0 1 1 0
metabolites,interfere 1.0 0.000143348623853 0 1 -1
identified,case 1.0 0.000143348623853 0 1 -1
antagonists,cyp1a2 1.0 0.000143348623853 0 1 -1
with,likewise 1.0 0.000143348623853 0 1 -1
period,was 1.0 0.000286697247706 0 2 -2
increased,decreased 0.333333333333 0.000143348623853 1 2 -1
for,this 0.6 0.00129013761468 3 12 -9
decided,to 1.0 0.000143348623853 1 0 1
dst,in 1.0 0.000286697247706 0 2 -2
delayed,elimination 1.0 0.000143348623853 0 1 -1
tonic,convulsion 1.0 0.000143348623853 0 1 -1
monitored,see 1.0 0.000143348623853 0 1 -1
modification,of 0.333333333333 0.000143348623853 1 2 -1
microtubules,on 1.0 0.000143348623853 0 1 -1
required,during 1.0 0.000286697247706 2 0 2
cimetidine,mg 1.0 0.000143348623853 0 1 -1
naflu,to 1.0 0.000143348623853 0 1 -1
sustiva,and 1.0 0.00043004587156 0 3 -3
also,decreased 1.0 0.000143348623853 0 1 -1
ns,absorbed 1.0 0.000143348623853 0 1 -1
mg,with 0.5 0.000573394495413 6 2 4
methotrexate,valdecoxib 1.0 0.000143348623853 0 1 -1
medications,for 1.0 0.000286697247706 0 2 -2
cyclosporin,reports 1.0 0.000143348623853 1 0 1
to,release 1.0 0.000143348623853 1 0 1
therapy,have 0.0 0.0 1 1 0
inhibitor,however 1.0 0.000143348623853 0 1 -1
luciferase,reporter 1.0 0.000143348623853 0 1 -1
dcg-iv,were 1.0 0.000143348623853 1 0 1
liver,which 1.0 0.000143348623853 1 0 1
nevertheless,the 1.0 0.00043004587156 3 0 3
daily,mcg 1.0 0.000143348623853 0 1 -1
least,the 1.0 0.000143348623853 0 1 -1
depletion,of 1.0 0.000143348623853 1 0 1
of,fat-soluble 0.0 0.0 1 1 0
effort,optimal 1.0 0.000143348623853 0 1 -1
of,decreased 0.666666666667 0.00172018348624 15 3 12
and,fibrosis 1.0 0.000143348623853 0 1 -1
properties,and 1.0 0.00043004587156 3 0 3
foscarnets,tendency 1.0 0.000143348623853 1 0 1
dose,may 0.0 0.0 4 4 0
render,oral 1.0 0.000286697247706 2 0 2
of,decreases 1.0 0.000143348623853 1 0 1
metabolizers,and 1.0 0.000143348623853 0 1 -1
hepatitis,and 1.0 0.000143348623853 0 1 -1
were,prohibited 1.0 0.000286697247706 0 2 -2
nac,and 1.0 0.000143348623853 0 1 -1
considerable,variability 1.0 0.000143348623853 0 1 -1
gastrointestinal,effects 1.0 0.000286697247706 2 0 2
prepared,by 1.0 0.000143348623853 0 1 -1
both,ethynyl 1.0 0.000143348623853 0 1 -1
other,no 1.0 0.000143348623853 0 1 -1
paroxetine,coadministration 0.333333333333 0.000143348623853 1 2 -1
metabolically,active 1.0 0.000143348623853 0 1 -1
on,interactions 1.0 0.000143348623853 0 1 -1
contraceptives,rofecoxib 1.0 0.000143348623853 0 1 -1
watched,very 1.0 0.000143348623853 1 0 1
group,sh 1.0 0.000143348623853 0 1 -1
complexes,thereof 1.0 0.000143348623853 0 1 -1
form,chelation 1.0 0.000143348623853 1 0 1
hydrochlorothiazide,hctz 1.0 0.000143348623853 0 1 -1
any,routine 1.0 0.000143348623853 0 1 -1
subsequently,found 1.0 0.000143348623853 0 1 -1
have,reported 1.0 0.000143348623853 0 1 -1
suggesting,a 0.333333333333 0.000143348623853 1 2 -1
expressed,in 1.0 0.000143348623853 0 1 -1
in,cocaine-treated 1.0 0.000143348623853 0 1 -1
ischemic,response 1.0 0.000143348623853 1 0 1
possible,be 1.0 0.000143348623853 1 0 1
copaxone,and 1.0 0.000286697247706 0 2 -2
with,non-pegylated 1.0 0.000143348623853 0 1 -1
receiving,with 1.0 0.000143348623853 1 0 1
camp-mediated,acid 1.0 0.000143348623853 0 1 -1
reverse,the 1.0 0.000286697247706 2 0 2
was,controlled 1.0 0.000143348623853 1 0 1
discussing,the 1.0 0.000143348623853 0 1 -1
platelet,agents 1.0 0.000143348623853 0 1 -1
vanillylmandelic,acid 1.0 0.000143348623853 0 1 -1
was,replaced 1.0 0.000143348623853 0 1 -1
parvum,in 1.0 0.000143348623853 0 1 -1
reactive,to 1.0 0.000573394495413 0 4 -4
in,hydatid 1.0 0.000143348623853 1 0 1
hypotension,requiring 1.0 0.000143348623853 0 1 -1
baraclude,with 1.0 0.000286697247706 0 2 -2
response,through 1.0 0.000143348623853 1 0 1
cough,and 0.0 0.0 1 1 0
although,minimal 1.0 0.000143348623853 0 1 -1
study,investigated 1.0 0.000143348623853 0 1 -1
chiefly,with 1.0 0.000143348623853 0 1 -1
groups,ie 1.0 0.000143348623853 0 1 -1
single,method 1.0 0.000143348623853 0 1 -1
prostaglandina,play 1.0 0.000143348623853 1 0 1
methotrexate,cyclosporine 1.0 0.000143348623853 0 1 -1
other,when 1.0 0.000286697247706 2 0 2
serum,enzymes 1.0 0.000143348623853 1 0 1
scintigraphy,employing 1.0 0.000143348623853 0 1 -1
study,at 1.0 0.000286697247706 0 2 -2
enzymes,responsible 1.0 0.000286697247706 0 2 -2
cyclosporine,elevated 1.0 0.000286697247706 2 0 2
avoided,because 0.333333333333 0.000143348623853 2 1 1
after,incubation 1.0 0.000143348623853 0 1 -1
in,parkinsons 1.0 0.000143348623853 1 0 1
mg,did 1.0 0.00143348623853 0 10 -10
agents,ammonium 1.0 0.000286697247706 2 0 2
is,initiated 0.6 0.000860091743119 8 2 6
with,ace 1.0 0.000286697247706 2 0 2
like,other 0.75 0.000860091743119 7 1 6
toxic,epidermal 1.0 0.000143348623853 0 1 -1
of,relevant 1.0 0.000286697247706 0 2 -2
manic-depressive,disorder 1.0 0.000143348623853 0 1 -1
been,more 1.0 0.000143348623853 0 1 -1
invirase,or 1.0 0.000286697247706 0 2 -2
interactions,phenytoin 1.0 0.000143348623853 0 1 -1
serum,nih-3t3 1.0 0.000143348623853 0 1 -1
cause,serious 1.0 0.000143348623853 1 0 1
are,applying 1.0 0.000143348623853 1 0 1
or,hepatotoxic 1.0 0.000143348623853 1 0 1
little,risk 1.0 0.000143348623853 0 1 -1
no,in 0.0 0.0 1 1 0
the,ratios 1.0 0.000143348623853 0 1 -1
displace,such 1.0 0.000143348623853 1 0 1
kg,with 1.0 0.000143348623853 1 0 1
measured,by 0.833333333333 0.00143348623853 1 11 -10
shown,between 1.0 0.000143348623853 1 0 1
the,alternate 1.0 0.000143348623853 1 0 1
if,pregnancy 1.0 0.000286697247706 0 2 -2
than,times 1.0 0.000143348623853 1 0 1
reliable,method 1.0 0.000143348623853 1 0 1
chemotherapy,in 1.0 0.000143348623853 0 1 -1
co-medications,that 0.0 0.0 1 1 0
work,has 1.0 0.000143348623853 0 1 -1
be,low 1.0 0.000143348623853 0 1 -1
and,reducing 1.0 0.000143348623853 1 0 1
liver,or 1.0 0.000143348623853 0 1 -1
at,ph 1.0 0.000143348623853 0 1 -1
potentiates,the 0.6 0.00043004587156 4 1 3
explained,either 1.0 0.000143348623853 0 1 -1
the,repeat 1.0 0.000143348623853 0 1 -1
a,test 1.0 0.000143348623853 0 1 -1
chop-haart,patients 1.0 0.00043004587156 0 3 -3
increased,following 1.0 0.000143348623853 1 0 1
intimately,related 1.0 0.000143348623853 0 1 -1
depends,on 1.0 0.000286697247706 0 2 -2
taken,as 0.0 0.0 1 1 0
taken,at 0.75 0.000860091743119 7 1 6
kappa,and 1.0 0.000143348623853 0 1 -1
inflammatory,reactions 1.0 0.000143348623853 1 0 1
individuals,because 1.0 0.000143348623853 0 1 -1
not,always 1.0 0.000143348623853 0 1 -1
either,accidental 1.0 0.000716743119266 0 5 -5
calculated,clearance 1.0 0.000143348623853 0 1 -1
concentrations,are 0.0 0.0 1 1 0
improving,the 1.0 0.000143348623853 0 1 -1
also,increased 0.333333333333 0.000143348623853 1 2 -1
perfused,pancreas 1.0 0.000143348623853 0 1 -1
anticonvulsants,increase 1.0 0.000143348623853 1 0 1
frequent,vital 1.0 0.000143348623853 0 1 -1
bilirubin,elevations 1.0 0.000143348623853 0 1 -1
potassium-depleting,and 1.0 0.000143348623853 0 1 -1
joint,dose-response 1.0 0.000143348623853 0 1 -1
toxicity,when 0.333333333333 0.000143348623853 2 1 1
the,cyp450 1.0 0.000143348623853 0 1 -1
by,minimally 1.0 0.000143348623853 0 1 -1
the,differences 1.0 0.000286697247706 0 2 -2
a,far 1.0 0.000143348623853 0 1 -1
formulation,of 0.2 0.000143348623853 2 3 -1
is,important 1.0 0.000860091743119 0 6 -6
m1,peak 1.0 0.000143348623853 1 0 1
injection,site 1.0 0.000286697247706 0 2 -2
limited,number 1.0 0.000286697247706 0 2 -2
values,by 1.0 0.000143348623853 0 1 -1
most,like 1.0 0.000143348623853 1 0 1
sites,for 1.0 0.000286697247706 0 2 -2
ketoconazole,did 1.0 0.000143348623853 0 1 -1
ibandronate,mg 1.0 0.000143348623853 0 1 -1
predicted,interactions 1.0 0.000143348623853 0 1 -1
the,r-value 1.0 0.000286697247706 0 2 -2
antiaddictive,efficacy 1.0 0.000143348623853 0 1 -1
glucose,intolerance 1.0 0.00043004587156 0 3 -3
soaps,and 1.0 0.000143348623853 0 1 -1
that,interferes 1.0 0.000143348623853 1 0 1
thioether,concentration 1.0 0.000143348623853 0 1 -1
effect,did 1.0 0.000143348623853 0 1 -1
effect,occurs 1.0 0.000143348623853 0 1 -1
a,daily 0.0 0.0 1 1 0
with,maximum 1.0 0.000143348623853 0 1 -1
be,taken 0.0869565217391 0.000573394495413 21 25 -4
enter,the 1.0 0.000143348623853 0 1 -1
without,bleeding 1.0 0.000143348623853 1 0 1
of,trimethyl 1.0 0.000143348623853 0 1 -1
unless,in 1.0 0.000143348623853 1 0 1
sucralfate,administered 1.0 0.000143348623853 1 0 1
to,high 0.333333333333 0.000143348623853 1 2 -1
with,hexalen 1.0 0.000143348623853 1 0 1
lethargy,drowsiness 1.0 0.000143348623853 0 1 -1
the,wild-type 1.0 0.000143348623853 0 1 -1
hydrochloride,and 1.0 0.00043004587156 0 3 -3
diuretic,therapy 1.0 0.00043004587156 3 0 3
the,harmonic 1.0 0.000143348623853 0 1 -1
animal,species 1.0 0.000143348623853 0 1 -1
the,alters 1.0 0.000143348623853 0 1 -1
the,co-administration 0.4 0.000573394495413 7 3 4
microdosed,minipill 1.0 0.000143348623853 1 0 1
required,the 1.0 0.000143348623853 0 1 -1
of,micrograms 0.0 0.0 1 1 0
enzyme,inhibitors 0.142857142857 0.000143348623853 4 3 1
anticipated,alternative 1.0 0.000143348623853 0 1 -1
monitor,for 1.0 0.000143348623853 0 1 -1
is,dependent 1.0 0.00043004587156 0 3 -3
exhibited,strong 1.0 0.000143348623853 1 0 1
patients,careful 1.0 0.000143348623853 0 1 -1
depression,may 0.333333333333 0.000143348623853 2 1 1
blockers,although 1.0 0.000286697247706 2 0 2
frequently,complex 1.0 0.000143348623853 0 1 -1
reproductive,toxicology 1.0 0.000143348623853 0 1 -1
dopamine2-,and 1.0 0.000143348623853 0 1 -1
oils,may 1.0 0.000143348623853 0 1 -1
or,grapefruit 1.0 0.000143348623853 0 1 -1
were,studied 0.6 0.00043004587156 1 4 -3
for,liver 1.0 0.000143348623853 0 1 -1
observed,closely 0.214285714286 0.000860091743119 11 17 -6
to,intravenous 1.0 0.000143348623853 1 0 1
when,celebrex 1.0 0.000143348623853 1 0 1
other,certain 1.0 0.000143348623853 1 0 1
in,rat 0.6 0.00043004587156 1 4 -3
saquinavir,the 1.0 0.000143348623853 0 1 -1
oral,h2-antagonists 1.0 0.000143348623853 0 1 -1
tracrium,should 1.0 0.000143348623853 1 0 1
is,insufficient 1.0 0.000143348623853 1 0 1
increased,side 1.0 0.000143348623853 0 1 -1
the,parent 0.6 0.00043004587156 1 4 -3
propranolol,in 1.0 0.000286697247706 0 2 -2
closely,monitor 1.0 0.00043004587156 0 3 -3
reductase,resulting 1.0 0.000143348623853 0 1 -1
inhibiting,yeast 1.0 0.000143348623853 0 1 -1
nimodipine,and 1.0 0.000143348623853 0 1 -1
reaction,time 1.0 0.000143348623853 1 0 1
be,necessary 0.25 0.000573394495413 6 10 -4
low-dose,has 1.0 0.000143348623853 1 0 1
level,p 1.0 0.000143348623853 0 1 -1
methotrexate,piperacillin 1.0 0.000143348623853 1 0 1
the,commonly 1.0 0.000143348623853 0 1 -1
or,preparations 1.0 0.000143348623853 0 1 -1
altered,pharmacoktnetics 1.0 0.000143348623853 0 1 -1
compounds,in 0.333333333333 0.000143348623853 1 2 -1
as,nsaids 1.0 0.000143348623853 0 1 -1
and,between 1.0 0.000143348623853 0 1 -1
in,animals 0.6 0.00043004587156 4 1 3
of,nonbenzodiazepine 1.0 0.000143348623853 1 0 1
windows,that 1.0 0.000286697247706 0 2 -2
hcl,was 1.0 0.000143348623853 0 1 -1
achieve,the 0.333333333333 0.000143348623853 2 1 1
cns,agents 1.0 0.000143348623853 1 0 1
of,megakaryocytes 1.0 0.000143348623853 1 0 1
up,and 1.0 0.000143348623853 0 1 -1
ccnu,either 1.0 0.000143348623853 0 1 -1
physiological,oral 1.0 0.00043004587156 0 3 -3
hunger,can 1.0 0.000143348623853 0 1 -1
medications,muscle 1.0 0.000143348623853 0 1 -1
if,casodex 1.0 0.000143348623853 1 0 1
reliable,when 1.0 0.000143348623853 1 0 1
by,indicating 1.0 0.000143348623853 0 1 -1
measurable,effect 1.0 0.000143348623853 0 1 -1
events,compared 1.0 0.000143348623853 1 0 1
trials,hypoglycemia 1.0 0.000143348623853 0 1 -1
to,took 1.0 0.000143348623853 1 0 1
where,is 1.0 0.000143348623853 0 1 -1
on,endotoxin-induced 1.0 0.000143348623853 0 1 -1
bioequivalent,to 1.0 0.000143348623853 0 1 -1
no,longer 1.0 0.000143348623853 0 1 -1
when,enablex 1.0 0.000143348623853 1 0 1
published,in 1.0 0.000143348623853 0 1 -1
at,the 0.666666666667 0.00344036697248 6 30 -24
and,pharmacokinetic 1.0 0.000143348623853 1 0 1
was,markedly 1.0 0.000143348623853 0 1 -1
materially,different 1.0 0.000143348623853 0 1 -1
indicated,alternative 1.0 0.000286697247706 0 2 -2
pharmacology,of 0.5 0.000286697247706 1 3 -2
of,apparent 1.0 0.000143348623853 1 0 1
use,however 1.0 0.000143348623853 0 1 -1
who,was 1.0 0.000143348623853 0 1 -1
and,c9 1.0 0.000573394495413 0 4 -4
basal,colonic 1.0 0.000143348623853 0 1 -1
die,from 1.0 0.000143348623853 0 1 -1
particularly,for 1.0 0.000286697247706 0 2 -2
well-known,potential 1.0 0.000143348623853 0 1 -1
is,genotoxic 1.0 0.000143348623853 0 1 -1
extrapolating,these 1.0 0.000143348623853 0 1 -1
sampling,the 1.0 0.000143348623853 0 1 -1
the,heat 1.0 0.000143348623853 0 1 -1
pharmacological,tool 1.0 0.000143348623853 0 1 -1
single-dose,nature 1.0 0.000143348623853 0 1 -1
liver,biopsy 1.0 0.000143348623853 0 1 -1
markedly,sensitive 1.0 0.000143348623853 0 1 -1
years,weight 1.0 0.000143348623853 0 1 -1
stimulation,is 0.0 0.0 2 2 0
inhibit,or 0.714285714286 0.000716743119266 1 6 -5
and,ci 1.0 0.000286697247706 0 2 -2
its,synthetic 1.0 0.000143348623853 0 1 -1
toxicity,may 0.714285714286 0.000716743119266 6 1 5
antacids,enteric 1.0 0.000143348623853 1 0 1
the,age 1.0 0.000143348623853 0 1 -1
myobloc,and 1.0 0.000143348623853 1 0 1
aprepitant,to 1.0 0.000286697247706 2 0 2
components,may 1.0 0.000143348623853 0 1 -1
and,enterococcus 1.0 0.000143348623853 0 1 -1
the,commercially 1.0 0.000143348623853 0 1 -1
provided,for 1.0 0.000143348623853 0 1 -1
ml,min 0.333333333333 0.000143348623853 1 2 -1
high,percentage 1.0 0.000143348623853 0 1 -1
carefully,titrated 1.0 0.000143348623853 1 0 1
of,nucleophosmin 1.0 0.000573394495413 0 4 -4
effective,use 1.0 0.000286697247706 0 2 -2
and,consideration 1.0 0.000143348623853 0 1 -1
although,increased 1.0 0.000286697247706 0 2 -2
non-pegylated,alfa-2a 1.0 0.000286697247706 0 2 -2
including,fever 1.0 0.000143348623853 1 0 1
partner,of 1.0 0.000143348623853 0 1 -1
or,some 1.0 0.000143348623853 1 0 1
more,effective 1.0 0.000143348623853 0 1 -1
amount,of 0.111111111111 0.000143348623853 5 4 1
probably,secondary 1.0 0.000143348623853 1 0 1
have,significant 0.0 0.0 1 1 0
disturbances,patients 1.0 0.000143348623853 0 1 -1
permits,at 1.0 0.000143348623853 1 0 1
bactericidal,action 1.0 0.000286697247706 2 0 2
p-glycoprotein,loop 1.0 0.000143348623853 0 1 -1
during,coadministration 1.0 0.00043004587156 3 0 3
is,lengthened 1.0 0.000143348623853 1 0 1
any,efficacy 1.0 0.000143348623853 0 1 -1
of,cyp3a 0.0 0.0 2 2 0
increased,systematically 1.0 0.000143348623853 0 1 -1
release,mg 1.0 0.000143348623853 0 1 -1
oi,rates 1.0 0.000143348623853 0 1 -1
reduction,of 0.241379310345 0.00100344036697 18 11 7
of,inapsine 0.0 0.0 1 1 0
fi,fr 1.0 0.000143348623853 0 1 -1
liver,to 1.0 0.000143348623853 0 1 -1
were,very 1.0 0.000143348623853 1 0 1
focuses,on 1.0 0.000143348623853 0 1 -1
interaction,should 0.555555555556 0.000716743119266 7 2 5
it,as 1.0 0.000143348623853 0 1 -1
fall,of 1.0 0.000143348623853 1 0 1
reduction,or 1.0 0.000143348623853 0 1 -1
no,adequate 1.0 0.000286697247706 0 2 -2
and,control 1.0 0.000286697247706 0 2 -2
metabolized,and 1.0 0.000286697247706 0 2 -2
hoof,twitch 0.2 0.000143348623853 2 3 -1
predispose,a 1.0 0.000143348623853 0 1 -1
levels,carbamazepine 1.0 0.000143348623853 1 0 1
foods,highly 1.0 0.000143348623853 0 1 -1
interactions,occurred 1.0 0.000286697247706 0 2 -2
when,gleevec 1.0 0.000143348623853 1 0 1
a,confirmation 1.0 0.000143348623853 0 1 -1
unreliable,prothrombin 0.0 0.0 2 2 0
nacmc,conjugated 1.0 0.000143348623853 0 1 -1
taxol,and 1.0 0.000143348623853 0 1 -1
flolan,to 1.0 0.000143348623853 1 0 1
prinivil,given 1.0 0.000143348623853 0 1 -1
median,tmax 1.0 0.000143348623853 0 1 -1
ortho-novum,produced 1.0 0.000143348623853 1 0 1
increased,gastric 1.0 0.000143348623853 0 1 -1
evaluate,the 0.75 0.000860091743119 1 7 -6
av,block 1.0 0.000143348623853 1 0 1
on,established 1.0 0.000143348623853 1 0 1
information,that 1.0 0.000143348623853 0 1 -1
abnormal,bleeding 1.0 0.000143348623853 0 1 -1
repeated,courses 1.0 0.000143348623853 0 1 -1
low,erpf 1.0 0.000143348623853 1 0 1
we,previously 1.0 0.000143348623853 0 1 -1
subjects,by 0.0 0.0 1 1 0
prolactin,secretion 1.0 0.000143348623853 0 1 -1
kg,such 1.0 0.000143348623853 0 1 -1
hypothalamic-pituitary,testicular 1.0 0.000143348623853 0 1 -1
only,re-results 1.0 0.000143348623853 0 1 -1
that,revlimid 1.0 0.000143348623853 0 1 -1
are,sometimes 1.0 0.000143348623853 0 1 -1
medications,most 1.0 0.000143348623853 0 1 -1
free,radical-mediated 1.0 0.000143348623853 1 0 1
animals,in 1.0 0.000286697247706 0 2 -2
baseline,vs 1.0 0.000143348623853 0 1 -1
interval,because 1.0 0.000143348623853 1 0 1
equal,concentrations 1.0 0.000143348623853 0 1 -1
tests,for 1.0 0.00043004587156 0 3 -3
toxic,effects 0.0 0.0 2 2 0
alternatives,in 1.0 0.000143348623853 0 1 -1
agonists,only 1.0 0.000143348623853 1 0 1
european,and 1.0 0.000143348623853 0 1 -1
cmax,but 1.0 0.000143348623853 0 1 -1
nondepolarizing,neuromuscular 0.333333333333 0.000143348623853 2 1 1
expected,that 0.0 0.0 2 2 0
groups,without 1.0 0.000143348623853 0 1 -1
measurements,should 1.0 0.000143348623853 0 1 -1
antipsychotic,eg 1.0 0.000143348623853 1 0 1
the,proliferation 1.0 0.000286697247706 2 0 2
anastrozole,inhibited 1.0 0.000143348623853 0 1 -1
whereas,exogenous 1.0 0.000143348623853 0 1 -1
of,women 1.0 0.000143348623853 0 1 -1
with,steady 1.0 0.000143348623853 1 0 1
the,plasma 0.041095890411 0.00043004587156 38 35 3
toxicity,and 0.5 0.000860091743119 3 9 -6
be,cautioned 1.0 0.00043004587156 0 3 -3
with,compromised 0.333333333333 0.000143348623853 2 1 1
half-life,leading 1.0 0.000143348623853 0 1 -1
initiated,cells 1.0 0.000143348623853 0 1 -1
a,closely 1.0 0.000143348623853 1 0 1
on,these 0.666666666667 0.000573394495413 1 5 -4
exists,the 1.0 0.000143348623853 0 1 -1
maois,selegiline 1.0 0.000143348623853 1 0 1
great,extent 1.0 0.000143348623853 0 1 -1
absorption,when 1.0 0.000143348623853 1 0 1
via-resistant,presumptive 1.0 0.000143348623853 0 1 -1
mu-,delta 1.0 0.000143348623853 0 1 -1
exhibit,additive 1.0 0.00043004587156 0 3 -3
significant,alterations 1.0 0.000143348623853 0 1 -1
other,ventricular 1.0 0.000143348623853 0 1 -1
on,efficacy 1.0 0.000143348623853 0 1 -1
some,further 1.0 0.000143348623853 1 0 1
resolved,when 1.0 0.000143348623853 0 1 -1
disorders,in 1.0 0.000143348623853 0 1 -1
steady-,state 1.0 0.000143348623853 1 0 1
of,pancreatic 1.0 0.000143348623853 1 0 1
effects,vioxx 1.0 0.000143348623853 0 1 -1
expected,based 1.0 0.000143348623853 0 1 -1
fertility,studies 1.0 0.000143348623853 0 1 -1
plasma,samples 1.0 0.000286697247706 0 2 -2
ataxia,a 1.0 0.000143348623853 0 1 -1
expected,with 0.6 0.00043004587156 1 4 -3
minutes,at 1.0 0.000143348623853 0 1 -1
and,side-effects 1.0 0.000143348623853 1 0 1
its,abrupt 1.0 0.000143348623853 1 0 1
reduced,ligand 1.0 0.000143348623853 0 1 -1
amiodarone,or 1.0 0.000143348623853 1 0 1
vitro,showed 1.0 0.000143348623853 0 1 -1
be,followed 1.0 0.00043004587156 0 3 -3
and,similarly 1.0 0.000143348623853 1 0 1
eye,product 1.0 0.000143348623853 1 0 1
sumatriptan,there 1.0 0.000143348623853 1 0 1
volunteers,developed 1.0 0.000143348623853 1 0 1
while,those 0.0 0.0 1 1 0
following,eye 1.0 0.000143348623853 1 0 1
or,exacerbation 1.0 0.000143348623853 1 0 1
x,mg 1.0 0.000286697247706 2 0 2
sprycel,plasma 1.0 0.000143348623853 0 1 -1
videx,didanosine 1.0 0.000286697247706 2 0 2
in,s 0.0 0.0 1 1 0
on,qtc 1.0 0.000143348623853 0 1 -1
is,frequent 1.0 0.000143348623853 0 1 -1
properties,relative 1.0 0.000143348623853 0 1 -1
with,bextra 0.333333333333 0.000143348623853 2 1 1
the,post-marketing 1.0 0.000143348623853 1 0 1
for,normal 1.0 0.000143348623853 0 1 -1
be,enhanced 0.428571428571 0.00043004587156 5 2 3
concomitantly,serum 1.0 0.000143348623853 1 0 1
ketoconazole,sensipar 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,were 1.0 0.000143348623853 0 1 -1
depression,such 1.0 0.000143348623853 1 0 1
furthermore,whenever 1.0 0.000716743119266 0 5 -5
fasted,and 1.0 0.000143348623853 0 1 -1
indandione,derivatives 1.0 0.000143348623853 1 0 1
the,hind 1.0 0.000143348623853 0 1 -1
that,therapy 1.0 0.000143348623853 0 1 -1
cilexetil,given 1.0 0.000143348623853 0 1 -1
for,the 0.493333333333 0.00530389908257 19 56 -37
tachycardia,was 1.0 0.000143348623853 1 0 1
and,sodium 0.272727272727 0.00043004587156 7 4 3
be,discontinued 0.428571428571 0.000860091743119 4 10 -6
simultaneous,ingestion 1.0 0.000143348623853 1 0 1
interval,significantly 1.0 0.000143348623853 1 0 1
their,relevance 1.0 0.000143348623853 0 1 -1
administration,and 0.333333333333 0.000143348623853 1 2 -1
to,study 1.0 0.000860091743119 0 6 -6
could,potentially 1.0 0.000143348623853 1 0 1
in,single 0.0 0.0 1 1 0
with,based 1.0 0.000143348623853 0 1 -1
a,chylomicron-like 1.0 0.000286697247706 0 2 -2
of,lovenox 1.0 0.000143348623853 0 1 -1
pharmacokinetic,effects 0.0 0.0 1 1 0
studies,at 1.0 0.000143348623853 0 1 -1
substantial,interaction 1.0 0.000143348623853 1 0 1
in,hepatic 1.0 0.000143348623853 0 1 -1
compromise,their 1.0 0.000143348623853 1 0 1
av,node 1.0 0.000143348623853 1 0 1
of,breakthrough 1.0 0.00043004587156 0 3 -3
potent,cyp 1.0 0.000143348623853 0 1 -1
inhibitors,because 1.0 0.000143348623853 1 0 1
the,stable 1.0 0.000286697247706 0 2 -2
the,welfare 1.0 0.000143348623853 0 1 -1
out,two 1.0 0.000143348623853 0 1 -1
insulin-sensitizing,effects 1.0 0.000143348623853 0 1 -1
ulceration,or 1.0 0.000286697247706 2 0 2
toxi-lab,a 1.0 0.000143348623853 0 1 -1
vs,logs 1.0 0.000143348623853 0 1 -1
enkephalinergic,neurons 1.0 0.000143348623853 1 0 1
block,pcp-induced 1.0 0.000143348623853 0 1 -1
obtained,should 1.0 0.000143348623853 1 0 1
thus,concomitant 0.0 0.0 1 1 0
b-adrenergic,blocking 1.0 0.000286697247706 0 2 -2
both,lean 1.0 0.000286697247706 0 2 -2
reported,interactions 1.0 0.000143348623853 0 1 -1
interactions,there 1.0 0.00129013761468 0 9 -9
hydrochloride,ferrous 1.0 0.000143348623853 1 0 1
omnicef,therapy 1.0 0.000286697247706 2 0 2
dogs,anesthetized 1.0 0.000143348623853 1 0 1
moderate,inhibitors 1.0 0.000143348623853 0 1 -1
alternative,error 1.0 0.000143348623853 0 1 -1
sunscreens,and 1.0 0.000143348623853 1 0 1
in,nonfailing 1.0 0.000143348623853 1 0 1
advised,and 1.0 0.000143348623853 1 0 1
weakness,myoclonus 1.0 0.000143348623853 0 1 -1
including,when 1.0 0.000143348623853 1 0 1
acamprosate,concomitantly 0.0 0.0 1 1 0
sodium,polystyrene 1.0 0.000143348623853 1 0 1
benefits,outweigh 1.0 0.00043004587156 3 0 3
accordingly,in 1.0 0.000286697247706 2 0 2
of,liquid 1.0 0.000143348623853 0 1 -1
drug-lab,interactions 1.0 0.000143348623853 0 1 -1
accordingly,if 1.0 0.000143348623853 0 1 -1
given,to 0.238095238095 0.000716743119266 8 13 -5
vasculopathy,and 1.0 0.000143348623853 0 1 -1
precipitation,procedure 1.0 0.000143348623853 0 1 -1
taking,on 1.0 0.000143348623853 0 1 -1
to,displace 1.0 0.000143348623853 1 0 1
left,ventricular 0.0 0.0 2 2 0
vaprisol,the 1.0 0.000143348623853 1 0 1
d,also 1.0 0.00043004587156 0 3 -3
small,study 1.0 0.000143348623853 0 1 -1
body,by 1.0 0.000143348623853 0 1 -1
be,particularly 1.0 0.000286697247706 0 2 -2
taking,or 0.2 0.000143348623853 2 3 -1
if,rebif 1.0 0.000143348623853 0 1 -1
and,younger 1.0 0.000143348623853 0 1 -1
evaluated,by 1.0 0.000143348623853 0 1 -1
orencia,and 1.0 0.000143348623853 1 0 1
aprepitant,is 1.0 0.000716743119266 0 5 -5
possible,enhancement 1.0 0.000143348623853 0 1 -1
immediate-early,genes 1.0 0.000143348623853 0 1 -1
slower,onset 1.0 0.000143348623853 1 0 1
concomitantly,plasma 1.0 0.000143348623853 0 1 -1
more,people 1.0 0.000143348623853 0 1 -1
either,alpha- 1.0 0.000143348623853 0 1 -1
dmpge2,in 1.0 0.000143348623853 0 1 -1
compounds,interfere 1.0 0.000143348623853 0 1 -1
cecum,in 1.0 0.000143348623853 0 1 -1
v,significantly 1.0 0.000143348623853 0 1 -1
with,disease 1.0 0.000143348623853 0 1 -1
bacteria,tested 1.0 0.000143348623853 0 1 -1
already,on 1.0 0.000143348623853 0 1 -1
ranges,within 1.0 0.000143348623853 0 1 -1
mg,separated 1.0 0.000143348623853 1 0 1
cefditoren,with 1.0 0.000143348623853 1 0 1
that,depending 1.0 0.000143348623853 0 1 -1
volunteers,co-administration 1.0 0.000143348623853 0 1 -1
lead,to 0.384615384615 0.0021502293578 12 27 -15
by,interfering 1.0 0.000143348623853 1 0 1
magnesium,magnesium-containing 1.0 0.00043004587156 3 0 3
oral,sulfate 1.0 0.000143348623853 1 0 1
guardians,carefully 1.0 0.000143348623853 0 1 -1
establish,corrective 1.0 0.000143348623853 0 1 -1
decreases,urinary 1.0 0.000143348623853 1 0 1
cell,activation 1.0 0.000143348623853 0 1 -1
other,schizophrenic 1.0 0.000143348623853 1 0 1
as,selective 1.0 0.000143348623853 1 0 1
maintenance,doses 0.333333333333 0.000143348623853 2 1 1
demonstrated,moderate 1.0 0.000143348623853 1 0 1
the,original 1.0 0.000143348623853 0 1 -1
desired,this 1.0 0.000143348623853 0 1 -1
certain,intravenously 1.0 0.000143348623853 1 0 1
alternative,therapeutic 1.0 0.000143348623853 0 1 -1
and,functional 1.0 0.000286697247706 0 2 -2
is,mixed 1.0 0.000143348623853 0 1 -1
usually,administered 1.0 0.000143348623853 1 0 1
chronic,experiments 1.0 0.000143348623853 0 1 -1
infusion,in 1.0 0.000143348623853 0 1 -1
lectin,which 1.0 0.000143348623853 0 1 -1
sublingual,may 1.0 0.000143348623853 0 1 -1
same,metabolic 1.0 0.000143348623853 0 1 -1
be,markedly 1.0 0.000143348623853 1 0 1
supplemented,with 0.333333333333 0.000143348623853 1 2 -1
noted,during 1.0 0.000143348623853 0 1 -1
regimens,lower 1.0 0.000143348623853 0 1 -1
detecting,alterations 1.0 0.000143348623853 0 1 -1
peritoneal,cavity 1.0 0.000143348623853 0 1 -1
when,is 0.5 0.00286697247706 30 10 20
when,it 0.25 0.000573394495413 10 6 4
investigated,the 1.0 0.000860091743119 0 6 -6
patient,specific 1.0 0.000143348623853 0 1 -1
are,activated 1.0 0.000143348623853 0 1 -1
may,partially 1.0 0.000286697247706 2 0 2
of,reducing 1.0 0.000143348623853 0 1 -1
possible,benefits 1.0 0.000143348623853 1 0 1
liver,disease 1.0 0.000143348623853 0 1 -1
discontinued,slowly 1.0 0.000143348623853 1 0 1
occurred,when 1.0 0.000716743119266 0 5 -5
cells,stably 1.0 0.000143348623853 0 1 -1
copegus,therapy 1.0 0.000143348623853 0 1 -1
presentation,and 1.0 0.000143348623853 0 1 -1
response,is 0.5 0.000286697247706 1 3 -2
activities,in 1.0 0.000143348623853 0 1 -1
diet,did 1.0 0.000143348623853 0 1 -1
five-fold,increase 1.0 0.000143348623853 1 0 1
response,in 0.142857142857 0.000143348623853 4 3 1
clamps,mmol 1.0 0.000143348623853 0 1 -1
mg,has 1.0 0.000143348623853 0 1 -1
response,ie 1.0 0.000573394495413 4 0 4
gritty,substance 1.0 0.000143348623853 1 0 1
b,antineoplastic 1.0 0.000143348623853 1 0 1
consequently,should 1.0 0.000143348623853 1 0 1
had,plasma 1.0 0.000143348623853 1 0 1
because,pregnancy 1.0 0.000143348623853 0 1 -1
blood,and 0.333333333333 0.000143348623853 1 2 -1
different,types 1.0 0.000143348623853 0 1 -1
hiv,classified 1.0 0.000143348623853 1 0 1
approach,can 1.0 0.000143348623853 0 1 -1
with,sulfamethoxazole 1.0 0.000143348623853 0 1 -1
expected,antidepressant 1.0 0.000143348623853 1 0 1
promotes,the 1.0 0.000143348623853 0 1 -1
plasminogen,antigen 1.0 0.000286697247706 0 2 -2
prior,ingestion 1.0 0.000143348623853 1 0 1
ci,were 1.0 0.000143348623853 0 1 -1
pressure,of 1.0 0.00043004587156 3 0 3
of,physiological 1.0 0.000143348623853 0 1 -1
of,itraconazole 0.25 0.000286697247706 5 3 2
cmax,values 1.0 0.000286697247706 0 2 -2
the,picr 1.0 0.000143348623853 0 1 -1
that,caspofungin 1.0 0.000143348623853 0 1 -1
the,antinociceptive 0.666666666667 0.000573394495413 5 1 4
pressure,or 1.0 0.00043004587156 0 3 -3
pregnancy,outcomes 1.0 0.000143348623853 0 1 -1
the,supplied 1.0 0.000143348623853 0 1 -1
by,and 0.612903225806 0.00272362385321 25 6 19
function,there 1.0 0.000143348623853 1 0 1
may,interact 0.0344827586207 0.000143348623853 15 14 1
by,any 0.333333333333 0.000143348623853 2 1 1
or,low-dose 1.0 0.000143348623853 1 0 1
review,was 1.0 0.000286697247706 0 2 -2
enhanced,absorption 1.0 0.000143348623853 0 1 -1
associated,in 0.333333333333 0.000143348623853 2 1 1
each,volunteer 1.0 0.000286697247706 0 2 -2
the,ermbt 1.0 0.000286697247706 0 2 -2
tested,was 1.0 0.000143348623853 0 1 -1
strains,but 1.0 0.000143348623853 0 1 -1
complex,formation 1.0 0.000143348623853 0 1 -1
also,an 1.0 0.000143348623853 0 1 -1
clinical,data 0.428571428571 0.00043004587156 2 5 -3
particles,of 1.0 0.00043004587156 0 3 -3
or,harm 1.0 0.000143348623853 0 1 -1
for,drug 1.0 0.000143348623853 0 1 -1
of,epidural 1.0 0.000143348623853 1 0 1
in,period 1.0 0.000286697247706 0 2 -2
each,healthy 1.0 0.000143348623853 0 1 -1
abruptly,discontinued 1.0 0.000143348623853 0 1 -1
be,accompanied 1.0 0.00043004587156 0 3 -3
with,to 0.333333333333 0.000143348623853 2 1 1
taking,when 0.0 0.0 1 1 0
bepridil,with 1.0 0.000143348623853 0 1 -1
drug,is 0.0 0.0 1 1 0
apparent,decrease 1.0 0.000143348623853 0 1 -1
by,displacing 1.0 0.000143348623853 1 0 1
steps,physicians 1.0 0.000143348623853 0 1 -1
tremulousness,and 1.0 0.000143348623853 1 0 1
many,drugs 1.0 0.000143348623853 0 1 -1
mg,times 0.5 0.000286697247706 1 3 -2
may,explain 1.0 0.000143348623853 0 1 -1
discontinuation,of 0.692307692308 0.00129013761468 11 2 9
neurotoxic,and 1.0 0.000143348623853 0 1 -1
l-ccg,was 1.0 0.000143348623853 0 1 -1
low,doses 1.0 0.000143348623853 0 1 -1
with,organ 1.0 0.000143348623853 0 1 -1
leaving,only 1.0 0.000143348623853 0 1 -1
the,biochemical 1.0 0.000860091743119 0 6 -6
genitourinary,symptoms 1.0 0.000143348623853 0 1 -1
supplement,containing 1.0 0.000143348623853 1 0 1
on,equetrotm 1.0 0.000143348623853 1 0 1
lipid,peroxidation 1.0 0.000143348623853 1 0 1
cyp,at 1.0 0.000143348623853 0 1 -1
but,have 1.0 0.000143348623853 0 1 -1
amiodarone,contraindicated 1.0 0.000143348623853 0 1 -1
decreased,effectiveness 0.0 0.0 1 1 0
they,may 0.692307692308 0.00129013761468 2 11 -9
possible,combined 1.0 0.000286697247706 0 2 -2
cfu,ml 1.0 0.000143348623853 0 1 -1
sedation,when 1.0 0.000143348623853 1 0 1
p,but 1.0 0.000143348623853 1 0 1
remaining,ci 1.0 0.000143348623853 0 1 -1
micrograms,ml 0.75 0.000860091743119 1 7 -6
to,improve 1.0 0.000286697247706 0 2 -2
plasma,albumin 1.0 0.000143348623853 1 0 1
modest,elevations 1.0 0.000143348623853 1 0 1
any,statistically 1.0 0.000143348623853 0 1 -1
requirement,may 1.0 0.000143348623853 0 1 -1
of,chop 1.0 0.000286697247706 0 2 -2
most,who 1.0 0.000143348623853 0 1 -1
kaletra,norvir 1.0 0.000143348623853 1 0 1
were,pi 1.0 0.000143348623853 0 1 -1
sequestrants,have 1.0 0.000143348623853 0 1 -1
endoscopic,gastroduodenal 1.0 0.000143348623853 0 1 -1
properly,and 1.0 0.000143348623853 0 1 -1
behavioral,response 1.0 0.000286697247706 0 2 -2
in,cyp3a4 1.0 0.000143348623853 0 1 -1
activities,similar 1.0 0.000143348623853 0 1 -1
cell,resistance 1.0 0.000143348623853 0 1 -1
separate,study 1.0 0.000286697247706 0 2 -2
prothrombin,times 0.333333333333 0.000573394495413 4 8 -4
negative,inotropic 1.0 0.00043004587156 3 0 3
then,remained 1.0 0.000143348623853 0 1 -1
recommended,during 0.6 0.00043004587156 4 1 3
glycosides,patients 1.0 0.000143348623853 0 1 -1
effect,may 0.0 0.0 4 4 0
be,closely 0.0909090909091 0.000286697247706 10 12 -2
that,tests 1.0 0.000143348623853 0 1 -1
alert,clinicians 1.0 0.000143348623853 1 0 1
ventricular,failure 0.333333333333 0.000143348623853 2 1 1
hepatic,enzymes 0.0 0.0 1 1 0
absorption,the 1.0 0.000143348623853 1 0 1
of,status 1.0 0.000286697247706 0 2 -2
function,and 0.8 0.00114678899083 1 9 -8
insp,or 1.0 0.000143348623853 0 1 -1
if,novolog 1.0 0.000143348623853 0 1 -1
of,bepridil 1.0 0.000286697247706 0 2 -2
up-titration,presumably 1.0 0.000143348623853 0 1 -1
factive,had 1.0 0.000286697247706 0 2 -2
hydroxylated,in 1.0 0.000143348623853 1 0 1
antidepressants,amphetamines 1.0 0.000286697247706 2 0 2
or,use 0.0 0.0 1 1 0
tikosyn,mcg 0.333333333333 0.000143348623853 2 1 1
is,hydroxylation 1.0 0.000143348623853 0 1 -1
the,anticoagulants 1.0 0.000143348623853 0 1 -1
twitch,from 1.0 0.000143348623853 1 0 1
neurons,fired 1.0 0.000143348623853 0 1 -1
media,a 1.0 0.000143348623853 1 0 1
this,setting 1.0 0.000143348623853 0 1 -1
severe,prolonged 1.0 0.000143348623853 1 0 1
divalent,and 1.0 0.000286697247706 2 0 2
irritation,in 1.0 0.000143348623853 0 1 -1
with,cancidas 1.0 0.000143348623853 1 0 1
concentrations,reduced 1.0 0.000286697247706 0 2 -2
cells,revealed 1.0 0.000143348623853 1 0 1
of,ewes 1.0 0.000143348623853 1 0 1
a,contraindication 1.0 0.000143348623853 0 1 -1
are,decreased 0.333333333333 0.000143348623853 2 1 1
heart,rate 0.25 0.000286697247706 3 5 -2
of,cellular 1.0 0.000143348623853 0 1 -1
lower,end 1.0 0.000143348623853 1 0 1
humans,is 1.0 0.000286697247706 0 2 -2
ic50,g 1.0 0.000143348623853 0 1 -1
designed,studies 1.0 0.000143348623853 0 1 -1
of,bacteria 1.0 0.000143348623853 0 1 -1
human,subjects 0.0 0.0 1 1 0
are,needed 1.0 0.00043004587156 0 3 -3
tentatively,supports 1.0 0.000143348623853 0 1 -1
antinociceptive,effect 0.333333333333 0.000286697247706 4 2 2
patient,taking 0.5 0.000286697247706 1 3 -2
trimethyl,lead 1.0 0.000143348623853 0 1 -1
alone,or 1.0 0.00157683486239 0 11 -11
produced,minor 1.0 0.000143348623853 1 0 1
basal,medium 1.0 0.000143348623853 0 1 -1
first,month 1.0 0.000143348623853 0 1 -1
a,thin-layer 1.0 0.000143348623853 0 1 -1
regimes,against 1.0 0.000143348623853 0 1 -1
strongly,induce 1.0 0.000143348623853 1 0 1
in,non-myelinated 1.0 0.000143348623853 0 1 -1
of,vitamin 0.25 0.000286697247706 5 3 2
define,positive 1.0 0.000143348623853 0 1 -1
tests,should 1.0 0.000716743119266 0 5 -5
not,modify 1.0 0.000286697247706 0 2 -2
later,developmental 1.0 0.000143348623853 0 1 -1
suprax,is 1.0 0.000143348623853 1 0 1
had,initial 1.0 0.000143348623853 0 1 -1
after,completion 1.0 0.000143348623853 1 0 1
subsequent,to 0.333333333333 0.000143348623853 1 2 -1
drug-interaction,studies 1.0 0.000286697247706 0 2 -2
of,channels 1.0 0.000143348623853 0 1 -1
hypertensive,response 1.0 0.000143348623853 1 0 1
such,data 1.0 0.000143348623853 0 1 -1
physicians,to 1.0 0.000143348623853 0 1 -1
some,and 1.0 0.000286697247706 2 0 2
while,taking 0.538461538462 0.00100344036697 3 10 -7
of,phosphorylation 1.0 0.000143348623853 0 1 -1
thiazide,may 0.2 0.000143348623853 3 2 1
too,frequent 1.0 0.000143348623853 0 1 -1
the,luteinizing 1.0 0.000143348623853 0 1 -1
with,lotensin 1.0 0.000143348623853 1 0 1
serotonin2-receptors,underlies 1.0 0.000143348623853 0 1 -1
the,minor 1.0 0.000143348623853 0 1 -1
mortality,rate 1.0 0.000143348623853 0 1 -1
significantly,while 1.0 0.000143348623853 0 1 -1
high,performance 1.0 0.000143348623853 0 1 -1
experimental,designs 1.0 0.000286697247706 0 2 -2
explain,in 1.0 0.000143348623853 0 1 -1
to,identify 1.0 0.00043004587156 0 3 -3
other,non-steroidal 1.0 0.000286697247706 2 0 2
both,as 1.0 0.000143348623853 1 0 1
subject,given 1.0 0.000143348623853 1 0 1
induce,p-450iie1 1.0 0.000143348623853 0 1 -1
urinary,bilirubin 1.0 0.000143348623853 0 1 -1
inhibitors,protease 1.0 0.000143348623853 0 1 -1
baseline,and 1.0 0.000286697247706 0 2 -2
even,after 1.0 0.000143348623853 0 1 -1
mice,treated 1.0 0.000143348623853 0 1 -1
disopyramide,increases 1.0 0.000143348623853 0 1 -1
of,serum-deprived 1.0 0.000143348623853 0 1 -1
uroxatral,and 1.0 0.000143348623853 0 1 -1
hours,p 1.0 0.000143348623853 0 1 -1
than,minutes 1.0 0.000143348623853 0 1 -1
natriuresis,is 1.0 0.000143348623853 1 0 1
maoi,within 1.0 0.000143348623853 1 0 1
to,relevant 1.0 0.000143348623853 0 1 -1
rearrangements,of 1.0 0.000143348623853 0 1 -1
crixivan,may 1.0 0.000143348623853 1 0 1
antiaggregant,prostacyclin 1.0 0.000143348623853 0 1 -1
by,checkerboard 1.0 0.000143348623853 0 1 -1
voltaren,cataflam 1.0 0.000143348623853 0 1 -1
ultimately,however 1.0 0.000143348623853 0 1 -1
on,evoked 1.0 0.000143348623853 0 1 -1
chlorthalidone,and 1.0 0.000286697247706 2 0 2
loperamide,and 0.0 0.0 1 1 0
method,of 0.5 0.000286697247706 3 1 2
variation,also 1.0 0.000143348623853 0 1 -1
method,or 1.0 0.000143348623853 0 1 -1
which,themselves 1.0 0.000143348623853 1 0 1
be,allowed 1.0 0.000143348623853 1 0 1
affect,strategies 1.0 0.000143348623853 0 1 -1
cyp3a4,which 1.0 0.000143348623853 0 1 -1
cytochromes,particularly 1.0 0.000143348623853 0 1 -1
romazicon,was 1.0 0.000143348623853 0 1 -1
weight,gain 0.333333333333 0.000143348623853 2 1 1
constitutes,the 1.0 0.000143348623853 0 1 -1
of,angiomax 0.0 0.0 1 1 0
potential,input 1.0 0.000143348623853 0 1 -1
hydrogen,maleate 1.0 0.000143348623853 1 0 1
cimetldine,cerivastatin 1.0 0.000143348623853 0 1 -1
medications,at 1.0 0.000143348623853 0 1 -1
were,evaluated 1.0 0.000143348623853 0 1 -1
stress,in 0.0 0.0 1 1 0
of,antipsychotic 1.0 0.000143348623853 1 0 1
coupling,between 1.0 0.000143348623853 0 1 -1
of,pregnant 1.0 0.000143348623853 0 1 -1
interactions,with 0.617021276596 0.00415711009174 9 38 -29
appeared,well 1.0 0.000286697247706 0 2 -2
new,agents 1.0 0.000143348623853 0 1 -1
including,products 1.0 0.000143348623853 1 0 1
protect,against 1.0 0.000143348623853 1 0 1
arrhythmia,bradycardia 1.0 0.000143348623853 1 0 1
to,antiepileptic 1.0 0.000143348623853 1 0 1
other,beta2 1.0 0.000143348623853 1 0 1
respectively,a 1.0 0.000286697247706 2 0 2
patient,may 1.0 0.000143348623853 1 0 1
be,advised 0.2 0.000143348623853 3 2 1
acute,phase 1.0 0.000286697247706 0 2 -2
respectively,p 1.0 0.000143348623853 0 1 -1
digoxin,and 1.0 0.000143348623853 1 0 1
taking,revia 1.0 0.000143348623853 1 0 1
tests,such 1.0 0.000286697247706 0 2 -2
inhibitor,maoi 1.0 0.000143348623853 0 1 -1
propoxyphene,in 1.0 0.000286697247706 2 0 2
itraconazole,and 0.714285714286 0.000716743119266 6 1 5
r-values,of 1.0 0.000143348623853 0 1 -1
instructions,and 1.0 0.000143348623853 0 1 -1
to,inactivate 1.0 0.000143348623853 1 0 1
irradiation,has 1.0 0.000143348623853 0 1 -1
and,nrtis 1.0 0.000143348623853 0 1 -1
the,basal 1.0 0.000286697247706 0 2 -2
ions,may 1.0 0.000143348623853 0 1 -1
increased,during 0.0 0.0 1 1 0
in,increase 1.0 0.000143348623853 1 0 1
state,was 1.0 0.000143348623853 0 1 -1
the,west 1.0 0.000143348623853 0 1 -1
necrotizing,myopathy 1.0 0.000143348623853 0 1 -1
and,coma 1.0 0.000143348623853 1 0 1
with,fluvoxamine 1.0 0.000143348623853 1 0 1
activity,acute 1.0 0.000143348623853 0 1 -1
hepatic,and 1.0 0.000143348623853 0 1 -1
has,been 0.0833333333333 0.00286697247706 130 110 20
be,guided 1.0 0.000143348623853 0 1 -1
the,should 0.25 0.000286697247706 3 5 -2
levetiracetam,had 1.0 0.000143348623853 0 1 -1
predictive,of 1.0 0.000143348623853 0 1 -1
ambulatory,patients 1.0 0.000143348623853 0 1 -1
cuprimine,another 1.0 0.000143348623853 1 0 1
or,minutes 1.0 0.000143348623853 1 0 1
no,volunteer 1.0 0.000143348623853 0 1 -1
is,generally 0.0 0.0 2 2 0
and,proquin 1.0 0.000143348623853 0 1 -1
pharmacodynamics,and 1.0 0.000143348623853 0 1 -1
if,b12 1.0 0.000143348623853 0 1 -1
are,vasoconstrictive 1.0 0.000143348623853 1 0 1
weeks,oral 1.0 0.000143348623853 0 1 -1
other,manufacturers 1.0 0.000143348623853 0 1 -1
of,repeat 1.0 0.000143348623853 0 1 -1
in,secretions 1.0 0.000143348623853 0 1 -1
bleeding,a 1.0 0.000143348623853 0 1 -1
systematically,evaluated 1.0 0.000143348623853 1 0 1
talk,to 1.0 0.000716743119266 0 5 -5
may,represent 1.0 0.000286697247706 0 2 -2
additional,reductions 1.0 0.000143348623853 1 0 1
other,channel 1.0 0.000143348623853 1 0 1
to,the 0.450980392157 0.00989105504587 42 111 -69
bullous,pemphigoid 1.0 0.000143348623853 1 0 1
certain,antipsychotic 1.0 0.000143348623853 0 1 -1
and,hypotension 1.0 0.000143348623853 0 1 -1
although,they 0.333333333333 0.000143348623853 1 2 -1
prostaglandins,play 1.0 0.000143348623853 1 0 1
or,accumulation 1.0 0.000143348623853 0 1 -1
the,digit 1.0 0.000143348623853 1 0 1
receiving,proleukin 1.0 0.000143348623853 1 0 1
reports,however 1.0 0.000143348623853 1 0 1
increase,oral 1.0 0.000286697247706 2 0 2
on,histamine- 1.0 0.000143348623853 1 0 1
by,peripheral 1.0 0.000286697247706 0 2 -2
dosing,concurrently 1.0 0.000143348623853 0 1 -1
acid,paba 1.0 0.000143348623853 1 0 1
certainly,during 1.0 0.000143348623853 1 0 1
and,have 0.555555555556 0.0021502293578 6 21 -15
betaseron,and 1.0 0.000143348623853 0 1 -1
adults,at 1.0 0.000143348623853 1 0 1
alterations,underlying 1.0 0.000143348623853 0 1 -1
also,discussed 1.0 0.000143348623853 0 1 -1
of,zinecard 1.0 0.000143348623853 0 1 -1
inhibiting,the 1.0 0.000573394495413 4 0 4
the,digi- 1.0 0.000143348623853 0 1 -1
phenytoin,no 1.0 0.000143348623853 0 1 -1
donor,compounds 1.0 0.000143348623853 1 0 1
mg,total 1.0 0.000143348623853 0 1 -1
and,day 1.0 0.000143348623853 1 0 1
with,l-tryptophan 1.0 0.000143348623853 0 1 -1
of,hydroxyzine 1.0 0.000143348623853 1 0 1
rat,were 1.0 0.000143348623853 0 1 -1
added,or 1.0 0.000286697247706 2 0 2
l50,mg 1.0 0.000143348623853 0 1 -1
urinary,hydroxy-corticosteroids 1.0 0.000143348623853 0 1 -1
in,fluoride 1.0 0.000143348623853 0 1 -1
of,hydroxide 0.0 0.0 1 1 0
one-stage,factor 1.0 0.000143348623853 0 1 -1
added,of 1.0 0.000143348623853 1 0 1
cyp3a4,cimetidine 1.0 0.000143348623853 1 0 1
max,increased 0.0 0.0 1 1 0
sc,injections 1.0 0.000143348623853 0 1 -1
outpatient,services 1.0 0.000143348623853 0 1 -1
heparin,other 1.0 0.000143348623853 0 1 -1
defense,of 1.0 0.000143348623853 1 0 1
receiving,hcl 1.0 0.000286697247706 2 0 2
a1,a2 1.0 0.000143348623853 0 1 -1
cyclophosphamide,treatment 1.0 0.000143348623853 1 0 1
requires,oral 1.0 0.000143348623853 0 1 -1
mechanisms,involving 1.0 0.000143348623853 1 0 1
of,admissions 1.0 0.000143348623853 0 1 -1
anaphylactic,shock 1.0 0.000143348623853 1 0 1
of,vasopressor 0.0 0.0 1 1 0
dasatinib,is 1.0 0.000286697247706 0 2 -2
viracept,antiarrhythmics 1.0 0.000143348623853 1 0 1
expected,and 1.0 0.000143348623853 1 0 1
as,imitrex 0.0 0.0 1 1 0
arenot,established 1.0 0.000286697247706 0 2 -2
alosetron,does 1.0 0.000143348623853 0 1 -1
of,minutes 1.0 0.000143348623853 0 1 -1
the,para-aminobenzoic 1.0 0.000143348623853 0 1 -1
significant,drug-drug 1.0 0.000573394495413 0 4 -4
ventricular,hypokinesia 1.0 0.000143348623853 1 0 1
an,antipsychotic 1.0 0.000143348623853 1 0 1
species,ros 1.0 0.000143348623853 0 1 -1
of,clozapine 0.5 0.000286697247706 3 1 2
total,exposure 1.0 0.000143348623853 0 1 -1
homodimeric,structure 1.0 0.000143348623853 0 1 -1
carbonate,or 1.0 0.000143348623853 1 0 1
either,protective 1.0 0.000143348623853 0 1 -1
each,preparation 1.0 0.000286697247706 0 2 -2
experience,on 1.0 0.000143348623853 0 1 -1
medical,considerations 1.0 0.000143348623853 0 1 -1
toradoloral,was 1.0 0.000143348623853 0 1 -1
mammalian,target 1.0 0.000143348623853 0 1 -1
tbg,deficiency 1.0 0.000143348623853 0 1 -1
major,enzyme 0.0 0.0 1 1 0
any,clinical 0.0 0.0 1 1 0
because,some 1.0 0.000286697247706 2 0 2
a2,c9 1.0 0.000143348623853 0 1 -1
avoided,in 0.0 0.0 3 3 0
of,patient 1.0 0.000143348623853 1 0 1
diseases,recent 1.0 0.000143348623853 0 1 -1
hepatic,microsomal 0.714285714286 0.000716743119266 1 6 -5
radiation,treatment 1.0 0.000143348623853 0 1 -1
day,a 1.0 0.000143348623853 1 0 1
importantly,we 1.0 0.000143348623853 0 1 -1
day,n 0.0 0.0 1 1 0
in,resorptions 1.0 0.000143348623853 0 1 -1
auc,hours 1.0 0.000143348623853 0 1 -1
two,outbreaks 1.0 0.000143348623853 0 1 -1
while,minimizing 1.0 0.000143348623853 0 1 -1
vitro,gleevec 1.0 0.000286697247706 0 2 -2
extensively,in 1.0 0.000143348623853 0 1 -1
a,simultaneous 1.0 0.000143348623853 1 0 1
both,were 1.0 0.000143348623853 0 1 -1
methods,from 1.0 0.000143348623853 0 1 -1
to,limited 1.0 0.000143348623853 0 1 -1
betagan,and 1.0 0.000143348623853 1 0 1
pancreatic,supplements 1.0 0.000143348623853 1 0 1
on,sensipar 1.0 0.000143348623853 0 1 -1
cell,number 1.0 0.000143348623853 1 0 1
hypotension,in 1.0 0.000286697247706 0 2 -2
first,contractile 1.0 0.000143348623853 0 1 -1
pegasys,should 1.0 0.000286697247706 0 2 -2
rats,were 0.714285714286 0.000716743119266 1 6 -5
keppra,mg 1.0 0.000716743119266 0 5 -5
death,due 1.0 0.000143348623853 1 0 1
sirolimus,mammalian 1.0 0.000143348623853 0 1 -1
h2-antagonists,and 1.0 0.000143348623853 0 1 -1
procedures,in 1.0 0.000143348623853 0 1 -1
demonstrated,between 0.0 0.0 1 1 0
system,should 1.0 0.000286697247706 0 2 -2
for,for 1.0 0.00043004587156 0 3 -3
the,type 0.666666666667 0.000573394495413 1 5 -4
medications,tylenol 1.0 0.000143348623853 1 0 1
components,of 1.0 0.000143348623853 0 1 -1
following,multiple 1.0 0.000143348623853 0 1 -1
day,qd 1.0 0.000143348623853 0 1 -1
mg,fe 1.0 0.000143348623853 1 0 1
control,atrial 1.0 0.000143348623853 1 0 1
diminishes,the 1.0 0.000143348623853 1 0 1
to,but 0.2 0.000143348623853 3 2 1
to,and 0.428571428571 0.000860091743119 4 10 -6
pcp,discrimination 1.0 0.000143348623853 0 1 -1
that,hydrochloride 1.0 0.000143348623853 0 1 -1
lean,rats 1.0 0.000143348623853 0 1 -1
arrhythmias,due 1.0 0.000143348623853 0 1 -1
taking,certain 1.0 0.000143348623853 0 1 -1
in,adequate 1.0 0.000286697247706 0 2 -2
ras-3t3,cells 1.0 0.00043004587156 0 3 -3
antidepressants,foradil 1.0 0.000143348623853 1 0 1
when,administering 0.157894736842 0.00043004587156 11 8 3
from,studies 1.0 0.000573394495413 0 4 -4
however,appropriate 1.0 0.000143348623853 1 0 1
low,dose 1.0 0.00043004587156 0 3 -3
six,subjects 1.0 0.000143348623853 1 0 1
cyp2d6,such 0.0 0.0 1 1 0
therapy,diabetes 1.0 0.000143348623853 0 1 -1
of,contraction 1.0 0.000143348623853 0 1 -1
itraconazole,plasma 1.0 0.000143348623853 1 0 1
in,lowered 0.0 0.0 1 1 0
phenotypic,subset 1.0 0.000143348623853 0 1 -1
bound,like 1.0 0.000143348623853 0 1 -1
following,drug 1.0 0.000143348623853 0 1 -1
these,compounds 1.0 0.00100344036697 0 7 -7
as,potent 1.0 0.000143348623853 0 1 -1
over,weeks 1.0 0.000143348623853 0 1 -1
systems,most 1.0 0.000143348623853 0 1 -1
interaction,with 0.612903225806 0.00272362385321 6 25 -19
metabolites,appear 1.0 0.000143348623853 0 1 -1
a,function 1.0 0.000143348623853 0 1 -1
altered,tsh 1.0 0.000143348623853 0 1 -1
agents,glutamic 1.0 0.000143348623853 1 0 1
hamsters,show 1.0 0.000143348623853 0 1 -1
clinically,significant 0.857142857143 0.00688073394495 4 52 -48
inhibited,the 0.5 0.000286697247706 3 1 2
clearance,mechanisms 1.0 0.000143348623853 0 1 -1
reuptake,inhibitors 0.142857142857 0.000286697247706 6 8 -2
seizures,in 1.0 0.000286697247706 2 0 2
been,established 0.0 0.0 4 4 0
serotonin,and 1.0 0.000143348623853 0 1 -1
depressants,the 1.0 0.000143348623853 1 0 1
duloxetine,to 1.0 0.000143348623853 0 1 -1
pains,or 1.0 0.000143348623853 0 1 -1
rapid,progression 1.0 0.000143348623853 0 1 -1
in,escalating 1.0 0.000143348623853 0 1 -1
have,cholesterol 1.0 0.000143348623853 1 0 1
reaction,to 0.714285714286 0.000716743119266 1 6 -5
effectiveness,against 1.0 0.000143348623853 0 1 -1
succinate,and 1.0 0.000143348623853 0 1 -1
rettgeri,were 1.0 0.000143348623853 0 1 -1
cause,immunosuppression 1.0 0.000143348623853 0 1 -1
during,continuous 1.0 0.000143348623853 0 1 -1
cisapride,can 1.0 0.000143348623853 0 1 -1
mean,sd 1.0 0.000143348623853 0 1 -1
test,interaction 1.0 0.000716743119266 0 5 -5
the,diabetics 1.0 0.000143348623853 0 1 -1
higher,end 1.0 0.000143348623853 0 1 -1
hyperglycemia,but 1.0 0.000143348623853 0 1 -1
by,high 1.0 0.000286697247706 2 0 2
certain,tetracyclic 1.0 0.000143348623853 0 1 -1
the,characteristics 1.0 0.000143348623853 0 1 -1
of,factive 0.333333333333 0.000143348623853 2 1 1
adverse,effects 0.333333333333 0.00114678899083 8 16 -8
ca,channel 1.0 0.00043004587156 0 3 -3
clearance,values 0.0 0.0 1 1 0
injection,should 1.0 0.000286697247706 0 2 -2
are,sequestered 1.0 0.000143348623853 0 1 -1
pain,mechanisms 1.0 0.000143348623853 0 1 -1
important,causes 1.0 0.000143348623853 0 1 -1
substrates,drugs 1.0 0.000143348623853 1 0 1
and,interfere 1.0 0.000143348623853 1 0 1
no,nutritional 1.0 0.000143348623853 0 1 -1
of,systemic 0.333333333333 0.000143348623853 2 1 1
of,krm-1648 1.0 0.000286697247706 0 2 -2
color,is 1.0 0.000143348623853 1 0 1
taken,when 0.333333333333 0.000286697247706 2 4 -2
taxol,is 1.0 0.000143348623853 0 1 -1
tablet,was 1.0 0.000143348623853 1 0 1
pocs,and 1.0 0.000286697247706 0 2 -2
of,cmi 1.0 0.000286697247706 2 0 2
incoordination,when 0.333333333333 0.000143348623853 2 1 1
human,fungal 1.0 0.000143348623853 0 1 -1
tumour,the 1.0 0.000143348623853 0 1 -1
interactions,by 1.0 0.000143348623853 0 1 -1
animals,male 1.0 0.000143348623853 0 1 -1
neuropathy,pancreatitis 1.0 0.000143348623853 0 1 -1
by,contrast 1.0 0.000143348623853 0 1 -1
blocking,action 0.333333333333 0.00043004587156 6 3 3
or,is 0.333333333333 0.000143348623853 2 1 1
tool,for 1.0 0.000573394495413 0 4 -4
oleate,and 1.0 0.000286697247706 0 2 -2
after,injection 1.0 0.000143348623853 1 0 1
or,iv 1.0 0.000143348623853 0 1 -1
group,of 0.666666666667 0.000573394495413 1 5 -4
desirable,to 1.0 0.000716743119266 0 5 -5
antidepressant,levels 1.0 0.000286697247706 2 0 2
vardenafil,and 0.0 0.0 1 1 0
acid,erythromycin 1.0 0.000143348623853 0 1 -1
decoy,and 1.0 0.000143348623853 0 1 -1
preanesthetic,or 1.0 0.000143348623853 0 1 -1
lh,follicle-stimulating 1.0 0.000143348623853 0 1 -1
mg,administered 0.333333333333 0.000143348623853 2 1 1
but,significantly 1.0 0.000286697247706 2 0 2
for,mg 1.0 0.000143348623853 1 0 1
of,hexanal-induced 1.0 0.000143348623853 0 1 -1
laboratory,preliminary 1.0 0.000143348623853 0 1 -1
becomes,sensitive 1.0 0.000143348623853 0 1 -1
that,cefditoren 0.0 0.0 1 1 0
usually,the 1.0 0.000143348623853 0 1 -1
of,herbal 1.0 0.000573394495413 0 4 -4
this,toxicity 1.0 0.000143348623853 0 1 -1
out,as 1.0 0.000143348623853 0 1 -1
from,week 1.0 0.000143348623853 0 1 -1
cyclosporine,large 1.0 0.000143348623853 0 1 -1
use,short-acting 1.0 0.000143348623853 1 0 1
by,detailed 1.0 0.000143348623853 0 1 -1
after,multiple 0.0 0.0 1 1 0
structures,and 1.0 0.000143348623853 0 1 -1
potent,loop 1.0 0.000143348623853 1 0 1
concurrent,administration 0.428571428571 0.0021502293578 25 10 15
week,about 1.0 0.000143348623853 0 1 -1
lower,rate 1.0 0.000143348623853 1 0 1
parenterally,administered 1.0 0.000143348623853 1 0 1
today,pharmacological 1.0 0.000143348623853 0 1 -1
the,occurrence 0.428571428571 0.00043004587156 2 5 -3
thiolated,carboxymethylcellulose 1.0 0.000143348623853 0 1 -1
ethynyl,and 1.0 0.000143348623853 0 1 -1
occurs,the 1.0 0.000143348623853 0 1 -1
parenteral,except 1.0 0.000143348623853 0 1 -1
thyroid,hormones 1.0 0.000143348623853 0 1 -1
indicate,that 0.153846153846 0.00114678899083 22 30 -8
study,coadministration 1.0 0.000286697247706 2 0 2
substrate,a 1.0 0.000143348623853 0 1 -1
or,retinyl 1.0 0.000286697247706 2 0 2
consistent,with 1.0 0.000716743119266 0 5 -5
its,dosage 1.0 0.000143348623853 1 0 1
antibiotics,videx 1.0 0.000143348623853 1 0 1
the,lowest 1.0 0.00043004587156 3 0 3
obtained,for 1.0 0.000143348623853 0 1 -1
there,does 1.0 0.000143348623853 0 1 -1
cyp2d6,resulted 1.0 0.000143348623853 1 0 1
no,treatment-related 1.0 0.000143348623853 0 1 -1
complex,overallactivity 1.0 0.000143348623853 0 1 -1
daily,brovana 1.0 0.000143348623853 0 1 -1
antiplatelet,therapies 1.0 0.000143348623853 0 1 -1
women,of 1.0 0.000573394495413 0 4 -4
tests,be 1.0 0.00043004587156 0 3 -3
digitalis,or 1.0 0.000143348623853 1 0 1
your,condition 1.0 0.000143348623853 0 1 -1
brain,and 1.0 0.000143348623853 1 0 1
a,series 1.0 0.000143348623853 0 1 -1
rapidly,and 1.0 0.000143348623853 0 1 -1
are,on 1.0 0.000573394495413 4 0 4
cyp2c19,the 1.0 0.000143348623853 0 1 -1
contraindicated,due 1.0 0.00143348623853 0 10 -10
effects,reduced 1.0 0.000143348623853 0 1 -1
be,reflective 1.0 0.000143348623853 0 1 -1
chemotherapy,and 1.0 0.000143348623853 0 1 -1
before,using 0.0 0.0 1 1 0
clinically,important 1.0 0.00272362385321 0 19 -19
this,being 1.0 0.000143348623853 0 1 -1
non-narcotic,analgesics 1.0 0.000143348623853 1 0 1
and,require 1.0 0.000143348623853 1 0 1
of,h1 1.0 0.000143348623853 1 0 1
of,h2 1.0 0.000286697247706 2 0 2
daily,with 0.0 0.0 1 1 0
coadministered,intravenously 1.0 0.000143348623853 1 0 1
read,circulars 1.0 0.000573394495413 0 4 -4
malignant,hyperpyrexia 1.0 0.000286697247706 0 2 -2
sex,men 1.0 0.000143348623853 0 1 -1
mineral,oil 1.0 0.000286697247706 2 0 2
the,abundance 1.0 0.000143348623853 0 1 -1
additional,efficacy 1.0 0.000143348623853 1 0 1
bovine,chromaffin 1.0 0.000286697247706 0 2 -2
of,strong 1.0 0.000286697247706 0 2 -2
occasionally,intensify 1.0 0.000143348623853 1 0 1
in,response 1.0 0.000716743119266 0 5 -5
impairment,may 1.0 0.000286697247706 0 2 -2
lymphomas,when 1.0 0.000143348623853 0 1 -1
increased,availability 1.0 0.000143348623853 0 1 -1
oxidase,reactions 1.0 0.000716743119266 0 5 -5
starlix,mg 1.0 0.000573394495413 0 4 -4
to,adversely 1.0 0.000143348623853 0 1 -1
be,watched 1.0 0.000143348623853 1 0 1
whether,injection 1.0 0.000143348623853 0 1 -1
methods,for 1.0 0.000143348623853 0 1 -1
increase,for 0.0 0.0 1 1 0
and,prolonged 0.333333333333 0.000143348623853 2 1 1
similar,concentrations 1.0 0.000143348623853 0 1 -1
exists,between 0.5 0.000286697247706 3 1 2
alg,mycophenolate 1.0 0.000143348623853 0 1 -1
when,colestid 1.0 0.000143348623853 1 0 1
readily,obtainable 1.0 0.000143348623853 0 1 -1
nitrates,the 0.0 0.0 1 1 0
fecal,as 1.0 0.000143348623853 0 1 -1
produce,some 1.0 0.000143348623853 0 1 -1
in,chick 1.0 0.000143348623853 0 1 -1
rely,on 1.0 0.000143348623853 0 1 -1
tablets,may 0.5 0.000286697247706 3 1 2
dialysis,solutions 1.0 0.000143348623853 0 1 -1
reasons,for 1.0 0.000143348623853 0 1 -1
gain,occurred 1.0 0.000143348623853 0 1 -1
of,medical 1.0 0.000286697247706 0 2 -2
be,less 0.5 0.000286697247706 1 3 -2
bolus,injections 1.0 0.000143348623853 0 1 -1
with,two 1.0 0.000143348623853 0 1 -1
ie,increased 1.0 0.000286697247706 2 0 2
that,lung 1.0 0.000143348623853 0 1 -1
toxic,such 1.0 0.000143348623853 1 0 1
self-reported,mood 1.0 0.000143348623853 0 1 -1
individuals,may 1.0 0.000286697247706 0 2 -2
time,responses 1.0 0.000143348623853 0 1 -1
absolute,abstinence 1.0 0.000143348623853 0 1 -1
rats,to 1.0 0.000143348623853 0 1 -1
impairment,there 1.0 0.000286697247706 0 2 -2
addicts,was 1.0 0.000143348623853 0 1 -1
on,days 0.0 0.0 3 3 0
inhibitors,with 1.0 0.000143348623853 1 0 1
unchanged,after 1.0 0.000143348623853 0 1 -1
failure,etc 1.0 0.000143348623853 1 0 1
other,hepatic 1.0 0.000143348623853 1 0 1
genetic,factors 1.0 0.000143348623853 0 1 -1
coumarin-derivative,should 1.0 0.000143348623853 0 1 -1
no,signs 0.0 0.0 1 1 0
urinary,assays 1.0 0.000143348623853 0 1 -1
of,over 1.0 0.000573394495413 0 4 -4
nevirapine,and 1.0 0.000286697247706 2 0 2
to,lowered 1.0 0.000143348623853 1 0 1
not,beadministered 1.0 0.000286697247706 2 0 2
recommended,that 0.0 0.0 18 18 0
patients,years 1.0 0.000143348623853 0 1 -1
body,weight 0.777777777778 0.00100344036697 1 8 -7
in,preventing 1.0 0.000143348623853 0 1 -1
treatment,produced 1.0 0.000143348623853 0 1 -1
on,day9 1.0 0.000143348623853 1 0 1
on,day5 0.0 0.0 1 1 0
valdecoxib,did 1.0 0.000143348623853 0 1 -1
many,such 1.0 0.000143348623853 0 1 -1
isoforms,cyp3a4 1.0 0.000143348623853 0 1 -1
minimally,absorbed 1.0 0.000143348623853 1 0 1
events,required 1.0 0.000143348623853 0 1 -1
blockade,was 0.0 0.0 1 1 0
dogs,approximately 1.0 0.000143348623853 0 1 -1
the,vehicle 1.0 0.000143348623853 1 0 1
when,channel 1.0 0.000286697247706 2 0 2
whether,meth 1.0 0.000143348623853 0 1 -1
hypertension,some 1.0 0.000143348623853 1 0 1
inhibitor,added 1.0 0.000143348623853 0 1 -1
antagonist,opioid 1.0 0.000143348623853 1 0 1
deficiencies,affecting 1.0 0.000143348623853 1 0 1
on,tikosyn 1.0 0.000143348623853 0 1 -1
failure,secondary 1.0 0.000143348623853 0 1 -1
wort,hypericum 1.0 0.00043004587156 0 3 -3
volunteers,exjade 1.0 0.000143348623853 0 1 -1
is,formed 1.0 0.000143348623853 0 1 -1
below,drugs 1.0 0.000143348623853 1 0 1
and,produced 0.5 0.000286697247706 1 3 -2
juice,and 1.0 0.000143348623853 1 0 1
with,suspension 1.0 0.000143348623853 0 1 -1
hypertension,administration 1.0 0.000286697247706 2 0 2
or,co-administration 1.0 0.000143348623853 1 0 1
included,in 1.0 0.000286697247706 0 2 -2
test,and 1.0 0.000143348623853 1 0 1
of,aerosolized 1.0 0.000143348623853 0 1 -1
increases,progressively 1.0 0.000143348623853 0 1 -1
induced,long 1.0 0.000143348623853 1 0 1
a,pregnancy 1.0 0.000143348623853 0 1 -1
further,fe 1.0 0.000143348623853 0 1 -1
our,patient 1.0 0.000143348623853 1 0 1
contraception,should 1.0 0.000286697247706 2 0 2
eg,are 1.0 0.000143348623853 0 1 -1
idv,exposure 1.0 0.000143348623853 0 1 -1
pathways,are 1.0 0.000143348623853 0 1 -1
time,was 1.0 0.000573394495413 0 4 -4
combination,may 1.0 0.00043004587156 3 0 3
nor,retinyl 1.0 0.000143348623853 1 0 1
special,precaution 1.0 0.000286697247706 0 2 -2
aminoglycosides,the 1.0 0.000143348623853 1 0 1
onset,can 1.0 0.000143348623853 1 0 1
survival,for 1.0 0.000143348623853 0 1 -1
nevirapine,may 1.0 0.000143348623853 1 0 1
coadministered,plasma 1.0 0.000143348623853 1 0 1
clinically,meaningful 0.666666666667 0.000573394495413 1 5 -4
because,the 0.333333333333 0.000860091743119 12 6 6
revlimid,is 1.0 0.000143348623853 0 1 -1
clozapine,potentially 1.0 0.000143348623853 1 0 1
oral,supplements 1.0 0.000143348623853 0 1 -1
decreased,and 1.0 0.000143348623853 1 0 1
mg,qhs 1.0 0.000143348623853 0 1 -1
good,with 1.0 0.000143348623853 0 1 -1
the,small 0.333333333333 0.000143348623853 1 2 -1
supervision,after 0.0 0.0 1 1 0
and,main 1.0 0.000286697247706 0 2 -2
in,survanta 1.0 0.000143348623853 0 1 -1
atacand,so 1.0 0.000143348623853 1 0 1
may,compete 1.0 0.000143348623853 1 0 1
or,ototoxicity 1.0 0.000143348623853 0 1 -1
developed,neutropenia 1.0 0.000286697247706 2 0 2
maximal,effects 1.0 0.000143348623853 0 1 -1
antacids,in 1.0 0.000286697247706 2 0 2
before,dosing 1.0 0.000143348623853 1 0 1
of,withdrawal 0.2 0.000143348623853 2 3 -1
co-administered,has 1.0 0.000143348623853 1 0 1
six,hours 1.0 0.000143348623853 0 1 -1
effective,while 1.0 0.000143348623853 1 0 1
given,supplemental 1.0 0.000143348623853 1 0 1
cyp450,isoenzymes 1.0 0.000286697247706 0 2 -2
for,novolog 1.0 0.000143348623853 0 1 -1
observation,period 1.0 0.000143348623853 0 1 -1
group,that 1.0 0.000286697247706 0 2 -2
in,arteries 1.0 0.000143348623853 0 1 -1
busulfex,were 1.0 0.000143348623853 1 0 1
establish,whether 1.0 0.000143348623853 0 1 -1
increases,excretion 1.0 0.000143348623853 1 0 1
severe,obstipation 1.0 0.000143348623853 1 0 1
orally,with 1.0 0.000143348623853 1 0 1
induce,cyp1a2 1.0 0.000286697247706 0 2 -2
monitored,after 1.0 0.000143348623853 1 0 1
group,than 1.0 0.000143348623853 0 1 -1
on,blood 0.5 0.000573394495413 2 6 -4
the,potential 0.232876712329 0.0024369266055 28 45 -17
safety,profiles 1.0 0.000143348623853 0 1 -1
control,inflammation 1.0 0.000143348623853 1 0 1
some,have 1.0 0.00043004587156 3 0 3
an,in 0.555555555556 0.000716743119266 2 7 -5
days,showed 1.0 0.000143348623853 0 1 -1
the,effect 0.220338983051 0.00372706422018 46 72 -26
thus,lower 1.0 0.000143348623853 1 0 1
recording,pipette 1.0 0.000143348623853 0 1 -1
gastrointestinal,adverse 1.0 0.00043004587156 0 3 -3
single,small 1.0 0.000143348623853 0 1 -1
receiving,single 1.0 0.000143348623853 0 1 -1
receptor,antagonists 0.5 0.000286697247706 3 1 2
sympathetic,activity 1.0 0.000286697247706 0 2 -2
phosphohydrolase,from 1.0 0.00043004587156 0 3 -3
fatal,convulsions 1.0 0.000286697247706 2 0 2
chick,by 1.0 0.000143348623853 0 1 -1
or,potentiating 1.0 0.000573394495413 4 0 4
aprepitant,reflects 1.0 0.000143348623853 1 0 1
of,norfloxacin 1.0 0.000143348623853 1 0 1
antibiotics-broad,spectrum 1.0 0.000143348623853 0 1 -1
plasmaconcentrations,may 1.0 0.000286697247706 2 0 2
based,tests 1.0 0.000143348623853 0 1 -1
until,the 0.714285714286 0.000716743119266 1 6 -5
symptoms,i 1.0 0.000143348623853 1 0 1
ed95,nimbex 1.0 0.000143348623853 1 0 1
malignancy,and 1.0 0.000286697247706 0 2 -2
symptoms,p 1.0 0.000143348623853 0 1 -1
it,appears 1.0 0.000143348623853 1 0 1
conditions,to 1.0 0.000286697247706 0 2 -2
rigidity,myoclonus 1.0 0.000143348623853 1 0 1
initiating,combination 1.0 0.000143348623853 1 0 1
in,clozapine 1.0 0.000143348623853 1 0 1
combination,oral 1.0 0.000286697247706 0 2 -2
that,mixing 1.0 0.000143348623853 0 1 -1
a,beta-adrenergic 0.0 0.0 1 1 0
and,aprepitant 1.0 0.000143348623853 1 0 1
patients,who 0.157894736842 0.00129013761468 24 33 -9
cyp2c9,isoenzyme 1.0 0.000143348623853 1 0 1
the,cocaine-treated 1.0 0.000286697247706 0 2 -2
glucose,tolerance 1.0 0.000143348623853 0 1 -1
study,it 1.0 0.000286697247706 0 2 -2
the,brovana 1.0 0.000143348623853 0 1 -1
also,ineffective 1.0 0.000143348623853 0 1 -1
considered,for 0.5 0.000286697247706 1 3 -2
and,ldl-c 1.0 0.000143348623853 0 1 -1
predominantly,by 1.0 0.000143348623853 0 1 -1
ribavirin,see 1.0 0.000143348623853 0 1 -1
study,in 0.0285714285714 0.000143348623853 18 17 1
in,nih-3t3 1.0 0.000143348623853 0 1 -1
in,ecg 1.0 0.000143348623853 0 1 -1
inhibit,cyp2d6 1.0 0.000286697247706 0 2 -2
procedures,when 1.0 0.000143348623853 0 1 -1
cytokines,cytokines 1.0 0.000143348623853 0 1 -1
than,weeks 1.0 0.000143348623853 1 0 1
and,antagonism 1.0 0.000143348623853 1 0 1
hydroxide,with 1.0 0.000143348623853 1 0 1
hyperplasia,observed 1.0 0.000143348623853 0 1 -1
dosed,as 1.0 0.000143348623853 0 1 -1
glyceryl,trinitrate 1.0 0.000143348623853 0 1 -1
thiazide,can 1.0 0.000143348623853 1 0 1
affected,prothrombin 1.0 0.000143348623853 0 1 -1
amplitude,of 1.0 0.000143348623853 0 1 -1
several,dose 1.0 0.000143348623853 0 1 -1
taxol,contains 1.0 0.000143348623853 0 1 -1
luteinizing,hormone 1.0 0.000286697247706 0 2 -2
weight,every 1.0 0.000143348623853 0 1 -1
in,normal 0.0833333333333 0.000286697247706 13 11 2
not,act 1.0 0.000143348623853 0 1 -1
significant,contributors 1.0 0.000143348623853 0 1 -1
tail-flick,and 1.0 0.000143348623853 0 1 -1
more,pharmacologic 1.0 0.000143348623853 0 1 -1
suggest,an 1.0 0.000286697247706 0 2 -2
descarboethoxyloratadine,after 1.0 0.000143348623853 0 1 -1
altered,serum 1.0 0.000143348623853 1 0 1
quantitative,and 1.0 0.000143348623853 0 1 -1
alcohol,or 1.0 0.000286697247706 0 2 -2
ht3,antagonist 1.0 0.000143348623853 1 0 1
l-glutamine,for 1.0 0.000143348623853 1 0 1
do,to 1.0 0.000143348623853 0 1 -1
can,induce 1.0 0.000143348623853 0 1 -1
effective,duration 0.0 0.0 1 1 0
enzymes,were 1.0 0.000143348623853 0 1 -1
tikosyn,and 0.0 0.0 1 1 0
want,to 1.0 0.000286697247706 0 2 -2
at,intramuscular 1.0 0.000143348623853 0 1 -1
not,receiving 1.0 0.00043004587156 3 0 3
cure,and 0.0 0.0 1 1 0
taken,in 0.6 0.000860091743119 2 8 -6
taking,a 0.0 0.0 2 2 0
drugs,that 0.173913043478 0.00114678899083 19 27 -8
to,pms 1.0 0.000143348623853 0 1 -1
as,specific 1.0 0.000143348623853 0 1 -1
for,cyp3a4 1.0 0.00043004587156 0 3 -3
cosmetics,that 1.0 0.000143348623853 0 1 -1
reports,and 1.0 0.000286697247706 0 2 -2
methyldopa,aldomet 1.0 0.000143348623853 1 0 1
substituted,for 1.0 0.000286697247706 0 2 -2
during,periods 1.0 0.000143348623853 1 0 1
interactions,when 0.0 0.0 3 3 0
levosimendan,does 1.0 0.000143348623853 0 1 -1
abrasive,soaps 1.0 0.000143348623853 0 1 -1
l057,was 1.0 0.000143348623853 0 1 -1
fold,than 1.0 0.000143348623853 0 1 -1
antabuse-like,side 1.0 0.000143348623853 1 0 1
dose-dependent,modification 1.0 0.000143348623853 1 0 1
optimal,dosing 1.0 0.000143348623853 0 1 -1
impaired,renal 0.0 0.0 2 2 0
potential,danger 1.0 0.000143348623853 1 0 1
one,treatment 1.0 0.000143348623853 0 1 -1
when,mefloquine 1.0 0.000143348623853 1 0 1
in,gonadotropin 1.0 0.000143348623853 0 1 -1
trileptal,dose 1.0 0.000143348623853 0 1 -1
to,products 1.0 0.000143348623853 1 0 1
emerge,if 1.0 0.000143348623853 1 0 1
preparations,and 1.0 0.00043004587156 0 3 -3
proposed,topical 1.0 0.000143348623853 0 1 -1
atomoxetine,is 1.0 0.000143348623853 0 1 -1
one,week 1.0 0.00043004587156 3 0 3
without,an 1.0 0.000143348623853 1 0 1
care,providers 1.0 0.000143348623853 0 1 -1
another,report 1.0 0.000143348623853 1 0 1
as,urinary 1.0 0.000143348623853 0 1 -1
of,heroin-related 1.0 0.000143348623853 1 0 1
acetaminophen,may 0.0 0.0 1 1 0
oral,may 0.142857142857 0.000143348623853 4 3 1
toxicity,where 1.0 0.000143348623853 0 1 -1
with,folate 1.0 0.000143348623853 1 0 1
tract,infections 1.0 0.000286697247706 0 2 -2
result,i 1.0 0.000143348623853 1 0 1
videx,hours 1.0 0.000143348623853 1 0 1
high-density,lipoprotein 1.0 0.000143348623853 0 1 -1
wshow,an 1.0 0.000143348623853 0 1 -1
anticoagulants,several 1.0 0.000143348623853 0 1 -1
adults,on 0.333333333333 0.000143348623853 1 2 -1
twenty-four,healthy 1.0 0.000143348623853 0 1 -1
this,medication 1.0 0.00043004587156 0 3 -3
with,videx 0.0 0.0 1 1 0
acts,as 1.0 0.000143348623853 1 0 1
as,have 0.333333333333 0.000143348623853 2 1 1
smaller,doses 1.0 0.000143348623853 1 0 1
several-fold,higher 1.0 0.000143348623853 0 1 -1
in,tumor 1.0 0.000143348623853 0 1 -1
specific,drug 1.0 0.000143348623853 0 1 -1
mptp,produced 1.0 0.000143348623853 1 0 1
p-glycoprotein,mediated 1.0 0.000286697247706 0 2 -2
available,for 1.0 0.00043004587156 0 3 -3
acid,precipitation 1.0 0.000143348623853 0 1 -1
the,cpk 1.0 0.000143348623853 0 1 -1
only,observed 0.0 0.0 1 1 0
of,administering 1.0 0.000286697247706 0 2 -2
cause,hypotension 1.0 0.000143348623853 0 1 -1
of,such 0.565217391304 0.00186353211009 5 18 -13
that,strongly 1.0 0.000143348623853 1 0 1
unsatisfactory,lipid 1.0 0.000143348623853 1 0 1
of,amicar 1.0 0.000573394495413 0 4 -4
injection,there 1.0 0.000143348623853 0 1 -1
for,hepatic 1.0 0.000143348623853 0 1 -1
decrease,and 1.0 0.000143348623853 0 1 -1
becoming,more 1.0 0.000143348623853 0 1 -1
dried,and 1.0 0.000143348623853 0 1 -1
min,dose 1.0 0.000143348623853 0 1 -1
lung,has 1.0 0.000143348623853 0 1 -1
high,as 1.0 0.00043004587156 0 3 -3
paper,critically 1.0 0.000143348623853 0 1 -1
a,highly 0.333333333333 0.000143348623853 1 2 -1
stimulants,including 1.0 0.000143348623853 1 0 1
as,formulations 1.0 0.000143348623853 1 0 1
groups,is 1.0 0.000143348623853 0 1 -1
induced,therapeutic 1.0 0.000143348623853 0 1 -1
twelve,strains 1.0 0.000143348623853 1 0 1
allowed,before 1.0 0.000143348623853 1 0 1
other,administered 1.0 0.000143348623853 0 1 -1
by,with 1.0 0.000143348623853 1 0 1
size,mydriasis 1.0 0.000143348623853 1 0 1
chronic,dosing 1.0 0.000143348623853 0 1 -1
agents,did 1.0 0.00043004587156 0 3 -3
safety,of 1.0 0.000716743119266 0 5 -5
of,orencia 1.0 0.000143348623853 1 0 1
severe,symptomatology 1.0 0.000143348623853 0 1 -1
pharmacodynamic,profile 1.0 0.000286697247706 0 2 -2
safety,or 1.0 0.000716743119266 0 5 -5
and,orange 1.0 0.000143348623853 0 1 -1
the,biogen 1.0 0.000143348623853 0 1 -1
concomitantly,patients 1.0 0.000143348623853 1 0 1
careful,patient 0.5 0.000286697247706 1 3 -2
been,case 1.0 0.000143348623853 0 1 -1
fat,digestion 1.0 0.000143348623853 0 1 -1
elicit,their 1.0 0.000143348623853 0 1 -1
europe,nimotop 1.0 0.000143348623853 1 0 1
use,instructions 1.0 0.000143348623853 0 1 -1
a,cascade 1.0 0.000143348623853 0 1 -1
the,cns-depressive 1.0 0.000286697247706 2 0 2
severe,hyperkalemia 1.0 0.000143348623853 1 0 1
needed,careful 1.0 0.000143348623853 0 1 -1
strongly,suggest 1.0 0.000143348623853 0 1 -1
twelve,healthy 1.0 0.000286697247706 0 2 -2
benefits,should 1.0 0.000143348623853 0 1 -1
life-threatening,reactions 1.0 0.00114678899083 0 8 -8
therapeutic,supplement 1.0 0.000143348623853 1 0 1
s,solutions 1.0 0.000286697247706 0 2 -2
when,coumarin 1.0 0.000143348623853 1 0 1
metabolism,studies 1.0 0.000716743119266 0 5 -5
in,amiodarone-treated 1.0 0.000143348623853 0 1 -1
initial,positive 1.0 0.000143348623853 0 1 -1
both,dose 1.0 0.000143348623853 0 1 -1
stomach,irritation 1.0 0.000143348623853 0 1 -1
control,rbc 1.0 0.000143348623853 0 1 -1
agents,causing 1.0 0.000286697247706 2 0 2
genotoxic,compounds--can 1.0 0.000143348623853 0 1 -1
prophylaxis,after 1.0 0.000143348623853 0 1 -1
total,auc 1.0 0.000143348623853 1 0 1
mouse,bone 1.0 0.000143348623853 0 1 -1
on,psychomotor 1.0 0.000143348623853 1 0 1
therapy,is 0.272727272727 0.000860091743119 8 14 -6
nephrotoxicity,may 1.0 0.000286697247706 2 0 2
implantable,contraceptives 1.0 0.000143348623853 1 0 1
which,must 1.0 0.000143348623853 0 1 -1
with,inhibition 1.0 0.000143348623853 1 0 1
being,metabolized 1.0 0.000143348623853 0 1 -1
adjustments,of 0.428571428571 0.00043004587156 2 5 -3
with,intravenous 1.0 0.00043004587156 0 3 -3
ast,when 1.0 0.000143348623853 1 0 1
of,levulan 1.0 0.000143348623853 0 1 -1
warranted,when 0.333333333333 0.000143348623853 1 2 -1
elevated,salivary 1.0 0.000143348623853 0 1 -1
a,false-positive 1.0 0.00229357798165 0 16 -16
prolonged,because 1.0 0.000143348623853 0 1 -1
and,orally 1.0 0.000143348623853 1 0 1
rabbit,gastric 1.0 0.000143348623853 0 1 -1
an,insufficient 1.0 0.000143348623853 0 1 -1
sgot,elevated 1.0 0.000143348623853 0 1 -1
of,andtolbutamide 1.0 0.000143348623853 0 1 -1
for,several 0.6 0.00043004587156 4 1 3
pregnancy,rates 1.0 0.000143348623853 0 1 -1
cause,respiratory 1.0 0.000143348623853 1 0 1
in,rheumatic 1.0 0.000143348623853 1 0 1
responding,for 1.0 0.000143348623853 0 1 -1
mean,renal 1.0 0.000143348623853 1 0 1
to,about 0.0 0.0 1 1 0
atp,oxaloacetate 1.0 0.000143348623853 0 1 -1
reverse,transcriptase 0.5 0.000286697247706 1 3 -2
have,potentially 1.0 0.000143348623853 0 1 -1
epidermal,necrolysis 1.0 0.000143348623853 0 1 -1
to,emerge 1.0 0.000143348623853 1 0 1
subtypes,in 1.0 0.000286697247706 0 2 -2
the,relationship 0.333333333333 0.000143348623853 1 2 -1
resists,dissolution 1.0 0.000143348623853 0 1 -1
sum,of 1.0 0.000143348623853 0 1 -1
absorbed,while 1.0 0.000143348623853 0 1 -1
preconstricted,with 1.0 0.000143348623853 0 1 -1
glycoprotein,iib 1.0 0.000143348623853 1 0 1
clastogenic,in 1.0 0.000143348623853 0 1 -1
cases,presented 1.0 0.000143348623853 0 1 -1
oral,were 0.333333333333 0.000143348623853 2 1 1
thyroglobulin,in 1.0 0.000143348623853 0 1 -1
seizure,threshold 1.0 0.000143348623853 1 0 1
ellence,and 1.0 0.000143348623853 0 1 -1
methods,toxi-lab 1.0 0.000143348623853 0 1 -1
allograft,recipients 1.0 0.000143348623853 0 1 -1
drugs,other 1.0 0.000143348623853 0 1 -1
mc,does 1.0 0.000286697247706 0 2 -2
leukemia,in 1.0 0.000143348623853 1 0 1
measures,to 1.0 0.000143348623853 0 1 -1
binds,a 1.0 0.000143348623853 0 1 -1
wish,to 1.0 0.000143348623853 1 0 1
or,pediatric 1.0 0.000286697247706 2 0 2
male,wistar 1.0 0.000286697247706 0 2 -2
doses,because 1.0 0.000143348623853 1 0 1
pediatric,and 1.0 0.000143348623853 0 1 -1
offspring,delivered 1.0 0.000143348623853 0 1 -1
temperatures,on 1.0 0.000143348623853 0 1 -1
of,should 0.217391304348 0.000716743119266 9 14 -5
likewise,further 1.0 0.000143348623853 0 1 -1
theoretically,l-arginine 1.0 0.000143348623853 1 0 1
ml,may 1.0 0.000143348623853 0 1 -1
no,clear 1.0 0.000143348623853 0 1 -1
during,the 0.411764705882 0.00200688073394 10 24 -14
platelets,recover 1.0 0.000143348623853 0 1 -1
on,cyp 1.0 0.000143348623853 0 1 -1
morphine,analgesia 1.0 0.000143348623853 0 1 -1
dehydration,secondary 1.0 0.000143348623853 1 0 1
da,sh 1.0 0.000143348623853 0 1 -1
daily,administration 1.0 0.000286697247706 0 2 -2
patients,met 1.0 0.000143348623853 0 1 -1
against,this 1.0 0.000143348623853 0 1 -1
nitrogen,mustard 1.0 0.000143348623853 0 1 -1
pentamidine,treatment 1.0 0.000143348623853 0 1 -1
treatment,i 1.0 0.000143348623853 0 1 -1
is,too 1.0 0.000143348623853 0 1 -1
amylase,an 1.0 0.000143348623853 0 1 -1
a,frequent 0.0 0.0 1 1 0
in,cardiac 1.0 0.000143348623853 1 0 1
or,t4 1.0 0.000286697247706 0 2 -2
crixivan,to 0.5 0.000286697247706 3 1 2
concomitantly,without 1.0 0.000143348623853 0 1 -1
it,is 0.231707317073 0.00544724770642 63 101 -38
the,hematopoietic 1.0 0.000143348623853 0 1 -1
l-phenylalanine,and 1.0 0.000286697247706 2 0 2
sporanox,nizoral 1.0 0.000143348623853 0 1 -1
nephrotoxicity,and 0.666666666667 0.000573394495413 1 5 -4
increasing,overall 1.0 0.000143348623853 0 1 -1
on,excystment 1.0 0.000286697247706 0 2 -2
to,do 1.0 0.000143348623853 0 1 -1
salicylates-salicylates,in 1.0 0.000143348623853 0 1 -1
either,had 1.0 0.000143348623853 1 0 1
lamivudine,and 1.0 0.000143348623853 1 0 1
for,topical 1.0 0.000143348623853 0 1 -1
totally,known 1.0 0.000143348623853 1 0 1
two,differ 1.0 0.000143348623853 0 1 -1
hypothyroidism,in 1.0 0.000143348623853 0 1 -1
agonist,but 1.0 0.000143348623853 1 0 1
significantly,fewer 1.0 0.000143348623853 0 1 -1
specific,neurobiological 1.0 0.000143348623853 0 1 -1
hydrochlorothiazide,a 1.0 0.000143348623853 0 1 -1
sympathetic,reflex 1.0 0.000143348623853 0 1 -1
simultaneously,with 0.333333333333 0.000143348623853 2 1 1
erythema,tenderness 1.0 0.000143348623853 0 1 -1
received,rantidine 1.0 0.000143348623853 0 1 -1
theoretically,occur 1.0 0.000143348623853 0 1 -1
may,raise 0.0 0.0 2 2 0
studies,it 1.0 0.00043004587156 0 3 -3
other,antiepilepsy 0.0 0.0 1 1 0
cardiac,effects 1.0 0.000143348623853 1 0 1
preparations,incubated 1.0 0.000143348623853 0 1 -1
isuprel,should 1.0 0.000143348623853 1 0 1
viral,loads 1.0 0.000143348623853 0 1 -1
as,appropriate 1.0 0.000143348623853 0 1 -1
induces,or 1.0 0.000286697247706 0 2 -2
oxypurines,hypoxanthine 1.0 0.000143348623853 1 0 1
placebo-controlled,clinical 1.0 0.000143348623853 0 1 -1
release,formulation 1.0 0.000143348623853 0 1 -1
serum,levels 0.125 0.00114678899083 36 28 8
of,dosage 0.8 0.00114678899083 1 9 -8
three-fold,compared 1.0 0.000143348623853 0 1 -1
the,case-control 1.0 0.000143348623853 1 0 1
administration,should 0.0 0.0 1 1 0
by,cgs 1.0 0.000143348623853 1 0 1
fortified,with 0.0 0.0 1 1 0
summarized,in 1.0 0.00043004587156 0 3 -3
muscle,relaxants 0.0588235294118 0.000143348623853 8 9 -1
required,medical 1.0 0.000143348623853 0 1 -1
and,hydroxide 0.0 0.0 1 1 0
some,resulting 1.0 0.00043004587156 3 0 3
pathways,on 1.0 0.000143348623853 0 1 -1
n,maintained 1.0 0.000143348623853 0 1 -1
concurent,therapy 1.0 0.000143348623853 1 0 1
model,peptide 1.0 0.000143348623853 0 1 -1
the,tmax 1.0 0.000143348623853 1 0 1
oral,hormonal 1.0 0.000143348623853 1 0 1
leukopenia,especially 1.0 0.000143348623853 0 1 -1
significant,decreases 1.0 0.000286697247706 2 0 2
lithium,generally 1.0 0.000716743119266 5 0 5
type,it 1.0 0.000143348623853 1 0 1
purinethol,or 1.0 0.000143348623853 1 0 1
im,approximately 1.0 0.000143348623853 0 1 -1
very,strong 1.0 0.000143348623853 1 0 1
and,electrolyte 0.0 0.0 1 1 0
aripiprazole,is 1.0 0.000286697247706 0 2 -2
or,lead 1.0 0.000143348623853 1 0 1
however,was 1.0 0.000143348623853 0 1 -1
single,compound 1.0 0.000143348623853 0 1 -1
epididymides,had 1.0 0.000143348623853 0 1 -1
on,male 1.0 0.000286697247706 0 2 -2
camptosar,would 1.0 0.000143348623853 1 0 1
received,increases 1.0 0.000143348623853 1 0 1
vasodilator,activity 0.0 0.0 1 1 0
elevated,liver 0.0 0.0 1 1 0
was,given 0.333333333333 0.000860091743119 6 12 -6
starting,treatment 1.0 0.000143348623853 0 1 -1
potency,of 1.0 0.000143348623853 0 1 -1
administered,a 0.333333333333 0.000143348623853 2 1 1
deficit,and 1.0 0.000143348623853 0 1 -1
desmopressin,is 1.0 0.000143348623853 0 1 -1
directed,by 1.0 0.000143348623853 0 1 -1
hereditary,antithrombin 1.0 0.000143348623853 1 0 1
information,regarding 1.0 0.000143348623853 0 1 -1
the,findings 1.0 0.000286697247706 0 2 -2
human,recommended 1.0 0.000286697247706 0 2 -2
years,who 1.0 0.000143348623853 1 0 1
a,presynaptic 1.0 0.000143348623853 0 1 -1
vitro,however 1.0 0.000143348623853 0 1 -1
sheep,interactions 1.0 0.000143348623853 0 1 -1
mc,decrease 1.0 0.000143348623853 0 1 -1
other,for 1.0 0.000143348623853 0 1 -1
normal,or 1.0 0.000143348623853 0 1 -1
be,catalyzed 1.0 0.000143348623853 0 1 -1
of,mixed-function 1.0 0.000143348623853 0 1 -1
preventing,erythro-fluorocitrate 1.0 0.000143348623853 0 1 -1
general,interactions 1.0 0.000143348623853 0 1 -1
exogenous,on 1.0 0.000143348623853 0 1 -1
on,therapy 1.0 0.000573394495413 4 0 4
efficacy,physicians 1.0 0.000143348623853 0 1 -1
tricyclic,in 1.0 0.000143348623853 1 0 1
by,enhanced 1.0 0.000143348623853 0 1 -1
disulfiram,to 1.0 0.000143348623853 1 0 1
already,receiving 0.0 0.0 2 2 0
no,effects 1.0 0.000716743119266 0 5 -5
concurrent,with 1.0 0.000286697247706 2 0 2
advisable,until 1.0 0.000286697247706 0 2 -2
optimal,therapeutic 1.0 0.000143348623853 0 1 -1
however,up 1.0 0.000143348623853 0 1 -1
properties,of 0.555555555556 0.000716743119266 2 7 -5
co-administered,with 0.0857142857143 0.00043004587156 19 16 3
dose,achieves 1.0 0.000143348623853 0 1 -1
properties,on 1.0 0.000143348623853 0 1 -1
or,life-threatening 0.777777777778 0.00100344036697 1 8 -7
theophylline,clearance 1.0 0.000143348623853 0 1 -1
exaggerated,leukopenia 1.0 0.000143348623853 0 1 -1
chloride-induced,gastrointestinal 1.0 0.000143348623853 1 0 1
from,muscle 1.0 0.000143348623853 0 1 -1
increased,norepinephrine-induced 1.0 0.000286697247706 0 2 -2
studies,nitrates 1.0 0.000143348623853 1 0 1
that,reportedly 1.0 0.000286697247706 2 0 2
the,mechanisms 1.0 0.00043004587156 0 3 -3
studies,is 1.0 0.000143348623853 0 1 -1
citrate,elevations 1.0 0.000143348623853 1 0 1
topoisomerases,in 1.0 0.000143348623853 0 1 -1
in,saline 1.0 0.000143348623853 0 1 -1
clinistix,and 1.0 0.000143348623853 0 1 -1
a,sprycel 1.0 0.000143348623853 0 1 -1
and,alkaline 1.0 0.000143348623853 0 1 -1
positive,test 1.0 0.000573394495413 0 4 -4
studies,ie 1.0 0.000143348623853 0 1 -1
has,specifically 1.0 0.000143348623853 0 1 -1
topoisomerases,is 1.0 0.000143348623853 0 1 -1
concentration,accompanied 1.0 0.000143348623853 1 0 1
is,manifested 1.0 0.000143348623853 0 1 -1
studies,in 0.512195121951 0.00301032110092 10 31 -21
h2,antagonist 1.0 0.000143348623853 0 1 -1
in,place 1.0 0.000143348623853 1 0 1
frequent,prothrombin 1.0 0.000286697247706 0 2 -2
the,iv 1.0 0.000143348623853 1 0 1
hypotension,which 1.0 0.000143348623853 1 0 1
with,metabolized 1.0 0.000286697247706 0 2 -2
contraceptives,coadministration 1.0 0.000143348623853 1 0 1
whether,ginsenosides-induced 1.0 0.000143348623853 0 1 -1
administered,h 1.0 0.000143348623853 0 1 -1
and,remnant 1.0 0.000143348623853 0 1 -1
close,to 1.0 0.000143348623853 0 1 -1
serotonergic,agents 0.333333333333 0.000143348623853 2 1 1
the,pharmacokinetits 1.0 0.000143348623853 0 1 -1
testing,was 1.0 0.000143348623853 0 1 -1
given,on 1.0 0.000143348623853 1 0 1
were,pharmacokinetic 1.0 0.000143348623853 0 1 -1
of,children 1.0 0.000143348623853 0 1 -1
same,time 0.333333333333 0.000143348623853 1 2 -1
hypercholesterolemic,patients 1.0 0.000143348623853 1 0 1
repeat,treatment 1.0 0.000143348623853 0 1 -1
humans,two 1.0 0.000143348623853 0 1 -1
mating,caused 1.0 0.000143348623853 0 1 -1
the,molecule 1.0 0.00043004587156 3 0 3
of,usually 1.0 0.000143348623853 1 0 1
cecectomized,than 1.0 0.000286697247706 0 2 -2
in,creatinine 1.0 0.000143348623853 1 0 1
of,tubular 0.0 0.0 2 2 0
oral,mg 0.5 0.000286697247706 1 3 -2
but,an 1.0 0.00043004587156 0 3 -3
the,reversal 1.0 0.000143348623853 1 0 1
counter,medicines 1.0 0.000143348623853 0 1 -1
nephrotoxic,agents 1.0 0.000286697247706 2 0 2
antiparkinsonian,drug 1.0 0.000143348623853 1 0 1
experienced,acute 1.0 0.000143348623853 1 0 1
several,short-term 1.0 0.000143348623853 0 1 -1
with,cholesterol 1.0 0.000143348623853 0 1 -1
pharmacology,pharmacokinetics 1.0 0.00043004587156 0 3 -3
received,an 1.0 0.000286697247706 0 2 -2
drugs,increased 1.0 0.000143348623853 0 1 -1
balance,technique 1.0 0.000143348623853 0 1 -1
include,some 1.0 0.000716743119266 0 5 -5
received,as 1.0 0.000143348623853 0 1 -1
in,circulating 1.0 0.000143348623853 0 1 -1
inducible,vana 1.0 0.000143348623853 0 1 -1
acetaminophen,tylenol 1.0 0.000143348623853 1 0 1
be,reliable 1.0 0.000143348623853 1 0 1
measures,of 1.0 0.000143348623853 0 1 -1
omnicef,for 1.0 0.000143348623853 0 1 -1
delay,in 0.333333333333 0.000143348623853 2 1 1
dysfunction,and 1.0 0.000143348623853 0 1 -1
of,tbars 1.0 0.000143348623853 1 0 1
pra,induced 1.0 0.000143348623853 0 1 -1
standard,deviation 1.0 0.000143348623853 1 0 1
and,reduces 1.0 0.000286697247706 2 0 2
acetylsalicylic,acid 0.454545454545 0.000716743119266 3 8 -5
treatment,potentiated 1.0 0.000143348623853 1 0 1
assay,and 1.0 0.00043004587156 0 3 -3
before,injection 1.0 0.000143348623853 0 1 -1
and,reduced 0.333333333333 0.000143348623853 1 2 -1
but,cases 1.0 0.000143348623853 1 0 1
of,reports 1.0 0.000286697247706 2 0 2
rat,kidney 1.0 0.000143348623853 0 1 -1
other,coadministered 0.333333333333 0.000143348623853 1 2 -1
with,kemstrotm 1.0 0.000143348623853 0 1 -1
tremors,and 1.0 0.000143348623853 0 1 -1
microsomal,drug 1.0 0.000143348623853 1 0 1
obtained,under 1.0 0.000286697247706 0 2 -2
administered,in 0.176470588235 0.00043004587156 7 10 -3
bleedings,have 1.0 0.000143348623853 0 1 -1
increase,slightly 1.0 0.000143348623853 1 0 1
was,unaltered 1.0 0.000143348623853 0 1 -1
membrane,phospholipids 1.0 0.000143348623853 0 1 -1
cmax,a 1.0 0.000573394495413 4 0 4
products,associated 1.0 0.000143348623853 0 1 -1
or,operating 1.0 0.000143348623853 0 1 -1
receiving,preparations 1.0 0.000286697247706 0 2 -2
experiment,rats 1.0 0.000143348623853 0 1 -1
oral,users 1.0 0.000143348623853 0 1 -1
double,the 1.0 0.000143348623853 1 0 1
relieve,acute 1.0 0.000143348623853 0 1 -1
qd,days 0.0 0.0 1 1 0
other,concurrent 1.0 0.000286697247706 2 0 2
diphenoxylate,hcl 1.0 0.000143348623853 1 0 1
poorly,tolerated 1.0 0.000143348623853 1 0 1
results,generated 1.0 0.000143348623853 0 1 -1
induce,a4 1.0 0.000143348623853 0 1 -1
oral,phenytoin 1.0 0.000143348623853 1 0 1
clozapine,caution 1.0 0.000143348623853 1 0 1
valdecoxib,mg 0.333333333333 0.000143348623853 1 2 -1
potential,make 1.0 0.000143348623853 0 1 -1
levels,when 1.0 0.000286697247706 0 2 -2
or,interaction 1.0 0.000143348623853 0 1 -1
bromide,is 1.0 0.000143348623853 1 0 1
ratio,inr 0.0 0.0 1 1 0
media,was 1.0 0.000286697247706 0 2 -2
structurally,related 1.0 0.000143348623853 1 0 1
maximal,hypotension 1.0 0.000143348623853 0 1 -1
was,sacrificed 1.0 0.000143348623853 0 1 -1
gemfibrozil,other 1.0 0.000143348623853 0 1 -1
in,iop 1.0 0.000143348623853 0 1 -1
rifabutin,coadministration 1.0 0.000143348623853 1 0 1
on,target 1.0 0.000143348623853 0 1 -1
properties,that 1.0 0.000286697247706 2 0 2
spray,the 1.0 0.000143348623853 1 0 1
perivascular,hemorrhages 1.0 0.000143348623853 0 1 -1
in,transferring 1.0 0.000143348623853 0 1 -1
anti-inflammatory,agents 0.777777777778 0.00100344036697 8 1 7
function,eg 1.0 0.000143348623853 1 0 1
that,concurrent 1.0 0.000286697247706 2 0 2
metabolizers,suggesting 1.0 0.000143348623853 1 0 1
long-term,consequences 1.0 0.000143348623853 0 1 -1
distinguishes,it 1.0 0.000143348623853 0 1 -1
containing,maalox 1.0 0.000143348623853 1 0 1
that,indocin 1.0 0.000143348623853 0 1 -1
degeneration,wallerian 1.0 0.000143348623853 0 1 -1
dose,adjustments 0.666666666667 0.000573394495413 1 5 -4
suggesting,no 1.0 0.000143348623853 0 1 -1
regimen,particularly 1.0 0.000143348623853 1 0 1
twofold,increase 1.0 0.000286697247706 2 0 2
frequent,laboratory 1.0 0.000143348623853 0 1 -1
vitamin,d2 1.0 0.00043004587156 3 0 3
vitamin,d3 1.0 0.000573394495413 4 0 4
minimized,by 1.0 0.000716743119266 5 0 5
most,patients 1.0 0.000143348623853 0 1 -1
in,dentistry 1.0 0.000143348623853 0 1 -1
extravasation,were 1.0 0.000143348623853 0 1 -1
l-arginine,supplements 1.0 0.000286697247706 2 0 2
that,topoisomerase 1.0 0.000143348623853 0 1 -1
in,previously 1.0 0.000143348623853 1 0 1
cmc-cys7,a 1.0 0.000143348623853 0 1 -1
united,kingdom 1.0 0.000143348623853 1 0 1
schizophrenia,in 1.0 0.000143348623853 0 1 -1
including,gastrointestinal 1.0 0.000143348623853 0 1 -1
cause,heart 1.0 0.000143348623853 1 0 1
angiotensinogen,renin 1.0 0.000286697247706 0 2 -2
no,complications 1.0 0.000143348623853 0 1 -1
be,well 0.0 0.0 1 1 0
inhibits,cyp3a4 0.6 0.00043004587156 1 4 -3
endotoxin-treated,rats 0.0 0.0 1 1 0
in,strains 1.0 0.000143348623853 0 1 -1
a,precipitous 1.0 0.000143348623853 1 0 1
to,experience 1.0 0.000143348623853 0 1 -1
even,more 1.0 0.000143348623853 1 0 1
methods,should 1.0 0.000143348623853 0 1 -1
chains,of 1.0 0.000143348623853 0 1 -1
without,clinical 1.0 0.000143348623853 1 0 1
or,vaginal 1.0 0.00043004587156 0 3 -3
overallactivity,against 1.0 0.000143348623853 0 1 -1
decreased,concentrations 1.0 0.000143348623853 1 0 1
risks,maximize 1.0 0.000143348623853 0 1 -1
capsule,twice 1.0 0.000143348623853 0 1 -1
represent,the 1.0 0.000143348623853 0 1 -1
during,controlled 1.0 0.000143348623853 1 0 1
continued,serum 1.0 0.000143348623853 0 1 -1
of,chylomicron-like 1.0 0.000143348623853 0 1 -1
drugs,drugs 1.0 0.000286697247706 0 2 -2
recall,reaction 1.0 0.000143348623853 0 1 -1
to,campath 1.0 0.000143348623853 0 1 -1
fertility,to 1.0 0.000143348623853 0 1 -1
cardiological,and 1.0 0.000143348623853 0 1 -1
hours,were 1.0 0.000143348623853 1 0 1
acidity,does 1.0 0.000143348623853 0 1 -1
physician,wishing 1.0 0.000143348623853 0 1 -1
concentrations,mics 1.0 0.000143348623853 0 1 -1
when,bactericidal 1.0 0.000143348623853 0 1 -1
cns,lesions 1.0 0.000143348623853 0 1 -1
loop,such 1.0 0.000143348623853 1 0 1
urinary,thioether 1.0 0.000143348623853 0 1 -1
should,focus 1.0 0.000143348623853 0 1 -1
relevant,changes 1.0 0.00100344036697 0 7 -7
we,call 1.0 0.000143348623853 0 1 -1
natriuresis,and 1.0 0.000143348623853 1 0 1
has,suggested 1.0 0.000143348623853 0 1 -1
when,at 1.0 0.000286697247706 2 0 2
retinyl,acetate 1.0 0.000860091743119 6 0 6
made,immediately 1.0 0.000143348623853 0 1 -1
and,healthy 1.0 0.000143348623853 0 1 -1
anti-inflammatory,activity 1.0 0.000286697247706 2 0 2
for,use 0.0 0.0 3 3 0
when,an 0.5 0.000286697247706 3 1 2
changes,occurred 1.0 0.000143348623853 0 1 -1
and,include 1.0 0.000143348623853 0 1 -1
pulmonary,symptomatology 1.0 0.000143348623853 1 0 1
disulfiram-ethanol,reaction 1.0 0.000143348623853 0 1 -1
minutes,to 1.0 0.000143348623853 0 1 -1
mec,values 1.0 0.000143348623853 0 1 -1
the,cardiovascular 0.333333333333 0.000286697247706 4 2 2
medical,complications 1.0 0.000143348623853 0 1 -1
attenuates,loss 1.0 0.000143348623853 1 0 1
lodine,should 1.0 0.000143348623853 0 1 -1
concomitant,on 1.0 0.000143348623853 0 1 -1
ethinyl,estradiol 0.0526315789474 0.000143348623853 10 9 1
seem,to 0.333333333333 0.000143348623853 1 2 -1
exposed,to 0.6 0.00043004587156 1 4 -3
concomitant,or 0.0 0.0 1 1 0
all,are 1.0 0.000143348623853 0 1 -1
and,strong 1.0 0.000143348623853 1 0 1
to,take 1.0 0.000286697247706 2 0 2
concerning,have 1.0 0.000143348623853 1 0 1
any,mechanism 1.0 0.000143348623853 0 1 -1
blocker,and 1.0 0.000143348623853 1 0 1
time,in 0.333333333333 0.000286697247706 4 2 2
time,it 1.0 0.000143348623853 0 1 -1
more,severe 1.0 0.000716743119266 0 5 -5
equivalent,volume 1.0 0.000143348623853 0 1 -1
time,is 1.0 0.00043004587156 3 0 3
because,does 1.0 0.000143348623853 0 1 -1
a,shift 1.0 0.000143348623853 0 1 -1
c12hr,by 1.0 0.000143348623853 1 0 1
remainder,no 1.0 0.000143348623853 0 1 -1
the,advantages 1.0 0.000143348623853 0 1 -1
practices,for 1.0 0.000143348623853 0 1 -1
methods,gdh 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,have 1.0 0.000286697247706 0 2 -2
subjects,nor 1.0 0.000143348623853 0 1 -1
is,highly 0.818181818182 0.00129013761468 1 10 -9
therefore,exposure 1.0 0.000143348623853 0 1 -1
solutions,until 1.0 0.000143348623853 0 1 -1
respectto,safety 1.0 0.000143348623853 0 1 -1
activity,preclinical 1.0 0.000143348623853 0 1 -1
had,intoxication 1.0 0.000143348623853 0 1 -1
still,kill 1.0 0.000143348623853 1 0 1
metabolites,is 1.0 0.000286697247706 0 2 -2
studies,to 1.0 0.00100344036697 0 7 -7
metabolites,in 1.0 0.000286697247706 0 2 -2
render,these 1.0 0.000143348623853 1 0 1
modest,inhibition 1.0 0.000143348623853 0 1 -1
experiences,of 1.0 0.000143348623853 1 0 1
serotoninergic,agents 1.0 0.000143348623853 1 0 1
of,busulfex 1.0 0.000143348623853 1 0 1
screen,compounds 1.0 0.000143348623853 0 1 -1
findings,should 1.0 0.000143348623853 0 1 -1
which,were 0.333333333333 0.000143348623853 1 2 -1
enzymes,showed 1.0 0.000143348623853 0 1 -1
abolished,as 1.0 0.000143348623853 1 0 1
at,increased 0.2 0.000143348623853 2 3 -1
ergot-containing,drugs 1.0 0.000143348623853 0 1 -1
of,reddish 1.0 0.000143348623853 0 1 -1
administered,agents 0.0 0.0 1 1 0
pcp,induced 1.0 0.000143348623853 0 1 -1
in,ventricular 1.0 0.000143348623853 0 1 -1
by,several 1.0 0.000143348623853 1 0 1
meclofenamate,sodium 0.2 0.000143348623853 3 2 1
taken,together 1.0 0.000286697247706 0 2 -2
preparations,have 1.0 0.000143348623853 0 1 -1
be,active 1.0 0.000143348623853 1 0 1
hc1,concomitant 1.0 0.000143348623853 1 0 1
since,the 0.111111111111 0.000286697247706 8 10 -2
to,that 0.555555555556 0.000716743119266 2 7 -5
diagnostic,or 1.0 0.000286697247706 0 2 -2
agonists,in 1.0 0.000143348623853 1 0 1
either,dosage 1.0 0.000143348623853 0 1 -1
enzyme,a4 1.0 0.000143348623853 0 1 -1
at,approximately 0.333333333333 0.000143348623853 1 2 -1
chromatin,and 0.0 0.0 1 1 0
degree,in 1.0 0.000286697247706 0 2 -2
of,gemzar 1.0 0.000143348623853 0 1 -1
on,furosemide-stimulated 1.0 0.000143348623853 0 1 -1
nicotinic,acid 0.75 0.000860091743119 1 7 -6
and,commentaries 1.0 0.000143348623853 0 1 -1
elderly,population 1.0 0.000143348623853 0 1 -1
with,with 0.0 0.0 2 2 0
pronounced,than 1.0 0.000143348623853 0 1 -1
syndrome,characterized 1.0 0.000143348623853 1 0 1
b,has 1.0 0.000143348623853 1 0 1
indomethacin,blunts 1.0 0.000143348623853 1 0 1
until,therapy 1.0 0.000143348623853 1 0 1
monitor,plasma 1.0 0.000143348623853 0 1 -1
absorption,and 0.333333333333 0.000286697247706 4 2 2
pyrantel,antiminth 1.0 0.000143348623853 1 0 1
investigated,against 1.0 0.000143348623853 0 1 -1
vardenafil,experienced 1.0 0.000143348623853 1 0 1
mesylate,was 1.0 0.000143348623853 1 0 1
that,such 1.0 0.000143348623853 0 1 -1
itself,could 1.0 0.000143348623853 0 1 -1
interaction,include 1.0 0.000286697247706 0 2 -2
is,greater 1.0 0.00043004587156 3 0 3
current,responses 1.0 0.000143348623853 1 0 1
bile-acidsequestering,agent 1.0 0.000143348623853 0 1 -1
and,prolongation 1.0 0.000716743119266 5 0 5
expected,when 1.0 0.000143348623853 1 0 1
including,and 0.0 0.0 4 4 0
by,nor 1.0 0.000143348623853 0 1 -1
gel,on 1.0 0.000143348623853 0 1 -1
index,apoptotic 1.0 0.000143348623853 0 1 -1
medicines,with 0.0 0.0 1 1 0
have,used 1.0 0.000286697247706 0 2 -2
paralytic,ileus 1.0 0.000143348623853 1 0 1
furthermore,caution 1.0 0.000143348623853 0 1 -1
both,agents 0.636363636364 0.00100344036697 2 9 -7
change,the 0.5 0.000573394495413 2 6 -4
tonevirapine,caution 1.0 0.000143348623853 0 1 -1
clearance,and 0.777777777778 0.00200688073394 16 2 14
fibrillation,when 1.0 0.000143348623853 1 0 1
supraspinal,brain 1.0 0.000143348623853 0 1 -1
disintegrating,tablet 1.0 0.000143348623853 1 0 1
less,marked 1.0 0.000286697247706 0 2 -2
tricyclic,have 1.0 0.000286697247706 2 0 2
permit,reductions 1.0 0.000143348623853 0 1 -1
g,resulted 1.0 0.000143348623853 1 0 1
two,metabolites 1.0 0.000143348623853 0 1 -1
oleate,in 1.0 0.000143348623853 0 1 -1
before,carrying 1.0 0.000286697247706 0 2 -2
nerve,damage 1.0 0.000143348623853 0 1 -1
inhibit,this 0.0 0.0 2 2 0
is,via 1.0 0.000143348623853 0 1 -1
to,bruising 1.0 0.000143348623853 0 1 -1
a,non-significantly 1.0 0.000143348623853 0 1 -1
through,competition 1.0 0.000286697247706 0 2 -2
pregnancy,registry 1.0 0.000143348623853 0 1 -1
euthyroid,state 1.0 0.000143348623853 0 1 -1
severe,hypotension 1.0 0.00043004587156 3 0 3
discrete,responses 1.0 0.000143348623853 0 1 -1
dose-dependent,inhibition 1.0 0.000143348623853 1 0 1
in,its 1.0 0.000286697247706 0 2 -2
when,was 0.375 0.00172018348624 22 10 12
make,normal 1.0 0.00100344036697 0 7 -7
dehydrogenase,inhibition 1.0 0.000143348623853 1 0 1
death,associated 1.0 0.000143348623853 1 0 1
diamond,trials 1.0 0.000286697247706 0 2 -2
nicotine,may 1.0 0.000143348623853 1 0 1
and,watery 1.0 0.000143348623853 0 1 -1
reported,laboratory 1.0 0.000143348623853 0 1 -1
cardiovascular,directly 1.0 0.000143348623853 0 1 -1
severe,neutropenia 1.0 0.000143348623853 0 1 -1
may,change 0.5 0.000286697247706 1 3 -2
anticholinesterase,treatment 1.0 0.000143348623853 0 1 -1
with,triamterene 1.0 0.000143348623853 0 1 -1
cysts,had 1.0 0.000143348623853 0 1 -1
mg,doses 1.0 0.000143348623853 1 0 1
aprepitant,and 0.0 0.0 1 1 0
the,primary 0.0909090909091 0.000143348623853 5 6 -1
flolan,was 1.0 0.000143348623853 1 0 1
onto,the 1.0 0.000143348623853 1 0 1
all,been 1.0 0.000143348623853 0 1 -1
indocin,should 1.0 0.000143348623853 1 0 1
a,true 0.0 0.0 1 1 0
amphetamines,inhibit 1.0 0.000286697247706 2 0 2
solution,or 1.0 0.00114678899083 0 8 -8
an,aed 1.0 0.000143348623853 0 1 -1
psychoactive,medications 1.0 0.000143348623853 1 0 1
neither,nor 0.0 0.0 2 2 0
on,metabolic 1.0 0.000286697247706 0 2 -2
or,hypo-thyroxine 1.0 0.000143348623853 0 1 -1
serious,arrhythmias 1.0 0.000143348623853 0 1 -1
phenytoin,dilantin 1.0 0.000143348623853 1 0 1
only,minor 1.0 0.000143348623853 1 0 1
a4,would 1.0 0.000143348623853 1 0 1
solution,of 1.0 0.000143348623853 0 1 -1
inhibitors,may 0.0 0.0 4 4 0
hours,should 0.2 0.000143348623853 3 2 1
bradycardia,has 1.0 0.000143348623853 0 1 -1
of,aed 1.0 0.00043004587156 0 3 -3
cyp3a4,pathway 1.0 0.000143348623853 1 0 1
to,consult 1.0 0.000286697247706 0 2 -2
could,be 0.428571428571 0.000860091743119 4 10 -6
deltasone,orasone 1.0 0.000143348623853 0 1 -1
available,about 1.0 0.000286697247706 0 2 -2
its,absorption 1.0 0.000143348623853 1 0 1
treat,the 1.0 0.000143348623853 0 1 -1
similarly,inhibit 1.0 0.000143348623853 1 0 1
induction,thus 1.0 0.000143348623853 1 0 1
similarity,of 1.0 0.000143348623853 0 1 -1
density,in 1.0 0.000143348623853 0 1 -1
products,h2-antagonists 1.0 0.000143348623853 0 1 -1
of,ganoderma 1.0 0.000286697247706 0 2 -2
simultaneously,or 0.0 0.0 1 1 0
n-multistix,sg 1.0 0.000143348623853 0 1 -1
and,observation 1.0 0.000143348623853 0 1 -1
depressants,may 0.0 0.0 4 4 0
positive,level 1.0 0.000143348623853 1 0 1
vasodilation,is 1.0 0.000143348623853 0 1 -1
d,were 1.0 0.000143348623853 1 0 1
been,demonstrated 0.0 0.0 5 5 0
surgery,or 1.0 0.000143348623853 0 1 -1
serum,enzyme 1.0 0.000143348623853 0 1 -1
were,above 1.0 0.000143348623853 1 0 1
defined,medium 1.0 0.000143348623853 0 1 -1
hormonal,may 0.8 0.00114678899083 9 1 8
by,nonsteroidal 1.0 0.000143348623853 1 0 1
as,they 0.0 0.0 3 3 0
could,create 1.0 0.00043004587156 0 3 -3
metoclopramide,when 1.0 0.000143348623853 1 0 1
the,interval 1.0 0.000143348623853 0 1 -1
monoamine,oxidases 1.0 0.000143348623853 0 1 -1
racemic,were 1.0 0.000143348623853 0 1 -1
not,readily 1.0 0.000143348623853 0 1 -1
shorter,durations 0.0 0.0 1 1 0
and,efficacy 0.375 0.000860091743119 5 11 -6
of,upper 0.6 0.00043004587156 1 4 -3
inducers,can 1.0 0.000143348623853 1 0 1
and,thereby 1.0 0.000143348623853 1 0 1
of,felbatol 0.0 0.0 4 4 0
to,dosing 0.6 0.00043004587156 4 1 3
conducted,between 1.0 0.000143348623853 1 0 1
interactions,benzodiazepines 1.0 0.000143348623853 1 0 1
combination,outweigh 1.0 0.000143348623853 1 0 1
above,ng 1.0 0.000143348623853 1 0 1
a,potentiation 1.0 0.000143348623853 1 0 1
this,mechanism 1.0 0.000143348623853 1 0 1
over,minutes 1.0 0.000143348623853 0 1 -1
use,should 1.0 0.00043004587156 0 3 -3
increases,plasma 1.0 0.000143348623853 0 1 -1
fo,the 1.0 0.000143348623853 0 1 -1
and,pruritus 1.0 0.000143348623853 0 1 -1
solutions,with 1.0 0.000143348623853 0 1 -1
median,of 1.0 0.000143348623853 1 0 1
with,in 0.1 0.000286697247706 9 11 -2
duloxetine,clinical 1.0 0.000143348623853 0 1 -1
adjustment,required 1.0 0.000143348623853 1 0 1
with,if 1.0 0.000143348623853 1 0 1
certain,malignancies 1.0 0.000143348623853 0 1 -1
studies,cytochrome 1.0 0.000286697247706 0 2 -2
skeletal,myopathy 1.0 0.000143348623853 0 1 -1
mefloquine,on 1.0 0.000143348623853 1 0 1
acute,increase 1.0 0.000143348623853 0 1 -1
animal,experience 1.0 0.000143348623853 1 0 1
with,is 0.0 0.0 4 4 0
with,it 1.0 0.000286697247706 0 2 -2
with,iv 1.0 0.000143348623853 0 1 -1
a,non- 1.0 0.000143348623853 1 0 1
rarely,reported 1.0 0.000286697247706 2 0 2
and,selected 1.0 0.000143348623853 0 1 -1
decreased,mean 1.0 0.000143348623853 1 0 1
implications,of 0.0 0.0 1 1 0
test,findings 1.0 0.000143348623853 0 1 -1
with,membranes 1.0 0.000143348623853 0 1 -1
patients,under 0.333333333333 0.000143348623853 1 2 -1
is,very 1.0 0.000286697247706 0 2 -2
are,case 1.0 0.000143348623853 1 0 1
method,such 1.0 0.000143348623853 0 1 -1
encephalopathy,are 1.0 0.000143348623853 0 1 -1
clearance,has 1.0 0.000143348623853 0 1 -1
nalfon,has 1.0 0.000143348623853 1 0 1
slight,delay 1.0 0.000143348623853 1 0 1
solution,was 1.0 0.000143348623853 0 1 -1
other,medicinal 1.0 0.000143348623853 0 1 -1
activity,large 1.0 0.000143348623853 0 1 -1
for,therapeutic 1.0 0.000286697247706 0 2 -2
cadmium,and 1.0 0.000716743119266 0 5 -5
variable,and 1.0 0.000143348623853 0 1 -1
the,required 1.0 0.000143348623853 1 0 1
indicators,differs 1.0 0.000143348623853 0 1 -1
preceding,the 1.0 0.000143348623853 0 1 -1
be,seen 0.333333333333 0.000143348623853 2 1 1
pharmacokinetic,basis 1.0 0.000143348623853 0 1 -1
with,tikosyn 0.0 0.0 3 3 0
excessive,release 1.0 0.000286697247706 0 2 -2
elevated,by 1.0 0.000143348623853 0 1 -1
ns,may 1.0 0.000143348623853 1 0 1
of,accumulation 1.0 0.000143348623853 0 1 -1
the,physiological 1.0 0.000143348623853 0 1 -1
cromolyn,sodium 0.333333333333 0.000143348623853 1 2 -1
are,illustrated 1.0 0.000143348623853 0 1 -1
drawn,and 1.0 0.000143348623853 0 1 -1
uptake,may 1.0 0.000143348623853 1 0 1
colchicine,para-aminosalicylic 1.0 0.000143348623853 1 0 1
cmax,cmin 1.0 0.000143348623853 0 1 -1
period,with 1.0 0.000143348623853 0 1 -1
and,including 1.0 0.000143348623853 0 1 -1
monitored,when 1.0 0.00157683486239 11 0 11
vascularity,of 1.0 0.000143348623853 0 1 -1
marrow,function 1.0 0.000143348623853 0 1 -1
response,duration 1.0 0.000143348623853 1 0 1
small,gtp-binding 1.0 0.000143348623853 0 1 -1
class,including 0.0 0.0 1 1 0
and,did 0.818181818182 0.00129013761468 1 10 -9
lipids,in 1.0 0.000143348623853 0 1 -1
function,hmg-coa 1.0 0.000143348623853 0 1 -1
four,resulted 1.0 0.000143348623853 1 0 1
experimental,soft-gelatin 1.0 0.000143348623853 1 0 1
prostatectomy,radiation 1.0 0.000143348623853 0 1 -1
between,argatroban 1.0 0.00043004587156 0 3 -3
rapidly,to 1.0 0.000143348623853 0 1 -1
a,schedule 1.0 0.000143348623853 1 0 1
known,metabolite 1.0 0.000143348623853 0 1 -1
overactive,pain 1.0 0.000143348623853 0 1 -1
induced,concentration-dependent 1.0 0.000143348623853 0 1 -1
hazard,to 0.0 0.0 1 1 0
are,advised 0.333333333333 0.000143348623853 1 2 -1
from,marine 1.0 0.000143348623853 0 1 -1
the,hepatoxicity 1.0 0.000143348623853 1 0 1
mcg,once 1.0 0.000286697247706 0 2 -2
the,aucs 1.0 0.000143348623853 0 1 -1
potentially,irritating 1.0 0.000143348623853 0 1 -1
agent,was 1.0 0.000143348623853 0 1 -1
of,compounds 0.2 0.000143348623853 3 2 1
to,define 1.0 0.000143348623853 0 1 -1
a,only 1.0 0.000143348623853 0 1 -1
mac,of 1.0 0.000143348623853 0 1 -1
receive,oral 1.0 0.000143348623853 0 1 -1
dosage,and 1.0 0.000573394495413 0 4 -4
be,alerted 1.0 0.000143348623853 0 1 -1
and,sigma-2 1.0 0.000143348623853 0 1 -1
chelation,complexes 1.0 0.000143348623853 1 0 1
alkalinization,of 1.0 0.000143348623853 0 1 -1
with,respect 1.0 0.00114678899083 0 8 -8
olanzapine,coadministration 1.0 0.000143348623853 1 0 1
pressure,medications 1.0 0.000143348623853 0 1 -1
decrease,renal 1.0 0.000286697247706 2 0 2
input,impedance 1.0 0.000143348623853 0 1 -1
and,xanthine 1.0 0.000143348623853 1 0 1
measuring,locomotor 1.0 0.000143348623853 0 1 -1
specific,patient 1.0 0.000143348623853 0 1 -1
quinidine,and 0.0 0.0 1 1 0
is,known 0.333333333333 0.000716743119266 5 10 -5
the,aldehyde 1.0 0.000143348623853 0 1 -1
than,expected 0.777777777778 0.00100344036697 1 8 -7
to,hypoglycemia 1.0 0.000286697247706 0 2 -2
patients,mixed 1.0 0.000143348623853 0 1 -1
initiated,to 1.0 0.000143348623853 1 0 1
inc,demonstrated 1.0 0.000143348623853 1 0 1
simultaneous,reduction 1.0 0.000143348623853 0 1 -1
activities,such 1.0 0.000143348623853 0 1 -1
of,discontinuing 1.0 0.000143348623853 1 0 1
the,label 1.0 0.000143348623853 1 0 1
regular,reevaluations 1.0 0.000143348623853 0 1 -1
and,fbs 1.0 0.000143348623853 1 0 1
avoided,as 1.0 0.00043004587156 0 3 -3
a,mg 0.0769230769231 0.000286697247706 12 14 -2
receiving,crixivan 1.0 0.000143348623853 1 0 1
avoided,at 1.0 0.000143348623853 0 1 -1
microtubules,appeared 1.0 0.000143348623853 0 1 -1
a6,or 1.0 0.000143348623853 0 1 -1
needed,due 1.0 0.000143348623853 0 1 -1
and,this 0.6 0.00043004587156 1 4 -3
meaningful,interactions 1.0 0.000286697247706 0 2 -2
verapamil,concomitant 1.0 0.000143348623853 0 1 -1
cytosol,to 1.0 0.000143348623853 0 1 -1
bid,were 1.0 0.000143348623853 0 1 -1
experienced,by 1.0 0.000143348623853 0 1 -1
of,enhancing 0.333333333333 0.000143348623853 1 2 -1
received,one 1.0 0.00043004587156 0 3 -3
failure,and 0.0 0.0 1 1 0
malignant,disease 1.0 0.000143348623853 0 1 -1
hcl,should 1.0 0.000143348623853 1 0 1
metabolism,of 0.323076923077 0.00301032110092 43 22 21
rifampin,cyp3a4 1.0 0.000143348623853 0 1 -1
study,both 1.0 0.000143348623853 0 1 -1
overlap,to 1.0 0.000143348623853 0 1 -1
cortex,of 1.0 0.000286697247706 0 2 -2
a,blunting 1.0 0.000143348623853 0 1 -1
bound,such 1.0 0.000143348623853 0 1 -1
at,different 1.0 0.00043004587156 0 3 -3
including,yields 1.0 0.000143348623853 1 0 1
is,applicable 1.0 0.000143348623853 0 1 -1
on,guinea 1.0 0.000143348623853 0 1 -1
coagulation,assays 1.0 0.000143348623853 0 1 -1
coagulation,should 1.0 0.000143348623853 0 1 -1
calan,sr 1.0 0.000143348623853 1 0 1
received,a 1.0 0.000286697247706 0 2 -2
ritonavir,and 1.0 0.000143348623853 1 0 1
tested,more 1.0 0.000143348623853 0 1 -1
or,ml 1.0 0.000143348623853 1 0 1
either,are 1.0 0.000143348623853 0 1 -1
or,mg 0.625 0.00286697247706 6 26 -20
of,regranex 1.0 0.000143348623853 0 1 -1
carbamazepine,steady-state 1.0 0.000143348623853 0 1 -1
provide,information 1.0 0.000143348623853 0 1 -1
individuals,are 1.0 0.000286697247706 0 2 -2
of,deficiency 1.0 0.000143348623853 0 1 -1
a,rapid 0.333333333333 0.000143348623853 2 1 1
cost-risk,benefit 1.0 0.000143348623853 0 1 -1
physiological,supplementation 1.0 0.000143348623853 0 1 -1
dysfunction,hyperpyrexia 1.0 0.000143348623853 1 0 1
in,close 1.0 0.000143348623853 0 1 -1
treatment,and 0.5 0.000286697247706 1 3 -2
dfur,fu 1.0 0.000143348623853 0 1 -1
fecal,and 1.0 0.000143348623853 0 1 -1
interaction,will 1.0 0.000143348623853 1 0 1
patients,below 1.0 0.000143348623853 0 1 -1
and,potassium-sparing 0.6 0.00043004587156 4 1 3
effect,relationship 1.0 0.00043004587156 3 0 3
pgp,increased 1.0 0.000286697247706 0 2 -2
in,significantly 1.0 0.000286697247706 2 0 2
reducing,the 0.333333333333 0.000143348623853 2 1 1
similar,length 1.0 0.000143348623853 1 0 1
cases,a 1.0 0.000143348623853 1 0 1
agent,metabolized 1.0 0.000143348623853 0 1 -1
of,under 1.0 0.000143348623853 1 0 1
chromatographic,assay 1.0 0.000286697247706 0 2 -2
post-heparin,lipolytic 1.0 0.000143348623853 1 0 1
pgf2alpha,produced 1.0 0.000143348623853 1 0 1
alteration,of 0.666666666667 0.000573394495413 1 5 -4
are,altered 1.0 0.000143348623853 1 0 1
the,active 0.4 0.000573394495413 3 7 -4
on-treatment,additive 1.0 0.000143348623853 0 1 -1
cautiously,as 1.0 0.000143348623853 0 1 -1
obtained,when 1.0 0.000286697247706 2 0 2
of,hours 1.0 0.000143348623853 1 0 1
effective,but 1.0 0.000143348623853 0 1 -1
severity,of 0.6 0.00043004587156 4 1 3
suprax,may 1.0 0.000143348623853 0 1 -1
plasma,concentrations 0.0277777777778 0.000573394495413 74 70 4
hyperthyroidism,or 1.0 0.000143348623853 0 1 -1
is,adsorption 1.0 0.000143348623853 1 0 1
by,catechol-o 1.0 0.000143348623853 0 1 -1
aerosol,with 1.0 0.000143348623853 1 0 1
receiving,oral 0.2 0.000143348623853 2 3 -1
response,multiple 1.0 0.000143348623853 0 1 -1
plasma,drug 1.0 0.000143348623853 0 1 -1
not,advisable 1.0 0.000143348623853 1 0 1
tolerance,min 1.0 0.000143348623853 0 1 -1
study,showed 1.0 0.000143348623853 0 1 -1
ruthenium,red 1.0 0.000286697247706 0 2 -2
simulect,with 1.0 0.000143348623853 0 1 -1
p450-linked,drug-metabolizing 1.0 0.000143348623853 0 1 -1
out,studies 1.0 0.000143348623853 0 1 -1
when,extended 1.0 0.000143348623853 0 1 -1
pharmacological,interactions 1.0 0.000286697247706 0 2 -2
mg,each 0.0 0.0 1 1 0
or,administration 1.0 0.000143348623853 0 1 -1
and,epidural 1.0 0.000143348623853 1 0 1
inhaled,medications 1.0 0.000143348623853 0 1 -1
and,metabolized 1.0 0.000143348623853 0 1 -1
and,intensify 0.555555555556 0.000716743119266 7 2 5
the,ratio 1.0 0.000143348623853 0 1 -1
pathway,for 0.333333333333 0.000143348623853 1 2 -1
while,additional 1.0 0.000143348623853 0 1 -1
a,primary 1.0 0.000143348623853 0 1 -1
the,roughly 1.0 0.000143348623853 0 1 -1
p,decreased 1.0 0.000143348623853 1 0 1
free,is 1.0 0.000143348623853 1 0 1
oral,the 0.2 0.000143348623853 2 3 -1
in,substantial 1.0 0.000286697247706 2 0 2
for,additional 1.0 0.000143348623853 1 0 1
increase3,ci 1.0 0.000143348623853 0 1 -1
intricately,associated 1.0 0.000143348623853 0 1 -1
reported,that 0.4 0.000573394495413 7 3 4
rapid,contraction 1.0 0.000143348623853 0 1 -1
ergosterol,the 1.0 0.000143348623853 0 1 -1
therapy,eg 0.0 0.0 1 1 0
insp,microm 1.0 0.000143348623853 0 1 -1
contraceptives,multiple 1.0 0.000286697247706 0 2 -2
mhd,however 1.0 0.000143348623853 0 1 -1
displace,other 1.0 0.000143348623853 0 1 -1
times,as 1.0 0.000286697247706 0 2 -2
that,observed 0.333333333333 0.000286697247706 4 2 2
injury,or 1.0 0.000286697247706 0 2 -2
assays,when 1.0 0.000143348623853 0 1 -1
facial,wasting 1.0 0.000143348623853 0 1 -1
enzymes,cytochrome 1.0 0.000143348623853 0 1 -1
no,significant 0.857142857143 0.00688073394495 4 52 -48
via,cyp 1.0 0.000143348623853 0 1 -1
isozymes,including 1.0 0.000143348623853 0 1 -1
a,spatial 1.0 0.000143348623853 0 1 -1
and,blood 0.428571428571 0.00043004587156 2 5 -3
that,mtx 1.0 0.000143348623853 0 1 -1
plus,mg 1.0 0.000143348623853 0 1 -1
contains,reports 1.0 0.000143348623853 0 1 -1
of,depression 1.0 0.00043004587156 0 3 -3
then,took 1.0 0.000143348623853 0 1 -1
significantly,greater 1.0 0.00043004587156 0 3 -3
are,overly 1.0 0.000143348623853 0 1 -1
nitrates,nifedipine 1.0 0.000143348623853 0 1 -1
lamprene,have 1.0 0.000143348623853 1 0 1
self-injection,of 1.0 0.000143348623853 0 1 -1
the,reported 1.0 0.000286697247706 0 2 -2
pharmacokinetics,and 1.0 0.00100344036697 0 7 -7
for,volatile 1.0 0.000143348623853 1 0 1
and,lethality 1.0 0.000143348623853 0 1 -1
thiazides,thiazides 1.0 0.00043004587156 0 3 -3
of,complicated 1.0 0.000143348623853 0 1 -1
or,generalized 1.0 0.000143348623853 0 1 -1
short-term,controlled 1.0 0.00043004587156 0 3 -3
other,cases 1.0 0.000143348623853 0 1 -1
reduced,twitch 1.0 0.000143348623853 0 1 -1
is,offset 1.0 0.000143348623853 0 1 -1
in,alcoholics 1.0 0.000143348623853 0 1 -1
gastrointestinal,ulceration 1.0 0.000143348623853 1 0 1
circulating,levels 1.0 0.000143348623853 0 1 -1
different,route 1.0 0.000143348623853 0 1 -1
inhibitors,thereby 1.0 0.000143348623853 1 0 1
homocysteine,excretion 1.0 0.000143348623853 0 1 -1
be,made 0.555555555556 0.000716743119266 2 7 -5
have,expanded 1.0 0.000143348623853 0 1 -1
successful,prophylaxis 1.0 0.000143348623853 0 1 -1
anticholinergic,in 1.0 0.000143348623853 0 1 -1
human,b 1.0 0.000143348623853 0 1 -1
administered,starlix 1.0 0.000143348623853 0 1 -1
mean,t 0.333333333333 0.000143348623853 1 2 -1
mean,reduction 1.0 0.000143348623853 0 1 -1
the,diabetic 1.0 0.000286697247706 0 2 -2
explored,further 1.0 0.000143348623853 0 1 -1
the,administrative 1.0 0.000143348623853 0 1 -1
mean,c 0.5 0.000286697247706 1 3 -2
inhibitors,inhibitors 1.0 0.000143348623853 0 1 -1
day,followed 1.0 0.000143348623853 1 0 1
maximum,levels 1.0 0.000143348623853 0 1 -1
the,recognition 1.0 0.000143348623853 0 1 -1
this,route 1.0 0.000143348623853 1 0 1
non-hodgkin,lymphoma 1.0 0.000143348623853 0 1 -1
of,ph 1.0 0.000143348623853 0 1 -1
first-episode,or 1.0 0.000143348623853 0 1 -1
complete,mental 1.0 0.000143348623853 0 1 -1
inhibit,cyp1a2 1.0 0.000143348623853 0 1 -1
mhd,the 1.0 0.000143348623853 0 1 -1
and,pth 1.0 0.000143348623853 1 0 1
of,developing 0.333333333333 0.000143348623853 2 1 1
on,some 1.0 0.000143348623853 0 1 -1
that,does 1.0 0.00172018348624 0 12 -12
abnormal,handling 1.0 0.000143348623853 0 1 -1
anxiety,associated 1.0 0.000143348623853 0 1 -1
potentiated,apparently 1.0 0.000143348623853 0 1 -1
can,have 1.0 0.000143348623853 0 1 -1
blood,concentrations 0.5 0.000286697247706 1 3 -2
metabolite,or 1.0 0.000143348623853 0 1 -1
block,following 0.0 0.0 1 1 0
of,release 1.0 0.000143348623853 0 1 -1
adverse,event 1.0 0.000143348623853 0 1 -1
to,suppress 1.0 0.000143348623853 0 1 -1
twitch,to 1.0 0.000143348623853 1 0 1
cyp2c9,such 1.0 0.000143348623853 1 0 1
metabolite,of 0.555555555556 0.000716743119266 2 7 -5
culture,medium 1.0 0.000143348623853 0 1 -1
ectopic,pacemaker 1.0 0.000143348623853 1 0 1
brevibloc,were 1.0 0.000286697247706 2 0 2
aquamephyton,synkayvite 1.0 0.000143348623853 0 1 -1
random,observations 1.0 0.000143348623853 1 0 1
antidiabetes,products 1.0 0.000143348623853 0 1 -1
which,we 1.0 0.000143348623853 0 1 -1
anti-globulin,tests 1.0 0.000143348623853 0 1 -1
system,although 1.0 0.000143348623853 0 1 -1
emphasize,that 1.0 0.000143348623853 0 1 -1
how,to 1.0 0.000286697247706 0 2 -2
encountered,with 1.0 0.000143348623853 0 1 -1
neurontin,capsule 1.0 0.000143348623853 1 0 1
reduction,tests 1.0 0.000286697247706 0 2 -2
patient,data 1.0 0.000143348623853 0 1 -1
in,rare 0.0 0.0 1 1 0
causal,relationship 0.5 0.000286697247706 1 3 -2
of,extraneals 1.0 0.000143348623853 0 1 -1
study,without 1.0 0.000143348623853 0 1 -1
if,used 0.333333333333 0.000143348623853 1 2 -1
methyltransferase,comt 1.0 0.000143348623853 0 1 -1
prothrombin,levels 1.0 0.000143348623853 0 1 -1
enzymes,of 1.0 0.00043004587156 3 0 3
occasionally,been 1.0 0.000286697247706 0 2 -2
serious,gi 1.0 0.000286697247706 2 0 2
diabetic,cinese 1.0 0.000143348623853 0 1 -1
this,strain 1.0 0.000143348623853 0 1 -1
and,above 1.0 0.000143348623853 0 1 -1
enzymes,or 1.0 0.000286697247706 0 2 -2
survival,were 1.0 0.000143348623853 0 1 -1
strategies,to 1.0 0.000143348623853 0 1 -1
of,male 0.0 0.0 2 2 0
following,specific 1.0 0.000143348623853 0 1 -1
markedly,inhibits 1.0 0.000286697247706 2 0 2
reddish,color 1.0 0.000143348623853 1 0 1
however,requirement 1.0 0.000143348623853 1 0 1
anticholinergic,agents 0.333333333333 0.000143348623853 2 1 1
mainly,receiving 1.0 0.000143348623853 0 1 -1
toxicity,characteristics 1.0 0.000143348623853 1 0 1
other,coumarin-derivative 1.0 0.000143348623853 0 1 -1
frequent,occurrence 1.0 0.000143348623853 0 1 -1
lapatinib,on 1.0 0.000143348623853 0 1 -1
female,dog 1.0 0.000286697247706 0 2 -2
mm,was 1.0 0.000143348623853 0 1 -1
cause-and,effect 1.0 0.000286697247706 2 0 2
or,therapeutic 1.0 0.000286697247706 0 2 -2
of,response 0.0 0.0 1 1 0
equetrotm,increases 1.0 0.000143348623853 1 0 1
relaxant,antagonists 1.0 0.000143348623853 0 1 -1
involving,otherwise 1.0 0.000143348623853 0 1 -1
chapter,covers 1.0 0.000143348623853 0 1 -1
beta,blockers 0.166666666667 0.000286697247706 5 7 -2
occur,they 1.0 0.000143348623853 0 1 -1
p450,metabolism 1.0 0.000143348623853 0 1 -1
exacerbated,in 1.0 0.000143348623853 0 1 -1
diarrhea,but 0.0 0.0 1 1 0
and,being 1.0 0.000143348623853 0 1 -1
added,beta-adrenergic 1.0 0.000143348623853 1 0 1
that,elspar 1.0 0.000143348623853 1 0 1
urinary,and 1.0 0.000143348623853 1 0 1
with,mtx 1.0 0.000143348623853 0 1 -1
temperature,began 1.0 0.000143348623853 0 1 -1
situation,and 1.0 0.000143348623853 0 1 -1
disturbances,left 1.0 0.000143348623853 1 0 1
tuberculosis,andusing 1.0 0.000143348623853 0 1 -1
bound,and 1.0 0.000143348623853 0 1 -1
or,pd 1.0 0.000143348623853 0 1 -1
retinal,tamponades 1.0 0.000143348623853 0 1 -1
block,morphine-induced 1.0 0.000143348623853 1 0 1
antiretroviral,plasma 1.0 0.000143348623853 0 1 -1
more,profound 1.0 0.000143348623853 1 0 1
to,inactive 1.0 0.000143348623853 0 1 -1
antiemetic,prophylaxis 0.0 0.0 1 1 0
example,since 1.0 0.000143348623853 1 0 1
possible,explanation 1.0 0.000143348623853 0 1 -1
acid,hepatotoxic 1.0 0.000143348623853 1 0 1
above,effects 1.0 0.000143348623853 1 0 1
macrolide,antibiotics 0.0 0.0 2 2 0
cases,from 1.0 0.000143348623853 0 1 -1
the,store 1.0 0.000143348623853 0 1 -1
cause,striking 1.0 0.000286697247706 2 0 2
keys,to 1.0 0.000143348623853 0 1 -1
admitted,to 1.0 0.000143348623853 0 1 -1
guanethidine,or 1.0 0.000143348623853 0 1 -1
activated,during 1.0 0.000143348623853 0 1 -1
and,transport 1.0 0.000143348623853 0 1 -1
in,tissue 1.0 0.000143348623853 1 0 1
negative,chronotropic 1.0 0.000143348623853 0 1 -1
ponstel,with 1.0 0.000143348623853 1 0 1
with,kineret 1.0 0.000143348623853 1 0 1
a,median 1.0 0.000286697247706 0 2 -2
gender,race 1.0 0.000143348623853 0 1 -1
in,cardioplegic 1.0 0.000143348623853 0 1 -1
would,occur 1.0 0.000143348623853 0 1 -1
of,diabetic 1.0 0.000286697247706 0 2 -2
kht,tumour 1.0 0.000143348623853 0 1 -1
when,hypothyroid 1.0 0.000143348623853 0 1 -1
single-dose,interaction 1.0 0.000143348623853 0 1 -1
in,rpmi1640 1.0 0.000143348623853 1 0 1
adverse,events 0.7 0.00200688073394 3 17 -14
values,all 1.0 0.000143348623853 0 1 -1
increased,and 0.333333333333 0.000573394495413 8 4 4
of,p-450iie1 1.0 0.000143348623853 1 0 1
nonetheless,they 1.0 0.000143348623853 0 1 -1
dose,mu 1.0 0.000143348623853 0 1 -1
are,generally 1.0 0.000143348623853 0 1 -1
single,daily 1.0 0.000143348623853 0 1 -1
cmin,auc 1.0 0.000143348623853 0 1 -1
inhibit,these 1.0 0.000143348623853 0 1 -1
topical,solution 1.0 0.000143348623853 0 1 -1
dose,mg 0.5 0.000286697247706 1 3 -2
further,no 1.0 0.000143348623853 0 1 -1
a,dysregulation 1.0 0.000143348623853 0 1 -1
inhibition,significantly 1.0 0.000143348623853 1 0 1
results,with 1.0 0.000143348623853 0 1 -1
prohibited,from 1.0 0.000143348623853 0 1 -1
eia,test 1.0 0.000286697247706 0 2 -2
with,enzyme 1.0 0.000143348623853 0 1 -1
and,either 1.0 0.000143348623853 0 1 -1
frequency,of 0.333333333333 0.00043004587156 3 6 -3
cases,reported 1.0 0.000143348623853 1 0 1
lists,of 1.0 0.000286697247706 0 2 -2
frequency,on 1.0 0.000143348623853 0 1 -1
include,aminosalicylic 1.0 0.000143348623853 1 0 1
advantages,over 1.0 0.000143348623853 0 1 -1
determinations,vitamin 1.0 0.000143348623853 1 0 1
catalyzed,by 1.0 0.000860091743119 0 6 -6
as,thiazide 1.0 0.000286697247706 2 0 2
behavioral,responsiveness 1.0 0.000143348623853 1 0 1
illnesses,dose 1.0 0.000143348623853 0 1 -1
of,drugs 0.6 0.00043004587156 1 4 -3
recent,studies 1.0 0.000286697247706 0 2 -2
or,hot 1.0 0.000143348623853 0 1 -1
decreased,alertness 1.0 0.000286697247706 2 0 2
evidenced,by 0.0 0.0 1 1 0
the,nerves 1.0 0.000286697247706 0 2 -2
partly,share 1.0 0.000143348623853 0 1 -1
sedation,or 0.5 0.000286697247706 1 3 -2
pharmacokinetic,disposition 1.0 0.000143348623853 0 1 -1
produces,depression 1.0 0.000143348623853 1 0 1
and,exposure 1.0 0.000143348623853 1 0 1
while,a 1.0 0.000143348623853 1 0 1
and,fenofibric 1.0 0.000143348623853 0 1 -1
syncope,presyncope 1.0 0.000143348623853 1 0 1
chromatogr,should 1.0 0.000143348623853 0 1 -1
acid,has 1.0 0.000143348623853 1 0 1
a,p-glycoprotein 1.0 0.000143348623853 1 0 1
index,including 1.0 0.000143348623853 1 0 1
products,containing 1.0 0.00100344036697 7 0 7
therapy,plasma 1.0 0.000143348623853 1 0 1
medication,iodine-containing 1.0 0.000143348623853 0 1 -1
with,synthetic 1.0 0.000143348623853 0 1 -1
related,presumably 1.0 0.000143348623853 1 0 1
common,component 1.0 0.000143348623853 1 0 1
cyp3a4,isoenzyme 1.0 0.00043004587156 0 3 -3
evidence,was 1.0 0.000143348623853 0 1 -1
subject,before 1.0 0.000143348623853 0 1 -1
on,stimulated 1.0 0.000143348623853 0 1 -1
depressants,eg 1.0 0.000143348623853 1 0 1
phenurone,since 1.0 0.000143348623853 1 0 1
with,intact 1.0 0.000143348623853 1 0 1
have,the 0.333333333333 0.000286697247706 2 4 -2
channels,in 1.0 0.000286697247706 0 2 -2
another,such 1.0 0.000143348623853 1 0 1
lower,in 0.0 0.0 2 2 0
on,platelet 0.0 0.0 2 2 0
alters,the 1.0 0.000143348623853 0 1 -1
are,cytochrome 1.0 0.000143348623853 1 0 1
esters,on 1.0 0.000143348623853 0 1 -1
mucosal,and 1.0 0.000143348623853 0 1 -1
findings,has 1.0 0.000143348623853 0 1 -1
prevent,opioid-induced 1.0 0.000143348623853 1 0 1
inr,values 1.0 0.000143348623853 0 1 -1
will,inhibit 1.0 0.000143348623853 0 1 -1
and,proton 1.0 0.000286697247706 0 2 -2
enzymes,respectively 1.0 0.000143348623853 1 0 1
adjustments,patients 1.0 0.000143348623853 1 0 1
discontinue,therapy 1.0 0.000143348623853 1 0 1
concerning,laboratory 1.0 0.000143348623853 0 1 -1
regimens,including 1.0 0.000143348623853 0 1 -1
on,aed 1.0 0.000143348623853 0 1 -1
of,duloxetine 0.0 0.0 2 2 0
since,nevirapinemay 1.0 0.000143348623853 1 0 1
between,neupogen 1.0 0.000143348623853 0 1 -1
is,no 0.888888888889 0.00229357798165 1 17 -16
of,resulted 1.0 0.000573394495413 4 0 4
that,maximally 1.0 0.000143348623853 0 1 -1
tricyclic,and 1.0 0.000286697247706 2 0 2
obstetric,blocks 0.0 0.0 1 1 0
the,core 1.0 0.000143348623853 0 1 -1
hydrochlorothiazide,in 1.0 0.000143348623853 1 0 1
add,a 1.0 0.000860091743119 6 0 6
other,should 1.0 0.000573394495413 4 0 4
metabolized,primarily 1.0 0.000143348623853 0 1 -1
than,plasma 1.0 0.000143348623853 0 1 -1
diagnosed,subjects 1.0 0.000143348623853 0 1 -1
conduction,when 1.0 0.000143348623853 1 0 1
concurrent,dosing 1.0 0.000143348623853 0 1 -1
unstable,with 1.0 0.000143348623853 0 1 -1
no,positive 1.0 0.000143348623853 0 1 -1
benzodiazepines,were 1.0 0.000143348623853 0 1 -1
for,albumin 1.0 0.000143348623853 0 1 -1
to,other 0.5 0.000286697247706 1 3 -2
or,beta-adrenergic 0.333333333333 0.000143348623853 1 2 -1
study,co-administration 0.0 0.0 1 1 0
established,a 1.0 0.000143348623853 1 0 1
acute,pulmonary 1.0 0.000143348623853 1 0 1
the,limits 1.0 0.000143348623853 0 1 -1
or,adrenergic 1.0 0.000143348623853 0 1 -1
these,studies 0.2 0.000143348623853 2 3 -1
therefore,increased 1.0 0.000143348623853 1 0 1
increased,plasma 0.0625 0.000286697247706 17 15 2
autonomic,neurotoxicity 1.0 0.000143348623853 0 1 -1
industrial,workers 1.0 0.000143348623853 0 1 -1
the,absolute 1.0 0.000143348623853 0 1 -1
other,b-lactam 1.0 0.00043004587156 3 0 3
substances,are 1.0 0.000143348623853 0 1 -1
studies,did 1.0 0.000573394495413 0 4 -4
zidovudine,there 1.0 0.000143348623853 0 1 -1
similar,frequency 1.0 0.000143348623853 0 1 -1
the,prescriber 1.0 0.000143348623853 0 1 -1
tumor,cells 1.0 0.000143348623853 0 1 -1
discontinuance,of 1.0 0.000143348623853 1 0 1
prescriber,when 1.0 0.000143348623853 0 1 -1
decrease,effectiveness 1.0 0.000143348623853 0 1 -1
the,anti-platelet 1.0 0.000143348623853 0 1 -1
selective,cyp3a4 1.0 0.000286697247706 2 0 2
taking,aminosalicylic 1.0 0.000143348623853 1 0 1
exogenous,and 1.0 0.000143348623853 0 1 -1
enablex,with 1.0 0.000143348623853 1 0 1
standing,systolic 1.0 0.000716743119266 5 0 5
pressure,effect 1.0 0.000143348623853 1 0 1
because,changes 1.0 0.000143348623853 1 0 1
medline,premedline 1.0 0.000143348623853 0 1 -1
the,desired 0.2 0.00043004587156 9 6 3
improve,this 1.0 0.000143348623853 0 1 -1
of,dependence 1.0 0.000286697247706 0 2 -2
after,drinking 1.0 0.000143348623853 1 0 1
lean,and 1.0 0.000716743119266 0 5 -5
probenecid,may 1.0 0.000286697247706 2 0 2
of,neurontin 1.0 0.00043004587156 0 3 -3
maybe,useful 1.0 0.000143348623853 0 1 -1
while,mean 1.0 0.000143348623853 0 1 -1
neuronal,apparatus 1.0 0.000143348623853 0 1 -1
overly,cautious 1.0 0.000143348623853 0 1 -1
procedure,the 1.0 0.000143348623853 0 1 -1
underlying,conditions 1.0 0.000143348623853 0 1 -1
methyltetrahydro-folate,and 1.0 0.000143348623853 0 1 -1
to,co-administer 1.0 0.000143348623853 1 0 1
is,minimized 1.0 0.000143348623853 0 1 -1
serum,prostate-specific 1.0 0.000143348623853 0 1 -1
tablets,a 1.0 0.000143348623853 1 0 1
vasopressin,was 1.0 0.000143348623853 0 1 -1
some,substances 1.0 0.000143348623853 0 1 -1
only,about 1.0 0.000143348623853 0 1 -1
circumstances,as 1.0 0.000143348623853 0 1 -1
therefore,potentially 1.0 0.000143348623853 1 0 1
trials,were 1.0 0.000286697247706 0 2 -2
increased,peak 1.0 0.000143348623853 1 0 1
investigated,whether 1.0 0.000286697247706 0 2 -2
glucuronidation,is 1.0 0.000143348623853 0 1 -1
antagonists,which 1.0 0.000143348623853 1 0 1
sympathetic,nervous 1.0 0.000286697247706 0 2 -2
as,co-activator 1.0 0.000143348623853 0 1 -1
category,c 1.0 0.000143348623853 0 1 -1
risk,is 1.0 0.000143348623853 0 1 -1
a,fall 1.0 0.000143348623853 0 1 -1
with,nucleophosmin 1.0 0.000143348623853 0 1 -1
of,temperature 1.0 0.000143348623853 0 1 -1
or,its 0.2 0.00043004587156 6 9 -3
general,utilizing 1.0 0.000143348623853 0 1 -1
blocker,given 1.0 0.000143348623853 1 0 1
gentamicin,is 1.0 0.000143348623853 0 1 -1
interference,with 0.4 0.000573394495413 3 7 -4
among,asian 1.0 0.000716743119266 0 5 -5
this,interaction 0.294117647059 0.00143348623853 12 22 -10
doses,on 1.0 0.000143348623853 0 1 -1
on,alone 1.0 0.000143348623853 0 1 -1
chapter,presents 1.0 0.000286697247706 0 2 -2
doses,of 0.155172413793 0.00258027522936 49 67 -18
tracrium,include 1.0 0.000143348623853 1 0 1
with,suboxone 1.0 0.000143348623853 1 0 1
were,the 1.0 0.00043004587156 0 3 -3
on,especially 1.0 0.000286697247706 2 0 2
doses,or 0.5 0.000286697247706 1 3 -2
markedly,decreased 0.0 0.0 1 1 0
subjects,twelve 1.0 0.000143348623853 0 1 -1
from,both 1.0 0.000286697247706 0 2 -2
cautious,in 1.0 0.000143348623853 0 1 -1
d6,many 1.0 0.000716743119266 0 5 -5
dental,complications 1.0 0.000143348623853 1 0 1
trials,no 1.0 0.000286697247706 0 2 -2
hiv,status 1.0 0.000143348623853 0 1 -1
is,comparable 1.0 0.000143348623853 0 1 -1
week,to 1.0 0.000573394495413 0 4 -4
when,maleate 1.0 0.000286697247706 2 0 2
regression,analyses 1.0 0.000143348623853 1 0 1
regimen,efficacy 1.0 0.000143348623853 0 1 -1
non-myelinated,axons 1.0 0.00043004587156 0 3 -3
high,in 0.0 0.0 1 1 0
breast,enlargement 1.0 0.000143348623853 0 1 -1
seizure,control 1.0 0.000143348623853 1 0 1
also,verified 1.0 0.000143348623853 0 1 -1
tnf-blocking,agents 1.0 0.000143348623853 1 0 1
that,should 0.0 0.0 3 3 0
since,ancobon 1.0 0.000143348623853 0 1 -1
prescribed,with 1.0 0.000143348623853 1 0 1
zebeta,should 1.0 0.000286697247706 2 0 2
formal,assessments 1.0 0.000286697247706 0 2 -2
massive,precipitation 1.0 0.000143348623853 0 1 -1
of,subutex 1.0 0.000143348623853 0 1 -1
curve,auc 1.0 0.000143348623853 0 1 -1
cancidas,has 1.0 0.000143348623853 0 1 -1
organic,cationic 0.0 0.0 1 1 0
of,sodium 0.384615384615 0.000716743119266 9 4 5
cyp1a2,cyp2c9 1.0 0.000716743119266 0 5 -5
the,sleeping 0.0 0.0 1 1 0
minutes,p 1.0 0.000143348623853 1 0 1
case,the 1.0 0.000143348623853 0 1 -1
hypertension,the 1.0 0.000143348623853 1 0 1
of,which 0.25 0.000573394495413 10 6 4
mothers,have 1.0 0.000143348623853 0 1 -1
these,patients 0.230769230769 0.00043004587156 5 8 -3
extent,than 1.0 0.000286697247706 0 2 -2
or,factors 1.0 0.000143348623853 0 1 -1
permeable,caspase-3 1.0 0.000143348623853 0 1 -1
inactivation,of 1.0 0.000143348623853 0 1 -1
in,four 1.0 0.000286697247706 0 2 -2
the,arrival 1.0 0.000143348623853 0 1 -1
by,ecg 1.0 0.000143348623853 0 1 -1
another,female 1.0 0.000143348623853 0 1 -1
secretion,of 0.333333333333 0.000573394495413 8 4 4
sgot,s-ast 1.0 0.000143348623853 0 1 -1
rationalized,at 1.0 0.000143348623853 0 1 -1
agents,sodium 1.0 0.000143348623853 1 0 1
secretion,or 1.0 0.000143348623853 0 1 -1
non-comparative,clinical 1.0 0.000143348623853 1 0 1
potentiate,the 0.487179487179 0.00272362385321 29 10 19
vivo,effects 1.0 0.000143348623853 0 1 -1
bioavailabillty,when 1.0 0.000143348623853 1 0 1
start,or 1.0 0.000143348623853 0 1 -1
from,inhibition 1.0 0.000143348623853 0 1 -1
sustained-release,channel 1.0 0.000143348623853 0 1 -1
start,of 1.0 0.000143348623853 1 0 1
serum,creatinine 0.25 0.000286697247706 5 3 2
appears,generally 1.0 0.000143348623853 0 1 -1
observe,that 1.0 0.000143348623853 0 1 -1
treatment,practices 1.0 0.000143348623853 0 1 -1
only,enhances 1.0 0.000143348623853 1 0 1
and,particularly 1.0 0.00043004587156 0 3 -3
layers,iv 1.0 0.000143348623853 0 1 -1
and,has 0.181818181818 0.000573394495413 13 9 4
affected,response 1.0 0.000143348623853 1 0 1
volunteers,have 0.6 0.00043004587156 1 4 -3
as,well 0.0731707317073 0.00043004587156 19 22 -3
have,erroneously 1.0 0.000143348623853 1 0 1
objective,to 1.0 0.000286697247706 0 2 -2
continue,treatment 1.0 0.000143348623853 1 0 1
and,inhibited 1.0 0.000143348623853 0 1 -1
and,had 0.777777777778 0.00100344036697 1 8 -7
antidiabetics,oral 1.0 0.000143348623853 1 0 1
man,was 1.0 0.000143348623853 0 1 -1
on,low-dose 1.0 0.000143348623853 0 1 -1
substrate,is 1.0 0.000286697247706 0 2 -2
to,activation 1.0 0.000143348623853 0 1 -1
a,maximum 0.5 0.000286697247706 3 1 2
prior,to 0.190476190476 0.00114678899083 25 17 8
advised,when 0.6 0.00043004587156 4 1 3
pharmaceutical,abstracts 1.0 0.000143348623853 0 1 -1
anticoagulants,are 1.0 0.000143348623853 1 0 1
addictive,medications 1.0 0.000143348623853 0 1 -1
of,efficacy 1.0 0.00043004587156 0 3 -3
compounds,including 1.0 0.000143348623853 1 0 1
generated,from 1.0 0.000143348623853 0 1 -1
a,solution 1.0 0.000143348623853 0 1 -1
tmax,and 1.0 0.000143348623853 0 1 -1
added,concentration 1.0 0.000143348623853 0 1 -1
by,up 1.0 0.000716743119266 5 0 5
with,resistance 1.0 0.000286697247706 0 2 -2
neurochemical,and 1.0 0.000286697247706 0 2 -2
rate,was 1.0 0.000143348623853 0 1 -1
events,is 1.0 0.000143348623853 0 1 -1
doses,and 1.0 0.000143348623853 1 0 1
cultures,superinduced 1.0 0.000143348623853 0 1 -1
combined,week 1.0 0.000143348623853 0 1 -1
acid,diminished 1.0 0.000143348623853 1 0 1
elucidate,metal 1.0 0.000143348623853 0 1 -1
angiomax,in 1.0 0.000143348623853 0 1 -1
for,initial 1.0 0.000143348623853 0 1 -1
for,flolan 1.0 0.000143348623853 1 0 1
events,in 1.0 0.00043004587156 0 3 -3
ast,and 1.0 0.000143348623853 1 0 1
grapefruit,juice 0.538461538462 0.00100344036697 3 10 -7
studies,however 1.0 0.000286697247706 0 2 -2
providers,are 1.0 0.000143348623853 0 1 -1
anti-inflammatory,drugs 0.666666666667 0.000573394495413 5 1 4
still,advisable 1.0 0.000143348623853 1 0 1
dosing,lower 1.0 0.000143348623853 1 0 1
until,his 1.0 0.000143348623853 0 1 -1
date,levosimendan 1.0 0.000143348623853 0 1 -1
auc,hrs 0.6 0.00043004587156 1 4 -3
toxoids,and 1.0 0.000143348623853 1 0 1
a,meal 0.0 0.0 1 1 0
herbal,remedy 1.0 0.000286697247706 0 2 -2
lithiums,renal 1.0 0.000143348623853 1 0 1
be,reassessed 1.0 0.000286697247706 0 2 -2
glutamatergic,activation 1.0 0.000143348623853 0 1 -1
and,inhibition 1.0 0.000143348623853 0 1 -1
coated,plus 1.0 0.000143348623853 0 1 -1
day-old,embryos 1.0 0.000143348623853 0 1 -1
using,labetalol 1.0 0.000143348623853 1 0 1
a,potently 1.0 0.000143348623853 0 1 -1
on,arterial 1.0 0.000143348623853 1 0 1
lodine,like 1.0 0.000143348623853 1 0 1
either,poor 1.0 0.000143348623853 0 1 -1
meperidine,amphetamines 1.0 0.000286697247706 2 0 2
and,st 1.0 0.000143348623853 0 1 -1
may,respond 1.0 0.000143348623853 0 1 -1
dizziness,nausea 1.0 0.000143348623853 0 1 -1
actions,of 0.6 0.00043004587156 1 4 -3
results,would 1.0 0.000143348623853 1 0 1
membrane,properties 1.0 0.000286697247706 0 2 -2
lesions,of 1.0 0.000143348623853 0 1 -1
small,changes 1.0 0.000143348623853 0 1 -1
parietal,cells 1.0 0.000143348623853 0 1 -1
gabitril,is 1.0 0.000143348623853 0 1 -1
pregnancies,conceived 1.0 0.000143348623853 0 1 -1
and,hypoglycemic 1.0 0.000143348623853 1 0 1
glands,was 1.0 0.000143348623853 0 1 -1
was,the 0.0 0.0 1 1 0
ulcers,in 1.0 0.000143348623853 0 1 -1
synthetic,on 1.0 0.000143348623853 0 1 -1
nac,for 1.0 0.000143348623853 0 1 -1
therapy,were 1.0 0.000286697247706 0 2 -2
of,trileptal 0.6 0.00043004587156 4 1 3
mofetil,respectively 1.0 0.000143348623853 1 0 1
both,a 1.0 0.000573394495413 0 4 -4
of,twice 1.0 0.000143348623853 0 1 -1
been,inconsistent 1.0 0.000143348623853 0 1 -1
skin,discoloration 1.0 0.000143348623853 0 1 -1
the,hormone 1.0 0.000143348623853 0 1 -1
are,reports 1.0 0.000143348623853 1 0 1
kg,every 1.0 0.000143348623853 0 1 -1
tracleer,and 1.0 0.000143348623853 1 0 1
reduced,thus 1.0 0.000143348623853 1 0 1
and,vasopressin 1.0 0.000143348623853 0 1 -1
blockers,adrenergic 0.333333333333 0.000143348623853 2 1 1
and,discusses 1.0 0.000143348623853 0 1 -1
renal,calculi 1.0 0.000143348623853 0 1 -1
include,but 1.0 0.000286697247706 0 2 -2
evaluating,serum 1.0 0.000143348623853 0 1 -1
prolongation,of 0.333333333333 0.00129013761468 18 9 9
intravascular,volume 1.0 0.000143348623853 1 0 1
if,possible 0.333333333333 0.000143348623853 2 1 1
s,isomers 1.0 0.000143348623853 0 1 -1
between,vidaza 1.0 0.000143348623853 0 1 -1
carbamazepine,felbatol 1.0 0.000143348623853 1 0 1
pah,cannot 1.0 0.000143348623853 1 0 1
as,nimbex 1.0 0.000143348623853 1 0 1
low,hepatic 1.0 0.000143348623853 0 1 -1
basis,did 1.0 0.000143348623853 0 1 -1
be,borne 0.0 0.0 1 1 0
its,lack 1.0 0.00043004587156 0 3 -3
begun,in 0.0 0.0 1 1 0
which,metabolizes 1.0 0.000143348623853 0 1 -1
concerns,the 1.0 0.000143348623853 0 1 -1
warfarin-type,cyp2c9 1.0 0.000143348623853 0 1 -1
which,involved 1.0 0.000143348623853 1 0 1
hour,before 0.142857142857 0.000143348623853 3 4 -1
usually,give 1.0 0.000143348623853 0 1 -1
constipation,blurred 1.0 0.000143348623853 1 0 1
to,effect 1.0 0.000143348623853 0 1 -1
somatic,disease 1.0 0.000143348623853 0 1 -1
to,vomiting 1.0 0.000143348623853 1 0 1
daily,taken 0.0 0.0 1 1 0
receive,an 1.0 0.000143348623853 0 1 -1
of,enterococci 1.0 0.00043004587156 0 3 -3
some,inhibiting 1.0 0.000143348623853 0 1 -1
values,of 0.333333333333 0.000286697247706 2 4 -2
antigout,oral 1.0 0.000143348623853 0 1 -1
every,weeks 1.0 0.000143348623853 0 1 -1
cimetidine,albendazole 1.0 0.000143348623853 1 0 1
pharmacologic,activities 1.0 0.000143348623853 0 1 -1
nitrite,after 1.0 0.000143348623853 1 0 1
hybridization,we 1.0 0.000143348623853 1 0 1
xr,may 1.0 0.000143348623853 1 0 1
levels,possibly 1.0 0.000143348623853 1 0 1
to,solvents 1.0 0.000143348623853 0 1 -1
current,therapies 1.0 0.000143348623853 0 1 -1
hydrate,dietary 1.0 0.000143348623853 1 0 1
borne,in 0.0 0.0 1 1 0
and,supplemental 1.0 0.000143348623853 1 0 1
because,their 1.0 0.000143348623853 1 0 1
determined,before 1.0 0.000143348623853 1 0 1
from,macrovascular 1.0 0.000143348623853 0 1 -1
genetically,nervous 1.0 0.000143348623853 0 1 -1
one,controlled 0.0 0.0 1 1 0
gentamicin,methionine 1.0 0.000143348623853 1 0 1
not,accompanied 1.0 0.000143348623853 0 1 -1
botulinum,prior 1.0 0.000143348623853 1 0 1
describe,modest 1.0 0.000143348623853 1 0 1
be,an 0.666666666667 0.00114678899083 2 10 -8
andtolbutamide,did 1.0 0.000143348623853 0 1 -1
the,accumulation 1.0 0.000143348623853 0 1 -1
sodium,acid 1.0 0.000286697247706 2 0 2
be,as 1.0 0.000143348623853 0 1 -1
enhanced,or 1.0 0.000143348623853 0 1 -1
the,optimal 1.0 0.000573394495413 0 4 -4
with,reduced 0.333333333333 0.000143348623853 2 1 1
or,potassium-depleting 1.0 0.000143348623853 0 1 -1
their,prothrombin 0.333333333333 0.000143348623853 2 1 1
for,alone 0.5 0.000286697247706 3 1 2
false-negative,results 1.0 0.000286697247706 0 2 -2
with,reduces 1.0 0.000143348623853 1 0 1
prinivil,was 1.0 0.000143348623853 0 1 -1
conservatively,adjusted 1.0 0.000143348623853 1 0 1
shown,increased 1.0 0.000143348623853 0 1 -1
caution,however 1.0 0.000286697247706 0 2 -2
label,should 1.0 0.000143348623853 1 0 1
has,much 1.0 0.000143348623853 0 1 -1
drugs,within 1.0 0.000143348623853 0 1 -1
sustained,elevation 1.0 0.000143348623853 1 0 1
adequate,monitoring 1.0 0.000143348623853 1 0 1
with,who 1.0 0.000143348623853 0 1 -1
cefotan,and 1.0 0.000143348623853 1 0 1
aluminum-containing,preparations 1.0 0.000143348623853 0 1 -1
x,m 1.0 0.000286697247706 2 0 2
on,in 0.333333333333 0.000286697247706 2 4 -2
combination,are 1.0 0.000143348623853 0 1 -1
ms,patients 0.0 0.0 1 1 0
days,because 1.0 0.000143348623853 1 0 1
ca,subtypes 1.0 0.000143348623853 0 1 -1
latency,for 1.0 0.000143348623853 0 1 -1
this,oral 1.0 0.000143348623853 0 1 -1
itself,was 1.0 0.000143348623853 0 1 -1
since,paranoid 1.0 0.000143348623853 1 0 1
free,ions 1.0 0.000143348623853 0 1 -1
the,vasoconstrictive 1.0 0.000143348623853 1 0 1
such,reduction 1.0 0.000143348623853 1 0 1
are,observed 1.0 0.000143348623853 0 1 -1
of,regular 1.0 0.000143348623853 0 1 -1
body,tremors 1.0 0.000143348623853 0 1 -1
since,may 1.0 0.000716743119266 5 0 5
with,beta-blockers 1.0 0.000143348623853 1 0 1
were,given 0.666666666667 0.000573394495413 1 5 -4
regulated,by 1.0 0.000143348623853 0 1 -1
approximately,to 0.2 0.000143348623853 3 2 1
xa,and 1.0 0.000286697247706 0 2 -2
administration,in 1.0 0.000143348623853 0 1 -1
however,another 1.0 0.000143348623853 1 0 1
enrolled,in 1.0 0.00043004587156 0 3 -3
give,a 1.0 0.000143348623853 0 1 -1
dexamethasone,suppression 1.0 0.000143348623853 0 1 -1
the,neutropenic 1.0 0.000143348623853 1 0 1
problems,encountered 1.0 0.000143348623853 0 1 -1
disodium,interferes 1.0 0.000143348623853 1 0 1
monomeric,members 1.0 0.000143348623853 0 1 -1
is,one 0.5 0.000286697247706 3 1 2
probable,that 1.0 0.000143348623853 0 1 -1
wshow,no 1.0 0.000143348623853 0 1 -1
that,poor 1.0 0.000143348623853 0 1 -1
have,enhanced 1.0 0.000143348623853 1 0 1
with,brain 1.0 0.000143348623853 0 1 -1
interaction,effects 1.0 0.000143348623853 0 1 -1
dissociation,of 1.0 0.000143348623853 0 1 -1
an,apparent 1.0 0.000286697247706 0 2 -2
dependent,diabetic 1.0 0.000143348623853 0 1 -1
requires,tikosyn 1.0 0.000143348623853 1 0 1
we,have 1.0 0.000860091743119 0 6 -6
the,menstrual 1.0 0.000143348623853 0 1 -1
acting,drugs 1.0 0.000143348623853 0 1 -1
blood,coagulation 0.5 0.000286697247706 1 3 -2
transfers,were 1.0 0.000143348623853 0 1 -1
reproduction,studies 1.0 0.000143348623853 0 1 -1
medicine,without 1.0 0.000143348623853 0 1 -1
reduced,infusion 1.0 0.000143348623853 1 0 1
bosentan-,and 1.0 0.000143348623853 0 1 -1
same,evening 1.0 0.000143348623853 1 0 1
physical,activity 1.0 0.000286697247706 0 2 -2
factors,of 1.0 0.000143348623853 0 1 -1
their,associated 1.0 0.000143348623853 0 1 -1
by,alterations 1.0 0.000286697247706 0 2 -2
rats,tarsal 1.0 0.000143348623853 0 1 -1
transport,of 0.333333333333 0.000143348623853 1 2 -1
this,defect 1.0 0.000286697247706 0 2 -2
when,screening 1.0 0.000143348623853 0 1 -1
pediapred,others 1.0 0.000143348623853 0 1 -1
angiotensin-converting,enzyme 0.333333333333 0.000143348623853 2 1 1
antagonist,has 1.0 0.000143348623853 1 0 1
interferences,and 1.0 0.000143348623853 0 1 -1
lanoxin,lanoxicaps 1.0 0.000143348623853 1 0 1
the,potency 1.0 0.000143348623853 0 1 -1
documented,hypokalemia 1.0 0.000143348623853 0 1 -1
an,isoform 1.0 0.000143348623853 1 0 1
further,enhanced 1.0 0.000143348623853 0 1 -1
properties,such 1.0 0.000143348623853 1 0 1
were,inconclusive 1.0 0.000143348623853 0 1 -1
the,maximal 1.0 0.000286697247706 0 2 -2
study,administration 1.0 0.000143348623853 1 0 1
vitro,results 1.0 0.000143348623853 0 1 -1
alone,auc 1.0 0.000143348623853 1 0 1
defense,may 1.0 0.000143348623853 0 1 -1
but,it 0.333333333333 0.000143348623853 1 2 -1
medication,interferes 1.0 0.000143348623853 0 1 -1
but,is 1.0 0.000143348623853 1 0 1
can,combine 1.0 0.000143348623853 1 0 1
other,antianxiety 1.0 0.000143348623853 1 0 1
but,in 1.0 0.000286697247706 0 2 -2
toxicity,was 0.0 0.0 2 2 0
on,chronic 0.666666666667 0.000573394495413 5 1 4
cholinergic,stimulation 1.0 0.000143348623853 0 1 -1
although,hydroxy-corticosteroid 1.0 0.000143348623853 0 1 -1
mixed,overdosage 1.0 0.000143348623853 1 0 1
antidepressants,in 1.0 0.000143348623853 1 0 1
day,with 0.0 0.0 1 1 0
in,using 0.333333333333 0.000286697247706 2 4 -2
therefore,be 0.333333333333 0.000286697247706 2 4 -2
of,pregnancy 1.0 0.000286697247706 0 2 -2
uterine,rupture 1.0 0.000143348623853 1 0 1
and,ng 1.0 0.000143348623853 1 0 1
inhibition,of 0.352941176471 0.00344036697248 22 46 -24
synergistically,augmented 1.0 0.000143348623853 0 1 -1
heparins,as 1.0 0.000143348623853 0 1 -1
and,no 0.647058823529 0.00157683486239 3 14 -11
romazicon,in 1.0 0.000143348623853 1 0 1
at,levels 1.0 0.000143348623853 0 1 -1
recipients,a 1.0 0.000143348623853 1 0 1
and,long 1.0 0.000286697247706 0 2 -2
rifabutin,and 1.0 0.000143348623853 0 1 -1
been,receiving 1.0 0.000286697247706 0 2 -2
because,xigris 1.0 0.000143348623853 0 1 -1
or,enhance 1.0 0.000143348623853 0 1 -1
the,microvascular 1.0 0.000143348623853 0 1 -1
two,retrospective 1.0 0.000143348623853 0 1 -1
of,onset 1.0 0.000143348623853 1 0 1
neurological,toxicity 1.0 0.000143348623853 0 1 -1
consider,starting 1.0 0.000143348623853 0 1 -1
oral,ethinyl 1.0 0.000143348623853 0 1 -1
in,hiv-infected 1.0 0.000286697247706 0 2 -2
and,n1 0.0 0.0 1 1 0
human,pharmacokinetics 1.0 0.000286697247706 2 0 2
suggested,to 0.0 0.0 1 1 0
concentration,ca 0.0 0.0 1 1 0
extent,and 1.0 0.000143348623853 0 1 -1
from,masking 1.0 0.000143348623853 0 1 -1
unresponsive,to 1.0 0.000860091743119 0 6 -6
administered,at 0.2 0.000286697247706 6 4 2
administered,as 1.0 0.00043004587156 0 3 -3
receiving,prothrombin 1.0 0.000143348623853 1 0 1
ns,mg 1.0 0.000143348623853 0 1 -1
insufficiency,in 1.0 0.000143348623853 0 1 -1
affect,cardiac 1.0 0.000143348623853 0 1 -1
prevention,of 1.0 0.000143348623853 0 1 -1
vre,is 1.0 0.000143348623853 0 1 -1
reassessed,and 1.0 0.000143348623853 0 1 -1
converted,difluoroacetone 1.0 0.000143348623853 0 1 -1
experience,when 1.0 0.000143348623853 1 0 1
and,axert 1.0 0.000143348623853 1 0 1
color,development 1.0 0.000143348623853 0 1 -1
for,ketogenic 1.0 0.000143348623853 0 1 -1
kg,enhanced 1.0 0.000143348623853 1 0 1
specific,effects 1.0 0.000143348623853 1 0 1
reported,from 1.0 0.000143348623853 1 0 1
excystment,rates 1.0 0.000286697247706 0 2 -2
of,cyp2c19 0.333333333333 0.000143348623853 1 2 -1
a,similar 0.333333333333 0.000716743119266 5 10 -5
from,microg 1.0 0.000143348623853 0 1 -1
require,immediate 1.0 0.000143348623853 0 1 -1
of,cytochrome 0.428571428571 0.00129013761468 6 15 -9
addition,the 0.6 0.00043004587156 1 4 -3
monurol,a 1.0 0.000143348623853 1 0 1
ermbt,after 1.0 0.000143348623853 0 1 -1
and,within 1.0 0.000143348623853 1 0 1
observed,and 1.0 0.000286697247706 0 2 -2
cyp2d6,has 1.0 0.000143348623853 0 1 -1
strong,inducers 1.0 0.000286697247706 0 2 -2
used,inconcomitant 1.0 0.000143348623853 0 1 -1
research,specific 1.0 0.000143348623853 0 1 -1
differential,scanning 1.0 0.000143348623853 0 1 -1
for,duloxetine 1.0 0.000143348623853 0 1 -1
known,whether 0.555555555556 0.000716743119266 2 7 -5
isolated,single 1.0 0.000143348623853 0 1 -1
no,carcinogenicity 1.0 0.000143348623853 0 1 -1
demonstrated,for 1.0 0.000143348623853 0 1 -1
sprycel,with 1.0 0.000143348623853 1 0 1
the,enzyme-inducing 1.0 0.000143348623853 1 0 1
leydig,cell 1.0 0.000143348623853 0 1 -1
comparative,analysis 1.0 0.000143348623853 0 1 -1
system,when 1.0 0.000143348623853 1 0 1
ml,maalox 1.0 0.000143348623853 1 0 1
day,there 0.0 0.0 1 1 0
and,avoidance 1.0 0.000286697247706 0 2 -2
tract,where 1.0 0.000143348623853 0 1 -1
partners,of 1.0 0.000143348623853 0 1 -1
concurrently,patients 1.0 0.000143348623853 1 0 1
concurrently,plasma 1.0 0.000143348623853 1 0 1
transcription,was 1.0 0.000143348623853 0 1 -1
is,made 1.0 0.000143348623853 0 1 -1
reddish,stools 1.0 0.000143348623853 0 1 -1
incompletely,responsive 1.0 0.000143348623853 0 1 -1
may,interfere 0.142857142857 0.000573394495413 16 12 4
d3,administration 1.0 0.000143348623853 1 0 1
inhibit,adrenal 1.0 0.000143348623853 1 0 1
of,antacids 1.0 0.000143348623853 0 1 -1
for,deoxycytidine 1.0 0.000143348623853 0 1 -1
that,will 1.0 0.000143348623853 0 1 -1
the,discontinuance 1.0 0.000143348623853 1 0 1
considerations,are 1.0 0.000143348623853 0 1 -1
trial,of 0.0 0.0 1 1 0
after,initiation 0.75 0.000860091743119 7 1 6
vistide,and 1.0 0.000143348623853 1 0 1
treatment,costs 1.0 0.00043004587156 0 3 -3
mortality,is 1.0 0.000143348623853 0 1 -1
a,trend 1.0 0.000143348623853 0 1 -1
plasma,substrate 1.0 0.000143348623853 0 1 -1
reduced,adp-induced 1.0 0.000143348623853 0 1 -1
mortality,in 1.0 0.000143348623853 0 1 -1
i,suggesting 1.0 0.000143348623853 0 1 -1
polysaccharides,and 1.0 0.000143348623853 0 1 -1
time,point 1.0 0.000143348623853 0 1 -1
additive,coadministration 1.0 0.000143348623853 1 0 1
digi-,tab 1.0 0.000143348623853 0 1 -1
similar,responses 1.0 0.000143348623853 0 1 -1
concomitantly,may 1.0 0.000286697247706 2 0 2
inhibit,metabolism 1.0 0.000286697247706 0 2 -2
grepafloxacin,like 1.0 0.000143348623853 1 0 1
system,depressants 0.333333333333 0.000573394495413 8 4 4
either,h2 1.0 0.000143348623853 0 1 -1
test,it 1.0 0.000286697247706 0 2 -2
or,tmax 1.0 0.000143348623853 0 1 -1
clearance,accelerated 1.0 0.000143348623853 1 0 1
mg,resulted 1.0 0.000286697247706 2 0 2
azole,antifungal 1.0 0.000143348623853 1 0 1
of,ethinyl 0.0 0.0 3 3 0
extensively,metabolized 0.428571428571 0.00043004587156 2 5 -3
albuterol,strattera 1.0 0.000143348623853 1 0 1
alcohol,there 1.0 0.000143348623853 0 1 -1
microtubules,was 1.0 0.000143348623853 0 1 -1
approximately,or 1.0 0.000143348623853 0 1 -1
playing,golf 1.0 0.000143348623853 0 1 -1
be,increased 0.0 0.0 11 11 0
drug,interactions 0.461538461538 0.00172018348624 7 19 -12
with,gastric 1.0 0.000143348623853 0 1 -1
approximately,of 0.333333333333 0.000143348623853 1 2 -1
is,still 0.333333333333 0.000143348623853 1 2 -1
particularly,with 1.0 0.000143348623853 1 0 1
severe,bronchospasm 1.0 0.000143348623853 1 0 1
dose-response,models 1.0 0.000143348623853 0 1 -1
inotropic,such 1.0 0.000143348623853 1 0 1
mtx,in 1.0 0.000143348623853 0 1 -1
antiprothrombinemic,effect 1.0 0.000143348623853 0 1 -1
any,procedure 1.0 0.000143348623853 0 1 -1
to,resulting 1.0 0.000143348623853 1 0 1
and,variable 1.0 0.000143348623853 0 1 -1
transit-enhancing,effect 1.0 0.000143348623853 0 1 -1
morphine,pharmacokinetic 1.0 0.000143348623853 0 1 -1
of,fibrinogen 1.0 0.000143348623853 0 1 -1
induce,cytochromes 1.0 0.000143348623853 0 1 -1
can,do 1.0 0.000143348623853 0 1 -1
the,calculated 1.0 0.000143348623853 0 1 -1
very,rapidly 1.0 0.000143348623853 0 1 -1
time,at 1.0 0.000143348623853 0 1 -1
as,has 0.0 0.0 1 1 0
time,as 1.0 0.000143348623853 1 0 1
strong,inhibitors 0.666666666667 0.000573394495413 1 5 -4
an,immune 1.0 0.000143348623853 0 1 -1
known,risk 1.0 0.000143348623853 0 1 -1
exhibited,dose-proportional 1.0 0.000143348623853 0 1 -1
guinea,pig 1.0 0.000143348623853 0 1 -1
discontinued,promptly 1.0 0.000143348623853 0 1 -1
those,observed 0.0 0.0 1 1 0
taking,vioxx 0.0 0.0 1 1 0
little,has 1.0 0.000143348623853 0 1 -1
crossover,design 1.0 0.000143348623853 0 1 -1
vary,in 1.0 0.000716743119266 0 5 -5
the,pd2 1.0 0.000143348623853 0 1 -1
two,to 1.0 0.000143348623853 1 0 1
by,confidence 1.0 0.000143348623853 0 1 -1
their,need 1.0 0.000143348623853 0 1 -1
evening,should 1.0 0.000143348623853 0 1 -1
free,and 1.0 0.000143348623853 1 0 1
and,cyp3a5 1.0 0.000143348623853 0 1 -1
toxicokinetic,studies 1.0 0.000143348623853 0 1 -1
the,degree 0.142857142857 0.000286697247706 8 6 2
combination,study 1.0 0.000143348623853 1 0 1
the,production 0.2 0.000143348623853 2 3 -1
secretion,stimulated 1.0 0.000143348623853 0 1 -1
safely,tolerated 1.0 0.000143348623853 0 1 -1
supplemental,l-glutamine 1.0 0.000286697247706 2 0 2
each,to 1.0 0.000143348623853 1 0 1
amicar,transient 1.0 0.000143348623853 0 1 -1
observations,from 1.0 0.000143348623853 0 1 -1
cell,from 1.0 0.000143348623853 0 1 -1
n,hypotension 1.0 0.000143348623853 1 0 1
efficacy,toxicity 1.0 0.000143348623853 0 1 -1
wallerian,degeneration 1.0 0.000143348623853 0 1 -1
prevention,studies 1.0 0.000143348623853 0 1 -1
needed,their 1.0 0.000143348623853 0 1 -1
diethylnitrosamine,during 1.0 0.000143348623853 0 1 -1
contraction,was 1.0 0.000286697247706 0 2 -2
celebrex,mg 1.0 0.000143348623853 1 0 1
ketoconazole,and 0.0 0.0 1 1 0
creatinine,despite 1.0 0.000143348623853 0 1 -1
probably,reduces 1.0 0.000143348623853 1 0 1
be,significantly 1.0 0.000286697247706 0 2 -2
to,cite 1.0 0.000143348623853 0 1 -1
accutane,has 1.0 0.000286697247706 0 2 -2
a,clinically 0.75 0.000860091743119 1 7 -6
were,deaths 1.0 0.000143348623853 0 1 -1
may,antagonise 1.0 0.000143348623853 0 1 -1
taking,to 1.0 0.000143348623853 1 0 1
interactions,following 1.0 0.000143348623853 0 1 -1
dose,decrease 1.0 0.000143348623853 1 0 1
dopa,decarboxylase 1.0 0.000286697247706 0 2 -2
currently,underway 1.0 0.000143348623853 0 1 -1
p,and 0.0 0.0 1 1 0
chemically,similar 1.0 0.000143348623853 0 1 -1
an,individualized 1.0 0.000143348623853 0 1 -1
are,co-administered 1.0 0.000143348623853 1 0 1
removes,the 1.0 0.000143348623853 1 0 1
daily,for 0.0434782608696 0.000143348623853 11 12 -1
report,that 1.0 0.000143348623853 1 0 1
be,terminated 1.0 0.000143348623853 1 0 1
intramuscularly,injected 1.0 0.000143348623853 0 1 -1
alkaloid,congener 1.0 0.000143348623853 0 1 -1
neonates,and 1.0 0.000143348623853 0 1 -1
close,clinical 1.0 0.000143348623853 0 1 -1
dose,during 1.0 0.000143348623853 0 1 -1
and,loss 1.0 0.000143348623853 1 0 1
bioavailability,of 0.3 0.000860091743119 7 13 -6
neuronal,damage 1.0 0.000143348623853 1 0 1
of,torsade 1.0 0.000286697247706 2 0 2
out,and 1.0 0.000286697247706 0 2 -2
increased,both 1.0 0.000286697247706 0 2 -2
drugs,prolonging 1.0 0.000143348623853 0 1 -1
the,therapy 0.0 0.0 1 1 0
in,approximately 0.2 0.000143348623853 2 3 -1
histidine,modification 1.0 0.000143348623853 0 1 -1
g,hr 1.0 0.000143348623853 0 1 -1
promote,absorption 1.0 0.00043004587156 3 0 3
both,alone 1.0 0.000143348623853 0 1 -1
c,antiarrhythrnics 1.0 0.000143348623853 0 1 -1
blood-glucose,lowering 0.333333333333 0.000286697247706 2 4 -2
administration,for 1.0 0.000286697247706 0 2 -2
early,evidence 1.0 0.000143348623853 0 1 -1
situations,occur 1.0 0.000143348623853 0 1 -1
several,interacting 1.0 0.000143348623853 0 1 -1
to,cadmium 1.0 0.000143348623853 0 1 -1
glucose,in 1.0 0.00186353211009 0 13 -13
the,mechanism 0.647058823529 0.00157683486239 3 14 -11
pregnant,and 1.0 0.000143348623853 0 1 -1
glucose,is 1.0 0.000286697247706 0 2 -2
that,interfere 0.333333333333 0.000286697247706 2 4 -2
serious,clinical 1.0 0.000143348623853 1 0 1
including,midamor 1.0 0.000143348623853 1 0 1
altered,for 1.0 0.000143348623853 0 1 -1
the,polyene 1.0 0.000143348623853 0 1 -1
insufficient,to 1.0 0.000143348623853 1 0 1
low,results 1.0 0.000143348623853 0 1 -1
with,multiple 0.428571428571 0.00043004587156 5 2 3
and,downward 1.0 0.000143348623853 1 0 1
complications,blurred 1.0 0.000143348623853 1 0 1
days,however 1.0 0.000143348623853 1 0 1
nizoral,muscle 1.0 0.000143348623853 0 1 -1
channel,an 1.0 0.000143348623853 0 1 -1
auc,was 1.0 0.00043004587156 0 3 -3
longer,intervals 1.0 0.000143348623853 1 0 1
compazine,sparine 1.0 0.000143348623853 0 1 -1
isolated,rabbit 1.0 0.000143348623853 0 1 -1
laboratory,monitoring 1.0 0.000286697247706 0 2 -2
those,receiving 0.333333333333 0.000143348623853 1 2 -1
celecoxib,metabolism 1.0 0.000143348623853 0 1 -1
day,decreases 1.0 0.000143348623853 1 0 1
agents,folic 1.0 0.000286697247706 0 2 -2
after,prolonged 1.0 0.000143348623853 0 1 -1
exists,in 1.0 0.000143348623853 0 1 -1
rofecoxib,mg 1.0 0.000143348623853 0 1 -1
n,had 1.0 0.000143348623853 0 1 -1
as,motrin 1.0 0.000143348623853 0 1 -1
blockers,certain 1.0 0.000143348623853 1 0 1
of,hepatic 0.142857142857 0.000286697247706 6 8 -2
conduction,such 1.0 0.000143348623853 1 0 1
or,quite 1.0 0.000716743119266 0 5 -5
without,alterations 1.0 0.000143348623853 0 1 -1
in,conjunction 0.0666666666667 0.000143348623853 8 7 1
an,active 1.0 0.00043004587156 0 3 -3
endogenous,prostaglandin 1.0 0.000143348623853 1 0 1
genetic,data 1.0 0.000143348623853 0 1 -1
the,tarceva 1.0 0.000143348623853 1 0 1
the,intracellular 0.2 0.000143348623853 3 2 1
phenothiazines,taking 1.0 0.000143348623853 1 0 1
over,three 1.0 0.000143348623853 0 1 -1
or,innovar 1.0 0.000143348623853 1 0 1
is,concluded 0.2 0.000143348623853 2 3 -1
serious,opportunistic 1.0 0.000143348623853 0 1 -1
n-oxide,were 1.0 0.000143348623853 0 1 -1
in,these 0.444444444444 0.00114678899083 5 13 -8
the,interindividual 1.0 0.000143348623853 0 1 -1
interactions,due 1.0 0.000286697247706 0 2 -2
given,injections 1.0 0.000143348623853 0 1 -1
of,prostaglandin 0.5 0.000286697247706 3 1 2
yielded,similar 1.0 0.000143348623853 0 1 -1
or,chronic 1.0 0.000143348623853 0 1 -1
trileptal,greater 1.0 0.000143348623853 1 0 1
pronounced,effect 1.0 0.000143348623853 1 0 1
tablets,should 0.0 0.0 1 1 0
of,combined 0.428571428571 0.00043004587156 2 5 -3
of,grapefruit 1.0 0.000573394495413 0 4 -4
capsules,are 1.0 0.000143348623853 1 0 1
agents,but 1.0 0.000143348623853 1 0 1
metabolism,to 1.0 0.000143348623853 1 0 1
protein-bound,pbi 1.0 0.00043004587156 0 3 -3
or,was 0.6 0.00043004587156 1 4 -3
unbound,to 1.0 0.000143348623853 0 1 -1
the,last 0.777777777778 0.00100344036697 1 8 -7
of,stress 1.0 0.000143348623853 0 1 -1
patients,concomitantly 0.666666666667 0.000573394495413 5 1 4
cell,permeability 1.0 0.000143348623853 0 1 -1
or,uridine 1.0 0.000143348623853 0 1 -1
a,slight 0.714285714286 0.000716743119266 6 1 5
nonsteroidal,antiinflammatory 0.333333333333 0.000143348623853 2 1 1
amplitudes,of 1.0 0.00043004587156 0 3 -3
in,but 1.0 0.000143348623853 1 0 1
minipill,preparations 1.0 0.000143348623853 1 0 1
prothrombin,time 0.142857142857 0.00129013761468 27 36 -9
additional,measures 1.0 0.000143348623853 0 1 -1
chylomicron-like,emulsions 1.0 0.000143348623853 0 1 -1
human,heart 1.0 0.000286697247706 0 2 -2
thus,agents 1.0 0.000143348623853 0 1 -1
the,implications 1.0 0.000143348623853 0 1 -1
days,should 1.0 0.000143348623853 1 0 1
been,done 0.0 0.0 1 1 0
the,lectin 1.0 0.000143348623853 0 1 -1
danger,of 1.0 0.00043004587156 3 0 3
concomitant,single 1.0 0.000143348623853 1 0 1
concentrations,fold 1.0 0.000143348623853 0 1 -1
nabilone,should 1.0 0.000143348623853 1 0 1
concentration,and 0.5 0.000573394495413 6 2 4
phenotype,and 1.0 0.000143348623853 0 1 -1
one,at 1.0 0.000143348623853 0 1 -1
thioridizine,or 1.0 0.000143348623853 0 1 -1
was,assessed 1.0 0.000143348623853 0 1 -1
simulect,is 1.0 0.000143348623853 0 1 -1
a2-selective,agonist 1.0 0.000143348623853 1 0 1
single,oral 0.2 0.000286697247706 4 6 -2
closely,watched 1.0 0.000143348623853 0 1 -1
a,pill 1.0 0.000143348623853 0 1 -1
inhibit,cyp 0.0 0.0 1 1 0
inulin,method 1.0 0.000143348623853 0 1 -1
employed,because 1.0 0.000143348623853 1 0 1
buspirone,hydrochloride 1.0 0.000143348623853 1 0 1
a,focus 1.0 0.000143348623853 0 1 -1
are,also 0.230769230769 0.00043004587156 5 8 -3
potassium-sparing,with 1.0 0.000143348623853 1 0 1
susceptible,patients 0.333333333333 0.000143348623853 1 2 -1
acarbose,has 0.0 0.0 1 1 0
by,following 1.0 0.000143348623853 1 0 1
exacerbation,or 1.0 0.000143348623853 1 0 1
with,an 0.161290322581 0.000716743119266 18 13 5
exacerbation,of 1.0 0.000143348623853 0 1 -1
with,as 0.333333333333 0.000286697247706 4 2 2
with,at 0.5 0.000286697247706 1 3 -2
significant,teratogenic 1.0 0.000143348623853 0 1 -1
important,alterations 1.0 0.000143348623853 0 1 -1
changes,may 1.0 0.00043004587156 0 3 -3
in,binding 1.0 0.000143348623853 1 0 1
or,even 1.0 0.000143348623853 0 1 -1
or,salicylic 1.0 0.000286697247706 0 2 -2
contraception,alone 1.0 0.000143348623853 0 1 -1
mean,inr 1.0 0.000143348623853 0 1 -1
dihydroxycholecalciferol,d3 1.0 0.000143348623853 0 1 -1
to,match 1.0 0.000143348623853 0 1 -1
duloxetine,and 0.0 0.0 1 1 0
other,strong 0.0 0.0 2 2 0
the,paraaminohippurate 1.0 0.000143348623853 0 1 -1
of,nondepolarizing 0.2 0.000143348623853 3 2 1
of,systemically 1.0 0.000143348623853 0 1 -1
that,take 1.0 0.000143348623853 0 1 -1
ability,of 0.5 0.000286697247706 1 3 -2
and,minimizes 1.0 0.000143348623853 1 0 1
n,vs 1.0 0.000143348623853 0 1 -1
fold,elevations 1.0 0.000143348623853 1 0 1
orally,inhaled 0.0 0.0 1 1 0
concomitant,agent 0.0 0.0 1 1 0
the,groups 0.333333333333 0.000143348623853 1 2 -1
studies,with 0.707317073171 0.00415711009174 6 35 -29
six,healthy 1.0 0.000143348623853 1 0 1
most,events 1.0 0.000143348623853 0 1 -1
was,combined 0.0 0.0 1 1 0
with,appropriate 1.0 0.000286697247706 0 2 -2
etopophos,with 1.0 0.000143348623853 1 0 1
anemia,associated 1.0 0.000143348623853 0 1 -1
translocation,when 1.0 0.000143348623853 0 1 -1
a,modest 0.5 0.000286697247706 3 1 2
oral,unreliable 1.0 0.000143348623853 1 0 1
days,or 1.0 0.000286697247706 0 2 -2
system,particularly 1.0 0.000143348623853 0 1 -1
and,long-term 1.0 0.000143348623853 0 1 -1
potentiating,action 1.0 0.000143348623853 1 0 1
with,rheumatoid 1.0 0.000143348623853 0 1 -1
taking,fortovase 1.0 0.000143348623853 0 1 -1
hivid,has 1.0 0.000143348623853 1 0 1
days,of 0.647058823529 0.00157683486239 3 14 -11
administrative,arrangements 1.0 0.000143348623853 0 1 -1
relevant,interaction 1.0 0.000143348623853 1 0 1
if,replacing 1.0 0.000143348623853 1 0 1
an,open 1.0 0.000286697247706 0 2 -2
vasoconstrictive,and 1.0 0.000143348623853 1 0 1
pemphigoid,and 1.0 0.000143348623853 1 0 1
data,raise 1.0 0.000143348623853 0 1 -1
and,undetectable 1.0 0.000143348623853 0 1 -1
highly,active 1.0 0.000286697247706 0 2 -2
proteins,or 1.0 0.000143348623853 1 0 1
or,swelling 1.0 0.000143348623853 0 1 -1
one-third,when 1.0 0.000143348623853 0 1 -1
b-cell,dependent 1.0 0.000143348623853 0 1 -1
its,breakdown 1.0 0.000143348623853 1 0 1
effects,due 0.333333333333 0.000143348623853 1 2 -1
high,risk 1.0 0.000860091743119 6 0 6
free,cmin 1.0 0.000143348623853 0 1 -1
day,the 1.0 0.000143348623853 0 1 -1
periodic,liver 1.0 0.000143348623853 0 1 -1
duloxetine-treated,patients 1.0 0.000143348623853 0 1 -1
instances,of 0.0 0.0 2 2 0
relating,to 1.0 0.000143348623853 0 1 -1
presents,a 1.0 0.000143348623853 0 1 -1
cystic,fluid 1.0 0.000143348623853 1 0 1
also,to 0.0 0.0 1 1 0
because,anafranil 1.0 0.000143348623853 1 0 1
n-allylnormetazocine,nanm 1.0 0.000143348623853 0 1 -1
suppress,reactions 1.0 0.000143348623853 0 1 -1
post,myocardial 1.0 0.000143348623853 0 1 -1
flares,coupled 1.0 0.000143348623853 0 1 -1
completely,cleared 1.0 0.000143348623853 0 1 -1
mydriasis,diplopia 1.0 0.000143348623853 0 1 -1
considered,by 1.0 0.000143348623853 0 1 -1
aeruginosa,serotype 1.0 0.000286697247706 0 2 -2
objective,was 1.0 0.000286697247706 0 2 -2
conclusions,everolimus 1.0 0.000143348623853 0 1 -1
required,when 0.25 0.000286697247706 3 5 -2
demonstrated,by 1.0 0.000286697247706 0 2 -2
out,mainly 1.0 0.000143348623853 0 1 -1
toxic,product 1.0 0.000143348623853 0 1 -1
infiltration,of 1.0 0.000143348623853 0 1 -1
these,differences 1.0 0.000286697247706 0 2 -2
that,either 1.0 0.00043004587156 0 3 -3
this,inhibitory 1.0 0.000143348623853 0 1 -1
and,acamprosate 1.0 0.000143348623853 0 1 -1
is,cleared 1.0 0.000143348623853 0 1 -1
to,after 0.0 0.0 1 1 0
pharmacodynamics,or 1.0 0.000143348623853 0 1 -1
leustatin,injection 1.0 0.000143348623853 0 1 -1
advisable,for 1.0 0.000143348623853 0 1 -1
the,combined 0.111111111111 0.000143348623853 5 4 1
been,co-administered 0.0 0.0 1 1 0
several,transcription 1.0 0.000143348623853 0 1 -1
serum,meq 1.0 0.000143348623853 1 0 1
observed,carefully 0.6 0.00043004587156 4 1 3
meal,of 1.0 0.000143348623853 0 1 -1
may,therefore 0.0 0.0 1 1 0
delaying,elimination 1.0 0.000286697247706 2 0 2
side,or 1.0 0.000143348623853 0 1 -1
are,usually 1.0 0.000143348623853 1 0 1
warfarin,digoxin 1.0 0.000143348623853 1 0 1
symptoms,severe 1.0 0.000143348623853 1 0 1
be,refractory 1.0 0.000143348623853 1 0 1
toxicity,occur 1.0 0.000143348623853 1 0 1
so,plasma 1.0 0.000143348623853 1 0 1
examining,mg 1.0 0.000143348623853 1 0 1
including,interactions 1.0 0.000143348623853 0 1 -1
between,june 1.0 0.000143348623853 0 1 -1
neither,influenced 1.0 0.000143348623853 0 1 -1
or,t 1.0 0.000286697247706 0 2 -2
or,s 0.0 0.0 1 1 0
general,such 1.0 0.000286697247706 2 0 2
or,x 1.0 0.000143348623853 0 1 -1
antidiuretic,activity 1.0 0.000143348623853 0 1 -1
or,a 0.333333333333 0.000286697247706 2 4 -2
or,n 1.0 0.000143348623853 1 0 1
or,m 1.0 0.000143348623853 0 1 -1
with,maois 1.0 0.000143348623853 1 0 1
or,h 0.333333333333 0.000143348623853 1 2 -1
and,that 0.5 0.00143348623853 5 15 -10
females,dosed 1.0 0.000143348623853 0 1 -1
also,additive 1.0 0.000143348623853 1 0 1
with,equetrotm 0.333333333333 0.000143348623853 1 2 -1
complete,across 1.0 0.000143348623853 0 1 -1
agents,these 0.0 0.0 1 1 0
multiple-dose,suggesting 1.0 0.000143348623853 0 1 -1
are,increased 1.0 0.00043004587156 3 0 3
urinary,protein 1.0 0.000143348623853 0 1 -1
pulmonary,function 1.0 0.000143348623853 0 1 -1
interacting,mechanisms 1.0 0.000143348623853 0 1 -1
the,anti-coagulant 1.0 0.000143348623853 0 1 -1
exogenous,respiration 1.0 0.000286697247706 0 2 -2
concentrations,that 1.0 0.000143348623853 0 1 -1
acitretin,interferes 1.0 0.000143348623853 1 0 1
nalfon,to 1.0 0.000143348623853 1 0 1
this,the 1.0 0.000143348623853 0 1 -1
l-tyrosine,and 1.0 0.000143348623853 1 0 1
dose,adjustment 0.36 0.00129013761468 8 17 -9
available,it 1.0 0.000143348623853 0 1 -1
special,populations 1.0 0.000143348623853 0 1 -1
biochemical,activity 1.0 0.000716743119266 0 5 -5
medicine,such 1.0 0.000143348623853 0 1 -1
to,vehicle- 1.0 0.000143348623853 1 0 1
mcg,of 0.0 0.0 1 1 0
substantial,increases 1.0 0.000143348623853 1 0 1
of,cefditoren 0.333333333333 0.000143348623853 2 1 1
about,one-half 1.0 0.000143348623853 0 1 -1
was,reduced 0.0 0.0 5 5 0
necessitating,an 0.0 0.0 1 1 0
plasma,kinetics 1.0 0.000143348623853 0 1 -1
enzyme,inhibitor 1.0 0.000143348623853 1 0 1
linear,logarithmic 1.0 0.000143348623853 0 1 -1
diminish,or 1.0 0.000143348623853 1 0 1
breakthrough,bleeding 1.0 0.000716743119266 0 5 -5
beginning,discontinuing 1.0 0.000143348623853 1 0 1
previous,findings 1.0 0.000143348623853 0 1 -1
and,current 1.0 0.000143348623853 1 0 1
improved,permeation 1.0 0.000143348623853 0 1 -1
data,where 1.0 0.000143348623853 1 0 1
between,trileptal 1.0 0.000143348623853 0 1 -1
before,intramuscular 1.0 0.000143348623853 1 0 1
overdose,cholinergic 1.0 0.000143348623853 0 1 -1
adequately,studied 1.0 0.000143348623853 0 1 -1
consequently,prothrombin 1.0 0.000143348623853 0 1 -1
prescribing,information 1.0 0.00043004587156 0 3 -3
toxicity,should 1.0 0.000286697247706 2 0 2
diplococcus,pneumoniae 1.0 0.000143348623853 0 1 -1
but,physicians 1.0 0.000286697247706 2 0 2
formation,that 1.0 0.000143348623853 0 1 -1
reuptake,and 1.0 0.000143348623853 1 0 1
regional,perfusion 1.0 0.000143348623853 0 1 -1
therapy,indicate 1.0 0.000143348623853 0 1 -1
patients,currently 0.0 0.0 1 1 0
subjects,when 1.0 0.000143348623853 1 0 1
depression,produced 1.0 0.000143348623853 0 1 -1
serum-deprived,serum 1.0 0.000143348623853 0 1 -1
mcg,bid 0.333333333333 0.000143348623853 2 1 1
mefloquineuine,causes 1.0 0.000143348623853 0 1 -1
whereas,b 1.0 0.000143348623853 0 1 -1
for,erectile 1.0 0.000143348623853 0 1 -1
therapies,may 1.0 0.000143348623853 0 1 -1
preliminary,whole-cell 1.0 0.000143348623853 0 1 -1
concentrations,may 0.5 0.000573394495413 2 6 -4
or,partner 1.0 0.000143348623853 0 1 -1
is,essentially 1.0 0.000143348623853 0 1 -1
it,concomitantly 0.0 0.0 1 1 0
channel-blockers,ace 1.0 0.000143348623853 0 1 -1
drug-drug,pharmacokinetic 1.0 0.000286697247706 0 2 -2
intravenous,placebo 1.0 0.000143348623853 0 1 -1
existing,clinical 1.0 0.000143348623853 0 1 -1
selegiline,combination 1.0 0.000143348623853 1 0 1
two,percent 1.0 0.000286697247706 2 0 2
with,hypercholesterolemia 1.0 0.000143348623853 0 1 -1
tikosyn,does 1.0 0.000286697247706 0 2 -2
however,since 0.0 0.0 1 1 0
general,no 1.0 0.000143348623853 0 1 -1
on,glycosides 1.0 0.000143348623853 0 1 -1
vasoactive,resulting 1.0 0.000143348623853 1 0 1
days,day 1.0 0.000143348623853 0 1 -1
or,biocytin 1.0 0.000286697247706 0 2 -2
mg,capsule 0.333333333333 0.000143348623853 2 1 1
degree,when 1.0 0.000143348623853 0 1 -1
therapeutic,windows 1.0 0.000286697247706 0 2 -2
same,enzyme 1.0 0.000143348623853 0 1 -1
closely,related 1.0 0.000286697247706 2 0 2
are,other 1.0 0.000143348623853 0 1 -1
involving,levo-dromoran 1.0 0.000143348623853 0 1 -1
detected,except 1.0 0.000143348623853 0 1 -1
mg,single 0.0 0.0 2 2 0
considerably,enhance 1.0 0.000143348623853 0 1 -1
blockers,cardiac 1.0 0.000286697247706 0 2 -2
are,dizziness 1.0 0.000143348623853 0 1 -1
since,nsaids 1.0 0.000143348623853 1 0 1
angina,myocardial 1.0 0.000143348623853 0 1 -1
proleukin-induced,side 1.0 0.000143348623853 1 0 1
with,emtriva 1.0 0.000143348623853 0 1 -1
p,in 0.0 0.0 1 1 0
predisposing,to 0.0 0.0 1 1 0
severe,events 1.0 0.000143348623853 0 1 -1
block,is 1.0 0.000143348623853 1 0 1
protein-bound,anafranil 1.0 0.000143348623853 0 1 -1
kidneys,and 1.0 0.00043004587156 0 3 -3
ventral,tubercle 1.0 0.000143348623853 0 1 -1
eight,healthy 0.0 0.0 1 1 0
elapse,before 0.428571428571 0.00043004587156 2 5 -3
p2,may 1.0 0.000143348623853 0 1 -1
drugs,aeds 0.333333333333 0.000143348623853 1 2 -1
for,which 1.0 0.000860091743119 0 6 -6
apoptosis,can 1.0 0.000143348623853 0 1 -1
central,stimulant 1.0 0.000573394495413 4 0 4
and,hour 1.0 0.000143348623853 1 0 1
beta-blockers,salts 1.0 0.000286697247706 2 0 2
decreasing,components 1.0 0.000143348623853 0 1 -1
mg,increased 1.0 0.00043004587156 3 0 3
be,mixed 1.0 0.000716743119266 0 5 -5
or,structural 1.0 0.000143348623853 0 1 -1
brevibloc,on 1.0 0.000143348623853 0 1 -1
withdrawn,at 1.0 0.000286697247706 2 0 2
nonsteroidal,probably 1.0 0.000143348623853 1 0 1
preparations,produced 1.0 0.000143348623853 0 1 -1
receiving,thiazide 1.0 0.000286697247706 0 2 -2
in,sensitivity 1.0 0.000143348623853 0 1 -1
although,much 1.0 0.000143348623853 0 1 -1
effects,deriving 1.0 0.000143348623853 0 1 -1
twice,the 1.0 0.00043004587156 0 3 -3
before,such 1.0 0.000143348623853 0 1 -1
cautiously,in 0.714285714286 0.000716743119266 6 1 5
cautiously,if 1.0 0.000143348623853 0 1 -1
many,of 1.0 0.000286697247706 0 2 -2
as,prolonged 1.0 0.000286697247706 0 2 -2
rupture,or 1.0 0.000143348623853 1 0 1
human,dose 1.0 0.00172018348624 0 12 -12
crescentic,iga 1.0 0.000143348623853 1 0 1
of,single 0.142857142857 0.000143348623853 3 4 -1
tremor,rigidity 1.0 0.000143348623853 0 1 -1
these,if 1.0 0.000143348623853 0 1 -1
critical,fall 1.0 0.000143348623853 0 1 -1
not,exhibit 0.0 0.0 1 1 0
superinduced,by 1.0 0.000143348623853 0 1 -1
on,developing 1.0 0.000143348623853 0 1 -1
data,showed 1.0 0.000143348623853 0 1 -1
with,derivatives 1.0 0.000143348623853 0 1 -1
preparations,should 1.0 0.00043004587156 0 3 -3
to,steady 1.0 0.000143348623853 1 0 1
are,considerably 1.0 0.000143348623853 0 1 -1
restricted,antagonist 1.0 0.000143348623853 1 0 1
agents,which 0.2 0.000143348623853 2 3 -1
is,different 1.0 0.000143348623853 1 0 1
probenecid,the 1.0 0.000143348623853 1 0 1
warfarin,the 0.2 0.000143348623853 2 3 -1
have,excluded 1.0 0.000286697247706 0 2 -2
acebutolol,and 1.0 0.000143348623853 0 1 -1
or,shampoos 1.0 0.000143348623853 0 1 -1
egf-,or 1.0 0.000143348623853 1 0 1
metabolism,was 1.0 0.000143348623853 0 1 -1
the,medium 1.0 0.000143348623853 0 1 -1
counts,related 1.0 0.000143348623853 0 1 -1
out,possible 1.0 0.000143348623853 0 1 -1
and,paraclinical 1.0 0.000143348623853 0 1 -1
auc,of 0.632653061224 0.00444380733945 40 9 31
enoxacin,does 1.0 0.000143348623853 0 1 -1
many,that 1.0 0.000716743119266 0 5 -5
auc,or 1.0 0.000286697247706 0 2 -2
of,serious 0.466666666667 0.00100344036697 11 4 7
neural,pathways 1.0 0.000143348623853 0 1 -1
potassium-depleting,are 1.0 0.000143348623853 1 0 1
by,protein-binding 1.0 0.000143348623853 0 1 -1
faslodex,in 1.0 0.00043004587156 0 3 -3
coadministered,than 1.0 0.000143348623853 1 0 1
receiving,nonselective 1.0 0.000143348623853 1 0 1
regularly,for 0.333333333333 0.000143348623853 1 2 -1
n,for 1.0 0.000143348623853 0 1 -1
either,medicine 1.0 0.000143348623853 1 0 1
we,examined 1.0 0.000286697247706 0 2 -2
regimens,has 1.0 0.000143348623853 0 1 -1
an,unsatisfactory 1.0 0.000143348623853 1 0 1
substrate,should 1.0 0.000143348623853 0 1 -1
several-,fold 1.0 0.000143348623853 0 1 -1
dipyridamole,may 1.0 0.000143348623853 1 0 1
of,lifestyle 1.0 0.000143348623853 0 1 -1
anagrelide,alone 1.0 0.000143348623853 1 0 1
vasorelaxation,in 1.0 0.000143348623853 0 1 -1
follicle-stimulating,hormone 1.0 0.000143348623853 0 1 -1
low,clinically 1.0 0.000143348623853 0 1 -1
interactions,observed 1.0 0.000143348623853 1 0 1
coingestion,of 1.0 0.000143348623853 1 0 1
competitive,inhibitor 1.0 0.000143348623853 1 0 1
asparagine,levels 1.0 0.000286697247706 2 0 2
pain,or 1.0 0.000143348623853 0 1 -1
diuretics,fosinopril 1.0 0.000143348623853 1 0 1
tablets,results 1.0 0.000286697247706 2 0 2
propranolol,increases 1.0 0.000143348623853 1 0 1
no,greater 1.0 0.000143348623853 1 0 1
rna,from 1.0 0.000143348623853 0 1 -1
taking,therapy 1.0 0.000143348623853 1 0 1
effect,will 1.0 0.000143348623853 1 0 1
longitudinal,studies 1.0 0.000143348623853 0 1 -1
and,during 1.0 0.00043004587156 0 3 -3
the,bmax 1.0 0.000143348623853 0 1 -1
processing,functions 1.0 0.000143348623853 0 1 -1
physicians,can 1.0 0.000143348623853 0 1 -1
controlled,parallel 1.0 0.000143348623853 0 1 -1
advantage,of 1.0 0.000143348623853 0 1 -1
at,intermediate 1.0 0.000143348623853 0 1 -1
subjects,administered 1.0 0.000143348623853 1 0 1
of,blocking 1.0 0.000286697247706 2 0 2
rise,to 0.0 0.0 1 1 0
the,major 0.733333333333 0.00157683486239 2 13 -11
fat,redistribution 1.0 0.000143348623853 0 1 -1
potential,components 1.0 0.000286697247706 0 2 -2
glyburide,glyburide 1.0 0.000143348623853 0 1 -1
the,derivative 1.0 0.000143348623853 0 1 -1
conditions,similar 1.0 0.000143348623853 1 0 1
approximately,equal 1.0 0.000143348623853 0 1 -1
present,a 0.0 0.0 1 1 0
consequently,with 1.0 0.000143348623853 0 1 -1
in,non-diabetics 1.0 0.000143348623853 0 1 -1
this,specificity 1.0 0.000143348623853 0 1 -1
arginine,in 1.0 0.000286697247706 0 2 -2
doxazosin,mesylate 1.0 0.000286697247706 0 2 -2
all,agents 1.0 0.000143348623853 0 1 -1
and,cmin 0.6 0.00043004587156 4 1 3
motor,effects 1.0 0.000143348623853 1 0 1
hcl,a 1.0 0.000143348623853 0 1 -1
conversely,at 1.0 0.000143348623853 0 1 -1
exposure,general 1.0 0.000143348623853 0 1 -1
confusional,states 1.0 0.000143348623853 1 0 1
type,diabetics 1.0 0.000143348623853 0 1 -1
were,elevated 1.0 0.000143348623853 0 1 -1
or,compounds 1.0 0.000143348623853 0 1 -1
derivatives,or 1.0 0.000286697247706 2 0 2
for,glycosuria 1.0 0.000143348623853 0 1 -1
anesthetics,general 1.0 0.000143348623853 1 0 1
main,hemostatic 1.0 0.000143348623853 1 0 1
t3,uptake 1.0 0.000573394495413 0 4 -4
the,cyp3a 1.0 0.000143348623853 0 1 -1
false,low 1.0 0.000143348623853 0 1 -1
levels,has 1.0 0.000143348623853 1 0 1
such,preparations 0.333333333333 0.000143348623853 1 2 -1
strong,cyp3a4 0.666666666667 0.000573394495413 5 1 4
clinical,importance 0.0 0.0 1 1 0
which,competes 1.0 0.000143348623853 1 0 1
and,potentiates 1.0 0.000143348623853 0 1 -1
habituating,potential 1.0 0.000143348623853 0 1 -1
fold,lower 1.0 0.000143348623853 1 0 1
and,neither 1.0 0.000143348623853 0 1 -1
on,in-vitro 1.0 0.000143348623853 0 1 -1
period,particularly 1.0 0.000143348623853 1 0 1
established,in 1.0 0.000143348623853 0 1 -1
taken,by 1.0 0.000286697247706 0 2 -2
resulting,respiratory 1.0 0.000143348623853 1 0 1
concomitant,chemotherapy 1.0 0.000143348623853 0 1 -1
at,some 1.0 0.000143348623853 1 0 1
infused,over 1.0 0.000143348623853 0 1 -1
liver,weight 1.0 0.000143348623853 0 1 -1
view,however 1.0 0.000143348623853 0 1 -1
not,significantly 0.851851851852 0.00329701834862 2 25 -23
of,mental 1.0 0.000143348623853 0 1 -1
the,blockade 1.0 0.000143348623853 0 1 -1
and,mmol 1.0 0.000143348623853 0 1 -1
concentrations,were 0.529411764706 0.00129013761468 4 13 -9
at,microm 0.0 0.0 1 1 0
with,fluoxetine 1.0 0.000143348623853 0 1 -1
kerastick,for 0.0 0.0 1 1 0
lodine,is 1.0 0.000143348623853 1 0 1
sympathomimet-ics,channel 1.0 0.000143348623853 0 1 -1
on,overall 1.0 0.000143348623853 0 1 -1
separated,from 1.0 0.000143348623853 1 0 1
excessive,widening 0.0 0.0 1 1 0
by,electrocardiographic 1.0 0.000286697247706 0 2 -2
no,platelet 1.0 0.000143348623853 0 1 -1
cyp2a6,cyp2c9 1.0 0.000573394495413 0 4 -4
determination,of 1.0 0.000716743119266 0 5 -5
mellitus,certain 1.0 0.000143348623853 0 1 -1
accumulated,in 1.0 0.000143348623853 1 0 1
gabitril,with 1.0 0.000286697247706 0 2 -2
sa,and 1.0 0.000143348623853 0 1 -1
significant,abnormal 1.0 0.000143348623853 0 1 -1
which,alterations 1.0 0.000143348623853 0 1 -1
receiving,to 1.0 0.000143348623853 1 0 1
administering,etopophos 1.0 0.000143348623853 1 0 1
an,excessive 0.6 0.00043004587156 4 1 3
those,undergoing 1.0 0.000143348623853 0 1 -1
serious,or 1.0 0.000286697247706 0 2 -2
prostaglandin,synthetase 1.0 0.000286697247706 0 2 -2
dosing,by 1.0 0.000143348623853 0 1 -1
cyp1a2,and 1.0 0.00043004587156 0 3 -3
pharmacokinetics,exposure-response 1.0 0.000143348623853 0 1 -1
enhancing,the 0.0 0.0 1 1 0
increased,metabolic 1.0 0.000143348623853 1 0 1
than,has 1.0 0.000143348623853 0 1 -1
relation,to 1.0 0.00043004587156 0 3 -3
known,interference 1.0 0.000143348623853 0 1 -1
activity,which 0.0 0.0 1 1 0
ulcerative,colitis 1.0 0.000143348623853 1 0 1
evaluated,these 1.0 0.000143348623853 0 1 -1
with,axert 1.0 0.000286697247706 2 0 2
like,or 1.0 0.00043004587156 3 0 3
compromise,the 0.0 0.0 1 1 0
or,only 1.0 0.000143348623853 0 1 -1
sodium,absorption 1.0 0.000143348623853 1 0 1
generally,been 1.0 0.000143348623853 0 1 -1
causing,uterine 1.0 0.000143348623853 1 0 1
be,associated 0.4 0.000573394495413 3 7 -4
mna,in 1.0 0.000143348623853 0 1 -1
digoxin,plasma 1.0 0.000143348623853 0 1 -1
possible,infiltration 1.0 0.000143348623853 0 1 -1
triazole,have 1.0 0.000143348623853 0 1 -1
member,have 1.0 0.000143348623853 1 0 1
paper,is 1.0 0.000143348623853 0 1 -1
of,etc 1.0 0.000143348623853 1 0 1
therapies,i 1.0 0.000143348623853 0 1 -1
spared,by 1.0 0.000143348623853 0 1 -1
from,several 1.0 0.000143348623853 0 1 -1
observed,following 0.333333333333 0.000286697247706 2 4 -2
has,sometimes 1.0 0.000143348623853 0 1 -1
parameters,and 0.0 0.0 1 1 0
circulation,the 1.0 0.000143348623853 1 0 1
its,potential 1.0 0.000143348623853 0 1 -1
which,suggested 1.0 0.000143348623853 0 1 -1
flolan,which 1.0 0.000143348623853 1 0 1
similar,efficacy 1.0 0.000143348623853 0 1 -1
day,dosing 1.0 0.000143348623853 0 1 -1
the,environment 1.0 0.000143348623853 0 1 -1
cancer,center 1.0 0.000143348623853 0 1 -1
of,neutropenia 1.0 0.000286697247706 2 0 2
lower,doses 0.6 0.000860091743119 2 8 -6
test,has 1.0 0.000143348623853 0 1 -1
oral,produced 1.0 0.000143348623853 1 0 1
considered,during 1.0 0.000143348623853 1 0 1
both,plasma 1.0 0.000143348623853 0 1 -1
a,regimen 1.0 0.000573394495413 4 0 4
sulfoxide,by 1.0 0.000143348623853 1 0 1
other,pathways 1.0 0.000286697247706 0 2 -2
improved,and 1.0 0.000143348623853 0 1 -1
though,individual 1.0 0.000143348623853 0 1 -1
is,especially 0.6 0.00043004587156 1 4 -3
substrate,the 1.0 0.000143348623853 1 0 1
were,homozygous 1.0 0.000143348623853 0 1 -1
cups,of 1.0 0.000143348623853 0 1 -1
vardenafil,should 1.0 0.000286697247706 2 0 2
r-warfarin,and 1.0 0.000143348623853 1 0 1
taxotere,as 1.0 0.000143348623853 0 1 -1
orudis,doses 1.0 0.000143348623853 0 1 -1
contraceptives,valdecoxib 1.0 0.000143348623853 0 1 -1
proposed,as 1.0 0.000286697247706 0 2 -2
flushing,mydriasis 1.0 0.000143348623853 1 0 1
weaken,the 1.0 0.000286697247706 2 0 2
a,history 0.5 0.000860091743119 3 9 -6
cases,where 1.0 0.000143348623853 0 1 -1
estimated,number 1.0 0.000143348623853 0 1 -1
too,little 1.0 0.000143348623853 0 1 -1
be,coad-ministered 1.0 0.000143348623853 0 1 -1
therapy,which 1.0 0.000286697247706 0 2 -2
and,under 0.0 0.0 1 1 0
it,from 1.0 0.000143348623853 0 1 -1
in,pharmacological 1.0 0.000143348623853 1 0 1
either,secobarbitone 1.0 0.000143348623853 1 0 1
aureus,to 1.0 0.000143348623853 0 1 -1
chinese,hamster 1.0 0.000286697247706 0 2 -2
for,insurances 1.0 0.000143348623853 0 1 -1
hivid,with 0.0 0.0 1 1 0
especially,when 1.0 0.000286697247706 2 0 2
therapeutic,range 0.333333333333 0.000143348623853 1 2 -1
carcinogenicity,studies 1.0 0.000143348623853 0 1 -1
hypoglycemia,and 1.0 0.000286697247706 0 2 -2
heparin,no 1.0 0.000143348623853 0 1 -1
studies,and 0.428571428571 0.00043004587156 2 5 -3
rr,is 1.0 0.000286697247706 0 2 -2
azole,agents 1.0 0.000286697247706 2 0 2
of,ketoconazole 1.0 0.000143348623853 1 0 1
underlies,the 1.0 0.000143348623853 0 1 -1
possibly,have 1.0 0.000143348623853 0 1 -1
a,member 1.0 0.000143348623853 1 0 1
potassium-sparing,each 1.0 0.000143348623853 0 1 -1
down-regulation,of 1.0 0.000143348623853 0 1 -1
cmax,auc 1.0 0.000143348623853 1 0 1
diabetes,used 1.0 0.000143348623853 1 0 1
starting,the 1.0 0.000143348623853 0 1 -1
and,titration 1.0 0.000143348623853 1 0 1
increased,steady-state 1.0 0.000143348623853 0 1 -1
excessive,fall 1.0 0.000143348623853 1 0 1
animals,treated 1.0 0.000143348623853 1 0 1
range,are 1.0 0.000143348623853 0 1 -1
gastric,fistulas 1.0 0.000143348623853 0 1 -1
to,treatment 1.0 0.000573394495413 0 4 -4
of,ci 0.0 0.0 1 1 0
recovery,and 1.0 0.000286697247706 0 2 -2
toxicity,tests 1.0 0.000143348623853 0 1 -1
of,ca 1.0 0.000143348623853 0 1 -1
that,caution 1.0 0.000143348623853 0 1 -1
clinically,necessary 1.0 0.000143348623853 1 0 1
ssris,ssris 1.0 0.000143348623853 1 0 1
on,cooling 1.0 0.000143348623853 0 1 -1
probenecid,increases 1.0 0.000143348623853 1 0 1
are,antagonized 0.333333333333 0.000143348623853 2 1 1
were,allowed 1.0 0.000143348623853 0 1 -1
of,commonly 1.0 0.000143348623853 0 1 -1
intraluminal,concentrations 1.0 0.000143348623853 0 1 -1
these,increased 0.0 0.0 1 1 0
almost,fold 1.0 0.000143348623853 1 0 1
zidovudine,ribavirin 1.0 0.000143348623853 1 0 1
increased,intracellular 1.0 0.000143348623853 0 1 -1
these,increases 0.333333333333 0.000143348623853 1 2 -1
containing,hydroxide 1.0 0.000143348623853 1 0 1
with,evidence 1.0 0.000143348623853 0 1 -1
occur,when 0.176470588235 0.00043004587156 10 7 3
pharmacogenetics,deals 1.0 0.000143348623853 0 1 -1
approximately,doubled 1.0 0.000143348623853 0 1 -1
concentration,during 1.0 0.000143348623853 1 0 1
b-,induced 1.0 0.000143348623853 1 0 1
individual,and 1.0 0.00043004587156 0 3 -3
phenytoin,may 1.0 0.000286697247706 0 2 -2
prostaglandin,synthesis 0.0 0.0 3 3 0
the,antidepressant 0.6 0.00043004587156 1 4 -3
lessen,the 1.0 0.000143348623853 0 1 -1
cypermethrin-induced,oxidative 1.0 0.000143348623853 1 0 1
how,it 1.0 0.000286697247706 0 2 -2
trials,the 1.0 0.00043004587156 0 3 -3
in,infants 1.0 0.000143348623853 0 1 -1
the,milk 1.0 0.000143348623853 0 1 -1
for,seizures 1.0 0.000286697247706 0 2 -2
agent,for 0.5 0.000286697247706 1 3 -2
relaxing,effect 1.0 0.000143348623853 1 0 1
population,chronically 1.0 0.000143348623853 0 1 -1
depressants,causing 1.0 0.000286697247706 2 0 2
altered,biodistribution 1.0 0.000143348623853 0 1 -1
urinary,values 1.0 0.000143348623853 0 1 -1
was,identical 1.0 0.000143348623853 0 1 -1
the,combination 0.217391304348 0.000716743119266 14 9 5
modifications,in 1.0 0.000143348623853 0 1 -1
administered,hours 0.714285714286 0.000716743119266 6 1 5
with,camptosar 1.0 0.000286697247706 2 0 2
a4,had 1.0 0.000143348623853 0 1 -1
pharmacologically,active 1.0 0.000143348623853 0 1 -1
decreases,platelet 1.0 0.000143348623853 0 1 -1
lying,the 1.0 0.000143348623853 1 0 1
serious,toxicity 0.0 0.0 1 1 0
bleeding,reduced 1.0 0.000143348623853 1 0 1
angiomax,should 1.0 0.000143348623853 0 1 -1
a4,has 1.0 0.000143348623853 0 1 -1
advantages,in 1.0 0.000143348623853 0 1 -1
prinivil,an 1.0 0.000143348623853 1 0 1
with,showed 1.0 0.000143348623853 0 1 -1
or,additional 1.0 0.000286697247706 0 2 -2
cell,type-specific 1.0 0.000143348623853 0 1 -1
normal,tissues 1.0 0.000143348623853 1 0 1
of,kidney 1.0 0.000143348623853 0 1 -1
type,depth 1.0 0.000143348623853 0 1 -1
protein-bound,would 1.0 0.000143348623853 0 1 -1
o-desacetylrifabutin,and 1.0 0.000143348623853 1 0 1
affected,during 1.0 0.000286697247706 0 2 -2
and,severe 0.0 0.0 1 1 0
mouth,constipation 1.0 0.000143348623853 1 0 1
clinically,compatible 1.0 0.000143348623853 0 1 -1
between,exogenous 1.0 0.000143348623853 0 1 -1
and,muscle 1.0 0.000143348623853 0 1 -1
the,numerous 1.0 0.000143348623853 0 1 -1
mice,but 1.0 0.000143348623853 0 1 -1
results,show 1.0 0.000143348623853 0 1 -1
situ,hybridization 1.0 0.000143348623853 1 0 1
blockers,are 1.0 0.000286697247706 2 0 2
conclusions,and 1.0 0.000143348623853 0 1 -1
therefore,mao 1.0 0.000143348623853 1 0 1
to,interference 1.0 0.000143348623853 0 1 -1
of,tbg 1.0 0.000143348623853 0 1 -1
practically,only 1.0 0.000143348623853 0 1 -1
is,shortened 1.0 0.000143348623853 1 0 1
rats,as 1.0 0.000143348623853 0 1 -1
rats,at 0.6 0.00043004587156 1 4 -3
the,components 1.0 0.000143348623853 0 1 -1
therefore,may 0.333333333333 0.000143348623853 1 2 -1
less,well 1.0 0.000143348623853 0 1 -1
anaphylactic,reactions 1.0 0.000143348623853 0 1 -1
included,mtx 1.0 0.000143348623853 0 1 -1
hrs,of 0.5 0.000286697247706 1 3 -2
small,volume 1.0 0.000143348623853 0 1 -1
status,for 1.0 0.000143348623853 0 1 -1
antihistamines,antimigraine 1.0 0.000143348623853 1 0 1
cushingoid,appearance 1.0 0.000143348623853 0 1 -1
or,diarrhea 1.0 0.000143348623853 1 0 1
metabolized,drugs 1.0 0.000143348623853 0 1 -1
affect,sinus 1.0 0.000143348623853 1 0 1
given,single 1.0 0.000143348623853 1 0 1
threshold,concurrent 1.0 0.000143348623853 1 0 1
given,singly 1.0 0.000143348623853 0 1 -1
pharmaco-dynamic,effects 1.0 0.000143348623853 0 1 -1
metabolite,i 1.0 0.00043004587156 0 3 -3
which,resulted 1.0 0.000143348623853 1 0 1
d,e 1.0 0.000143348623853 0 1 -1
for,adverse 0.5 0.000286697247706 1 3 -2
d,h 0.428571428571 0.00043004587156 5 2 3
necessary,because 1.0 0.000143348623853 1 0 1
least,one 0.5 0.000286697247706 1 3 -2
were,already 1.0 0.000286697247706 0 2 -2
therapies,for 1.0 0.000143348623853 0 1 -1
other,week 1.0 0.000143348623853 0 1 -1
monkeys,were 1.0 0.000286697247706 0 2 -2
three,metabolites 1.0 0.000143348623853 0 1 -1
odontoid,and 1.0 0.000143348623853 0 1 -1
transcriptase,inhibitors 0.333333333333 0.000143348623853 1 2 -1
added,drug 1.0 0.000286697247706 0 2 -2
extent,by 1.0 0.000143348623853 0 1 -1
combination,to 1.0 0.000143348623853 1 0 1
with,homology 1.0 0.000143348623853 0 1 -1
a,rate 1.0 0.000286697247706 2 0 2
the,diarrhea-inducing 1.0 0.000143348623853 0 1 -1
with,higher 1.0 0.000286697247706 2 0 2
to,replicate 1.0 0.000143348623853 0 1 -1
be,paid 1.0 0.000143348623853 0 1 -1
retrospective,analysis 1.0 0.000143348623853 0 1 -1
toxicity,resulting 1.0 0.000143348623853 0 1 -1
at,hours 1.0 0.000143348623853 1 0 1
of,maximum 1.0 0.000143348623853 1 0 1
have,experienced 1.0 0.00043004587156 0 3 -3
concentration,for 1.0 0.000143348623853 0 1 -1
hormonal,replacement 1.0 0.000143348623853 0 1 -1
mean,half-life 1.0 0.000143348623853 1 0 1
taking,acamprosate 1.0 0.000143348623853 1 0 1
period,b 1.0 0.000143348623853 0 1 -1
period,a 1.0 0.000143348623853 0 1 -1
antacids,kaolin-pectin 1.0 0.000143348623853 1 0 1
humans,show 1.0 0.000143348623853 1 0 1
as,systemic 1.0 0.000143348623853 0 1 -1
drugs,the 1.0 0.000286697247706 2 0 2
have,caused 1.0 0.000143348623853 1 0 1
subutex,and 1.0 0.000143348623853 1 0 1
for,serotonin 1.0 0.000143348623853 0 1 -1
increased,renal 1.0 0.000286697247706 0 2 -2
agents,demonstrated 1.0 0.000143348623853 0 1 -1
and,subcutaneous 1.0 0.000143348623853 0 1 -1
one,day 1.0 0.000286697247706 0 2 -2
an,aluminum-containing 1.0 0.000143348623853 0 1 -1
anticoagulants,there 1.0 0.000286697247706 2 0 2
micromol,l 0.333333333333 0.000143348623853 1 2 -1
of,improving 1.0 0.000143348623853 0 1 -1
death,have 0.0 0.0 1 1 0
performance,for 1.0 0.000286697247706 2 0 2
a,body 1.0 0.000143348623853 0 1 -1
motor,skills 1.0 0.000286697247706 0 2 -2
that,because 1.0 0.000286697247706 0 2 -2
this,paper 1.0 0.00100344036697 0 7 -7
before,adrenal 1.0 0.000143348623853 0 1 -1
hormone-binding,globulin 1.0 0.000143348623853 0 1 -1
least,two 0.333333333333 0.000143348623853 1 2 -1
trileptal,and 1.0 0.000143348623853 0 1 -1
option,in 1.0 0.000143348623853 0 1 -1
arava,was 1.0 0.000143348623853 1 0 1
formed,by 1.0 0.000143348623853 0 1 -1
forming,a 1.0 0.000143348623853 0 1 -1
as,platelet 1.0 0.000143348623853 0 1 -1
staphylococcus,aureus 0.0 0.0 1 1 0
the,levulan 1.0 0.000143348623853 1 0 1
and,hiv 1.0 0.000143348623853 0 1 -1
time,from 0.0 0.0 1 1 0
such,patients 0.571428571429 0.00114678899083 3 11 -8
notable,that 1.0 0.000143348623853 0 1 -1
except,at 1.0 0.000143348623853 0 1 -1
or,cervical 1.0 0.000143348623853 1 0 1
a,decreased 1.0 0.000573394495413 4 0 4
for,additive 0.0 0.0 2 2 0
start,and 1.0 0.000143348623853 1 0 1
the,patch-clamp 1.0 0.000143348623853 0 1 -1
been,completely 1.0 0.000143348623853 0 1 -1
alone,versus 1.0 0.000143348623853 0 1 -1
of,followed 1.0 0.000143348623853 1 0 1
complex,fashion 1.0 0.000143348623853 0 1 -1
main,results 1.0 0.000286697247706 0 2 -2
analog,of 1.0 0.000286697247706 0 2 -2
no,adverse 1.0 0.000286697247706 0 2 -2
duloxetine,with 0.0 0.0 1 1 0
not,antagonize 1.0 0.000143348623853 1 0 1
trilisate,disalcid 1.0 0.000143348623853 1 0 1
and,partly 1.0 0.000143348623853 1 0 1
of,lodine 1.0 0.000143348623853 1 0 1
cns,stimulation 1.0 0.00043004587156 3 0 3
tract,to 1.0 0.000143348623853 1 0 1
the,atropine-like 1.0 0.000143348623853 0 1 -1
both,hypo- 1.0 0.000143348623853 0 1 -1
indifferent,for 1.0 0.000286697247706 2 0 2
detect,ketone 1.0 0.000143348623853 0 1 -1
the,were 1.0 0.000143348623853 0 1 -1
statistical,analysis 1.0 0.000143348623853 0 1 -1
medicines,during 1.0 0.000143348623853 1 0 1
a,standing 1.0 0.000573394495413 4 0 4
mesenteric,ganglion 1.0 0.000143348623853 0 1 -1
three,weeks 0.333333333333 0.000143348623853 2 1 1
combined,exposure 1.0 0.000143348623853 0 1 -1
microm,preferentially 1.0 0.000143348623853 1 0 1
a,cell-free 1.0 0.000143348623853 0 1 -1
animal,data 1.0 0.000143348623853 0 1 -1
with,enhances 1.0 0.000143348623853 1 0 1
by,stimulating 1.0 0.000143348623853 0 1 -1
be,re-treated 1.0 0.000143348623853 0 1 -1
mean,terminal 1.0 0.000286697247706 2 0 2
were,supersensitive 1.0 0.000286697247706 2 0 2
during,early 1.0 0.000143348623853 1 0 1
following,coadministration 0.333333333333 0.000143348623853 1 2 -1
ocular,and 1.0 0.000143348623853 0 1 -1
concentrations,mmol 1.0 0.000143348623853 0 1 -1
individuals,plasma 1.0 0.000143348623853 1 0 1
diuretics,etodolac 1.0 0.000143348623853 0 1 -1
some,patients 0.25 0.00114678899083 20 12 8
normal,daily 1.0 0.000143348623853 0 1 -1
substrate,agent 1.0 0.000143348623853 0 1 -1
and,lead 0.0 0.0 1 1 0
after,inhalational 1.0 0.000143348623853 0 1 -1
suggested,while 1.0 0.000143348623853 0 1 -1
photosensitivity,reaction 1.0 0.000143348623853 1 0 1
and,positive 1.0 0.000143348623853 0 1 -1
sickness,center 1.0 0.000143348623853 0 1 -1
this,product 1.0 0.000286697247706 0 2 -2
specifically,due 1.0 0.000143348623853 0 1 -1
vivo,metabolic 1.0 0.000286697247706 0 2 -2
one,hyperglycaemic 1.0 0.000143348623853 0 1 -1
dolasetron,mesylate 1.0 0.000143348623853 0 1 -1
all,research 1.0 0.000143348623853 0 1 -1
anion,plasma 1.0 0.000143348623853 1 0 1
for,aerobic 1.0 0.000143348623853 0 1 -1
phenobarbitol,rifabutin 1.0 0.000143348623853 0 1 -1
some,blockers 1.0 0.000143348623853 1 0 1
unpredictable,potentiation 1.0 0.000143348623853 1 0 1
be,rationalized 1.0 0.000143348623853 0 1 -1
racemic,did 1.0 0.000143348623853 0 1 -1
herbal,supplement 1.0 0.000143348623853 0 1 -1
range,years 1.0 0.000143348623853 0 1 -1
group,vs 1.0 0.000143348623853 0 1 -1
a,dramatic 1.0 0.000286697247706 0 2 -2
and,shorter 1.0 0.000143348623853 0 1 -1
a,fold 0.5 0.000860091743119 9 3 6
chromaffin,cell 1.0 0.000286697247706 0 2 -2
in,simultaneous 1.0 0.000143348623853 1 0 1
of,offers 1.0 0.000143348623853 0 1 -1
cells,u937 1.0 0.000143348623853 1 0 1
antacids,administration 0.0 0.0 1 1 0
taxotere,with 1.0 0.000143348623853 0 1 -1
clinical,situation 1.0 0.000143348623853 0 1 -1
both,t4 1.0 0.000143348623853 1 0 1
to,less 1.0 0.000143348623853 0 1 -1
following,simultaneous 1.0 0.000143348623853 1 0 1
hcl,and 0.5 0.000286697247706 3 1 2
increased,concentrations 1.0 0.000573394495413 0 4 -4
mucus,the 1.0 0.000143348623853 0 1 -1
interactions,posed 1.0 0.000143348623853 0 1 -1
weeks,with 0.333333333333 0.000143348623853 2 1 1
to,its 0.5 0.000573394495413 2 6 -4
month,washout 1.0 0.000143348623853 0 1 -1
rat,brain 1.0 0.000143348623853 1 0 1
vasopressor,for 1.0 0.000143348623853 1 0 1
vr,pediatric 1.0 0.000143348623853 0 1 -1
increased,its 1.0 0.000143348623853 0 1 -1
of,fell 1.0 0.000143348623853 1 0 1
three,separate 1.0 0.000143348623853 0 1 -1
estrogens,may 1.0 0.000143348623853 1 0 1
etc,increase 1.0 0.00043004587156 3 0 3
both,to 1.0 0.000143348623853 0 1 -1
for,renal 1.0 0.000143348623853 1 0 1
placebo,controlled 1.0 0.000143348623853 0 1 -1
administered,metabolized 1.0 0.000143348623853 0 1 -1
sn38,levels 1.0 0.000143348623853 0 1 -1
with,desirable 1.0 0.000143348623853 0 1 -1
phenobarbital,estimates 1.0 0.000143348623853 0 1 -1
lodine,indocin 1.0 0.000143348623853 0 1 -1
other,aeds 1.0 0.00043004587156 0 3 -3
demonstrate,a 1.0 0.000143348623853 0 1 -1
the,bactec 1.0 0.000143348623853 0 1 -1
therefore,careful 1.0 0.000143348623853 0 1 -1
no,studies 0.333333333333 0.000143348623853 1 2 -1
significantly,improved 1.0 0.000286697247706 0 2 -2
of,loop 1.0 0.000860091743119 6 0 6
significantly,improves 1.0 0.000143348623853 0 1 -1
the,enzymes 1.0 0.000143348623853 0 1 -1
brain,although 1.0 0.000143348623853 0 1 -1
a,supersensitivity 1.0 0.000143348623853 1 0 1
mg,twice 0.368421052632 0.00100344036697 6 13 -7
acne,transient 1.0 0.000143348623853 0 1 -1
inhibitors,was 1.0 0.000286697247706 2 0 2
epinephrine,may 1.0 0.000143348623853 1 0 1
as,control 1.0 0.000143348623853 0 1 -1
arrests,have 1.0 0.000143348623853 0 1 -1
cisapride,is 1.0 0.000143348623853 0 1 -1
instances,a 1.0 0.000143348623853 1 0 1
this,is 0.833333333333 0.00143348623853 1 11 -10
unchanged,following 1.0 0.000286697247706 0 2 -2
may,prevent 0.333333333333 0.000143348623853 2 1 1
this,in 1.0 0.000143348623853 0 1 -1
b23,antisense 1.0 0.000143348623853 0 1 -1
given,both 1.0 0.000143348623853 1 0 1
as,camptosar 1.0 0.000143348623853 1 0 1
and,indicated 1.0 0.000143348623853 0 1 -1
anavar,anadrol 1.0 0.000143348623853 0 1 -1
promethazine,coadministration 1.0 0.000143348623853 1 0 1
light,meal 0.0 0.0 1 1 0
hours,prior 0.555555555556 0.000716743119266 7 2 5
a,combination 1.0 0.00043004587156 0 3 -3
ampicillin,amoxicillin 1.0 0.000143348623853 1 0 1
as,prophylaxis 1.0 0.000143348623853 0 1 -1
cyp1a2,substrate 1.0 0.000143348623853 0 1 -1
reaction,with 1.0 0.000143348623853 0 1 -1
warfarin-type,therapy 1.0 0.000143348623853 1 0 1
hours,apart 0.0 0.0 1 1 0
of,high 0.0 0.0 2 2 0
and,squirrel 1.0 0.000143348623853 0 1 -1
consider,additive 1.0 0.000143348623853 1 0 1
thereafter,at 1.0 0.000143348623853 0 1 -1
anti-hiv,reverse 1.0 0.000143348623853 0 1 -1
iopidine,ophthalmic 0.0 0.0 1 1 0
shortly,after 0.333333333333 0.000143348623853 1 2 -1
on,an 0.6 0.00043004587156 1 4 -3
itraconazole,was 1.0 0.000143348623853 1 0 1
increased,severity 1.0 0.000143348623853 1 0 1
two-way,crossover 1.0 0.000143348623853 0 1 -1
second,contractile 0.0 0.0 1 1 0
we,obtained 1.0 0.000143348623853 0 1 -1
lasma,concentrations 1.0 0.000143348623853 0 1 -1
on,av 1.0 0.000143348623853 1 0 1
a,non-specific 1.0 0.000143348623853 0 1 -1
at,exposure 1.0 0.000143348623853 0 1 -1
inclusive,viracept 1.0 0.000143348623853 0 1 -1
and,antacids 1.0 0.000143348623853 1 0 1
studied,but 0.0 0.0 2 2 0
enterocolitis,diarrhea 1.0 0.000143348623853 1 0 1
week,prior 1.0 0.000143348623853 1 0 1
the,range 1.0 0.00100344036697 0 7 -7
the,antipsychotic 1.0 0.000143348623853 0 1 -1
interaction,during 1.0 0.000143348623853 0 1 -1
fewer,interactions 1.0 0.000143348623853 0 1 -1
and,impaired 0.333333333333 0.000143348623853 2 1 1
a,mixed-function 1.0 0.000143348623853 0 1 -1
the,trans-diol 1.0 0.000143348623853 0 1 -1
felt,that 1.0 0.000143348623853 1 0 1
for,drugs 0.0 0.0 1 1 0
a,cyp2c9 1.0 0.00043004587156 3 0 3
following,nicotinic 1.0 0.000143348623853 0 1 -1
encystment,at 1.0 0.000143348623853 0 1 -1
an,area 1.0 0.000143348623853 0 1 -1
which,certain 1.0 0.000143348623853 0 1 -1
lie,in 1.0 0.000143348623853 0 1 -1
application,of 0.6 0.00043004587156 1 4 -3
on,embryo 1.0 0.000143348623853 0 1 -1
rate,cmax 1.0 0.000143348623853 1 0 1
contain,an 1.0 0.000143348623853 1 0 1
precipitate,seizures 1.0 0.000143348623853 1 0 1
with,blood 0.333333333333 0.000286697247706 2 4 -2
model,in 1.0 0.000143348623853 0 1 -1
elspar,can 1.0 0.000143348623853 1 0 1
test,results 0.6 0.00043004587156 1 4 -3
parietal,cell 1.0 0.000286697247706 0 2 -2
model,is 1.0 0.000143348623853 0 1 -1
significant,effect 0.935483870968 0.00415711009174 1 30 -29
methotrexate,renal 1.0 0.000143348623853 1 0 1
dysphoria,and 1.0 0.000143348623853 0 1 -1
little,is 1.0 0.000286697247706 0 2 -2
carbamazepine,due 1.0 0.000143348623853 0 1 -1
tot,the 1.0 0.000143348623853 0 1 -1
uptake,sites 1.0 0.000143348623853 0 1 -1
phenobarbital,or 1.0 0.000143348623853 0 1 -1
controlled,studies 0.5 0.000286697247706 1 3 -2
with,failed 1.0 0.000143348623853 0 1 -1
risk,factors 0.0 0.0 1 1 0
precipitated,by 1.0 0.000286697247706 0 2 -2
little,if 1.0 0.000143348623853 0 1 -1
krm-1648,exhibited 1.0 0.000143348623853 1 0 1
that,from 1.0 0.000143348623853 0 1 -1
mao-b,inhibitor 1.0 0.000143348623853 0 1 -1
of,free 0.333333333333 0.000143348623853 1 2 -1
concentrations,which 0.0 0.0 1 1 0
involving,either 1.0 0.000143348623853 0 1 -1
are,very 1.0 0.000143348623853 1 0 1
elements,ethacrynic 1.0 0.000143348623853 1 0 1
pharmacology-related,endocrine 1.0 0.000143348623853 0 1 -1
also,inhibit 1.0 0.000143348623853 0 1 -1
by,pbi 1.0 0.000286697247706 0 2 -2
these,determinations 1.0 0.000143348623853 0 1 -1
and,bound 1.0 0.000143348623853 1 0 1
volunteers,ingesting 1.0 0.000143348623853 1 0 1
of,tca5 1.0 0.000143348623853 0 1 -1
bred,control 1.0 0.000143348623853 0 1 -1
thereafter,and 1.0 0.000143348623853 1 0 1
this,should 1.0 0.00043004587156 0 3 -3
of,angiotensin 0.5 0.000286697247706 3 1 2
or,type 1.0 0.000143348623853 1 0 1
by,cytochrome 0.619047619048 0.00186353211009 4 17 -13
calcium,particularly 1.0 0.000143348623853 0 1 -1
in,altering 1.0 0.000143348623853 0 1 -1
was,necessary 1.0 0.000286697247706 2 0 2
zero,to 1.0 0.000143348623853 0 1 -1
carcinogenesis,pegasys 1.0 0.000143348623853 0 1 -1
response,induced 0.0 0.0 1 1 0
a,macrolide 1.0 0.000143348623853 0 1 -1
in,of 0.0 0.0 2 2 0
product,with 1.0 0.000143348623853 0 1 -1
in,oa 1.0 0.000143348623853 0 1 -1
in,doses 0.0 0.0 1 1 0
in,on 1.0 0.000143348623853 0 1 -1
conventional,it 1.0 0.000143348623853 0 1 -1
indication,of 1.0 0.000143348623853 0 1 -1
less,caspase-3 1.0 0.000143348623853 0 1 -1
such,medication 1.0 0.000143348623853 0 1 -1
in,or 1.0 0.000716743119266 0 5 -5
stelazine,vesprin 1.0 0.000143348623853 0 1 -1
hypertension,patients 1.0 0.000143348623853 0 1 -1
established,therapy 1.0 0.000143348623853 1 0 1
cardiovascular,depression 1.0 0.000143348623853 0 1 -1
table,a 1.0 0.000143348623853 0 1 -1
and,nondepolarizing 1.0 0.000143348623853 0 1 -1
enable,cells 1.0 0.000143348623853 0 1 -1
to,starting 1.0 0.000143348623853 0 1 -1
and,subjective 1.0 0.000143348623853 0 1 -1
bacterial,mutation 1.0 0.000143348623853 0 1 -1
demonstrated,marked 1.0 0.000143348623853 0 1 -1
in,relationship 1.0 0.000143348623853 0 1 -1
lotensin,was 1.0 0.000143348623853 0 1 -1
digitalized,patient 1.0 0.000143348623853 0 1 -1
regimens,in 1.0 0.000286697247706 0 2 -2
a,report 1.0 0.000143348623853 1 0 1
were,seen 0.714285714286 0.000716743119266 1 6 -5
low-molecular,weight 1.0 0.000143348623853 0 1 -1
and,progression 1.0 0.000143348623853 0 1 -1
condition,corrected 1.0 0.000143348623853 0 1 -1
minimum,concentration 1.0 0.00043004587156 0 3 -3
last,years 1.0 0.000143348623853 0 1 -1
area,and 1.0 0.000143348623853 0 1 -1
levels,are 0.5 0.000286697247706 1 3 -2
evidence,has 1.0 0.000143348623853 1 0 1
dose,did 1.0 0.000143348623853 0 1 -1
adrenocorticoids,metabolic 1.0 0.000143348623853 0 1 -1
plasma,clearance 0.0 0.0 2 2 0
new,york 1.0 0.000143348623853 0 1 -1
a,large 0.333333333333 0.000143348623853 1 2 -1
antipsychotic,activity 1.0 0.000143348623853 0 1 -1
another,hmg-coa 1.0 0.000143348623853 1 0 1
store,from 1.0 0.000143348623853 0 1 -1
window,such 1.0 0.000143348623853 1 0 1
the,modified 1.0 0.000143348623853 0 1 -1
follow-up,opportunistic 1.0 0.000143348623853 0 1 -1
trials,with 0.0 0.0 1 1 0
antagonists,tested 1.0 0.000143348623853 0 1 -1
with,concomitant 0.0909090909091 0.000286697247706 10 12 -2
interaction,studies 0.953488372093 0.011754587156 2 84 -82
potentials,were 1.0 0.000286697247706 0 2 -2
to,marked 1.0 0.000143348623853 1 0 1
this,finding 1.0 0.00114678899083 0 8 -8
to,or 0.8 0.00114678899083 9 1 8
dosage,range 1.0 0.000143348623853 1 0 1
myelosuppression,and 1.0 0.000143348623853 1 0 1
other,local 1.0 0.000143348623853 1 0 1
the,growth 1.0 0.000573394495413 0 4 -4
to,of 1.0 0.00114678899083 0 8 -8
study,objective 1.0 0.000143348623853 0 1 -1
a2,cyp1a2 1.0 0.000143348623853 0 1 -1
degeneration,of 1.0 0.000143348623853 0 1 -1
beverages,is 1.0 0.000143348623853 1 0 1
higher,dose 1.0 0.000286697247706 0 2 -2
to,oh 1.0 0.000143348623853 0 1 -1
coagulation,time 1.0 0.000143348623853 1 0 1
adequate,period 1.0 0.000143348623853 0 1 -1
aviano,cancer 1.0 0.000143348623853 0 1 -1
received,maoi 1.0 0.000143348623853 1 0 1
atoxic,since 1.0 0.000143348623853 0 1 -1
serum,supplemented 1.0 0.000143348623853 0 1 -1
porter-silber,test 1.0 0.000143348623853 0 1 -1
a,control 0.0 0.0 1 1 0
light,dark 1.0 0.00043004587156 0 3 -3
experiments,on 1.0 0.000286697247706 0 2 -2
transferring,the 1.0 0.000143348623853 0 1 -1
cyp3a4,or 1.0 0.000286697247706 0 2 -2
the,gi 1.0 0.000143348623853 1 0 1
expected,because 1.0 0.000143348623853 0 1 -1
disease,states 1.0 0.000573394495413 0 4 -4
addition,of 0.125 0.000286697247706 9 7 2
two,consecutive 1.0 0.000143348623853 0 1 -1
optimum,therapeutic 1.0 0.000286697247706 0 2 -2
attenuated,the 1.0 0.000286697247706 2 0 2
addition,or 1.0 0.000143348623853 0 1 -1
cortex,which 1.0 0.000143348623853 0 1 -1
injection,concentrate 1.0 0.000143348623853 1 0 1
pcp,dcg-iv 1.0 0.000143348623853 0 1 -1
increase,cyp 1.0 0.000143348623853 1 0 1
single,or 1.0 0.000286697247706 0 2 -2
concomitantly,to 1.0 0.000143348623853 1 0 1
of,all 0.5 0.000286697247706 1 3 -2
administered,antiepileptic 1.0 0.000143348623853 1 0 1
vitro,binding 0.0 0.0 1 1 0
arimidex,with 1.0 0.000143348623853 0 1 -1
times,weekly 1.0 0.000143348623853 0 1 -1
agents,chloral 1.0 0.000143348623853 0 1 -1
some,leading 1.0 0.000143348623853 1 0 1
the,particular 1.0 0.000143348623853 0 1 -1
an,equivalent 1.0 0.000286697247706 0 2 -2
b12,supplement 1.0 0.000143348623853 1 0 1
permeation,was 1.0 0.000143348623853 0 1 -1
during,toradol 1.0 0.000143348623853 1 0 1
serious,falls 1.0 0.000143348623853 1 0 1
valdecoxib,caused 1.0 0.000143348623853 1 0 1
section,were 1.0 0.00043004587156 0 3 -3
events,occurred 1.0 0.000143348623853 0 1 -1
completion,of 0.0 0.0 1 1 0
is,cas 1.0 0.000143348623853 0 1 -1
its,effectiveness 1.0 0.000143348623853 0 1 -1
then,with 1.0 0.000143348623853 0 1 -1
commonly,in 1.0 0.000143348623853 1 0 1
a,diagnostic 1.0 0.000143348623853 0 1 -1
xanthine-derived,antagonists 1.0 0.000143348623853 0 1 -1
the,fractional 1.0 0.000143348623853 0 1 -1
is,totally 1.0 0.000143348623853 0 1 -1
bleeding,or 1.0 0.000143348623853 0 1 -1
vivo,clinically 1.0 0.000143348623853 0 1 -1
of,psychiatric 1.0 0.000143348623853 1 0 1
induce,hypercalcemia 1.0 0.00043004587156 0 3 -3
in,unexpectedly 0.0 0.0 1 1 0
p450,pathway 1.0 0.000143348623853 0 1 -1
marketed,in 1.0 0.000143348623853 0 1 -1
informed,that 1.0 0.000143348623853 0 1 -1
boric,acid 1.0 0.000143348623853 1 0 1
provoke,vasoconstriction 1.0 0.000143348623853 1 0 1
cerulein--an,analog 1.0 0.000143348623853 0 1 -1
other,membrane 1.0 0.000143348623853 0 1 -1
five,times 1.0 0.000143348623853 0 1 -1
period,demonstrated 1.0 0.000143348623853 0 1 -1
formed,with 1.0 0.000143348623853 1 0 1
parenteral,route 1.0 0.000143348623853 0 1 -1
northern,blot 1.0 0.000143348623853 0 1 -1
observed,more 1.0 0.000143348623853 0 1 -1
an,effector 1.0 0.000286697247706 0 2 -2
and,continued 1.0 0.000143348623853 0 1 -1
done,during 1.0 0.000143348623853 0 1 -1
nondepolarizing,muscle 0.0 0.0 1 1 0
of,also 1.0 0.000143348623853 0 1 -1
to,accident 1.0 0.000143348623853 0 1 -1
increased,appetite 1.0 0.000143348623853 0 1 -1
first,day 1.0 0.000143348623853 0 1 -1
induce,hepatic 0.0 0.0 1 1 0
of,lamprene 1.0 0.000143348623853 1 0 1
in,iso-sensitest 1.0 0.000143348623853 0 1 -1
matrix,protein 1.0 0.000143348623853 0 1 -1
revealed,concentration 1.0 0.000143348623853 0 1 -1
inhibits,c9 1.0 0.000143348623853 0 1 -1
orphan,status 1.0 0.000143348623853 0 1 -1
for,ototoxicity 1.0 0.000143348623853 1 0 1
oral,doses 0.111111111111 0.000143348623853 5 4 1
or,potentiate 1.0 0.000286697247706 2 0 2
nursing,infant 1.0 0.000143348623853 0 1 -1
node,conduction 1.0 0.000143348623853 1 0 1
a,double 1.0 0.000143348623853 0 1 -1
hormonalmethods,of 1.0 0.000143348623853 1 0 1
symptoms,such 1.0 0.000143348623853 0 1 -1
agents,calcium-channel 1.0 0.000143348623853 0 1 -1
residues,on 1.0 0.000286697247706 0 2 -2
euphoria,excitement 1.0 0.000143348623853 0 1 -1
by,ex 1.0 0.000143348623853 0 1 -1
remaining,cases 1.0 0.000143348623853 0 1 -1
as,his 1.0 0.000143348623853 0 1 -1
rebound,hypertension 1.0 0.000286697247706 2 0 2
initial,oral 1.0 0.000143348623853 1 0 1
via,conjugation 1.0 0.000143348623853 1 0 1
ptca,pci 1.0 0.000143348623853 1 0 1
enbrel,was 0.0 0.0 1 1 0
replacement,may 1.0 0.000143348623853 0 1 -1
possible,when 1.0 0.000143348623853 0 1 -1
were,within 0.0 0.0 1 1 0
when,videx 1.0 0.000143348623853 1 0 1
vary,as 1.0 0.000143348623853 0 1 -1
activity,appeared 1.0 0.000143348623853 1 0 1
appropriate,doses 1.0 0.00114678899083 0 8 -8
acidic,such 1.0 0.000143348623853 1 0 1
limit,of 1.0 0.000286697247706 0 2 -2
to,know 1.0 0.000143348623853 0 1 -1
of,l-phenylalanine 1.0 0.000143348623853 1 0 1
the,non-renal 1.0 0.000143348623853 1 0 1
patients,understand 1.0 0.000143348623853 0 1 -1
relationships,between 1.0 0.000286697247706 0 2 -2
tricyclic,flupenthixol 1.0 0.000143348623853 1 0 1
of,was 0.268292682927 0.00157683486239 15 26 -11
biocytin,compared 1.0 0.000143348623853 0 1 -1
is,strong 1.0 0.000143348623853 0 1 -1
the,agents 0.2 0.000143348623853 2 3 -1
severely,depressed 1.0 0.000143348623853 0 1 -1
and,non-gastrointestinal 1.0 0.000143348623853 0 1 -1
generation,more 1.0 0.000143348623853 0 1 -1
concomitantly,including 1.0 0.000143348623853 0 1 -1
dosage,one 1.0 0.000143348623853 0 1 -1
the,spinal 1.0 0.000143348623853 0 1 -1
cyp2c19,cyp2e1 1.0 0.000143348623853 0 1 -1
hemodialysis,until 1.0 0.000143348623853 0 1 -1
false,positive 1.0 0.000573394495413 0 4 -4
tricyclic,when 1.0 0.000143348623853 1 0 1
recording,higher 1.0 0.000143348623853 0 1 -1
injection,produced 1.0 0.000143348623853 0 1 -1
ganglion,blocking 1.0 0.000143348623853 0 1 -1
bumetanide-induced,increase 1.0 0.000143348623853 1 0 1
with,diagnostic 1.0 0.000143348623853 0 1 -1
formed,cysts 1.0 0.000143348623853 0 1 -1
mg,once-daily 1.0 0.000143348623853 0 1 -1
a,all 1.0 0.000143348623853 0 1 -1
muscle,relaxing 1.0 0.000143348623853 1 0 1
azithromycin,did 1.0 0.000143348623853 0 1 -1
natrecor,with 1.0 0.000143348623853 0 1 -1
performed,within 1.0 0.000143348623853 0 1 -1
inr,were 1.0 0.000143348623853 0 1 -1
nonfunctioning,gland 1.0 0.000143348623853 1 0 1
avoid,use 1.0 0.000143348623853 0 1 -1
coad-ministered,with 1.0 0.000143348623853 0 1 -1
for,commonly 1.0 0.000143348623853 0 1 -1
efficacy,is 1.0 0.00043004587156 3 0 3
when,parenteral 1.0 0.000143348623853 0 1 -1
subcutaneous,dose 1.0 0.000143348623853 1 0 1
urinary,antiseptic 1.0 0.000143348623853 1 0 1
with,concentrations 1.0 0.000143348623853 0 1 -1
toxicologic,profile 1.0 0.000143348623853 0 1 -1
a,tendency 0.0 0.0 1 1 0
these,polyene 1.0 0.000143348623853 0 1 -1
actions,after 1.0 0.000143348623853 0 1 -1
alteration,caused 1.0 0.000143348623853 0 1 -1
methotrexate,an 1.0 0.000143348623853 1 0 1
p450,a2 0.0 0.0 2 2 0
were,indifferent 1.0 0.000286697247706 2 0 2
competitive,renal 1.0 0.000143348623853 1 0 1
at,micromol 1.0 0.000143348623853 1 0 1
transiently,elevated 1.0 0.000143348623853 0 1 -1
reaction,and 0.6 0.00043004587156 1 4 -3
hepatotoxic,potential 1.0 0.000143348623853 1 0 1
receiving,including 1.0 0.000143348623853 0 1 -1
stopping,fluvoxamine 1.0 0.000143348623853 1 0 1
and,delay 1.0 0.000143348623853 0 1 -1
the,incidence 0.363636363636 0.00114678899083 7 15 -8
tikosyn,had 1.0 0.000143348623853 0 1 -1
compounds,like 1.0 0.000143348623853 1 0 1
occasions,resulted 1.0 0.000286697247706 2 0 2
pressure,response 1.0 0.000143348623853 0 1 -1
of,defecation 1.0 0.000143348623853 0 1 -1
usually,such 1.0 0.000143348623853 0 1 -1
other,coumarin-like 1.0 0.000143348623853 1 0 1
taking,placebo 1.0 0.000286697247706 0 2 -2
being,monitored 1.0 0.000143348623853 0 1 -1
with,vardenafil 1.0 0.00100344036697 7 0 7
clearance,prolongation 1.0 0.000143348623853 0 1 -1
the,not 1.0 0.000143348623853 0 1 -1
of,prothrombin 0.142857142857 0.000143348623853 4 3 1
methods,commonly 1.0 0.000143348623853 0 1 -1
omeprazole,omeprazole 1.0 0.000143348623853 0 1 -1
individuals,receiving 1.0 0.000143348623853 1 0 1
or,over-the 1.0 0.000286697247706 0 2 -2
probably,should 1.0 0.000143348623853 0 1 -1
effects,both 1.0 0.000143348623853 0 1 -1
caffeine,enoxacin 1.0 0.000143348623853 1 0 1
in,induction 1.0 0.000286697247706 2 0 2
pregnancy,has 1.0 0.000143348623853 0 1 -1
concurrently,increases 1.0 0.000286697247706 2 0 2
these,larger 1.0 0.000143348623853 1 0 1
and,minimal 1.0 0.000286697247706 0 2 -2
advised,especially 1.0 0.000143348623853 0 1 -1
many,selective 1.0 0.000286697247706 0 2 -2
aed,interactions 1.0 0.000143348623853 0 1 -1
ki,of 1.0 0.000143348623853 0 1 -1
stimulated,hz 1.0 0.000143348623853 0 1 -1
limb,injury 1.0 0.000143348623853 0 1 -1
caspase-3,inhibitor 1.0 0.000143348623853 0 1 -1
compromise,have 1.0 0.000143348623853 1 0 1
and,treatments 1.0 0.000143348623853 0 1 -1
important,interactions 1.0 0.000573394495413 0 4 -4
studies,do 1.0 0.000143348623853 1 0 1
doctor,or 1.0 0.00043004587156 0 3 -3
is,within 1.0 0.000143348623853 0 1 -1
marine,coelenterates 1.0 0.000143348623853 0 1 -1
processes,automatic 1.0 0.000143348623853 0 1 -1
powder,or 1.0 0.000143348623853 1 0 1
are,equipotent 1.0 0.000143348623853 0 1 -1
be,continued 1.0 0.000143348623853 1 0 1
two,weeks 0.333333333333 0.000143348623853 2 1 1
events,were 0.333333333333 0.000143348623853 1 2 -1
clearance,based 1.0 0.000143348623853 1 0 1
nor,appears 1.0 0.000143348623853 0 1 -1
exposure,was 1.0 0.000286697247706 2 0 2
to,rats 0.5 0.000286697247706 1 3 -2
cortex,that 1.0 0.000143348623853 1 0 1
any,interaction 1.0 0.000286697247706 0 2 -2
vivo,and 0.6 0.00043004587156 1 4 -3
vs,for 1.0 0.000143348623853 0 1 -1
as,might 1.0 0.000143348623853 1 0 1
of,l-glutamine 1.0 0.000286697247706 2 0 2
with,myopathy 1.0 0.000143348623853 0 1 -1
metabolic,pathway 1.0 0.00043004587156 0 3 -3
prostaglandin,f2alpha 0.0 0.0 1 1 0
the,bactericidal 1.0 0.000573394495413 4 0 4
two,treatment 1.0 0.000143348623853 0 1 -1
results,together 1.0 0.000143348623853 0 1 -1
over,time 1.0 0.00043004587156 0 3 -3
racemic,titrated 1.0 0.000143348623853 0 1 -1
dietary,treatments 1.0 0.000143348623853 0 1 -1
slow-channel,blockers 1.0 0.000143348623853 0 1 -1
blockers,including 1.0 0.000286697247706 0 2 -2
by,the 0.608695652174 0.00802752293578 18 74 -56
have,been 0.0962962962963 0.00372706422018 122 148 -26
these,enzyme 1.0 0.000143348623853 0 1 -1
animals,to 1.0 0.000286697247706 0 2 -2
preparations,containing 0.333333333333 0.000143348623853 2 1 1
whose,efficacy 1.0 0.000143348623853 1 0 1
altering,activity 1.0 0.000143348623853 0 1 -1
response,to 0.459459459459 0.0024369266055 10 27 -17
of,zdv 1.0 0.000143348623853 1 0 1
dose,used 1.0 0.000143348623853 0 1 -1
with,whole-cell 1.0 0.000143348623853 0 1 -1
inhaled,with 1.0 0.000143348623853 0 1 -1
repeated,injection 1.0 0.000143348623853 0 1 -1
the,physician 0.333333333333 0.000573394495413 4 8 -4
caspofungin,is 1.0 0.000143348623853 0 1 -1
gleevec,gleevec 1.0 0.000143348623853 1 0 1
increased,interaction 1.0 0.000286697247706 0 2 -2
also,results 1.0 0.000143348623853 0 1 -1
metabolites,oxo-desethylzaleplon 1.0 0.000143348623853 0 1 -1
other,common 1.0 0.000143348623853 0 1 -1
areas,of 1.0 0.000143348623853 0 1 -1
carcinogenesis,study 1.0 0.000143348623853 0 1 -1
differences,are 1.0 0.000143348623853 0 1 -1
hypertension,were 1.0 0.000143348623853 0 1 -1
relationship,have 1.0 0.000143348623853 1 0 1
stimulus-induced,neural 1.0 0.000143348623853 0 1 -1
all,in 1.0 0.00043004587156 0 3 -3
tid,the 1.0 0.000143348623853 1 0 1
who,increase 1.0 0.000143348623853 1 0 1
lapatinib,did 1.0 0.000143348623853 0 1 -1
particularly,since 1.0 0.000143348623853 1 0 1
showed,hormonal 1.0 0.000143348623853 0 1 -1
toxic,concentrations 1.0 0.000143348623853 1 0 1
inhibit,both 1.0 0.000573394495413 4 0 4
substantia,gelatinosa 1.0 0.000143348623853 0 1 -1
min,for 0.333333333333 0.000143348623853 2 1 1
report,to 1.0 0.000143348623853 0 1 -1
additive,central 1.0 0.000143348623853 1 0 1
blocking,add 1.0 0.000143348623853 1 0 1
are,incompatible 0.0 0.0 1 1 0
especially,at 1.0 0.000143348623853 0 1 -1
is,that 1.0 0.000143348623853 0 1 -1
five,days 1.0 0.00043004587156 0 3 -3
volunteers,for 1.0 0.000143348623853 0 1 -1
midazolam,used 1.0 0.000143348623853 1 0 1
thereby,decreasing 1.0 0.000286697247706 2 0 2
noncardioselective,porpranolol 1.0 0.000143348623853 1 0 1
concentration,mic 1.0 0.000143348623853 0 1 -1
fertility,as 1.0 0.000143348623853 0 1 -1
nicotine,nicotine 1.0 0.000143348623853 1 0 1
observed,by 1.0 0.000143348623853 0 1 -1
progression,as 1.0 0.000143348623853 0 1 -1
ems,selective 1.0 0.000143348623853 0 1 -1
monitoring,devices 1.0 0.000143348623853 0 1 -1
beta-blockers,concomitant 1.0 0.000143348623853 1 0 1
beta-1a,avonex 0.0 0.0 1 1 0
intramuscular,injection 1.0 0.000143348623853 1 0 1
immediate,and 1.0 0.000143348623853 1 0 1
a,survey 1.0 0.000143348623853 0 1 -1
than,in 0.4 0.000573394495413 3 7 -4
interaction,is 0.555555555556 0.000716743119266 2 7 -5
of,iressa 1.0 0.000143348623853 1 0 1
system,cyp3a4 1.0 0.000143348623853 0 1 -1
two,medicines 1.0 0.000143348623853 1 0 1
with,likely 1.0 0.000143348623853 0 1 -1
b12,which 1.0 0.000143348623853 1 0 1
concentrations,prior 1.0 0.000143348623853 0 1 -1
to,decreased 0.6 0.00043004587156 4 1 3
whom,died 1.0 0.000143348623853 0 1 -1
itraconazole,enhances 1.0 0.000143348623853 1 0 1
clofibric,acid 1.0 0.000143348623853 1 0 1
vitro,cytogenetics 1.0 0.000143348623853 0 1 -1
substantive,effect 1.0 0.000143348623853 0 1 -1
interaction,in 1.0 0.000286697247706 0 2 -2
abnormalities,elevated 1.0 0.000143348623853 0 1 -1
analgesic,effect 1.0 0.000143348623853 1 0 1
knowledge,of 1.0 0.000143348623853 0 1 -1
reduced,response 1.0 0.000573394495413 0 4 -4
efficacy,should 1.0 0.000286697247706 0 2 -2
w,in 1.0 0.000143348623853 1 0 1
clozapine,dose 1.0 0.000143348623853 0 1 -1
unrestricted,use 1.0 0.000143348623853 0 1 -1
rabbits,backwards 1.0 0.000143348623853 0 1 -1
normal,dose 1.0 0.000143348623853 1 0 1
with,see 1.0 0.000143348623853 1 0 1
nonbarbiturate,antianxiety 1.0 0.000143348623853 1 0 1
have,synergistic 1.0 0.000143348623853 1 0 1
adenocarcinomas,induced 0.0 0.0 1 1 0
tumors,was 1.0 0.000143348623853 0 1 -1
kg,weight 1.0 0.000143348623853 1 0 1
time,to 0.5 0.000286697247706 1 3 -2
between,older 1.0 0.000143348623853 0 1 -1
increased,gleevec 1.0 0.000143348623853 1 0 1
changed,and 1.0 0.000143348623853 0 1 -1
including,cefotaxime 1.0 0.000143348623853 0 1 -1
agents,to 1.0 0.00043004587156 0 3 -3
cgs21680,was 1.0 0.000143348623853 1 0 1
eg,grapefruit 1.0 0.000143348623853 0 1 -1
reported,significantly 1.0 0.000143348623853 0 1 -1
potent,inhalational 1.0 0.000143348623853 1 0 1
of,pra 1.0 0.000143348623853 0 1 -1
while,they 1.0 0.000143348623853 0 1 -1
excreted,unchanged 1.0 0.000143348623853 0 1 -1
c,treated 1.0 0.000143348623853 0 1 -1
everolimus,exposure-response 1.0 0.000143348623853 0 1 -1
pressure,by 1.0 0.000143348623853 1 0 1
v,concentrations 1.0 0.000286697247706 0 2 -2
imipramine,coadministration 1.0 0.000143348623853 1 0 1
lectin,and 1.0 0.000286697247706 0 2 -2
substrates,or 1.0 0.000143348623853 0 1 -1
thiazide,acidic 1.0 0.000143348623853 1 0 1
substrates,of 0.714285714286 0.000716743119266 1 6 -5
treated,aggressively 1.0 0.000143348623853 0 1 -1
as,v 1.0 0.000860091743119 0 6 -6
recommendations,are 1.0 0.000143348623853 0 1 -1
levels,total 1.0 0.000143348623853 1 0 1
as,a 0.489361702128 0.00329701834862 12 35 -23
as,g 1.0 0.000143348623853 1 0 1
as,k 1.0 0.000143348623853 0 1 -1
have,increased 0.0 0.0 1 1 0
toxicities,or 1.0 0.000143348623853 0 1 -1
electrocardiograms,were 1.0 0.000143348623853 0 1 -1
myoclonus,tremor 1.0 0.000143348623853 0 1 -1
cytochrome,p450 0.768421052632 0.0104644495413 11 84 -73
liver,blood 1.0 0.000143348623853 0 1 -1
its,metabolites 0.818181818182 0.00129013761468 1 10 -9
sample,is 1.0 0.000143348623853 0 1 -1
estrogens,tend 1.0 0.000143348623853 0 1 -1
although,results 1.0 0.000143348623853 0 1 -1
positive,urine 1.0 0.000143348623853 0 1 -1
carrying,out 1.0 0.000286697247706 0 2 -2
alter,cardiac 1.0 0.000143348623853 1 0 1
for,relief 1.0 0.000143348623853 0 1 -1
cell,counts 1.0 0.000143348623853 0 1 -1
is,proposed 1.0 0.000286697247706 0 2 -2
thrombin,clotting 1.0 0.000143348623853 0 1 -1
sites,between 1.0 0.000143348623853 0 1 -1
and,systemic 0.5 0.000286697247706 1 3 -2
patient,already 1.0 0.000286697247706 0 2 -2
number,fell 1.0 0.000143348623853 0 1 -1
rabbits,failed 1.0 0.000143348623853 0 1 -1
with,prior 1.0 0.000143348623853 1 0 1
mm,promoted 1.0 0.000143348623853 0 1 -1
completed,at 1.0 0.000143348623853 0 1 -1
as,cns 1.0 0.000143348623853 0 1 -1
the,transport 1.0 0.000286697247706 0 2 -2
exposed,histidines 1.0 0.000143348623853 0 1 -1
mg,experienced 1.0 0.000143348623853 1 0 1
mefloquine,may 1.0 0.000143348623853 1 0 1
cation-containing,products 1.0 0.000143348623853 1 0 1
mixed,signalled-unsignalled 1.0 0.000143348623853 0 1 -1
vivo,to 1.0 0.000143348623853 0 1 -1
with,medication 1.0 0.000143348623853 0 1 -1
following,adrenocorticoids 1.0 0.000143348623853 1 0 1
since,vitamin 1.0 0.00043004587156 0 3 -3
channel,blocking 1.0 0.000286697247706 0 2 -2
phenytoin,intoxication 0.0 0.0 1 1 0
avoided,when 1.0 0.000143348623853 1 0 1
that,like 1.0 0.000143348623853 1 0 1
may,bring 1.0 0.000143348623853 0 1 -1
therapy,was 1.0 0.000573394495413 4 0 4
hyperglycemia,and 0.6 0.00043004587156 1 4 -3
omnicef,should 1.0 0.000286697247706 2 0 2
alterations,of 0.5 0.000286697247706 1 3 -2
used,some 1.0 0.000286697247706 0 2 -2
being,treated 0.25 0.000573394495413 10 6 4
a,stable 0.333333333333 0.000286697247706 2 4 -2
and,angiotensin 0.5 0.000286697247706 1 3 -2
study,conducted 0.0 0.0 1 1 0
once,a 1.0 0.000286697247706 0 2 -2
information,digoxin 1.0 0.000143348623853 0 1 -1
leading,to 0.185185185185 0.000716743119266 16 11 5
concentrations,from 1.0 0.000143348623853 1 0 1
dysfunction,or 1.0 0.000143348623853 0 1 -1
may,render 1.0 0.00043004587156 3 0 3
hydrolase,inhibitors 1.0 0.000143348623853 0 1 -1
induced,by 0.217391304348 0.000716743119266 9 14 -5
parent,and 0.6 0.00043004587156 1 4 -3
to,obtain 1.0 0.000143348623853 1 0 1
receiving,intravenous 0.0 0.0 1 1 0
including,cyp1a2 1.0 0.000286697247706 0 2 -2
mg,four 1.0 0.000143348623853 0 1 -1
the,chance 0.0 0.0 5 5 0
the,b-blocking 1.0 0.000143348623853 1 0 1
the,hypoglycemic 1.0 0.000860091743119 6 0 6
induction,of 0.272727272727 0.00043004587156 4 7 -3
presence,of 0.348837209302 0.0021502293578 14 29 -15
sildenafil,has 1.0 0.000143348623853 0 1 -1
would,worsen 1.0 0.000143348623853 1 0 1
last,morning 1.0 0.000143348623853 0 1 -1
presence,or 1.0 0.00043004587156 0 3 -3
in,pediatric 0.333333333333 0.000143348623853 1 2 -1
renal,insufficiency 0.666666666667 0.000573394495413 1 5 -4
additive,cns 1.0 0.000860091743119 6 0 6
gastrointestinal,irritation 1.0 0.000143348623853 1 0 1
week,leaving 1.0 0.000143348623853 0 1 -1
of,lymphatic 1.0 0.000143348623853 1 0 1
to,investigate 1.0 0.000716743119266 0 5 -5
in,concentration 1.0 0.000143348623853 0 1 -1
sodium,from 1.0 0.000143348623853 1 0 1
inhibitory,or 1.0 0.000143348623853 0 1 -1
steroid,hormones 1.0 0.000143348623853 1 0 1
disease,may 1.0 0.000143348623853 1 0 1
study,involving 0.5 0.000286697247706 1 3 -2
on,hepatic 1.0 0.000286697247706 0 2 -2
by,two 1.0 0.000143348623853 0 1 -1
patients,receive 1.0 0.000286697247706 0 2 -2
the,inhibitor 1.0 0.000143348623853 0 1 -1
revia,the 1.0 0.000143348623853 1 0 1
action,is 1.0 0.000143348623853 0 1 -1
action,it 1.0 0.000143348623853 1 0 1
monitor,tca 1.0 0.000573394495413 0 4 -4
half-life,by 1.0 0.000286697247706 2 0 2
salicylate,assays 1.0 0.000143348623853 0 1 -1
lies,both 1.0 0.000143348623853 0 1 -1
among,bosentan- 1.0 0.000143348623853 0 1 -1
development,including 1.0 0.000143348623853 0 1 -1
essential,conduct 1.0 0.000143348623853 0 1 -1
after,colestid 1.0 0.000143348623853 0 1 -1
sinus,medicines 1.0 0.000143348623853 1 0 1
suppress,the 0.0 0.0 1 1 0
and,levels 0.333333333333 0.000143348623853 1 2 -1
and,infants 1.0 0.000143348623853 0 1 -1
preparations,micro-dosed 1.0 0.000143348623853 1 0 1
metanephrine,normetanephrine 1.0 0.000143348623853 0 1 -1
method,be 1.0 0.000286697247706 0 2 -2
expected,steady-state 1.0 0.000143348623853 1 0 1
continuous,intravenous 1.0 0.000143348623853 0 1 -1
nursing,while 1.0 0.000143348623853 0 1 -1
endothelium-intact,aortic 1.0 0.000143348623853 1 0 1
cyclopentyl-1,dipropylxanthine 1.0 0.000143348623853 0 1 -1
undergo,renal 1.0 0.000143348623853 0 1 -1
nonsteroial,anti-inflammatory 1.0 0.000143348623853 1 0 1
or,neurotoxic 1.0 0.000143348623853 0 1 -1
bezalip,or 1.0 0.000716743119266 5 0 5
searches,of 1.0 0.000143348623853 0 1 -1
clinical,experiences 1.0 0.000143348623853 0 1 -1
nonabsorbable,given 1.0 0.000143348623853 1 0 1
subjects,was 1.0 0.000143348623853 1 0 1
individuals,who 1.0 0.000143348623853 0 1 -1
d6,or 1.0 0.000143348623853 0 1 -1
endocrine,function 1.0 0.000143348623853 0 1 -1
in,zollinger-ellison 1.0 0.000143348623853 0 1 -1
in,lysing 1.0 0.000143348623853 0 1 -1
usually,occurred 1.0 0.000143348623853 0 1 -1
are,cyp3a4 1.0 0.000143348623853 1 0 1
and,properties 1.0 0.000143348623853 0 1 -1
if,they 1.0 0.000573394495413 0 4 -4
be,longer 1.0 0.000143348623853 0 1 -1
and,august 1.0 0.000143348623853 0 1 -1
hypoglycemic,agents 0.538461538462 0.00100344036697 10 3 7
taking,ace 1.0 0.000143348623853 0 1 -1
be,efficacious 1.0 0.000143348623853 0 1 -1
and,penthrane 1.0 0.000143348623853 1 0 1
additive,effect 0.6 0.000860091743119 8 2 6
inhibitory,effect 0.0 0.0 3 3 0
hydrochloride,with 1.0 0.000286697247706 2 0 2
and,impairment 1.0 0.000143348623853 0 1 -1
experienced,severe 1.0 0.000143348623853 1 0 1
also,involved 1.0 0.000143348623853 1 0 1
iv,is 1.0 0.000143348623853 1 0 1
irradiation,are 1.0 0.000143348623853 0 1 -1
iv,im 1.0 0.000143348623853 1 0 1
days,did 1.0 0.00114678899083 0 8 -8
iv,in 1.0 0.000143348623853 0 1 -1
above,findings 1.0 0.000143348623853 0 1 -1
between,ellence 1.0 0.000143348623853 0 1 -1
a,plasma 1.0 0.000143348623853 0 1 -1
or,pharmacist 1.0 0.000286697247706 0 2 -2
as,directed 1.0 0.000286697247706 0 2 -2
withdrawn,within 1.0 0.000143348623853 0 1 -1
any,amine 1.0 0.000143348623853 1 0 1
in,immune 1.0 0.000143348623853 0 1 -1
as,ace 1.0 0.000143348623853 0 1 -1
sulfapyridine,may 1.0 0.000143348623853 1 0 1
metabolites,had 1.0 0.000143348623853 0 1 -1
depending,on 1.0 0.00129013761468 0 9 -9
trileptal,on 1.0 0.000143348623853 0 1 -1
metabolites,has 1.0 0.000143348623853 0 1 -1
system,leading 1.0 0.00043004587156 0 3 -3
h1,and 1.0 0.000143348623853 1 0 1
loop,sparing 1.0 0.000143348623853 0 1 -1
above,the 1.0 0.000143348623853 0 1 -1
in,prothrombin 0.571428571429 0.00114678899083 3 11 -8
and,adverse 1.0 0.000143348623853 0 1 -1
of,erythema 1.0 0.000286697247706 0 2 -2
with,constant 1.0 0.000143348623853 0 1 -1
trileptal,was 1.0 0.000143348623853 1 0 1
withdrawn,in 1.0 0.000143348623853 0 1 -1
reported,following 0.555555555556 0.000716743119266 7 2 5
inhibits,gastric 1.0 0.000143348623853 0 1 -1
high,concentration 1.0 0.000143348623853 1 0 1
important,determinant 0.333333333333 0.000143348623853 2 1 1
days,does 1.0 0.000143348623853 0 1 -1
paper,attempts 1.0 0.000143348623853 0 1 -1
lysing,human 1.0 0.000143348623853 0 1 -1
of,gabitril 1.0 0.00043004587156 0 3 -3
prophylaxis,contributed 1.0 0.000143348623853 0 1 -1
contents,of 1.0 0.000286697247706 0 2 -2
enzymes,i 1.0 0.000143348623853 0 1 -1
before,use 0.333333333333 0.000286697247706 2 4 -2
hypoglycemia,oral 1.0 0.000286697247706 0 2 -2
month,and 1.0 0.000143348623853 0 1 -1
incidence,or 1.0 0.000143348623853 1 0 1
broad,spectrum 1.0 0.000143348623853 0 1 -1
moderate,hypertension 0.333333333333 0.000143348623853 2 1 1
incidence,of 0.555555555556 0.00286697247706 8 28 -20
limited,in 1.0 0.000143348623853 1 0 1
a,poor 1.0 0.000143348623853 0 1 -1
these,reactions 1.0 0.000716743119266 0 5 -5
and,heart-rate 1.0 0.000143348623853 1 0 1
receiving,camptosar 1.0 0.000143348623853 1 0 1
labeling,can 1.0 0.000143348623853 0 1 -1
regular,users 1.0 0.000286697247706 0 2 -2
be,used 0.00826446280992 0.000143348623853 61 60 1
given,sc 1.0 0.000143348623853 0 1 -1
clearance,a 0.0 0.0 1 1 0
with,resulting 1.0 0.000143348623853 1 0 1
training-induced,neurobiological 1.0 0.000143348623853 0 1 -1
foscavir,and 1.0 0.000286697247706 2 0 2
serotypes,at 1.0 0.000286697247706 0 2 -2
increased,total 1.0 0.000286697247706 0 2 -2
sh,da 1.0 0.000143348623853 0 1 -1
such,agents 1.0 0.000716743119266 0 5 -5
av,nodal 1.0 0.000286697247706 2 0 2
gemzar,and 1.0 0.000143348623853 0 1 -1
is,combined 1.0 0.000286697247706 2 0 2
of,metabotropic 1.0 0.000143348623853 0 1 -1
contains,dehydrated 1.0 0.000143348623853 0 1 -1
during,studies 1.0 0.000143348623853 1 0 1
each,serum 1.0 0.000143348623853 0 1 -1
severe,recalcitrant 1.0 0.000143348623853 0 1 -1
active,suggesting 1.0 0.000143348623853 0 1 -1
was,determined 1.0 0.000286697247706 0 2 -2
lowering,effect 0.6 0.00043004587156 1 4 -3
metabolites,were 1.0 0.000286697247706 0 2 -2
advised,to 0.428571428571 0.00043004587156 2 5 -3
of,necessary 1.0 0.000143348623853 0 1 -1
in,extremely 1.0 0.000143348623853 0 1 -1
in,auc 0.263157894737 0.000716743119266 12 7 5
with,prolonged 1.0 0.000143348623853 0 1 -1
other,hydroxymethylglutaryl 1.0 0.000143348623853 1 0 1
approximate,increase 1.0 0.000573394495413 4 0 4
threefold,from 1.0 0.000143348623853 1 0 1
of,salicylic 1.0 0.000143348623853 1 0 1
your,skin 1.0 0.000143348623853 0 1 -1
cyclophosphamide,used 1.0 0.000143348623853 1 0 1
furosemide,may 1.0 0.00043004587156 3 0 3
decreased,symptoms 1.0 0.000143348623853 1 0 1
in,effects 0.0 0.0 1 1 0
is,given 0.0967741935484 0.00043004587156 14 17 -3
must,take 1.0 0.000143348623853 0 1 -1
endorphinergic,system 1.0 0.000286697247706 0 2 -2
variability,in 0.0 0.0 2 2 0
lumen,at 1.0 0.000143348623853 0 1 -1
nervous,system 0.037037037037 0.000143348623853 14 13 1
nifedipine,may 1.0 0.000143348623853 0 1 -1
paper,lists 1.0 0.000143348623853 0 1 -1
utilization,with 1.0 0.000143348623853 0 1 -1
was,considered 1.0 0.000143348623853 0 1 -1
hypothyroidism,may 1.0 0.000143348623853 0 1 -1
are,all 1.0 0.000286697247706 2 0 2
as,was 0.0 0.0 1 1 0
person,and 1.0 0.000143348623853 0 1 -1
induced,hypotension 1.0 0.000143348623853 0 1 -1
tcas,such 1.0 0.000143348623853 1 0 1
bronchodilators,has 1.0 0.000143348623853 1 0 1
for,up 0.0 0.0 3 3 0
terfenadine,astemizole 1.0 0.000143348623853 0 1 -1
affect,safety 1.0 0.000143348623853 0 1 -1
oral,ccnu 0.0 0.0 2 2 0
mefloquineuine,on 1.0 0.000143348623853 0 1 -1
tolerated,dose 1.0 0.000143348623853 0 1 -1
indocin,has 1.0 0.000286697247706 2 0 2
emptying,may 1.0 0.000143348623853 1 0 1
glutathione,levels 1.0 0.000143348623853 1 0 1
this,antagonistic 1.0 0.000143348623853 1 0 1
preferentially,blocked 1.0 0.000143348623853 1 0 1
could,exaggerate 1.0 0.000286697247706 2 0 2
citalopram,citalopram 1.0 0.000143348623853 1 0 1
study,was 1.0 0.0021502293578 0 15 -15
reactions,of 0.0 0.0 1 1 0
b,i 0.2 0.000286697247706 6 4 2
s-warfarin,and 1.0 0.000143348623853 1 0 1
combined,effects 0.0 0.0 1 1 0
include,nucleoside 1.0 0.000143348623853 0 1 -1
for,prolonged 1.0 0.000143348623853 0 1 -1
antagonists,hypertension 1.0 0.000143348623853 1 0 1
suggest,that 0.1 0.000860091743119 27 33 -6
and,cmax 0.263157894737 0.000716743119266 7 12 -5
other,statins 1.0 0.000143348623853 1 0 1
hypotensive,effects 0.777777777778 0.00100344036697 8 1 7
depressed,at 1.0 0.000143348623853 0 1 -1
also,suggest 0.5 0.000286697247706 1 3 -2
justifies,the 1.0 0.000143348623853 0 1 -1
or,inducers 1.0 0.00100344036697 0 7 -7
normal,subjects 0.142857142857 0.000143348623853 3 4 -1
hormone,therapy 1.0 0.000143348623853 0 1 -1
to,pre-gentamycin 1.0 0.000143348623853 0 1 -1
edema,nausea 1.0 0.000143348623853 0 1 -1
the,elimination 0.272727272727 0.00043004587156 7 4 3
nsaids,aspirin 1.0 0.000143348623853 0 1 -1
exists,not 1.0 0.000143348623853 0 1 -1
complex,of 1.0 0.000143348623853 0 1 -1
as,protease 1.0 0.000286697247706 2 0 2
phe-nothiazines,products 1.0 0.000143348623853 0 1 -1
month,at 1.0 0.000143348623853 0 1 -1
serum,at 1.0 0.000143348623853 0 1 -1
inducers,drugs 1.0 0.000143348623853 0 1 -1
body,fat 1.0 0.000143348623853 0 1 -1
dimenhydrinate,may 1.0 0.000143348623853 1 0 1
treat,hypertension 1.0 0.000286697247706 0 2 -2
adjustment,to 1.0 0.000286697247706 0 2 -2
mononuclear,cell 1.0 0.000143348623853 0 1 -1
and,viable 1.0 0.000143348623853 0 1 -1
inhibitory,effects 0.6 0.00043004587156 1 4 -3
with,monoamine 0.6 0.00043004587156 4 1 3
doses,decreased 1.0 0.000143348623853 0 1 -1
data,have 1.0 0.000143348623853 0 1 -1
group,interaction 1.0 0.000143348623853 0 1 -1
blockers,should 1.0 0.000286697247706 2 0 2
been,one 1.0 0.000143348623853 1 0 1
lodine,as 1.0 0.000143348623853 0 1 -1
prostaglandin,synthase 1.0 0.000143348623853 1 0 1
half-life,may 1.0 0.000143348623853 1 0 1
and,until 1.0 0.000286697247706 0 2 -2
sometimes,with 1.0 0.000286697247706 0 2 -2
acid,reactive 1.0 0.000143348623853 0 1 -1
adults,and 1.0 0.000143348623853 0 1 -1
dosed,with 0.333333333333 0.000143348623853 1 2 -1
rr,reduced 1.0 0.000143348623853 0 1 -1
conversely,decreases 1.0 0.000143348623853 1 0 1
weight,to 0.333333333333 0.000143348623853 1 2 -1
of,hospital 1.0 0.000143348623853 0 1 -1
such,combinations 1.0 0.000286697247706 0 2 -2
available,kits 1.0 0.000143348623853 0 1 -1
therefore,foradil 1.0 0.000143348623853 0 1 -1
these,results 0.428571428571 0.00129013761468 6 15 -9
to,reverse 1.0 0.000143348623853 0 1 -1
ii,or 1.0 0.000143348623853 0 1 -1
alpha-adrenergic,stimulants 1.0 0.000143348623853 1 0 1
minutes,were 1.0 0.000143348623853 0 1 -1
by,alveoli 1.0 0.000143348623853 0 1 -1
cytochrome,p450iid6 0.333333333333 0.000143348623853 1 2 -1
been,diagnosed 1.0 0.000286697247706 0 2 -2
corrected,qt 1.0 0.00043004587156 0 3 -3
modest,effect 1.0 0.000286697247706 2 0 2
initiated,or 0.333333333333 0.000143348623853 1 2 -1
use,has 1.0 0.000143348623853 1 0 1
the,mediation 1.0 0.000143348623853 0 1 -1
pegasys,alone 1.0 0.000286697247706 0 2 -2
found,or 1.0 0.00043004587156 3 0 3
vardenafil,dosing 1.0 0.000143348623853 1 0 1
value,of 1.0 0.000716743119266 0 5 -5
african,and 1.0 0.000716743119266 0 5 -5
subjects,with 0.75 0.000860091743119 1 7 -6
between,area 1.0 0.000143348623853 0 1 -1
pregnancy,occurs 1.0 0.000286697247706 0 2 -2
methylpyrazole,mg 0.0 0.0 1 1 0
cyp3a4,eg 1.0 0.000716743119266 5 0 5
menstrual,rhythm 1.0 0.000143348623853 0 1 -1
those,contained 1.0 0.000143348623853 1 0 1
long-term,high-dose 0.0 0.0 1 1 0
or,minus 0.333333333333 0.000143348623853 1 2 -1
of,among 1.0 0.000143348623853 1 0 1
monitored,particularly 1.0 0.000286697247706 2 0 2
if,peganone 1.0 0.000143348623853 1 0 1
to,modify 1.0 0.000143348623853 0 1 -1
indicates,either 1.0 0.000143348623853 0 1 -1
an,empty 1.0 0.000143348623853 0 1 -1
insulins,ability 1.0 0.000143348623853 0 1 -1
are,several 1.0 0.000143348623853 0 1 -1
isoenzymes,therefore 1.0 0.000143348623853 0 1 -1
not,interact 1.0 0.000286697247706 0 2 -2
blockers,derivatives 1.0 0.000143348623853 1 0 1
be,conducted 1.0 0.000143348623853 0 1 -1
vancomycin,resistance 1.0 0.000143348623853 0 1 -1
adapting,of 1.0 0.000143348623853 0 1 -1
antagonist,were 1.0 0.000143348623853 0 1 -1
as,diphen-hydramine 1.0 0.000143348623853 0 1 -1
competitive,interaction 1.0 0.000143348623853 1 0 1
a,tumor 1.0 0.000143348623853 0 1 -1
cocaine-treated,sst 1.0 0.000143348623853 0 1 -1
because,oral 1.0 0.000143348623853 1 0 1
unaltered,in 1.0 0.000143348623853 0 1 -1
therapy,should 0.142857142857 0.000286697247706 8 6 2
system,are 1.0 0.000143348623853 0 1 -1
be,unaffected 1.0 0.000143348623853 0 1 -1
results,are 1.0 0.000573394495413 0 4 -4
introduced,at 1.0 0.000143348623853 1 0 1
same,day 1.0 0.000143348623853 1 0 1
is,obtained 1.0 0.000143348623853 0 1 -1
not,affected 1.0 0.00301032110092 0 21 -21
that,may 0.0212765957447 0.000143348623853 24 23 1
or,implant 1.0 0.000143348623853 0 1 -1
however,prudent 0.0 0.0 1 1 0
doses,higher 1.0 0.000286697247706 0 2 -2
major,psychotic 1.0 0.000143348623853 1 0 1
amount,absorbed 1.0 0.000143348623853 0 1 -1
proposed,in 1.0 0.000143348623853 0 1 -1
that,disease 1.0 0.000143348623853 0 1 -1
a,delay 1.0 0.000143348623853 1 0 1
and,intestinal 1.0 0.000143348623853 0 1 -1
increased,by 0.333333333333 0.00114678899083 16 8 8
significantly,more 1.0 0.000286697247706 0 2 -2
information,is 1.0 0.000286697247706 0 2 -2
the,bumetanide-induced 1.0 0.000143348623853 1 0 1
in,cases 0.333333333333 0.000286697247706 4 2 2
nevirapine,is 1.0 0.000286697247706 0 2 -2
monkeys,following 1.0 0.000143348623853 0 1 -1
indicated,because 1.0 0.00043004587156 0 3 -3
formulation,with 1.0 0.000286697247706 2 0 2
patients,this 1.0 0.000143348623853 0 1 -1
surveillance,of 1.0 0.000143348623853 0 1 -1
expected,physiologic 1.0 0.000143348623853 0 1 -1
such,the 1.0 0.000286697247706 0 2 -2
in,rabbit 1.0 0.000286697247706 2 0 2
heroin-related,deaths 1.0 0.000143348623853 1 0 1
sulfoxide,were 1.0 0.000143348623853 1 0 1
repeat,doses 1.0 0.000143348623853 0 1 -1
receiving,a 0.0 0.0 3 3 0
local,which 1.0 0.000143348623853 1 0 1
corticosteroids,and 1.0 0.000143348623853 1 0 1
approximately,threefold 1.0 0.000143348623853 1 0 1
blood,lipids 1.0 0.000143348623853 0 1 -1
m2,plus 1.0 0.000143348623853 0 1 -1
should,only 1.0 0.000286697247706 2 0 2
after,coadministration 1.0 0.000143348623853 0 1 -1
heparinized,patients 1.0 0.000143348623853 1 0 1
of,therapy 0.111111111111 0.000286697247706 10 8 2
topical,injectable 1.0 0.000143348623853 0 1 -1
met,acr 1.0 0.000143348623853 0 1 -1
cns,depressive 1.0 0.000143348623853 1 0 1
vasospastic,reactions 1.0 0.000143348623853 1 0 1
could,decrease 1.0 0.000143348623853 0 1 -1
dosage,inhibited 1.0 0.000143348623853 0 1 -1
weight,approximately 1.0 0.000143348623853 0 1 -1
allows,physicians 1.0 0.000143348623853 0 1 -1
for,eight 1.0 0.000143348623853 1 0 1
via,a 1.0 0.000143348623853 0 1 -1
often,used 1.0 0.000143348623853 0 1 -1
usually,within 1.0 0.000143348623853 1 0 1
bioavailability,parameters 1.0 0.000143348623853 0 1 -1
oral,channel 1.0 0.000143348623853 0 1 -1
concurrently,taking 1.0 0.00043004587156 0 3 -3
mainly,concerns 1.0 0.000143348623853 0 1 -1
copegus,pegasys 1.0 0.000143348623853 0 1 -1
for,alterations 1.0 0.000286697247706 2 0 2
acetate,x 1.0 0.000143348623853 1 0 1
tumors,by 1.0 0.000143348623853 0 1 -1
known,caution 1.0 0.000143348623853 1 0 1
differences,between 1.0 0.000716743119266 0 5 -5
as,dose 1.0 0.000143348623853 0 1 -1
or,complete 1.0 0.000143348623853 1 0 1
hemodynamic,compromise 1.0 0.000143348623853 1 0 1
measurements,are 1.0 0.000143348623853 0 1 -1
lower,the 0.333333333333 0.000143348623853 2 1 1
cholesterol,and 0.0 0.0 1 1 0
effects,particularly 1.0 0.000143348623853 1 0 1
cohort,design 1.0 0.000143348623853 1 0 1
month,toxicology 1.0 0.000143348623853 0 1 -1
a,such 0.333333333333 0.000143348623853 1 2 -1
depressant,effect 0.0 0.0 2 2 0
atropinization,flushing 1.0 0.000143348623853 1 0 1
anti-peptic,agents 1.0 0.000143348623853 0 1 -1
apoptosis,induced 1.0 0.000286697247706 0 2 -2
two,hours 1.0 0.00043004587156 0 3 -3
these,potential 1.0 0.000143348623853 0 1 -1
sensitive,assay 1.0 0.000143348623853 0 1 -1
min,interval 1.0 0.000143348623853 1 0 1
a,reliable 1.0 0.000143348623853 1 0 1
with,antithrombin 1.0 0.000286697247706 2 0 2
and,against 1.0 0.000143348623853 0 1 -1
the,treated 1.0 0.000143348623853 0 1 -1
initiated,adjusted 1.0 0.000143348623853 1 0 1
regimens,where 1.0 0.000143348623853 0 1 -1
years,of 1.0 0.000573394495413 0 4 -4
these,and 1.0 0.000573394495413 0 4 -4
years,on 1.0 0.000143348623853 0 1 -1
has,importance 1.0 0.000143348623853 0 1 -1
desirable,antimuscarinic 1.0 0.000143348623853 0 1 -1
camptosar,the 1.0 0.000143348623853 1 0 1
similar,combination 1.0 0.000143348623853 0 1 -1
metabolizers,which 1.0 0.000143348623853 0 1 -1
of,interferences 1.0 0.000143348623853 0 1 -1
intraocular,pressure 1.0 0.000143348623853 0 1 -1
recent,study 1.0 0.000143348623853 1 0 1
while,plasma 1.0 0.000143348623853 1 0 1
angiotensin,converting 0.2 0.000143348623853 3 2 1
either,these 0.333333333333 0.000286697247706 2 4 -2
and,elevation 1.0 0.000286697247706 0 2 -2
dosages,may 0.0 0.0 1 1 0
lithium,in 1.0 0.000143348623853 1 0 1
inducers,are 0.333333333333 0.000143348623853 1 2 -1
later,also 1.0 0.000143348623853 1 0 1
and,substrates 1.0 0.000143348623853 1 0 1
conduction,observed 1.0 0.000143348623853 1 0 1
propranolol,may 1.0 0.000143348623853 1 0 1
toradol,and 0.333333333333 0.000143348623853 2 1 1
derivatives,k 1.0 0.000143348623853 0 1 -1
variably,increased 1.0 0.000143348623853 0 1 -1
together,caution 1.0 0.000143348623853 0 1 -1
with,small 1.0 0.000143348623853 1 0 1
in,u937 1.0 0.000143348623853 1 0 1
effects,when 0.75 0.000860091743119 7 1 6
phosphokinase,diffuse 1.0 0.000143348623853 0 1 -1
receiving,replacement 1.0 0.000143348623853 1 0 1
given,consideration 1.0 0.00100344036697 7 0 7
roughly,twofold 1.0 0.000143348623853 0 1 -1
although,a 1.0 0.00043004587156 3 0 3
determine,the 1.0 0.000573394495413 0 4 -4
reduced,although 1.0 0.000143348623853 1 0 1
although,c 1.0 0.000143348623853 0 1 -1
most,of 0.6 0.00043004587156 1 4 -3
noted,below 1.0 0.000286697247706 0 2 -2
direct,and 1.0 0.000143348623853 0 1 -1
a,non-enzyme 1.0 0.000143348623853 0 1 -1
automaticity,as 1.0 0.000143348623853 1 0 1
node,function 1.0 0.000143348623853 1 0 1
and,provide 1.0 0.000143348623853 1 0 1
decarboxylase,inhibitor 1.0 0.000143348623853 0 1 -1
of,kg 0.333333333333 0.000143348623853 1 2 -1
acarbose,was 1.0 0.000143348623853 0 1 -1
at,min 1.0 0.000143348623853 0 1 -1
in,most 0.333333333333 0.000143348623853 2 1 1
automatic,behavior 1.0 0.000143348623853 0 1 -1
as,normal 1.0 0.000143348623853 0 1 -1
breakfast,cereals 1.0 0.000143348623853 0 1 -1
if,sprycel 1.0 0.000143348623853 0 1 -1
neuromuscular,paralysis 1.0 0.000143348623853 0 1 -1
the,steady 0.333333333333 0.000143348623853 1 2 -1
the,principal 0.0 0.0 1 1 0
levels,close 1.0 0.000143348623853 0 1 -1
tubercle,of 1.0 0.000143348623853 0 1 -1
either,prophylactic 1.0 0.000143348623853 0 1 -1
be,abnormal 1.0 0.000143348623853 0 1 -1
metabolism,hormone 1.0 0.000143348623853 0 1 -1
considerable,effect 1.0 0.000143348623853 1 0 1
related,psychoses 1.0 0.000286697247706 0 2 -2
with,angiotensin- 1.0 0.000143348623853 0 1 -1
relaxants,most 1.0 0.000143348623853 1 0 1
and,vii 1.0 0.000143348623853 0 1 -1
h,in 1.0 0.000143348623853 0 1 -1
anticoagulants,in 0.0 0.0 1 1 0
that,and 0.272727272727 0.00043004587156 4 7 -3
weight,was 0.333333333333 0.000143348623853 1 2 -1
doses,did 1.0 0.000143348623853 0 1 -1
on,may 1.0 0.000286697247706 2 0 2
citrate,potentiate 1.0 0.000143348623853 1 0 1
aim,of 1.0 0.000286697247706 0 2 -2
feels,that 1.0 0.000143348623853 0 1 -1
receiving,in 1.0 0.000143348623853 1 0 1
vii,antigen 1.0 0.000286697247706 0 2 -2
the,ccnu 1.0 0.000143348623853 0 1 -1
property,of 1.0 0.000143348623853 1 0 1
or,reduce 0.0 0.0 1 1 0
in,thedosage 1.0 0.000286697247706 0 2 -2
sixty-two,of 1.0 0.000143348623853 0 1 -1
as,part 1.0 0.000286697247706 0 2 -2
at,and 0.6 0.00043004587156 1 4 -3
cyclooxygenase-2,cox-2 1.0 0.000143348623853 0 1 -1
the,carpophores 1.0 0.000143348623853 0 1 -1
infections,because 1.0 0.000143348623853 0 1 -1
pharmacokinetics,in 1.0 0.00043004587156 0 3 -3
with,ototoxic 1.0 0.000143348623853 1 0 1
products,should 1.0 0.000143348623853 0 1 -1
damage,could 1.0 0.000143348623853 0 1 -1
distribution,of 0.333333333333 0.000286697247706 2 4 -2
from,faslodex 1.0 0.000143348623853 0 1 -1
qt,c 0.333333333333 0.000143348623853 2 1 1
by,range 1.0 0.000143348623853 1 0 1
were,maintained 1.0 0.000286697247706 0 2 -2
or,cardiac 1.0 0.00043004587156 0 3 -3
decrease,glutathione 1.0 0.000143348623853 1 0 1
k,antagonists 0.0 0.0 2 2 0
exposed,histidine 1.0 0.000143348623853 0 1 -1
assessed,by 1.0 0.000573394495413 0 4 -4
of,chloral 1.0 0.000143348623853 0 1 -1
along,with 0.5 0.000286697247706 1 3 -2
anaphylaxis,have 1.0 0.000143348623853 0 1 -1
affect,gastrointestinal 1.0 0.000143348623853 1 0 1
starting,st 1.0 0.000143348623853 0 1 -1
a,rapidly 1.0 0.000286697247706 0 2 -2
serotonin,reuptake 0.0 0.0 9 9 0
nonsteroidal,anti 1.0 0.000143348623853 1 0 1
incombination,with 1.0 0.000143348623853 0 1 -1
are,multiple 1.0 0.000143348623853 0 1 -1
occur,sometimes 1.0 0.000286697247706 0 2 -2
development,at 1.0 0.000143348623853 0 1 -1
patients,consuming 1.0 0.000143348623853 1 0 1
with,antacids 1.0 0.000143348623853 1 0 1
occurred,three 1.0 0.000143348623853 0 1 -1
concentrations,during 1.0 0.000143348623853 1 0 1
anti-platelet,effect 1.0 0.000143348623853 0 1 -1
myopathy,when 1.0 0.000286697247706 0 2 -2
allergic,reactions 1.0 0.000143348623853 0 1 -1
initial,or 1.0 0.00043004587156 0 3 -3
likely,viracept 1.0 0.000143348623853 1 0 1
differential,regulation 1.0 0.000143348623853 0 1 -1
abnormalities,such 1.0 0.000143348623853 1 0 1
when,dosed 1.0 0.000143348623853 0 1 -1
the,reductions 1.0 0.000143348623853 0 1 -1
is,active 1.0 0.000143348623853 0 1 -1
norpace,or 1.0 0.000143348623853 1 0 1
administration,mg 1.0 0.000143348623853 0 1 -1
when,doses 1.0 0.000143348623853 1 0 1
with,left 1.0 0.000143348623853 0 1 -1
was,covalently 1.0 0.000143348623853 0 1 -1
treatment,following 1.0 0.000143348623853 1 0 1
except,in 0.0 0.0 1 1 0
role,of 1.0 0.000860091743119 0 6 -6
well-controlled,study 1.0 0.000143348623853 0 1 -1
taking,these 0.333333333333 0.000143348623853 1 2 -1
acid,the 1.0 0.000143348623853 0 1 -1
however,a 0.333333333333 0.000143348623853 1 2 -1
therefore,patients 0.142857142857 0.000143348623853 4 3 1
considered,although 1.0 0.000143348623853 0 1 -1
by,bacterial 1.0 0.000143348623853 1 0 1
one,class 0.6 0.00043004587156 4 1 3
kg,decreased 1.0 0.000143348623853 1 0 1
c,for 1.0 0.000143348623853 0 1 -1
absorption,acting 1.0 0.000143348623853 1 0 1
by,gram-negative 1.0 0.000143348623853 0 1 -1
kg,decreases 1.0 0.000143348623853 0 1 -1
blocking,agents 0.0588235294118 0.000286697247706 18 16 2
soluble,to 1.0 0.000286697247706 0 2 -2
bar-press,behavior 1.0 0.000143348623853 0 1 -1
other,especially 1.0 0.000143348623853 0 1 -1
times,with 1.0 0.000143348623853 1 0 1
toxicity,investigation 1.0 0.000143348623853 0 1 -1
are,actively 1.0 0.000143348623853 1 0 1
unfractionated,up 1.0 0.000143348623853 0 1 -1
frequent,determination 1.0 0.000143348623853 0 1 -1
stabilized,see 1.0 0.000143348623853 0 1 -1
mean,arterial 1.0 0.000143348623853 1 0 1
has,reduced 0.5 0.000286697247706 1 3 -2
during,accutane 1.0 0.000143348623853 0 1 -1
on,and 0.5 0.000286697247706 3 1 2
nac,decreased 1.0 0.000143348623853 0 1 -1
on,any 1.0 0.000143348623853 0 1 -1
cerebri,benign 1.0 0.000143348623853 1 0 1
cephalosporins-cephalosporins,containing 1.0 0.000143348623853 0 1 -1
several,well-controlled 1.0 0.000143348623853 0 1 -1
interactions,caused 1.0 0.000286697247706 0 2 -2
ldl,cholesterol 1.0 0.000286697247706 0 2 -2
felbamate,treatment 1.0 0.000143348623853 1 0 1
cyp3a4,cyp2c9 1.0 0.000143348623853 0 1 -1
volunteers,when 1.0 0.000143348623853 0 1 -1
after,co-treatment 1.0 0.000143348623853 1 0 1
cyp3a4,may 1.0 0.00043004587156 0 3 -3
inducer,should 1.0 0.000286697247706 2 0 2
an,decrease 1.0 0.000286697247706 2 0 2
that,although 0.0 0.0 1 1 0
prolong,both 1.0 0.00043004587156 0 3 -3
as,back 1.0 0.000143348623853 0 1 -1
affect,abilify 1.0 0.000143348623853 0 1 -1
eszopiclone,is 1.0 0.000143348623853 0 1 -1
necessary,during 0.0 0.0 1 1 0
female,fertility 1.0 0.00043004587156 0 3 -3
and,male 1.0 0.000143348623853 0 1 -1
age,range 1.0 0.000143348623853 0 1 -1
locomotor,responses 1.0 0.000143348623853 0 1 -1
human,volunteers 1.0 0.000143348623853 0 1 -1
were,between 1.0 0.000143348623853 0 1 -1
monitor,serum 1.0 0.000143348623853 0 1 -1
following,six 1.0 0.000143348623853 0 1 -1
administered,cautiously 1.0 0.000143348623853 0 1 -1
produced,only 1.0 0.000143348623853 1 0 1
in,hyperuricemic 1.0 0.000143348623853 0 1 -1
immune,function 1.0 0.000286697247706 0 2 -2
especially,with 1.0 0.000286697247706 0 2 -2
dehydration,have 1.0 0.000143348623853 1 0 1
argatroban,is 1.0 0.000143348623853 0 1 -1
hence,is 1.0 0.000143348623853 1 0 1
in,geriatric 1.0 0.000143348623853 0 1 -1
certain,tumor 1.0 0.000143348623853 0 1 -1
chemical,color 1.0 0.000143348623853 0 1 -1
no,interaction 0.714285714286 0.000716743119266 1 6 -5
with,and 0.0819672131148 0.000716743119266 28 33 -5
possible,extrarenal 1.0 0.000143348623853 0 1 -1
intake,which 1.0 0.000143348623853 0 1 -1
aspirin,should 1.0 0.00043004587156 3 0 3
supplements,on 1.0 0.000143348623853 0 1 -1
are,associated 1.0 0.000573394495413 0 4 -4
glucose-specific,method 1.0 0.000143348623853 0 1 -1
supplements,and 0.666666666667 0.000573394495413 5 1 4
pharmacokinetic,dosing 1.0 0.000286697247706 0 2 -2
medical,practice 1.0 0.000143348623853 1 0 1
supplements,or 0.333333333333 0.000143348623853 1 2 -1
dihydroxyflavone,with 1.0 0.000143348623853 0 1 -1
when,animals 1.0 0.000143348623853 0 1 -1
that,antagonized 1.0 0.000143348623853 1 0 1
of,depressive 1.0 0.000143348623853 0 1 -1
in,children 1.0 0.000143348623853 0 1 -1
testes,and 1.0 0.000143348623853 0 1 -1
clonazepam,does 1.0 0.000143348623853 0 1 -1
lessened,active 1.0 0.000143348623853 0 1 -1
group,did 1.0 0.000143348623853 0 1 -1
insulin,increased 1.0 0.000143348623853 0 1 -1
of,humorsol 1.0 0.000143348623853 1 0 1
a,functioning 1.0 0.000143348623853 1 0 1
agents,contraindicated 1.0 0.000143348623853 0 1 -1
the,force 1.0 0.000143348623853 0 1 -1
with,ventricular 1.0 0.000143348623853 1 0 1
three,doses 1.0 0.000143348623853 1 0 1
values,being 1.0 0.000143348623853 0 1 -1
dissolution,until 1.0 0.000143348623853 0 1 -1
stimulating,factor 1.0 0.000143348623853 0 1 -1
cause,too 1.0 0.000143348623853 0 1 -1
medication,including 1.0 0.000143348623853 1 0 1
agents,since 0.2 0.000143348623853 2 3 -1
evidently,a 1.0 0.000143348623853 0 1 -1
in,nine 1.0 0.000143348623853 0 1 -1
to,electrolyte 0.0 0.0 1 1 0
lovastatin,is 1.0 0.000143348623853 0 1 -1
concurrently,use 1.0 0.000143348623853 1 0 1
channel,subtypes 1.0 0.00043004587156 0 3 -3
of,histidine 1.0 0.000143348623853 0 1 -1
with,activase 1.0 0.000143348623853 0 1 -1
whether,other 1.0 0.000143348623853 0 1 -1
can,result 0.538461538462 0.00100344036697 10 3 7
cannot,be 0.714285714286 0.000716743119266 1 6 -5
iso-sensitest,broth 1.0 0.000143348623853 0 1 -1
two-year,carcinogenesis 1.0 0.000143348623853 0 1 -1
of,induction 1.0 0.000286697247706 0 2 -2
protein,zaleplon 1.0 0.000143348623853 0 1 -1
functional,coupling 1.0 0.000143348623853 0 1 -1
adverse,interactions 1.0 0.000143348623853 0 1 -1
weight,range 1.0 0.000143348623853 0 1 -1
that,affect 0.555555555556 0.000716743119266 2 7 -5
above,behavioral 1.0 0.000143348623853 0 1 -1
of,glucose 1.0 0.00043004587156 0 3 -3
intracellular,resistance 1.0 0.000143348623853 0 1 -1
with,severely 1.0 0.000143348623853 0 1 -1
and,symptoms 0.714285714286 0.000716743119266 6 1 5
captopril,may 1.0 0.000143348623853 0 1 -1
were,demonstrated 1.0 0.000143348623853 0 1 -1
methenamine,therapy 1.0 0.000286697247706 2 0 2
receiving,cautious 1.0 0.000143348623853 1 0 1
performed,and 1.0 0.00043004587156 0 3 -3
oral,formulations 1.0 0.000143348623853 1 0 1
kg,daily 1.0 0.000143348623853 0 1 -1
protein,tyrosine 1.0 0.000143348623853 0 1 -1
mesylate,may 1.0 0.000143348623853 1 0 1
propanol,mg 1.0 0.000143348623853 1 0 1
among,co-administered 1.0 0.000143348623853 0 1 -1
women,should 1.0 0.000143348623853 0 1 -1
large,number 1.0 0.000143348623853 0 1 -1
table,aed 1.0 0.000143348623853 0 1 -1
singly,or 1.0 0.000143348623853 0 1 -1
of,could 1.0 0.000143348623853 1 0 1
previous,experience 1.0 0.000143348623853 0 1 -1
clinical,practice 1.0 0.000143348623853 1 0 1
gene,transcription 1.0 0.000143348623853 0 1 -1
steady-state,levels 1.0 0.000143348623853 0 1 -1
theophylline,alone 1.0 0.000143348623853 0 1 -1
cotherapy,an 1.0 0.000143348623853 0 1 -1
the,three 1.0 0.000573394495413 0 4 -4
a,short-term 1.0 0.000143348623853 0 1 -1
drugs,nsaids 0.0 0.0 1 1 0
trials,similar 1.0 0.000143348623853 0 1 -1
describes,a 0.0 0.0 1 1 0
rating,scale 1.0 0.000143348623853 1 0 1
placebo,and 1.0 0.00043004587156 0 3 -3
beta,to 1.0 0.000143348623853 0 1 -1
findings,are 1.0 0.000143348623853 0 1 -1
patients,no 1.0 0.000286697247706 0 2 -2
no,documentation 1.0 0.000143348623853 0 1 -1
inducers,indicate 1.0 0.000143348623853 1 0 1
blockers,sustained-release 1.0 0.000143348623853 0 1 -1
pharmacodynamics,ecg 1.0 0.000143348623853 0 1 -1
were,positive 1.0 0.000143348623853 0 1 -1
anti-asthma,medications 1.0 0.000143348623853 0 1 -1
median,survival 1.0 0.000143348623853 0 1 -1
metabolites,including 1.0 0.000143348623853 0 1 -1
or,enantiomer 1.0 0.000143348623853 0 1 -1
designs,for 1.0 0.000286697247706 0 2 -2
addition,does 1.0 0.000143348623853 0 1 -1
imipramine,mg 1.0 0.000143348623853 0 1 -1
metabolic,clearance 0.5 0.000573394495413 6 2 4
been,effectively 1.0 0.000143348623853 0 1 -1
cinese,hamsters 1.0 0.000143348623853 0 1 -1
pruritus,rash 1.0 0.000143348623853 0 1 -1
produce,aucs 1.0 0.000143348623853 1 0 1
serum,level 0.666666666667 0.000573394495413 5 1 4
range,in 1.0 0.000143348623853 1 0 1
brain,sites 1.0 0.000143348623853 0 1 -1
led,to 0.666666666667 0.000573394495413 5 1 4
to,subjects 1.0 0.000573394495413 4 0 4
of,resistant 1.0 0.000143348623853 0 1 -1
others,reported 1.0 0.000143348623853 0 1 -1
assay,in 1.0 0.000286697247706 0 2 -2
protein,reorganization 1.0 0.000143348623853 0 1 -1
auc,based 1.0 0.000143348623853 0 1 -1
to,increase3 1.0 0.000143348623853 0 1 -1
appropriate,observation 1.0 0.000573394495413 4 0 4
infarction,there 1.0 0.000143348623853 0 1 -1
praziquantel,in 1.0 0.000143348623853 1 0 1
systems,responsible 1.0 0.000143348623853 0 1 -1
a,potentially 0.333333333333 0.000143348623853 2 1 1
have,previously 0.333333333333 0.000143348623853 1 2 -1
however,mg 1.0 0.000143348623853 1 0 1
of,p-glycoprotein 1.0 0.000286697247706 0 2 -2
by,n6-cyclopentyladenosine 1.0 0.000143348623853 1 0 1
decreased,blood 1.0 0.000143348623853 1 0 1
zyvox,may 1.0 0.000143348623853 1 0 1
clinicians,should 1.0 0.000143348623853 1 0 1
using,small 1.0 0.000143348623853 1 0 1
given,when 1.0 0.000143348623853 0 1 -1
in,cardiovascular 1.0 0.000143348623853 0 1 -1
infusion,of 1.0 0.000716743119266 0 5 -5
carbonic,anhydrase 0.5 0.000286697247706 3 1 2
to,increased 0.0 0.0 7 7 0
and,absorption 0.0 0.0 1 1 0
barbiturates,and 1.0 0.000286697247706 2 0 2
regimen,reduces 1.0 0.000143348623853 0 1 -1
accomplished,through 1.0 0.000143348623853 0 1 -1
to,increases 1.0 0.000286697247706 0 2 -2
electrocardiograms,performed 1.0 0.000143348623853 0 1 -1
and,aluminum-containing 0.0 0.0 1 1 0
principal,pathway 1.0 0.000143348623853 1 0 1
of,anti-factor 1.0 0.000286697247706 0 2 -2
doubled,in 1.0 0.000286697247706 0 2 -2
calculi,the 1.0 0.000143348623853 0 1 -1
have,centroblast 1.0 0.000143348623853 0 1 -1
when,treatment 1.0 0.000143348623853 0 1 -1
patient,group 1.0 0.000143348623853 0 1 -1
heparin-induced,thrombocytopenia 1.0 0.000143348623853 0 1 -1
including,other 1.0 0.000143348623853 1 0 1
by,without 1.0 0.000286697247706 2 0 2
levetiracetam,and 1.0 0.000143348623853 0 1 -1
circulars,for 1.0 0.000573394495413 0 4 -4
a,and 0.5 0.000286697247706 3 1 2
there,may 0.428571428571 0.00043004587156 2 5 -3
relaxants,that 1.0 0.000143348623853 0 1 -1
sodium,unreliable 1.0 0.000143348623853 1 0 1
aprepitant,when 1.0 0.000573394495413 4 0 4
in,isolated 0.333333333333 0.000143348623853 1 2 -1
imitrex,nasal 1.0 0.000143348623853 0 1 -1
patients,n 0.333333333333 0.000143348623853 1 2 -1
successfully,concurrently 1.0 0.000286697247706 0 2 -2
mice,c57bl 1.0 0.000143348623853 0 1 -1
only,slightly 0.0 0.0 1 1 0
of,dogs 1.0 0.000143348623853 0 1 -1
may,accelerate 1.0 0.000143348623853 0 1 -1
patients,a 1.0 0.000143348623853 0 1 -1
carbamazepine,isoniazid 1.0 0.000143348623853 1 0 1
products,are 1.0 0.00100344036697 0 7 -7
the,glucosyl 1.0 0.000143348623853 0 1 -1
vitro,therefore 1.0 0.000143348623853 0 1 -1
steady-state,blood 0.0 0.0 1 1 0
by,tromethamine 1.0 0.000143348623853 1 0 1
after,mefloquineuine 1.0 0.000143348623853 0 1 -1
when,co-administered 0.333333333333 0.00043004587156 6 3 3
intervals,and 1.0 0.000143348623853 0 1 -1
or,loss 1.0 0.000143348623853 0 1 -1
check,coagulation 1.0 0.000143348623853 1 0 1
undergo,enterohepatic 1.0 0.000143348623853 1 0 1
during,concomitant 0.0769230769231 0.000143348623853 7 6 1
this,technique 1.0 0.000143348623853 0 1 -1
experiments,demonstrated 1.0 0.000143348623853 0 1 -1
with,against 0.0 0.0 1 1 0
symptoms,termed 1.0 0.000143348623853 1 0 1
higher,and 1.0 0.000286697247706 0 2 -2
of,uptake 1.0 0.000286697247706 0 2 -2
such,reactions 1.0 0.000143348623853 0 1 -1
adrenoreceptors,on 1.0 0.000143348623853 0 1 -1
them,are 1.0 0.000143348623853 0 1 -1
discontinuing,or 1.0 0.000143348623853 1 0 1
hepatic,cytochrome 0.5 0.000286697247706 1 3 -2
due,not 1.0 0.000143348623853 1 0 1
therefore,cyp3a4 1.0 0.000143348623853 1 0 1
and,cancer 1.0 0.000143348623853 0 1 -1
administering,taxol 1.0 0.000286697247706 0 2 -2
medicines,since 1.0 0.000143348623853 1 0 1
breast,milk 1.0 0.000143348623853 0 1 -1
trypanosomiasis,uganda 1.0 0.000143348623853 0 1 -1
therapeutic,superiority 1.0 0.000143348623853 0 1 -1
divergently,selected 1.0 0.000143348623853 0 1 -1
creatinine,an 1.0 0.000143348623853 1 0 1
hydrochloride,alone 1.0 0.000143348623853 0 1 -1
levamisole,hydrochloride 1.0 0.000143348623853 1 0 1
many,concomitant 1.0 0.000143348623853 0 1 -1
preceding,effect 1.0 0.000143348623853 0 1 -1
vaiproic,acid 1.0 0.000143348623853 1 0 1
retrospectively,a 1.0 0.000143348623853 0 1 -1
conclusion,these 1.0 0.000143348623853 0 1 -1
an,can 1.0 0.000143348623853 1 0 1
in,pigeons 0.666666666667 0.000573394495413 1 5 -4
completed,with 1.0 0.000143348623853 0 1 -1
process,can 1.0 0.000143348623853 0 1 -1
er,extended 1.0 0.000143348623853 0 1 -1
may,lead 0.769230769231 0.00286697247706 3 23 -20
sole,protease 1.0 0.000286697247706 0 2 -2
a,great 1.0 0.000143348623853 0 1 -1
reported,during 0.2 0.000286697247706 6 4 2
that,you 0.333333333333 0.000143348623853 2 1 1
amicar,at 1.0 0.000143348623853 0 1 -1
groups,and 1.0 0.000143348623853 0 1 -1
the,addition 0.176470588235 0.00043004587156 10 7 3
the,free 0.5 0.000286697247706 1 3 -2
indinavir,has 1.0 0.000143348623853 1 0 1
anaesthesia,and 1.0 0.000143348623853 0 1 -1
cholestyramine,and 1.0 0.00043004587156 3 0 3
proportional,over 1.0 0.000143348623853 0 1 -1
blockers,nonsteroidal 1.0 0.000143348623853 0 1 -1
for,approximately 1.0 0.000143348623853 0 1 -1
known,at 1.0 0.000143348623853 0 1 -1
induction,data 1.0 0.000143348623853 0 1 -1
p450,a4 0.3 0.000860091743119 7 13 -6
p450,a6 1.0 0.000143348623853 0 1 -1
cell,tumors 1.0 0.000143348623853 0 1 -1
severe,anaphylactic 1.0 0.000573394495413 0 4 -4
digoxin,rofecoxib 1.0 0.000143348623853 0 1 -1
following,dosing 1.0 0.000143348623853 0 1 -1
efavirenz,has 1.0 0.000286697247706 0 2 -2
blunt,adrenal 1.0 0.000143348623853 0 1 -1
the,decision 1.0 0.000286697247706 0 2 -2
interactions,should 1.0 0.000286697247706 0 2 -2
medical,backgrounds 1.0 0.000143348623853 0 1 -1
perhaps,other 1.0 0.000143348623853 0 1 -1
thus,when 1.0 0.000573394495413 4 0 4
rashes,in 1.0 0.000143348623853 1 0 1
occur,with 0.6 0.00129013761468 3 12 -9
concentrations,tested 1.0 0.000143348623853 0 1 -1
im,reduced 1.0 0.000143348623853 1 0 1
both,ca 1.0 0.000143348623853 1 0 1
aed,induces 1.0 0.000143348623853 0 1 -1
pressor,amines 1.0 0.000286697247706 0 2 -2
cmc-cys7,from 1.0 0.000143348623853 0 1 -1
debrisoquin,hydroxylase 1.0 0.000143348623853 0 1 -1
employed,since 1.0 0.000143348623853 1 0 1
tissue,although 1.0 0.000143348623853 0 1 -1
if,supplements 1.0 0.000143348623853 1 0 1
orencia,administered 1.0 0.000143348623853 1 0 1
the,potent 1.0 0.000573394495413 4 0 4
either,grapefruit 1.0 0.000143348623853 0 1 -1
the,mao-b 1.0 0.000143348623853 0 1 -1
or,four 1.0 0.000143348623853 0 1 -1
of,clolar 1.0 0.000143348623853 0 1 -1
relative,bioavailability 1.0 0.000143348623853 0 1 -1
c57bl,n 1.0 0.00043004587156 0 3 -3
or,monitoring 1.0 0.000286697247706 0 2 -2
months,received 1.0 0.000143348623853 0 1 -1
by,other 0.5 0.000286697247706 1 3 -2
effects,including 1.0 0.000286697247706 2 0 2
addition,we 1.0 0.000143348623853 0 1 -1
oxypurines,in 1.0 0.000143348623853 0 1 -1
before,morning 1.0 0.000143348623853 0 1 -1
m,g 0.0 0.0 2 2 0
edecrin,may 1.0 0.000143348623853 1 0 1
m,i 1.0 0.000143348623853 1 0 1
vitro,have 1.0 0.000143348623853 0 1 -1
the,understanding 1.0 0.000143348623853 0 1 -1
anticoagulants,increased 1.0 0.000143348623853 1 0 1
this,procedure 1.0 0.000143348623853 0 1 -1
neuropathy,include 1.0 0.000143348623853 0 1 -1
m,v 1.0 0.000573394495413 0 4 -4
n-methyllevallorphan,mg 0.0 0.0 1 1 0
of,pi 1.0 0.000143348623853 0 1 -1
ionized,concurrent 1.0 0.000143348623853 0 1 -1
of,monoamine 1.0 0.000143348623853 1 0 1
other,cause 1.0 0.000286697247706 2 0 2
metabolite,concentration 1.0 0.000143348623853 1 0 1
at,all 0.0 0.0 2 2 0
become,subtherapeutic 1.0 0.000143348623853 1 0 1
become,pregnant 1.0 0.000143348623853 0 1 -1
central,importance 1.0 0.000143348623853 0 1 -1
situ,and 1.0 0.000143348623853 0 1 -1
between,b12 1.0 0.000143348623853 1 0 1
and,can 0.411764705882 0.00100344036697 12 5 7
a,channel 1.0 0.000143348623853 0 1 -1
potent,cytochrome 1.0 0.000143348623853 1 0 1
alfenta,my 1.0 0.000143348623853 0 1 -1
of,pt 1.0 0.000143348623853 0 1 -1
dosage,replacement 1.0 0.000143348623853 0 1 -1
levels,the 0.333333333333 0.000143348623853 2 1 1
possible,decreased 1.0 0.000286697247706 0 2 -2
utilizing,commercially 1.0 0.000143348623853 0 1 -1
enzymes,bun 1.0 0.000143348623853 1 0 1
far,more 1.0 0.000143348623853 0 1 -1
these,behavioral 1.0 0.000143348623853 0 1 -1
have,also 0.2 0.000286697247706 4 6 -2
causally,related 1.0 0.000143348623853 0 1 -1
iv,has 1.0 0.000143348623853 0 1 -1
recognized,as 1.0 0.000143348623853 0 1 -1
warfarin,increased 1.0 0.000143348623853 1 0 1
against,the 0.0 0.0 4 4 0
evident,on 1.0 0.000143348623853 0 1 -1
mg,vardenafil 0.5 0.000286697247706 3 1 2
clomiphene,citrate 1.0 0.000143348623853 0 1 -1
platelet,adhesion 1.0 0.000143348623853 0 1 -1
or,are 0.454545454545 0.000716743119266 8 3 5
urinary,excretion 0.2 0.00043004587156 9 6 3
cevimeline,might 1.0 0.000143348623853 0 1 -1
depressive,and 1.0 0.000143348623853 0 1 -1
procedures,for 1.0 0.000143348623853 0 1 -1
with,injectable 1.0 0.000143348623853 1 0 1
no,confirmed 1.0 0.000143348623853 0 1 -1
flolan,is 1.0 0.000143348623853 1 0 1
or,special 1.0 0.000143348623853 0 1 -1
significantly,inhibited 1.0 0.000286697247706 2 0 2
neutropenia,cells 1.0 0.000143348623853 0 1 -1
pharmacokinetics,analysis 1.0 0.000143348623853 0 1 -1
are,ge 1.0 0.000143348623853 0 1 -1
in,intact 1.0 0.000143348623853 0 1 -1
flolan,in 1.0 0.000143348623853 0 1 -1
myocardial,injury 1.0 0.000143348623853 1 0 1
nm,absorbing 1.0 0.000143348623853 0 1 -1
of,hypoxic 1.0 0.000143348623853 0 1 -1
into,consideration 0.333333333333 0.000143348623853 1 2 -1
aminoglutethimide,aminoglutethimide 1.0 0.000143348623853 1 0 1
nonadditive,independent 1.0 0.000143348623853 0 1 -1
thyroiditis,bullous 1.0 0.000143348623853 1 0 1
should,allow 1.0 0.000143348623853 0 1 -1
many,patients 1.0 0.000143348623853 0 1 -1
continue,the 0.0 0.0 1 1 0
of,ranging 1.0 0.000143348623853 1 0 1
plasma-level,of 1.0 0.000143348623853 1 0 1
of,pain 1.0 0.000143348623853 0 1 -1
of,oxidative 1.0 0.000143348623853 0 1 -1
of,bombesin-enhanced 1.0 0.000143348623853 1 0 1
is,felt 1.0 0.000143348623853 1 0 1
by,mg 0.0 0.0 1 1 0
these,case 1.0 0.000143348623853 0 1 -1
prefrontal,cortical 1.0 0.000143348623853 0 1 -1
route,is 1.0 0.000143348623853 0 1 -1
mg,produced 1.0 0.000716743119266 5 0 5
cytoskeleton-associated,that 1.0 0.000143348623853 0 1 -1
from,dependence 1.0 0.000143348623853 0 1 -1
since,sodium 1.0 0.000143348623853 0 1 -1
groups,of 1.0 0.000716743119266 0 5 -5
the,placental 1.0 0.000143348623853 0 1 -1
homocysteine,by 1.0 0.000143348623853 0 1 -1
different,than 1.0 0.000143348623853 1 0 1
route,in 1.0 0.000143348623853 0 1 -1
and,what 1.0 0.000143348623853 0 1 -1
other,traditional 1.0 0.000143348623853 0 1 -1
cholestyramine,an 1.0 0.000143348623853 1 0 1
cross-reactivity,of 1.0 0.000143348623853 1 0 1
short-acting,and 1.0 0.000143348623853 1 0 1
or,dose 1.0 0.000286697247706 0 2 -2
product,containing 1.0 0.000143348623853 1 0 1
discussed,herein 1.0 0.000143348623853 0 1 -1
incoordination,have 1.0 0.000143348623853 1 0 1
restricted,pulmonary 1.0 0.000143348623853 0 1 -1
anxiety,during 1.0 0.000143348623853 0 1 -1
blood,thinners 0.333333333333 0.000143348623853 2 1 1
morphological,markers 1.0 0.000143348623853 1 0 1
vs,when 1.0 0.000143348623853 1 0 1
possible,lack 1.0 0.000143348623853 0 1 -1
expected,magnitude 1.0 0.000286697247706 0 2 -2
mtx,were 1.0 0.000143348623853 0 1 -1
measure,glucose 1.0 0.000143348623853 0 1 -1
aucs,and 1.0 0.000143348623853 0 1 -1
the,protective 1.0 0.000143348623853 1 0 1
clearly,show 1.0 0.000143348623853 0 1 -1
at,clinically 1.0 0.00043004587156 0 3 -3
frequently,limits 1.0 0.000143348623853 0 1 -1
be,rarely 1.0 0.000286697247706 2 0 2
benzodiazepines,gi 0.0 0.0 1 1 0
be,further 1.0 0.000143348623853 0 1 -1
the,hour 1.0 0.00043004587156 0 3 -3
mhd,concentration 1.0 0.000143348623853 0 1 -1
o-gallate,and 1.0 0.000143348623853 0 1 -1
of,milk 1.0 0.000143348623853 0 1 -1
felbatol,given 1.0 0.000286697247706 2 0 2
had,liver 1.0 0.000143348623853 0 1 -1
fever,tremulousness 1.0 0.000143348623853 1 0 1
concentrations,mg 1.0 0.000143348623853 0 1 -1
use,folate 1.0 0.000143348623853 0 1 -1
methotrexate,in 1.0 0.000143348623853 0 1 -1
quantities,of 1.0 0.000286697247706 0 2 -2
toradol,to 1.0 0.000143348623853 1 0 1
in,about 0.0 0.0 1 1 0
the,guinea-pig 1.0 0.000143348623853 0 1 -1
ii,v 1.0 0.000143348623853 0 1 -1
plenaxis,is 1.0 0.000143348623853 0 1 -1
passage,and 1.0 0.000143348623853 0 1 -1
not,demonstrated 1.0 0.00043004587156 0 3 -3
with,proleukin 1.0 0.000286697247706 2 0 2
consequences,hunger 1.0 0.000143348623853 0 1 -1
glomerular,filtration 1.0 0.00043004587156 0 3 -3
of,non-potassium 1.0 0.000143348623853 1 0 1
states,and 1.0 0.000286697247706 0 2 -2
associated,with 0.111111111111 0.00143348623853 40 50 -10
of,medline 1.0 0.000143348623853 0 1 -1
for,clinically 1.0 0.000286697247706 0 2 -2
aggregation,time 1.0 0.000143348623853 0 1 -1
caution,should 0.0724637681159 0.000716743119266 32 37 -5
covalently,linked 1.0 0.000143348623853 0 1 -1
diabetes,mellitus 1.0 0.00114678899083 0 8 -8
acinar,cells 1.0 0.000143348623853 0 1 -1
orudis,orudis 1.0 0.000143348623853 0 1 -1
plasma,in 1.0 0.000143348623853 0 1 -1
true,decrease 1.0 0.000143348623853 0 1 -1
two-fold,or 1.0 0.000143348623853 1 0 1
doubling,in 1.0 0.000143348623853 1 0 1
patients,gland 1.0 0.000143348623853 0 1 -1
allow,development 1.0 0.000143348623853 0 1 -1
plasma,is 1.0 0.000286697247706 0 2 -2
two-fold,of 1.0 0.000143348623853 1 0 1
tolerance,and 1.0 0.000143348623853 0 1 -1
from,approximately 1.0 0.000143348623853 1 0 1
pressure,should 1.0 0.000143348623853 0 1 -1
transfusion,practices 1.0 0.000143348623853 0 1 -1
rheumatoid,arthritis 1.0 0.000860091743119 0 6 -6
absorption,excessive 1.0 0.000143348623853 0 1 -1
mesenteric,resistance 1.0 0.000143348623853 0 1 -1
x,use 1.0 0.000143348623853 0 1 -1
phenytoin,amphetamines 1.0 0.000286697247706 2 0 2
catabloism,of 1.0 0.000143348623853 0 1 -1
rats,and 1.0 0.00043004587156 0 3 -3
decrease,to 1.0 0.000286697247706 2 0 2
shbg,leading 1.0 0.000286697247706 0 2 -2
tolazamide,a 1.0 0.000143348623853 1 0 1
by,perivascular 1.0 0.000143348623853 0 1 -1
loop,and 1.0 0.000143348623853 0 1 -1
and,pharmacist 1.0 0.000143348623853 0 1 -1
coadministration,loratadine 1.0 0.000143348623853 0 1 -1
during,five 1.0 0.000143348623853 0 1 -1
their,binding 1.0 0.000286697247706 0 2 -2
isoenzyme,could 1.0 0.000143348623853 0 1 -1
methodology,used 1.0 0.000143348623853 0 1 -1
in,metabolism 0.5 0.000286697247706 1 3 -2
their,relative 1.0 0.000143348623853 0 1 -1
in,cmax 0.875 0.00200688073394 15 1 14
positively-charged,bile 1.0 0.000143348623853 0 1 -1
unlike,mc 1.0 0.000143348623853 0 1 -1
cyp3a,compounds 1.0 0.000143348623853 1 0 1
of,studies 0.333333333333 0.000143348623853 1 2 -1
of,parametric 1.0 0.000143348623853 0 1 -1
imitrex,talk 1.0 0.000143348623853 0 1 -1
system,depressant 1.0 0.000143348623853 0 1 -1
avoid,them 1.0 0.000143348623853 0 1 -1
growth,both 1.0 0.000143348623853 0 1 -1
can,generally 1.0 0.000143348623853 0 1 -1
i,tranexamic 1.0 0.000143348623853 0 1 -1
isoforms,cyp2c8 1.0 0.000143348623853 0 1 -1
of,while 0.0 0.0 2 2 0
studies,coadministration 1.0 0.000143348623853 0 1 -1
amicar,necessary 1.0 0.000143348623853 0 1 -1
implants,and 1.0 0.000143348623853 0 1 -1
to,enroll 1.0 0.000143348623853 0 1 -1
mutagenic,or 1.0 0.000143348623853 0 1 -1
setting,clinical 1.0 0.000143348623853 0 1 -1
using,but 1.0 0.000286697247706 0 2 -2
binds,differently 1.0 0.000143348623853 0 1 -1
adequacy,of 1.0 0.000143348623853 0 1 -1
present,as 1.0 0.000143348623853 1 0 1
comorbidity,and 1.0 0.000143348623853 0 1 -1
effects,such 0.5 0.000286697247706 3 1 2
basis,increased 1.0 0.000143348623853 0 1 -1
compared,pharmacokinetics 1.0 0.000143348623853 0 1 -1
of,co-administered 1.0 0.000143348623853 0 1 -1
secretion,blocking 1.0 0.000143348623853 0 1 -1
any,nonlinear 1.0 0.000143348623853 0 1 -1
vivo,drug-drug 0.0 0.0 1 1 0
of,blockers 1.0 0.000143348623853 0 1 -1
into,light 1.0 0.000143348623853 0 1 -1
was,shown 0.25 0.000286697247706 3 5 -2
a,wax 1.0 0.000143348623853 1 0 1
however,serum 1.0 0.000143348623853 1 0 1
topical,or 1.0 0.00043004587156 0 3 -3
normal,within 1.0 0.000143348623853 0 1 -1
investigated,using 1.0 0.000143348623853 1 0 1
for,evidence 0.666666666667 0.000573394495413 1 5 -4
is,found 1.0 0.000143348623853 0 1 -1
including,ganglionic 1.0 0.000143348623853 1 0 1
exposures,similar 1.0 0.000143348623853 0 1 -1
paraaminohippurate,method 1.0 0.000143348623853 0 1 -1
exercise,that 1.0 0.000143348623853 0 1 -1
after,concurrent 0.0 0.0 1 1 0
chapter,including 1.0 0.000143348623853 0 1 -1
fertility,and 1.0 0.000286697247706 0 2 -2
headaches,and 1.0 0.000286697247706 0 2 -2
principles,observed 1.0 0.000143348623853 0 1 -1
of,aldehyde 1.0 0.000143348623853 0 1 -1
sodium,thiosulfate 1.0 0.000143348623853 1 0 1
hcl,blunts 1.0 0.000143348623853 1 0 1
and,phase 1.0 0.000143348623853 0 1 -1
nephrotoxic,compounds 1.0 0.000143348623853 0 1 -1
it,palliates 1.0 0.000143348623853 0 1 -1
the,mitogenic 1.0 0.000286697247706 2 0 2
factor,for 1.0 0.000286697247706 0 2 -2
match,an 1.0 0.000143348623853 0 1 -1
is,unclear 0.0 0.0 1 1 0
not,benefit 1.0 0.000143348623853 1 0 1
an,appropriate 1.0 0.000143348623853 1 0 1
the,lack 1.0 0.00043004587156 0 3 -3
exerts,its 1.0 0.000143348623853 0 1 -1
of,sites 1.0 0.000143348623853 0 1 -1
l,to 1.0 0.000143348623853 1 0 1
kg,induced 1.0 0.000143348623853 0 1 -1
interval,may 1.0 0.000143348623853 0 1 -1
requires,close 1.0 0.00043004587156 3 0 3
toward,normal 1.0 0.000143348623853 0 1 -1
no,increase 0.333333333333 0.000286697247706 2 4 -2
of,uricosuric 1.0 0.000286697247706 2 0 2
previously,administered 0.0 0.0 1 1 0
products,oral 1.0 0.000573394495413 0 4 -4
a,narrow 0.0 0.0 4 4 0
time,have 0.333333333333 0.000143348623853 2 1 1
other,medicines 0.333333333333 0.000143348623853 1 2 -1
tests,pregnancy 1.0 0.000143348623853 0 1 -1
including,sulfate 0.0 0.0 1 1 0
trazodone,hydrochloride 1.0 0.000143348623853 1 0 1
of,tumors 1.0 0.000143348623853 0 1 -1
progression,in 1.0 0.000286697247706 0 2 -2
organic,l-arginine 1.0 0.000143348623853 1 0 1
recommended,dosages 1.0 0.000143348623853 1 0 1
carrier,density 1.0 0.000143348623853 0 1 -1
without,using 1.0 0.000143348623853 0 1 -1
in,all 0.0 0.0 2 2 0
then,received 1.0 0.000143348623853 0 1 -1
binding,after 1.0 0.000143348623853 0 1 -1
etc,and 1.0 0.000143348623853 0 1 -1
either,diabetics 1.0 0.000143348623853 0 1 -1
nicardipine,hcl 1.0 0.000143348623853 1 0 1
in,accordance 1.0 0.000573394495413 0 4 -4
concomitantly,in 1.0 0.000143348623853 1 0 1
of,stereoselectivity 1.0 0.000143348623853 0 1 -1
and,cyp1a2 1.0 0.00043004587156 0 3 -3
sensitization,similar 1.0 0.000143348623853 0 1 -1
warfarin,atorvastatin 1.0 0.000143348623853 0 1 -1
clinical,evidence 0.666666666667 0.000573394495413 1 5 -4
compromised,renal 1.0 0.000286697247706 2 0 2
without,coadministration 1.0 0.000143348623853 0 1 -1
usual,of 1.0 0.000143348623853 0 1 -1
cns,drugs 1.0 0.000143348623853 0 1 -1
of,insect 1.0 0.000143348623853 1 0 1
t,cell 1.0 0.000143348623853 0 1 -1
sodium,levels 1.0 0.000143348623853 0 1 -1
schedule,of 0.333333333333 0.000143348623853 1 2 -1
given,without 1.0 0.000286697247706 0 2 -2
thus,it 1.0 0.000143348623853 0 1 -1
intravenous,iv 1.0 0.000143348623853 1 0 1
food,interactions 1.0 0.000143348623853 0 1 -1
fec-100,chemotherapies 1.0 0.000143348623853 0 1 -1
the,aucasian 1.0 0.000143348623853 0 1 -1
gastrointestinal,absorption 0.428571428571 0.00043004587156 5 2 3
thus,in 0.0 0.0 1 1 0
thus,if 0.333333333333 0.000286697247706 2 4 -2
in,cat 1.0 0.000143348623853 0 1 -1
normal,healthy 1.0 0.000573394495413 0 4 -4
atypical,antipsychotic 1.0 0.00043004587156 0 3 -3
pathophysiologic,abnormality 1.0 0.000143348623853 0 1 -1
oxide,donor 1.0 0.000143348623853 1 0 1
after,to 1.0 0.000143348623853 0 1 -1
for,when 0.0 0.0 1 1 0
can,in 0.0 0.0 1 1 0
with,precedex 1.0 0.000143348623853 1 0 1
of,probenecid 1.0 0.000143348623853 0 1 -1
tambocor,to 1.0 0.000143348623853 1 0 1
increased,regional 1.0 0.000143348623853 0 1 -1
etc,should 1.0 0.000143348623853 0 1 -1
no,cns 1.0 0.000143348623853 0 1 -1
deferasirox,should 1.0 0.000143348623853 0 1 -1
acidity,duloxetine 1.0 0.000143348623853 0 1 -1
and,antihypertensive 1.0 0.00043004587156 3 0 3
been,characterized 1.0 0.000286697247706 0 2 -2
experience,profile 1.0 0.000143348623853 0 1 -1
usual,and 1.0 0.000143348623853 1 0 1
lag,phase 1.0 0.000143348623853 0 1 -1
minimally,or 1.0 0.000143348623853 1 0 1
complex,ii-vii 1.0 0.000286697247706 0 2 -2
interval,and 1.0 0.000286697247706 0 2 -2
copegus,pregnancy 1.0 0.000143348623853 0 1 -1
have,included 1.0 0.000143348623853 0 1 -1
showing,a 1.0 0.000143348623853 0 1 -1
nutrient,absorption 1.0 0.000143348623853 1 0 1
both,compounds 1.0 0.000143348623853 0 1 -1
renal,and 0.4 0.000573394495413 3 7 -4
sparing,thiazide 1.0 0.000143348623853 0 1 -1
significantly,increase 1.0 0.000143348623853 0 1 -1
this,agent 1.0 0.000286697247706 0 2 -2
fat-soluble,should 1.0 0.000143348623853 0 1 -1
are,known 0.789473684211 0.0021502293578 2 17 -15
convulsions,have 0.0 0.0 1 1 0
atac,trial 1.0 0.000143348623853 1 0 1
citrate,and 1.0 0.000143348623853 0 1 -1
administering,cerebyx 1.0 0.000143348623853 0 1 -1
intravenous,dose 0.333333333333 0.000143348623853 1 2 -1
effect,in 0.428571428571 0.00043004587156 5 2 3
effect,is 0.333333333333 0.000286697247706 2 4 -2
long-acting,such 1.0 0.000143348623853 0 1 -1
particularly,important 1.0 0.000143348623853 0 1 -1
serum,thyroxine-binding 1.0 0.000143348623853 0 1 -1
therefore,viracept 1.0 0.000143348623853 1 0 1
iv,dose 1.0 0.000143348623853 1 0 1
seminiferous,tubular 1.0 0.000143348623853 0 1 -1
subcutaneous,infusion 1.0 0.000143348623853 0 1 -1
hippocampal,lesions 1.0 0.000286697247706 0 2 -2
thiazide,diuretics 1.0 0.000143348623853 1 0 1
drug-specific,interactions 1.0 0.000143348623853 0 1 -1
when,anafranil 1.0 0.000143348623853 1 0 1
s,or 1.0 0.000143348623853 0 1 -1
protein,with 1.0 0.000143348623853 0 1 -1
and,complexes 1.0 0.000143348623853 0 1 -1
lithium-a,interaction 1.0 0.000143348623853 0 1 -1
s,of 1.0 0.000286697247706 0 2 -2
were,potentiated 1.0 0.000286697247706 2 0 2
under,years 1.0 0.000143348623853 0 1 -1
additional,interaction 1.0 0.000286697247706 0 2 -2
different,descending 1.0 0.000286697247706 0 2 -2
marketing,experiences 1.0 0.000143348623853 1 0 1
x,c3h 1.0 0.000143348623853 0 1 -1
been,received 1.0 0.000286697247706 0 2 -2
monitored,by 1.0 0.00043004587156 0 3 -3
decrease,in 0.508196721311 0.00444380733945 46 15 31
severe,adverse 1.0 0.000143348623853 0 1 -1
doses,which 1.0 0.000143348623853 0 1 -1
impairment,clcr 1.0 0.000143348623853 1 0 1
not,result 0.833333333333 0.00143348623853 1 11 -10
diarrhea,model 1.0 0.000143348623853 0 1 -1
tablets,and 0.2 0.000143348623853 3 2 1
be,achieved 1.0 0.000286697247706 0 2 -2
review,papers 1.0 0.000143348623853 0 1 -1
marrow,erythrocytes 1.0 0.000143348623853 0 1 -1
disturbances,and 0.0 0.0 1 1 0
of,organic 1.0 0.000143348623853 1 0 1
phenytoin,keppra 1.0 0.000143348623853 0 1 -1
chloroprocaine,inhibits 1.0 0.000143348623853 0 1 -1
the,pediatric 1.0 0.000860091743119 6 0 6
either,procedure 1.0 0.000143348623853 0 1 -1
avonex,indicates 1.0 0.000143348623853 0 1 -1
viracept,may 1.0 0.000143348623853 0 1 -1
in,type 1.0 0.000143348623853 1 0 1
but,was 1.0 0.000143348623853 0 1 -1
requires,immediate 1.0 0.000143348623853 0 1 -1
extensively,used 1.0 0.000143348623853 0 1 -1
the,antinonciceptive 1.0 0.000143348623853 0 1 -1
the,plasma-level 1.0 0.000143348623853 1 0 1
fruit,juices 0.333333333333 0.000143348623853 1 2 -1
procedure,it 1.0 0.000143348623853 0 1 -1
pathways,have 1.0 0.000143348623853 0 1 -1
of,producing 1.0 0.000143348623853 0 1 -1
procedure,in 1.0 0.000143348623853 0 1 -1
subjects,than 1.0 0.000143348623853 0 1 -1
such,doses 1.0 0.000286697247706 0 2 -2
preliminary,studies 1.0 0.000286697247706 2 0 2
exercised,during 1.0 0.000143348623853 1 0 1
members,of 0.0 0.0 2 2 0
of,lower 1.0 0.000143348623853 0 1 -1
for,accutane 1.0 0.000143348623853 0 1 -1
reliable,affinity 1.0 0.000143348623853 0 1 -1
if,treatment 0.0 0.0 1 1 0
the,duration 0.230769230769 0.00043004587156 5 8 -3
fluorescein,naflu 1.0 0.000143348623853 0 1 -1
posing,a 1.0 0.000143348623853 0 1 -1
the,clinician 0.6 0.00043004587156 1 4 -3
wide,variety 1.0 0.000286697247706 0 2 -2
or,ibuprofen 1.0 0.000143348623853 1 0 1
then,begins 0.2 0.000143348623853 2 3 -1
agents,known 0.0 0.0 1 1 0
abnormal,topoisomerase 1.0 0.000143348623853 0 1 -1
volunteer,reported 1.0 0.000143348623853 0 1 -1
theophylline-related,adverse 1.0 0.000143348623853 1 0 1
felbatol,as 0.333333333333 0.000143348623853 2 1 1
therapeutic,agents 1.0 0.000286697247706 0 2 -2
remained,the 1.0 0.000143348623853 0 1 -1
addition,reduced 1.0 0.000143348623853 0 1 -1
and,very 1.0 0.000143348623853 1 0 1
receiving,beta-adrenergic 1.0 0.000286697247706 2 0 2
high,oral 1.0 0.00043004587156 0 3 -3
other,currently 1.0 0.000143348623853 0 1 -1
by,six 1.0 0.000143348623853 0 1 -1
sodium,kg 1.0 0.000143348623853 1 0 1
combination,with 0.404761904762 0.00487385321101 25 59 -34
with,simultaneous 0.0 0.0 2 2 0
secretion,via 0.0 0.0 1 1 0
dosed,weekly 1.0 0.000143348623853 0 1 -1
metabolizers,of 0.0 0.0 2 2 0
done,to 1.0 0.000143348623853 1 0 1
increase,exposure 1.0 0.000143348623853 1 0 1
efficacy,over 1.0 0.000143348623853 1 0 1
in,uninfected 1.0 0.000143348623853 1 0 1
following,treatment 1.0 0.000286697247706 0 2 -2
display,the 1.0 0.000143348623853 0 1 -1
and,auc 0.307692307692 0.00114678899083 17 9 8
days,prior 1.0 0.000143348623853 0 1 -1
and,molt-4 1.0 0.000143348623853 1 0 1
animal,studies 0.5 0.000573394495413 6 2 4
certain,could 1.0 0.000143348623853 0 1 -1
flexible,and 1.0 0.000143348623853 0 1 -1
theophylline,combined 1.0 0.000143348623853 0 1 -1
caution,because 1.0 0.00043004587156 3 0 3
approximately,msec 1.0 0.000143348623853 1 0 1
together,especially 1.0 0.000143348623853 0 1 -1
intact,endothelium 1.0 0.000143348623853 1 0 1
control,period 1.0 0.000143348623853 1 0 1
individualized,fixed 1.0 0.000143348623853 0 1 -1
multiple,effects 1.0 0.000143348623853 1 0 1
any,pharmacokinetic 1.0 0.000143348623853 0 1 -1
apple,may 1.0 0.000143348623853 0 1 -1
involved,the 1.0 0.000143348623853 0 1 -1
locomotion,in 1.0 0.000143348623853 0 1 -1
administering,peganone 1.0 0.000143348623853 1 0 1
and,ethacrynic 1.0 0.000143348623853 1 0 1
reported,pretreatment 1.0 0.000143348623853 0 1 -1
antistress,effects 1.0 0.000143348623853 0 1 -1
catabolism,of 1.0 0.000143348623853 0 1 -1
a,phase 1.0 0.000143348623853 1 0 1
monoamines,from 1.0 0.000286697247706 0 2 -2
function,as 0.2 0.000143348623853 2 3 -1
c9,should 1.0 0.000143348623853 0 1 -1
and,micrograms 1.0 0.000573394495413 0 4 -4
catecholamine-depleting,such 1.0 0.00043004587156 3 0 3
experienced,problems 1.0 0.000286697247706 0 2 -2
that,no 0.2 0.000143348623853 2 3 -1
eg,flu-like 1.0 0.000143348623853 0 1 -1
nerve,preparations 1.0 0.000143348623853 0 1 -1
sodium,given 1.0 0.000143348623853 0 1 -1
mediate,and 1.0 0.000143348623853 0 1 -1
tablets,benedicts 1.0 0.000143348623853 0 1 -1
be,hazardous 1.0 0.000143348623853 0 1 -1
sufficient,however 1.0 0.000143348623853 0 1 -1
hypoglycemia,which 1.0 0.000286697247706 0 2 -2
plasma,protein- 1.0 0.000143348623853 0 1 -1
have,no 0.636363636364 0.00100344036697 2 9 -7
d3,and 0.0 0.0 1 1 0
antagonized,by 0.0 0.0 3 3 0
the,hmg-coa 0.0 0.0 1 1 0
mg,given 1.0 0.000143348623853 1 0 1
uroxatral,should 1.0 0.000143348623853 1 0 1
administering,this 1.0 0.000143348623853 0 1 -1
reduced,upon 1.0 0.000143348623853 1 0 1
resistance,which 1.0 0.000143348623853 0 1 -1
medications,besides 1.0 0.000143348623853 0 1 -1
more,information 1.0 0.000143348623853 0 1 -1
deletion,of 1.0 0.000143348623853 0 1 -1
bepridil,has 1.0 0.000143348623853 0 1 -1
thiazide,agents 1.0 0.000143348623853 0 1 -1
procrit,with 1.0 0.000143348623853 0 1 -1
of,block 1.0 0.000143348623853 1 0 1
was,related 1.0 0.000143348623853 0 1 -1
this,number 1.0 0.000143348623853 0 1 -1
plasma,proteins 0.857142857143 0.00172018348624 1 13 -12
hr,should 1.0 0.000143348623853 0 1 -1
been,evaluated 0.4 0.000573394495413 3 7 -4
alfenta,clearance 1.0 0.000143348623853 1 0 1
primary,sources 1.0 0.000143348623853 0 1 -1
and,hydroxy 1.0 0.000143348623853 0 1 -1
pointes,have 1.0 0.000143348623853 0 1 -1
with,parasite 1.0 0.000143348623853 0 1 -1
can,occur 0.2 0.000143348623853 2 3 -1
interval,observed 1.0 0.000143348623853 1 0 1
trials,mesylate 1.0 0.000143348623853 0 1 -1
medications,have 1.0 0.00043004587156 0 3 -3
in,reduced 0.5 0.000286697247706 3 1 2
antigen,validation 1.0 0.000143348623853 0 1 -1
under,lying 1.0 0.000143348623853 1 0 1
were,antagonized 1.0 0.000143348623853 0 1 -1
limited,as 1.0 0.000143348623853 0 1 -1
medicinal,products 0.25 0.000286697247706 3 5 -2
empty,stomach 1.0 0.000143348623853 0 1 -1
under,similar 1.0 0.000143348623853 0 1 -1
be,cautious 1.0 0.000286697247706 2 0 2
psa,decreased 1.0 0.000143348623853 0 1 -1
discontinuing,hydrochloride 0.0 0.0 1 1 0
indicating,that 1.0 0.000573394495413 0 4 -4
behavior,and 1.0 0.000143348623853 0 1 -1
revealed,no 1.0 0.000286697247706 0 2 -2
agents,it 1.0 0.000143348623853 1 0 1
general,cognitive 1.0 0.000143348623853 0 1 -1
agents,is 0.6 0.000860091743119 2 8 -6
aeds,whether 1.0 0.000143348623853 0 1 -1
drug,known 1.0 0.000143348623853 0 1 -1
cardiovascular,hypotension 1.0 0.000143348623853 0 1 -1
of,pah 1.0 0.000143348623853 1 0 1
while,not 1.0 0.000143348623853 1 0 1
of,triazo 1.0 0.000143348623853 0 1 -1
of,mcg 1.0 0.000286697247706 0 2 -2
depletion,are 1.0 0.000143348623853 0 1 -1
the,successive 0.0 0.0 1 1 0
caffeine-related,adverse 1.0 0.000143348623853 1 0 1
system,development 1.0 0.000286697247706 0 2 -2
contemplated,the 1.0 0.000716743119266 0 5 -5
mydriasis,resulting 1.0 0.000143348623853 1 0 1
with,pulmonary 1.0 0.000143348623853 0 1 -1
performed,when 0.0 0.0 1 1 0
six,cytochrome 1.0 0.000143348623853 0 1 -1
eg,could 1.0 0.000143348623853 1 0 1
are,recommended 1.0 0.000143348623853 1 0 1
hepatic,enzyme 0.428571428571 0.00043004587156 5 2 3
suppress,bone 1.0 0.000143348623853 0 1 -1
propanol,was 1.0 0.000143348623853 0 1 -1
patient,is 0.0 0.0 3 3 0
of,convulsions 1.0 0.000143348623853 0 1 -1
to,characterize 1.0 0.000286697247706 0 2 -2
dictates,careful 1.0 0.000143348623853 1 0 1
patient,in 1.0 0.00043004587156 0 3 -3
of,pediatric 1.0 0.000143348623853 0 1 -1
exceed,micrograms 1.0 0.000143348623853 0 1 -1
estradiol,should 1.0 0.000143348623853 1 0 1
another,oral 1.0 0.000143348623853 1 0 1
and,serosal 1.0 0.000143348623853 0 1 -1
is,difficult 1.0 0.000143348623853 0 1 -1
system,decreased 1.0 0.000143348623853 0 1 -1
the,volatile 1.0 0.000143348623853 0 1 -1
substances,that 0.8 0.00114678899083 1 9 -8
prolonged,menstrual 1.0 0.000143348623853 0 1 -1
ci,of 1.0 0.00043004587156 0 3 -3
arc,gene 1.0 0.000143348623853 0 1 -1
such,factors 1.0 0.000143348623853 0 1 -1
hepatitis,has 0.0 0.0 1 1 0
ibandronate,osteoporosis 1.0 0.000143348623853 0 1 -1
with,nm 1.0 0.000143348623853 0 1 -1
with,no 1.0 0.00114678899083 0 8 -8
or,discontinued 0.333333333333 0.000143348623853 1 2 -1
people,use 1.0 0.000143348623853 0 1 -1
be,titrated 0.0 0.0 1 1 0
or,discontinues 1.0 0.000143348623853 1 0 1
anorexia,tachypnea 1.0 0.000143348623853 1 0 1
the,cyp1a2 1.0 0.000143348623853 0 1 -1
safe,sexual 1.0 0.000143348623853 0 1 -1
bacterial,metabolism 1.0 0.000143348623853 1 0 1
potential,of 0.0909090909091 0.000143348623853 6 5 1
are,determined 1.0 0.000143348623853 0 1 -1
potential,on 1.0 0.000143348623853 0 1 -1
urine,red-orange 1.0 0.000143348623853 0 1 -1
evidence,for 1.0 0.00043004587156 0 3 -3
medroxyprogesterone,acetate 1.0 0.000143348623853 1 0 1
users,of 0.333333333333 0.000286697247706 2 4 -2
in,inhibiting 0.0 0.0 1 1 0
an,alternative 1.0 0.00043004587156 0 3 -3
with,because 0.666666666667 0.000573394495413 5 1 4
systemic,antiretroviral 1.0 0.000143348623853 0 1 -1
dog,that 1.0 0.000143348623853 0 1 -1
and,ocular 1.0 0.000286697247706 0 2 -2
or,clinical 1.0 0.000143348623853 0 1 -1
did,indeed 1.0 0.000143348623853 1 0 1
include,certain 1.0 0.00043004587156 3 0 3
diseases,such 1.0 0.000143348623853 0 1 -1
could,result 1.0 0.00043004587156 0 3 -3
the,glucosylation 1.0 0.000143348623853 0 1 -1
patients,using 0.0 0.0 3 3 0
disposition,of 1.0 0.00114678899083 0 8 -8
in,treatment-naive 1.0 0.000143348623853 0 1 -1
steadystate,cmin 1.0 0.000143348623853 1 0 1
and,epididymides 1.0 0.000143348623853 0 1 -1
it,substituted 1.0 0.000143348623853 0 1 -1
interactions,between 0.878787878788 0.00415711009174 2 31 -29
contraindicated,in 0.2 0.000143348623853 3 2 1
a,symptomatic 1.0 0.000143348623853 0 1 -1
cetaminophen,hepatoxicity 1.0 0.000143348623853 0 1 -1
all,three 1.0 0.000143348623853 0 1 -1
potassium,since 1.0 0.000143348623853 0 1 -1
coreg,is 1.0 0.000286697247706 2 0 2
nsaids,a 1.0 0.000143348623853 0 1 -1
result,of 0.75 0.000860091743119 1 7 -6
whether,an 1.0 0.000143348623853 0 1 -1
data,intables 1.0 0.000143348623853 0 1 -1
fluvoxamine,inhibits 1.0 0.000143348623853 1 0 1
on,glucocorticoid-induced 1.0 0.000143348623853 0 1 -1
hypoprothrombinemic,effect 1.0 0.000143348623853 0 1 -1
to,measure 1.0 0.00043004587156 0 3 -3
corn,oil 1.0 0.000143348623853 0 1 -1
prostaglandins,and 1.0 0.000143348623853 0 1 -1
ineffective,if 1.0 0.000143348623853 1 0 1
and,bmax 1.0 0.000143348623853 0 1 -1
of,childbearing 1.0 0.000573394495413 0 4 -4
ineffective,in 1.0 0.00043004587156 0 3 -3
ketoconazole,ketoconazole 0.333333333333 0.000286697247706 4 2 2
proleukin,treatment 1.0 0.000143348623853 0 1 -1
population,in 1.0 0.000143348623853 0 1 -1
in,chemical 1.0 0.000143348623853 0 1 -1
signs,or 1.0 0.00043004587156 3 0 3
subjects,experienced 1.0 0.000286697247706 2 0 2
reevaluations,of 1.0 0.000143348623853 0 1 -1
systemic,and 0.0 0.0 1 1 0
isozymes,responsible 1.0 0.000286697247706 2 0 2
may,exacerbate 1.0 0.000573394495413 4 0 4
care,when 1.0 0.000143348623853 1 0 1
causing,a 1.0 0.000143348623853 1 0 1
biological,indicators 1.0 0.000143348623853 0 1 -1
medications,is 1.0 0.000143348623853 1 0 1
interaction,captopril 1.0 0.000143348623853 0 1 -1
akineton,are 1.0 0.000143348623853 1 0 1
will,result 1.0 0.000286697247706 0 2 -2
receiving,infusions 1.0 0.000143348623853 0 1 -1
intestinal,transits 1.0 0.000143348623853 0 1 -1
some,indications 1.0 0.000143348623853 0 1 -1
a,physician 1.0 0.000143348623853 1 0 1
and,alternative 1.0 0.00043004587156 3 0 3
of,interaction 0.882352941176 0.0021502293578 1 16 -15
is,inadequate 1.0 0.000143348623853 0 1 -1
medications,in 1.0 0.000143348623853 0 1 -1
tricor,with 1.0 0.00043004587156 3 0 3
peganone,used 1.0 0.000143348623853 0 1 -1
twitch,for 1.0 0.000143348623853 0 1 -1
mefloquine,therapy 1.0 0.000143348623853 0 1 -1
metabolite,n-desmethyldiazepam 1.0 0.000143348623853 1 0 1
inhibitors,somatostatin 1.0 0.000286697247706 0 2 -2
active,isomer 1.0 0.000286697247706 2 0 2
of,levels 0.0 0.0 1 1 0
cell,including 1.0 0.000143348623853 0 1 -1
to,units 1.0 0.000143348623853 0 1 -1
adrenal,function 1.0 0.000143348623853 0 1 -1
systemic,antimicrobial 1.0 0.000143348623853 0 1 -1
whose,pulmonary 1.0 0.000143348623853 0 1 -1
binding,lectin 1.0 0.000143348623853 0 1 -1
and,nsaids 1.0 0.000573394495413 4 0 4
groups,were 1.0 0.000286697247706 0 2 -2
cns,depressants 0.578947368421 0.00157683486239 15 4 11
call,that 1.0 0.000143348623853 0 1 -1
p-450iie1,in 1.0 0.000143348623853 1 0 1
is,demonstrated 1.0 0.000143348623853 0 1 -1
agents,have 0.4 0.000573394495413 3 7 -4
supraventricular,arrhythmias 1.0 0.000143348623853 0 1 -1
made,on 1.0 0.000143348623853 0 1 -1
view,of 0.0 0.0 1 1 0
strongly,support 1.0 0.000143348623853 0 1 -1
age,objective 1.0 0.000143348623853 0 1 -1
produce,an 1.0 0.000143348623853 1 0 1
by,irreversible 1.0 0.000143348623853 1 0 1
serum,proteins 0.0 0.0 1 1 0
low,clearance 1.0 0.000143348623853 0 1 -1
thereby,raising 1.0 0.000143348623853 1 0 1
giving,up 1.0 0.000143348623853 0 1 -1
inhibitor,of 0.173913043478 0.00114678899083 19 27 -8
prophylaxis,of 1.0 0.000143348623853 0 1 -1
preparation,this 1.0 0.000143348623853 1 0 1
cimetidine,is 1.0 0.000143348623853 1 0 1
while,mc 1.0 0.000143348623853 0 1 -1
between,folic 1.0 0.000143348623853 0 1 -1
or,potentiated 1.0 0.000143348623853 1 0 1
an,approximately 1.0 0.000286697247706 2 0 2
enterococcus,faecalis 1.0 0.000286697247706 0 2 -2
only,on 1.0 0.000143348623853 0 1 -1
index,and 1.0 0.000143348623853 0 1 -1
the,seminiferous 1.0 0.000143348623853 0 1 -1
consider,hmg-coa 1.0 0.000143348623853 1 0 1
both,than 1.0 0.000143348623853 0 1 -1
intestinal,permeability 1.0 0.000143348623853 1 0 1
surgical,procedures 1.0 0.000143348623853 1 0 1
produced,some 1.0 0.000143348623853 0 1 -1
indicated,the 1.0 0.000143348623853 0 1 -1
hctz,mg 1.0 0.000143348623853 0 1 -1
infection,in 1.0 0.000143348623853 1 0 1
muscle,pain 1.0 0.00043004587156 0 3 -3
versus,mg 1.0 0.000143348623853 0 1 -1
our,objective 1.0 0.000286697247706 0 2 -2
alternative,therapy 0.0 0.0 1 1 0
infection,is 1.0 0.000286697247706 0 2 -2
to,erythro-fluorocitrate 0.0 0.0 1 1 0
administered,safely 1.0 0.00043004587156 0 3 -3
most,likely 1.0 0.000143348623853 1 0 1
morphine,prolonged 0.0 0.0 1 1 0
synergism,with 0.0 0.0 1 1 0
ingested,simultaneously 1.0 0.000143348623853 1 0 1
receiving,resulted 1.0 0.000143348623853 0 1 -1
cortisol,levels 1.0 0.000143348623853 0 1 -1
asthma,or 1.0 0.000286697247706 0 2 -2
of,ophthalmic 1.0 0.000143348623853 0 1 -1
are,excreted 1.0 0.000573394495413 0 4 -4
drugs,results 1.0 0.000143348623853 0 1 -1
particular,and 1.0 0.000143348623853 0 1 -1
if,labetalol 1.0 0.000143348623853 1 0 1
in,water 1.0 0.000286697247706 0 2 -2
misonidazole,also 1.0 0.000143348623853 0 1 -1
be,deeper 1.0 0.000143348623853 1 0 1
topical,medications 1.0 0.000143348623853 0 1 -1
following,an 0.0 0.0 1 1 0
with,cns-active 1.0 0.000143348623853 0 1 -1
mustard,etc 1.0 0.000143348623853 0 1 -1
drugs,on 0.333333333333 0.000143348623853 1 2 -1
week,course 1.0 0.00043004587156 3 0 3
association,with 0.0 0.0 3 3 0
drugs,or 1.0 0.000143348623853 0 1 -1
reported,chiefly 1.0 0.000143348623853 0 1 -1
in,association 0.0 0.0 3 3 0
tissue,culture 0.333333333333 0.000143348623853 2 1 1
or,fortovase 1.0 0.000143348623853 0 1 -1
necessary,factor 1.0 0.000143348623853 0 1 -1
therefore,change 1.0 0.000143348623853 0 1 -1
previous,reports 0.0 0.0 1 1 0
to,hydrochloride 1.0 0.000143348623853 0 1 -1
addition,higher-than 1.0 0.000143348623853 1 0 1
the,secretion 1.0 0.000286697247706 0 2 -2
is,significantly 0.0 0.0 1 1 0
sensipar,on 1.0 0.000143348623853 0 1 -1
bound,from 1.0 0.000143348623853 0 1 -1
inhibitor,may 1.0 0.000143348623853 1 0 1
gastrointestinal,events 1.0 0.000143348623853 0 1 -1
other,drug 0.666666666667 0.000573394495413 1 5 -4
studies,sodium 1.0 0.000143348623853 0 1 -1
detect,an 1.0 0.000143348623853 0 1 -1
a,d-gal 1.0 0.000143348623853 0 1 -1
by,rats 1.0 0.000143348623853 0 1 -1
with,ovcon-35 1.0 0.000143348623853 1 0 1
to,designing 1.0 0.000143348623853 0 1 -1
for,clindamycin-sensitive 1.0 0.000143348623853 0 1 -1
impaired,ventricular 1.0 0.000143348623853 0 1 -1
stably,transfected 1.0 0.000143348623853 0 1 -1
picr,detected 1.0 0.000143348623853 0 1 -1
not,attenuated 1.0 0.000143348623853 0 1 -1
nizoral,tablets 0.333333333333 0.000143348623853 2 1 1
erythromycin,mg 0.0 0.0 1 1 0
diet,for 1.0 0.000143348623853 1 0 1
anti-inflammatory,may 1.0 0.000143348623853 1 0 1
been,shown 0.32 0.00229357798165 33 17 16
prodrug,form 1.0 0.000143348623853 0 1 -1
containing,ferrous 1.0 0.000143348623853 1 0 1
ewes,given 1.0 0.000143348623853 1 0 1
age,and 1.0 0.00043004587156 0 3 -3
the,relation 1.0 0.000286697247706 0 2 -2
by,decreasing 1.0 0.00043004587156 3 0 3
and,amphotericin 1.0 0.000143348623853 1 0 1
or,abrasive 1.0 0.000143348623853 0 1 -1
most,commonly 0.333333333333 0.000143348623853 1 2 -1
total,rna 1.0 0.000143348623853 0 1 -1
but,not 0.151515151515 0.000716743119266 14 19 -5
goal-directed,behavior 1.0 0.000143348623853 0 1 -1
different,and 1.0 0.000143348623853 0 1 -1
application,mode 1.0 0.000143348623853 0 1 -1
severity,and 1.0 0.000143348623853 1 0 1
glyburide,etodolac 1.0 0.000143348623853 0 1 -1
supplements,have 1.0 0.000143348623853 0 1 -1
however,coadministration 1.0 0.000143348623853 0 1 -1
protein-bound,such 1.0 0.000143348623853 0 1 -1
of,adjusted 1.0 0.00043004587156 0 3 -3
steady-state,with 0.0 0.0 1 1 0
rashes,is 1.0 0.000143348623853 1 0 1
disorder,tremor 1.0 0.000143348623853 0 1 -1
mean,number 1.0 0.000143348623853 0 1 -1
inotropic,properties 1.0 0.000143348623853 1 0 1
acetate,were 1.0 0.000143348623853 0 1 -1
of,impaired 0.333333333333 0.000143348623853 2 1 1
reached,borderline 1.0 0.000143348623853 0 1 -1
in,clinically- 1.0 0.000143348623853 0 1 -1
constriction,were 1.0 0.000143348623853 0 1 -1
necessary,to 0.25 0.000286697247706 3 5 -2
glutamate,mglur 1.0 0.000143348623853 0 1 -1
inhibits,platelet 1.0 0.000143348623853 1 0 1
maximize,benefits 1.0 0.000143348623853 0 1 -1
dispersible,tablet 1.0 0.000143348623853 1 0 1
without,endothelium 1.0 0.000143348623853 0 1 -1
interaction,this 1.0 0.000143348623853 1 0 1
that,clorazepate 1.0 0.000143348623853 1 0 1
weight,for 1.0 0.000143348623853 0 1 -1
oral,and 0.333333333333 0.00114678899083 16 8 8
by,multiple 1.0 0.000286697247706 0 2 -2
serum-deprived,ras-3t3 1.0 0.000143348623853 0 1 -1
may,induce 0.333333333333 0.00043004587156 6 3 3
those,of 0.5 0.000573394495413 2 6 -4
patients,that 1.0 0.000143348623853 1 0 1
those,on 1.0 0.000143348623853 1 0 1
estradiol,mg 1.0 0.000143348623853 0 1 -1
to,terminate 1.0 0.000143348623853 0 1 -1
through,the 0.5 0.000286697247706 1 3 -2
episodes,permit 1.0 0.000143348623853 0 1 -1
include,the 1.0 0.00100344036697 0 7 -7
d1,receptors 1.0 0.000143348623853 0 1 -1
symptoms,excitement 1.0 0.000143348623853 0 1 -1
falsely,elevated 1.0 0.00043004587156 0 3 -3
cases,in 1.0 0.000143348623853 1 0 1
although,have 1.0 0.000143348623853 1 0 1
similarly,decreased 1.0 0.000286697247706 2 0 2
or,cramps 1.0 0.000143348623853 0 1 -1
when,prinivil 1.0 0.000143348623853 0 1 -1
cases,is 1.0 0.000143348623853 0 1 -1
comparable,activity 1.0 0.000143348623853 0 1 -1
effect,between 1.0 0.000143348623853 1 0 1
and,pregnancy 1.0 0.000143348623853 0 1 -1
been,found 0.411764705882 0.00100344036697 5 12 -7
administration,affects 1.0 0.000143348623853 0 1 -1
atiii,no 1.0 0.000143348623853 0 1 -1
benefit,balance 1.0 0.000143348623853 0 1 -1
against,taking 1.0 0.000143348623853 1 0 1
of,metabolized 1.0 0.00143348623853 0 10 -10
foradil,fumarate 1.0 0.000143348623853 0 1 -1
orally,given 1.0 0.000143348623853 0 1 -1
tract,hydoxide 1.0 0.000143348623853 1 0 1
in,dietary-obese 1.0 0.000143348623853 0 1 -1
neutralizing,agent 1.0 0.000143348623853 1 0 1
mcg,per 1.0 0.000143348623853 0 1 -1
therefore,little 1.0 0.000143348623853 0 1 -1
lumen,to 1.0 0.000143348623853 0 1 -1
a,negative 1.0 0.000143348623853 0 1 -1
jaffe,reaction 1.0 0.000286697247706 0 2 -2
of,st 1.0 0.00043004587156 0 3 -3
placebo,n 1.0 0.000143348623853 0 1 -1
division,of 1.0 0.000143348623853 0 1 -1
international,literature 1.0 0.000143348623853 0 1 -1
plendil,with 1.0 0.000143348623853 0 1 -1
erroneously,low 1.0 0.000143348623853 1 0 1
with,cardiac 1.0 0.000286697247706 0 2 -2
to,human 0.75 0.000860091743119 1 7 -6
flow,and 1.0 0.000286697247706 0 2 -2
myelosuppression,following 1.0 0.000143348623853 0 1 -1
venlafaxine,coadministration 1.0 0.000143348623853 0 1 -1
definitively,demonstrated 1.0 0.000143348623853 1 0 1
normal,cells 1.0 0.00043004587156 0 3 -3
rarely,when 1.0 0.000143348623853 1 0 1
oral,co-administration 1.0 0.000143348623853 1 0 1
administered,one 0.333333333333 0.000143348623853 1 2 -1
may,want 1.0 0.000143348623853 0 1 -1
severe,myopathy 1.0 0.000143348623853 1 0 1
major,cytochrome 1.0 0.000573394495413 0 4 -4
and,urinary 0.6 0.00043004587156 4 1 3
apparent,volume 1.0 0.000143348623853 0 1 -1
antiinflammatories,and 1.0 0.000143348623853 0 1 -1
azlocillin,should 1.0 0.000143348623853 1 0 1
and,about 0.0 0.0 1 1 0
in,slight 1.0 0.000143348623853 1 0 1
the,mouse 1.0 0.000143348623853 0 1 -1
findings,to 0.0 0.0 1 1 0
accidental,diagnostic 1.0 0.000716743119266 0 5 -5
also,been 0.428571428571 0.000860091743119 4 10 -6
being,developed 1.0 0.000143348623853 0 1 -1
individualized,when 1.0 0.000143348623853 0 1 -1
no,laboratory 1.0 0.000143348623853 0 1 -1
by,reductions 1.0 0.000143348623853 0 1 -1
thedosage,of 1.0 0.000286697247706 0 2 -2
higher,frequency 1.0 0.000143348623853 0 1 -1
equal,groups 1.0 0.000143348623853 0 1 -1
adl,a 1.0 0.000143348623853 1 0 1
a,sharp 1.0 0.000143348623853 1 0 1
transaminases,have 1.0 0.000143348623853 0 1 -1
dst,false-negative 1.0 0.000143348623853 0 1 -1
theasinensin,a 1.0 0.000143348623853 0 1 -1
in,serum 0.1875 0.000860091743119 13 19 -6
propantheline,and 1.0 0.000143348623853 1 0 1
qt,intervals 1.0 0.000286697247706 0 2 -2
in,respect 1.0 0.000143348623853 0 1 -1
supersensitivity,to 1.0 0.000143348623853 1 0 1
concomitant,therapies 1.0 0.000286697247706 0 2 -2
instituted,as 1.0 0.000143348623853 1 0 1
ethanol,nutrition 1.0 0.000143348623853 1 0 1
concentration,dependent 1.0 0.000143348623853 0 1 -1
or,s- 1.0 0.000143348623853 0 1 -1
initiating,extraneal 1.0 0.000143348623853 1 0 1
the,less 1.0 0.000143348623853 1 0 1
the,atypical 1.0 0.000143348623853 0 1 -1
nsaid,users 1.0 0.000143348623853 0 1 -1
with,adefovir 1.0 0.000143348623853 0 1 -1
by,induction 1.0 0.000143348623853 0 1 -1
for,less 1.0 0.000286697247706 0 2 -2
for,early 1.0 0.000143348623853 0 1 -1
and,cardiovascular 0.0 0.0 2 2 0
before,any 1.0 0.000143348623853 1 0 1
and,pharmacological 1.0 0.000286697247706 0 2 -2
daily,dose 0.333333333333 0.000573394495413 4 8 -4
in,parietal 1.0 0.000143348623853 0 1 -1
development,is 1.0 0.000143348623853 0 1 -1
before,and 1.0 0.000286697247706 0 2 -2
of,cycles 1.0 0.000143348623853 0 1 -1
and,indanedione 1.0 0.000143348623853 0 1 -1
inhibit,k 1.0 0.000143348623853 0 1 -1
single,high 1.0 0.000143348623853 1 0 1
felodipine,is 1.0 0.000143348623853 0 1 -1
or,st 1.0 0.000143348623853 1 0 1
not,necessitate 1.0 0.000286697247706 0 2 -2
subtypes,although 1.0 0.000143348623853 0 1 -1
reflex,and 1.0 0.000286697247706 0 2 -2
separate,brain 1.0 0.000143348623853 0 1 -1
or,impair 1.0 0.000143348623853 0 1 -1
cyp2d6,minor 1.0 0.000143348623853 0 1 -1
particularly,the 0.0 0.0 1 1 0
an,encephalopathic 1.0 0.000143348623853 1 0 1
demonstrated,effectiveness 1.0 0.000143348623853 0 1 -1
and,sometimes 1.0 0.000143348623853 1 0 1
biological,and 1.0 0.000143348623853 1 0 1
and,high 0.333333333333 0.000143348623853 1 2 -1
medication,is 1.0 0.000143348623853 0 1 -1
beta,blocker 1.0 0.000286697247706 2 0 2
seeds,of 1.0 0.000143348623853 0 1 -1
by,injection 1.0 0.000143348623853 0 1 -1
erythro-fluorocitrate,synthesis 1.0 0.00043004587156 0 3 -3
at,which 1.0 0.000143348623853 0 1 -1
findings,asymptomatic 1.0 0.000143348623853 0 1 -1
function,secondary 1.0 0.000286697247706 0 2 -2
may,however 1.0 0.000143348623853 0 1 -1
sometimes,used 1.0 0.000143348623853 0 1 -1
know,if 1.0 0.000143348623853 1 0 1
pharmacokinetic,screening 1.0 0.000143348623853 0 1 -1
marked,changes 1.0 0.000143348623853 1 0 1
activity,would 1.0 0.000143348623853 0 1 -1
to,hatching 1.0 0.000143348623853 0 1 -1
optimal,dose 1.0 0.000286697247706 0 2 -2
isozyme,which 1.0 0.000143348623853 0 1 -1
inhibition,can 1.0 0.000143348623853 0 1 -1
proteins,that 1.0 0.000143348623853 0 1 -1
with,acetylsalicylic 1.0 0.000143348623853 0 1 -1
infusions,myelosuppression 1.0 0.000143348623853 1 0 1
thus,concentrations 1.0 0.000143348623853 0 1 -1
while,only 0.0 0.0 1 1 0
candida,albicans 1.0 0.000143348623853 0 1 -1
serious,constellation 1.0 0.000143348623853 1 0 1
propecia,mg 1.0 0.000143348623853 0 1 -1
individual,who 1.0 0.000716743119266 0 5 -5
xigris,present 1.0 0.000286697247706 0 2 -2
distribution,have 1.0 0.000143348623853 0 1 -1
and,fundus 1.0 0.000143348623853 0 1 -1
our,results 1.0 0.000143348623853 0 1 -1
little,consideration 1.0 0.000143348623853 0 1 -1
using,romazicon 1.0 0.000143348623853 1 0 1
in,regimens 1.0 0.000143348623853 0 1 -1
gain,when 1.0 0.000143348623853 1 0 1
affect,bioavailabillty 1.0 0.000143348623853 0 1 -1
a,marketed 1.0 0.000143348623853 1 0 1
of,candesartan 1.0 0.000143348623853 0 1 -1
aggressively,with 1.0 0.000143348623853 0 1 -1
cns-impairing,effects 1.0 0.000143348623853 1 0 1
activation,of 0.818181818182 0.00129013761468 1 10 -9
a,mouse 1.0 0.000143348623853 0 1 -1
excessive,reduction 1.0 0.000716743119266 5 0 5
and,subcortical 1.0 0.000143348623853 0 1 -1
intersubject,variability 1.0 0.000143348623853 1 0 1
vehicle-,progesterone- 1.0 0.000143348623853 1 0 1
small,extent 1.0 0.000143348623853 0 1 -1
on,immunosuppression 1.0 0.000143348623853 0 1 -1
contained,plus 1.0 0.000143348623853 0 1 -1
other,inducers 0.333333333333 0.000143348623853 2 1 1
from,to 0.222222222222 0.000573394495413 7 11 -4
daily,oral 1.0 0.000143348623853 0 1 -1
fold,of 1.0 0.000143348623853 1 0 1
responding,significantly 1.0 0.000143348623853 0 1 -1
interactions,for 0.666666666667 0.000573394495413 5 1 4
initial,release 1.0 0.000143348623853 1 0 1
fold,on 1.0 0.00043004587156 3 0 3
using,bromocriptine 1.0 0.000143348623853 1 0 1
following,have 1.0 0.000143348623853 0 1 -1
analysis,and 1.0 0.000286697247706 0 2 -2
including,acetylsalicylic 1.0 0.000143348623853 0 1 -1
administered,following 0.0 0.0 1 1 0
attempting,to 1.0 0.000143348623853 0 1 -1
its,proposed 1.0 0.000143348623853 0 1 -1
prolong,the 0.2 0.00043004587156 9 6 3
be,mimicked 1.0 0.000143348623853 0 1 -1
part,to 0.0 0.0 1 1 0
vaccines,neurological 1.0 0.000143348623853 0 1 -1
weeks,as 1.0 0.000143348623853 0 1 -1
tachycardia,ventricular 1.0 0.000143348623853 1 0 1
nociception,was 1.0 0.000143348623853 0 1 -1
situations,avoid 1.0 0.000143348623853 0 1 -1
therapy,resulted 1.0 0.000143348623853 0 1 -1
topoisomerase-targeted,chemotherapy 1.0 0.000143348623853 0 1 -1
survival,in 1.0 0.000286697247706 0 2 -2
cyp,c19 1.0 0.00043004587156 0 3 -3
drug,name 1.0 0.000286697247706 0 2 -2
every,hours 0.0666666666667 0.000143348623853 8 7 1
discontinue,after 1.0 0.000143348623853 1 0 1
ninds,t-pa 1.0 0.000143348623853 0 1 -1
of,septic 1.0 0.000143348623853 0 1 -1
electron,microscopy 1.0 0.000143348623853 0 1 -1
of,robinul 1.0 0.000286697247706 2 0 2
known,about 1.0 0.000143348623853 0 1 -1
not,generally 1.0 0.000286697247706 2 0 2
diclofenac,like 1.0 0.000143348623853 0 1 -1
myocardium,may 1.0 0.000143348623853 1 0 1
factrel,test 1.0 0.000143348623853 0 1 -1
approved,in 1.0 0.000286697247706 0 2 -2
antigen,viii 1.0 0.000286697247706 0 2 -2
impair,glomerular 1.0 0.000143348623853 0 1 -1
was,performed 1.0 0.00043004587156 0 3 -3
sgot,ast 1.0 0.000143348623853 1 0 1
combined,actions 1.0 0.000286697247706 0 2 -2
into,the 0.5 0.000286697247706 1 3 -2
adenylate,cyclase 1.0 0.000143348623853 0 1 -1
cells,during 1.0 0.000143348623853 0 1 -1
nd,female 1.0 0.000143348623853 0 1 -1
week,intervals 1.0 0.000143348623853 0 1 -1
has,greater 1.0 0.000143348623853 0 1 -1
physiological,tolerance 1.0 0.000143348623853 0 1 -1
appropriate,interval 1.0 0.000143348623853 0 1 -1
metabolic,profiles 1.0 0.000143348623853 0 1 -1
two,are 0.0 0.0 2 2 0
pharmacist,before 1.0 0.000143348623853 0 1 -1
to,pi-based 1.0 0.000143348623853 0 1 -1
daily,as 0.0 0.0 2 2 0
salts,with 1.0 0.000143348623853 0 1 -1
testicular,axis 1.0 0.000143348623853 0 1 -1
after,myocardial 1.0 0.000143348623853 0 1 -1
including,preparations 1.0 0.000143348623853 0 1 -1
conflicting,results 0.333333333333 0.000143348623853 2 1 1
spinal,substantia 1.0 0.000286697247706 0 2 -2
bactericidal,effect 1.0 0.000143348623853 1 0 1
the,properties 1.0 0.000143348623853 0 1 -1
dose,greater 1.0 0.000143348623853 0 1 -1
under,steady 1.0 0.000286697247706 0 2 -2
usually,mild 1.0 0.000143348623853 0 1 -1
chylomicron,metabolism 1.0 0.000143348623853 0 1 -1
in,meclofenamate 1.0 0.000143348623853 0 1 -1
hematologic,studies 1.0 0.000143348623853 0 1 -1
in,hypertensive 1.0 0.000143348623853 0 1 -1
of,tumor 1.0 0.000143348623853 0 1 -1
agents,structurally 1.0 0.000143348623853 1 0 1
although,romazicon 1.0 0.000143348623853 1 0 1
and,inotropic 1.0 0.000143348623853 1 0 1
is,reaching 1.0 0.000143348623853 0 1 -1
etodolac,is 1.0 0.000286697247706 0 2 -2
rash,while 1.0 0.000143348623853 1 0 1
the,ssris 0.6 0.00043004587156 4 1 3
as,sequential 1.0 0.000143348623853 1 0 1
antacid,the 1.0 0.000143348623853 0 1 -1
pharmacokinetics,during 1.0 0.000143348623853 0 1 -1
receiving,hmg-coa 1.0 0.000143348623853 1 0 1
of,thereby 1.0 0.000286697247706 2 0 2
epigallocatechin-3,o-gallate 1.0 0.000143348623853 0 1 -1
nonsmoking,healthy 1.0 0.000143348623853 0 1 -1
adjustment,or 1.0 0.000143348623853 0 1 -1
pig,small 1.0 0.000143348623853 0 1 -1
fluconazole,concomitant 1.0 0.000143348623853 1 0 1
such,arrhythmias 1.0 0.000143348623853 0 1 -1
predispose,the 1.0 0.000143348623853 1 0 1
by,cyp3a4 0.333333333333 0.00043004587156 3 6 -3
tolerated,when 1.0 0.000143348623853 0 1 -1
the,blood-sugar 1.0 0.000143348623853 1 0 1
tablets,injection 1.0 0.000143348623853 1 0 1
young,healthy 1.0 0.000143348623853 0 1 -1
anticoagulants,flurbiprofen 1.0 0.000143348623853 1 0 1
biocytin,was 1.0 0.000143348623853 0 1 -1
volume,in 1.0 0.000143348623853 1 0 1
patient,populations 0.0 0.0 1 1 0
antagonists,are 1.0 0.000143348623853 1 0 1
given,within 1.0 0.000143348623853 0 1 -1
taking,bextra 1.0 0.000143348623853 1 0 1
not,excluded 1.0 0.000143348623853 0 1 -1
for,some 1.0 0.000143348623853 0 1 -1
lorazepam,injection 1.0 0.000143348623853 1 0 1
diminished,effects 1.0 0.000143348623853 1 0 1
observed,between 0.666666666667 0.000573394495413 1 5 -4
some,nsaids 1.0 0.000143348623853 1 0 1
states,of 1.0 0.000143348623853 0 1 -1
interval,on 1.0 0.00100344036697 7 0 7
interval,of 0.5 0.000286697247706 1 3 -2
infections,have 1.0 0.000143348623853 0 1 -1
states,or 1.0 0.000143348623853 0 1 -1
minimally,excreted 1.0 0.000143348623853 0 1 -1
users,causes 1.0 0.000143348623853 0 1 -1
large,numbers 1.0 0.000143348623853 0 1 -1
the,lipid-lowering 1.0 0.000143348623853 0 1 -1
is,warranted 0.2 0.000143348623853 3 2 1
experiments,using 1.0 0.000143348623853 0 1 -1
suppression,of 0.428571428571 0.00043004587156 2 5 -3
affect,pharmacodynamics 1.0 0.000143348623853 1 0 1
however,from 1.0 0.000143348623853 1 0 1
competitive,inhibition 1.0 0.000143348623853 0 1 -1
although,many 1.0 0.000286697247706 0 2 -2
received,amevive 1.0 0.000143348623853 0 1 -1
humans,may 1.0 0.000143348623853 1 0 1
dermatologist,and 1.0 0.000143348623853 0 1 -1
specific,studies 0.6 0.00043004587156 1 4 -3
medication,review 1.0 0.000143348623853 0 1 -1
translocating,action 1.0 0.000143348623853 0 1 -1
interactions,cimetidine 1.0 0.000286697247706 0 2 -2
acid-base,and 0.0 0.0 1 1 0
has,sufficient 1.0 0.000143348623853 0 1 -1
ketone,bodies 1.0 0.000143348623853 0 1 -1
to,additional 1.0 0.000143348623853 0 1 -1
cancidas,are 1.0 0.000143348623853 0 1 -1
the,cyp2d6 0.5 0.000286697247706 1 3 -2
cmax,vs 1.0 0.000143348623853 0 1 -1
their,o-desacetyl 1.0 0.000143348623853 0 1 -1
a,times 1.0 0.000143348623853 1 0 1
concern,thus 1.0 0.000143348623853 0 1 -1
not,materially 1.0 0.000143348623853 0 1 -1
below,the 0.333333333333 0.000143348623853 1 2 -1
labetalol,hcl 0.333333333333 0.000286697247706 4 2 2
with,alkaline 1.0 0.000286697247706 0 2 -2
combining,these 1.0 0.000143348623853 0 1 -1
of,birth 1.0 0.000143348623853 1 0 1
accordingly,careful 1.0 0.000143348623853 1 0 1
to,p450-based 1.0 0.000143348623853 0 1 -1
toxicity,characterized 0.2 0.000143348623853 2 3 -1
with,tam 1.0 0.000143348623853 0 1 -1
causes,of 1.0 0.000143348623853 0 1 -1
half,life 1.0 0.000143348623853 1 0 1
with,epilepsy 1.0 0.000573394495413 0 4 -4
with,features 1.0 0.000143348623853 0 1 -1
increasing,their 1.0 0.000286697247706 0 2 -2
leprosy-associated,inflammatory 1.0 0.000143348623853 1 0 1
gastrointestinal,transit 0.0 0.0 2 2 0
then,mg 1.0 0.000143348623853 0 1 -1
m-toluamide,a 1.0 0.000143348623853 1 0 1
similar,in 1.0 0.00043004587156 0 3 -3
nd,series 1.0 0.000143348623853 0 1 -1
concentration,were 1.0 0.000143348623853 0 1 -1
in,mediating 1.0 0.000143348623853 0 1 -1
increased,after 1.0 0.000143348623853 0 1 -1
deficient,in 1.0 0.000143348623853 0 1 -1
syndrome,in 0.0 0.0 1 1 0
be,given 0.0 0.0 18 18 0
or,similar 1.0 0.000286697247706 2 0 2
the,ed50 1.0 0.000143348623853 1 0 1
in,vivo 0.441860465116 0.00272362385321 12 31 -19
receiving,catecholamine-depleting 1.0 0.00043004587156 3 0 3
or,triazolam 1.0 0.000143348623853 0 1 -1
or,supplements 0.6 0.00043004587156 1 4 -3
concomitant,protease 1.0 0.000143348623853 1 0 1
fatal,when 1.0 0.000143348623853 1 0 1
still,significant 1.0 0.000143348623853 0 1 -1
patients,vs 1.0 0.000143348623853 0 1 -1
their,increased 1.0 0.000143348623853 0 1 -1
trials,in 0.0 0.0 1 1 0
finding,that 1.0 0.000143348623853 0 1 -1
prophylactic,low 1.0 0.000286697247706 0 2 -2
and,somnolence 1.0 0.000143348623853 1 0 1
that,its 1.0 0.000143348623853 0 1 -1
diclofenac,does 1.0 0.000143348623853 0 1 -1
and,thereafter 1.0 0.000143348623853 0 1 -1
of,subjects 0.555555555556 0.000716743119266 7 2 5
tricyclic,antidepressant 1.0 0.000573394495413 0 4 -4
activase,in 1.0 0.000143348623853 0 1 -1
especially,central 1.0 0.000143348623853 0 1 -1
which,inflammation 1.0 0.000143348623853 0 1 -1
as,ironing 1.0 0.000143348623853 0 1 -1
eg,selective 1.0 0.000143348623853 0 1 -1
especially,or 1.0 0.000143348623853 0 1 -1
changes,in 0.694915254237 0.00587729357798 9 50 -41
information,should 1.0 0.000143348623853 0 1 -1
by,gleevec 1.0 0.000143348623853 1 0 1
of,o-desacetylrifabutin 1.0 0.000143348623853 1 0 1
sodium,was 1.0 0.000286697247706 0 2 -2
potentially,nephrotoxic 1.0 0.000286697247706 2 0 2
administered,simultaneously 1.0 0.000143348623853 1 0 1
relate,to 1.0 0.000143348623853 0 1 -1
in,relation 1.0 0.00043004587156 0 3 -3
that,results 0.333333333333 0.000143348623853 2 1 1
disease,erectile 1.0 0.000143348623853 0 1 -1
method,for 1.0 0.000286697247706 0 2 -2
cyp2d6,because 1.0 0.000143348623853 0 1 -1
palytoxin-induced,contraction 1.0 0.000143348623853 0 1 -1
underlying,neural 1.0 0.000143348623853 0 1 -1
protein,carbamazepine 1.0 0.000143348623853 0 1 -1
of,fluvoxamine 1.0 0.000143348623853 1 0 1
enzyme,systems 0.5 0.000286697247706 1 3 -2
and,mask 1.0 0.000143348623853 0 1 -1
depletion,may 1.0 0.000143348623853 1 0 1
ns,and 1.0 0.000143348623853 0 1 -1
injection,and 1.0 0.000716743119266 5 0 5
formally,evaluated 1.0 0.000143348623853 0 1 -1
assay,as 1.0 0.000143348623853 0 1 -1
synthetic,by 1.0 0.000143348623853 1 0 1
bun,and 1.0 0.000143348623853 1 0 1
was,too 1.0 0.000143348623853 0 1 -1
intake,and 1.0 0.000143348623853 0 1 -1
follow-up,liver 1.0 0.000143348623853 0 1 -1
renal,uptake 1.0 0.000143348623853 1 0 1
the,dst 1.0 0.000286697247706 0 2 -2
creatinine,in 1.0 0.000286697247706 2 0 2
creatinine,if 1.0 0.000143348623853 0 1 -1
also,affect 1.0 0.000143348623853 0 1 -1
avoided,also 1.0 0.000143348623853 1 0 1
two,multiple-dose 1.0 0.000143348623853 0 1 -1
documentation,of 1.0 0.000143348623853 0 1 -1
in,renal 0.0 0.0 4 4 0
for,gout 1.0 0.000143348623853 0 1 -1
niddm,subjects 1.0 0.000143348623853 0 1 -1
awareness,of 1.0 0.000143348623853 1 0 1
others,that 1.0 0.000143348623853 1 0 1
use,foradil 1.0 0.000143348623853 0 1 -1
chapters,cover 1.0 0.000143348623853 0 1 -1
a,crossover 1.0 0.000143348623853 1 0 1
have,one 1.0 0.000143348623853 0 1 -1
when,tumor 1.0 0.000143348623853 0 1 -1
bextra,in 1.0 0.000286697247706 2 0 2
particularly,susceptible 1.0 0.000143348623853 0 1 -1
bextra,is 1.0 0.000143348623853 0 1 -1
direct,coombs 1.0 0.000573394495413 0 4 -4
are,often 1.0 0.000286697247706 0 2 -2
saquinavir,steady-state 1.0 0.000143348623853 1 0 1
hormonal,contraceptives 0.0 0.0 1 1 0
alternatives,are 1.0 0.000143348623853 0 1 -1
agents,were 1.0 0.000286697247706 0 2 -2
dexamethasone,aprepitant 1.0 0.000143348623853 1 0 1
six,sudden 1.0 0.000143348623853 0 1 -1
the,long-term 1.0 0.000286697247706 0 2 -2
motility,agent 1.0 0.000143348623853 0 1 -1
and,h-triolein 1.0 0.000143348623853 0 1 -1
consideration,in 0.75 0.000860091743119 7 1 6
ldh,were 1.0 0.000143348623853 0 1 -1
a,considerable 0.0 0.0 1 1 0
pharmacokinetic,study 0.333333333333 0.000286697247706 2 4 -2
physostigmine,briefly 1.0 0.000143348623853 0 1 -1
methotrexate,ketoprofen 1.0 0.000143348623853 1 0 1
nonselective,inhibitor 0.0 0.0 1 1 0
period,in 0.6 0.00043004587156 4 1 3
to,iii 1.0 0.000286697247706 0 2 -2
velcade,treatment 1.0 0.000143348623853 1 0 1
other,factors 1.0 0.00043004587156 0 3 -3
oxytocic,agents 1.0 0.000286697247706 0 2 -2
fold,in 0.333333333333 0.000143348623853 2 1 1
xenobiotic,metabolism 1.0 0.000143348623853 0 1 -1
because,binds 1.0 0.000143348623853 0 1 -1
racemic,nor 1.0 0.000143348623853 0 1 -1
maintenance,dose 1.0 0.000573394495413 4 0 4
pharmacokinetic,interaction 0.789473684211 0.0021502293578 2 17 -15
and,extent 0.142857142857 0.000143348623853 3 4 -1
a,further 0.333333333333 0.000143348623853 2 1 1
been,filtrated 1.0 0.000143348623853 1 0 1
delirium,has 1.0 0.000143348623853 1 0 1
overall,treatment 1.0 0.000143348623853 0 1 -1
attention,and 1.0 0.000143348623853 0 1 -1
prealbumin,tbpa 1.0 0.000143348623853 0 1 -1
on,protein 1.0 0.000143348623853 0 1 -1
action,may 1.0 0.000143348623853 0 1 -1
the,octapeptide 1.0 0.000143348623853 0 1 -1
pharmaceuticals,inc 1.0 0.000143348623853 1 0 1
as,being 1.0 0.000143348623853 0 1 -1
quinolones,have 1.0 0.00043004587156 3 0 3
of,components 1.0 0.000286697247706 0 2 -2
reports,indicate 1.0 0.000286697247706 2 0 2
or,nsaids 0.0 0.0 1 1 0
motility,lowers 1.0 0.000143348623853 1 0 1
serum,without 1.0 0.000143348623853 0 1 -1
of,sular 1.0 0.000286697247706 2 0 2
via,p450 1.0 0.000143348623853 1 0 1
and,vi 1.0 0.000143348623853 0 1 -1
of,radio-iodine 1.0 0.000143348623853 0 1 -1
tell,your 0.333333333333 0.000143348623853 1 2 -1
a,recently 1.0 0.000143348623853 0 1 -1
are,capable 1.0 0.000286697247706 0 2 -2
to,provide 1.0 0.00043004587156 0 3 -3
and,vs 1.0 0.000143348623853 0 1 -1
one-stage,coagulation 1.0 0.000143348623853 0 1 -1
uptakes,which 1.0 0.000143348623853 0 1 -1
with,synergistically 1.0 0.000143348623853 0 1 -1
superiority,compared 1.0 0.000143348623853 0 1 -1
and,appropriate 0.142857142857 0.000143348623853 3 4 -1
was,about 0.0 0.0 2 2 0
the,pharmacokinetics 0.827586206897 0.0137614678899 10 106 -96
pulsatile,choroidal 1.0 0.000143348623853 0 1 -1
inducers,it 1.0 0.000143348623853 1 0 1
oxide,to 1.0 0.000143348623853 1 0 1
prednisolone,ethinyl 1.0 0.000143348623853 1 0 1
tolerance,in 1.0 0.000286697247706 2 0 2
infusion,solutions 1.0 0.000143348623853 0 1 -1
human,novolog 1.0 0.000143348623853 0 1 -1
actions,desirable 1.0 0.000286697247706 0 2 -2
is,bound 1.0 0.000143348623853 0 1 -1
the,systemic 0.142857142857 0.000143348623853 4 3 1
dose,level 1.0 0.000143348623853 0 1 -1
in,control 1.0 0.000286697247706 0 2 -2
in,non-specialist 1.0 0.000143348623853 0 1 -1
for,most 1.0 0.000286697247706 0 2 -2
until,blood 0.333333333333 0.000143348623853 1 2 -1
short-acting,aerosol 1.0 0.000143348623853 0 1 -1
l,induced 1.0 0.000143348623853 0 1 -1
indanavir,ketoconazole 1.0 0.000143348623853 0 1 -1
and,diamond 1.0 0.000143348623853 1 0 1
known,if 0.666666666667 0.000573394495413 1 5 -4
butalbital,and 1.0 0.000143348623853 1 0 1
these,potentially 1.0 0.000143348623853 1 0 1
rigidity,dystonia 1.0 0.000143348623853 0 1 -1
levels,effects 1.0 0.000143348623853 0 1 -1
instances,and 1.0 0.000143348623853 1 0 1
sali-cylates,nsaids 1.0 0.000143348623853 0 1 -1
may,underlie 1.0 0.000143348623853 0 1 -1
was,treated 1.0 0.00043004587156 0 3 -3
birth,control 0.333333333333 0.000143348623853 1 2 -1
anesthetized,swine 1.0 0.000143348623853 0 1 -1
studying,of 1.0 0.000143348623853 0 1 -1
received,epirubicin-based 1.0 0.000143348623853 0 1 -1
reactions,are 1.0 0.000143348623853 0 1 -1
washout,period 1.0 0.00043004587156 0 3 -3
and,enable 1.0 0.000143348623853 0 1 -1
groups,sh 1.0 0.000143348623853 0 1 -1
these,pharmacokinetic 0.0 0.0 2 2 0
to,dose-related 1.0 0.000143348623853 1 0 1
using,rat 1.0 0.000143348623853 0 1 -1
binding,activity 1.0 0.000143348623853 0 1 -1
r-warfarin,a 1.0 0.000143348623853 1 0 1
on,its 1.0 0.000143348623853 0 1 -1
hepatotoxicity,concomitant 1.0 0.000143348623853 1 0 1
v,decreased 1.0 0.000143348623853 0 1 -1
with,diethyl 1.0 0.000143348623853 0 1 -1
and,kytril 1.0 0.000143348623853 0 1 -1
solution,dried 1.0 0.000143348623853 0 1 -1
neutrophils,such 1.0 0.000143348623853 0 1 -1
although,combinations 1.0 0.000143348623853 0 1 -1
hyperglycaemia,increased 1.0 0.000143348623853 0 1 -1
and,but 1.0 0.000143348623853 1 0 1
pci,co-administration 1.0 0.000143348623853 1 0 1
physciains,it 1.0 0.000143348623853 0 1 -1
chelated,extracellular 1.0 0.000143348623853 0 1 -1
therefore,smaller 1.0 0.000143348623853 0 1 -1
ssris,may 1.0 0.000143348623853 1 0 1
for,preparations 0.2 0.000143348623853 2 3 -1
taxol,therapy 1.0 0.000286697247706 0 2 -2
inter-patient,variability 1.0 0.000143348623853 0 1 -1
of,pcp-induced 1.0 0.000143348623853 0 1 -1
in,intensive 1.0 0.000143348623853 0 1 -1
continuation,of 1.0 0.000286697247706 0 2 -2
further,they 1.0 0.000143348623853 0 1 -1
of,incubation 1.0 0.000143348623853 0 1 -1
underlying,the 1.0 0.000286697247706 0 2 -2
results,confirm 1.0 0.000143348623853 0 1 -1
like,and 1.0 0.000143348623853 0 1 -1
all,associated 1.0 0.000143348623853 1 0 1
dosage,was 1.0 0.000143348623853 0 1 -1
anticoagulants,blood 1.0 0.000143348623853 0 1 -1
we,propose 1.0 0.000143348623853 1 0 1
reaction,since 1.0 0.000143348623853 0 1 -1
performed,examining 1.0 0.000143348623853 0 1 -1
consider,doubling 1.0 0.000143348623853 0 1 -1
anafranil,by 1.0 0.000143348623853 0 1 -1
though,such 1.0 0.000286697247706 0 2 -2
similar,to 0.4 0.00114678899083 6 14 -8
salicylate,levels 1.0 0.000143348623853 0 1 -1
between,h-spiroperidol 1.0 0.000286697247706 0 2 -2
therapeutic,levels 1.0 0.000286697247706 0 2 -2
to,hormone 1.0 0.000143348623853 0 1 -1
supports,the 1.0 0.000143348623853 0 1 -1
performed,coadministration 1.0 0.000143348623853 1 0 1
or,during 0.333333333333 0.000143348623853 1 2 -1
other,neither 1.0 0.000143348623853 0 1 -1
duloxetine,did 1.0 0.000143348623853 0 1 -1
neurological,and 1.0 0.000143348623853 0 1 -1
for,one 0.333333333333 0.000143348623853 1 2 -1
blocking,agent 0.0 0.0 2 2 0
carbamazepine,in 1.0 0.000143348623853 1 0 1
racemic,citalopram 1.0 0.000143348623853 1 0 1
insufficiency,especially 1.0 0.000143348623853 0 1 -1
b3,niacin 1.0 0.000143348623853 1 0 1
nnrtis,nevirapine 1.0 0.000143348623853 1 0 1
using,clinitest 1.0 0.000573394495413 0 4 -4
alkaline,phosphatase 1.0 0.00043004587156 0 3 -3
day,mg 1.0 0.000143348623853 0 1 -1
phenytoin,and 0.6 0.00043004587156 4 1 3
and,l-lysine 1.0 0.000143348623853 1 0 1
bactercidal,effect 1.0 0.000143348623853 1 0 1
occurs,while 1.0 0.000143348623853 0 1 -1
vitro,interaction 0.333333333333 0.000143348623853 2 1 1
therefore,and 1.0 0.000286697247706 2 0 2
live,typhoid 1.0 0.000143348623853 1 0 1
tended,to 0.0 0.0 1 1 0
e2,may 1.0 0.000143348623853 1 0 1
to,accomplish 1.0 0.000143348623853 0 1 -1
kerlone,with 1.0 0.000143348623853 0 1 -1
event,of 1.0 0.000143348623853 0 1 -1
of,nociception 1.0 0.000143348623853 0 1 -1
the,gaba-ergic 1.0 0.000143348623853 1 0 1
when,starlix 1.0 0.000286697247706 0 2 -2
a,krm-1648 1.0 0.000143348623853 0 1 -1
to,miracidia 1.0 0.000286697247706 0 2 -2
interaction,also 1.0 0.00043004587156 0 3 -3
observed,only 1.0 0.000143348623853 0 1 -1
antidiabetic,oral 1.0 0.000573394495413 0 4 -4
mg,should 1.0 0.000286697247706 0 2 -2
clinical,implications 0.333333333333 0.000143348623853 1 2 -1
pi,affecting 1.0 0.000143348623853 0 1 -1
creatinine,values 1.0 0.000143348623853 0 1 -1
hydroxy-3,methylglutaryl 1.0 0.000143348623853 0 1 -1
each,subject 1.0 0.00043004587156 0 3 -3
less,effective 0.0 0.0 1 1 0
bosentan,has 1.0 0.000143348623853 0 1 -1
made,when 1.0 0.000286697247706 0 2 -2
hours,and 0.0 0.0 1 1 0
inhibition,induced 0.2 0.000143348623853 3 2 1
in,ra 1.0 0.000143348623853 0 1 -1
increased,angiotensinogen 1.0 0.000286697247706 0 2 -2
treatment,or 1.0 0.000286697247706 0 2 -2
products,concurrent 1.0 0.000143348623853 1 0 1
require,replacement 1.0 0.000143348623853 1 0 1
cervical,vertebra 1.0 0.000143348623853 0 1 -1
in,r-values 1.0 0.000143348623853 0 1 -1
treatment,on 1.0 0.000143348623853 0 1 -1
treatment,of 0.65 0.00372706422018 7 33 -26
recommended,twice 1.0 0.000143348623853 0 1 -1
reformed,microtubules 1.0 0.000143348623853 0 1 -1
or,treatment 1.0 0.000143348623853 0 1 -1
digoxin,salicylate 1.0 0.000143348623853 1 0 1
satisfactory,hypotensive 1.0 0.000143348623853 1 0 1
diamox,may 1.0 0.000143348623853 1 0 1
acids,and 1.0 0.000143348623853 0 1 -1
s,sarcoma 1.0 0.000143348623853 0 1 -1
metabolism,which 1.0 0.000143348623853 1 0 1
sodium,iodide 0.0 0.0 1 1 0
isolated,reports 1.0 0.00043004587156 3 0 3
week,intraperitoneal 1.0 0.000143348623853 0 1 -1
features,resembling 1.0 0.000143348623853 0 1 -1
interferes,minimally 1.0 0.000143348623853 1 0 1
septra,gantrisin 1.0 0.000143348623853 0 1 -1
administered,minute 1.0 0.000143348623853 1 0 1
cell,permeable 1.0 0.000143348623853 0 1 -1
likely,that 0.5 0.000286697247706 1 3 -2
reduced,p450 1.0 0.000716743119266 0 5 -5
ischemic,heart 0.0 0.0 2 2 0
undesirable,effects 1.0 0.000143348623853 1 0 1
virtually,all 1.0 0.000143348623853 0 1 -1
ml,day 1.0 0.000143348623853 0 1 -1
may,protect 1.0 0.000143348623853 1 0 1
equally,antagonized 1.0 0.000143348623853 1 0 1
the,qrs 0.0 0.0 1 1 0
syndrome,cognitive 1.0 0.000143348623853 1 0 1
uptake,to 1.0 0.000143348623853 1 0 1
involving,alprazolam 1.0 0.000143348623853 1 0 1
and,release 1.0 0.000716743119266 0 5 -5
at,periodic 1.0 0.000143348623853 1 0 1
enough,during 1.0 0.000143348623853 1 0 1
a,subgroup 1.0 0.000143348623853 0 1 -1
completely,metabolised 1.0 0.000143348623853 0 1 -1
or,eliminated 1.0 0.000143348623853 1 0 1
inducers,include 1.0 0.000143348623853 0 1 -1
important,to 1.0 0.000143348623853 0 1 -1
assays,using 1.0 0.000143348623853 0 1 -1
gradual,withdrawal 1.0 0.000143348623853 0 1 -1
administering,to 1.0 0.000286697247706 2 0 2
reduced,creatinine 1.0 0.000143348623853 1 0 1
d6,ic50 1.0 0.000143348623853 0 1 -1
inhibitors,eg 0.0 0.0 1 1 0
be,recommended 1.0 0.000286697247706 0 2 -2
inhibitors,coadministration 1.0 0.000143348623853 1 0 1
parenterally,special 1.0 0.000286697247706 0 2 -2
the,oral 0.4 0.00114678899083 14 6 8
independent,of 1.0 0.000286697247706 0 2 -2
like,cannot 1.0 0.000143348623853 0 1 -1
major,contributing 1.0 0.000143348623853 1 0 1
model,the 1.0 0.000143348623853 0 1 -1
neurotransmitter,systems 1.0 0.000143348623853 0 1 -1
in,clearance 0.4 0.000573394495413 7 3 4
or,back-up 1.0 0.000143348623853 1 0 1
of,susceptibility 1.0 0.000143348623853 0 1 -1
present,in 0.714285714286 0.000716743119266 1 6 -5
estrogen-containing,oral 0.0 0.0 1 1 0
its,enantiomer 1.0 0.000143348623853 0 1 -1
and,chronic 1.0 0.000143348623853 0 1 -1
lower,concentrations 1.0 0.000143348623853 0 1 -1
spleen,following 1.0 0.000143348623853 0 1 -1
p-450,enzymes 1.0 0.000143348623853 0 1 -1
concentrations,producing 1.0 0.000143348623853 0 1 -1
since,cholestyramine 1.0 0.000143348623853 0 1 -1
nafarelin,acetate 1.0 0.000143348623853 0 1 -1
therefore,or 1.0 0.000143348623853 1 0 1
monitoring,should 1.0 0.000143348623853 0 1 -1
the,rd 1.0 0.000143348623853 0 1 -1
inherent,in 1.0 0.000143348623853 1 0 1
can,form 1.0 0.000143348623853 1 0 1
receiving,diabinese 1.0 0.000573394495413 0 4 -4
main,non-infection 1.0 0.000143348623853 0 1 -1
and,memory 1.0 0.000143348623853 0 1 -1
of,low 0.666666666667 0.000573394495413 1 5 -4
sterilize,the 1.0 0.000143348623853 0 1 -1
from,plasma 0.0 0.0 1 1 0
by,cgs21680 1.0 0.000143348623853 1 0 1
clidinium,may 1.0 0.000143348623853 1 0 1
when,using 0.4 0.000573394495413 3 7 -4
when,suprax 1.0 0.000143348623853 1 0 1
lymphocytes,in 1.0 0.000143348623853 0 1 -1
reversing,resistance 1.0 0.000143348623853 0 1 -1
combined,oral 1.0 0.000143348623853 0 1 -1
in,total 0.0 0.0 1 1 0
uremic,patients 1.0 0.000143348623853 0 1 -1
these,components 1.0 0.000143348623853 0 1 -1
time,monitored 1.0 0.000143348623853 1 0 1
value,one 1.0 0.000143348623853 0 1 -1
intracellular,mobilization 1.0 0.000143348623853 0 1 -1
up,to 0.25 0.00114678899083 12 20 -8
formal,drug-interaction 1.0 0.000286697247706 0 2 -2
basal,and 1.0 0.000143348623853 0 1 -1
uptake-1,occurs 1.0 0.000143348623853 0 1 -1
patient,should 0.5 0.00200688073394 7 21 -14
nonetheless,since 0.0 0.0 1 1 0
and,differed 1.0 0.000143348623853 0 1 -1
caverject,the 1.0 0.000143348623853 0 1 -1
prozac,sporanox 1.0 0.000143348623853 0 1 -1
eldepryl,and 1.0 0.000143348623853 0 1 -1
dose,increases 1.0 0.000286697247706 0 2 -2
familial,hyper- 1.0 0.000143348623853 0 1 -1
thus,leading 1.0 0.000143348623853 1 0 1
tilade,has 1.0 0.000143348623853 0 1 -1
dose,increased 1.0 0.000143348623853 0 1 -1
of,arc 1.0 0.000143348623853 0 1 -1
or,calmodulin 1.0 0.000143348623853 0 1 -1
essential,the 1.0 0.000143348623853 0 1 -1
to,existing 1.0 0.000143348623853 0 1 -1
were,investigated 1.0 0.000573394495413 0 4 -4
as,clinistix 1.0 0.000716743119266 0 5 -5
test,dsst 1.0 0.000143348623853 1 0 1
cns,depression 0.0 0.0 3 3 0
electrocardiographic,qt 1.0 0.000286697247706 0 2 -2
requiring,an 1.0 0.000143348623853 1 0 1
hepatic,function 1.0 0.000143348623853 0 1 -1
ethoxzolamide,may 1.0 0.000143348623853 1 0 1
potentially,arise 1.0 0.000143348623853 1 0 1
of,major 1.0 0.000286697247706 2 0 2
retention,tend 1.0 0.000143348623853 0 1 -1
related,ethacrynic 1.0 0.000143348623853 0 1 -1
congener,is 1.0 0.000143348623853 0 1 -1
directed,to 1.0 0.000143348623853 1 0 1
curves,derived 1.0 0.000143348623853 1 0 1
allopurinol,the 1.0 0.000286697247706 2 0 2
catabolism,has 1.0 0.000143348623853 0 1 -1
pegasys,every 1.0 0.000143348623853 0 1 -1
in,cyp 1.0 0.000143348623853 1 0 1
drug,laboratory 0.966101694915 0.00817087155963 1 58 -57
its,activity 1.0 0.000286697247706 0 2 -2
intravenous,at 1.0 0.000143348623853 0 1 -1
thus,an 0.0 0.0 1 1 0
approximately,with 1.0 0.000143348623853 1 0 1
to,significant 0.333333333333 0.000143348623853 1 2 -1
noradrenaline-precontracted,arteries 1.0 0.000143348623853 0 1 -1
not,an 1.0 0.000573394495413 0 4 -4
not,at 0.0 0.0 1 1 0
weakness,hyperreflexia 0.6 0.00043004587156 4 1 3
and,hours 0.6 0.00043004587156 1 4 -3
artery,vasospasm 1.0 0.000143348623853 1 0 1
be,modified 0.333333333333 0.000143348623853 1 2 -1
stable,and 1.0 0.000143348623853 0 1 -1
was,washed 1.0 0.000143348623853 0 1 -1
machinery,or 1.0 0.000143348623853 0 1 -1
severe,in 1.0 0.000143348623853 0 1 -1
milk,at 1.0 0.000143348623853 0 1 -1
as,oral 1.0 0.000143348623853 0 1 -1
received,concomitant 1.0 0.00043004587156 0 3 -3
enzymes,and 0.6 0.00043004587156 1 4 -3
is,introduced 1.0 0.000143348623853 1 0 1
carefully,observed 0.0 0.0 1 1 0
or,changed 1.0 0.000143348623853 1 0 1
at,six 1.0 0.000143348623853 1 0 1
index,fici 1.0 0.000143348623853 0 1 -1
presented,of 1.0 0.000143348623853 0 1 -1
only,in 0.333333333333 0.000286697247706 2 4 -2
with,preparations 1.0 0.000286697247706 2 0 2
aucs,of 1.0 0.000143348623853 0 1 -1
short,sedation 1.0 0.000143348623853 0 1 -1
and,gastric 1.0 0.000143348623853 0 1 -1
studies,adjuvant 1.0 0.000143348623853 1 0 1
and,could 1.0 0.000143348623853 0 1 -1
blockers,concurrently 1.0 0.000143348623853 0 1 -1
use,caution 1.0 0.000143348623853 0 1 -1
avoid,the 0.5 0.000286697247706 3 1 2
the,highest 1.0 0.000573394495413 0 4 -4
challenged,with 1.0 0.000143348623853 0 1 -1
its,antidiuretic 1.0 0.000143348623853 0 1 -1
enteric,coating 0.333333333333 0.000143348623853 1 2 -1
was,potentiated 1.0 0.000143348623853 0 1 -1
ergamisol,levamisole 1.0 0.000143348623853 1 0 1
of,difluoro-2 0.0 0.0 1 1 0
relationship,with 1.0 0.000143348623853 1 0 1
prothrombin,test 1.0 0.000286697247706 0 2 -2
if,signs 1.0 0.000143348623853 1 0 1
possible,hypokalemic 1.0 0.000143348623853 1 0 1
reactions,have 0.2 0.000143348623853 2 3 -1
is,minimally 1.0 0.000143348623853 1 0 1
no,measurable 1.0 0.000143348623853 0 1 -1
spinal,cord 1.0 0.000143348623853 0 1 -1
starting,a 1.0 0.000143348623853 1 0 1
on,cyp450 1.0 0.000143348623853 0 1 -1
tarceva,with 1.0 0.000143348623853 1 0 1
an,increased 0.25 0.00143348623853 15 25 -10
prothrombin,and 1.0 0.00043004587156 0 3 -3
with,age-dependent 1.0 0.000143348623853 0 1 -1
now,available 1.0 0.000143348623853 0 1 -1
the,displacing 1.0 0.000143348623853 0 1 -1
tetracyclines,concomitant 1.0 0.000143348623853 1 0 1
n,received 1.0 0.000143348623853 0 1 -1
macrolide,azole 1.0 0.000143348623853 1 0 1
a,lack 1.0 0.000143348623853 0 1 -1
neutrophil,counts 0.0 0.0 1 1 0
of,schizophrenia 1.0 0.000286697247706 0 2 -2
of,schizophrenic 0.0 0.0 1 1 0
patients,with 0.531914893617 0.010751146789 33 108 -75
may,present 0.333333333333 0.000143348623853 2 1 1
persist,for 1.0 0.000143348623853 0 1 -1
brovana,doses 1.0 0.000143348623853 0 1 -1
were,concomitantly 0.0 0.0 2 2 0
electroconvulsive,therapy 1.0 0.000143348623853 0 1 -1
suggested,may 1.0 0.000143348623853 0 1 -1
g,kg 0.555555555556 0.000716743119266 2 7 -5
enterococci,vre 1.0 0.000143348623853 0 1 -1
with,hypertension 1.0 0.000143348623853 1 0 1
metabolite,formation 1.0 0.000143348623853 0 1 -1
of,dyspnea 1.0 0.000143348623853 0 1 -1
antagonise,the 1.0 0.000286697247706 0 2 -2
after,sudden 1.0 0.000143348623853 1 0 1
mechanism,and 0.333333333333 0.000143348623853 1 2 -1
with,all 0.2 0.000143348623853 2 3 -1
within,days 0.333333333333 0.000143348623853 2 1 1
chemotherapy,agents 1.0 0.000286697247706 0 2 -2
penetrates,both 1.0 0.000143348623853 0 1 -1
dose,until 1.0 0.000143348623853 1 0 1
presumably,because 1.0 0.000143348623853 1 0 1
of,lng 1.0 0.000143348623853 0 1 -1
labelling,of 1.0 0.000143348623853 0 1 -1
therefore,co-administration 1.0 0.000573394495413 4 0 4
indicated,they 1.0 0.000286697247706 0 2 -2
vitro,metabolism 1.0 0.000716743119266 0 5 -5
polyamines,might 1.0 0.000143348623853 0 1 -1
an,association 0.0 0.0 1 1 0
by,cercariae 1.0 0.000143348623853 0 1 -1
theoretical,basis 1.0 0.000286697247706 2 0 2
to,eliminate 1.0 0.000143348623853 1 0 1
increase,increase 1.0 0.000143348623853 0 1 -1
organometals,also 1.0 0.000143348623853 0 1 -1
stopping,concomitantly 1.0 0.000286697247706 0 2 -2
and,anaprox 1.0 0.000143348623853 0 1 -1
res,have 1.0 0.000143348623853 0 1 -1
since,foscavir 1.0 0.000143348623853 0 1 -1
using,tricor 1.0 0.000143348623853 1 0 1
motility,of 1.0 0.000143348623853 1 0 1
otherwise,healthy 0.6 0.00043004587156 1 4 -3
same,areas 1.0 0.000143348623853 0 1 -1
side-effect,profiles 1.0 0.000143348623853 0 1 -1
and,every 1.0 0.000143348623853 0 1 -1
been,explored 1.0 0.000143348623853 0 1 -1
glycosides,therapeutic 1.0 0.000143348623853 0 1 -1
injury,should 1.0 0.000143348623853 0 1 -1
the,immediate 0.0 0.0 1 1 0
sedation,with 1.0 0.000143348623853 0 1 -1
agents,for 0.0 0.0 1 1 0
theraputic,agents 1.0 0.000143348623853 0 1 -1
but,quickens 1.0 0.000143348623853 1 0 1
motility,agents 1.0 0.000143348623853 0 1 -1
respiratory,arrest 1.0 0.000143348623853 0 1 -1
involvement,labeling 1.0 0.000143348623853 0 1 -1
girdle,and 1.0 0.000143348623853 0 1 -1
related,may 1.0 0.000286697247706 2 0 2
a,broad 1.0 0.00043004587156 0 3 -3
avoid,impeding 0.0 0.0 2 2 0
after,a 0.2 0.00043004587156 9 6 3
within,class 1.0 0.000143348623853 0 1 -1
as,in 0.333333333333 0.000143348623853 1 2 -1
replacing,by 1.0 0.000143348623853 1 0 1
renal,disease 1.0 0.000143348623853 0 1 -1
after,h 1.0 0.000143348623853 0 1 -1
inhalations,than 1.0 0.000143348623853 0 1 -1
or,deletion 1.0 0.000143348623853 0 1 -1
the,prophylactic 1.0 0.000143348623853 1 0 1
gravis,inflammatory 1.0 0.000143348623853 1 0 1
stimulate,egf- 1.0 0.000143348623853 1 0 1
blood,is 1.0 0.000143348623853 1 0 1
apparatus,of 1.0 0.000143348623853 0 1 -1
grade,i 1.0 0.000143348623853 0 1 -1
blood,in 1.0 0.000143348623853 0 1 -1
nsaids,the 0.0 0.0 1 1 0
day,preferably 1.0 0.000143348623853 0 1 -1
misleading,information 1.0 0.000143348623853 0 1 -1
preparations,increases 1.0 0.000143348623853 0 1 -1
enzymes,including 1.0 0.000143348623853 0 1 -1
even,death 1.0 0.000143348623853 0 1 -1
malabsorption,of 1.0 0.000143348623853 1 0 1
sulfamethoxazole,concomitant 1.0 0.000143348623853 0 1 -1
anticipated,if 1.0 0.000143348623853 1 0 1
averaged,s 0.0 0.0 1 1 0
induction,and 1.0 0.000143348623853 1 0 1
one,gram 1.0 0.000143348623853 1 0 1
apparent,total 1.0 0.000143348623853 1 0 1
day,regimen 0.666666666667 0.000573394495413 5 1 4
complex,between 1.0 0.000143348623853 1 0 1
they,respond 1.0 0.000143348623853 0 1 -1
acute,angina 1.0 0.000143348623853 0 1 -1
costs,inpatient 1.0 0.000143348623853 0 1 -1
were,examined 1.0 0.000143348623853 0 1 -1
risk,in 1.0 0.000143348623853 1 0 1
drugs,administered 1.0 0.000143348623853 0 1 -1
ionized,species 1.0 0.000286697247706 2 0 2
latent,complications 1.0 0.000143348623853 0 1 -1
clearance,is 0.6 0.00043004587156 4 1 3
observation,is 0.0 0.0 1 1 0
inhibition,linezolid 1.0 0.000143348623853 0 1 -1
local,irritation 1.0 0.000143348623853 0 1 -1
or,milk 1.0 0.000143348623853 0 1 -1
clearance,in 0.5 0.000286697247706 3 1 2
both,chylomicron 1.0 0.000143348623853 0 1 -1
coombs,tests 1.0 0.00043004587156 0 3 -3
and,black 1.0 0.000143348623853 0 1 -1
and,occurred 0.0 0.0 1 1 0
john,s 0.75 0.000860091743119 1 7 -6
atrophy,and 1.0 0.000143348623853 0 1 -1
with,indocin 1.0 0.000143348623853 0 1 -1
with,which 0.2 0.000143348623853 2 3 -1
groups,receiving 1.0 0.000143348623853 1 0 1
category,x 1.0 0.000143348623853 0 1 -1
anagrelide,demonstrates 0.0 0.0 1 1 0
however,neither 1.0 0.000143348623853 0 1 -1
shown,to 0.307692307692 0.00229357798165 34 18 16
other,fruit 1.0 0.000143348623853 0 1 -1
administered,daily 1.0 0.000143348623853 0 1 -1
receptors,mc 1.0 0.000143348623853 0 1 -1
changing,the 1.0 0.000143348623853 1 0 1
of,endoscopic 1.0 0.000143348623853 0 1 -1
interferons,such 1.0 0.000143348623853 0 1 -1
symbol,copying 1.0 0.000143348623853 1 0 1
acute,episode 1.0 0.000143348623853 0 1 -1
may,impair 0.5 0.000573394495413 2 6 -4
of,great 1.0 0.000143348623853 0 1 -1
optimal,care 1.0 0.000143348623853 0 1 -1
in,metabolic 1.0 0.000143348623853 1 0 1
slight,intrinsic 1.0 0.000143348623853 1 0 1
injectable,transdermal 1.0 0.000286697247706 2 0 2
ortho-novum,increased 1.0 0.000143348623853 1 0 1
reported,cases 1.0 0.000143348623853 0 1 -1
one,ng 1.0 0.000143348623853 0 1 -1
chronic,weeks 1.0 0.000143348623853 0 1 -1
exposure,during 1.0 0.000143348623853 0 1 -1
advantage,when 1.0 0.000143348623853 0 1 -1
among,the 0.428571428571 0.00043004587156 2 5 -3
to,sinus 1.0 0.000143348623853 1 0 1
in,falsely 1.0 0.000143348623853 0 1 -1
eg,would 1.0 0.000143348623853 1 0 1
amprenavir,and 1.0 0.00043004587156 3 0 3
agent,which 1.0 0.000143348623853 0 1 -1
therefore,interactions 1.0 0.000286697247706 0 2 -2
traditional,agents 1.0 0.000143348623853 0 1 -1
the,efficacy 0.0909090909091 0.000143348623853 6 5 1
videx,with 1.0 0.000143348623853 0 1 -1
intestinal,permeation 1.0 0.000286697247706 0 2 -2
absorption,or 1.0 0.00043004587156 0 3 -3
n,with 1.0 0.000143348623853 0 1 -1
much,statistical 1.0 0.000143348623853 0 1 -1
in,three 1.0 0.00043004587156 0 3 -3
effects,are 0.0 0.0 2 2 0
adenosine,dipyridamole 1.0 0.000143348623853 1 0 1
camptosar,with 1.0 0.000143348623853 0 1 -1
bear,directly 1.0 0.000143348623853 1 0 1
dipivoxil,or 1.0 0.000143348623853 0 1 -1
male,and 0.5 0.000286697247706 1 3 -2
further,data 1.0 0.000286697247706 0 2 -2
a,prolongation 0.0 0.0 3 3 0
an,eight-fold 1.0 0.000286697247706 2 0 2
in,thyroxine 1.0 0.000143348623853 0 1 -1
a,were 1.0 0.000143348623853 0 1 -1
to,in-creased 1.0 0.000143348623853 0 1 -1
nonketotic,genetically 1.0 0.000143348623853 0 1 -1
be,detrimental 1.0 0.000143348623853 0 1 -1
factors,is 1.0 0.000143348623853 0 1 -1
a,nonsteroidal 0.0 0.0 1 1 0
although,may 1.0 0.000143348623853 1 0 1
therapy,free 1.0 0.000143348623853 1 0 1
which,affect 1.0 0.000143348623853 0 1 -1
taken,and 1.0 0.000143348623853 1 0 1
and,butyrophenone 1.0 0.000143348623853 1 0 1
high,viral 1.0 0.000143348623853 0 1 -1
essentially,no 1.0 0.000143348623853 0 1 -1
cancidas,mg 1.0 0.000143348623853 1 0 1
which,erbitux 1.0 0.000143348623853 0 1 -1
therapies,including 1.0 0.000143348623853 0 1 -1
also,receiving 1.0 0.000286697247706 0 2 -2
medicines,or 1.0 0.000286697247706 2 0 2
causing,renin 1.0 0.000286697247706 2 0 2
control,blood 0.0 0.0 1 1 0
other,chemotherapy 1.0 0.000143348623853 0 1 -1
for,altering 1.0 0.000286697247706 0 2 -2
phosphorylated,which 1.0 0.000143348623853 1 0 1
ester,fractional 1.0 0.000143348623853 0 1 -1
interaction,information 1.0 0.000143348623853 0 1 -1
affects,expression 1.0 0.000143348623853 0 1 -1
whereas,in 1.0 0.000286697247706 0 2 -2
complex,renal 1.0 0.000143348623853 0 1 -1
is,augmented 0.333333333333 0.000143348623853 2 1 1
on,bone 1.0 0.000286697247706 0 2 -2
with,sprycel 0.5 0.000286697247706 1 3 -2
effects,noted 1.0 0.000143348623853 0 1 -1
acid,decrease 1.0 0.000143348623853 1 0 1
other,dialysis 1.0 0.000143348623853 0 1 -1
observed,on 1.0 0.000143348623853 1 0 1
area,bsa 1.0 0.000286697247706 0 2 -2
coadministered,for 1.0 0.000143348623853 0 1 -1
contraceptive,based 1.0 0.000143348623853 0 1 -1
not,particularly 1.0 0.000143348623853 0 1 -1
briefly,reduced 1.0 0.000143348623853 0 1 -1
increase,blood 0.2 0.000143348623853 2 3 -1
the,regulation 1.0 0.000286697247706 0 2 -2
steady-state,auc 1.0 0.000573394495413 4 0 4
diclofenac,administration 1.0 0.000143348623853 0 1 -1
stimulation,and 1.0 0.000143348623853 0 1 -1
levsin,is 1.0 0.000143348623853 1 0 1
the,elevation 0.0 0.0 1 1 0
was,reached 1.0 0.000143348623853 0 1 -1
given,intraluminally 1.0 0.000143348623853 0 1 -1
group,were 1.0 0.000143348623853 1 0 1
amenorrhea,the 1.0 0.000143348623853 0 1 -1
with,copper 1.0 0.00043004587156 0 3 -3
of,gene 1.0 0.000143348623853 0 1 -1
during,adjunctive 1.0 0.000143348623853 1 0 1
gradually,decreasing 1.0 0.000143348623853 0 1 -1
sucralfate,metal 1.0 0.000143348623853 0 1 -1
with,altered 0.0 0.0 1 1 0
function,will 1.0 0.000143348623853 0 1 -1
by,auc0-24hr 0.0 0.0 1 1 0
of,microsomal 0.0 0.0 1 1 0
not,correlate 1.0 0.000143348623853 0 1 -1
models,based 1.0 0.000143348623853 0 1 -1
agenerase,crixivan 1.0 0.000143348623853 1 0 1
whose,absorption 0.0 0.0 1 1 0
excluded,based 1.0 0.000143348623853 0 1 -1
neuromuscular,blockade 0.0 0.0 3 3 0
to,mac 1.0 0.000143348623853 0 1 -1
care,professionals 1.0 0.000143348623853 0 1 -1
facultative,and 1.0 0.000143348623853 0 1 -1
following,subcutaneous 1.0 0.000143348623853 0 1 -1
to,two 1.0 0.000286697247706 2 0 2
kg,days 1.0 0.000286697247706 0 2 -2
of,skin 0.333333333333 0.000143348623853 1 2 -1
phenytoin,phenobarbital 0.333333333333 0.000143348623853 2 1 1
to,increase 0.391304347826 0.00258027522936 32 14 18
to,may 0.0 0.0 1 1 0
in,ovarian 1.0 0.000143348623853 1 0 1
effect,with 0.6 0.00043004587156 4 1 3
erythromycin,has 1.0 0.00043004587156 3 0 3
be,checked 1.0 0.000143348623853 1 0 1
aeruginosa,particularly 1.0 0.000143348623853 0 1 -1
no,causal 1.0 0.000143348623853 0 1 -1
the,gastrointestinal 0.333333333333 0.00043004587156 6 3 3
auc,cmax 0.333333333333 0.000143348623853 2 1 1
antacids,aluminum- 1.0 0.000143348623853 1 0 1
maximum,relaxation 1.0 0.000143348623853 0 1 -1
methods,hydrocortisone 1.0 0.000143348623853 0 1 -1
glucose,should 1.0 0.000143348623853 1 0 1
hydrocodone,coadministration 1.0 0.000143348623853 0 1 -1
mg,starlix 1.0 0.000143348623853 0 1 -1
cyp2d6,and 0.5 0.000286697247706 1 3 -2
required,except 1.0 0.000143348623853 0 1 -1
crossover,study 0.0 0.0 3 3 0
th,and 1.0 0.000286697247706 0 2 -2
section,as 1.0 0.000143348623853 0 1 -1
methods,such 1.0 0.000143348623853 0 1 -1
reactions,thought 1.0 0.000143348623853 0 1 -1
defect,is 1.0 0.000143348623853 0 1 -1
they,might 1.0 0.000143348623853 1 0 1
than,patients 1.0 0.000143348623853 0 1 -1
when,dosing 1.0 0.000143348623853 0 1 -1
inhibiting,may 1.0 0.000143348623853 1 0 1
progestational,such 1.0 0.000143348623853 0 1 -1
anion,exchange 1.0 0.000143348623853 0 1 -1
adults,to 1.0 0.000143348623853 0 1 -1
following,initiation 1.0 0.000286697247706 2 0 2
interaction,may 0.666666666667 0.000573394495413 1 5 -4
plasticity,triggered 1.0 0.000143348623853 0 1 -1
a,molecular 1.0 0.000143348623853 1 0 1
acamprosate,does 1.0 0.000143348623853 0 1 -1
clearance,with 0.0 0.0 1 1 0
broad-spectrum,antibiotics-broad 1.0 0.000143348623853 0 1 -1
also,significantly 1.0 0.000143348623853 1 0 1
the,two 0.333333333333 0.00100344036697 7 14 -7
prednisolone,sodium 1.0 0.000143348623853 0 1 -1
mammary,gland 1.0 0.000286697247706 0 2 -2
outcome,of 1.0 0.000143348623853 0 1 -1
variability,component 1.0 0.000143348623853 1 0 1
polymer,conjugates 1.0 0.000143348623853 0 1 -1
whether,is 1.0 0.000143348623853 0 1 -1
these,inhibiting 1.0 0.000716743119266 0 5 -5
the,pelvic 1.0 0.000143348623853 0 1 -1
antidotal,properties 1.0 0.000143348623853 1 0 1
structural,heart 1.0 0.000286697247706 0 2 -2
medications,they 1.0 0.000143348623853 0 1 -1
information,processing 1.0 0.000143348623853 0 1 -1
periodically,in 1.0 0.000143348623853 0 1 -1
urobilin,due 1.0 0.000143348623853 0 1 -1
that,tam 1.0 0.000143348623853 1 0 1
biotransformation,of 1.0 0.000143348623853 0 1 -1
potentially,alter 1.0 0.000143348623853 0 1 -1
high,trileptal 1.0 0.000143348623853 1 0 1
seventeen,percent 1.0 0.000143348623853 0 1 -1
for,anaphylactic 1.0 0.000143348623853 0 1 -1
action,by 0.0 0.0 1 1 0
abolished,both 1.0 0.000143348623853 0 1 -1
with,neurons 1.0 0.000143348623853 0 1 -1
from,patients 1.0 0.000716743119266 0 5 -5
nine,otherwise 1.0 0.000143348623853 0 1 -1
other,progestational 1.0 0.000286697247706 0 2 -2
their,combined 1.0 0.000286697247706 2 0 2
and,range 1.0 0.000143348623853 1 0 1
miracidia,are 1.0 0.000143348623853 0 1 -1
cardiac,abnormalities 1.0 0.000143348623853 1 0 1
minimizes,this 1.0 0.000143348623853 1 0 1
female,have 1.0 0.000143348623853 0 1 -1
induce,metabolism 1.0 0.000143348623853 1 0 1
from,those 1.0 0.000143348623853 0 1 -1
focus,on 1.0 0.000286697247706 0 2 -2
salts,medicine 1.0 0.000143348623853 0 1 -1
approximately,mean 1.0 0.000143348623853 1 0 1
vitro,study 0.0 0.0 1 1 0
with,clinitest 1.0 0.000573394495413 0 4 -4
the,higher 0.5 0.000286697247706 1 3 -2
metal,concentration 1.0 0.000143348623853 0 1 -1
of,concomitant 0.44 0.00157683486239 7 18 -11
patients,following 1.0 0.000143348623853 0 1 -1
the,united 0.6 0.00043004587156 1 4 -3
can,not 1.0 0.000143348623853 1 0 1
likely,will 1.0 0.000143348623853 1 0 1
used,while 1.0 0.000143348623853 0 1 -1
a6,b6 1.0 0.000143348623853 0 1 -1
clonazepam,would 1.0 0.000143348623853 0 1 -1
with,fentanyl 1.0 0.000143348623853 0 1 -1
if,such 1.0 0.00114678899083 0 8 -8
nephrotoxic,myelotoxic 1.0 0.000143348623853 1 0 1
comparisons,to 1.0 0.000143348623853 0 1 -1
administered,within 1.0 0.000143348623853 1 0 1
these,small 1.0 0.000143348623853 0 1 -1
p-glycoprotein,substrate 1.0 0.000143348623853 1 0 1
if,renal 1.0 0.000143348623853 0 1 -1
of,prolonged 1.0 0.00043004587156 3 0 3
gastric,acid 0.0 0.0 1 1 0
shown,on 1.0 0.000286697247706 0 2 -2
preanesthetic,and 1.0 0.000143348623853 0 1 -1
cardiovasculars,cardiac 1.0 0.000143348623853 0 1 -1
competing,memory 1.0 0.000143348623853 0 1 -1
subnormal,release 1.0 0.000143348623853 0 1 -1
cardiac,capacity 1.0 0.000143348623853 0 1 -1
indinavir,is 1.0 0.000286697247706 0 2 -2
of,infections 1.0 0.000286697247706 0 2 -2
the,herbal 1.0 0.000143348623853 0 1 -1
however,are 1.0 0.000143348623853 0 1 -1
times,maximum 1.0 0.000143348623853 0 1 -1
pharmacokinetic,profile 0.333333333333 0.000143348623853 2 1 1
thus,careful 1.0 0.000143348623853 1 0 1
lower,when 1.0 0.000143348623853 1 0 1
nausea,vomiting 1.0 0.000143348623853 0 1 -1
ed50,of 1.0 0.000143348623853 1 0 1
without,evidence 1.0 0.00129013761468 0 9 -9
greater,antitumour 1.0 0.000143348623853 0 1 -1
cardiac,h2 1.0 0.000143348623853 0 1 -1
obtained,after 1.0 0.000143348623853 1 0 1
cyp,isoenzymes 1.0 0.000286697247706 0 2 -2
cyp,isoforms 1.0 0.000286697247706 0 2 -2
igm,can 1.0 0.000143348623853 0 1 -1
as,and 0.297297297297 0.00157683486239 24 13 11
last,two 1.0 0.000143348623853 0 1 -1
possible,effects 1.0 0.000286697247706 0 2 -2
auc,were 1.0 0.00043004587156 0 3 -3
and,micromol 1.0 0.000143348623853 0 1 -1
cyp3a,may 1.0 0.000286697247706 0 2 -2
included,into 1.0 0.000143348623853 0 1 -1
any,prescription 1.0 0.000143348623853 0 1 -1
kg,hours 1.0 0.000143348623853 1 0 1
require,exogenous 1.0 0.000143348623853 0 1 -1
concurrently,with 0.0454545454545 0.000286697247706 21 23 -2
enoxaparin,dosed 1.0 0.000143348623853 0 1 -1
mg,kg 0.493670886076 0.00559059633028 20 59 -39
x,l 1.0 0.000143348623853 0 1 -1
toxicity,study 1.0 0.000143348623853 0 1 -1
a,helpful 1.0 0.000143348623853 0 1 -1
busulfex,may 1.0 0.000143348623853 1 0 1
profile,of 0.75 0.000860091743119 1 7 -6
vitro,may 1.0 0.000143348623853 1 0 1
pancreatic,release 1.0 0.000143348623853 0 1 -1
half-life,or 1.0 0.000143348623853 1 0 1
reexacerbation,of 1.0 0.000143348623853 1 0 1
samples,also 1.0 0.000143348623853 0 1 -1
trials,however 1.0 0.000143348623853 0 1 -1
profile,or 1.0 0.000143348623853 0 1 -1
in,glycemia 1.0 0.000143348623853 0 1 -1
other,vasoconstrictor 1.0 0.000143348623853 1 0 1
half-life,of 0.0588235294118 0.000143348623853 9 8 1
cyp3a4,isoform 1.0 0.000143348623853 0 1 -1
high,fever 1.0 0.000143348623853 1 0 1
pyrocarbonate,could 1.0 0.000143348623853 0 1 -1
therefore,serum 1.0 0.000573394495413 0 4 -4
digoxin,studies 1.0 0.000286697247706 0 2 -2
of,day-old 1.0 0.000143348623853 1 0 1
not,report 1.0 0.000143348623853 0 1 -1
about,of 1.0 0.000716743119266 0 5 -5
mrna,level 1.0 0.000143348623853 1 0 1
diuretic,natriuretic 1.0 0.000143348623853 1 0 1
controlled,with 1.0 0.000143348623853 1 0 1
however,increasing 1.0 0.000143348623853 0 1 -1
or,more 0.428571428571 0.000860091743119 4 10 -6
as,monotherapy 1.0 0.000143348623853 0 1 -1
underway,to 1.0 0.000143348623853 0 1 -1
with,cns 1.0 0.000286697247706 2 0 2
on,dogs 1.0 0.000143348623853 0 1 -1
radio-iodine,uptake 1.0 0.000143348623853 0 1 -1
inhibitors,simvastatin 1.0 0.000143348623853 0 1 -1
work,exists 1.0 0.000143348623853 0 1 -1
specific,substrates 1.0 0.000143348623853 0 1 -1
coadministered,prescribers 1.0 0.000143348623853 0 1 -1
to,any 0.5 0.000286697247706 1 3 -2
anafranil,with 1.0 0.000143348623853 0 1 -1
infant,formula 1.0 0.000143348623853 0 1 -1
anti-apoptotic,effect 1.0 0.000143348623853 0 1 -1
embryocidal,effects 1.0 0.000143348623853 0 1 -1
elements,only 1.0 0.000143348623853 0 1 -1
from,urine 1.0 0.000143348623853 0 1 -1
enzymes,such 0.333333333333 0.000143348623853 1 2 -1
is,thus 0.333333333333 0.000143348623853 1 2 -1
studies,used 1.0 0.000143348623853 0 1 -1
lethargy,and 1.0 0.000286697247706 2 0 2
hyperpolarization,and 1.0 0.000143348623853 0 1 -1
certain,cyp450 1.0 0.000143348623853 0 1 -1
cyp,inducers 1.0 0.000143348623853 1 0 1
and,agonists 1.0 0.000143348623853 0 1 -1
of,effective 1.0 0.000143348623853 0 1 -1
done,with 1.0 0.000286697247706 0 2 -2
to,min 1.0 0.000143348623853 0 1 -1
diffusible,treatment 1.0 0.000143348623853 0 1 -1
and,individual 1.0 0.000143348623853 1 0 1
hormonal,including 1.0 0.000143348623853 1 0 1
oral,platelet 1.0 0.000143348623853 0 1 -1
volunteers,no 1.0 0.000286697247706 0 2 -2
hydrochloride,concomitantly 0.0 0.0 1 1 0
vasoconstrictor,can 1.0 0.000143348623853 1 0 1
corrective,measures 1.0 0.000286697247706 0 2 -2
antithrombotics,aspirin 1.0 0.000143348623853 0 1 -1
before,being 1.0 0.000143348623853 0 1 -1
probenecid,interferes 1.0 0.000143348623853 1 0 1
statistical,significance 1.0 0.000143348623853 0 1 -1
isolates,synergy 1.0 0.000143348623853 0 1 -1
tumor,and 1.0 0.000143348623853 0 1 -1
insp,induced 0.0 0.0 1 1 0
amounts,of 1.0 0.000286697247706 0 2 -2
steady-state,concentrations 0.0 0.0 1 1 0
analyte,is 1.0 0.000143348623853 0 1 -1
furosemide,in 1.0 0.000143348623853 0 1 -1
and,evening 1.0 0.000143348623853 0 1 -1
acid,were 1.0 0.000286697247706 0 2 -2
discontinue,nursing 1.0 0.00043004587156 0 3 -3
properties,may 1.0 0.000286697247706 2 0 2
pipette,yielded 1.0 0.000143348623853 0 1 -1
measured,four 1.0 0.000143348623853 0 1 -1
cells,was 1.0 0.000286697247706 0 2 -2
all,strains 1.0 0.000286697247706 0 2 -2
activity,was 1.0 0.000573394495413 0 4 -4
wear,off 1.0 0.000143348623853 0 1 -1
harm,to 1.0 0.000143348623853 0 1 -1
aortic,rings 0.0 0.0 2 2 0
stopped,without 1.0 0.000143348623853 0 1 -1
drugs,tend 1.0 0.000143348623853 0 1 -1
evaluated,but 1.0 0.00043004587156 3 0 3
morbidity,and 1.0 0.000143348623853 0 1 -1
mouth,and 0.333333333333 0.000143348623853 2 1 1
greatest,value 1.0 0.000143348623853 0 1 -1
skin,reactions 1.0 0.000286697247706 0 2 -2
effectiveness,when 1.0 0.000143348623853 0 1 -1
well,defined 1.0 0.000143348623853 0 1 -1
and,function 1.0 0.000143348623853 0 1 -1
conduction,disturbance 1.0 0.000143348623853 1 0 1
auc,and 0.157894736842 0.000860091743119 22 16 6
gastrointestinal,ph 1.0 0.000143348623853 0 1 -1
contrast,nucleophosmin 1.0 0.000143348623853 0 1 -1
n,are 1.0 0.000143348623853 0 1 -1
c,diethyl 1.0 0.000143348623853 0 1 -1
similar,association 1.0 0.000286697247706 0 2 -2
are,analgesic 1.0 0.000143348623853 0 1 -1
methotrexate-related,toxicity 1.0 0.000286697247706 2 0 2
three,agents 1.0 0.000143348623853 0 1 -1
physicians,are 0.333333333333 0.000143348623853 2 1 1
cardiac,two 1.0 0.000143348623853 0 1 -1
clonazepam,on 1.0 0.000143348623853 0 1 -1
if,higher 1.0 0.000143348623853 0 1 -1
reactions,to 0.333333333333 0.000286697247706 2 4 -2
oz,has 1.0 0.000143348623853 0 1 -1
and,zdv 1.0 0.000143348623853 0 1 -1
nelfinavir,is 1.0 0.000286697247706 0 2 -2
a,substrates 1.0 0.000143348623853 0 1 -1
from,april 1.0 0.000143348623853 0 1 -1
supine,systolic 1.0 0.000143348623853 1 0 1
depth,of 0.0 0.0 1 1 0
understandable,because 1.0 0.000143348623853 0 1 -1
given,fu 1.0 0.000143348623853 0 1 -1
complication,of 1.0 0.000143348623853 0 1 -1
without,any 1.0 0.00043004587156 0 3 -3
oral,overload 1.0 0.000143348623853 0 1 -1
natriuretic,and 1.0 0.00114678899083 8 0 8
potential,inhibitor 1.0 0.000143348623853 1 0 1
ketorolac,is 1.0 0.000143348623853 0 1 -1
cef-120,or 1.0 0.000143348623853 0 1 -1
without,and 1.0 0.000286697247706 0 2 -2
question,of 1.0 0.000143348623853 0 1 -1
general,significant 1.0 0.000143348623853 0 1 -1
half-life,was 1.0 0.000143348623853 0 1 -1
and,preparations 1.0 0.000143348623853 1 0 1
life-threatening,interactions 1.0 0.000143348623853 1 0 1
be,introduced 1.0 0.000143348623853 1 0 1
chronic,hepatitis 1.0 0.000143348623853 0 1 -1
the,cell 1.0 0.000143348623853 0 1 -1
because,plasma 1.0 0.000143348623853 1 0 1
exposure,approximately 1.0 0.000143348623853 0 1 -1
d,by 1.0 0.00043004587156 3 0 3
anticoagulents,may 1.0 0.000143348623853 0 1 -1
compounds,metabolized 1.0 0.000143348623853 0 1 -1
another,and 1.0 0.000143348623853 1 0 1
two,hundred 1.0 0.000143348623853 0 1 -1
dysfunction,associated 1.0 0.000143348623853 0 1 -1
conclusions,sildenafil 1.0 0.000143348623853 0 1 -1
increase,their 0.0 0.0 2 2 0
factor,synthesis 1.0 0.000143348623853 0 1 -1
admini,stered 1.0 0.000143348623853 1 0 1
with,central 0.5 0.000286697247706 3 1 2
inhibitors,maoi 1.0 0.000573394495413 4 0 4
remicade,used 1.0 0.000143348623853 1 0 1
or,side 1.0 0.000143348623853 0 1 -1
as,increasing 1.0 0.000143348623853 0 1 -1
population,plasma 1.0 0.000143348623853 0 1 -1
on,insp 1.0 0.000143348623853 0 1 -1
these,facts 1.0 0.000143348623853 0 1 -1
laboratory,test 0.964285714286 0.00774082568807 1 55 -54
brovana,at 1.0 0.000143348623853 0 1 -1
capable,of 0.5 0.000286697247706 1 3 -2
pulmonary,or 1.0 0.000143348623853 0 1 -1
brovana,as 1.0 0.000143348623853 1 0 1
induce,an 1.0 0.000143348623853 0 1 -1
studies,when 1.0 0.000143348623853 0 1 -1
germinal,centers 1.0 0.000143348623853 0 1 -1
relation,with 1.0 0.000143348623853 0 1 -1
on,stable 1.0 0.000286697247706 0 2 -2
disease,is 1.0 0.000573394495413 0 4 -4
assay,methods 1.0 0.000143348623853 0 1 -1
arc,activity-regulated 1.0 0.000143348623853 0 1 -1
skills,or 1.0 0.000143348623853 0 1 -1
was,decreased 0.0909090909091 0.000143348623853 5 6 -1
disease,in 1.0 0.000573394495413 0 4 -4
from,existing 1.0 0.000143348623853 0 1 -1
cyp2c8,c9 1.0 0.000143348623853 0 1 -1
therapy,administration 1.0 0.000143348623853 0 1 -1
by,agents 1.0 0.000143348623853 0 1 -1
sudden,increase 1.0 0.000143348623853 1 0 1
taking,tysabri 1.0 0.000143348623853 0 1 -1
antimicrobial,activity 1.0 0.00043004587156 0 3 -3
sandimmune--on,hepatic 1.0 0.000143348623853 0 1 -1
biocytin,in 1.0 0.000143348623853 0 1 -1
videx,chewable 1.0 0.000860091743119 6 0 6
available,regarding 1.0 0.000286697247706 0 2 -2
cream,cream 1.0 0.000143348623853 0 1 -1
the,may 0.0909090909091 0.000143348623853 6 5 1
weighted,least 1.0 0.000143348623853 0 1 -1
one,with 1.0 0.000143348623853 0 1 -1
changes,northern 1.0 0.000143348623853 0 1 -1
the,mao 1.0 0.000143348623853 1 0 1
medial,survival 1.0 0.000143348623853 0 1 -1
a,cns 1.0 0.000143348623853 0 1 -1
lapatinib,undergoes 1.0 0.000143348623853 0 1 -1
interactions,alteration 1.0 0.000286697247706 0 2 -2
increase,susceptibility 1.0 0.000143348623853 0 1 -1
thyroid,products 1.0 0.000143348623853 0 1 -1
last,intravenous 1.0 0.000143348623853 1 0 1
d6,in 1.0 0.000143348623853 0 1 -1
pegasys,has 1.0 0.000286697247706 0 2 -2
considered,particularly 1.0 0.000286697247706 0 2 -2
until,specific 1.0 0.000143348623853 0 1 -1
a,massive 1.0 0.000143348623853 0 1 -1
aspirin-mediated,inhibition 1.0 0.000143348623853 0 1 -1
labeling,of 1.0 0.000143348623853 0 1 -1
for,preservation 1.0 0.000143348623853 0 1 -1
other,folic 1.0 0.000143348623853 1 0 1
possible,and 1.0 0.000143348623853 1 0 1
medications,motion 1.0 0.000143348623853 0 1 -1
transferase,enzyme 1.0 0.000143348623853 0 1 -1
lipitor,atromid-s 1.0 0.000143348623853 1 0 1
q12h,for 0.0 0.0 1 1 0
more,importantly 1.0 0.000143348623853 0 1 -1
thus,patients 0.0 0.0 1 1 0
dryness,of 0.0 0.0 1 1 0
potentially,associated 1.0 0.000143348623853 1 0 1
conjugation,at 1.0 0.000286697247706 0 2 -2
in,lipid 1.0 0.000143348623853 1 0 1
enzyme,supplements 1.0 0.000143348623853 0 1 -1
amiodarone,should 1.0 0.000143348623853 0 1 -1
proposed,by 1.0 0.000143348623853 0 1 -1
potent,inducer 0.2 0.000143348623853 3 2 1
least,minutes 0.333333333333 0.000143348623853 2 1 1
metabolite,and 1.0 0.000143348623853 0 1 -1
therapy,particularly 1.0 0.000143348623853 0 1 -1
and,adjustment 1.0 0.000716743119266 5 0 5
the,initiated 1.0 0.000143348623853 0 1 -1
is,co-administered 0.5 0.000573394495413 6 2 4
mice,selectively 1.0 0.000143348623853 0 1 -1
have,examined 1.0 0.000143348623853 0 1 -1
ethanolysis,reaction 1.0 0.000143348623853 1 0 1
dosing,of 0.0 0.0 3 3 0
without,coadministered 1.0 0.000143348623853 0 1 -1
that,experience 1.0 0.000143348623853 0 1 -1
conducted,for 1.0 0.000286697247706 0 2 -2
prevent,or 1.0 0.000143348623853 0 1 -1
of,femara 0.333333333333 0.000143348623853 1 2 -1
dosing,caution 1.0 0.000143348623853 1 0 1
cmin,are 1.0 0.000143348623853 0 1 -1
dosing,or 1.0 0.000143348623853 0 1 -1
circulating,active 1.0 0.000143348623853 0 1 -1
we,incorporate 1.0 0.000143348623853 0 1 -1
caspofungin,acetate 1.0 0.000143348623853 0 1 -1
human,in 0.0 0.0 1 1 0
but,statistically 1.0 0.000143348623853 1 0 1
day,groups 1.0 0.000143348623853 1 0 1
full,dose 1.0 0.000143348623853 0 1 -1
b,this 1.0 0.000143348623853 0 1 -1
a,selective 0.0 0.0 1 1 0
ph,may 1.0 0.00043004587156 0 3 -3
exemestane,is 1.0 0.000143348623853 0 1 -1
after,their 1.0 0.000143348623853 0 1 -1
coagulation,have 1.0 0.000143348623853 1 0 1
or,pcp 0.333333333333 0.000143348623853 2 1 1
adjusted,upward 1.0 0.000143348623853 1 0 1
daily,inhalation 0.333333333333 0.000143348623853 1 2 -1
principal,given 1.0 0.000143348623853 0 1 -1
via,organic 1.0 0.000143348623853 1 0 1
taking,another 0.5 0.000286697247706 1 3 -2
the,end 1.0 0.00043004587156 0 3 -3
with,various 0.0 0.0 1 1 0
no,human 1.0 0.000286697247706 0 2 -2
taking,acarbose 0.0 0.0 1 1 0
creams,lotions 1.0 0.000143348623853 0 1 -1
of,congestive 1.0 0.000143348623853 1 0 1
particular,a2 1.0 0.000143348623853 0 1 -1
hyperthermia,rigidity 1.0 0.000143348623853 1 0 1
a,six-day 1.0 0.000143348623853 1 0 1
world,health 1.0 0.000143348623853 0 1 -1
betaseron,administration 1.0 0.000143348623853 1 0 1
measured,from 1.0 0.000143348623853 0 1 -1
dip-stick,methodology 1.0 0.000143348623853 0 1 -1
starlix,and 1.0 0.000286697247706 2 0 2
higher,proportion 1.0 0.000143348623853 0 1 -1
is,catalyzed 1.0 0.000573394495413 0 4 -4
usually,observed 1.0 0.000143348623853 0 1 -1
blood,pressure 0.025641025641 0.000143348623853 20 19 1
thus,should 1.0 0.000286697247706 2 0 2
compared,with 0.44 0.00157683486239 7 18 -11
with,complex 1.0 0.000143348623853 0 1 -1
caution,when 1.0 0.000286697247706 0 2 -2
this,neurotoxic 1.0 0.000143348623853 1 0 1
its,capacity 0.0 0.0 1 1 0
marked,reductions 1.0 0.000143348623853 0 1 -1
that,result 1.0 0.000286697247706 0 2 -2
are,applicable 1.0 0.000143348623853 0 1 -1
stabilized,on 0.0 0.0 3 3 0
week,controlled 1.0 0.000143348623853 0 1 -1
increased,with 0.2 0.000143348623853 2 3 -1
patients,taking 0.176470588235 0.00172018348624 40 28 12
drinking,during 1.0 0.000143348623853 1 0 1
a,guide 1.0 0.000143348623853 1 0 1
and,minutes 1.0 0.000143348623853 0 1 -1
hyperreflexia,and 0.6 0.00043004587156 4 1 3
drugs,sporadic 1.0 0.000143348623853 1 0 1
and,presumably 1.0 0.000143348623853 0 1 -1
any,route 1.0 0.000143348623853 1 0 1
or,unusual 1.0 0.000143348623853 0 1 -1
events,when 1.0 0.000286697247706 0 2 -2
clarithromycin,telithromycin 1.0 0.000143348623853 0 1 -1
levodopa,and 1.0 0.000143348623853 1 0 1
measures,included 1.0 0.000143348623853 0 1 -1
significant,respiratory 1.0 0.000143348623853 1 0 1
a,tablet 1.0 0.000286697247706 2 0 2
functions,transcription 1.0 0.000143348623853 0 1 -1
arava,with 1.0 0.000143348623853 1 0 1
reduced,tysabri 1.0 0.000143348623853 1 0 1
food,has 1.0 0.000143348623853 0 1 -1
antagonist,class 1.0 0.000143348623853 1 0 1
protein,binding 0.368421052632 0.00100344036697 6 13 -7
control,supraventricular 1.0 0.000143348623853 1 0 1
was,partially 1.0 0.000143348623853 1 0 1
eight,hiv-infected 0.0 0.0 1 1 0
the,compatibility 1.0 0.000143348623853 0 1 -1
present,whether 1.0 0.000143348623853 0 1 -1
morning,dose 1.0 0.000286697247706 0 2 -2
potassium,levels 0.333333333333 0.000143348623853 1 2 -1
gland,has 1.0 0.000143348623853 0 1 -1
d6,they 1.0 0.000716743119266 0 5 -5
methylpyrazole,seen 1.0 0.000143348623853 1 0 1
reduced,accordingly 1.0 0.000143348623853 1 0 1
the,involvement 0.0 0.0 1 1 0
juices,fruit 1.0 0.000143348623853 0 1 -1
everolimus,steady 1.0 0.000143348623853 0 1 -1
are,reported 0.333333333333 0.000143348623853 2 1 1
patients,concurrently 0.333333333333 0.000143348623853 1 2 -1
by,inhibiting 1.0 0.000573394495413 4 0 4
from,bovine 1.0 0.000143348623853 0 1 -1
study,to 1.0 0.000286697247706 0 2 -2
or,verapamil 1.0 0.000143348623853 1 0 1
stimulants,and 1.0 0.000143348623853 1 0 1
nevertheless,plasma 1.0 0.000143348623853 0 1 -1
its,affinity 1.0 0.00043004587156 0 3 -3
reactions,dyspnea 1.0 0.000143348623853 0 1 -1
to,discriminate 1.0 0.000143348623853 0 1 -1
electrolyte,abnormalities 1.0 0.000143348623853 1 0 1
may,remain 1.0 0.000143348623853 0 1 -1
age-dependent,alterations 1.0 0.000143348623853 0 1 -1
microsomes,inhibition 1.0 0.000143348623853 1 0 1
iiia4,inhibitor 1.0 0.000143348623853 1 0 1
of,fe 0.0 0.0 1 1 0
vitro,effect 1.0 0.000143348623853 0 1 -1
digoxin,the 1.0 0.000143348623853 0 1 -1
including,complete 1.0 0.000143348623853 0 1 -1
and,agents 0.5 0.000573394495413 6 2 4
vardenafil,with 0.333333333333 0.000143348623853 2 1 1
weeks,in 0.0 0.0 1 1 0
subjects,the 0.333333333333 0.000143348623853 1 2 -1
attacks,during 1.0 0.000143348623853 0 1 -1
or,logistic 1.0 0.000143348623853 0 1 -1
or,from 0.0 0.0 1 1 0
labeled,with 1.0 0.000143348623853 0 1 -1
been,definitely 1.0 0.000143348623853 0 1 -1
rationale,stress 1.0 0.000143348623853 0 1 -1
four,chemotherapeutic 1.0 0.000143348623853 0 1 -1
function,for 1.0 0.000143348623853 0 1 -1
hepatotoxicity,asymptomatic 1.0 0.000143348623853 0 1 -1
or,hypotension 1.0 0.000286697247706 2 0 2
isoenzyme,in 1.0 0.000143348623853 1 0 1
when,lexapro 1.0 0.000143348623853 1 0 1
invirase,kaletra 1.0 0.000143348623853 1 0 1
one,to 1.0 0.000143348623853 0 1 -1
mediated,through 1.0 0.000143348623853 0 1 -1
inactivate,the 1.0 0.000143348623853 1 0 1
isoenzyme,is 1.0 0.000143348623853 0 1 -1
methods,healthy 1.0 0.000143348623853 0 1 -1
salivary,cortisol 1.0 0.000286697247706 0 2 -2
determinations,of 0.0 0.0 1 1 0
abnormal,laboratory 1.0 0.000143348623853 0 1 -1
not,all 1.0 0.000286697247706 0 2 -2
agents,insulin 1.0 0.000143348623853 0 1 -1
increasing,blood 1.0 0.000143348623853 1 0 1
disulfiram,alone 1.0 0.000143348623853 0 1 -1
frequently,enough 1.0 0.000143348623853 1 0 1
statistically,or 1.0 0.000143348623853 0 1 -1
influence,through 1.0 0.000143348623853 0 1 -1
chloramphenicol,has 1.0 0.000143348623853 1 0 1
but,endogenous 1.0 0.000143348623853 0 1 -1
electrolyte,and 1.0 0.000143348623853 0 1 -1
antigen,psa 1.0 0.000143348623853 0 1 -1
literature,between 1.0 0.000143348623853 0 1 -1
to,substantially 1.0 0.000143348623853 0 1 -1
of,preliminary 1.0 0.000143348623853 1 0 1
months,of 1.0 0.000286697247706 0 2 -2
auc,exhibited 1.0 0.000143348623853 0 1 -1
of,component 1.0 0.000143348623853 0 1 -1
nitric,oxide 1.0 0.000143348623853 1 0 1
in,adjuvant 1.0 0.000143348623853 0 1 -1
proved,to 1.0 0.000143348623853 0 1 -1
indicate,a 1.0 0.000286697247706 2 0 2
exploited,in 1.0 0.000143348623853 0 1 -1
and,oral 0.368421052632 0.00100344036697 13 6 7
such,measurements 1.0 0.000143348623853 0 1 -1
ketoconazole,itraconazole 1.0 0.000143348623853 0 1 -1
to,pentobarbital-induced 1.0 0.000143348623853 0 1 -1
store,and 1.0 0.000143348623853 0 1 -1
approximately,decrease 1.0 0.000286697247706 2 0 2
minor,increase 1.0 0.000143348623853 1 0 1
increases,ranging 1.0 0.000286697247706 0 2 -2
alone,in 1.0 0.000573394495413 0 4 -4
as,nonsteroidal 0.0 0.0 1 1 0
ovariectomy,female 1.0 0.000143348623853 0 1 -1
and,enhance 0.333333333333 0.000143348623853 2 1 1
cns-depressant,action 1.0 0.000143348623853 1 0 1
in,administering 1.0 0.000143348623853 0 1 -1
both,cyp3a4 1.0 0.000143348623853 0 1 -1
lethal,dose 1.0 0.000143348623853 0 1 -1
the,iop 1.0 0.000143348623853 1 0 1
aggregation,inhibitors 1.0 0.000143348623853 1 0 1
that,reduce 0.0 0.0 1 1 0
shock,in 1.0 0.000143348623853 0 1 -1
assessed,in 1.0 0.00100344036697 0 7 -7
a,chemically 1.0 0.000143348623853 0 1 -1
hormonal,by 1.0 0.000143348623853 0 1 -1
keppra,and 1.0 0.000286697247706 0 2 -2
c,interval 0.333333333333 0.000143348623853 2 1 1
group,resulted 1.0 0.000143348623853 1 0 1
modifies,metabolism 1.0 0.000143348623853 1 0 1
atg,alg 1.0 0.000143348623853 0 1 -1
hepatic,transaminases 1.0 0.000143348623853 0 1 -1
normal,metabolizers 1.0 0.000860091743119 0 6 -6
considerable,caution 1.0 0.000143348623853 1 0 1
interaction,observed 1.0 0.000143348623853 1 0 1
not,increase 1.0 0.000716743119266 0 5 -5
pregnancies,the 1.0 0.000143348623853 0 1 -1
susceptibility,through 1.0 0.000143348623853 0 1 -1
alprazolam,metabolism 1.0 0.000143348623853 0 1 -1
patient,feels 1.0 0.000143348623853 0 1 -1
ingested,being 1.0 0.000143348623853 1 0 1
heparins,effect 1.0 0.000143348623853 0 1 -1
systemic,concentrations 1.0 0.000143348623853 1 0 1
with,thiazide 1.0 0.000143348623853 1 0 1
should,refer 1.0 0.000143348623853 0 1 -1
there,appears 1.0 0.000143348623853 0 1 -1
agitation,motor 1.0 0.000143348623853 0 1 -1
materials,amino 1.0 0.000143348623853 0 1 -1
or,slightly 1.0 0.000143348623853 1 0 1
depression,hypotension 0.0 0.0 1 1 0
for,a 0.666666666667 0.00172018348624 3 15 -12
stomach,does 1.0 0.000143348623853 0 1 -1
oral,an 0.0 0.0 1 1 0
chronically,implanted 1.0 0.000143348623853 0 1 -1
the,anticholinesterase 1.0 0.000143348623853 1 0 1
to,during 0.0 0.0 1 1 0
with,enzyme-based 1.0 0.00043004587156 0 3 -3
when,itraconazole 1.0 0.00043004587156 3 0 3
oral,poc 1.0 0.000143348623853 0 1 -1
d6,may 1.0 0.000860091743119 0 6 -6
welchol,decreased 1.0 0.000143348623853 1 0 1
as,renal 1.0 0.000143348623853 0 1 -1
position,and 1.0 0.000143348623853 0 1 -1
in,time 1.0 0.000143348623853 1 0 1
treated,by 1.0 0.000143348623853 0 1 -1
results,bombesin 1.0 0.000143348623853 0 1 -1
hyperplasia,bph 1.0 0.000143348623853 0 1 -1
minutes,post 1.0 0.000143348623853 0 1 -1
for,type 1.0 0.000286697247706 0 2 -2
cause,neutropenia 1.0 0.000143348623853 0 1 -1
including,with 1.0 0.000286697247706 2 0 2
using,or 1.0 0.000143348623853 1 0 1
plate,counts 1.0 0.000143348623853 0 1 -1
been,documented 1.0 0.000143348623853 0 1 -1
tagamet,mg 1.0 0.000143348623853 1 0 1
cardioselective,could 1.0 0.000286697247706 0 2 -2
a,second 1.0 0.000573394495413 0 4 -4
of,adrenocorticoids 1.0 0.000143348623853 0 1 -1
the,alkaloid 1.0 0.000143348623853 1 0 1
these,is 0.5 0.000286697247706 1 3 -2
level,by 1.0 0.000143348623853 0 1 -1
highly,potent 1.0 0.000143348623853 1 0 1
is,concurrently 1.0 0.000143348623853 0 1 -1
separate,single 1.0 0.000143348623853 0 1 -1
other,published 1.0 0.000143348623853 1 0 1
returned,to 0.714285714286 0.000716743119266 1 6 -5
these,in 0.777777777778 0.00100344036697 1 8 -7
a4,cyp 1.0 0.000143348623853 1 0 1
oxc,and 1.0 0.000286697247706 0 2 -2
expression,in 1.0 0.000143348623853 0 1 -1
range,of 0.454545454545 0.000716743119266 3 8 -5
and,ethinyl 0.6 0.00043004587156 4 1 3
an,improved 1.0 0.000143348623853 0 1 -1
prospective,studies 1.0 0.000143348623853 0 1 -1
most,closely 1.0 0.000143348623853 0 1 -1
juices,such 1.0 0.000286697247706 0 2 -2
produced,their 1.0 0.000143348623853 0 1 -1
they,could 1.0 0.000143348623853 0 1 -1
isoenzymes,carbamazepine 1.0 0.000143348623853 0 1 -1
mucosal,accumulation 1.0 0.000143348623853 0 1 -1
specified,appropriate 1.0 0.000286697247706 0 2 -2
increased,sedation 0.2 0.000143348623853 2 3 -1
drugs,have 1.0 0.000143348623853 0 1 -1
to,interact 0.4 0.000573394495413 3 7 -4
affects,prothrombin 1.0 0.000143348623853 0 1 -1
precedex,with 1.0 0.000143348623853 1 0 1
to,displacement 1.0 0.000143348623853 0 1 -1
astemizole,and 1.0 0.000143348623853 0 1 -1
under,treatment 0.0 0.0 1 1 0
allergens,may 1.0 0.000716743119266 0 5 -5
this,problem 1.0 0.000143348623853 0 1 -1
altered,hypo-prothrombinemic 1.0 0.000143348623853 0 1 -1
that,received 1.0 0.00043004587156 0 3 -3
given,later 1.0 0.000143348623853 1 0 1
return,toward 1.0 0.000143348623853 0 1 -1
given,compensatory 1.0 0.000143348623853 0 1 -1
co-treatment,with 1.0 0.000143348623853 1 0 1
with,increases 0.6 0.00043004587156 1 4 -3
hypertension,have 1.0 0.000143348623853 0 1 -1
they,occur 1.0 0.000143348623853 0 1 -1
harmonic,mean 1.0 0.000143348623853 0 1 -1
calcium-blocking,agents 1.0 0.000143348623853 0 1 -1
with,increased 0.4 0.000573394495413 7 3 4
may,potentiate 0.6 0.00301032110092 28 7 21
concurrent,use 0.037037037037 0.000286697247706 28 26 2
b23,and 1.0 0.000143348623853 0 1 -1
and,you 1.0 0.000143348623853 1 0 1
inhibit,p450 0.714285714286 0.000716743119266 1 6 -5
deaths,due 1.0 0.000143348623853 0 1 -1
to,topo 1.0 0.000143348623853 0 1 -1
carcinogenic,potential 1.0 0.000286697247706 0 2 -2
has,the 0.333333333333 0.000573394495413 4 8 -4
no,study 1.0 0.000143348623853 1 0 1
the,geometric 0.0 0.0 1 1 0
be,exacerbated 0.333333333333 0.000143348623853 2 1 1
lodine,capsules 1.0 0.000143348623853 1 0 1
arrest,cardiac 1.0 0.000143348623853 0 1 -1
the,interpretation 1.0 0.000143348623853 0 1 -1
inhibitors,prolong 1.0 0.000716743119266 5 0 5
was,longer 1.0 0.000143348623853 1 0 1
bismuth,subsalicylate 1.0 0.000143348623853 1 0 1
desethylzaleplon,formed 1.0 0.000143348623853 0 1 -1
interferes,with 0.166666666667 0.000286697247706 7 5 2
tablets,containing 1.0 0.000143348623853 0 1 -1
of,alcoholic 1.0 0.000143348623853 0 1 -1
again,given 1.0 0.000143348623853 0 1 -1
components,with 1.0 0.000143348623853 0 1 -1
measured,using 1.0 0.000143348623853 0 1 -1
microsomal,ethoxycoumarine 1.0 0.000143348623853 0 1 -1
diminish,oral 1.0 0.000286697247706 2 0 2
tracleer,is 0.0 0.0 1 1 0
axons,contained 1.0 0.000143348623853 0 1 -1
hcl,no 1.0 0.000143348623853 1 0 1
is,continued 1.0 0.000286697247706 0 2 -2
careful,tapering 1.0 0.000143348623853 0 1 -1
trademark,of 1.0 0.000143348623853 0 1 -1
determine,blood 1.0 0.000286697247706 0 2 -2
general,and 1.0 0.000286697247706 0 2 -2
require,a 0.333333333333 0.000143348623853 2 1 1
pupil,constriction 1.0 0.000286697247706 0 2 -2
or,h1-blocking 1.0 0.000143348623853 1 0 1
rpmi1640,containing 0.0 0.0 1 1 0
include,hypotension 1.0 0.000143348623853 1 0 1
general,any 1.0 0.000143348623853 0 1 -1
experiments,we 1.0 0.000143348623853 0 1 -1
revia,may 1.0 0.000143348623853 1 0 1
sequential,trials 1.0 0.000143348623853 0 1 -1
recovered,from 1.0 0.000143348623853 1 0 1
targretin,capsules 1.0 0.000286697247706 2 0 2
reported,predominantly 1.0 0.000143348623853 1 0 1
chlorpromazine,blocks 1.0 0.000286697247706 2 0 2
for,creatinine 1.0 0.000143348623853 0 1 -1
decreased,slightly 1.0 0.000143348623853 1 0 1
so,for 1.0 0.000143348623853 0 1 -1
and,left 1.0 0.000143348623853 1 0 1
whether,amevive 1.0 0.000143348623853 0 1 -1
and,related 0.0 0.0 3 3 0
in,gastric 1.0 0.000143348623853 1 0 1
p-glycoprotein,and 1.0 0.000143348623853 0 1 -1
the,q-t 1.0 0.000143348623853 0 1 -1
reactions,secondary 1.0 0.000143348623853 0 1 -1
methionine,may 1.0 0.000143348623853 1 0 1
of,gibaldi 1.0 0.000143348623853 0 1 -1
lower,intestine 1.0 0.000143348623853 1 0 1
individuals,treated 1.0 0.000143348623853 1 0 1
used,many 1.0 0.000143348623853 0 1 -1
human,immediately 1.0 0.000143348623853 0 1 -1
microm,inhibited 1.0 0.000143348623853 1 0 1
amines,but 1.0 0.000286697247706 0 2 -2
not,reduce 1.0 0.000143348623853 0 1 -1
of,prostate 1.0 0.000143348623853 1 0 1
most,ssris 1.0 0.000143348623853 0 1 -1
or,given 1.0 0.000143348623853 0 1 -1
similar,decreases 1.0 0.000143348623853 0 1 -1
resolved,within 1.0 0.000143348623853 0 1 -1
rates,compliance 1.0 0.000143348623853 0 1 -1
sulfacetamide,preparations 1.0 0.000143348623853 1 0 1
mean,distribution 1.0 0.000143348623853 0 1 -1
digoxin,digoxin 1.0 0.000143348623853 1 0 1
phenytoin,population 1.0 0.000143348623853 1 0 1
for,possible 0.6 0.00043004587156 1 4 -3
may,exhibit 1.0 0.00043004587156 3 0 3
gene,under 1.0 0.000143348623853 0 1 -1
slowing,potentiates 1.0 0.000286697247706 0 2 -2
between,treatments 1.0 0.000143348623853 0 1 -1
can,reduce 1.0 0.0021502293578 15 0 15
the,co-administered 1.0 0.000143348623853 0 1 -1
prostin,e2 1.0 0.000143348623853 1 0 1
york,heart 1.0 0.000143348623853 0 1 -1
are,dryness 1.0 0.000143348623853 0 1 -1
total,were 1.0 0.000286697247706 0 2 -2
vardenafil,when 1.0 0.000143348623853 0 1 -1
the,steroidal 1.0 0.000143348623853 1 0 1
dopamine,antagonists 1.0 0.000143348623853 1 0 1
favorable,effects 1.0 0.000143348623853 0 1 -1
mg,decreased 1.0 0.000143348623853 1 0 1
cholinergic,role 1.0 0.000143348623853 0 1 -1
a4,c9 1.0 0.000143348623853 0 1 -1
have,demonstrated 0.230769230769 0.00043004587156 5 8 -3
possible,pharmacokinetic 1.0 0.000143348623853 1 0 1
in,users 1.0 0.000286697247706 0 2 -2
drawn,up 1.0 0.000143348623853 0 1 -1
international,pharmaceutical 1.0 0.000143348623853 0 1 -1
patients,were 1.0 0.00114678899083 0 8 -8
been,reported 0.448648648649 0.0118979357798 134 51 83
in,interactions 1.0 0.000143348623853 1 0 1
formal,studies 1.0 0.00043004587156 0 3 -3
vascular,resistance 0.0 0.0 1 1 0
dl,submitted 1.0 0.000143348623853 0 1 -1
however,has 1.0 0.000143348623853 1 0 1
agents,may 0.185185185185 0.000716743119266 16 11 5
pulmonary,wedge 1.0 0.000143348623853 1 0 1
possible,interactions 0.333333333333 0.000286697247706 2 4 -2
cercarial,encystment 1.0 0.000143348623853 0 1 -1
appears,that 1.0 0.000143348623853 1 0 1
interrupted,in 1.0 0.000143348623853 0 1 -1
these,categories 1.0 0.000143348623853 1 0 1
nimbex,may 1.0 0.000143348623853 1 0 1
procedures,were 1.0 0.000143348623853 0 1 -1
action,independent 1.0 0.000143348623853 0 1 -1
increased,fold 0.333333333333 0.000143348623853 2 1 1
parameters,were 1.0 0.000143348623853 0 1 -1
cell,functions 1.0 0.000143348623853 0 1 -1
of,fibrinolysis 1.0 0.000143348623853 0 1 -1
dynacirc,an 1.0 0.000143348623853 0 1 -1
n-octyl,and 1.0 0.000143348623853 0 1 -1
are,unknown 1.0 0.000286697247706 2 0 2
actions,or 1.0 0.000143348623853 0 1 -1
apoptotic,index 1.0 0.000143348623853 0 1 -1
other,phe-nothiazines 1.0 0.000143348623853 0 1 -1
enzyme-inducer,did 1.0 0.000143348623853 1 0 1
the,hplc 1.0 0.000143348623853 0 1 -1
therapeutic,monitoring 0.333333333333 0.000143348623853 1 2 -1
antiretroviral,regimens 1.0 0.000143348623853 0 1 -1
decrease,elimination 1.0 0.000143348623853 1 0 1
sildenafil,dose 1.0 0.000143348623853 1 0 1
receiving,careful 1.0 0.000143348623853 1 0 1
hypokalemic,effect 1.0 0.000143348623853 1 0 1
maximum,approved 1.0 0.000143348623853 1 0 1
and,dose 0.333333333333 0.000143348623853 2 1 1
on,than 1.0 0.000143348623853 1 0 1
be,adjusted 0.25 0.000286697247706 3 5 -2
prolongation,and 1.0 0.000573394495413 0 4 -4
significantly,to 1.0 0.000143348623853 0 1 -1
tc,suspension 1.0 0.000286697247706 2 0 2
dysfunction,as 1.0 0.000143348623853 0 1 -1
prevent,folic 1.0 0.000143348623853 0 1 -1
other,are 1.0 0.000143348623853 0 1 -1
blood-pressure,and 1.0 0.000143348623853 1 0 1
monthly,comparison 1.0 0.000143348623853 0 1 -1
metabolic,responses 1.0 0.000143348623853 0 1 -1
the,pathogenic 1.0 0.000143348623853 0 1 -1
treatment,resulted 1.0 0.000143348623853 1 0 1
and,potency 1.0 0.000143348623853 0 1 -1
peak,latency 1.0 0.000143348623853 0 1 -1
concomitant,administration 0.337423312883 0.00788417431193 109 54 55
loop,potassium-sparing 1.0 0.000286697247706 2 0 2
however,due 1.0 0.000143348623853 1 0 1
lomefloxacin,is 1.0 0.000143348623853 0 1 -1
aftercare,approaches 1.0 0.000143348623853 0 1 -1
haldol,has 1.0 0.000143348623853 0 1 -1
a,mild 0.0 0.0 1 1 0
responses,alternative 1.0 0.000143348623853 0 1 -1
instituted,may 1.0 0.00043004587156 3 0 3
gonadotropin-releasing,hormone 1.0 0.000143348623853 0 1 -1
are,inhibitors 0.6 0.00043004587156 1 4 -3
this,formal 1.0 0.000143348623853 0 1 -1
and,interact 1.0 0.000143348623853 1 0 1
of,increasing 1.0 0.000143348623853 1 0 1
rapid,equilibration 1.0 0.000143348623853 0 1 -1
or,embryocidal 1.0 0.000143348623853 0 1 -1
when,tested 1.0 0.000286697247706 0 2 -2
discontinued,or 1.0 0.000143348623853 1 0 1
nsaids,may 0.8 0.00114678899083 9 1 8
hydroxy-1,on 1.0 0.000143348623853 1 0 1
as,long 0.0 0.0 1 1 0
and,hypoglycemia 0.0 0.0 1 1 0
any,cyp 1.0 0.000143348623853 0 1 -1
vitro,was 1.0 0.000286697247706 0 2 -2
may,include 1.0 0.000143348623853 0 1 -1
the,bronchodilator 1.0 0.000143348623853 0 1 -1
mounted,in 1.0 0.000143348623853 0 1 -1
thus,smaller 1.0 0.000143348623853 1 0 1
of,crixivan 0.142857142857 0.000143348623853 4 3 1
time,for 0.333333333333 0.000143348623853 1 2 -1
metabolized,mainly 1.0 0.00043004587156 0 3 -3
aluminum,hydroxide- 1.0 0.000143348623853 0 1 -1
professionals,be 1.0 0.000143348623853 0 1 -1
psa,when 1.0 0.000143348623853 0 1 -1
been,observed 0.6 0.00344036697248 8 32 -24
peptidase,and 1.0 0.000143348623853 0 1 -1
n1,while 1.0 0.000143348623853 1 0 1
indicated,by 0.0 0.0 2 2 0
significant,effects 0.833333333333 0.00143348623853 1 11 -10
scales,vital 1.0 0.000143348623853 0 1 -1
produces,cardiopulmonary 1.0 0.000143348623853 0 1 -1
an,intravenous 0.2 0.000143348623853 3 2 1
trinitrate,isosorbide 1.0 0.000143348623853 0 1 -1
continued,for 1.0 0.000143348623853 0 1 -1
samples,from 1.0 0.000143348623853 0 1 -1
additional,animals 1.0 0.000143348623853 0 1 -1
exjade,should 0.0 0.0 1 1 0
of,organogenesis 1.0 0.000143348623853 0 1 -1
agonists,has 1.0 0.000143348623853 0 1 -1
counts,in 1.0 0.000143348623853 1 0 1
tumour,and 1.0 0.000143348623853 1 0 1
characteristics,of 1.0 0.000143348623853 0 1 -1
h,s 1.0 0.000143348623853 1 0 1
autonomic,instability 1.0 0.000143348623853 1 0 1
systemic,clearance 1.0 0.000143348623853 1 0 1
or,decreases 1.0 0.000143348623853 1 0 1
h,e 0.428571428571 0.00043004587156 5 2 3
ea,was 1.0 0.000143348623853 0 1 -1
far,greater 1.0 0.000286697247706 0 2 -2
cns,effects 0.0 0.0 4 4 0
to,gonadotropin-releasing 1.0 0.000143348623853 0 1 -1
psychoses,to 1.0 0.000286697247706 0 2 -2
subjects,did 1.0 0.000143348623853 0 1 -1
weight,w 1.0 0.000143348623853 1 0 1
peak,serum 1.0 0.000286697247706 2 0 2
the,genetically 1.0 0.000286697247706 0 2 -2
nuclear,matrix 0.0 0.0 1 1 0
are,encouraged 1.0 0.000143348623853 0 1 -1
benazepril,like 1.0 0.000143348623853 1 0 1
documented,prothrombin 1.0 0.000143348623853 0 1 -1
as,used 1.0 0.000143348623853 1 0 1
cyclosporin,after 1.0 0.000143348623853 1 0 1
inhibitors,beta 1.0 0.000143348623853 0 1 -1
beta-lactamtype,or 1.0 0.000143348623853 1 0 1
or,due 1.0 0.000286697247706 0 2 -2
sporadic,cases 1.0 0.000143348623853 1 0 1
switching,from 0.6 0.00043004587156 4 1 3
stimulation,of 1.0 0.000286697247706 0 2 -2
analyses,indicate 0.5 0.000286697247706 3 1 2
infants,which 1.0 0.000143348623853 0 1 -1
on,reports 1.0 0.000286697247706 2 0 2
dmpge2-induced,jejunal 1.0 0.000143348623853 0 1 -1
substrate,alpha-1 1.0 0.000286697247706 0 2 -2
of,of 0.333333333333 0.000286697247706 2 4 -2
chapter,focuses 1.0 0.000143348623853 0 1 -1
enterohepatic,circulation 1.0 0.000143348623853 1 0 1
and,it 0.0 0.0 5 5 0
of,already 1.0 0.000143348623853 1 0 1
and,iv 0.2 0.000143348623853 2 3 -1
lexapro,for 1.0 0.000143348623853 1 0 1
use,of 0.0197628458498 0.000716743119266 124 129 -5
and,is 0.314285714286 0.00157683486239 23 12 11
hypertension,in 1.0 0.000286697247706 2 0 2
cyp3a4,and 0.833333333333 0.00143348623853 1 11 -10
and,if 0.5 0.000286697247706 1 3 -2
the,aim 1.0 0.000286697247706 0 2 -2
tubular,secretion 0.411764705882 0.00100344036697 12 5 7
that,concomitant 0.25 0.000286697247706 5 3 2
and,in 0.194444444444 0.00200688073394 29 43 -14
out,whether 1.0 0.000143348623853 0 1 -1
and,ii 1.0 0.000143348623853 0 1 -1
intensify,the 0.636363636364 0.00100344036697 9 2 7
given,after 0.0 0.0 1 1 0
respect,of 1.0 0.000143348623853 0 1 -1
such,medications 1.0 0.000143348623853 1 0 1
symptoms,and 1.0 0.000286697247706 0 2 -2
ponstel,and 1.0 0.000143348623853 1 0 1
events,by 1.0 0.000143348623853 1 0 1
augmentation,of 1.0 0.000143348623853 0 1 -1
benzodiazepine,class 1.0 0.000143348623853 1 0 1
herbs,such 1.0 0.000143348623853 1 0 1
hypotension,av 1.0 0.000143348623853 1 0 1
taking,tricyclic 0.0 0.0 1 1 0
different,responses 1.0 0.000143348623853 0 1 -1
male,lean 1.0 0.000143348623853 0 1 -1
relaxants,may 1.0 0.000143348623853 1 0 1
accelerates,the 1.0 0.000143348623853 1 0 1
such,that 1.0 0.000286697247706 2 0 2
produce,malabsorption 1.0 0.000143348623853 1 0 1
received,among 1.0 0.000143348623853 0 1 -1
modulation,of 0.0 0.0 1 1 0
of,apoptosis 0.0 0.0 1 1 0
reports,have 0.5 0.000286697247706 3 1 2
known,to 0.620689655172 0.00516055045872 11 47 -36
note,dissolution 1.0 0.000143348623853 0 1 -1
for,results 1.0 0.000143348623853 0 1 -1
eight,experiments 1.0 0.000143348623853 0 1 -1
exercised,because 0.0 0.0 1 1 0
esmolol,hcl 1.0 0.000143348623853 0 1 -1
in,limiting 1.0 0.000143348623853 0 1 -1
mg,reduced 1.0 0.000143348623853 1 0 1
of,copegus 1.0 0.000143348623853 1 0 1
day,after 1.0 0.000143348623853 0 1 -1
regimen,be 1.0 0.000143348623853 0 1 -1
triazolam,combined 1.0 0.000143348623853 0 1 -1
acquired,behavioral 1.0 0.000143348623853 0 1 -1
initiating,and 1.0 0.000143348623853 1 0 1
was,superior 1.0 0.000143348623853 0 1 -1
palliates,deficiencies 1.0 0.000143348623853 0 1 -1
a,known 0.0 0.0 4 4 0
hz,degrees 1.0 0.000143348623853 0 1 -1
working,properly 1.0 0.000143348623853 0 1 -1
than,when 0.75 0.000860091743119 7 1 6
arava,and 1.0 0.000143348623853 1 0 1
behaviors,which 1.0 0.000143348623853 0 1 -1
n-desmethyldiazepam,there 1.0 0.000143348623853 1 0 1
has,generally 1.0 0.000143348623853 0 1 -1
corneal,lesions 1.0 0.000143348623853 1 0 1
concentrations,dosage 1.0 0.000143348623853 1 0 1
to,offer 1.0 0.000143348623853 0 1 -1
previously,stable 1.0 0.000286697247706 2 0 2
when,concomitant 1.0 0.000573394495413 4 0 4
and,molecular 1.0 0.000143348623853 0 1 -1
inhalation,are 1.0 0.000143348623853 1 0 1
mixed,with 1.0 0.000716743119266 0 5 -5
mechanism,may 1.0 0.000143348623853 1 0 1
minimized,or 1.0 0.000143348623853 1 0 1
interaction,can 1.0 0.000286697247706 0 2 -2
on,dosing 1.0 0.000143348623853 0 1 -1
with,transdermal 1.0 0.000143348623853 1 0 1
recently,identified 1.0 0.000143348623853 0 1 -1
impedance,and 1.0 0.000143348623853 0 1 -1
anti-,inflammatory 1.0 0.000143348623853 1 0 1
experience,fewer 1.0 0.000143348623853 0 1 -1
corticosteroids,concomitant 1.0 0.000143348623853 1 0 1
l-lysine,may 1.0 0.000143348623853 1 0 1
and,need 1.0 0.000143348623853 0 1 -1
as,factor 1.0 0.000286697247706 0 2 -2
not,in 0.5 0.000286697247706 3 1 2
frontal,cortex 1.0 0.000143348623853 0 1 -1
of,chloroprocaine 1.0 0.000143348623853 0 1 -1
the,odontoid 1.0 0.000143348623853 0 1 -1
rebound,in 1.0 0.000143348623853 1 0 1
induces,the 1.0 0.000143348623853 0 1 -1
cyp4a9,and 1.0 0.000143348623853 0 1 -1
if,hypotension 1.0 0.000143348623853 0 1 -1
d,agonists 0.0 0.0 1 1 0
to,electrophilic 1.0 0.000143348623853 0 1 -1
the,terms 1.0 0.000143348623853 0 1 -1
when,assessed 1.0 0.000143348623853 0 1 -1
or,within 0.0 0.0 4 4 0
fortovase,and 1.0 0.000143348623853 0 1 -1
reaching,a 1.0 0.000286697247706 0 2 -2
choline,arthropan 1.0 0.000143348623853 1 0 1
tarsal,flexure 1.0 0.000143348623853 0 1 -1
duration,but 1.0 0.000143348623853 1 0 1
characterize,the 1.0 0.000286697247706 0 2 -2
following,was 1.0 0.000143348623853 0 1 -1
vasorelaxation,differs 1.0 0.000143348623853 0 1 -1
effect,reduction 1.0 0.000143348623853 0 1 -1
or,increasing 1.0 0.000716743119266 5 0 5
rare,occasions 1.0 0.000286697247706 2 0 2
and,anticipation 1.0 0.000143348623853 0 1 -1
studied,in 0.888888888889 0.00229357798165 1 17 -16
eliminated,in 1.0 0.000286697247706 0 2 -2
these,disorders 1.0 0.000143348623853 0 1 -1
comparative,data 1.0 0.000286697247706 0 2 -2
affect,idv 1.0 0.000143348623853 0 1 -1
increases,ethinyl 1.0 0.000143348623853 0 1 -1
same,group 1.0 0.000143348623853 0 1 -1
and,area 0.0 0.0 1 1 0
triclofos,sodium 1.0 0.000143348623853 1 0 1
the,predominant 1.0 0.000286697247706 0 2 -2
artifactually,altered 1.0 0.000143348623853 0 1 -1
accordingly,and 1.0 0.000143348623853 1 0 1
given,alone 1.0 0.000286697247706 0 2 -2
it,was 0.263157894737 0.000716743119266 7 12 -5
nonlethal,and 1.0 0.000143348623853 0 1 -1
users,particularly 1.0 0.000143348623853 1 0 1
epoxide,reductase 1.0 0.000143348623853 0 1 -1
toradol,was 1.0 0.000143348623853 1 0 1
a,three- 1.0 0.000143348623853 0 1 -1
day,did 1.0 0.000143348623853 0 1 -1
the,selective 0.75 0.000860091743119 1 7 -6
topoisomerase,quantity 1.0 0.000143348623853 0 1 -1
physiologic,activity 1.0 0.000143348623853 1 0 1
volume,depletion 1.0 0.000143348623853 1 0 1
nociception,and 1.0 0.000143348623853 0 1 -1
an,containing 1.0 0.000143348623853 1 0 1
moderate,cyp3a4 1.0 0.000143348623853 1 0 1
state,vioxx 1.0 0.000143348623853 0 1 -1
same,degree 1.0 0.000143348623853 0 1 -1
the,mucosal 1.0 0.000286697247706 0 2 -2
time,within 1.0 0.000143348623853 1 0 1
for,arrhythmias 1.0 0.000143348623853 0 1 -1
highly,sensitive 1.0 0.000143348623853 0 1 -1
latter,agents 1.0 0.000143348623853 1 0 1
agent,orally 1.0 0.000143348623853 1 0 1
the,clinically 0.0 0.0 1 1 0
with,oral 0.473684210526 0.00129013761468 14 5 9
from,interactions 1.0 0.000143348623853 0 1 -1
with,non-steroidal 1.0 0.000143348623853 1 0 1
cytochrome,p- 1.0 0.000143348623853 0 1 -1
of,iiia4 1.0 0.000143348623853 1 0 1
usedas,the 1.0 0.000143348623853 1 0 1
pursue,qualification 1.0 0.000143348623853 0 1 -1
or,used 1.0 0.000143348623853 0 1 -1
crossover,clinical 1.0 0.000143348623853 0 1 -1
any,reduction 1.0 0.000143348623853 1 0 1
reverse,triiodothyronine 1.0 0.000143348623853 0 1 -1
practice,the 1.0 0.000143348623853 0 1 -1
carcinogenicity,study 1.0 0.000143348623853 0 1 -1
as,noted 0.0 0.0 1 1 0
poor,absorption 1.0 0.000143348623853 0 1 -1
using,duloxetine 1.0 0.000143348623853 0 1 -1
the,vitamin 1.0 0.00043004587156 0 3 -3
treatment,improves 1.0 0.000143348623853 0 1 -1
extended,release 0.0 0.0 2 2 0
human,red 1.0 0.000143348623853 0 1 -1
such,concomitant 1.0 0.000143348623853 0 1 -1
ratio,r 1.0 0.000143348623853 0 1 -1
marrow,megakaryocytes 1.0 0.000143348623853 0 1 -1
about,to 0.333333333333 0.000143348623853 1 2 -1
class,examples 1.0 0.000143348623853 0 1 -1
hour,apart 1.0 0.000143348623853 1 0 1
developing,peripheral 1.0 0.000143348623853 1 0 1
black,cohosh 1.0 0.000143348623853 0 1 -1
ca,and 0.0 0.0 1 1 0
in,premenopausal 1.0 0.000143348623853 0 1 -1
when,eulexin 1.0 0.000143348623853 1 0 1
amprenavir,does 1.0 0.000143348623853 0 1 -1
ibuprofen,as 1.0 0.000143348623853 1 0 1
offered,by 1.0 0.000143348623853 0 1 -1
including,ketorolac 1.0 0.000143348623853 0 1 -1
because,have 1.0 0.000143348623853 1 0 1
by,high-performance 1.0 0.000143348623853 0 1 -1
have,renal 1.0 0.000143348623853 0 1 -1
feeding,and 1.0 0.000143348623853 0 1 -1
studied,the 1.0 0.000143348623853 1 0 1
interactions,prolongation 1.0 0.000143348623853 0 1 -1
being,designed 1.0 0.000143348623853 0 1 -1
multiple,interacting 1.0 0.000143348623853 0 1 -1
transient,delirium 1.0 0.000143348623853 1 0 1
and,tnf 0.0 0.0 1 1 0
intensified,electrolyte 1.0 0.000286697247706 0 2 -2
uncomplicated,urinary 1.0 0.000143348623853 0 1 -1
informed,when 1.0 0.000143348623853 0 1 -1
mentax,butenafine 1.0 0.000143348623853 0 1 -1
their,vasospastic 1.0 0.000143348623853 1 0 1
href,frova_od 1.0 0.000143348623853 1 0 1
each,of 1.0 0.000716743119266 0 5 -5
who,begin 1.0 0.000143348623853 1 0 1
in,therapy 1.0 0.000286697247706 0 2 -2
have,negative 0.333333333333 0.000143348623853 1 2 -1
day,withdrawal 1.0 0.00043004587156 0 3 -3
or,excessive 1.0 0.000143348623853 0 1 -1
could,cause 0.5 0.000286697247706 3 1 2
some,colorimetric 1.0 0.000143348623853 0 1 -1
of,antifibrinolytic 1.0 0.000143348623853 0 1 -1
their,similar 1.0 0.000143348623853 1 0 1
taking,and 0.714285714286 0.000716743119266 6 1 5
of,creatinine 1.0 0.000286697247706 0 2 -2
taken,with 0.111111111111 0.000143348623853 4 5 -1
with,vioxx 1.0 0.000286697247706 2 0 2
tablets,was 1.0 0.000143348623853 0 1 -1
selective,serotonin 0.25 0.000573394495413 6 10 -4
stable,exposure 1.0 0.000143348623853 0 1 -1
occurred,following 1.0 0.000143348623853 1 0 1
tissue,damage 1.0 0.000143348623853 1 0 1
insp,together 1.0 0.000143348623853 1 0 1
reduce,both 1.0 0.000143348623853 1 0 1
administered,shortly 0.0 0.0 1 1 0
after,withdrawal 1.0 0.000286697247706 0 2 -2
of,marked 1.0 0.000143348623853 1 0 1
sertraline,neutralized 1.0 0.000143348623853 0 1 -1
used,after 1.0 0.000143348623853 0 1 -1
reaction,after 1.0 0.000143348623853 0 1 -1
fecal,loss 1.0 0.000143348623853 0 1 -1
reduced,significantly 1.0 0.000143348623853 0 1 -1
improves,quality 1.0 0.000143348623853 0 1 -1
since,has 1.0 0.000143348623853 0 1 -1
cardiac,deaths 1.0 0.000143348623853 0 1 -1
eclampsia,some 1.0 0.000143348623853 0 1 -1
intercurrent,use 1.0 0.000143348623853 0 1 -1
clinical,signs 1.0 0.000143348623853 1 0 1
who,do 1.0 0.000143348623853 0 1 -1
history,of 0.538461538462 0.00100344036697 3 10 -7
are,taken 1.0 0.000286697247706 2 0 2
juice,which 1.0 0.000143348623853 0 1 -1
most,common 1.0 0.000573394495413 0 4 -4
pressure,caution 1.0 0.000143348623853 1 0 1
slow,the 1.0 0.000143348623853 1 0 1
specific,and 1.0 0.000286697247706 0 2 -2
they,also 1.0 0.000143348623853 0 1 -1
selectively,prevent 1.0 0.000143348623853 1 0 1
and,because 0.142857142857 0.000143348623853 4 3 1
postdose,a 1.0 0.000143348623853 1 0 1
reported,concomitant 1.0 0.000143348623853 1 0 1
pharmacokinetic,or 1.0 0.00100344036697 0 7 -7
transplant,patients 1.0 0.000286697247706 2 0 2
combination,have 1.0 0.000143348623853 0 1 -1
sch-23390,but 1.0 0.000143348623853 1 0 1
complete,loss 1.0 0.000143348623853 0 1 -1
that,the 0.150684931507 0.00157683486239 31 42 -11
hiv,protease 0.5 0.000286697247706 1 3 -2
or,kidney 1.0 0.000143348623853 0 1 -1
or,alternatively 1.0 0.000143348623853 0 1 -1
olanzapine,a 1.0 0.000143348623853 0 1 -1
qtc,increase 1.0 0.000286697247706 0 2 -2
a,single 0.142857142857 0.00157683486239 33 44 -11
as,liver 1.0 0.000143348623853 1 0 1
clearance,at 1.0 0.000143348623853 0 1 -1
general,although 1.0 0.000143348623853 0 1 -1
doses,correspond 1.0 0.000286697247706 0 2 -2
medium,consisting 1.0 0.000143348623853 0 1 -1
or,substantially 1.0 0.000143348623853 1 0 1
metabolism,or 0.5 0.000286697247706 1 3 -2
marplan,nardil 1.0 0.000143348623853 0 1 -1
profound,when 1.0 0.000143348623853 1 0 1
weeks,should 1.0 0.000286697247706 2 0 2
mu,kg 1.0 0.000143348623853 0 1 -1
size,is 1.0 0.000143348623853 0 1 -1
administering,gleevec 1.0 0.000286697247706 2 0 2
to,plus 1.0 0.000143348623853 0 1 -1
be,especially 1.0 0.000143348623853 0 1 -1
using,long-acting 1.0 0.000143348623853 1 0 1
preparations,since 1.0 0.000143348623853 1 0 1
s,effect 1.0 0.000143348623853 1 0 1
additional,that 0.0 0.0 1 1 0
h2,antagonists 0.333333333333 0.000143348623853 1 2 -1
blockade,may 1.0 0.000143348623853 1 0 1
as,etc 1.0 0.000143348623853 1 0 1
not,posing 1.0 0.000143348623853 0 1 -1
which,healthy 0.0 0.0 1 1 0
in,nephrosis 1.0 0.000143348623853 0 1 -1
therapeutic,action 1.0 0.000143348623853 1 0 1
highest,dose 1.0 0.000143348623853 0 1 -1
had,only 1.0 0.000143348623853 1 0 1
and,safety 1.0 0.00100344036697 0 7 -7
the,dose-limiting 1.0 0.000143348623853 0 1 -1
to,change 0.2 0.000143348623853 2 3 -1
proposed,that 0.333333333333 0.000143348623853 1 2 -1
niacin,antihypertensive 1.0 0.000143348623853 1 0 1
studies,was 1.0 0.000286697247706 0 2 -2
pharmacokinetic,interactions 0.875 0.00200688073394 1 15 -14
inhibit,alprazolam 1.0 0.000143348623853 0 1 -1
to,leading 1.0 0.000143348623853 1 0 1
the,with 1.0 0.000143348623853 1 0 1
reflexes,hourly 1.0 0.000143348623853 0 1 -1
bosentan,had 1.0 0.000143348623853 0 1 -1
spectrophotometrically,determined 1.0 0.000143348623853 0 1 -1
healthy,male 0.571428571429 0.00114678899083 3 11 -8
a,hazard 0.0 0.0 1 1 0
caused,excessive 1.0 0.000286697247706 0 2 -2
conduction,eg 1.0 0.000143348623853 1 0 1
withdrawal,from 1.0 0.000143348623853 0 1 -1
diet,or 1.0 0.000143348623853 0 1 -1
pyrazolone,derivatives 1.0 0.000143348623853 1 0 1
thyroid,preparations 1.0 0.000143348623853 1 0 1
hyperglycemia,were 1.0 0.000143348623853 0 1 -1
occurred,at 1.0 0.000143348623853 1 0 1
complications,considerably 1.0 0.000143348623853 0 1 -1
of,aprepitant 0.263157894737 0.000716743119266 12 7 5
gsh,and 1.0 0.000143348623853 0 1 -1
nuromax,is 1.0 0.000143348623853 1 0 1
nutraceutical,st 1.0 0.000143348623853 0 1 -1
patients,chronically 1.0 0.000143348623853 1 0 1
of,hepatitis 1.0 0.000143348623853 1 0 1
mucosa,caused 1.0 0.000143348623853 1 0 1
spent,in 0.0 0.0 1 1 0
fold,during 1.0 0.000143348623853 1 0 1
not,to 0.142857142857 0.000143348623853 3 4 -1
of,are 0.222222222222 0.000573394495413 11 7 4
assay,xigris 1.0 0.000143348623853 0 1 -1
agents,although 1.0 0.000143348623853 1 0 1
clotting,factor 1.0 0.000286697247706 0 2 -2
increase,serum 0.333333333333 0.000286697247706 2 4 -2
activities,of 1.0 0.000143348623853 0 1 -1
an,are 1.0 0.000143348623853 1 0 1
interactions,cephalosporins 1.0 0.000286697247706 0 2 -2
dysfunction,with 1.0 0.000143348623853 0 1 -1
brain,edema 1.0 0.000143348623853 1 0 1
for,measurement 1.0 0.000286697247706 0 2 -2
by,inducing 1.0 0.000143348623853 0 1 -1
of,potassium-sparing 1.0 0.000143348623853 0 1 -1
nor,should 1.0 0.000143348623853 1 0 1
rats,simultaneous 1.0 0.000143348623853 1 0 1
allopurinol,increased 1.0 0.000143348623853 0 1 -1
underlying,disease 1.0 0.000143348623853 0 1 -1
and,single 1.0 0.000143348623853 0 1 -1
supraventricular,arrhythmia 1.0 0.000143348623853 1 0 1
and,intraindividual 1.0 0.000143348623853 0 1 -1
manageable,without 1.0 0.000143348623853 0 1 -1
dose,relationship 1.0 0.000143348623853 0 1 -1
agents,anesthetics 1.0 0.000143348623853 1 0 1
and,vasoactive 1.0 0.000143348623853 1 0 1
itraconazole,mg 1.0 0.000143348623853 0 1 -1
and,maximal 1.0 0.000143348623853 1 0 1
d6,cyp2d6 1.0 0.000143348623853 0 1 -1
the,listed 1.0 0.000286697247706 0 2 -2
dose,based 1.0 0.000716743119266 0 5 -5
min,over 1.0 0.000143348623853 0 1 -1
for,injection 1.0 0.000286697247706 2 0 2
as,post 1.0 0.000143348623853 1 0 1
medication,patients 1.0 0.000143348623853 0 1 -1
multiple,sclerosis 1.0 0.000143348623853 0 1 -1
following,beta-adrenergic 1.0 0.000143348623853 0 1 -1
levels,monitored 1.0 0.000143348623853 1 0 1
were,performed 1.0 0.00043004587156 0 3 -3
platelets,leukocytes 1.0 0.000143348623853 0 1 -1
half-lives,of 1.0 0.000143348623853 0 1 -1
by,adl 1.0 0.000143348623853 0 1 -1
outset,of 1.0 0.000143348623853 0 1 -1
time,were 1.0 0.000286697247706 0 2 -2
theo-dur,and 1.0 0.000143348623853 1 0 1
monitored,especially 0.0 0.0 1 1 0
can,follow 1.0 0.000143348623853 1 0 1
water,orange 1.0 0.000143348623853 0 1 -1
reduce,hepatic 1.0 0.000143348623853 1 0 1
l,were 1.0 0.00043004587156 0 3 -3
d2-antagonists,such 1.0 0.000143348623853 1 0 1
disease,morbidity 1.0 0.000143348623853 0 1 -1
serum,assays 1.0 0.000143348623853 0 1 -1
be,separated 0.0 0.0 1 1 0
once,the 1.0 0.000143348623853 0 1 -1
but,its 1.0 0.000143348623853 0 1 -1
phosphorylation,of 0.0 0.0 3 3 0
hydrogen,breath 1.0 0.000143348623853 0 1 -1
in,sub-therapeutic 1.0 0.000143348623853 1 0 1
misonidazole,reduced 1.0 0.000143348623853 1 0 1
hypotensive,using 1.0 0.000143348623853 1 0 1
drug,or 1.0 0.000286697247706 0 2 -2
in,myopathy 1.0 0.000143348623853 0 1 -1
single,enzyme 1.0 0.000143348623853 0 1 -1
greater,ischemic 1.0 0.000143348623853 1 0 1
with,potent 0.0 0.0 3 3 0
these,combinations 1.0 0.000286697247706 0 2 -2
volunteers,administration 1.0 0.000143348623853 0 1 -1
involve,individual 1.0 0.000143348623853 0 1 -1
a,pure 1.0 0.000143348623853 1 0 1
which,includes 1.0 0.000143348623853 0 1 -1
in,uterine 1.0 0.000143348623853 1 0 1
fronti,res 1.0 0.000143348623853 0 1 -1
in,breast 1.0 0.000143348623853 0 1 -1
modified,by 1.0 0.000143348623853 1 0 1
propranolols,hypotensive 1.0 0.000143348623853 1 0 1
of,dimethylprostaglandin 1.0 0.000143348623853 0 1 -1
for,decreased 1.0 0.000143348623853 0 1 -1
cell,membrane 1.0 0.000143348623853 0 1 -1
weakness,in 1.0 0.000143348623853 1 0 1
not,vary 1.0 0.000143348623853 0 1 -1
serum,amylase 1.0 0.000143348623853 0 1 -1
when,known 1.0 0.000143348623853 0 1 -1
his,risk 1.0 0.000143348623853 0 1 -1
clorazepate,dipotassium 1.0 0.000143348623853 1 0 1
inhibitor,being 1.0 0.000143348623853 0 1 -1
nalfon,the 1.0 0.000143348623853 1 0 1
erroneous,and 1.0 0.000143348623853 0 1 -1
on,the 0.626459143969 0.0230791284404 48 209 -161
and,organic 1.0 0.000286697247706 2 0 2
recommended,since 1.0 0.000143348623853 1 0 1
glycemic,control 1.0 0.000286697247706 0 2 -2
clear,reproducible 1.0 0.000143348623853 0 1 -1
administered,and 0.0 0.0 1 1 0
reached,whereas 1.0 0.000143348623853 0 1 -1
theoretically,possible 0.0 0.0 1 1 0
of,nephrolithiasis 1.0 0.000143348623853 1 0 1
are,thought 1.0 0.000286697247706 0 2 -2
determined,on 0.0 0.0 1 1 0
varying,degrees 1.0 0.000143348623853 0 1 -1
is,principally 1.0 0.000143348623853 0 1 -1
pi,was 1.0 0.000143348623853 0 1 -1
cimetidine,cimetidine 0.666666666667 0.000573394495413 5 1 4
levels,about 1.0 0.000143348623853 0 1 -1
adrenergic,agonists 1.0 0.000143348623853 1 0 1
is,related 1.0 0.000143348623853 0 1 -1
hydrolase,carbamazepine 1.0 0.000143348623853 0 1 -1
in,areas 1.0 0.000143348623853 0 1 -1
generally,converted 1.0 0.000143348623853 1 0 1
unrecognized,interactions 1.0 0.000143348623853 0 1 -1
affinity,binding 1.0 0.000286697247706 0 2 -2
arc,mrna 0.0 0.0 1 1 0
not,limited 0.0 0.0 2 2 0
urine,creatinine 1.0 0.00043004587156 0 3 -3
by,mug 1.0 0.000286697247706 0 2 -2
indications,and 1.0 0.000143348623853 0 1 -1
the,immunodepressant--the 1.0 0.000143348623853 0 1 -1
available,to 1.0 0.000143348623853 0 1 -1
on,application 1.0 0.000143348623853 0 1 -1
lofexidine,may 1.0 0.000286697247706 2 0 2
psychotropic,agents 1.0 0.000286697247706 2 0 2
multiple-dose,interaction 1.0 0.000143348623853 0 1 -1
effect,beyond 1.0 0.000143348623853 1 0 1
given,hours 0.333333333333 0.000143348623853 2 1 1
felbatol,to 1.0 0.000143348623853 1 0 1
of,mean 1.0 0.000143348623853 1 0 1
mean,daily 1.0 0.000143348623853 0 1 -1
to,therapy 0.5 0.000286697247706 3 1 2
phosphatases,in 1.0 0.000143348623853 0 1 -1
by,mu- 1.0 0.000143348623853 0 1 -1
and,concurrent 1.0 0.000286697247706 2 0 2
received,chop-haart 1.0 0.000143348623853 0 1 -1
ibogaine,attenuates 1.0 0.000143348623853 1 0 1
in,glutamatergic 1.0 0.000143348623853 0 1 -1
in,switching 0.6 0.00043004587156 4 1 3
with,targretin 1.0 0.000143348623853 1 0 1
with,since 1.0 0.00043004587156 3 0 3
ca,i 0.0 0.0 1 1 0
or,when 1.0 0.00043004587156 0 3 -3
sustiva,mg 0.0 0.0 1 1 0
elevated,blood 1.0 0.000143348623853 0 1 -1
age,gender 1.0 0.000143348623853 0 1 -1
coadministration,n 1.0 0.000143348623853 1 0 1
physician,may 1.0 0.000143348623853 1 0 1
dependency,of 1.0 0.000143348623853 0 1 -1
removal,was 1.0 0.000143348623853 0 1 -1
involving,renal 1.0 0.000143348623853 1 0 1
a,later 1.0 0.000286697247706 0 2 -2
the,french 1.0 0.000143348623853 0 1 -1
muscle,in 1.0 0.000143348623853 1 0 1
comprehensive,information 1.0 0.000143348623853 0 1 -1
and,scanning 1.0 0.000143348623853 0 1 -1
neoral,sandimmune 1.0 0.000143348623853 1 0 1
size,to 1.0 0.000143348623853 0 1 -1
on,drug 1.0 0.00043004587156 0 3 -3
italy,from 1.0 0.000143348623853 0 1 -1
useful,pharmacological 1.0 0.000143348623853 0 1 -1
required,will 1.0 0.000143348623853 0 1 -1
of,anaphylactic 0.5 0.000286697247706 1 3 -2
is,particularly 1.0 0.000286697247706 0 2 -2
the,identity 1.0 0.000143348623853 0 1 -1
proteins,other 1.0 0.000286697247706 0 2 -2
seroquel,is 1.0 0.000143348623853 0 1 -1
tachycardia,dryness 1.0 0.000143348623853 1 0 1
animals,edetate 1.0 0.000143348623853 1 0 1
pi,related 1.0 0.000143348623853 0 1 -1
brevibloc,and 0.0 0.0 1 1 0
speech,coordination 1.0 0.000143348623853 0 1 -1
wort,may 0.5 0.000286697247706 1 3 -2
rabbit,erythrocyte 1.0 0.000143348623853 0 1 -1
a,sensitivity 1.0 0.000143348623853 0 1 -1
with,laboratory 1.0 0.000143348623853 0 1 -1
and,certain 0.333333333333 0.000143348623853 2 1 1
lesser,extent 0.333333333333 0.000143348623853 1 2 -1
depressant,cns 1.0 0.000143348623853 0 1 -1
sometimes,fatal 1.0 0.000143348623853 1 0 1
with,allopurinol 1.0 0.000143348623853 1 0 1
oral,absorption 1.0 0.00043004587156 3 0 3
inhibitor,nnrti 1.0 0.000143348623853 0 1 -1
the,acquisition 1.0 0.000143348623853 0 1 -1
with,available 1.0 0.000143348623853 1 0 1
in,females 0.333333333333 0.000143348623853 1 2 -1
on,coumarin-type 1.0 0.000143348623853 1 0 1
evident,following 1.0 0.000143348623853 0 1 -1
cared,for 1.0 0.000143348623853 0 1 -1
strattera,should 0.0 0.0 1 1 0
the,cmax 0.571428571429 0.00114678899083 11 3 8
total,formation 1.0 0.000143348623853 1 0 1
or,corticosteroids 1.0 0.000143348623853 0 1 -1
d,for 1.0 0.000286697247706 2 0 2
intravenous,amphotericin 1.0 0.000143348623853 1 0 1
be,at 0.666666666667 0.000573394495413 1 5 -4
to,closely 1.0 0.000143348623853 0 1 -1
benefits,and 0.0 0.0 1 1 0
experiments,for 1.0 0.000143348623853 0 1 -1
mc,block 1.0 0.000143348623853 1 0 1
containing,either 1.0 0.000143348623853 0 1 -1
rings,with 0.0 0.0 1 1 0
with,natrecor 1.0 0.000286697247706 0 2 -2
a,weak 0.5 0.000286697247706 1 3 -2
drug,treatment 1.0 0.000143348623853 0 1 -1
receiving,combination 1.0 0.000143348623853 1 0 1
can,displace 1.0 0.000143348623853 1 0 1
lastly,local 1.0 0.000143348623853 0 1 -1
aerobic,facultative 1.0 0.000143348623853 0 1 -1
numerous,liver 1.0 0.000143348623853 0 1 -1
spectrum,may 1.0 0.000143348623853 0 1 -1
substitutes,containing 1.0 0.000286697247706 0 2 -2
withhold,during 1.0 0.000143348623853 1 0 1
or,h2antagonists 1.0 0.000143348623853 1 0 1
aminotransferase,determinations 1.0 0.000143348623853 0 1 -1
and,pharmaco-dynamic 1.0 0.000143348623853 0 1 -1
flushing,and 1.0 0.000143348623853 0 1 -1
gradual,in 1.0 0.000143348623853 1 0 1
the,modulatory 1.0 0.000143348623853 0 1 -1
addicts,were 1.0 0.000143348623853 1 0 1
and,heparin 1.0 0.000143348623853 1 0 1
weak,effect 1.0 0.000143348623853 1 0 1
like,smoking 1.0 0.000143348623853 0 1 -1
similar,interaction 0.333333333333 0.000143348623853 1 2 -1
double,blind 1.0 0.000143348623853 0 1 -1
anti-neoplastic,agents 1.0 0.000143348623853 0 1 -1
as,cyp3a4 1.0 0.000143348623853 1 0 1
exact,length 1.0 0.000143348623853 0 1 -1
weighed,against 0.333333333333 0.000143348623853 1 2 -1
is,required 0.538461538462 0.00100344036697 3 10 -7
male,volunteers 0.5 0.000573394495413 2 6 -4
with,bioavailability 1.0 0.000143348623853 0 1 -1
pulmonary,extract 1.0 0.000143348623853 0 1 -1
when,eye 1.0 0.000143348623853 0 1 -1
and,beta-blocking 1.0 0.000143348623853 0 1 -1
thus,could 1.0 0.000143348623853 0 1 -1
heavy,intake 1.0 0.000143348623853 1 0 1
meal,hour 1.0 0.000143348623853 0 1 -1
animal,toxicology 1.0 0.000143348623853 0 1 -1
leukocytosis,elevated 1.0 0.000143348623853 1 0 1
did,occur 1.0 0.000143348623853 0 1 -1
as,determined 1.0 0.000143348623853 0 1 -1
taking,any 0.5 0.000286697247706 1 3 -2
with,radiation 1.0 0.000143348623853 0 1 -1
administered,due 1.0 0.000143348623853 0 1 -1
be,altered 1.0 0.000143348623853 0 1 -1
fired,spontaneous 1.0 0.000143348623853 0 1 -1
indeed,have 1.0 0.000143348623853 1 0 1
in,arc 1.0 0.000143348623853 1 0 1
antifungals,protease 1.0 0.000143348623853 0 1 -1
c19,inhibitors 1.0 0.000143348623853 0 1 -1
starlix,three 1.0 0.000143348623853 0 1 -1
should,receive 0.333333333333 0.000143348623853 2 1 1
thus,the 0.0 0.0 3 3 0
will,occur 1.0 0.000143348623853 0 1 -1
preparations,which 1.0 0.000143348623853 0 1 -1
glucose,metabolism 1.0 0.00043004587156 0 3 -3
animal,models 1.0 0.000143348623853 0 1 -1
chloral,hydrate 0.142857142857 0.000143348623853 4 3 1
before,initiating 0.6 0.00043004587156 1 4 -3
to,occasionally 0.5 0.000286697247706 1 3 -2
a,stimulator 1.0 0.000143348623853 1 0 1
fu,bolus-ifl 1.0 0.000143348623853 0 1 -1
given,did 1.0 0.000143348623853 0 1 -1
was,similar 1.0 0.00129013761468 0 9 -9
may,wish 1.0 0.000143348623853 1 0 1
the,outcome 1.0 0.000143348623853 0 1 -1
infarction,vs 1.0 0.000143348623853 1 0 1
cefizox,nephrotoxicity 1.0 0.000143348623853 1 0 1
data,which 1.0 0.000143348623853 1 0 1
fluorescence,labelled 1.0 0.000143348623853 0 1 -1
carefully,for 1.0 0.000573394495413 4 0 4
antisense,oligomer 1.0 0.000143348623853 0 1 -1
no,cyp3a4 1.0 0.000143348623853 0 1 -1
is,little 1.0 0.00043004587156 0 3 -3
its,effects 1.0 0.000286697247706 0 2 -2
adrenergic,antagonism 1.0 0.000143348623853 1 0 1
commonly,to 1.0 0.000143348623853 0 1 -1
dynacirc,has 1.0 0.000143348623853 0 1 -1
c19,d6 1.0 0.000860091743119 0 6 -6
trace,elements 1.0 0.000143348623853 0 1 -1
patients,without 0.0 0.0 1 1 0
membrane,sterol 1.0 0.000143348623853 0 1 -1
and,chop 1.0 0.000143348623853 0 1 -1
representations,of 1.0 0.000143348623853 0 1 -1
a,combined 1.0 0.000143348623853 0 1 -1
pharmacokinetic,and 1.0 0.000286697247706 0 2 -2
of,mefloquineuine 1.0 0.000286697247706 0 2 -2
cardiovascular,are 1.0 0.000143348623853 0 1 -1
thorough,medication 1.0 0.000143348623853 0 1 -1
flow,caused 1.0 0.000143348623853 0 1 -1
with,compared 1.0 0.000286697247706 2 0 2
these,same 1.0 0.000143348623853 0 1 -1
be,approved 1.0 0.000143348623853 0 1 -1
suspension,were 1.0 0.000143348623853 1 0 1
distribution,metabolism 1.0 0.000143348623853 0 1 -1
were,found 1.0 0.000573394495413 0 4 -4
ninth,day 1.0 0.000143348623853 0 1 -1
kidneys,along 1.0 0.000143348623853 0 1 -1
of,sulfoxide 0.333333333333 0.000143348623853 2 1 1
mesenteric,arteries 1.0 0.000286697247706 0 2 -2
acid,sali-cylates 1.0 0.000143348623853 0 1 -1
beta-blockers,and 1.0 0.000143348623853 1 0 1
phosphorylated,concentration 1.0 0.000143348623853 0 1 -1
of,bezalip 1.0 0.000143348623853 1 0 1
with,containing 1.0 0.000286697247706 2 0 2
krm-1648,has 1.0 0.000143348623853 0 1 -1
brain,hemorrhage 1.0 0.000286697247706 0 2 -2
ganglionic,or 1.0 0.000143348623853 0 1 -1
administration,systemic 1.0 0.000143348623853 1 0 1
has,received 1.0 0.000143348623853 1 0 1
was,poorly 1.0 0.000143348623853 1 0 1
increased,dosages 1.0 0.000143348623853 1 0 1
with,products 1.0 0.000143348623853 1 0 1
day9,of 1.0 0.000143348623853 1 0 1
emergency,situation 1.0 0.000143348623853 1 0 1
subsequently,administered 1.0 0.000143348623853 1 0 1
compounds,meclofenamic 1.0 0.000143348623853 1 0 1
pbi,levels 1.0 0.000143348623853 0 1 -1
of,disease 1.0 0.000286697247706 0 2 -2
pacemaker,in 1.0 0.000143348623853 0 1 -1
medications,on 1.0 0.000143348623853 0 1 -1
single-dose,crossover 1.0 0.000143348623853 1 0 1
or,systemic 0.0 0.0 1 1 0
organoleads,are 1.0 0.000143348623853 0 1 -1
normal,male 1.0 0.000143348623853 1 0 1
steady-state,peak 1.0 0.000143348623853 1 0 1
for,diagnosis 1.0 0.000286697247706 0 2 -2
rapidly,by 1.0 0.000143348623853 0 1 -1
oral,cough 1.0 0.000143348623853 0 1 -1
infectious,complications 1.0 0.000143348623853 0 1 -1
verapamil,also 1.0 0.000143348623853 1 0 1
requiring,increased 1.0 0.000143348623853 1 0 1
by,separate 1.0 0.000143348623853 0 1 -1
who,take 1.0 0.00043004587156 0 3 -3
once-daily,dose 1.0 0.000143348623853 0 1 -1
coronary,oral 1.0 0.000143348623853 0 1 -1
mm,had 1.0 0.000143348623853 0 1 -1
tea,polyphenols 1.0 0.000143348623853 0 1 -1
if,prinivil 1.0 0.000143348623853 1 0 1
and,inhibits 1.0 0.000143348623853 1 0 1
while,transfer 1.0 0.000143348623853 0 1 -1
increased,susceptibility 1.0 0.000143348623853 0 1 -1
affect,responding 1.0 0.000143348623853 0 1 -1
isolates,of 1.0 0.000143348623853 0 1 -1
or,herb 1.0 0.000286697247706 0 2 -2
is,due 0.5 0.000286697247706 3 1 2
affects,the 1.0 0.000143348623853 1 0 1
patients,random 1.0 0.000143348623853 0 1 -1
of,lessened 1.0 0.000143348623853 0 1 -1
and,quinolones 1.0 0.000143348623853 0 1 -1
cyp2d6,or 1.0 0.000143348623853 0 1 -1
to,baseline 1.0 0.000143348623853 1 0 1
depletor,should 1.0 0.00043004587156 0 3 -3
gdh,pqq 1.0 0.000143348623853 0 1 -1
produce,severe 1.0 0.000716743119266 5 0 5
attention,should 1.0 0.000286697247706 0 2 -2
to,values 1.0 0.000143348623853 0 1 -1
by,fluorimetric 1.0 0.000143348623853 0 1 -1
performed,on 1.0 0.000573394495413 0 4 -4
s,d 0.0 0.0 1 1 0
drug,administration 1.0 0.000143348623853 0 1 -1
control,side 1.0 0.000143348623853 0 1 -1
s,a 1.0 0.000143348623853 1 0 1
and,permit 1.0 0.000143348623853 0 1 -1
s,c 1.0 0.000286697247706 2 0 2
the,general 1.0 0.000860091743119 0 6 -6
interval,clinical 1.0 0.000143348623853 0 1 -1
vitro,aspirin-mediated 1.0 0.000143348623853 0 1 -1
days,are 1.0 0.000143348623853 0 1 -1
blood,cell 1.0 0.000143348623853 0 1 -1
phenothiazine-related,compounds 1.0 0.000143348623853 1 0 1
usage,of 1.0 0.000143348623853 0 1 -1
a,decision 1.0 0.00043004587156 0 3 -3
substrate,with 1.0 0.000143348623853 1 0 1
for,subsequent 1.0 0.000143348623853 0 1 -1
cholestyramine,resin 1.0 0.000143348623853 0 1 -1
of,hcl 0.333333333333 0.000143348623853 2 1 1
include,acute 1.0 0.000143348623853 1 0 1
females,and 0.0 0.0 1 1 0
reduce,basal 1.0 0.000143348623853 0 1 -1
associated,side-effect 1.0 0.000143348623853 0 1 -1
may,regulate 1.0 0.000143348623853 1 0 1
fivefold,increase 1.0 0.000143348623853 0 1 -1
although,acid-base 1.0 0.000143348623853 1 0 1
practitioners,any 1.0 0.000143348623853 0 1 -1
components,in 1.0 0.000143348623853 0 1 -1
because,reduces 1.0 0.000143348623853 1 0 1
on,responses 1.0 0.000143348623853 0 1 -1
well,after 1.0 0.000143348623853 0 1 -1
transplant,recipients 0.0 0.0 1 1 0
r-warfarin,or 1.0 0.000143348623853 0 1 -1
others,prelone 1.0 0.000143348623853 0 1 -1
disorder,requires 1.0 0.000143348623853 0 1 -1
significant,change 1.0 0.000573394495413 0 4 -4
using,morphological 1.0 0.000143348623853 1 0 1
concentrates,should 1.0 0.000143348623853 0 1 -1
disorders,treated 1.0 0.000143348623853 1 0 1
of,myelotoxicity 1.0 0.000143348623853 0 1 -1
mtc-methylene,diphosphonate 1.0 0.000143348623853 1 0 1
drugs,clonazepam 1.0 0.000143348623853 0 1 -1
active,tubular 0.0 0.0 1 1 0
this,patient 1.0 0.000143348623853 0 1 -1
iron,supplements 1.0 0.000143348623853 1 0 1
clotting,time 1.0 0.00043004587156 0 3 -3
and,combined 1.0 0.000143348623853 0 1 -1
first,phase 1.0 0.000143348623853 0 1 -1
many,and 1.0 0.000143348623853 0 1 -1
continuing,rise 1.0 0.000143348623853 0 1 -1
lower,with 1.0 0.000143348623853 0 1 -1
enzyme,in 1.0 0.000143348623853 0 1 -1
fexofenadine,has 1.0 0.000143348623853 0 1 -1
in,order 0.578947368421 0.00157683486239 4 15 -11
or,intravenous 1.0 0.000286697247706 2 0 2
and,given 1.0 0.000143348623853 0 1 -1
are,potentiated 1.0 0.000143348623853 1 0 1
fexofenadine,had 1.0 0.000143348623853 0 1 -1
by,either 0.428571428571 0.00043004587156 5 2 3
query,patients 1.0 0.000143348623853 0 1 -1
individual,glucose 1.0 0.000143348623853 1 0 1
decrease,blood 0.5 0.000286697247706 3 1 2
thereby,potentially 1.0 0.000143348623853 1 0 1
and,pre-sacral 1.0 0.000143348623853 0 1 -1
cause,headaches 1.0 0.000286697247706 0 2 -2
example,complications 1.0 0.000143348623853 0 1 -1
is,decreased 1.0 0.000716743119266 0 5 -5
the,initial 0.230769230769 0.00043004587156 5 8 -3
additive,or 0.6 0.00043004587156 4 1 3
inhibitor,increased 1.0 0.000143348623853 1 0 1
other,topical 1.0 0.000286697247706 0 2 -2
therapy,mainly 1.0 0.000143348623853 0 1 -1
high,blood 1.0 0.000286697247706 2 0 2
these,experiences 1.0 0.000143348623853 0 1 -1
l-glutamine,was 1.0 0.000143348623853 0 1 -1
cell,could 1.0 0.000143348623853 0 1 -1
inhibitor,increases 1.0 0.000143348623853 1 0 1
increased,or 1.0 0.000143348623853 0 1 -1
are,present 1.0 0.000143348623853 0 1 -1
the,animals 1.0 0.000143348623853 0 1 -1
this,increased 1.0 0.000286697247706 0 2 -2
fehlings,solution 1.0 0.00043004587156 0 3 -3
ml,with 0.333333333333 0.000143348623853 2 1 1
herbal,products 1.0 0.000286697247706 0 2 -2
is,seen 1.0 0.000143348623853 0 1 -1
muscle,was 1.0 0.000143348623853 0 1 -1
mineral,oil-concomitant 1.0 0.000143348623853 1 0 1
seizures,may 1.0 0.000143348623853 0 1 -1
reflects,an 1.0 0.000143348623853 1 0 1
or,ldh 1.0 0.000143348623853 0 1 -1
capsules,since 1.0 0.000143348623853 1 0 1
this,slowing 1.0 0.000286697247706 0 2 -2
other,acting 1.0 0.000286697247706 0 2 -2
recommended,unless 1.0 0.000143348623853 1 0 1
future,studies 1.0 0.000143348623853 0 1 -1
week,following 1.0 0.000143348623853 0 1 -1
acute,release 1.0 0.000143348623853 0 1 -1
of,antidepressant 0.5 0.000286697247706 1 3 -2
of,mouth 1.0 0.000143348623853 0 1 -1
various,cytochrome 1.0 0.000143348623853 0 1 -1
other,antituberculous 1.0 0.000143348623853 1 0 1
needed,when 0.0 0.0 1 1 0
problem,not 1.0 0.000143348623853 0 1 -1
of,learning 1.0 0.000143348623853 0 1 -1
the,induction 0.333333333333 0.000143348623853 2 1 1
synthesis,interfere 1.0 0.000143348623853 0 1 -1
homodimeric,disintegrin 1.0 0.000286697247706 0 2 -2
had,increased 1.0 0.000143348623853 0 1 -1
both,renal 1.0 0.000143348623853 0 1 -1
the,v 1.0 0.000143348623853 0 1 -1
tumors,of 1.0 0.000143348623853 0 1 -1
the,transfusion 1.0 0.000143348623853 0 1 -1
other,clinically 1.0 0.000143348623853 0 1 -1
the,c 0.333333333333 0.000143348623853 2 1 1
the,d 1.0 0.000143348623853 0 1 -1
lower,affinity 1.0 0.000143348623853 1 0 1
isoproterenol,hydrochloride 1.0 0.000143348623853 1 0 1
the,k 1.0 0.000143348623853 0 1 -1
the,kidneys 1.0 0.000286697247706 0 2 -2
antimicrobial,and 1.0 0.000143348623853 1 0 1
ml,administered 1.0 0.000143348623853 1 0 1
over,patients 0.5 0.000286697247706 1 3 -2
demonstrated,the 1.0 0.000143348623853 0 1 -1
been,used 0.75 0.00172018348624 2 14 -12
of,gleevec 1.0 0.000143348623853 1 0 1
reaction,either 1.0 0.000143348623853 0 1 -1
potentially,resulting 1.0 0.000286697247706 2 0 2
possibly,causing 1.0 0.000143348623853 1 0 1
propoxyphene,the 1.0 0.000143348623853 0 1 -1
sulfosalicylic,acid 1.0 0.000143348623853 0 1 -1
injury,as 1.0 0.000143348623853 0 1 -1
resistance,arteries 1.0 0.000286697247706 0 2 -2
symptoms,resolved 1.0 0.000286697247706 0 2 -2
further,reduced 1.0 0.000143348623853 0 1 -1
serious,interactions 1.0 0.000143348623853 1 0 1
more,malignant 1.0 0.000143348623853 0 1 -1
and,e1 1.0 0.000143348623853 0 1 -1
are,anticipated 1.0 0.000143348623853 0 1 -1
fi,or 1.0 0.000143348623853 1 0 1
and,secondary 0.0 0.0 1 1 0
through,various 1.0 0.000143348623853 0 1 -1
recognition,of 1.0 0.000143348623853 0 1 -1
containing,buffer 1.0 0.000143348623853 1 0 1
activity,enough 1.0 0.000143348623853 0 1 -1
minimal,inhibitory 1.0 0.000573394495413 0 4 -4
they,should 0.733333333333 0.00157683486239 2 13 -11
of,cyp1a2 0.0 0.0 1 1 0
diabetics,blood-sugar 1.0 0.000143348623853 0 1 -1
of,cyp1a1 1.0 0.000143348623853 0 1 -1
higher,incidence 0.0 0.0 1 1 0
by,concentrations 1.0 0.000143348623853 0 1 -1
latency,to 1.0 0.000143348623853 0 1 -1
with,larger 1.0 0.000286697247706 0 2 -2
a,pheochromocytoma 1.0 0.000143348623853 0 1 -1
dizziness,weakness 1.0 0.000143348623853 0 1 -1
proliferation-dependent,but 1.0 0.000143348623853 0 1 -1
by,platelets 1.0 0.000143348623853 0 1 -1
among,ras 1.0 0.000143348623853 0 1 -1
large,reduction 1.0 0.000143348623853 1 0 1
auc,after 1.0 0.00043004587156 3 0 3
greatest,in 1.0 0.000286697247706 0 2 -2
is,co 1.0 0.000143348623853 0 1 -1
note,all 1.0 0.000143348623853 0 1 -1
qd,is 1.0 0.000143348623853 1 0 1
transferred,to 1.0 0.000143348623853 0 1 -1
the,history 1.0 0.000143348623853 0 1 -1
efficacious,effects 1.0 0.000143348623853 0 1 -1
the,insp 1.0 0.000286697247706 0 2 -2
clozapine,should 1.0 0.000143348623853 0 1 -1
antiepilepsy,aeds 1.0 0.000143348623853 0 1 -1
the,polymer 1.0 0.000143348623853 0 1 -1
pressure,were 1.0 0.000143348623853 0 1 -1
than,two 1.0 0.000143348623853 1 0 1
rat,liver 1.0 0.000286697247706 0 2 -2
qd,in 1.0 0.000143348623853 0 1 -1
one-tenth,of 0.0 0.0 1 1 0
same,procedure 1.0 0.000286697247706 0 2 -2
orange,juices 1.0 0.000286697247706 0 2 -2
substantial,accumulation 1.0 0.000143348623853 1 0 1
and,pseudomonas 1.0 0.000143348623853 0 1 -1
lysate,of 1.0 0.000143348623853 0 1 -1
and,enhanced 1.0 0.000143348623853 0 1 -1
pcp,in 0.6 0.00043004587156 1 4 -3
anti-glaucoma,action 1.0 0.000143348623853 1 0 1
pulse,of 1.0 0.000286697247706 0 2 -2
and,thromboxane 1.0 0.000143348623853 0 1 -1
receiving,increased 1.0 0.000143348623853 0 1 -1
new,anaesthetic 1.0 0.000143348623853 0 1 -1
other,cns-active 0.0 0.0 1 1 0
day,relative 1.0 0.000143348623853 1 0 1
decreases,heart 1.0 0.000143348623853 0 1 -1
enzyme,responsible 1.0 0.000143348623853 1 0 1
more,when 1.0 0.000143348623853 0 1 -1
of,nm 1.0 0.000143348623853 0 1 -1
fulvestrant,is 1.0 0.000286697247706 0 2 -2
amerge,tablets 1.0 0.000143348623853 0 1 -1
or,anticoagulation 1.0 0.000143348623853 0 1 -1
to,diseases 1.0 0.000143348623853 0 1 -1
be,extrapolated 1.0 0.000143348623853 0 1 -1
syndrome,associated 1.0 0.000143348623853 1 0 1
antagonists,particularly 1.0 0.000143348623853 1 0 1
after,remained 1.0 0.000143348623853 0 1 -1
an,ability 1.0 0.000143348623853 0 1 -1
dosed,to 1.0 0.000143348623853 0 1 -1
pressure,without 1.0 0.000143348623853 1 0 1
no,deleterious 1.0 0.000143348623853 0 1 -1
or,delayed 1.0 0.000143348623853 1 0 1
somnolence,have 1.0 0.000143348623853 1 0 1
with,was 0.2 0.000143348623853 3 2 1
the,patch 1.0 0.000143348623853 0 1 -1
the,current 1.0 0.000286697247706 0 2 -2
carbachol-stimulated,intracellular 1.0 0.000143348623853 1 0 1
against,bacillus 1.0 0.000143348623853 1 0 1
for,and 0.571428571429 0.00114678899083 3 11 -8
coadministration,in 1.0 0.000143348623853 0 1 -1
was,enhanced 1.0 0.000286697247706 0 2 -2
in,small 1.0 0.000143348623853 0 1 -1
association,of 1.0 0.000143348623853 0 1 -1
cyclosporine,l-arginine 1.0 0.000143348623853 1 0 1
acetate,at 1.0 0.000143348623853 1 0 1
case,to 1.0 0.000143348623853 0 1 -1
the,enkephalinergic 1.0 0.000143348623853 1 0 1
kg,doses 1.0 0.000143348623853 1 0 1
using,cardiac 1.0 0.000143348623853 0 1 -1
concomitantly,careful 1.0 0.000143348623853 0 1 -1
for,any 0.777777777778 0.00100344036697 1 8 -7
chelation,and 1.0 0.000143348623853 0 1 -1
metabolite,may 0.0 0.0 1 1 0
of,cancidas 0.333333333333 0.000143348623853 2 1 1
p450iid6,such 1.0 0.000143348623853 1 0 1
exposure,auc0-12 1.0 0.000143348623853 0 1 -1
displays,both 1.0 0.000143348623853 0 1 -1
dosage,modifications 1.0 0.000286697247706 0 2 -2
necrosis,and 1.0 0.000143348623853 0 1 -1
electrolyte,imbalance 1.0 0.000143348623853 0 1 -1
cgs,an 1.0 0.000143348623853 1 0 1
by,forming 1.0 0.000143348623853 0 1 -1
acting,including 1.0 0.000143348623853 0 1 -1
been,recognized 1.0 0.000143348623853 0 1 -1
the,hatching 1.0 0.000143348623853 0 1 -1
may,lower 1.0 0.000143348623853 1 0 1
gammaherpes,virus 1.0 0.000143348623853 0 1 -1
nor,is 1.0 0.000143348623853 0 1 -1
diuretics,diclofenac 1.0 0.000143348623853 1 0 1
oxidase,in 0.0 0.0 1 1 0
and,inr 1.0 0.000143348623853 0 1 -1
initiated,after 1.0 0.000143348623853 0 1 -1
altering,cyp1a2-mediated 1.0 0.000143348623853 0 1 -1
if,necessary 0.666666666667 0.000573394495413 1 5 -4
an,inducer 0.714285714286 0.000716743119266 1 6 -5
data,presented 1.0 0.000143348623853 0 1 -1
serum,hormone 1.0 0.000143348623853 0 1 -1
depression,when 1.0 0.000143348623853 1 0 1
uterine,hypertonus 1.0 0.000143348623853 1 0 1
and,inn 1.0 0.000143348623853 0 1 -1
interval,certain 1.0 0.000286697247706 2 0 2
using,anafranil 1.0 0.000143348623853 0 1 -1
renally,impaired 1.0 0.000143348623853 0 1 -1
induce,fungal 1.0 0.000143348623853 1 0 1
or,non-opioid 1.0 0.000143348623853 0 1 -1
may,block 1.0 0.000143348623853 1 0 1
methods,we 1.0 0.000143348623853 0 1 -1
intervals,during 1.0 0.000143348623853 0 1 -1
a4,isozyme 1.0 0.000143348623853 0 1 -1
hepatic,oxidation 1.0 0.000143348623853 1 0 1
are,facilitated 1.0 0.000143348623853 0 1 -1
bind,other 0.333333333333 0.000143348623853 1 2 -1
furosemide,when 1.0 0.000143348623853 1 0 1
of,future 1.0 0.000143348623853 0 1 -1
and,longer 1.0 0.000143348623853 1 0 1
be,considered 0.421052631579 0.00229357798165 11 27 -16
volunteers,increased 1.0 0.000143348623853 0 1 -1
pyknotic,nuclei 1.0 0.000143348623853 0 1 -1
tetracycline,a 1.0 0.000286697247706 2 0 2
lexapro,did 1.0 0.000143348623853 1 0 1
extensive,cyp2d6 1.0 0.000143348623853 0 1 -1
single,dosage 1.0 0.000143348623853 0 1 -1
or,sodium 1.0 0.000143348623853 1 0 1
with,significantly 0.0 0.0 1 1 0
acid,nsaids 1.0 0.000143348623853 0 1 -1
inhalation,dose 0.333333333333 0.000143348623853 1 2 -1
anti-inflammatory,but 1.0 0.000143348623853 0 1 -1
clcr,and 1.0 0.000143348623853 1 0 1
active,therapy 1.0 0.000286697247706 0 2 -2
to,alpha 1.0 0.000143348623853 0 1 -1
which,can 0.2 0.000286697247706 6 4 2
hydrocortisone,mg 1.0 0.000143348623853 0 1 -1
barpress,response 1.0 0.000143348623853 0 1 -1
or,discontinue 1.0 0.000143348623853 0 1 -1
alpha,cell 1.0 0.000143348623853 0 1 -1
blockers,also 1.0 0.000143348623853 0 1 -1
mean,template 1.0 0.000143348623853 0 1 -1
highly,susceptible 1.0 0.000143348623853 0 1 -1
other,known 0.0 0.0 3 3 0
lodosyn,and 1.0 0.000143348623853 0 1 -1
to,monitor 0.636363636364 0.00100344036697 2 9 -7
because,efficient 1.0 0.000143348623853 0 1 -1
and,ast 1.0 0.000143348623853 1 0 1
avoid,bleeding 1.0 0.000143348623853 1 0 1
mac,out 1.0 0.000143348623853 0 1 -1
showed,significant 1.0 0.000143348623853 0 1 -1
extent,of 0.739130434783 0.0024369266055 3 20 -17
months,had 1.0 0.000143348623853 0 1 -1
rejection,episodes 1.0 0.000143348623853 0 1 -1
uptake-1,carrier 1.0 0.000143348623853 0 1 -1
griseofulvin,may 1.0 0.000143348623853 1 0 1
either,long-acting 1.0 0.000143348623853 0 1 -1
the,glands 1.0 0.000286697247706 0 2 -2
beyond,that 1.0 0.000143348623853 1 0 1
cyp3a4,cyp2d6 1.0 0.000286697247706 0 2 -2
of,hctz 1.0 0.000143348623853 0 1 -1
mitogenic,activity 1.0 0.000143348623853 1 0 1
competitively,inhibit 1.0 0.000143348623853 1 0 1
conducted,although 1.0 0.000143348623853 0 1 -1
experience,significantly 1.0 0.000143348623853 0 1 -1
using,the 0.6 0.000860091743119 2 8 -6
suppresses,gastric 1.0 0.000143348623853 0 1 -1
the,problems 1.0 0.000286697247706 0 2 -2
stress,induction 1.0 0.000143348623853 0 1 -1
from,an 1.0 0.00043004587156 0 3 -3
myalgia,and 1.0 0.000143348623853 1 0 1
metabolism,decreased 1.0 0.000143348623853 1 0 1
addition,results 1.0 0.000143348623853 1 0 1
the,study 1.0 0.00114678899083 0 8 -8
from,at 1.0 0.000143348623853 0 1 -1
abnormal,in 1.0 0.000143348623853 0 1 -1
irrespective,of 1.0 0.000143348623853 0 1 -1
of,miles 1.0 0.000143348623853 0 1 -1
if,diminished 1.0 0.000143348623853 1 0 1
vitro,appears 1.0 0.000143348623853 1 0 1
proliferates,in 1.0 0.000143348623853 0 1 -1
mixtures,should 1.0 0.000143348623853 0 1 -1
trexan,with 1.0 0.000143348623853 0 1 -1
was,co-administered 0.333333333333 0.000286697247706 2 4 -2
produced,average 1.0 0.000143348623853 1 0 1
daily,may 1.0 0.000143348623853 1 0 1
coexisting,in 1.0 0.000143348623853 0 1 -1
however,neuromuscular 1.0 0.000143348623853 0 1 -1
then,wait 1.0 0.000143348623853 1 0 1
its,permeation 1.0 0.000143348623853 0 1 -1
of,dissolution 1.0 0.00043004587156 0 3 -3
channel,and 1.0 0.000143348623853 0 1 -1
fold,increase 0.047619047619 0.000143348623853 11 10 1
resistant,strains 1.0 0.000143348623853 0 1 -1
at,weekly 1.0 0.000286697247706 0 2 -2
cns,cardiac 1.0 0.000143348623853 0 1 -1
may,give 1.0 0.000143348623853 1 0 1
subset,to 1.0 0.000143348623853 0 1 -1
of,for 0.666666666667 0.000573394495413 1 5 -4
of,our 1.0 0.000143348623853 1 0 1
theoretically,could 1.0 0.000143348623853 0 1 -1
minutes,after 0.0 0.0 1 1 0
triacylglycerol,synthesis 1.0 0.000143348623853 0 1 -1
between,intravenous 1.0 0.000143348623853 0 1 -1
a,defined 1.0 0.000143348623853 0 1 -1
the,number 0.6 0.000860091743119 2 8 -6
is,considered 1.0 0.000716743119266 0 5 -5
bile,acid 0.5 0.000286697247706 3 1 2
prothrombin,or 1.0 0.000143348623853 0 1 -1
least,seven 1.0 0.000143348623853 0 1 -1
oxidase,inhibitors 0.809523809524 0.0024369266055 19 2 17
theophylline,enoxacin 1.0 0.000143348623853 1 0 1
vitro,to 1.0 0.000143348623853 0 1 -1
oxidase,inhibitory 1.0 0.000143348623853 0 1 -1
route,of 0.0 0.0 1 1 0
psychotic,reaction 1.0 0.000143348623853 0 1 -1
toradol,induces 1.0 0.000143348623853 0 1 -1
coadministration,with 0.333333333333 0.000573394495413 8 4 4
vasospastic,effects 1.0 0.000143348623853 1 0 1
rat,the 1.0 0.000143348623853 0 1 -1
water-miscible,or 1.0 0.000143348623853 0 1 -1
hydrate,may 1.0 0.000143348623853 1 0 1
factors,such 1.0 0.00043004587156 0 3 -3
an,with 1.0 0.000143348623853 1 0 1
mainly,metabolized 0.0 0.0 1 1 0
products,have 1.0 0.000143348623853 0 1 -1
which,a 0.0 0.0 1 1 0
affecting,patients 1.0 0.000143348623853 0 1 -1
perfusion,did 1.0 0.000143348623853 0 1 -1
which,d 1.0 0.000143348623853 1 0 1
thyroid,administration 1.0 0.000143348623853 1 0 1
toxic,effect 1.0 0.000143348623853 1 0 1
best,approach 1.0 0.000143348623853 0 1 -1
the,rate-decreasing 1.0 0.000143348623853 1 0 1
months,the 1.0 0.000143348623853 0 1 -1
the,during 1.0 0.000143348623853 1 0 1
chylomicron,intravascular 1.0 0.000143348623853 0 1 -1
the,bad 1.0 0.000143348623853 1 0 1
or,fertility 1.0 0.000143348623853 0 1 -1
events,with 1.0 0.000143348623853 0 1 -1
prevention,and 1.0 0.000143348623853 0 1 -1
effects,following 1.0 0.000143348623853 0 1 -1
with,biliary 1.0 0.000143348623853 0 1 -1
with,lowered 1.0 0.000286697247706 2 0 2
d2o,was 1.0 0.000143348623853 0 1 -1
basic,area 1.0 0.000143348623853 0 1 -1
which,increased 1.0 0.000143348623853 0 1 -1
increasing,serum 0.333333333333 0.000143348623853 2 1 1
days,increased 1.0 0.00043004587156 3 0 3
dexamethasone,had 1.0 0.000143348623853 0 1 -1
lower,respectively 1.0 0.000143348623853 0 1 -1
men,who 1.0 0.000143348623853 0 1 -1
days,increases 1.0 0.000143348623853 0 1 -1
these,reports 1.0 0.00043004587156 0 3 -3
which,increases 1.0 0.000143348623853 1 0 1
concomitant,supplementation 1.0 0.000143348623853 0 1 -1
other,asthma 1.0 0.000143348623853 0 1 -1
non-governmental,organisation 1.0 0.000143348623853 0 1 -1
findings,suggest 1.0 0.000573394495413 0 4 -4
invirase,is 1.0 0.000143348623853 1 0 1
conditions,duloxetine 1.0 0.000143348623853 0 1 -1
metabolic,interference 1.0 0.000143348623853 0 1 -1
thyroxine,output 1.0 0.000143348623853 0 1 -1
and,regulation 1.0 0.000143348623853 0 1 -1
l-ccg,on 1.0 0.000143348623853 0 1 -1
valproate,tiagabine 1.0 0.000143348623853 1 0 1
best,adaptive 1.0 0.000143348623853 0 1 -1
increased,risk 0.142857142857 0.000573394495413 12 16 -4
therapeutic,actions 1.0 0.000143348623853 1 0 1
auc,decreased 1.0 0.000143348623853 1 0 1
a,useful 1.0 0.000286697247706 0 2 -2
affect,metabolism 1.0 0.000143348623853 0 1 -1
with,plendil 1.0 0.000143348623853 0 1 -1
characterized,by 0.25 0.000286697247706 3 5 -2
and,cyp 1.0 0.000716743119266 0 5 -5
initiating,adjusting 1.0 0.000573394495413 4 0 4
to,occur 0.6 0.00043004587156 1 4 -3
sympathetic,effects 1.0 0.000143348623853 1 0 1
reduction,as 1.0 0.000143348623853 0 1 -1
positive,and 1.0 0.000716743119266 0 5 -5
laboratory,tests 0.866666666667 0.00186353211009 1 14 -13
examinations,for 1.0 0.000143348623853 0 1 -1
ex,vivo 1.0 0.000143348623853 0 1 -1
to,published 1.0 0.000143348623853 0 1 -1
antiasthmatic,dose 1.0 0.000143348623853 0 1 -1
drawn,either 1.0 0.000143348623853 0 1 -1
important,determinants 1.0 0.000143348623853 0 1 -1
suppression,by 1.0 0.000286697247706 2 0 2
with,therapeutic 0.0 0.0 1 1 0
clinical,trials 0.783783783784 0.00415711009174 4 33 -29
presents,findings 1.0 0.000143348623853 0 1 -1
of,acarbose 1.0 0.000143348623853 1 0 1
disease,rather 1.0 0.000143348623853 0 1 -1
experience,toxicity 1.0 0.000143348623853 1 0 1
or,renal 0.6 0.00043004587156 1 4 -3
amphetamines,potentiate 1.0 0.000286697247706 2 0 2
of,k-dependent 1.0 0.000286697247706 0 2 -2
ions,in 1.0 0.000143348623853 0 1 -1
patients,should 0.166666666667 0.000573394495413 10 14 -4
meq,l 0.0 0.0 1 1 0
prescribing,concomitantly 1.0 0.000143348623853 0 1 -1
ca,dependent 1.0 0.000143348623853 0 1 -1
excretion,glucuronidation 1.0 0.000143348623853 0 1 -1
episodes,of 1.0 0.000143348623853 0 1 -1
c9,c19 1.0 0.00129013761468 0 9 -9
colony,stimulating 1.0 0.000143348623853 0 1 -1
or,blood 1.0 0.000143348623853 0 1 -1
well-defined,pharmacokinetic-pharmacodynamic 1.0 0.000143348623853 0 1 -1
curare-like,compounds 1.0 0.000286697247706 2 0 2
week,for 1.0 0.000143348623853 1 0 1
nerve,transmission 1.0 0.000143348623853 0 1 -1
first,rapid 1.0 0.000143348623853 0 1 -1
plasma,flow 1.0 0.000286697247706 0 2 -2
infusions,of 0.333333333333 0.000143348623853 1 2 -1
rate,and 0.333333333333 0.00043004587156 3 6 -3
the,monoamine 1.0 0.000143348623853 0 1 -1
is,summarized 1.0 0.000143348623853 0 1 -1
by,brevibloc 1.0 0.000143348623853 1 0 1
the,antianginal 1.0 0.000143348623853 0 1 -1
immunoreactive,concentrations 1.0 0.000143348623853 0 1 -1
after,administration 0.0769230769231 0.000143348623853 6 7 -1
condition,worse 1.0 0.000143348623853 0 1 -1
tumor,virus 1.0 0.000143348623853 0 1 -1
antihypertensive,action 0.0 0.0 1 1 0
major,circulating 1.0 0.000143348623853 0 1 -1
terminate,treatment 1.0 0.000143348623853 0 1 -1
that,inhibited 1.0 0.000286697247706 0 2 -2
chronic,treatment 0.0 0.0 1 1 0
maxipime,because 1.0 0.000143348623853 1 0 1
produced,no 1.0 0.000286697247706 0 2 -2
of,grade 1.0 0.000143348623853 0 1 -1
numerous,potentiation 1.0 0.000143348623853 0 1 -1
disturbances,such 1.0 0.000143348623853 0 1 -1
and,local 0.333333333333 0.000143348623853 1 2 -1
react,with 1.0 0.000143348623853 1 0 1
function,the 0.333333333333 0.000143348623853 1 2 -1
epirubicin-based,chemotherapy 1.0 0.000143348623853 0 1 -1
administration,however 1.0 0.000143348623853 0 1 -1
hypoglycemics,bepridil 1.0 0.000143348623853 0 1 -1
marker,substrates 1.0 0.000143348623853 0 1 -1
to,nearly 1.0 0.000143348623853 0 1 -1
hiv-nhl,the 1.0 0.000143348623853 0 1 -1
been,cited 1.0 0.000143348623853 0 1 -1
renal,prostaglandin 1.0 0.00043004587156 0 3 -3
of,chronically 1.0 0.000143348623853 0 1 -1
poisoning,although 1.0 0.000143348623853 1 0 1
tachycardia,and 1.0 0.000286697247706 0 2 -2
herbal,remedies 1.0 0.000573394495413 0 4 -4
with,its 0.2 0.000143348623853 2 3 -1
cholesterol,synthesis 1.0 0.000143348623853 0 1 -1
urinary,acidifying 1.0 0.00043004587156 3 0 3
the,cns 0.0 0.0 4 4 0
studies,designed 1.0 0.000143348623853 0 1 -1
oral,aprepitant 1.0 0.000143348623853 1 0 1
adversely,affected 0.0 0.0 1 1 0
administered,over 1.0 0.000143348623853 0 1 -1
inducer,a 1.0 0.000143348623853 0 1 -1
logarithmic,fashion 1.0 0.000143348623853 0 1 -1
strains,of 0.75 0.000860091743119 1 7 -6
that,serum 1.0 0.000286697247706 2 0 2
and,bretylium 1.0 0.000143348623853 0 1 -1
plasma,levels 0.259259259259 0.00401376146789 68 40 28
agent,that 1.0 0.000573394495413 0 4 -4
a,compensatory 1.0 0.000143348623853 0 1 -1
dysfunction,is 1.0 0.000286697247706 0 2 -2
its,two 1.0 0.000143348623853 0 1 -1
now,strong 1.0 0.000143348623853 0 1 -1
have,discontinued 1.0 0.000143348623853 0 1 -1
be,substrates 1.0 0.000143348623853 0 1 -1
containing,and 1.0 0.000286697247706 2 0 2
extent,to 0.666666666667 0.000573394495413 5 1 4
patients,ci 1.0 0.000143348623853 0 1 -1
lethargy,fever 1.0 0.000143348623853 1 0 1
dose-dependent,increase 1.0 0.000143348623853 1 0 1
tenormin,sectral 1.0 0.000143348623853 0 1 -1
b,the 1.0 0.00043004587156 0 3 -3
electrophilic,agents 1.0 0.000143348623853 0 1 -1
variable,half-life 1.0 0.000143348623853 0 1 -1
better,after 1.0 0.000143348623853 0 1 -1
conference,reviews 1.0 0.000143348623853 0 1 -1
in,diabetics 0.333333333333 0.000143348623853 1 2 -1
second,hour 1.0 0.000143348623853 0 1 -1
with,nnrtis 1.0 0.000143348623853 0 1 -1
ml,nor 1.0 0.000143348623853 0 1 -1
age,or 1.0 0.000143348623853 0 1 -1
other,multivalent 1.0 0.000286697247706 2 0 2
are,developed 1.0 0.000143348623853 0 1 -1
antagonistic,effect 1.0 0.000143348623853 1 0 1
duloxetine,is 1.0 0.000143348623853 0 1 -1
the,trials 1.0 0.000286697247706 0 2 -2
some,the 1.0 0.000143348623853 0 1 -1
age,of 1.0 0.000143348623853 0 1 -1
recommended,dose 0.454545454545 0.000716743119266 3 8 -5
sparing,agents 1.0 0.000286697247706 0 2 -2
aluminum-containing,products 1.0 0.000143348623853 1 0 1
a,that 0.6 0.00043004587156 1 4 -3
an,adjustment 1.0 0.000573394495413 0 4 -4
in,by 1.0 0.000143348623853 1 0 1
stabilized,for 1.0 0.000143348623853 0 1 -1
necessary,can 1.0 0.000143348623853 0 1 -1
to,albumin 1.0 0.000143348623853 0 1 -1
that,produces 1.0 0.000143348623853 0 1 -1
therefore,has 0.6 0.00043004587156 1 4 -3
quinidine,immediate 1.0 0.000143348623853 1 0 1
whether,similar 1.0 0.000143348623853 0 1 -1
more,than 0.5 0.000860091743119 3 9 -6
may,possibly 1.0 0.000143348623853 0 1 -1
striatum,str 1.0 0.000143348623853 0 1 -1
except,that 1.0 0.000143348623853 1 0 1
significant,p 1.0 0.000143348623853 0 1 -1
however,no 1.0 0.000860091743119 0 6 -6
products,medicated 1.0 0.000143348623853 0 1 -1
of,inducing 1.0 0.000143348623853 0 1 -1
it,would 0.0 0.0 1 1 0
digitalized,hypothyroid 1.0 0.000143348623853 1 0 1
a,significantly 1.0 0.00043004587156 0 3 -3
hydrocortisone,elevated 1.0 0.000143348623853 0 1 -1
mediated,metabolism 1.0 0.000143348623853 0 1 -1
premedication,for 1.0 0.000143348623853 0 1 -1
iv,and 1.0 0.000143348623853 0 1 -1
in,either 1.0 0.000860091743119 0 6 -6
human,interaction 1.0 0.00043004587156 0 3 -3
schizoaffective,disorder 1.0 0.000143348623853 1 0 1
a,which 1.0 0.000143348623853 1 0 1
other,central 0.333333333333 0.000286697247706 4 2 2
low-dose,hcl 1.0 0.000143348623853 1 0 1
group,the 1.0 0.000143348623853 0 1 -1
on,this 1.0 0.000286697247706 0 2 -2
micro-dosed,progesterone 1.0 0.000143348623853 1 0 1
inhibits,metabolism 1.0 0.000143348623853 1 0 1
any,medication 1.0 0.000143348623853 1 0 1
others,medrol 1.0 0.000143348623853 0 1 -1
smx,such 1.0 0.000143348623853 0 1 -1
class,may 0.0 0.0 1 1 0
were,equivocally 1.0 0.000143348623853 1 0 1
also,there 1.0 0.000143348623853 0 1 -1
tests,showed 1.0 0.000143348623853 0 1 -1
and,descarboethoxyloratadine 1.0 0.000143348623853 0 1 -1
l-name,and 1.0 0.000143348623853 0 1 -1
nanm,decreased 1.0 0.000143348623853 0 1 -1
rats,increased 1.0 0.000143348623853 1 0 1
steady-state,plasma 0.0 0.0 5 5 0
amines,may 1.0 0.000143348623853 1 0 1
the,palytoxin-induced 1.0 0.000143348623853 0 1 -1
mammalian,cell 1.0 0.000143348623853 0 1 -1
experiments,the 1.0 0.000143348623853 0 1 -1
ages,to 1.0 0.000143348623853 1 0 1
for,varying 1.0 0.000143348623853 0 1 -1
caution,only 1.0 0.000143348623853 0 1 -1
of,toradol 0.428571428571 0.00043004587156 5 2 3
taxol,was 1.0 0.000286697247706 2 0 2
also,was 1.0 0.000143348623853 0 1 -1
the,hepatic 0.142857142857 0.000143348623853 4 3 1
blunted,by 1.0 0.000286697247706 2 0 2
vitro,chromosomal 1.0 0.000143348623853 0 1 -1
of,visual 1.0 0.000143348623853 0 1 -1
with,celebrex 1.0 0.000286697247706 2 0 2
d,co-administered 1.0 0.000286697247706 2 0 2
vitro,in 0.0 0.0 1 1 0
increases,qt 1.0 0.000143348623853 0 1 -1
concentrations,up 1.0 0.000286697247706 0 2 -2
for,drug-induced 1.0 0.000143348623853 0 1 -1
antagonist,eg 1.0 0.000143348623853 1 0 1
when,adjustment 1.0 0.000143348623853 0 1 -1
leukocyte,production 1.0 0.000143348623853 0 1 -1
type,and 1.0 0.000143348623853 0 1 -1
elemental,primarily 1.0 0.000143348623853 0 1 -1
these,stimulants 1.0 0.000143348623853 0 1 -1
in,high 0.0 0.0 1 1 0
therefore,concurrent 0.333333333333 0.000143348623853 2 1 1
antacids,and 1.0 0.000286697247706 2 0 2
in,treatment 1.0 0.000143348623853 0 1 -1
of,required 1.0 0.000286697247706 2 0 2
nonsteroidal,can 1.0 0.000143348623853 1 0 1
the,overall 0.0 0.0 1 1 0
precipitating,coronary 1.0 0.000143348623853 0 1 -1
bumetanide,may 1.0 0.000143348623853 1 0 1
before,idv 1.0 0.000143348623853 0 1 -1
acetohydroxamic,acid 1.0 0.000143348623853 0 1 -1
pressure,deep 1.0 0.000143348623853 0 1 -1
respectively,on 1.0 0.000143348623853 1 0 1
was,fold 1.0 0.000143348623853 0 1 -1
respectively,of 0.0 0.0 1 1 0
antacids,concomitant 0.0 0.0 2 2 0
carbidopa-levodopa,combination 1.0 0.000143348623853 0 1 -1
and,an 0.25 0.000860091743119 15 9 6
in,seven 1.0 0.000286697247706 0 2 -2
systemic,levels 0.333333333333 0.000143348623853 1 2 -1
and,maois 1.0 0.000286697247706 2 0 2
in,resistance 1.0 0.000143348623853 0 1 -1
with,taxol 1.0 0.000143348623853 0 1 -1
and,at 0.142857142857 0.000143348623853 3 4 -1
and,av 0.333333333333 0.000143348623853 1 2 -1
target,sites 1.0 0.000143348623853 0 1 -1
and,as 0.2 0.000143348623853 2 3 -1
with,hydrochloride 1.0 0.000143348623853 0 1 -1
translocation,of 1.0 0.000286697247706 0 2 -2
p450,d6 1.0 0.00559059633028 0 39 -39
lowered,numbers 1.0 0.000143348623853 0 1 -1
and,hydrochloride 1.0 0.000143348623853 0 1 -1
certain,factors 1.0 0.000143348623853 0 1 -1
result,when 1.0 0.000143348623853 0 1 -1
divided,into 0.333333333333 0.000143348623853 1 2 -1
fluoride,or 1.0 0.000143348623853 0 1 -1
angiotensin,and 1.0 0.000143348623853 0 1 -1
topoisomerase,activity 1.0 0.000143348623853 0 1 -1
ketones,and 1.0 0.000143348623853 0 1 -1
taking,patients 1.0 0.00043004587156 0 3 -3
thus,certain 1.0 0.000143348623853 0 1 -1
lipid,response 0.333333333333 0.000143348623853 1 2 -1
kemstro,the 1.0 0.000143348623853 0 1 -1
gvia,omega-agatoxin 1.0 0.000143348623853 0 1 -1
the,acquired 1.0 0.000143348623853 0 1 -1
the,order 1.0 0.000143348623853 0 1 -1
dual-memory,theories 1.0 0.000143348623853 0 1 -1
wasting,facial 1.0 0.000143348623853 0 1 -1
from,healthy 1.0 0.000143348623853 0 1 -1
in,bovine 1.0 0.000573394495413 0 4 -4
to,have 0.470588235294 0.00229357798165 9 25 -16
administering,hcl 1.0 0.000143348623853 1 0 1
drugs,significant 1.0 0.000143348623853 1 0 1
lose,the 1.0 0.000143348623853 0 1 -1
test,interferences 1.0 0.000143348623853 0 1 -1
variation,in 0.0 0.0 1 1 0
tubular,transport 1.0 0.000143348623853 1 0 1
antagonists,since 1.0 0.000143348623853 1 0 1
for,studying 1.0 0.000143348623853 0 1 -1
was,included 1.0 0.00043004587156 0 3 -3
by,concomitant 0.272727272727 0.00043004587156 7 4 3
change,fasting 1.0 0.000143348623853 0 1 -1
or,another 1.0 0.000143348623853 1 0 1
administered,before 1.0 0.000143348623853 0 1 -1
qd,was 1.0 0.000143348623853 0 1 -1
kadian,ms 1.0 0.000143348623853 1 0 1
the,sexological 1.0 0.000143348623853 0 1 -1
vardenafil,in 0.333333333333 0.000143348623853 2 1 1
pivoxil,administered 1.0 0.000143348623853 1 0 1
selective,regulation 1.0 0.000143348623853 0 1 -1
ip,or 1.0 0.000143348623853 1 0 1
its,major 1.0 0.00043004587156 0 3 -3
administration,may 1.0 0.000286697247706 2 0 2
disulfiram,should 1.0 0.000143348623853 1 0 1
a,false 1.0 0.000573394495413 0 4 -4
through,searches 1.0 0.000143348623853 0 1 -1
improvements,in 1.0 0.000286697247706 0 2 -2
contractility,conductivity 1.0 0.000143348623853 1 0 1
courses,of 1.0 0.000286697247706 0 2 -2
addition,to 0.0 0.0 3 3 0
to,mouse 1.0 0.000143348623853 0 1 -1
with,causes 1.0 0.000143348623853 1 0 1
natriuretic,effect 0.714285714286 0.000716743119266 6 1 5
depressants,are 1.0 0.000143348623853 1 0 1
conjugation,with 1.0 0.000143348623853 1 0 1
no,observed 1.0 0.000143348623853 0 1 -1
tizoxanide,is 1.0 0.000143348623853 0 1 -1
of,oxidized 1.0 0.000143348623853 0 1 -1
parameters,of 0.333333333333 0.000143348623853 1 2 -1
and,omega-conotoxin 1.0 0.000143348623853 0 1 -1
aggregation,in 1.0 0.000143348623853 0 1 -1
any,significant 0.5 0.000286697247706 1 3 -2
when,midamor 1.0 0.000143348623853 1 0 1
two,at 1.0 0.000143348623853 0 1 -1
were,thus 1.0 0.000143348623853 0 1 -1
withdrawal,of 0.333333333333 0.000143348623853 1 2 -1
was,undertaken 1.0 0.000143348623853 0 1 -1
permanent,nerve 1.0 0.000143348623853 0 1 -1
be,of 0.428571428571 0.00043004587156 2 5 -3
infants,has 1.0 0.000143348623853 0 1 -1
as,triazolopyridazines 1.0 0.000143348623853 1 0 1
phenytoin,increases 1.0 0.000143348623853 1 0 1
capsules,with 0.0 0.0 1 1 0
long-acting,is 1.0 0.000143348623853 0 1 -1
one,volunteer 1.0 0.000143348623853 0 1 -1
preparations,eg 1.0 0.00043004587156 3 0 3
methadone,dose 1.0 0.000143348623853 0 1 -1
sodium,citrate 1.0 0.000143348623853 1 0 1
a,toxicology 1.0 0.000143348623853 1 0 1
profound,collapse 1.0 0.000143348623853 0 1 -1
or,because 1.0 0.000143348623853 1 0 1
the,hyperplasia 1.0 0.000143348623853 0 1 -1
and,human 0.333333333333 0.000143348623853 1 2 -1
therapy,omnicef 1.0 0.000286697247706 2 0 2
that,requirements 1.0 0.000143348623853 1 0 1
kidney,cell 1.0 0.000143348623853 0 1 -1
system,with 1.0 0.000143348623853 1 0 1
concentrate,should 1.0 0.000143348623853 1 0 1
in,low 1.0 0.000286697247706 2 0 2
were,enrolled 1.0 0.000143348623853 0 1 -1
minutes,of 0.0 0.0 1 1 0
by,h2 1.0 0.000143348623853 1 0 1
normovolemic,healthy 1.0 0.000143348623853 1 0 1
periods,blood 1.0 0.000143348623853 0 1 -1
lcv,infection 1.0 0.000143348623853 0 1 -1
taking,antiseizure 1.0 0.000143348623853 0 1 -1
l-phenylalanine,may 1.0 0.000143348623853 1 0 1
and,flare 1.0 0.000143348623853 0 1 -1
parental,mcf-7 1.0 0.000143348623853 0 1 -1
been,termed 1.0 0.000143348623853 0 1 -1
topo,i 1.0 0.000143348623853 0 1 -1
perioperative,period 1.0 0.000143348623853 1 0 1
sonata,to 1.0 0.000143348623853 0 1 -1
cyp3a4,inhibitor 0.4 0.000573394495413 7 3 4
conclude,that 0.0 0.0 2 2 0
approximately,by 1.0 0.000143348623853 1 0 1
intravenously,injected 1.0 0.000143348623853 0 1 -1
was,taking 1.0 0.000143348623853 0 1 -1
novoseven,and 1.0 0.000143348623853 0 1 -1
pulmonary,disease 1.0 0.000143348623853 0 1 -1
been,well 1.0 0.000286697247706 0 2 -2
omeprazole,should 1.0 0.000143348623853 0 1 -1
a,decline 1.0 0.000143348623853 0 1 -1
other,systemic 1.0 0.000143348623853 1 0 1
therefore,coadministration 0.0 0.0 1 1 0
gastric,ph 0.333333333333 0.000286697247706 4 2 2
are,examples 0.6 0.00043004587156 1 4 -3
extent,enhanced 1.0 0.000143348623853 0 1 -1
however,its 1.0 0.000143348623853 0 1 -1
given,prior 0.0 0.0 1 1 0
anaphylactic,reaction 0.666666666667 0.000573394495413 1 5 -4
carbamazepine,tiagabine 1.0 0.000143348623853 0 1 -1
platelet,function 0.230769230769 0.00043004587156 5 8 -3
active,epoxide 1.0 0.000143348623853 0 1 -1
colchicine,is 1.0 0.000143348623853 1 0 1
dose,limiting 1.0 0.000143348623853 0 1 -1
similar,with 1.0 0.000143348623853 0 1 -1
these,included 1.0 0.000143348623853 0 1 -1
markedly,reduced 1.0 0.000143348623853 1 0 1
of,binding 0.333333333333 0.000143348623853 1 2 -1
frova_od,htm 1.0 0.000143348623853 1 0 1
studies,of 0.461538461538 0.00172018348624 7 19 -12
a,chop-like 1.0 0.000143348623853 0 1 -1
mumol,liter 1.0 0.000143348623853 1 0 1
studies,on 1.0 0.000860091743119 0 6 -6
blunt,the 0.0 0.0 2 2 0
parameters,without 1.0 0.000143348623853 0 1 -1
that,interactions 1.0 0.000143348623853 0 1 -1
studies,or 1.0 0.00043004587156 0 3 -3
supraventricular,tachycardia 1.0 0.000143348623853 1 0 1
in,decreasing 1.0 0.000143348623853 0 1 -1
ht2a,than 1.0 0.000143348623853 0 1 -1
ibuprofen,is 1.0 0.000143348623853 0 1 -1
two-way,interaction 1.0 0.000143348623853 1 0 1
is,postulated 1.0 0.000143348623853 0 1 -1
particularly,when 1.0 0.000286697247706 0 2 -2
three,lines 1.0 0.000143348623853 0 1 -1
levo-dromoran,with 1.0 0.000143348623853 1 0 1
of,dosages 1.0 0.000286697247706 0 2 -2
also,influence 1.0 0.000143348623853 0 1 -1
inflammatory,with 1.0 0.000143348623853 1 0 1
of,suggesting 1.0 0.000143348623853 0 1 -1
fixed-ratio,fi 1.0 0.000143348623853 0 1 -1
sulfonate,soybean 1.0 0.000143348623853 1 0 1
received,in 1.0 0.000143348623853 0 1 -1
of,cholino- 1.0 0.000143348623853 0 1 -1
of,mice 1.0 0.000286697247706 0 2 -2
rifampin,has 1.0 0.000143348623853 1 0 1
depressants,such 1.0 0.00043004587156 3 0 3
either,increase 1.0 0.000143348623853 1 0 1
than,suggest 1.0 0.000286697247706 2 0 2
arava,to 1.0 0.000143348623853 1 0 1
increased,ectopic 1.0 0.000143348623853 1 0 1
not,diminish 1.0 0.000143348623853 0 1 -1
in,excretion 1.0 0.000143348623853 1 0 1
last,chapters 1.0 0.000143348623853 0 1 -1
decision,should 1.0 0.000286697247706 0 2 -2
compounds,that 0.333333333333 0.000286697247706 4 2 2
adrenal,synthesis 1.0 0.000143348623853 1 0 1
to,evaluate 0.818181818182 0.00129013761468 1 10 -9
has,recovered 1.0 0.000143348623853 1 0 1
receiving,inspra 1.0 0.000143348623853 0 1 -1
evidence,in 1.0 0.00043004587156 0 3 -3
rats,have 1.0 0.000143348623853 1 0 1
not,required 1.0 0.000143348623853 0 1 -1
taking,an 0.0 0.0 1 1 0
taking,as 1.0 0.000143348623853 0 1 -1
counteract,the 1.0 0.00100344036697 7 0 7
while,no 0.333333333333 0.000143348623853 1 2 -1
of,aczone 1.0 0.000143348623853 0 1 -1
allergens,either 1.0 0.000143348623853 0 1 -1
estrogen-containing,compounds 1.0 0.000143348623853 1 0 1
only,increases 1.0 0.000143348623853 0 1 -1
sera,from 1.0 0.000143348623853 0 1 -1
aprepitant,on 1.0 0.000286697247706 2 0 2
half-life,decreased 1.0 0.000143348623853 1 0 1
not,nanm 1.0 0.000286697247706 2 0 2
pacemaker,activity 1.0 0.000143348623853 1 0 1
genetically,initiated 1.0 0.000143348623853 0 1 -1
to,potentiate 0.333333333333 0.000143348623853 2 1 1
under,acidic 1.0 0.000143348623853 1 0 1
each,study 1.0 0.000286697247706 0 2 -2
the,elevated 1.0 0.000143348623853 0 1 -1
pharmacogenetics,pharmacogenetics 1.0 0.000143348623853 0 1 -1
levels,then 1.0 0.000143348623853 0 1 -1
between,study 1.0 0.000143348623853 0 1 -1
net,decrease 1.0 0.000143348623853 1 0 1
neuron,blockade 1.0 0.000143348623853 1 0 1
subjects,were 1.0 0.00043004587156 0 3 -3
since,invirase 1.0 0.000143348623853 1 0 1
hypotension,vs 1.0 0.000143348623853 1 0 1
a,reduction 0.307692307692 0.00114678899083 17 9 8
preparation,before 1.0 0.000143348623853 0 1 -1
azole,inhibits 1.0 0.000143348623853 1 0 1
peptide,in 1.0 0.000143348623853 0 1 -1
oil-concomitant,intake 1.0 0.000143348623853 1 0 1
of,zyvox 1.0 0.000143348623853 1 0 1
inhibits,hepatic 1.0 0.000143348623853 0 1 -1
sustivahas,the 1.0 0.000143348623853 0 1 -1
deleted,from 1.0 0.000286697247706 2 0 2
on,glycemia 1.0 0.000143348623853 0 1 -1
metastasis,of 0.0 0.0 1 1 0
parenteral,or 1.0 0.000143348623853 0 1 -1
be,compromised 1.0 0.000143348623853 1 0 1
limited,data 1.0 0.000143348623853 1 0 1
increased,cns 1.0 0.000143348623853 1 0 1
such,concurrently 1.0 0.000143348623853 0 1 -1
anti-arrhythmics,and 1.0 0.000143348623853 1 0 1
terminated,the 1.0 0.000143348623853 1 0 1
concurrently,concentrations 1.0 0.000143348623853 1 0 1
is,erroneous 1.0 0.000143348623853 0 1 -1
linked,drug-metabolizing 1.0 0.000143348623853 0 1 -1
important,potentiation 1.0 0.000143348623853 0 1 -1
the,acid 1.0 0.000143348623853 0 1 -1
relevant,pharmacokinetic 1.0 0.00043004587156 0 3 -3
other,possible 1.0 0.000143348623853 0 1 -1
when,equetrotm 1.0 0.000143348623853 1 0 1
first,dose 1.0 0.000143348623853 0 1 -1
studied,following 1.0 0.000143348623853 0 1 -1
effect,the 0.0 0.0 1 1 0
metabolized,to 1.0 0.000716743119266 0 5 -5
function,or 0.6 0.00043004587156 1 4 -3
enzyme,preparations 1.0 0.000143348623853 1 0 1
cover,interactions 1.0 0.000143348623853 0 1 -1
the,adrenergic 0.0 0.0 1 1 0
the,concentration-time 1.0 0.000143348623853 0 1 -1
function,of 0.333333333333 0.000143348623853 1 2 -1
patient,died 1.0 0.000143348623853 0 1 -1
may,sometimes 1.0 0.000286697247706 0 2 -2
thus,no 1.0 0.000143348623853 0 1 -1
or,synergistic 1.0 0.000143348623853 0 1 -1
erythrocytes,in 1.0 0.000143348623853 0 1 -1
dependency,and 1.0 0.000143348623853 0 1 -1
so,careful 1.0 0.000143348623853 1 0 1
kemstrotm,was 1.0 0.000143348623853 0 1 -1
the,sole 0.333333333333 0.000143348623853 1 2 -1
m2,given 1.0 0.000143348623853 1 0 1
this,information 0.0 0.0 1 1 0
perioperative,administration 1.0 0.000143348623853 0 1 -1
lessened,physiologic 1.0 0.000143348623853 1 0 1
patients,had 1.0 0.000143348623853 0 1 -1
inhibitors,hypertensive 1.0 0.000143348623853 1 0 1
results,obtained 1.0 0.000143348623853 0 1 -1
l-histidine,was 1.0 0.000143348623853 1 0 1
arrhythmias,and 1.0 0.000143348623853 1 0 1
taxol,should 1.0 0.000143348623853 0 1 -1
that,intensive 1.0 0.000143348623853 0 1 -1
dimethylprostaglandin,e2-induced 1.0 0.000143348623853 0 1 -1
clearance,between 1.0 0.000143348623853 0 1 -1
depression,the 1.0 0.000143348623853 0 1 -1
over,hours 1.0 0.000143348623853 0 1 -1
is,far 1.0 0.000143348623853 0 1 -1
excess,may 1.0 0.000143348623853 1 0 1
attenuation,of 1.0 0.000143348623853 1 0 1
trial,as 1.0 0.000143348623853 1 0 1
mouth,or 1.0 0.000143348623853 0 1 -1
test,abnormalities 1.0 0.000286697247706 0 2 -2
instances,however 1.0 0.000143348623853 0 1 -1
pressure,in 1.0 0.000143348623853 0 1 -1
is,available 1.0 0.000286697247706 0 2 -2
see,a 1.0 0.000286697247706 2 0 2
a,stimulating 1.0 0.000143348623853 1 0 1
the,context 1.0 0.000286697247706 0 2 -2
lowered,the 1.0 0.000286697247706 2 0 2
by,all 1.0 0.000143348623853 0 1 -1
following,or 0.0 0.0 1 1 0
adult,wistar 1.0 0.000143348623853 0 1 -1
further,these 1.0 0.000143348623853 0 1 -1
maintain,barpress 1.0 0.000143348623853 0 1 -1
efficient,substrate 1.0 0.000143348623853 0 1 -1
by,alt 1.0 0.000143348623853 0 1 -1
upon,the 0.2 0.000143348623853 2 3 -1
as,tolerance 1.0 0.000143348623853 0 1 -1
myocardium,to 0.5 0.000286697247706 3 1 2
medication,used 1.0 0.000143348623853 0 1 -1
urinary,uric 1.0 0.000143348623853 1 0 1
isoenzymes,tested 1.0 0.000143348623853 0 1 -1
these,medications 0.5 0.000573394495413 2 6 -4
cyp3a,inducers 1.0 0.000143348623853 1 0 1
cyp,c9 1.0 0.000573394495413 0 4 -4
net,effects 1.0 0.000143348623853 1 0 1
particles,in 1.0 0.000143348623853 0 1 -1
of,indicate 1.0 0.000143348623853 0 1 -1
a,linear 1.0 0.000143348623853 0 1 -1
of,nonsmoking 1.0 0.000143348623853 0 1 -1
study,effects 1.0 0.000143348623853 0 1 -1
cells,by 1.0 0.000143348623853 0 1 -1
rate,increased 1.0 0.000143348623853 0 1 -1
decrease,vascular 1.0 0.000143348623853 1 0 1
minus,s 1.0 0.000286697247706 0 2 -2
its,inhibitory 0.0 0.0 1 1 0
live,and 1.0 0.000143348623853 1 0 1
midazolam,aprepitant 1.0 0.000143348623853 1 0 1
produced,depletions 1.0 0.000143348623853 1 0 1
hepatic,there 1.0 0.000143348623853 0 1 -1
acute,pharmacological 1.0 0.000143348623853 0 1 -1
the,r 0.0 0.0 1 1 0
particular,low 1.0 0.000143348623853 0 1 -1
other,caution 1.0 0.000286697247706 2 0 2
commonly,reported 1.0 0.000143348623853 1 0 1
discontinuation,is 1.0 0.000143348623853 0 1 -1
receptor-binding,activity 1.0 0.000143348623853 0 1 -1
hepatotoxic,influenza 1.0 0.000143348623853 1 0 1
tendency,toward 1.0 0.000143348623853 0 1 -1
k,may 1.0 0.00043004587156 3 0 3
ast,sgot 1.0 0.000143348623853 0 1 -1
medical,intervention 1.0 0.000143348623853 0 1 -1
time,or 0.571428571429 0.00114678899083 3 11 -8
enantiomer,nanm 1.0 0.000143348623853 0 1 -1
produces,a 1.0 0.000286697247706 2 0 2
while,gallic 1.0 0.000143348623853 0 1 -1
time,of 0.5 0.000286697247706 1 3 -2
interaction,study 0.6 0.00172018348624 4 16 -12
the,inhibits 1.0 0.000143348623853 0 1 -1
appropriate,in 1.0 0.000143348623853 0 1 -1
compete,for 0.333333333333 0.000143348623853 1 2 -1
hypotension,with 1.0 0.000143348623853 1 0 1
vitro,studies 0.615384615385 0.0045871559633 10 42 -32
because,of 0.03125 0.000286697247706 31 33 -2
evidently,the 1.0 0.000143348623853 1 0 1
by,nuromax 1.0 0.000143348623853 1 0 1
placebo,were 1.0 0.000143348623853 0 1 -1
p53,mouse 1.0 0.000143348623853 0 1 -1
or,orally 1.0 0.000143348623853 0 1 -1
experiences,eg 1.0 0.000143348623853 0 1 -1
serum,transaminase 1.0 0.000143348623853 0 1 -1
upon,pcp 1.0 0.000143348623853 0 1 -1
a,wide 1.0 0.000286697247706 0 2 -2
any,known 1.0 0.000286697247706 2 0 2
because,or 1.0 0.000143348623853 0 1 -1
q,i 1.0 0.000143348623853 1 0 1
q,d 0.333333333333 0.000143348623853 2 1 1
receiving,therapy 0.5 0.000286697247706 3 1 2
on,total 0.0 0.0 1 1 0
the,vasodilating 1.0 0.000573394495413 4 0 4
functionally,distinguishes 1.0 0.000143348623853 0 1 -1
acid,prolonged 1.0 0.000143348623853 1 0 1
hypercalcemia,too 1.0 0.000143348623853 1 0 1
were,no 0.9 0.00258027522936 1 19 -18
factors,vii 1.0 0.000286697247706 0 2 -2
that,have 0.2 0.00043004587156 9 6 3
tendency,produced 1.0 0.000143348623853 1 0 1
toxicity,in 0.666666666667 0.000573394495413 5 1 4
concentrations,achieved 1.0 0.000143348623853 0 1 -1
the,hospital 1.0 0.000143348623853 0 1 -1
viagra,and 1.0 0.000143348623853 0 1 -1
phasic,contraction 1.0 0.000143348623853 0 1 -1
be,co-administered 0.6 0.00043004587156 1 4 -3
patients,when 1.0 0.00043004587156 3 0 3
secretion,has 1.0 0.000143348623853 1 0 1
conversely,adverse 1.0 0.000143348623853 0 1 -1
survival,was 1.0 0.000143348623853 0 1 -1
practice,additional 1.0 0.000143348623853 0 1 -1
therapeutic,indices 0.0 0.0 1 1 0
slow,gastric 1.0 0.000143348623853 0 1 -1
by,endothelial 1.0 0.000286697247706 0 2 -2
antiinflammatory,including 1.0 0.000143348623853 1 0 1
with,cyp1a2 0.0 0.0 1 1 0
aeds,on 1.0 0.000143348623853 1 0 1
insert,of 1.0 0.000143348623853 0 1 -1
isoform,and 1.0 0.000143348623853 0 1 -1
strain,c57bl 1.0 0.000143348623853 0 1 -1
mutagenesis,and 1.0 0.000143348623853 0 1 -1
wellbutrin,should 1.0 0.000143348623853 1 0 1
of,tarceva 1.0 0.000143348623853 0 1 -1
adrenocorticoids,cortisone-like 1.0 0.000143348623853 1 0 1
data,demonstrate 1.0 0.000143348623853 0 1 -1
was,demonstrated 1.0 0.000143348623853 0 1 -1
in,clotting 1.0 0.00043004587156 0 3 -3
antihypertensives,bumetanide 1.0 0.000143348623853 1 0 1
the,perfused 1.0 0.000143348623853 0 1 -1
given,and 0.0 0.0 1 1 0
these,isoenzymes 1.0 0.000286697247706 0 2 -2
equilibration,of 1.0 0.000143348623853 0 1 -1
and,sex 1.0 0.000143348623853 0 1 -1
these,imidazole 1.0 0.000143348623853 0 1 -1
and,see 1.0 0.000143348623853 1 0 1
initial,step 1.0 0.000143348623853 0 1 -1
d3,the 1.0 0.000143348623853 0 1 -1
hypokinesia,and 1.0 0.000143348623853 1 0 1
no,autoinduction 1.0 0.000143348623853 0 1 -1
aerosol,has 1.0 0.000143348623853 0 1 -1
for,deriving 1.0 0.000143348623853 0 1 -1
the,bioavailability 0.363636363636 0.00114678899083 7 15 -8
with,irradiation 1.0 0.000143348623853 0 1 -1
of,skeletal 0.0 0.0 1 1 0
intestinal,cancers 1.0 0.000286697247706 0 2 -2
the,coat-core 1.0 0.000143348623853 1 0 1
reduce,or 1.0 0.000286697247706 2 0 2
between,epa 1.0 0.000143348623853 1 0 1
monitored,at 0.0 0.0 1 1 0
avoidance,behaviour 1.0 0.000286697247706 0 2 -2
coagulation,indices 1.0 0.000286697247706 0 2 -2
dostinex,should 1.0 0.000143348623853 1 0 1
by,minimal 1.0 0.000143348623853 0 1 -1
gel,in 1.0 0.000143348623853 0 1 -1
possible,cns 1.0 0.000143348623853 0 1 -1
enantiomers,or 1.0 0.000143348623853 0 1 -1
with,single 1.0 0.000143348623853 0 1 -1
hydrolysis,to 1.0 0.000143348623853 0 1 -1
nsaids,on 1.0 0.000286697247706 2 0 2
physical,dependency 1.0 0.000143348623853 0 1 -1
hydroxytolbutamide,and 1.0 0.000286697247706 0 2 -2
full,recovery 1.0 0.000143348623853 0 1 -1
reaction,may 0.0 0.0 1 1 0
significantly,increased 0.555555555556 0.000716743119266 7 2 5
required,with 1.0 0.000143348623853 0 1 -1
glycosides,heart 1.0 0.000143348623853 1 0 1
mefloquine,administration 1.0 0.000143348623853 0 1 -1
liver,metabolic 1.0 0.000143348623853 0 1 -1
not,due 0.0 0.0 1 1 0
induced,skin 1.0 0.000143348623853 0 1 -1
of,spermatozoa 1.0 0.000143348623853 0 1 -1
before,dose-limiting 1.0 0.000143348623853 0 1 -1
with,other 0.228571428571 0.0045871559633 54 86 -32
in,liver 0.333333333333 0.000286697247706 2 4 -2
was,variably 1.0 0.000143348623853 0 1 -1
the,gradual 0.333333333333 0.000143348623853 2 1 1
safely,co-administered 1.0 0.000143348623853 0 1 -1
of,probably 1.0 0.000143348623853 1 0 1
thereby,cause 1.0 0.000143348623853 0 1 -1
monomeric,disintegrins 1.0 0.000143348623853 0 1 -1
study,dosed 1.0 0.000143348623853 0 1 -1
always,predictive 1.0 0.000143348623853 0 1 -1
on,insulins 1.0 0.000143348623853 0 1 -1
serum-supplemented,nih-3t3 1.0 0.000143348623853 0 1 -1
uncontrolled,domestic 1.0 0.000143348623853 0 1 -1
reported,with 0.391304347826 0.00129013761468 16 7 9
the,peripheral 0.0 0.0 1 1 0
long-term,studies 1.0 0.000286697247706 0 2 -2
enzyme,involved 1.0 0.000143348623853 0 1 -1
dpcpx-induced,anxiogenic 1.0 0.000143348623853 1 0 1
rarely,with 1.0 0.000286697247706 2 0 2
and,adult 1.0 0.000143348623853 0 1 -1
injection,medicine 1.0 0.000143348623853 0 1 -1
from,anaesthesia 1.0 0.000143348623853 0 1 -1
triglycerides,or 1.0 0.000143348623853 0 1 -1
function,seen 1.0 0.000143348623853 0 1 -1
are,possible 1.0 0.000143348623853 0 1 -1
marked,inhibition 1.0 0.000143348623853 0 1 -1
these,cases 1.0 0.00043004587156 0 3 -3
concomitant,were 1.0 0.000143348623853 0 1 -1
fluoroquinolones,macrolide 1.0 0.000143348623853 0 1 -1
hormonal,contraception 1.0 0.000143348623853 0 1 -1
gradually,returned 1.0 0.000143348623853 0 1 -1
spray,during 1.0 0.000143348623853 0 1 -1
clinical,differences 1.0 0.000143348623853 0 1 -1
antibiotics,chloramphenicol 1.0 0.000143348623853 1 0 1
over,use 1.0 0.000143348623853 1 0 1
special,patient 1.0 0.000143348623853 0 1 -1
though,this 1.0 0.000143348623853 1 0 1
tamponades,in 1.0 0.000143348623853 0 1 -1
precedex,a 1.0 0.000143348623853 1 0 1
cortisol,and 1.0 0.000143348623853 0 1 -1
embryogenesis,of 1.0 0.000143348623853 0 1 -1
re-exposure,in 1.0 0.000143348623853 0 1 -1
clinical,problems 1.0 0.000716743119266 5 0 5
finding,no 1.0 0.000143348623853 0 1 -1
solutions,and 1.0 0.000286697247706 0 2 -2
either,age 1.0 0.000143348623853 0 1 -1
with,plenaxis 1.0 0.000286697247706 0 2 -2
pharmacotherapy,of 1.0 0.000143348623853 0 1 -1
slower,gastrointestinal 1.0 0.000143348623853 1 0 1
nsaids,concomitantly 1.0 0.000573394495413 4 0 4
the,glomerular 1.0 0.000143348623853 0 1 -1
cessation,with 1.0 0.000143348623853 0 1 -1
small,decrease 0.5 0.000286697247706 3 1 2
and,fatal 1.0 0.000286697247706 2 0 2
kg,produced 0.0 0.0 1 1 0
you,take 0.0 0.0 1 1 0
a,microdilution 1.0 0.000143348623853 0 1 -1
pills,is 1.0 0.000143348623853 1 0 1
lucidum,extract 1.0 0.000143348623853 0 1 -1
increased,hepatotoxicity 1.0 0.000143348623853 1 0 1
dosed,at 1.0 0.000573394495413 0 4 -4
agents,increase 1.0 0.000286697247706 0 2 -2
that,exogenous 1.0 0.000143348623853 0 1 -1
disorders,can 1.0 0.000143348623853 0 1 -1
similar,proportion 1.0 0.000143348623853 1 0 1
from,co-therapy 1.0 0.000573394495413 0 4 -4
addition,under 1.0 0.000286697247706 0 2 -2
as,mg 0.0 0.0 4 4 0
clinical,pharmacology 0.272727272727 0.00043004587156 4 7 -3
administered,radiographic 1.0 0.000143348623853 1 0 1
flow,seen 1.0 0.000143348623853 0 1 -1
the,fda 1.0 0.000143348623853 0 1 -1
rashes,were 1.0 0.000143348623853 0 1 -1
which,the 0.6 0.00043004587156 1 4 -3
that,variable 1.0 0.000143348623853 1 0 1
ensure,clinically 1.0 0.000143348623853 1 0 1
recommended,for 0.0 0.0 4 4 0
one,must 1.0 0.000143348623853 0 1 -1
rhesus,monkeys 1.0 0.000286697247706 0 2 -2
including,may 0.0 0.0 2 2 0
and,close 1.0 0.000143348623853 0 1 -1
weakness,who 1.0 0.000143348623853 0 1 -1
acid,supplements 1.0 0.000143348623853 0 1 -1
the,chemical 1.0 0.000143348623853 1 0 1
coreg,slow 1.0 0.000143348623853 1 0 1
and,exhibit 1.0 0.000143348623853 0 1 -1
including,man 1.0 0.000143348623853 0 1 -1
imipramine,hydrochloride 1.0 0.000143348623853 1 0 1
being,rapidly 1.0 0.000143348623853 0 1 -1
blood,cells 1.0 0.000143348623853 0 1 -1
on,scintigraphy 1.0 0.000143348623853 0 1 -1
peroral,administration 1.0 0.000143348623853 0 1 -1
the,antiprothrombinemic 1.0 0.000143348623853 0 1 -1
displacement,of 0.6 0.00043004587156 1 4 -3
characteristics,for 1.0 0.000143348623853 0 1 -1
monitor,prothrombin 1.0 0.000143348623853 0 1 -1
a,direct 0.2 0.000143348623853 2 3 -1
effectiveness,and 1.0 0.000143348623853 1 0 1
clinically,normal 1.0 0.000143348623853 0 1 -1
as,differin 1.0 0.000143348623853 0 1 -1
symptomatology,is 1.0 0.000143348623853 0 1 -1
impair,intestinal 1.0 0.00043004587156 0 3 -3
as,there 1.0 0.000143348623853 0 1 -1
inotropic,agents 1.0 0.000143348623853 1 0 1
indocin,may 1.0 0.000143348623853 0 1 -1
about,the 0.5 0.000286697247706 1 3 -2
to,convulsions 1.0 0.000143348623853 1 0 1
scintigraphic,results 1.0 0.000143348623853 0 1 -1
an,used 1.0 0.000143348623853 0 1 -1
placebo,with 1.0 0.000143348623853 0 1 -1
some,strains 1.0 0.000143348623853 0 1 -1
mean,apparent 1.0 0.000143348623853 1 0 1
and,fentanyl 1.0 0.000143348623853 1 0 1
tid,study 1.0 0.000143348623853 0 1 -1
of,when 0.0 0.0 8 8 0
proliferation,in 0.0 0.0 1 1 0
ganglionic,peripheral 1.0 0.000143348623853 0 1 -1
auc,by 0.428571428571 0.00043004587156 5 2 3
of,having 1.0 0.000286697247706 0 2 -2
for,other 0.714285714286 0.000716743119266 1 6 -5
adenosine,effects 1.0 0.000143348623853 1 0 1
alfenta,induction 1.0 0.000143348623853 1 0 1
a,single-dose 0.5 0.000286697247706 1 3 -2
tolbutamide,in 1.0 0.000286697247706 0 2 -2
after,tracleer 1.0 0.000143348623853 1 0 1
males,who 1.0 0.000143348623853 0 1 -1
may,persist 1.0 0.000143348623853 0 1 -1
vitro,concentrations 1.0 0.000143348623853 0 1 -1
etc,but 1.0 0.000143348623853 1 0 1
on,patient 1.0 0.000143348623853 0 1 -1
with,concomitantly 0.0 0.0 1 1 0
small,pulse 1.0 0.000143348623853 0 1 -1
one,animal 1.0 0.000143348623853 0 1 -1
hdl,and 1.0 0.000286697247706 0 2 -2
chapter,and 1.0 0.000143348623853 0 1 -1
emerging,roles 1.0 0.000143348623853 0 1 -1
drug,nutritional 1.0 0.000143348623853 0 1 -1
nephrolithiasis,is 1.0 0.000143348623853 1 0 1
pulsation,amplitude 1.0 0.000143348623853 0 1 -1
converted,to 1.0 0.000286697247706 2 0 2
antagonist,and 1.0 0.000143348623853 1 0 1
a,substrate 0.894736842105 0.0024369266055 1 18 -17
in-vitro,studies 1.0 0.000143348623853 0 1 -1
minimal,bactericidal 1.0 0.000143348623853 0 1 -1
intravenous,antagonists 1.0 0.000143348623853 1 0 1
in,alcoholic 1.0 0.000143348623853 1 0 1
class,antimicrobial 1.0 0.000143348623853 1 0 1
the,dosage 0.25 0.000860091743119 9 15 -6
no,well-known 1.0 0.000143348623853 0 1 -1
and,another 1.0 0.000143348623853 1 0 1
be,premedicated 1.0 0.000143348623853 0 1 -1
validation,of 1.0 0.000143348623853 0 1 -1
hyperkalemia,serum 1.0 0.000143348623853 1 0 1
studies,evaluating 1.0 0.000286697247706 0 2 -2
other,precautions 1.0 0.000143348623853 0 1 -1
on,two 1.0 0.000143348623853 0 1 -1
require,anticoagulation 1.0 0.000143348623853 0 1 -1
oral,on 1.0 0.000286697247706 0 2 -2
cerubidine,should 1.0 0.000143348623853 1 0 1
and,also 0.25 0.000286697247706 5 3 2
potent,effect 1.0 0.000143348623853 0 1 -1
unless,the 1.0 0.00043004587156 3 0 3
oral,or 0.0909090909091 0.000143348623853 6 5 1
also,inhibited 1.0 0.000143348623853 1 0 1
observations,strongly 1.0 0.000143348623853 0 1 -1
atrial,fibrillation 1.0 0.000143348623853 1 0 1
approximately,one-thousandth 1.0 0.000143348623853 0 1 -1
photic,stimulation 1.0 0.000143348623853 0 1 -1
in,lowering 1.0 0.000286697247706 2 0 2
approached,with 1.0 0.000286697247706 2 0 2
of,precipitating 1.0 0.000143348623853 0 1 -1
usually,reversible 1.0 0.000143348623853 1 0 1
of,intravenously 0.0 0.0 1 1 0
absorption,decreases 1.0 0.000143348623853 1 0 1
with,opioid-evoked 1.0 0.000143348623853 0 1 -1
function,tests 0.666666666667 0.000573394495413 1 5 -4
daily,under 1.0 0.000143348623853 0 1 -1
if,abruptly 1.0 0.000143348623853 0 1 -1
appointments,since 1.0 0.000143348623853 0 1 -1
protocol,for 1.0 0.000143348623853 0 1 -1
take,and 1.0 0.000143348623853 1 0 1
type,ii 1.0 0.000143348623853 1 0 1
see,drug 1.0 0.000143348623853 0 1 -1
that,mediate 1.0 0.000143348623853 0 1 -1
investigated,as 1.0 0.000143348623853 0 1 -1
rauwolfia,alkaloid 1.0 0.000143348623853 1 0 1
i,cigarettes 1.0 0.000143348623853 0 1 -1
metabolite,which 1.0 0.000286697247706 2 0 2
of,equivalent 0.333333333333 0.000143348623853 2 1 1
following,synthetic 1.0 0.000143348623853 0 1 -1
otherwise,specified 1.0 0.000286697247706 0 2 -2
identify,any 1.0 0.000143348623853 0 1 -1
are,a 0.5 0.000286697247706 1 3 -2
as,compulsion 1.0 0.000143348623853 0 1 -1
oral,medications 1.0 0.000143348623853 1 0 1
of,tricyclic 0.5 0.000286697247706 1 3 -2
in,well-controlled 1.0 0.000286697247706 2 0 2
supplements,theoretically 1.0 0.000143348623853 1 0 1
weaken,or 1.0 0.000143348623853 0 1 -1
viracept,resulted 0.714285714286 0.000716743119266 6 1 5
agents,calcium-blocking 1.0 0.000143348623853 0 1 -1
that,lower 0.0 0.0 1 1 0
including,medications 1.0 0.000143348623853 1 0 1
inhibit,high 1.0 0.000143348623853 0 1 -1
the,monomeric 1.0 0.000143348623853 0 1 -1
adrenergic,blockers 0.0 0.0 2 2 0
a,carbonic 1.0 0.000143348623853 0 1 -1
of,frova 1.0 0.000143348623853 0 1 -1
transient,dose-dependent 1.0 0.000143348623853 1 0 1
with,double 1.0 0.000143348623853 0 1 -1
and,sustiva 1.0 0.000143348623853 0 1 -1
kidney,homogenates 1.0 0.000143348623853 0 1 -1
toxicology,of 1.0 0.000143348623853 0 1 -1
interactions,indicate 1.0 0.000143348623853 0 1 -1
on,circulating 1.0 0.000143348623853 0 1 -1
cortical,tissues 1.0 0.000143348623853 0 1 -1
decreased,measured 1.0 0.000143348623853 1 0 1
that,seeds 1.0 0.000143348623853 0 1 -1
cyp2c9,and 1.0 0.000716743119266 0 5 -5
arise,from 0.0 0.0 1 1 0
steady-state,l50 1.0 0.000143348623853 0 1 -1
from,membrane 1.0 0.000143348623853 0 1 -1
ames,company 1.0 0.000143348623853 0 1 -1
dextromethorphan,is 1.0 0.000286697247706 0 2 -2
to,controls 1.0 0.000143348623853 0 1 -1
muscle,to 1.0 0.000143348623853 1 0 1
subjects,reports 1.0 0.000143348623853 0 1 -1
table,potential 1.0 0.000143348623853 0 1 -1
have,selected 1.0 0.000143348623853 0 1 -1
characterization,or 1.0 0.000143348623853 0 1 -1
other,oxytocic 1.0 0.000286697247706 0 2 -2
lithium,ibuprofen 1.0 0.000143348623853 1 0 1
copd,symptoms 1.0 0.000143348623853 0 1 -1
agonist,such 1.0 0.000143348623853 1 0 1
concentration,increased 0.714285714286 0.000716743119266 1 6 -5
trials,specifically 1.0 0.000143348623853 0 1 -1
through,increased 1.0 0.000286697247706 2 0 2
highintersubject,variability 1.0 0.000143348623853 0 1 -1
of,nanm 0.0 0.0 2 2 0
neither,were 1.0 0.000143348623853 0 1 -1
and,alpha-adrenergic 1.0 0.000143348623853 1 0 1
consequently,concomitant 1.0 0.000143348623853 1 0 1
the,recording 1.0 0.000143348623853 0 1 -1
later,all 1.0 0.000143348623853 0 1 -1
and,retard 1.0 0.000143348623853 0 1 -1
ratios,of 1.0 0.000143348623853 0 1 -1
cns,depressant 0.428571428571 0.000860091743119 10 4 6
in,divided 1.0 0.000143348623853 0 1 -1
authors,investigated 1.0 0.000143348623853 0 1 -1
affecting,the 1.0 0.000573394495413 4 0 4
can,increase 0.2 0.000143348623853 2 3 -1
channels,and 1.0 0.000143348623853 0 1 -1
t4,levels 1.0 0.000286697247706 0 2 -2
a,highest 1.0 0.000143348623853 0 1 -1
and,follow-up 1.0 0.000573394495413 0 4 -4
report,any 1.0 0.000143348623853 0 1 -1
were,picr 1.0 0.000143348623853 0 1 -1
only,with 0.714285714286 0.000716743119266 1 6 -5
much,more 1.0 0.000143348623853 0 1 -1
more,frequently 1.0 0.000573394495413 0 4 -4
first,study 0.0 0.0 1 1 0
cytochrome,p450-linked 1.0 0.000143348623853 0 1 -1
hemostasis,and 0.333333333333 0.000143348623853 2 1 1
was,hours 1.0 0.000143348623853 0 1 -1
non-selective,beta-adrenergic 1.0 0.000143348623853 1 0 1
and,induce 0.0 0.0 1 1 0
restlessness,muscle 1.0 0.000143348623853 0 1 -1
and,subsequent 1.0 0.000143348623853 0 1 -1
who,were 0.375 0.000860091743119 5 11 -6
or,weaken 1.0 0.000286697247706 2 0 2
drug,food 1.0 0.000143348623853 0 1 -1
compromised,cardiovascular 1.0 0.000143348623853 0 1 -1
either,potentiate 1.0 0.000286697247706 2 0 2
a,lower 0.333333333333 0.000286697247706 2 4 -2
clearance,when 1.0 0.000143348623853 1 0 1
proportionate,responses 1.0 0.000143348623853 0 1 -1
in,the 0.386416861827 0.0236525229358 131 296 -165
sr,by 1.0 0.000143348623853 1 0 1
so,that 0.0 0.0 1 1 0
survanta,and 1.0 0.000143348623853 0 1 -1
and,aminoglycosides 1.0 0.000143348623853 1 0 1
not,compensate 1.0 0.000286697247706 2 0 2
and,most 1.0 0.000143348623853 0 1 -1
and,concentrations 0.0 0.0 1 1 0
hrs,c 1.0 0.000143348623853 0 1 -1
recommended,because 1.0 0.000716743119266 5 0 5
clonazepam,literature 1.0 0.000143348623853 0 1 -1
gastrointestinal,acidifying 1.0 0.000143348623853 1 0 1
interactions,food 1.0 0.000143348623853 1 0 1
since,blood 1.0 0.00043004587156 0 3 -3
cold,allergy 1.0 0.000143348623853 0 1 -1
little,adequate 1.0 0.000143348623853 0 1 -1
b,and 1.0 0.000716743119266 5 0 5
hepatic,extraction 1.0 0.000143348623853 0 1 -1
following,co-administration 1.0 0.000286697247706 0 2 -2
was,misused 1.0 0.000143348623853 0 1 -1
volunteers,receiving 1.0 0.00043004587156 3 0 3
or,s-warfarin 1.0 0.000143348623853 0 1 -1
microm,which 1.0 0.000143348623853 0 1 -1
dietary,interferes 1.0 0.000143348623853 0 1 -1
withdrawal,period 1.0 0.00043004587156 0 3 -3
is,presently 1.0 0.000143348623853 0 1 -1
corrected,whenever 1.0 0.000143348623853 0 1 -1
mammary,tumor 1.0 0.000143348623853 0 1 -1
to,serum 0.333333333333 0.000143348623853 2 1 1
the,hyperuricemia 1.0 0.000143348623853 1 0 1
nimbex,and 0.0 0.0 1 1 0
male,rhesus 1.0 0.000143348623853 0 1 -1
mean,qt 1.0 0.000143348623853 1 0 1
and,requiring 1.0 0.000143348623853 1 0 1
co-administration,of 0.157894736842 0.00172018348624 44 32 12
to,develop 1.0 0.000143348623853 1 0 1
intervals,between 1.0 0.000143348623853 1 0 1
calcium-containing,medicines 1.0 0.000143348623853 0 1 -1
or,kineret 1.0 0.000143348623853 0 1 -1
with,thrombolytic 1.0 0.000143348623853 0 1 -1
co-administration,or 1.0 0.000143348623853 0 1 -1
insufficiency,and 1.0 0.000143348623853 0 1 -1
been,determined 1.0 0.000143348623853 0 1 -1
by,suggest 1.0 0.000143348623853 0 1 -1
tadalafil,dose 1.0 0.000143348623853 1 0 1
psychological,and 1.0 0.000143348623853 0 1 -1
fed,state 1.0 0.000143348623853 1 0 1
p450,isoenzyme 1.0 0.000286697247706 0 2 -2
of,loratadine 1.0 0.000143348623853 0 1 -1
a,monoamine 1.0 0.000143348623853 0 1 -1
potential,interaction 0.5 0.000573394495413 6 2 4
antagonists,administered 1.0 0.000143348623853 0 1 -1
escalate,the 1.0 0.000143348623853 0 1 -1
controlled,trials 1.0 0.000286697247706 0 2 -2
appetite,and 1.0 0.000143348623853 0 1 -1
free,of 1.0 0.000143348623853 0 1 -1
cell,mitogen 1.0 0.000143348623853 0 1 -1
with,platelet-aggregation 1.0 0.000143348623853 1 0 1
followed,by 0.25 0.000573394495413 6 10 -4
bowel,disease 1.0 0.000143348623853 0 1 -1
metabolites,may 1.0 0.000143348623853 0 1 -1
respiration,and 1.0 0.000143348623853 0 1 -1
indocin,does 1.0 0.000143348623853 0 1 -1
exjade,pharmacokinetics 1.0 0.000143348623853 0 1 -1
on,gastric 1.0 0.000143348623853 0 1 -1
are,dose 1.0 0.000143348623853 0 1 -1
drug-induced,renal 1.0 0.000143348623853 0 1 -1
salts,may 1.0 0.000143348623853 1 0 1
hypo-,and 1.0 0.000143348623853 0 1 -1
and,october 1.0 0.000143348623853 0 1 -1
frequent,maintenance 1.0 0.000143348623853 1 0 1
in,ewes 1.0 0.000143348623853 1 0 1
and,randomly 1.0 0.000143348623853 0 1 -1
results,and 1.0 0.000143348623853 1 0 1
slight,increases 1.0 0.000143348623853 1 0 1
arrangements,in 1.0 0.000143348623853 0 1 -1
were,followed 1.0 0.000143348623853 0 1 -1
kinetics,of 1.0 0.000143348623853 0 1 -1
active,dose 1.0 0.000143348623853 0 1 -1
k,epoxide 1.0 0.000143348623853 0 1 -1
roegnik,grade 1.0 0.000143348623853 0 1 -1
monkeys,nanm 1.0 0.000143348623853 0 1 -1
techniques,confirmation 1.0 0.000143348623853 0 1 -1
treated,simultaneously 1.0 0.000143348623853 0 1 -1
in,basal 1.0 0.000143348623853 0 1 -1
to,escalate 1.0 0.000143348623853 0 1 -1
until,reaching 1.0 0.000143348623853 0 1 -1
for,or 1.0 0.00043004587156 0 3 -3
type,of 0.0 0.0 1 1 0
situation,special 1.0 0.000143348623853 0 1 -1
for,of 0.0 0.0 1 1 0
crohn,s 1.0 0.000573394495413 0 4 -4
for,on 1.0 0.000143348623853 0 1 -1
iva-sensitive,p-type 1.0 0.000143348623853 0 1 -1
if,systemic 1.0 0.000143348623853 0 1 -1
subjects,single-dose 1.0 0.000143348623853 0 1 -1
to,phenytoin 1.0 0.000143348623853 1 0 1
marplan,parnate 1.0 0.000143348623853 0 1 -1
similar,events 1.0 0.000143348623853 0 1 -1
cyp3a4-eplerenone,metabolism 1.0 0.000143348623853 0 1 -1
reduction,was 0.0 0.0 1 1 0
given,in 0.142857142857 0.000143348623853 3 4 -1
inhibits,cyp2d6 1.0 0.000143348623853 0 1 -1
calcium-channel,blocking 1.0 0.000143348623853 0 1 -1
antipsychotic,agents 1.0 0.000286697247706 2 0 2
nasal,spray 0.333333333333 0.000143348623853 2 1 1
and,relative 1.0 0.000143348623853 0 1 -1
dependent,areas 1.0 0.000143348623853 0 1 -1
possible,additive 0.111111111111 0.000143348623853 4 5 -1
the,metabolism 0.193548387097 0.00172018348624 37 25 12
receptor,blockers 1.0 0.000143348623853 0 1 -1
of,neural 1.0 0.000143348623853 0 1 -1
mediated,clearance 1.0 0.000143348623853 0 1 -1
with,aprepitant 1.0 0.00043004587156 3 0 3
this,period 1.0 0.000143348623853 0 1 -1
be,even 1.0 0.000143348623853 1 0 1
their,action 1.0 0.000143348623853 0 1 -1
profiles,clinically 1.0 0.000143348623853 0 1 -1
in,effect 0.0 0.0 1 1 0
metabolism,very 1.0 0.000143348623853 0 1 -1
cyp3a4,below 1.0 0.000143348623853 0 1 -1
provided,significant 1.0 0.000143348623853 1 0 1
levo-dromoran,has 1.0 0.000143348623853 1 0 1
with,propecia 1.0 0.000143348623853 0 1 -1
cyp1a2,concomitant 1.0 0.000143348623853 1 0 1
also,being 0.0 0.0 1 1 0
before,prescribing 1.0 0.000143348623853 0 1 -1
while,receiving 1.0 0.000143348623853 1 0 1
every,mac 1.0 0.000143348623853 0 1 -1
nifedipine,did 1.0 0.000143348623853 0 1 -1
cells,even 1.0 0.000143348623853 0 1 -1
inhibitor,and 0.0 0.0 1 1 0
as,garlic 1.0 0.000143348623853 1 0 1
of,water 1.0 0.000143348623853 0 1 -1
chop-haart,compared 1.0 0.000143348623853 0 1 -1
blood,area 1.0 0.000143348623853 1 0 1
concentrations,with 1.0 0.000143348623853 1 0 1
qualitative,differences 1.0 0.000143348623853 0 1 -1
are,due 1.0 0.000143348623853 1 0 1
affect,patient 1.0 0.000143348623853 0 1 -1
metabolic,probe 1.0 0.000286697247706 0 2 -2
half,of 1.0 0.000573394495413 0 4 -4
resistant,clinical 1.0 0.000143348623853 0 1 -1
theophylline,theophylline 1.0 0.000143348623853 0 1 -1
progesterone-,and 1.0 0.000143348623853 1 0 1
veratrum,alkaloids 1.0 0.00043004587156 3 0 3
since,chronic 1.0 0.000143348623853 0 1 -1
acetate,in 1.0 0.000143348623853 1 0 1
humorsol,with 1.0 0.000143348623853 1 0 1
prinivil,alone 1.0 0.000143348623853 0 1 -1
no,specific 0.777777777778 0.00100344036697 1 8 -7
non-ionized,species 1.0 0.000143348623853 1 0 1
acetate,is 1.0 0.000286697247706 0 2 -2
humans,that 1.0 0.000143348623853 0 1 -1
reduced,clearance 0.428571428571 0.00043004587156 2 5 -3
hits,are 1.0 0.000143348623853 0 1 -1
hemorrhage,was 1.0 0.000143348623853 0 1 -1
that,act 1.0 0.000143348623853 1 0 1
care,and 1.0 0.000143348623853 0 1 -1
of,non-depolarising 1.0 0.000143348623853 1 0 1
campath,may 1.0 0.000143348623853 0 1 -1
facilitation,or 1.0 0.000143348623853 0 1 -1
occurring,interactions 1.0 0.000143348623853 1 0 1
given,before 1.0 0.000143348623853 0 1 -1
made,by 1.0 0.000143348623853 0 1 -1
alterations,caused 1.0 0.000143348623853 1 0 1
reported,regarding 1.0 0.000143348623853 0 1 -1
digoxin,is 1.0 0.000143348623853 0 1 -1
enhanced,drug 1.0 0.000143348623853 0 1 -1
pharmacological,i 1.0 0.000143348623853 0 1 -1
day,for 0.619047619048 0.00186353211009 4 17 -13
i,insulin-dependent 1.0 0.000143348623853 0 1 -1
in,monkeys 0.333333333333 0.000143348623853 1 2 -1
increase,daily 1.0 0.000143348623853 0 1 -1
be,sensitive 1.0 0.000286697247706 0 2 -2
by,therapy 0.333333333333 0.000143348623853 2 1 1
whenever,these 1.0 0.000143348623853 0 1 -1
non-diabetic,and 1.0 0.000143348623853 0 1 -1
risk,to 1.0 0.000286697247706 0 2 -2
mg,when 0.5 0.000286697247706 1 3 -2
subjects,but 1.0 0.000143348623853 0 1 -1
observed,during 0.6 0.00043004587156 1 4 -3
severe,and 0.0 0.0 1 1 0
older,adults 1.0 0.000143348623853 0 1 -1
methods,of 0.333333333333 0.000143348623853 1 2 -1
impairment,and 1.0 0.000143348623853 0 1 -1
the,location 1.0 0.000143348623853 0 1 -1
hypotensite,effects 1.0 0.000143348623853 1 0 1
therefore,hormonal 1.0 0.000143348623853 1 0 1
excessive,prolongation 1.0 0.000143348623853 1 0 1
need,to 0.0666666666667 0.000143348623853 8 7 1
to,hypertensive 1.0 0.000286697247706 0 2 -2
a4,such 1.0 0.000143348623853 1 0 1
of,absolute 1.0 0.000143348623853 0 1 -1
h2,blockers 0.333333333333 0.000286697247706 4 2 2
coadminstration,with 1.0 0.000143348623853 0 1 -1
quinolone,antibiotics 1.0 0.000286697247706 2 0 2
than,have 1.0 0.000143348623853 0 1 -1
as,colostrum 1.0 0.000143348623853 0 1 -1
interactions,are 0.5 0.000286697247706 1 3 -2
times,comparable 1.0 0.000143348623853 0 1 -1
develop,toxicity 1.0 0.000143348623853 1 0 1
be,recognized 1.0 0.00043004587156 0 3 -3
adjusted,accordingly 1.0 0.000143348623853 1 0 1
with,isocarboxazid 1.0 0.000143348623853 0 1 -1
less,specific 1.0 0.000143348623853 0 1 -1
cas,but 1.0 0.000143348623853 1 0 1
overdosage,or 1.0 0.000143348623853 1 0 1
then,analysing 1.0 0.000143348623853 0 1 -1
the,usual 0.5 0.00114678899083 4 12 -8
monitor,levels 1.0 0.000143348623853 0 1 -1
liver,microsomes 0.818181818182 0.00129013761468 1 10 -9
with,addictive 1.0 0.000143348623853 0 1 -1
complications,compared 1.0 0.00043004587156 3 0 3
an,inhibitory 1.0 0.000143348623853 0 1 -1
rapidly,growing 1.0 0.000143348623853 0 1 -1
is,low 1.0 0.000143348623853 0 1 -1
quinolones,including 1.0 0.000573394495413 4 0 4
gram,absorption 1.0 0.000143348623853 1 0 1
reduced,about 1.0 0.000143348623853 0 1 -1
lymphocyte,disorders 1.0 0.000143348623853 0 1 -1
glucose,concentrations 1.0 0.00043004587156 3 0 3
therefore,when 0.692307692308 0.00129013761468 11 2 9
elimination,the 1.0 0.000143348623853 1 0 1
levels,fluctuated 1.0 0.000143348623853 0 1 -1
can,deplete 1.0 0.000143348623853 1 0 1
tasks,in 1.0 0.000143348623853 0 1 -1
co-administered,but 1.0 0.000143348623853 0 1 -1
the,coat-a 1.0 0.000143348623853 0 1 -1
other,nondepolarizing 0.0 0.0 1 1 0
anticoagulants,oral 0.333333333333 0.000143348623853 1 2 -1
ferricyanide,test 1.0 0.000286697247706 0 2 -2
pancreas,of 1.0 0.000143348623853 0 1 -1
male,sprague-dawley 1.0 0.000143348623853 0 1 -1
and,signs 0.0 0.0 1 1 0
of,substances 1.0 0.000860091743119 0 6 -6
volunteers,were 1.0 0.00043004587156 0 3 -3
agents,receiving 1.0 0.000143348623853 1 0 1
study,demonstrates 1.0 0.000143348623853 1 0 1
m,decins 1.0 0.000143348623853 0 1 -1
diarrhea,would 1.0 0.000143348623853 1 0 1
several,cardiovascular 1.0 0.000143348623853 0 1 -1
probenecid,prolonged 1.0 0.000143348623853 0 1 -1
epoxide,which 1.0 0.000143348623853 0 1 -1
same,efficacy 1.0 0.000143348623853 0 1 -1
iodine,or 1.0 0.000143348623853 1 0 1
from,in 0.333333333333 0.000286697247706 2 4 -2
rate,requirements 1.0 0.000143348623853 1 0 1
contraindicated,specifically 1.0 0.000143348623853 0 1 -1
an,isocaloric 1.0 0.000143348623853 0 1 -1
might,blunt 1.0 0.000143348623853 0 1 -1
inhibition,in 1.0 0.000143348623853 0 1 -1
p450,system 0.75 0.000860091743119 1 7 -6
therefore,monitoring 1.0 0.000716743119266 0 5 -5
or,which 1.0 0.000143348623853 1 0 1
not,meaningfully 1.0 0.000143348623853 0 1 -1
similar,potential 1.0 0.000286697247706 2 0 2
cases,your 1.0 0.000143348623853 0 1 -1
hours,for 0.666666666667 0.000573394495413 1 5 -4
non-depolarizing,muscle 1.0 0.000143348623853 1 0 1
reveal,other 1.0 0.000143348623853 0 1 -1
with,acamprosate 0.0 0.0 1 1 0
and,make 1.0 0.000716743119266 0 5 -5
of,activase 1.0 0.000286697247706 0 2 -2
biotransformation,system 1.0 0.000286697247706 2 0 2
diabinese,the 1.0 0.000573394495413 0 4 -4
with,prinivil 1.0 0.000286697247706 2 0 2
antacids,on 1.0 0.000143348623853 0 1 -1
transient,drowsiness 1.0 0.000143348623853 0 1 -1
with,lean 1.0 0.000143348623853 0 1 -1
antacids,or 0.333333333333 0.000143348623853 2 1 1
the,target 1.0 0.000143348623853 0 1 -1
of,myalgia 1.0 0.000143348623853 1 0 1
nucleoside,analogues 1.0 0.000143348623853 1 0 1
prednisone,rofecoxib 1.0 0.000143348623853 0 1 -1
and,duration 0.0 0.0 2 2 0
acid,although 1.0 0.000143348623853 0 1 -1
and,cleansers 1.0 0.000143348623853 0 1 -1
regimen,i 1.0 0.000143348623853 0 1 -1
within,less 1.0 0.000143348623853 0 1 -1
cholecystokinin--of,h-spiroperidol 1.0 0.000143348623853 0 1 -1
sexual,dysfunction 1.0 0.000286697247706 0 2 -2
and,lack 1.0 0.000143348623853 0 1 -1
consequence,of 1.0 0.000286697247706 2 0 2
iodide,i131 1.0 0.000143348623853 1 0 1
irritation,subjects 1.0 0.000143348623853 0 1 -1
because,they 0.25 0.000286697247706 5 3 2
interrupted,when 1.0 0.000143348623853 0 1 -1
in,therapeutic 0.0 0.0 1 1 0
including,persistent 1.0 0.000143348623853 0 1 -1
synergistic,such 1.0 0.000286697247706 2 0 2
of,hypothyroidism 1.0 0.000143348623853 0 1 -1
downstream,of 1.0 0.000143348623853 0 1 -1
tranxene,is 1.0 0.000143348623853 0 1 -1
hiv-1,seropositive 1.0 0.000286697247706 0 2 -2
mc,ameliorate 1.0 0.000143348623853 0 1 -1
b-cell,lymphoma 1.0 0.000143348623853 0 1 -1
observations,have 1.0 0.000860091743119 6 0 6
potentially,important 0.0 0.0 1 1 0
cancer,recurrence 1.0 0.000143348623853 0 1 -1
warranted,and 0.0 0.0 1 1 0
animal,literature 1.0 0.000143348623853 0 1 -1
piperidine,prevents 1.0 0.000143348623853 1 0 1
of,brovana 0.333333333333 0.000143348623853 1 2 -1
days,into 1.0 0.000143348623853 0 1 -1
mutation,assay 1.0 0.000143348623853 0 1 -1
possible,increased 1.0 0.00043004587156 0 3 -3
also,should 1.0 0.000143348623853 1 0 1
acid,fruit 1.0 0.000143348623853 1 0 1
association,has 1.0 0.000143348623853 0 1 -1
the,authors 1.0 0.00043004587156 0 3 -3
of,contrast 1.0 0.000143348623853 0 1 -1
pr,interval 1.0 0.000143348623853 1 0 1
not,displace 1.0 0.000143348623853 0 1 -1
preparations,may 1.0 0.000286697247706 2 0 2
disruption,of 1.0 0.000143348623853 0 1 -1
at,steady-state 0.6 0.00043004587156 1 4 -3
potent,non-nucleoside 1.0 0.000143348623853 0 1 -1
or,deleted 1.0 0.000286697247706 2 0 2
following,other 1.0 0.000143348623853 0 1 -1
increased,volume 1.0 0.000286697247706 0 2 -2
assumed,to 1.0 0.000143348623853 0 1 -1
the,ecg 1.0 0.000143348623853 1 0 1
coumadin,other 1.0 0.000143348623853 0 1 -1
on,weeks 1.0 0.000143348623853 0 1 -1
and,nonzero 1.0 0.000143348623853 0 1 -1
study,of 0.333333333333 0.00129013761468 9 18 -9
been,reports 0.333333333333 0.000716743119266 10 5 5
cyp2c9,catalyzed 1.0 0.000143348623853 1 0 1
inhibitors,concomitantly 1.0 0.000143348623853 0 1 -1
action,potentials 1.0 0.000143348623853 0 1 -1
now,cared 1.0 0.000143348623853 0 1 -1
impair,the 0.0 0.0 1 1 0
study,or 0.0 0.0 1 1 0
article,looks 1.0 0.000143348623853 0 1 -1
may,provoke 0.0 0.0 1 1 0
after,nasal 1.0 0.000143348623853 1 0 1
other,high 1.0 0.000143348623853 0 1 -1
hypercalcemia,by 1.0 0.00043004587156 0 3 -3
binding,proteins 0.333333333333 0.000143348623853 1 2 -1
appearance,of 0.5 0.000286697247706 1 3 -2
possessing,properties 1.0 0.000143348623853 0 1 -1
leucovorin,the 1.0 0.000143348623853 1 0 1
ginsenosides-induced,inhibition 1.0 0.000143348623853 0 1 -1
or,prolong 0.6 0.00043004587156 1 4 -3
with,escalating 1.0 0.000143348623853 0 1 -1
inhibitors,include 1.0 0.000143348623853 0 1 -1
day,group 1.0 0.000143348623853 1 0 1
the,toxicity 0.4 0.000573394495413 3 7 -4
and,dyspnea 1.0 0.000143348623853 1 0 1
steady,partner 1.0 0.000143348623853 0 1 -1
theophylline,in 1.0 0.000143348623853 0 1 -1
to,cytochrome 1.0 0.000143348623853 1 0 1
nabilone,has 1.0 0.000143348623853 1 0 1
testing,a 1.0 0.000143348623853 0 1 -1
nacmc,and 1.0 0.000143348623853 0 1 -1
taking,nsaids 1.0 0.000573394495413 4 0 4
agents,in 0.384615384615 0.000716743119266 4 9 -5
other,than 0.636363636364 0.00100344036697 2 9 -7
gastrointestinal,motility 0.333333333333 0.000143348623853 2 1 1
while,other 1.0 0.000143348623853 0 1 -1
of,another 0.333333333333 0.000143348623853 2 1 1
sprycel,must 1.0 0.000143348623853 0 1 -1
transfusion,cross-matching 1.0 0.000143348623853 0 1 -1
use,forms 1.0 0.000143348623853 0 1 -1
other,depressasnts 1.0 0.000143348623853 1 0 1
interactions,dactinomycin 1.0 0.000143348623853 0 1 -1
delta,and 1.0 0.000143348623853 0 1 -1
tid,were 1.0 0.000143348623853 0 1 -1
other,that 0.2 0.00100344036697 14 21 -7
massive,seizures 1.0 0.000143348623853 0 1 -1
mean,age 1.0 0.000143348623853 0 1 -1
low-dose,with 1.0 0.000143348623853 1 0 1
or,parenteral 1.0 0.000286697247706 0 2 -2
more,with 1.0 0.000143348623853 1 0 1
function,should 0.272727272727 0.00043004587156 7 4 3
cmin,concentration 0.333333333333 0.000143348623853 1 2 -1
diabetic,patients 0.538461538462 0.00100344036697 3 10 -7
reversible,nonselective 1.0 0.000143348623853 0 1 -1
its,n-demethylated 1.0 0.000143348623853 0 1 -1
on,components 1.0 0.000143348623853 1 0 1
drugs,alcohol 1.0 0.000143348623853 0 1 -1
disease,except 1.0 0.000143348623853 1 0 1
potentiate,amphotericin 1.0 0.000143348623853 1 0 1
disease,who 1.0 0.000143348623853 0 1 -1
these,tests 1.0 0.00043004587156 0 3 -3
of,methylpyrazole 0.333333333333 0.000143348623853 2 1 1
when,subjects 1.0 0.000143348623853 0 1 -1
body,clearance 0.5 0.000286697247706 3 1 2
other,medications 0.333333333333 0.000573394495413 4 8 -4
malignancies,is 1.0 0.000143348623853 0 1 -1
addition,administration 1.0 0.000286697247706 0 2 -2
or,acquired 1.0 0.000143348623853 0 1 -1
to,lose 1.0 0.000143348623853 0 1 -1
has,not 0.58024691358 0.0067373853211 17 64 -47
of,less 0.6 0.00043004587156 4 1 3
is,neither 1.0 0.000143348623853 0 1 -1
ibuprofen,l-arginine 1.0 0.000143348623853 1 0 1
or,incompletely 1.0 0.000143348623853 0 1 -1
metabolism,rifampin 1.0 0.000143348623853 1 0 1
and,reuptake 1.0 0.00043004587156 3 0 3
of,certain 0.166666666667 0.000286697247706 7 5 2
potentiate,adverse 1.0 0.000143348623853 1 0 1
narcotics,non-narcotic 1.0 0.000143348623853 1 0 1
stimulatory,effects 1.0 0.000286697247706 2 0 2
and,followed 1.0 0.000143348623853 0 1 -1
exercised,if 0.5 0.000286697247706 3 1 2
hamster,s 1.0 0.000143348623853 0 1 -1
the,percentage 0.333333333333 0.000143348623853 1 2 -1
exercised,in 0.6 0.00043004587156 1 4 -3
administered,concurrently 0.217391304348 0.000716743119266 14 9 5
than,that 0.2 0.000143348623853 3 2 1
no,prolongation 1.0 0.000143348623853 0 1 -1
carbamazepine,carbamazepine 1.0 0.000143348623853 1 0 1
this,transient 1.0 0.000143348623853 0 1 -1
day,course 1.0 0.000143348623853 0 1 -1
the,bactercidal 1.0 0.000143348623853 1 0 1
midlands,a 1.0 0.000143348623853 0 1 -1
histamine-,or 1.0 0.000143348623853 1 0 1
steroidal,and 1.0 0.000143348623853 0 1 -1
mortality,was 1.0 0.000143348623853 0 1 -1
and,therapy 0.0 0.0 3 3 0
cause,induction 1.0 0.000143348623853 0 1 -1
limit,values 1.0 0.000143348623853 0 1 -1
hematuria,and 1.0 0.000143348623853 0 1 -1
form,unless 1.0 0.000143348623853 0 1 -1
to,initiating 1.0 0.000143348623853 1 0 1
followed,and 1.0 0.000143348623853 0 1 -1
soybean,flour 1.0 0.000143348623853 1 0 1
on,precautions 1.0 0.000143348623853 0 1 -1
irreversible,brain 1.0 0.000143348623853 1 0 1
seizure,associated 1.0 0.000143348623853 0 1 -1
cyp2d6,inhibitor 1.0 0.000143348623853 0 1 -1
is,predominantly 1.0 0.000716743119266 0 5 -5
bleeding,when 1.0 0.000143348623853 1 0 1
neuropsychiatric,events 1.0 0.000143348623853 1 0 1
decreased,response 1.0 0.000286697247706 0 2 -2
to,alleviate 1.0 0.000286697247706 0 2 -2
design,open-label 1.0 0.000143348623853 0 1 -1
drug,and 1.0 0.000143348623853 0 1 -1
agent,plus 1.0 0.000143348623853 0 1 -1
levels,did 1.0 0.000286697247706 0 2 -2
and,dilantin 1.0 0.000143348623853 1 0 1
depression,or 0.0 0.0 1 1 0
of,listed 1.0 0.000143348623853 0 1 -1
be,deficient 1.0 0.000143348623853 0 1 -1
patients,five 1.0 0.000143348623853 0 1 -1
dcg-iv,and 1.0 0.00043004587156 0 3 -3
mglur,agonists 1.0 0.000143348623853 0 1 -1
depression,of 1.0 0.00043004587156 3 0 3
valproic,acid 0.2 0.000286697247706 6 4 2
anaerobic,bacteria 1.0 0.000143348623853 0 1 -1
medication,monitored 1.0 0.000143348623853 0 1 -1
digoxin,keppra 1.0 0.000143348623853 0 1 -1
either,the 1.0 0.00258027522936 0 18 -18
several,closely 1.0 0.000143348623853 1 0 1
significantly,interact 1.0 0.000143348623853 0 1 -1
caused,no 1.0 0.000286697247706 0 2 -2
over,the 0.714285714286 0.000716743119266 1 6 -5
days,intraperitoneally 1.0 0.000143348623853 1 0 1
hivid-associated,adverse 1.0 0.000143348623853 1 0 1
avastin,when 1.0 0.000143348623853 0 1 -1
these,trials 1.0 0.000143348623853 0 1 -1
release,tablets 1.0 0.000286697247706 2 0 2
recurrence,of 1.0 0.000143348623853 0 1 -1
i,the 1.0 0.000143348623853 0 1 -1
in,ultimate 1.0 0.000143348623853 1 0 1
addicts,vs 1.0 0.000143348623853 0 1 -1
alpha-blockers,when 1.0 0.000143348623853 1 0 1
ovcon-35,resulted 1.0 0.000143348623853 1 0 1
angina,or 1.0 0.000143348623853 1 0 1
day,days 0.0 0.0 1 1 0
orencia,mtx 1.0 0.000143348623853 0 1 -1
of,pipracil 0.0 0.0 1 1 0
by,amphotericin 1.0 0.000143348623853 0 1 -1
recently,been 1.0 0.000143348623853 0 1 -1
nanm,was 1.0 0.000143348623853 0 1 -1
occasional,doses 1.0 0.000143348623853 0 1 -1
gastric,glands 1.0 0.000143348623853 0 1 -1
sulfate,prednisolone 1.0 0.000143348623853 0 1 -1
lipoprotein,cholesterol 1.0 0.000286697247706 0 2 -2
urinary,levels 1.0 0.000143348623853 0 1 -1
randomized,crossover 1.0 0.00043004587156 0 3 -3
cerebral,and 0.0 0.0 2 2 0
the,dissolution 1.0 0.000286697247706 0 2 -2
bacterial,infection 1.0 0.000143348623853 0 1 -1
antianginal,effectiveness 1.0 0.000143348623853 0 1 -1
certain,with 1.0 0.000143348623853 0 1 -1
when,infection 1.0 0.000143348623853 1 0 1
octapeptide,cholecystokinin--of 1.0 0.000143348623853 0 1 -1
trough,cmin 0.5 0.000286697247706 1 3 -2
structures,of 1.0 0.000143348623853 0 1 -1
miracidia,from 1.0 0.000143348623853 0 1 -1
sulphydryl-containing,amino 1.0 0.000143348623853 0 1 -1
roles,of 1.0 0.000143348623853 0 1 -1
included,brovana 1.0 0.000143348623853 0 1 -1
inhibit,sodium 1.0 0.000143348623853 1 0 1
reported,between 1.0 0.000286697247706 0 2 -2
mexate,use 1.0 0.000143348623853 1 0 1
this,decrease 0.0 0.0 2 2 0
intolerance,and 1.0 0.000286697247706 0 2 -2
abolished,by 1.0 0.000143348623853 1 0 1
benedicts,or 1.0 0.000143348623853 0 1 -1
preparations,antidiarrheal 1.0 0.000143348623853 1 0 1
cns,toxicity 1.0 0.000143348623853 0 1 -1
micronase,the 1.0 0.000573394495413 0 4 -4
the,chop-haart 1.0 0.000286697247706 0 2 -2
mg,rat 1.0 0.00043004587156 0 3 -3
patients,including 1.0 0.000286697247706 0 2 -2
used,physiological 1.0 0.000143348623853 0 1 -1
hypotension,oliguria 1.0 0.000143348623853 0 1 -1
aggregation,response 1.0 0.000143348623853 0 1 -1
lansoprazole,has 1.0 0.000143348623853 0 1 -1
hypoxanthine,and 1.0 0.000143348623853 1 0 1
disorder,abdominal 1.0 0.000143348623853 0 1 -1
are,metabolized 0.52 0.00186353211009 6 19 -13
extraction,j 1.0 0.000143348623853 0 1 -1
tract,by 1.0 0.000143348623853 1 0 1
adult,diabetics 1.0 0.000143348623853 0 1 -1
skin,wheals 1.0 0.000143348623853 0 1 -1
only,bodyweight 1.0 0.000143348623853 0 1 -1
equal,to 1.0 0.000286697247706 0 2 -2
nm,oh 1.0 0.000143348623853 0 1 -1
alerted,to 1.0 0.000143348623853 0 1 -1
delayed,for 1.0 0.000143348623853 1 0 1
force,of 1.0 0.000143348623853 0 1 -1
in,citrate 1.0 0.000143348623853 0 1 -1
microsomes,to 1.0 0.000143348623853 0 1 -1
events,or 0.6 0.00043004587156 1 4 -3
in,dogs 0.0 0.0 3 3 0
as,compared 0.333333333333 0.000573394495413 8 4 4
conditions,of 1.0 0.000143348623853 0 1 -1
relatively,specific 1.0 0.000143348623853 0 1 -1
conditions,or 1.0 0.000286697247706 0 2 -2
lung,survanta 1.0 0.000143348623853 0 1 -1
with,brevibloc 1.0 0.000143348623853 0 1 -1
lamivudine,is 1.0 0.000143348623853 0 1 -1
therefore,we 1.0 0.000143348623853 0 1 -1
cerebyx,are 1.0 0.000143348623853 0 1 -1
pcp-induced,behaviors 1.0 0.000143348623853 0 1 -1
also,due 1.0 0.000143348623853 1 0 1
for,minutes 1.0 0.000143348623853 0 1 -1
use,may 0.5 0.000573394495413 2 6 -4
by,could 1.0 0.000143348623853 0 1 -1
but,regular 1.0 0.000143348623853 0 1 -1
and,ototoxicity 0.333333333333 0.000143348623853 1 2 -1
follow,the 1.0 0.000143348623853 1 0 1
agents,iodine-containing 1.0 0.000143348623853 0 1 -1
times,increase 1.0 0.000143348623853 1 0 1
augmentation,persisted 1.0 0.000143348623853 0 1 -1
definite,nondepolarizing 1.0 0.000143348623853 0 1 -1
warfarin,and 1.0 0.000143348623853 1 0 1
slower,renal 1.0 0.000143348623853 1 0 1
enbrel,ci 1.0 0.000143348623853 1 0 1
temperatures,in 1.0 0.000143348623853 0 1 -1
by,effects 1.0 0.000143348623853 0 1 -1
kd,and 1.0 0.000143348623853 0 1 -1
toradol,oral 1.0 0.000143348623853 1 0 1
altered,when 1.0 0.000286697247706 0 2 -2
by,resulting 0.0 0.0 1 1 0
observed,that 0.2 0.000143348623853 2 3 -1
an,organophosphorous 1.0 0.000143348623853 0 1 -1
vitro,show 1.0 0.000143348623853 0 1 -1
has,on 1.0 0.000286697247706 2 0 2
appropriate,laboratory 1.0 0.000143348623853 1 0 1
had,a 0.666666666667 0.00114678899083 2 10 -8
since,pletal 1.0 0.000143348623853 1 0 1
diphenhydramine,diphenhydramine 1.0 0.000143348623853 0 1 -1
fosinopril,may 1.0 0.000143348623853 0 1 -1
administered,to 0.466666666667 0.00200688073394 8 22 -14
context,of 1.0 0.000143348623853 0 1 -1
although,theoretically 1.0 0.000143348623853 1 0 1
on,milk 1.0 0.000143348623853 0 1 -1
mydriasis,tachycardia 1.0 0.000143348623853 1 0 1
and,cns 0.0 0.0 2 2 0
dexrazoxane,was 1.0 0.000143348623853 0 1 -1
used,only 1.0 0.000286697247706 0 2 -2
increases,bioavailability 1.0 0.000143348623853 0 1 -1
taken,hours 1.0 0.000143348623853 0 1 -1
pretreatment,with 0.333333333333 0.000286697247706 4 2 2
infusion,than 1.0 0.000143348623853 0 1 -1
mg,a 0.0 0.0 1 1 0
mg,b 0.0 0.0 6 6 0
mg,d 1.0 0.000143348623853 0 1 -1
mg,h 1.0 0.000143348623853 1 0 1
single,pancreatic 1.0 0.000143348623853 0 1 -1
to,by 1.0 0.00043004587156 0 3 -3
mg,l 0.0 0.0 1 1 0
mg,m 1.0 0.000143348623853 0 1 -1
sampled,at 1.0 0.000143348623853 0 1 -1
a,novel 0.0 0.0 2 2 0
mg,q 0.5 0.000286697247706 3 1 2
mg,t 1.0 0.00043004587156 3 0 3
to,be 0.344537815126 0.00587729357798 39 80 -41
mg,x 1.0 0.000143348623853 0 1 -1
of,meclofenamate 1.0 0.000143348623853 0 1 -1
cyp3a4,with 1.0 0.000143348623853 0 1 -1
biliary,excretion 1.0 0.000143348623853 0 1 -1
under,the 0.0588235294118 0.000143348623853 9 8 1
by,thyroxine-binding 1.0 0.000143348623853 0 1 -1
trial,data 1.0 0.000143348623853 1 0 1
a,typical 1.0 0.000143348623853 0 1 -1
used,if 1.0 0.000860091743119 6 0 6
aims,hypothesis 1.0 0.000143348623853 0 1 -1
marketed,chewable 1.0 0.000143348623853 1 0 1
used,in 0.21875 0.00200688073394 25 39 -14
not,studied 0.6 0.00043004587156 1 4 -3
used,it 0.0 0.0 1 1 0
been,adequately 1.0 0.000286697247706 0 2 -2
naproxen,sodium 1.0 0.000143348623853 1 0 1
bactericidal,concentration 1.0 0.000143348623853 0 1 -1
were,killed 1.0 0.000143348623853 0 1 -1
foods,or 1.0 0.000143348623853 1 0 1
clotting,factors 1.0 0.000143348623853 0 1 -1
bioavailability,relative 1.0 0.000143348623853 0 1 -1
flurbiprofen,did 0.0 0.0 1 1 0
by,plate 1.0 0.000143348623853 0 1 -1
recommendations,were 1.0 0.000143348623853 0 1 -1
published,accounts 1.0 0.000143348623853 0 1 -1
unlike,nucleolin 1.0 0.000143348623853 0 1 -1
i,selective 1.0 0.000143348623853 1 0 1
with,cordarone 1.0 0.000143348623853 0 1 -1
four,days 1.0 0.000143348623853 0 1 -1
single-dose,coadministration 1.0 0.000143348623853 1 0 1
arrhythmias,qt 1.0 0.000143348623853 0 1 -1
therefore,colestld 1.0 0.000143348623853 0 1 -1
specific,d1 1.0 0.000143348623853 1 0 1
probably,for 1.0 0.000143348623853 0 1 -1
to,possible 0.142857142857 0.000143348623853 3 4 -1
conducted,no 1.0 0.000143348623853 0 1 -1
studies,strongly 1.0 0.000143348623853 0 1 -1
rachitic,chicks 1.0 0.000143348623853 1 0 1
receive,initial 1.0 0.000143348623853 1 0 1
to,hypotension 1.0 0.000143348623853 1 0 1
clinistix,or 1.0 0.000573394495413 0 4 -4
hydroxide,does 1.0 0.000143348623853 0 1 -1
behaviour,of 1.0 0.00043004587156 0 3 -3
to,possibly 1.0 0.000143348623853 1 0 1
estimation,of 1.0 0.000143348623853 0 1 -1
tolerance,to 1.0 0.000286697247706 2 0 2
important,regulation 1.0 0.000143348623853 0 1 -1
other,have 0.692307692308 0.00129013761468 2 11 -9
chop,alone 1.0 0.000143348623853 0 1 -1
co-administration,leading 1.0 0.000143348623853 1 0 1
endocrine,status 1.0 0.000143348623853 0 1 -1
these,areas 1.0 0.000143348623853 0 1 -1
and,automaticity 1.0 0.000143348623853 1 0 1
hours,before 0.25 0.000573394495413 10 6 4
kg,and 0.333333333333 0.000286697247706 2 4 -2
quantitatively,related 1.0 0.000143348623853 0 1 -1
its,serum 0.0 0.0 1 1 0
uptake-1,were 1.0 0.000143348623853 0 1 -1
plus,were 1.0 0.000143348623853 0 1 -1
a4,isozymes 1.0 0.000143348623853 0 1 -1
inadequate,systematic 1.0 0.000143348623853 0 1 -1
groups,then 1.0 0.000143348623853 0 1 -1
enhancing,effects 1.0 0.000143348623853 0 1 -1
a,return 1.0 0.000143348623853 0 1 -1
thus,necessitating 1.0 0.000143348623853 1 0 1
microsomes,the 1.0 0.000143348623853 0 1 -1
ketorolac,does 1.0 0.000143348623853 0 1 -1
cortisol,thyroid-stimulating 1.0 0.000143348623853 0 1 -1
and,apple 1.0 0.000143348623853 0 1 -1
a,renal 1.0 0.000143348623853 0 1 -1
ototoxicity,is 1.0 0.000143348623853 1 0 1
no,igg 1.0 0.000143348623853 0 1 -1
elimination,half 1.0 0.000143348623853 1 0 1
affect,its 1.0 0.000286697247706 0 2 -2
of,erection 1.0 0.000143348623853 0 1 -1
there,also 1.0 0.000143348623853 0 1 -1
lower,auc 1.0 0.000143348623853 0 1 -1
alcohol,increases 1.0 0.000143348623853 0 1 -1
kg,the 1.0 0.000143348623853 0 1 -1
suggested,in 1.0 0.000143348623853 0 1 -1
can,antagonize 1.0 0.000286697247706 2 0 2
of,coly-mycin 1.0 0.000143348623853 1 0 1
hydroxides,does 1.0 0.000143348623853 0 1 -1
is,evidently 1.0 0.000143348623853 0 1 -1
activated,the 1.0 0.000143348623853 0 1 -1
a,prospective 1.0 0.000143348623853 0 1 -1
on,or 0.0 0.0 1 1 0
the,excretion 0.333333333333 0.000143348623853 2 1 1
s,concomitantly 1.0 0.000143348623853 1 0 1
nonabsorbable,complex 1.0 0.000143348623853 1 0 1
sensitive,cyp3a4 1.0 0.000143348623853 1 0 1
significant,shifts 1.0 0.000143348623853 0 1 -1
therapy,discontinuation 1.0 0.000143348623853 1 0 1
abundance,and 1.0 0.000143348623853 0 1 -1
edema,and 1.0 0.000143348623853 0 1 -1
pressor,effects 0.333333333333 0.000143348623853 2 1 1
hepatotoxicity,are 1.0 0.000143348623853 1 0 1
are,effective 1.0 0.000143348623853 0 1 -1
a,causal 0.333333333333 0.000143348623853 1 2 -1
these,cyp3a4 0.0 0.0 1 1 0
conduction,abnormalities 1.0 0.000143348623853 0 1 -1
showed,moderate 1.0 0.000143348623853 0 1 -1
of,gastric 0.333333333333 0.000143348623853 1 2 -1
racemic,exposure 1.0 0.000143348623853 1 0 1
administration,of 0.166666666667 0.00831422018349 203 145 58
different,way 1.0 0.000143348623853 0 1 -1
in,qt 1.0 0.000143348623853 1 0 1
pharmacokinetics,of 0.81308411215 0.0124713302752 10 97 -87
administration,on 1.0 0.00043004587156 0 3 -3
flu-like,effects 1.0 0.000143348623853 0 1 -1
administration,or 1.0 0.000143348623853 0 1 -1
indocin,can 1.0 0.000286697247706 2 0 2
concentrations,after 1.0 0.000143348623853 1 0 1
is,negligible 1.0 0.000143348623853 0 1 -1
antidepressant,when 1.0 0.000143348623853 1 0 1
l057,in 1.0 0.000143348623853 0 1 -1
completely,absorbed 1.0 0.000143348623853 0 1 -1
pharmacokinetics,or 1.0 0.000573394495413 0 4 -4
received,pelvic 1.0 0.000143348623853 0 1 -1
is,going 1.0 0.000716743119266 0 5 -5
as,implants 1.0 0.000143348623853 0 1 -1
bone,loss 1.0 0.000286697247706 0 2 -2
amphotericin,foscarnet 1.0 0.000143348623853 1 0 1
of,desired 1.0 0.000143348623853 0 1 -1
shown,that 0.128205128205 0.000716743119266 17 22 -5
decreasing,according 1.0 0.000143348623853 0 1 -1
c3h,hen 1.0 0.000143348623853 0 1 -1
bilirubin,times 1.0 0.000143348623853 0 1 -1
acid,indicating 1.0 0.000143348623853 0 1 -1
doses,for 1.0 0.00114678899083 0 8 -8
macrolide,such 0.0 0.0 1 1 0
of,four 0.333333333333 0.000143348623853 2 1 1
derivatives,antimycobacterial 1.0 0.000143348623853 1 0 1
food,on 1.0 0.000143348623853 0 1 -1
important,in 1.0 0.00043004587156 0 3 -3
food,or 1.0 0.00043004587156 0 3 -3
effectiveness,by 0.0 0.0 1 1 0
concentration,is 0.333333333333 0.000143348623853 1 2 -1
sugar,concentrations 1.0 0.000143348623853 1 0 1
post,and 1.0 0.000143348623853 0 1 -1
control,pills 1.0 0.000286697247706 0 2 -2
with,primarily 1.0 0.000143348623853 0 1 -1
their,bioavailability 1.0 0.000143348623853 1 0 1
human,studies 1.0 0.000286697247706 0 2 -2
significantly,reduce 1.0 0.000286697247706 0 2 -2
disease,and 0.6 0.00043004587156 1 4 -3
matched,with 1.0 0.000143348623853 0 1 -1
produce,persistently 1.0 0.000143348623853 0 1 -1
rats,administered 1.0 0.000143348623853 0 1 -1
affecting,blood 1.0 0.000143348623853 1 0 1
of,anti-platelet 1.0 0.000143348623853 0 1 -1
as,slowly 1.0 0.000143348623853 1 0 1
intravenous,without 1.0 0.000143348623853 1 0 1
third,of 1.0 0.000143348623853 1 0 1
although,the 0.1 0.000286697247706 9 11 -2
concentrations,fo 1.0 0.000143348623853 0 1 -1
juice,increases 1.0 0.000143348623853 0 1 -1
cannulation,decreased 1.0 0.000143348623853 0 1 -1
acetaminophen,a 1.0 0.000143348623853 1 0 1
a,double-blind 1.0 0.000286697247706 0 2 -2
enoxacin,is 1.0 0.000286697247706 2 0 2
psychostimulant,self-administration 1.0 0.000143348623853 0 1 -1
avoided,beta-blockers 1.0 0.000143348623853 1 0 1
whole,blood 1.0 0.000286697247706 2 0 2
explanation,for 1.0 0.000143348623853 0 1 -1
impaired,vs 1.0 0.000143348623853 0 1 -1
combination,procedures 1.0 0.000143348623853 0 1 -1
either,single 1.0 0.000286697247706 0 2 -2
dependent,on 1.0 0.000143348623853 0 1 -1
crystalline,preparations 1.0 0.000143348623853 0 1 -1
dizziness,effects 1.0 0.000143348623853 0 1 -1
rapid,avoidance 1.0 0.000143348623853 0 1 -1
and,emit-d 1.0 0.000143348623853 0 1 -1
b6,physiological 1.0 0.000143348623853 0 1 -1
is,needed 0.6 0.00043004587156 1 4 -3
sensipar,may 1.0 0.000143348623853 1 0 1
pharmacological,treatment 1.0 0.000286697247706 0 2 -2
other,inhaled 1.0 0.000143348623853 0 1 -1
the,qt 0.818181818182 0.00129013761468 10 1 9
interactions,mediated 1.0 0.000286697247706 0 2 -2
reports,suggesting 1.0 0.000143348623853 1 0 1
mainly,by 1.0 0.000143348623853 0 1 -1
innovar,on 1.0 0.000143348623853 0 1 -1
flecainide,is 1.0 0.000143348623853 0 1 -1
yielded,a 1.0 0.000143348623853 0 1 -1
apart,on 1.0 0.000143348623853 1 0 1
and,mumol 1.0 0.000143348623853 1 0 1
especially,important 0.5 0.000286697247706 1 3 -2
metabolism,are 1.0 0.00043004587156 0 3 -3
for,death 1.0 0.000143348623853 0 1 -1
because,moderate 1.0 0.000143348623853 1 0 1
inhibition,at 1.0 0.000143348623853 0 1 -1
fetus,due 1.0 0.000143348623853 0 1 -1
c,has 1.0 0.000143348623853 0 1 -1
as,inotropes 1.0 0.000143348623853 1 0 1
miracidia,demonstrated 1.0 0.000143348623853 0 1 -1
conclusions,interpretation 1.0 0.000143348623853 0 1 -1
human,breast 1.0 0.000143348623853 1 0 1
regardless,of 0.5 0.000286697247706 1 3 -2
hydroxy-estazolam,and 1.0 0.000143348623853 0 1 -1
is,markedly 1.0 0.000143348623853 1 0 1
stable,prothrombin 1.0 0.000143348623853 0 1 -1
hydrochloride,binds 1.0 0.000143348623853 0 1 -1
solid,phase 1.0 0.000143348623853 0 1 -1
results,during 0.0 0.0 1 1 0
em,individuals 1.0 0.000143348623853 1 0 1
on,monotherapy 1.0 0.000143348623853 0 1 -1
multiple,exposure 1.0 0.000286697247706 0 2 -2
fat,soluble 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,and 1.0 0.000143348623853 1 0 1
to,approximate 1.0 0.000143348623853 0 1 -1
produces,whole 1.0 0.000143348623853 0 1 -1
blood,levels 0.0434782608696 0.000143348623853 11 12 -1
excystment,in 1.0 0.000143348623853 0 1 -1
on,recovery 1.0 0.000143348623853 0 1 -1
system,have 1.0 0.000143348623853 0 1 -1
of,cerebyx 1.0 0.000143348623853 0 1 -1
receiving,decreased 1.0 0.000143348623853 1 0 1
prevention,in 1.0 0.000143348623853 0 1 -1
glycemia,in 1.0 0.000143348623853 0 1 -1
gly-buride,and 1.0 0.000143348623853 0 1 -1
tnf,blocking 0.333333333333 0.000143348623853 1 2 -1
taking,prothrombin 1.0 0.000143348623853 1 0 1
anticoagulation,effects 0.333333333333 0.000143348623853 1 2 -1
prothrombin,measures 1.0 0.000143348623853 0 1 -1
enlargement,and 0.0 0.0 1 1 0
inhibit,renal 1.0 0.000143348623853 1 0 1
effects,divalproex 1.0 0.000143348623853 1 0 1
oil,interferes 1.0 0.000143348623853 1 0 1
also,showed 1.0 0.000143348623853 0 1 -1
organs,actively 1.0 0.000143348623853 0 1 -1
endogenous,respiration 1.0 0.000143348623853 0 1 -1
alternative,treatment 1.0 0.000143348623853 0 1 -1
mucosa,mounted 1.0 0.000143348623853 0 1 -1
there,has 0.2 0.000143348623853 2 3 -1
with,strong 0.333333333333 0.000143348623853 2 1 1
the,decreases 1.0 0.000143348623853 1 0 1
gentamicin,did 1.0 0.000143348623853 0 1 -1
mna,may 1.0 0.000143348623853 0 1 -1
enzyme-based,tests 1.0 0.00043004587156 0 3 -3
works,differently 1.0 0.000143348623853 0 1 -1
are,related 1.0 0.000143348623853 0 1 -1
and,escherichia 1.0 0.000143348623853 0 1 -1
therapy,may 0.166666666667 0.000286697247706 5 7 -2
mg,dosage 1.0 0.000143348623853 0 1 -1
cyp2d6,isoenzyme 0.333333333333 0.000143348623853 2 1 1
derived,from 0.0 0.0 2 2 0
definitely,determined 1.0 0.000143348623853 0 1 -1
non-steroidal,anti-inflammatory 0.8 0.00114678899083 9 1 8
non-ossification,of 1.0 0.000143348623853 0 1 -1
cardiac,dysrhythmias 1.0 0.00043004587156 3 0 3
minimise,the 1.0 0.000143348623853 0 1 -1
jaff,reaction 1.0 0.000143348623853 0 1 -1
watched,during 1.0 0.000143348623853 0 1 -1
consciousness,caused 1.0 0.000143348623853 1 0 1
cyp,metabolism 1.0 0.000143348623853 1 0 1
its,normal 1.0 0.000143348623853 1 0 1
clinical,status 1.0 0.000143348623853 1 0 1
bodys,ability 1.0 0.000143348623853 0 1 -1
of,aliskiren 1.0 0.000143348623853 0 1 -1
cardiovascular,concurrently 1.0 0.000143348623853 0 1 -1
serial,pharmacokinetic 1.0 0.000286697247706 0 2 -2
is,also 0.142857142857 0.000286697247706 6 8 -2
did,not 0.888111888112 0.0182052752294 8 135 -127
and,exert 1.0 0.000286697247706 0 2 -2
concurrent,treatment 0.333333333333 0.000143348623853 1 2 -1
aetiopathogenic--,for 1.0 0.000143348623853 0 1 -1
vitamin,b3 1.0 0.000143348623853 1 0 1
initiated,a 1.0 0.000143348623853 0 1 -1
and,mefloquine 1.0 0.000143348623853 0 1 -1
groups,achieving 1.0 0.000143348623853 0 1 -1
two,capsules 1.0 0.000143348623853 0 1 -1
minutes,following 1.0 0.000286697247706 2 0 2
as,arrhythmias 1.0 0.000143348623853 1 0 1
two,hormonal 1.0 0.000143348623853 1 0 1
sudden,cardiac 1.0 0.000143348623853 0 1 -1
rate,requirement 1.0 0.000143348623853 0 1 -1
inhibitors,duragesic 1.0 0.000143348623853 1 0 1
events,should 1.0 0.000143348623853 0 1 -1
concomitantly,by 1.0 0.000143348623853 1 0 1
bilirubin,and 1.0 0.000143348623853 0 1 -1
anticholinesterase,overdose 1.0 0.000143348623853 0 1 -1
coenzyme,a 0.333333333333 0.000143348623853 1 2 -1
therapy,after 1.0 0.000143348623853 1 0 1
schizophrenia,or 1.0 0.000286697247706 0 2 -2
c9,decreased 1.0 0.000143348623853 1 0 1
endotoxin-induced,changes 1.0 0.000143348623853 0 1 -1
treated,with 0.044776119403 0.00043004587156 32 35 -3
with,nutrition 1.0 0.000143348623853 0 1 -1
pharmacokinetits,of 1.0 0.000143348623853 0 1 -1
vitro,finding 1.0 0.000286697247706 0 2 -2
cardiac,monitoring 1.0 0.000143348623853 0 1 -1
oils,should 1.0 0.000143348623853 0 1 -1
faster,with 1.0 0.000143348623853 1 0 1
add,some 1.0 0.000143348623853 1 0 1
drug-drug,interaction 0.666666666667 0.00114678899083 2 10 -8
trial,in 0.333333333333 0.000143348623853 1 2 -1
unexpectedly,low 1.0 0.000143348623853 1 0 1
cervical,breast 1.0 0.000143348623853 0 1 -1
preparations,minipills 1.0 0.000143348623853 1 0 1
the,hypothalamic-pituitary 1.0 0.000143348623853 0 1 -1
of,mutagenicity 1.0 0.000143348623853 0 1 -1
male,or 1.0 0.000143348623853 0 1 -1
patient,response 1.0 0.000286697247706 0 2 -2
potent,cyp3a4 0.333333333333 0.000573394495413 8 4 4
diftitox,had 1.0 0.000143348623853 0 1 -1
diamond,patient 1.0 0.000143348623853 1 0 1
resorptions,or 1.0 0.000143348623853 0 1 -1
butenafine,hcl 1.0 0.000143348623853 0 1 -1
sodium,and 0.2 0.000286697247706 6 4 2
dose,group 1.0 0.000143348623853 0 1 -1
and,qtc 1.0 0.000143348623853 0 1 -1
is,antagonized 1.0 0.000143348623853 1 0 1
were,coadministered 0.5 0.000286697247706 3 1 2
more,conservatively 1.0 0.000143348623853 1 0 1
inducer,such 1.0 0.000143348623853 0 1 -1
turn,controls 1.0 0.000143348623853 0 1 -1
impaired,psychomotor 1.0 0.000286697247706 2 0 2
and,inducible 1.0 0.000143348623853 0 1 -1
increased,activity 0.0 0.0 1 1 0
hyperglycemic,effects 1.0 0.000143348623853 0 1 -1
maoi,could 1.0 0.000143348623853 1 0 1
when,co 1.0 0.000143348623853 1 0 1
orally,min 1.0 0.000143348623853 0 1 -1
diabetic,and 1.0 0.00043004587156 0 3 -3
severe,allergic 1.0 0.000143348623853 0 1 -1
and,sucralfate 1.0 0.000143348623853 1 0 1
extremely,cautiously 1.0 0.000143348623853 1 0 1
color,alkaline 1.0 0.000143348623853 0 1 -1
route,they 1.0 0.000143348623853 1 0 1
discusses,the 1.0 0.000286697247706 0 2 -2
is,desirable 1.0 0.000716743119266 0 5 -5
the,ototoxic 1.0 0.00043004587156 3 0 3
effect,to 1.0 0.000143348623853 1 0 1
largely,unbound 1.0 0.000143348623853 0 1 -1
possibility,that 0.6 0.00043004587156 4 1 3
in,mice 1.0 0.000860091743119 0 6 -6
four-session,placebo-controlled 1.0 0.000143348623853 0 1 -1
to,mice 1.0 0.000286697247706 0 2 -2
its,action 1.0 0.000143348623853 1 0 1
interaction,within 1.0 0.000143348623853 0 1 -1
first,and 0.333333333333 0.000143348623853 2 1 1
following,methyl-4 1.0 0.000143348623853 0 1 -1
variability,for 1.0 0.000143348623853 0 1 -1
found,between 1.0 0.000286697247706 0 2 -2
other,ht1b 0.0 0.0 1 1 0
primarily,h2 1.0 0.000143348623853 0 1 -1
inhibit,cytochrome 0.846153846154 0.00157683486239 1 12 -11
and,perhaps 1.0 0.000286697247706 0 2 -2
not,extend 1.0 0.000143348623853 0 1 -1
a,comparison 0.333333333333 0.000143348623853 1 2 -1
urinary,alkalinizing 0.0 0.0 1 1 0
hypotension,will 1.0 0.000143348623853 1 0 1
controls,levels 1.0 0.000143348623853 0 1 -1
chinese,hamsters 1.0 0.000143348623853 0 1 -1
you,are 0.166666666667 0.000286697247706 5 7 -2
that,incidence 1.0 0.000143348623853 0 1 -1
anabolin,anavar 1.0 0.000143348623853 0 1 -1
hyperthyroid,patients 1.0 0.000143348623853 0 1 -1
considered,and 0.5 0.000286697247706 1 3 -2
orally,ingested 1.0 0.000143348623853 0 1 -1
aom,mg 1.0 0.000143348623853 0 1 -1
of,colony 1.0 0.000143348623853 0 1 -1
can,be 0.230769230769 0.00129013761468 15 24 -9
d,the 1.0 0.00043004587156 0 3 -3
needing,to 1.0 0.000143348623853 0 1 -1
influenza,virus 1.0 0.000143348623853 1 0 1
brain,chemical 1.0 0.000143348623853 0 1 -1
certain,narcotic 1.0 0.000143348623853 1 0 1
instability,with 1.0 0.000143348623853 1 0 1
especially,and 1.0 0.000143348623853 0 1 -1
no,formal 1.0 0.0045871559633 0 32 -32
altered,its 1.0 0.000143348623853 0 1 -1
in,connection 1.0 0.000143348623853 0 1 -1
pose,a 0.0 0.0 1 1 0
significantly,decrease 1.0 0.000143348623853 1 0 1
zmax,have 1.0 0.000143348623853 0 1 -1
and,synergistic 1.0 0.000286697247706 2 0 2
brevibloc,but 1.0 0.000143348623853 1 0 1
oral,parenteral 1.0 0.000143348623853 0 1 -1
receiving,low 0.0 0.0 1 1 0
toxicity,at 1.0 0.000143348623853 1 0 1
the,ph 1.0 0.000143348623853 1 0 1
whereas,h-spiroperidol 1.0 0.000143348623853 0 1 -1
conservative,approach 1.0 0.000143348623853 0 1 -1
vasodilator,effects 1.0 0.000143348623853 0 1 -1
cations,multivitamins 1.0 0.000143348623853 0 1 -1
least,an 1.0 0.000143348623853 0 1 -1
and,kht 1.0 0.000143348623853 0 1 -1
h,without 1.0 0.000143348623853 1 0 1
on,mtc-mdp 1.0 0.000143348623853 1 0 1
penicillin-type,are 1.0 0.000143348623853 1 0 1
the,corrected 1.0 0.000143348623853 0 1 -1
index,digoxin 1.0 0.000286697247706 0 2 -2
the,salt 1.0 0.000573394495413 4 0 4
platelet,count 1.0 0.000143348623853 0 1 -1
and,urine 0.5 0.000860091743119 3 9 -6
weight,and 1.0 0.000573394495413 0 4 -4
and,results 1.0 0.000143348623853 1 0 1
chemotherapies,breast 1.0 0.000143348623853 0 1 -1
and,smx 1.0 0.000143348623853 0 1 -1
its,synergism 1.0 0.000143348623853 1 0 1
be,clinically 0.333333333333 0.000143348623853 1 2 -1
partially,related 1.0 0.000143348623853 1 0 1
precipitation,of 1.0 0.000143348623853 0 1 -1
brain,was 1.0 0.000143348623853 1 0 1
depress,prolactin 1.0 0.000143348623853 0 1 -1
initial,presentation 1.0 0.000143348623853 1 0 1
great,potential 1.0 0.000143348623853 0 1 -1
atp,and 1.0 0.000143348623853 0 1 -1
therapy,alone 1.0 0.000143348623853 0 1 -1
interactions,hyperaminotransferasemia 1.0 0.000143348623853 0 1 -1
ganglionic,blocking 0.333333333333 0.000143348623853 2 1 1
class,which 1.0 0.000143348623853 0 1 -1
monitored,if 1.0 0.000286697247706 2 0 2
the,nad 1.0 0.000143348623853 1 0 1
the,nac 1.0 0.000286697247706 0 2 -2
local,use 1.0 0.000143348623853 0 1 -1
level,to 0.333333333333 0.000143348623853 1 2 -1
monitored,in 0.2 0.000143348623853 3 2 1
contraction,followed 1.0 0.000143348623853 0 1 -1
free,fraction 0.333333333333 0.000143348623853 1 2 -1
enhancement,effect 1.0 0.000143348623853 1 0 1
suboxone,should 1.0 0.000143348623853 1 0 1
also,likely 1.0 0.000143348623853 1 0 1
intables,and 1.0 0.000143348623853 0 1 -1
as,the 0.1 0.000286697247706 9 11 -2
concomitant,augmentin 1.0 0.000143348623853 0 1 -1
limb,digital 1.0 0.000143348623853 0 1 -1
moderate,renal 1.0 0.000143348623853 0 1 -1
also,extensively 1.0 0.000143348623853 0 1 -1
subjects,have 1.0 0.000286697247706 0 2 -2
by,protecting 1.0 0.000143348623853 0 1 -1
stimulated,with 1.0 0.000143348623853 0 1 -1
on,dopamine2- 1.0 0.000143348623853 0 1 -1
vana,antisense 1.0 0.000143348623853 0 1 -1
rings,from 1.0 0.000143348623853 1 0 1
a,minor 0.5 0.000286697247706 1 3 -2
that,it 1.0 0.000143348623853 1 0 1
blockade,of 0.0 0.0 2 2 0
that,is 0.851851851852 0.00329701834862 2 25 -23
inhibitors,ssris 0.0909090909091 0.000143348623853 5 6 -1
hydroxide,hydroxide 1.0 0.000143348623853 1 0 1
antiepileptic,the 1.0 0.000143348623853 0 1 -1
that,in 0.428571428571 0.000860091743119 4 10 -6
nonsteroidal,given 1.0 0.000143348623853 0 1 -1
of,caucasians 1.0 0.000716743119266 0 5 -5
suspension,reduces 1.0 0.000143348623853 1 0 1
fibrulation,and 1.0 0.000143348623853 1 0 1
with,potassium-depleting 1.0 0.000143348623853 1 0 1
receiving,these 0.2 0.000143348623853 2 3 -1
may,decrease 0.372549019608 0.00272362385321 35 16 19
oral,was 1.0 0.000143348623853 1 0 1
rat,stomach 1.0 0.000143348623853 1 0 1
when,another 1.0 0.000143348623853 0 1 -1
pigeons,did 1.0 0.000143348623853 0 1 -1
the,block 1.0 0.000143348623853 0 1 -1
redistributed,type 1.0 0.000143348623853 0 1 -1
functions,i 1.0 0.000143348623853 0 1 -1
cultures,stimulated 1.0 0.000143348623853 0 1 -1
mercaptopurine,azathioprine 1.0 0.000143348623853 1 0 1
other,calcium-containing 1.0 0.000143348623853 0 1 -1
literature,article 1.0 0.000143348623853 1 0 1
to,sexual 1.0 0.000143348623853 0 1 -1
six-day,course 1.0 0.000143348623853 1 0 1
inflammation,is 1.0 0.000143348623853 0 1 -1
substances,demonstrated 1.0 0.000143348623853 1 0 1
have,detrimental 1.0 0.000286697247706 0 2 -2
embryos,in 1.0 0.000143348623853 1 0 1
receiving,alone 1.0 0.000143348623853 0 1 -1
inhibit,platelet 0.0 0.0 1 1 0
with,chop 1.0 0.000143348623853 0 1 -1
concomitantly,becausedecreases 1.0 0.000286697247706 2 0 2
p450iid6,may 1.0 0.000143348623853 0 1 -1
that,zebeta 1.0 0.000143348623853 1 0 1
micrograms,kg 1.0 0.000143348623853 0 1 -1
other,reported 1.0 0.000143348623853 0 1 -1
when,coreg 1.0 0.000143348623853 1 0 1
lowest,recommended 1.0 0.000143348623853 1 0 1
prevent,excessive 1.0 0.000143348623853 1 0 1
dyspnea,hypotension 1.0 0.000143348623853 0 1 -1
in,various 1.0 0.000143348623853 0 1 -1
and,ventral 1.0 0.000143348623853 0 1 -1
skin,tests 1.0 0.000143348623853 0 1 -1
with,cyp3a4 0.333333333333 0.000143348623853 1 2 -1
steady-state,exposure 1.0 0.000143348623853 0 1 -1
combined,treatment 0.333333333333 0.000143348623853 2 1 1
mucosal,cell 1.0 0.000143348623853 0 1 -1
acid,etc 1.0 0.000286697247706 2 0 2
d2,vitamin 1.0 0.00043004587156 3 0 3
orthostatic,changes 1.0 0.000143348623853 1 0 1
and,probably 1.0 0.000143348623853 0 1 -1
and,background 1.0 0.000143348623853 0 1 -1
the,international 1.0 0.000143348623853 0 1 -1
blocking,compounds 1.0 0.000143348623853 0 1 -1
on,pregnancy 1.0 0.000143348623853 0 1 -1
mediated,primarily 1.0 0.000143348623853 0 1 -1
of,psychotic 1.0 0.000286697247706 0 2 -2
hypoglycemia,may 1.0 0.000286697247706 0 2 -2
and,those 1.0 0.000573394495413 0 4 -4
the,rebound 1.0 0.000143348623853 1 0 1
expected,between 1.0 0.000143348623853 0 1 -1
shown,casodex 1.0 0.000143348623853 1 0 1
systemically,administered 1.0 0.000143348623853 0 1 -1
the,preservative 1.0 0.000143348623853 1 0 1
with,cardiovascular 1.0 0.000286697247706 0 2 -2
otthostatic,hypotension 1.0 0.000143348623853 0 1 -1
therapy,nicotinic 1.0 0.000143348623853 1 0 1
fertility,of 1.0 0.00043004587156 0 3 -3
concurrent,and 0.0 0.0 1 1 0
in,parentheses 1.0 0.000143348623853 0 1 -1
was,seen 0.4 0.000573394495413 3 7 -4
known,metabolic 1.0 0.000143348623853 0 1 -1
fertility,or 1.0 0.000143348623853 0 1 -1
aspergillus,eia 1.0 0.000286697247706 0 2 -2
discontinued,before 1.0 0.00043004587156 0 3 -3
p450-mediated,metabolism 1.0 0.000143348623853 0 1 -1
potential,effects 0.5 0.000286697247706 3 1 2
a,class 1.0 0.000143348623853 0 1 -1
no,pharmacodynamic 1.0 0.00043004587156 0 3 -3
mediate,the 1.0 0.000143348623853 0 1 -1
as,from 1.0 0.000143348623853 1 0 1
vii,viii 1.0 0.000286697247706 0 2 -2
inhibitors,but 1.0 0.000143348623853 0 1 -1
rifampin,rifampin 1.0 0.000143348623853 1 0 1
supplement,food 1.0 0.000286697247706 0 2 -2
effective,forms 1.0 0.000143348623853 0 1 -1
baseline,neutrophil 1.0 0.000143348623853 0 1 -1
its,three 1.0 0.000143348623853 0 1 -1
of,oleate 1.0 0.000286697247706 0 2 -2
propanolol,the 1.0 0.000143348623853 0 1 -1
relaxants,and 0.6 0.00043004587156 4 1 3
its,long-lasting 1.0 0.000143348623853 0 1 -1
metabolized,at 1.0 0.000143348623853 0 1 -1
produce,vertigo 0.0 0.0 2 2 0
animals,where 1.0 0.000143348623853 0 1 -1
increases,metabolic 1.0 0.000143348623853 0 1 -1
concentration,index 1.0 0.000143348623853 0 1 -1
most,other 1.0 0.000286697247706 2 0 2
cause,bleeding 1.0 0.000143348623853 0 1 -1
from,clinical 0.5 0.000286697247706 1 3 -2
appropriately,regardless 1.0 0.000143348623853 0 1 -1
proposed,mechanisms 1.0 0.000143348623853 0 1 -1
mefloquine,is 1.0 0.000143348623853 1 0 1
looks,at 1.0 0.000143348623853 0 1 -1
of,although 1.0 0.000286697247706 2 0 2
treatment,groups 1.0 0.000286697247706 0 2 -2
mm,is 1.0 0.000143348623853 0 1 -1
mg,tablets 0.0 0.0 1 1 0
interpreting,the 1.0 0.000143348623853 0 1 -1
in,nnrti-na 1.0 0.000143348623853 0 1 -1
additional,dose 1.0 0.000143348623853 0 1 -1
the,bowel 1.0 0.000143348623853 0 1 -1
modified,if 1.0 0.000143348623853 0 1 -1
volatile,agent 1.0 0.000143348623853 0 1 -1
reaction,although 1.0 0.000143348623853 1 0 1
n3,for 1.0 0.000143348623853 0 1 -1
episodes,and 1.0 0.000143348623853 0 1 -1
means,of 0.5 0.000286697247706 1 3 -2
for,only 1.0 0.000143348623853 0 1 -1
clinical,comments 1.0 0.000143348623853 0 1 -1
contin,prelone 1.0 0.000143348623853 1 0 1
and,sulfate 1.0 0.000143348623853 1 0 1
agents,by 1.0 0.000286697247706 2 0 2
effects,affecting 0.333333333333 0.000286697247706 4 2 2
showed,comparable 1.0 0.000143348623853 0 1 -1
is,assumed 1.0 0.000143348623853 0 1 -1
not,appreciably 1.0 0.000286697247706 0 2 -2
monitoring,the 1.0 0.000143348623853 0 1 -1
but,increased 1.0 0.000286697247706 0 2 -2
observed,which 1.0 0.000286697247706 2 0 2
neuromuscular,weakness 1.0 0.000143348623853 1 0 1
tysabri,dose 1.0 0.000143348623853 0 1 -1
very,sensitive 1.0 0.000143348623853 0 1 -1
hypertonus,possibly 1.0 0.000143348623853 1 0 1
patient,pharmacokinetic 1.0 0.000143348623853 1 0 1
days,as 1.0 0.000143348623853 1 0 1
two,agents 0.0 0.0 1 1 0
usually,involves 1.0 0.000143348623853 0 1 -1
to,test 1.0 0.000143348623853 0 1 -1
bid,was 1.0 0.000143348623853 1 0 1
neurons,including 1.0 0.000143348623853 0 1 -1
patients,exposed 0.0 0.0 1 1 0
from,cholinergic 1.0 0.000143348623853 1 0 1
levels,indicating 1.0 0.000143348623853 0 1 -1
serum,salicylate 1.0 0.000143348623853 0 1 -1
omega-conotoxin,gvia 1.0 0.000286697247706 0 2 -2
thiazide,and 1.0 0.000573394495413 4 0 4
structure,of 1.0 0.000143348623853 0 1 -1
of,sympatholytic 1.0 0.000286697247706 0 2 -2
drugs,to 1.0 0.000286697247706 0 2 -2
men,and 1.0 0.000143348623853 0 1 -1
cysteine,was 1.0 0.000143348623853 0 1 -1
to,alter 0.333333333333 0.000286697247706 2 4 -2
single,dose 0.121951219512 0.000716743119266 18 23 -5
interactions,effect 1.0 0.000286697247706 0 2 -2
or,seen 1.0 0.000143348623853 0 1 -1
propose,these 1.0 0.000143348623853 1 0 1
spices,or 1.0 0.000143348623853 0 1 -1
of,vardenafil 0.5 0.000860091743119 9 3 6
of,nuromax 0.333333333333 0.000143348623853 1 2 -1
psychotropic,medications 1.0 0.00043004587156 3 0 3
foradil,should 0.5 0.000286697247706 1 3 -2
pharmacodynamics,blood 1.0 0.000143348623853 0 1 -1
concentration-dependent,relaxation 1.0 0.000143348623853 0 1 -1
investigated,in 1.0 0.00100344036697 0 7 -7
in,niddm 1.0 0.000143348623853 0 1 -1
intravenous,may 1.0 0.000143348623853 1 0 1
f1,that 1.0 0.000143348623853 0 1 -1
substrates,and 1.0 0.00043004587156 0 3 -3
mood,and 1.0 0.000143348623853 0 1 -1
and,transient 0.0 0.0 1 1 0
decreases,clearance 1.0 0.000286697247706 2 0 2
may,bind 0.333333333333 0.000143348623853 2 1 1
cyp1a2,cyp3a 1.0 0.000143348623853 1 0 1
absorption,from 0.333333333333 0.000143348623853 2 1 1
aged,or 1.0 0.000143348623853 0 1 -1
vioxx,is 0.333333333333 0.000143348623853 1 2 -1
and,potent 1.0 0.000143348623853 0 1 -1
the,permeability 1.0 0.000143348623853 0 1 -1
be,effective 0.333333333333 0.000143348623853 2 1 1
will,increase 0.0 0.0 1 1 0
and,anti-infectives 1.0 0.000143348623853 0 1 -1
filtration,or 1.0 0.000143348623853 0 1 -1
affinity,kd 1.0 0.000143348623853 0 1 -1
stability,in 1.0 0.000143348623853 0 1 -1
give,little 1.0 0.000143348623853 0 1 -1
decreased,by 0.333333333333 0.000716743119266 10 5 5
reviewed,and 1.0 0.000143348623853 1 0 1
cause,and 1.0 0.000143348623853 1 0 1
sonata,reflecting 1.0 0.000143348623853 0 1 -1
compounds,may 1.0 0.000143348623853 0 1 -1
be,exercised 0.128205128205 0.000716743119266 17 22 -5
actions,and 0.333333333333 0.000143348623853 1 2 -1
agent,may 0.5 0.000286697247706 1 3 -2
surprisingly,green 1.0 0.000143348623853 0 1 -1
both,should 1.0 0.000286697247706 0 2 -2
mg,potentiated 1.0 0.000143348623853 1 0 1
these,alterations 1.0 0.000143348623853 1 0 1
or,will 0.333333333333 0.000143348623853 2 1 1
be,coadministered 0.75 0.000860091743119 1 7 -6
article,will 1.0 0.000143348623853 0 1 -1
three,types 1.0 0.000286697247706 0 2 -2
secretion,while 1.0 0.000143348623853 1 0 1
a,or 0.333333333333 0.000143348623853 1 2 -1
plus,for 1.0 0.000143348623853 0 1 -1
require,interruption 1.0 0.000143348623853 0 1 -1
buspirone,hcl 1.0 0.00043004587156 3 0 3
of,sensipar 0.333333333333 0.000143348623853 2 1 1
contrast,increased 1.0 0.000143348623853 0 1 -1
facts,should 1.0 0.000143348623853 0 1 -1
in,overdose 1.0 0.000143348623853 1 0 1
this,pharmacodynamic 1.0 0.000143348623853 0 1 -1
indirect-acting,agents 1.0 0.000143348623853 1 0 1
antagonist,that 1.0 0.000143348623853 1 0 1
counts,of 1.0 0.000143348623853 0 1 -1
formulation,the 1.0 0.000143348623853 0 1 -1
methadone,levels 1.0 0.000143348623853 1 0 1
rats,epidural 1.0 0.000143348623853 1 0 1
and,products 1.0 0.000143348623853 0 1 -1
also,does 1.0 0.000286697247706 0 2 -2
maintenance,bolus 1.0 0.000143348623853 0 1 -1
specific,interaction 0.833333333333 0.00143348623853 1 11 -10
glycemia,after 1.0 0.000143348623853 0 1 -1
elderly,and 1.0 0.000286697247706 0 2 -2
since,there 0.333333333333 0.000286697247706 4 2 2
increased,exposure 0.6 0.00043004587156 4 1 3
until,data 1.0 0.000143348623853 1 0 1
gleevec,is 1.0 0.000143348623853 1 0 1
also,adversely 1.0 0.000143348623853 1 0 1
were,drinking 1.0 0.000143348623853 1 0 1
rate,but 1.0 0.000286697247706 0 2 -2
paralysis,may 1.0 0.000143348623853 0 1 -1
or,who 1.0 0.000286697247706 2 0 2
extensive,concomitant 1.0 0.000143348623853 0 1 -1
the,use 0.433962264151 0.00329701834862 15 38 -23
neomycin,has 1.0 0.000143348623853 0 1 -1
the,reduction 0.428571428571 0.00043004587156 2 5 -3
the,secretory 1.0 0.000143348623853 1 0 1
ii,the 1.0 0.000143348623853 0 1 -1
dietary,concentration 1.0 0.000143348623853 0 1 -1
company,division 1.0 0.000143348623853 0 1 -1
the,nerve 1.0 0.000143348623853 0 1 -1
ccnu,by 1.0 0.000143348623853 1 0 1
abortifacient,or 1.0 0.000143348623853 0 1 -1
women,with 1.0 0.000143348623853 0 1 -1
above,and 1.0 0.000143348623853 0 1 -1
many,including 1.0 0.000143348623853 0 1 -1
u937,and 1.0 0.000143348623853 1 0 1
in,five 0.0 0.0 1 1 0
receiving,tricyclic 1.0 0.000143348623853 1 0 1
peak,blood 1.0 0.000143348623853 1 0 1
existing,therapy 1.0 0.000143348623853 0 1 -1
no,reported 1.0 0.000573394495413 0 4 -4
some,like 1.0 0.000143348623853 1 0 1
globulin,cbg 1.0 0.000286697247706 0 2 -2
another,that 1.0 0.00043004587156 0 3 -3
with,schizophrenia 1.0 0.00043004587156 0 3 -3
greater,eaca 1.0 0.000143348623853 0 1 -1
net,effect 1.0 0.000143348623853 0 1 -1
isoenzyme,daily 1.0 0.000143348623853 1 0 1
resemble,poor 1.0 0.000286697247706 0 2 -2
interconversion,between 1.0 0.000143348623853 0 1 -1
evoked,potential 1.0 0.000286697247706 0 2 -2
patients,nor 1.0 0.000143348623853 0 1 -1
patients,not 1.0 0.00043004587156 3 0 3
events,from 1.0 0.000143348623853 0 1 -1
among,these 1.0 0.000286697247706 0 2 -2
facilitate,and 1.0 0.000143348623853 0 1 -1
of,tracleer 1.0 0.000143348623853 1 0 1
pigeons,but 1.0 0.000143348623853 1 0 1
sodium,channels 1.0 0.000143348623853 0 1 -1
iv,such 1.0 0.000143348623853 0 1 -1
the,volunteers 0.0 0.0 1 1 0
cyclic,amp 1.0 0.000143348623853 0 1 -1
analgesic,adjuvants 1.0 0.000143348623853 0 1 -1
marrow,suppression 0.0 0.0 1 1 0
without,indicated 1.0 0.000143348623853 0 1 -1
in,women 1.0 0.000573394495413 0 4 -4
acanthus,obtained 1.0 0.000143348623853 0 1 -1
lead,electrocardiograms 1.0 0.000143348623853 0 1 -1
salt,substitutes 0.5 0.000286697247706 1 3 -2
hormone,concentrations 1.0 0.000286697247706 0 2 -2
cyp2c8,drugs 1.0 0.000143348623853 0 1 -1
in,postmarketing 0.0 0.0 1 1 0
lowered,plasma 1.0 0.000143348623853 0 1 -1
vehicle,corn 1.0 0.000143348623853 0 1 -1
of,results 1.0 0.000143348623853 1 0 1
only,improve 1.0 0.000143348623853 0 1 -1
of,adenocard 1.0 0.000143348623853 1 0 1
fractional,mucosal 1.0 0.000143348623853 0 1 -1
the,first-pass 0.333333333333 0.000143348623853 2 1 1
that,impairment 1.0 0.000143348623853 0 1 -1
medications,included 1.0 0.000143348623853 0 1 -1
be,rechallenged 1.0 0.000143348623853 0 1 -1
before,parathyroid-function 1.0 0.000143348623853 0 1 -1
the,suppression 1.0 0.000286697247706 0 2 -2
presents,information 1.0 0.000143348623853 0 1 -1
others,are 1.0 0.000143348623853 1 0 1
ermbt,and 1.0 0.000143348623853 0 1 -1
indicated,for 1.0 0.000143348623853 0 1 -1
supporting,blood 1.0 0.000143348623853 0 1 -1
g,hour 1.0 0.000143348623853 1 0 1
potentiation,by 1.0 0.000143348623853 1 0 1
permeability,of 1.0 0.000286697247706 0 2 -2
contact,and 1.0 0.000143348623853 0 1 -1
decreased,serum 1.0 0.000286697247706 2 0 2
hormone,may 0.0 0.0 1 1 0
by,minutes 1.0 0.000143348623853 1 0 1
subcutaneous,injection 1.0 0.000143348623853 0 1 -1
parallel,group 1.0 0.000286697247706 0 2 -2
times,or 1.0 0.000143348623853 0 1 -1
not,potent 1.0 0.000143348623853 0 1 -1
of,fenofibric 1.0 0.000143348623853 0 1 -1
indications,of 1.0 0.000143348623853 0 1 -1
also,diminished 1.0 0.000143348623853 0 1 -1
these,oral 1.0 0.000143348623853 1 0 1
the,acid-catalyzed 1.0 0.000143348623853 0 1 -1
and,inhibitors 0.0 0.0 2 2 0
viii,ix 1.0 0.00043004587156 0 3 -3
ocupress,should 1.0 0.000143348623853 1 0 1
critical,to 1.0 0.000143348623853 0 1 -1
parasite,reduction 1.0 0.000143348623853 0 1 -1
anticoagulants,combination 1.0 0.000143348623853 1 0 1
may,emerge 1.0 0.000143348623853 1 0 1
sensitize,the 0.6 0.00043004587156 4 1 3
the,antitumour 0.0 0.0 1 1 0
with,cmi 1.0 0.000286697247706 2 0 2
especially,of 1.0 0.000143348623853 0 1 -1
plus,or 0.333333333333 0.000143348623853 1 2 -1
of,radiolabeled 1.0 0.000143348623853 0 1 -1
food,isoniazid 1.0 0.000143348623853 0 1 -1
with,serotoninergic 1.0 0.000143348623853 1 0 1
if,cefotan 1.0 0.000143348623853 1 0 1
activase,with 1.0 0.000143348623853 0 1 -1
primates,and 1.0 0.000143348623853 0 1 -1
cyp1a2,or 1.0 0.000143348623853 0 1 -1
frequent,the 1.0 0.000143348623853 0 1 -1
may,add 1.0 0.000286697247706 2 0 2
given,oral 1.0 0.000143348623853 0 1 -1
use,clinicians 1.0 0.000143348623853 1 0 1
from,single 1.0 0.000143348623853 0 1 -1
vaccines,patients 1.0 0.000143348623853 1 0 1
bupropz_od,htm 1.0 0.000143348623853 1 0 1
eg,may 1.0 0.00114678899083 8 0 8
additive,and 1.0 0.000143348623853 0 1 -1
kingdom,with 1.0 0.000143348623853 1 0 1
interactions,must 1.0 0.000143348623853 1 0 1
long,half-lives 1.0 0.000143348623853 0 1 -1
in,ephesus 1.0 0.000143348623853 0 1 -1
nsaids,monoamine 1.0 0.000143348623853 1 0 1
may,result 0.0508474576271 0.00043004587156 31 28 3
hundred,mg 1.0 0.000143348623853 0 1 -1
given,as 0.0909090909091 0.000143348623853 5 6 -1
commonly,associated 1.0 0.000143348623853 0 1 -1
toxic,to 1.0 0.000286697247706 0 2 -2
this,inhibition 1.0 0.000143348623853 0 1 -1
dienes,approximately 1.0 0.000143348623853 0 1 -1
converting,difluoro-2 1.0 0.000143348623853 1 0 1
you,more 1.0 0.000143348623853 0 1 -1
volunteers,mg 1.0 0.000143348623853 0 1 -1
meal,would 1.0 0.000143348623853 0 1 -1
risk,relative 1.0 0.000143348623853 0 1 -1
challenge,either 1.0 0.000716743119266 0 5 -5
powders,showed 1.0 0.000143348623853 1 0 1
fetal,toxicity 1.0 0.000143348623853 0 1 -1
cmax,and 0.448275862069 0.00186353211009 21 8 13
described,little 1.0 0.000143348623853 0 1 -1
administration,even 1.0 0.000143348623853 0 1 -1
trough,concentrations 0.111111111111 0.000143348623853 5 4 1
limited,clinical 0.333333333333 0.000143348623853 2 1 1
used,concomitantly 0.2 0.00114678899083 24 16 8
cyp3a4,should 1.0 0.000143348623853 1 0 1
gram-negative,and 1.0 0.000143348623853 0 1 -1
sustiva,in 1.0 0.000143348623853 0 1 -1
given,with 0.217391304348 0.000716743119266 14 9 5
dose-time,effects 1.0 0.000143348623853 0 1 -1
states,underlying 1.0 0.000143348623853 0 1 -1
by,pretreatment 1.0 0.000286697247706 2 0 2
about,possible 1.0 0.000143348623853 0 1 -1
sterol,in 1.0 0.000286697247706 0 2 -2
cellular,and 1.0 0.000143348623853 0 1 -1
of,cutaneous 1.0 0.000143348623853 0 1 -1
metabolism,would 1.0 0.000143348623853 0 1 -1
receiving,have 1.0 0.000143348623853 0 1 -1
intracellular,and 1.0 0.000143348623853 0 1 -1
elimination,rate 1.0 0.000286697247706 0 2 -2
are,supported 1.0 0.000143348623853 0 1 -1
antiviral,activity 1.0 0.000143348623853 1 0 1
as,shown 1.0 0.000143348623853 1 0 1
with,human 1.0 0.000716743119266 0 5 -5
medications,especially 1.0 0.000143348623853 0 1 -1
only,where 1.0 0.000143348623853 1 0 1
same,episode 1.0 0.000143348623853 0 1 -1
day,pretreatment 1.0 0.000143348623853 0 1 -1
and,concurrently 1.0 0.00043004587156 3 0 3
alkaloids,and 1.0 0.000286697247706 2 0 2
or,hypomagnesemia 1.0 0.000143348623853 0 1 -1
metabolite,m1 1.0 0.000143348623853 0 1 -1
upon,concomitant 1.0 0.000143348623853 1 0 1
in,rats 0.166666666667 0.000286697247706 7 5 2
of,suggest 1.0 0.000143348623853 1 0 1
fe,abstract 1.0 0.000143348623853 0 1 -1
epoxide,hydrolase 1.0 0.00043004587156 0 3 -3
work,involved 1.0 0.000143348623853 0 1 -1
the,morning 1.0 0.000143348623853 0 1 -1
in,europe 1.0 0.000143348623853 1 0 1
losartan,bosentan 1.0 0.000143348623853 0 1 -1
coupled,with 1.0 0.000143348623853 0 1 -1
we,observed 1.0 0.000143348623853 1 0 1
single,study 1.0 0.000143348623853 1 0 1
taking,tarceva 1.0 0.000143348623853 1 0 1
starlix,the 1.0 0.000143348623853 0 1 -1
additional,stimulus 1.0 0.000143348623853 0 1 -1
or,mimic 1.0 0.000143348623853 0 1 -1
adjust,the 1.0 0.000143348623853 1 0 1
is,recommended 0.0434782608696 0.00043004587156 36 33 3
or,sensitivity 1.0 0.000143348623853 0 1 -1
for,yeast 1.0 0.000143348623853 0 1 -1
the,latency 1.0 0.000143348623853 0 1 -1
to,adjust 1.0 0.000143348623853 1 0 1
with,coadministered 0.0 0.0 1 1 0
do,not 0.545454545455 0.00172018348624 5 17 -12
cause,elevated 1.0 0.000143348623853 1 0 1
total,hormone 1.0 0.00043004587156 0 3 -3
intravenous,hydration 1.0 0.000143348623853 0 1 -1
some,including 1.0 0.000286697247706 2 0 2
with,hivid 0.333333333333 0.000143348623853 1 2 -1
gtp-binding,proteins 1.0 0.000143348623853 0 1 -1
the,preceding 1.0 0.000286697247706 0 2 -2
patient,compliance 1.0 0.000143348623853 0 1 -1
antimicrobial,effect 1.0 0.000143348623853 0 1 -1
therapy,for 1.0 0.00043004587156 0 3 -3
normal,but 1.0 0.000143348623853 1 0 1
least,five 1.0 0.000143348623853 0 1 -1
lapatinib,is 1.0 0.000143348623853 0 1 -1
evaluated,and 0.333333333333 0.000143348623853 1 2 -1
both,control 1.0 0.000143348623853 0 1 -1
measurement,of 0.833333333333 0.00143348623853 1 11 -10
possibly,concomitant 1.0 0.000143348623853 1 0 1
nc,denotes 1.0 0.000143348623853 1 0 1
effective,first-line 1.0 0.000143348623853 0 1 -1
subjective,responses 1.0 0.000143348623853 0 1 -1
patients,along 1.0 0.000143348623853 0 1 -1
enzyme,may 1.0 0.000286697247706 0 2 -2
welchol,with 1.0 0.000143348623853 0 1 -1
above,of 1.0 0.000143348623853 1 0 1
for,such 1.0 0.000573394495413 0 4 -4
sativum,and 1.0 0.000143348623853 1 0 1
of,interactions 0.0909090909091 0.000143348623853 5 6 -1
chemicals,that 1.0 0.000143348623853 0 1 -1
will,describe 1.0 0.000143348623853 0 1 -1
elicited,enhancement 1.0 0.000143348623853 1 0 1
current,information 1.0 0.000143348623853 0 1 -1
rats,fasted 1.0 0.000143348623853 0 1 -1
other,alternatives 1.0 0.000143348623853 0 1 -1
thus,support 1.0 0.000143348623853 0 1 -1
many,like 1.0 0.000143348623853 0 1 -1
abnormalities,were 1.0 0.000143348623853 0 1 -1
metabolized,predominantly 1.0 0.000143348623853 0 1 -1
accidental,contact 1.0 0.000143348623853 0 1 -1
supplements,should 1.0 0.000286697247706 0 2 -2
walking,without 1.0 0.000143348623853 0 1 -1
and,collagen-induced 1.0 0.000143348623853 0 1 -1
management,and 1.0 0.000286697247706 0 2 -2
vs,end 1.0 0.000143348623853 0 1 -1
a,exerts 1.0 0.000143348623853 0 1 -1
other,formal 1.0 0.000143348623853 0 1 -1
signs,irrespective 1.0 0.000143348623853 0 1 -1
oral,cordarone 1.0 0.000143348623853 0 1 -1
additive,to 1.0 0.000143348623853 1 0 1
urinary,catecholamine 1.0 0.000143348623853 0 1 -1
their,differential 1.0 0.000143348623853 0 1 -1
pronounced,if 1.0 0.000143348623853 1 0 1
interaction,cannot 1.0 0.000143348623853 0 1 -1
to,changes 1.0 0.000143348623853 0 1 -1
completely,antagonized 1.0 0.000143348623853 1 0 1
failing,hearts 1.0 0.000143348623853 0 1 -1
less,active 1.0 0.000143348623853 1 0 1
blot,analysis 1.0 0.000143348623853 0 1 -1
for,symptoms 1.0 0.000143348623853 0 1 -1
has,additive 1.0 0.000286697247706 2 0 2
from,the 0.384615384615 0.0021502293578 12 27 -15
an,effort 1.0 0.000143348623853 0 1 -1
cardioplegic,solutions 1.0 0.000143348623853 0 1 -1
the,resistance 1.0 0.000143348623853 0 1 -1
of,prophylactic 1.0 0.000143348623853 0 1 -1
lodine,can 0.0 0.0 1 1 0
of,vasoconstrictor 1.0 0.000143348623853 0 1 -1
triazolam,erythromycin 1.0 0.000143348623853 1 0 1
hydantoin,antiepileptic 1.0 0.000143348623853 1 0 1
bound,by 1.0 0.000143348623853 1 0 1
days,while 1.0 0.000143348623853 1 0 1
a,glucose-specific 1.0 0.000143348623853 0 1 -1
for,chop-haart 1.0 0.000143348623853 0 1 -1
of,crushed 1.0 0.000143348623853 0 1 -1
reductase,inhibitors 0.0769230769231 0.000143348623853 6 7 -1
also,collected 1.0 0.000143348623853 0 1 -1
be,consistent 1.0 0.000143348623853 0 1 -1
herbal,product 1.0 0.000143348623853 0 1 -1
inspra,should 1.0 0.000143348623853 0 1 -1
diminished,by 1.0 0.000143348623853 0 1 -1
while,decreasing 1.0 0.000143348623853 0 1 -1
by,one 1.0 0.000143348623853 0 1 -1
increased,all 1.0 0.000143348623853 0 1 -1
clinical,patterns 1.0 0.000143348623853 0 1 -1
pain,arthralgia 1.0 0.000143348623853 0 1 -1
antihypertensive,necessitating 1.0 0.000143348623853 1 0 1
substrate,and 0.142857142857 0.000143348623853 3 4 -1
more,frequent 1.0 0.00043004587156 0 3 -3
differential,diagnosis 1.0 0.000143348623853 0 1 -1
transient,outward 1.0 0.000143348623853 0 1 -1
a4,activity 1.0 0.000143348623853 0 1 -1
renal,precipitation 1.0 0.000143348623853 0 1 -1
interference,between 1.0 0.000143348623853 0 1 -1
s,effects 1.0 0.000143348623853 0 1 -1
cardioactive,or 1.0 0.000143348623853 0 1 -1
integrity,of 1.0 0.000143348623853 0 1 -1
was,maintained 1.0 0.000143348623853 0 1 -1
precedex,for 1.0 0.000143348623853 0 1 -1
a,disulfiram-like 1.0 0.000286697247706 0 2 -2
anion-exchange,resins 1.0 0.000143348623853 1 0 1
and,buspirone 1.0 0.000143348623853 1 0 1
a,well 1.0 0.000143348623853 0 1 -1
b,intravenous 1.0 0.000143348623853 1 0 1
on,hormonal 1.0 0.000143348623853 0 1 -1
inrifabutin,exposure 1.0 0.000143348623853 0 1 -1
small,effect 0.0 0.0 1 1 0
including,normal 1.0 0.000143348623853 0 1 -1
most,significant 1.0 0.000143348623853 0 1 -1
hydroxide,containing 1.0 0.000286697247706 2 0 2
carbamazepine,population 1.0 0.000143348623853 1 0 1
nutrition,herb 1.0 0.000143348623853 1 0 1
loratadine,mg 1.0 0.000286697247706 0 2 -2
support,its 1.0 0.000143348623853 0 1 -1
improves,the 1.0 0.000143348623853 0 1 -1
monkeys,at 1.0 0.000286697247706 0 2 -2
of,protein 1.0 0.000286697247706 0 2 -2
with,advanced 1.0 0.000143348623853 0 1 -1
and,lipids 1.0 0.000143348623853 0 1 -1
plasma,pharmacokinetics 1.0 0.000143348623853 0 1 -1
by,flushing 1.0 0.000143348623853 0 1 -1
eg,dizziness 1.0 0.000143348623853 0 1 -1
orally,for 1.0 0.000143348623853 1 0 1
asthma,control 1.0 0.000143348623853 0 1 -1
cerebroactive,drugs 1.0 0.000143348623853 0 1 -1
similar,temporal 1.0 0.000143348623853 0 1 -1
was,totally 1.0 0.000143348623853 0 1 -1
decreases,renal 1.0 0.000143348623853 1 0 1
increased,to 0.5 0.000286697247706 1 3 -2
fatigue,hypotension 1.0 0.000143348623853 0 1 -1
with,avastin 1.0 0.000143348623853 0 1 -1
a,nonhormonal 1.0 0.000860091743119 0 6 -6
new,cases 1.0 0.000286697247706 0 2 -2
sustained-release,calan 1.0 0.000143348623853 1 0 1
when,treated 1.0 0.000143348623853 0 1 -1
the,magnitude 0.5 0.000860091743119 3 9 -6
that,mptp 1.0 0.000143348623853 1 0 1
on,half-life 1.0 0.000143348623853 1 0 1
common,side 1.0 0.000143348623853 0 1 -1
tbars,in 1.0 0.000143348623853 0 1 -1
pharmacological,therapy 1.0 0.000286697247706 0 2 -2
describing,patients 1.0 0.000143348623853 1 0 1
an,elevation 0.6 0.00043004587156 4 1 3
potently,inhibits 1.0 0.000286697247706 2 0 2
therapy,dose 0.0 0.0 2 2 0
cohort,received 1.0 0.000143348623853 0 1 -1
monotherapy,for 1.0 0.000143348623853 0 1 -1
hour,prior 1.0 0.000143348623853 1 0 1
dosage,schedule 1.0 0.000143348623853 1 0 1
possible,dosage 1.0 0.000143348623853 0 1 -1
with,differin 1.0 0.000143348623853 0 1 -1
in,serum-supplemented 1.0 0.000143348623853 0 1 -1
absolute,but 1.0 0.000143348623853 0 1 -1
n-diethyl,m-toluamide 1.0 0.000143348623853 1 0 1
a,kda 1.0 0.000143348623853 0 1 -1
when,and 0.62962962963 0.0024369266055 22 5 17
four,educational 1.0 0.000143348623853 0 1 -1
of,serotonin 0.333333333333 0.000143348623853 2 1 1
qt,prolongation 0.5 0.000286697247706 1 3 -2
lowered,blood 1.0 0.000143348623853 1 0 1
limits,of 1.0 0.000143348623853 0 1 -1
appropriate,actions 1.0 0.000143348623853 0 1 -1
of,animals 1.0 0.000143348623853 0 1 -1
by,weakness 1.0 0.000143348623853 1 0 1
males,dosed 1.0 0.000143348623853 0 1 -1
this,can 1.0 0.00043004587156 0 3 -3
and,death 1.0 0.000143348623853 1 0 1
is,a 0.461538461538 0.00516055045872 21 57 -36
more,severely 1.0 0.000143348623853 0 1 -1
system,ketoconazole 1.0 0.000143348623853 1 0 1
adrenergic,stimulant 1.0 0.000143348623853 0 1 -1
study,we 1.0 0.000573394495413 0 4 -4
each,other 0.428571428571 0.00043004587156 5 2 3
or,substrates 1.0 0.000143348623853 1 0 1
who,become 1.0 0.000143348623853 0 1 -1
substrate,response 1.0 0.000143348623853 0 1 -1
therapy,includes 1.0 0.000143348623853 0 1 -1
capsules,indocin 1.0 0.000143348623853 1 0 1
depresses,tubular 1.0 0.000143348623853 1 0 1
contents,and 1.0 0.000143348623853 0 1 -1
and,evidence 1.0 0.000143348623853 1 0 1
axis,in 1.0 0.000143348623853 0 1 -1
through,redundancy 1.0 0.000143348623853 0 1 -1
suggestive,of 1.0 0.000143348623853 1 0 1
of,hydroxylamine 1.0 0.000286697247706 0 2 -2
instances,resulted 1.0 0.000143348623853 1 0 1
and,central 1.0 0.000143348623853 0 1 -1
liver,is 1.0 0.000143348623853 1 0 1
and,epoxide 1.0 0.000286697247706 0 2 -2
is,reasonable 0.2 0.000143348623853 2 3 -1
as,indicated 0.2 0.000143348623853 2 3 -1
part,of 1.0 0.00043004587156 0 3 -3
increased,intestinal 1.0 0.000143348623853 1 0 1
alt,in 1.0 0.000286697247706 2 0 2
a,non-comparative 1.0 0.000143348623853 1 0 1
total,clearance 1.0 0.000143348623853 1 0 1
age,may 1.0 0.000143348623853 0 1 -1
naproxen,had 1.0 0.000143348623853 0 1 -1
about,two 1.0 0.000143348623853 1 0 1
interactions,use 1.0 0.000143348623853 0 1 -1
or,closely 1.0 0.000143348623853 0 1 -1
angiotensin-,converting 1.0 0.000143348623853 0 1 -1
reappearance,on 1.0 0.000143348623853 0 1 -1
when,vioxx 0.0 0.0 1 1 0
an,additive 0.882352941176 0.0021502293578 16 1 15
with,daily 1.0 0.000286697247706 0 2 -2
not,these 1.0 0.000143348623853 0 1 -1
case,in 1.0 0.000143348623853 0 1 -1
days,later 1.0 0.000286697247706 0 2 -2
serum,psa 1.0 0.000286697247706 0 2 -2
take,into 1.0 0.000143348623853 0 1 -1
of,b 1.0 0.00043004587156 0 3 -3
of,a 0.157024793388 0.00272362385321 51 70 -19
toxicity,since 1.0 0.000143348623853 0 1 -1
of,g 0.142857142857 0.000143348623853 4 3 1
doses,trough 1.0 0.000143348623853 0 1 -1
of,d 0.333333333333 0.000143348623853 1 2 -1
doses,may 0.333333333333 0.000143348623853 2 1 1
missing,a 1.0 0.000143348623853 0 1 -1
of,n 0.0 0.0 1 1 0
of,m 0.142857142857 0.000143348623853 3 4 -1
hemoptysis,hematemesis 1.0 0.000143348623853 0 1 -1
of,r 0.5 0.000286697247706 1 3 -2
of,p 1.0 0.000143348623853 1 0 1
tmp,smx 1.0 0.000143348623853 0 1 -1
of,v 1.0 0.000143348623853 1 0 1
of,u 1.0 0.000143348623853 0 1 -1
of,t 1.0 0.000143348623853 1 0 1
randomized,in 1.0 0.000143348623853 0 1 -1
of,x 1.0 0.000143348623853 1 0 1
or,tachycardia 1.0 0.000143348623853 0 1 -1
may,vary 1.0 0.00114678899083 0 8 -8
reduced,plasma 0.5 0.000286697247706 3 1 2
tail-flick,response 0.0 0.0 1 1 0
days,followed 1.0 0.000573394495413 0 4 -4
requires,more 1.0 0.000286697247706 0 2 -2
inhibitors,nalidixic 1.0 0.000143348623853 1 0 1
depressants,using 1.0 0.000143348623853 1 0 1
anabolic,particularly 1.0 0.000143348623853 0 1 -1
gastrointestinal,tract 0.333333333333 0.000143348623853 2 1 1
multivitamins,or 1.0 0.000143348623853 1 0 1
angina,pectoris 1.0 0.000143348623853 1 0 1
slight,but 1.0 0.000143348623853 1 0 1
with,major 1.0 0.000143348623853 1 0 1
possible,with 1.0 0.000143348623853 0 1 -1
concerned,variable 1.0 0.000143348623853 0 1 -1
stability,of 1.0 0.000286697247706 0 2 -2
very,closely 1.0 0.000143348623853 1 0 1
tight,seal 1.0 0.000286697247706 0 2 -2
is,less 0.0 0.0 1 1 0
of,coumarin-type 1.0 0.000143348623853 0 1 -1
oral,certain 1.0 0.000143348623853 1 0 1
approximately,twice 1.0 0.000143348623853 1 0 1
sites,or 1.0 0.000143348623853 1 0 1
iodinated,cholestographic 1.0 0.000143348623853 0 1 -1
inhibitors,concomitant 1.0 0.000286697247706 0 2 -2
carbamazepine,has 1.0 0.000143348623853 0 1 -1
and,model 1.0 0.000143348623853 0 1 -1
opioid-dependent,patients 1.0 0.000143348623853 0 1 -1
different,site 1.0 0.000143348623853 0 1 -1
coagulation,times 1.0 0.000143348623853 0 1 -1
agents,possible 1.0 0.000143348623853 0 1 -1
seen,on 0.333333333333 0.000143348623853 1 2 -1
juice,should 0.333333333333 0.000143348623853 1 2 -1
v,readily 1.0 0.000143348623853 0 1 -1
on,certain 0.0 0.0 1 1 0
on,investigation 1.0 0.000143348623853 0 1 -1
volume,fewer 1.0 0.000143348623853 0 1 -1
with,sustained-release 1.0 0.000143348623853 0 1 -1
doses,mg 0.2 0.000143348623853 2 3 -1
cyp3a4,inhibitors 0.1 0.000286697247706 11 9 2
nuromax,include 1.0 0.000143348623853 1 0 1
intubating,dose 1.0 0.000143348623853 1 0 1
of,elemental 1.0 0.000143348623853 1 0 1
available,data 0.666666666667 0.000573394495413 1 5 -4
hypothesis,there 1.0 0.000143348623853 0 1 -1
poor-risk,aids-related 1.0 0.000143348623853 0 1 -1
same,target 1.0 0.000143348623853 0 1 -1
cause,direct 1.0 0.000143348623853 0 1 -1
is,accelerated 1.0 0.000143348623853 1 0 1
release,but 0.333333333333 0.000143348623853 1 2 -1
diminished,prothrombin 1.0 0.000143348623853 1 0 1
cytochalasin,d 0.333333333333 0.000143348623853 2 1 1
volunteers,took 1.0 0.000143348623853 0 1 -1
tinnitus,and 1.0 0.000143348623853 1 0 1
synthetic,possibly 1.0 0.000143348623853 1 0 1
one,possible 1.0 0.000143348623853 0 1 -1
used,combined 1.0 0.000143348623853 0 1 -1
a,subsequent 1.0 0.000143348623853 1 0 1
idv,does 1.0 0.000143348623853 0 1 -1
stereoisomers,of 1.0 0.000143348623853 0 1 -1
studied,of 1.0 0.000143348623853 0 1 -1
protein,in 1.0 0.000143348623853 1 0 1
monthly,was 1.0 0.000143348623853 0 1 -1
protein,is 1.0 0.000143348623853 0 1 -1
relationship,has 0.5 0.000286697247706 1 3 -2
vitamin,k 0.6 0.00043004587156 4 1 3
titration,of 0.0 0.0 1 1 0
pregnancy,pregnancy 1.0 0.000286697247706 0 2 -2
vitamin,e 1.0 0.000143348623853 1 0 1
platelia,aspergillus 1.0 0.000286697247706 0 2 -2
vitamin,c 0.0 0.0 2 2 0
vitamin,a 1.0 0.000286697247706 2 0 2
light,and 1.0 0.000143348623853 0 1 -1
have,higher 1.0 0.00100344036697 0 7 -7
without,other 1.0 0.00043004587156 3 0 3
acetaminophen,oral 1.0 0.000143348623853 1 0 1
approximately,one-tenth 1.0 0.000143348623853 0 1 -1
deficiency,due 1.0 0.000143348623853 0 1 -1
hours,was 1.0 0.000143348623853 1 0 1
with,adrenergic 1.0 0.000143348623853 0 1 -1
kg,subcutaneous 1.0 0.000143348623853 0 1 -1
containing,for 1.0 0.000143348623853 1 0 1
agents,leading 1.0 0.00043004587156 3 0 3
glycemic,levels 1.0 0.000143348623853 0 1 -1
dl,triglycerides 1.0 0.000143348623853 0 1 -1
therefore,necessary 1.0 0.000143348623853 0 1 -1
geriatric,subjects 1.0 0.000143348623853 0 1 -1
activation,and 1.0 0.000286697247706 0 2 -2
about,one-third 1.0 0.000143348623853 1 0 1
are,referred 1.0 0.000286697247706 0 2 -2
cancer,metastasis 1.0 0.000286697247706 0 2 -2
potentiating,cns 1.0 0.000143348623853 1 0 1
milk,there 1.0 0.000143348623853 0 1 -1
alkaloids,is 1.0 0.000143348623853 1 0 1
time,plasma 1.0 0.000143348623853 0 1 -1
catecholamines,in 1.0 0.000143348623853 0 1 -1
observations,are 1.0 0.000143348623853 0 1 -1
deterioration,in 1.0 0.000143348623853 0 1 -1
and,lower 0.333333333333 0.000143348623853 2 1 1
hormone,indicating 1.0 0.000143348623853 0 1 -1
anticoagulation,should 1.0 0.000286697247706 0 2 -2
not,co-administered 1.0 0.000143348623853 0 1 -1
dopamine,da 1.0 0.000143348623853 0 1 -1
and,hc1 1.0 0.000143348623853 1 0 1
product,can 1.0 0.000143348623853 0 1 -1
morphine-induced,locomotion 1.0 0.000143348623853 0 1 -1
the,frontal 1.0 0.000143348623853 0 1 -1
lower,relative 1.0 0.000143348623853 0 1 -1
these,cells 1.0 0.000143348623853 0 1 -1
an,a2-selective 1.0 0.000143348623853 1 0 1
hormones,were 1.0 0.000143348623853 0 1 -1
mimic,underdosage 1.0 0.000143348623853 0 1 -1
is,indicated 0.333333333333 0.000716743119266 5 10 -5
severe,persistent 0.333333333333 0.000143348623853 1 2 -1
hepatic,injury 1.0 0.000143348623853 0 1 -1
themselves,to 1.0 0.000143348623853 0 1 -1
agents--a,class 1.0 0.000143348623853 0 1 -1
inotropic,and 1.0 0.000143348623853 0 1 -1
blunts,the 1.0 0.000286697247706 2 0 2
dopamine,d2 1.0 0.000143348623853 1 0 1
any,evidence 1.0 0.00043004587156 0 3 -3
assessment,of 1.0 0.000143348623853 0 1 -1
constant,values 1.0 0.000143348623853 0 1 -1
and,cautioned 1.0 0.000286697247706 0 2 -2
a,during 1.0 0.000143348623853 0 1 -1
with,local 1.0 0.000143348623853 0 1 -1
attenuating,s 1.0 0.000143348623853 1 0 1
levels,but 1.0 0.000143348623853 0 1 -1
the,psychostimulant 1.0 0.000143348623853 0 1 -1
and,cadmium 1.0 0.000286697247706 0 2 -2
with,hydroxide 1.0 0.000143348623853 1 0 1
were,diagnosed 1.0 0.000143348623853 0 1 -1
of,perivascular 1.0 0.000143348623853 0 1 -1
receiving,ace 1.0 0.00043004587156 3 0 3
pharmacological,pharmacodynamic 1.0 0.000143348623853 1 0 1
brain,systems 1.0 0.000143348623853 0 1 -1
sgpt,s-alt 1.0 0.000143348623853 0 1 -1
were,undetectable 1.0 0.000143348623853 0 1 -1
absorption,mean 1.0 0.000143348623853 1 0 1
gris-peg,nizoral 1.0 0.000143348623853 1 0 1
exact,place 1.0 0.000143348623853 0 1 -1
meal,or 1.0 0.000143348623853 0 1 -1
in,extrapolating 1.0 0.000143348623853 0 1 -1
showed,variable 1.0 0.000143348623853 0 1 -1
tremor,as 1.0 0.000143348623853 1 0 1
under,steady-state 1.0 0.000286697247706 0 2 -2
blocker,should 1.0 0.000143348623853 1 0 1
used,and 1.0 0.000143348623853 0 1 -1
and,rises 1.0 0.000143348623853 1 0 1
avoided,while 1.0 0.000143348623853 0 1 -1
serum,time 1.0 0.000143348623853 0 1 -1
the,epa 1.0 0.000143348623853 0 1 -1
procedure,for 1.0 0.000143348623853 0 1 -1
hypotension,related 0.0 0.0 1 1 0
a4,grapefruit 1.0 0.000143348623853 1 0 1
these,aeds 1.0 0.000286697247706 0 2 -2
phenobarbital,decreases 1.0 0.000143348623853 1 0 1
commentaries,and 1.0 0.000143348623853 0 1 -1
reported,l-histidine 1.0 0.000143348623853 1 0 1
of,acetate 0.0 0.0 1 1 0
by,prothrombin 1.0 0.000143348623853 0 1 -1
actinic,keratoses 1.0 0.000143348623853 1 0 1
ventricular,tachycardia 0.2 0.000143348623853 3 2 1
ketogenic,because 1.0 0.000143348623853 0 1 -1
micrograms,completely 1.0 0.000143348623853 1 0 1
ii,vii 1.0 0.000286697247706 0 2 -2
since,aminotransferase 1.0 0.000143348623853 0 1 -1
of,erythrocyte 1.0 0.000143348623853 1 0 1
prolonged,recovery 1.0 0.000143348623853 1 0 1
antihypertensive,medications 0.333333333333 0.000143348623853 2 1 1
response,rates 1.0 0.00043004587156 0 3 -3
anticoagulants,caution 1.0 0.000143348623853 1 0 1
maalox,on 1.0 0.000143348623853 0 1 -1
prolonged,gastrointestinal 0.0 0.0 1 1 0
volunteers,toradoloral 1.0 0.000143348623853 0 1 -1
rapidly,identified 1.0 0.000143348623853 0 1 -1
cns-depressive,effect 1.0 0.000143348623853 1 0 1
ointments,or 1.0 0.000143348623853 0 1 -1
was,extensive 1.0 0.000143348623853 0 1 -1
synergistic,elevation 1.0 0.000143348623853 1 0 1
not,totally 1.0 0.000143348623853 1 0 1
in,addition 0.375 0.00258027522936 15 33 -18
metabolizing,itself 1.0 0.000143348623853 0 1 -1
the,skeletal 1.0 0.000143348623853 1 0 1
the,concentrations 0.2 0.000143348623853 2 3 -1
with,dynacirc 1.0 0.000143348623853 0 1 -1
within,several 1.0 0.000143348623853 0 1 -1
on,patients 1.0 0.000286697247706 0 2 -2
blockade,associated 1.0 0.000143348623853 0 1 -1
decreased,plasma 0.142857142857 0.000143348623853 4 3 1
either,interaction 1.0 0.000143348623853 0 1 -1
dissolution,of 1.0 0.00043004587156 0 3 -3
and,respiratory 1.0 0.000143348623853 0 1 -1
gabitril,on 1.0 0.000143348623853 0 1 -1
between,and 0.31914893617 0.0021502293578 16 31 -15
that,herbal 1.0 0.000143348623853 0 1 -1
reaction,injection 1.0 0.000143348623853 0 1 -1
of,microtubules 1.0 0.000286697247706 0 2 -2
pegasys,once 1.0 0.000143348623853 1 0 1
another,positively-charged 1.0 0.000143348623853 0 1 -1
further,alterations 1.0 0.000143348623853 1 0 1
naproxen,the 1.0 0.000143348623853 1 0 1
agonists,dcg-iv 1.0 0.000143348623853 0 1 -1
or,estrogen-containing 1.0 0.000143348623853 1 0 1
auc,a 1.0 0.000286697247706 2 0 2
auc,c 1.0 0.000286697247706 0 2 -2
now,clear 1.0 0.000143348623853 0 1 -1
transits,were 1.0 0.000143348623853 0 1 -1
permeation,studies 1.0 0.000143348623853 0 1 -1
a,female 1.0 0.000143348623853 0 1 -1
studies,involving 0.0 0.0 3 3 0
p450,inducers 1.0 0.000143348623853 1 0 1
pegasys,and 1.0 0.000286697247706 0 2 -2
amevive,should 1.0 0.000143348623853 0 1 -1
because,bleeding 1.0 0.000143348623853 1 0 1
randomized,to 1.0 0.000143348623853 0 1 -1
of,contraception 0.142857142857 0.000143348623853 3 4 -1
not,confirm 1.0 0.000143348623853 0 1 -1
avoid,potentiation 1.0 0.000143348623853 0 1 -1
plendil,the 1.0 0.000143348623853 0 1 -1
macrolide,class 1.0 0.000143348623853 1 0 1
discusses,current 1.0 0.000143348623853 0 1 -1
car,or 1.0 0.000143348623853 0 1 -1
or,immediately 1.0 0.000143348623853 1 0 1
misonidazole,has 1.0 0.000143348623853 1 0 1
which,inhibit 0.0 0.0 3 3 0
c,and 1.0 0.000573394495413 4 0 4
of,mineral 1.0 0.000143348623853 1 0 1
mice,from 1.0 0.000143348623853 0 1 -1
the,contraceptive 1.0 0.000143348623853 1 0 1
intentional,or 1.0 0.000143348623853 1 0 1
the,that 0.75 0.000860091743119 1 7 -6
used,as 0.333333333333 0.000143348623853 1 2 -1
of,arachidonate- 1.0 0.000143348623853 0 1 -1
a,rise 1.0 0.000143348623853 1 0 1
cyp3a4,to 1.0 0.000143348623853 0 1 -1
provide,therapeutic 1.0 0.000143348623853 0 1 -1
are,found 1.0 0.000143348623853 1 0 1
containing,trisilicate 1.0 0.000143348623853 1 0 1
following,observations 1.0 0.000143348623853 0 1 -1
action,exists 1.0 0.000143348623853 0 1 -1
to,admission 1.0 0.000143348623853 0 1 -1
therefore,there 1.0 0.000286697247706 0 2 -2
some,has 1.0 0.000143348623853 1 0 1
fundus,pulsation 1.0 0.000286697247706 0 2 -2
possible,increase 1.0 0.000143348623853 1 0 1
receiving,medications 1.0 0.000143348623853 0 1 -1
as,increasingly 1.0 0.000143348623853 0 1 -1
persons,taking 1.0 0.000143348623853 0 1 -1
immunogenicity,re-exposure 1.0 0.000143348623853 0 1 -1
man,include 0.0 0.0 1 1 0
medications,such 0.6 0.00043004587156 1 4 -3
probably,accomplished 1.0 0.000143348623853 0 1 -1
neuroeffector,defects 1.0 0.000143348623853 0 1 -1
serum,pregnancy 1.0 0.000143348623853 0 1 -1
and,coagulation 1.0 0.000143348623853 0 1 -1
growth,caused 1.0 0.000143348623853 0 1 -1
b-lactam,inhibits 1.0 0.000143348623853 1 0 1
their,metabolism 1.0 0.000143348623853 1 0 1
increase,by 1.0 0.000143348623853 1 0 1
arrhythmias,in 1.0 0.000573394495413 0 4 -4
mc,probably 1.0 0.000143348623853 0 1 -1
and,anaerobic 1.0 0.000286697247706 0 2 -2
and,seem 1.0 0.000143348623853 0 1 -1
or,biweekly 1.0 0.000286697247706 0 2 -2
cardiac,stimulants 1.0 0.000143348623853 1 0 1
interactions,interactions 1.0 0.000143348623853 0 1 -1
medicines,should 1.0 0.000286697247706 0 2 -2
receiving,the 0.230769230769 0.00043004587156 5 8 -3
in,slow 1.0 0.000143348623853 0 1 -1
a,regular 1.0 0.000143348623853 0 1 -1
and,flares 1.0 0.000143348623853 0 1 -1
vitro,experiments 1.0 0.000143348623853 0 1 -1
literature,contains 1.0 0.000143348623853 0 1 -1
lanoxicaps,that 1.0 0.000143348623853 1 0 1
or,monoamine 1.0 0.000143348623853 1 0 1
the,ibandronate 1.0 0.000143348623853 0 1 -1
drug,regimens 1.0 0.000143348623853 0 1 -1
approximately,one-third 1.0 0.000143348623853 1 0 1
may,produce 0.037037037037 0.000143348623853 13 14 -1
mean,increase 1.0 0.000286697247706 2 0 2
cold,preparations 0.0 0.0 1 1 0
c9,by 1.0 0.000143348623853 1 0 1
increase,growth 1.0 0.000143348623853 0 1 -1
dystonia,ataxia 1.0 0.000143348623853 0 1 -1
withdrawal,symptoms 1.0 0.000143348623853 0 1 -1
which,increase 1.0 0.000143348623853 1 0 1
of,with 0.2 0.00329701834862 69 46 23
with,occasional 1.0 0.000143348623853 0 1 -1
nevirapinemay,lower 1.0 0.000143348623853 1 0 1
are,summarized 1.0 0.000573394495413 0 4 -4
for,adult-onset 1.0 0.000143348623853 1 0 1
a,with 0.5 0.000286697247706 1 3 -2
with,arimidex 1.0 0.000143348623853 1 0 1
and,classes 1.0 0.000143348623853 1 0 1
than,usual 0.333333333333 0.000143348623853 1 2 -1
to,compromise 1.0 0.000143348623853 1 0 1
concomitantly,the 0.714285714286 0.000716743119266 6 1 5
on,gm 1.0 0.000143348623853 1 0 1
charcoal,administration 1.0 0.000143348623853 1 0 1
on,gi 1.0 0.000286697247706 2 0 2
sensitize,resistant 1.0 0.000143348623853 0 1 -1
evident,by 1.0 0.000143348623853 0 1 -1
addition,alone 1.0 0.000143348623853 1 0 1
cyp2d6,increased 1.0 0.000143348623853 1 0 1
co-administered,to 1.0 0.000143348623853 1 0 1
signs,salivary 1.0 0.000143348623853 0 1 -1
n,combination 1.0 0.000143348623853 1 0 1
and,containing 1.0 0.000286697247706 2 0 2
binding,is 0.0 0.0 1 1 0
in,cerebral 0.333333333333 0.000143348623853 1 2 -1
inhibitors,are 1.0 0.000286697247706 0 2 -2
instances,has 1.0 0.000143348623853 0 1 -1
oral,regularly 1.0 0.000143348623853 0 1 -1
clinical,pharmacology-pharmacokinetics 1.0 0.000143348623853 0 1 -1
medications,are 0.2 0.000143348623853 2 3 -1
interactions,resulting 1.0 0.000143348623853 0 1 -1
or,halogenated 1.0 0.000286697247706 2 0 2
in,ameliorating 1.0 0.000143348623853 0 1 -1
cards,mac 1.0 0.000143348623853 0 1 -1
compound,is 1.0 0.000143348623853 0 1 -1
in,in 1.0 0.000860091743119 0 6 -6
transdermal,system 1.0 0.000143348623853 1 0 1
a,genetic 1.0 0.000143348623853 0 1 -1
eg,have 1.0 0.000143348623853 0 1 -1
disintegrin,and 1.0 0.000143348623853 0 1 -1
were,lowered 1.0 0.000143348623853 0 1 -1
available,in 1.0 0.000143348623853 0 1 -1
hypokalemia,they 1.0 0.00043004587156 0 3 -3
recurred,when 1.0 0.000143348623853 0 1 -1
cyclosporine,digoxin 1.0 0.000143348623853 1 0 1
and,plasma 0.0 0.0 3 3 0
amitriptyline,in 1.0 0.000143348623853 1 0 1
vitro,tests 1.0 0.000143348623853 0 1 -1
immunosuppressive,and 1.0 0.000143348623853 0 1 -1
any,additional 1.0 0.000286697247706 2 0 2
altered,in 1.0 0.000286697247706 0 2 -2
be,negatively 1.0 0.000143348623853 0 1 -1
likely,and 1.0 0.000286697247706 0 2 -2
iv,ace 1.0 0.000143348623853 0 1 -1
the,ultimate 1.0 0.000143348623853 0 1 -1
atromid-s,is 1.0 0.000143348623853 1 0 1
in,enterococcus 1.0 0.000143348623853 0 1 -1
symptomatology,due 1.0 0.000143348623853 1 0 1
been,systematically 1.0 0.000143348623853 1 0 1
and,mortality 1.0 0.000286697247706 0 2 -2
with,camp 0.0 0.0 1 1 0
show,on-treatment 1.0 0.000143348623853 0 1 -1
to,agents 1.0 0.000143348623853 1 0 1
in,prolonging 1.0 0.000143348623853 1 0 1
regimens,containing 1.0 0.000143348623853 1 0 1
kidney,and 1.0 0.000286697247706 0 2 -2
of,methaemoglobinaemia 1.0 0.000143348623853 0 1 -1
cefotan,was 1.0 0.000143348623853 0 1 -1
pesticide,the 1.0 0.000143348623853 0 1 -1
performance,was 1.0 0.000143348623853 1 0 1
factors,in 1.0 0.000286697247706 0 2 -2
corticosteroid,binding 1.0 0.000143348623853 0 1 -1
and,side 1.0 0.000143348623853 0 1 -1
showed,anxiogenic 1.0 0.000143348623853 0 1 -1
and,comparison 1.0 0.000143348623853 0 1 -1
to,induction 0.0 0.0 1 1 0
injection,in 0.0 0.0 1 1 0
the,myasthenic 1.0 0.000143348623853 1 0 1
c,drug 1.0 0.000143348623853 0 1 -1
systemic,etc 1.0 0.000143348623853 1 0 1
sympathomimetic,amines 1.0 0.000143348623853 1 0 1
closely,if 1.0 0.000143348623853 1 0 1
tambocor,are 1.0 0.000143348623853 1 0 1
closely,in 0.333333333333 0.000143348623853 2 1 1
injection,is 1.0 0.000143348623853 0 1 -1
treatment,with 0.0819672131148 0.000716743119266 33 28 5
duragesic,is 0.0 0.0 1 1 0
hcl,may 1.0 0.000143348623853 1 0 1
simultaneous,fold 1.0 0.000143348623853 1 0 1
recombinant,shuttle 1.0 0.000143348623853 0 1 -1
desyrel,and 1.0 0.000143348623853 1 0 1
blocks,the 1.0 0.000286697247706 2 0 2
tested,in 1.0 0.000716743119266 0 5 -5
when,selecting 1.0 0.000286697247706 2 0 2
aluminum-containing,had 1.0 0.000143348623853 0 1 -1
hormone,or 1.0 0.000286697247706 0 2 -2
abnormalities,arrhythmia 1.0 0.000143348623853 1 0 1
oral,suspension 1.0 0.000286697247706 0 2 -2
for,quantitation 1.0 0.000143348623853 0 1 -1
several,classes 1.0 0.000143348623853 0 1 -1
centroblast,proliferation 1.0 0.000143348623853 0 1 -1
substances,grapefruit 1.0 0.000143348623853 0 1 -1
using,immunoanalytical 1.0 0.000143348623853 0 1 -1
but,ki 1.0 0.000143348623853 0 1 -1
cross-matching,procedures 1.0 0.000143348623853 0 1 -1
error,structures 1.0 0.000143348623853 0 1 -1
to,further 0.0 0.0 1 1 0
shown,not 1.0 0.000143348623853 0 1 -1
although,other 1.0 0.000143348623853 0 1 -1
comparing,once-monthly 1.0 0.000143348623853 0 1 -1
microsomes,demonstrated 1.0 0.000143348623853 0 1 -1
extra,doses 1.0 0.000143348623853 0 1 -1
flucoxacillin,and 1.0 0.000143348623853 0 1 -1
r-warfarin,the 1.0 0.000143348623853 1 0 1
that,ecg 1.0 0.000143348623853 1 0 1
dysuria,impotence 1.0 0.000143348623853 0 1 -1
determine,whether 0.666666666667 0.000573394495413 1 5 -4
potassium-sparing,and 1.0 0.000286697247706 0 2 -2
and,symptomatic 1.0 0.000143348623853 0 1 -1
determined,after 1.0 0.000286697247706 0 2 -2
is,impaired 1.0 0.000573394495413 4 0 4
with,population 1.0 0.000143348623853 0 1 -1
oral,resulting 1.0 0.000143348623853 0 1 -1
stimulation,by 1.0 0.000143348623853 0 1 -1
iv,have 1.0 0.000143348623853 0 1 -1
relative,importance 1.0 0.000143348623853 0 1 -1
exerts,a 1.0 0.000143348623853 1 0 1
structural,alterations 1.0 0.000143348623853 0 1 -1
the,and 0.0434782608696 0.000143348623853 11 12 -1
a,new 1.0 0.000286697247706 0 2 -2
occasionally,taxol 1.0 0.000143348623853 0 1 -1
only,protein 1.0 0.000143348623853 0 1 -1
motility,may 0.0 0.0 1 1 0
gastrointestinal,bleeding 1.0 0.000143348623853 1 0 1
testing,transaminases 1.0 0.000143348623853 0 1 -1
ergotamine-containing,or 1.0 0.00043004587156 3 0 3
reduce,intestinal 1.0 0.00043004587156 3 0 3
when,indocin 0.6 0.00043004587156 4 1 3
not,lead 1.0 0.000143348623853 0 1 -1
are,taking 0.2 0.000286697247706 4 6 -2
peptide,that 1.0 0.000143348623853 0 1 -1
concentration,as 1.0 0.00043004587156 0 3 -3
spaces,have 1.0 0.000143348623853 0 1 -1
vasopressor,and 1.0 0.000143348623853 0 1 -1
sulfa,medicines 1.0 0.000143348623853 1 0 1
of,doubled 1.0 0.000143348623853 1 0 1
more,reactive 1.0 0.000573394495413 0 4 -4
and,twice-a 1.0 0.000143348623853 0 1 -1
provided,to 1.0 0.000286697247706 0 2 -2
of,mortality 1.0 0.000143348623853 0 1 -1
this,medicine 1.0 0.000860091743119 0 6 -6
from,concomitant 0.333333333333 0.000143348623853 1 2 -1
of,about 1.0 0.000286697247706 2 0 2
binding,may 1.0 0.000143348623853 1 0 1
the,behavioral 1.0 0.000860091743119 0 6 -6
running,a 1.0 0.000143348623853 0 1 -1
transcription,replication 1.0 0.000143348623853 0 1 -1
deaths,reveal 1.0 0.000143348623853 1 0 1
insufficiency,or 1.0 0.000286697247706 0 2 -2
produced,reliable 1.0 0.000143348623853 0 1 -1
the,heart 1.0 0.000143348623853 1 0 1
fold,respectively 1.0 0.000143348623853 1 0 1
biocytin,with 1.0 0.000286697247706 0 2 -2
drugs,and 0.0 0.0 1 1 0
extensive,metabolism 1.0 0.000143348623853 0 1 -1
placebo,day 1.0 0.000143348623853 0 1 -1
effects,breast 1.0 0.000143348623853 0 1 -1
the,beneficial 1.0 0.00043004587156 3 0 3
and,n-cetyl 1.0 0.000143348623853 0 1 -1
contraceptives,including 1.0 0.000143348623853 1 0 1
consequence,when 1.0 0.000143348623853 1 0 1
time,determinations 1.0 0.000286697247706 2 0 2
to,pressor 0.5 0.000286697247706 1 3 -2
neither,metabolized 1.0 0.000143348623853 0 1 -1
simultaneously,because 1.0 0.000143348623853 1 0 1
together,the 0.0 0.0 1 1 0
of,cholecystokinin 1.0 0.000143348623853 0 1 -1
opportunistic,infection 1.0 0.000143348623853 0 1 -1
binding,with 1.0 0.000143348623853 0 1 -1
must,be 0.217391304348 0.000716743119266 9 14 -5
are,synergistic 1.0 0.000286697247706 2 0 2
cyp3a4,in 0.5 0.000286697247706 1 3 -2
pathway,in 1.0 0.000143348623853 0 1 -1
increase,its 1.0 0.000143348623853 1 0 1
novel,purification 1.0 0.000143348623853 0 1 -1
aeruginosa,as 1.0 0.000143348623853 0 1 -1
by,synthetic 1.0 0.000143348623853 0 1 -1
capsules,every 1.0 0.000143348623853 1 0 1
cyp3a4,is 1.0 0.00043004587156 0 3 -3
is,prescribed 1.0 0.000143348623853 0 1 -1
heart,failure 0.384615384615 0.000716743119266 4 9 -5
few,individuals 1.0 0.000143348623853 0 1 -1
produced,enhanced 1.0 0.000143348623853 0 1 -1
sites,are 1.0 0.000143348623853 0 1 -1
have,benign 1.0 0.000143348623853 0 1 -1
received,the 1.0 0.000143348623853 1 0 1
different,type 1.0 0.000143348623853 1 0 1
sometimes,prescribed 1.0 0.000143348623853 1 0 1
diminished,renal 1.0 0.000143348623853 1 0 1
ironically,are 1.0 0.000143348623853 0 1 -1
may,precipitate 0.6 0.00043004587156 4 1 3
single,in 1.0 0.000143348623853 0 1 -1
play,a 1.0 0.00043004587156 0 3 -3
pyrocarbonate,at 1.0 0.000143348623853 0 1 -1
change,with 1.0 0.000286697247706 0 2 -2
two,different 1.0 0.000573394495413 0 4 -4
mediated,reduction 1.0 0.000143348623853 0 1 -1
or,careful 1.0 0.000143348623853 1 0 1
aldosterone,production 1.0 0.000143348623853 0 1 -1
secondary,enzymes 1.0 0.000143348623853 1 0 1
or,bleeding 1.0 0.000286697247706 2 0 2
of,prinivil 0.0 0.0 1 1 0
and,total 0.333333333333 0.000143348623853 1 2 -1
their,dosage 1.0 0.00043004587156 3 0 3
gradual,dose 1.0 0.000143348623853 0 1 -1
anticholinergic,may 1.0 0.000143348623853 1 0 1
concomitant,intravenous 1.0 0.000143348623853 1 0 1
adverse,reactions 0.636363636364 0.00100344036697 2 9 -7
which,required 1.0 0.000143348623853 0 1 -1
auc,with 1.0 0.000143348623853 0 1 -1
taking,chronically 0.0 0.0 1 1 0
during,days 1.0 0.000143348623853 0 1 -1
data,do 1.0 0.000143348623853 0 1 -1
inhibit,cyp450s 1.0 0.000143348623853 0 1 -1
of,tcamay 1.0 0.000143348623853 0 1 -1
by,ergosterol 1.0 0.000143348623853 0 1 -1
which,requires 1.0 0.000286697247706 0 2 -2
differential,effects 1.0 0.00043004587156 0 3 -3
of,substantial 1.0 0.000143348623853 1 0 1
parasympathomimetic,effects 1.0 0.000143348623853 0 1 -1
cause,of 0.5 0.000286697247706 1 3 -2
monitoring,may 1.0 0.00043004587156 0 3 -3
cyp3a4,substrate 0.0666666666667 0.000143348623853 7 8 -1
sodium,should 1.0 0.000143348623853 0 1 -1
placebo,as 1.0 0.000143348623853 0 1 -1
primarily,degraded 1.0 0.000143348623853 0 1 -1
elevate,plasma 1.0 0.000143348623853 1 0 1
positive,direct 1.0 0.000716743119266 0 5 -5
cause,or 0.0 0.0 1 1 0
the,enhancement 0.0 0.0 1 1 0
alter,gastrointestinal 1.0 0.000143348623853 1 0 1
itraconazole,has 1.0 0.000143348623853 1 0 1
different,from 1.0 0.000286697247706 0 2 -2
who,use 1.0 0.000143348623853 0 1 -1
plasma,cortisol 1.0 0.000143348623853 0 1 -1
levels,significantly 1.0 0.000143348623853 0 1 -1
for,toxicity 0.0 0.0 1 1 0
specific,rare 1.0 0.000143348623853 0 1 -1
when,ht1 1.0 0.000143348623853 1 0 1
other,macrolide 0.0 0.0 1 1 0
bactrim,septra 1.0 0.000143348623853 0 1 -1
to,were 1.0 0.000143348623853 0 1 -1
the,bio-rad 1.0 0.000286697247706 0 2 -2
matulane,eldepryl 1.0 0.000143348623853 0 1 -1
oral,increased 0.333333333333 0.000143348623853 2 1 1
rhabdomyolysis,secondary 1.0 0.000143348623853 1 0 1
antianxiety,and 1.0 0.000143348623853 0 1 -1
experience,large 1.0 0.000143348623853 0 1 -1
delavirdine-based,regimens 1.0 0.000143348623853 0 1 -1
after,oral 1.0 0.000286697247706 0 2 -2
dea,concentrations 1.0 0.000143348623853 0 1 -1
after,alphagan 1.0 0.000143348623853 0 1 -1
fractional,clearance 0.0 0.0 1 1 0
bid,mg 1.0 0.000143348623853 1 0 1
inducer,at 1.0 0.000143348623853 1 0 1
oral,decreased 1.0 0.000143348623853 0 1 -1
for,clinical 1.0 0.000286697247706 0 2 -2
sufficient,data 1.0 0.000143348623853 0 1 -1
neutrophils,recover 1.0 0.000143348623853 0 1 -1
that,acute 1.0 0.000143348623853 0 1 -1
from,working 1.0 0.000143348623853 0 1 -1
human,hepatic 1.0 0.000143348623853 0 1 -1
including,convulsions 1.0 0.000143348623853 1 0 1
v,cmc-cys7 1.0 0.000143348623853 0 1 -1
that,these 0.555555555556 0.000716743119266 2 7 -5
those,off 1.0 0.000143348623853 0 1 -1
inhibitor,to 0.333333333333 0.000143348623853 1 2 -1
isozyme,activity 1.0 0.000716743119266 0 5 -5
coating,of 1.0 0.000143348623853 1 0 1
its,structural 1.0 0.000143348623853 1 0 1
on,ecg 1.0 0.000143348623853 0 1 -1
also,regulated 1.0 0.000143348623853 0 1 -1
by,ci 1.0 0.000286697247706 0 2 -2
metabolite,exposure 1.0 0.000143348623853 1 0 1
decreasing,the 0.333333333333 0.000143348623853 2 1 1
after,an 1.0 0.000143348623853 0 1 -1
in,maximal 0.0 0.0 1 1 0
the,traction 1.0 0.000143348623853 0 1 -1
p450,isozyme 1.0 0.000286697247706 0 2 -2
wellbutrin,tablets 1.0 0.000143348623853 1 0 1
of,keppra 1.0 0.000143348623853 0 1 -1
are,enhanced 1.0 0.000143348623853 1 0 1
liquid,did 1.0 0.000143348623853 0 1 -1
niacin,nicotinic 1.0 0.000286697247706 0 2 -2
events,including 1.0 0.000286697247706 0 2 -2
significance,as 1.0 0.000143348623853 0 1 -1
for,cyp2d6 1.0 0.000143348623853 1 0 1
not,inhibit 1.0 0.00143348623853 0 10 -10
inhibitors,drugs 1.0 0.000143348623853 1 0 1
weak,inducer 1.0 0.000143348623853 0 1 -1
amplitude,but 1.0 0.000143348623853 0 1 -1
hypomagnesemia,should 1.0 0.000143348623853 0 1 -1
developed,a 1.0 0.000143348623853 0 1 -1
i,severe 1.0 0.000143348623853 1 0 1
could,enhance 0.0 0.0 1 1 0
some,oxytocic 1.0 0.000143348623853 1 0 1
temperature,changes 1.0 0.000143348623853 0 1 -1
the,levorotatory 1.0 0.000143348623853 0 1 -1
take,epa 1.0 0.000286697247706 0 2 -2
and,serious 1.0 0.000143348623853 1 0 1
cyp2c19,and 1.0 0.000573394495413 0 4 -4
however,l-name 1.0 0.000143348623853 0 1 -1
of,glycemic 1.0 0.000143348623853 0 1 -1
of,glycemia 1.0 0.000143348623853 0 1 -1
cessation,such 1.0 0.000143348623853 0 1 -1
least,in 0.333333333333 0.000143348623853 1 2 -1
on,was 1.0 0.000286697247706 0 2 -2
the,feasibility 1.0 0.000143348623853 0 1 -1
glucose,alkaline 1.0 0.000143348623853 0 1 -1
common,with 1.0 0.000143348623853 1 0 1
impaired,suppression 1.0 0.000143348623853 0 1 -1
trial,a 1.0 0.000143348623853 0 1 -1
fold,prolongation 1.0 0.000286697247706 0 2 -2
fatalities,have 1.0 0.000143348623853 0 1 -1
clinical,interaction 1.0 0.00129013761468 0 9 -9
undergoes,extensive 1.0 0.000143348623853 0 1 -1
of,indocin 0.428571428571 0.00043004587156 5 2 3
infection,and 0.0 0.0 1 1 0
as,topical 1.0 0.000143348623853 0 1 -1
allergy,or 1.0 0.000143348623853 0 1 -1
in,hospitals 1.0 0.000143348623853 0 1 -1
microalbuminuria,inspra 1.0 0.000143348623853 1 0 1
compliance,poor 1.0 0.000143348623853 0 1 -1
their,reappearance 1.0 0.000143348623853 0 1 -1
relevant,consequences 1.0 0.000143348623853 1 0 1
risk,for 0.6 0.00043004587156 1 4 -3
low,serum 1.0 0.000143348623853 0 1 -1
ankle,edema 1.0 0.000143348623853 0 1 -1
acarbose,and 1.0 0.000143348623853 1 0 1
gel,and 1.0 0.000143348623853 0 1 -1
probably,is 1.0 0.000143348623853 1 0 1
the,contribution 1.0 0.000286697247706 0 2 -2
here,we 1.0 0.00043004587156 0 3 -3
in,deficits 1.0 0.000143348623853 0 1 -1
length,of 0.0 0.0 1 1 0
phenytoin,accutane 1.0 0.000143348623853 0 1 -1
a,temporary 1.0 0.000143348623853 0 1 -1
has,an 0.714285714286 0.000716743119266 1 6 -5
activity,than 1.0 0.000143348623853 0 1 -1
novolog,is 1.0 0.000143348623853 0 1 -1
could,not 1.0 0.000286697247706 0 2 -2
the,fluoride 1.0 0.000143348623853 1 0 1
bound,monoamine 1.0 0.00043004587156 3 0 3
activator,of 1.0 0.000143348623853 0 1 -1
who,is 0.666666666667 0.000573394495413 1 5 -4
ssri,is 1.0 0.000573394495413 4 0 4
noted,when 1.0 0.00043004587156 0 3 -3
doctor,and 1.0 0.000143348623853 0 1 -1
vivo,as 1.0 0.000143348623853 1 0 1
general,concern 1.0 0.000143348623853 0 1 -1
share,a 1.0 0.000143348623853 0 1 -1
medications,associated 1.0 0.000143348623853 0 1 -1
of,immobilised 1.0 0.000143348623853 0 1 -1
dose,groups 1.0 0.000143348623853 0 1 -1
took,either 1.0 0.000143348623853 0 1 -1
the,theophylline-induced 1.0 0.000143348623853 1 0 1
of,pharmacologic 0.0 0.0 1 1 0
has,benefits 1.0 0.000143348623853 0 1 -1
prothrombin,determinations 1.0 0.000143348623853 0 1 -1
triphosphate,metabolite 1.0 0.000143348623853 0 1 -1
of,representative 1.0 0.000143348623853 0 1 -1
fenofibric,acid 1.0 0.000286697247706 0 2 -2
receiving,zyvox 1.0 0.000143348623853 1 0 1
depletors,should 1.0 0.000143348623853 1 0 1
developed,severe 1.0 0.000286697247706 0 2 -2
ketoconazole,combined 1.0 0.000143348623853 1 0 1
that,an 0.6 0.00043004587156 1 4 -3
kg,dose 0.6 0.00043004587156 1 4 -3
for,known 1.0 0.000143348623853 1 0 1
administered,during 0.5 0.000286697247706 1 3 -2
that,at 0.333333333333 0.000143348623853 2 1 1
administering,different 1.0 0.000286697247706 0 2 -2
recent,developments 1.0 0.000143348623853 0 1 -1
that,as 1.0 0.000143348623853 0 1 -1
the,expected 1.0 0.000286697247706 0 2 -2
as,akineton 1.0 0.000143348623853 1 0 1
this,allows 1.0 0.000143348623853 1 0 1
extraction,has 1.0 0.000143348623853 0 1 -1
paroxetine,produced 1.0 0.000143348623853 1 0 1
cortisol,does 1.0 0.000143348623853 0 1 -1
nonhormonal,product 1.0 0.000860091743119 0 6 -6
receiving,coumarin-type 1.0 0.000143348623853 1 0 1
the,non-depolarizing 1.0 0.000143348623853 1 0 1
known,interactions 1.0 0.000716743119266 0 5 -5
receptors,are 1.0 0.000143348623853 0 1 -1
cluster,of 1.0 0.000143348623853 0 1 -1
with,careful 0.2 0.000143348623853 2 3 -1
week,study 1.0 0.000143348623853 0 1 -1
citrate,accumulation 1.0 0.000143348623853 0 1 -1
as,reflected 1.0 0.000143348623853 1 0 1
this,reason 0.0 0.0 1 1 0
ethanol,clinical 1.0 0.000143348623853 1 0 1
a,interaction 0.428571428571 0.00043004587156 2 5 -3
for,metabolite 1.0 0.000143348623853 0 1 -1
co-administered,which 1.0 0.000143348623853 1 0 1
capsules,garlic 1.0 0.000143348623853 0 1 -1
v,nacmc 1.0 0.000143348623853 0 1 -1
or,female 1.0 0.000143348623853 0 1 -1
were,grouped 1.0 0.000143348623853 0 1 -1
rocaltrol,may 1.0 0.00043004587156 0 3 -3
relaxants,birth 1.0 0.000143348623853 0 1 -1
tachyarrhythmias,as 1.0 0.000143348623853 0 1 -1
women,were 1.0 0.000143348623853 0 1 -1
and,increasing 1.0 0.000286697247706 2 0 2
the,toxicokinetic 1.0 0.000143348623853 0 1 -1
absorption,is 1.0 0.000143348623853 0 1 -1
agents,given 1.0 0.000143348623853 0 1 -1
is,such 1.0 0.000143348623853 0 1 -1
absorption,in 1.0 0.00043004587156 3 0 3
m,inhibits 1.0 0.000143348623853 1 0 1
and,rhabdomyolysis 1.0 0.000286697247706 0 2 -2
function,to 1.0 0.000143348623853 0 1 -1
been,collected 1.0 0.000143348623853 0 1 -1
implants,injectables 1.0 0.000143348623853 0 1 -1
susceptibility,in 1.0 0.000143348623853 0 1 -1
the,main 0.333333333333 0.000143348623853 1 2 -1
drop,in 1.0 0.000143348623853 1 0 1
a,month 1.0 0.00043004587156 0 3 -3
dehydrated,usp 1.0 0.000143348623853 0 1 -1
cyp3a4,enzyme 1.0 0.000143348623853 0 1 -1
in,chemotherapy 1.0 0.000286697247706 0 2 -2
information,concerning 1.0 0.000143348623853 0 1 -1
olanzapine,treatment 1.0 0.000143348623853 0 1 -1
requires,maintaining 1.0 0.000143348623853 0 1 -1
ectopic,pregnancies 1.0 0.000143348623853 0 1 -1
a,light 0.5 0.000286697247706 1 3 -2
warfarin,in 1.0 0.00043004587156 0 3 -3
of,acute 1.0 0.000716743119266 0 5 -5
rats,in 0.5 0.000286697247706 1 3 -2
is,critical 1.0 0.000143348623853 0 1 -1
increases,is 1.0 0.000143348623853 0 1 -1
subsequently,increase 1.0 0.000143348623853 0 1 -1
regimens,for 1.0 0.000143348623853 0 1 -1
pharmacology,study 0.0 0.0 1 1 0
host,defense 1.0 0.000143348623853 0 1 -1
brain,damage 1.0 0.000143348623853 1 0 1
increases,in 0.0188679245283 0.000143348623853 26 27 -1
tetracyclines,since 1.0 0.000143348623853 1 0 1
human,therapeutic 1.0 0.000143348623853 1 0 1
pharmacologic,interactions 1.0 0.000143348623853 0 1 -1
p-glycoprotein,transporter 1.0 0.000143348623853 0 1 -1
events,and 1.0 0.000286697247706 0 2 -2
therapeutic,to 1.0 0.000286697247706 0 2 -2
such,use 1.0 0.000143348623853 1 0 1
respectively,responsible 1.0 0.000143348623853 1 0 1
mesylate,in 1.0 0.000143348623853 1 0 1
oral,increase 1.0 0.000143348623853 0 1 -1
your,bodys 1.0 0.000143348623853 0 1 -1
interacting,simultaneously 1.0 0.000143348623853 0 1 -1
the,slow 1.0 0.000143348623853 0 1 -1
their,practitioners 1.0 0.000143348623853 0 1 -1
receptors,sodium 1.0 0.000143348623853 0 1 -1
studies,using 1.0 0.000286697247706 0 2 -2
the,event 1.0 0.000143348623853 0 1 -1
oral,hypoglycemic 0.4 0.000573394495413 7 3 4
or,cyp2d6 1.0 0.000143348623853 1 0 1
with,lymphoma 1.0 0.000143348623853 0 1 -1
or,tumor 1.0 0.000143348623853 0 1 -1
biopsy,roegnik 1.0 0.000143348623853 0 1 -1
from,human 1.0 0.000143348623853 0 1 -1
if,significant 1.0 0.000143348623853 0 1 -1
affected,by 0.8 0.00344036697248 3 27 -24
important,relationships 1.0 0.000143348623853 0 1 -1
especially,hematologic 1.0 0.000143348623853 0 1 -1
relapses,for 1.0 0.000143348623853 0 1 -1
lovastatin,therapy 1.0 0.000143348623853 0 1 -1
metabolized,in 1.0 0.000573394495413 0 4 -4
on,combination 1.0 0.000143348623853 0 1 -1
of,indigestion 1.0 0.000143348623853 1 0 1
normal,value 1.0 0.000143348623853 0 1 -1
of,cyp2a6 1.0 0.000143348623853 1 0 1
this,conference 1.0 0.000143348623853 0 1 -1
rats,pd2 1.0 0.000143348623853 1 0 1
the,continuing 1.0 0.000143348623853 0 1 -1
digoxin,nimodipine 1.0 0.000143348623853 0 1 -1
basis,it 1.0 0.000143348623853 0 1 -1
or,before 1.0 0.000143348623853 0 1 -1
certain,anticancer 1.0 0.000143348623853 1 0 1
procedure,even 1.0 0.000143348623853 0 1 -1
of,supplemental 0.0 0.0 1 1 0
inhibitory,towards 1.0 0.000143348623853 0 1 -1
of,kerlone 1.0 0.000143348623853 0 1 -1
day,will 1.0 0.000143348623853 1 0 1
oh,d3 0.5 0.000286697247706 1 3 -2
anion,itself 1.0 0.000143348623853 0 1 -1
carbamazepine,levels 1.0 0.000143348623853 1 0 1
a,given 1.0 0.00100344036697 0 7 -7
some,other 1.0 0.000286697247706 2 0 2
thinners,coumadin 1.0 0.000143348623853 0 1 -1
iga,glomerulonephritis 1.0 0.000143348623853 1 0 1
non-,steroidal 1.0 0.000286697247706 2 0 2
disturbances,including 1.0 0.000143348623853 0 1 -1
cells,to 1.0 0.00043004587156 0 3 -3
potentiated,the 0.6 0.00043004587156 4 1 3
in,disposition 1.0 0.000143348623853 0 1 -1
with,most 1.0 0.000286697247706 2 0 2
increases,hcl 1.0 0.000143348623853 1 0 1
occur,if 0.333333333333 0.000143348623853 1 2 -1
significantly,decreased 0.6 0.000860091743119 8 2 6
phenobarbital,amphetamines 1.0 0.000286697247706 2 0 2
and,transits 1.0 0.000143348623853 0 1 -1
occur,in 0.5 0.000860091743119 3 9 -6
should,practice 1.0 0.000143348623853 0 1 -1
warnings,and 1.0 0.000143348623853 0 1 -1
significantly,decreases 1.0 0.000143348623853 1 0 1
or,coma 1.0 0.000143348623853 0 1 -1
receiving,such 1.0 0.000143348623853 0 1 -1
cell,killing 1.0 0.000143348623853 0 1 -1
interval,between 1.0 0.000286697247706 0 2 -2
micrograms,equally 1.0 0.000143348623853 1 0 1
rats,giving 1.0 0.000143348623853 0 1 -1
or,activated 1.0 0.000143348623853 1 0 1
substrates,in 1.0 0.000143348623853 0 1 -1
care,units 1.0 0.000143348623853 0 1 -1
so,active 1.0 0.000143348623853 0 1 -1
ca,release 1.0 0.000143348623853 0 1 -1
fluid,contents 1.0 0.000143348623853 0 1 -1
substrates,is 1.0 0.000143348623853 0 1 -1
injectable,an 1.0 0.000143348623853 1 0 1
axis,was 1.0 0.000143348623853 0 1 -1
factors,involved 1.0 0.000143348623853 0 1 -1
others,may 1.0 0.000286697247706 0 2 -2
severe,peripheral 0.333333333333 0.000143348623853 2 1 1
would,include 1.0 0.000143348623853 0 1 -1
alveolar,concentration 1.0 0.000286697247706 2 0 2
toxicity,to 1.0 0.000286697247706 0 2 -2
usually,in 1.0 0.000143348623853 0 1 -1
and,instruct 1.0 0.000143348623853 0 1 -1
ix,and 1.0 0.000143348623853 0 1 -1
relapse,rehospitalisation 1.0 0.000143348623853 0 1 -1
all,elevations 1.0 0.000143348623853 0 1 -1
controlled,trial 1.0 0.000143348623853 0 1 -1
subjects,increased 1.0 0.000286697247706 2 0 2
present,work 1.0 0.000143348623853 0 1 -1
accutane,a 1.0 0.000143348623853 0 1 -1
reduced,tolerance 1.0 0.000143348623853 1 0 1
or,surgery 1.0 0.000143348623853 0 1 -1
with,incisive 1.0 0.000143348623853 0 1 -1
subsequent,adjustment 1.0 0.000143348623853 0 1 -1
nuprin,others 1.0 0.000143348623853 0 1 -1
or,cardiovascular 1.0 0.000143348623853 0 1 -1
expected,changes 1.0 0.000143348623853 0 1 -1
on,clinical 0.333333333333 0.000143348623853 1 2 -1
individual,isoform 1.0 0.000143348623853 0 1 -1
the,benefits 0.333333333333 0.000143348623853 2 1 1
pelvic,abdominal 1.0 0.000143348623853 0 1 -1
pancreatitis,in 1.0 0.000143348623853 0 1 -1
was,expected 1.0 0.000143348623853 0 1 -1
confirm,the 1.0 0.000143348623853 0 1 -1
by,competitive 1.0 0.000143348623853 1 0 1
instances,in 1.0 0.000143348623853 0 1 -1
below,increase 1.0 0.000143348623853 0 1 -1
antipyrine,pharmacokinetics 1.0 0.000143348623853 0 1 -1
dose,fractions 1.0 0.000143348623853 0 1 -1
strongyloidiasis,during 1.0 0.000143348623853 1 0 1
generally,believed 1.0 0.000143348623853 0 1 -1
verapamil,produced 1.0 0.000143348623853 0 1 -1
curve,and 1.0 0.000143348623853 1 0 1
reactive,encephalopathy 1.0 0.000143348623853 0 1 -1
fade,recovery 1.0 0.000143348623853 1 0 1
with,anti-neoplastic 1.0 0.000143348623853 0 1 -1
partially,counteract 1.0 0.000286697247706 2 0 2
or,thiazide 1.0 0.000143348623853 1 0 1
than,mm 1.0 0.000143348623853 0 1 -1
intracranial,pressure 1.0 0.000143348623853 1 0 1
temperature,in 1.0 0.000143348623853 0 1 -1
than,mg 0.714285714286 0.000716743119266 1 6 -5
of,topoisomerases 1.0 0.000286697247706 0 2 -2
epithelium,proliferates 1.0 0.000143348623853 0 1 -1
a,patient 0.241379310345 0.00200688073394 22 36 -14
hours,q24h 1.0 0.000143348623853 1 0 1
demonstrated,superiority 1.0 0.000143348623853 0 1 -1
agents,along 1.0 0.000143348623853 1 0 1
pathophysiologic,consequences 1.0 0.000143348623853 0 1 -1
experiences,and 1.0 0.000143348623853 1 0 1
fully,characterized 1.0 0.000143348623853 1 0 1
impair,liver 1.0 0.000143348623853 0 1 -1
a,agent 1.0 0.000143348623853 1 0 1
use,unless 1.0 0.000143348623853 0 1 -1
on,indicates 1.0 0.000143348623853 1 0 1
in,regard 1.0 0.000143348623853 0 1 -1
nor,of 1.0 0.000143348623853 0 1 -1
adjustment,may 0.5 0.000286697247706 1 3 -2
the,endotoxin-treated 1.0 0.000143348623853 1 0 1
encountered,such 1.0 0.000143348623853 0 1 -1
by,dmpge2 1.0 0.000143348623853 0 1 -1
adrenergic,from 1.0 0.000143348623853 0 1 -1
given,doses 1.0 0.000143348623853 0 1 -1
in,combining 1.0 0.000143348623853 1 0 1
from,its 1.0 0.000573394495413 4 0 4
deficiencies,by 1.0 0.000143348623853 0 1 -1
adjustment,should 1.0 0.000143348623853 1 0 1
shown,by 1.0 0.000143348623853 0 1 -1
crises,have 1.0 0.000143348623853 1 0 1
develop,in 1.0 0.000143348623853 1 0 1
includes,such 1.0 0.000143348623853 0 1 -1
with,intramuscular 1.0 0.000143348623853 0 1 -1
is,not 0.454545454545 0.00716743119266 30 80 -50
is,now 1.0 0.000573394495413 0 4 -4
be,decreased 0.454545454545 0.000716743119266 3 8 -5
safety,concern 1.0 0.000143348623853 0 1 -1
pharmacodynamic,drug-drug 1.0 0.000143348623853 0 1 -1
site,reactions 1.0 0.000143348623853 0 1 -1
enzyme-inducing,properties 1.0 0.000143348623853 1 0 1
prophylaxis,may 1.0 0.000143348623853 1 0 1
the,function 0.333333333333 0.000143348623853 1 2 -1
and,pupil 1.0 0.000286697247706 0 2 -2
more,efficient 1.0 0.000143348623853 0 1 -1
the,intestine 0.5 0.000286697247706 1 3 -2
prolonged,therapy 1.0 0.000143348623853 0 1 -1
pure,agonist 1.0 0.000143348623853 1 0 1
is,adjusted 1.0 0.000143348623853 1 0 1
hard,gelatin 1.0 0.000143348623853 0 1 -1
apraclonidine,should 1.0 0.000143348623853 1 0 1
study,cytochrome 1.0 0.000143348623853 0 1 -1
increase,due 1.0 0.000143348623853 1 0 1
interactions,were 1.0 0.00143348623853 0 10 -10
percent,of 0.333333333333 0.000143348623853 2 1 1
cyp3a4,such 1.0 0.000286697247706 2 0 2
a,net 0.6 0.00043004587156 4 1 3
investigator,found 1.0 0.000286697247706 0 2 -2
concerning,published 1.0 0.000143348623853 0 1 -1
therefore,injection 1.0 0.000143348623853 0 1 -1
sodium,blood 1.0 0.000143348623853 1 0 1
margin,such 1.0 0.000143348623853 0 1 -1
b12,status 1.0 0.000143348623853 0 1 -1
a,chemical 1.0 0.000143348623853 0 1 -1
concomitant,high-dose 1.0 0.000143348623853 1 0 1
supplemental,in 1.0 0.000143348623853 1 0 1
specifically,through 1.0 0.000143348623853 0 1 -1
patient,was 1.0 0.000573394495413 0 4 -4
innovar,vet 1.0 0.000143348623853 1 0 1
times,daily 0.2 0.000143348623853 2 3 -1
and,primarily 1.0 0.000573394495413 0 4 -4
as,evidenced 0.0 0.0 1 1 0
during,sexual 1.0 0.000143348623853 0 1 -1
pharmacologically,with 1.0 0.000143348623853 1 0 1
of,ascorbic 0.6 0.00043004587156 1 4 -3
taste,disorder 1.0 0.000143348623853 0 1 -1
the,translocation 1.0 0.00043004587156 0 3 -3
mouth,thirst 1.0 0.000143348623853 0 1 -1
not,bind 1.0 0.000143348623853 0 1 -1
receiving,acarbose 1.0 0.000286697247706 0 2 -2
was,independent 1.0 0.000143348623853 0 1 -1
primary,rabbit 1.0 0.000143348623853 0 1 -1
when,simulect 1.0 0.000143348623853 0 1 -1
in,dosing 1.0 0.000143348623853 0 1 -1
were,unaltered 1.0 0.000143348623853 0 1 -1
nonclinical,studies 1.0 0.000143348623853 0 1 -1
to,bind 1.0 0.000286697247706 0 2 -2
patients,suffering 1.0 0.00043004587156 3 0 3
norepinephrine,amphetamines 1.0 0.000286697247706 2 0 2
collapse,respiratory 1.0 0.000143348623853 0 1 -1
in,mortality 1.0 0.000143348623853 0 1 -1
greater,patients 1.0 0.000143348623853 1 0 1
avoid,saw 1.0 0.000143348623853 0 1 -1
minimum,effective 1.0 0.000143348623853 0 1 -1
metabolism,using 1.0 0.000143348623853 0 1 -1
a,high 0.166666666667 0.000286697247706 7 5 2
significant,interactions 0.888888888889 0.00229357798165 1 17 -16
that,clearance 1.0 0.00043004587156 3 0 3
kg,resulted 1.0 0.000143348623853 0 1 -1
this,drug 1.0 0.000143348623853 0 1 -1
changes,resulting 1.0 0.000143348623853 0 1 -1
respectively,compared 1.0 0.000143348623853 1 0 1
because,accutane 1.0 0.000143348623853 1 0 1
inhibitors,elevated 1.0 0.000143348623853 0 1 -1
tests,common 1.0 0.000143348623853 0 1 -1
neural,plasticity 1.0 0.000286697247706 0 2 -2
metformin,when 1.0 0.000143348623853 0 1 -1
both,instances 1.0 0.000143348623853 0 1 -1
volunteer,was 1.0 0.000143348623853 0 1 -1
possible,administration 1.0 0.000143348623853 0 1 -1
patients,serum 1.0 0.000286697247706 0 2 -2
of,caution 0.333333333333 0.000143348623853 2 1 1
in,reversible 1.0 0.000143348623853 1 0 1
repeated,challenge 1.0 0.000860091743119 0 6 -6
medications,patients 1.0 0.000143348623853 1 0 1
the,association 1.0 0.000143348623853 0 1 -1
tacrolimus,co-administration 1.0 0.000143348623853 0 1 -1
interacts,with 1.0 0.00043004587156 0 3 -3
found,to 0.52 0.00186353211009 6 19 -13
the,conventional 1.0 0.000143348623853 0 1 -1
medications,concurrent 1.0 0.000286697247706 0 2 -2
such,interaction 1.0 0.000143348623853 0 1 -1
discontinued,prior 1.0 0.000286697247706 0 2 -2
deprived,of 1.0 0.000143348623853 0 1 -1
day,twice 1.0 0.000143348623853 0 1 -1
thrombocytopenia,or 1.0 0.000143348623853 0 1 -1
peripherally,restricted 1.0 0.000143348623853 1 0 1
that,might 0.333333333333 0.000143348623853 1 2 -1
the,substrate 1.0 0.000143348623853 0 1 -1
novel,peripherally 1.0 0.000143348623853 1 0 1
isosorbide,dinitrate 0.0 0.0 1 1 0
as,common 1.0 0.000143348623853 0 1 -1
drops,containing 1.0 0.000143348623853 0 1 -1
before,one 1.0 0.000143348623853 0 1 -1
inn,when 1.0 0.000143348623853 0 1 -1
b23,activation 1.0 0.000143348623853 0 1 -1
the,female 1.0 0.000143348623853 0 1 -1
amevive,administered 1.0 0.000143348623853 0 1 -1
antiparkinson,or 1.0 0.000143348623853 1 0 1
control,program 1.0 0.000143348623853 0 1 -1
prolong,ecg 1.0 0.000143348623853 0 1 -1
gastric,emptying 0.333333333333 0.000143348623853 1 2 -1
this,could 0.714285714286 0.000716743119266 1 6 -5
cholesterol,low-density 1.0 0.000143348623853 0 1 -1
when,therapy 0.333333333333 0.000286697247706 4 2 2
clinical,monitoring 1.0 0.000286697247706 0 2 -2
low,compared 1.0 0.000143348623853 0 1 -1
or,subsequent 1.0 0.000143348623853 1 0 1
cns-active,should 1.0 0.000143348623853 1 0 1
ketamine,is 1.0 0.000143348623853 0 1 -1
manifested,as 1.0 0.000143348623853 0 1 -1
the,european 1.0 0.000143348623853 0 1 -1
and,a4 1.0 0.000573394495413 0 4 -4
magnesium-containing,concomitant 1.0 0.000143348623853 1 0 1
a,peptide 1.0 0.000143348623853 0 1 -1
in,interpreting 1.0 0.000143348623853 0 1 -1
certain,are 1.0 0.000143348623853 0 1 -1
amphetamines,enhance 1.0 0.000286697247706 2 0 2
and,testicular 1.0 0.000143348623853 0 1 -1
from,male 1.0 0.000143348623853 0 1 -1
potential,nephrotoxicity 1.0 0.000143348623853 0 1 -1
elevated,alkaline 1.0 0.000143348623853 0 1 -1
renal,vascular 1.0 0.000143348623853 0 1 -1
of,psychotropic 1.0 0.000143348623853 1 0 1
bradycardia,which 0.2 0.000143348623853 2 3 -1
including,hyperglycemia 1.0 0.000143348623853 1 0 1
e-strain,subjects 1.0 0.000286697247706 0 2 -2
available,from 1.0 0.00043004587156 0 3 -3
efficiently,inhibited 1.0 0.000143348623853 0 1 -1
or,maintain 1.0 0.000143348623853 0 1 -1
haart,with 1.0 0.000143348623853 0 1 -1
vasodilation,induced 1.0 0.000143348623853 1 0 1
prescribe,this 1.0 0.000143348623853 0 1 -1
and,normal 0.333333333333 0.000143348623853 2 1 1
amphotericin,b- 1.0 0.000143348623853 1 0 1
low,initial 1.0 0.000143348623853 0 1 -1
further,deterioration 1.0 0.000286697247706 2 0 2
situations,when 1.0 0.000286697247706 0 2 -2
supersensitive,to 1.0 0.000286697247706 2 0 2
produced,additive 1.0 0.000286697247706 2 0 2
to,ace 1.0 0.000286697247706 2 0 2
minor,metabolic 1.0 0.000143348623853 0 1 -1
infarction,during 1.0 0.000143348623853 0 1 -1
the-curve,auc 1.0 0.000143348623853 0 1 -1
binding,thiazide 1.0 0.000143348623853 1 0 1
local,agents 1.0 0.000286697247706 0 2 -2
reversible,increases 1.0 0.000143348623853 1 0 1
we,carried 1.0 0.000143348623853 0 1 -1
dosing,adjustments 1.0 0.000143348623853 0 1 -1
medical,supervision 0.333333333333 0.000143348623853 1 2 -1
studies,caused 1.0 0.000143348623853 0 1 -1
with,thus 1.0 0.000143348623853 0 1 -1
fatal,cardiac 1.0 0.000143348623853 0 1 -1
reduced,antihypertensive 1.0 0.000143348623853 0 1 -1
since,are 1.0 0.000143348623853 1 0 1
by,meth 1.0 0.000143348623853 0 1 -1
man,the 1.0 0.000143348623853 1 0 1
b-cell,hyperplasia 1.0 0.000143348623853 0 1 -1
doubled,the 1.0 0.000143348623853 1 0 1
and,mental 1.0 0.000143348623853 1 0 1
should,have 0.4 0.000573394495413 3 7 -4
additive,ocular 1.0 0.000143348623853 0 1 -1
is,taken 0.0 0.0 3 3 0
with,hepatic 0.6 0.00043004587156 1 4 -3
norfluoxe-tine,have 1.0 0.000143348623853 0 1 -1
depend,on 0.428571428571 0.00043004587156 5 2 3
received,muscle 1.0 0.000143348623853 1 0 1
produce,antabuse-like 1.0 0.000143348623853 1 0 1
with,tests 1.0 0.000286697247706 0 2 -2
produced,pharmacological 1.0 0.000143348623853 0 1 -1
to,each 1.0 0.000286697247706 0 2 -2
exposure,despite 1.0 0.000143348623853 0 1 -1
system,at 1.0 0.000143348623853 1 0 1
complications,of 0.5 0.000286697247706 1 3 -2
interacting,which 1.0 0.000143348623853 0 1 -1
elderly,patients 0.5 0.000286697247706 1 3 -2
volunteers,a 1.0 0.00043004587156 3 0 3
interactions,pi 1.0 0.000143348623853 0 1 -1
to,pursue 1.0 0.000143348623853 0 1 -1
irregularities,were 1.0 0.000143348623853 0 1 -1
synthesis,within 1.0 0.000143348623853 0 1 -1
whose,plasma 1.0 0.000143348623853 0 1 -1
producing,transient 1.0 0.000143348623853 0 1 -1
combination,hormonal 0.692307692308 0.00129013761468 11 2 9
agents,experience 1.0 0.000143348623853 1 0 1
tension,hoof 1.0 0.000143348623853 0 1 -1
in,such 0.454545454545 0.000716743119266 3 8 -5
can,significantly 0.0 0.0 1 1 0
complete,after 1.0 0.000143348623853 0 1 -1
would,cause 1.0 0.000143348623853 0 1 -1
once,weekly 0.333333333333 0.000143348623853 2 1 1
were,detected 1.0 0.000143348623853 0 1 -1
aminotransferases,was 1.0 0.000143348623853 0 1 -1
tricor,and 1.0 0.000143348623853 1 0 1
toxic,when 1.0 0.000716743119266 0 5 -5
cardiovascular,status 1.0 0.000143348623853 0 1 -1
subjects,there 1.0 0.000143348623853 0 1 -1
longterm,treatment 1.0 0.000143348623853 0 1 -1
rifampin,an 1.0 0.000143348623853 1 0 1
memory,system 1.0 0.000143348623853 0 1 -1
although,betagan 1.0 0.000143348623853 1 0 1
allowing,gradually 1.0 0.000143348623853 0 1 -1
consciousness,when 1.0 0.000143348623853 1 0 1
cyp2e1,or 1.0 0.000286697247706 0 2 -2
fluctuations,of 1.0 0.000143348623853 1 0 1
signs,of 0.466666666667 0.00100344036697 4 11 -7
intravascular,catabolism 1.0 0.000143348623853 0 1 -1
pharmacologic,effects 0.333333333333 0.000143348623853 2 1 1
membrane,potential 1.0 0.000143348623853 0 1 -1
fat-soluble,including 1.0 0.000143348623853 1 0 1
is,considerable 1.0 0.000143348623853 0 1 -1
heart,medicine 1.0 0.000143348623853 1 0 1
extract,from 1.0 0.000286697247706 0 2 -2
subject,to 1.0 0.000573394495413 0 4 -4
cyp3a4,rifampin 1.0 0.000143348623853 0 1 -1
since,inhibits 1.0 0.000143348623853 1 0 1
and,decrease 0.142857142857 0.000286697247706 8 6 2
a,less 0.333333333333 0.000143348623853 2 1 1
liver,tumors 1.0 0.000286697247706 0 2 -2
found,with 1.0 0.000286697247706 0 2 -2
date,on 1.0 0.000286697247706 0 2 -2
modest,cyp2d6 1.0 0.000143348623853 1 0 1
although,overall 1.0 0.000143348623853 1 0 1
reports,regarding 1.0 0.000143348623853 0 1 -1
nsaids,is 1.0 0.000286697247706 2 0 2
and,may 0.308641975309 0.00358371559633 53 28 25
technique,and 1.0 0.000143348623853 0 1 -1
and,mac 1.0 0.000143348623853 1 0 1
linezolid,is 1.0 0.000143348623853 0 1 -1
prevent,maltose 1.0 0.000143348623853 0 1 -1
digit,symbol 1.0 0.000143348623853 1 0 1
the,aberrant 1.0 0.000143348623853 0 1 -1
and,fsh 1.0 0.000143348623853 0 1 -1
hypomania,restlessness 1.0 0.000143348623853 0 1 -1
a2,and 1.0 0.000143348623853 1 0 1
depressed,in 1.0 0.000143348623853 1 0 1
days,before 0.5 0.000286697247706 3 1 2
ibuprofen,produced 1.0 0.000143348623853 1 0 1
antithyroid,agents 0.0 0.0 1 1 0
cautiously,and 0.333333333333 0.000143348623853 1 2 -1
reasons,it 1.0 0.000143348623853 1 0 1
be,included 1.0 0.000143348623853 0 1 -1
total,daily 1.0 0.000286697247706 0 2 -2
antipsychotic,medications 1.0 0.000143348623853 0 1 -1
elevated,creatine 1.0 0.000143348623853 0 1 -1
surface,histidine 1.0 0.000143348623853 0 1 -1
this,parenteral 1.0 0.000143348623853 1 0 1
were,inhibited 1.0 0.000286697247706 0 2 -2
and,degenerative 1.0 0.000143348623853 0 1 -1
conditions,had 1.0 0.000143348623853 0 1 -1
that,dose 1.0 0.000143348623853 1 0 1
in,proportion 1.0 0.000143348623853 0 1 -1
to,highintersubject 1.0 0.000143348623853 0 1 -1
was,inhibited 1.0 0.000143348623853 0 1 -1
the,absence 0.454545454545 0.000716743119266 3 8 -5
or,others 1.0 0.000143348623853 0 1 -1
decrease,between 1.0 0.000143348623853 0 1 -1
cytochrome,cyp 1.0 0.000286697247706 0 2 -2
or,above 1.0 0.000143348623853 1 0 1
a4,and 1.0 0.000716743119266 0 5 -5
ketoprofen,like 1.0 0.000143348623853 1 0 1
heparin,effect 0.0 0.0 1 1 0
functioning,gland 1.0 0.000143348623853 1 0 1
requirements,of 1.0 0.000143348623853 1 0 1
half-life,increased 0.5 0.000286697247706 3 1 2
local,or 1.0 0.000143348623853 1 0 1
cns,effect 1.0 0.000143348623853 1 0 1
acidic,or 1.0 0.000143348623853 1 0 1
gastric,hydrochloric 1.0 0.000143348623853 0 1 -1
aed,on 1.0 0.000143348623853 0 1 -1
not,administered 1.0 0.000143348623853 0 1 -1
ototoxicity,were 1.0 0.000143348623853 0 1 -1
drugs,enhancing 1.0 0.000143348623853 0 1 -1
of,sustained-release 1.0 0.000143348623853 1 0 1
interaction,was 1.0 0.000860091743119 0 6 -6
inhibitors,indinavir 1.0 0.000143348623853 1 0 1
the,purification 1.0 0.000143348623853 0 1 -1
concentrations,observed 1.0 0.000143348623853 0 1 -1
day,administration 1.0 0.000143348623853 0 1 -1
alkalinizing,agents 0.333333333333 0.000143348623853 2 1 1
humans,and 0.333333333333 0.000143348623853 1 2 -1
a,pacemaker 1.0 0.000143348623853 0 1 -1
by,was 1.0 0.000286697247706 2 0 2
combination,see 1.0 0.000143348623853 0 1 -1
form,a 1.0 0.000286697247706 2 0 2
are,so-called 1.0 0.000286697247706 0 2 -2
recognized,by 1.0 0.000143348623853 0 1 -1
anticholinesterases,neostgmine 1.0 0.000143348623853 0 1 -1
type,i 1.0 0.000143348623853 0 1 -1
was,obtained 1.0 0.00043004587156 0 3 -3
of,exposure 0.714285714286 0.000716743119266 1 6 -5
in,mcf-7 1.0 0.000143348623853 0 1 -1
the,unrestricted 1.0 0.000143348623853 0 1 -1
in,excessive 1.0 0.000286697247706 2 0 2
dosage,should 0.6 0.00043004587156 4 1 3
found,in 0.666666666667 0.000573394495413 1 5 -4
and,tablets 1.0 0.00043004587156 3 0 3
abnormalities,related 1.0 0.000143348623853 0 1 -1
gain,somnolence 1.0 0.000143348623853 0 1 -1
a,competitive 1.0 0.000143348623853 1 0 1
other,nsaid 0.0 0.0 1 1 0
stool,in 1.0 0.00043004587156 0 3 -3
affect,other 1.0 0.000286697247706 0 2 -2
cyclosporine,administration 1.0 0.000143348623853 1 0 1
hematologic,and 1.0 0.000143348623853 0 1 -1
vivo,studies 0.428571428571 0.00043004587156 2 5 -3
your,physician 1.0 0.000143348623853 0 1 -1
some,forms 1.0 0.000143348623853 0 1 -1
of,cardiopulmonary 1.0 0.000143348623853 0 1 -1
the,fetal 1.0 0.000143348623853 0 1 -1
produced,a 0.5 0.000860091743119 9 3 6
and,chemotherapy 1.0 0.000143348623853 0 1 -1
studied,certain 1.0 0.000143348623853 1 0 1
lodine,and 1.0 0.000143348623853 1 0 1
mefloquineuine,and 1.0 0.000143348623853 0 1 -1
to,platelet 1.0 0.000143348623853 0 1 -1
increased,altretamines 1.0 0.000143348623853 1 0 1
aed,concentration 1.0 0.000143348623853 0 1 -1
four,kinds 1.0 0.000143348623853 0 1 -1
addiction,while 1.0 0.000143348623853 0 1 -1
synthesis,have 1.0 0.000143348623853 1 0 1
and,pharmacokinetics 1.0 0.00043004587156 0 3 -3
of,phosphorylated 1.0 0.000143348623853 0 1 -1
same,cytochrome 1.0 0.000143348623853 0 1 -1
identifications,of 1.0 0.000143348623853 0 1 -1
mitogen,and 1.0 0.000143348623853 0 1 -1
changed,by 1.0 0.000143348623853 1 0 1
proliferation,and 1.0 0.000143348623853 0 1 -1
bacteriostatic,such 1.0 0.000143348623853 1 0 1
indomethacin,are 1.0 0.000143348623853 0 1 -1
multivalent,cations 1.0 0.00043004587156 3 0 3
pharmacokinetics,were 1.0 0.000716743119266 0 5 -5
and,clearance 1.0 0.000143348623853 0 1 -1
pharmacological,analysis 1.0 0.000143348623853 0 1 -1
the,parietal 1.0 0.000143348623853 0 1 -1
have,lower 1.0 0.000143348623853 0 1 -1
to,although 1.0 0.000143348623853 1 0 1
trecator,may 1.0 0.000143348623853 1 0 1
least,halved 1.0 0.000143348623853 1 0 1
other,including 0.0 0.0 2 2 0
hypokalemia,may 0.333333333333 0.000143348623853 2 1 1
vs,respectively 1.0 0.000143348623853 0 1 -1
mg,ml 1.0 0.00043004587156 0 3 -3
of,mixing 1.0 0.000143348623853 0 1 -1
hemorrhage,and 1.0 0.000143348623853 0 1 -1
on,bsa 1.0 0.000573394495413 0 4 -4
indigestion,remedies 1.0 0.000143348623853 1 0 1
period,following 0.0 0.0 1 1 0
of,upward 1.0 0.000143348623853 0 1 -1
peak,concentration 1.0 0.00043004587156 0 3 -3
decreases,stomach 1.0 0.000143348623853 0 1 -1
alkaloids,may 1.0 0.000143348623853 1 0 1
total,drug 1.0 0.000143348623853 0 1 -1
applied,for 1.0 0.000143348623853 0 1 -1
other,there 1.0 0.000143348623853 0 1 -1
although,lexapro 1.0 0.000143348623853 1 0 1
with,inducers 1.0 0.000143348623853 1 0 1
depressants,or 1.0 0.000286697247706 2 0 2
usually,well 0.0 0.0 1 1 0
metal,toxicity 1.0 0.000573394495413 0 4 -4
reduced,levels 1.0 0.000143348623853 0 1 -1
information,on 1.0 0.00114678899083 0 8 -8
the,aptt 1.0 0.000286697247706 0 2 -2
hemostatic,defense 1.0 0.000143348623853 1 0 1
using,these 0.6 0.00043004587156 1 4 -3
an,intubating 1.0 0.000143348623853 1 0 1
lipoproteins,and 1.0 0.000143348623853 0 1 -1
and,crystalline 1.0 0.000143348623853 0 1 -1
matrix,may 1.0 0.000143348623853 1 0 1
pronounced,secretory 1.0 0.000143348623853 0 1 -1
drugs,at 1.0 0.000143348623853 0 1 -1
study,with 0.636363636364 0.00100344036697 2 9 -7
widespread,effects 1.0 0.000143348623853 0 1 -1
trials,due 1.0 0.000143348623853 0 1 -1
blood,elements 1.0 0.000143348623853 1 0 1
report,l-glutamine 1.0 0.000143348623853 1 0 1
it,adversely 1.0 0.000143348623853 1 0 1
concurrent,usage 1.0 0.000143348623853 0 1 -1
various,doses 1.0 0.000143348623853 0 1 -1
of,absorbed 0.0 0.0 1 1 0
suffering,from 1.0 0.000143348623853 1 0 1
and,and 0.0909090909091 0.00043004587156 15 18 -3
and,any 1.0 0.000860091743119 0 6 -6
carbamazepine,is 1.0 0.000573394495413 0 4 -4
and,cortex 1.0 0.000143348623853 1 0 1
hydrophilic,molecule 1.0 0.000143348623853 0 1 -1
of,after 1.0 0.000573394495413 0 4 -4
note,if 1.0 0.000143348623853 0 1 -1
a,period 0.333333333333 0.000143348623853 2 1 1
of,baseline 1.0 0.000143348623853 0 1 -1
laboratory,interactions 1.0 0.000143348623853 0 1 -1
a,critical 1.0 0.000286697247706 0 2 -2
potassium,enalapril 1.0 0.000143348623853 1 0 1
res,is 1.0 0.000143348623853 0 1 -1
it,can 1.0 0.000143348623853 0 1 -1
the,size 1.0 0.000143348623853 0 1 -1
inhibitors,maois 1.0 0.000143348623853 1 0 1
specific,applications 1.0 0.000143348623853 0 1 -1
recovery,programs 1.0 0.000143348623853 0 1 -1
xanthine,derivatives 0.0 0.0 1 1 0
cyp4a11,with 1.0 0.000143348623853 0 1 -1
of,at 0.214285714286 0.000860091743119 11 17 -6
responses,have 0.0 0.0 1 1 0
for,seven 1.0 0.000143348623853 0 1 -1
uncompromised,elderly 1.0 0.000143348623853 0 1 -1
or,equal 1.0 0.000143348623853 0 1 -1
of,xanthine 1.0 0.000143348623853 0 1 -1
specific,isoenzyme 1.0 0.000143348623853 0 1 -1
data,vardenafil 1.0 0.000143348623853 1 0 1
study,evoked 1.0 0.000143348623853 0 1 -1
increasing,use 1.0 0.000143348623853 0 1 -1
of,targretin 1.0 0.000143348623853 1 0 1
early,therapy 1.0 0.000143348623853 1 0 1
and,prevention 1.0 0.000143348623853 0 1 -1
alcohol,although 1.0 0.000143348623853 1 0 1
and,antidotal 1.0 0.000143348623853 1 0 1
blocking,effect 1.0 0.000143348623853 1 0 1
like,monoamine 1.0 0.000143348623853 1 0 1
cholestyramine,may 1.0 0.00043004587156 3 0 3
against,mycobacteriumavium-intracellulare 1.0 0.000143348623853 0 1 -1
amprenavir,inhibits 1.0 0.000143348623853 0 1 -1
reported,intermenstrual 1.0 0.000143348623853 0 1 -1
acetaminophen,and 0.0 0.0 1 1 0
i,neurotransmitter 1.0 0.000143348623853 0 1 -1
variables,of 1.0 0.000143348623853 0 1 -1
cramps,muscular 1.0 0.000143348623853 0 1 -1
on,clonidines 1.0 0.000143348623853 0 1 -1
theoretically,might 1.0 0.000143348623853 0 1 -1
methotrexate,ibuprofen 1.0 0.000143348623853 1 0 1
modifications,based 1.0 0.000143348623853 0 1 -1
to,should 1.0 0.000286697247706 2 0 2
from,results 1.0 0.000143348623853 0 1 -1
studies,caution 1.0 0.000143348623853 0 1 -1
at,low 1.0 0.000286697247706 0 2 -2
and,prothrombin 0.2 0.000143348623853 2 3 -1
completely,blocked 1.0 0.000143348623853 1 0 1
intravenous,agents 1.0 0.000143348623853 0 1 -1
in,external 1.0 0.000143348623853 0 1 -1
within,the 0.5 0.000860091743119 3 9 -6
in,poor 1.0 0.000143348623853 0 1 -1
interactions,amerge 1.0 0.000143348623853 0 1 -1
nevertheless,clinical 1.0 0.000143348623853 1 0 1
aureus,a 1.0 0.000143348623853 1 0 1
daily,to 1.0 0.000286697247706 0 2 -2
alter,hormone 1.0 0.000143348623853 0 1 -1
test,which 1.0 0.000143348623853 0 1 -1
cimetidine,does 1.0 0.000143348623853 0 1 -1
cells,are 1.0 0.000143348623853 0 1 -1
have,all 1.0 0.000143348623853 0 1 -1
effects,ways 1.0 0.000143348623853 0 1 -1
exceeded,in 1.0 0.000143348623853 1 0 1
the,experience 1.0 0.000143348623853 0 1 -1
renin,substrate 1.0 0.000286697247706 0 2 -2
in,turn 0.333333333333 0.000143348623853 1 2 -1
was,applied 1.0 0.000143348623853 1 0 1
importance,have 1.0 0.000143348623853 0 1 -1
renal,vasodilator 1.0 0.000143348623853 0 1 -1
hypoxic,respiratory 1.0 0.000143348623853 0 1 -1
ki,value 1.0 0.000143348623853 0 1 -1
accentuate,the 1.0 0.000286697247706 2 0 2
with,uricosuric 1.0 0.000143348623853 0 1 -1
accutane,and 1.0 0.000143348623853 1 0 1
the,appropriate 1.0 0.00129013761468 0 9 -9
a,limited 1.0 0.000286697247706 0 2 -2
electrocardiographic,parameters 1.0 0.00043004587156 0 3 -3
this,enzyme 0.25 0.000286697247706 3 5 -2
administered,until 1.0 0.000143348623853 1 0 1
pneumocystis,carinii 1.0 0.000143348623853 1 0 1
monitored,for 0.111111111111 0.000143348623853 4 5 -1
level,was 1.0 0.000143348623853 0 1 -1
genetic,predisposition 1.0 0.000143348623853 0 1 -1
concentration-time,curve 0.6 0.00043004587156 1 4 -3
interferometric,measurement 1.0 0.000143348623853 0 1 -1
model,primary 1.0 0.000143348623853 0 1 -1
therefore,this 1.0 0.000143348623853 0 1 -1
significantly,alter 0.0 0.0 1 1 0
although,there 0.272727272727 0.00043004587156 4 7 -3
between,uroxatral 1.0 0.000143348623853 0 1 -1
peripheral,edema 1.0 0.000143348623853 0 1 -1
to,antagonize 1.0 0.000286697247706 2 0 2
significantly,lower 1.0 0.000286697247706 0 2 -2
with,ganglionic 1.0 0.000286697247706 0 2 -2
extensor,tension 1.0 0.000143348623853 0 1 -1
are,reduced 1.0 0.000286697247706 2 0 2
nsaids,antigout 1.0 0.000143348623853 0 1 -1
taking,beta 0.333333333333 0.000143348623853 1 2 -1
reduced,activity 1.0 0.00043004587156 0 3 -3
bacteria,except 1.0 0.000143348623853 0 1 -1
ranitidine,produced 1.0 0.000286697247706 0 2 -2
prostin,vr 1.0 0.000143348623853 0 1 -1
urinary,alkalinizers 1.0 0.000143348623853 0 1 -1
no,inhibition 1.0 0.000286697247706 0 2 -2
b12,because 1.0 0.000143348623853 0 1 -1
with,moderate 0.0 0.0 1 1 0
with,racemic 1.0 0.000286697247706 2 0 2
with,either 0.272727272727 0.00043004587156 4 7 -3
year,indicating 1.0 0.000143348623853 0 1 -1
slowly,over 1.0 0.000143348623853 1 0 1
other,such 0.2 0.000143348623853 2 3 -1
dictate,against 1.0 0.000143348623853 1 0 1
trials,using 1.0 0.000143348623853 0 1 -1
in,post-marketing 0.6 0.00043004587156 4 1 3
cardiovascular,morbidity 1.0 0.000143348623853 0 1 -1
of,pseudotumor 1.0 0.000143348623853 1 0 1
the,morbidity 1.0 0.000143348623853 0 1 -1
minor,contribution 1.0 0.000143348623853 0 1 -1
with,atacand 1.0 0.000143348623853 1 0 1
cmax,at 1.0 0.000143348623853 0 1 -1
interference,may 1.0 0.000143348623853 0 1 -1
starting,other 1.0 0.000143348623853 0 1 -1
and,inducers 0.0 0.0 1 1 0
medications,varied 1.0 0.000143348623853 0 1 -1
arthritis,patients 1.0 0.000286697247706 0 2 -2
receiving,tablets 1.0 0.000143348623853 0 1 -1
accordance,with 1.0 0.000573394495413 0 4 -4
to,healthy 0.466666666667 0.00100344036697 4 11 -7
lasting,inhibition 1.0 0.000143348623853 0 1 -1
o11,strains 1.0 0.000286697247706 0 2 -2
increase,generation 1.0 0.000143348623853 0 1 -1
asymptomatic,liver 1.0 0.000143348623853 0 1 -1
ml,kg 1.0 0.000143348623853 0 1 -1
demonstrated,hypokalemia 1.0 0.00043004587156 0 3 -3
stable,plasma 1.0 0.000286697247706 2 0 2
other,broad-spectrum 1.0 0.000143348623853 1 0 1
sexual,intercourse 1.0 0.000286697247706 0 2 -2
generate,the 1.0 0.000143348623853 0 1 -1
times,long-sedation 1.0 0.000143348623853 0 1 -1
in,sn38 1.0 0.000143348623853 0 1 -1
and,pulsatile 1.0 0.000143348623853 0 1 -1
are,given 0.0769230769231 0.000143348623853 6 7 -1
relationships,and 1.0 0.000143348623853 0 1 -1
antibiotics,no 1.0 0.000143348623853 0 1 -1
to,suppression 1.0 0.000143348623853 0 1 -1
lasting,depletions 1.0 0.000143348623853 1 0 1
while,you 1.0 0.000286697247706 2 0 2
a,nonlinear 1.0 0.000143348623853 0 1 -1
however,beta 1.0 0.000143348623853 0 1 -1
cmax,increased 1.0 0.000143348623853 1 0 1
avoid,additive 1.0 0.000143348623853 1 0 1
n,was 1.0 0.000143348623853 0 1 -1
that,dopamine 1.0 0.000143348623853 1 0 1
water,from 1.0 0.000143348623853 0 1 -1
have,several 1.0 0.000143348623853 0 1 -1
o,every 1.0 0.000143348623853 1 0 1
with,decreased 1.0 0.000143348623853 0 1 -1
abnormalities,and 1.0 0.000286697247706 2 0 2
the,experiments 1.0 0.000143348623853 0 1 -1
with,tuberculosis 0.0 0.0 1 1 0
cycle,duration 1.0 0.000143348623853 0 1 -1
without,disturbing 1.0 0.000143348623853 0 1 -1
unusually,high 1.0 0.000143348623853 1 0 1
coagulation,factors 1.0 0.000143348623853 0 1 -1
samples,does 1.0 0.000143348623853 0 1 -1
especially,true 1.0 0.000143348623853 0 1 -1
what,modern 1.0 0.000143348623853 0 1 -1
with,decreases 1.0 0.000143348623853 1 0 1
the,antagonism 1.0 0.000143348623853 1 0 1
trials,to 1.0 0.000143348623853 0 1 -1
increasing,its 1.0 0.000286697247706 2 0 2
pgp,may 1.0 0.000143348623853 0 1 -1
and,post-implantation 1.0 0.000143348623853 0 1 -1
pathway,showed 1.0 0.000143348623853 1 0 1
cns-active,has 1.0 0.000286697247706 0 2 -2
the,antagonist 1.0 0.000143348623853 0 1 -1
substitute,for 1.0 0.000573394495413 0 4 -4
small,or 1.0 0.000716743119266 0 5 -5
mug,or 1.0 0.000286697247706 0 2 -2
heart,disease 0.333333333333 0.000286697247706 2 4 -2
tremor,in 1.0 0.000143348623853 0 1 -1
small,initial 1.0 0.000143348623853 1 0 1
healthy,subjects 0.0909090909091 0.00043004587156 15 18 -3
acetate,stimulated 1.0 0.000143348623853 1 0 1
atorvastatin,plasma 1.0 0.000143348623853 0 1 -1
ketamine,marked 1.0 0.000143348623853 1 0 1
on,aliskiren 1.0 0.000143348623853 0 1 -1
substances,including 1.0 0.000143348623853 0 1 -1
not,tested 1.0 0.000143348623853 0 1 -1
least,six 1.0 0.000143348623853 0 1 -1
average,decreases 1.0 0.000143348623853 1 0 1
care,professional 1.0 0.000143348623853 1 0 1
metabolites,with 0.333333333333 0.000143348623853 1 2 -1
hours,postdose 1.0 0.000143348623853 1 0 1
for,periods 1.0 0.000143348623853 0 1 -1
nifedipine,vardenafil 1.0 0.000143348623853 0 1 -1
the,considerable 1.0 0.000143348623853 0 1 -1
drug,class 1.0 0.00043004587156 0 3 -3
hormones,such 1.0 0.000143348623853 1 0 1
syndrome,requires 1.0 0.000143348623853 0 1 -1
of,medicinal 1.0 0.000143348623853 1 0 1
c,or 1.0 0.000143348623853 0 1 -1
day,orally 1.0 0.000143348623853 1 0 1
requiring,treatment 1.0 0.000143348623853 0 1 -1
not,associated 1.0 0.000286697247706 0 2 -2
expression,by 1.0 0.000143348623853 0 1 -1
stimulant,type 1.0 0.000143348623853 0 1 -1
tend,to 1.0 0.000860091743119 0 6 -6
increase,the 0.232 0.00415711009174 77 48 29
neither,sodium 1.0 0.000143348623853 0 1 -1
lorazepam,coadministration 1.0 0.000143348623853 0 1 -1
which,eight 1.0 0.000143348623853 0 1 -1
magnesium,infusions 1.0 0.000143348623853 0 1 -1
of,interfere 1.0 0.000143348623853 1 0 1
including,tricor 1.0 0.000143348623853 1 0 1
nor,the 1.0 0.000143348623853 0 1 -1
kits,with 1.0 0.000143348623853 0 1 -1
laboratories,platelia 1.0 0.000286697247706 0 2 -2
safety,have 1.0 0.000716743119266 0 5 -5
this,phenomenon 1.0 0.000286697247706 0 2 -2
factor,concentration 1.0 0.000143348623853 0 1 -1
of,treatments 1.0 0.000143348623853 0 1 -1
of,eleven 1.0 0.000143348623853 1 0 1
to,prinivil 1.0 0.000143348623853 0 1 -1
oral,agents 0.75 0.000860091743119 1 7 -6
many,other 1.0 0.000860091743119 0 6 -6
depression,stupor 1.0 0.000143348623853 1 0 1
and,concomitantly 0.25 0.000286697247706 5 3 2
on,female 1.0 0.000143348623853 0 1 -1
ratios,confidence 1.0 0.000143348623853 0 1 -1
other,lesions 1.0 0.000143348623853 0 1 -1
the,biologic 1.0 0.000143348623853 1 0 1
and,hydroxides 0.333333333333 0.000143348623853 1 2 -1
recommended,due 1.0 0.00043004587156 3 0 3
to,accutane 1.0 0.000286697247706 0 2 -2
platelet,nucleotide 1.0 0.000143348623853 0 1 -1
for,patients 0.666666666667 0.00114678899083 2 10 -8
other,in 1.0 0.000286697247706 0 2 -2
but,may 0.111111111111 0.000143348623853 5 4 1
other,is 0.666666666667 0.000573394495413 1 5 -4
by,conjugation 1.0 0.000143348623853 0 1 -1
stop,any 1.0 0.000143348623853 0 1 -1
obstetrical,cardiological 1.0 0.000143348623853 0 1 -1
in,many 1.0 0.000143348623853 0 1 -1
food,see 1.0 0.000143348623853 0 1 -1
also,prolong 1.0 0.000143348623853 0 1 -1
by,lowering 1.0 0.000143348623853 1 0 1
analyzed,for 1.0 0.000286697247706 0 2 -2
be,weighed 0.333333333333 0.000143348623853 1 2 -1
molecular,weight 1.0 0.000143348623853 0 1 -1
from,multiple 1.0 0.000143348623853 0 1 -1
vitro,and 0.384615384615 0.000716743119266 4 9 -5
oral,inhaled 1.0 0.000143348623853 0 1 -1
altered,safety 1.0 0.000143348623853 0 1 -1
renal,elimination 0.5 0.000286697247706 1 3 -2
other,cardiovascular 1.0 0.000143348623853 0 1 -1
alcohol,g 1.0 0.000143348623853 0 1 -1
beta-receptor,agonist 1.0 0.000143348623853 0 1 -1
dose,reduced 1.0 0.000143348623853 1 0 1
weeks,after 0.142857142857 0.000143348623853 4 3 1
and,pancreatic 1.0 0.000143348623853 1 0 1
twice,a 1.0 0.00043004587156 0 3 -3
compounds,should 1.0 0.000286697247706 2 0 2
inhibitors,interfere 1.0 0.000143348623853 0 1 -1
and,except 1.0 0.000143348623853 0 1 -1
of,zebeta 0.333333333333 0.000143348623853 2 1 1
in,diabetes 1.0 0.000143348623853 0 1 -1
inr,should 1.0 0.000143348623853 1 0 1
cognitive,enhancing 1.0 0.000143348623853 0 1 -1
and,mcg 1.0 0.000286697247706 0 2 -2
if,mepron 1.0 0.000143348623853 0 1 -1
subjects,stabilized 1.0 0.000143348623853 1 0 1
of,reportedly 1.0 0.000143348623853 1 0 1
vasoconstrictive,action 1.0 0.000143348623853 1 0 1
transit,time 0.0 0.0 2 2 0
kg,per 0.0 0.0 1 1 0
so,formed 1.0 0.000143348623853 0 1 -1
amplitude,data 1.0 0.000143348623853 0 1 -1
patients,was 1.0 0.000143348623853 0 1 -1
and,cyp2d6 1.0 0.00043004587156 0 3 -3
addressing,information 1.0 0.000143348623853 0 1 -1
study,by 1.0 0.000143348623853 0 1 -1
globulin,tbg 1.0 0.000573394495413 0 4 -4
bradycardia,or 0.0 0.0 1 1 0
fumarate,seroquel 1.0 0.000143348623853 0 1 -1
l-glutamine,and 1.0 0.000286697247706 2 0 2
animals,were 1.0 0.00043004587156 0 3 -3
negative,on 1.0 0.000143348623853 0 1 -1
too,small 1.0 0.000143348623853 0 1 -1
receiving,itraconazole 1.0 0.000286697247706 2 0 2
possible,before 1.0 0.000143348623853 0 1 -1
small,yet 1.0 0.000143348623853 0 1 -1
krm-1648,either 1.0 0.000286697247706 0 2 -2
dose,selection 1.0 0.000143348623853 0 1 -1
of,viracept 0.5 0.000286697247706 1 3 -2
hot,drinks 1.0 0.000143348623853 0 1 -1
studies,document 1.0 0.000143348623853 0 1 -1
such,inactivation 1.0 0.000143348623853 0 1 -1
for,evaluating 1.0 0.000143348623853 0 1 -1
of,substrates 1.0 0.000143348623853 0 1 -1
the,gonadotropin 1.0 0.000143348623853 0 1 -1
inclusion,on 1.0 0.000143348623853 0 1 -1
with,described 1.0 0.000143348623853 0 1 -1
cells,for 1.0 0.000143348623853 0 1 -1
determined,prior 1.0 0.000143348623853 1 0 1
dose,proportional 1.0 0.000143348623853 0 1 -1
adolescent,presents 1.0 0.000143348623853 0 1 -1
if,any 0.333333333333 0.000286697247706 2 4 -2
with,torsades 1.0 0.000143348623853 0 1 -1
p-450,isozymes 1.0 0.000286697247706 2 0 2
state,level 1.0 0.000143348623853 0 1 -1
if,and 0.5 0.000286697247706 3 1 2
the,washout 1.0 0.000143348623853 0 1 -1
vioxx,antiplatelet 1.0 0.000143348623853 0 1 -1
other,antiplatelet 1.0 0.000143348623853 1 0 1
dose,and 0.2 0.000286697247706 4 6 -2
reported,examples 1.0 0.00043004587156 0 3 -3
therapy,are 1.0 0.000143348623853 1 0 1
a,higher 0.230769230769 0.00043004587156 5 8 -3
recordings,of 1.0 0.000286697247706 0 2 -2
and,both 1.0 0.00043004587156 0 3 -3
radioimmunoassay,or 1.0 0.000286697247706 0 2 -2
anti-cryptosporidial,activity 1.0 0.000143348623853 0 1 -1
of,toxicity 0.375 0.000860091743119 11 5 6
ganglion,hypogastric 1.0 0.000143348623853 0 1 -1
c,completely 1.0 0.000143348623853 1 0 1
and,herbs 1.0 0.000143348623853 1 0 1
criteria,was 1.0 0.000143348623853 0 1 -1
initiating,a 1.0 0.000143348623853 1 0 1
suggested,by 1.0 0.000143348623853 0 1 -1
caused,an 0.0 0.0 1 1 0
jejunal,net 1.0 0.000143348623853 0 1 -1
unaffected,by 0.714285714286 0.000716743119266 1 6 -5
day,monotherapy 1.0 0.000143348623853 0 1 -1
pipette,compared 1.0 0.000143348623853 0 1 -1
specific,to 1.0 0.000143348623853 0 1 -1
direct,cardiac 1.0 0.000143348623853 1 0 1
with,nalfon 1.0 0.000143348623853 1 0 1
in,balance 1.0 0.000143348623853 0 1 -1
minipills,that 1.0 0.000143348623853 1 0 1
fixed,g 1.0 0.000143348623853 0 1 -1
users,experiencing 1.0 0.000143348623853 0 1 -1
nevertheless,there 1.0 0.000143348623853 0 1 -1
only,requires 1.0 0.000143348623853 0 1 -1
tricyclic,metabolism 1.0 0.000143348623853 1 0 1
milk,ejection 1.0 0.000286697247706 0 2 -2
possible,decrease 0.5 0.000286697247706 3 1 2
caution,may 1.0 0.000143348623853 0 1 -1
were,approximately 0.0 0.0 1 1 0
be,affected 0.142857142857 0.000143348623853 3 4 -1
than,peak 1.0 0.000143348623853 0 1 -1
trials,a 1.0 0.000143348623853 0 1 -1
cssmax,of 1.0 0.000143348623853 0 1 -1
co-administration,mean 1.0 0.000143348623853 0 1 -1
from,high-estradiol 1.0 0.000143348623853 1 0 1
plenaxis,and 1.0 0.000143348623853 0 1 -1
clinical,use 0.333333333333 0.000143348623853 1 2 -1
enzymes,e1 1.0 0.000143348623853 0 1 -1
hypersensitive,to 1.0 0.000143348623853 1 0 1
uric,acid 0.333333333333 0.000143348623853 2 1 1
egf,ng 1.0 0.000143348623853 0 1 -1
to,inhibitors 1.0 0.000143348623853 0 1 -1
and,certainly 1.0 0.000143348623853 1 0 1
anti-inflammatory,nsaids 0.333333333333 0.000143348623853 2 1 1
inhibits,or 1.0 0.000143348623853 0 1 -1
daily,did 1.0 0.00114678899083 0 8 -8
reported,drug-laboratory 1.0 0.000286697247706 0 2 -2
the,carbachol-stimulated 1.0 0.000143348623853 1 0 1
higher,rate 1.0 0.000143348623853 0 1 -1
reductase,inhibitor 0.5 0.000286697247706 3 1 2
arrest,with 1.0 0.000143348623853 0 1 -1
plasma,enzymes 1.0 0.000143348623853 0 1 -1
cercariae,and 1.0 0.000143348623853 0 1 -1
are,extensively 1.0 0.000143348623853 1 0 1
into,patients 1.0 0.000143348623853 0 1 -1
l,with 1.0 0.000143348623853 0 1 -1
rhabdomyolysis,including 1.0 0.000143348623853 0 1 -1
of,metabolizing 1.0 0.000143348623853 0 1 -1
fluvoxamine,increased 1.0 0.000143348623853 1 0 1
fashion,to 1.0 0.000143348623853 0 1 -1
even,if 1.0 0.000286697247706 0 2 -2
the,pancreatic 1.0 0.000286697247706 0 2 -2
been,conflicting 1.0 0.000143348623853 1 0 1
or,less 0.5 0.000286697247706 1 3 -2
recently,received 1.0 0.000143348623853 1 0 1
dosage,reduction 1.0 0.000286697247706 0 2 -2
vidaza,and 1.0 0.000143348623853 0 1 -1
especially,resistant 1.0 0.000143348623853 0 1 -1
and,calcium-rich 1.0 0.000143348623853 1 0 1
studies,intravenous 1.0 0.000143348623853 0 1 -1
symptomatic,hyperlactatemia 1.0 0.000143348623853 0 1 -1
is,moderately 1.0 0.000143348623853 0 1 -1
compounds,block 1.0 0.000143348623853 0 1 -1
correlative,clinical 1.0 0.000143348623853 0 1 -1
coumarin-type,anticoagulants 1.0 0.000143348623853 0 1 -1
be,changed 1.0 0.000143348623853 0 1 -1
males,in 1.0 0.000143348623853 0 1 -1
promoter-vana,antisense 1.0 0.000143348623853 0 1 -1
arthritis,clinical 1.0 0.000143348623853 0 1 -1
after,extensive 1.0 0.000143348623853 0 1 -1
eproxindine,ethanol 1.0 0.000143348623853 1 0 1
demonstrated,widespread 1.0 0.000143348623853 0 1 -1
population,affected 1.0 0.000143348623853 0 1 -1
ritonavir,combined 1.0 0.000143348623853 0 1 -1
during,august 1.0 0.000143348623853 0 1 -1
inhalation,mefenamic 1.0 0.000143348623853 1 0 1
of,scotland 1.0 0.000143348623853 0 1 -1
dosing,interval 1.0 0.000143348623853 0 1 -1
of,cyp450 1.0 0.000286697247706 0 2 -2
and,after 1.0 0.000716743119266 0 5 -5
as,phlebitis 1.0 0.000143348623853 0 1 -1
tcamay,become 1.0 0.000143348623853 0 1 -1
of,acetylsalicylic 1.0 0.000286697247706 0 2 -2
with,compounds 1.0 0.000143348623853 1 0 1
with,mild 0.0 0.0 2 2 0
kg,twice 1.0 0.000143348623853 0 1 -1
as,p-glycoprotein 1.0 0.000143348623853 1 0 1
in,an 0.375 0.00258027522936 33 15 18
at,high 0.142857142857 0.000143348623853 3 4 -1
of,tyrosine 1.0 0.000143348623853 0 1 -1
supplements,oral 1.0 0.000143348623853 0 1 -1
serum,in 1.0 0.000143348623853 0 1 -1
is,probable 1.0 0.000143348623853 0 1 -1
sodium,following 1.0 0.000143348623853 0 1 -1
but,decreased 1.0 0.000143348623853 1 0 1
and,do 1.0 0.000286697247706 0 2 -2
more,pronounced 0.555555555556 0.000716743119266 2 7 -5
certain,concomitant 1.0 0.000286697247706 0 2 -2
and,minor 1.0 0.000143348623853 0 1 -1
concentrations,ranging 1.0 0.00043004587156 0 3 -3
x,complex 1.0 0.000286697247706 0 2 -2
or,tsh 1.0 0.000143348623853 0 1 -1
ketoconazole,has 1.0 0.000143348623853 1 0 1
and,north 1.0 0.000143348623853 0 1 -1
system,that 1.0 0.000286697247706 0 2 -2
been,isolated 1.0 0.00043004587156 3 0 3
extract,alone 1.0 0.000143348623853 0 1 -1
concentration,was 0.6 0.00043004587156 1 4 -3
effect,digitalis 1.0 0.000143348623853 1 0 1
inferior,mesenteric 1.0 0.000143348623853 0 1 -1
of,foods 1.0 0.000143348623853 0 1 -1
by,overcoming 1.0 0.000143348623853 0 1 -1
or,activase 1.0 0.000143348623853 0 1 -1
transdermal,with 1.0 0.000143348623853 1 0 1
of,ruthenium 1.0 0.000286697247706 0 2 -2
and,immediately 1.0 0.000143348623853 1 0 1
vitro,can 1.0 0.000143348623853 1 0 1
be,applied 1.0 0.000286697247706 0 2 -2
isoenzyme,cyp2d6 1.0 0.000143348623853 0 1 -1
with,physicians 1.0 0.000143348623853 0 1 -1
genotypes,of 1.0 0.000143348623853 0 1 -1
perfusion,in 1.0 0.000143348623853 0 1 -1
substrates,for 1.0 0.00129013761468 0 9 -9
succinylcholine,may 1.0 0.000143348623853 0 1 -1
admission,the 1.0 0.000143348623853 0 1 -1
between,novoseven 1.0 0.000143348623853 0 1 -1
certain,protease 1.0 0.000143348623853 0 1 -1
cyp3a,channel 1.0 0.000143348623853 0 1 -1
in,placental 1.0 0.000143348623853 0 1 -1
to,regimen 1.0 0.000143348623853 0 1 -1
may,inhibit 0.375 0.000860091743119 11 5 6
envisaged,in 1.0 0.000143348623853 0 1 -1
eliminate,the 1.0 0.000143348623853 1 0 1
it,be 1.0 0.000143348623853 1 0 1
traction,of 1.0 0.000143348623853 0 1 -1
cancers,were 1.0 0.000143348623853 0 1 -1
difluoroacetone,a 1.0 0.000143348623853 0 1 -1
the,latter 0.0 0.0 1 1 0
during,omnicef 1.0 0.000286697247706 2 0 2
whom,either 1.0 0.000143348623853 0 1 -1
related,anabolic 0.0 0.0 1 1 0
the,color 1.0 0.000143348623853 0 1 -1
cycles,of 1.0 0.000143348623853 0 1 -1
is,clinically 0.333333333333 0.000286697247706 4 2 2
treated,at 1.0 0.000143348623853 0 1 -1
that,sensitize 1.0 0.000143348623853 1 0 1
it,by 1.0 0.000143348623853 0 1 -1
the,auc 0.581395348837 0.00358371559633 34 9 25
netilmicin,should 1.0 0.000143348623853 1 0 1
or,abolish 1.0 0.000143348623853 1 0 1
and,class 1.0 0.000143348623853 1 0 1
in,excess 1.0 0.000143348623853 0 1 -1
to,mg 0.148936170213 0.00100344036697 20 27 -7
potently,enhanced 1.0 0.000143348623853 0 1 -1
meal,h 1.0 0.000143348623853 1 0 1
astramorph,kadian 1.0 0.000143348623853 1 0 1
thermal,analysis 1.0 0.000143348623853 0 1 -1
to,mm 1.0 0.000286697247706 0 2 -2
to,ml 0.0 0.0 2 2 0
neurontin,in 1.0 0.000143348623853 0 1 -1
inhibitory,potential 1.0 0.000143348623853 0 1 -1
both,mc 1.0 0.000143348623853 0 1 -1
decrease,extracellular 1.0 0.000143348623853 0 1 -1
was,reported 1.0 0.000143348623853 1 0 1
pharmacodynamic-related,interactions 1.0 0.000143348623853 0 1 -1
bacterial,mutagenicity 1.0 0.000143348623853 0 1 -1
conjugates,on 1.0 0.000143348623853 0 1 -1
was,lowered 1.0 0.000143348623853 1 0 1
cyp3a4,as 1.0 0.000286697247706 0 2 -2
its,primary 1.0 0.000143348623853 1 0 1
the,at 1.0 0.000143348623853 0 1 -1
non-nucleoside,reverse 0.5 0.000286697247706 1 3 -2
impairment,reportedly 1.0 0.000143348623853 1 0 1
breath,test 1.0 0.000143348623853 0 1 -1
be,continuously 1.0 0.000143348623853 1 0 1
hypoglycemic,action 1.0 0.000573394495413 4 0 4
utilization,including 1.0 0.000143348623853 1 0 1
attenuates,but 1.0 0.000143348623853 1 0 1
cyp2c8,cyp2c9 1.0 0.000143348623853 0 1 -1
myasthenia,gravis 1.0 0.000143348623853 1 0 1
kcl,mmol 1.0 0.000143348623853 0 1 -1
a,dose-dependent 0.428571428571 0.00043004587156 5 2 3
and,antithrombin 1.0 0.000286697247706 0 2 -2
minimized,to 1.0 0.000143348623853 0 1 -1
is,unlikely 1.0 0.00229357798165 0 16 -16
can,take 1.0 0.000143348623853 0 1 -1
and,mepron 1.0 0.000143348623853 1 0 1
mothers,fulvestrant 1.0 0.000143348623853 0 1 -1
activity,eg 1.0 0.000286697247706 2 0 2
ritonavir,coadministration 1.0 0.000143348623853 1 0 1
are,either 0.0 0.0 1 1 0
epirubicin-containing,cef-120 1.0 0.000143348623853 0 1 -1
over,a 0.333333333333 0.000143348623853 1 2 -1
pharmaceutical,treatment 1.0 0.000143348623853 0 1 -1
after,insertion 1.0 0.000143348623853 0 1 -1
biopharmaceutical,properties 1.0 0.000143348623853 0 1 -1
other,protein-bound 1.0 0.000143348623853 0 1 -1
by,non-steroidal 1.0 0.000143348623853 1 0 1
to,effects 0.0 0.0 1 1 0
considerably,lower 0.6 0.00043004587156 4 1 3
concomitantly,physicians 1.0 0.000143348623853 1 0 1
bleeding,in 1.0 0.000143348623853 1 0 1
gastrointestinal,secretion 1.0 0.000143348623853 1 0 1
other,components 1.0 0.000143348623853 0 1 -1
extremities,and 1.0 0.000286697247706 0 2 -2
and,diabetic 1.0 0.000143348623853 0 1 -1
was,pharmacodynamic 1.0 0.000286697247706 0 2 -2
bleeding,if 1.0 0.000143348623853 1 0 1
and,receptors 1.0 0.000143348623853 1 0 1
hypertension,where 1.0 0.000143348623853 0 1 -1
using,should 1.0 0.000143348623853 1 0 1
bleeding,is 1.0 0.000143348623853 0 1 -1
and,anticoagulants 1.0 0.000143348623853 1 0 1
this,potentiation 1.0 0.000143348623853 1 0 1
or,partly 1.0 0.000143348623853 0 1 -1
regimens,was 1.0 0.000143348623853 0 1 -1
inhibitors,acetylsalicylic 1.0 0.000143348623853 0 1 -1
amphetamines,can 0.0 0.0 1 1 0
substantially,the 1.0 0.000143348623853 1 0 1
humans,have 1.0 0.000573394495413 0 4 -4
are,hypersensitive 1.0 0.000143348623853 1 0 1
however,ldl-c 0.0 0.0 1 1 0
we,report 1.0 0.000143348623853 1 0 1
expected,to 0.210526315789 0.00114678899083 15 23 -8
weakness,may 1.0 0.000143348623853 1 0 1
asymptomatic,increases 1.0 0.000143348623853 0 1 -1
reach,maximum 1.0 0.000143348623853 0 1 -1
muscle,biopsy 1.0 0.000143348623853 0 1 -1
was,improved 1.0 0.000143348623853 0 1 -1
hepatic,insufficiency 1.0 0.000143348623853 0 1 -1
diabetic,individuals 1.0 0.000143348623853 0 1 -1
fed,further 1.0 0.000143348623853 0 1 -1
rabbits,dosed 1.0 0.000143348623853 0 1 -1
not,reported 0.0 0.0 2 2 0
major,clinical 1.0 0.000143348623853 1 0 1
and,organoleads 1.0 0.000143348623853 0 1 -1
pegasys,on 1.0 0.000143348623853 0 1 -1
female,volunteers 0.333333333333 0.000143348623853 1 2 -1
plasma,or 1.0 0.000286697247706 0 2 -2
several,clinically 1.0 0.000143348623853 0 1 -1
minimal,effects 1.0 0.000143348623853 0 1 -1
v,and 1.0 0.000286697247706 0 2 -2
substantially,greater 1.0 0.000143348623853 0 1 -1
plasma,of 1.0 0.000143348623853 0 1 -1
serotoninergic,central 1.0 0.000143348623853 0 1 -1
receive,these 1.0 0.000143348623853 0 1 -1
a,recent 1.0 0.000286697247706 2 0 2
this,appears 1.0 0.000143348623853 1 0 1
found,that 1.0 0.000143348623853 1 0 1
bleeding,have 1.0 0.000286697247706 2 0 2
concomitant,strong 1.0 0.000143348623853 0 1 -1
min,fasting 1.0 0.000143348623853 0 1 -1
inhibit,accumulation 1.0 0.000143348623853 1 0 1
metabolism,due 1.0 0.000143348623853 1 0 1
on,placental 1.0 0.000143348623853 0 1 -1
creatinine,and 1.0 0.000286697247706 2 0 2
cyp3a4,responsible 1.0 0.000143348623853 0 1 -1
show,any 1.0 0.000143348623853 0 1 -1
antagonists,co-administration 1.0 0.000143348623853 1 0 1
exhibit,a 1.0 0.000143348623853 1 0 1
significance,is 0.333333333333 0.000143348623853 1 2 -1
acid,metabolism 1.0 0.000286697247706 0 2 -2
lower,maintenance 1.0 0.000143348623853 1 0 1
these,six 1.0 0.000286697247706 0 2 -2
and,interactions 1.0 0.000286697247706 0 2 -2
of,cyp-2c19 1.0 0.000143348623853 0 1 -1
rats,arteries 1.0 0.000143348623853 0 1 -1
significance,if 1.0 0.000143348623853 0 1 -1
significance,in 1.0 0.000143348623853 0 1 -1
results,regarding 1.0 0.000143348623853 1 0 1
received,chop 1.0 0.000143348623853 0 1 -1
serum,electrolytes 1.0 0.000143348623853 0 1 -1
control,rats 1.0 0.000573394495413 0 4 -4
raise,the 0.0 0.0 3 3 0
appearing,on 1.0 0.000143348623853 0 1 -1
increasingly,important 1.0 0.000143348623853 0 1 -1
adequate,degree 1.0 0.000143348623853 0 1 -1
being,used 1.0 0.000286697247706 0 2 -2
receiving,could 1.0 0.000143348623853 0 1 -1
the,cure 0.0 0.0 1 1 0
concentrations,has 1.0 0.000573394495413 0 4 -4
contraceptives,an 1.0 0.000143348623853 1 0 1
renal,plasma 1.0 0.000286697247706 0 2 -2
or,dosage 1.0 0.000143348623853 0 1 -1
camp,in 1.0 0.000143348623853 0 1 -1
intramuscular,doses 1.0 0.000286697247706 0 2 -2
by,added 1.0 0.000143348623853 0 1 -1
cells,were 1.0 0.000143348623853 0 1 -1
argatroban,and 0.5 0.000286697247706 1 3 -2
only,n3 1.0 0.000143348623853 0 1 -1
toxicity,from 1.0 0.000143348623853 0 1 -1
short-acting,inhaled 1.0 0.000143348623853 0 1 -1
the,pharmacodynamic 0.75 0.000860091743119 1 7 -6
in,toxicity 1.0 0.000143348623853 1 0 1
antidepressant,class 1.0 0.000286697247706 0 2 -2
have,little 1.0 0.000143348623853 0 1 -1
on,them 1.0 0.000143348623853 0 1 -1
normal,variability 1.0 0.000143348623853 1 0 1
must,elapse 0.6 0.00043004587156 1 4 -3
arrest,during 1.0 0.000143348623853 0 1 -1
doubling,of 1.0 0.000143348623853 1 0 1
substrate,for 0.833333333333 0.00143348623853 1 11 -10
mechanism,s 1.0 0.000286697247706 0 2 -2
dolasetron,does 1.0 0.000143348623853 0 1 -1
max,and 1.0 0.000573394495413 0 4 -4
affect,their 1.0 0.000143348623853 0 1 -1
hypotension,seen 1.0 0.000143348623853 1 0 1
and,irrational 1.0 0.000143348623853 1 0 1
for,potentially 1.0 0.000143348623853 1 0 1
measured,toxicity 1.0 0.000143348623853 0 1 -1
haart,is 1.0 0.000286697247706 0 2 -2
inhibitors,nefazodone 1.0 0.000143348623853 0 1 -1
interactions,noted 1.0 0.000143348623853 0 1 -1
be,halved 1.0 0.000143348623853 1 0 1
aspects,of 1.0 0.000143348623853 0 1 -1
this,possibility 1.0 0.000143348623853 0 1 -1
vivo,it 1.0 0.000143348623853 0 1 -1
support,these 1.0 0.000143348623853 0 1 -1
hours,following 0.666666666667 0.000573394495413 1 5 -4
agent,known 1.0 0.000143348623853 0 1 -1
where,iressa 1.0 0.000143348623853 1 0 1
divided,attention 1.0 0.000143348623853 1 0 1
an,deficiency 1.0 0.000143348623853 1 0 1
tmp,and 1.0 0.000143348623853 0 1 -1
of,nmda 1.0 0.000143348623853 0 1 -1
fecal,blood 1.0 0.000143348623853 0 1 -1
nor,did 1.0 0.000143348623853 0 1 -1
doctor,if 0.333333333333 0.000143348623853 1 2 -1
with,krm-1648 1.0 0.000143348623853 1 0 1
times,the 0.733333333333 0.00157683486239 2 13 -11
and,careful 0.333333333333 0.000286697247706 2 4 -2
oral-dose,clearance 1.0 0.000143348623853 1 0 1
is,potentially 1.0 0.000143348623853 0 1 -1
the,interactions 0.5 0.000286697247706 1 3 -2
mefenamic,acid 0.333333333333 0.000143348623853 2 1 1
function,simultaneous 1.0 0.000143348623853 0 1 -1
see,if 1.0 0.000143348623853 1 0 1
more,susceptible 1.0 0.000143348623853 0 1 -1
inhibits,adp 1.0 0.000143348623853 0 1 -1
an,arbutamine-mediated 1.0 0.000143348623853 1 0 1
results,the 0.0 0.0 1 1 0
fourteen,days 1.0 0.000143348623853 0 1 -1
receive,tablets 1.0 0.000143348623853 0 1 -1
chronic,concurrent 1.0 0.000143348623853 1 0 1
nanm,were 0.0 0.0 1 1 0
certain,compounds 1.0 0.000143348623853 1 0 1
require,higher 1.0 0.000286697247706 0 2 -2
because,prostaglandina 1.0 0.000143348623853 1 0 1
the,sirolimus-diltiazem 1.0 0.000143348623853 1 0 1
test,was 1.0 0.000143348623853 0 1 -1
combination,therapies 1.0 0.000143348623853 0 1 -1
contractility,and 1.0 0.000143348623853 0 1 -1
on,cure 1.0 0.000143348623853 0 1 -1
threshold,voltage-dependent 1.0 0.00043004587156 0 3 -3
clolar,with 1.0 0.000143348623853 0 1 -1
rifampin,co-administration 1.0 0.000143348623853 1 0 1
nonlinear,kinetic 1.0 0.000143348623853 0 1 -1
acid,increased 1.0 0.000143348623853 1 0 1
activity,based 1.0 0.000143348623853 0 1 -1
concentration,ranges 1.0 0.000143348623853 0 1 -1
coadministering,medications 1.0 0.000143348623853 0 1 -1
decrease,serum 0.0 0.0 2 2 0
the,hazards 1.0 0.000143348623853 0 1 -1
while,it 1.0 0.000143348623853 0 1 -1
probably,at 1.0 0.000143348623853 1 0 1
esomeprazole,may 1.0 0.000143348623853 0 1 -1
while,in 1.0 0.000143348623853 0 1 -1
opioid,analgesics 1.0 0.000143348623853 1 0 1
prospective,clinical 1.0 0.000143348623853 0 1 -1
partially,impaired 1.0 0.000143348623853 0 1 -1
sodium,including 1.0 0.000286697247706 2 0 2
the,pi 1.0 0.000143348623853 0 1 -1
convulsions,occurring 1.0 0.000143348623853 0 1 -1
reported,among 1.0 0.000286697247706 2 0 2
the,antioxidative 1.0 0.000143348623853 0 1 -1
however,reduced 1.0 0.000143348623853 1 0 1
experimental,animals 1.0 0.000143348623853 0 1 -1
are,employed 1.0 0.000143348623853 1 0 1
had,opioid-antagonist 1.0 0.000143348623853 0 1 -1
done,at 1.0 0.000286697247706 0 2 -2
medical,examinations 1.0 0.000143348623853 0 1 -1
other,plasma 1.0 0.000286697247706 0 2 -2
nsaids,like 1.0 0.000143348623853 1 0 1
monitored,they 1.0 0.000143348623853 0 1 -1
for,urinary 1.0 0.000573394495413 0 4 -4
benefit,of 0.0 0.0 1 1 0
red,blood 1.0 0.000143348623853 0 1 -1
natural,history 1.0 0.000143348623853 0 1 -1
with,commonly 1.0 0.000573394495413 0 4 -4
metabolism,by 0.5 0.000286697247706 1 3 -2
trends,are 1.0 0.000143348623853 0 1 -1
first-line,therapy 1.0 0.000143348623853 0 1 -1
medicine,that 1.0 0.000143348623853 1 0 1
a,study 0.1 0.000573394495413 22 18 4
study,rats 1.0 0.000143348623853 1 0 1
acetazolamide,azole 1.0 0.000143348623853 1 0 1
mask,the 0.333333333333 0.000143348623853 1 2 -1
when,concurrent 1.0 0.000286697247706 0 2 -2
with,angina 1.0 0.000143348623853 1 0 1
deaths,from 1.0 0.000143348623853 1 0 1
frequent,cause 1.0 0.000143348623853 1 0 1
of,neoplasia 1.0 0.000143348623853 0 1 -1
employing,mtc-mdp 1.0 0.000143348623853 0 1 -1
seizures,when 1.0 0.000286697247706 0 2 -2
than,recommended 1.0 0.000143348623853 1 0 1
primarily,eliminated 1.0 0.000143348623853 0 1 -1
relaxant,effect 1.0 0.000143348623853 1 0 1
environmental,may 1.0 0.000143348623853 1 0 1
initial,treatment 1.0 0.000286697247706 0 2 -2
net,fluid 1.0 0.000143348623853 0 1 -1
taxol,concomitantly 1.0 0.000143348623853 0 1 -1
of,steady-state 1.0 0.000286697247706 0 2 -2
concentration,data 1.0 0.000143348623853 0 1 -1
potentially,clinically 1.0 0.000143348623853 0 1 -1
the,population 1.0 0.00043004587156 0 3 -3
cause,additive 1.0 0.000143348623853 1 0 1
contraception,inwomen 1.0 0.000143348623853 1 0 1
calcium,antagonists 1.0 0.000143348623853 1 0 1
sensitivity,of 1.0 0.00043004587156 0 3 -3
longer,marketed 1.0 0.000143348623853 0 1 -1
chemotherapy,regimen 1.0 0.000143348623853 0 1 -1
with,extracellular 1.0 0.000143348623853 1 0 1
reduced,interaction 1.0 0.000143348623853 0 1 -1
isoproterenol,alone 1.0 0.000143348623853 0 1 -1
to,determine 0.333333333333 0.00114678899083 8 16 -8
pegasys,to 1.0 0.000143348623853 0 1 -1
calcium-entry,blocking 1.0 0.000143348623853 0 1 -1
from,study 1.0 0.000143348623853 0 1 -1
increasing,the 0.6 0.00129013761468 12 3 9
n,mean 1.0 0.000143348623853 1 0 1
absorption,as 1.0 0.000143348623853 0 1 -1
that,peak 1.0 0.000143348623853 0 1 -1
tablets,compared 1.0 0.000143348623853 0 1 -1
for,extravasation 1.0 0.000143348623853 0 1 -1
uptake,and 1.0 0.000143348623853 1 0 1
during,this 1.0 0.000143348623853 0 1 -1
in,mind 0.2 0.000143348623853 2 3 -1
medicine,with 1.0 0.000286697247706 0 2 -2
than,and 0.6 0.00043004587156 1 4 -3
including,reactions 1.0 0.000143348623853 0 1 -1
incompatibility,of 1.0 0.000286697247706 0 2 -2
inhibitor,is 0.333333333333 0.000143348623853 1 2 -1
inhibitor,it 1.0 0.000143348623853 1 0 1
capsules,mg 0.0 0.0 1 1 0
had,depleting 1.0 0.000143348623853 0 1 -1
polyphenols,as 1.0 0.000143348623853 0 1 -1
inhibitor,in 0.333333333333 0.000143348623853 1 2 -1
drugs,with 0.6 0.00043004587156 1 4 -3
in,surgery 1.0 0.000143348623853 0 1 -1
range,when 1.0 0.000143348623853 0 1 -1
test,agent 1.0 0.000143348623853 0 1 -1
are,suddenly 1.0 0.000143348623853 0 1 -1
of,myocardial 1.0 0.000286697247706 0 2 -2
and,infusion 1.0 0.000143348623853 1 0 1
moreover,the 1.0 0.00043004587156 0 3 -3
was,made 1.0 0.000143348623853 0 1 -1
the,disruptive 1.0 0.000143348623853 1 0 1
having,similar 1.0 0.000143348623853 1 0 1
occur,at 1.0 0.000143348623853 0 1 -1
contraception,simultaneously 1.0 0.000143348623853 0 1 -1
relaxants,has 1.0 0.000143348623853 0 1 -1
phencyclidine,pcp 1.0 0.000143348623853 0 1 -1
or,peripheral 1.0 0.000143348623853 0 1 -1
be,caused 1.0 0.000143348623853 0 1 -1
given,should 1.0 0.000286697247706 2 0 2
possible,pharmacodynamic 1.0 0.000143348623853 1 0 1
determining,the 1.0 0.000143348623853 0 1 -1
sular,with 1.0 0.000143348623853 1 0 1
the,importance 1.0 0.00043004587156 0 3 -3
a,well-defined 1.0 0.000143348623853 0 1 -1
pqq-based,methods 1.0 0.000143348623853 0 1 -1
the,adequacy 1.0 0.000143348623853 0 1 -1
the,stimulatory 1.0 0.000143348623853 1 0 1
on,p450 1.0 0.000143348623853 0 1 -1
later,by 1.0 0.000143348623853 0 1 -1
vs,spared 1.0 0.000143348623853 0 1 -1
active,triphosphate 1.0 0.000143348623853 0 1 -1
developing,an 1.0 0.000143348623853 1 0 1
therapy,such 0.0 0.0 1 1 0
felbatol,the 1.0 0.000286697247706 0 2 -2
tambocor,clinical 1.0 0.000143348623853 0 1 -1
in,conditions 1.0 0.000143348623853 0 1 -1
and,glycemic 1.0 0.000143348623853 0 1 -1
subsequent,diagnostic 1.0 0.000143348623853 0 1 -1
potential,prolonged 1.0 0.000143348623853 0 1 -1
ethanol-drug,reaction 1.0 0.000143348623853 0 1 -1
patient,to 0.0 0.0 1 1 0
however,preliminary 1.0 0.000143348623853 0 1 -1
secretion,are 1.0 0.000286697247706 0 2 -2
with,accutane 1.0 0.000143348623853 1 0 1
and,norethindrone 1.0 0.000143348623853 1 0 1
sample,of 1.0 0.000143348623853 0 1 -1
at,either 1.0 0.000143348623853 0 1 -1
reported,musculoskeletal 1.0 0.000143348623853 0 1 -1
and,arthralgia 1.0 0.000143348623853 1 0 1
intravenous,sodium 0.0 0.0 1 1 0
enzyme,that 1.0 0.000143348623853 0 1 -1
advised,in 0.111111111111 0.000143348623853 4 5 -1
p-aminosalicylic,acid 1.0 0.000143348623853 0 1 -1
experience,increased 1.0 0.000143348623853 0 1 -1
advised,if 1.0 0.000573394495413 0 4 -4
consideration,before 1.0 0.000143348623853 0 1 -1
proteins,of 1.0 0.000143348623853 0 1 -1
easy,and 1.0 0.000143348623853 0 1 -1
is,small 0.0 0.0 1 1 0
therapy,when 1.0 0.000143348623853 1 0 1
take,to 1.0 0.000143348623853 0 1 -1
to,encystment 1.0 0.000143348623853 0 1 -1
sarcoma,taxol 1.0 0.000143348623853 0 1 -1
of,wheal 1.0 0.000143348623853 0 1 -1
effect,of 0.148514851485 0.0043004587156 86 116 -30
with,potassium-sparing 0.0 0.0 1 1 0
effect,on 0.640287769784 0.0127580275229 25 114 -89
these,other 1.0 0.000573394495413 0 4 -4
solution,with 1.0 0.000143348623853 0 1 -1
of,methotrexate-related 1.0 0.000286697247706 2 0 2
of,spontaneous 0.0 0.0 2 2 0
health,objectives 1.0 0.000143348623853 0 1 -1
an,anionic-binding 1.0 0.000143348623853 1 0 1
inspra,and 1.0 0.000143348623853 1 0 1
was,inadequate 1.0 0.000143348623853 0 1 -1
area,under 0.333333333333 0.000716743119266 10 5 5
proportion,to 1.0 0.000143348623853 0 1 -1
electrocardiogram,and 1.0 0.000143348623853 0 1 -1
is,inadvisable 1.0 0.000143348623853 1 0 1
cyp2d6,with 1.0 0.000143348623853 0 1 -1
health,organization 1.0 0.000143348623853 0 1 -1
recorded,while 1.0 0.000143348623853 0 1 -1
using,pocs 1.0 0.000143348623853 0 1 -1
indicating,strong 1.0 0.000143348623853 0 1 -1
in,life-threatening 1.0 0.000143348623853 0 1 -1
it,may 0.666666666667 0.00114678899083 2 10 -8
monitored,closely 0.0909090909091 0.000143348623853 6 5 1
cyp450,enzymes 1.0 0.000143348623853 0 1 -1
also,result 1.0 0.000573394495413 4 0 4
including,both 1.0 0.000143348623853 1 0 1
subject,received 1.0 0.000143348623853 0 1 -1
cell,or 1.0 0.000143348623853 0 1 -1
chop,patients 1.0 0.00043004587156 0 3 -3
t3,levels 1.0 0.000286697247706 0 2 -2
cell,of 1.0 0.000143348623853 0 1 -1
each,significantly 1.0 0.000143348623853 0 1 -1
kg,via 1.0 0.000143348623853 1 0 1
alone,can 0.0 0.0 1 1 0
administered,have 1.0 0.000143348623853 0 1 -1
anagrelide,is 1.0 0.000286697247706 0 2 -2
alternatively,the 1.0 0.000143348623853 0 1 -1
and,subsalicylate 1.0 0.000143348623853 1 0 1
cyp2a6,and 1.0 0.000143348623853 0 1 -1
protein,and 1.0 0.000143348623853 0 1 -1
or,altering 1.0 0.000143348623853 0 1 -1
inhibit,cyp3a 1.0 0.000143348623853 0 1 -1
about,times 1.0 0.000573394495413 0 4 -4
conversion,could 1.0 0.000143348623853 0 1 -1
precede,dosing 1.0 0.000143348623853 0 1 -1
agranulocytosis,as 1.0 0.000143348623853 0 1 -1
effect,although 1.0 0.000143348623853 0 1 -1
adrenergic,are 1.0 0.000143348623853 1 0 1
no,drug-drug 1.0 0.000286697247706 0 2 -2
rash,pruritus 1.0 0.000143348623853 0 1 -1
the,several-fold 1.0 0.000143348623853 0 1 -1
a4,but 1.0 0.000286697247706 0 2 -2
warned,of 0.5 0.000286697247706 1 3 -2
stable,therapy 1.0 0.000143348623853 0 1 -1
premature,ventricular 1.0 0.000143348623853 0 1 -1
if,or 0.333333333333 0.000143348623853 2 1 1
were,and 0.6 0.00043004587156 1 4 -3
and,antidiuretic 1.0 0.000143348623853 0 1 -1
sigma-2,receptors 1.0 0.000143348623853 0 1 -1
kind,with 1.0 0.000143348623853 1 0 1
whether,to 1.0 0.00043004587156 0 3 -3
lipid,metabolism 1.0 0.000143348623853 0 1 -1
between,revia 1.0 0.000143348623853 0 1 -1
soriatane,therapy 1.0 0.000143348623853 0 1 -1
hippocampal,adenylate 1.0 0.000143348623853 0 1 -1
utero,serum 1.0 0.000143348623853 0 1 -1
stomach,to 1.0 0.000143348623853 1 0 1
from,severe 1.0 0.000143348623853 1 0 1
undetectable,ng 1.0 0.000143348623853 0 1 -1
reversal,in 1.0 0.000143348623853 0 1 -1
may,activate 1.0 0.000143348623853 0 1 -1
the,exogenous 1.0 0.000143348623853 0 1 -1
similar,among 1.0 0.000143348623853 0 1 -1
hypericum,perforatum 1.0 0.00043004587156 0 3 -3
action,on 0.0 0.0 2 2 0
with,faslodex 1.0 0.000143348623853 0 1 -1
effective,and 1.0 0.000143348623853 0 1 -1
action,of 0.450980392157 0.00329701834862 37 14 23
altered,plasma 1.0 0.000143348623853 0 1 -1
were,stabilized 1.0 0.000286697247706 0 2 -2
phenytoin,protease 1.0 0.000143348623853 1 0 1
myocarditis,ventricular 1.0 0.000143348623853 1 0 1
and,antagonists 1.0 0.000286697247706 2 0 2
and,ischemia 1.0 0.000286697247706 0 2 -2
action,or 1.0 0.000286697247706 0 2 -2
monooxygenase,activities 1.0 0.000143348623853 0 1 -1
or,multiple 1.0 0.000143348623853 0 1 -1
has,slight 1.0 0.000143348623853 0 1 -1
the,frequent 1.0 0.000143348623853 0 1 -1
prostatic,hyperplasia 1.0 0.000143348623853 0 1 -1
the,anxiogenic 1.0 0.000143348623853 1 0 1
by,qtc 1.0 0.000286697247706 0 2 -2
hours,does 1.0 0.000286697247706 2 0 2
pharmacological,properties 1.0 0.000143348623853 0 1 -1
showed,the 1.0 0.000286697247706 0 2 -2
the,hydroxytamoxifen 1.0 0.000143348623853 0 1 -1
broadening,indications 1.0 0.000143348623853 0 1 -1
increased,when 0.428571428571 0.00043004587156 5 2 3
larger,doses 0.6 0.00043004587156 1 4 -3
retrospective,studies 1.0 0.000143348623853 0 1 -1
and,racemic 1.0 0.000143348623853 0 1 -1
visual,analogue 1.0 0.000143348623853 0 1 -1
the,efflux 1.0 0.000143348623853 0 1 -1
correct,the 1.0 0.000143348623853 0 1 -1
oral,with 1.0 0.000286697247706 2 0 2
maximizing,therapy 1.0 0.000143348623853 0 1 -1
other,concomitant 1.0 0.000716743119266 0 5 -5
determinations,are 1.0 0.00043004587156 0 3 -3
include,such 1.0 0.000143348623853 0 1 -1
alternative,or 0.0 0.0 1 1 0
by,reaction 1.0 0.000143348623853 0 1 -1
alternately,when 1.0 0.000143348623853 0 1 -1
cmi,because 1.0 0.000143348623853 1 0 1
of,coronary 1.0 0.000143348623853 0 1 -1
estimates,of 1.0 0.000860091743119 0 6 -6
linked,to 1.0 0.000143348623853 0 1 -1
depressants,other 1.0 0.000143348623853 0 1 -1
decreased,along 1.0 0.000143348623853 0 1 -1
their,corresponding 1.0 0.000143348623853 0 1 -1
use,only 1.0 0.000143348623853 0 1 -1
with,less 1.0 0.00043004587156 0 3 -3
catechol-o,methyltransferase 1.0 0.000143348623853 0 1 -1
containing,mg 0.5 0.000286697247706 1 3 -2
resveratrol,micromol 1.0 0.000143348623853 0 1 -1
in,states 1.0 0.000143348623853 0 1 -1
myopathy,which 1.0 0.000143348623853 0 1 -1
family,education 1.0 0.000143348623853 0 1 -1
initiation,of 0.266666666667 0.00114678899083 19 11 8
background,since 1.0 0.000143348623853 0 1 -1
first-pass,metabolism 1.0 0.000286697247706 0 2 -2
receptors,to 1.0 0.000143348623853 0 1 -1
acute,administration 1.0 0.000143348623853 0 1 -1
in,cortisol 1.0 0.000143348623853 0 1 -1
to,deaths 1.0 0.000143348623853 0 1 -1
variations,in 1.0 0.000143348623853 0 1 -1
addition,based 1.0 0.000143348623853 0 1 -1
gleevec,oral-dose 1.0 0.000143348623853 1 0 1
epidural,local 1.0 0.000143348623853 1 0 1
diseases,of 1.0 0.000143348623853 0 1 -1
chapter,considers 1.0 0.000143348623853 0 1 -1
may,subsequently 1.0 0.000143348623853 0 1 -1
a,nonlethal 0.0 0.0 1 1 0
this,pathogen 1.0 0.000143348623853 0 1 -1
respectively,and 1.0 0.000573394495413 4 0 4
uncertain,mechanism 1.0 0.000143348623853 0 1 -1
flushing,skin 1.0 0.000143348623853 0 1 -1
lotensin,can 1.0 0.000286697247706 2 0 2
precautions,and 1.0 0.000143348623853 0 1 -1
and,implications 1.0 0.000143348623853 0 1 -1
synthesis,in 1.0 0.000143348623853 0 1 -1
lexapro,is 1.0 0.000143348623853 1 0 1
synthesis,it 1.0 0.000143348623853 1 0 1
high,dose 0.5 0.000286697247706 3 1 2
finding,is 1.0 0.000143348623853 0 1 -1
the,probable 1.0 0.000143348623853 1 0 1
mean,steady-state 0.0 0.0 1 1 0
platelet,antiaggregant 1.0 0.000143348623853 0 1 -1
furosemide,administered 1.0 0.000143348623853 0 1 -1
or,prolactin 1.0 0.000143348623853 0 1 -1
mcg,ml 1.0 0.000143348623853 0 1 -1
diethyl,pyrocarbonate 1.0 0.000573394495413 0 4 -4
the,resolution 1.0 0.000143348623853 1 0 1
time,scale 1.0 0.000143348623853 0 1 -1
not,inhibitory 1.0 0.000143348623853 0 1 -1
cevimeline,should 0.0 0.0 1 1 0
with,each 0.0 0.0 2 2 0
not,inhibitors 1.0 0.000143348623853 0 1 -1
pra,as 1.0 0.000143348623853 0 1 -1
at,low-levels 1.0 0.000143348623853 0 1 -1
administering,mepron 1.0 0.000143348623853 0 1 -1
as,sulfamethoxazole-trimethoprim 1.0 0.000143348623853 0 1 -1
lower,plasma 0.6 0.00043004587156 4 1 3
oxcarbazepine,was 1.0 0.000143348623853 0 1 -1
of,fludara 1.0 0.000143348623853 1 0 1
sequestrants,may 1.0 0.000143348623853 1 0 1
agents,on 1.0 0.000143348623853 0 1 -1
coelenterates,of 1.0 0.000143348623853 0 1 -1
cholestyramine,the 1.0 0.000143348623853 0 1 -1
responses,being 1.0 0.000143348623853 0 1 -1
agents,of 0.5 0.000286697247706 1 3 -2
is,changed 0.0 0.0 1 1 0
or,stopping 0.333333333333 0.000143348623853 1 2 -1
the,neuron 1.0 0.000143348623853 1 0 1
with,release 1.0 0.000143348623853 0 1 -1
a,rauwolfia 1.0 0.000143348623853 1 0 1
of,min 1.0 0.000286697247706 2 0 2
fraction,fdf 1.0 0.000143348623853 1 0 1
contraceptives,a 1.0 0.000143348623853 0 1 -1
atracurium,was 1.0 0.000143348623853 0 1 -1
the,microsomal 1.0 0.000573394495413 0 4 -4
if,are 1.0 0.000143348623853 1 0 1
that,this 1.0 0.00043004587156 0 3 -3
day,when 1.0 0.00043004587156 3 0 3
by,repeated 1.0 0.000143348623853 0 1 -1
be,advocated 1.0 0.000143348623853 0 1 -1
subjects,and 1.0 0.000143348623853 1 0 1
levels,increased 1.0 0.000286697247706 2 0 2
withdrawal,syndrome 1.0 0.000143348623853 1 0 1
reached,on 1.0 0.000143348623853 0 1 -1
reversible,reduction 1.0 0.000143348623853 0 1 -1
should,take 0.0 0.0 1 1 0
and,clotibrate 1.0 0.000143348623853 0 1 -1
significant,hyperprolactinaemia 1.0 0.000143348623853 0 1 -1
use,glucose 1.0 0.000143348623853 0 1 -1
and,hivid 1.0 0.000143348623853 1 0 1
patient,on 1.0 0.000286697247706 2 0 2
the,translocating 1.0 0.000143348623853 0 1 -1
on,absorption 0.5 0.000286697247706 1 3 -2
does,not 0.87012987013 0.00960435779817 5 72 -67
system,is 1.0 0.000286697247706 0 2 -2
conditions,concentrations 1.0 0.000143348623853 0 1 -1
stomach,drugs 1.0 0.000143348623853 1 0 1
patient,or 1.0 0.000286697247706 0 2 -2
first,post-transplant 1.0 0.000143348623853 0 1 -1
several,which 1.0 0.000143348623853 0 1 -1
not,affect 0.833333333333 0.00573394495413 4 44 -40
delirium,high 1.0 0.000143348623853 1 0 1
arrhythmias,have 0.0 0.0 1 1 0
severe,autonomic 1.0 0.000143348623853 0 1 -1
membrane,was 1.0 0.000143348623853 0 1 -1
with,signs 1.0 0.000143348623853 1 0 1
effectively,and 1.0 0.000143348623853 0 1 -1
agents,prinivil 1.0 0.000143348623853 0 1 -1
kill,curves 1.0 0.000143348623853 1 0 1
an,evaluation 1.0 0.000143348623853 0 1 -1
of,wellbutrin 0.333333333333 0.000143348623853 2 1 1
usual,doses 1.0 0.000860091743119 0 6 -6
and,weight 1.0 0.000286697247706 2 0 2
to,times 1.0 0.000286697247706 0 2 -2
cyp2c9,cyp2d6 1.0 0.00043004587156 0 3 -3
alpha-,or 1.0 0.000143348623853 0 1 -1
taking,medications 1.0 0.000286697247706 0 2 -2
between,the 0.764705882353 0.00186353211009 2 15 -13
nonsedating,and 1.0 0.000143348623853 1 0 1
no,special 1.0 0.000143348623853 0 1 -1
the,depth 1.0 0.000143348623853 1 0 1
further,is 1.0 0.000143348623853 0 1 -1
rifampin,is 1.0 0.000143348623853 0 1 -1
are,poorly 1.0 0.000143348623853 0 1 -1
n3,showing 1.0 0.000143348623853 0 1 -1
with,wellbutrin 1.0 0.000143348623853 1 0 1
serum,endogenous 1.0 0.00043004587156 0 3 -3
physiology,the 1.0 0.000143348623853 0 1 -1
hormone,response 1.0 0.000143348623853 1 0 1
johns,wort 0.666666666667 0.000573394495413 1 5 -4
coadministered,steady-state 1.0 0.000143348623853 1 0 1
gets,absorbed 1.0 0.000143348623853 1 0 1
was,concluded 0.0 0.0 1 1 0
could,occur 1.0 0.000143348623853 0 1 -1
for,mec 1.0 0.000143348623853 0 1 -1
hydrochloride,was 0.333333333333 0.000143348623853 1 2 -1
cyclic,may 1.0 0.000143348623853 1 0 1
gland,who 1.0 0.000286697247706 2 0 2
concomitant,hydrochloride 1.0 0.000143348623853 0 1 -1
unknown,how 1.0 0.000143348623853 0 1 -1
reactions,is 0.0 0.0 1 1 0
constant,volume 1.0 0.000143348623853 0 1 -1
effectiveness,is 1.0 0.000143348623853 0 1 -1
oxo-desethylzaleplon,glucuronide 1.0 0.000143348623853 0 1 -1
chronically,ill 1.0 0.000143348623853 0 1 -1
single,metal 1.0 0.000286697247706 0 2 -2
effectiveness,in 1.0 0.00043004587156 0 3 -3
of,unprotected 1.0 0.000143348623853 0 1 -1
reactions,in 1.0 0.00043004587156 0 3 -3
augmented,the 0.0 0.0 1 1 0
the,animal 1.0 0.000143348623853 0 1 -1
the,pharmacology 0.5 0.000286697247706 1 3 -2
advised,digoxin 1.0 0.000143348623853 0 1 -1
interval,whole 1.0 0.000143348623853 1 0 1
displace,tightly 1.0 0.000143348623853 0 1 -1
other,antineoplastic 1.0 0.000143348623853 1 0 1
a,vitamin 0.0 0.0 1 1 0
with,repeated 1.0 0.000143348623853 0 1 -1
agents,enalapril 1.0 0.000143348623853 0 1 -1
in,female 1.0 0.00100344036697 0 7 -7
a,follow-up 1.0 0.000143348623853 0 1 -1
time-curve,increased 1.0 0.000143348623853 1 0 1
of,baraclude 1.0 0.000286697247706 0 2 -2
just,prior 1.0 0.000143348623853 0 1 -1
whose,mothers 1.0 0.000286697247706 0 2 -2
any,clinically 1.0 0.000860091743119 0 6 -6
as,which 1.0 0.000143348623853 1 0 1
at,that 1.0 0.000143348623853 0 1 -1
after,ethyl 1.0 0.000143348623853 1 0 1
one,strain 1.0 0.000143348623853 0 1 -1
month,of 1.0 0.000143348623853 0 1 -1
inhibited,high 1.0 0.000143348623853 0 1 -1
or,dialysis 1.0 0.000143348623853 1 0 1
chills,nausea 1.0 0.000143348623853 0 1 -1
redundancy,at 1.0 0.000143348623853 0 1 -1
drug-induced,cns-related 1.0 0.000143348623853 0 1 -1
indomethacin,may 1.0 0.000143348623853 0 1 -1
consequences,could 1.0 0.000143348623853 0 1 -1
peptide,and 1.0 0.000143348623853 0 1 -1
cholinesterase,inhibitors 1.0 0.000286697247706 2 0 2
parenteral,should 1.0 0.000143348623853 1 0 1
socioeconomic,factors 1.0 0.000143348623853 0 1 -1
the,serotonergic 1.0 0.000143348623853 1 0 1
d,of 1.0 0.000143348623853 0 1 -1
ibogaine,produces 1.0 0.000143348623853 0 1 -1
been,completed 1.0 0.000143348623853 0 1 -1
induced,locomotion 1.0 0.000143348623853 0 1 -1
d,or 0.0 0.0 1 1 0
patients,are 0.0 0.0 3 3 0
conduction,through 1.0 0.000143348623853 1 0 1
or,fr 1.0 0.000143348623853 1 0 1
unexplored,area 1.0 0.000143348623853 0 1 -1
can,prevent 1.0 0.000143348623853 0 1 -1
not,produce 1.0 0.000573394495413 0 4 -4
ccnu,is 1.0 0.000143348623853 0 1 -1
a,href 1.0 0.000286697247706 2 0 2
after,chronic 1.0 0.000143348623853 0 1 -1
that,appears 1.0 0.000143348623853 0 1 -1
organ,transplant 1.0 0.000143348623853 1 0 1
anticonvulsants,in 1.0 0.000143348623853 1 0 1
because,renal 1.0 0.000143348623853 1 0 1
as,psoriasis 1.0 0.000143348623853 0 1 -1
degrees,of 0.0 0.0 2 2 0
atorvastatin,atorvastatin 1.0 0.000143348623853 1 0 1
is,administered 0.463414634146 0.00272362385321 30 11 19
that,resemble 1.0 0.000143348623853 0 1 -1
dosing,reduced 1.0 0.000143348623853 0 1 -1
of,polyenes 1.0 0.000143348623853 0 1 -1
employed,cautiously 1.0 0.000143348623853 0 1 -1
kd,of 1.0 0.000286697247706 0 2 -2
of,locomotor 1.0 0.000143348623853 0 1 -1
findings,in 1.0 0.000143348623853 0 1 -1
failure,elevated 1.0 0.000143348623853 0 1 -1
erbitux,was 1.0 0.000143348623853 0 1 -1
and,min 0.333333333333 0.000143348623853 2 1 1
during,initial 1.0 0.000143348623853 0 1 -1
reverse,resistance 1.0 0.000143348623853 0 1 -1
particularly,diabetics 1.0 0.000143348623853 1 0 1
contraceptives,the 1.0 0.000143348623853 0 1 -1
dogs,one 1.0 0.000143348623853 0 1 -1
both,and 0.0 0.0 11 11 0
renal,retention 1.0 0.000143348623853 0 1 -1
at,arterial 1.0 0.000143348623853 0 1 -1
quetiapine,fumarate 1.0 0.000143348623853 0 1 -1
hormonal,increasing 1.0 0.000143348623853 1 0 1
as,one 1.0 0.000143348623853 0 1 -1
since,higher 1.0 0.000143348623853 1 0 1
enterococcus,three 1.0 0.000143348623853 0 1 -1
components,n1 1.0 0.000143348623853 0 1 -1
medications,should 1.0 0.00043004587156 0 3 -3
produced,plasma 1.0 0.000143348623853 0 1 -1
qd,cohort 1.0 0.000143348623853 0 1 -1
day,increased 1.0 0.000143348623853 1 0 1
was,grams 1.0 0.000143348623853 0 1 -1
identified,that 1.0 0.000143348623853 0 1 -1
isrecommended,in 1.0 0.000143348623853 1 0 1
integrifolia,jackfruit 1.0 0.000143348623853 0 1 -1
no,information 1.0 0.000716743119266 0 5 -5
important,that 0.5 0.000286697247706 1 3 -2
dl,were 1.0 0.000143348623853 0 1 -1
performed,weekly 1.0 0.000143348623853 0 1 -1
another,interaction 1.0 0.000143348623853 1 0 1
s,nephrotoxicity 1.0 0.000143348623853 0 1 -1
fever,severe 1.0 0.000143348623853 1 0 1
on,intestinal 1.0 0.000143348623853 0 1 -1
m1,which 1.0 0.000143348623853 0 1 -1
ml,resulted 1.0 0.000143348623853 0 1 -1
dilation,diaphoresis 1.0 0.000143348623853 0 1 -1
clinical,pharmacokinetic 1.0 0.000286697247706 0 2 -2
the,natriuretic 0.857142857143 0.00172018348624 13 1 12
date,has 1.0 0.000143348623853 0 1 -1
additionally,there 1.0 0.000143348623853 0 1 -1
appropriate,monitoring 1.0 0.000143348623853 1 0 1
camp,whereas 1.0 0.000143348623853 1 0 1
loss,caused 1.0 0.00043004587156 3 0 3
gamma,glutamyl 1.0 0.000143348623853 0 1 -1
reassessed,periodically 1.0 0.000143348623853 0 1 -1
duragesic,transdermal 1.0 0.000143348623853 1 0 1
possible,atrioventricular 1.0 0.000143348623853 1 0 1
cause,coronary 1.0 0.000143348623853 1 0 1
loss,associated 1.0 0.000286697247706 2 0 2
off,before 1.0 0.000143348623853 0 1 -1
maximum,calculated 1.0 0.000143348623853 0 1 -1
pediatric,powder 1.0 0.00114678899083 8 0 8
chylomicron-like,emulsion 1.0 0.000286697247706 0 2 -2
in,free 0.0 0.0 2 2 0
vessels,was 1.0 0.000143348623853 0 1 -1
receiving,bolus-ifl 1.0 0.00043004587156 0 3 -3
mouth,urinary 1.0 0.000286697247706 2 0 2
it,interfere 1.0 0.000143348623853 0 1 -1
we,reviewed 1.0 0.000143348623853 0 1 -1
of,n-methylthiotetrazole 1.0 0.000143348623853 0 1 -1
or,qtc 1.0 0.000143348623853 0 1 -1
that,block 1.0 0.000143348623853 0 1 -1
competitively,displaces 1.0 0.000143348623853 1 0 1
drug,effects 1.0 0.000143348623853 0 1 -1
require,dosage 0.333333333333 0.000143348623853 1 2 -1
oral,self-administration 1.0 0.000143348623853 0 1 -1
concomitant,substrate 1.0 0.000143348623853 0 1 -1
intervals,until 1.0 0.00043004587156 0 3 -3
levels,with 0.0 0.0 2 2 0
when,placed 1.0 0.000143348623853 0 1 -1
with,hypokalemia 1.0 0.000143348623853 0 1 -1
indanedione,including 1.0 0.000143348623853 0 1 -1
delay,intestinal 1.0 0.000860091743119 6 0 6
drugs,is 1.0 0.000143348623853 0 1 -1
the,within 1.0 0.000143348623853 1 0 1
p-,by 1.0 0.000143348623853 0 1 -1
these,enzymes 1.0 0.000573394495413 0 4 -4
large,amounts 1.0 0.000143348623853 1 0 1
end,fo 1.0 0.000143348623853 0 1 -1
possibly,by 1.0 0.00043004587156 3 0 3
drugs,has 0.0 0.0 1 1 0
drugs,in 0.428571428571 0.00043004587156 2 5 -3
keratoses,treated 1.0 0.000143348623853 1 0 1
are,available 1.0 0.00114678899083 0 8 -8
relational,the 1.0 0.000143348623853 0 1 -1
metabolize,to 1.0 0.000143348623853 0 1 -1
local,close 1.0 0.000143348623853 0 1 -1
of,involvement 1.0 0.000143348623853 0 1 -1
and,effective 1.0 0.000143348623853 0 1 -1
wait,weeks 1.0 0.000286697247706 2 0 2
foscavir,decreases 1.0 0.000143348623853 0 1 -1
clinically,in 1.0 0.000143348623853 0 1 -1
other,ht1 0.0 0.0 1 1 0
been,excreted 1.0 0.000143348623853 0 1 -1
of,supplements 1.0 0.000143348623853 1 0 1
of,proton 1.0 0.000143348623853 0 1 -1
de,pointe 1.0 0.000143348623853 0 1 -1
nerve,degeneration 1.0 0.000143348623853 0 1 -1
moderately,reduced 1.0 0.000143348623853 0 1 -1
first,hours 1.0 0.000143348623853 0 1 -1
showed,a 0.333333333333 0.000143348623853 2 1 1
complete,heart 1.0 0.000143348623853 0 1 -1
see,whether 1.0 0.000143348623853 1 0 1
with,soriatane 1.0 0.000143348623853 0 1 -1
that,increase 0.333333333333 0.000143348623853 2 1 1
antacid,magnesium-aluminum 1.0 0.000143348623853 0 1 -1
by,mouth 0.0 0.0 1 1 0
h,extent 1.0 0.000143348623853 0 1 -1
care,should 0.428571428571 0.00043004587156 2 5 -3
actions,that 1.0 0.000143348623853 0 1 -1
motrin,advil 1.0 0.000143348623853 0 1 -1
and,cytoprotective 1.0 0.000143348623853 0 1 -1
only,to 1.0 0.000143348623853 1 0 1
isoenzymes,has 1.0 0.000143348623853 0 1 -1
alternately,provided 1.0 0.000143348623853 0 1 -1
with,metal 1.0 0.000143348623853 1 0 1
are,no 0.904761904762 0.00272362385321 1 20 -19
performed,based 1.0 0.000143348623853 1 0 1
tosylate,these 1.0 0.000143348623853 0 1 -1
not,greatly 1.0 0.000143348623853 0 1 -1
nizatidine,does 1.0 0.000143348623853 0 1 -1
for,heparins 1.0 0.000143348623853 0 1 -1
for,occult 1.0 0.000143348623853 0 1 -1
certain,especially 0.333333333333 0.000143348623853 1 2 -1
of,hansten 1.0 0.000143348623853 0 1 -1
appropriate,dosage 0.555555555556 0.000716743119266 2 7 -5
the,need 0.555555555556 0.000716743119266 2 7 -5
parenteral,are 1.0 0.000143348623853 0 1 -1
or,maximum 1.0 0.000143348623853 0 1 -1
immunosuppression,are 1.0 0.000143348623853 0 1 -1
morphine,toradoliv 1.0 0.000143348623853 0 1 -1
investigation,of 1.0 0.000143348623853 0 1 -1
ge,nerally 1.0 0.000143348623853 0 1 -1
aptt,to 1.0 0.000143348623853 0 1 -1
prinivil,attenuates 1.0 0.000143348623853 1 0 1
examined,in 1.0 0.000143348623853 0 1 -1
oral,adl 1.0 0.000143348623853 0 1 -1
patients,administered 1.0 0.000143348623853 1 0 1
hormone,activity 1.0 0.000143348623853 0 1 -1
a,non-matched 1.0 0.000143348623853 1 0 1
similar,effect 1.0 0.00043004587156 0 3 -3
an,animal 1.0 0.000143348623853 1 0 1
alterations,were 1.0 0.000143348623853 0 1 -1
reactions,patients 1.0 0.000143348623853 1 0 1
with,antiplatelet 1.0 0.000286697247706 2 0 2
irrational,behavior 1.0 0.000143348623853 1 0 1
simultaneous,treatment 1.0 0.000143348623853 1 0 1
non-steroidal,the 1.0 0.000143348623853 1 0 1
nucleus,accumbens 1.0 0.000286697247706 0 2 -2
phase,schizophrenia 1.0 0.000143348623853 0 1 -1
with,prothrombin 1.0 0.000143348623853 1 0 1
acetylcysteine,interference 1.0 0.000143348623853 0 1 -1
time,hydrogen 1.0 0.000143348623853 0 1 -1
factors,v 1.0 0.000143348623853 0 1 -1
antagonists,such 0.5 0.000286697247706 3 1 2
decreased,effect 1.0 0.000143348623853 0 1 -1
with,bioassay 1.0 0.000143348623853 0 1 -1
increased,risks 0.0 0.0 1 1 0
a,major 0.6 0.00043004587156 1 4 -3
uncontrolled,data 1.0 0.000143348623853 0 1 -1
drops,unless 1.0 0.000143348623853 0 1 -1
may,reveal 1.0 0.000143348623853 0 1 -1
foscarnet,and 1.0 0.000143348623853 1 0 1
or,vitamin 1.0 0.000143348623853 1 0 1
abolish,the 1.0 0.000143348623853 1 0 1
sex,hormone-binding 1.0 0.000143348623853 0 1 -1
dose-proportional,stable 1.0 0.000143348623853 0 1 -1
to,reported 1.0 0.000143348623853 1 0 1
understanding,the 1.0 0.000143348623853 0 1 -1
any,other 0.666666666667 0.000573394495413 1 5 -4
both,tissues 1.0 0.000143348623853 0 1 -1
addition,is 1.0 0.000143348623853 0 1 -1
condition,may 1.0 0.000143348623853 0 1 -1
folic,acid 0.5 0.000573394495413 2 6 -4
october,of 1.0 0.000143348623853 0 1 -1
artocarpus,integrifolia 1.0 0.000143348623853 0 1 -1
of,if 1.0 0.00043004587156 3 0 3
to,adverse 1.0 0.000143348623853 0 1 -1
if,their 1.0 0.000143348623853 1 0 1
monitoring,with 1.0 0.000143348623853 0 1 -1
of,it 0.2 0.000143348623853 3 2 1
of,is 0.0222222222222 0.000143348623853 22 23 -1
versus,nonfailing 1.0 0.000143348623853 0 1 -1
may,weaken 1.0 0.000143348623853 0 1 -1
also,markedly 1.0 0.000143348623853 1 0 1
xr,should 1.0 0.000286697247706 0 2 -2
non-matched,historicalcontrol 1.0 0.000143348623853 1 0 1
route,may 1.0 0.000143348623853 0 1 -1
and,postsedative 1.0 0.000143348623853 0 1 -1
given,high 1.0 0.000143348623853 1 0 1
days,the 1.0 0.000143348623853 0 1 -1
levels,utilizing 1.0 0.000143348623853 0 1 -1
cellular,sensitivity 1.0 0.000143348623853 0 1 -1
show,significant 1.0 0.000143348623853 0 1 -1
can,the 1.0 0.000143348623853 0 1 -1
occurs,is 1.0 0.000143348623853 0 1 -1
or,for 1.0 0.000286697247706 0 2 -2
as,acute 1.0 0.000286697247706 0 2 -2
alternative,non-cyp3a4 1.0 0.000143348623853 0 1 -1
excreted,via 1.0 0.000286697247706 0 2 -2
towards,the 1.0 0.000143348623853 0 1 -1
discontinued,hours 1.0 0.000143348623853 0 1 -1
strong,selective 1.0 0.000286697247706 2 0 2
occurs,in 1.0 0.000286697247706 0 2 -2
observed,effects 1.0 0.000143348623853 0 1 -1
l-ccg,upon 1.0 0.000143348623853 0 1 -1
various,dual-memory 1.0 0.000143348623853 0 1 -1
pain,and 1.0 0.000143348623853 0 1 -1
particularly,of 1.0 0.000143348623853 1 0 1
slow,chylomicron 1.0 0.000143348623853 0 1 -1
and,implantable 1.0 0.000286697247706 2 0 2
receiving,gm 1.0 0.000143348623853 1 0 1
in,studies 0.666666666667 0.000573394495413 1 5 -4
acute,toxicity 0.25 0.000286697247706 3 5 -2
nasal,vasoconstrictor 1.0 0.000143348623853 0 1 -1
polymorphic,proliferation 1.0 0.000143348623853 0 1 -1
sodium,a 1.0 0.000143348623853 1 0 1
as,causally 1.0 0.000143348623853 0 1 -1
microsome,studies 1.0 0.000143348623853 0 1 -1
glycosides,could 1.0 0.000143348623853 1 0 1
cholecystokinin,octapeptide 1.0 0.000286697247706 0 2 -2
on,tyrosine 1.0 0.000143348623853 1 0 1
exercise,testing 1.0 0.000143348623853 0 1 -1
for,nsclc 1.0 0.000143348623853 0 1 -1
days,achieved 1.0 0.000286697247706 0 2 -2
a,protein 1.0 0.000143348623853 0 1 -1
lines,u937 1.0 0.000143348623853 1 0 1
vesicles,along 1.0 0.000143348623853 0 1 -1
cmax,is 1.0 0.000143348623853 0 1 -1
are,responsible 1.0 0.000286697247706 0 2 -2
time,should 0.5 0.000286697247706 3 1 2
metabolite,by 1.0 0.000286697247706 2 0 2
the,cytosol 1.0 0.000143348623853 0 1 -1
significant,sustained 1.0 0.000143348623853 1 0 1
results,we 1.0 0.000143348623853 0 1 -1
maximally,suppresses 1.0 0.000143348623853 0 1 -1
liver,enzyme 1.0 0.000143348623853 1 0 1
occurs,when 1.0 0.000286697247706 0 2 -2
of,days 1.0 0.000143348623853 0 1 -1
a,long-acting 1.0 0.000143348623853 0 1 -1
evidence,suggest 1.0 0.000143348623853 0 1 -1
exposure,following 1.0 0.000143348623853 1 0 1
the,antiepileptic 1.0 0.000143348623853 1 0 1
and,thiazide 1.0 0.000143348623853 1 0 1
on,inositol 1.0 0.000286697247706 0 2 -2
development,of 0.75 0.00172018348624 2 14 -12
slight,effects 1.0 0.000143348623853 0 1 -1
frequent,peripheral 1.0 0.000143348623853 0 1 -1
ml,sc 1.0 0.000143348623853 0 1 -1
was,designed 1.0 0.000286697247706 0 2 -2
regular,monitoring 1.0 0.000143348623853 0 1 -1
of,revia 0.0 0.0 1 1 0
curve,of 0.0 0.0 2 2 0
palytoxin,ptx 1.0 0.000143348623853 0 1 -1
levetiracetam,circulates 1.0 0.000143348623853 0 1 -1
fractional,transfer 1.0 0.000143348623853 0 1 -1
is,characterised 1.0 0.000143348623853 0 1 -1
usually,clear 1.0 0.000143348623853 0 1 -1
by,especially 1.0 0.000143348623853 1 0 1
diazepam,valium 1.0 0.000143348623853 0 1 -1
with,such 0.333333333333 0.000286697247706 2 4 -2
daily,resulted 1.0 0.00043004587156 3 0 3
role,in 0.428571428571 0.00043004587156 2 5 -3
of,chemotherapy 1.0 0.000143348623853 0 1 -1
a,hit 1.0 0.000143348623853 0 1 -1
catecholamine-depleting,may 1.0 0.000286697247706 2 0 2
and,which 0.333333333333 0.000573394495413 8 4 4
other,tegretol 1.0 0.000143348623853 0 1 -1
potentiation,effects 1.0 0.000143348623853 0 1 -1
are,occurred 1.0 0.000143348623853 0 1 -1
assays,caution 1.0 0.000143348623853 0 1 -1
no,drug-specific 1.0 0.000143348623853 0 1 -1
studies,demonstrate 1.0 0.000286697247706 0 2 -2
is,based 1.0 0.000143348623853 0 1 -1
west,midlands 1.0 0.000143348623853 0 1 -1
not,been 0.458823529412 0.00559059633028 23 62 -39
interactions,might 1.0 0.000143348623853 0 1 -1
therefore,not 0.5 0.000286697247706 3 1 2
major,metabolites 1.0 0.000143348623853 0 1 -1
strategies,will 1.0 0.000143348623853 0 1 -1
total,circulating 1.0 0.000286697247706 0 2 -2
report,nine 1.0 0.000143348623853 1 0 1
higher,approximately 1.0 0.000143348623853 0 1 -1
maois,which 1.0 0.000143348623853 0 1 -1
expressed,by 1.0 0.000143348623853 0 1 -1
times,without 1.0 0.000143348623853 0 1 -1
with,whose 1.0 0.000143348623853 0 1 -1
increased,blood 0.333333333333 0.000143348623853 1 2 -1
on,all 1.0 0.000143348623853 0 1 -1
inr,or 1.0 0.000143348623853 0 1 -1
enzymatic-based,assays 1.0 0.000143348623853 0 1 -1
exjade,with 1.0 0.000143348623853 0 1 -1
test,sample 1.0 0.000143348623853 0 1 -1
behaviour,when 1.0 0.000143348623853 0 1 -1
actions,were 1.0 0.000143348623853 1 0 1
href,bupropz_od 1.0 0.000143348623853 1 0 1
vasoconstricting,agents 1.0 0.000143348623853 1 0 1
from,serum-deprived 1.0 0.000143348623853 0 1 -1
period,before 1.0 0.000143348623853 0 1 -1
therefore,proton 1.0 0.000143348623853 1 0 1
lessen,its 1.0 0.000143348623853 0 1 -1
is,some 1.0 0.000143348623853 1 0 1
that,resistance 1.0 0.000143348623853 0 1 -1
or,orange 1.0 0.000143348623853 0 1 -1
of,surface 1.0 0.000143348623853 0 1 -1
was,found 0.384615384615 0.000716743119266 4 9 -5
tam,induces 1.0 0.000143348623853 0 1 -1
or,were 1.0 0.00043004587156 0 3 -3
thyroid-binding,globulin 1.0 0.00043004587156 0 3 -3
and,many 1.0 0.000716743119266 0 5 -5
doxorubicin,caused 1.0 0.000143348623853 1 0 1
only,if 0.5 0.000286697247706 1 3 -2
with,isosorbide 1.0 0.000143348623853 0 1 -1
had,effects 1.0 0.000143348623853 0 1 -1
exercised,nonetheless 1.0 0.000143348623853 1 0 1
of,additional 1.0 0.00043004587156 0 3 -3
took,mg 1.0 0.000286697247706 0 2 -2
meaningful,increases 1.0 0.000143348623853 0 1 -1
from,ng 1.0 0.000143348623853 0 1 -1
intravenous,application 1.0 0.000143348623853 0 1 -1
inhibition,are 1.0 0.000143348623853 1 0 1
might,decrease 1.0 0.000143348623853 1 0 1
max,were 1.0 0.000286697247706 0 2 -2
cell,accumulation 1.0 0.000143348623853 0 1 -1
with,enzymatic-based 1.0 0.000143348623853 0 1 -1
enhancement,of 0.142857142857 0.000143348623853 3 4 -1
glucose,utilization 1.0 0.000143348623853 0 1 -1
with,alt 1.0 0.000143348623853 0 1 -1
metabolized,should 1.0 0.000143348623853 1 0 1
in,part 0.666666666667 0.000573394495413 1 5 -4
potentials,with 1.0 0.000143348623853 0 1 -1
to,hyperglycemia 1.0 0.000143348623853 0 1 -1
and,produce 1.0 0.000573394495413 0 4 -4
markedly,increased 1.0 0.000286697247706 2 0 2
chemical,reaction 1.0 0.000143348623853 1 0 1
of,users 1.0 0.000143348623853 1 0 1
be,a 1.0 0.00114678899083 0 8 -8
iv,compared 1.0 0.000143348623853 0 1 -1
with,both 1.0 0.000143348623853 0 1 -1
significant,metabolism 1.0 0.000143348623853 1 0 1
other,as 1.0 0.000143348623853 1 0 1
other,at 1.0 0.000143348623853 0 1 -1
survival,of 1.0 0.000286697247706 0 2 -2
treatment,studies 1.0 0.000143348623853 0 1 -1
transcription,factor 1.0 0.000143348623853 0 1 -1
duloxetine,both 1.0 0.000143348623853 0 1 -1
is,reported 0.5 0.000286697247706 1 3 -2
that,falsely 1.0 0.000143348623853 0 1 -1
containing,gram 1.0 0.000143348623853 1 0 1
on,hepatotoxicity 1.0 0.000143348623853 1 0 1
reaction,profile 1.0 0.000143348623853 0 1 -1
the,hypothesis 1.0 0.000286697247706 0 2 -2
serum,tests 1.0 0.000143348623853 0 1 -1
for,increased 0.2 0.000143348623853 2 3 -1
fetal,abnormalities 1.0 0.000143348623853 0 1 -1
of,use 1.0 0.00043004587156 0 3 -3
defect,in 1.0 0.00043004587156 0 3 -3
measurements,with 1.0 0.000143348623853 0 1 -1
french,non-governmental 1.0 0.000143348623853 0 1 -1
of,usp 1.0 0.000143348623853 1 0 1
months,at 1.0 0.000286697247706 0 2 -2
with,radiotherapy 1.0 0.000143348623853 0 1 -1
of,epa 1.0 0.000143348623853 0 1 -1
isoforms,tested 1.0 0.000143348623853 0 1 -1
trials,suggest 1.0 0.000286697247706 0 2 -2
and,serotonin2-receptors 1.0 0.000143348623853 0 1 -1
significant,increase 0.636363636364 0.00100344036697 9 2 7
hypercholesterolemia,concomitant 1.0 0.000143348623853 0 1 -1
trials,flolan 1.0 0.000143348623853 1 0 1
however,possible 1.0 0.000143348623853 1 0 1
concentration,except 1.0 0.000143348623853 0 1 -1
seizures,have 1.0 0.00043004587156 3 0 3
systematic,changes 1.0 0.000143348623853 0 1 -1
two,instances 1.0 0.000143348623853 1 0 1
indicate,no 1.0 0.000143348623853 0 1 -1
implicated,in 0.0 0.0 1 1 0
however,pretreatment 1.0 0.000143348623853 0 1 -1
reduction,should 1.0 0.000143348623853 0 1 -1
serotonin,syndrome 0.5 0.000286697247706 3 1 2
influence,serum 1.0 0.000143348623853 0 1 -1
range,observed 1.0 0.000143348623853 0 1 -1
gvia,n-type 1.0 0.000143348623853 0 1 -1
causing,an 1.0 0.000143348623853 1 0 1
prescribers,are 1.0 0.000286697247706 0 2 -2
epileptic,patients 0.0 0.0 2 2 0
anxiety,depressive 1.0 0.000143348623853 0 1 -1
besides,their 1.0 0.000143348623853 0 1 -1
diarrhea,induced 1.0 0.000143348623853 1 0 1
be,improved 1.0 0.000143348623853 0 1 -1
bsa,increases 1.0 0.000143348623853 0 1 -1
fewer,infusion 1.0 0.000143348623853 0 1 -1
distribution,and 1.0 0.000286697247706 0 2 -2
differently,from 1.0 0.000286697247706 0 2 -2
rifampin,markedly 1.0 0.000143348623853 1 0 1
additional,significantly 1.0 0.000143348623853 1 0 1
but,does 0.0 0.0 1 1 0
other,hand 0.666666666667 0.000573394495413 1 5 -4
when,administered 0.0 0.0 15 15 0
mean,aucs 1.0 0.000143348623853 0 1 -1
the,cyp2b6 1.0 0.000143348623853 1 0 1
when,heart 1.0 0.000143348623853 1 0 1
following,medications 0.0 0.0 1 1 0
during,treatment 0.142857142857 0.000286697247706 6 8 -2
while,fractional 1.0 0.000143348623853 0 1 -1
than,from 1.0 0.000143348623853 0 1 -1
cases,should 1.0 0.000143348623853 0 1 -1
disease,including 1.0 0.000143348623853 0 1 -1
blockers,patients 1.0 0.000286697247706 0 2 -2
after,introduction 1.0 0.000143348623853 1 0 1
is,unavailable 1.0 0.000143348623853 0 1 -1
be,unlikely 1.0 0.000286697247706 0 2 -2
to,daily 1.0 0.000143348623853 0 1 -1
administered,weekly 1.0 0.000143348623853 0 1 -1
day,doses 1.0 0.000143348623853 0 1 -1
clo-4,simultaneously 1.0 0.000143348623853 0 1 -1
of,neutrophils 1.0 0.000143348623853 0 1 -1
therefore,concomitant 0.5 0.000286697247706 3 1 2
d,produced 1.0 0.000286697247706 2 0 2
pancreatitis,possibly 1.0 0.000143348623853 1 0 1
increased,serum 0.0 0.0 6 6 0
various,ca 1.0 0.000143348623853 0 1 -1
formula,mg 1.0 0.000143348623853 0 1 -1
mental,and 1.0 0.000143348623853 0 1 -1
beta-blockers,serum 1.0 0.000143348623853 0 1 -1
of,orally 0.5 0.000286697247706 1 3 -2
or,concurrent 0.333333333333 0.000143348623853 2 1 1
antiretroviral,medications 1.0 0.000143348623853 0 1 -1
potential,should 1.0 0.000286697247706 0 2 -2
antibiotics,such 1.0 0.000143348623853 1 0 1
zidovudine,should 1.0 0.000143348623853 1 0 1
for,serious 0.777777777778 0.00200688073394 2 16 -14
here,may 1.0 0.000143348623853 0 1 -1
total,picr 1.0 0.000143348623853 0 1 -1
peripheral,neuropathy 0.6 0.00043004587156 1 4 -3
and,its 0.142857142857 0.000716743119266 15 20 -5
addition,studies 1.0 0.000143348623853 0 1 -1
to,for 1.0 0.000143348623853 1 0 1
torsades,de 0.6 0.00043004587156 1 4 -3
increase,steady-state 1.0 0.000143348623853 0 1 -1
types,is 1.0 0.000143348623853 0 1 -1
streptococcus,pyogenes 1.0 0.000143348623853 0 1 -1
given,several 1.0 0.000143348623853 0 1 -1
hyperbilirubinemia,confusion 1.0 0.000143348623853 1 0 1
a,complex 0.333333333333 0.000143348623853 1 2 -1
central,effects 1.0 0.000143348623853 1 0 1
provide,a 1.0 0.000143348623853 0 1 -1
serum,concentrations 0.0666666666667 0.000286697247706 16 14 2
and,dna-damaging 1.0 0.000143348623853 0 1 -1
of,absorption 0.230769230769 0.00043004587156 5 8 -3
human,plasma 1.0 0.00100344036697 0 7 -7
inhibit,neuronal 1.0 0.000143348623853 0 1 -1
b,for 1.0 0.000143348623853 0 1 -1
at,five 1.0 0.000143348623853 0 1 -1
or,methylthiadiazole 1.0 0.000143348623853 0 1 -1
pups,from 1.0 0.000143348623853 0 1 -1
an,angiotensin-converting 1.0 0.000143348623853 1 0 1
with,inhibiting 1.0 0.000143348623853 0 1 -1
that,larger 1.0 0.000143348623853 0 1 -1
acid-base,balance 1.0 0.000143348623853 0 1 -1
tcaplasma,levels 1.0 0.000143348623853 0 1 -1
effects,could 1.0 0.000143348623853 1 0 1
an,approximate 1.0 0.00129013761468 9 0 9
the,cumulative 1.0 0.000143348623853 0 1 -1
the,csf 1.0 0.000143348623853 0 1 -1
may,arise 1.0 0.000143348623853 0 1 -1
hepatic,failure 1.0 0.000143348623853 0 1 -1
though,less 1.0 0.000286697247706 0 2 -2
were,each 1.0 0.000286697247706 0 2 -2
significantly,in 1.0 0.000286697247706 0 2 -2
increase,respiratory 1.0 0.000143348623853 1 0 1
cytochrome,isozymes 1.0 0.000143348623853 0 1 -1
insufficiency,resulted 1.0 0.000143348623853 0 1 -1
inhibitors,long-term 1.0 0.000143348623853 1 0 1
contrast,mm 1.0 0.000143348623853 0 1 -1
monitor,tcaplasma 1.0 0.000143348623853 0 1 -1
that,more 1.0 0.000143348623853 0 1 -1
in,layers 1.0 0.000143348623853 0 1 -1
a,maneuver 1.0 0.000143348623853 0 1 -1
changes,of 1.0 0.000143348623853 0 1 -1
changes,on 1.0 0.000143348623853 0 1 -1
lymphoma,cells 1.0 0.000143348623853 0 1 -1
worsening,asthma 1.0 0.000143348623853 0 1 -1
of,does 0.5 0.000286697247706 1 3 -2
hypoglycemics,initiating 1.0 0.000143348623853 0 1 -1
apoptosis,assessed 1.0 0.000143348623853 1 0 1
potential,there 1.0 0.000143348623853 0 1 -1
aware,when 1.0 0.000143348623853 1 0 1
the,comparative 1.0 0.000143348623853 0 1 -1
myelopoesis,drugs 1.0 0.000143348623853 0 1 -1
congenital,or 1.0 0.000143348623853 0 1 -1
increasingly,popular 1.0 0.000143348623853 0 1 -1
is,easy 1.0 0.000143348623853 0 1 -1
prinivil,at 1.0 0.000143348623853 1 0 1
diarrhea,hypotension 1.0 0.000143348623853 0 1 -1
withdrawn,and 1.0 0.000143348623853 0 1 -1
nnrtis,occur 1.0 0.000143348623853 0 1 -1
usually,severe 1.0 0.000143348623853 0 1 -1
phenergan,mellaril 1.0 0.000143348623853 0 1 -1
acid,aminocaproic 1.0 0.000143348623853 0 1 -1
as,diminished 1.0 0.000143348623853 1 0 1
on,phosphate 1.0 0.00043004587156 0 3 -3
e,mg 1.0 0.000143348623853 1 0 1
necessitate,raising 1.0 0.000143348623853 1 0 1
renal,nonrenal 1.0 0.000143348623853 0 1 -1
active,renal 0.0 0.0 1 1 0
by,infusion 1.0 0.000286697247706 0 2 -2
by,hepatic 0.5 0.000286697247706 3 1 2
than,changes 1.0 0.000143348623853 0 1 -1
is,stable 1.0 0.000716743119266 0 5 -5
vivo,interaction 1.0 0.000860091743119 0 6 -6
rarely,associated 1.0 0.000286697247706 2 0 2
definitely,indicated 1.0 0.000143348623853 1 0 1
pruritus,ankle 1.0 0.000143348623853 0 1 -1
additionally,did 1.0 0.000143348623853 0 1 -1
patient,currently 1.0 0.000286697247706 2 0 2
interactions,certain 1.0 0.000286697247706 0 2 -2
no,related 1.0 0.000143348623853 0 1 -1
agents,derivatives 1.0 0.000286697247706 0 2 -2
from,therapy 1.0 0.000143348623853 0 1 -1
a,metabolized 1.0 0.000143348623853 0 1 -1
including,hypertensive 1.0 0.000143348623853 1 0 1
release,whereas 1.0 0.000143348623853 0 1 -1
episode,despite 1.0 0.000143348623853 0 1 -1
compliance,especially 1.0 0.000143348623853 0 1 -1
tolbutamides,conversion 1.0 0.000143348623853 0 1 -1
or,elevated 1.0 0.000286697247706 2 0 2
concentrations,drugs 1.0 0.000143348623853 1 0 1
deet,toxicity 1.0 0.000143348623853 0 1 -1
with,spectrophotometrically 1.0 0.000143348623853 0 1 -1
wild-type,alleles 1.0 0.000143348623853 0 1 -1
or,excess 1.0 0.000143348623853 1 0 1
sufficient,function 1.0 0.000143348623853 0 1 -1
adverse,neuropsychiatric 1.0 0.000143348623853 1 0 1
those,patients 0.0 0.0 2 2 0
estrogens,female 1.0 0.000143348623853 0 1 -1
metformin,in 0.0 0.0 1 1 0
after,clinical 1.0 0.000143348623853 0 1 -1
antagonists,may 1.0 0.000286697247706 2 0 2
to,was 1.0 0.000716743119266 5 0 5
taking,the 0.5 0.000286697247706 1 3 -2
the,breath 1.0 0.000143348623853 0 1 -1
have,allergic 1.0 0.000143348623853 0 1 -1
probenecid,depresses 1.0 0.000143348623853 1 0 1
the,starting 1.0 0.000286697247706 0 2 -2
withdrawal,and 0.0 0.0 1 1 0
coumarin-derivative,concomitantly 1.0 0.000143348623853 1 0 1
depressants,but 1.0 0.000143348623853 0 1 -1
on,smooth 1.0 0.000143348623853 0 1 -1
not,extensively 1.0 0.000143348623853 0 1 -1
receiving,and 0.25 0.000286697247706 5 3 2
concomitant,compared 1.0 0.000143348623853 0 1 -1
symptomatic,orthostatic 1.0 0.000286697247706 2 0 2
prolongation,ischemic 1.0 0.000143348623853 1 0 1
no,abortifacient 1.0 0.000143348623853 0 1 -1
repeated,each 1.0 0.000143348623853 0 1 -1
novel,chemical 1.0 0.000143348623853 1 0 1
is,excreted 1.0 0.000573394495413 0 4 -4
ra,clinical 1.0 0.000143348623853 0 1 -1
total,body 0.0 0.0 3 3 0
efficacy,and 1.0 0.00172018348624 0 12 -12
by,that 1.0 0.000143348623853 1 0 1
or,inactivity 1.0 0.000143348623853 0 1 -1
permit,larger 1.0 0.000143348623853 0 1 -1
nsaid,or 1.0 0.000143348623853 1 0 1
in,pcp 1.0 0.000143348623853 0 1 -1
by,barton 1.0 0.000143348623853 0 1 -1
urine,or 1.0 0.000286697247706 0 2 -2
observed,there 1.0 0.000143348623853 0 1 -1
rat,s 1.0 0.000143348623853 0 1 -1
urine,of 1.0 0.000286697247706 0 2 -2
cyp2d6,was 1.0 0.000143348623853 0 1 -1
significant,reductions 1.0 0.000143348623853 1 0 1
th,days 1.0 0.000143348623853 0 1 -1
of,including 1.0 0.00043004587156 3 0 3
period,of 0.142857142857 0.000143348623853 3 4 -1
the,tolerability 1.0 0.000143348623853 0 1 -1
oral,resulted 1.0 0.000143348623853 1 0 1
erection,disorders 1.0 0.000143348623853 0 1 -1
the,is 0.75 0.000860091743119 1 7 -6
been,compared 1.0 0.000143348623853 0 1 -1
bovine,thyroglobulin 1.0 0.000143348623853 0 1 -1
the,difference 1.0 0.000286697247706 0 2 -2
that,chloral 1.0 0.000143348623853 0 1 -1
and,n-oxide 1.0 0.000143348623853 0 1 -1
the,ic 1.0 0.000143348623853 0 1 -1
the,lysate 1.0 0.000143348623853 0 1 -1
therefore,to 0.0 0.0 1 1 0
tablets,at 0.0 0.0 1 1 0
the,in 0.466666666667 0.00100344036697 4 11 -7
concomitantly,and 1.0 0.000143348623853 1 0 1
was,achieved 1.0 0.000143348623853 0 1 -1
intestinal,lumen 1.0 0.000143348623853 0 1 -1
acceleration,of 1.0 0.000143348623853 0 1 -1
attenuates,certain 1.0 0.000143348623853 1 0 1
of,medication 1.0 0.000286697247706 0 2 -2
for,week 1.0 0.000143348623853 0 1 -1
p-450,linked 1.0 0.000143348623853 0 1 -1
concomitantly,any 1.0 0.000143348623853 1 0 1
cyp3a4,inducer 0.555555555556 0.000716743119266 7 2 5
studies,should 1.0 0.000143348623853 0 1 -1
serum,protein 0.333333333333 0.000143348623853 1 2 -1
at,stable 1.0 0.000143348623853 0 1 -1
increase,or 0.333333333333 0.000573394495413 4 8 -4
a,delayed 1.0 0.000143348623853 0 1 -1
enhanced,side 1.0 0.000143348623853 1 0 1
conducted,at 1.0 0.000143348623853 0 1 -1
first,sixty 1.0 0.000143348623853 1 0 1
data,to 0.0 0.0 1 1 0
which,concurrent 1.0 0.000143348623853 0 1 -1
all,metabolized 1.0 0.000143348623853 1 0 1
conduction,channel 1.0 0.000143348623853 1 0 1
emphasis,on 1.0 0.000143348623853 0 1 -1
causative,factors 1.0 0.000143348623853 0 1 -1
during,placebo 1.0 0.000143348623853 0 1 -1
a,prolonged 1.0 0.000143348623853 0 1 -1
no,substantive 1.0 0.000143348623853 0 1 -1
five,or 1.0 0.000143348623853 0 1 -1
sedation,time 1.0 0.000143348623853 0 1 -1
renin,activity 1.0 0.000286697247706 0 2 -2
inapsine,the 1.0 0.000143348623853 1 0 1
sprycel,close 1.0 0.000143348623853 0 1 -1
terms,viagra 1.0 0.000143348623853 0 1 -1
in,function 1.0 0.000143348623853 0 1 -1
containing,preparations 1.0 0.000143348623853 1 0 1
lactating,dams 1.0 0.000143348623853 0 1 -1
vasoconstrictor,but 1.0 0.000143348623853 0 1 -1
found,minutes 1.0 0.000143348623853 0 1 -1
injected,a 1.0 0.000143348623853 0 1 -1
a,growing 1.0 0.000143348623853 0 1 -1
this,response 1.0 0.000860091743119 0 6 -6
serum,clearance 1.0 0.000143348623853 1 0 1
with,urine 1.0 0.000143348623853 0 1 -1
s,response 0.0 0.0 1 1 0
iv,was 1.0 0.000143348623853 0 1 -1
by,serum 1.0 0.000143348623853 0 1 -1
evident,in 1.0 0.000286697247706 0 2 -2
nucleotide,release 1.0 0.000143348623853 0 1 -1
coli,and 1.0 0.000143348623853 0 1 -1
whether,would 1.0 0.000143348623853 0 1 -1
to,exposures 1.0 0.000143348623853 0 1 -1
concentrations,found 1.0 0.000143348623853 0 1 -1
and,proleukin 1.0 0.000143348623853 1 0 1
in,particular 0.666666666667 0.000573394495413 1 5 -4
agents,concurrent 0.0 0.0 1 1 0
volunteers,with 0.0 0.0 1 1 0
isoenzyme,and 1.0 0.000286697247706 0 2 -2
of,appropriate 1.0 0.000143348623853 0 1 -1
concomitant,n 1.0 0.000143348623853 1 0 1
deaths,associated 1.0 0.000143348623853 0 1 -1
the,including 1.0 0.000286697247706 2 0 2
nonclinical,data 1.0 0.000143348623853 0 1 -1
vivo,micronucleus 1.0 0.000143348623853 0 1 -1
not,markedly 1.0 0.000143348623853 0 1 -1
ht3,zofran 1.0 0.000143348623853 0 1 -1
fluvoxamine,has 1.0 0.000143348623853 1 0 1
estrogen-containing,therapies 1.0 0.000143348623853 1 0 1
caucasians,are 1.0 0.000716743119266 0 5 -5
inactivated,due 1.0 0.000143348623853 1 0 1
gabapentin,had 1.0 0.000143348623853 0 1 -1
dose-related,decrease 1.0 0.000143348623853 1 0 1
however,to 1.0 0.000143348623853 0 1 -1
specific,activity 1.0 0.000143348623853 0 1 -1
medication,and 1.0 0.000286697247706 0 2 -2
i,relational 1.0 0.000143348623853 0 1 -1
abstract,truncated 1.0 0.000286697247706 0 2 -2
subjective,and 1.0 0.000286697247706 0 2 -2
be,ingested 1.0 0.000143348623853 1 0 1
emulsions,in 1.0 0.000143348623853 0 1 -1
sampling,for 1.0 0.000143348623853 0 1 -1
digitalis,vitamin 1.0 0.00043004587156 3 0 3
inhibit,cyp2e1 1.0 0.000143348623853 0 1 -1
manner,relative 1.0 0.000143348623853 0 1 -1
isolated,cases 1.0 0.000286697247706 2 0 2
ii,clinical 1.0 0.000143348623853 1 0 1
m1,the 1.0 0.000143348623853 1 0 1
of,cardiovascular 1.0 0.000573394495413 0 4 -4
fashion,as 1.0 0.000143348623853 1 0 1
these,drugs 1.0 0.000573394495413 0 4 -4
fashion,at 1.0 0.000143348623853 0 1 -1
are,concurrently 0.333333333333 0.000143348623853 2 1 1
with,water-miscible 1.0 0.000143348623853 0 1 -1
sometimes,proves 1.0 0.000143348623853 1 0 1
hemostasis,nsaids 1.0 0.000143348623853 0 1 -1
angiomax,and 1.0 0.000143348623853 0 1 -1
dyspnea,palpitation 1.0 0.000143348623853 0 1 -1
extracellular,levels 1.0 0.000143348623853 0 1 -1
combinations,were 1.0 0.000143348623853 0 1 -1
therapy,oral 1.0 0.000143348623853 0 1 -1
serum,potassium 0.0 0.0 3 3 0
dofetilide,is 1.0 0.00043004587156 0 3 -3
detection,of 1.0 0.000143348623853 0 1 -1
potentially,favorable 1.0 0.000143348623853 0 1 -1
influence,on 0.333333333333 0.000143348623853 1 2 -1
both,synthetic 1.0 0.00043004587156 3 0 3
influence,of 1.0 0.00157683486239 0 11 -11
clearance,that 1.0 0.000143348623853 1 0 1
these,techniques 1.0 0.000143348623853 0 1 -1
well,and 1.0 0.000143348623853 0 1 -1
delay,elimination 1.0 0.000143348623853 0 1 -1
treatment,folic 1.0 0.000143348623853 1 0 1
inhibitors,or 0.176470588235 0.00043004587156 7 10 -3
have,resulted 1.0 0.00043004587156 3 0 3
inhibitors,on 0.333333333333 0.000143348623853 1 2 -1
that,polyamines 1.0 0.000143348623853 0 1 -1
hypertension,which 1.0 0.000143348623853 1 0 1
i,may 1.0 0.000143348623853 0 1 -1
inhibitors,of 0.238095238095 0.00143348623853 16 26 -10
including,anaphylaxis 1.0 0.000143348623853 0 1 -1
range,while 1.0 0.000143348623853 0 1 -1
closely,to 0.555555555556 0.000716743119266 7 2 5
cause,abnormal 1.0 0.000143348623853 1 0 1
spermine,mm 1.0 0.000143348623853 0 1 -1
of,changes 0.333333333333 0.000143348623853 2 1 1
arm,was 1.0 0.000143348623853 0 1 -1
disease,control 1.0 0.000143348623853 1 0 1
of,changed 1.0 0.000143348623853 1 0 1
treatment,in 0.777777777778 0.00100344036697 1 8 -7
between,given 1.0 0.000143348623853 0 1 -1
and,hdl2 1.0 0.000286697247706 0 2 -2
case,that 1.0 0.000143348623853 1 0 1
reveal,frequent 1.0 0.000143348623853 1 0 1
effects,not 1.0 0.000143348623853 0 1 -1
the,thioether 1.0 0.000286697247706 0 2 -2
treatment,is 1.0 0.00129013761468 0 9 -9
the,nasal 1.0 0.000143348623853 1 0 1
the,density 1.0 0.000143348623853 0 1 -1
pneumonia,treatment 1.0 0.000143348623853 1 0 1
two,patients 1.0 0.000286697247706 2 0 2
were,accompanied 1.0 0.000286697247706 0 2 -2
various,such 1.0 0.000143348623853 1 0 1
time-dependent,inhibitor 1.0 0.000143348623853 0 1 -1
rr,microm 1.0 0.000286697247706 2 0 2
long-term,carcinogenicity 1.0 0.000143348623853 0 1 -1
a,fluoroquinolone 1.0 0.000143348623853 1 0 1
case,of 0.2 0.000286697247706 4 6 -2
itraconazole,therapy 1.0 0.000143348623853 1 0 1
cyp2c9,at 1.0 0.000143348623853 0 1 -1
repeated,mg 1.0 0.000143348623853 0 1 -1
three,patients 1.0 0.000143348623853 0 1 -1
isoforms,cyp1a2 1.0 0.000143348623853 0 1 -1
before,you 1.0 0.000143348623853 0 1 -1
conduction,can 1.0 0.000143348623853 1 0 1
ucb,l057 1.0 0.000286697247706 0 2 -2
the,qtc 0.333333333333 0.000143348623853 2 1 1
resins,since 1.0 0.000143348623853 1 0 1
serotonin,in 1.0 0.000143348623853 0 1 -1
of,inspra 1.0 0.000286697247706 2 0 2
at,relatively 1.0 0.000143348623853 0 1 -1
and,potential 1.0 0.000573394495413 0 4 -4
stimulated,by 1.0 0.000143348623853 0 1 -1
doubt,complex 1.0 0.000143348623853 0 1 -1
and,identifications 1.0 0.000143348623853 0 1 -1
danger,inherent 1.0 0.000143348623853 1 0 1
serentil,trilafon 1.0 0.000143348623853 0 1 -1
concentration,to 1.0 0.000143348623853 0 1 -1
gel,has 1.0 0.000143348623853 0 1 -1
peripheral,vasoconstriction 1.0 0.000143348623853 1 0 1
adequate,treatment 1.0 0.000143348623853 0 1 -1
dietary,concentrations 1.0 0.000143348623853 0 1 -1
serum,should 1.0 0.000286697247706 0 2 -2
contraceptives,it 1.0 0.000143348623853 0 1 -1
adjustment,for 0.333333333333 0.000143348623853 1 2 -1
several,studies 1.0 0.000286697247706 0 2 -2
anti-malarial,such 1.0 0.000143348623853 1 0 1
the,additive 1.0 0.00043004587156 0 3 -3
the,qt0 1.0 0.000143348623853 0 1 -1
survival,needs 1.0 0.000143348623853 0 1 -1
in,hormone 1.0 0.000143348623853 0 1 -1
and,extra 1.0 0.000143348623853 0 1 -1
anticholinesterase,agents 1.0 0.000286697247706 2 0 2
or,pharmacodynamics 1.0 0.00043004587156 0 3 -3
his,her 1.0 0.000143348623853 0 1 -1
men,years 1.0 0.000143348623853 0 1 -1
tests,corticosteroids 1.0 0.000143348623853 0 1 -1
iv,attenuate 1.0 0.000143348623853 1 0 1
day,showed 0.0 0.0 1 1 0
inhibiting,effects 1.0 0.000143348623853 0 1 -1
in,inr 0.333333333333 0.000143348623853 1 2 -1
infection,with 1.0 0.000143348623853 0 1 -1
routine,monitoring 1.0 0.000143348623853 0 1 -1
hyperpyrexia,can 1.0 0.000286697247706 0 2 -2
three,hours 1.0 0.000143348623853 0 1 -1
c19,ic50 1.0 0.000143348623853 0 1 -1
therefore,in 1.0 0.000286697247706 0 2 -2
discussed,in 1.0 0.000573394495413 0 4 -4
by,overdose 1.0 0.000143348623853 1 0 1
geometric,mean 0.0 0.0 1 1 0
therefore,if 0.555555555556 0.000716743119266 2 7 -5
the,to 1.0 0.000286697247706 0 2 -2
the,th 0.333333333333 0.000286697247706 2 4 -2
instructions,for 1.0 0.000143348623853 0 1 -1
three,strains 1.0 0.000286697247706 0 2 -2
with,dual 1.0 0.000143348623853 0 1 -1
sulindac,the 1.0 0.000143348623853 1 0 1
therefore,it 0.636363636364 0.00100344036697 2 9 -7
a,pulse 1.0 0.000143348623853 0 1 -1
antipsychotic,was 1.0 0.000143348623853 0 1 -1
clonidine,hydrochloride 1.0 0.000143348623853 1 0 1
body,it 1.0 0.000143348623853 0 1 -1
ketoconazole,mg 0.333333333333 0.000143348623853 1 2 -1
phosphorylation,inhibition 1.0 0.000143348623853 1 0 1
who,have 0.263157894737 0.000716743119266 7 12 -5
in,dependence 1.0 0.000143348623853 0 1 -1
depressants,with 1.0 0.000143348623853 0 1 -1
be,important 1.0 0.000286697247706 0 2 -2
done,it 1.0 0.000143348623853 0 1 -1
of,romazicon 1.0 0.00043004587156 0 3 -3
in,north 1.0 0.000143348623853 0 1 -1
avoid,concomitant 1.0 0.000143348623853 0 1 -1
renal,tubular 0.636363636364 0.00100344036697 9 2 7
carbimazole,and 1.0 0.000143348623853 1 0 1
diabetic,rats 1.0 0.000143348623853 0 1 -1
maleate,mg 1.0 0.000286697247706 2 0 2
the,determination 1.0 0.000286697247706 0 2 -2
autonomic,irritability 1.0 0.000143348623853 1 0 1
provoke,convulsions 1.0 0.000143348623853 0 1 -1
caution,dose 1.0 0.000143348623853 0 1 -1
cyp450,a4 1.0 0.000143348623853 0 1 -1
was,discontinued 1.0 0.000286697247706 0 2 -2
any,one 1.0 0.000143348623853 0 1 -1
immune,system 1.0 0.000573394495413 0 4 -4
lymphoid,malignancy 1.0 0.000143348623853 0 1 -1
multiple,oral 0.0 0.0 1 1 0
metabolism,could 1.0 0.000143348623853 0 1 -1
antagonists,hmg-coa 1.0 0.000143348623853 0 1 -1
phosphatase,should 1.0 0.000143348623853 0 1 -1
have,an 0.142857142857 0.000286697247706 8 6 2
continued,if 1.0 0.000143348623853 1 0 1
positive,tests 1.0 0.000143348623853 0 1 -1
hexokinase,method 1.0 0.000286697247706 0 2 -2
volume,and 1.0 0.000143348623853 1 0 1
body,via 1.0 0.000143348623853 1 0 1
analogues,should 1.0 0.00043004587156 0 3 -3
of,salmonella 1.0 0.000143348623853 0 1 -1
agents,primarily 1.0 0.000143348623853 0 1 -1
resistance,mesenteric 1.0 0.000143348623853 0 1 -1
degrees,c 1.0 0.00043004587156 0 3 -3
busulfex,at 1.0 0.000143348623853 1 0 1
relevance,continues 1.0 0.000143348623853 0 1 -1
nmda-ergic,activation 1.0 0.000143348623853 0 1 -1
and,aetiopathogenic-- 1.0 0.000143348623853 0 1 -1
not,start 1.0 0.000143348623853 0 1 -1
also,refer 1.0 0.000143348623853 0 1 -1
a,role 1.0 0.000573394495413 0 4 -4
coating,may 1.0 0.000143348623853 0 1 -1
with,specific 1.0 0.000143348623853 0 1 -1
of,fibric 1.0 0.000143348623853 0 1 -1
cations,such 1.0 0.00043004587156 3 0 3
with,patients 1.0 0.000286697247706 2 0 2
disease,spinal 1.0 0.000143348623853 0 1 -1
and,factors 1.0 0.000286697247706 0 2 -2
of,atrovent 0.0 0.0 1 1 0
cpa,an 1.0 0.000143348623853 1 0 1
anticonvulsants,phenytoin 0.0 0.0 1 1 0
reduce,serum 1.0 0.000143348623853 1 0 1
interactions,frova 1.0 0.000143348623853 0 1 -1
early,studies 1.0 0.000143348623853 0 1 -1
the,template 1.0 0.000143348623853 0 1 -1
of,genomes 1.0 0.000143348623853 0 1 -1
picr,could 1.0 0.000143348623853 0 1 -1
generate,concentration-response 1.0 0.000143348623853 0 1 -1
fluids,might 1.0 0.000286697247706 0 2 -2
potent,inhibitor 0.142857142857 0.000286697247706 8 6 2
may,substantially 1.0 0.000573394495413 4 0 4
with,subsequent 1.0 0.000286697247706 0 2 -2
the,cytochrome 0.7 0.00401376146789 6 34 -28
did,slightly 1.0 0.000143348623853 1 0 1
neonates,is 1.0 0.000143348623853 0 1 -1
the,endometrium 1.0 0.000143348623853 0 1 -1
and,theoretically 1.0 0.000143348623853 0 1 -1
to,ejaculate 1.0 0.000143348623853 0 1 -1
sufficient,to 0.714285714286 0.000716743119266 1 6 -5
intravenous,or 1.0 0.000143348623853 1 0 1
than,parkinsons 1.0 0.000143348623853 0 1 -1
righting,reflex 1.0 0.000286697247706 0 2 -2
notably,oral 1.0 0.000143348623853 1 0 1
m,basis 1.0 0.000143348623853 0 1 -1
stupor,and 1.0 0.000143348623853 1 0 1
the,reservoir 1.0 0.000143348623853 0 1 -1
as,uncompromised 1.0 0.000143348623853 0 1 -1
to,suggest 1.0 0.000143348623853 0 1 -1
united,states 1.0 0.000573394495413 0 4 -4
inhibitor,at 0.0 0.0 1 1 0
ethanol,sonata 1.0 0.000143348623853 1 0 1
special,consideration 1.0 0.000143348623853 1 0 1
themselves,produce 1.0 0.000143348623853 1 0 1
investigated,simulect 1.0 0.000143348623853 0 1 -1
day,fecal 1.0 0.000143348623853 0 1 -1
of,symptom 1.0 0.000143348623853 1 0 1
design,cross-sectional 1.0 0.000143348623853 0 1 -1
that,dosage 1.0 0.000143348623853 0 1 -1
remnant,removal 1.0 0.000143348623853 0 1 -1
the,consequences 1.0 0.000143348623853 0 1 -1
amevive,in 1.0 0.00043004587156 0 3 -3
stimulating,effect 1.0 0.000143348623853 1 0 1
amevive,is 1.0 0.000286697247706 0 2 -2
when,cancidas 1.0 0.000286697247706 2 0 2
for,binding 0.333333333333 0.000143348623853 1 2 -1
nsaid,and 1.0 0.000143348623853 0 1 -1
de,pointes-type 1.0 0.000143348623853 0 1 -1
between,xanthine 1.0 0.000143348623853 1 0 1
produced,distinctive 1.0 0.000143348623853 0 1 -1
discontinuing,the 1.0 0.000716743119266 5 0 5
activity,are 1.0 0.000143348623853 0 1 -1
cyclase,activity 1.0 0.000143348623853 0 1 -1
clinicians,to 1.0 0.000143348623853 1 0 1
observed,to 0.5 0.000286697247706 3 1 2
and,stability 1.0 0.000143348623853 0 1 -1
some,reports 0.5 0.000286697247706 3 1 2
year,pharmacokinetics 1.0 0.000143348623853 0 1 -1
toradol,on 0.0 0.0 1 1 0
unexpected,adverse 1.0 0.000286697247706 0 2 -2
coumarin-derivative,such 1.0 0.000143348623853 1 0 1
b-blocking,properties 1.0 0.000716743119266 5 0 5
data,appeared 1.0 0.000143348623853 0 1 -1
with,nph 1.0 0.000286697247706 0 2 -2
thrombocytopenia,the 1.0 0.000286697247706 0 2 -2
furosemide,clinical 1.0 0.000716743119266 5 0 5
monitored,and 0.0769230769231 0.000143348623853 6 7 -1
was,effective 1.0 0.000143348623853 1 0 1
acid,from 1.0 0.000286697247706 0 2 -2
day,each 1.0 0.000143348623853 0 1 -1
combined,hyperglycaemia 1.0 0.000143348623853 0 1 -1
low-density,lipoproteins 1.0 0.000143348623853 0 1 -1
alpha,interferons 1.0 0.000143348623853 0 1 -1
status,before 1.0 0.000143348623853 0 1 -1
beta-adrenergic,blocker 1.0 0.000143348623853 1 0 1
eliminated,the 1.0 0.000143348623853 1 0 1
question,the 1.0 0.000143348623853 0 1 -1
malignant,phenotype 1.0 0.000143348623853 0 1 -1
alkaline,earth 1.0 0.000286697247706 0 2 -2
or,tenofovir 1.0 0.000143348623853 0 1 -1
of,diarrhea 1.0 0.000143348623853 1 0 1
limit,decrease 1.0 0.000143348623853 0 1 -1
diuretic,hydrochlorothiazide 1.0 0.000143348623853 1 0 1
allopurinol,in 1.0 0.000143348623853 0 1 -1
life-threatening,ventricular 1.0 0.000143348623853 0 1 -1
theories,have 1.0 0.000143348623853 0 1 -1
superiority,of 1.0 0.000143348623853 0 1 -1
nonrenal,clearance 1.0 0.000143348623853 0 1 -1
not,rely 1.0 0.000143348623853 0 1 -1
with,st 1.0 0.000143348623853 0 1 -1
site,reaction 1.0 0.000143348623853 0 1 -1
and,miotic 1.0 0.000143348623853 0 1 -1
lesser,but 1.0 0.000143348623853 0 1 -1
of,diverse 1.0 0.000143348623853 0 1 -1
of,mcf-7 1.0 0.000143348623853 0 1 -1
formulation,comparable 1.0 0.000286697247706 2 0 2
stimulated,but 1.0 0.000143348623853 1 0 1
omniscan,interferes 1.0 0.000143348623853 0 1 -1
and,reached 1.0 0.000143348623853 1 0 1
increase,two-fold 1.0 0.000143348623853 1 0 1
mtc-mdp,as 1.0 0.000143348623853 0 1 -1
paper,reviews 1.0 0.000143348623853 0 1 -1
fractional,inhibitory 1.0 0.000143348623853 0 1 -1
fraction,suggesting 1.0 0.000143348623853 0 1 -1
to,crixivan 1.0 0.000286697247706 0 2 -2
of,mefenamic 0.0 0.0 1 1 0
of,urinary 1.0 0.00043004587156 0 3 -3
was,with 1.0 0.000143348623853 1 0 1
and,type 0.6 0.00043004587156 4 1 3
hypotension,patients 1.0 0.00043004587156 3 0 3
after,receiving 1.0 0.000286697247706 2 0 2
revealed,necrotizing 1.0 0.000143348623853 0 1 -1
oral,load 1.0 0.000143348623853 0 1 -1
were,in 0.333333333333 0.000143348623853 1 2 -1
motility,in 0.333333333333 0.000143348623853 1 2 -1
no,binding 1.0 0.000143348623853 0 1 -1
electrolyte,loss 1.0 0.000286697247706 2 0 2
of,combination 0.0 0.0 1 1 0
n,the 1.0 0.000143348623853 1 0 1
complicated,or 1.0 0.000143348623853 0 1 -1
fold,increases 0.0 0.0 1 1 0
before,to 1.0 0.000286697247706 0 2 -2
we,present 1.0 0.000143348623853 0 1 -1
in,proprietary 1.0 0.000143348623853 1 0 1
with,amevive 1.0 0.000143348623853 0 1 -1
seen,prior 1.0 0.000143348623853 1 0 1
agents,clomipramine 1.0 0.000143348623853 1 0 1
as,myelosuppression 1.0 0.000143348623853 1 0 1
quai,and 1.0 0.000143348623853 0 1 -1
altering,prothrombin 1.0 0.000143348623853 1 0 1
of,ergocalcitriol 0.333333333333 0.000286697247706 2 4 -2
striatal,concentrations 1.0 0.000143348623853 1 0 1
assistance,in 1.0 0.000143348623853 0 1 -1
inhibitors,prostaglandin 1.0 0.000143348623853 0 1 -1
administered,hydrochloride 1.0 0.000143348623853 0 1 -1
and,effects 0.25 0.000286697247706 5 3 2
efficacy,the 1.0 0.000143348623853 0 1 -1
systemic,non-hodgkin 1.0 0.000143348623853 0 1 -1
copegus,should 1.0 0.000143348623853 0 1 -1
with,prolongation 1.0 0.000143348623853 0 1 -1
twitch,was 0.333333333333 0.000143348623853 1 2 -1
introductory,chapter 1.0 0.000143348623853 0 1 -1
significant,degree 1.0 0.000286697247706 0 2 -2
and,cholestytamine 1.0 0.000143348623853 1 0 1
proof,of 1.0 0.000143348623853 0 1 -1
pharmacokinetics,produced 1.0 0.000143348623853 1 0 1
because,nephrotoxicity 1.0 0.000143348623853 1 0 1
and,would 0.0 0.0 2 2 0
immunodeficiency,virus-positive 1.0 0.000143348623853 0 1 -1
was,prevented 1.0 0.000286697247706 2 0 2
similar,compounds 1.0 0.000143348623853 0 1 -1
verapamil,coadministration 1.0 0.000143348623853 1 0 1
blood,plasma 1.0 0.000286697247706 0 2 -2
rats,responses 1.0 0.000143348623853 0 1 -1
aprepitant,given 1.0 0.000143348623853 1 0 1
the,curariform 1.0 0.000143348623853 1 0 1
reports,of 0.116279069767 0.000716743119266 24 19 5
designing,experiments 1.0 0.000143348623853 0 1 -1
is,almost 1.0 0.000143348623853 0 1 -1
the,effectiveness 0.111111111111 0.000143348623853 5 4 1
hydrochloride,in 1.0 0.000143348623853 1 0 1
clearance,of 0.448275862069 0.00372706422018 42 16 26
contraceptives,may 1.0 0.000143348623853 0 1 -1
account,the 1.0 0.000286697247706 0 2 -2
appeared,to 0.25 0.000286697247706 5 3 2
can,prolong 0.0 0.0 1 1 0
antiepilepsy,drugs 0.0 0.0 1 1 0
clearance,or 0.666666666667 0.000573394495413 1 5 -4
hydrochloride,is 0.2 0.000143348623853 3 2 1
of,dialyzable 1.0 0.000143348623853 0 1 -1
also,interfere 1.0 0.000143348623853 1 0 1
may,intensify 0.333333333333 0.000143348623853 1 2 -1
of,potential 0.0 0.0 1 1 0
dosing,schedule 1.0 0.000143348623853 0 1 -1
one,dose 0.0 0.0 1 1 0
report,the 1.0 0.000143348623853 1 0 1
whom,renal 1.0 0.000143348623853 0 1 -1
diuretics,studies 1.0 0.000143348623853 1 0 1
served,as 1.0 0.000286697247706 0 2 -2
of,platelet 0.5 0.000286697247706 1 3 -2
elimination,but 1.0 0.000143348623853 1 0 1
following,administration 0.0 0.0 4 4 0
following,symptom 1.0 0.000143348623853 0 1 -1
cystic,fibrosis 1.0 0.000143348623853 0 1 -1
of,inhibition 0.555555555556 0.000716743119266 7 2 5
in,multiple 1.0 0.000286697247706 0 2 -2
indicating,an 1.0 0.000143348623853 0 1 -1
which,only 1.0 0.000143348623853 0 1 -1
add,to 1.0 0.000286697247706 2 0 2
failure,cannot 1.0 0.000143348623853 0 1 -1
blockade,by 1.0 0.000286697247706 2 0 2
cyp3a4,alter 1.0 0.000143348623853 0 1 -1
or,with 0.176470588235 0.00043004587156 7 10 -3
oral,azole 1.0 0.000143348623853 1 0 1
sodium,alone 1.0 0.000143348623853 0 1 -1
nature,of 1.0 0.00043004587156 0 3 -3
the,inhibiting 1.0 0.000143348623853 0 1 -1
v,has 1.0 0.000143348623853 0 1 -1
their,effectiveness 1.0 0.000143348623853 0 1 -1
ssris,many 1.0 0.000143348623853 0 1 -1
taking,labetalol 1.0 0.000143348623853 1 0 1
with,fondaparinux 1.0 0.000143348623853 0 1 -1
difference,between 1.0 0.000286697247706 0 2 -2
dpcpx,in 1.0 0.000143348623853 0 1 -1
above,or 0.333333333333 0.000143348623853 1 2 -1
or,radiation 1.0 0.000143348623853 0 1 -1
containing,medicines 1.0 0.000143348623853 1 0 1
significantly,lowered 1.0 0.000143348623853 0 1 -1
clonidine,therapy 1.0 0.000143348623853 0 1 -1
cause,much 1.0 0.000143348623853 0 1 -1
therapy,the 0.2 0.000143348623853 3 2 1
during,administration 0.2 0.000143348623853 3 2 1
felbatol,therapy 1.0 0.000143348623853 0 1 -1
binding,domain 1.0 0.000143348623853 0 1 -1
kappa-selective,was 1.0 0.000143348623853 0 1 -1
tcas,decrease 1.0 0.000143348623853 1 0 1
to,rachitic 1.0 0.000143348623853 1 0 1
cardiac,output 1.0 0.000286697247706 2 0 2
mc,a 1.0 0.000143348623853 0 1 -1
cmax,respectively 1.0 0.000143348623853 0 1 -1
dosing,regimens 1.0 0.000286697247706 0 2 -2
confidence,limit 1.0 0.000143348623853 0 1 -1
in,phase 1.0 0.000286697247706 0 2 -2
mellitus,and 1.0 0.000143348623853 0 1 -1
internal,application 1.0 0.000143348623853 0 1 -1
indomethacin,concomitant 1.0 0.000143348623853 1 0 1
on,blocking 1.0 0.000143348623853 0 1 -1
be,under 1.0 0.000143348623853 0 1 -1
the,appearance 0.5 0.000286697247706 1 3 -2
methotrexate,vioxx 1.0 0.000143348623853 0 1 -1
pyrocarbonate,revealed 1.0 0.000143348623853 0 1 -1
synthesis,secretion 1.0 0.000286697247706 0 2 -2
interactions,increases 1.0 0.000143348623853 0 1 -1
against,engaging 1.0 0.000143348623853 0 1 -1
growth,response 1.0 0.000143348623853 0 1 -1
generalized,urticaria 1.0 0.000143348623853 0 1 -1
sinus,arrest 1.0 0.000143348623853 0 1 -1
proof,by 1.0 0.000143348623853 0 1 -1
that,contains 1.0 0.000143348623853 0 1 -1
indirect,antiglobulin 1.0 0.000143348623853 0 1 -1
when,systemic 1.0 0.000143348623853 1 0 1
the,impact 1.0 0.00043004587156 0 3 -3
their,condition 1.0 0.000143348623853 0 1 -1
testing,of 1.0 0.000143348623853 0 1 -1
supplements,with 1.0 0.000143348623853 0 1 -1
years,old 1.0 0.000143348623853 0 1 -1
although,activation 1.0 0.000143348623853 0 1 -1
tolerability,of 1.0 0.000143348623853 0 1 -1
cholestyramine,cholestyramine 1.0 0.000716743119266 5 0 5
of,level 1.0 0.000143348623853 1 0 1
of,excretion 0.5 0.000286697247706 1 3 -2
protective,or 1.0 0.000143348623853 0 1 -1
of,may 0.424242424242 0.00401376146789 47 19 28
of,pcp 0.5 0.000573394495413 2 6 -4
rats,whereas 1.0 0.000143348623853 0 1 -1
safety,and 0.714285714286 0.00143348623853 2 12 -10
its,pharmacologically 1.0 0.000143348623853 0 1 -1
excessively,to 1.0 0.000143348623853 0 1 -1
stereoselective,behavioral 1.0 0.000143348623853 0 1 -1
the,bleeding 1.0 0.000143348623853 1 0 1
of,mao 0.0 0.0 1 1 0
component,p2 1.0 0.000286697247706 0 2 -2
of,mac 1.0 0.000143348623853 0 1 -1
samples,may 1.0 0.000143348623853 0 1 -1
neurotoxin,serotypes 1.0 0.000286697247706 0 2 -2
false,increases 1.0 0.00043004587156 0 3 -3
be,informed 1.0 0.000286697247706 0 2 -2
secondary,deficiencies 1.0 0.000143348623853 0 1 -1
k,can 1.0 0.000143348623853 1 0 1
contraindicated,since 1.0 0.000143348623853 0 1 -1
result,that 1.0 0.000143348623853 0 1 -1
useful,tool 1.0 0.000143348623853 0 1 -1
patients,either 1.0 0.000143348623853 0 1 -1
results,sildenafil 1.0 0.000143348623853 0 1 -1
amprenavir,decreased 1.0 0.000143348623853 0 1 -1
iii,human 1.0 0.000143348623853 1 0 1
digoxin,half-life 1.0 0.000143348623853 0 1 -1
function,are 1.0 0.000286697247706 0 2 -2
protein,added 1.0 0.000143348623853 0 1 -1
ml,the 1.0 0.000143348623853 1 0 1
unprotected,by 1.0 0.000143348623853 0 1 -1
full,duration 1.0 0.000143348623853 0 1 -1
cyclosporine,doses 1.0 0.000143348623853 0 1 -1
of,diamox 1.0 0.000286697247706 2 0 2
compound,and 1.0 0.000143348623853 0 1 -1
humira,may 1.0 0.000143348623853 1 0 1
under,therapy 1.0 0.000143348623853 1 0 1
formulations,of 1.0 0.000143348623853 1 0 1
control,should 1.0 0.000143348623853 1 0 1
failure,receiving 1.0 0.000143348623853 1 0 1
data,and 1.0 0.000143348623853 0 1 -1
on,maintenance 1.0 0.000143348623853 0 1 -1
glands,with 1.0 0.000286697247706 0 2 -2
ci,in 1.0 0.000286697247706 0 2 -2
administering,celebrex 1.0 0.000143348623853 1 0 1
back,pain 1.0 0.000143348623853 0 1 -1
that,prolonged 1.0 0.000143348623853 0 1 -1
ranitidine,mg 1.0 0.000143348623853 0 1 -1
no,evaluation 1.0 0.000143348623853 0 1 -1
cytotoxic,agents 1.0 0.000143348623853 1 0 1
than,optimal 1.0 0.000143348623853 0 1 -1
day,has 1.0 0.000143348623853 0 1 -1
persistence,of 1.0 0.000143348623853 0 1 -1
there,are 0.666666666667 0.00344036697248 6 30 -24
concentrations,caution 1.0 0.000143348623853 1 0 1
screening,for 1.0 0.000143348623853 0 1 -1
with,moieties 1.0 0.000143348623853 0 1 -1
cyp,enzyme 1.0 0.000143348623853 0 1 -1
more,were 1.0 0.000143348623853 0 1 -1
the,a-v 1.0 0.000143348623853 1 0 1
deficiency,is 1.0 0.000143348623853 0 1 -1
ld50,of 1.0 0.000143348623853 1 0 1
these,instances 1.0 0.000143348623853 0 1 -1
consequently,interactions 1.0 0.000143348623853 0 1 -1
significant,inhibition 0.333333333333 0.000143348623853 1 2 -1
novolog,with 1.0 0.000286697247706 0 2 -2
users,is 1.0 0.000143348623853 0 1 -1
consequently,the 1.0 0.000286697247706 2 0 2
reactions,at 1.0 0.000143348623853 0 1 -1
of,virologic 1.0 0.00043004587156 0 3 -3
that,acarbose 1.0 0.000143348623853 0 1 -1
release,from 1.0 0.000143348623853 1 0 1
that,several 1.0 0.000143348623853 0 1 -1
maximum,human 0.0 0.0 1 1 0
isolates,and 1.0 0.000143348623853 0 1 -1
small,when 1.0 0.000143348623853 1 0 1
year,risk 1.0 0.000143348623853 0 1 -1
more,likely 1.0 0.000286697247706 0 2 -2
fibers,in 1.0 0.000143348623853 0 1 -1
to,exaggerated 1.0 0.000143348623853 0 1 -1
conditioning,processes 1.0 0.000143348623853 0 1 -1
cause,a 0.0 0.0 6 6 0
who,received 0.555555555556 0.000716743119266 2 7 -5
tumor,response 1.0 0.000143348623853 0 1 -1
cause,k 1.0 0.000143348623853 0 1 -1
optimal,and 1.0 0.000143348623853 0 1 -1
separate,randomized 1.0 0.000143348623853 0 1 -1
as,interaction 1.0 0.000143348623853 0 1 -1
concentrations,was 1.0 0.000143348623853 0 1 -1
and,medical 1.0 0.000143348623853 0 1 -1
digoxin,sonata 1.0 0.000143348623853 0 1 -1
other,anti-asthma 1.0 0.000143348623853 0 1 -1
group,specifically 1.0 0.000143348623853 0 1 -1
disulfiram-like,reaction 1.0 0.000286697247706 0 2 -2
psychotomimetic,effects 1.0 0.000143348623853 0 1 -1
four,subjects 1.0 0.000143348623853 0 1 -1
these,peptides 1.0 0.000143348623853 0 1 -1
p,the 1.0 0.000143348623853 1 0 1
january,and 1.0 0.000143348623853 0 1 -1
are,strong 1.0 0.000143348623853 0 1 -1
any,combination 1.0 0.000143348623853 0 1 -1
a,twofold 1.0 0.000143348623853 1 0 1
in,hematologic 1.0 0.000143348623853 0 1 -1
fluid,were 1.0 0.000143348623853 1 0 1
affect,duloxetine 1.0 0.000143348623853 0 1 -1
interactions,that 1.0 0.000143348623853 0 1 -1
vaccine,inhalation 1.0 0.000143348623853 1 0 1
reactions,was 1.0 0.000143348623853 0 1 -1
hydrochlorothiazide,given 1.0 0.000143348623853 1 0 1
or,but 1.0 0.000143348623853 1 0 1
recommended,depending 1.0 0.000143348623853 0 1 -1
and,uptake 1.0 0.000286697247706 0 2 -2
determined,urinary 1.0 0.000143348623853 0 1 -1
to,iodinated 1.0 0.000143348623853 1 0 1
agents,was 1.0 0.000286697247706 0 2 -2
may,also 0.272727272727 0.00129013761468 12 21 -9
of,coagulation 1.0 0.000143348623853 0 1 -1
symptom,control 1.0 0.000143348623853 1 0 1
pivoxil,had 1.0 0.000143348623853 0 1 -1
that,some 1.0 0.000143348623853 0 1 -1
antitumor,activity 1.0 0.000143348623853 0 1 -1
hepatotoxic,medications 0.0 0.0 1 1 0
no,dose 1.0 0.00143348623853 0 10 -10
of,pegasys 1.0 0.00100344036697 0 7 -7
potentiates,increasing 1.0 0.000286697247706 0 2 -2
cisplatin,was 1.0 0.000143348623853 0 1 -1
cmax,the 1.0 0.000143348623853 0 1 -1
mug,ml 1.0 0.000286697247706 0 2 -2
acting,nitrates 1.0 0.000143348623853 0 1 -1
nardil,matulane 1.0 0.000143348623853 0 1 -1
faecalis,atcc 1.0 0.000143348623853 0 1 -1
dosing,beta-1a 1.0 0.000143348623853 1 0 1
no,detectable 1.0 0.000143348623853 0 1 -1
n-type,or 1.0 0.000143348623853 0 1 -1
nerve,vacuolation 1.0 0.000143348623853 0 1 -1
a,antimicrobial 1.0 0.000286697247706 2 0 2
use,by 1.0 0.000143348623853 0 1 -1
without,difficulty 1.0 0.000143348623853 0 1 -1
approximately,times 0.5 0.000573394495413 2 6 -4
serious,reaction 1.0 0.000143348623853 1 0 1
a,chronic 1.0 0.000143348623853 0 1 -1
n,cmax 1.0 0.000143348623853 0 1 -1
a,precipitating 1.0 0.000143348623853 0 1 -1
given,concomitantly 0.166666666667 0.000573394495413 10 14 -4
some,are 1.0 0.000143348623853 0 1 -1
careful,observations 1.0 0.000143348623853 1 0 1
an,earlier 1.0 0.000143348623853 0 1 -1
produce,artifactually 1.0 0.000143348623853 0 1 -1
by,those 1.0 0.000286697247706 0 2 -2
this,acid-catalyzed 1.0 0.000143348623853 0 1 -1
suspending,use 1.0 0.000143348623853 1 0 1
the,supplements 1.0 0.000143348623853 0 1 -1
average,infusion 1.0 0.000143348623853 0 1 -1
and,haldol 1.0 0.000143348623853 0 1 -1
specifically,been 1.0 0.000286697247706 0 2 -2
failure,have 1.0 0.000143348623853 1 0 1
sometimes,mcg 1.0 0.000143348623853 0 1 -1
patch-clamp,whole-cell 1.0 0.000143348623853 0 1 -1
than,one 1.0 0.000286697247706 0 2 -2
colonic,fluid 1.0 0.000286697247706 0 2 -2
not,conclude 1.0 0.000143348623853 0 1 -1
the,treatment 0.454545454545 0.0021502293578 9 24 -15
chemical,carcinogen 1.0 0.000143348623853 0 1 -1
of,influence 1.0 0.000143348623853 0 1 -1
the,second 0.555555555556 0.000716743119266 2 7 -5
hyperkalemia,in 1.0 0.000143348623853 1 0 1
and,channel 0.333333333333 0.000143348623853 2 1 1
to,saline 1.0 0.000143348623853 0 1 -1
mice,showed 1.0 0.000286697247706 0 2 -2
lymphocytopenia,has 1.0 0.000143348623853 1 0 1
oral,a 1.0 0.000143348623853 1 0 1
mg,m2 0.428571428571 0.00043004587156 2 5 -3
and,highly 1.0 0.000143348623853 0 1 -1
or,similarly 1.0 0.000143348623853 0 1 -1
that,not 1.0 0.000143348623853 1 0 1
sinus,rhythm 1.0 0.000143348623853 1 0 1
intercourse,without 1.0 0.000143348623853 0 1 -1
concentrations,lower 1.0 0.000143348623853 0 1 -1
effects,by 0.0 0.0 1 1 0
widening,of 0.0 0.0 1 1 0
cmax,t1 1.0 0.000143348623853 1 0 1
public,feels 1.0 0.000143348623853 0 1 -1
measured,near 1.0 0.000143348623853 0 1 -1
phosphate,transport 1.0 0.00043004587156 0 3 -3
chronic,treatments 1.0 0.000143348623853 0 1 -1
fluoxetine,ocs 1.0 0.000143348623853 0 1 -1
infection,oi 1.0 0.000143348623853 0 1 -1
if,hydrochloride 1.0 0.000143348623853 1 0 1
finding,to 1.0 0.000143348623853 0 1 -1
hatching,survival 1.0 0.000143348623853 0 1 -1
significant,fluctuations 1.0 0.000143348623853 1 0 1
given,plasma 1.0 0.000143348623853 0 1 -1
mg,mg 1.0 0.00043004587156 0 3 -3
pointes-type,ventricular 1.0 0.000143348623853 0 1 -1
or,no 0.142857142857 0.000143348623853 3 4 -1
caused,subnormal 1.0 0.000143348623853 0 1 -1
toxicity,have 1.0 0.000573394495413 4 0 4
gleevec,will 1.0 0.000143348623853 1 0 1
models,and 1.0 0.000143348623853 0 1 -1
tambocor,has 1.0 0.000286697247706 0 2 -2
increased,rate 0.333333333333 0.000143348623853 2 1 1
severe,orthostatic 1.0 0.000143348623853 1 0 1
periods,with 1.0 0.000143348623853 0 1 -1
derivatives,indandione 1.0 0.000143348623853 1 0 1
impotence,inability 1.0 0.000143348623853 0 1 -1
only,when 1.0 0.000143348623853 0 1 -1
arthritis,and 1.0 0.000143348623853 0 1 -1
to,environmental 1.0 0.000143348623853 1 0 1
administered,several 1.0 0.000143348623853 0 1 -1
including,sodium 1.0 0.000143348623853 1 0 1
two-fold,increase 1.0 0.000143348623853 1 0 1
carried,out 1.0 0.00157683486239 0 11 -11
activated,prothrombin 1.0 0.000143348623853 0 1 -1
synthetic,hydroalcoholic 1.0 0.000143348623853 0 1 -1
blood,platelets 1.0 0.000143348623853 1 0 1
metabolite,have 1.0 0.000143348623853 0 1 -1
and,endocrine 1.0 0.000143348623853 0 1 -1
of,disrupts 1.0 0.000143348623853 0 1 -1
clearance,such 1.0 0.000143348623853 1 0 1
second,response 1.0 0.000143348623853 0 1 -1
acid,antagonists 1.0 0.000143348623853 1 0 1
metabolised,therefore 1.0 0.000143348623853 0 1 -1
fractions,of 1.0 0.000143348623853 0 1 -1
did,it 1.0 0.000143348623853 0 1 -1
of,fertility 1.0 0.000573394495413 0 4 -4
hallucinations,and 1.0 0.000143348623853 1 0 1
fractions,on 1.0 0.000143348623853 0 1 -1
approximately,the 1.0 0.000143348623853 0 1 -1
inhibits,cyp1a2 1.0 0.000143348623853 0 1 -1
symptoms,of 0.333333333333 0.000573394495413 8 4 4
events,have 0.333333333333 0.000143348623853 2 1 1
zalcitabine,also 1.0 0.000143348623853 1 0 1
toxicity,because 1.0 0.000143348623853 0 1 -1
tolbutamide,aprepitant 1.0 0.000143348623853 1 0 1
sildenafil,is 0.0 0.0 1 1 0
transient,peak 1.0 0.000143348623853 0 1 -1
no,pharmacokinetic-based 1.0 0.000143348623853 0 1 -1
cyp,p450 1.0 0.000143348623853 0 1 -1
insufficient,plasma 1.0 0.000143348623853 1 0 1
that,concentrations 1.0 0.000143348623853 1 0 1
both,sensory 1.0 0.000143348623853 1 0 1
commonly,used 1.0 0.00129013761468 0 9 -9
inderal,tenormin 1.0 0.000143348623853 0 1 -1
receptors,such 1.0 0.000143348623853 1 0 1
an,alteration 1.0 0.00043004587156 0 3 -3
histology,of 1.0 0.000143348623853 0 1 -1
of,once 1.0 0.000286697247706 2 0 2
obesity,dorsocervical 1.0 0.000143348623853 0 1 -1
rantidine,hydrochloride 1.0 0.000143348623853 0 1 -1
lithium,toxicity 1.0 0.00043004587156 3 0 3
erythromycin,on 1.0 0.000143348623853 0 1 -1
high-dose,mg 1.0 0.000143348623853 1 0 1
important,role 0.333333333333 0.000143348623853 2 1 1
at,steady 0.111111111111 0.000143348623853 4 5 -1
predictable,sympathetic 1.0 0.000143348623853 1 0 1
time,when 0.0 0.0 1 1 0
ketoconazole,fexofenadine 1.0 0.000143348623853 0 1 -1
ways,of 1.0 0.000143348623853 0 1 -1
microsomes,suggest 1.0 0.000143348623853 0 1 -1
review,of 0.5 0.000286697247706 1 3 -2
a,pharmacokinetic 0.2 0.000286697247706 4 6 -2
for,strains 0.0 0.0 1 1 0
table,table 1.0 0.000143348623853 0 1 -1
bezalip,and 1.0 0.000143348623853 1 0 1
of,nevirapine 1.0 0.000143348623853 0 1 -1
commonly,employed 1.0 0.00043004587156 0 3 -3
strain,of 1.0 0.000286697247706 0 2 -2
ancobon,does 1.0 0.000143348623853 0 1 -1
conversely,the 0.0 0.0 1 1 0
strategy,can 1.0 0.000143348623853 0 1 -1
in,rheumatoid 1.0 0.000573394495413 0 4 -4
times,less 1.0 0.000143348623853 0 1 -1
surface,area 1.0 0.00043004587156 0 3 -3
also,included 1.0 0.000143348623853 0 1 -1
also,shown 0.333333333333 0.000143348623853 1 2 -1
for,by 1.0 0.000143348623853 1 0 1
plays,an 1.0 0.000143348623853 0 1 -1
sgot,alt 1.0 0.000143348623853 0 1 -1
a,reduced 0.333333333333 0.000143348623853 1 2 -1
the,total 0.666666666667 0.000573394495413 1 5 -4
which,causes 1.0 0.000143348623853 1 0 1
antihistamines,amphetamines 1.0 0.000286697247706 2 0 2
intravenous,bolus 1.0 0.000143348623853 0 1 -1
cyp,a4 0.6 0.00129013761468 3 12 -9
therefore,subtle 1.0 0.000143348623853 0 1 -1
combination,arenot 1.0 0.000286697247706 0 2 -2
fici,was 1.0 0.000143348623853 0 1 -1
as,salicylic 1.0 0.000143348623853 0 1 -1
dosing,may 1.0 0.000143348623853 0 1 -1
from,breast 1.0 0.000143348623853 0 1 -1
occurs,with 1.0 0.000860091743119 0 6 -6
acamprosate,produced 1.0 0.000143348623853 1 0 1
radioactive,derivative 1.0 0.000143348623853 0 1 -1
would,not 1.0 0.00114678899083 0 8 -8
cases,of 0.157894736842 0.00043004587156 8 11 -3
pharmacokinetic,variables 1.0 0.000286697247706 0 2 -2
of,amevive 1.0 0.000573394495413 0 4 -4
because,prostaglandins 1.0 0.000143348623853 1 0 1
enzymes,the 1.0 0.000143348623853 1 0 1
aggregation,the 1.0 0.000143348623853 0 1 -1
observed,for 0.473684210526 0.00129013761468 5 14 -9
are,substrates 1.0 0.0021502293578 0 15 -15
and,lessened 1.0 0.000143348623853 1 0 1
and,unexpected 1.0 0.000143348623853 0 1 -1
clonidines,analgesic 1.0 0.000143348623853 0 1 -1
high,inter-patient 1.0 0.000143348623853 0 1 -1
b12,deficiency 1.0 0.000143348623853 0 1 -1
biocytin,inclusion 1.0 0.000143348623853 0 1 -1
blood,auc0-12 1.0 0.000143348623853 1 0 1
cream,and 1.0 0.000143348623853 0 1 -1
both,human 1.0 0.000143348623853 0 1 -1
do,occur 1.0 0.000143348623853 0 1 -1
rebif,is 1.0 0.000286697247706 0 2 -2
although,additional 1.0 0.000143348623853 0 1 -1
to,representing 1.0 0.000143348623853 1 0 1
g,bolus 1.0 0.000286697247706 0 2 -2
crucial,to 1.0 0.000143348623853 0 1 -1
in,causing 1.0 0.000143348623853 1 0 1
cyp2c8,in 1.0 0.000143348623853 0 1 -1
not,equivalent 1.0 0.000143348623853 0 1 -1
insulin,a 1.0 0.000143348623853 0 1 -1
doses,up 0.75 0.000860091743119 1 7 -6
mean,ratios 1.0 0.000143348623853 0 1 -1
agitation,progressing 1.0 0.000143348623853 1 0 1
own,pre- 1.0 0.000143348623853 0 1 -1
altered,decrease 1.0 0.000143348623853 1 0 1
disease,on 1.0 0.000143348623853 0 1 -1
disease,or 1.0 0.000143348623853 1 0 1
of,different 1.0 0.000573394495413 0 4 -4
acute,symptoms 1.0 0.000143348623853 0 1 -1
times,more 1.0 0.000143348623853 0 1 -1
be,due 0.714285714286 0.000716743119266 1 6 -5
intestine,kidneys 1.0 0.00043004587156 0 3 -3
cyp3a,cytochrome 1.0 0.000143348623853 0 1 -1
or,videx 1.0 0.00043004587156 3 0 3
greater,in 0.142857142857 0.000143348623853 4 3 1
and,free 1.0 0.000143348623853 0 1 -1
elements,had 1.0 0.000143348623853 0 1 -1
genetically,diabetic 1.0 0.000286697247706 0 2 -2
diarrhea,and 0.0 0.0 1 1 0
sodium,sulfate 1.0 0.000143348623853 0 1 -1
ask,your 1.0 0.000143348623853 0 1 -1
epidural,include 1.0 0.000143348623853 1 0 1
atrioventricular,conduction 1.0 0.000143348623853 1 0 1
foradil,is 1.0 0.000143348623853 0 1 -1
since,drowsiness 1.0 0.000143348623853 0 1 -1
rashes,with 1.0 0.000143348623853 0 1 -1
although,certain 1.0 0.000143348623853 0 1 -1
preparations,nsaids 1.0 0.000143348623853 0 1 -1
a,multiple 0.0 0.0 1 1 0
was,far 1.0 0.000143348623853 0 1 -1
twofold,at 1.0 0.000143348623853 0 1 -1
whether,this 0.777777777778 0.00100344036697 1 8 -7
are,becoming 1.0 0.000143348623853 0 1 -1
for,realization 1.0 0.000143348623853 0 1 -1
antagonism,between 1.0 0.000143348623853 1 0 1
further,in 1.0 0.00043004587156 0 3 -3
to,exceed 1.0 0.00043004587156 3 0 3
climbing,paperhanging 1.0 0.000143348623853 0 1 -1
further,if 1.0 0.000143348623853 0 1 -1
of,creams 1.0 0.000143348623853 0 1 -1
are,receiving 0.6 0.00043004587156 4 1 3
mood,states 1.0 0.000143348623853 0 1 -1
transmission,at 1.0 0.000143348623853 0 1 -1
advantages,and 1.0 0.000143348623853 0 1 -1
mg,subcutaneous 1.0 0.000143348623853 0 1 -1
what,to 1.0 0.000143348623853 0 1 -1
toradol,with 1.0 0.000143348623853 0 1 -1
therapeutic,interval 1.0 0.000143348623853 0 1 -1
eg,an 1.0 0.000143348623853 1 0 1
triazolam,no 1.0 0.000143348623853 0 1 -1
will,have 0.0 0.0 1 1 0
inhibitor,plus 1.0 0.000143348623853 1 0 1
prolonging,the 1.0 0.000143348623853 0 1 -1
improved,glucose 1.0 0.000143348623853 0 1 -1
of,pharmacogenetics 1.0 0.000143348623853 0 1 -1
phenyl-butazone,sodium 1.0 0.000143348623853 0 1 -1
needs,urgently 1.0 0.000143348623853 0 1 -1
after,consumption 1.0 0.000143348623853 0 1 -1
made,to 1.0 0.000143348623853 0 1 -1
the,beginning 1.0 0.000286697247706 0 2 -2
dangerous,machinery 1.0 0.000143348623853 0 1 -1
antimuscarinic,effects 0.0 0.0 1 1 0
concurrently,administered 0.5 0.000286697247706 1 3 -2
than,or 1.0 0.000143348623853 0 1 -1
metoprolol,administration 1.0 0.000143348623853 1 0 1
in,hypothyroid 1.0 0.00043004587156 0 3 -3
concurrently,without 1.0 0.000143348623853 0 1 -1
bioavailability,auc 0.6 0.00043004587156 1 4 -3
toxicity,has 1.0 0.000573394495413 4 0 4
cataflam,lodine 1.0 0.000143348623853 0 1 -1
or,qt 1.0 0.000143348623853 0 1 -1
using,isoform 1.0 0.000143348623853 0 1 -1
hydroxide,reduce 1.0 0.000143348623853 1 0 1
transient,and 1.0 0.000143348623853 0 1 -1
manner,similar 1.0 0.000143348623853 0 1 -1
exposure-response,relationships 1.0 0.000286697247706 0 2 -2
wheals,and 1.0 0.000143348623853 0 1 -1
anticancer,and 1.0 0.000143348623853 1 0 1
with,little 1.0 0.000286697247706 2 0 2
synergism,between 1.0 0.000143348623853 1 0 1
increased,catabloism 1.0 0.000143348623853 0 1 -1
and,extensive 1.0 0.000143348623853 0 1 -1
regulate,the 1.0 0.000143348623853 1 0 1
potential,adverse 1.0 0.000143348623853 0 1 -1
inactive,metabolites 1.0 0.000143348623853 0 1 -1
bind,to 1.0 0.000143348623853 0 1 -1
large,decrease 1.0 0.000143348623853 0 1 -1
and,prevalence 1.0 0.000143348623853 0 1 -1
a,has 1.0 0.000143348623853 1 0 1
retard,may 1.0 0.000143348623853 1 0 1
iressa,may 1.0 0.000143348623853 1 0 1
in,other 0.333333333333 0.000143348623853 1 2 -1
data,emphasize 1.0 0.000143348623853 0 1 -1
of,basal 1.0 0.000143348623853 0 1 -1
is,increased 0.666666666667 0.000573394495413 5 1 4
including,nonsteroidal 1.0 0.000573394495413 4 0 4
studied,for 1.0 0.000143348623853 0 1 -1
states,careful 1.0 0.000143348623853 0 1 -1
and,administration 1.0 0.000286697247706 0 2 -2
when,initiating 1.0 0.00114678899083 8 0 8
significant,changes 1.0 0.00129013761468 0 9 -9
nalfon,may 1.0 0.000286697247706 2 0 2
markedly,increases 1.0 0.000143348623853 1 0 1
tmax,by 1.0 0.000143348623853 1 0 1
mycobacteriumavium-intracellulare,complex 1.0 0.000143348623853 0 1 -1
of,enflurane 1.0 0.000143348623853 0 1 -1
with,infusion 1.0 0.000143348623853 0 1 -1
equetrotm,and 0.0 0.0 1 1 0
bolus-ifl,with 1.0 0.000143348623853 0 1 -1
activation,in 1.0 0.000143348623853 0 1 -1
responses,and 1.0 0.000143348623853 0 1 -1
ingested,or 1.0 0.000143348623853 0 1 -1
dosage,reduced 1.0 0.000143348623853 1 0 1
bring,into 1.0 0.000143348623853 0 1 -1
provide,misleading 1.0 0.000143348623853 0 1 -1
nonselective,monoamine 1.0 0.000143348623853 1 0 1
pharmacology,drug- 1.0 0.000143348623853 0 1 -1
free,concentrations 1.0 0.000286697247706 0 2 -2
faecalis,and 1.0 0.000143348623853 0 1 -1
fluconazole,an 1.0 0.000143348623853 1 0 1
only,at 1.0 0.000716743119266 0 5 -5
only,as 1.0 0.000143348623853 0 1 -1
cmc-cys,conjugates 1.0 0.000143348623853 0 1 -1
be,without 1.0 0.000143348623853 1 0 1
not,shown 0.0 0.0 1 1 0
low-dose,mg 1.0 0.000286697247706 0 2 -2
a,proper 1.0 0.000143348623853 0 1 -1
neurons,hyperpolarized 1.0 0.000286697247706 0 2 -2
by,certain 1.0 0.00043004587156 3 0 3
the,uptake 0.0 0.0 1 1 0
similar,regardless 1.0 0.000143348623853 0 1 -1
fold,at 1.0 0.000143348623853 1 0 1
plasma,and 0.2 0.000286697247706 4 6 -2
and,toxicokinetic 1.0 0.000143348623853 0 1 -1
although,inhibition 1.0 0.000143348623853 0 1 -1
cytoplasmic,condensation 1.0 0.000143348623853 0 1 -1
cyp3a4,nor 1.0 0.000143348623853 0 1 -1
since,elevations 1.0 0.000143348623853 0 1 -1
infarction,myocarditis 1.0 0.000143348623853 1 0 1
for,interactions 0.5 0.000286697247706 1 3 -2
approximately,twofold 0.0 0.0 1 1 0
discontinued,for 1.0 0.000143348623853 1 0 1
probably,the 1.0 0.000143348623853 0 1 -1
of,bleeding 0.142857142857 0.000143348623853 3 4 -1
drugs,hallucinations 1.0 0.000143348623853 1 0 1
make,your 1.0 0.000143348623853 0 1 -1
become,more 1.0 0.000286697247706 0 2 -2
supplements,affect 1.0 0.000143348623853 0 1 -1
blockers,such 0.0 0.0 1 1 0
this,difference 1.0 0.000143348623853 0 1 -1
acid,because 1.0 0.000143348623853 1 0 1
kg,person 1.0 0.000286697247706 0 2 -2
urine,using 1.0 0.000573394495413 0 4 -4
gaba-positive,be 1.0 0.000143348623853 0 1 -1
multiple,fixed-interval 1.0 0.000143348623853 0 1 -1
toxic,action 1.0 0.000143348623853 0 1 -1
and,indocin 1.0 0.000143348623853 1 0 1
with,viracept 0.714285714286 0.000716743119266 6 1 5
potentiating,effect 1.0 0.00043004587156 3 0 3
tests,based 1.0 0.000860091743119 0 6 -6
time,sst 1.0 0.000143348623853 0 1 -1
per,kg 1.0 0.000143348623853 1 0 1
increased,clinical 1.0 0.000143348623853 1 0 1
ic,was 1.0 0.000143348623853 0 1 -1
was,admitted 1.0 0.000143348623853 0 1 -1
comparing,the 1.0 0.000286697247706 0 2 -2
impairment,in 1.0 0.000143348623853 0 1 -1
other,binding 1.0 0.000286697247706 0 2 -2
is,mg 1.0 0.000143348623853 0 1 -1
are,lower 1.0 0.000143348623853 0 1 -1
diminished,response 1.0 0.000143348623853 1 0 1
formation,from 1.0 0.000143348623853 1 0 1
on,travelers 1.0 0.000143348623853 1 0 1
daily,or 1.0 0.000143348623853 0 1 -1
uniformity,and 1.0 0.000143348623853 0 1 -1
an,hydroxide 1.0 0.000286697247706 2 0 2
the,conversion 0.666666666667 0.000573394495413 1 5 -4
interaction,because 1.0 0.000143348623853 0 1 -1
neither,reversed 1.0 0.000143348623853 1 0 1
human,serum 0.666666666667 0.000573394495413 1 5 -4
the,absorption 0.515151515152 0.0024369266055 25 8 17
daily,of 0.0 0.0 1 1 0
symptoms,usually 1.0 0.000143348623853 0 1 -1
following,chronic 1.0 0.000143348623853 0 1 -1
andusing,a 1.0 0.000143348623853 0 1 -1
tablet,volume 1.0 0.000143348623853 0 1 -1
theophylline,as 1.0 0.000143348623853 1 0 1
adults,were 1.0 0.000143348623853 0 1 -1
trisphosphate-induced,responses 1.0 0.000143348623853 0 1 -1
sodium,binding 1.0 0.000143348623853 1 0 1
catecholamine,depletors 1.0 0.000143348623853 1 0 1
of,action 0.692307692308 0.00129013761468 2 11 -9
either,s 1.0 0.000143348623853 0 1 -1
and,other 0.0869565217391 0.00114678899083 42 50 -8
prolonged,infusion 1.0 0.000143348623853 0 1 -1
different,for 1.0 0.000143348623853 0 1 -1
and,less 1.0 0.000143348623853 0 1 -1
account,for 1.0 0.000286697247706 0 2 -2
adjustment,is 0.555555555556 0.000716743119266 2 7 -5
taking,both 1.0 0.000286697247706 2 0 2
which,leads 1.0 0.000143348623853 0 1 -1
hypercalcemia,in 1.0 0.00043004587156 3 0 3
commonly,found 1.0 0.000143348623853 0 1 -1
resin,may 1.0 0.000143348623853 0 1 -1
decreased,synthesis 1.0 0.000286697247706 2 0 2
hydroxyzine,must 1.0 0.000143348623853 1 0 1
or,weakness 1.0 0.000143348623853 0 1 -1
substrates,that 1.0 0.000143348623853 1 0 1
interactions,attributed 1.0 0.000143348623853 1 0 1
adjustment,in 1.0 0.00043004587156 0 3 -3
volume,of 0.636363636364 0.00100344036697 2 9 -7
as,high-dose 1.0 0.000143348623853 0 1 -1
differently,than 1.0 0.000143348623853 0 1 -1
of,neuronal 1.0 0.000143348623853 0 1 -1
therapy,with 0.363636363636 0.00229357798165 30 14 16
variability,however 1.0 0.000143348623853 0 1 -1
amplifies,the 1.0 0.000143348623853 1 0 1
mellitus,or 1.0 0.000143348623853 0 1 -1
approximately,bpm 1.0 0.000143348623853 0 1 -1
neurontin,and 1.0 0.000143348623853 0 1 -1
dyspnea,requiring 1.0 0.000143348623853 0 1 -1
chromosomal,aberration 1.0 0.000143348623853 0 1 -1
following,ultracentrifugation 1.0 0.000143348623853 0 1 -1
methotrexate,humira 1.0 0.000143348623853 0 1 -1
stomach,of 1.0 0.000143348623853 1 0 1
might,be 0.333333333333 0.000286697247706 2 4 -2
adequate,methods 1.0 0.000143348623853 0 1 -1
q24h,for 0.0 0.0 1 1 0
volunteer,showed 1.0 0.000143348623853 0 1 -1
same,age 1.0 0.000143348623853 0 1 -1
of,mefloquine 0.5 0.000286697247706 3 1 2
ii,receptor 0.0 0.0 1 1 0
the,judgment 1.0 0.000143348623853 1 0 1
ugt,enzymes 1.0 0.000143348623853 0 1 -1
at,an 1.0 0.000286697247706 2 0 2
taking,since 1.0 0.000286697247706 2 0 2
an,analysis 1.0 0.000143348623853 1 0 1
and,maalox 1.0 0.000143348623853 1 0 1
have,occasionally 1.0 0.000286697247706 0 2 -2
counts,for 1.0 0.000143348623853 0 1 -1
at,as 1.0 0.000286697247706 0 2 -2
hydrocodone,increases 1.0 0.000143348623853 1 0 1
and,body 1.0 0.000143348623853 0 1 -1
first,cervical 1.0 0.000143348623853 0 1 -1
enzymes,primarily 1.0 0.000143348623853 0 1 -1
trileptal,topamax 1.0 0.000143348623853 1 0 1
ph,was 0.0 0.0 1 1 0
difference,was 1.0 0.000286697247706 0 2 -2
a,corresponding 1.0 0.000286697247706 2 0 2
sodium,the 1.0 0.000143348623853 0 1 -1
of,uptake-1 1.0 0.000286697247706 0 2 -2
one,additional 1.0 0.000143348623853 0 1 -1
versus,normal 1.0 0.000143348623853 0 1 -1
trials,database 1.0 0.000143348623853 0 1 -1
tachycardia,have 1.0 0.000143348623853 1 0 1
seropositive,subjects 1.0 0.000286697247706 0 2 -2
various,oral 1.0 0.000143348623853 0 1 -1
established,interactions 1.0 0.000143348623853 0 1 -1
as,such 1.0 0.000573394495413 0 4 -4
interactions,naproxen 1.0 0.000143348623853 0 1 -1
balanced,by 1.0 0.000143348623853 0 1 -1
pediatrics,mean 1.0 0.000143348623853 1 0 1
metabolites,dfur 1.0 0.000143348623853 0 1 -1
nonsteroidal,the 1.0 0.000143348623853 1 0 1
adapter,protein 1.0 0.000143348623853 0 1 -1
daily,followed 1.0 0.000143348623853 1 0 1
intravenous,injection 1.0 0.000286697247706 2 0 2
copper,reduction 1.0 0.000286697247706 0 2 -2
the,dependence 1.0 0.000143348623853 0 1 -1
the,dependency 1.0 0.000143348623853 0 1 -1
with,interferon 1.0 0.000143348623853 0 1 -1
bioavailability,and 1.0 0.000286697247706 0 2 -2
products,with 0.333333333333 0.000143348623853 2 1 1
taking,mao 1.0 0.000143348623853 1 0 1
in,two-lever 1.0 0.000143348623853 0 1 -1
a,parallel 1.0 0.000143348623853 0 1 -1
efficacy,safety 1.0 0.000143348623853 0 1 -1
the,hydantoin 1.0 0.000143348623853 1 0 1
infections,was 1.0 0.000286697247706 2 0 2
brovana,may 1.0 0.000286697247706 2 0 2
of,non-steroidal 1.0 0.000143348623853 1 0 1
was,administered 0.0810810810811 0.00043004587156 17 20 -3
randomized,multiple-dose 1.0 0.000143348623853 0 1 -1
or,tes-tape 1.0 0.000573394495413 0 4 -4
both,cyp2c9 1.0 0.000143348623853 0 1 -1
these,trace 1.0 0.000143348623853 0 1 -1
nsaids,can 1.0 0.000860091743119 6 0 6
applications,of 1.0 0.000143348623853 0 1 -1
return,to 1.0 0.000143348623853 0 1 -1
following,mating 1.0 0.000143348623853 0 1 -1
binding,entacapone 1.0 0.000143348623853 0 1 -1
of,beta-adrenoceptor 1.0 0.000286697247706 2 0 2
apokyn,and 1.0 0.000143348623853 0 1 -1
of,bioavailability 0.2 0.000143348623853 2 3 -1
trials,of 0.714285714286 0.000716743119266 1 6 -5
products,st 1.0 0.000286697247706 0 2 -2
drowsiness,was 1.0 0.000143348623853 0 1 -1
when,prescribing 1.0 0.000286697247706 0 2 -2
week,trial 1.0 0.000143348623853 0 1 -1
using,in 0.0 0.0 1 1 0
and,serum 0.0 0.0 2 2 0
lipid-lowering,activity 1.0 0.000143348623853 0 1 -1
antidepressant,was 1.0 0.000143348623853 0 1 -1
either,too 1.0 0.000143348623853 0 1 -1
formal,drug-drug 1.0 0.000286697247706 0 2 -2
patients,to 0.0 0.0 2 2 0
contain,deet 1.0 0.000143348623853 1 0 1
of,vitamin-d 1.0 0.000143348623853 0 1 -1
using,it 0.333333333333 0.000143348623853 2 1 1
were,evident 1.0 0.000286697247706 0 2 -2
sumatriptan,has 1.0 0.000143348623853 1 0 1
minimum,alveolar 1.0 0.000286697247706 2 0 2
disrupts,the 1.0 0.000143348623853 0 1 -1
specific,clinical 1.0 0.000143348623853 0 1 -1
although,did 1.0 0.000143348623853 1 0 1
potentiates,other 1.0 0.000143348623853 1 0 1
as,hours 1.0 0.000143348623853 1 0 1
serious,reactions 1.0 0.000286697247706 0 2 -2
precursor,to 1.0 0.000143348623853 0 1 -1
may,augment 1.0 0.00043004587156 3 0 3
over,several 1.0 0.000143348623853 1 0 1
those,taking 0.0 0.0 1 1 0
antipyrine,antipyrine 1.0 0.000143348623853 0 1 -1
inhibitors,atomoxetine 1.0 0.000143348623853 0 1 -1
reported,for 1.0 0.00043004587156 0 3 -3
prostate,cancer 1.0 0.000143348623853 0 1 -1
im,once 0.0 0.0 1 1 0
cimetidine,at 1.0 0.000286697247706 2 0 2
with,amenorrhea 1.0 0.000143348623853 0 1 -1
normal,minutes 1.0 0.000143348623853 0 1 -1
potential,intravenous 1.0 0.000143348623853 1 0 1
cimetidine,an 1.0 0.000143348623853 1 0 1
by,gradually 1.0 0.000143348623853 0 1 -1
basis,this 1.0 0.000143348623853 0 1 -1
contrast,preliminary 1.0 0.000143348623853 0 1 -1
metacercariae,of 1.0 0.000143348623853 0 1 -1
either,a 1.0 0.000143348623853 0 1 -1
the,experiment 1.0 0.000143348623853 0 1 -1
plasma,auc 0.0909090909091 0.000143348623853 5 6 -1
above,data 1.0 0.000143348623853 0 1 -1
medicinal,or 1.0 0.000143348623853 0 1 -1
in,individual 1.0 0.000143348623853 0 1 -1
no,data 1.0 0.00129013761468 0 9 -9
to,assist 1.0 0.000143348623853 0 1 -1
times,should 0.0 0.0 1 1 0
for,p450 1.0 0.000716743119266 0 5 -5
reliable,increases 1.0 0.000143348623853 0 1 -1
healthy,men 1.0 0.000143348623853 0 1 -1
or,mao-inhibitors 1.0 0.000143348623853 1 0 1
since,zarontin 1.0 0.000143348623853 1 0 1
ip,injections 1.0 0.000143348623853 0 1 -1
herbal,preparations 1.0 0.000143348623853 0 1 -1
could,affect 1.0 0.000143348623853 0 1 -1
column,or 1.0 0.000573394495413 0 4 -4
or,herbal 1.0 0.000143348623853 0 1 -1
meaningful,changes 1.0 0.000286697247706 0 2 -2
really,needed 1.0 0.000143348623853 0 1 -1
c19,cyp 1.0 0.000143348623853 0 1 -1
anafranil,caution 1.0 0.000143348623853 0 1 -1
three,equal 1.0 0.000143348623853 0 1 -1
of,unsteady 1.0 0.000143348623853 1 0 1
the,task 1.0 0.000143348623853 0 1 -1
and,aggressive 1.0 0.000143348623853 0 1 -1
did,augment 1.0 0.000143348623853 1 0 1
mcf-7,cells 1.0 0.000716743119266 0 5 -5
oil,ml 1.0 0.000286697247706 0 2 -2
in,non-human 1.0 0.000143348623853 0 1 -1
diuretics,furosemide 1.0 0.000143348623853 0 1 -1
by,bretylium 1.0 0.000143348623853 1 0 1
intervals,as 1.0 0.000143348623853 0 1 -1
was,monitored 1.0 0.000143348623853 0 1 -1
on,average 0.0 0.0 1 1 0
were,unaffected 0.5 0.000286697247706 1 3 -2
see,dosage 1.0 0.000286697247706 0 2 -2
so,called 1.0 0.00043004587156 0 3 -3
develop,increased 1.0 0.000143348623853 1 0 1
in,evaluating 1.0 0.000286697247706 0 2 -2
the,hemodynamic 1.0 0.000143348623853 1 0 1
investigating,possible 1.0 0.000143348623853 0 1 -1
the,superiority 1.0 0.000143348623853 0 1 -1
patients,liver 1.0 0.000143348623853 1 0 1
are,indicated 1.0 0.000286697247706 0 2 -2
by,this 0.4 0.000573394495413 3 7 -4
fdf,at 0.5 0.000286697247706 3 1 2
may,even 0.0 0.0 1 1 0
reduces,both 1.0 0.000143348623853 1 0 1
their,coagulation 1.0 0.000143348623853 1 0 1
block,may 1.0 0.000286697247706 2 0 2
and,t3 0.0 0.0 1 1 0
recover,to 1.0 0.000143348623853 0 1 -1
being,homocysteine 1.0 0.000143348623853 0 1 -1
herein,with 1.0 0.000143348623853 0 1 -1
day,lexapro 1.0 0.000143348623853 1 0 1
acid,are 1.0 0.000143348623853 0 1 -1
cns,including 1.0 0.000143348623853 0 1 -1
are,coadministered 1.0 0.000143348623853 1 0 1
synergism,in 1.0 0.000143348623853 1 0 1
the,known 0.333333333333 0.000286697247706 2 4 -2
reported,neuropsychiatric 1.0 0.000143348623853 0 1 -1
oxidation,which 1.0 0.000143348623853 0 1 -1
responding,produced 1.0 0.000143348623853 1 0 1
cocaine,sometimes 1.0 0.000143348623853 1 0 1
norpace,does 1.0 0.000143348623853 0 1 -1
greater,than 0.125 0.000286697247706 7 9 -2
however,careful 1.0 0.000143348623853 1 0 1
interferon,beta 1.0 0.000143348623853 0 1 -1
combination,therapy 0.636363636364 0.00100344036697 2 9 -7
and,to 0.612903225806 0.00272362385321 6 25 -19
and,tm 1.0 0.000143348623853 1 0 1
coombs,reactions 1.0 0.000143348623853 0 1 -1
and,th 1.0 0.000143348623853 0 1 -1
conducted,it 1.0 0.000143348623853 1 0 1
status,is 1.0 0.000143348623853 1 0 1
simultaneous,use 0.428571428571 0.00043004587156 2 5 -3
nsaids,are 1.0 0.000286697247706 2 0 2
a,separate 0.333333333333 0.000143348623853 1 2 -1
anions,other 1.0 0.000143348623853 0 1 -1
with,short 1.0 0.000143348623853 0 1 -1
conducted,in 0.8 0.00114678899083 1 9 -8
most,out 1.0 0.000143348623853 0 1 -1
status,in 1.0 0.000143348623853 0 1 -1
been,no 1.0 0.00129013761468 0 9 -9
diagnosis,or 1.0 0.000143348623853 0 1 -1
betagan,used 1.0 0.000143348623853 1 0 1
acarbose,the 1.0 0.000143348623853 0 1 -1
of,enablex 1.0 0.000286697247706 2 0 2
inhibit,the 0.0 0.0 22 22 0
plasma,thrombin 1.0 0.000143348623853 0 1 -1
by,possibly 1.0 0.000286697247706 2 0 2
last,act 1.0 0.000143348623853 0 1 -1
the,estrogenic 1.0 0.000143348623853 0 1 -1
diagnosis,of 1.0 0.000286697247706 0 2 -2
tumor,cell 1.0 0.000143348623853 0 1 -1
by,administration 0.5 0.000286697247706 1 3 -2
to,diminish 1.0 0.000286697247706 2 0 2
pulmonary,arterial 1.0 0.000143348623853 0 1 -1
effect,has 0.5 0.000286697247706 1 3 -2
replacement,increases 1.0 0.000143348623853 0 1 -1
within,minutes 0.0 0.0 1 1 0
agitation,while 1.0 0.000143348623853 0 1 -1
recent,radiation 1.0 0.000143348623853 0 1 -1
objectives,to 1.0 0.000286697247706 0 2 -2
the,from 1.0 0.000286697247706 2 0 2
of,initiated 1.0 0.000143348623853 0 1 -1
ii,antagonists 0.0 0.0 1 1 0
wellbutrin,following 1.0 0.000143348623853 0 1 -1
and,frova 1.0 0.000143348623853 1 0 1
is,unaltered 1.0 0.000143348623853 0 1 -1
aliskiren,on 1.0 0.000143348623853 0 1 -1
slow,metabolizers 1.0 0.000143348623853 0 1 -1
the,reflex 1.0 0.000143348623853 1 0 1
tylenol,chloromycetin 1.0 0.000143348623853 1 0 1
thio,compounds 1.0 0.000143348623853 0 1 -1
to,midcycle 1.0 0.000143348623853 0 1 -1
qd,increased 1.0 0.000143348623853 1 0 1
while,attenuating 1.0 0.000143348623853 1 0 1
both,which 1.0 0.000143348623853 0 1 -1
to,abnormal 1.0 0.000143348623853 0 1 -1
in,plasmaconcentrations 1.0 0.000286697247706 2 0 2
a,ten-subject 1.0 0.000143348623853 1 0 1
three,cancer 1.0 0.000143348623853 1 0 1
for,dosage 1.0 0.000143348623853 0 1 -1
tam,enhances 1.0 0.000143348623853 1 0 1
be,prevented 1.0 0.000143348623853 1 0 1
absorption,metabolism 1.0 0.000143348623853 0 1 -1
including,more 1.0 0.000143348623853 0 1 -1
inhibit,cyp3a4 0.666666666667 0.000573394495413 1 5 -4
not,reached 1.0 0.000143348623853 0 1 -1
alertness,such 1.0 0.000143348623853 0 1 -1
both,its 1.0 0.000286697247706 0 2 -2
myocardium,versus 1.0 0.000143348623853 0 1 -1
or,induce 1.0 0.000860091743119 0 6 -6
invasion,of 1.0 0.000143348623853 1 0 1
different,ca 1.0 0.000143348623853 0 1 -1
radical-mediated,tissue 1.0 0.000143348623853 1 0 1
the,conclusion 1.0 0.000143348623853 1 0 1
assess,if 1.0 0.000286697247706 0 2 -2
loss,or 1.0 0.000143348623853 0 1 -1
during,placebo-controlled 1.0 0.000143348623853 0 1 -1
loss,of 0.625 0.00143348623853 3 13 -10
cause,increased 0.2 0.000143348623853 2 3 -1
decreases,blood 1.0 0.000143348623853 1 0 1
concentrations,below 1.0 0.000143348623853 1 0 1
the,coumarin 1.0 0.000143348623853 0 1 -1
substantial,period 1.0 0.000143348623853 0 1 -1
with,biocytin 1.0 0.000143348623853 0 1 -1
subjects,dosed 1.0 0.000286697247706 2 0 2
thrombolytic,agents 1.0 0.000143348623853 0 1 -1
first,response 1.0 0.000143348623853 0 1 -1
days,through 1.0 0.000143348623853 1 0 1
neostgmine,can 1.0 0.000143348623853 0 1 -1
retard,is 1.0 0.000286697247706 2 0 2
the,precipitate 1.0 0.000143348623853 0 1 -1
possibly,increase 1.0 0.000143348623853 1 0 1
indocyanine,green 1.0 0.000143348623853 0 1 -1
effect,and 0.428571428571 0.00043004587156 2 5 -3
a2,an 1.0 0.000143348623853 1 0 1
antiseizure,medication 1.0 0.000143348623853 0 1 -1
are,withdrawn 1.0 0.00100344036697 0 7 -7
reaction,during 1.0 0.000143348623853 0 1 -1
or,antagonist 1.0 0.000143348623853 0 1 -1
persists,as 1.0 0.000143348623853 1 0 1
or,antagonise 1.0 0.000143348623853 0 1 -1
pharmacologic,studies 1.0 0.000143348623853 1 0 1
cns,acting 1.0 0.000143348623853 0 1 -1
these,concomitant 1.0 0.000143348623853 1 0 1
to,plenaxis 1.0 0.000143348623853 0 1 -1
report,a 1.0 0.000143348623853 0 1 -1
after,missing 1.0 0.000143348623853 0 1 -1
of,oral 0.0588235294118 0.000286697247706 18 16 2
weak,c19 1.0 0.000143348623853 0 1 -1
with,absorption 0.6 0.00043004587156 4 1 3
in,lean 1.0 0.000143348623853 0 1 -1
event,in 1.0 0.000143348623853 0 1 -1
known,health 1.0 0.000143348623853 0 1 -1
compounds,enhanced 1.0 0.000143348623853 0 1 -1
currently,no 1.0 0.00043004587156 0 3 -3
s,augmentation 1.0 0.000143348623853 0 1 -1
inr,international 1.0 0.000143348623853 1 0 1
other,myelosuppressive 1.0 0.000143348623853 0 1 -1
hormone,lh 1.0 0.000143348623853 0 1 -1
supplementation,which 1.0 0.000143348623853 0 1 -1
tested,to 1.0 0.000286697247706 0 2 -2
additive,with 1.0 0.000573394495413 4 0 4
and,family 1.0 0.000143348623853 0 1 -1
mesylate,with 1.0 0.000143348623853 1 0 1
radiation,therapy 1.0 0.000573394495413 0 4 -4
confirmed,for 1.0 0.000143348623853 0 1 -1
vitro,mixing 1.0 0.000143348623853 1 0 1
in,fi 0.0 0.0 1 1 0
by,increasing 0.0 0.0 2 2 0
after,perfusion 1.0 0.000143348623853 0 1 -1
to,similar 1.0 0.000143348623853 0 1 -1
however,the 0.555555555556 0.00143348623853 4 14 -10
the,contrary 1.0 0.000143348623853 1 0 1
briefly,exposed 1.0 0.000143348623853 0 1 -1
brovana,are 1.0 0.000143348623853 0 1 -1
because,cyp2d6 1.0 0.000143348623853 0 1 -1
approximately,um 1.0 0.000143348623853 0 1 -1
occupational,exposure 1.0 0.000143348623853 0 1 -1
listed,isoforms 1.0 0.000143348623853 0 1 -1
suspension,yielded 1.0 0.000143348623853 0 1 -1
intermenstrual,bleeding 1.0 0.000143348623853 0 1 -1
or,fatal 1.0 0.000143348623853 0 1 -1
with,hard 1.0 0.000143348623853 0 1 -1
antiarrhythmics,antihistamines 1.0 0.000143348623853 1 0 1
near,the 1.0 0.000143348623853 0 1 -1
and,uncontrolled 1.0 0.000143348623853 0 1 -1
exogenous,also 1.0 0.000143348623853 1 0 1
receiving,nalfon 1.0 0.000143348623853 1 0 1
are,less 1.0 0.000143348623853 0 1 -1
cells,respond 1.0 0.000143348623853 0 1 -1
significantly,with 1.0 0.000286697247706 0 2 -2
impaired,but 1.0 0.000143348623853 0 1 -1
therefore,clozapine 1.0 0.000143348623853 0 1 -1
additional,clinical 1.0 0.000286697247706 0 2 -2
an,adolescent 0.0 0.0 1 1 0
of,phosphatidate 1.0 0.000286697247706 0 2 -2
was,significantly 0.285714285714 0.000573394495413 5 9 -4
in,locomotor 1.0 0.000286697247706 0 2 -2
and,screening 1.0 0.000143348623853 0 1 -1
restricted,and 1.0 0.000143348623853 0 1 -1
to,acute 1.0 0.000143348623853 0 1 -1
that,adl 1.0 0.000143348623853 1 0 1
and,reinstate 1.0 0.000143348623853 0 1 -1
therapies,commonly 1.0 0.000143348623853 0 1 -1
improved,when 1.0 0.000143348623853 0 1 -1
the,marrow 1.0 0.000143348623853 0 1 -1
the,obstetrical 1.0 0.000143348623853 0 1 -1
undergoing,ptca 1.0 0.000143348623853 1 0 1
radiographic,iodinated 1.0 0.000143348623853 1 0 1
hydrocarbon,increase 1.0 0.000143348623853 1 0 1
hydrochloride,desyrel 1.0 0.000143348623853 1 0 1
pressure,control 1.0 0.000143348623853 0 1 -1
including,inhaled 1.0 0.000143348623853 0 1 -1
used,preanesthetic 1.0 0.000143348623853 0 1 -1
with,expected 1.0 0.000143348623853 0 1 -1
ergotamine-containing,when 1.0 0.000143348623853 1 0 1
morphine,a 1.0 0.000143348623853 1 0 1
chapter,discusses 1.0 0.000143348623853 0 1 -1
potential,exists 0.6 0.00043004587156 1 4 -3
potentiated,and 1.0 0.000286697247706 2 0 2
for,establishing 1.0 0.000143348623853 0 1 -1
are,intimately 1.0 0.000143348623853 0 1 -1
of,dehydration 1.0 0.000143348623853 1 0 1
containing,a 1.0 0.000143348623853 0 1 -1
theophylline,grepafloxacin 1.0 0.000143348623853 1 0 1
by,cytochromes 1.0 0.000143348623853 0 1 -1
pharmacokinetics,effectiveness 1.0 0.000143348623853 0 1 -1
immediately,beginning 1.0 0.000143348623853 1 0 1
resistance,in 1.0 0.000286697247706 0 2 -2
as,nuromax 1.0 0.000143348623853 1 0 1
days,for 1.0 0.000286697247706 0 2 -2
experienced,a 1.0 0.000716743119266 5 0 5
volunteers,established 1.0 0.000143348623853 0 1 -1
known,inhibition 0.333333333333 0.000143348623853 1 2 -1
where,abuse 1.0 0.000143348623853 0 1 -1
combinations,are 1.0 0.000143348623853 0 1 -1
ergot-type,oxytocic 0.333333333333 0.000143348623853 1 2 -1
resistance,is 1.0 0.000143348623853 0 1 -1
blood,glucose 0.0526315789474 0.000143348623853 9 10 -1
or,guardian 1.0 0.000143348623853 0 1 -1
carboxymethylcellulose,in 1.0 0.000143348623853 0 1 -1
that,binds 1.0 0.000143348623853 0 1 -1
enhancing,effect 1.0 0.000143348623853 0 1 -1
early-phase,schizophrenia 1.0 0.000143348623853 0 1 -1
nephrosis,acromegaly 1.0 0.000143348623853 0 1 -1
whenever,possible 1.0 0.000143348623853 0 1 -1
allopurinol,inhibits 1.0 0.000143348623853 1 0 1
mainly,on 1.0 0.000143348623853 0 1 -1
nonsteroidal,were 1.0 0.000286697247706 0 2 -2
brevibloc,steady-state 1.0 0.000143348623853 1 0 1
and,of 0.333333333333 0.00043004587156 3 6 -3
mhd,and 1.0 0.000143348623853 0 1 -1
and,on 0.6 0.00129013761468 3 12 -9
of,trazodone 1.0 0.000143348623853 1 0 1
may,provide 1.0 0.000143348623853 0 1 -1
reactions,related 1.0 0.000143348623853 0 1 -1
primary,elimination 1.0 0.000143348623853 1 0 1
coagulation,factor 1.0 0.000143348623853 0 1 -1
and,or 0.0 0.0 45 45 0
citrate,has 1.0 0.000143348623853 0 1 -1
inducer,with 1.0 0.000143348623853 1 0 1
state,auc 1.0 0.000143348623853 1 0 1
registered,trademark 1.0 0.000143348623853 0 1 -1
supplementation,with 1.0 0.000143348623853 0 1 -1
conduct,close 1.0 0.000143348623853 0 1 -1
sex,hormone 0.0 0.0 1 1 0
conducted,to 1.0 0.000860091743119 0 6 -6
depressants,should 1.0 0.000143348623853 1 0 1
concomitantly,of 1.0 0.000143348623853 0 1 -1
will,lead 1.0 0.000143348623853 1 0 1
of,age 1.0 0.000573394495413 0 4 -4
have,failed 1.0 0.000143348623853 0 1 -1
from,receiving 1.0 0.000143348623853 0 1 -1
are,part 1.0 0.000143348623853 0 1 -1
c-17,alkylated 1.0 0.000143348623853 0 1 -1
data,in 0.714285714286 0.000716743119266 1 6 -5
reluctance,to 1.0 0.000143348623853 0 1 -1
requirements,but 1.0 0.000143348623853 0 1 -1
in,nociception 1.0 0.000143348623853 0 1 -1
or,serial 1.0 0.000286697247706 0 2 -2
growing,class 1.0 0.000143348623853 0 1 -1
data,is 1.0 0.000143348623853 0 1 -1
of,corneal 1.0 0.000143348623853 1 0 1
reaction,on 1.0 0.000143348623853 0 1 -1
ventricular,fibrillation 0.0 0.0 1 1 0
have,revealed 1.0 0.000143348623853 0 1 -1
virus,hiv 1.0 0.000143348623853 0 1 -1
with,difluoro-2 1.0 0.000143348623853 1 0 1
gold,salts 1.0 0.000143348623853 0 1 -1
when,lodine 1.0 0.000143348623853 1 0 1
mean,concentrations 1.0 0.000143348623853 0 1 -1
romazicon,may 1.0 0.000143348623853 0 1 -1
postmarketing,experience 0.0 0.0 1 1 0
dogs,deprived 1.0 0.000143348623853 0 1 -1
leukocyte,transfusions 1.0 0.000143348623853 1 0 1
pyrocarbonate,abolished 1.0 0.000143348623853 0 1 -1
of,mevacor 1.0 0.000143348623853 0 1 -1
close,supervision 0.2 0.000143348623853 2 3 -1
direction,of 1.0 0.000143348623853 0 1 -1
rat,milk 1.0 0.000143348623853 0 1 -1
in,practice 1.0 0.000143348623853 0 1 -1
significant,only 1.0 0.000143348623853 0 1 -1
notified,immediately 1.0 0.000143348623853 0 1 -1
in,peak 0.666666666667 0.000573394495413 5 1 4
prevalence,of 1.0 0.000860091743119 0 6 -6
and,administration-dosage 1.0 0.000143348623853 0 1 -1
vitro,excystment 1.0 0.000286697247706 0 2 -2
of,protein-bound 1.0 0.000143348623853 0 1 -1
amide-type,local 1.0 0.000143348623853 1 0 1
decrease,metabolism 0.0 0.0 1 1 0
products,you 1.0 0.000143348623853 0 1 -1
was,started 1.0 0.000143348623853 0 1 -1
bolus-ifl,in 1.0 0.000143348623853 0 1 -1
bsa,and 1.0 0.000143348623853 0 1 -1
of,drug-induced 1.0 0.000143348623853 0 1 -1
hexanal-induced,sleep 1.0 0.000143348623853 0 1 -1
studies,that 1.0 0.000143348623853 0 1 -1
necessary,should 1.0 0.000143348623853 0 1 -1
change,of 0.333333333333 0.000286697247706 4 2 2
failure,nyha 1.0 0.000143348623853 0 1 -1
of,pgf2alpha 1.0 0.000143348623853 1 0 1
candesartan,cilexetil 1.0 0.000143348623853 0 1 -1
superiority,over 1.0 0.000143348623853 0 1 -1
enalapril,and 0.0 0.0 1 1 0
in,zaleplons 1.0 0.000143348623853 1 0 1
identify,chromatin 1.0 0.000143348623853 1 0 1
therapies,in 1.0 0.000143348623853 0 1 -1
include,one 1.0 0.000143348623853 0 1 -1
i,increase 1.0 0.000143348623853 1 0 1
parameters,affected 1.0 0.000143348623853 0 1 -1
substrate,resulted 1.0 0.000143348623853 1 0 1
special,attention 1.0 0.000143348623853 0 1 -1
include,extreme 1.0 0.000143348623853 1 0 1
agents,employed 1.0 0.000143348623853 1 0 1
the,cns-depressant 1.0 0.000143348623853 1 0 1
administered,with 0.191489361702 0.00129013761468 28 19 9
not,on 1.0 0.000143348623853 0 1 -1
moderate,to 1.0 0.000286697247706 2 0 2
potentially,interfere 1.0 0.000143348623853 0 1 -1
committed,step 1.0 0.000143348623853 1 0 1
which,inhibits 0.0 0.0 1 1 0
cautioned,that 1.0 0.000143348623853 0 1 -1
plasmacytic,hyperplasia 1.0 0.000143348623853 0 1 -1
the,hypotension 1.0 0.00043004587156 3 0 3
a,resulting 1.0 0.000143348623853 1 0 1
affect,subjective 1.0 0.000143348623853 0 1 -1
for,determining 1.0 0.000143348623853 0 1 -1
thus,dosed 1.0 0.000143348623853 0 1 -1
iodine-containing,compounds 1.0 0.000143348623853 0 1 -1
time,by 0.333333333333 0.000143348623853 1 2 -1
inhibits,both 1.0 0.000143348623853 1 0 1
time,be 1.0 0.000286697247706 2 0 2
similar,median 1.0 0.000143348623853 0 1 -1
microgram,ml 1.0 0.000143348623853 0 1 -1
this,category 0.333333333333 0.000143348623853 1 2 -1
administered,or 0.0 0.0 1 1 0
can,decrease 0.333333333333 0.000143348623853 2 1 1
remedies,with 1.0 0.000143348623853 0 1 -1
other,drugs 0.8 0.00229357798165 2 18 -16
published,over 1.0 0.000143348623853 0 1 -1
ribavirin,is 1.0 0.000143348623853 0 1 -1
interest,from 1.0 0.000143348623853 0 1 -1
expanded,our 1.0 0.000143348623853 0 1 -1
balanced,two-period 1.0 0.000143348623853 0 1 -1
either,in 1.0 0.000143348623853 0 1 -1
observed,the 1.0 0.000143348623853 0 1 -1
are,renally 1.0 0.000143348623853 0 1 -1
either,is 0.5 0.000286697247706 1 3 -2
lymphocyte,counts 1.0 0.000143348623853 0 1 -1
preparations,st 1.0 0.000143348623853 0 1 -1
additive,hypotensite 1.0 0.000143348623853 1 0 1
mao-inhibitors,with 1.0 0.000143348623853 1 0 1
c9,human 1.0 0.000143348623853 0 1 -1
nephrotoxic,such 1.0 0.000143348623853 1 0 1
to,wide 1.0 0.000143348623853 1 0 1
for,equetrotm 0.0 0.0 1 1 0
experience,gained 1.0 0.000143348623853 0 1 -1
affinity,substrates 1.0 0.000143348623853 0 1 -1
other,potentially 0.2 0.000143348623853 2 3 -1
of,american 1.0 0.000143348623853 0 1 -1
rate,when 1.0 0.000143348623853 1 0 1
assumed,that 1.0 0.000143348623853 0 1 -1
dose,study 0.333333333333 0.000143348623853 2 1 1
iodinated,contrast 1.0 0.000143348623853 1 0 1
mercapturic,acids 1.0 0.000143348623853 0 1 -1
is,completely 1.0 0.000143348623853 0 1 -1
poorly,understood 1.0 0.000143348623853 0 1 -1
or,undesirable 1.0 0.000286697247706 0 2 -2
these,models 1.0 0.000143348623853 0 1 -1
including,indocin 1.0 0.000286697247706 2 0 2
was,approximately 1.0 0.000286697247706 0 2 -2
insulin,sulfonylureas 1.0 0.000143348623853 0 1 -1
molecular,differences 1.0 0.000143348623853 0 1 -1
per,patients 1.0 0.000143348623853 0 1 -1
factor,treatment 1.0 0.000143348623853 0 1 -1
of,three 1.0 0.000143348623853 0 1 -1
or,neuromuscular 1.0 0.000143348623853 0 1 -1
between,deficiency 1.0 0.000143348623853 0 1 -1
serum,half-life 0.333333333333 0.000143348623853 2 1 1
but,which 1.0 0.000143348623853 0 1 -1
with,aluminum- 1.0 0.000143348623853 0 1 -1
aripiprazole,also 1.0 0.000143348623853 0 1 -1
highly,fortified 1.0 0.000143348623853 0 1 -1
produced,smaller 1.0 0.000286697247706 0 2 -2
results,demonstrate 1.0 0.000286697247706 0 2 -2
volunteers,coadministration 1.0 0.000143348623853 0 1 -1
when,increases 1.0 0.000143348623853 0 1 -1
showed,an 1.0 0.000143348623853 1 0 1
directly,interfere 1.0 0.000143348623853 1 0 1
with,affected 1.0 0.000143348623853 0 1 -1
codeine,in 1.0 0.000143348623853 1 0 1
arabinoside,a 1.0 0.000143348623853 1 0 1
to,hypoparathyroid 1.0 0.000286697247706 2 0 2
one,treated 1.0 0.000143348623853 0 1 -1
in,spite 1.0 0.00043004587156 0 3 -3
also,concomitant 1.0 0.000143348623853 1 0 1
antitubercular,serum 1.0 0.000143348623853 0 1 -1
vivo,by 1.0 0.000143348623853 0 1 -1
decrease,ci 1.0 0.000573394495413 0 4 -4
seen,when 0.0 0.0 2 2 0
vivo,rodent 1.0 0.000143348623853 0 1 -1
with,measurement 1.0 0.00043004587156 0 3 -3
resulted,from 0.0 0.0 1 1 0
cytochrome,p450iiia4 1.0 0.000143348623853 1 0 1
is,conceived 1.0 0.000143348623853 0 1 -1
or,placebo 1.0 0.000573394495413 0 4 -4
as,operating 1.0 0.000143348623853 0 1 -1
more,competing 1.0 0.000143348623853 0 1 -1
acidosis,have 1.0 0.000143348623853 0 1 -1
turn,discussing 1.0 0.000143348623853 0 1 -1
between,smoking 1.0 0.000143348623853 0 1 -1
behavioral,effects 1.0 0.000860091743119 0 6 -6
of,addicts 1.0 0.000143348623853 0 1 -1
between,use 1.0 0.000143348623853 1 0 1
animals,are 1.0 0.000143348623853 0 1 -1
and,the 0.422818791946 0.00903096330275 43 106 -63
containing,regimen 1.0 0.000143348623853 0 1 -1
were,as 1.0 0.000143348623853 0 1 -1
on,should 0.5 0.000286697247706 3 1 2
prolonged,by 0.5 0.000286697247706 3 1 2
agents,ethinyl 1.0 0.000143348623853 0 1 -1
administered,immediately 1.0 0.000143348623853 1 0 1
of,non-nucleoside 1.0 0.000143348623853 0 1 -1
infusion,or 1.0 0.000143348623853 0 1 -1
administering,or 1.0 0.000143348623853 1 0 1
dose,increase 0.142857142857 0.000143348623853 4 3 1
any,such 1.0 0.000143348623853 1 0 1
unrelated,to 1.0 0.000143348623853 0 1 -1
isozymes,may 1.0 0.000286697247706 0 2 -2
phosphatase,and 1.0 0.000286697247706 0 2 -2
as,inr 1.0 0.000143348623853 1 0 1
supplement,st 1.0 0.000143348623853 0 1 -1
absolute,number 1.0 0.000143348623853 0 1 -1
pressure,usually 1.0 0.000143348623853 1 0 1
is,usually 0.0 0.0 1 1 0
class,iii 1.0 0.000143348623853 1 0 1
available,hmgcoa 1.0 0.000143348623853 0 1 -1
prescribed,for 1.0 0.00100344036697 0 7 -7
arrhythmias,including 1.0 0.000143348623853 0 1 -1
deriving,from 1.0 0.000143348623853 0 1 -1
of,simulect 1.0 0.000143348623853 1 0 1
particularly,dangerous 1.0 0.000143348623853 0 1 -1
approved,prescription 1.0 0.000143348623853 1 0 1
felbatol,on 0.0 0.0 1 1 0
side,effect 1.0 0.000286697247706 0 2 -2
catecholamine,depletor 1.0 0.00043004587156 0 3 -3
cocaine-treated,groups 1.0 0.000143348623853 0 1 -1
suggesting,that 0.272727272727 0.00043004587156 7 4 3
digitalis,enhanced 1.0 0.000143348623853 0 1 -1
iegs,has 1.0 0.000143348623853 0 1 -1
gene,expression 1.0 0.00043004587156 0 3 -3
available,uncontrolled 1.0 0.000143348623853 0 1 -1
to,factrel 1.0 0.000143348623853 1 0 1
a,concomitantly 1.0 0.000143348623853 1 0 1
that,time 1.0 0.000143348623853 0 1 -1
mean,change 0.333333333333 0.000143348623853 1 2 -1
state,and 1.0 0.000286697247706 2 0 2
continues,to 1.0 0.000143348623853 0 1 -1
other,which 0.428571428571 0.00043004587156 2 5 -3
antiepileptic,drugs 0.6 0.00043004587156 4 1 3
decreases,serum 1.0 0.000143348623853 0 1 -1
absorption,after 1.0 0.000143348623853 0 1 -1
irregularities,have 1.0 0.000286697247706 0 2 -2
resecting,the 1.0 0.000143348623853 0 1 -1
been,some 1.0 0.000143348623853 1 0 1
common,medications 1.0 0.000143348623853 0 1 -1
that,d1 1.0 0.000143348623853 0 1 -1
pharmacological,doses 1.0 0.000143348623853 0 1 -1
flucytosine,while 1.0 0.000143348623853 1 0 1
probenecid,as 1.0 0.000573394495413 4 0 4
verapamil,the 1.0 0.000143348623853 1 0 1
each,task 1.0 0.000286697247706 0 2 -2
clinitest,benedicts 1.0 0.000143348623853 0 1 -1
subjects,r 1.0 0.000143348623853 0 1 -1
subjects,n 0.0 0.0 1 1 0
evaluate,interactions 1.0 0.000143348623853 0 1 -1
disintegrins,and 1.0 0.000143348623853 0 1 -1
observation,of 1.0 0.000860091743119 6 0 6
least,hour 0.333333333333 0.000143348623853 2 1 1
overload,both 1.0 0.000143348623853 0 1 -1
report,of 0.5 0.000286697247706 3 1 2
that,do 0.0 0.0 1 1 0
fluid,by 1.0 0.000143348623853 0 1 -1
initiated,apparent 1.0 0.000143348623853 1 0 1
several,interaction 1.0 0.000143348623853 0 1 -1
of,urate 1.0 0.000143348623853 1 0 1
over,to 1.0 0.000143348623853 0 1 -1
this,study 0.7 0.00200688073394 3 17 -14
tbg,may 1.0 0.000143348623853 0 1 -1
inhibiting,eg 1.0 0.000143348623853 1 0 1
visual,cortex 1.0 0.000286697247706 0 2 -2
sparine,phenergan 1.0 0.000143348623853 0 1 -1
l,while 1.0 0.000143348623853 0 1 -1
level,while 0.0 0.0 1 1 0
tambocor,with 1.0 0.000143348623853 0 1 -1
as,recommended 1.0 0.000143348623853 0 1 -1
literature,suggest 1.0 0.000143348623853 1 0 1
precautions,probably 1.0 0.000143348623853 0 1 -1
cyp3a4,the 1.0 0.000143348623853 1 0 1
inhibitors,calcium-channel 1.0 0.000143348623853 0 1 -1
have,not 0.758241758242 0.00989105504587 11 80 -69
can,suppress 1.0 0.000143348623853 1 0 1
botulinum,neurotoxin 1.0 0.000286697247706 0 2 -2
colony,forming 1.0 0.000143348623853 0 1 -1
an,erection 1.0 0.000143348623853 0 1 -1
cyp2a6,hydroxylation 1.0 0.000143348623853 1 0 1
increased,incidence 0.8 0.00114678899083 1 9 -8
hours,based 1.0 0.000143348623853 0 1 -1
inhibitors,guanethidine 1.0 0.000143348623853 0 1 -1
occurs,dose 1.0 0.000143348623853 1 0 1
meth,induced 1.0 0.000143348623853 0 1 -1
the,calcium-entry 1.0 0.000143348623853 0 1 -1
patients,available 1.0 0.000143348623853 0 1 -1
hydrochloride,therapy 1.0 0.000143348623853 1 0 1
measurable,limit 1.0 0.000143348623853 1 0 1
considerations,as 1.0 0.000143348623853 0 1 -1
on,metabolism 0.6 0.00043004587156 1 4 -3
excitement,hypomania 1.0 0.000143348623853 0 1 -1
tendency,to 1.0 0.000286697247706 2 0 2
exposure,be 1.0 0.000143348623853 0 1 -1
plasma,membrane 1.0 0.000143348623853 0 1 -1
blockers,isolated 1.0 0.000143348623853 1 0 1
intestinal,beta-glucuronidase 1.0 0.000143348623853 0 1 -1
weeks,were 1.0 0.000143348623853 0 1 -1
syndrome,can 1.0 0.000143348623853 1 0 1
reports,we 1.0 0.000143348623853 0 1 -1
those,such 1.0 0.000143348623853 0 1 -1
medications,other 1.0 0.000143348623853 0 1 -1
going,to 1.0 0.000716743119266 0 5 -5
laboratorytest,interactions 1.0 0.000143348623853 0 1 -1
a4,especially 1.0 0.000143348623853 0 1 -1
which,may 0.166666666667 0.000860091743119 15 21 -6
first,step 1.0 0.000143348623853 0 1 -1
sular,tended 1.0 0.000143348623853 1 0 1
recovery,took 1.0 0.000143348623853 1 0 1
used,they 1.0 0.000143348623853 0 1 -1
under,fasting 1.0 0.000143348623853 0 1 -1
most,psychoactive 1.0 0.000143348623853 1 0 1
part,a 1.0 0.000143348623853 0 1 -1
excretion,but 1.0 0.000143348623853 1 0 1
may,enhance 0.761904761905 0.0045871559633 37 5 32
can,correct 1.0 0.000143348623853 0 1 -1
for,kappa 1.0 0.000143348623853 0 1 -1
folate,may 1.0 0.000143348623853 0 1 -1
encountered,in 1.0 0.000143348623853 0 1 -1
nose,may 1.0 0.000143348623853 1 0 1
database,three 1.0 0.000143348623853 0 1 -1
that,buspirone 1.0 0.000143348623853 1 0 1
periodic,serum 1.0 0.000143348623853 1 0 1
drowsiness-causing,any 1.0 0.000143348623853 0 1 -1
result,is 1.0 0.000286697247706 0 2 -2
was,documented 1.0 0.000143348623853 0 1 -1
of,cyp2d6 0.4 0.000573394495413 3 7 -4
pharmacokinetic,studies 0.5 0.000860091743119 3 9 -6
similarity,to 1.0 0.000143348623853 1 0 1
organic,if 1.0 0.000143348623853 1 0 1
in,hypercholesterolemic 0.0 0.0 1 1 0
doses,should 0.333333333333 0.000143348623853 1 2 -1
recommended,maximum 1.0 0.000286697247706 2 0 2
maalox,maalox 1.0 0.000143348623853 1 0 1
observed,in 0.764705882353 0.00372706422018 4 30 -26
method,the 1.0 0.000143348623853 0 1 -1
observed,it 0.0 0.0 1 1 0
way,crossover 1.0 0.000143348623853 0 1 -1
practice,dictates 1.0 0.000143348623853 1 0 1
to,unique 1.0 0.000143348623853 0 1 -1
high,plasma 1.0 0.000143348623853 0 1 -1
effects,is 1.0 0.000143348623853 1 0 1
effects,in 0.5 0.000860091743119 3 9 -6
systemic,exposure 0.166666666667 0.000286697247706 5 7 -2
which,confirms 1.0 0.000143348623853 0 1 -1
polyenes,are 1.0 0.000143348623853 0 1 -1
kidney,diseases 1.0 0.000143348623853 0 1 -1
reported,here 1.0 0.000143348623853 0 1 -1
agents,channel 1.0 0.000143348623853 1 0 1
patients,beginning 1.0 0.000143348623853 1 0 1
of,parietal 1.0 0.000143348623853 0 1 -1
vary,and 1.0 0.000143348623853 0 1 -1
the,underlying 0.0 0.0 1 1 0
viracept,with 1.0 0.000143348623853 1 0 1
associated,adverse 1.0 0.000143348623853 0 1 -1
dependent,measures 1.0 0.000143348623853 0 1 -1
and,adjust 0.0 0.0 1 1 0
ames,n-multistix 1.0 0.000143348623853 0 1 -1
u,of 1.0 0.000143348623853 0 1 -1
although,combining 1.0 0.000143348623853 0 1 -1
use,the 1.0 0.00043004587156 0 3 -3
three,pharmacokinetic 1.0 0.000143348623853 0 1 -1
probably,due 1.0 0.000143348623853 0 1 -1
effects,blood 1.0 0.000143348623853 0 1 -1
drug,eg 1.0 0.000143348623853 1 0 1
human,liver 0.866666666667 0.00186353211009 1 14 -13
with,cgs 1.0 0.000143348623853 1 0 1
not,clear 1.0 0.000286697247706 0 2 -2
psychotropic,have 1.0 0.000143348623853 1 0 1
volatile,inhalation 1.0 0.000143348623853 1 0 1
of,needed 1.0 0.000143348623853 1 0 1
as,those 0.5 0.000286697247706 1 3 -2
taken,during 0.5 0.000286697247706 3 1 2
times,mouse 1.0 0.000143348623853 0 1 -1
acetazolamide,reduces 1.0 0.000143348623853 1 0 1
published,information 1.0 0.000143348623853 0 1 -1
cause,increases 1.0 0.00043004587156 0 3 -3
of,d-penicillamine 1.0 0.000143348623853 0 1 -1
ewes,with 1.0 0.000143348623853 1 0 1
n-dodecyl,gallate 1.0 0.000143348623853 0 1 -1
gst,activity 1.0 0.000143348623853 0 1 -1
of,its 0.384615384615 0.00143348623853 8 18 -10
ammonium,chloride 1.0 0.000286697247706 2 0 2
pivoxil,be 0.0 0.0 1 1 0
platelet,inhibitors 0.333333333333 0.000143348623853 1 2 -1
hepatic,impairment 1.0 0.000573394495413 0 4 -4
hippocampus,as 1.0 0.000143348623853 0 1 -1
serial,measurement 1.0 0.000143348623853 1 0 1
distribution,pathways 1.0 0.000143348623853 0 1 -1
respectively,when 1.0 0.000286697247706 2 0 2
aspirin,concurrent 1.0 0.000286697247706 2 0 2
control,vs 1.0 0.000143348623853 1 0 1
reports,that 1.0 0.000286697247706 2 0 2
decreased,on 1.0 0.000143348623853 1 0 1
therapy,who 1.0 0.000143348623853 1 0 1
maintained,by 1.0 0.000143348623853 0 1 -1
and,compared 1.0 0.000286697247706 0 2 -2
administered,without 1.0 0.000143348623853 0 1 -1
of,amprenavir 1.0 0.000143348623853 1 0 1
a,reversible 0.333333333333 0.000143348623853 1 2 -1
aminosalicylic,acid 1.0 0.000716743119266 5 0 5
smaller,initial 1.0 0.000143348623853 1 0 1
clinically,relevant 0.619047619048 0.00186353211009 4 17 -13
approach,to 1.0 0.00043004587156 0 3 -3
thioethers,in 1.0 0.000143348623853 0 1 -1
nephrotoxic,because 1.0 0.000143348623853 0 1 -1
earlier,than 1.0 0.000143348623853 1 0 1
tolerant,patients 1.0 0.000143348623853 0 1 -1
treatment,discontinued 1.0 0.000143348623853 0 1 -1
even,decrease 1.0 0.000143348623853 0 1 -1
combinational,action 1.0 0.000143348623853 0 1 -1
reduction,when 1.0 0.000143348623853 1 0 1
fumarate,capsules 1.0 0.000143348623853 0 1 -1
with,combination 1.0 0.000143348623853 0 1 -1
following,oral 1.0 0.000286697247706 0 2 -2
nacmc,at 1.0 0.000143348623853 0 1 -1
cimetidine,ranitidine 1.0 0.000143348623853 1 0 1
be,elevated 1.0 0.000286697247706 0 2 -2
inhibited,cyp 1.0 0.000143348623853 0 1 -1
enzyme,activities 1.0 0.000143348623853 0 1 -1
for,oral 0.166666666667 0.000286697247706 7 5 2
those,found 0.0 0.0 1 1 0
either,inhibitors 1.0 0.000143348623853 0 1 -1
menstrual,cycles 1.0 0.000143348623853 0 1 -1
of,activity 1.0 0.000143348623853 0 1 -1
between,mao 1.0 0.000143348623853 1 0 1
supplements,has 1.0 0.000143348623853 0 1 -1
whether,or 1.0 0.000286697247706 0 2 -2
direction,and 1.0 0.000143348623853 0 1 -1
consumption,of 0.0 0.0 1 1 0
products,that 0.0 0.0 1 1 0
source,or 1.0 0.000143348623853 0 1 -1
carbamazepine,combined 1.0 0.000143348623853 0 1 -1
animals,demonstrate 1.0 0.000143348623853 1 0 1
to,enhancing 1.0 0.000143348623853 1 0 1
factor,viii 1.0 0.000143348623853 0 1 -1
was,dialyzed 1.0 0.000143348623853 0 1 -1
of,enterobacteriaceae 1.0 0.000143348623853 0 1 -1
including,myocardial 1.0 0.000143348623853 1 0 1
corticosteroids,or 1.0 0.000143348623853 0 1 -1
including,but 1.0 0.000143348623853 1 0 1
obtained,either 1.0 0.000143348623853 0 1 -1
selection,of 1.0 0.000143348623853 0 1 -1
of,leading 1.0 0.000716743119266 5 0 5
there,were 0.846153846154 0.00315366972477 2 24 -22
pregnant,into 1.0 0.000143348623853 0 1 -1
intestinal,absorption 0.111111111111 0.000143348623853 4 5 -1
monkeys,responding 1.0 0.000143348623853 0 1 -1
with,lipid-lowering 1.0 0.000143348623853 0 1 -1
doses,could 1.0 0.000143348623853 0 1 -1
monitor,cardiovascular 1.0 0.000143348623853 0 1 -1
concomitant,antihypertensive 1.0 0.000143348623853 1 0 1
been,noted 0.333333333333 0.000143348623853 2 1 1
inhibitors,warning 1.0 0.000143348623853 0 1 -1
focus,is 1.0 0.000143348623853 0 1 -1
receive,intermittent 1.0 0.000143348623853 0 1 -1
coffee,and 1.0 0.000143348623853 0 1 -1
studied,than 1.0 0.000143348623853 0 1 -1
and,doses 1.0 0.000143348623853 0 1 -1
cyp2d6,cyp2e1 1.0 0.000716743119266 0 5 -5
frequently,and 1.0 0.000143348623853 0 1 -1
of,botox 1.0 0.000143348623853 1 0 1
prophylactic,doses 1.0 0.000143348623853 0 1 -1
with,innovar 1.0 0.000143348623853 1 0 1
be,maintained 0.0 0.0 1 1 0
receiving,hctz 1.0 0.000143348623853 1 0 1
induce,early 1.0 0.000143348623853 0 1 -1
was,used 0.25 0.000286697247706 3 5 -2
therapy,including 1.0 0.00043004587156 0 3 -3
of,antagonism 1.0 0.000143348623853 0 1 -1
disulfiram,appears 1.0 0.000143348623853 0 1 -1
sacrificed,in 1.0 0.000143348623853 0 1 -1
certain,by 1.0 0.000143348623853 1 0 1
occasionally,experience 1.0 0.000716743119266 5 0 5
performed,to 1.0 0.000143348623853 0 1 -1
symptomatic,hypotension 1.0 0.000143348623853 0 1 -1
or,serum 0.333333333333 0.000143348623853 1 2 -1
the,dimethylprostaglandin 1.0 0.000143348623853 0 1 -1
factors,studied 1.0 0.000143348623853 1 0 1
procedure,should 1.0 0.000143348623853 0 1 -1
and,cystic 1.0 0.000143348623853 1 0 1
the,cognitive 1.0 0.000143348623853 1 0 1
receiving,blocking 1.0 0.000143348623853 0 1 -1
of,udp-glucuronyl 1.0 0.000143348623853 0 1 -1
family,cyp3a4 1.0 0.000143348623853 0 1 -1
requirements,may 0.0 0.0 1 1 0
organ,may 1.0 0.000143348623853 0 1 -1
dorsocervical,fat 1.0 0.000143348623853 0 1 -1
to,depress 0.333333333333 0.000143348623853 2 1 1
involving,healthy 0.0 0.0 1 1 0
necessary,but 1.0 0.000143348623853 0 1 -1
is,similar 1.0 0.000143348623853 1 0 1
of,young 1.0 0.000143348623853 0 1 -1
of,symptoms 0.0 0.0 1 1 0
fetal,variations 1.0 0.000143348623853 0 1 -1
potentiation,resulted 1.0 0.000143348623853 0 1 -1
gm,day 1.0 0.000143348623853 1 0 1
to,inter-patient 1.0 0.000143348623853 1 0 1
additional,concomitant 1.0 0.000143348623853 0 1 -1
carbohydrate-splitting,enzymes 1.0 0.000143348623853 1 0 1
the,medications 1.0 0.000143348623853 0 1 -1
direct,pharmacokinetic 1.0 0.000143348623853 0 1 -1
compounds,tested 1.0 0.000143348623853 0 1 -1
on,cyp1a2 1.0 0.000286697247706 0 2 -2
prolonging,av 1.0 0.000143348623853 1 0 1
the,stomach 0.5 0.000286697247706 3 1 2
levels,have 0.25 0.000286697247706 3 5 -2
y1,cells 1.0 0.000143348623853 0 1 -1
appropriate,plasma 1.0 0.000143348623853 0 1 -1
acetylcholinesterase,ache 1.0 0.000143348623853 1 0 1
of,lapatinib 1.0 0.000143348623853 0 1 -1
of,following 1.0 0.000286697247706 0 2 -2
isoenzymes,cyp2c9 1.0 0.000143348623853 0 1 -1
have,neuromuscular 1.0 0.000286697247706 2 0 2
l-methionine,may 1.0 0.000143348623853 1 0 1
inapsine,required 1.0 0.000143348623853 0 1 -1
hctz,alone 0.0 0.0 1 1 0
efficacy,data 1.0 0.00043004587156 0 3 -3
before,meals 1.0 0.000573394495413 0 4 -4
excretion,compared 1.0 0.000286697247706 2 0 2
indicates,deterioration 1.0 0.000143348623853 0 1 -1
were,subsequently 0.0 0.0 1 1 0
metab-olizers,resemble 1.0 0.000143348623853 0 1 -1
was,explored 1.0 0.000143348623853 0 1 -1
were,taken 1.0 0.00043004587156 0 3 -3
and,amantadine 1.0 0.000143348623853 1 0 1
agents,contribute 1.0 0.000143348623853 0 1 -1
treatment,dyspnea 1.0 0.000143348623853 0 1 -1
in,mac 1.0 0.000143348623853 0 1 -1
relaxants,are 1.0 0.000286697247706 0 2 -2
palpitations,or 1.0 0.000143348623853 0 1 -1
adrenal,and 1.0 0.000143348623853 0 1 -1
been,seen 0.2 0.000143348623853 3 2 1
when,coadministered 0.272727272727 0.000860091743119 14 8 6
treatment,age 1.0 0.000143348623853 0 1 -1
in,man 0.25 0.000286697247706 3 5 -2
of,pseudomonas 1.0 0.000286697247706 0 2 -2
antiarrhythmic,agents 1.0 0.000143348623853 0 1 -1
one,month 1.0 0.000143348623853 0 1 -1
on,previous 1.0 0.000143348623853 0 1 -1
with,copd 1.0 0.000143348623853 0 1 -1
system,or 0.0 0.0 1 1 0
mg,qid 0.0 0.0 1 1 0
mouse,mammary 1.0 0.000286697247706 0 2 -2
did,produce 1.0 0.000143348623853 0 1 -1
these,were 0.333333333333 0.000143348623853 1 2 -1
general,the 1.0 0.000143348623853 0 1 -1
taken,concurrently 0.2 0.000143348623853 2 3 -1
anti,inflammatory 1.0 0.000143348623853 1 0 1
to,all 1.0 0.000143348623853 0 1 -1
acids,or 1.0 0.000143348623853 0 1 -1
ketoprofen,does 1.0 0.000143348623853 0 1 -1
neuromuscular,transmission 0.333333333333 0.000143348623853 2 1 1
warfarin,keppra 1.0 0.000143348623853 0 1 -1
component,of 1.0 0.000286697247706 2 0 2
cancer,diabetes 1.0 0.000143348623853 0 1 -1
limited,pk 1.0 0.000143348623853 0 1 -1
are,critical 1.0 0.000143348623853 0 1 -1
a,subclone 1.0 0.000143348623853 0 1 -1
iboga,alkaloid 1.0 0.000143348623853 0 1 -1
magnesium-containing,preparations 1.0 0.00043004587156 3 0 3
per,mac 1.0 0.000143348623853 0 1 -1
mediation,of 1.0 0.000143348623853 0 1 -1
abrupt,suppression 1.0 0.000143348623853 1 0 1
between,discontinuation 1.0 0.000286697247706 2 0 2
like,aleve 1.0 0.000143348623853 1 0 1
drugs,whose 0.333333333333 0.000143348623853 2 1 1
studies,indicate 0.25 0.000573394495413 6 10 -4
determined,that 1.0 0.000143348623853 0 1 -1
normally,be 1.0 0.000143348623853 0 1 -1
incorporate,the 1.0 0.000143348623853 0 1 -1
depends,not 1.0 0.000143348623853 0 1 -1
function,since 1.0 0.000143348623853 0 1 -1
curves,relatively 1.0 0.000143348623853 0 1 -1
reduced,subjects 1.0 0.000143348623853 0 1 -1
as,other 1.0 0.000286697247706 2 0 2
hepatic,k 1.0 0.000143348623853 0 1 -1
of,tcas 0.142857142857 0.000143348623853 3 4 -1
ketoconazole,co-administration 1.0 0.000286697247706 2 0 2
confirmed,by 1.0 0.000143348623853 0 1 -1
fasting,glycemia 1.0 0.000143348623853 0 1 -1
systems,has 1.0 0.000143348623853 1 0 1
levels,may 0.333333333333 0.000716743119266 5 10 -5
abstracts,using 1.0 0.000143348623853 0 1 -1
overdose,especially 1.0 0.000143348623853 1 0 1
or,inactivated 1.0 0.000143348623853 1 0 1
withdrawn,several 1.0 0.000143348623853 1 0 1
vivo,evidence 1.0 0.000143348623853 0 1 -1
and,nuclear 1.0 0.000143348623853 1 0 1
hydrochloride,could 1.0 0.000143348623853 0 1 -1
newly,introduced 1.0 0.000143348623853 0 1 -1
deethylase,in 1.0 0.000143348623853 0 1 -1
other,narcotic 1.0 0.000143348623853 1 0 1
cell,type 1.0 0.000143348623853 0 1 -1
with,fluothane 1.0 0.000143348623853 1 0 1
of,method 1.0 0.000143348623853 0 1 -1
be,lower 0.333333333333 0.000143348623853 1 2 -1
the,diamond 1.0 0.000286697247706 0 2 -2
had,had 1.0 0.000143348623853 0 1 -1
restriction,or 1.0 0.000143348623853 1 0 1
of,hemorrhage 1.0 0.000286697247706 0 2 -2
approximately,and 0.428571428571 0.00043004587156 5 2 3
cyclosporine,concomitant 1.0 0.000143348623853 0 1 -1
any,patient 1.0 0.000143348623853 0 1 -1
effects,without 1.0 0.000143348623853 1 0 1
altered,coagulation 1.0 0.000143348623853 1 0 1
nonfailing,myocardium 1.0 0.000143348623853 1 0 1
block,with 1.0 0.000143348623853 0 1 -1
in,corrected 1.0 0.000143348623853 0 1 -1
particularly,cautious 1.0 0.000143348623853 0 1 -1
inactivity,of 1.0 0.000143348623853 0 1 -1
the,clinic 1.0 0.000143348623853 0 1 -1
careful,titration 1.0 0.000286697247706 0 2 -2
determining,synergism 1.0 0.000143348623853 0 1 -1
bun,serum 1.0 0.000143348623853 1 0 1
a,review 0.0 0.0 1 1 0
include,vaiproic 1.0 0.000143348623853 1 0 1
hydrochloride,not 1.0 0.000143348623853 1 0 1
after,approximately 1.0 0.000143348623853 0 1 -1
tricor,at 1.0 0.000143348623853 1 0 1
mechanisms,underlying 1.0 0.000286697247706 0 2 -2
primarily,cyp3a4 1.0 0.000143348623853 0 1 -1
control,in 1.0 0.00043004587156 0 3 -3
decreased,to 1.0 0.000143348623853 1 0 1
difluoroacetone,in 1.0 0.000143348623853 1 0 1
m,m 0.333333333333 0.000143348623853 1 2 -1
rarely,in 1.0 0.000143348623853 1 0 1
values,after 1.0 0.000143348623853 0 1 -1
enhance,nutrient 1.0 0.000143348623853 1 0 1
fasting,conditions 1.0 0.000143348623853 0 1 -1
various,temperatures 1.0 0.000143348623853 0 1 -1
depresses,bone 1.0 0.000143348623853 0 1 -1
severe,malaria 1.0 0.000143348623853 0 1 -1
significant,elevations 1.0 0.000143348623853 0 1 -1
the,human 1.0 0.00229357798165 0 16 -16
as,videx 1.0 0.000286697247706 2 0 2
functions,as 1.0 0.000143348623853 0 1 -1
day,provided 1.0 0.000143348623853 1 0 1
times,a 0.333333333333 0.000143348623853 1 2 -1
the,jaff 1.0 0.000143348623853 0 1 -1
soft,and 1.0 0.000143348623853 0 1 -1
study,who 1.0 0.000143348623853 1 0 1
marked,hypertension 1.0 0.000143348623853 1 0 1
an,blood 1.0 0.000143348623853 1 0 1
of,voltage-dependent 1.0 0.000143348623853 0 1 -1
with,lodine 1.0 0.000143348623853 0 1 -1
alpha,and 1.0 0.000143348623853 0 1 -1
been,rare 0.428571428571 0.00043004587156 5 2 3
temperature,was 1.0 0.000143348623853 1 0 1
dosage,accordingly 1.0 0.000143348623853 0 1 -1
p2,while 1.0 0.000143348623853 0 1 -1
catecholamine-depleting,agents 1.0 0.000143348623853 1 0 1
were,increased 0.0769230769231 0.000143348623853 7 6 1
a,sulfa-based 1.0 0.000143348623853 0 1 -1
markers,that 1.0 0.000143348623853 1 0 1
irritating,topical 1.0 0.000143348623853 0 1 -1
using,preparations 1.0 0.000143348623853 0 1 -1
fatal,hepatic 1.0 0.000143348623853 0 1 -1
desired,therapeutic 1.0 0.000143348623853 0 1 -1
concomitant,crohn 1.0 0.000143348623853 0 1 -1
enhance,cns 1.0 0.000143348623853 1 0 1
for,five 1.0 0.000143348623853 0 1 -1
between,taxol 1.0 0.000143348623853 0 1 -1
some,medications 1.0 0.000143348623853 0 1 -1
between,or 1.0 0.000143348623853 1 0 1
profiles,of 1.0 0.000143348623853 0 1 -1
hypertension,including 1.0 0.000143348623853 1 0 1
by,intermediate 1.0 0.000143348623853 1 0 1
between,oh 1.0 0.000143348623853 0 1 -1
guardian,see 1.0 0.000143348623853 0 1 -1
viable,counts 1.0 0.000286697247706 0 2 -2
both,resorptions 0.0 0.0 1 1 0
its,approval 1.0 0.000143348623853 0 1 -1
channel,blocker 1.0 0.000286697247706 0 2 -2
atovaquone,is 1.0 0.000143348623853 0 1 -1
practice,resulted 1.0 0.000143348623853 0 1 -1
hepatic,clearance 1.0 0.000143348623853 0 1 -1
intolerance,prior 1.0 0.000143348623853 0 1 -1
hyperlipidaemia,and 1.0 0.000143348623853 0 1 -1
the,relevance 0.5 0.000286697247706 1 3 -2
cervical,laceration 1.0 0.000143348623853 1 0 1
of,midcycle 1.0 0.000143348623853 0 1 -1
the,level 0.454545454545 0.000716743119266 3 8 -5
requiring,complete 1.0 0.000143348623853 0 1 -1
empiric,adjustment 1.0 0.000143348623853 0 1 -1
of,malignant 0.0 0.0 1 1 0
not,suffer 1.0 0.000143348623853 0 1 -1
for,recovery 1.0 0.000143348623853 0 1 -1
paid,to 1.0 0.000143348623853 0 1 -1
the,value 1.0 0.000143348623853 0 1 -1
study,comparing 1.0 0.000286697247706 0 2 -2
ultracentrifugation,indicated 1.0 0.000143348623853 0 1 -1
hydrochloride,given 1.0 0.000143348623853 1 0 1
since,an 1.0 0.000143348623853 1 0 1
performed,in 1.0 0.000716743119266 0 5 -5
greater,degrees 1.0 0.000143348623853 1 0 1
co-infected,with 1.0 0.000143348623853 0 1 -1
relationship,between 1.0 0.000286697247706 0 2 -2
performed,if 1.0 0.000143348623853 0 1 -1
a2,a6 1.0 0.000573394495413 0 4 -4
kg,ip 1.0 0.000143348623853 1 0 1
kg,in 1.0 0.000143348623853 0 1 -1
were,a 1.0 0.000143348623853 0 1 -1
prescription,and 1.0 0.000143348623853 0 1 -1
rating,scales 1.0 0.000143348623853 0 1 -1
the,advice 1.0 0.000143348623853 1 0 1
methylxanthines,and 1.0 0.000143348623853 1 0 1
new,combination 1.0 0.000143348623853 0 1 -1
the,interaction 0.625 0.00286697247706 6 26 -20
randomized,trial 1.0 0.000143348623853 1 0 1
metabolizing,enzymes 1.0 0.00043004587156 0 3 -3
extensive,metabolizers 1.0 0.000143348623853 1 0 1
hcl,an 1.0 0.000143348623853 0 1 -1
effects,similar 1.0 0.000143348623853 0 1 -1
specific,pharmacokinetic 1.0 0.000286697247706 0 2 -2
over-the,counter 1.0 0.000286697247706 0 2 -2
of,these 0.561904761905 0.00845756880734 23 82 -59
different,botulinum 1.0 0.000286697247706 0 2 -2
maximal,decrease 1.0 0.000143348623853 0 1 -1
was,detected 1.0 0.000286697247706 0 2 -2
administered,iron-fortified 1.0 0.000143348623853 0 1 -1
this,treatment 1.0 0.000143348623853 0 1 -1
hypotensive,episodes 1.0 0.000143348623853 1 0 1
been,described 1.0 0.000286697247706 0 2 -2
that,was 0.2 0.000143348623853 2 3 -1
by,which 0.0 0.0 1 1 0
of,sensitivity 1.0 0.000143348623853 0 1 -1
in,detecting 1.0 0.000143348623853 0 1 -1
mg,intravenous 1.0 0.000143348623853 0 1 -1
of,life- 1.0 0.000143348623853 1 0 1
pharmacodynamics,arecoline 1.0 0.000143348623853 1 0 1
of,medications 1.0 0.00043004587156 0 3 -3
and,fr 1.0 0.000143348623853 0 1 -1
and,hyperglycemia 1.0 0.000143348623853 0 1 -1
and,hyperglycemic 1.0 0.000143348623853 0 1 -1
agent,can 1.0 0.000716743119266 5 0 5
significantly,inhibit 0.333333333333 0.000143348623853 2 1 1
relative,absorption 1.0 0.000143348623853 0 1 -1
to,their 0.75 0.000860091743119 1 7 -6
were,only 1.0 0.000286697247706 0 2 -2
results,do 1.0 0.000143348623853 1 0 1
blood,concentration 0.0 0.0 1 1 0
other,primarily 1.0 0.000143348623853 0 1 -1
large,doses 1.0 0.000573394495413 0 4 -4
interaction,sites 1.0 0.000143348623853 0 1 -1
increased,lipid 1.0 0.000143348623853 0 1 -1
intravenous,has 0.0 0.0 1 1 0
iron-fortified,infant 1.0 0.000143348623853 0 1 -1
compatible,with 1.0 0.000143348623853 0 1 -1
steady,state 0.238095238095 0.000716743119266 8 13 -5
l,for 1.0 0.000143348623853 0 1 -1
transporter,p-glycoprotein 1.0 0.000143348623853 0 1 -1
profound,hypotension 1.0 0.000143348623853 1 0 1
administration,was 1.0 0.000143348623853 1 0 1
similarly,to 1.0 0.000143348623853 1 0 1
related,metabolic 1.0 0.000143348623853 0 1 -1
consume,and 1.0 0.000143348623853 1 0 1
metabolite,after 1.0 0.000143348623853 0 1 -1
produce,serious 1.0 0.000143348623853 0 1 -1
a,laser 1.0 0.000143348623853 0 1 -1
and,confusional 1.0 0.000143348623853 1 0 1
nondepolarizing,blocking 1.0 0.000143348623853 0 1 -1
a,supplement 1.0 0.000143348623853 0 1 -1
in,individuals 1.0 0.000286697247706 0 2 -2
bmax,of 1.0 0.000143348623853 0 1 -1
lunch,doses 1.0 0.000143348623853 0 1 -1
in,experiments 1.0 0.000143348623853 0 1 -1
apparently,by 1.0 0.000143348623853 0 1 -1
panretin,gel 0.333333333333 0.000143348623853 1 2 -1
butyrophenones,such 1.0 0.000143348623853 1 0 1
example,may 1.0 0.000143348623853 0 1 -1
elderly,may 1.0 0.000143348623853 1 0 1
small,doses 1.0 0.000143348623853 1 0 1
metal,cations 0.333333333333 0.000143348623853 2 1 1
attenuate,loss 1.0 0.00043004587156 3 0 3
reflect,the 1.0 0.000143348623853 0 1 -1
amyl,nitrite 1.0 0.000143348623853 1 0 1
racemic,for 1.0 0.000143348623853 0 1 -1
increased,in 0.666666666667 0.000573394495413 1 5 -4
groups,which 1.0 0.000143348623853 0 1 -1
overdose,with 1.0 0.000143348623853 1 0 1
when,evaluating 1.0 0.00043004587156 0 3 -3
neurons,and 1.0 0.000143348623853 1 0 1
increased,if 1.0 0.000143348623853 1 0 1
pi-based,therapy 1.0 0.000143348623853 0 1 -1
in,acutely 1.0 0.000143348623853 0 1 -1
hivid,should 0.333333333333 0.000143348623853 1 2 -1
tests,response 1.0 0.000143348623853 0 1 -1
monitoring,can 1.0 0.000143348623853 1 0 1
low,and 1.0 0.000143348623853 0 1 -1
antineoplastic,agents 0.333333333333 0.000286697247706 4 2 2
of,epirubicin-containing 1.0 0.000143348623853 0 1 -1
other,through 1.0 0.000286697247706 0 2 -2
and,stimulatory 1.0 0.000143348623853 1 0 1
the,danger 1.0 0.00043004587156 3 0 3
following,mptp 1.0 0.000143348623853 0 1 -1
gelatin,capsules 1.0 0.000143348623853 0 1 -1
or,magnesium-containing 1.0 0.000143348623853 1 0 1
substantially,increased 1.0 0.000143348623853 1 0 1
predict,specific 1.0 0.000143348623853 0 1 -1
both,periods 1.0 0.000286697247706 0 2 -2
weight,were 1.0 0.000143348623853 0 1 -1
the,labeling 1.0 0.000143348623853 0 1 -1
at,specified 1.0 0.000143348623853 0 1 -1
p2,however 1.0 0.000143348623853 0 1 -1
others,choline 1.0 0.000143348623853 1 0 1
kg,s 1.0 0.000286697247706 2 0 2
been,obtained 1.0 0.000143348623853 0 1 -1
which,suggest 1.0 0.000143348623853 1 0 1
however,administration 1.0 0.000143348623853 0 1 -1
permitil,compazine 1.0 0.000143348623853 0 1 -1
azathioprine,allopurinol 1.0 0.000143348623853 1 0 1
mg,sodium 1.0 0.000286697247706 2 0 2
metabolic,abnormalities 1.0 0.000143348623853 0 1 -1
hour,after 0.2 0.000143348623853 3 2 1
dramatically,from 1.0 0.000143348623853 0 1 -1
and,mild-to 1.0 0.000143348623853 0 1 -1
kg,m 1.0 0.000143348623853 0 1 -1
were,tested 1.0 0.000143348623853 0 1 -1
ml,and 0.2 0.000143348623853 2 3 -1
either,occurred 1.0 0.000143348623853 0 1 -1
also,were 1.0 0.000143348623853 0 1 -1
relevant,laboratory 1.0 0.000143348623853 0 1 -1
as,possible 1.0 0.000286697247706 0 2 -2
tumors,is 1.0 0.000143348623853 0 1 -1
in,hyperthyroid 1.0 0.000143348623853 0 1 -1
a,drug-drug 0.0 0.0 1 1 0
theoretically,interfere 1.0 0.000143348623853 0 1 -1
vasospasm,and 0.333333333333 0.000143348623853 1 2 -1
other,had 1.0 0.000143348623853 0 1 -1
possible,effectiveness 1.0 0.000143348623853 1 0 1
such,methods 1.0 0.000143348623853 0 1 -1
the,binding 0.2 0.000286697247706 4 6 -2
defecation,episodes 1.0 0.000143348623853 0 1 -1
may,reduce 0.45 0.00258027522936 29 11 18
concentration,should 0.5 0.000286697247706 1 3 -2
by,factors 1.0 0.000143348623853 0 1 -1
hepatic,toxicity 0.0 0.0 1 1 0
ptx,c129h223n3o54 1.0 0.000143348623853 0 1 -1
necessary,eg 1.0 0.000143348623853 1 0 1
define,the 1.0 0.000286697247706 0 2 -2
no,clinical 0.846153846154 0.00157683486239 1 12 -11
before,blood 1.0 0.000143348623853 1 0 1
whenever,one 1.0 0.000716743119266 0 5 -5
above,chronic 1.0 0.000143348623853 0 1 -1
acarbose,may 1.0 0.000143348623853 0 1 -1
the,ingested 1.0 0.000143348623853 1 0 1
from,succinylcholine-induced 1.0 0.000143348623853 1 0 1
difluoroacetone,to 1.0 0.000143348623853 0 1 -1
biogen,pregnancy 1.0 0.000143348623853 0 1 -1
chop,plus 1.0 0.000143348623853 0 1 -1
antacids,may 1.0 0.000143348623853 1 0 1
inspra,is 1.0 0.000143348623853 1 0 1
or,stimulus 1.0 0.000143348623853 0 1 -1
risks,arising 1.0 0.000143348623853 0 1 -1
this,disease 1.0 0.000143348623853 0 1 -1
to,exposure 1.0 0.000286697247706 0 2 -2
diet,high 0.0 0.0 1 1 0
mainly,eliminated 1.0 0.000143348623853 0 1 -1
on,concomitant 0.2 0.000286697247706 4 6 -2
may,reach 1.0 0.000143348623853 0 1 -1
interactions,false 1.0 0.000143348623853 0 1 -1
of,carcinogen 1.0 0.000143348623853 0 1 -1
membranes,and 1.0 0.000143348623853 0 1 -1
may,react 1.0 0.000143348623853 1 0 1
hyperpolarized,by 1.0 0.000286697247706 0 2 -2
enhanced,secretion 1.0 0.000143348623853 0 1 -1
an,endemic 1.0 0.000143348623853 0 1 -1
magan,or 1.0 0.000143348623853 1 0 1
developing,mathematical 1.0 0.000143348623853 0 1 -1
has,demonstrated 1.0 0.000286697247706 0 2 -2
antiedematous,action 1.0 0.000143348623853 1 0 1
the,reluctance 1.0 0.000143348623853 0 1 -1
studies,hydrochloride 1.0 0.000143348623853 0 1 -1
of,d2 1.0 0.00043004587156 0 3 -3
when,rebif 1.0 0.000143348623853 0 1 -1
rates,were 1.0 0.000143348623853 0 1 -1
h-2,antagonists 1.0 0.000143348623853 0 1 -1
optimal,pharmacokinetics 1.0 0.000143348623853 0 1 -1
a,cyp3a 1.0 0.000143348623853 0 1 -1
a,cetaminophen 1.0 0.000143348623853 0 1 -1
of,do 1.0 0.000143348623853 0 1 -1
magnitude,or 1.0 0.000143348623853 0 1 -1
usp,or 1.0 0.000143348623853 1 0 1
adjustment,as 1.0 0.000143348623853 0 1 -1
chewable,buffered 1.0 0.00100344036697 7 0 7
four,times 1.0 0.00043004587156 0 3 -3
magnitude,of 0.777777777778 0.00100344036697 1 8 -7
inadvisable,to 1.0 0.000143348623853 1 0 1
stavudine,and 1.0 0.000143348623853 1 0 1
combinations,or 1.0 0.000143348623853 0 1 -1
iiia4,blocks 1.0 0.000143348623853 1 0 1
celebrex,can 1.0 0.000143348623853 1 0 1
terfenadine,administration 1.0 0.000143348623853 0 1 -1
to,indirect-acting 1.0 0.000143348623853 1 0 1
although,one 1.0 0.000143348623853 0 1 -1
combinations,of 0.142857142857 0.000143348623853 4 3 1
postoperative,pain 1.0 0.000143348623853 0 1 -1
weeks,of 0.333333333333 0.000143348623853 1 2 -1
of,coadministered 1.0 0.00043004587156 0 3 -3
although,no 0.142857142857 0.000143348623853 4 3 1
a,car 1.0 0.000143348623853 0 1 -1
isoenzyme,of 1.0 0.000143348623853 0 1 -1
extend,outside 1.0 0.000143348623853 0 1 -1
concentrating,as 1.0 0.000143348623853 0 1 -1
to,prescribe 1.0 0.000143348623853 0 1 -1
sequestered,in 1.0 0.000143348623853 0 1 -1
adjustments,considered 1.0 0.000143348623853 1 0 1
properties,during 1.0 0.000143348623853 0 1 -1
agent,or 1.0 0.00043004587156 0 3 -3
not,different 1.0 0.000143348623853 0 1 -1
or,clinitest 1.0 0.000143348623853 0 1 -1
cardiovascular,disease 0.714285714286 0.000716743119266 1 6 -5
to,cups 1.0 0.000143348623853 0 1 -1
create,possible 1.0 0.00043004587156 0 3 -3
agent,of 1.0 0.000286697247706 0 2 -2
in,adverse 1.0 0.000716743119266 0 5 -5
together,with 0.25 0.000286697247706 3 5 -2
agent,on 1.0 0.000286697247706 0 2 -2
imidazole,compounds 1.0 0.000143348623853 1 0 1
to,extravasation 1.0 0.000143348623853 0 1 -1
drugs,decreasing 1.0 0.000143348623853 1 0 1
local,since 1.0 0.000143348623853 1 0 1
difluoroacetone,did 1.0 0.000143348623853 0 1 -1
have,contributed 1.0 0.000143348623853 0 1 -1
their,tolerance 1.0 0.000143348623853 1 0 1
the,hypoprothrombinemia 1.0 0.000143348623853 0 1 -1
the,cost-risk 1.0 0.000143348623853 0 1 -1
the,hypoprothrombinemic 1.0 0.000143348623853 0 1 -1
these,purposes 1.0 0.000143348623853 0 1 -1
nhl,characteristics 1.0 0.000143348623853 0 1 -1
under,clinical 1.0 0.000143348623853 0 1 -1
place,of 0.0 0.0 1 1 0
selegiline,hydrochloride 1.0 0.000143348623853 1 0 1
supervision,of 1.0 0.000143348623853 0 1 -1
organisms,but 1.0 0.000143348623853 0 1 -1
preparations,novolog 1.0 0.000143348623853 0 1 -1
prothrombin,complex 1.0 0.000143348623853 0 1 -1
detected,in 1.0 0.00043004587156 0 3 -3
elevations,with 1.0 0.000143348623853 0 1 -1
with,attenuated 1.0 0.000143348623853 0 1 -1
and,motor 0.0 0.0 1 1 0
judgment,of 1.0 0.000143348623853 1 0 1
of,ucb 1.0 0.000143348623853 0 1 -1
deficiencies,constitute 1.0 0.000143348623853 0 1 -1
co-administered,dose 1.0 0.000143348623853 0 1 -1
h,did 1.0 0.000143348623853 0 1 -1
literature,revealed 1.0 0.000143348623853 1 0 1
for,neurons 1.0 0.000143348623853 0 1 -1
day,have 1.0 0.000143348623853 1 0 1
following,agents 0.0 0.0 3 3 0
rate,increase 1.0 0.000143348623853 1 0 1
vivo,tests 1.0 0.000143348623853 0 1 -1
plasma,elimination 1.0 0.000143348623853 0 1 -1
cells,express 1.0 0.000143348623853 0 1 -1
systematically,in 1.0 0.000143348623853 0 1 -1
their,physicians 1.0 0.000143348623853 0 1 -1
also,has 0.6 0.00043004587156 1 4 -3
synaptic,concentration 1.0 0.000143348623853 0 1 -1
minor,changes 1.0 0.000286697247706 2 0 2
increased,binding 1.0 0.000143348623853 0 1 -1
potassium-sparing,on 1.0 0.000143348623853 1 0 1
consult,the 1.0 0.000286697247706 0 2 -2
longer,latencies 1.0 0.000143348623853 0 1 -1
intrathecal,micrograms 1.0 0.000143348623853 1 0 1
however,may 1.0 0.000143348623853 0 1 -1
barbiturates,may 1.0 0.000143348623853 1 0 1
of,tca 1.0 0.000573394495413 0 4 -4
simple,and 1.0 0.000143348623853 0 1 -1
thioridazine,coadministration 1.0 0.000143348623853 1 0 1
greater,amount 1.0 0.000143348623853 1 0 1
potentiate,sulfate 1.0 0.000143348623853 0 1 -1
herb,interactions 0.333333333333 0.000143348623853 1 2 -1
valproate,mg 1.0 0.000143348623853 0 1 -1
daily,was 1.0 0.000286697247706 0 2 -2
and,menstrual 1.0 0.000286697247706 0 2 -2
as,seen 1.0 0.000143348623853 0 1 -1
the,antinaturetic 1.0 0.000143348623853 1 0 1
it,should 0.538461538462 0.00100344036697 3 10 -7
environment,and 1.0 0.000143348623853 0 1 -1
decreased,the 0.6875 0.00315366972477 27 5 22
of,relapse 1.0 0.000143348623853 0 1 -1
by,camptosar 1.0 0.000143348623853 1 0 1
supplements,use 1.0 0.000143348623853 1 0 1
antiacid,didanosine 1.0 0.000143348623853 0 1 -1
depletion,which 1.0 0.000143348623853 0 1 -1
advised,nonetheless 1.0 0.000143348623853 0 1 -1
without,replacement 1.0 0.000143348623853 0 1 -1
for,hours 0.333333333333 0.000143348623853 1 2 -1
patterns,during 1.0 0.000143348623853 0 1 -1
radioligand,binding 1.0 0.000143348623853 0 1 -1
marked,symptomatic 1.0 0.000286697247706 2 0 2
dong,quai 1.0 0.000143348623853 0 1 -1
timi-ii,isis-2 1.0 0.000143348623853 0 1 -1
bwt,were 1.0 0.000143348623853 0 1 -1
cardiovascular,adverse 0.0 0.0 1 1 0
interactions,may 0.333333333333 0.000573394495413 8 4 4
to,induce 0.538461538462 0.00100344036697 3 10 -7
spontaneous,motility 0.0 0.0 2 2 0
albumin,could 1.0 0.000143348623853 0 1 -1
between,toradol 1.0 0.000143348623853 1 0 1
bound,to 0.875 0.00200688073394 1 15 -14
interact,with 0.0810810810811 0.00043004587156 20 17 3
human,pharmacokinetic 1.0 0.000143348623853 1 0 1
chicks,was 1.0 0.000143348623853 1 0 1
study,attempting 1.0 0.000143348623853 0 1 -1
usual,recommended 1.0 0.000143348623853 0 1 -1
ml,twice 1.0 0.000143348623853 1 0 1
random,sample 1.0 0.000143348623853 0 1 -1
reaction,between 1.0 0.000143348623853 1 0 1
open-label,three-phase 1.0 0.000143348623853 0 1 -1
using,an 0.0 0.0 1 1 0
or,stereotypic 1.0 0.000143348623853 0 1 -1
with,one-stage 1.0 0.000286697247706 0 2 -2
all,antagonists 1.0 0.000143348623853 0 1 -1
neuronal,uptake 1.0 0.000143348623853 0 1 -1
with,hepatotoxic 1.0 0.000143348623853 1 0 1
of,neurotoxic 1.0 0.000143348623853 1 0 1
no,more 1.0 0.000143348623853 0 1 -1
intraperitoneal,injections 1.0 0.000143348623853 0 1 -1
pronounced,inhibition 1.0 0.000143348623853 0 1 -1
of,atherosclerotic 1.0 0.000286697247706 0 2 -2
expression,of 1.0 0.000286697247706 0 2 -2
with,demonstrated 1.0 0.000286697247706 0 2 -2
responses,in 0.333333333333 0.000143348623853 1 2 -1
the,soluble 1.0 0.000286697247706 0 2 -2
double-blind,comparative 1.0 0.000143348623853 0 1 -1
cimetidine,in 1.0 0.00043004587156 3 0 3
concentration,that 1.0 0.000286697247706 0 2 -2
range,and 1.0 0.000143348623853 0 1 -1
anticoagulants,altered 1.0 0.000143348623853 1 0 1
amantadine,and 1.0 0.000143348623853 1 0 1
safe,dosing 1.0 0.000143348623853 0 1 -1
that,meth 1.0 0.000143348623853 1 0 1
are,now 1.0 0.000143348623853 0 1 -1
are,not 0.818181818182 0.00387041284404 3 30 -27
elimination,is 1.0 0.000286697247706 0 2 -2
platelet,aggregation 0.555555555556 0.000716743119266 2 7 -5
of,ergotamine-containing 1.0 0.000573394495413 4 0 4
another,extended 1.0 0.000143348623853 0 1 -1
in,false-positive 1.0 0.000143348623853 0 1 -1
without,tdp 1.0 0.000143348623853 0 1 -1
be,reversed 0.0 0.0 1 1 0
maintain,satisfactory 1.0 0.000286697247706 0 2 -2
kidney,recipients 1.0 0.000143348623853 0 1 -1
is,possible 0.5 0.000286697247706 3 1 2
anticoagulation,may 1.0 0.000143348623853 0 1 -1
interindividual,variability 1.0 0.000143348623853 1 0 1
with,practically 1.0 0.000143348623853 0 1 -1
neutropenia,and 0.333333333333 0.000143348623853 2 1 1
a,consequence 1.0 0.00043004587156 3 0 3
consider,discontinuation 1.0 0.000143348623853 1 0 1
actively,concentrating 1.0 0.000143348623853 0 1 -1
difficile,a 1.0 0.000143348623853 0 1 -1
ic50,from 1.0 0.000143348623853 0 1 -1
decreased,prothrom-bin 1.0 0.000286697247706 2 0 2
confusion,disorientation 1.0 0.000143348623853 0 1 -1
attention,must 0.0 0.0 1 1 0
patients,being 0.2 0.000286697247706 6 4 2
addition,that 1.0 0.000143348623853 1 0 1
in,both 0.692307692308 0.00129013761468 2 11 -9
time,necessitating 1.0 0.000143348623853 0 1 -1
dilantin,phenobarbital 1.0 0.000143348623853 1 0 1
bile,acids 1.0 0.000143348623853 0 1 -1
no,interactive 1.0 0.000143348623853 0 1 -1
among,patients 0.5 0.000286697247706 3 1 2
test,alterations 1.0 0.000143348623853 0 1 -1
becausedecreases,in 1.0 0.000286697247706 2 0 2
moieties,are 1.0 0.000143348623853 0 1 -1
cancer,res 1.0 0.000143348623853 0 1 -1
thus,appeared 1.0 0.000143348623853 1 0 1
result,in 0.0707070707071 0.00100344036697 53 46 7
to,screen 1.0 0.000286697247706 0 2 -2
administered,rapidly 1.0 0.000143348623853 0 1 -1
ribavirin,ribavirin 1.0 0.000143348623853 0 1 -1
initial,clinical 1.0 0.000143348623853 0 1 -1
pesticide,gliftor 1.0 0.000143348623853 0 1 -1
associated,dental 1.0 0.000143348623853 1 0 1
sulfate,may 1.0 0.000286697247706 2 0 2
intervals,in 1.0 0.000143348623853 0 1 -1
day,microg 1.0 0.000143348623853 0 1 -1
serum,protein-bound 1.0 0.000143348623853 0 1 -1
preventing,its 1.0 0.000143348623853 1 0 1
in,platelets 1.0 0.000286697247706 0 2 -2
substantial,number 1.0 0.000143348623853 1 0 1
cessation,of 1.0 0.000143348623853 0 1 -1
challenge,or 1.0 0.000143348623853 0 1 -1
survive,in 1.0 0.000143348623853 0 1 -1
suggest,similar 1.0 0.000143348623853 0 1 -1
studies,case 1.0 0.000143348623853 0 1 -1
had,chemotherapy 1.0 0.000143348623853 0 1 -1
alone,were 1.0 0.000143348623853 0 1 -1
of,competitive 0.333333333333 0.000143348623853 1 2 -1
impaired,cardiac 1.0 0.000143348623853 0 1 -1
bolus,doses 1.0 0.000143348623853 0 1 -1
tolerance,secretion 1.0 0.000143348623853 0 1 -1
pattern,of 1.0 0.00043004587156 0 3 -3
have,decreased 0.0 0.0 2 2 0
hamsters,in 1.0 0.000143348623853 0 1 -1
based,methods 1.0 0.000143348623853 0 1 -1
aggregation,but 1.0 0.000143348623853 1 0 1
interaction,occurred 1.0 0.000143348623853 0 1 -1
cellular,permeability 1.0 0.000143348623853 0 1 -1
test,for 0.714285714286 0.000716743119266 1 6 -5
persistent,hypertension 0.333333333333 0.000143348623853 1 2 -1
lipids,pretreatment 1.0 0.000143348623853 0 1 -1
classified,as 0.0 0.0 1 1 0
xigris,may 1.0 0.000143348623853 0 1 -1
bacteriostatic,may 1.0 0.00043004587156 3 0 3
its,therapeutic 1.0 0.000286697247706 0 2 -2
and,adrenoreceptors 1.0 0.000143348623853 0 1 -1
classified,using 1.0 0.000143348623853 0 1 -1
after,being 1.0 0.000143348623853 0 1 -1
medications,applied 1.0 0.000143348623853 0 1 -1
mouse,and 1.0 0.000143348623853 0 1 -1
gastrointestinal,toxicity 1.0 0.00043004587156 3 0 3
aspirin,vardenafil 1.0 0.000143348623853 0 1 -1
also,indicate 1.0 0.000143348623853 0 1 -1
viracept,astramorph 1.0 0.000143348623853 1 0 1
should,precede 1.0 0.000143348623853 0 1 -1
obtained,by 1.0 0.000143348623853 0 1 -1
approximately,hours 1.0 0.000143348623853 1 0 1
are,mainly 0.333333333333 0.000143348623853 1 2 -1
and,well-controlled 1.0 0.000573394495413 0 4 -4
spleen,and 1.0 0.000143348623853 0 1 -1
and,cyclopentyl-1 1.0 0.000143348623853 0 1 -1
rifampin,following 1.0 0.000143348623853 1 0 1
time,partial 1.0 0.00043004587156 0 3 -3
the,profile 1.0 0.000143348623853 0 1 -1
may,mask 1.0 0.000143348623853 0 1 -1
limiting,may 1.0 0.000143348623853 0 1 -1
cytosine,arabinoside 1.0 0.000143348623853 1 0 1
were,unchanged 1.0 0.000573394495413 0 4 -4
cyclosporine,because 1.0 0.000143348623853 1 0 1
cyclopentolate,may 1.0 0.000143348623853 1 0 1
monitored,with 1.0 0.000286697247706 0 2 -2
with,beta-adrenergic 0.5 0.000286697247706 3 1 2
a,homodimeric 1.0 0.000143348623853 0 1 -1
induced,resulting 1.0 0.000143348623853 0 1 -1
also,modify 1.0 0.000143348623853 0 1 -1
than,normal 1.0 0.000143348623853 0 1 -1
and,css 1.0 0.000143348623853 1 0 1
a4,as 1.0 0.000143348623853 0 1 -1
modern,medications 1.0 0.000143348623853 0 1 -1
c8,c9 1.0 0.000143348623853 0 1 -1
certain,and 1.0 0.000716743119266 5 0 5
studies,angiomax 1.0 0.000143348623853 0 1 -1
experiencing,increases 1.0 0.000143348623853 1 0 1
testing,should 1.0 0.000143348623853 1 0 1
no,safety 1.0 0.00043004587156 0 3 -3
adjuvant,trials 1.0 0.000143348623853 0 1 -1
that,cyp3a4 1.0 0.000143348623853 0 1 -1
on,respiration 1.0 0.000143348623853 0 1 -1
or,ast 1.0 0.000143348623853 0 1 -1
conceived,that 1.0 0.000143348623853 0 1 -1
nitrobluetetrazolium,test 1.0 0.000143348623853 0 1 -1
hexalen,and 1.0 0.000286697247706 2 0 2
poor,d6 1.0 0.000143348623853 0 1 -1
hansten,into 1.0 0.000143348623853 0 1 -1
decrease,clozapine 1.0 0.000143348623853 1 0 1
with,weakness 1.0 0.000143348623853 1 0 1
moreover,each 1.0 0.000143348623853 0 1 -1
any,condition 1.0 0.000143348623853 1 0 1
kytril,have 1.0 0.000143348623853 0 1 -1
accelerated,markedly 1.0 0.000143348623853 1 0 1
concentrations,and 0.1 0.000286697247706 9 11 -2
phlebitis,cellulitis 1.0 0.000143348623853 0 1 -1
recommended,human 1.0 0.00043004587156 0 3 -3
others,with 1.0 0.000143348623853 0 1 -1
interrupted,or 1.0 0.000143348623853 0 1 -1
benefits,of 0.0 0.0 2 2 0
diamox,in 1.0 0.000143348623853 1 0 1
were,significantly 0.5 0.000286697247706 1 3 -2
medication,such 0.0 0.0 1 1 0
altered,topo 1.0 0.000143348623853 0 1 -1
theophylline-related,side-effects 1.0 0.000143348623853 1 0 1
prior,administration 0.0 0.0 2 2 0
drug,taking 1.0 0.000143348623853 0 1 -1
interval,caution 1.0 0.000143348623853 0 1 -1
to,sodium 1.0 0.000143348623853 0 1 -1
cerebral,memory 1.0 0.000143348623853 0 1 -1
enhanced,and 1.0 0.000143348623853 1 0 1
the,tremor 1.0 0.000143348623853 0 1 -1
pharmacoeconomic,analyses 1.0 0.000143348623853 0 1 -1
red,cells 1.0 0.000143348623853 0 1 -1
status,at 1.0 0.000143348623853 0 1 -1
are,obtained 0.0 0.0 1 1 0
be,inhibited 0.333333333333 0.000286697247706 4 2 2
of,aggression 1.0 0.000143348623853 0 1 -1
elevations,of 0.428571428571 0.00043004587156 2 5 -3
inhibitors,concurrent 0.0 0.0 2 2 0
elevations,on 1.0 0.000143348623853 1 0 1
day,about 1.0 0.000143348623853 0 1 -1
serum,total 1.0 0.000286697247706 0 2 -2
partly,antagonized 1.0 0.000143348623853 1 0 1
before,day 1.0 0.000143348623853 0 1 -1
and,inflammatory 1.0 0.000143348623853 1 0 1
clearance,this 1.0 0.000143348623853 0 1 -1
with,their 0.0 0.0 1 1 0
that,tikosyn 1.0 0.000286697247706 0 2 -2
the,suitability 1.0 0.000143348623853 0 1 -1
open-label,two-way 1.0 0.000143348623853 0 1 -1
individual,inr 1.0 0.000143348623853 0 1 -1
orally,prior 1.0 0.000143348623853 1 0 1
than,two-second 1.0 0.000143348623853 1 0 1
sample,size 1.0 0.000143348623853 0 1 -1
related,member 1.0 0.000143348623853 1 0 1
medicines,including 1.0 0.000286697247706 0 2 -2
temperature,returned 1.0 0.000143348623853 0 1 -1
be,clastogenic 1.0 0.000143348623853 0 1 -1
smokers,and 1.0 0.000143348623853 0 1 -1
for,subjects 1.0 0.000143348623853 0 1 -1
deep,tendon 1.0 0.000143348623853 0 1 -1
therapy,had 1.0 0.000143348623853 0 1 -1
ferrous,sulfate 1.0 0.000286697247706 2 0 2
regression,and 1.0 0.000143348623853 0 1 -1
in,view 0.333333333333 0.000143348623853 1 2 -1
relaxants,eg 1.0 0.000143348623853 1 0 1
by,sodium 1.0 0.000286697247706 0 2 -2
digitalis,toxicity 1.0 0.000143348623853 1 0 1
methotrexate,nsaids 1.0 0.000143348623853 1 0 1
therapy,has 1.0 0.000286697247706 0 2 -2
enablex,should 1.0 0.000143348623853 1 0 1
tenormin,plus 1.0 0.000143348623853 0 1 -1
that,interacts 1.0 0.000143348623853 0 1 -1
epinephrine,should 0.0 0.0 1 1 0
dimethylprostaglandin,e2 1.0 0.000143348623853 0 1 -1
be,aware 0.0 0.0 2 2 0
at,degrees 1.0 0.000286697247706 0 2 -2
may,wear 1.0 0.000143348623853 0 1 -1
decreased,dosing 1.0 0.000143348623853 0 1 -1
that,lodine 1.0 0.000143348623853 1 0 1
b,or 1.0 0.00043004587156 0 3 -3
smaller,week 1.0 0.000143348623853 0 1 -1
your,health 1.0 0.000143348623853 1 0 1
with,ischemic 0.333333333333 0.000143348623853 1 2 -1
to,preclude 1.0 0.000573394495413 0 4 -4
in,cynomolgus 1.0 0.000286697247706 0 2 -2
bleeding,are 1.0 0.000286697247706 2 0 2
but,no 0.0 0.0 2 2 0
the,detection 1.0 0.000143348623853 0 1 -1
suddenly,exceeded 1.0 0.000143348623853 0 1 -1
breast,and 1.0 0.000143348623853 0 1 -1
mechanisms,of 1.0 0.000716743119266 0 5 -5
started,in 1.0 0.000143348623853 1 0 1
kinetics,equilibrium 1.0 0.000143348623853 0 1 -1
selected,a 1.0 0.000143348623853 0 1 -1
which,concomitant 1.0 0.000143348623853 1 0 1
phenobarbital,the 0.333333333333 0.000143348623853 2 1 1
cyp450,metabolized 1.0 0.000143348623853 0 1 -1
creatine,phosphokinase 1.0 0.000143348623853 0 1 -1
being,reached 1.0 0.000143348623853 0 1 -1
when,mesylate 1.0 0.000143348623853 1 0 1
b-blocking,agent 1.0 0.000143348623853 1 0 1
antagonists,cimetidine 1.0 0.000286697247706 2 0 2
discontinued,it 1.0 0.000143348623853 1 0 1
take,first 1.0 0.000143348623853 1 0 1
desired,lactulose-induced 1.0 0.000143348623853 1 0 1
retention,in 1.0 0.000143348623853 0 1 -1
to,fade 1.0 0.000143348623853 1 0 1
subjects,ingesting 1.0 0.000143348623853 1 0 1
situ,ligated 1.0 0.000143348623853 0 1 -1
active,sulfide 1.0 0.000143348623853 1 0 1
discontinued,if 1.0 0.000143348623853 0 1 -1
and,failed 1.0 0.000143348623853 0 1 -1
involving,six-healthy 1.0 0.000143348623853 0 1 -1
in,sprycel 1.0 0.000143348623853 0 1 -1
shampoos,for 1.0 0.000143348623853 0 1 -1
primary,addiction 1.0 0.000143348623853 0 1 -1
discontinued,in 0.333333333333 0.000143348623853 1 2 -1
formal,interaction 1.0 0.00258027522936 0 18 -18
part,from 1.0 0.000143348623853 0 1 -1
readily,penetrates 1.0 0.000143348623853 0 1 -1
as,effective 1.0 0.000286697247706 0 2 -2
the,emerging 1.0 0.000143348623853 0 1 -1
elevated,glucose 1.0 0.000143348623853 0 1 -1
compounds,eg 1.0 0.000143348623853 1 0 1
those,enzymes 1.0 0.000143348623853 0 1 -1
heparin,sodium 1.0 0.000286697247706 0 2 -2
acetazolamide,decreases 1.0 0.000143348623853 1 0 1
displace,from 0.333333333333 0.000143348623853 1 2 -1
side,reactions 1.0 0.000143348623853 1 0 1
that,blockers 1.0 0.000143348623853 0 1 -1
nutritional,supplement 1.0 0.000286697247706 0 2 -2
underdosage,myasthenic 1.0 0.000143348623853 0 1 -1
that,patients 0.333333333333 0.000143348623853 1 2 -1
inhibit,cyps 1.0 0.000143348623853 0 1 -1
although,consistent 1.0 0.000143348623853 0 1 -1
significantly,without 1.0 0.000143348623853 0 1 -1
titrated,to 0.6 0.000860091743119 2 8 -6
hours,of 0.454545454545 0.000716743119266 8 3 5
was,observed 0.230769230769 0.000860091743119 10 16 -6
isozyme,and 0.5 0.000573394495413 2 6 -4
also,cause 1.0 0.000143348623853 0 1 -1
taking,most 1.0 0.000143348623853 0 1 -1
hours,or 0.6 0.00043004587156 1 4 -3
no,change 0.4 0.000573394495413 3 7 -4
by,its 1.0 0.000286697247706 2 0 2
be,restricted 1.0 0.000143348623853 0 1 -1
bleeding,particularly 1.0 0.000143348623853 1 0 1
are,incompletely 1.0 0.000143348623853 0 1 -1
serum,binding 1.0 0.000143348623853 1 0 1
to,form 1.0 0.000286697247706 2 0 2
extensively,studied 1.0 0.000286697247706 0 2 -2
baraclude,is 1.0 0.000143348623853 0 1 -1
that,encodes 1.0 0.000143348623853 0 1 -1
kidneys,coadministration 1.0 0.000143348623853 0 1 -1
cyp,drug 1.0 0.000143348623853 0 1 -1
study,suggest 1.0 0.000143348623853 0 1 -1
enzymes,inducers 1.0 0.000143348623853 0 1 -1
be,superior 1.0 0.000143348623853 0 1 -1
that,genetic 1.0 0.000143348623853 0 1 -1
mesylate,tablets 1.0 0.000286697247706 0 2 -2
consequently,tracleer 1.0 0.000143348623853 0 1 -1
para-aminosalicylic,acid 1.0 0.000143348623853 1 0 1
porter-silber,reaction 1.0 0.000143348623853 0 1 -1
respectively,in 0.5 0.000286697247706 1 3 -2
cobalt,excretion 1.0 0.000143348623853 0 1 -1
has,stabilized 1.0 0.000286697247706 0 2 -2
the,model 1.0 0.000143348623853 0 1 -1
dmpge2,induced 1.0 0.000143348623853 0 1 -1
these,preparations 1.0 0.000143348623853 0 1 -1
meant,to 1.0 0.000143348623853 0 1 -1
may,increase 0.27619047619 0.00415711009174 67 38 29
for,interaction 0.555555555556 0.000716743119266 2 7 -5
drowsiness,restlessness 1.0 0.000143348623853 0 1 -1
dmpge2,induces 1.0 0.000143348623853 0 1 -1
findings,these 1.0 0.000143348623853 0 1 -1
consequently,caution 1.0 0.000286697247706 0 2 -2
higher,cardiac 1.0 0.000143348623853 1 0 1
rabbit,following 1.0 0.000143348623853 0 1 -1
can,exert 1.0 0.000143348623853 0 1 -1
when,clozapine 1.0 0.000143348623853 1 0 1
two-lever,discrimination 1.0 0.000143348623853 0 1 -1
states,associated 1.0 0.000143348623853 0 1 -1
mean,area 0.0 0.0 1 1 0
or,imuran 1.0 0.000143348623853 1 0 1
mean,clearances 1.0 0.000143348623853 1 0 1
antihypertensive,additive 1.0 0.000143348623853 0 1 -1
fluorimetric,or 1.0 0.000143348623853 0 1 -1
use,in 0.4 0.000573394495413 3 7 -4
medications,which 1.0 0.000143348623853 0 1 -1
between,toradoliv 1.0 0.000143348623853 0 1 -1
established,and 1.0 0.000286697247706 0 2 -2
coli,in 1.0 0.000286697247706 0 2 -2
use,if 1.0 0.000143348623853 0 1 -1
erythro-fluorocitrate,from 1.0 0.000143348623853 0 1 -1
patients,coadministered 1.0 0.000143348623853 1 0 1
especially,patients 1.0 0.000143348623853 0 1 -1
and,gi 1.0 0.000143348623853 0 1 -1
clindamycin,has 1.0 0.000143348623853 1 0 1
cysteine,conjugation 1.0 0.000143348623853 0 1 -1
cancer,were 0.0 0.0 1 1 0
and,sinus 1.0 0.000143348623853 1 0 1
interactions,have 0.666666666667 0.00286697247706 5 25 -20
etonogestrel,may 1.0 0.000143348623853 1 0 1
renal,excretion 0.2 0.000286697247706 6 4 2
parameters,is 1.0 0.000143348623853 0 1 -1
or,both 0.555555555556 0.000716743119266 2 7 -5
parameters,in 1.0 0.000143348623853 1 0 1
an,index 1.0 0.000286697247706 0 2 -2
monotherapy,did 1.0 0.000143348623853 0 1 -1
serious,events 1.0 0.000143348623853 0 1 -1
singly,and 1.0 0.000143348623853 0 1 -1
l,of 1.0 0.000143348623853 0 1 -1
release,in 0.666666666667 0.000573394495413 1 5 -4
direct,effect 1.0 0.000143348623853 0 1 -1
corresponding,values 1.0 0.000286697247706 0 2 -2
false,elevations 1.0 0.000143348623853 0 1 -1
l,or 1.0 0.000716743119266 0 5 -5
are,indeed 1.0 0.000143348623853 0 1 -1
proposed,specific 1.0 0.000143348623853 0 1 -1
twitch,allowed 1.0 0.000143348623853 0 1 -1
of,vioxx 0.0 0.0 2 2 0
of,renal 0.565217391304 0.00186353211009 5 18 -13
four,doses 1.0 0.000143348623853 0 1 -1
can,interfere 1.0 0.000286697247706 2 0 2
ldl-c,reduction 0.333333333333 0.000143348623853 1 2 -1
taken,within 0.2 0.000143348623853 3 2 1
nonprescription,products 1.0 0.000143348623853 0 1 -1
to,ph 1.0 0.000143348623853 0 1 -1
irinotecan,concentrations 1.0 0.000143348623853 0 1 -1
from,chronic 1.0 0.000143348623853 1 0 1
research,has 1.0 0.000143348623853 0 1 -1
of,erection-supporting 1.0 0.000143348623853 0 1 -1
decrease,for 1.0 0.000143348623853 1 0 1
isomer,on 1.0 0.000143348623853 0 1 -1
eg,and 1.0 0.00129013761468 9 0 9
renal,cationic 1.0 0.000143348623853 0 1 -1
excreted,slowly 1.0 0.000143348623853 0 1 -1
times,have 1.0 0.000143348623853 0 1 -1
sugar,in 1.0 0.000143348623853 1 0 1
attention,test 1.0 0.000143348623853 1 0 1
bioequivalence,study 1.0 0.000143348623853 0 1 -1
of,tasks 1.0 0.000143348623853 0 1 -1
tranxene,tablets 1.0 0.000143348623853 0 1 -1
were,precise 1.0 0.000143348623853 0 1 -1
not,mix 1.0 0.000143348623853 0 1 -1
noninsulin,dependent 1.0 0.000143348623853 0 1 -1
therapies,as 1.0 0.000143348623853 0 1 -1
these,together 1.0 0.000143348623853 0 1 -1
by,his 1.0 0.000143348623853 0 1 -1
multiple-dose,pharmacokinetic 1.0 0.000143348623853 0 1 -1
aged,years 0.0 0.0 1 1 0
to,chelated 1.0 0.000143348623853 0 1 -1
antagonized,in 1.0 0.000143348623853 1 0 1
be,completed 1.0 0.000143348623853 0 1 -1
interaction,depends 1.0 0.000143348623853 0 1 -1
of,collapse 1.0 0.000143348623853 0 1 -1
tca,is 0.6 0.00043004587156 1 4 -3
morphology,pyknotic 1.0 0.000143348623853 0 1 -1
increased,intraocular 1.0 0.000143348623853 0 1 -1
low,temperatures 1.0 0.000143348623853 0 1 -1
elimination,of 0.2 0.00043004587156 9 6 3
urine,for 1.0 0.000143348623853 0 1 -1
suggesting,an 1.0 0.000143348623853 1 0 1
of-low,rates 1.0 0.000143348623853 0 1 -1
continuous,and 1.0 0.000143348623853 0 1 -1
bradycardia,qt 1.0 0.000143348623853 1 0 1
dose,levels 1.0 0.000286697247706 0 2 -2
with,ethyl 1.0 0.000143348623853 1 0 1
which,to 1.0 0.000143348623853 0 1 -1
with,benedicts 1.0 0.000143348623853 0 1 -1
seen,in 0.555555555556 0.00143348623853 4 14 -10
and,unpredictable 1.0 0.000143348623853 1 0 1
five,commonly 1.0 0.000143348623853 0 1 -1
clinician,depends 1.0 0.000143348623853 0 1 -1
eg,rt-pa 1.0 0.000143348623853 0 1 -1
of,aom 1.0 0.000143348623853 0 1 -1
if,intravenous 1.0 0.000143348623853 1 0 1
assay,with 1.0 0.000143348623853 0 1 -1
cardiotoxic,or 1.0 0.000143348623853 1 0 1
of,aminotransferase 1.0 0.000143348623853 0 1 -1
study,data 1.0 0.000143348623853 1 0 1
inconclusive,with 1.0 0.000143348623853 0 1 -1
an,opposite 1.0 0.000143348623853 1 0 1
rxlist,com 1.0 0.000143348623853 0 1 -1
tablets,simultaneous 1.0 0.000143348623853 1 0 1
hour,observation 1.0 0.000143348623853 0 1 -1
older,patients 1.0 0.000143348623853 0 1 -1
in,cecectomized 1.0 0.00100344036697 0 7 -7
enteric,coated 0.0 0.0 1 1 0
to,continue 0.5 0.000286697247706 3 1 2
long-acting,or 1.0 0.000143348623853 1 0 1
a,specific 1.0 0.00043004587156 0 3 -3
measuring,serum 1.0 0.000143348623853 0 1 -1
normally,with 1.0 0.000143348623853 0 1 -1
producing,low 1.0 0.000143348623853 0 1 -1
general,these 1.0 0.000143348623853 0 1 -1
tid,mg 1.0 0.000143348623853 1 0 1
researchers,have 1.0 0.000143348623853 0 1 -1
for,placebo 1.0 0.000143348623853 0 1 -1
accumbens,nac 1.0 0.000143348623853 0 1 -1
function,clinical 1.0 0.000286697247706 0 2 -2
on,bioavailability 1.0 0.000143348623853 0 1 -1
on,kinetics 1.0 0.000143348623853 1 0 1
been,frequently 1.0 0.000143348623853 0 1 -1
involving,the 1.0 0.000143348623853 1 0 1
prinivil,can 1.0 0.000143348623853 1 0 1
case,were 1.0 0.000143348623853 0 1 -1
with,chronic 0.5 0.000286697247706 1 3 -2
preparation,was 1.0 0.000143348623853 0 1 -1
bid,a 1.0 0.000286697247706 2 0 2
parorchis,acanthus 1.0 0.000286697247706 0 2 -2
spray,but 1.0 0.000143348623853 1 0 1
steady-state,maximum 1.0 0.000143348623853 0 1 -1
aspirin,increased 1.0 0.000143348623853 0 1 -1
bid,n 1.0 0.000143348623853 0 1 -1
whom,therapy 1.0 0.000716743119266 5 0 5
its,renal 1.0 0.00043004587156 3 0 3
shuttle,vectors 1.0 0.000143348623853 0 1 -1
kidney,allograft 1.0 0.000143348623853 0 1 -1
stimulant,action 1.0 0.000143348623853 0 1 -1
concomitant,treatment 0.294117647059 0.000716743119266 11 6 5
with,activity--such 1.0 0.000143348623853 1 0 1
crohns,disease 1.0 0.000143348623853 1 0 1
oxidation,system 1.0 0.000143348623853 0 1 -1
physician,is 1.0 0.000286697247706 0 2 -2
at,risk 1.0 0.000143348623853 0 1 -1
of,pulse 1.0 0.000143348623853 0 1 -1
was,resistant 1.0 0.000143348623853 0 1 -1
metabolic,effects 0.333333333333 0.000143348623853 2 1 1
the,mucocutaneous 1.0 0.000143348623853 0 1 -1
probably,has 1.0 0.000143348623853 0 1 -1
pumps,for 1.0 0.000143348623853 0 1 -1
surgery,because 1.0 0.000143348623853 0 1 -1
serum,measurements 1.0 0.000143348623853 0 1 -1
exposures,in 1.0 0.000143348623853 0 1 -1
the,renin-angiotensin 1.0 0.000143348623853 0 1 -1
nsaids,affect 1.0 0.000143348623853 1 0 1
inhibitory,concentration 1.0 0.000573394495413 0 4 -4
moreover,additional 1.0 0.000143348623853 0 1 -1
cephalosporin,before 1.0 0.000143348623853 0 1 -1
hydrate,diet 1.0 0.000143348623853 1 0 1
increase,was 1.0 0.000143348623853 0 1 -1
significantly,superior 1.0 0.000143348623853 0 1 -1
following,macrolide 1.0 0.000143348623853 1 0 1
six,of 1.0 0.000143348623853 1 0 1
and,without 0.714285714286 0.000716743119266 1 6 -5
to,year 1.0 0.000143348623853 0 1 -1
the,minimal 1.0 0.000286697247706 0 2 -2
additive,when 1.0 0.000286697247706 0 2 -2
induced,responses 0.0 0.0 1 1 0
the,purpose 1.0 0.000286697247706 0 2 -2
effects,prothrombin 1.0 0.000143348623853 1 0 1
aureus,diplococcus 1.0 0.000143348623853 0 1 -1
studies,failed 1.0 0.000286697247706 0 2 -2
healthy,normal 1.0 0.000143348623853 0 1 -1
monitored,because 1.0 0.000286697247706 2 0 2
trials,was 1.0 0.000143348623853 0 1 -1
we,could 1.0 0.000143348623853 0 1 -1
on,diuretic 1.0 0.00043004587156 3 0 3
compensatory,increase 1.0 0.000143348623853 0 1 -1
general,exaggeration 1.0 0.000143348623853 1 0 1
may,thereby 1.0 0.000143348623853 0 1 -1
early,components 1.0 0.000143348623853 1 0 1
sodium,capsules 0.0 0.0 1 1 0
therapy,could 1.0 0.000143348623853 1 0 1
pseudomonas,strains 1.0 0.000143348623853 0 1 -1
the,biological 0.6 0.00043004587156 1 4 -3
remedy,use 1.0 0.000286697247706 0 2 -2
this,reported 1.0 0.000143348623853 0 1 -1
the,mixing 1.0 0.000143348623853 1 0 1
to,microg 1.0 0.00043004587156 0 3 -3
beta-adrenoceptor,blocking 1.0 0.000286697247706 2 0 2
digoxin,concentrations 1.0 0.000143348623853 1 0 1
one,study 0.5 0.000573394495413 2 6 -4
humans,was 1.0 0.000143348623853 0 1 -1
consequently,alter 1.0 0.000143348623853 0 1 -1
additionally,and 1.0 0.000143348623853 0 1 -1
in,uremic 1.0 0.000143348623853 0 1 -1
monitored,appropriately 1.0 0.000143348623853 0 1 -1
three,products 1.0 0.000143348623853 1 0 1
to,minutes 0.333333333333 0.000143348623853 1 2 -1
denotes,a 1.0 0.000143348623853 1 0 1
not,contain 1.0 0.000143348623853 1 0 1
oral,has 0.142857142857 0.000143348623853 4 3 1
expression,was 1.0 0.000143348623853 0 1 -1
patients,transient 1.0 0.000143348623853 0 1 -1
with,combined 1.0 0.000143348623853 1 0 1
state,plasma 0.2 0.000143348623853 3 2 1
vomiting,pruritus 1.0 0.000143348623853 0 1 -1
respiratory,failure 1.0 0.000143348623853 0 1 -1
double-blind,fashion 1.0 0.000143348623853 0 1 -1
feedback,alterations 1.0 0.000143348623853 0 1 -1
duloxetine,may 1.0 0.000143348623853 0 1 -1
induce,both 1.0 0.000143348623853 0 1 -1
level,in 0.0 0.0 1 1 0
patients,enrolled 1.0 0.000286697247706 0 2 -2
of,potentiating 1.0 0.000143348623853 1 0 1
alone,and 0.111111111111 0.000286697247706 8 10 -2
green,tea 1.0 0.000286697247706 0 2 -2
hours,two 1.0 0.000143348623853 0 1 -1
tca,plasma 1.0 0.000573394495413 0 4 -4
in,proteins 1.0 0.000143348623853 0 1 -1
take,a 0.0 0.0 1 1 0
produce,false-positive 1.0 0.000143348623853 0 1 -1
level,is 1.0 0.000286697247706 0 2 -2
with,elevated 0.5 0.000286697247706 3 1 2
susceptible,to 1.0 0.000716743119266 0 5 -5
reach,cmax 1.0 0.000143348623853 0 1 -1
bioavailabillty,and 1.0 0.000143348623853 0 1 -1
levels,should 0.461538461538 0.00172018348624 7 19 -12
this,test 1.0 0.000143348623853 0 1 -1
sodium,pertechnetate 1.0 0.000143348623853 0 1 -1
produce,electrocardiographic 1.0 0.000143348623853 1 0 1
d,but 0.0 0.0 2 2 0
nizoral,sporanox 1.0 0.000143348623853 1 0 1
monitored,to 0.0 0.0 1 1 0
gi,motility 1.0 0.000286697247706 0 2 -2
prostate,epithelium 1.0 0.000143348623853 1 0 1
taken,into 0.333333333333 0.000286697247706 2 4 -2
peripheral,blood 0.0 0.0 2 2 0
oral,therapies 1.0 0.000143348623853 0 1 -1
to,observations 1.0 0.000143348623853 0 1 -1
healthy,adults 1.0 0.000286697247706 0 2 -2
evoked,potentials 1.0 0.00043004587156 0 3 -3
as,strong 1.0 0.000143348623853 0 1 -1
a,greater 0.142857142857 0.000143348623853 4 3 1
of,microg 1.0 0.000716743119266 0 5 -5
posed,by 1.0 0.000143348623853 0 1 -1
other,neuromuscular 1.0 0.000286697247706 2 0 2
by,vasopressin 1.0 0.000143348623853 0 1 -1
humans,can 1.0 0.000143348623853 1 0 1
transdermal,may 1.0 0.000143348623853 1 0 1
reactions,when 1.0 0.000143348623853 0 1 -1
adult-onset,diabetics 1.0 0.000143348623853 1 0 1
in,chapter 1.0 0.000143348623853 0 1 -1
treatment,which 1.0 0.000143348623853 1 0 1
including,antiparkinsonism 1.0 0.000143348623853 0 1 -1
differs,in 1.0 0.000143348623853 0 1 -1
with,dsm-iv 1.0 0.000143348623853 1 0 1
n,as 1.0 0.000143348623853 0 1 -1
the,proton 1.0 0.000143348623853 1 0 1
cold,and 0.0 0.0 1 1 0
this,did 1.0 0.000286697247706 0 2 -2
were,due 1.0 0.000143348623853 0 1 -1
p-type,in 1.0 0.000143348623853 0 1 -1
of,organs 1.0 0.000143348623853 0 1 -1
differences,in 1.0 0.00157683486239 0 11 -11
to,patient 1.0 0.000143348623853 0 1 -1
hour,infusion 1.0 0.000143348623853 0 1 -1
nanm,antagonized 1.0 0.000143348623853 1 0 1
however,decreases 1.0 0.000143348623853 0 1 -1
currently,there 1.0 0.00043004587156 0 3 -3
primary,form 1.0 0.000143348623853 0 1 -1
as,feso4 1.0 0.000143348623853 1 0 1
rats,was 1.0 0.000286697247706 0 2 -2
increased,urinary 1.0 0.000143348623853 0 1 -1
of,cromolyn 1.0 0.000143348623853 1 0 1
agents,that 0.0 0.0 7 7 0
cyp3a,a 1.0 0.000143348623853 1 0 1
were,kept 1.0 0.000143348623853 0 1 -1
and,were 0.36 0.00129013761468 8 17 -9
contraceptives,keppra 1.0 0.000143348623853 0 1 -1
bioavailability,is 1.0 0.000143348623853 1 0 1
predominant,plasma 1.0 0.000143348623853 0 1 -1
mouth,anorexia 1.0 0.000143348623853 0 1 -1
such,drugs 1.0 0.00043004587156 0 3 -3
for,regarding 1.0 0.000143348623853 0 1 -1
the,male 1.0 0.000143348623853 0 1 -1
first,synthetic 1.0 0.000143348623853 0 1 -1
tumour,total 1.0 0.000143348623853 0 1 -1
two,single 1.0 0.000143348623853 0 1 -1
than,second 1.0 0.000143348623853 0 1 -1
this,strategy 1.0 0.000143348623853 0 1 -1
intraventricular,and 1.0 0.00043004587156 0 3 -3
warfarin,no 1.0 0.000143348623853 0 1 -1
when,duragesic 1.0 0.000143348623853 0 1 -1
antidiuretic,hormone 1.0 0.000143348623853 0 1 -1
precipitation,occurs 1.0 0.000143348623853 0 1 -1
both,products 1.0 0.000143348623853 0 1 -1
serious,side 1.0 0.000143348623853 0 1 -1
inhibit,phosphatase 1.0 0.000143348623853 1 0 1
sodium,excretion 1.0 0.000286697247706 2 0 2
acting,triclofos 1.0 0.000143348623853 1 0 1
with,divalent 1.0 0.000143348623853 0 1 -1
underestimates,the 1.0 0.000143348623853 0 1 -1
exposures,proposed 1.0 0.000143348623853 0 1 -1
proliferation,stimulated 1.0 0.000143348623853 1 0 1
sometimes,be 1.0 0.000286697247706 0 2 -2
development,and 1.0 0.000143348623853 0 1 -1
and,joint 0.0 0.0 1 1 0
other,kits 1.0 0.000143348623853 0 1 -1
cell-free,system 1.0 0.000143348623853 0 1 -1
representative,metabolized 1.0 0.000143348623853 0 1 -1
metabolism,concomitant 1.0 0.000143348623853 0 1 -1
estimated,as 1.0 0.000143348623853 0 1 -1
s,interresponse 1.0 0.000143348623853 0 1 -1
flupenthixol,may 1.0 0.000143348623853 1 0 1
typically,nonlinear 1.0 0.000143348623853 0 1 -1
site,for 1.0 0.000143348623853 0 1 -1
phospholipids,as 1.0 0.000143348623853 0 1 -1
and,pharmacodynamic 1.0 0.000143348623853 0 1 -1
blockers,may 0.333333333333 0.000286697247706 4 2 2
cause,qt 1.0 0.000143348623853 0 1 -1
observed,at 1.0 0.000143348623853 0 1 -1
tsh,secretion 1.0 0.000143348623853 0 1 -1
in,inaccurately 1.0 0.000143348623853 0 1 -1
pcp,for 1.0 0.000143348623853 0 1 -1
see,contraindications 1.0 0.000143348623853 0 1 -1
of,application 1.0 0.000143348623853 0 1 -1
growth,of 1.0 0.00043004587156 0 3 -3
negligible,interactions 1.0 0.000143348623853 0 1 -1
weakness,associated 1.0 0.000143348623853 0 1 -1
bedtime,has 1.0 0.000143348623853 0 1 -1
however,appear 1.0 0.000143348623853 0 1 -1
increased,approximately 0.666666666667 0.000573394495413 5 1 4
others,plasma 1.0 0.000143348623853 0 1 -1
atherosclerotic,cardiovascular 1.0 0.000143348623853 0 1 -1
are,listed 0.5 0.000286697247706 1 3 -2
adrenergic,neuron 1.0 0.000143348623853 0 1 -1
consulting,the 1.0 0.000286697247706 0 2 -2
resulting,from 0.428571428571 0.00043004587156 2 5 -3
female,rats 1.0 0.000716743119266 0 5 -5
speed-up,this 1.0 0.000143348623853 0 1 -1
by,known 1.0 0.000143348623853 0 1 -1
reduced,absorption 1.0 0.000143348623853 0 1 -1
a,dissociation 1.0 0.000143348623853 0 1 -1
phosphorylation,in 0.2 0.000143348623853 2 3 -1
coupled,to 1.0 0.000286697247706 0 2 -2
in,proliferating 1.0 0.000143348623853 0 1 -1
effect,by 1.0 0.000143348623853 0 1 -1
sacrificed,and 1.0 0.000143348623853 0 1 -1
flushing,rash 1.0 0.000143348623853 0 1 -1
method,this 1.0 0.000143348623853 0 1 -1
no,dosing 1.0 0.000143348623853 0 1 -1
account,bezalip 1.0 0.000143348623853 1 0 1
were,collected 1.0 0.000143348623853 0 1 -1
mean,peak 1.0 0.000286697247706 2 0 2
that,with 1.0 0.000143348623853 0 1 -1
liver,increasing 1.0 0.000143348623853 0 1 -1
coombs,test 1.0 0.000573394495413 0 4 -4
represents,an 1.0 0.000143348623853 0 1 -1
for,two 1.0 0.000143348623853 1 0 1
affected,when 1.0 0.000286697247706 0 2 -2
that,their 1.0 0.000143348623853 0 1 -1
arecoline,eproxindine 1.0 0.000143348623853 1 0 1
centers,of 1.0 0.000143348623853 0 1 -1
hippocampus,is 1.0 0.000143348623853 0 1 -1
other,nsaids 0.8 0.00114678899083 9 1 8
increased,potential 0.333333333333 0.000143348623853 1 2 -1
exjade,had 1.0 0.000143348623853 0 1 -1
muscle,relaxant 0.333333333333 0.000143348623853 2 1 1
index,such 1.0 0.000143348623853 1 0 1
c,a 1.0 0.000143348623853 1 0 1
developed,as 1.0 0.000143348623853 0 1 -1
a,cardioselective 1.0 0.000143348623853 0 1 -1
constipation,and 1.0 0.000143348623853 0 1 -1
patient,continued 1.0 0.000143348623853 0 1 -1
about,mm 1.0 0.000143348623853 1 0 1
well,studied 1.0 0.000286697247706 0 2 -2
hypoglycemic,medications 1.0 0.000143348623853 1 0 1
consequences,of 1.0 0.00043004587156 0 3 -3
because,it 1.0 0.00043004587156 0 3 -3
a,agonist 1.0 0.000286697247706 2 0 2
tumor,versus 1.0 0.000143348623853 0 1 -1
gland,in 1.0 0.000143348623853 0 1 -1
of,accutane 1.0 0.000143348623853 1 0 1
tissues,of 1.0 0.000286697247706 0 2 -2
totally,inhibited 1.0 0.000143348623853 0 1 -1
days,to 1.0 0.000286697247706 0 2 -2
various,chemotherapy 1.0 0.000143348623853 0 1 -1
oral,to 1.0 0.000143348623853 0 1 -1
plasma,mean 1.0 0.000143348623853 1 0 1
in,elevated 0.818181818182 0.00129013761468 10 1 9
kept,in 0.5 0.000286697247706 1 3 -2
infant,has 1.0 0.000143348623853 0 1 -1
is,used 0.529411764706 0.00129013761468 13 4 9
many,used 1.0 0.000143348623853 0 1 -1
determined,in 1.0 0.000143348623853 0 1 -1
in,some 0.470588235294 0.00229357798165 25 9 16
and,two 1.0 0.000143348623853 0 1 -1
or,can 1.0 0.000286697247706 2 0 2
status,of 1.0 0.000286697247706 0 2 -2
a,mechanism 1.0 0.000143348623853 1 0 1
effects,an 0.0 0.0 1 1 0
inhibitor,resulted 1.0 0.000143348623853 0 1 -1
patients,given 0.333333333333 0.000143348623853 2 1 1
plasma,protein 1.0 0.00143348623853 0 10 -10
distilled,and 1.0 0.000143348623853 0 1 -1
toxicity,of 0.428571428571 0.000860091743119 4 10 -6
the,phenotype 1.0 0.000143348623853 0 1 -1
predominantly,mediated 1.0 0.00043004587156 0 3 -3
fever,chills 1.0 0.000143348623853 0 1 -1
n-allylnormetazocine,in 1.0 0.000143348623853 0 1 -1
domestic,studies 1.0 0.000143348623853 0 1 -1
is,both 1.0 0.000286697247706 0 2 -2
life,in 1.0 0.000143348623853 0 1 -1
the,risk 0.047619047619 0.00043004587156 30 33 -3
transaminase,levels 1.0 0.000143348623853 0 1 -1
on,bleeding 1.0 0.000143348623853 0 1 -1
is,observed 1.0 0.000143348623853 0 1 -1
systemic,it 1.0 0.000143348623853 1 0 1
c9,with 1.0 0.000143348623853 0 1 -1
and,serotoninergic 1.0 0.000143348623853 0 1 -1
a,profound 1.0 0.000286697247706 0 2 -2
when,giving 1.0 0.000286697247706 0 2 -2
or,every 1.0 0.000143348623853 0 1 -1
of,cholinergic 1.0 0.000143348623853 0 1 -1
heparin,since 1.0 0.000143348623853 0 1 -1
as,manifested 1.0 0.000143348623853 0 1 -1
moreover,its 1.0 0.000143348623853 0 1 -1
s-alt,levels 1.0 0.000143348623853 0 1 -1
leukopenic,activity 1.0 0.000143348623853 1 0 1
metoclopramide,bioavailability 1.0 0.000143348623853 1 0 1
d3,oh 1.0 0.000143348623853 0 1 -1
dynamic,and 1.0 0.000143348623853 0 1 -1
other,cns 0.666666666667 0.00172018348624 15 3 12
is,evidence 1.0 0.000286697247706 0 2 -2
cardiovascular,in 1.0 0.000143348623853 0 1 -1
might,interfere 1.0 0.000143348623853 0 1 -1
contraceptive,effect 1.0 0.000143348623853 1 0 1
that,platelet 1.0 0.000143348623853 0 1 -1
assigned,to 1.0 0.000286697247706 0 2 -2
decreased,pharmacologic 1.0 0.000143348623853 0 1 -1
antagonists,a 1.0 0.000143348623853 0 1 -1
insulin-induced,hypoglycemia 1.0 0.000143348623853 0 1 -1
for,weeks 0.142857142857 0.000143348623853 3 4 -1
effects,concomitant 1.0 0.000143348623853 0 1 -1
relative,avidities 1.0 0.000143348623853 0 1 -1
maprotiline,risk 1.0 0.000143348623853 0 1 -1
a,two-way 1.0 0.000143348623853 1 0 1
specifically,cytochromes 1.0 0.000143348623853 0 1 -1
variety,of 1.0 0.00229357798165 0 16 -16
ontario,alone 1.0 0.000143348623853 0 1 -1
pregnant,rhesus 1.0 0.000143348623853 0 1 -1
each,agent 1.0 0.000143348623853 0 1 -1
changes,seen 1.0 0.000143348623853 0 1 -1
kineret,and 1.0 0.000286697247706 2 0 2
hydroxydesloratadine,were 1.0 0.000143348623853 0 1 -1
s,and 0.333333333333 0.000143348623853 1 2 -1
h-triolein,at 1.0 0.000143348623853 0 1 -1
capsules,and 1.0 0.000286697247706 2 0 2
following,laboratory 1.0 0.000143348623853 0 1 -1
concentrate,and 1.0 0.000143348623853 1 0 1
deep-seated,infection 1.0 0.000143348623853 0 1 -1
of,heart 0.0 0.0 1 1 0
nephropathy,were 1.0 0.000143348623853 0 1 -1
alone,produced 1.0 0.000286697247706 0 2 -2
nephrotoxicity,with 1.0 0.000143348623853 1 0 1
against,positive 1.0 0.000143348623853 0 1 -1
potentiation,of 0.454545454545 0.000716743119266 3 8 -5
the,district 1.0 0.000143348623853 0 1 -1
potassium-depleting,agents 1.0 0.000143348623853 1 0 1
inr,and 0.0 0.0 1 1 0
days,oral 1.0 0.000143348623853 0 1 -1
to,alterations 0.333333333333 0.000143348623853 1 2 -1
atracurium,infusion 1.0 0.000143348623853 0 1 -1
uncontrolled,study 1.0 0.000143348623853 0 1 -1
for,developing 1.0 0.000143348623853 0 1 -1
vitro,perfused 1.0 0.000143348623853 0 1 -1
to,such 1.0 0.000573394495413 0 4 -4
there,exists 1.0 0.000143348623853 0 1 -1
cell,growth 1.0 0.000143348623853 0 1 -1
welfare,of 1.0 0.000143348623853 0 1 -1
occur,because 1.0 0.000143348623853 1 0 1
or,channel 0.0 0.0 1 1 0
established,that 0.333333333333 0.000143348623853 2 1 1
c9,respectively 1.0 0.000143348623853 0 1 -1
toxicity,including 0.0 0.0 1 1 0
rats,hours 1.0 0.000143348623853 0 1 -1
turn,resulted 1.0 0.000143348623853 1 0 1
a,low 1.0 0.00043004587156 0 3 -3
of,associated 1.0 0.000143348623853 0 1 -1
and,fehling 1.0 0.000286697247706 0 2 -2
mediated,signalling 1.0 0.000143348623853 0 1 -1
of,administered 0.777777777778 0.00100344036697 1 8 -7
from,control 1.0 0.000143348623853 0 1 -1
but,returned 1.0 0.000143348623853 0 1 -1
copegus,in 1.0 0.000143348623853 0 1 -1
treat,an 1.0 0.000143348623853 0 1 -1
or,activity 0.0 0.0 1 1 0
both,s-warfarin 1.0 0.000143348623853 1 0 1
as,convulsions 1.0 0.000143348623853 1 0 1
not,only 0.5 0.000573394495413 2 6 -4
adjusted,when 1.0 0.000143348623853 0 1 -1
relaxation,of 1.0 0.000286697247706 0 2 -2
when,briefly 1.0 0.000143348623853 0 1 -1
altering,their 1.0 0.000143348623853 0 1 -1
received,general 1.0 0.000143348623853 0 1 -1
with,coadministration 0.272727272727 0.00043004587156 7 4 3
diabetics,should 1.0 0.000143348623853 0 1 -1
phosphatidate,phosphohydrolase 1.0 0.000286697247706 0 2 -2
kidney,by 1.0 0.000143348623853 0 1 -1
reversible,upon 1.0 0.000143348623853 1 0 1
inhibitor,does 1.0 0.000143348623853 0 1 -1
but,coadministration 1.0 0.000143348623853 0 1 -1
bound,drugs 1.0 0.000143348623853 0 1 -1
immunodeficiencies,including 1.0 0.000143348623853 0 1 -1
the,normal 0.666666666667 0.000573394495413 1 5 -4
poor,substrate 1.0 0.000143348623853 0 1 -1
or,anaphylactic 1.0 0.000143348623853 0 1 -1
sites,may 1.0 0.000143348623853 0 1 -1
times,higher 0.333333333333 0.000143348623853 1 2 -1
other,potential 1.0 0.000143348623853 0 1 -1
topical,has 1.0 0.000143348623853 0 1 -1
with,significant 1.0 0.000143348623853 0 1 -1
sign,monitoring 1.0 0.000143348623853 0 1 -1
antacids,the 1.0 0.000143348623853 0 1 -1
triple,therapy 1.0 0.000143348623853 0 1 -1
phenomenon,has 1.0 0.000143348623853 0 1 -1
case,summary 1.0 0.000143348623853 0 1 -1
through,pharmacokinetic 1.0 0.000143348623853 0 1 -1
co-administration,systemic 1.0 0.000143348623853 0 1 -1
overcoming,tumor 1.0 0.000143348623853 0 1 -1
had,already 1.0 0.000143348623853 0 1 -1
citalopram,since 1.0 0.000143348623853 1 0 1
receiving,will 1.0 0.000143348623853 1 0 1
isozyme,cyp2c9 1.0 0.000143348623853 0 1 -1
interaction,and 1.0 0.000286697247706 0 2 -2
significantly,include 1.0 0.000286697247706 2 0 2
example,inducers 1.0 0.000143348623853 0 1 -1
lysate,derived 1.0 0.000143348623853 0 1 -1
side,chains 1.0 0.000143348623853 0 1 -1
more,potent 1.0 0.00043004587156 0 3 -3
or,disruption 1.0 0.000143348623853 0 1 -1
analogues,didanosine 1.0 0.000143348623853 1 0 1
proteins,are 1.0 0.000143348623853 0 1 -1
the,peak 0.666666666667 0.000573394495413 1 5 -4
triamterene,concomitant 1.0 0.000143348623853 0 1 -1
of,clinical 0.5 0.000860091743119 3 9 -6
concurrently,treated 1.0 0.000143348623853 1 0 1
receiving,concomitantly 1.0 0.00043004587156 3 0 3
reduced,from 1.0 0.000286697247706 2 0 2
raise,serum 1.0 0.000286697247706 2 0 2
alt,sgpt 1.0 0.000143348623853 0 1 -1
increased,monitoring 1.0 0.000143348623853 1 0 1
of,whom 1.0 0.000143348623853 0 1 -1
of,severe 0.375 0.000860091743119 5 11 -6
iatrogenic,alteration 1.0 0.000143348623853 0 1 -1
intensive,control 1.0 0.000143348623853 0 1 -1
contraceptives,estrogens 1.0 0.000143348623853 0 1 -1
of,treatment 0.176470588235 0.00043004587156 10 7 3
progestogen,administration 1.0 0.000143348623853 0 1 -1
fibrosis,have 1.0 0.000143348623853 0 1 -1
uricosuric,such 1.0 0.000143348623853 1 0 1
acid,excretion 1.0 0.000143348623853 1 0 1
aspirin,may 1.0 0.000143348623853 1 0 1
vardenafil,had 1.0 0.000143348623853 0 1 -1
high,degree 1.0 0.000286697247706 0 2 -2
belladonna,alkaloids 1.0 0.000143348623853 1 0 1
of,responses 1.0 0.000143348623853 0 1 -1
and,r-warfarin 1.0 0.000143348623853 1 0 1
decreased,probably 1.0 0.000143348623853 0 1 -1
purification,protocol 1.0 0.000143348623853 0 1 -1
between,systemic 1.0 0.000143348623853 0 1 -1
control,at 1.0 0.000143348623853 0 1 -1
the,lymphoid 1.0 0.000143348623853 0 1 -1
more,prolonged 1.0 0.000143348623853 1 0 1
and,incoordination 0.6 0.00043004587156 4 1 3
with,some 0.272727272727 0.00043004587156 4 7 -3
geocillin,carbenicillin 1.0 0.000143348623853 1 0 1
although,this 1.0 0.000286697247706 2 0 2
and,prescription 1.0 0.000143348623853 0 1 -1
study,baboons 1.0 0.000143348623853 0 1 -1
smoking,adapting 1.0 0.000143348623853 0 1 -1
influence,the 0.6 0.00129013761468 3 12 -9
digoxin,in 0.5 0.000286697247706 1 3 -2
than,nanm 1.0 0.000143348623853 0 1 -1
produced,either 1.0 0.000143348623853 0 1 -1
pregnancy,only 1.0 0.000286697247706 0 2 -2
of,addiction 1.0 0.000143348623853 0 1 -1
a,muscle 1.0 0.000143348623853 0 1 -1
significant,reduction 1.0 0.000143348623853 1 0 1
derivatives,and 1.0 0.000716743119266 5 0 5
results,insulin 1.0 0.000143348623853 0 1 -1
current,theories 1.0 0.000143348623853 0 1 -1
agent,should 0.5 0.000286697247706 1 3 -2
decrease,overall 1.0 0.000143348623853 0 1 -1
a,valid 1.0 0.000143348623853 1 0 1
both,elements 1.0 0.000143348623853 0 1 -1
altered,distribution 1.0 0.000143348623853 1 0 1
diabetes,were 1.0 0.000143348623853 0 1 -1
a,year-old 1.0 0.000143348623853 0 1 -1
hot,kidney 1.0 0.000143348623853 0 1 -1
the,increases 1.0 0.000286697247706 2 0 2
nonrenal,and 1.0 0.000143348623853 0 1 -1
days,has 0.5 0.000286697247706 3 1 2
such,information 1.0 0.000143348623853 0 1 -1
copegus,did 1.0 0.000143348623853 0 1 -1
long,periods 1.0 0.000143348623853 0 1 -1
six,patients 1.0 0.000143348623853 0 1 -1
the,increased 0.0909090909091 0.000143348623853 6 5 1
as,vertigo 1.0 0.000143348623853 1 0 1
aberrant,and 1.0 0.000143348623853 0 1 -1
days,had 1.0 0.000573394495413 0 4 -4
occur,between 1.0 0.000143348623853 1 0 1
ordinarily,a 1.0 0.000143348623853 0 1 -1
that,contain 1.0 0.000143348623853 1 0 1
reduction,with 1.0 0.000143348623853 0 1 -1
quinolones,form 1.0 0.00043004587156 0 3 -3
the,compromised 1.0 0.000143348623853 0 1 -1
chemotherapeutic,agents 1.0 0.000143348623853 0 1 -1
hypotension,was 1.0 0.000286697247706 0 2 -2
sequential,infusions 1.0 0.000143348623853 1 0 1
increased,frequency 1.0 0.000143348623853 0 1 -1
in,antiapoptotic 1.0 0.000143348623853 0 1 -1
will,not 0.2 0.000143348623853 2 3 -1
glucose,monitoring 1.0 0.000143348623853 0 1 -1
minus,in 1.0 0.000143348623853 1 0 1
be,adversely 1.0 0.000143348623853 0 1 -1
small,with 1.0 0.000143348623853 0 1 -1
synergism,has 1.0 0.000143348623853 1 0 1
of,recovery 1.0 0.000286697247706 0 2 -2
ratio,between 1.0 0.000143348623853 0 1 -1
cases,with 1.0 0.000143348623853 0 1 -1
monkeys,given 1.0 0.000143348623853 0 1 -1
cyp3a,and 0.333333333333 0.000143348623853 1 2 -1
or,patients 0.333333333333 0.000143348623853 1 2 -1
ketoconazole,concomitant 1.0 0.000143348623853 0 1 -1
or,maintenance 1.0 0.000143348623853 0 1 -1
deeper,and 1.0 0.000143348623853 1 0 1
cooling,the 1.0 0.000143348623853 0 1 -1
that,both 0.333333333333 0.000143348623853 1 2 -1
chlorthalidone,may 1.0 0.000143348623853 1 0 1
monitor,concentrations 1.0 0.000143348623853 1 0 1
education,on 1.0 0.000143348623853 0 1 -1
determine,its 1.0 0.000143348623853 0 1 -1
both,weight 1.0 0.000143348623853 1 0 1
systems,lapatinib 1.0 0.000286697247706 0 2 -2
been,greater 1.0 0.000286697247706 2 0 2
ventricular,cardiac 1.0 0.000143348623853 0 1 -1
not,effected 1.0 0.000143348623853 0 1 -1
cyp2d6,in 1.0 0.000143348623853 0 1 -1
emit-d,a 1.0 0.000143348623853 0 1 -1
protein,bound 0.333333333333 0.00043004587156 3 6 -3
decreased,from 1.0 0.000143348623853 0 1 -1
to,infusions 1.0 0.000143348623853 1 0 1
micrococcus,luteus 1.0 0.000143348623853 0 1 -1
both,steady-state 1.0 0.000143348623853 0 1 -1
benedicts,solution 1.0 0.000573394495413 0 4 -4
cyp2d6,is 1.0 0.00043004587156 0 3 -3
mice,a 1.0 0.000143348623853 0 1 -1
when,analgesia 1.0 0.000143348623853 1 0 1
performed,at 1.0 0.000573394495413 0 4 -4
of,p450 0.2 0.000143348623853 2 3 -1
bile,and 1.0 0.000143348623853 1 0 1
caution,and 0.692307692308 0.00129013761468 2 11 -9
other,agent 1.0 0.000143348623853 0 1 -1
cmax,were 1.0 0.000143348623853 0 1 -1
such,interactions 1.0 0.000573394495413 0 4 -4
the,approach 1.0 0.000143348623853 0 1 -1
aliskiren,based 1.0 0.000143348623853 0 1 -1
fertility,were 1.0 0.000143348623853 0 1 -1
function,such 1.0 0.000143348623853 1 0 1
experience,may 1.0 0.000143348623853 0 1 -1
small,number 1.0 0.000143348623853 0 1 -1
or,repeated 1.0 0.000286697247706 0 2 -2
minimum,inhibitory 1.0 0.000286697247706 0 2 -2
and,calcidiol 1.0 0.00043004587156 3 0 3
patch,pipette 1.0 0.000143348623853 0 1 -1
on,intact 1.0 0.000143348623853 0 1 -1
frequent,for 1.0 0.000143348623853 0 1 -1
severe,anemia 1.0 0.000143348623853 0 1 -1
latent,diabetes 1.0 0.000143348623853 0 1 -1
no,rashes 1.0 0.000143348623853 0 1 -1
or,total 1.0 0.000286697247706 0 2 -2
as,effects 1.0 0.000143348623853 0 1 -1
meaningfully,alter 1.0 0.000143348623853 0 1 -1
or,dietary 1.0 0.000143348623853 0 1 -1
patients,suspected 1.0 0.000143348623853 0 1 -1
of,arsenical 1.0 0.000286697247706 0 2 -2
oligomer,significantly 1.0 0.000143348623853 0 1 -1
grepafloxacin,is 1.0 0.000143348623853 1 0 1
to,expect 0.2 0.000143348623853 2 3 -1
study,and 1.0 0.000860091743119 0 6 -6
should,be 0.116104868914 0.0088876146789 236 298 -62
inducer,the 1.0 0.000143348623853 1 0 1
nosebleeds,hemoptysis 1.0 0.000143348623853 0 1 -1
postulated,that 1.0 0.000143348623853 0 1 -1
adult,patients 1.0 0.000143348623853 0 1 -1
significant,interference 1.0 0.000143348623853 0 1 -1
achieved,either 1.0 0.000143348623853 0 1 -1
combination,regimens 1.0 0.000143348623853 1 0 1
of,zmax 1.0 0.000143348623853 0 1 -1
blockers,calcium-channel 1.0 0.000143348623853 0 1 -1
effective,concentration 1.0 0.000143348623853 0 1 -1
exjade,tablets 1.0 0.000143348623853 0 1 -1
entacapone,is 1.0 0.000143348623853 0 1 -1
well-known,interactions 1.0 0.000143348623853 0 1 -1
the,lst 1.0 0.00043004587156 0 3 -3
or,as 1.0 0.000286697247706 2 0 2
against,symptoms 1.0 0.000143348623853 0 1 -1
sirolimus-diltiazem,interaction 1.0 0.000143348623853 1 0 1
or,av 1.0 0.000143348623853 1 0 1
or,at 1.0 0.000573394495413 0 4 -4
recommended,weekly 1.0 0.000143348623853 0 1 -1
different,times 1.0 0.000286697247706 0 2 -2
been,prescribed 1.0 0.000143348623853 0 1 -1
periods,of 0.333333333333 0.000143348623853 1 2 -1
were,measured 1.0 0.000573394495413 0 4 -4
these,on 1.0 0.000286697247706 0 2 -2
rare,reports 0.428571428571 0.00043004587156 5 2 3
or,an 0.5 0.000286697247706 1 3 -2
does,induce 1.0 0.000143348623853 0 1 -1
the,hypertensive 1.0 0.000143348623853 1 0 1
these,lines 1.0 0.000143348623853 0 1 -1
enuresis,urinary 1.0 0.000143348623853 0 1 -1
p,less 1.0 0.000143348623853 0 1 -1
since,is 0.428571428571 0.00043004587156 2 5 -3
conducted,with 0.5 0.000286697247706 1 3 -2
since,it 0.5 0.000286697247706 1 3 -2
antagonist,sch-23390 1.0 0.000143348623853 1 0 1
diltiazem,is 1.0 0.000143348623853 0 1 -1
cyp1a1,cyp1a2 1.0 0.000143348623853 0 1 -1
standard,dose 1.0 0.000143348623853 1 0 1
listed,here 1.0 0.000143348623853 0 1 -1
template,bleeding 1.0 0.000286697247706 0 2 -2
included,a 1.0 0.000143348623853 0 1 -1
patient,shows 1.0 0.000143348623853 0 1 -1
higher,dosages 1.0 0.000143348623853 0 1 -1
cyp3a4,rifampicin 1.0 0.000143348623853 1 0 1
micronucleus,test 1.0 0.000143348623853 0 1 -1
through,hours 1.0 0.000143348623853 0 1 -1
tablet,if 1.0 0.000143348623853 1 0 1
increased,an 1.0 0.000143348623853 1 0 1
norepinephrine-induced,platel 1.0 0.000143348623853 0 1 -1
increased,at 1.0 0.000143348623853 0 1 -1
increased,as 1.0 0.000143348623853 0 1 -1
camp-stimulated,acid 1.0 0.000143348623853 1 0 1
chromatography,procedure 1.0 0.000143348623853 0 1 -1
as,thorazine 1.0 0.000143348623853 0 1 -1
severe,reaction 1.0 0.000143348623853 0 1 -1
levels,thereby 1.0 0.000143348623853 0 1 -1
transfusions,acute 1.0 0.000143348623853 1 0 1
by,include 1.0 0.000143348623853 1 0 1
receiving,azole 1.0 0.000143348623853 1 0 1
pass,secondary 1.0 0.000143348623853 0 1 -1
mefloquine,although 1.0 0.000143348623853 1 0 1
dose,required 1.0 0.000143348623853 0 1 -1
both,species 1.0 0.000286697247706 2 0 2
few,weeks 1.0 0.000143348623853 1 0 1
other,doses 1.0 0.000286697247706 0 2 -2
an,acute 1.0 0.000143348623853 0 1 -1
ii,diabetic 1.0 0.000143348623853 1 0 1
co-administration,is 1.0 0.000286697247706 0 2 -2
found,no 1.0 0.000286697247706 0 2 -2
on,tolerance 1.0 0.000143348623853 0 1 -1
concluded,from 1.0 0.000143348623853 0 1 -1
specific,toxicities 1.0 0.000143348623853 0 1 -1
acting,on 1.0 0.000286697247706 0 2 -2
are,performed 1.0 0.000286697247706 0 2 -2
cyp1a2,a6 1.0 0.000143348623853 0 1 -1
activated,in 1.0 0.000143348623853 1 0 1
their,pharmacological 1.0 0.000143348623853 0 1 -1
nerves,and 1.0 0.000286697247706 0 2 -2
no,long-term 1.0 0.000143348623853 0 1 -1
synthetic,steroidal 1.0 0.000143348623853 0 1 -1
fluoxetine,indanavir 1.0 0.000143348623853 0 1 -1
anesthesia,severe 1.0 0.000143348623853 1 0 1
to,minimise 1.0 0.000286697247706 0 2 -2
concomitan,administration 1.0 0.000143348623853 1 0 1
glucuronide,account 1.0 0.000143348623853 0 1 -1
endogenous,secretion 1.0 0.000143348623853 0 1 -1
conditioning,and 1.0 0.000143348623853 0 1 -1
danazol,the 1.0 0.000143348623853 1 0 1
co-administration,enhances 1.0 0.000143348623853 1 0 1
d,and 0.2 0.000143348623853 2 3 -1
of,myopathy 0.428571428571 0.00043004587156 2 5 -3
kg,removes 1.0 0.000143348623853 1 0 1
has,a 0.2 0.000286697247706 6 4 2
meal,and 0.0 0.0 1 1 0
developments,in 1.0 0.000143348623853 0 1 -1
weekly,dose 1.0 0.000143348623853 0 1 -1
suitability,of 1.0 0.000143348623853 0 1 -1
interaction,trials 1.0 0.000143348623853 0 1 -1
to,slower 1.0 0.000143348623853 1 0 1
product,in 1.0 0.000143348623853 0 1 -1
indocin,is 1.0 0.00043004587156 3 0 3
than,myopathy 1.0 0.000143348623853 0 1 -1
population,about 1.0 0.000716743119266 0 5 -5
both,increase 1.0 0.000143348623853 1 0 1
their,effects 1.0 0.000143348623853 0 1 -1
other,hiv 1.0 0.000143348623853 0 1 -1
alkalinizers,decrease 1.0 0.000143348623853 0 1 -1
taxol,mg 1.0 0.000143348623853 1 0 1
the,relative 1.0 0.000286697247706 0 2 -2
other,diagnostic 1.0 0.000143348623853 0 1 -1
new,oral 1.0 0.000143348623853 0 1 -1
pruritus,and 1.0 0.000286697247706 0 2 -2
ways,to 1.0 0.000143348623853 0 1 -1
in,ambulatory 1.0 0.000143348623853 0 1 -1
muscular,fatigue 1.0 0.000143348623853 0 1 -1
hypotensive,response 1.0 0.000143348623853 0 1 -1
dose-limiting,organ 1.0 0.000143348623853 0 1 -1
regular,basis 1.0 0.000143348623853 0 1 -1
behavioral,sensitization 1.0 0.000143348623853 0 1 -1
of,intravenous 0.2 0.000143348623853 3 2 1
discontinued,from 1.0 0.000143348623853 0 1 -1
superior,to 1.0 0.00043004587156 0 3 -3
nueronal,cell 1.0 0.000143348623853 0 1 -1
decline,in 1.0 0.000143348623853 0 1 -1
were,divided 1.0 0.000286697247706 0 2 -2
cell,mutation 1.0 0.000143348623853 0 1 -1
toxicity,were 1.0 0.000143348623853 1 0 1
for,in 1.0 0.000716743119266 0 5 -5
treatment,for 1.0 0.00100344036697 0 7 -7
for,is 1.0 0.000143348623853 0 1 -1
with,serum 1.0 0.00043004587156 0 3 -3
as,grapefruit 1.0 0.000143348623853 0 1 -1
nor,high 1.0 0.000143348623853 0 1 -1
produce,local 1.0 0.000143348623853 0 1 -1
in,concert 1.0 0.000143348623853 0 1 -1
rarely,to 0.0 0.0 1 1 0
enalapril,iv 1.0 0.000143348623853 0 1 -1
the,exception 1.0 0.00043004587156 0 3 -3
anaesthetised,with 1.0 0.000143348623853 1 0 1
verified,by 1.0 0.000143348623853 0 1 -1
sympathomimetic,agents 1.0 0.000143348623853 0 1 -1
interactions,oral 1.0 0.000143348623853 0 1 -1
higher,free 1.0 0.000143348623853 0 1 -1
that,included 1.0 0.000286697247706 0 2 -2
nanm,failed 1.0 0.000143348623853 0 1 -1
than,with 0.5 0.000286697247706 1 3 -2
porpranolol,may 1.0 0.000143348623853 1 0 1
is,limited 0.6 0.00043004587156 1 4 -3
that,includes 1.0 0.000143348623853 0 1 -1
also,referred 1.0 0.000143348623853 0 1 -1
stimulating,properties 1.0 0.000143348623853 0 1 -1
sustained-release,tablets 1.0 0.000143348623853 0 1 -1
neither,racemic 1.0 0.000143348623853 0 1 -1
the,antithrombotic 1.0 0.000143348623853 1 0 1
the,medial 1.0 0.000143348623853 0 1 -1
h,among 1.0 0.000143348623853 1 0 1
indocin,have 1.0 0.000143348623853 0 1 -1
qd,or 1.0 0.000286697247706 0 2 -2
before,the 0.111111111111 0.000143348623853 4 5 -1
hypertension,and 0.333333333333 0.000143348623853 1 2 -1
parameters,should 1.0 0.000286697247706 0 2 -2
if,taken 1.0 0.000143348623853 0 1 -1
thyroid,hormonal 1.0 0.000143348623853 0 1 -1
tricyclic,thereby 1.0 0.000143348623853 1 0 1
novolog,were 1.0 0.000143348623853 0 1 -1
and,ace 1.0 0.000143348623853 1 0 1
between,both 1.0 0.000286697247706 0 2 -2
qd,of 1.0 0.000143348623853 0 1 -1
was,unaffected 0.0 0.0 1 1 0
alert,to 1.0 0.000286697247706 2 0 2
chronic,administration 0.0 0.0 2 2 0
topamax,felbatol 1.0 0.000143348623853 1 0 1
of,post-heparin 1.0 0.000143348623853 1 0 1
pretreatment,augmented 1.0 0.000143348623853 1 0 1
then,hoof 1.0 0.000143348623853 0 1 -1
depakene,use 1.0 0.000143348623853 0 1 -1
slightly,greater 1.0 0.000143348623853 1 0 1
identified,as 1.0 0.000143348623853 0 1 -1
receiving,long- 1.0 0.000143348623853 1 0 1
of,lh 1.0 0.000143348623853 0 1 -1
hydroxy,indoleacetic 1.0 0.000143348623853 0 1 -1
these,findings 0.777777777778 0.00100344036697 1 8 -7
and,diabetes 1.0 0.000143348623853 0 1 -1
lymphomas,occur 1.0 0.000143348623853 0 1 -1
to,treatpatients 1.0 0.000143348623853 0 1 -1
accident,suicide 1.0 0.000143348623853 0 1 -1
pentagastrin-,and 1.0 0.000143348623853 0 1 -1
concentrations,only 1.0 0.000143348623853 0 1 -1
than,episodes 1.0 0.000143348623853 0 1 -1
we,assessed 1.0 0.000143348623853 0 1 -1
in,clinical 0.708333333333 0.00487385321101 7 41 -34
use,for 1.0 0.000286697247706 0 2 -2
liver,cytochrome 1.0 0.00043004587156 0 3 -3
following,intravenous 1.0 0.000143348623853 0 1 -1
the,individual 1.0 0.00043004587156 0 3 -3
pointes,most 1.0 0.000143348623853 1 0 1
are,potent 1.0 0.00043004587156 3 0 3
may,rise 1.0 0.000143348623853 0 1 -1
coagulation,ketoprofen 1.0 0.000143348623853 0 1 -1
plasma,after 1.0 0.000143348623853 0 1 -1
omega-agatoxin,iva 1.0 0.000143348623853 0 1 -1
and,constructive 1.0 0.000143348623853 0 1 -1
reports,there 1.0 0.000143348623853 1 0 1
fell,to 1.0 0.000143348623853 0 1 -1
tenofovir,disoproxil 1.0 0.000143348623853 0 1 -1
potential,decrease 1.0 0.000143348623853 0 1 -1
international,normalized 0.6 0.00043004587156 4 1 3
enhanced,learning 1.0 0.000143348623853 0 1 -1
are,carried 1.0 0.000143348623853 0 1 -1
healthy,young 1.0 0.000143348623853 0 1 -1
of,produced 1.0 0.000143348623853 1 0 1
usual,prescription 1.0 0.000143348623853 1 0 1
receiving,hydrochloride 0.0 0.0 1 1 0
and,lethal 1.0 0.000143348623853 0 1 -1
methadone,maintained 1.0 0.000143348623853 1 0 1
starlix,is 0.0 0.0 1 1 0
therefore,a 0.6 0.00043004587156 1 4 -3
screening,urine 1.0 0.000143348623853 0 1 -1
and,congestive 1.0 0.000143348623853 1 0 1
such,individuals 1.0 0.000286697247706 0 2 -2
exposure,auc0-30 1.0 0.000286697247706 0 2 -2
phenytoin,isoniazid 1.0 0.000143348623853 1 0 1
inhibitors,grapefruit 0.0 0.0 1 1 0
mcg,twice 1.0 0.000143348623853 0 1 -1
the,most 0.8 0.00114678899083 1 9 -8
metal,mixtures 1.0 0.000143348623853 0 1 -1
medicines,may 1.0 0.000860091743119 0 6 -6
had,been 1.0 0.000143348623853 0 1 -1
decreased,thiazides 1.0 0.000143348623853 0 1 -1
platelets,in 1.0 0.000143348623853 0 1 -1
major,are 1.0 0.000143348623853 1 0 1
osteomalacia,in 1.0 0.000143348623853 0 1 -1
factors,that 1.0 0.000143348623853 0 1 -1
that,apoptosis 1.0 0.000143348623853 0 1 -1
combined,hormonal 1.0 0.000286697247706 0 2 -2
concentrations,reach 1.0 0.000143348623853 1 0 1
no,evidence 1.0 0.00286697247706 0 20 -20
zdv,as 1.0 0.000143348623853 1 0 1
myoclonus,autonomic 1.0 0.000143348623853 1 0 1
immediate,release 1.0 0.00043004587156 3 0 3
in,which 0.238095238095 0.000716743119266 8 13 -5
common,adverse 1.0 0.00043004587156 0 3 -3
converting,enzyme 0.0 0.0 3 3 0
with,mhd 1.0 0.000143348623853 0 1 -1
are,cyp 1.0 0.000143348623853 1 0 1
or,driving 1.0 0.000143348623853 0 1 -1
cyp1a2,was 1.0 0.000143348623853 0 1 -1
when,new 1.0 0.000143348623853 0 1 -1
not,established 1.0 0.000143348623853 1 0 1
urticaria,require 1.0 0.000143348623853 0 1 -1
prolonged,concurrent 1.0 0.000143348623853 0 1 -1
death,from 1.0 0.000143348623853 0 1 -1
exercised,and 1.0 0.000143348623853 0 1 -1
mesenteric,vasodilation 0.0 0.0 1 1 0
is,either 0.333333333333 0.000143348623853 1 2 -1
anticholinergics,antagonize 1.0 0.000143348623853 0 1 -1
b,can 1.0 0.000143348623853 0 1 -1
table,additional 1.0 0.000143348623853 0 1 -1
using,stadol 1.0 0.000143348623853 0 1 -1
formation,of 0.333333333333 0.000143348623853 1 2 -1
with,potentiates 1.0 0.000143348623853 0 1 -1
important,pharmacokinetic 1.0 0.000573394495413 0 4 -4
sources,for 1.0 0.000143348623853 0 1 -1
contraindicated,and 1.0 0.000143348623853 1 0 1
human,immunodeficiency 1.0 0.00043004587156 0 3 -3
opportunistic,infections 1.0 0.000143348623853 0 1 -1
intestine,thus 1.0 0.000143348623853 1 0 1
diltiazem,plasma 1.0 0.000143348623853 0 1 -1
gl,was 0.0 0.0 1 1 0
by,oxc 1.0 0.000286697247706 0 2 -2
finasteride,had 1.0 0.000143348623853 0 1 -1
with,highly 1.0 0.000286697247706 0 2 -2
day,until 1.0 0.000143348623853 0 1 -1
the,role 1.0 0.000716743119266 0 5 -5
when,agents 1.0 0.000143348623853 1 0 1
they,are 0.4 0.000573394495413 3 7 -4
given,the 0.444444444444 0.00114678899083 5 13 -8
c19,substrate 1.0 0.000143348623853 0 1 -1
too,was 1.0 0.000143348623853 0 1 -1
advanced,hiv 1.0 0.000143348623853 0 1 -1
in,preterm 1.0 0.000143348623853 0 1 -1
with,administration 1.0 0.000286697247706 0 2 -2
and,embryonic 1.0 0.000143348623853 0 1 -1
may,use 1.0 0.000143348623853 0 1 -1
how,soon 1.0 0.000143348623853 1 0 1
derivative,implications 1.0 0.000143348623853 0 1 -1
mellitus,ischemic 1.0 0.000143348623853 0 1 -1
during,or 1.0 0.000286697247706 2 0 2
unconjugated,nacmc 1.0 0.000143348623853 0 1 -1
greater,understanding 1.0 0.000143348623853 0 1 -1
nyha,class 1.0 0.000143348623853 0 1 -1
between,keppra 1.0 0.000286697247706 0 2 -2
d6,isozyme 1.0 0.000716743119266 0 5 -5
complications,and 1.0 0.000143348623853 0 1 -1
hypertriglyceridemia,was 1.0 0.000143348623853 0 1 -1
high-dose,and 1.0 0.000143348623853 1 0 1
the,preparation 1.0 0.000143348623853 1 0 1
the,package 0.0 0.0 2 2 0
arsenical,encephalopathy 1.0 0.000143348623853 0 1 -1
either,humira 1.0 0.000143348623853 0 1 -1
adult,volunteers 1.0 0.000143348623853 0 1 -1
other,injectable 1.0 0.000143348623853 1 0 1
mg,controlled-release 1.0 0.000143348623853 1 0 1
accelerate,the 1.0 0.000143348623853 0 1 -1
multiple,cytochrome 1.0 0.000143348623853 0 1 -1
of,modest 1.0 0.000286697247706 0 2 -2
and,patients 0.333333333333 0.000286697247706 2 4 -2
these,three 1.0 0.000143348623853 1 0 1
both,increases 1.0 0.000143348623853 1 0 1
hypertension,when 1.0 0.000143348623853 1 0 1
consciousness,confusion 1.0 0.000143348623853 0 1 -1
www,rxlist 1.0 0.000143348623853 0 1 -1
on,a 0.6 0.00172018348624 4 16 -12
hypertensive,responses 1.0 0.000143348623853 1 0 1
k,contribution 1.0 0.000143348623853 0 1 -1
m2,without 1.0 0.000143348623853 0 1 -1
mevacor,in 1.0 0.000143348623853 0 1 -1
studies,had 1.0 0.000143348623853 0 1 -1
strabismus,miosis 1.0 0.000143348623853 0 1 -1
therapies,should 0.0 0.0 1 1 0
normal,antiasthmatic 1.0 0.000143348623853 0 1 -1
xigris,caution 1.0 0.000143348623853 0 1 -1
machinery,while 1.0 0.000143348623853 0 1 -1
descending,pain 1.0 0.000286697247706 0 2 -2
other,by 1.0 0.000286697247706 0 2 -2
a,consequent 1.0 0.000143348623853 1 0 1
competitive,suppression 1.0 0.000143348623853 0 1 -1
or,dysfunction 1.0 0.000143348623853 0 1 -1
an,eg 1.0 0.000143348623853 1 0 1
no,differences 1.0 0.00043004587156 0 3 -3
other,antiepileptic 0.2 0.000143348623853 3 2 1
are,representations 1.0 0.000143348623853 0 1 -1
responses,both 1.0 0.000143348623853 1 0 1
specifically,examining 1.0 0.000143348623853 0 1 -1
is,potentiated 1.0 0.00043004587156 3 0 3
a,year 1.0 0.000143348623853 0 1 -1
of,resveratrol-induced 1.0 0.000286697247706 0 2 -2
factors,and 1.0 0.000143348623853 0 1 -1
or,igm 1.0 0.000143348623853 0 1 -1
inositol,trisphosphate-induced 1.0 0.000143348623853 0 1 -1
aleve,or 1.0 0.000143348623853 1 0 1
were,considered 1.0 0.000143348623853 1 0 1
you,think 1.0 0.000143348623853 0 1 -1
three,times 0.142857142857 0.000143348623853 3 4 -1
to,regulate 1.0 0.000143348623853 0 1 -1
to,result 0.5 0.000573394495413 6 2 4
not,detected 1.0 0.000143348623853 0 1 -1
pharmacokinetic,evaluation 1.0 0.000143348623853 0 1 -1
additional,at 1.0 0.000143348623853 0 1 -1
ellence,with 1.0 0.000143348623853 1 0 1
inhibitors,oral 1.0 0.000143348623853 0 1 -1
lithium,inhibition 1.0 0.000143348623853 0 1 -1
complete,prescribing 1.0 0.000143348623853 0 1 -1
to,proleukin 1.0 0.000143348623853 0 1 -1
cause,the 1.0 0.000143348623853 1 0 1
nuclei,chromatin 1.0 0.000143348623853 0 1 -1
dealt,with 1.0 0.000143348623853 0 1 -1
could,increase 0.555555555556 0.000716743119266 2 7 -5
of,memory 1.0 0.000143348623853 0 1 -1
plasma,was 1.0 0.000286697247706 0 2 -2
immunoanalytical,methods 1.0 0.000143348623853 0 1 -1
been,carried 1.0 0.000286697247706 0 2 -2
comt,hormone 1.0 0.000143348623853 0 1 -1
repeat,dose 1.0 0.000143348623853 0 1 -1
immunosuppressant,metabolized 1.0 0.000143348623853 0 1 -1
in,certain 1.0 0.000143348623853 0 1 -1
of,placebo 1.0 0.000143348623853 0 1 -1
recommended,based 1.0 0.000286697247706 0 2 -2
in,study 1.0 0.000573394495413 0 4 -4
to,those 0.166666666667 0.000286697247706 5 7 -2
by,profound 1.0 0.000143348623853 0 1 -1
include,and 1.0 0.000286697247706 0 2 -2
on,balance 1.0 0.000143348623853 1 0 1
the,kidney 1.0 0.00043004587156 0 3 -3
psa,levels 1.0 0.000286697247706 0 2 -2
a4,enzymes 1.0 0.000143348623853 0 1 -1
adrenocortical,dependent 1.0 0.000143348623853 1 0 1
is,subject 1.0 0.000286697247706 0 2 -2
the,day 0.2 0.000143348623853 3 2 1
potassium-containing,salt 0.0 0.0 1 1 0
neither,case 1.0 0.000143348623853 0 1 -1
day,racemic 0.333333333333 0.000143348623853 1 2 -1
men,for 1.0 0.000143348623853 0 1 -1
being,dosed 1.0 0.000143348623853 0 1 -1
and,poor-risk 1.0 0.000143348623853 0 1 -1
has,to 1.0 0.000143348623853 0 1 -1
was,studied 1.0 0.00100344036697 0 7 -7
reactions,such 1.0 0.0021502293578 0 15 -15
strong,affinity 1.0 0.000143348623853 0 1 -1
and,cyp2c8 1.0 0.000286697247706 0 2 -2
factive,with 1.0 0.000143348623853 1 0 1
chelator,therapies 1.0 0.000143348623853 0 1 -1
diflunisal,decreased 1.0 0.000286697247706 2 0 2
avonex,mcg 0.0 0.0 1 1 0
culture,and 1.0 0.000143348623853 1 0 1
fraction,in 1.0 0.000143348623853 0 1 -1
agents,with 0.428571428571 0.000860091743119 10 4 6
beta-adrenergic,blocking 0.304347826087 0.00100344036697 15 8 7
o-glucuronidation,ki 1.0 0.000143348623853 0 1 -1
who,switched 1.0 0.000143348623853 0 1 -1
weeks,may 0.333333333333 0.000286697247706 2 4 -2
containing,carbohydrate-splitting 1.0 0.000143348623853 1 0 1
at,to 0.0 0.0 1 1 0
vitro,inhibitor 1.0 0.000143348623853 0 1 -1
and,nonsteroidal 0.5 0.000286697247706 1 3 -2
in,our 1.0 0.000143348623853 0 1 -1
logical,approach 1.0 0.000143348623853 0 1 -1
and,cosmetics 1.0 0.000143348623853 0 1 -1
tests,benedict 1.0 0.000143348623853 0 1 -1
the,cyclooxygenase-2 1.0 0.000143348623853 0 1 -1
cyp3a4,metabolic 1.0 0.000143348623853 0 1 -1
picr,so 1.0 0.000143348623853 0 1 -1
tikosyn,with 1.0 0.000143348623853 1 0 1
antagonist,effect 1.0 0.000143348623853 0 1 -1
or,vehicle 1.0 0.000143348623853 0 1 -1
the,syndrome 1.0 0.000143348623853 0 1 -1
used,general 1.0 0.000143348623853 0 1 -1
concomitantly,administered 0.636363636364 0.00100344036697 2 9 -7
aware,of 1.0 0.000286697247706 0 2 -2
sodium,fluorescein 1.0 0.000143348623853 0 1 -1
with,the 0.11801242236 0.00272362385321 71 90 -19
pd2,values 0.333333333333 0.000143348623853 2 1 1
to,nonlethal 1.0 0.000143348623853 0 1 -1
substrate,single 1.0 0.000286697247706 0 2 -2
comprehensive,review 1.0 0.000143348623853 0 1 -1
that,functional 1.0 0.000143348623853 0 1 -1
to,reductions 1.0 0.000143348623853 0 1 -1
variable,elevations 1.0 0.000143348623853 0 1 -1
preparations,are 1.0 0.000286697247706 2 0 2
low,measurement 1.0 0.000143348623853 0 1 -1
a,few 0.5 0.000286697247706 3 1 2
by,chronic 1.0 0.000143348623853 1 0 1
seen,as 0.0 0.0 1 1 0
levels,occurred 1.0 0.000143348623853 1 0 1
studies,investigating 1.0 0.000143348623853 0 1 -1
alkylated,such 1.0 0.000143348623853 0 1 -1
useful,for 1.0 0.000286697247706 0 2 -2
numbers,of 1.0 0.00043004587156 0 3 -3
paper,was 1.0 0.000143348623853 0 1 -1
was,calculated 1.0 0.000143348623853 0 1 -1
of,betaseron 1.0 0.000143348623853 1 0 1
of,chemicals 1.0 0.000143348623853 0 1 -1
s,alpha 1.0 0.000143348623853 0 1 -1
translates,into 1.0 0.000143348623853 0 1 -1
pletal,does 1.0 0.000143348623853 0 1 -1
arachidonic,acid 1.0 0.00043004587156 0 3 -3
at,doses 0.2 0.00043004587156 6 9 -3
fibrinolysis,is 1.0 0.000143348623853 0 1 -1
disposition,may 1.0 0.000143348623853 0 1 -1
plans,for 1.0 0.000143348623853 0 1 -1
urine,test 1.0 0.00043004587156 0 3 -3
may,make 1.0 0.000573394495413 0 4 -4
discuss,the 1.0 0.000143348623853 0 1 -1
few,days 1.0 0.000286697247706 2 0 2
using,comparisons 1.0 0.000143348623853 0 1 -1
taking,low-dose 1.0 0.000286697247706 0 2 -2
experiments,reported 1.0 0.000143348623853 0 1 -1
potency,and 1.0 0.000143348623853 0 1 -1
have,more 1.0 0.000143348623853 0 1 -1
level,that 0.0 0.0 1 1 0
response,and 1.0 0.000860091743119 0 6 -6
a,cyp2d6 1.0 0.000143348623853 1 0 1
aid,in 1.0 0.000143348623853 0 1 -1
c9,and 1.0 0.000286697247706 0 2 -2
depression,in 1.0 0.000286697247706 0 2 -2
express,the 1.0 0.000143348623853 0 1 -1
tysabri,and 1.0 0.000143348623853 0 1 -1
may,accentuate 0.333333333333 0.000143348623853 2 1 1
ml,have 1.0 0.000143348623853 0 1 -1
depression,is 1.0 0.000143348623853 0 1 -1
performance,liquid 1.0 0.000143348623853 0 1 -1
studies,tilade 1.0 0.000143348623853 0 1 -1
patients,as 1.0 0.000286697247706 0 2 -2
of,maternal 1.0 0.000143348623853 0 1 -1
implant,have 1.0 0.000143348623853 0 1 -1
other,pharmacokinetic 1.0 0.000143348623853 0 1 -1
agents,gastrointestinal 1.0 0.000286697247706 2 0 2
studies,were 0.833333333333 0.00143348623853 1 11 -10
immunization,cannot 1.0 0.000143348623853 1 0 1
current,evidence 0.0 0.0 1 1 0
thienobenzodiazepine,derivative 1.0 0.000143348623853 0 1 -1
thirty,male 1.0 0.000143348623853 0 1 -1
a4,increased 1.0 0.000143348623853 1 0 1
metabolite,hydroxy-estazolam 1.0 0.000143348623853 0 1 -1
or,fec-100 1.0 0.000143348623853 0 1 -1
studies,wshow 1.0 0.000143348623853 1 0 1
people,who 1.0 0.000143348623853 1 0 1
are,that 1.0 0.000143348623853 0 1 -1
dyslipidemia,hypertension 1.0 0.000143348623853 0 1 -1
using,two 1.0 0.000143348623853 0 1 -1
for,were 1.0 0.000143348623853 0 1 -1
which,support 1.0 0.000143348623853 0 1 -1
subcutaneous,injections 1.0 0.000286697247706 0 2 -2
prolongation,which 1.0 0.000143348623853 0 1 -1
discontinued,at 0.0 0.0 1 1 0
unbound,bound 1.0 0.000143348623853 0 1 -1
triple,combination 1.0 0.000143348623853 0 1 -1
might,help 1.0 0.000143348623853 0 1 -1
or,inhibits 1.0 0.000143348623853 0 1 -1
in,de 1.0 0.000286697247706 0 2 -2
excess,of 1.0 0.000143348623853 0 1 -1
or,stopped 1.0 0.000143348623853 1 0 1
tablets,usp 0.0 0.0 1 1 0
and,decreases 0.0 0.0 1 1 0
receiving,mg 0.0 0.0 2 2 0
activity,for 1.0 0.000143348623853 0 1 -1
essential,close 1.0 0.000143348623853 0 1 -1
mesylate,did 1.0 0.000143348623853 0 1 -1
if,changes 1.0 0.000143348623853 0 1 -1
bones,the 1.0 0.00043004587156 0 3 -3
intravenous,was 1.0 0.000143348623853 1 0 1
days,resulted 1.0 0.000716743119266 5 0 5
with,care 1.0 0.000716743119266 5 0 5
period,immediately 1.0 0.000143348623853 0 1 -1
to,chemically 1.0 0.000143348623853 0 1 -1
as,hypotension 1.0 0.000143348623853 0 1 -1
other,inhibitors 1.0 0.000143348623853 1 0 1
skin,products 1.0 0.000143348623853 0 1 -1
be,initiated 0.2 0.000143348623853 2 3 -1
time,caused 1.0 0.000143348623853 0 1 -1
gleevec,increased 1.0 0.000143348623853 1 0 1
zebeta,on 1.0 0.000143348623853 0 1 -1
different,tasks 1.0 0.000143348623853 0 1 -1
nanm,or 0.333333333333 0.000143348623853 2 1 1
possible,diminished 1.0 0.000143348623853 0 1 -1
not,meant 1.0 0.000143348623853 0 1 -1
gleevec,increases 1.0 0.000143348623853 1 0 1
with,alone 0.6 0.00043004587156 4 1 3
seal,recordings 1.0 0.000286697247706 0 2 -2
not,noted 1.0 0.000143348623853 0 1 -1
of,goal-directed 1.0 0.000143348623853 0 1 -1
a,maximal 1.0 0.000143348623853 0 1 -1
affect,conversion 1.0 0.000143348623853 0 1 -1
or,depresses 1.0 0.000143348623853 0 1 -1
are,discussed 1.0 0.000573394495413 0 4 -4
contraception,and 1.0 0.000143348623853 0 1 -1
min,and 1.0 0.000143348623853 0 1 -1
for,excretion 1.0 0.000143348623853 1 0 1
str,or 1.0 0.000286697247706 0 2 -2
pneumoniae,streptococcus 1.0 0.000143348623853 0 1 -1
reversible,enhancement 1.0 0.000143348623853 1 0 1
in,electrically 1.0 0.000143348623853 0 1 -1
s,bioavailability 1.0 0.000143348623853 0 1 -1
certain,may 1.0 0.000143348623853 1 0 1
receiving,ganglion 1.0 0.000143348623853 0 1 -1
however,interactions 1.0 0.000143348623853 1 0 1
and,risks 1.0 0.000143348623853 1 0 1
diffraction,differential 1.0 0.000143348623853 0 1 -1
transfer,to 1.0 0.00043004587156 0 3 -3
and,nor 1.0 0.000143348623853 0 1 -1
rifampin,may 1.0 0.000143348623853 1 0 1
ibandronate,was 1.0 0.000143348623853 0 1 -1
coadministered,in 1.0 0.000143348623853 0 1 -1
kaolin-pectin,certain 1.0 0.000143348623853 1 0 1
hypokalemia,which 1.0 0.000143348623853 1 0 1
neurotoxicity,whereas 1.0 0.000143348623853 0 1 -1
demographics,nhl 1.0 0.000143348623853 0 1 -1
reduces,basal 1.0 0.000143348623853 0 1 -1
inhibitors,reports 1.0 0.00043004587156 3 0 3
to,temporarily 1.0 0.000286697247706 2 0 2
clinician,should 1.0 0.000143348623853 1 0 1
weeks,prior 0.2 0.000143348623853 2 3 -1
inhibit,c9 1.0 0.000143348623853 0 1 -1
or,may 0.809523809524 0.0024369266055 19 2 17
concomitantly,only 1.0 0.000286697247706 0 2 -2
though,has 1.0 0.000286697247706 0 2 -2
requirements,i 1.0 0.000143348623853 0 1 -1
ironing,kilometers 1.0 0.000143348623853 0 1 -1
levels,cfu 1.0 0.000143348623853 0 1 -1
stimulant,effects 1.0 0.000286697247706 2 0 2
antigen,were 1.0 0.000143348623853 0 1 -1
tubules,seminiferous 1.0 0.000143348623853 0 1 -1
from,these 0.5 0.000286697247706 1 3 -2
group,served 1.0 0.000143348623853 0 1 -1
when,treating 1.0 0.00043004587156 0 3 -3
any,great 1.0 0.000143348623853 0 1 -1
and,excretion 0.0 0.0 1 1 0
reportedly,resulted 1.0 0.000143348623853 1 0 1
by,patients 0.714285714286 0.000716743119266 6 1 5
ml,approximately 1.0 0.000143348623853 0 1 -1
pipracil,may 1.0 0.000143348623853 0 1 -1
further,route 1.0 0.000143348623853 0 1 -1
use,as 1.0 0.000143348623853 0 1 -1
inserts,of 1.0 0.000143348623853 0 1 -1
tolerated,but 0.0 0.0 1 1 0
but,these 0.333333333333 0.000143348623853 2 1 1
use,at 1.0 0.000143348623853 0 1 -1
other,was 1.0 0.000143348623853 0 1 -1
therapy,depends 1.0 0.000143348623853 0 1 -1
greater,risk 1.0 0.000286697247706 0 2 -2
concomitant,serotonergic 1.0 0.000143348623853 1 0 1
the,ace 1.0 0.00043004587156 3 0 3
cyp,isozymes 1.0 0.000143348623853 0 1 -1
weak,acids 1.0 0.000143348623853 1 0 1
other,combinations 1.0 0.000143348623853 0 1 -1
be,approached 0.777777777778 0.00100344036697 8 1 7
initial,dosing 1.0 0.000143348623853 0 1 -1
important,effect 1.0 0.000860091743119 0 6 -6
toxic,and 1.0 0.000143348623853 1 0 1
additional,supine 1.0 0.000143348623853 1 0 1
patients,may 0.294117647059 0.000716743119266 6 11 -5
the,beta-adrenergic 1.0 0.000143348623853 1 0 1
immunosuppressives,cyclosporine 1.0 0.000143348623853 0 1 -1
ascorbic,acid 0.428571428571 0.00043004587156 2 5 -3
genetic,variation 1.0 0.000286697247706 0 2 -2
vasoconstriction,in 1.0 0.000143348623853 1 0 1
mu,systems 1.0 0.000143348623853 0 1 -1
that,cause 1.0 0.00043004587156 3 0 3
nnrti-na,ve 1.0 0.000143348623853 0 1 -1
for,chelation 1.0 0.000143348623853 0 1 -1
two,reverse 1.0 0.000143348623853 0 1 -1
with,clomiphene 1.0 0.000143348623853 0 1 -1
transfer,from 1.0 0.000143348623853 0 1 -1
if,clearance 1.0 0.000143348623853 1 0 1
disorders,and 1.0 0.000143348623853 0 1 -1
blocker,was 1.0 0.000143348623853 0 1 -1
for,example 0.25 0.000286697247706 3 5 -2
mg,ethinyl 1.0 0.000286697247706 0 2 -2
benefit,compared 1.0 0.000286697247706 2 0 2
still,unknown 1.0 0.000143348623853 0 1 -1
urine,by 1.0 0.000143348623853 0 1 -1
which,becomes 1.0 0.000143348623853 0 1 -1
or,trivalent 1.0 0.000286697247706 0 2 -2
very,little 0.0 0.0 1 1 0
as,international 1.0 0.000143348623853 1 0 1
popular,in 1.0 0.000143348623853 0 1 -1
the,substantial 1.0 0.000143348623853 1 0 1
higher,risk 1.0 0.000286697247706 0 2 -2
at,daily 1.0 0.000143348623853 0 1 -1
glucose,blood 1.0 0.000143348623853 0 1 -1
a,proposed 1.0 0.000143348623853 0 1 -1
aeds,were 1.0 0.000143348623853 0 1 -1
vancomycin-resistant,strains 1.0 0.000143348623853 0 1 -1
are,based 1.0 0.000286697247706 0 2 -2
antidiabetics,because 1.0 0.000143348623853 1 0 1
subjects,no 0.333333333333 0.000143348623853 1 2 -1
albumin,may 1.0 0.000143348623853 0 1 -1
and,systolic 1.0 0.000143348623853 0 1 -1
above,experiments 1.0 0.000143348623853 0 1 -1
containing,cremophor 1.0 0.000143348623853 1 0 1
involving,even 1.0 0.000286697247706 0 2 -2
intravenously,administered 1.0 0.00043004587156 3 0 3
with,brovana 1.0 0.000143348623853 0 1 -1
potent,inhibitors 0.2 0.000143348623853 2 3 -1
both,dietary 1.0 0.000143348623853 0 1 -1
after,repeated 1.0 0.000143348623853 1 0 1
camptosar,and 0.333333333333 0.000143348623853 2 1 1
on,possible 1.0 0.000143348623853 1 0 1
vardenafil,or 1.0 0.000143348623853 1 0 1
not,needed 1.0 0.000143348623853 1 0 1
arthropan,magan 1.0 0.000143348623853 1 0 1
family,may 1.0 0.000143348623853 0 1 -1
cyp-mediated,drug 1.0 0.000143348623853 0 1 -1
take,place 1.0 0.000143348623853 0 1 -1
agents,increasing 0.333333333333 0.000143348623853 2 1 1
registry,by 1.0 0.000143348623853 0 1 -1
to,ensure 0.333333333333 0.000143348623853 2 1 1
advise,on 1.0 0.000143348623853 0 1 -1
stimulator,of 1.0 0.000143348623853 1 0 1
ergocalcitriol,by 0.333333333333 0.000143348623853 2 1 1
decreased,bioavailability 1.0 0.000143348623853 1 0 1
renal,function 0.142857142857 0.000573394495413 12 16 -4
to,extend 1.0 0.000143348623853 1 0 1
deaths,among 1.0 0.000143348623853 0 1 -1
doses,greater 1.0 0.000286697247706 0 2 -2
for,blood 1.0 0.000143348623853 0 1 -1
emtriva,has 1.0 0.000143348623853 0 1 -1
physiological,doses 1.0 0.000143348623853 0 1 -1
nor,inhibits 1.0 0.000143348623853 0 1 -1
significantly,bind 1.0 0.000143348623853 0 1 -1
proposed,mechanism 1.0 0.000143348623853 0 1 -1
that,identify 1.0 0.000143348623853 1 0 1
was,exposed 1.0 0.000143348623853 0 1 -1
acid,metabolite 0.5 0.000286697247706 1 3 -2
narrow,therapeutic 0.166666666667 0.000286697247706 5 7 -2
receptors,in 1.0 0.000143348623853 0 1 -1
nsaids,through 1.0 0.000143348623853 1 0 1
dosing,effects 1.0 0.000143348623853 0 1 -1
phosphorylation,status 1.0 0.000143348623853 0 1 -1
cmin,concentrations 1.0 0.000286697247706 0 2 -2
demonstrated,large 1.0 0.000143348623853 0 1 -1
a,metabolite 0.0 0.0 2 2 0
other,ace 1.0 0.000143348623853 1 0 1
mao,inhibition 1.0 0.000143348623853 0 1 -1
with,sexual 1.0 0.000143348623853 0 1 -1
in,reference 1.0 0.000143348623853 0 1 -1
not,interfere 1.0 0.00143348623853 0 10 -10
sodium,carboxymethylcellulose 1.0 0.000143348623853 0 1 -1
hyperthyroidism,hypertension 1.0 0.000143348623853 0 1 -1
dose,administration 0.333333333333 0.000143348623853 1 2 -1
table,effects 1.0 0.000286697247706 0 2 -2
of,calcium-channel 1.0 0.000143348623853 0 1 -1
inhibitor,should 1.0 0.000143348623853 1 0 1
in,utero 1.0 0.000286697247706 0 2 -2
cefamandole,naftate 1.0 0.000143348623853 0 1 -1
if,coreg 1.0 0.000143348623853 1 0 1
in,lymphocyte 1.0 0.000143348623853 0 1 -1
changes,and 0.0 0.0 1 1 0
since,symptoms 1.0 0.000143348623853 0 1 -1
evaluated,after 1.0 0.000143348623853 1 0 1
containing,side 1.0 0.000143348623853 0 1 -1
be,produced 0.333333333333 0.000143348623853 1 2 -1
gold,is 1.0 0.000143348623853 0 1 -1
be,reviewed 0.333333333333 0.000143348623853 2 1 1
maintained,on 0.0 0.0 2 2 0
anti-depressants,could 1.0 0.000143348623853 1 0 1
possible,increases 1.0 0.000143348623853 0 1 -1
the,diabectics 1.0 0.000143348623853 0 1 -1
lowering,of 1.0 0.000143348623853 1 0 1
vanh,promoter-vana 1.0 0.000143348623853 0 1 -1
gland,of 1.0 0.000143348623853 0 1 -1
to,week 1.0 0.000143348623853 0 1 -1
serotonergic,effects 1.0 0.000143348623853 1 0 1
to,elevated 1.0 0.000573394495413 4 0 4
disturbance,rarely 1.0 0.000143348623853 1 0 1
in,establishing 1.0 0.000143348623853 0 1 -1
relaxants,intravenous 1.0 0.000143348623853 0 1 -1
tested,for 1.0 0.000286697247706 0 2 -2
are,rare 1.0 0.000143348623853 1 0 1
sprague-dawley,rats 1.0 0.000143348623853 0 1 -1
morning,and 1.0 0.000286697247706 0 2 -2
observed,increase 1.0 0.000143348623853 1 0 1
most,may 1.0 0.000143348623853 0 1 -1
pharmacokinetics,at 1.0 0.000143348623853 0 1 -1
aspirin,ketoprofen 1.0 0.000143348623853 0 1 -1
these,could 1.0 0.000143348623853 1 0 1
intervals,usually 1.0 0.000143348623853 0 1 -1
applying,panretin 1.0 0.000143348623853 1 0 1
cecum,and 1.0 0.000143348623853 0 1 -1
patients,over 1.0 0.000143348623853 1 0 1
interactions,positive 1.0 0.000143348623853 0 1 -1
lst,mice 1.0 0.00043004587156 0 3 -3
diagnosed,schizophrenia 1.0 0.000143348623853 1 0 1
oxolinic,acid 1.0 0.000143348623853 1 0 1
gathered,for 1.0 0.000143348623853 0 1 -1
system,careful 1.0 0.000286697247706 0 2 -2
trans-diol,by 1.0 0.000143348623853 0 1 -1
some,early 1.0 0.000143348623853 0 1 -1
ethopropazine,may 1.0 0.000143348623853 1 0 1
be,delayed 0.333333333333 0.000143348623853 1 2 -1
ibogaine,but 1.0 0.000143348623853 0 1 -1
that,increased 0.333333333333 0.000143348623853 1 2 -1
of,crude 1.0 0.000143348623853 0 1 -1
studies,received 1.0 0.000286697247706 0 2 -2
less,toxic 1.0 0.000143348623853 0 1 -1
reported,dose 1.0 0.000143348623853 0 1 -1
x,iu 1.0 0.000143348623853 0 1 -1
reducing,absorption 1.0 0.000143348623853 1 0 1
stable,on 1.0 0.000716743119266 0 5 -5
possible,role 1.0 0.000143348623853 0 1 -1
cyst,patients 1.0 0.000143348623853 1 0 1
six,typical 1.0 0.000143348623853 0 1 -1
organic,cation 0.0 0.0 1 1 0
caffeine,administered 1.0 0.000143348623853 1 0 1
of,food 1.0 0.000286697247706 0 2 -2
not,under 1.0 0.000143348623853 0 1 -1
oral,for 1.0 0.000286697247706 2 0 2
advice,of 1.0 0.000143348623853 1 0 1
extraneal,in 1.0 0.000143348623853 1 0 1
potentiate,blood-pressure 1.0 0.000143348623853 1 0 1
eight-fold,increase 1.0 0.000573394495413 4 0 4
following,eight 1.0 0.000143348623853 0 1 -1
of,seizures 1.0 0.000286697247706 2 0 2
levels,and 0.291666666667 0.00200688073394 31 17 14
functional,antagonism 1.0 0.00043004587156 3 0 3
isoenzymes,may 1.0 0.000286697247706 0 2 -2
food,is 1.0 0.000143348623853 1 0 1
certain,tend 1.0 0.00043004587156 0 3 -3
blood,can 1.0 0.000143348623853 0 1 -1
of,arimidex 1.0 0.000286697247706 0 2 -2
the,nonsteroidal 1.0 0.000143348623853 1 0 1
may,need 0.272727272727 0.00043004587156 7 4 3
earth,and 1.0 0.000286697247706 0 2 -2
dosage,adjustment 0.5 0.00172018348624 6 18 -12
uptake,blocking 1.0 0.000143348623853 0 1 -1
and,rats 1.0 0.000143348623853 1 0 1
food,in 1.0 0.000143348623853 0 1 -1
the,significant 1.0 0.000143348623853 0 1 -1
psoriasis,rheumatoid 1.0 0.000143348623853 0 1 -1
increase,high-density 1.0 0.000143348623853 0 1 -1
toxicology,study 1.0 0.000143348623853 0 1 -1
studies,m1 1.0 0.000286697247706 0 2 -2
main,route 1.0 0.000143348623853 0 1 -1
be,receiving 1.0 0.000143348623853 1 0 1
of,cause 1.0 0.000143348623853 0 1 -1
and,monitored 1.0 0.000143348623853 0 1 -1
displace,acidic 1.0 0.000143348623853 1 0 1
multi-day,course 1.0 0.000143348623853 1 0 1
impact,of 1.0 0.00043004587156 0 3 -3
not,induce 1.0 0.000573394495413 0 4 -4
size,of 1.0 0.000143348623853 0 1 -1
impact,on 0.333333333333 0.000143348623853 1 2 -1
postmarketing,observations 1.0 0.000143348623853 1 0 1
hormone,as 1.0 0.000143348623853 0 1 -1
be,excluded 1.0 0.000143348623853 0 1 -1
omeprazole,the 1.0 0.000143348623853 0 1 -1
ph,on 1.0 0.000143348623853 0 1 -1
ph,of 1.0 0.000143348623853 1 0 1
a,small 0.384615384615 0.000716743119266 4 9 -5
fold,when 1.0 0.000143348623853 1 0 1
direct,effects 1.0 0.000143348623853 0 1 -1
amines,have 1.0 0.000143348623853 1 0 1
effects,prolonged 1.0 0.000143348623853 1 0 1
other,additive 1.0 0.000143348623853 0 1 -1
monotherapy,given 1.0 0.000143348623853 0 1 -1
synthetic,and 1.0 0.00043004587156 3 0 3
increase,excretion 1.0 0.000143348623853 0 1 -1
cardiac,arrythmias 1.0 0.000143348623853 1 0 1
efficacy,as 1.0 0.000143348623853 0 1 -1
rarely,euphoria 1.0 0.000143348623853 0 1 -1
evidence,on 1.0 0.000143348623853 0 1 -1
was,due 1.0 0.00043004587156 0 3 -3
the,additional 1.0 0.000143348623853 0 1 -1
the,choice 1.0 0.000143348623853 0 1 -1
dmpge2,mg 0.5 0.000286697247706 1 3 -2
lipid,profile 1.0 0.000143348623853 0 1 -1
worsening,renal 1.0 0.000143348623853 0 1 -1
enzymes,have 1.0 0.000143348623853 0 1 -1
design,of 1.0 0.000143348623853 0 1 -1
a,risk 0.5 0.000286697247706 3 1 2
at,m 0.0 0.0 1 1 0
highly,protein-bound 1.0 0.000573394495413 0 4 -4
max,auc 1.0 0.000143348623853 0 1 -1
at,h 1.0 0.000286697247706 0 2 -2
survanta,a 1.0 0.000143348623853 0 1 -1
be,aggravated 1.0 0.000143348623853 1 0 1
at,c 1.0 0.000143348623853 0 1 -1
antidepressants,use 1.0 0.000143348623853 1 0 1
when,potent 1.0 0.000143348623853 1 0 1
recommended,not 0.5 0.000286697247706 3 1 2
excystment,of 1.0 0.000143348623853 0 1 -1
normal,release 1.0 0.000143348623853 0 1 -1
metabolized,particularly 1.0 0.000143348623853 0 1 -1
alcohol,when 1.0 0.000143348623853 0 1 -1
was,correlated 1.0 0.000143348623853 0 1 -1
separate,group 1.0 0.000143348623853 1 0 1
exaggeration,of 1.0 0.000143348623853 1 0 1
continued,to 1.0 0.000143348623853 0 1 -1
commonly,occurring 1.0 0.000143348623853 1 0 1
treat,pneumocystis 0.0 0.0 1 1 0
in,combination 0.362637362637 0.00473050458716 29 62 -33
qtc,prolongation 1.0 0.00043004587156 0 3 -3
rifabutin,another 1.0 0.000143348623853 0 1 -1
controlled-release,capsule 1.0 0.000143348623853 1 0 1
of,genetically 1.0 0.000143348623853 0 1 -1
maintaining,a 1.0 0.000143348623853 0 1 -1
the,condition 1.0 0.000143348623853 0 1 -1
possible,over- 1.0 0.00043004587156 3 0 3
hyperuricemic,patients 1.0 0.000143348623853 0 1 -1
doses,three 1.0 0.000143348623853 0 1 -1
of,previously 0.0 0.0 1 1 0
clinically,or 1.0 0.000143348623853 0 1 -1
other,clotting 1.0 0.000143348623853 0 1 -1
loss,results 1.0 0.000143348623853 0 1 -1
have,frequent 1.0 0.000143348623853 0 1 -1
n,in 1.0 0.000286697247706 0 2 -2
fulvestrant,was 1.0 0.000286697247706 0 2 -2
cleansers,soaps 1.0 0.000143348623853 0 1 -1
depressed,the 0.0 0.0 1 1 0
kt,oruvail 1.0 0.000143348623853 0 1 -1
it,enhances 1.0 0.000143348623853 0 1 -1
to,prolong 0.333333333333 0.000286697247706 4 2 2
confirmation,should 1.0 0.000143348623853 0 1 -1
l-glutamine,has 1.0 0.000143348623853 0 1 -1
low-dose,plus 1.0 0.000143348623853 0 1 -1
each,successive 1.0 0.000143348623853 0 1 -1
hours,after 0.047619047619 0.000143348623853 11 10 1
sildenafil,citrate 0.0 0.0 1 1 0
carbidopa,given 1.0 0.000143348623853 0 1 -1
pharmacokinetic,drug-drug 1.0 0.000573394495413 0 4 -4
moribund,condition 1.0 0.000143348623853 0 1 -1
onset,and 1.0 0.000143348623853 1 0 1
enhance,toxicity 1.0 0.000143348623853 0 1 -1
a,concentration 1.0 0.00043004587156 0 3 -3
day,proved 1.0 0.000143348623853 0 1 -1
cyclopropane,or 1.0 0.000143348623853 1 0 1
in,effectiveness 1.0 0.000143348623853 1 0 1
from,cotherapy 1.0 0.000143348623853 0 1 -1
treated,concomitantly 0.0 0.0 1 1 0
sulfamethoxazole-trimethoprim,bactrim 1.0 0.000143348623853 0 1 -1
lines,divergently 1.0 0.000143348623853 0 1 -1
now,appearing 1.0 0.000143348623853 0 1 -1
time,window 1.0 0.000143348623853 1 0 1
factive,and 1.0 0.000143348623853 1 0 1
drugs,highly 1.0 0.00043004587156 0 3 -3
of,veratrum 1.0 0.000143348623853 1 0 1
function,is 0.333333333333 0.000143348623853 1 2 -1
furthermore,no 1.0 0.000143348623853 0 1 -1
a4,ic50 1.0 0.000143348623853 0 1 -1
increasing,steady-state 1.0 0.000143348623853 1 0 1
cascade,impactor 1.0 0.000143348623853 0 1 -1
cough,cold 1.0 0.000143348623853 0 1 -1
been,treated 0.0 0.0 1 1 0
function,in 1.0 0.000286697247706 0 2 -2
susceptibility,to 1.0 0.000716743119266 0 5 -5
scanning,calorimetry 1.0 0.000143348623853 0 1 -1
exclusively,by 1.0 0.000143348623853 0 1 -1
copd,medications 1.0 0.000143348623853 0 1 -1
ultimate,effect 1.0 0.000143348623853 0 1 -1
repeated,doses 0.0 0.0 1 1 0
urinary,metanephrine 1.0 0.000143348623853 0 1 -1
steady-state,serum 1.0 0.000716743119266 5 0 5
these,does 1.0 0.000143348623853 0 1 -1
addiction,research 1.0 0.000143348623853 0 1 -1
induced,hypertension 1.0 0.000286697247706 0 2 -2
or,oils 1.0 0.000143348623853 0 1 -1
oxidase,mao 0.2 0.000286697247706 4 6 -2
administered,after 1.0 0.000286697247706 0 2 -2
in,unconjugated 1.0 0.000143348623853 0 1 -1
of,naflu 1.0 0.00043004587156 0 3 -3
or,symptoms 1.0 0.00043004587156 3 0 3
between,mentax 1.0 0.000143348623853 0 1 -1
the,control 1.0 0.000716743119266 0 5 -5
significant,alteration 1.0 0.000143348623853 1 0 1
chemotherapy,can 1.0 0.000143348623853 0 1 -1
other,therapy 1.0 0.000286697247706 0 2 -2
activity,has 1.0 0.000143348623853 0 1 -1
be,related 1.0 0.000716743119266 0 5 -5
some,organisms 1.0 0.000143348623853 1 0 1
bilirubin,urobilin 1.0 0.000143348623853 0 1 -1
mental,alertness 1.0 0.000143348623853 0 1 -1
the,histology 1.0 0.000143348623853 0 1 -1
patient,care 1.0 0.000143348623853 0 1 -1
percentage,of 0.5 0.000286697247706 1 3 -2
tnf-blocking,agent 1.0 0.000143348623853 1 0 1
a,local 1.0 0.000143348623853 0 1 -1
following,ip 1.0 0.000143348623853 0 1 -1
as,binding 1.0 0.000143348623853 0 1 -1
have,to 1.0 0.000143348623853 0 1 -1
screen,for 1.0 0.000143348623853 0 1 -1
may,pose 1.0 0.000716743119266 5 0 5
a,common 0.5 0.000286697247706 1 3 -2
parentheses,were 1.0 0.000143348623853 0 1 -1
depend,upon 1.0 0.000286697247706 0 2 -2
specifically,they 1.0 0.000143348623853 0 1 -1
been,safely 1.0 0.000860091743119 0 6 -6
studies,without 1.0 0.000143348623853 0 1 -1
a,diabetic 1.0 0.000143348623853 1 0 1
isoflurane,and 1.0 0.000143348623853 1 0 1
app,polymer 1.0 0.000143348623853 0 1 -1
safe,problem 1.0 0.000143348623853 1 0 1
other,compounds 1.0 0.000143348623853 0 1 -1
spermine,and 1.0 0.000143348623853 0 1 -1
tachypnea,lethargy 1.0 0.000143348623853 1 0 1
injected,and 1.0 0.000143348623853 0 1 -1
particular,mao 1.0 0.000143348623853 0 1 -1
e,mesylate 0.428571428571 0.00043004587156 5 2 3
phosphorylation,at 1.0 0.000143348623853 1 0 1
fold,elevation 1.0 0.000143348623853 1 0 1
also,have 0.333333333333 0.000143348623853 1 2 -1
phenytoin,etodolac 1.0 0.000143348623853 0 1 -1
or,have 1.0 0.000143348623853 0 1 -1
p450,cyp450 1.0 0.000143348623853 0 1 -1
dose,modification 1.0 0.000286697247706 0 2 -2
take,st 1.0 0.000143348623853 0 1 -1
amevive,a 1.0 0.000143348623853 0 1 -1
included,self-reported 1.0 0.000143348623853 0 1 -1
mg,taken 1.0 0.000143348623853 1 0 1
consisted,of 1.0 0.00043004587156 0 3 -3
were,more 0.5 0.000286697247706 1 3 -2
dose-dependent,manner 0.333333333333 0.000143348623853 2 1 1
was,withdrawn 1.0 0.000143348623853 0 1 -1
four,hours 1.0 0.000143348623853 0 1 -1
constitute,the 1.0 0.000143348623853 0 1 -1
psychotropic,that 1.0 0.000143348623853 1 0 1
modification,abolished 1.0 0.000143348623853 0 1 -1
t24,cells 1.0 0.000143348623853 1 0 1
begin,therapy 1.0 0.000143348623853 0 1 -1
to,results 1.0 0.000143348623853 1 0 1
level,dosage 1.0 0.000143348623853 1 0 1
for,bacterial 1.0 0.000143348623853 0 1 -1
are,unaltered 1.0 0.000143348623853 0 1 -1
on,safety 1.0 0.000143348623853 0 1 -1
fondaparinux,neither 1.0 0.000143348623853 0 1 -1
diabetes,there 1.0 0.000143348623853 0 1 -1
than,doubled 1.0 0.000143348623853 0 1 -1
for,characterization 1.0 0.000143348623853 0 1 -1
dysfunction,may 1.0 0.000143348623853 0 1 -1
between,solvents 1.0 0.000286697247706 0 2 -2
its,components 1.0 0.000143348623853 0 1 -1
haloperidol,haloperidol 1.0 0.000286697247706 2 0 2
and,study 1.0 0.000143348623853 0 1 -1
terfenadine,no 1.0 0.000143348623853 0 1 -1
a,potential 0.166666666667 0.000286697247706 7 5 2
non-diabetics,with 1.0 0.000143348623853 0 1 -1
june,and 1.0 0.000143348623853 0 1 -1
pathogens,of 1.0 0.000143348623853 0 1 -1
postmarketing,reports 0.333333333333 0.000143348623853 2 1 1
assays,based 1.0 0.000286697247706 0 2 -2
or,norpace 1.0 0.000143348623853 1 0 1
supplementation,and 1.0 0.000143348623853 0 1 -1
and,several 1.0 0.000143348623853 0 1 -1
to,patients 0.224489795918 0.00157683486239 30 19 11
while,using 1.0 0.000143348623853 0 1 -1
n1,n2 1.0 0.000143348623853 0 1 -1
between,ssris 1.0 0.000143348623853 0 1 -1
proteins,indicate 1.0 0.000143348623853 0 1 -1
pentobarbital-induced,sedation 1.0 0.000143348623853 0 1 -1
exacerbate,the 1.0 0.00043004587156 3 0 3
interaction,could 1.0 0.000143348623853 0 1 -1
thiazides,should 1.0 0.000286697247706 0 2 -2
initiating,tcatreatment 1.0 0.000143348623853 1 0 1
acid,channel 1.0 0.000286697247706 0 2 -2
arising,from 1.0 0.000143348623853 0 1 -1
inhibitor,cannot 1.0 0.000143348623853 0 1 -1
the,substances 1.0 0.000143348623853 0 1 -1
orders,of 1.0 0.000143348623853 0 1 -1
marked,effect 1.0 0.000143348623853 1 0 1
threatening,cardiac 1.0 0.000143348623853 1 0 1
recognized,that 1.0 0.00043004587156 0 3 -3
tumor,vascularity 1.0 0.000143348623853 0 1 -1
of,particularly 1.0 0.000143348623853 1 0 1
be,ascertained 1.0 0.000143348623853 0 1 -1
small,increase 1.0 0.000143348623853 0 1 -1
cpk,were 1.0 0.000143348623853 0 1 -1
interaction,would 1.0 0.000286697247706 0 2 -2
concentrations,increase 1.0 0.000143348623853 1 0 1
hit,in 1.0 0.000143348623853 0 1 -1
rifampin,increases 1.0 0.000143348623853 1 0 1
aeds,in 1.0 0.000143348623853 1 0 1
interactions,vardenafil 1.0 0.000143348623853 0 1 -1
was,altered 1.0 0.000286697247706 0 2 -2
to,these 0.333333333333 0.000143348623853 2 1 1
carbamazepine,epoxide 1.0 0.000143348623853 0 1 -1
administered,could 1.0 0.000143348623853 0 1 -1
day,divided 1.0 0.000143348623853 1 0 1
bioassay,procedures 1.0 0.000143348623853 0 1 -1
flexure,of 1.0 0.000143348623853 0 1 -1
at,baseline 1.0 0.00043004587156 0 3 -3
however,concomitant 0.0 0.0 1 1 0
increase,sensitivity 0.0 0.0 2 2 0
inducer,may 1.0 0.000143348623853 1 0 1
cyp3a4,there 1.0 0.000143348623853 0 1 -1
preceded,by 1.0 0.000143348623853 0 1 -1
activity,data 1.0 0.000143348623853 0 1 -1
discontinued,because 1.0 0.000143348623853 0 1 -1
reinforcing,effects 1.0 0.000143348623853 0 1 -1
whereas,urinary 1.0 0.000143348623853 0 1 -1
mealtime,dosing 1.0 0.000143348623853 0 1 -1
methadone,coadministration 1.0 0.000143348623853 1 0 1
iii,and 1.0 0.000286697247706 0 2 -2
episode,of 1.0 0.000143348623853 0 1 -1
upward,the 1.0 0.000143348623853 1 0 1
therefore,extreme 1.0 0.000143348623853 1 0 1
trend,to 1.0 0.000143348623853 0 1 -1
this,secretory 1.0 0.000143348623853 0 1 -1
of,serum 0.619047619048 0.00186353211009 4 17 -13
measured,during 1.0 0.000143348623853 0 1 -1
were,conducted 0.8 0.00114678899083 1 9 -8
case,reports 0.5 0.000286697247706 1 3 -2
developed,in 1.0 0.000143348623853 1 0 1
case,per 1.0 0.000143348623853 0 1 -1
qt,qtc 1.0 0.000286697247706 0 2 -2
be,exceeded 1.0 0.000286697247706 2 0 2
nsaids,in 0.333333333333 0.000143348623853 1 2 -1
and,intravenously 1.0 0.000143348623853 1 0 1
competitive,displacement 1.0 0.000143348623853 0 1 -1
and,injectables 1.0 0.000143348623853 0 1 -1
inhibit,gastrointestinal 1.0 0.000143348623853 0 1 -1
mechanisms,will 1.0 0.000143348623853 0 1 -1
thioether,excretion 1.0 0.000143348623853 0 1 -1
reactions,develop 1.0 0.000143348623853 1 0 1
hunger,and 1.0 0.000143348623853 0 1 -1
killing,relative 1.0 0.000143348623853 0 1 -1
alters,hormone 1.0 0.000143348623853 0 1 -1
potentiating,the 1.0 0.000143348623853 0 1 -1
calcium,channel-blocking 1.0 0.000143348623853 0 1 -1
including,produce 1.0 0.000286697247706 2 0 2
bpm,and 1.0 0.000143348623853 0 1 -1
transits,or 1.0 0.000143348623853 0 1 -1
tarceva,dose 0.0 0.0 1 1 0
activity,transient 1.0 0.000143348623853 1 0 1
of,tail-flick 1.0 0.000143348623853 0 1 -1
containing,regimens 1.0 0.000143348623853 1 0 1
components,are 1.0 0.000286697247706 0 2 -2
that,or 0.333333333333 0.000143348623853 2 1 1
of,phosphatase 1.0 0.000143348623853 0 1 -1
potential,treatment 1.0 0.000143348623853 0 1 -1
when,taken 0.333333333333 0.000286697247706 2 4 -2
halved,and 1.0 0.000143348623853 1 0 1
th,week 1.0 0.000143348623853 0 1 -1
patients,guardians 1.0 0.000143348623853 0 1 -1
factor,assays 1.0 0.000143348623853 0 1 -1
the,test 0.0 0.0 1 1 0
in,contrast 1.0 0.00129013761468 0 9 -9
that,keppra 1.0 0.000143348623853 0 1 -1
therefore,such 1.0 0.000286697247706 2 0 2
reported,due 1.0 0.000143348623853 1 0 1
alpha-agonists,as 1.0 0.000143348623853 0 1 -1
substitution,test 1.0 0.000143348623853 1 0 1
majority,of 1.0 0.000573394495413 0 4 -4
elevated,serum 1.0 0.00186353211009 13 0 13
divided,doses 1.0 0.000143348623853 0 1 -1
a,serotonin 1.0 0.000143348623853 1 0 1
dependence,may 1.0 0.000143348623853 0 1 -1
in,urinary 0.5 0.000286697247706 3 1 2
to,when 1.0 0.000716743119266 5 0 5
achieved,within 1.0 0.000143348623853 0 1 -1
maximizing,benefit 1.0 0.000143348623853 0 1 -1
gram,positive 1.0 0.000143348623853 0 1 -1
glibenclamide,in 1.0 0.000143348623853 1 0 1
nystagmus,strabismus 1.0 0.000143348623853 0 1 -1
medicine,due 1.0 0.000143348623853 0 1 -1
cmax,levels 1.0 0.000143348623853 0 1 -1
with,carbamazepine 1.0 0.000143348623853 1 0 1
synthesis,by 1.0 0.000286697247706 0 2 -2
in,reducing 1.0 0.000143348623853 1 0 1
with,acute 0.5 0.000286697247706 3 1 2
involved,concomitant 1.0 0.000143348623853 1 0 1
intraventricular,injection 0.333333333333 0.000143348623853 2 1 1
quinolones,may 1.0 0.000143348623853 1 0 1
serious,symptoms 1.0 0.000286697247706 2 0 2
subsalicylate,should 1.0 0.000143348623853 1 0 1
patients,lowered 1.0 0.000143348623853 1 0 1
malaria,mefloquine 1.0 0.000143348623853 0 1 -1
function,who 1.0 0.000286697247706 2 0 2
non-steroidal,agents 1.0 0.000286697247706 2 0 2
of,invirase 1.0 0.000143348623853 0 1 -1
affected,significantly 1.0 0.000143348623853 0 1 -1
cholesterol,subfraction 1.0 0.000286697247706 0 2 -2
than,users 1.0 0.000143348623853 1 0 1
relation,between 1.0 0.000143348623853 0 1 -1
case-control,and 1.0 0.000143348623853 1 0 1
inotropes,and 1.0 0.000143348623853 1 0 1
agents,having 0.333333333333 0.000143348623853 1 2 -1
concentrations,recognition 1.0 0.000143348623853 0 1 -1
thinners,may 1.0 0.000143348623853 1 0 1
indocin,reduces 1.0 0.000143348623853 0 1 -1
had,to 1.0 0.000143348623853 0 1 -1
hour,lag 1.0 0.000143348623853 0 1 -1
maximal,exercise 1.0 0.000143348623853 0 1 -1
as,of 1.0 0.000143348623853 0 1 -1
subcortical,structures 1.0 0.000143348623853 0 1 -1
these,events 1.0 0.000716743119266 0 5 -5
d,doses 1.0 0.000143348623853 0 1 -1
narcotic,such 1.0 0.000143348623853 1 0 1
abnormalities,has 1.0 0.000143348623853 0 1 -1
including,adverse 1.0 0.000143348623853 0 1 -1
serum,auc 1.0 0.000143348623853 1 0 1
and,bradyarrhythmias 1.0 0.000143348623853 0 1 -1
zalcitabine,inhibited 1.0 0.000143348623853 1 0 1
also,appeared 1.0 0.000143348623853 1 0 1
recovery,of 0.0 0.0 2 2 0
also,albumin 1.0 0.000143348623853 0 1 -1
or,including 1.0 0.000143348623853 0 1 -1
to,pooled 1.0 0.000143348623853 0 1 -1
of,dry 1.0 0.000143348623853 1 0 1
and,compromise 1.0 0.000143348623853 1 0 1
have,pre-existing 1.0 0.000143348623853 1 0 1
intake,approximately 1.0 0.000143348623853 1 0 1
failure,who 1.0 0.000143348623853 0 1 -1
most,subjects 1.0 0.000143348623853 1 0 1
affect,central 1.0 0.000143348623853 0 1 -1
probenecid,a 1.0 0.000143348623853 0 1 -1
either,inhibit 1.0 0.000143348623853 1 0 1
pesticides,this 1.0 0.000143348623853 0 1 -1
transferase,gst 1.0 0.000143348623853 0 1 -1
drug,effect 1.0 0.000143348623853 0 1 -1
pharmacological,interaction 0.0 0.0 1 1 0
of,prostigmin 1.0 0.000143348623853 0 1 -1
starting,dose 1.0 0.000286697247706 0 2 -2
cells,compared 1.0 0.000143348623853 0 1 -1
warning,potential 1.0 0.000143348623853 0 1 -1
including,the 1.0 0.000573394495413 0 4 -4
screening,patients 1.0 0.000143348623853 0 1 -1
to,lessen 1.0 0.000143348623853 0 1 -1
severe,hypoglycemia 1.0 0.000860091743119 6 0 6
utility,of 1.0 0.000143348623853 0 1 -1
blocking,cardiac 1.0 0.000143348623853 1 0 1
degree,should 1.0 0.000143348623853 0 1 -1
quickens,the 1.0 0.000143348623853 1 0 1
or,angiotensin 1.0 0.000143348623853 0 1 -1
the,ninth 1.0 0.000143348623853 0 1 -1
difference,exists 1.0 0.000143348623853 0 1 -1
coagulation,tests 1.0 0.000573394495413 0 4 -4
cr,lower 1.0 0.000143348623853 1 0 1
as,valium 1.0 0.000143348623853 1 0 1
c19,weak 1.0 0.000143348623853 0 1 -1
proliferation,of 1.0 0.00043004587156 3 0 3
whether,also 1.0 0.000143348623853 0 1 -1
refractory,to 1.0 0.000143348623853 1 0 1
containing,should 1.0 0.000143348623853 0 1 -1
the,depressant 1.0 0.000143348623853 1 0 1
because,severe 1.0 0.000286697247706 2 0 2
with,mg 0.0697674418605 0.00043004587156 23 20 3
of,duragesic 1.0 0.000143348623853 1 0 1
with,ml 1.0 0.000143348623853 1 0 1
with,drugs 1.0 0.000573394495413 0 4 -4
plasma,concentration-time 0.333333333333 0.000143348623853 1 2 -1
a,maintenance 0.5 0.000286697247706 3 1 2
sd,cumulative 1.0 0.000143348623853 0 1 -1
accumbens,but 1.0 0.000143348623853 0 1 -1
mm,or 1.0 0.000143348623853 0 1 -1
additive,adverse 1.0 0.000143348623853 1 0 1
elevation,of 0.272727272727 0.00043004587156 7 4 3
the,activation 0.333333333333 0.000143348623853 1 2 -1
hcl,special 1.0 0.000143348623853 0 1 -1
necessitated,changes 1.0 0.000143348623853 1 0 1
implication,that 1.0 0.000143348623853 1 0 1
failure,may 1.0 0.000143348623853 0 1 -1
secretion,p-aminosalicylic 1.0 0.000143348623853 0 1 -1
maintenance,level 0.0 0.0 1 1 0
gleevec,with 1.0 0.000286697247706 2 0 2
minutes,any 1.0 0.000143348623853 1 0 1
three,clinical 1.0 0.000143348623853 0 1 -1
of,bradycardia 1.0 0.000143348623853 0 1 -1
abdominal,irradiation 1.0 0.000143348623853 0 1 -1
the,nature 1.0 0.000286697247706 0 2 -2
than,those 0.5 0.000286697247706 3 1 2
study,indicates 1.0 0.000143348623853 0 1 -1
original,medication 1.0 0.000143348623853 0 1 -1
b-lactam,co-administration 1.0 0.000143348623853 1 0 1
before,there 1.0 0.000143348623853 0 1 -1
duodenum,and 1.0 0.000143348623853 0 1 -1
no,interactions 1.0 0.00172018348624 0 12 -12
a4,c19 1.0 0.000143348623853 0 1 -1
the,available 1.0 0.000143348623853 0 1 -1
differs,from 1.0 0.000143348623853 0 1 -1
effects,seen 0.0 0.0 1 1 0
pharmacokinetics,auc 1.0 0.000143348623853 0 1 -1
inducers,inhibitors 1.0 0.000143348623853 1 0 1
normal,fat 1.0 0.000143348623853 0 1 -1
with,experimental 1.0 0.000143348623853 1 0 1
exposure,when 1.0 0.000143348623853 1 0 1
upon,chylomicron 1.0 0.000143348623853 0 1 -1
had,little 1.0 0.000143348623853 0 1 -1
then,titrated 1.0 0.000143348623853 1 0 1
antagonism,exists 1.0 0.00043004587156 3 0 3
titers,may 1.0 0.000143348623853 0 1 -1
the,fraction 1.0 0.00100344036697 0 7 -7
where,serious 1.0 0.000143348623853 0 1 -1
oral,in 1.0 0.000573394495413 0 4 -4
or,copd 1.0 0.000286697247706 0 2 -2
been,administered 0.571428571429 0.00114678899083 3 11 -8
oral,is 1.0 0.000143348623853 1 0 1
omeprazole,is 1.0 0.000143348623853 0 1 -1
find,out 1.0 0.000143348623853 0 1 -1
by,after 1.0 0.00043004587156 0 3 -3
output,and 1.0 0.000286697247706 2 0 2
therefore,more 1.0 0.000143348623853 0 1 -1
metabolite,has 1.0 0.000143348623853 0 1 -1
sans,fronti 1.0 0.000143348623853 0 1 -1
potent,inhibition 1.0 0.000143348623853 0 1 -1
studied,extensively 1.0 0.000143348623853 0 1 -1
nrtis,are 1.0 0.000143348623853 0 1 -1
derivative,while 1.0 0.000143348623853 0 1 -1
ras,during 1.0 0.000286697247706 0 2 -2
to,inhibit 0.2 0.00043004587156 6 9 -3
was,separated 0.0 0.0 1 1 0
administered,dilute 1.0 0.000143348623853 0 1 -1
function,care 1.0 0.000143348623853 0 1 -1
known,drug 1.0 0.000143348623853 0 1 -1
cells,but 1.0 0.000143348623853 1 0 1
demonstrated,no 1.0 0.000716743119266 0 5 -5
index,of 1.0 0.000573394495413 0 4 -4
mg,also 1.0 0.000143348623853 0 1 -1
two,groups 1.0 0.00043004587156 0 3 -3
are,tolerated 1.0 0.000143348623853 0 1 -1
locomotor,activities 1.0 0.000286697247706 0 2 -2
index,or 1.0 0.000143348623853 0 1 -1
dopamine-induced,renal 1.0 0.000143348623853 0 1 -1
hyperpyrexia,eight 1.0 0.000143348623853 0 1 -1
pharmacokinetic,data 0.333333333333 0.000286697247706 4 2 2
day,are 1.0 0.000286697247706 0 2 -2
and,cushingoid 1.0 0.000143348623853 0 1 -1
check,serum 1.0 0.000143348623853 0 1 -1
increased,exposures 0.333333333333 0.000143348623853 2 1 1
s,solution 1.0 0.00043004587156 0 3 -3
neither,subject 1.0 0.000143348623853 0 1 -1
assigned,in 1.0 0.000143348623853 0 1 -1
alone,vs 1.0 0.000143348623853 0 1 -1
may,modify 1.0 0.000143348623853 0 1 -1
in,inhibition 1.0 0.000143348623853 1 0 1
possibly,related 1.0 0.000143348623853 1 0 1
enterococci,highlights 1.0 0.000143348623853 0 1 -1
or,laboratory 1.0 0.000143348623853 0 1 -1
class,see 1.0 0.000143348623853 1 0 1
if,patients 0.0 0.0 1 1 0
of,drug 1.0 0.00043004587156 0 3 -3
ig,for 1.0 0.000143348623853 1 0 1
relevance,of 0.777777777778 0.00100344036697 1 8 -7
recommended,as 1.0 0.000143348623853 0 1 -1
measures,for 1.0 0.000143348623853 0 1 -1
from,eggs 1.0 0.000143348623853 0 1 -1
recommended,at 1.0 0.000143348623853 0 1 -1
vioxx,concomitantly 1.0 0.000143348623853 1 0 1
for,many 1.0 0.000143348623853 0 1 -1
blocks,and 0.6 0.00043004587156 4 1 3
diminish,fluoride 1.0 0.000143348623853 0 1 -1
enhance,activity 1.0 0.000143348623853 1 0 1
up,a 1.0 0.000143348623853 0 1 -1
with,beta-receptor 1.0 0.000143348623853 0 1 -1
each,be 1.0 0.000143348623853 1 0 1
exposure,is 1.0 0.000143348623853 0 1 -1
exposure,in 1.0 0.000860091743119 0 6 -6
to,moderate 0.333333333333 0.000143348623853 2 1 1
generally,recommended 1.0 0.000286697247706 2 0 2
experience,of 1.0 0.000143348623853 1 0 1
certain,hmg-coa 1.0 0.000143348623853 1 0 1
with,baseline 1.0 0.000143348623853 0 1 -1
reactions,should 1.0 0.000143348623853 0 1 -1
with,dose 1.0 0.000143348623853 0 1 -1
fold,which 1.0 0.000143348623853 1 0 1
fe,per 1.0 0.000143348623853 1 0 1
ketones,in 1.0 0.000286697247706 0 2 -2
and,glucose 1.0 0.000143348623853 0 1 -1
mean,trough 0.333333333333 0.000143348623853 1 2 -1
or,fehlings 1.0 0.000143348623853 0 1 -1
keppra,is 1.0 0.000143348623853 0 1 -1
hepatotoxic,effects 1.0 0.000143348623853 1 0 1
initiating,tca 1.0 0.000573394495413 0 4 -4
studies,these 1.0 0.000143348623853 0 1 -1
of,fundus 1.0 0.000143348623853 0 1 -1
hormone,synthesis 1.0 0.000286697247706 0 2 -2
take,tricor 1.0 0.000143348623853 1 0 1
for,development 1.0 0.000143348623853 1 0 1
preparations,before 0.2 0.000143348623853 2 3 -1
are,likely 0.142857142857 0.000143348623853 3 4 -1
this,section 1.0 0.000573394495413 0 4 -4
first,experiment 1.0 0.000143348623853 0 1 -1
or,in 0.533333333333 0.00229357798165 7 23 -16
urine,has 1.0 0.000143348623853 0 1 -1
or,if 0.0 0.0 1 1 0
mg,by 1.0 0.000143348623853 1 0 1
inducing,activity 1.0 0.000143348623853 0 1 -1
product,interactions 1.0 0.000143348623853 0 1 -1
or,lime 1.0 0.000143348623853 0 1 -1
the,time 0.4 0.000573394495413 3 7 -4
conceived,while 1.0 0.000143348623853 0 1 -1
despite,the 1.0 0.000143348623853 0 1 -1
didanosine,co-administration 1.0 0.000143348623853 1 0 1
cholestyramine,increases 1.0 0.000143348623853 0 1 -1
luteus,mic 1.0 0.000143348623853 0 1 -1
monitoring,allows 1.0 0.000143348623853 0 1 -1
indocin,given 1.0 0.000143348623853 1 0 1
rewarming,was 1.0 0.000143348623853 0 1 -1
usual,amounts 1.0 0.000286697247706 0 2 -2
amiodarone,caused 1.0 0.000143348623853 0 1 -1
other,cardioactive 0.333333333333 0.000143348623853 1 2 -1
long,surgical 1.0 0.000143348623853 1 0 1
activator,binding 1.0 0.000143348623853 0 1 -1
auc,more 1.0 0.000143348623853 0 1 -1
that,transferred 1.0 0.000143348623853 0 1 -1
its,protein 1.0 0.000143348623853 1 0 1
theophylline-induced,anxiogenic 0.0 0.0 1 1 0
by,radioimmunoassay 1.0 0.000286697247706 0 2 -2
enhancing,absorption 1.0 0.000143348623853 1 0 1
aware,that 1.0 0.000143348623853 1 0 1
are,eclampsia 1.0 0.000143348623853 0 1 -1
interacting,with 1.0 0.000143348623853 0 1 -1
and,malignant 1.0 0.000286697247706 0 2 -2
administer,levsin 1.0 0.000143348623853 0 1 -1
initiating,therapy 1.0 0.000286697247706 2 0 2
glycemia,induced 1.0 0.000143348623853 0 1 -1
carefully,if 1.0 0.000143348623853 1 0 1
by,hour 1.0 0.000143348623853 1 0 1
tylenol,with 1.0 0.000143348623853 1 0 1
grapefruit,and 1.0 0.000143348623853 0 1 -1
carefully,in 1.0 0.000143348623853 0 1 -1
thrombin,or 1.0 0.000143348623853 0 1 -1
cyp1a2,is 0.0 0.0 1 1 0
theoretically,adversely 1.0 0.000143348623853 1 0 1
and,isoniazid 1.0 0.000143348623853 1 0 1
as,to 0.6 0.00043004587156 1 4 -3
and,diarrhea 1.0 0.000143348623853 1 0 1
d,have 1.0 0.000573394495413 0 4 -4
glucocorticoid-induced,gene 1.0 0.00043004587156 0 3 -3
bid,day 0.0 0.0 1 1 0
cyp1a2,in 1.0 0.000143348623853 0 1 -1
of,did 1.0 0.00100344036697 0 7 -7
because,nalfon 1.0 0.000143348623853 1 0 1
hypotension,caused 1.0 0.000143348623853 1 0 1
should,provide 1.0 0.000143348623853 0 1 -1
their,clearance 1.0 0.000143348623853 0 1 -1
are,important 1.0 0.000286697247706 0 2 -2
to,substrates 1.0 0.000143348623853 0 1 -1
cause,changes 1.0 0.000286697247706 2 0 2
initiated,cell 1.0 0.000143348623853 0 1 -1
glucose,lowering 1.0 0.000143348623853 1 0 1
nervous,e-strain 1.0 0.000143348623853 0 1 -1
auc0-24hr,in 0.0 0.0 1 1 0
treatment,cessation 1.0 0.000143348623853 0 1 -1
a,cause 1.0 0.000143348623853 1 0 1
with,maleate 1.0 0.000143348623853 1 0 1
any,alterations 1.0 0.000143348623853 0 1 -1
co-activator,in 1.0 0.000143348623853 0 1 -1
nonlinear,weighted 1.0 0.000143348623853 0 1 -1
took,min 1.0 0.000286697247706 2 0 2
begin,taking 1.0 0.000143348623853 1 0 1
essential,tissue 1.0 0.000143348623853 0 1 -1
gl,with 0.0 0.0 1 1 0
glucuronidation,of 1.0 0.000143348623853 0 1 -1
decrease,sprycel 1.0 0.000143348623853 0 1 -1
animal,model 1.0 0.000143348623853 1 0 1
of,effect 1.0 0.000286697247706 0 2 -2
stable,dosage 0.2 0.000143348623853 2 3 -1
one,man 1.0 0.000143348623853 1 0 1
non,soluble 1.0 0.000143348623853 0 1 -1
diabetes,medicine 1.0 0.000143348623853 1 0 1
already,stabilized 0.0 0.0 1 1 0
platelets,plays 1.0 0.000143348623853 0 1 -1
aspecific,treatments 1.0 0.000143348623853 0 1 -1
solutions,should 1.0 0.000143348623853 0 1 -1
therapy,in 0.0 0.0 2 2 0
of,buforin 1.0 0.000286697247706 0 2 -2
therapy,if 1.0 0.000143348623853 1 0 1
mutagenesis,pegasys 1.0 0.000143348623853 0 1 -1
interactions,no 1.0 0.000860091743119 0 6 -6
therapy,it 1.0 0.000143348623853 1 0 1
sleeping,sickness 1.0 0.000143348623853 0 1 -1
combining,with 0.0 0.0 1 1 0
broth,using 1.0 0.000143348623853 0 1 -1
prudent,medical 1.0 0.000143348623853 1 0 1
biliary,route 1.0 0.000143348623853 0 1 -1
inappropriate,being 1.0 0.000143348623853 0 1 -1
the,types 1.0 0.000286697247706 0 2 -2
alertness,and 1.0 0.000286697247706 2 0 2
remains,constant 1.0 0.000143348623853 0 1 -1
taken,concomitantly 0.428571428571 0.00043004587156 2 5 -3
bound,should 1.0 0.000286697247706 0 2 -2
or,metabolite 1.0 0.000143348623853 0 1 -1
reported,by 1.0 0.000286697247706 0 2 -2
received,plus 1.0 0.000143348623853 0 1 -1
binding,globulin 1.0 0.00043004587156 0 3 -3
crossover,double-blind 1.0 0.000143348623853 0 1 -1
pharmacokinetics,pharmacodynamics 1.0 0.000286697247706 0 2 -2
after,and 1.0 0.000143348623853 1 0 1
for,at 0.666666666667 0.000573394495413 1 5 -4
for,as 1.0 0.000143348623853 0 1 -1
improve,the 1.0 0.000286697247706 0 2 -2
for,an 0.428571428571 0.00043004587156 2 5 -3
elevating,duodenal 1.0 0.000143348623853 1 0 1
becomes,complete 1.0 0.000143348623853 0 1 -1
urinary,recovery 1.0 0.000143348623853 0 1 -1
large,quantities 1.0 0.000143348623853 0 1 -1
of,ames 1.0 0.000143348623853 0 1 -1
protease,inhibitors 0.142857142857 0.000286697247706 6 8 -2
coadministered,although 1.0 0.000143348623853 0 1 -1
clastogenic,to 1.0 0.000143348623853 0 1 -1
is,intricately 1.0 0.000143348623853 0 1 -1
cells,at 1.0 0.000143348623853 0 1 -1
increased,effects 0.0 0.0 2 2 0
when,amines 1.0 0.000143348623853 1 0 1
and,hydroxydesloratadine 1.0 0.000286697247706 0 2 -2
may,if 1.0 0.000143348623853 0 1 -1
striatal,but 1.0 0.000143348623853 1 0 1
thiazide,to 1.0 0.000286697247706 2 0 2
occur,potentiating 1.0 0.000143348623853 0 1 -1
given,or 1.0 0.000143348623853 0 1 -1
dose,resulted 0.333333333333 0.000143348623853 1 2 -1
exhibited,no 1.0 0.000143348623853 0 1 -1
slightly,enhance 1.0 0.000143348623853 1 0 1
be,cyp 1.0 0.000286697247706 2 0 2
its,vasculature 1.0 0.000143348623853 0 1 -1
serious,sometimes 1.0 0.000286697247706 2 0 2
agents,nsaids 1.0 0.000286697247706 2 0 2
administration,trough 1.0 0.000143348623853 0 1 -1
signalling,or 1.0 0.000143348623853 0 1 -1
adverse,reaction 1.0 0.000573394495413 0 4 -4
insufficient,intake 1.0 0.000143348623853 0 1 -1
mean,sem 1.0 0.000143348623853 0 1 -1
not,necessary 1.0 0.000143348623853 0 1 -1
of,potent 0.0 0.0 1 1 0
aminotransferase,sgot 1.0 0.000143348623853 0 1 -1
to,bleeding 1.0 0.000143348623853 1 0 1
of,hydrophobic 1.0 0.000143348623853 0 1 -1
enzymes,evaluated 1.0 0.000143348623853 0 1 -1
urine,immunoreactive 1.0 0.000143348623853 0 1 -1
hiv-nhl,who 1.0 0.000143348623853 0 1 -1
diagnostic,dip-stick 1.0 0.000143348623853 0 1 -1
phenylbutazone,phenylbutazone 1.0 0.000143348623853 1 0 1
cyp3a4,would 1.0 0.000286697247706 0 2 -2
the,world 1.0 0.000286697247706 0 2 -2
and,laboratory 1.0 0.00100344036697 0 7 -7
major,metabolic 1.0 0.000143348623853 0 1 -1
potential,drug 1.0 0.000286697247706 0 2 -2
of,to 0.05 0.000286697247706 21 19 2
that,glucose 1.0 0.000860091743119 0 6 -6
on,pentagastrin- 1.0 0.000143348623853 0 1 -1
decreases,in 0.0769230769231 0.000143348623853 7 6 1
subclone,of 1.0 0.000143348623853 0 1 -1
human,cells 1.0 0.000143348623853 0 1 -1
are,co 1.0 0.000143348623853 1 0 1
complex,effect 1.0 0.000143348623853 1 0 1
such,users 1.0 0.000143348623853 0 1 -1
atrophy,was 1.0 0.000143348623853 0 1 -1
established,but 0.5 0.000286697247706 1 3 -2
sensipar,sensipar 1.0 0.000143348623853 0 1 -1
d,concentrations 1.0 0.00043004587156 0 3 -3
have,additive 1.0 0.000573394495413 4 0 4
of,t4 1.0 0.000143348623853 0 1 -1
certain,other 1.0 0.000143348623853 0 1 -1
titration,should 1.0 0.000143348623853 0 1 -1
will,be 0.555555555556 0.000716743119266 2 7 -5
tbg,concentrations 1.0 0.000143348623853 0 1 -1
no,are 1.0 0.000143348623853 0 1 -1
h-spiroperidol,binding 1.0 0.000143348623853 0 1 -1
task,considered 1.0 0.000143348623853 0 1 -1
binding,experiments 1.0 0.000143348623853 0 1 -1
having,a 1.0 0.00043004587156 0 3 -3
inhibitors,mao 1.0 0.000143348623853 0 1 -1
selective,inhibitors 1.0 0.000143348623853 0 1 -1
on,mhd 1.0 0.000143348623853 0 1 -1
schizophrenic,patients 0.333333333333 0.000143348623853 2 1 1
dosing,requirements 1.0 0.000143348623853 0 1 -1
ephedrine,may 1.0 0.000143348623853 1 0 1
here,commonly 1.0 0.000143348623853 0 1 -1
identical,but 1.0 0.000143348623853 0 1 -1
receiving,brovana 1.0 0.000143348623853 0 1 -1
when,given 0.128205128205 0.000716743119266 17 22 -5
short-lasting,as 1.0 0.000143348623853 0 1 -1
single,tonic 1.0 0.000143348623853 0 1 -1
be,directed 1.0 0.000143348623853 1 0 1
highest,level 1.0 0.000143348623853 0 1 -1
epidemiological,studies 1.0 0.000143348623853 1 0 1
felbatol,causes 1.0 0.00043004587156 3 0 3
interaction,probably 1.0 0.000143348623853 1 0 1
levels,were 0.0769230769231 0.000143348623853 7 6 1
within14,days 1.0 0.000143348623853 1 0 1
mrna,in 1.0 0.000143348623853 0 1 -1
isoform,is 1.0 0.000143348623853 0 1 -1
mepron,concurrently 1.0 0.000143348623853 0 1 -1
astringents,spices 1.0 0.000143348623853 0 1 -1
and,safely 1.0 0.000143348623853 0 1 -1
were,not 0.924528301887 0.00702408256881 2 51 -49
is,consistent 1.0 0.000143348623853 0 1 -1
common,findings 1.0 0.000143348623853 0 1 -1
with,gastrointestinal 1.0 0.000143348623853 1 0 1
and,valproic 0.333333333333 0.000143348623853 2 1 1
would,permit 1.0 0.000143348623853 0 1 -1
between,apokyn 1.0 0.000143348623853 0 1 -1
cause,dna 1.0 0.000143348623853 0 1 -1
and,served 1.0 0.000143348623853 0 1 -1
the,anesthesiologist 1.0 0.000286697247706 0 2 -2
additionally,anti-malarial 1.0 0.000143348623853 1 0 1
of,homocysteine 1.0 0.000143348623853 0 1 -1
o,induced 1.0 0.000143348623853 1 0 1
complex,concentrates 1.0 0.000143348623853 0 1 -1
the,enteric 0.0 0.0 1 1 0
a,third 1.0 0.000143348623853 0 1 -1
different,days 1.0 0.000143348623853 0 1 -1
sodium,or 1.0 0.000143348623853 1 0 1
precise,and 1.0 0.000143348623853 0 1 -1
changed,to 1.0 0.000143348623853 0 1 -1
the,antidiarrheal 1.0 0.000143348623853 0 1 -1
neither,sufficient 1.0 0.000143348623853 0 1 -1
treated,according 1.0 0.000143348623853 0 1 -1
and,ulcerative 1.0 0.000143348623853 1 0 1
the,day-to 1.0 0.000143348623853 0 1 -1
h,for 1.0 0.000143348623853 0 1 -1
depression,hallucinations 1.0 0.000143348623853 0 1 -1
no,alteration 1.0 0.00043004587156 0 3 -3
especially,the 1.0 0.000143348623853 1 0 1
a,narrower 1.0 0.000143348623853 0 1 -1
and,induction 1.0 0.000143348623853 0 1 -1
state,in 1.0 0.000143348623853 0 1 -1
cerebyx,were 1.0 0.000143348623853 0 1 -1
severe,enterocolitis 1.0 0.000143348623853 1 0 1
increased,metabolism 1.0 0.000573394495413 4 0 4
indinavir-based,regimens 1.0 0.000143348623853 0 1 -1
if,an 0.333333333333 0.000143348623853 1 2 -1
is,maintained 1.0 0.000143348623853 0 1 -1
of,formal 1.0 0.000143348623853 0 1 -1
accordingly,renal 1.0 0.000143348623853 0 1 -1
cytogenetics,study 1.0 0.000143348623853 0 1 -1
recovery,from 0.333333333333 0.000143348623853 1 2 -1
estrogenic,component 1.0 0.000143348623853 0 1 -1
following,concomitant 0.272727272727 0.00043004587156 7 4 3
lowered,from 1.0 0.000143348623853 0 1 -1
on,potassium 1.0 0.000143348623853 1 0 1
article,reported 1.0 0.000143348623853 1 0 1
study,patients 1.0 0.00043004587156 0 3 -3
consideration,should 0.25 0.000286697247706 3 5 -2
lowest,effective 1.0 0.000286697247706 2 0 2
studies,some 1.0 0.000143348623853 0 1 -1
been,little 1.0 0.000143348623853 0 1 -1
when,alfenta 1.0 0.000143348623853 1 0 1
considering,the 1.0 0.000143348623853 1 0 1
for,peroral 1.0 0.000143348623853 0 1 -1
sleep,time 1.0 0.000143348623853 0 1 -1
nor,does 1.0 0.00043004587156 0 3 -3
some,instances 1.0 0.000286697247706 2 0 2
dogs,the 1.0 0.000143348623853 1 0 1
the,nucleus 1.0 0.000143348623853 0 1 -1
hydroxyphenyl,piperidine 1.0 0.000143348623853 1 0 1
when,this 0.333333333333 0.000143348623853 1 2 -1
tml,manifested 1.0 0.000143348623853 0 1 -1
memory,that 1.0 0.000286697247706 0 2 -2
clearances,of 1.0 0.000143348623853 1 0 1
site,fecal 1.0 0.000143348623853 0 1 -1
of,diabetes 1.0 0.00043004587156 0 3 -3
submitted,to 1.0 0.00043004587156 0 3 -3
suspension,can 1.0 0.000286697247706 0 2 -2
dose,at 1.0 0.000286697247706 0 2 -2
acarbose,due 1.0 0.000143348623853 1 0 1
inflammation,associated 1.0 0.000143348623853 1 0 1
nor,binding 1.0 0.000143348623853 0 1 -1
contraception,during 1.0 0.000143348623853 1 0 1
be,interpreted 1.0 0.000573394495413 0 4 -4
exogenously,infused 1.0 0.000143348623853 0 1 -1
mean,values 1.0 0.000143348623853 0 1 -1
h,concomitant 1.0 0.000143348623853 0 1 -1
drug,metabolizing 1.0 0.00043004587156 0 3 -3
on,separate 1.0 0.000143348623853 1 0 1
those,used 1.0 0.000286697247706 0 2 -2
antagonists,is 1.0 0.000143348623853 1 0 1
or,known 1.0 0.000143348623853 1 0 1
vivo,resulted 1.0 0.000143348623853 0 1 -1
factor,concentrates 1.0 0.000143348623853 0 1 -1
drug,clearance 1.0 0.000143348623853 0 1 -1
preparation,causing 1.0 0.000143348623853 1 0 1
the,elderly 0.333333333333 0.000286697247706 2 4 -2
auc,higher 1.0 0.000143348623853 1 0 1
growing,problem 1.0 0.000143348623853 0 1 -1
cmc-cys,exhibiting 1.0 0.000143348623853 0 1 -1
after,min 1.0 0.000143348623853 0 1 -1
antagonists,in 1.0 0.000286697247706 0 2 -2
p450,enzymes 0.818181818182 0.00129013761468 1 10 -9
partner,causes 1.0 0.000143348623853 0 1 -1
activity,but 1.0 0.000286697247706 0 2 -2
estradiol,were 1.0 0.000143348623853 0 1 -1
the,ureidopenicillins 1.0 0.000143348623853 1 0 1
pcp,treatment 1.0 0.000143348623853 1 0 1
in,fold 1.0 0.000143348623853 1 0 1
include,azole 1.0 0.000143348623853 0 1 -1
report,which 1.0 0.000143348623853 1 0 1
trans-3,dimethyl-4 1.0 0.000143348623853 1 0 1
mellitus,may 1.0 0.000143348623853 0 1 -1
dihydropyridine,channel 1.0 0.000143348623853 1 0 1
dogs,in 1.0 0.000143348623853 0 1 -1
co-administer,and 1.0 0.000143348623853 1 0 1
plus,avastin 1.0 0.000143348623853 0 1 -1
intravenous,use 1.0 0.000143348623853 0 1 -1
similar,affinities 1.0 0.000143348623853 0 1 -1
bactericidal,activity 1.0 0.000143348623853 0 1 -1
in,platelet 1.0 0.00043004587156 0 3 -3
healthy,subject 1.0 0.000143348623853 0 1 -1
only,be 0.333333333333 0.000143348623853 2 1 1
taking,metabolized 1.0 0.000143348623853 0 1 -1
metabolized,through 1.0 0.00043004587156 0 3 -3
after,multiple-dose 1.0 0.000143348623853 0 1 -1
was,compared 1.0 0.000143348623853 0 1 -1
reportedly,may 1.0 0.000286697247706 2 0 2
evaluating,abnormal 1.0 0.000143348623853 0 1 -1
disodium,in 1.0 0.000143348623853 1 0 1
account,when 1.0 0.000143348623853 0 1 -1
uricosuric,agents 0.5 0.000286697247706 3 1 2
a,strong 0.333333333333 0.00043004587156 6 3 3
as,for 1.0 0.000286697247706 0 2 -2
alterations,associated 1.0 0.000143348623853 0 1 -1
malignant,cells 1.0 0.000143348623853 1 0 1
action,in 1.0 0.000143348623853 0 1 -1
nephrotoxicity,frequently 1.0 0.000143348623853 0 1 -1
desirable,or 1.0 0.000286697247706 0 2 -2
exhibit,minimal 1.0 0.000143348623853 0 1 -1
cardiovascular,action 1.0 0.000143348623853 1 0 1
act,on 0.0 0.0 1 1 0
hemodynamic,and 1.0 0.000143348623853 0 1 -1
an,mg 1.0 0.000143348623853 0 1 -1
increased,vasoconstriction 1.0 0.000143348623853 1 0 1
possibility,nitric 1.0 0.000143348623853 1 0 1
diplopia,dysarthria 1.0 0.000143348623853 0 1 -1
pharmacist,can 1.0 0.000143348623853 0 1 -1
collected,on 1.0 0.000143348623853 0 1 -1
antiapoptotic,effect 1.0 0.000143348623853 0 1 -1
with,orally 1.0 0.000143348623853 1 0 1
ethopropazine,can 1.0 0.000143348623853 1 0 1
attenuate,some 1.0 0.000286697247706 0 2 -2
the,prothrombin 0.0666666666667 0.000143348623853 7 8 -1
including,ethacrynic 1.0 0.000143348623853 1 0 1
valium,and 1.0 0.000143348623853 1 0 1
several,have 1.0 0.000143348623853 1 0 1
by,about 0.555555555556 0.000716743119266 7 2 5
constant,was 1.0 0.000143348623853 0 1 -1
probenecid,given 1.0 0.000143348623853 1 0 1
arthritis,thyroiditis 1.0 0.000143348623853 1 0 1
year,monthly 1.0 0.000143348623853 0 1 -1
depleting,added 1.0 0.000143348623853 0 1 -1
depression,producing 1.0 0.000286697247706 0 2 -2
data,available 1.0 0.00043004587156 0 3 -3
trials,showed 1.0 0.000143348623853 0 1 -1
some,gram-positive 1.0 0.000143348623853 0 1 -1
by,during 1.0 0.000286697247706 0 2 -2
prescribing,for 1.0 0.000143348623853 0 1 -1
previously,unrecognized 1.0 0.000143348623853 1 0 1
are,direct 1.0 0.000143348623853 1 0 1
last,day 1.0 0.000143348623853 0 1 -1
a,newly 1.0 0.000143348623853 0 1 -1
misonidazole,protects 1.0 0.000143348623853 1 0 1
if,these 0.75 0.000860091743119 1 7 -6
responds,excessively 1.0 0.000143348623853 0 1 -1
and,even 0.333333333333 0.000143348623853 1 2 -1
receive,mg 0.0 0.0 1 1 0
drugs,metabolized 0.866666666667 0.00186353211009 1 14 -13
cyp3a4,inducing 1.0 0.000143348623853 0 1 -1
respond,to 1.0 0.000143348623853 0 1 -1
results,from 0.571428571429 0.00114678899083 3 11 -8
still,other 1.0 0.000143348623853 0 1 -1
most,excretion 1.0 0.000143348623853 0 1 -1
acid,oxolinic 1.0 0.000143348623853 1 0 1
in,dealing 1.0 0.000143348623853 0 1 -1
weeks,following 1.0 0.000143348623853 0 1 -1
differ,and 1.0 0.000143348623853 0 1 -1
at,these 1.0 0.000143348623853 1 0 1
adjuvant,treatment 1.0 0.000143348623853 1 0 1
in,day-old 1.0 0.000143348623853 0 1 -1
results,suggest 0.0909090909091 0.000143348623853 5 6 -1
are,contraindicated 0.333333333333 0.000143348623853 1 2 -1
excretion,a 1.0 0.000143348623853 0 1 -1
to,bovine 1.0 0.000143348623853 0 1 -1
was,preceded 1.0 0.000143348623853 0 1 -1
in,psychiatric 1.0 0.000143348623853 1 0 1
concern,regarding 1.0 0.000143348623853 0 1 -1
creatinine,have 1.0 0.000143348623853 0 1 -1
an,solution 1.0 0.000143348623853 0 1 -1
total,amount 1.0 0.000143348623853 0 1 -1
clinical,acumen 1.0 0.000143348623853 0 1 -1
of,insufficient 1.0 0.000143348623853 1 0 1
a,manner 1.0 0.000143348623853 0 1 -1
thioether,assay 1.0 0.000286697247706 0 2 -2
catecholamine,levels 1.0 0.000143348623853 0 1 -1
and,losartan 1.0 0.000143348623853 0 1 -1
incubation,in 1.0 0.000143348623853 0 1 -1
the,cyp3a4 0.2 0.000286697247706 4 6 -2
coating,that 1.0 0.000143348623853 0 1 -1
bladder,cancer 1.0 0.000143348623853 0 1 -1
of,taxotere 1.0 0.000143348623853 0 1 -1
and,acid-base 1.0 0.000143348623853 0 1 -1
levels,resulting 1.0 0.000143348623853 1 0 1
anesthetics,sedatives 1.0 0.000143348623853 1 0 1
single-dose,administration 1.0 0.000143348623853 0 1 -1
for,sustiva 1.0 0.000143348623853 0 1 -1
and,para-aminobenzoic 1.0 0.000143348623853 1 0 1
including,blood 1.0 0.000143348623853 0 1 -1
methodology,for 1.0 0.000143348623853 0 1 -1
artery,disease 1.0 0.000286697247706 0 2 -2
transport,systems 1.0 0.000286697247706 0 2 -2
by,these 1.0 0.000716743119266 0 5 -5
refludan,on 1.0 0.000143348623853 0 1 -1
motor,weakness 1.0 0.000143348623853 0 1 -1
required,it 1.0 0.000143348623853 1 0 1
required,in 1.0 0.000143348623853 0 1 -1
gentamycin,reduced 1.0 0.000143348623853 0 1 -1
to,control 0.0 0.0 4 4 0
adl,prevents 1.0 0.000143348623853 1 0 1
required,if 1.0 0.000716743119266 0 5 -5
was,followed 1.0 0.000143348623853 1 0 1
interaction,whole 1.0 0.000143348623853 1 0 1
the,stereoisomers 1.0 0.000143348623853 0 1 -1
blood,at 1.0 0.000143348623853 0 1 -1
used,to 0.692307692308 0.00258027522936 4 22 -18
blood-sugar,reducing 1.0 0.000143348623853 1 0 1
adrenergic,antagonists 1.0 0.000143348623853 1 0 1
an,unusually 1.0 0.000143348623853 1 0 1
its,binding 1.0 0.00043004587156 3 0 3
hormonal,co-administration 1.0 0.000143348623853 1 0 1
this,interference 1.0 0.000286697247706 0 2 -2
tiagabine,causes 1.0 0.000143348623853 1 0 1
an,omega-conotoxin 1.0 0.000143348623853 0 1 -1
significant,adverse 1.0 0.000143348623853 0 1 -1
pituitary,secretion 1.0 0.000143348623853 0 1 -1
receiving,antabuse 1.0 0.000143348623853 1 0 1
contraindications,significant 1.0 0.000143348623853 0 1 -1
metabolism,carbohydrate 1.0 0.000143348623853 0 1 -1
and,natural 1.0 0.000143348623853 0 1 -1
employed,in 1.0 0.000143348623853 0 1 -1
and,non- 1.0 0.000143348623853 1 0 1
tca,concentrations 1.0 0.000143348623853 1 0 1
days,there 1.0 0.000143348623853 0 1 -1
causes,no 1.0 0.000143348623853 0 1 -1
half,returned 1.0 0.000143348623853 0 1 -1
antagonists,and 0.0 0.0 4 4 0
reviewed,the 1.0 0.000143348623853 0 1 -1
alkaloids,should 1.0 0.000143348623853 1 0 1
cardioactive,compounds 1.0 0.000143348623853 1 0 1
the,enzyme 0.333333333333 0.000143348623853 1 2 -1
and,nonadditive 1.0 0.000143348623853 0 1 -1
the,cyp3a4-mediated 1.0 0.000143348623853 1 0 1
because,there 0.2 0.000143348623853 3 2 1
using,this 1.0 0.000286697247706 0 2 -2
best,tool 1.0 0.000143348623853 0 1 -1
topical,products 1.0 0.000143348623853 0 1 -1
for,plasma 1.0 0.000143348623853 0 1 -1
may,subject 1.0 0.000143348623853 0 1 -1
erythromycin,co-administration 1.0 0.000143348623853 0 1 -1
elements,were 1.0 0.000143348623853 0 1 -1
post-marketing,observations 1.0 0.00043004587156 3 0 3
to,maximize 1.0 0.000286697247706 0 2 -2
metabolic,disturbances 1.0 0.000143348623853 0 1 -1
to,treated 1.0 0.000143348623853 0 1 -1
results,raise 1.0 0.000143348623853 1 0 1
complexometric,methods 1.0 0.000143348623853 0 1 -1
increase,levels 1.0 0.000143348623853 0 1 -1
laboratory,assessments 1.0 0.000143348623853 0 1 -1
serum,reverse 1.0 0.000143348623853 0 1 -1
established,if 1.0 0.000143348623853 0 1 -1
trial,that 1.0 0.000143348623853 0 1 -1
failure,post-myocardial 1.0 0.000143348623853 0 1 -1
of,osteomalacia 1.0 0.000143348623853 0 1 -1
not,enhance 0.0 0.0 1 1 0
both,first 1.0 0.000143348623853 1 0 1
blood-sugar,levels 1.0 0.000143348623853 0 1 -1
colonic,transit-enhancing 1.0 0.000143348623853 0 1 -1
anticoagulants,interaction 1.0 0.000286697247706 0 2 -2
of,antigout 1.0 0.000143348623853 0 1 -1
human,bladder 1.0 0.000143348623853 0 1 -1
however,under 1.0 0.000143348623853 0 1 -1
radiolabeled,ions 1.0 0.000143348623853 0 1 -1
the,remainder 1.0 0.000286697247706 0 2 -2
patients,if 1.0 0.000143348623853 1 0 1
stopped,to 1.0 0.000143348623853 1 0 1
patients,in 0.571428571429 0.00114678899083 3 11 -8
hemiballismus,hyperreflexia 1.0 0.000143348623853 0 1 -1
of,tolerance 0.0 0.0 1 1 0
therapeutic,doses 0.2 0.000143348623853 2 3 -1
patients,is 0.333333333333 0.000143348623853 1 2 -1
antagonists,after 1.0 0.000143348623853 1 0 1
and,timing 1.0 0.000143348623853 0 1 -1
assessments,of 1.0 0.00043004587156 0 3 -3
the,sum 1.0 0.000143348623853 0 1 -1
steady-state,epoxide 1.0 0.000143348623853 1 0 1
steady-state,trough 0.111111111111 0.000143348623853 4 5 -1
predominantly,metabolized 0.0 0.0 2 2 0
use,cannot 1.0 0.000143348623853 0 1 -1
antagonism,has 1.0 0.000286697247706 2 0 2
chronic,obstructive 1.0 0.000143348623853 0 1 -1
preceding,lists 1.0 0.000143348623853 0 1 -1
have,their 0.2 0.000143348623853 2 3 -1
substrates,known 1.0 0.000143348623853 1 0 1
the,signs 0.5 0.000286697247706 1 3 -2
slightly,the 1.0 0.000143348623853 1 0 1
that,mesylate 1.0 0.000143348623853 0 1 -1
by,monitoring 1.0 0.000143348623853 0 1 -1
mean,additional 1.0 0.000143348623853 1 0 1
clinical,presentation 1.0 0.000143348623853 0 1 -1
not,clinically 1.0 0.000143348623853 0 1 -1
metabolizing,isozyme 1.0 0.000716743119266 0 5 -5
mc,mg 1.0 0.000143348623853 0 1 -1
day-to,day 1.0 0.000143348623853 0 1 -1
humans,remain 1.0 0.000143348623853 0 1 -1
limits,the 1.0 0.000143348623853 0 1 -1
to,detect 1.0 0.000143348623853 0 1 -1
of,humans 1.0 0.000143348623853 0 1 -1
differential-reinforcement,of-low 1.0 0.000143348623853 0 1 -1
deterioration,of 0.333333333333 0.000143348623853 2 1 1
cumulative,incidence 1.0 0.000143348623853 0 1 -1
nelfinavir,steady-state 1.0 0.000143348623853 1 0 1
excessive,effects 1.0 0.000143348623853 1 0 1
a,volatile 1.0 0.000143348623853 0 1 -1
rat,fibroblast 1.0 0.000143348623853 0 1 -1
altered,to 1.0 0.000143348623853 0 1 -1
was,ng 1.0 0.000143348623853 1 0 1
where,and 1.0 0.000143348623853 0 1 -1
was,no 0.84 0.00301032110092 2 23 -21
a,very 0.0 0.0 1 1 0
might,have 1.0 0.000286697247706 0 2 -2
for,active 0.0 0.0 1 1 0
pt,and 0.0 0.0 1 1 0
until,clinical 1.0 0.000143348623853 0 1 -1
with,serious 1.0 0.000286697247706 0 2 -2
weekly,doses 1.0 0.000143348623853 0 1 -1
which,blood 1.0 0.000143348623853 0 1 -1
the,anion 1.0 0.000143348623853 0 1 -1
can,potentially 0.0 0.0 1 1 0
pressor,agent 1.0 0.000286697247706 0 2 -2
nnrti-based,regimens 1.0 0.000143348623853 0 1 -1
non-opioid,agonist 1.0 0.000143348623853 0 1 -1
or,preanesthetic 1.0 0.000143348623853 0 1 -1
or,concurrently 1.0 0.000286697247706 2 0 2
dose,once 1.0 0.000143348623853 0 1 -1
in,cell 0.333333333333 0.000143348623853 1 2 -1
drug,combinations 1.0 0.000143348623853 0 1 -1
neuropathy,or 0.0 0.0 1 1 0
a,pharmacodynamic 1.0 0.000143348623853 1 0 1
detectable,effect 1.0 0.000143348623853 0 1 -1
azoles,are 1.0 0.000143348623853 0 1 -1
testicular,leydig 1.0 0.000143348623853 0 1 -1
enzyme,system 0.272727272727 0.00043004587156 4 7 -3
excretion,seen 1.0 0.000143348623853 1 0 1
levels,produced 1.0 0.000143348623853 0 1 -1
after,the 0.181818181818 0.000573394495413 9 13 -4
was,between 1.0 0.000143348623853 0 1 -1
any,new 1.0 0.000143348623853 0 1 -1
the,glucocorticoid-induced 1.0 0.000286697247706 0 2 -2
include,medications 1.0 0.000143348623853 0 1 -1
patients,anaesthetised 1.0 0.000143348623853 1 0 1
even,clozapine 1.0 0.000143348623853 0 1 -1
on,arteries 1.0 0.000143348623853 0 1 -1
analgesics,agonist 1.0 0.000143348623853 1 0 1
vomiting,diarrhea 1.0 0.000143348623853 0 1 -1
increases,gastrointestinal 1.0 0.000143348623853 1 0 1
severely,impaired 1.0 0.000143348623853 0 1 -1
high-dose,a 1.0 0.000143348623853 1 0 1
lansoprazole,causes 1.0 0.000143348623853 0 1 -1
clinical,course 1.0 0.000143348623853 0 1 -1
mic,of 1.0 0.000143348623853 0 1 -1
lowest,possible 1.0 0.000143348623853 1 0 1
programs,should 1.0 0.000143348623853 0 1 -1
dantrium,is 1.0 0.000143348623853 0 1 -1
channel,blockers 0.368421052632 0.00100344036697 13 6 7
of,endotoxin-treated 0.0 0.0 1 1 0
disorders,has 1.0 0.000143348623853 1 0 1
mc,decreases 1.0 0.000143348623853 0 1 -1
and,zidovudine 1.0 0.000143348623853 1 0 1
certain,tcas 1.0 0.000143348623853 1 0 1
aminoglycoside,are 1.0 0.000143348623853 1 0 1
frequently,observed 1.0 0.000143348623853 0 1 -1
when,bezalip 1.0 0.000286697247706 2 0 2
oh,metabolite 1.0 0.000143348623853 0 1 -1
glatiramer,acetate 1.0 0.000143348623853 0 1 -1
these,would 0.0 0.0 1 1 0
induction,tool 1.0 0.000143348623853 0 1 -1
data,show 1.0 0.000143348623853 1 0 1
data,regarding 1.0 0.000143348623853 0 1 -1
weekly,during 1.0 0.000286697247706 0 2 -2
severe,bradycardia 1.0 0.000143348623853 0 1 -1
subjects,receiving 0.454545454545 0.000716743119266 8 3 5
cure,rates 1.0 0.000143348623853 0 1 -1
oral,contraceptives 0.8 0.00114678899083 1 9 -8
approximately,ml 1.0 0.000143348623853 0 1 -1
of,several 0.6 0.00043004587156 1 4 -3
of,clinically 1.0 0.000860091743119 0 6 -6
magnesium-aluminum,hydroxide 1.0 0.000143348623853 0 1 -1
and,indirect 1.0 0.000143348623853 0 1 -1
some,that 1.0 0.000716743119266 0 5 -5
tolerance,allowing 1.0 0.000143348623853 0 1 -1
antiparkinsonian,agents 1.0 0.000143348623853 1 0 1
considered,to 0.6 0.00043004587156 1 4 -3
in,screening 1.0 0.000143348623853 0 1 -1
the,reports 1.0 0.000143348623853 1 0 1
of,plasma 0.142857142857 0.00043004587156 9 12 -3
excretion,too 1.0 0.000143348623853 0 1 -1
as,antiparkinson 1.0 0.000143348623853 1 0 1
these,should 0.2 0.000286697247706 4 6 -2
specificity,we 1.0 0.000143348623853 0 1 -1
synergistic,effect 0.333333333333 0.000143348623853 1 2 -1
more,specific 1.0 0.00043004587156 0 3 -3
a4,to 1.0 0.000143348623853 0 1 -1
efficient,labeling 1.0 0.000143348623853 0 1 -1
antihistamines,contraindicated 1.0 0.000143348623853 0 1 -1
the,zevalin 1.0 0.000143348623853 0 1 -1
metastasis,through 1.0 0.000143348623853 0 1 -1
from,nerves 1.0 0.000143348623853 0 1 -1
concentrations,just 1.0 0.000143348623853 0 1 -1
the,depression 1.0 0.000286697247706 2 0 2
its,metabolism 0.333333333333 0.000143348623853 1 2 -1
acquired,immunodeficiencies 1.0 0.000143348623853 0 1 -1
inhalational,muscle 1.0 0.000143348623853 0 1 -1
conversion,from 1.0 0.000143348623853 0 1 -1
furthermore,and 0.0 0.0 1 1 0
urate,are 1.0 0.000143348623853 1 0 1
or,toxicity 1.0 0.000143348623853 0 1 -1
may,undergo 1.0 0.000143348623853 0 1 -1
much,in 0.0 0.0 1 1 0
rate,in 1.0 0.000143348623853 0 1 -1
is,lower 1.0 0.000143348623853 0 1 -1
of,steps 1.0 0.000143348623853 0 1 -1
above,this 1.0 0.000143348623853 0 1 -1
combined,chemotherapy 1.0 0.000143348623853 0 1 -1
of,tachyarrhythmias 1.0 0.000143348623853 0 1 -1
signalled-unsignalled,differential-reinforcement 1.0 0.000143348623853 0 1 -1
nevirapine-,or 1.0 0.000143348623853 0 1 -1
and,renin 1.0 0.000143348623853 0 1 -1
used,on 1.0 0.000143348623853 0 1 -1
therapy,see 1.0 0.000143348623853 0 1 -1
rheumatic,disease 1.0 0.000143348623853 1 0 1
physicians,query 1.0 0.000143348623853 0 1 -1
elisa,and 1.0 0.000143348623853 0 1 -1
giving,superimposed 1.0 0.000143348623853 0 1 -1
endocrine,feedback 1.0 0.000143348623853 0 1 -1
predispose,to 1.0 0.000143348623853 0 1 -1
this,therapy 1.0 0.000143348623853 0 1 -1
the,reduced 1.0 0.00043004587156 0 3 -3
eggs,was 1.0 0.000143348623853 0 1 -1
to,low 1.0 0.000143348623853 0 1 -1
necrolysis,has 1.0 0.000143348623853 0 1 -1
conjugates,was 1.0 0.000143348623853 0 1 -1
are,compelling 1.0 0.000143348623853 0 1 -1
cfus,were 1.0 0.000143348623853 0 1 -1
sores,or 1.0 0.000143348623853 0 1 -1
coumarin,type 1.0 0.000143348623853 0 1 -1
the,cns-impairing 1.0 0.000143348623853 1 0 1
celebrex,may 1.0 0.000143348623853 1 0 1
related,both 1.0 0.000143348623853 0 1 -1
maintain,levels 1.0 0.000143348623853 1 0 1
by,interaction 1.0 0.000143348623853 1 0 1
tendon,reflexes 1.0 0.000143348623853 0 1 -1
already,seen 1.0 0.000143348623853 0 1 -1
udp-glucuronyl,transferase 1.0 0.000286697247706 0 2 -2
angina,patients 1.0 0.000143348623853 0 1 -1
importance,to 1.0 0.000143348623853 0 1 -1
and,consensus 1.0 0.000143348623853 0 1 -1
of,interference 1.0 0.000286697247706 0 2 -2
patients,combined 1.0 0.000143348623853 1 0 1
downward,dose 1.0 0.000143348623853 1 0 1
repeating,the 1.0 0.000143348623853 0 1 -1
one,should 1.0 0.000143348623853 0 1 -1
of,sn38 1.0 0.000143348623853 0 1 -1
phenobarbital,toxicity 1.0 0.000143348623853 1 0 1
in,increasing 1.0 0.000143348623853 0 1 -1
unchanged,hours 1.0 0.000143348623853 0 1 -1
mg,combined 1.0 0.000143348623853 1 0 1
oral,antifungal 1.0 0.000143348623853 1 0 1
constellation,of 1.0 0.000143348623853 1 0 1
topo,in 1.0 0.000143348623853 0 1 -1
and,coexisting 1.0 0.000143348623853 0 1 -1
initiation,is 1.0 0.000143348623853 0 1 -1
of,averaged 1.0 0.000143348623853 1 0 1
dose,had 1.0 0.000573394495413 0 4 -4
limited,experience 1.0 0.000286697247706 0 2 -2
with,coronary 1.0 0.00100344036697 0 7 -7
evaluated,the 1.0 0.000286697247706 0 2 -2
additive,pharmacodynamic 1.0 0.000143348623853 0 1 -1
prescribers,should 1.0 0.000143348623853 0 1 -1
when,serious 1.0 0.000143348623853 0 1 -1
dose,when 1.0 0.000286697247706 2 0 2
sulfonamide,is 1.0 0.000143348623853 1 0 1
trials,patients 1.0 0.000286697247706 0 2 -2
who,are 0.214285714286 0.000860091743119 17 11 6
short,s 1.0 0.000143348623853 0 1 -1
differences,can 1.0 0.000143348623853 0 1 -1
antibiotics,in 1.0 0.000143348623853 1 0 1
inhibiting,activity 1.0 0.000143348623853 0 1 -1
secretions,such 1.0 0.000143348623853 0 1 -1
have,cns 1.0 0.000143348623853 0 1 -1
of,maalox 1.0 0.000143348623853 0 1 -1
receiving,n 1.0 0.000143348623853 0 1 -1
discontinued,that 1.0 0.000143348623853 0 1 -1
mixed-function,mono-oxidases 1.0 0.000143348623853 0 1 -1
studies,have 0.686746987952 0.00817087155963 13 70 -57
the,concurrent 0.222222222222 0.000573394495413 7 11 -4
increased,above 1.0 0.000143348623853 0 1 -1
eprosartan,doses 1.0 0.000143348623853 0 1 -1
saquinavir,coadministration 1.0 0.000143348623853 1 0 1
of,indications 1.0 0.000143348623853 0 1 -1
c9,d6 1.0 0.000143348623853 0 1 -1
require,lower 1.0 0.00100344036697 0 7 -7
a,one-week 1.0 0.000143348623853 1 0 1
the,perfusion 1.0 0.000143348623853 0 1 -1
postoperatively,patients 1.0 0.000143348623853 0 1 -1
their,antiseizure 1.0 0.000143348623853 0 1 -1
lithium,carbonate 0.333333333333 0.000143348623853 2 1 1
enhanced,bone 1.0 0.000143348623853 1 0 1
receive,adl 1.0 0.000143348623853 0 1 -1
dose,was 1.0 0.000573394495413 0 4 -4
containing,iodine-containing 1.0 0.000143348623853 0 1 -1
at,receptors 1.0 0.000143348623853 1 0 1
is,altered 1.0 0.000143348623853 0 1 -1
received,mg 0.75 0.000860091743119 1 7 -6
clinically,because 1.0 0.000143348623853 0 1 -1
pharmacokinetics,if 1.0 0.000143348623853 0 1 -1
hamster,responds 1.0 0.000143348623853 0 1 -1
a2,d6 1.0 0.000143348623853 0 1 -1
this,conjugated 1.0 0.000143348623853 0 1 -1
intensive,care 1.0 0.000143348623853 0 1 -1
the,locomotor 1.0 0.000286697247706 0 2 -2
somatropin,excessive 1.0 0.000143348623853 0 1 -1
which,ssri-tcainteractions 1.0 0.000143348623853 1 0 1
pcp,combination 1.0 0.000143348623853 0 1 -1
exhibit,binding 1.0 0.000143348623853 0 1 -1
half,the 1.0 0.000143348623853 1 0 1
digoxin,enoxacin 1.0 0.000143348623853 1 0 1
serum,have 1.0 0.000143348623853 0 1 -1
or,caused 1.0 0.000143348623853 0 1 -1
s,regimen 1.0 0.000143348623853 1 0 1
generally,should 1.0 0.000716743119266 5 0 5
other,centrally 0.333333333333 0.000143348623853 2 1 1
these,doses 0.6 0.00043004587156 1 4 -3
drugs,aripiprazole 1.0 0.000143348623853 0 1 -1
with,diabetes 1.0 0.000143348623853 0 1 -1
two,compounds 1.0 0.000143348623853 0 1 -1
dysarthria,incoordination 1.0 0.000143348623853 0 1 -1
by,column 1.0 0.000573394495413 0 4 -4
well,above 1.0 0.000143348623853 0 1 -1
minutes,faster 1.0 0.000143348623853 1 0 1
antagonist,was 1.0 0.000143348623853 1 0 1
two,or 0.0 0.0 1 1 0
esomeprazole,inhibits 1.0 0.000143348623853 0 1 -1
exist,on 1.0 0.000143348623853 0 1 -1
block,produced 1.0 0.000143348623853 0 1 -1
cmi,has 1.0 0.000286697247706 2 0 2
inducers,or 1.0 0.000143348623853 0 1 -1
cholesterol,the 1.0 0.000143348623853 0 1 -1
pupillary,dilation 1.0 0.000143348623853 0 1 -1
two,of 0.0 0.0 2 2 0
of,taxol 0.777777777778 0.00100344036697 1 8 -7
two,on 1.0 0.000143348623853 0 1 -1
without,altering 1.0 0.000143348623853 1 0 1
dose,followed 1.0 0.000143348623853 1 0 1
responsible,for 0.0 0.0 7 7 0
be,combined 0.0 0.0 2 2 0
with,invirase 1.0 0.000143348623853 0 1 -1
exceed,a 1.0 0.000860091743119 6 0 6
concentration,of 0.0588235294118 0.000286697247706 18 16 2
be,different 1.0 0.000143348623853 0 1 -1
isoflurane,or 1.0 0.000143348623853 1 0 1
a4,isoenzyme 1.0 0.000143348623853 0 1 -1
of,cmax 1.0 0.000286697247706 0 2 -2
induction,or 1.0 0.000286697247706 0 2 -2
concentration,or 1.0 0.000286697247706 0 2 -2
hypothesis,of 1.0 0.000143348623853 0 1 -1
closely,associated 1.0 0.000143348623853 0 1 -1
decreases,aldosterone 1.0 0.000143348623853 0 1 -1
anticoagulant,activity 1.0 0.000143348623853 1 0 1
peritoneal,metastasis 0.0 0.0 1 1 0
s-,enantiomers 1.0 0.000143348623853 0 1 -1
changes,are 1.0 0.000286697247706 0 2 -2
tam,significantly 1.0 0.000143348623853 1 0 1
of,dose 1.0 0.000143348623853 1 0 1
vitro,at 1.0 0.000286697247706 0 2 -2
endothelial,function 1.0 0.000143348623853 0 1 -1
on,rewarming 1.0 0.000143348623853 0 1 -1
and,was 0.555555555556 0.000716743119266 2 7 -5
or,disposition 1.0 0.000143348623853 0 1 -1
or,skin 1.0 0.000143348623853 0 1 -1
oral,compared 1.0 0.000143348623853 0 1 -1
logistic,probability 1.0 0.000143348623853 0 1 -1
on,discrimination 1.0 0.000143348623853 0 1 -1
injection,of 0.142857142857 0.000286697247706 8 6 2
hormone,is 1.0 0.000143348623853 0 1 -1
on,fetal 1.0 0.000143348623853 0 1 -1
negative,results 1.0 0.000143348623853 0 1 -1
during,use 1.0 0.000143348623853 0 1 -1
slowly,dissolving 1.0 0.000143348623853 1 0 1
a,gritty 1.0 0.000143348623853 1 0 1
and,pharmacologic 1.0 0.000143348623853 0 1 -1
hyperglycaemia,and 1.0 0.000143348623853 0 1 -1
be,impaired 1.0 0.000143348623853 0 1 -1
alone,has 1.0 0.000143348623853 1 0 1
twenty,four 1.0 0.000143348623853 0 1 -1
replicate,this 1.0 0.000143348623853 0 1 -1
magnesium,aluminum-containing 1.0 0.000143348623853 0 1 -1
corresponding,to 1.0 0.000143348623853 0 1 -1
therefore,no 1.0 0.000143348623853 0 1 -1
alone,had 1.0 0.000286697247706 2 0 2
efficacy,in 1.0 0.00043004587156 0 3 -3
the,sa 1.0 0.000143348623853 0 1 -1
ia,such 1.0 0.000143348623853 1 0 1
such,as 0.0 0.0 95 95 0
produce,false 1.0 0.00043004587156 0 3 -3
cocaine-induced,increases 1.0 0.000143348623853 1 0 1
adverse,clinical 1.0 0.000143348623853 0 1 -1
were,agonists 1.0 0.000143348623853 1 0 1
has,focused 1.0 0.000143348623853 0 1 -1
d,had 1.0 0.000143348623853 0 1 -1
potential,that 1.0 0.000143348623853 0 1 -1
liver,microsome 1.0 0.000143348623853 0 1 -1
cortex,and 1.0 0.000143348623853 0 1 -1
in,serious 1.0 0.000286697247706 0 2 -2
isoen-zymes,cyp2c8 1.0 0.000143348623853 0 1 -1
with,slow-release 1.0 0.000143348623853 0 1 -1
cyclosporine,combination 1.0 0.000143348623853 1 0 1
toxicologic,and 1.0 0.000143348623853 0 1 -1
of,diet 1.0 0.000143348623853 0 1 -1
devices,and 1.0 0.000143348623853 0 1 -1
six,cases 1.0 0.000143348623853 0 1 -1
cremophor,el 1.0 0.000143348623853 1 0 1
choline,trilisate 1.0 0.000143348623853 1 0 1
administered,mg 0.333333333333 0.000143348623853 1 2 -1
active,phosphorylated 1.0 0.000143348623853 1 0 1
gastroduodenal,ulcers 1.0 0.000143348623853 0 1 -1
however,co-administration 1.0 0.000143348623853 0 1 -1
be,assumed 1.0 0.000143348623853 0 1 -1
these,precautions 1.0 0.000143348623853 0 1 -1
or,oral 0.25 0.000286697247706 3 5 -2
agents,enhanced 1.0 0.000143348623853 1 0 1
such,an 0.428571428571 0.00043004587156 2 5 -3
however,somepatients 1.0 0.000143348623853 0 1 -1
the,deaths 1.0 0.000143348623853 0 1 -1
induced,in 1.0 0.000143348623853 0 1 -1
reporter,gene 1.0 0.000143348623853 0 1 -1
the,fischer-344 1.0 0.000143348623853 0 1 -1
a,four-session 1.0 0.000143348623853 0 1 -1
l-tryptophan,may 1.0 0.000143348623853 0 1 -1
studied,alternative 1.0 0.000143348623853 1 0 1
on,cytochrome 1.0 0.000143348623853 0 1 -1
aggregation,and 1.0 0.000286697247706 0 2 -2
and,stimulation 1.0 0.000143348623853 0 1 -1
protective,effect 1.0 0.000143348623853 1 0 1
approximate,decrease 1.0 0.000573394495413 4 0 4
mepron,suspension 1.0 0.000143348623853 1 0 1
incompatible,with 1.0 0.000143348623853 0 1 -1
mutagenicity,studies 1.0 0.000143348623853 0 1 -1
small,groups 1.0 0.000143348623853 0 1 -1
estrogen,oral 1.0 0.000143348623853 0 1 -1
inhibitor,due 1.0 0.000143348623853 0 1 -1
with,phenyl-butazone 1.0 0.000143348623853 0 1 -1
that,resists 1.0 0.000143348623853 0 1 -1
we,noted 1.0 0.000143348623853 0 1 -1
fe,over 1.0 0.000143348623853 0 1 -1
nucleophosmin,b23 1.0 0.00114678899083 0 8 -8
cellular,uptake 1.0 0.000143348623853 1 0 1
globulin,thereby 1.0 0.000143348623853 0 1 -1
are,few 1.0 0.000143348623853 0 1 -1
see,illustrated 1.0 0.000143348623853 0 1 -1
interval,were 0.333333333333 0.000143348623853 1 2 -1
iressa,and 1.0 0.000286697247706 2 0 2
pharmacokinetic,analyses 0.2 0.000143348623853 3 2 1
and,intravenous 0.0 0.0 3 3 0
reports,describing 1.0 0.000143348623853 1 0 1
on,different 1.0 0.000143348623853 0 1 -1
higher,respectively 1.0 0.000143348623853 0 1 -1
fehling,s 1.0 0.00043004587156 0 3 -3
eprosartan,up 1.0 0.000143348623853 0 1 -1
orudis,kt 1.0 0.000143348623853 0 1 -1
after,overload 1.0 0.000143348623853 0 1 -1
any,effect 1.0 0.00043004587156 0 3 -3
not,by 0.333333333333 0.000143348623853 2 1 1
systematically,between 1.0 0.000143348623853 0 1 -1
animals,dosed 1.0 0.000286697247706 0 2 -2
cases,and 1.0 0.000286697247706 0 2 -2
block,contortrostatin-induced 1.0 0.000143348623853 1 0 1
there,is 0.484848484848 0.0045871559633 17 49 -32
secondary,actions 1.0 0.000143348623853 1 0 1
slightly,increased 1.0 0.000143348623853 0 1 -1
or,glycoprotein 1.0 0.000143348623853 1 0 1
in,death 1.0 0.000143348623853 1 0 1
voltage-dependent,ca 1.0 0.000716743119266 0 5 -5
of,endotoxin-induced 1.0 0.000143348623853 1 0 1
mouse,carcinogenicity 1.0 0.000143348623853 0 1 -1
not,be 0.123966942149 0.0021502293578 68 53 15
its,effect 0.333333333333 0.000143348623853 1 2 -1
acute,myocardial 1.0 0.000286697247706 0 2 -2
agents,nitrogen 1.0 0.000143348623853 0 1 -1
central,pathways 1.0 0.000143348623853 0 1 -1
of,protease 1.0 0.000143348623853 0 1 -1
its,acid 1.0 0.000143348623853 0 1 -1
cyp1a2,inhibit 1.0 0.000143348623853 0 1 -1
data,no 1.0 0.000143348623853 0 1 -1
with,healthy 1.0 0.000143348623853 0 1 -1
phase,of 1.0 0.000143348623853 0 1 -1
reduce,the 0.653846153846 0.00487385321101 43 9 34
and,beta 0.333333333333 0.000286697247706 4 2 2
disease,can 1.0 0.000143348623853 0 1 -1
showed,differential 1.0 0.000143348623853 0 1 -1
driving,a 1.0 0.000286697247706 0 2 -2
by,cyp1a2 1.0 0.000143348623853 0 1 -1
for,p-glycoprotein 1.0 0.000286697247706 0 2 -2
strength,over 1.0 0.000143348623853 0 1 -1
naproxen,may 1.0 0.000286697247706 0 2 -2
radiotherapy,may 1.0 0.000143348623853 0 1 -1
since,exhibits 1.0 0.000143348623853 1 0 1
epidemic,proportions 1.0 0.000143348623853 0 1 -1
mhd,induce 1.0 0.000143348623853 0 1 -1
the,body 0.6 0.00043004587156 1 4 -3
their,usual 0.0 0.0 1 1 0
vehicle,or 1.0 0.000143348623853 1 0 1
smooth,muscle 1.0 0.000143348623853 0 1 -1
the,phosphohydrolase 1.0 0.000286697247706 0 2 -2
of,particular 0.6 0.00043004587156 1 4 -3
serum,txb2 1.0 0.000143348623853 0 1 -1
know,how 1.0 0.000143348623853 0 1 -1
gel,interacts 1.0 0.000143348623853 0 1 -1
in,hiv-1 1.0 0.000286697247706 0 2 -2
upon,combination 1.0 0.000143348623853 1 0 1
cause,an 0.2 0.000143348623853 3 2 1
adaptive,value 1.0 0.000143348623853 0 1 -1
in,anhydrous 1.0 0.000143348623853 1 0 1
preparations,to 1.0 0.000143348623853 0 1 -1
as,sole 1.0 0.000143348623853 0 1 -1
isozymes,are 1.0 0.000143348623853 0 1 -1
patients,demonstrated 0.0 0.0 1 1 0
combination,has 1.0 0.000143348623853 1 0 1
supervision,for 1.0 0.000143348623853 0 1 -1
agents,calcium 1.0 0.000143348623853 0 1 -1
hdl2,cholesterol 1.0 0.000286697247706 0 2 -2
no,discernible 1.0 0.000143348623853 0 1 -1
because,competitively 1.0 0.000143348623853 1 0 1
or,hours 0.454545454545 0.000716743119266 8 3 5
paba,containing 1.0 0.000143348623853 1 0 1
study,following 1.0 0.000143348623853 0 1 -1
observations,suggest 1.0 0.000143348623853 0 1 -1
concentrations,when 0.0 0.0 2 2 0
and,triglycerides 0.0 0.0 1 1 0
stereoselectivity,in 1.0 0.000143348623853 0 1 -1
or,duloxetine 1.0 0.000143348623853 0 1 -1
hypoglycemia,have 1.0 0.000143348623853 1 0 1
a,water 1.0 0.000143348623853 0 1 -1
daily,given 1.0 0.000143348623853 1 0 1
must,not 0.333333333333 0.000143348623853 2 1 1
containing,divalent 1.0 0.000286697247706 2 0 2
in,pharmacokinetic 1.0 0.000143348623853 0 1 -1
sparing,such 1.0 0.000143348623853 1 0 1
addition,deaths 1.0 0.000143348623853 1 0 1
com,cgi 1.0 0.000143348623853 0 1 -1
and,significantly 1.0 0.000573394495413 4 0 4
live-attenuated,should 1.0 0.000143348623853 1 0 1
and,seven 1.0 0.000143348623853 0 1 -1
is,followed 1.0 0.000143348623853 0 1 -1
cmaxss,peak 1.0 0.000143348623853 0 1 -1
rifampin,when 1.0 0.000143348623853 1 0 1
tests,have 1.0 0.000860091743119 0 6 -6
benign,ovarian 1.0 0.000143348623853 0 1 -1
alone,caused 1.0 0.000143348623853 0 1 -1
viracept,should 1.0 0.000286697247706 2 0 2
addition,and 1.0 0.000143348623853 0 1 -1
mitogenic,effect 1.0 0.000143348623853 1 0 1
multivitamin,preparations 1.0 0.000143348623853 1 0 1
sulfate,neuromuscular 1.0 0.000143348623853 0 1 -1
albumin,binding 0.0 0.0 1 1 0
giving,these 1.0 0.000286697247706 0 2 -2
concomitantly,toxicity 1.0 0.000143348623853 1 0 1
nor,were 1.0 0.000143348623853 0 1 -1
when,sodium 1.0 0.000143348623853 1 0 1
coadministering,these 1.0 0.000143348623853 1 0 1
of,pregnancies 1.0 0.000143348623853 0 1 -1
placental,margin 1.0 0.000143348623853 0 1 -1
when,anti-globulin 1.0 0.000143348623853 0 1 -1
developmental,acquisition 1.0 0.000143348623853 0 1 -1
characteristic,apoptotic 1.0 0.000143348623853 0 1 -1
loratadine,and 1.0 0.000143348623853 0 1 -1
on,fi 1.0 0.000143348623853 1 0 1
plasma,renin 1.0 0.00043004587156 0 3 -3
older,men 1.0 0.000143348623853 0 1 -1
binding,decrease 1.0 0.000143348623853 1 0 1
the,prescribing 1.0 0.000286697247706 0 2 -2
on,felbatol 0.5 0.000286697247706 1 3 -2
medication,may 0.0 0.0 1 1 0
time,inr 0.333333333333 0.000143348623853 1 2 -1
have,clinically 0.666666666667 0.000573394495413 1 5 -4
fade,hoof 1.0 0.000143348623853 1 0 1
between,treatment 1.0 0.000143348623853 0 1 -1
cautioned,about 1.0 0.000143348623853 0 1 -1
with,within 1.0 0.000143348623853 0 1 -1
wide,distribution 1.0 0.000143348623853 0 1 -1
patients,approximately 1.0 0.000143348623853 0 1 -1
of,suprax 1.0 0.000143348623853 0 1 -1
dose,pharmacokinetics 1.0 0.000286697247706 0 2 -2
epilepsy,also 1.0 0.000143348623853 0 1 -1
the,prevention 1.0 0.000143348623853 0 1 -1
least,of 1.0 0.000143348623853 0 1 -1
diabetic,patient 1.0 0.000286697247706 2 0 2
i,binding 1.0 0.000143348623853 0 1 -1
repeated,dosing 1.0 0.000143348623853 0 1 -1
increased,bioavailability 1.0 0.000143348623853 0 1 -1
the,aviano 1.0 0.000143348623853 0 1 -1
mm3,and 1.0 0.000143348623853 0 1 -1
intact,liver 1.0 0.000143348623853 0 1 -1
be,prepared 1.0 0.000143348623853 0 1 -1
doses,from 1.0 0.000143348623853 0 1 -1
celebrex,is 0.0 0.0 1 1 0
the,drying 1.0 0.000143348623853 1 0 1
receiving,appeared 1.0 0.000143348623853 1 0 1
purposes,cannot 1.0 0.000143348623853 0 1 -1
were,intravenously 1.0 0.000143348623853 0 1 -1
chronic,activation 1.0 0.000143348623853 0 1 -1
alone,the 1.0 0.000143348623853 1 0 1
precipitation,in 1.0 0.000143348623853 0 1 -1
differences,were 1.0 0.000716743119266 0 5 -5
warfarin,a 1.0 0.000143348623853 0 1 -1
minor,side 1.0 0.000143348623853 0 1 -1
induce,serious 1.0 0.000143348623853 0 1 -1
these,individuals 1.0 0.000286697247706 0 2 -2
of,cardiac 0.333333333333 0.000143348623853 2 1 1
not,mutagenic 1.0 0.000286697247706 0 2 -2
alternate,treatments 1.0 0.000143348623853 0 1 -1
be,warned 0.5 0.000286697247706 1 3 -2
agonists,compared 1.0 0.000143348623853 0 1 -1
conventional,formulation 1.0 0.000143348623853 0 1 -1
that,resulted 0.0 0.0 1 1 0
and,completely 1.0 0.000143348623853 1 0 1
subjective,effects 1.0 0.000143348623853 0 1 -1
discrimination,and 1.0 0.00043004587156 0 3 -3
however,adenocard 1.0 0.000143348623853 0 1 -1
between,camptosar 1.0 0.000143348623853 0 1 -1
no,controlled 1.0 0.000143348623853 0 1 -1
two,regimens 1.0 0.000143348623853 0 1 -1
negative,symptoms 1.0 0.000573394495413 0 4 -4
for,uptake-1 1.0 0.000143348623853 0 1 -1
and,citrate 1.0 0.000143348623853 1 0 1
dose,should 0.28 0.00100344036697 16 9 7
significant,deterioration 1.0 0.000143348623853 0 1 -1
continuously,observed 1.0 0.000143348623853 1 0 1
liver,transaminases 1.0 0.000143348623853 0 1 -1
identify,characteristics 1.0 0.000143348623853 0 1 -1
the,resulting 0.5 0.000286697247706 1 3 -2
joint,exposure 1.0 0.000143348623853 0 1 -1
inhibitor,which 1.0 0.000143348623853 1 0 1
l-ccg,were 1.0 0.000143348623853 0 1 -1
exposure,for 1.0 0.000286697247706 0 2 -2
allergic,reaction 1.0 0.000143348623853 1 0 1
b,injection 1.0 0.000143348623853 1 0 1
the,area 0.714285714286 0.000716743119266 6 1 5
other,tnfa-blocking 1.0 0.000143348623853 1 0 1
directly,to 1.0 0.000143348623853 0 1 -1
and,gastrointestinal 1.0 0.000143348623853 0 1 -1
antibiotics,rifampin 1.0 0.000143348623853 0 1 -1
cholestographic,agents 1.0 0.000143348623853 0 1 -1
intensity,uniformity 1.0 0.000143348623853 0 1 -1
risks,to 1.0 0.000143348623853 1 0 1
a,dihydropyridine 1.0 0.000143348623853 0 1 -1
liver,enzymes 0.333333333333 0.000143348623853 2 1 1
may,selectively 1.0 0.000143348623853 1 0 1
non-cyp3a4,substrate 1.0 0.000143348623853 0 1 -1
hospitals,usually 1.0 0.000143348623853 0 1 -1
as,cough 1.0 0.000143348623853 1 0 1
not,appear 0.846153846154 0.00157683486239 1 12 -11
a4,may 0.333333333333 0.000143348623853 1 2 -1
macrolide,inhibit 1.0 0.000143348623853 1 0 1
concentrations,to 0.333333333333 0.000143348623853 2 1 1
the,diet 0.0 0.0 1 1 0
as,stadol 1.0 0.000286697247706 0 2 -2
light,zone 0.0 0.0 1 1 0
abciximab,have 1.0 0.000143348623853 0 1 -1
levels,achieved 1.0 0.000286697247706 0 2 -2
was,evaluated 1.0 0.00157683486239 0 11 -11
investigations,into 1.0 0.000143348623853 0 1 -1
significantly,interfere 1.0 0.000143348623853 0 1 -1
concentration,may 0.75 0.000860091743119 1 7 -6
if,administered 0.0 0.0 1 1 0
absorption,of 0.368421052632 0.00301032110092 39 18 21
although,specific 0.2 0.000143348623853 2 3 -1
was,also 1.0 0.00100344036697 0 7 -7
significantly,altered 0.5 0.000286697247706 1 3 -2
hydration,sodium 1.0 0.000143348623853 0 1 -1
increasing,incidence 1.0 0.000143348623853 0 1 -1
a,diminished 1.0 0.000286697247706 2 0 2
has,revealed 1.0 0.000143348623853 0 1 -1
broad,population 1.0 0.000143348623853 0 1 -1
plus,without 1.0 0.000143348623853 0 1 -1
of,nalfon 1.0 0.00043004587156 3 0 3
infusion,was 1.0 0.000143348623853 0 1 -1
when,the 0.407407407407 0.00157683486239 8 19 -11
css,max 1.0 0.000143348623853 1 0 1
is,rapid 1.0 0.000286697247706 0 2 -2
potentially,may 1.0 0.000143348623853 1 0 1
noted,to 1.0 0.000286697247706 2 0 2
the,training 1.0 0.000143348623853 0 1 -1
summary,a 1.0 0.000143348623853 0 1 -1
isolated,from 1.0 0.000143348623853 0 1 -1
subtypes,by 1.0 0.000143348623853 0 1 -1
neuropathy,during 1.0 0.000143348623853 0 1 -1
oxidase,inhibiting 1.0 0.000143348623853 1 0 1
increases,of 0.6 0.00043004587156 1 4 -3
in,vitro 0.528571428571 0.0106077981651 33 107 -74
subject,demonstrated 1.0 0.000143348623853 0 1 -1
for,proper 1.0 0.000143348623853 0 1 -1
of,deaths 1.0 0.00043004587156 0 3 -3
alkaloid,while 1.0 0.000143348623853 1 0 1
residual,effects 1.0 0.000143348623853 1 0 1
with,antifungal 1.0 0.000143348623853 0 1 -1
frova,is 1.0 0.000143348623853 0 1 -1
and,tachycardia 1.0 0.000143348623853 1 0 1
produce,toxicity 1.0 0.000143348623853 0 1 -1
of,ionized 1.0 0.000143348623853 0 1 -1
and,non-selective 1.0 0.00043004587156 3 0 3
bph,psa 1.0 0.000143348623853 0 1 -1
structures,whereas 1.0 0.000143348623853 0 1 -1
reactions,and 1.0 0.000143348623853 0 1 -1
copying,test 1.0 0.000143348623853 1 0 1
x,h 1.0 0.000143348623853 1 0 1
if,indocin 1.0 0.000143348623853 1 0 1
ketoprofen,decreases 1.0 0.000143348623853 0 1 -1
cephalosporins,are 1.0 0.000286697247706 0 2 -2
by,elevated 1.0 0.000143348623853 1 0 1
mucosa,the 1.0 0.000143348623853 0 1 -1
on,decreased 1.0 0.000286697247706 2 0 2
were,comparable 1.0 0.000143348623853 1 0 1
is,at 1.0 0.000573394495413 0 4 -4
optic,nerve 1.0 0.000286697247706 0 2 -2
order,to 0.578947368421 0.00157683486239 4 15 -11
ip,the 1.0 0.000143348623853 1 0 1
including,quinolone 1.0 0.000143348623853 1 0 1
particles,appeared 1.0 0.000143348623853 0 1 -1
have,in 1.0 0.000143348623853 1 0 1
group,developed 1.0 0.000143348623853 0 1 -1
negative,bacteria 1.0 0.000143348623853 0 1 -1
to,achieve 0.333333333333 0.000286697247706 4 2 2
for,documented 1.0 0.000143348623853 0 1 -1
childbearing,potential 1.0 0.000573394495413 0 4 -4
enhances,cocaine-induced 1.0 0.000143348623853 1 0 1
influenced,the 1.0 0.000143348623853 0 1 -1
one,mg 0.333333333333 0.000143348623853 2 1 1
administration,one 1.0 0.000143348623853 0 1 -1
with,wthionamide 1.0 0.000143348623853 0 1 -1
tuberculosis,showed 1.0 0.000143348623853 1 0 1
and,parnate 1.0 0.000143348623853 0 1 -1
antifungals,in 1.0 0.000143348623853 1 0 1
nephrotoxic,potential 0.0 0.0 1 1 0
in,levels 0.0 0.0 3 3 0
proteins,at 1.0 0.000143348623853 0 1 -1
conditions,that 1.0 0.000143348623853 0 1 -1
in,urine 0.6 0.00043004587156 1 4 -3
interactions,particularly 1.0 0.000143348623853 0 1 -1
accounts,in 1.0 0.000143348623853 0 1 -1
is,normal 1.0 0.000143348623853 1 0 1
pletal,is 1.0 0.000143348623853 1 0 1
citrate,a 1.0 0.000143348623853 0 1 -1
to,lie 1.0 0.000143348623853 0 1 -1
data,obtained 1.0 0.000143348623853 0 1 -1
synergistic,for 1.0 0.000143348623853 1 0 1
with,eg 1.0 0.000143348623853 0 1 -1
basis,of 0.538461538462 0.00100344036697 3 10 -7
altered,it 1.0 0.000143348623853 0 1 -1
agents,or 0.0 0.0 5 5 0
by,active 0.0 0.0 1 1 0
closely,particularly 1.0 0.000143348623853 0 1 -1
antihistamines,benzodiazepines 1.0 0.000143348623853 0 1 -1
in,pharmacokinetics 0.5 0.000286697247706 1 3 -2
treating,patients 1.0 0.00043004587156 0 3 -3
when,myocardial 1.0 0.000143348623853 1 0 1
ptx,m 1.0 0.000143348623853 1 0 1
containing,mcg 1.0 0.000143348623853 1 0 1
decrease,plasma 0.333333333333 0.000573394495413 8 4 4
negatively,impacted 1.0 0.000143348623853 0 1 -1
unknown,whether 1.0 0.000286697247706 0 2 -2
didanosine-placebo,tablets 1.0 0.000143348623853 1 0 1
by,compared 1.0 0.000286697247706 2 0 2
of,placental 1.0 0.000143348623853 1 0 1
some,individuals 1.0 0.000143348623853 1 0 1
etodolac,has 1.0 0.00043004587156 0 3 -3
other,coadministration 1.0 0.000143348623853 0 1 -1
drug-drug,interactions 0.777777777778 0.00200688073394 2 16 -14
hydrochloride,injection 1.0 0.000143348623853 1 0 1
reactive,substances 1.0 0.000143348623853 0 1 -1
both,aldehyde 1.0 0.000143348623853 1 0 1
absorbing,materials 1.0 0.000143348623853 0 1 -1
all,patients 0.714285714286 0.000716743119266 1 6 -5
of,proteins 1.0 0.000143348623853 0 1 -1
measured,as 1.0 0.000286697247706 2 0 2
measured,at 1.0 0.000143348623853 0 1 -1
creatinine,makes 1.0 0.000143348623853 0 1 -1
for,exjade 1.0 0.000143348623853 1 0 1
encystment,and 1.0 0.000143348623853 0 1 -1
sandimmune,hiv 1.0 0.000143348623853 1 0 1
or,prolonged 1.0 0.00043004587156 0 3 -3
but,can 0.333333333333 0.000143348623853 1 2 -1
steroids,enhance 1.0 0.000143348623853 1 0 1
for,n 1.0 0.000143348623853 1 0 1
of,reactive 1.0 0.000143348623853 0 1 -1
for,h 1.0 0.000573394495413 0 4 -4
for,i 1.0 0.000143348623853 1 0 1
avoid,dong 1.0 0.000143348623853 0 1 -1
tricky,using 1.0 0.000143348623853 0 1 -1
with,active 1.0 0.000286697247706 2 0 2
oral,as 1.0 0.000143348623853 0 1 -1
is,useful 1.0 0.000143348623853 0 1 -1
least,miu 1.0 0.000143348623853 0 1 -1
smx,were 1.0 0.000143348623853 0 1 -1
the,replication 1.0 0.000143348623853 1 0 1
domain,decoy 1.0 0.000143348623853 0 1 -1
benzodiazepines,combination 1.0 0.000143348623853 1 0 1
prosom,is 1.0 0.000143348623853 0 1 -1
differin,gel 1.0 0.000286697247706 0 2 -2
concomitantly,prothrombin 1.0 0.000716743119266 0 5 -5
methotrexate,caution 1.0 0.000143348623853 1 0 1
pregnancy,cromolyn 1.0 0.000143348623853 0 1 -1
induce,the 0.0 0.0 3 3 0
mg,p 1.0 0.000143348623853 1 0 1
auc,to 1.0 0.00043004587156 3 0 3
exposure,of 0.777777777778 0.00100344036697 8 1 7
use,such 1.0 0.000143348623853 0 1 -1
acid,nonsteroidal 1.0 0.000143348623853 1 0 1
hydrolyzed,intravenous 1.0 0.000143348623853 0 1 -1
decreased,active 1.0 0.000143348623853 1 0 1
reduce,seizure 1.0 0.000143348623853 1 0 1
that,frequent 1.0 0.000143348623853 0 1 -1
allow,for 1.0 0.000286697247706 0 2 -2
mixtures,had 1.0 0.000143348623853 0 1 -1
after,previous 1.0 0.000143348623853 0 1 -1
hemorrhage,should 1.0 0.000286697247706 0 2 -2
s,wort 0.75 0.000860091743119 1 7 -6
continue,to 0.0 0.0 1 1 0
videx,therapy 1.0 0.000143348623853 0 1 -1
significantly,longer 1.0 0.000143348623853 0 1 -1
complications,related 1.0 0.000143348623853 0 1 -1
n-type,channel 1.0 0.000143348623853 0 1 -1
disease,aged 1.0 0.000143348623853 0 1 -1
false-positive,urine 1.0 0.000143348623853 0 1 -1
the,key 1.0 0.000143348623853 0 1 -1
agents,aspirin 1.0 0.000286697247706 2 0 2
by,approx 1.0 0.000143348623853 1 0 1
occurred,during 1.0 0.000143348623853 0 1 -1
of,nephrotoxicity 0.0 0.0 1 1 0
including,have 1.0 0.000286697247706 2 0 2
plus,highly 1.0 0.000143348623853 0 1 -1
elspar,or 1.0 0.000143348623853 1 0 1
olanzapine,demonstrated 1.0 0.000143348623853 0 1 -1
hormonal,are 0.0 0.0 1 1 0
of,assays 1.0 0.000143348623853 0 1 -1
and,drug 1.0 0.00043004587156 0 3 -3
liver,was 1.0 0.000143348623853 0 1 -1
retention,blurred 1.0 0.000143348623853 1 0 1
and,potentiate 1.0 0.000143348623853 0 1 -1
of,gross 1.0 0.000143348623853 0 1 -1
imidazoles,etc 1.0 0.000143348623853 1 0 1
this,effect 0.5 0.000860091743119 3 9 -6
dosage,are 0.333333333333 0.000143348623853 2 1 1
were,systematically 1.0 0.000143348623853 0 1 -1
areas,where 1.0 0.000143348623853 0 1 -1
expect,that 0.2 0.000143348623853 2 3 -1
beginning,or 1.0 0.000143348623853 1 0 1
require,additional 0.0 0.0 1 1 0
for,longitudinal 1.0 0.000143348623853 0 1 -1
impair,fertility 1.0 0.000143348623853 0 1 -1
of,microdosed 1.0 0.000286697247706 2 0 2
thioxanthene,and 1.0 0.000143348623853 1 0 1
or,decreased 0.0 0.0 1 1 0
dsm-iv,diagnosed 1.0 0.000143348623853 1 0 1
atherosclerotic,disease 1.0 0.000143348623853 0 1 -1
hypotension,bradycardia 1.0 0.000286697247706 0 2 -2
solution,can 1.0 0.000143348623853 1 0 1
mg,week 1.0 0.000143348623853 1 0 1
approximately,when 0.714285714286 0.000716743119266 6 1 5
when,d2o 1.0 0.000143348623853 0 1 -1
mptp,induced 1.0 0.000143348623853 1 0 1
rates,than 1.0 0.000143348623853 0 1 -1
recommended,it 1.0 0.000143348623853 1 0 1
and,susceptibility 1.0 0.00043004587156 0 3 -3
and,by 0.0909090909091 0.000143348623853 6 5 1
recommended,in 0.714285714286 0.000716743119266 1 6 -5
lymphocytes,mammalian 1.0 0.000143348623853 0 1 -1
and,veratrum 1.0 0.000143348623853 1 0 1
the,reaction 0.0 0.0 1 1 0
survanta,increased 1.0 0.000143348623853 0 1 -1
sedation,within 1.0 0.000143348623853 0 1 -1
subjects,treated 1.0 0.000286697247706 0 2 -2
miosis,mydriasis 1.0 0.000143348623853 0 1 -1
untreated,hypothyroidism 1.0 0.000143348623853 0 1 -1
other,cytochrome 1.0 0.000143348623853 0 1 -1
take,advantage 1.0 0.000143348623853 0 1 -1
urine,samples 1.0 0.000143348623853 0 1 -1
a,is 0.666666666667 0.000573394495413 5 1 4
avidities,for 1.0 0.000143348623853 0 1 -1
currents,in 1.0 0.000143348623853 0 1 -1
but,still 1.0 0.000143348623853 0 1 -1
achieves,a 1.0 0.000143348623853 0 1 -1
whereas,the 0.6 0.00043004587156 1 4 -3
glycosides,amphotericin 1.0 0.000143348623853 1 0 1
if,leprosy-associated 1.0 0.000143348623853 1 0 1
fold,compared 1.0 0.000143348623853 1 0 1
capsules,should 1.0 0.000143348623853 0 1 -1
indocin,and 0.714285714286 0.000716743119266 6 1 5
blood,loss 1.0 0.000143348623853 0 1 -1
a6,c9 1.0 0.00043004587156 0 3 -3
respiratory,exchange 1.0 0.000143348623853 0 1 -1
tea,gallocatechins 1.0 0.000143348623853 0 1 -1
appear,before 1.0 0.000143348623853 0 1 -1
with,severe 0.5 0.000286697247706 1 3 -2
effects,and 0.176470588235 0.00043004587156 7 10 -3
a,stock 1.0 0.000143348623853 0 1 -1
hypotensive,effect 1.0 0.00143348623853 10 0 10
follow-up,study 1.0 0.000143348623853 0 1 -1
this,metabolism 1.0 0.000143348623853 0 1 -1
be,resistant 1.0 0.000143348623853 1 0 1
nsaid,has 1.0 0.000143348623853 0 1 -1
of,short-acting 1.0 0.000143348623853 0 1 -1
with,proscar 1.0 0.000143348623853 0 1 -1
phenytoin,decreases 1.0 0.000143348623853 0 1 -1
monitored,forevidence 1.0 0.000143348623853 1 0 1
principles,of 1.0 0.000143348623853 0 1 -1
excretion,ibuprofen 1.0 0.000143348623853 0 1 -1
with,xigris 1.0 0.000286697247706 0 2 -2
results,hydrocortisone 1.0 0.000143348623853 0 1 -1
a,false-negative 1.0 0.000286697247706 0 2 -2
recent,case 1.0 0.000143348623853 1 0 1
years,at 1.0 0.000143348623853 0 1 -1
phenobarbital,coadministration 1.0 0.000143348623853 1 0 1
and,women 1.0 0.000143348623853 0 1 -1
volunteers,show 1.0 0.000143348623853 0 1 -1
aom,and 1.0 0.000143348623853 0 1 -1
tests,were 1.0 0.000143348623853 0 1 -1
healthy,non-smoking 1.0 0.000143348623853 0 1 -1
medication,authorization 1.0 0.000143348623853 0 1 -1
not,a 0.692307692308 0.00129013761468 2 11 -9
a,case 0.0 0.0 2 2 0
differ,significantly 1.0 0.000143348623853 0 1 -1
suggest,these 1.0 0.000143348623853 0 1 -1
habituation,or 1.0 0.000143348623853 0 1 -1
when,oral 1.0 0.000143348623853 0 1 -1
agents,should 0.51724137931 0.0021502293578 7 22 -15
the,added 0.0 0.0 1 1 0
fibrinogen,to 1.0 0.000143348623853 0 1 -1
alkaline,urine 1.0 0.000143348623853 0 1 -1
to,reassess 1.0 0.000143348623853 0 1 -1
performed,doses 1.0 0.000143348623853 0 1 -1
treatment,ataxia 1.0 0.000143348623853 0 1 -1
induce,microsomal 1.0 0.000143348623853 1 0 1
tubular,organic 0.0 0.0 1 1 0
juice,resulted 1.0 0.000143348623853 0 1 -1
a6,and 1.0 0.000143348623853 0 1 -1
angioedema,or 1.0 0.000143348623853 0 1 -1
to,aid 1.0 0.000143348623853 0 1 -1
bid,did 1.0 0.00043004587156 0 3 -3
for,changes 1.0 0.00043004587156 0 3 -3
cyp2d6,inhibitory 1.0 0.000143348623853 1 0 1
d-gal,binding 1.0 0.000143348623853 0 1 -1
chop-haart,group 1.0 0.000143348623853 0 1 -1
cyp2d6,inhibitors 1.0 0.000143348623853 0 1 -1
either,enbrel 1.0 0.000143348623853 1 0 1
and,celexa 1.0 0.000143348623853 1 0 1
but,one 1.0 0.000143348623853 0 1 -1
post-marketing,reports 1.0 0.000143348623853 0 1 -1
laboratory,studies 1.0 0.000143348623853 0 1 -1
absorption,results 1.0 0.000143348623853 0 1 -1
differed,from 1.0 0.000143348623853 0 1 -1
extravasation,it 1.0 0.000143348623853 0 1 -1
the,offspring 1.0 0.000143348623853 0 1 -1
concern,about 1.0 0.000143348623853 1 0 1
a,host 1.0 0.000143348623853 0 1 -1
cord,injuries 1.0 0.000143348623853 0 1 -1
studies,show 1.0 0.000286697247706 0 2 -2
of,argatroban 0.2 0.000143348623853 2 3 -1
known,photosensitizing 1.0 0.000143348623853 1 0 1
suspected,of 1.0 0.000143348623853 0 1 -1
affect,steady-state 1.0 0.000143348623853 0 1 -1
animal,and 1.0 0.000143348623853 0 1 -1
invirase,and 1.0 0.000143348623853 0 1 -1
reported,itraconazole 1.0 0.000143348623853 0 1 -1
antigout,medications 1.0 0.000143348623853 0 1 -1
c9,cyp 1.0 0.000143348623853 0 1 -1
possibility,should 1.0 0.000143348623853 0 1 -1
were,used 0.333333333333 0.000286697247706 2 4 -2
g,sometimes 1.0 0.000143348623853 0 1 -1
of,ponstel 1.0 0.000286697247706 2 0 2
therefore,periodic 1.0 0.000143348623853 0 1 -1
methamphetamine,like 1.0 0.000143348623853 1 0 1
an,anion 1.0 0.000143348623853 0 1 -1
careful,attention 0.0 0.0 1 1 0
p1,and 0.333333333333 0.000143348623853 1 2 -1
felbatol,phenytoin 1.0 0.000143348623853 1 0 1
toward,cyp3a4 1.0 0.000143348623853 0 1 -1
worsen,the 0.0 0.0 1 1 0
cox-2,inhibitor 1.0 0.000143348623853 0 1 -1
likelihood,of 0.333333333333 0.000286697247706 4 2 2
of,conjugated 1.0 0.000286697247706 0 2 -2
area,of 1.0 0.000286697247706 0 2 -2
to,invirase 1.0 0.000143348623853 0 1 -1
inhibitors,macrolide 1.0 0.000143348623853 0 1 -1
a,loss 1.0 0.000143348623853 0 1 -1
glucosylation,of 1.0 0.000143348623853 0 1 -1
concomitant,such 1.0 0.000143348623853 0 1 -1
cyp3a4,substrates 0.0 0.0 2 2 0
supplements,taken 1.0 0.000143348623853 1 0 1
therapy,at 1.0 0.000143348623853 0 1 -1
by,nonlethal 1.0 0.000143348623853 0 1 -1
in,human 0.739130434783 0.0024369266055 3 20 -17
ros,has 1.0 0.000143348623853 0 1 -1
simvastatin,cyp3a4 1.0 0.000143348623853 0 1 -1
approximately,fold 0.25 0.000286697247706 5 3 2
of,otthostatic 1.0 0.000143348623853 0 1 -1
effect,was 0.2 0.000143348623853 2 3 -1
patients,those 1.0 0.000143348623853 0 1 -1
these,steps 1.0 0.000143348623853 0 1 -1
medicines,diabetic 1.0 0.000143348623853 1 0 1
meth,caused 1.0 0.000143348623853 1 0 1
the,possible 0.2 0.000286697247706 4 6 -2
kg,diet 1.0 0.000143348623853 1 0 1
adequate,numbers 1.0 0.000143348623853 0 1 -1
kidney,on 1.0 0.000143348623853 0 1 -1
assay,for 1.0 0.000143348623853 0 1 -1
cancer,cell 1.0 0.000143348623853 0 1 -1
reuptake,inhibitor 1.0 0.00043004587156 3 0 3
possible,the 1.0 0.000286697247706 0 2 -2
hormone,concomitant 1.0 0.000143348623853 1 0 1
upon,administration 1.0 0.000143348623853 1 0 1
affect,this 1.0 0.000143348623853 0 1 -1
receiving,injection 1.0 0.000143348623853 0 1 -1
have,identified 1.0 0.000143348623853 1 0 1
slow,phasic 1.0 0.000143348623853 0 1 -1
glyburide,the 1.0 0.000143348623853 1 0 1
patients,than 1.0 0.000143348623853 0 1 -1
selective,methods 1.0 0.000143348623853 0 1 -1
no,changes 1.0 0.000286697247706 0 2 -2
disalcid,others 1.0 0.000143348623853 1 0 1
only,half 1.0 0.000143348623853 0 1 -1
serum,samples 1.0 0.000143348623853 0 1 -1
hearts,new 1.0 0.000143348623853 0 1 -1
and,asa 1.0 0.000143348623853 0 1 -1
m,and 1.0 0.000143348623853 0 1 -1
support,the 1.0 0.000286697247706 0 2 -2
drugs,affecting 1.0 0.000143348623853 0 1 -1
cells,in 1.0 0.000286697247706 0 2 -2
weekly,dosage 1.0 0.000143348623853 1 0 1
factor,iegs 1.0 0.000143348623853 0 1 -1
inhibitors,including 0.0 0.0 2 2 0
were,noted 0.714285714286 0.000716743119266 1 6 -5
multiple,dosing 1.0 0.000286697247706 2 0 2
volunteers,or 1.0 0.000143348623853 0 1 -1
well-controlled,patients 1.0 0.000286697247706 2 0 2
by,pcp 1.0 0.000143348623853 0 1 -1
in,visual 1.0 0.000143348623853 0 1 -1
cautioned,against 1.0 0.000286697247706 0 2 -2
a,soft 1.0 0.000143348623853 0 1 -1
volunteers,of 1.0 0.000143348623853 1 0 1
were,concurrently 1.0 0.000286697247706 0 2 -2
treated,rats 1.0 0.000143348623853 1 0 1
benefit,while 1.0 0.000143348623853 0 1 -1
bolus,of 1.0 0.000143348623853 0 1 -1
glucose,levels 0.5 0.000573394495413 2 6 -4
small,gradual 0.0 0.0 1 1 0
not,cause 1.0 0.000716743119266 0 5 -5
wasting,breast 1.0 0.000143348623853 0 1 -1
subjects,given 1.0 0.000286697247706 2 0 2
in,otherwise 0.333333333333 0.000143348623853 1 2 -1
with,supplements 1.0 0.000143348623853 0 1 -1
insert,for 1.0 0.000286697247706 2 0 2
considered,whenever 1.0 0.000143348623853 0 1 -1
the,stress 1.0 0.000143348623853 0 1 -1
decrease,prior 1.0 0.000143348623853 0 1 -1
d,at 1.0 0.000143348623853 1 0 1
for,reexacerbation 1.0 0.000143348623853 1 0 1
potentially,aggravating 1.0 0.000143348623853 1 0 1
other,methods 1.0 0.000143348623853 0 1 -1
vii-x,complex 1.0 0.000286697247706 0 2 -2
with,thioridizine 1.0 0.000143348623853 0 1 -1
iga,is 1.0 0.000286697247706 0 2 -2
two,potentially 1.0 0.000143348623853 1 0 1
three,groups 1.0 0.000143348623853 0 1 -1
the,tardive 1.0 0.000143348623853 1 0 1
given,number 1.0 0.000143348623853 0 1 -1
count,prothrombin 1.0 0.000143348623853 0 1 -1
decrease,anti-inflammatory 1.0 0.000143348623853 1 0 1
the,amplitudes 1.0 0.00043004587156 0 3 -3
enterobacteriaceae,and 1.0 0.000143348623853 0 1 -1
therapies,that 1.0 0.000143348623853 0 1 -1
the,porter-silber 1.0 0.000286697247706 0 2 -2
gross,motor 1.0 0.000143348623853 0 1 -1
are,highly 0.333333333333 0.000286697247706 4 2 2
ibuprofen,and 1.0 0.000143348623853 1 0 1
by,blocking 1.0 0.000143348623853 1 0 1
interval,msec 1.0 0.000143348623853 1 0 1
an,elisa 1.0 0.000143348623853 0 1 -1
date,in 1.0 0.000143348623853 0 1 -1
pharmacokinetic,parameters 0.75 0.000860091743119 1 7 -6
demonstrated,only 1.0 0.000143348623853 0 1 -1
taking,that 1.0 0.000143348623853 0 1 -1
fluctuations,in 1.0 0.000143348623853 1 0 1
all,subjects 0.333333333333 0.000143348623853 1 2 -1
tagamet,apparently 1.0 0.000143348623853 1 0 1
of,ellence 0.0 0.0 1 1 0
and,gamma 1.0 0.000143348623853 0 1 -1
is,feasible 1.0 0.000143348623853 0 1 -1
recommended,to 0.333333333333 0.000143348623853 2 1 1
only,hyperglycemia 1.0 0.000143348623853 0 1 -1
apoptosis,in 1.0 0.000286697247706 0 2 -2
therefore,administration 1.0 0.00043004587156 0 3 -3
infusions,can 1.0 0.000143348623853 0 1 -1
cells,and 1.0 0.000286697247706 0 2 -2
this,process 1.0 0.000143348623853 0 1 -1
incomplete,depletion 1.0 0.000143348623853 0 1 -1
was,well 1.0 0.000143348623853 0 1 -1
wshow,that 0.0 0.0 1 1 0
protease,inhibitor 0.5 0.000286697247706 1 3 -2
levels,for 1.0 0.000143348623853 0 1 -1
min,mean 1.0 0.000143348623853 1 0 1
to,establish 0.333333333333 0.000143348623853 1 2 -1
amitriptyline,concurrent 1.0 0.000143348623853 1 0 1
glucuronidation,and 1.0 0.000143348623853 0 1 -1
synthesis,and 0.5 0.000286697247706 1 3 -2
with,type 1.0 0.00043004587156 0 3 -3
randomly,assigned 1.0 0.00043004587156 0 3 -3
a,hmg-coa 1.0 0.000143348623853 1 0 1
and,mg2 1.0 0.000143348623853 0 1 -1
mofetil,ml 1.0 0.000143348623853 0 1 -1
in,organ 1.0 0.000143348623853 1 0 1
coadministered,oral 1.0 0.000143348623853 1 0 1
urine,glucose 1.0 0.000143348623853 0 1 -1
diazepam,at 1.0 0.000143348623853 1 0 1
dose,even 1.0 0.000143348623853 0 1 -1
with,difluoroacetone 1.0 0.000143348623853 0 1 -1
with,ibandronate 1.0 0.000286697247706 0 2 -2
on,over 1.0 0.000143348623853 0 1 -1
and,low 1.0 0.000286697247706 0 2 -2
also,potentiate 1.0 0.000143348623853 1 0 1
listed,in 1.0 0.000286697247706 0 2 -2
certain,brain 1.0 0.000143348623853 0 1 -1
week,endoscopy 1.0 0.000143348623853 0 1 -1
c19,and 1.0 0.000143348623853 0 1 -1
increases,platelet 1.0 0.000143348623853 0 1 -1
triazolo-benzodiazepines,dihydropyridine 1.0 0.000143348623853 1 0 1
receiving,tambocor 1.0 0.000143348623853 1 0 1
dexbrompheniramine,can 1.0 0.000286697247706 2 0 2
oral,contraceptive 1.0 0.000286697247706 0 2 -2
second,test 1.0 0.000143348623853 0 1 -1
since,this 1.0 0.000143348623853 0 1 -1
times,and 1.0 0.000143348623853 0 1 -1
divalent,or 1.0 0.000286697247706 0 2 -2
both,groups 1.0 0.000716743119266 0 5 -5
or,to 0.333333333333 0.000716743119266 5 10 -5
consequences,following 1.0 0.000286697247706 0 2 -2
category,and 0.333333333333 0.000143348623853 1 2 -1
study,a 0.0 0.0 1 1 0
bedtime,and 1.0 0.000143348623853 0 1 -1
study,n 1.0 0.000143348623853 1 0 1
n,later 1.0 0.000143348623853 0 1 -1
studied,with 0.0 0.0 1 1 0
which,prolong 1.0 0.000143348623853 0 1 -1
of,central 1.0 0.000286697247706 2 0 2
during,pregnancy 1.0 0.00043004587156 0 3 -3
of,adequate 0.0 0.0 1 1 0
ophthalmic,suspension 1.0 0.000143348623853 0 1 -1
since,both 0.0 0.0 1 1 0
beta,cells 1.0 0.000143348623853 0 1 -1
or,t3 1.0 0.000286697247706 0 2 -2
believed,to 1.0 0.000143348623853 0 1 -1
increase,plasmaconcentration 1.0 0.000143348623853 1 0 1
that,levels 1.0 0.000573394495413 4 0 4
one,event 1.0 0.000143348623853 0 1 -1
sustiva,has 1.0 0.000143348623853 1 0 1
studies,vardenafil 1.0 0.000143348623853 0 1 -1
is,more 1.0 0.000143348623853 0 1 -1
antihistamines,may 1.0 0.00043004587156 3 0 3
correlated,with 1.0 0.000286697247706 0 2 -2
dose,in 0.272727272727 0.00043004587156 4 7 -3
insulin,parameters 1.0 0.000143348623853 0 1 -1
dose,if 1.0 0.000143348623853 1 0 1
oral,birth 1.0 0.000143348623853 0 1 -1
table,changes 1.0 0.000143348623853 0 1 -1
constant,while 1.0 0.000143348623853 0 1 -1
similarly,there 1.0 0.000143348623853 0 1 -1
can,blunt 1.0 0.000143348623853 0 1 -1
nsclc,patients 1.0 0.000143348623853 0 1 -1
cyp1a2-mediated,metabolism 1.0 0.000143348623853 0 1 -1
dose,is 0.333333333333 0.000143348623853 2 1 1
for,free 1.0 0.000143348623853 0 1 -1
to,open 1.0 0.000143348623853 1 0 1
medication,tell 1.0 0.000143348623853 0 1 -1
misuse,of 1.0 0.000143348623853 1 0 1
because,amplifies 1.0 0.000143348623853 1 0 1
accumulation,characteristic 1.0 0.000143348623853 0 1 -1
by,competing 1.0 0.000286697247706 2 0 2
reflective,of 1.0 0.000143348623853 0 1 -1
small,clinical 1.0 0.000143348623853 0 1 -1
suspected,to 1.0 0.000286697247706 0 2 -2
usually,prescribed 1.0 0.00100344036697 0 7 -7
tiagabine,had 1.0 0.000286697247706 0 2 -2
taking,monoamine 1.0 0.000143348623853 1 0 1
no,clinically 0.953488372093 0.00587729357798 1 42 -41
longer,in 0.0 0.0 1 1 0
serial,plasma 1.0 0.000143348623853 0 1 -1
arrival,of 1.0 0.000143348623853 0 1 -1
is,notable 1.0 0.000143348623853 0 1 -1
designed,to 1.0 0.00043004587156 0 3 -3
or,abolished 1.0 0.000143348623853 1 0 1
both,of 0.5 0.000286697247706 1 3 -2
atromid-s,neoral 1.0 0.000143348623853 1 0 1
well,acquainted 1.0 0.000143348623853 0 1 -1
neurotoxic,therapy 1.0 0.000143348623853 0 1 -1
synthase,inhibiting 1.0 0.000143348623853 1 0 1
the,site 1.0 0.00043004587156 0 3 -3
would,coincide 1.0 0.000143348623853 0 1 -1
agents,class 1.0 0.000143348623853 0 1 -1
in,overall 1.0 0.000143348623853 0 1 -1
ethanol,or 1.0 0.000143348623853 0 1 -1
the,more 1.0 0.000143348623853 0 1 -1
an,i-labelled 1.0 0.000286697247706 0 2 -2
his,death 1.0 0.000143348623853 0 1 -1
therefore,intake 1.0 0.000143348623853 0 1 -1
unless,really 1.0 0.000143348623853 0 1 -1
hormonal,components 1.0 0.000143348623853 1 0 1
action,which 1.0 0.000143348623853 0 1 -1
and,concentration 1.0 0.000143348623853 0 1 -1
decrease,platelet 1.0 0.00043004587156 0 3 -3
this,property 1.0 0.000143348623853 0 1 -1
ketoconazole,potential 1.0 0.000143348623853 1 0 1
we,demonstrate 1.0 0.000286697247706 0 2 -2
seemingly,adequate 1.0 0.000143348623853 0 1 -1
a,should 1.0 0.000143348623853 1 0 1
metabolism,inhibitors 1.0 0.000143348623853 1 0 1
cimetidine,concomitant 0.0 0.0 1 1 0
drug,metabolized 1.0 0.000143348623853 0 1 -1
problems,will 1.0 0.000716743119266 5 0 5
human,trials 1.0 0.000143348623853 1 0 1
safely,to 1.0 0.000143348623853 0 1 -1
following,table 1.0 0.000286697247706 0 2 -2
can,give 0.5 0.000286697247706 1 3 -2
be,unresponsive 1.0 0.000860091743119 0 6 -6
given,very 1.0 0.000143348623853 1 0 1
agents,patients 1.0 0.000143348623853 1 0 1
antiretroviral,agents 1.0 0.000286697247706 0 2 -2
b-lactam,renal 1.0 0.000143348623853 1 0 1
patients,received 1.0 0.000286697247706 0 2 -2
mice,and 1.0 0.000143348623853 0 1 -1
most,and 1.0 0.000143348623853 0 1 -1
than,the 1.0 0.00229357798165 0 16 -16
inducer,although 1.0 0.000143348623853 0 1 -1
antagonistic,to 1.0 0.000143348623853 1 0 1
through,effects 1.0 0.000143348623853 1 0 1
groups,fed 1.0 0.000143348623853 0 1 -1
erythro-fluorocitrate,in 1.0 0.000143348623853 1 0 1
be,alert 0.0 0.0 2 2 0
although,studies 1.0 0.000143348623853 0 1 -1
of,limit 1.0 0.000143348623853 0 1 -1
also,assessed 1.0 0.000143348623853 0 1 -1
were,reflected 1.0 0.000143348623853 0 1 -1
novo,renal 1.0 0.000143348623853 0 1 -1
histidine,residues 1.0 0.000716743119266 0 5 -5
interest,to 1.0 0.000143348623853 0 1 -1
symptoms,support 1.0 0.000143348623853 0 1 -1
only,significantly 1.0 0.000143348623853 0 1 -1
nih-3t3,cells 1.0 0.000286697247706 0 2 -2
excretion,and 0.333333333333 0.000143348623853 1 2 -1
approval,by 1.0 0.000143348623853 0 1 -1
a,tool 1.0 0.000143348623853 0 1 -1
to,topoisomerase-targeted 1.0 0.000143348623853 0 1 -1
gel,with 1.0 0.000143348623853 0 1 -1
by,intraventricular 0.333333333333 0.000143348623853 1 2 -1
the,link 1.0 0.000143348623853 0 1 -1
antimicrobial,combinations 0.0 0.0 1 1 0
eight,poisonings 1.0 0.000143348623853 0 1 -1
potential,effect 1.0 0.000286697247706 0 2 -2
body,and 1.0 0.000143348623853 0 1 -1
auc0-120hr,by 1.0 0.000143348623853 1 0 1
there,was 0.631578947368 0.00344036697248 7 31 -24
isoenzymes,will 1.0 0.000143348623853 0 1 -1
deals,with 1.0 0.000143348623853 0 1 -1
therapeutic,window 1.0 0.000143348623853 1 0 1
study,which 1.0 0.000143348623853 0 1 -1
trisphosphate,insp 1.0 0.000143348623853 0 1 -1
of,and 0.258687258687 0.00960435779817 163 96 67
and,proposed 1.0 0.000143348623853 0 1 -1
once,every 1.0 0.000286697247706 0 2 -2
was,established 1.0 0.000143348623853 0 1 -1
to,loss 1.0 0.00114678899083 0 8 -8
for,virtually 1.0 0.000143348623853 0 1 -1
of,gl 0.5 0.000286697247706 1 3 -2
of,gi 1.0 0.00043004587156 3 0 3
specific,for 1.0 0.000143348623853 0 1 -1
medications,were 0.333333333333 0.000143348623853 1 2 -1
administration,appeared 1.0 0.000143348623853 0 1 -1
use,younger 1.0 0.000143348623853 0 1 -1
develop,delirium 1.0 0.000143348623853 1 0 1
agents,other 1.0 0.000143348623853 1 0 1
anticoagulant,therapy 1.0 0.000143348623853 1 0 1
causing,no 1.0 0.000143348623853 0 1 -1
collapse,and 1.0 0.000143348623853 0 1 -1
salt,intake 1.0 0.000716743119266 5 0 5
parametric,dose-response 1.0 0.000143348623853 0 1 -1
hormonal,since 1.0 0.000143348623853 0 1 -1
vascular,response 1.0 0.000143348623853 1 0 1
of,extractable 1.0 0.000143348623853 0 1 -1
capacity,to 0.333333333333 0.000143348623853 1 2 -1
administered,concomitantly 0.105263157895 0.000573394495413 21 17 4
a,family 0.333333333333 0.000143348623853 1 2 -1
highlights,novel 1.0 0.000143348623853 0 1 -1
daily,morning 1.0 0.000143348623853 0 1 -1
units,day 1.0 0.000143348623853 0 1 -1
loop,or 1.0 0.000143348623853 1 0 1
intervals,caution 1.0 0.000143348623853 0 1 -1
increased,his 1.0 0.000143348623853 0 1 -1
gram,of 1.0 0.000286697247706 2 0 2
agents,produced 1.0 0.000143348623853 0 1 -1
with,systemically-administered 1.0 0.000143348623853 1 0 1
physiologic,effects 1.0 0.000143348623853 0 1 -1
the,germinal 1.0 0.000143348623853 0 1 -1
inhibited,to 1.0 0.000143348623853 0 1 -1
antacids,nonclinical 1.0 0.000143348623853 0 1 -1
for,auc 0.333333333333 0.000143348623853 1 2 -1
bsa,when 1.0 0.000286697247706 0 2 -2
of,demonstrated 1.0 0.00043004587156 0 3 -3
diuresis,electrocardiogram 1.0 0.000143348623853 0 1 -1
exjade,and 1.0 0.000286697247706 0 2 -2
corticotropin,acth 1.0 0.000143348623853 1 0 1
non-steroidal,antiinflammatory 1.0 0.000143348623853 1 0 1
by,antiresistance 1.0 0.000143348623853 0 1 -1
of,arava 1.0 0.000286697247706 2 0 2
urine,when 1.0 0.000286697247706 0 2 -2
revealed,a 1.0 0.000143348623853 0 1 -1
that,fluvoxamine 1.0 0.000143348623853 1 0 1
of,ovulation 1.0 0.000143348623853 0 1 -1
history,prior 1.0 0.000143348623853 0 1 -1
is,metabolized 1.0 0.00387041284404 0 27 -27
mean,changes 1.0 0.000143348623853 0 1 -1
diastolic,or 1.0 0.000143348623853 0 1 -1
a,displays 1.0 0.000143348623853 0 1 -1
have,had 1.0 0.000143348623853 1 0 1
man,we 1.0 0.000143348623853 0 1 -1
including,electrocardiographic 1.0 0.000143348623853 0 1 -1
castor,oil 1.0 0.000143348623853 0 1 -1
that,exposure 1.0 0.000286697247706 2 0 2
by,inhibition 0.142857142857 0.000143348623853 3 4 -1
tachycardia,in 1.0 0.000143348623853 1 0 1
a,steady 1.0 0.000143348623853 0 1 -1
dinitrate,may 1.0 0.000143348623853 1 0 1
the,pattern 1.0 0.000143348623853 0 1 -1
glucose,tests 1.0 0.000860091743119 0 6 -6
in,increases 1.0 0.000573394495413 4 0 4
state,while 1.0 0.000143348623853 1 0 1
in,increased 0.142857142857 0.00043004587156 12 9 3
significance,the 1.0 0.000143348623853 0 1 -1
microdilution,method 1.0 0.000143348623853 0 1 -1
abuse,of 1.0 0.000143348623853 0 1 -1
ml,at 1.0 0.000143348623853 0 1 -1
sites,in 1.0 0.00043004587156 0 3 -3
without,mg 1.0 0.000143348623853 0 1 -1
by,using 1.0 0.00043004587156 0 3 -3
agents,highly 1.0 0.000143348623853 0 1 -1
buffalo,hump 1.0 0.000143348623853 0 1 -1
their,patients 1.0 0.000143348623853 0 1 -1
learning,and 1.0 0.000286697247706 0 2 -2
results,everolimus 1.0 0.000143348623853 0 1 -1
toxicity,such 1.0 0.000143348623853 0 1 -1
to,need 1.0 0.000143348623853 0 1 -1
other,nonsteroidal 0.333333333333 0.00043004587156 6 3 3
in,previous 0.0 0.0 1 1 0
iodine-containing,preparations 1.0 0.000143348623853 0 1 -1
by,therapeutic 1.0 0.000143348623853 0 1 -1
that,associated 1.0 0.000143348623853 0 1 -1
cimetidine,increased 0.0 0.0 1 1 0
symptoms,should 1.0 0.000143348623853 0 1 -1
mg,tricor 1.0 0.000286697247706 2 0 2
analgesia,and 1.0 0.000286697247706 0 2 -2
cimetidine,increases 1.0 0.000143348623853 1 0 1
to,administering 1.0 0.000143348623853 1 0 1
after,cessation 1.0 0.000286697247706 0 2 -2
if,effect 1.0 0.000143348623853 0 1 -1
seven,days 1.0 0.00043004587156 0 3 -3
h,up 1.0 0.000143348623853 0 1 -1
cytochromes,p450 1.0 0.000286697247706 0 2 -2
kit,may 1.0 0.000143348623853 0 1 -1
vitamin-d,mediated 1.0 0.000143348623853 0 1 -1
incubation,at 1.0 0.000143348623853 0 1 -1
or,after 1.0 0.00043004587156 3 0 3
by,self-injection 1.0 0.000143348623853 0 1 -1
unlikely,that 1.0 0.000573394495413 0 4 -4
inhibition,was 1.0 0.000143348623853 0 1 -1
thromboplastin,time 1.0 0.00043004587156 0 3 -3
chlorotrianisene,may 1.0 0.000143348623853 1 0 1
recorded,with 1.0 0.000143348623853 0 1 -1
avoid,while 1.0 0.000143348623853 1 0 1
patient,maintained 1.0 0.000286697247706 2 0 2
by,determination 1.0 0.000286697247706 0 2 -2
a,including 1.0 0.000143348623853 1 0 1
accounts,for 1.0 0.000143348623853 0 1 -1
faecalis,by 1.0 0.000143348623853 0 1 -1
mice,min 1.0 0.000143348623853 0 1 -1
dosing,has 1.0 0.000143348623853 0 1 -1
formed,via 1.0 0.000143348623853 0 1 -1
cardiac,contractility 0.333333333333 0.000143348623853 2 1 1
studied,as 1.0 0.000143348623853 0 1 -1
acceptable,alternatives 1.0 0.000143348623853 0 1 -1
times,rat 1.0 0.000143348623853 0 1 -1
excreted,in 1.0 0.000860091743119 0 6 -6
to,recommend 1.0 0.000143348623853 0 1 -1
caused,to 1.0 0.000143348623853 1 0 1
average,and 1.0 0.000143348623853 1 0 1
kaposi,s 1.0 0.000143348623853 0 1 -1
further,increased 1.0 0.000143348623853 0 1 -1
clozapine,is 0.0 0.0 1 1 0
test,period 1.0 0.000143348623853 1 0 1
accutane,have 1.0 0.000143348623853 0 1 -1
clozapine,in 1.0 0.000143348623853 0 1 -1
undergoing,vigorous 1.0 0.000143348623853 0 1 -1
the,severity 1.0 0.000143348623853 1 0 1
failure,are 1.0 0.000143348623853 0 1 -1
when,proquin 1.0 0.000143348623853 0 1 -1
on,natriuresis 1.0 0.000143348623853 1 0 1
of,would 1.0 0.000143348623853 0 1 -1
heat,stimulus 1.0 0.000143348623853 0 1 -1
of,concurrently 1.0 0.000143348623853 0 1 -1
the,inr 1.0 0.000143348623853 0 1 -1
decrease,mean 1.0 0.000143348623853 0 1 -1
or,subjective 1.0 0.000143348623853 0 1 -1
orthostatic,hypotension 0.2 0.000143348623853 3 2 1
known,which 1.0 0.000143348623853 0 1 -1
sodium,nor 1.0 0.000143348623853 0 1 -1
sst,were 1.0 0.000143348623853 0 1 -1
the,survanta 1.0 0.000143348623853 0 1 -1
uptake,inhibitor 1.0 0.000143348623853 0 1 -1
to,accelerate 1.0 0.000143348623853 0 1 -1
intravenous,topical 1.0 0.00043004587156 0 3 -3
test,but 1.0 0.000143348623853 0 1 -1
totally,atoxic 1.0 0.000143348623853 0 1 -1
upon,cytochrome 1.0 0.000143348623853 0 1 -1
see,warnings 0.2 0.000143348623853 2 3 -1
drug-laboratory,test 1.0 0.000573394495413 0 4 -4
higher,degrees 1.0 0.000143348623853 1 0 1
transient,increase 1.0 0.000143348623853 0 1 -1
failure,during 1.0 0.000143348623853 0 1 -1
and,acute 1.0 0.000143348623853 1 0 1
glucose,enzymatic 1.0 0.000143348623853 0 1 -1
impactor,for 1.0 0.000143348623853 0 1 -1
lithium,nonsteroidal 1.0 0.000143348623853 1 0 1
from,ois 1.0 0.000143348623853 0 1 -1
and,these 1.0 0.00143348623853 0 10 -10
c,max 0.454545454545 0.000716743119266 3 8 -5
vs,and 0.0 0.0 1 1 0
covers,pharmacology 1.0 0.000143348623853 0 1 -1
eaca,inhibits 1.0 0.000143348623853 0 1 -1
will,interfere 1.0 0.000143348623853 1 0 1
advantages,offered 1.0 0.000143348623853 0 1 -1
and,moderate 1.0 0.000143348623853 1 0 1
cas,a 1.0 0.000143348623853 0 1 -1
include,a 1.0 0.000143348623853 0 1 -1
products,ace 1.0 0.000286697247706 0 2 -2
copaxone,has 1.0 0.000143348623853 0 1 -1
decrease,absorption 1.0 0.000143348623853 1 0 1
pronounced,in 1.0 0.00043004587156 0 3 -3
buforin,ii 0.5 0.000286697247706 1 3 -2
in,concentrations 1.0 0.000286697247706 2 0 2
inr,at 1.0 0.000143348623853 0 1 -1
multiple,doses 0.0769230769231 0.000143348623853 6 7 -1
tests,benedicts 1.0 0.000286697247706 0 2 -2
presentation,of 1.0 0.000143348623853 1 0 1
therefore,prothrombin 1.0 0.000143348623853 1 0 1
during,whole-cell 1.0 0.000143348623853 0 1 -1
bsa,caused 1.0 0.000143348623853 0 1 -1
as,choline 1.0 0.000143348623853 1 0 1
as,acetylsalicylic 0.333333333333 0.000143348623853 2 1 1
false-positive,test 1.0 0.000143348623853 0 1 -1
ast,times 1.0 0.000143348623853 0 1 -1
glutathione,use 1.0 0.000143348623853 1 0 1
concentration,especially 1.0 0.000143348623853 1 0 1
altered,consciousness 1.0 0.000143348623853 1 0 1
mean,maximum 1.0 0.000143348623853 1 0 1
significant,hypotension 1.0 0.000143348623853 1 0 1
blood,samples 1.0 0.00043004587156 0 3 -3
transfected,with 1.0 0.000143348623853 0 1 -1
hcl,has 0.0 0.0 1 1 0
hg,compared 1.0 0.000286697247706 2 0 2
equivalent,to 0.0 0.0 2 2 0
also,taking 1.0 0.000143348623853 1 0 1
intoxication,plasma 1.0 0.000143348623853 0 1 -1
combines,with 1.0 0.000143348623853 0 1 -1
angiotensins,inhibited 1.0 0.000143348623853 0 1 -1
suitable,coagulation 0.428571428571 0.00043004587156 2 5 -3
half-life,less 1.0 0.000143348623853 0 1 -1
contraception,is 1.0 0.000143348623853 0 1 -1
the,simplest 1.0 0.000143348623853 0 1 -1
arrhythmias,who 1.0 0.000143348623853 0 1 -1
agents,are 0.538461538462 0.00100344036697 10 3 7
phenobarbital,primidone 1.0 0.000143348623853 1 0 1
this,oxidation 1.0 0.000143348623853 0 1 -1
normal,levels 1.0 0.000143348623853 0 1 -1
bound,would 1.0 0.000143348623853 0 1 -1
dasatinib,and 1.0 0.000143348623853 0 1 -1
as,competition 0.0 0.0 1 1 0
kda,adapter 1.0 0.000143348623853 0 1 -1
following,interactions 0.2 0.000143348623853 2 3 -1
animal,or 1.0 0.000143348623853 0 1 -1
inhibitory,activity 0.0 0.0 2 2 0
used,during 1.0 0.000716743119266 0 5 -5
trials,performed 1.0 0.000143348623853 0 1 -1
transport,were 1.0 0.000143348623853 0 1 -1
gel,until 1.0 0.000143348623853 0 1 -1
impairment,particularly 1.0 0.000143348623853 0 1 -1
deficits,in 1.0 0.000143348623853 0 1 -1
conditions,and 1.0 0.000143348623853 0 1 -1
mice,in 1.0 0.000143348623853 0 1 -1
a,mao 1.0 0.000143348623853 1 0 1
dissolution,in 1.0 0.000143348623853 0 1 -1
of,intrinsic 1.0 0.000143348623853 0 1 -1
estradiol,levels 1.0 0.000143348623853 1 0 1
moderate,inducer 1.0 0.000143348623853 0 1 -1
vioxx,therapy 1.0 0.000143348623853 1 0 1
every,other 1.0 0.000573394495413 0 4 -4
and,commonly 1.0 0.000143348623853 0 1 -1
a,may 1.0 0.000143348623853 1 0 1
prepared,in 1.0 0.000143348623853 0 1 -1
different,levels 1.0 0.000143348623853 0 1 -1
and,numerous 1.0 0.000143348623853 0 1 -1
enhanced,clearance 1.0 0.000143348623853 1 0 1
times,after 1.0 0.000143348623853 0 1 -1
carefully,considered 1.0 0.000143348623853 1 0 1
clear,within 1.0 0.000143348623853 0 1 -1
study,suggested 1.0 0.000143348623853 0 1 -1
class,drug 1.0 0.000286697247706 0 2 -2
however,were 1.0 0.000143348623853 0 1 -1
develop,physiological 1.0 0.000143348623853 0 1 -1
additional,research 1.0 0.000143348623853 0 1 -1
pigeons,and 1.0 0.00043004587156 0 3 -3
beta,adrenergic-blocking 1.0 0.000143348623853 0 1 -1
bar-press,response 1.0 0.000143348623853 0 1 -1
antimicrobial,agents 1.0 0.000143348623853 0 1 -1
much,as 0.333333333333 0.000143348623853 1 2 -1
psychotic,patients 1.0 0.000286697247706 0 2 -2
perfused,pancreases 1.0 0.000143348623853 0 1 -1
or,hits 1.0 0.000143348623853 0 1 -1
therefore,doses 1.0 0.000143348623853 0 1 -1
in,one 0.2 0.000286697247706 4 6 -2
rate,at 1.0 0.000286697247706 0 2 -2
combined,transcriptional 1.0 0.000143348623853 0 1 -1
enhanced,tendency 1.0 0.000143348623853 0 1 -1
data,relating 1.0 0.000143348623853 0 1 -1
between,zoladex 1.0 0.000143348623853 0 1 -1
the,neurochemical 1.0 0.000143348623853 0 1 -1
less,enzyme 1.0 0.000286697247706 0 2 -2
of,bextra 1.0 0.000143348623853 0 1 -1
and,international 0.0 0.0 1 1 0
gelatinosa,neurons 1.0 0.000143348623853 0 1 -1
when,combining 1.0 0.000143348623853 0 1 -1
if,co-administration 1.0 0.000286697247706 0 2 -2
selective,marker 1.0 0.000143348623853 0 1 -1
aptt,assay 1.0 0.000143348623853 0 1 -1
concentration,time-curve 1.0 0.000143348623853 1 0 1
substantial,inactivation 1.0 0.000143348623853 1 0 1
t1,of 1.0 0.000143348623853 1 0 1
hepatotoxicity,of 1.0 0.000143348623853 1 0 1
increased,over 1.0 0.000143348623853 1 0 1
administration,reaching 1.0 0.000143348623853 0 1 -1
was,tested 1.0 0.00043004587156 0 3 -3
and,renal 0.2 0.000286697247706 6 4 2
in,b-cell 1.0 0.000143348623853 0 1 -1
literature,that 1.0 0.000143348623853 0 1 -1
african,trypanosomiasis 1.0 0.000143348623853 0 1 -1
activity,ganglionic 1.0 0.000143348623853 0 1 -1
with,congestive 0.333333333333 0.000143348623853 1 2 -1
neuron,blocking 1.0 0.000143348623853 0 1 -1
compounds,are 0.0 0.0 1 1 0
require,the 1.0 0.000143348623853 0 1 -1
with,general 1.0 0.000286697247706 0 2 -2
unexpected,hypotension 1.0 0.000143348623853 0 1 -1
these,two 0.666666666667 0.000573394495413 1 5 -4
arrhythmias,or 1.0 0.000143348623853 0 1 -1
relationship,to 1.0 0.000286697247706 0 2 -2
that,range 1.0 0.000143348623853 1 0 1
alternate,or 1.0 0.000143348623853 0 1 -1
cimetidine,coadministration 1.0 0.000143348623853 1 0 1
concentration,in 1.0 0.000143348623853 0 1 -1
apply,to 1.0 0.000143348623853 0 1 -1
been,associated 0.285714285714 0.00114678899083 18 10 8
active,metabolite 0.181818181818 0.000573394495413 9 13 -4
inability,to 1.0 0.000143348623853 0 1 -1
acquisition,cost 1.0 0.000286697247706 0 2 -2
vii,when 1.0 0.000143348623853 0 1 -1
and,tumour 1.0 0.000143348623853 0 1 -1
being,withdrawn 0.6 0.00043004587156 1 4 -3
additional,pharmacokinetic 1.0 0.000143348623853 0 1 -1
beadministered,concomitantly 1.0 0.000286697247706 2 0 2
addition,new 1.0 0.000286697247706 0 2 -2
not,antagonized 1.0 0.000143348623853 0 1 -1
immune,response 1.0 0.000286697247706 0 2 -2
providing,for 1.0 0.000143348623853 0 1 -1
regimen,of 0.428571428571 0.000860091743119 10 4 6
undergo,hydrolysis 1.0 0.000143348623853 0 1 -1
v,solution 1.0 0.000143348623853 0 1 -1
ratio,and 1.0 0.000143348623853 0 1 -1
node,higher 1.0 0.000143348623853 1 0 1
cells,from 1.0 0.000143348623853 0 1 -1
temporarily,raise 1.0 0.000143348623853 1 0 1
than,pediatrics 1.0 0.000143348623853 1 0 1
ethanol,an 1.0 0.000143348623853 1 0 1
suspension,contains 1.0 0.000143348623853 0 1 -1
chloramphenicol,or 1.0 0.000143348623853 1 0 1
greater,when 1.0 0.000143348623853 1 0 1
methods,the 1.0 0.000143348623853 0 1 -1
and,reduction 1.0 0.000143348623853 1 0 1
alfenta,can 1.0 0.000143348623853 1 0 1
fluoroquinolone,has 1.0 0.000143348623853 1 0 1
adp,and 1.0 0.000143348623853 0 1 -1
fluoride,levels 1.0 0.000143348623853 0 1 -1
also,resolved 1.0 0.000143348623853 0 1 -1
cell,body 1.0 0.000143348623853 0 1 -1
borderline,statistical 1.0 0.000143348623853 0 1 -1
the,beta 1.0 0.000143348623853 1 0 1
to,receive 1.0 0.000573394495413 0 4 -4
generally,asymptomatic 1.0 0.000143348623853 0 1 -1
of,uncertain 1.0 0.000143348623853 0 1 -1
used,anti-peptic 1.0 0.000143348623853 0 1 -1
slight,decrease 1.0 0.000286697247706 2 0 2
d6,hydroxylase 1.0 0.000573394495413 0 4 -4
higher,changes 1.0 0.000143348623853 0 1 -1
sharp,fall 1.0 0.000143348623853 1 0 1
warnings,congestive 1.0 0.000143348623853 0 1 -1
on,either 1.0 0.00129013761468 0 9 -9
critical,role 1.0 0.000143348623853 0 1 -1
studies,indicated 1.0 0.000286697247706 0 2 -2
maximum,tolerated 1.0 0.000143348623853 0 1 -1
perforatum,warning 1.0 0.000143348623853 0 1 -1
qd,has 1.0 0.000143348623853 0 1 -1
the,inulin 1.0 0.000143348623853 0 1 -1
agents,when 0.6 0.00043004587156 4 1 3
as,low 1.0 0.000143348623853 0 1 -1
mono-oxidases,in 1.0 0.000143348623853 0 1 -1
with,had 1.0 0.000286697247706 0 2 -2
orally,has 1.0 0.000143348623853 0 1 -1
or,times 1.0 0.000143348623853 0 1 -1
concurrent,therapy 0.111111111111 0.000143348623853 5 4 1
days,plus 1.0 0.000143348623853 0 1 -1
with,flolan 1.0 0.000286697247706 2 0 2
with,has 0.0909090909091 0.000143348623853 5 6 -1
cancidas,and 1.0 0.000143348623853 1 0 1
hyperpyrexia,has 1.0 0.000143348623853 1 0 1
telithromycin,hiv 1.0 0.000143348623853 0 1 -1
taking,vitamin 1.0 0.000143348623853 1 0 1
tested,and 1.0 0.000143348623853 0 1 -1
cpk,some 1.0 0.000143348623853 0 1 -1
as,loop 1.0 0.000143348623853 1 0 1
their,concurrent 1.0 0.000143348623853 0 1 -1
cimetidine,a 1.0 0.000143348623853 1 0 1
txb2,generation 1.0 0.000143348623853 0 1 -1
anafranil,in 1.0 0.000143348623853 0 1 -1
in,density 1.0 0.000143348623853 0 1 -1
cyp2d6,many 1.0 0.000143348623853 0 1 -1
degree,of 0.157894736842 0.00043004587156 8 11 -3
anafranil,is 0.333333333333 0.000143348623853 2 1 1
give,you 1.0 0.000143348623853 0 1 -1
pain,tinnitus 1.0 0.000143348623853 0 1 -1
that,haldol 1.0 0.000143348623853 1 0 1
intraperitoneal,doses 1.0 0.000143348623853 1 0 1
factors,as 1.0 0.000143348623853 0 1 -1
possible,potentiation 1.0 0.000143348623853 0 1 -1
usually,recommended 1.0 0.000143348623853 0 1 -1
pegasys,may 1.0 0.000143348623853 0 1 -1
and,short-acting 1.0 0.000143348623853 0 1 -1
welchol,has 1.0 0.000143348623853 0 1 -1
i,acute 1.0 0.000143348623853 0 1 -1
of,fatty 1.0 0.000143348623853 0 1 -1
the,can 1.0 0.000143348623853 0 1 -1
therefore,use 1.0 0.000143348623853 1 0 1
systems,and 1.0 0.000286697247706 0 2 -2
his,logical 1.0 0.000143348623853 0 1 -1
endothelial,denudation 1.0 0.000143348623853 0 1 -1
constructive,alternatives 1.0 0.000143348623853 0 1 -1
result,may 1.0 0.000286697247706 0 2 -2
fibrillation,their 1.0 0.000143348623853 1 0 1
agents,actions 1.0 0.000143348623853 0 1 -1
hypokalemia,and 1.0 0.000143348623853 0 1 -1
in,myocardium 1.0 0.000143348623853 0 1 -1
likely,by 1.0 0.000143348623853 1 0 1
with,hyperthyroidism 1.0 0.000143348623853 0 1 -1
the,protein 0.0 0.0 2 2 0
pegasys,is 1.0 0.000286697247706 0 2 -2
reported,very 1.0 0.000143348623853 1 0 1
that,alters 1.0 0.000143348623853 0 1 -1
some,general 1.0 0.000143348623853 0 1 -1
her,and 1.0 0.000143348623853 0 1 -1
same,proportions 1.0 0.000143348623853 0 1 -1
on,monoamine 1.0 0.000143348623853 0 1 -1
conclusions,macrolide 1.0 0.000143348623853 1 0 1
the,evening 0.333333333333 0.000143348623853 1 2 -1
glutamic,acid 1.0 0.000143348623853 1 0 1
educational,messages 1.0 0.000143348623853 0 1 -1
but,mc 1.0 0.000143348623853 1 0 1
identified,involving 1.0 0.000143348623853 1 0 1
m,ptx 1.0 0.000143348623853 1 0 1
trials,that 1.0 0.000143348623853 0 1 -1
a,balanced 1.0 0.000143348623853 0 1 -1
by,decreased 0.5 0.000286697247706 3 1 2
anticoagulants,including 1.0 0.000143348623853 1 0 1
mimic,certain 1.0 0.000143348623853 0 1 -1
of,cancer 1.0 0.000286697247706 0 2 -2
during,short-term 1.0 0.000143348623853 0 1 -1
albicans,one 1.0 0.000143348623853 0 1 -1
the,prolongation 0.333333333333 0.000143348623853 2 1 1
serum,uric 0.333333333333 0.000143348623853 1 2 -1
multidrug-resistant,organisms 1.0 0.000143348623853 0 1 -1
increase,risk 1.0 0.000143348623853 0 1 -1
all,animals 1.0 0.000286697247706 0 2 -2
of,catecholamines 1.0 0.000143348623853 0 1 -1
high,affinity 1.0 0.00043004587156 0 3 -3
digoxin,supraventricular 1.0 0.000143348623853 0 1 -1
all,volunteers 1.0 0.000143348623853 0 1 -1
that,seen 1.0 0.000143348623853 0 1 -1
and,usually 1.0 0.000286697247706 2 0 2
optimal,designs 1.0 0.000143348623853 0 1 -1
structurally,distinct 1.0 0.000143348623853 0 1 -1
antipsychotic,efficacy 1.0 0.000143348623853 0 1 -1
extrapyramidal,symptoms 0.0 0.0 1 1 0
job,appointments 1.0 0.000143348623853 0 1 -1
neurons,displaying 1.0 0.000143348623853 0 1 -1
squares,approach 1.0 0.000143348623853 0 1 -1
consequently,plasma 1.0 0.000143348623853 0 1 -1
include,increased 1.0 0.000143348623853 1 0 1
with,grapefruit 1.0 0.000143348623853 0 1 -1
more,feasible 1.0 0.000143348623853 0 1 -1
paroxetine,mg 1.0 0.000143348623853 1 0 1
who,has 1.0 0.000286697247706 2 0 2
low,affinity 1.0 0.000143348623853 0 1 -1
m2,dose 1.0 0.000286697247706 0 2 -2
who,had 0.666666666667 0.000573394495413 1 5 -4
and,persistent 1.0 0.000143348623853 1 0 1
this,effort 1.0 0.000143348623853 0 1 -1
of,intramuscularly 1.0 0.000143348623853 0 1 -1
non-potassium,sparing 1.0 0.000143348623853 1 0 1
substances,affect 1.0 0.000286697247706 0 2 -2
acid,as 1.0 0.000143348623853 1 0 1
but,did 0.2 0.000143348623853 3 2 1
give,rise 0.0 0.0 1 1 0
of,body 1.0 0.000286697247706 0 2 -2
findings,indicate 1.0 0.000143348623853 0 1 -1
cyp3a4,ketoconazole 1.0 0.000143348623853 0 1 -1
data,that 1.0 0.000143348623853 0 1 -1
bruising,nosebleeds 1.0 0.000143348623853 0 1 -1
tumor,that 1.0 0.000143348623853 0 1 -1
clinical,isolates 1.0 0.000286697247706 0 2 -2
produced,approximately 1.0 0.000143348623853 0 1 -1
ns,is 1.0 0.000143348623853 1 0 1
day,approximately 1.0 0.000573394495413 0 4 -4
and,requires 0.333333333333 0.000143348623853 2 1 1
of,hmg-coa 0.2 0.000143348623853 2 3 -1
this,change 1.0 0.000143348623853 0 1 -1
rat,days 1.0 0.00043004587156 0 3 -3
placebo-controlled,trial 1.0 0.000143348623853 1 0 1
by,is 0.0 0.0 1 1 0
at,bedtime 1.0 0.000286697247706 0 2 -2
and,tenofovir 1.0 0.000143348623853 0 1 -1
phospholine,iodide 1.0 0.000143348623853 1 0 1
v,v 1.0 0.000143348623853 0 1 -1
reduced,dosage 1.0 0.000143348623853 1 0 1
l-arginine,may 1.0 0.000286697247706 2 0 2
ocular,blood 1.0 0.000143348623853 0 1 -1
unknown,slightly 1.0 0.000143348623853 1 0 1
placebo,for 1.0 0.000143348623853 0 1 -1
without,the 1.0 0.00043004587156 0 3 -3
dysrhythmias,and 1.0 0.000143348623853 1 0 1
ovarian,granulosa 1.0 0.000143348623853 0 1 -1
on,clearance 1.0 0.00043004587156 0 3 -3
cold,binding 1.0 0.000143348623853 0 1 -1
arrhythmias,may 0.333333333333 0.000143348623853 1 2 -1
in,subjects 0.4 0.000573394495413 3 7 -4
elevations,and 0.0 0.0 1 1 0
both,crixivan 1.0 0.000143348623853 0 1 -1
needed,the 0.0 0.0 1 1 0
rats,received 1.0 0.000143348623853 0 1 -1
four,male 1.0 0.000143348623853 0 1 -1
effects,makes 1.0 0.000143348623853 0 1 -1
reduced,the 0.5 0.000860091743119 9 3 6
in,cpk 1.0 0.000143348623853 0 1 -1
antagonists,decreased 1.0 0.000143348623853 0 1 -1
added,one 1.0 0.000143348623853 0 1 -1
effects,were 0.666666666667 0.00114678899083 2 10 -8
medical,attention 1.0 0.000143348623853 0 1 -1
fasting,or 1.0 0.000143348623853 0 1 -1
become,abruptly 1.0 0.000716743119266 0 5 -5
increased,because 1.0 0.000143348623853 0 1 -1
to,various 1.0 0.000143348623853 0 1 -1
and,whether 1.0 0.000143348623853 0 1 -1
prevented,by 1.0 0.00043004587156 3 0 3
hypnotics,contraindicated 1.0 0.000143348623853 0 1 -1
raise,blood 1.0 0.000143348623853 0 1 -1
consistent,effects 1.0 0.000143348623853 0 1 -1
a,inhaler 1.0 0.000143348623853 1 0 1
agents,because 1.0 0.000143348623853 0 1 -1
b,estradiol 1.0 0.000143348623853 0 1 -1
pretreatment,period 1.0 0.000143348623853 0 1 -1
sugar,level 1.0 0.000143348623853 0 1 -1
acetaminophen,pharmacokinetic 1.0 0.000143348623853 0 1 -1
cholinergic,reactions 1.0 0.000143348623853 0 1 -1
on,those 1.0 0.000143348623853 0 1 -1
was,increased 0.0769230769231 0.000143348623853 6 7 -1
other,therapies 1.0 0.000143348623853 0 1 -1
induce,cyp3a 1.0 0.000143348623853 0 1 -1
to,nonsteroidal 1.0 0.000143348623853 1 0 1
alcoholic,beverages 0.333333333333 0.000143348623853 1 2 -1
that,suppress 1.0 0.000143348623853 0 1 -1
endometrium,and 1.0 0.000143348623853 0 1 -1
cause,in 1.0 0.000143348623853 0 1 -1
and,changes 1.0 0.000286697247706 0 2 -2
and,cyp2a6 1.0 0.000143348623853 0 1 -1
rates,of 0.333333333333 0.000143348623853 1 2 -1
femara,in 1.0 0.000143348623853 0 1 -1
pyogenes,and 1.0 0.000143348623853 0 1 -1
understanding,and 1.0 0.000143348623853 0 1 -1
gastrointestinal,lesions 1.0 0.000143348623853 1 0 1
methoxycoronaridine,mc 1.0 0.000143348623853 0 1 -1
fold,the 1.0 0.000143348623853 0 1 -1
requirement,i 1.0 0.000143348623853 1 0 1
of,exogenous 1.0 0.000143348623853 0 1 -1
day5,of 1.0 0.000143348623853 1 0 1
avonex,and 1.0 0.000143348623853 0 1 -1
drawn,if 1.0 0.000143348623853 1 0 1
block,were 1.0 0.000143348623853 0 1 -1
in,supporting 1.0 0.000143348623853 0 1 -1
including,those 0.2 0.000143348623853 2 3 -1
meclofenamic,acid 1.0 0.000143348623853 1 0 1
hour,blood 1.0 0.000143348623853 1 0 1
synergistic,depressant 1.0 0.000143348623853 0 1 -1
inducer,of 0.4 0.000573394495413 3 7 -4
cognitive,dysfunction 1.0 0.000143348623853 1 0 1
with,impaired 0.25 0.000286697247706 3 5 -2
greater,therapeutic 1.0 0.000143348623853 0 1 -1
important,for 1.0 0.000573394495413 0 4 -4
inducer,or 1.0 0.000143348623853 1 0 1
additional,calcium-containing 1.0 0.00043004587156 0 3 -3
bid,on 1.0 0.000286697247706 0 2 -2
cohort,data 1.0 0.000143348623853 0 1 -1
facilitate,the 1.0 0.000143348623853 0 1 -1
wort,in 1.0 0.000143348623853 0 1 -1
m,was 1.0 0.000143348623853 0 1 -1
is,understandable 1.0 0.000143348623853 0 1 -1
become,manifest 1.0 0.000143348623853 0 1 -1
experience,a 1.0 0.000286697247706 2 0 2
between,plasma 1.0 0.000143348623853 0 1 -1
with,agents 0.111111111111 0.000143348623853 4 5 -1
clonidine,may 1.0 0.000143348623853 1 0 1
by,as 0.0 0.0 1 1 0
mild,and 1.0 0.000143348623853 0 1 -1
between,homopolyribonucleotides 1.0 0.000143348623853 0 1 -1
not,reveal 1.0 0.000143348623853 0 1 -1
predominantly,eliminated 1.0 0.000143348623853 0 1 -1
by,at 0.333333333333 0.000143348623853 2 1 1
to,enhanced 1.0 0.000143348623853 0 1 -1
ethyl,increases 1.0 0.000143348623853 1 0 1
also,using 1.0 0.000143348623853 1 0 1
serious,drug 1.0 0.000143348623853 0 1 -1
showed,no 1.0 0.00043004587156 0 3 -3
condensation,nuclear 1.0 0.000143348623853 0 1 -1
by,an 0.25 0.000286697247706 3 5 -2
significance,of 0.833333333333 0.00286697247706 2 22 -20
vascular,dilation 1.0 0.000143348623853 1 0 1
proteins,may 1.0 0.000573394495413 0 4 -4
failure,severe 1.0 0.000143348623853 1 0 1
of,significant 1.0 0.000286697247706 2 0 2
appropriate,package 1.0 0.000143348623853 0 1 -1
general,public 1.0 0.000143348623853 0 1 -1
diets,containing 1.0 0.000143348623853 0 1 -1
respiration,becomes 1.0 0.000143348623853 0 1 -1
ii,alone 1.0 0.000286697247706 0 2 -2
difficulty,once 1.0 0.000143348623853 0 1 -1
trough,plasma 0.0 0.0 2 2 0
more,cardiovascular 1.0 0.000143348623853 0 1 -1
is,rapidly 1.0 0.000143348623853 0 1 -1
significantly,p 1.0 0.000143348623853 1 0 1
limbic,integration 1.0 0.000143348623853 0 1 -1
adjusting,and 1.0 0.00043004587156 3 0 3
paraclinical,pattern 1.0 0.000143348623853 0 1 -1
ranging,from 0.428571428571 0.00043004587156 2 5 -3
responses,to 0.75 0.000860091743119 1 7 -6
remain,some 1.0 0.000143348623853 0 1 -1
profiles,comparable 1.0 0.000143348623853 0 1 -1
epa,supplements 0.666666666667 0.000573394495413 1 5 -4
are,above 1.0 0.000143348623853 0 1 -1
to,fold 1.0 0.000860091743119 6 0 6
respectively,have 1.0 0.000143348623853 0 1 -1
with,regimens 1.0 0.000143348623853 0 1 -1
the,initiate 1.0 0.000143348623853 1 0 1
mixed-function,oxidase 1.0 0.000143348623853 0 1 -1
protein-bound,have 1.0 0.000143348623853 0 1 -1
and,cardiac 0.333333333333 0.000286697247706 4 2 2
sinus,node 1.0 0.000143348623853 1 0 1
and,lodine 0.0 0.0 1 1 0
but,dose-dependently 1.0 0.000143348623853 1 0 1
that,would 1.0 0.000286697247706 0 2 -2
megakaryocytes,with 0.0 0.0 1 1 0
tnf,antagonists 1.0 0.000143348623853 1 0 1
carefully,about 1.0 0.000143348623853 0 1 -1
retinopathy,nephropathy 1.0 0.000143348623853 0 1 -1
is,started 1.0 0.000286697247706 2 0 2
elimination,may 1.0 0.000143348623853 0 1 -1
squirrel,monkeys 1.0 0.000143348623853 0 1 -1
granulosa,cell 1.0 0.000143348623853 0 1 -1
apparent,factor 1.0 0.000143348623853 0 1 -1
a,starting 1.0 0.000143348623853 0 1 -1
absorption,site 1.0 0.000143348623853 0 1 -1
following,nimbex 1.0 0.000143348623853 1 0 1
target,cell 1.0 0.000143348623853 0 1 -1
to,rule 1.0 0.000286697247706 0 2 -2
solvents,have 1.0 0.000143348623853 0 1 -1
preservative,in 1.0 0.000143348623853 1 0 1
following,information 1.0 0.000286697247706 0 2 -2
data,indicate 0.555555555556 0.000716743119266 7 2 5
day,as 0.0 0.0 1 1 0
to,individuals 1.0 0.000286697247706 0 2 -2
regranex,gel 1.0 0.000286697247706 0 2 -2
and,experimental 1.0 0.000143348623853 0 1 -1
mean,decreases 1.0 0.000143348623853 0 1 -1
evaluated,in 1.0 0.0021502293578 0 15 -15
does,affect 1.0 0.000143348623853 0 1 -1
no,potential 1.0 0.000143348623853 0 1 -1
agonist,effects 1.0 0.000143348623853 0 1 -1
experience,bleeding 1.0 0.000286697247706 2 0 2
and,elicit 1.0 0.000143348623853 0 1 -1
contain,a 1.0 0.000143348623853 0 1 -1
from,on 1.0 0.000143348623853 1 0 1
to,copaxone 1.0 0.000143348623853 0 1 -1
of,human 0.666666666667 0.000573394495413 1 5 -4
the,user 1.0 0.000143348623853 0 1 -1
the,aerosol 1.0 0.00043004587156 0 3 -3
be,encountered 1.0 0.000143348623853 0 1 -1
tikosyn,as 1.0 0.000143348623853 1 0 1
of,guinea-pig 1.0 0.000143348623853 0 1 -1
a,trans-3 1.0 0.000143348623853 1 0 1
suppressed,by 1.0 0.000286697247706 0 2 -2
tykerb,is 1.0 0.000286697247706 0 2 -2
cause,hypertension 1.0 0.000143348623853 1 0 1
trials,concomitant 1.0 0.000143348623853 0 1 -1
blockers,l-type 1.0 0.000143348623853 0 1 -1
the,constituents 1.0 0.000143348623853 0 1 -1
when,multiple 1.0 0.000286697247706 2 0 2
zollinger-ellison,ze 1.0 0.000143348623853 0 1 -1
aucss,h 1.0 0.000143348623853 0 1 -1
patient,access 1.0 0.000143348623853 0 1 -1
of,intestinal 0.5 0.000286697247706 1 3 -2
rats,appear 1.0 0.000143348623853 0 1 -1
action,should 1.0 0.000143348623853 0 1 -1
concomitant,medications 0.882352941176 0.0021502293578 1 16 -15
on,auc 1.0 0.000143348623853 0 1 -1
for,increases 0.0 0.0 1 1 0
indicating,no 1.0 0.000286697247706 0 2 -2
videx,should 0.0 0.0 1 1 0
frequently,thereafter 1.0 0.000143348623853 1 0 1
protein-,bound 1.0 0.000143348623853 0 1 -1
days,produced 0.0 0.0 1 1 0
reduction,were 1.0 0.000143348623853 0 1 -1
amevive,continued 1.0 0.000143348623853 0 1 -1
antidepressant,eg 1.0 0.000143348623853 1 0 1
median,follow-up 1.0 0.000286697247706 0 2 -2
fibric,acid 1.0 0.000286697247706 0 2 -2
and,activity 1.0 0.000143348623853 0 1 -1
and,extends 1.0 0.000143348623853 1 0 1
preparations,sunscreens 1.0 0.000143348623853 1 0 1
antacid,products 1.0 0.000143348623853 0 1 -1
counter,cough 1.0 0.000143348623853 0 1 -1
here,demonstrate 1.0 0.000143348623853 0 1 -1
tbars,levels 1.0 0.000143348623853 1 0 1
that,intraventricular 1.0 0.000143348623853 0 1 -1
stimulus,of 1.0 0.000143348623853 0 1 -1
metabolizers,after 1.0 0.000143348623853 0 1 -1
enzyme,inducers 0.666666666667 0.000573394495413 5 1 4
many,people 1.0 0.000143348623853 0 1 -1
pharmacologic,mechanism 1.0 0.000143348623853 0 1 -1
with,anion-exchange 1.0 0.000143348623853 1 0 1
cells,whereas 1.0 0.000286697247706 0 2 -2
vitro,data 0.2 0.000286697247706 4 6 -2
on,resistance 1.0 0.000143348623853 0 1 -1
evaluated,cyp1a2 1.0 0.000143348623853 0 1 -1
cyp2e1,but 1.0 0.000143348623853 0 1 -1
angiomax,does 1.0 0.000143348623853 0 1 -1
unsteady,gait 1.0 0.000143348623853 1 0 1
intoxication,after 1.0 0.000143348623853 0 1 -1
cyp1a2,inducers 1.0 0.000143348623853 0 1 -1
classes,or 1.0 0.000143348623853 1 0 1
differential,thermal 1.0 0.000143348623853 0 1 -1
anticoagulation,test 1.0 0.000143348623853 1 0 1
clindamycin-sensitive,isolates 1.0 0.000143348623853 0 1 -1
classes,of 0.333333333333 0.000143348623853 1 2 -1
agents,lower 1.0 0.000286697247706 0 2 -2
during,conversion 1.0 0.000143348623853 0 1 -1
affect,bleeding 0.0 0.0 1 1 0
cardioactive,drugs 1.0 0.000143348623853 0 1 -1
weeks,and 1.0 0.000286697247706 0 2 -2
local,like 1.0 0.000143348623853 0 1 -1
kg,day 0.52380952381 0.00157683486239 5 16 -11
the,disposition 1.0 0.000860091743119 0 6 -6
negatively,coupled 1.0 0.000143348623853 0 1 -1
ingredient,of 1.0 0.000143348623853 0 1 -1
aggravated,by 1.0 0.000143348623853 1 0 1
oral,heparin 1.0 0.000143348623853 0 1 -1
and,levonorgestrel-treated 1.0 0.000143348623853 0 1 -1
extends,its 1.0 0.000143348623853 1 0 1
change,significantly 1.0 0.000143348623853 0 1 -1
zyvox,or 1.0 0.000143348623853 1 0 1
agents,seizures 1.0 0.000143348623853 1 0 1
ethoxycoumarine,deethylase 1.0 0.000143348623853 0 1 -1
latencies,to 1.0 0.000143348623853 0 1 -1
antagonists,because 1.0 0.000143348623853 1 0 1
action,are 1.0 0.000143348623853 0 1 -1
normal,when 1.0 0.000143348623853 0 1 -1
enzyme,oxidation 1.0 0.000143348623853 0 1 -1
neupogen,and 1.0 0.000143348623853 0 1 -1
to,warrant 1.0 0.000143348623853 1 0 1
and,suboxone 1.0 0.000143348623853 1 0 1
of,patients 0.422222222222 0.00272362385321 13 32 -19
the,perioperative 1.0 0.000143348623853 1 0 1
cefuroxime,does 1.0 0.000143348623853 0 1 -1
cost,of 1.0 0.000143348623853 0 1 -1
these,supplements 1.0 0.000143348623853 0 1 -1
scale,of 1.0 0.000286697247706 0 2 -2
during,co-administration 1.0 0.000143348623853 0 1 -1
other,creams 1.0 0.000143348623853 0 1 -1
kg,bwt 1.0 0.000143348623853 0 1 -1
by,age 1.0 0.000143348623853 0 1 -1
prothrom-bin,time 1.0 0.000286697247706 2 0 2
the,ninds 1.0 0.000143348623853 0 1 -1
reason,the 0.0 0.0 1 1 0
the,diets 1.0 0.000143348623853 0 1 -1
of,elevated 1.0 0.000286697247706 0 2 -2
administration,does 1.0 0.000143348623853 0 1 -1
of,hivid 0.333333333333 0.000143348623853 1 2 -1
obstruction,and 1.0 0.000143348623853 0 1 -1
zyvox,and 1.0 0.000286697247706 2 0 2
is,sensitive 1.0 0.000143348623853 0 1 -1
examples,include 1.0 0.000143348623853 0 1 -1
the,solubility 1.0 0.000143348623853 0 1 -1
of,gly-buride 1.0 0.000143348623853 0 1 -1
of,amphotericin 0.0 0.0 2 2 0
that,induce 0.285714285714 0.000573394495413 5 9 -4
were,cardiac 1.0 0.000286697247706 0 2 -2
drug,side 1.0 0.000143348623853 0 1 -1
therapeutic,effects 0.333333333333 0.000143348623853 2 1 1
with,simulect 1.0 0.000143348623853 0 1 -1
elimination,and 0.333333333333 0.000286697247706 4 2 2
and,lymphopenia 1.0 0.000143348623853 0 1 -1
of,theophylline 1.0 0.000143348623853 0 1 -1
daypro,and 1.0 0.000143348623853 0 1 -1
proteins,is 0.5 0.000286697247706 1 3 -2
reduced,while 1.0 0.000143348623853 1 0 1
of,cyp2c9 0.5 0.000286697247706 1 3 -2
minutes,before 1.0 0.000286697247706 2 0 2
an,initial 1.0 0.000286697247706 0 2 -2
as,anorexia 1.0 0.000143348623853 1 0 1
parathyroid-function,tests 1.0 0.000143348623853 0 1 -1
ketoconazole,erythromycin 1.0 0.000143348623853 0 1 -1
of,beta 1.0 0.000286697247706 2 0 2
proteins,in 1.0 0.000286697247706 0 2 -2
inhibitor,on 1.0 0.000143348623853 0 1 -1
be,patient 1.0 0.000143348623853 0 1 -1
b6,d6 1.0 0.000143348623853 0 1 -1
also,induced 1.0 0.000143348623853 0 1 -1
however,reports 1.0 0.000143348623853 1 0 1
recorded,at 1.0 0.000143348623853 0 1 -1
naftate,cephalothin 1.0 0.000143348623853 0 1 -1
of,heparinized 1.0 0.000143348623853 1 0 1
also,induces 1.0 0.000143348623853 0 1 -1
of,settings 1.0 0.000143348623853 0 1 -1
inhibitor,or 1.0 0.000143348623853 0 1 -1
memory,systems 1.0 0.000286697247706 0 2 -2
pressor,agents 1.0 0.000286697247706 0 2 -2
receive,concomitant 1.0 0.000143348623853 0 1 -1
be,analyzed 1.0 0.000143348623853 0 1 -1
pulmonary,granulomata 1.0 0.000143348623853 0 1 -1
simply,normalizing 1.0 0.000143348623853 0 1 -1
it,alter 1.0 0.000143348623853 0 1 -1
and,medication 1.0 0.000143348623853 1 0 1
this,time 1.0 0.000143348623853 1 0 1
and,partial 1.0 0.000143348623853 0 1 -1
with,use 1.0 0.000286697247706 0 2 -2
of,postoperative 1.0 0.000143348623853 0 1 -1
levels,limit 1.0 0.000143348623853 1 0 1
sleep,drowsiness-causing 1.0 0.000143348623853 0 1 -1
gas,chromatographic-mass 1.0 0.000143348623853 0 1 -1
were,randomly 1.0 0.00043004587156 0 3 -3
hr,p 1.0 0.000143348623853 0 1 -1
achieved,with 1.0 0.000143348623853 0 1 -1
design,that 1.0 0.000143348623853 1 0 1
volunteers,there 0.5 0.000286697247706 1 3 -2
of,increases 0.333333333333 0.000143348623853 2 1 1
explored,with 1.0 0.000143348623853 0 1 -1
as,subsequent 1.0 0.000143348623853 0 1 -1
no,cases 1.0 0.000143348623853 0 1 -1
of,mood 1.0 0.000143348623853 0 1 -1
antibiotics,pregnancy 1.0 0.000143348623853 0 1 -1
of,increased 0.185185185185 0.000716743119266 16 11 5
from,dietary-obese 1.0 0.00043004587156 0 3 -3
randomized,balanced 1.0 0.000143348623853 0 1 -1
the,acceleration 1.0 0.000143348623853 0 1 -1
as,intravenous 1.0 0.000143348623853 0 1 -1
using,acetate 1.0 0.000143348623853 1 0 1
cecectomized,rats 1.0 0.000286697247706 0 2 -2
three,duloxetine-treated 1.0 0.000143348623853 0 1 -1
acumen,but 1.0 0.000143348623853 0 1 -1
tests,are 1.0 0.00043004587156 0 3 -3
one,third 1.0 0.000143348623853 1 0 1
twitch,strength 1.0 0.000143348623853 0 1 -1
to,accompany 1.0 0.000143348623853 0 1 -1
fenbufen,is 1.0 0.000286697247706 0 2 -2
a,dosage 1.0 0.000143348623853 0 1 -1
an,open-label 1.0 0.000143348623853 0 1 -1
digoxin,coadministration 1.0 0.000143348623853 1 0 1
with,long- 1.0 0.000143348623853 0 1 -1
enzymes,lapatinib 1.0 0.000143348623853 0 1 -1
certain,microsomal 1.0 0.000143348623853 1 0 1
thyroid,physiology 1.0 0.000143348623853 0 1 -1
the,rbc 1.0 0.000286697247706 0 2 -2
to,require 1.0 0.000143348623853 1 0 1
usually,this 1.0 0.000143348623853 0 1 -1
strains,combinations 1.0 0.000143348623853 0 1 -1
than,of 1.0 0.000286697247706 0 2 -2
off,medications 1.0 0.000143348623853 0 1 -1
warfarin-vitamin,k 1.0 0.000143348623853 1 0 1
haldol,may 1.0 0.000143348623853 1 0 1
tricyclic,tcas 1.0 0.000143348623853 0 1 -1
would,warrant 1.0 0.000143348623853 0 1 -1
with,vitamin 0.333333333333 0.00043004587156 6 3 3
to,several- 1.0 0.000143348623853 0 1 -1
rapid,fluctuations 1.0 0.000143348623853 1 0 1
hepatic,metabolic 1.0 0.000143348623853 0 1 -1
are,currently 1.0 0.000286697247706 0 2 -2
polymer,p 1.0 0.000143348623853 0 1 -1
rat,thoracic 1.0 0.000143348623853 0 1 -1
recommended,dosage 1.0 0.000143348623853 0 1 -1
other,muscle 1.0 0.000143348623853 0 1 -1
being,either 1.0 0.000143348623853 0 1 -1
tablets,are 0.333333333333 0.000143348623853 1 2 -1
d6,the 1.0 0.00143348623853 0 10 -10
alone,at 0.333333333333 0.000143348623853 1 2 -1
primate,gammaherpes 1.0 0.000143348623853 0 1 -1
measured,in 1.0 0.000143348623853 0 1 -1
and,repeated 1.0 0.000286697247706 0 2 -2
acetaminophen,in 1.0 0.000143348623853 1 0 1
with,your 1.0 0.000143348623853 0 1 -1
isosorbide,mononitrate 1.0 0.000143348623853 1 0 1
in,cyp2d6 0.0 0.0 1 1 0
for,months 1.0 0.000286697247706 0 2 -2
and,begin 1.0 0.000143348623853 0 1 -1
include,sufficient 1.0 0.000143348623853 0 1 -1
seriously,worsening 1.0 0.000143348623853 0 1 -1
cardiac,channel 1.0 0.000143348623853 0 1 -1
backgrounds,of 1.0 0.000143348623853 0 1 -1
also,occur 1.0 0.000286697247706 0 2 -2
are,coupled 1.0 0.000143348623853 0 1 -1
cyclosporine,and 1.0 0.000143348623853 1 0 1
and,then 0.166666666667 0.000286697247706 5 7 -2
antagonists,should 1.0 0.000286697247706 2 0 2
is,running 1.0 0.000143348623853 0 1 -1
novoseven,should 1.0 0.000143348623853 0 1 -1
and,they 1.0 0.000286697247706 0 2 -2
ii-vii,x 1.0 0.000286697247706 0 2 -2
overall,response 0.0 0.0 1 1 0
requiring,any 1.0 0.000143348623853 0 1 -1
for,cmax 0.0 0.0 1 1 0
with,glycosides 1.0 0.000143348623853 1 0 1
the,jaffe 1.0 0.000143348623853 0 1 -1
enhancing,selective 1.0 0.000143348623853 0 1 -1
is,associated 1.0 0.00043004587156 0 3 -3
is,contemplated 1.0 0.000716743119266 0 5 -5
when,cyp3a4 1.0 0.000143348623853 0 1 -1
with,heparin-induced 1.0 0.000143348623853 0 1 -1
release,captopril 1.0 0.000143348623853 1 0 1
hydrochloric,acid 1.0 0.000143348623853 0 1 -1
uptake,producing 1.0 0.000143348623853 0 1 -1
preparations,or 1.0 0.000143348623853 0 1 -1
cell,and 1.0 0.000143348623853 0 1 -1
special,monitoring 1.0 0.000143348623853 0 1 -1
interactions,finasteride 1.0 0.000143348623853 0 1 -1
the,lumen 1.0 0.000143348623853 0 1 -1
other,isoforms 1.0 0.000286697247706 0 2 -2
margin,after 1.0 0.000143348623853 0 1 -1
and,displacement 1.0 0.000143348623853 1 0 1
etc,that 1.0 0.000143348623853 1 0 1
terms,of 1.0 0.00043004587156 0 3 -3
by,concurrent 0.333333333333 0.000143348623853 2 1 1
either,and 0.0 0.0 1 1 0
the,high-dose 1.0 0.000143348623853 1 0 1
was,present 1.0 0.00043004587156 0 3 -3
in,neither 1.0 0.000143348623853 0 1 -1
reduction,that 1.0 0.000143348623853 0 1 -1
suppress,certain 1.0 0.000143348623853 0 1 -1
d6,c9 1.0 0.000143348623853 0 1 -1
includes,most 1.0 0.000143348623853 0 1 -1
adjustments,may 1.0 0.000860091743119 0 6 -6
c23,down-regulation 1.0 0.000143348623853 0 1 -1
enzymatic,glucose 1.0 0.000860091743119 0 6 -6
alone,they 1.0 0.000143348623853 1 0 1
lower,pulmonary 1.0 0.000143348623853 1 0 1
noted,in 0.6 0.00043004587156 1 4 -3
interactions,thiazides 1.0 0.000143348623853 0 1 -1
same,interactions 1.0 0.000143348623853 0 1 -1
a,safety 1.0 0.000143348623853 0 1 -1
physician,even 1.0 0.000143348623853 0 1 -1
vs,placebo 1.0 0.000143348623853 0 1 -1
renin,levels 1.0 0.000143348623853 0 1 -1
trials,heart 1.0 0.000143348623853 0 1 -1
the,metabolic 1.0 0.000860091743119 6 0 6
and,agitation 1.0 0.000143348623853 0 1 -1
characteristics,hiv 1.0 0.000143348623853 0 1 -1
responsiveness,to 1.0 0.00043004587156 0 3 -3
or,delavirdine-based 1.0 0.000143348623853 0 1 -1
recommendation,to 1.0 0.000143348623853 0 1 -1
pigeons,nanm 1.0 0.000143348623853 0 1 -1
preliminary,data 0.0 0.0 1 1 0
received,alone 1.0 0.000286697247706 0 2 -2
in,glucose 1.0 0.000143348623853 1 0 1
investigations,indicate 1.0 0.000143348623853 0 1 -1
mean,of 0.333333333333 0.000143348623853 1 2 -1
cell,the 1.0 0.000143348623853 0 1 -1
is,critically 1.0 0.000143348623853 0 1 -1
that,m 1.0 0.000143348623853 0 1 -1
supplements,might 1.0 0.000143348623853 0 1 -1
have,occurred 0.0 0.0 5 5 0
or,weight 1.0 0.000143348623853 0 1 -1
protein,may 0.0 0.0 1 1 0
of,dmpge2 1.0 0.00043004587156 0 3 -3
of,enbrel 1.0 0.000143348623853 0 1 -1
taxol,infusions 1.0 0.000143348623853 0 1 -1
organophosphorous,compound 1.0 0.000143348623853 0 1 -1
calorimetry,differential 1.0 0.000143348623853 0 1 -1
as,age 1.0 0.000143348623853 0 1 -1
started,thus 1.0 0.000143348623853 1 0 1
with,hiv-nhl 1.0 0.000143348623853 0 1 -1
bad,general 1.0 0.000143348623853 1 0 1
decision,must 1.0 0.000143348623853 0 1 -1
for,long 1.0 0.000143348623853 0 1 -1
medications,including 1.0 0.000143348623853 0 1 -1
of,retinopathy 1.0 0.000143348623853 0 1 -1
safely,coadministered 1.0 0.000286697247706 0 2 -2
change,after 1.0 0.000143348623853 0 1 -1
the,persistence 1.0 0.000143348623853 0 1 -1
and,platelets 1.0 0.000143348623853 0 1 -1
dosing,should 1.0 0.000286697247706 0 2 -2
may,share 1.0 0.000143348623853 0 1 -1
may,alter 0.2 0.000286697247706 6 4 2
of,cyp 0.6 0.00043004587156 1 4 -3
an,interactive 1.0 0.000286697247706 0 2 -2
lh,and 1.0 0.000143348623853 0 1 -1
assessed,the 1.0 0.000143348623853 0 1 -1
against,sera 1.0 0.000143348623853 0 1 -1
are,frequently 1.0 0.000286697247706 0 2 -2
vitro,the 1.0 0.000286697247706 0 2 -2
isoniazid,may 1.0 0.000143348623853 1 0 1
certain,tricyclic 1.0 0.000143348623853 1 0 1
prolongation,with 1.0 0.000143348623853 0 1 -1
elemental,reduced 1.0 0.000143348623853 1 0 1
pathway,that 1.0 0.000143348623853 0 1 -1
a,preparation 1.0 0.000143348623853 1 0 1
fold,higher 0.0 0.0 1 1 0
fsh,to 1.0 0.000143348623853 0 1 -1
whereas,none 1.0 0.000143348623853 0 1 -1
platelet-aggregation,reactions 1.0 0.000143348623853 1 0 1
to,transport-related 1.0 0.000143348623853 1 0 1
cholesterol,levels 0.0 0.0 1 1 0
day,variability 1.0 0.000143348623853 0 1 -1
fat,enlargement 1.0 0.000143348623853 0 1 -1
nalfon,and 1.0 0.000286697247706 2 0 2
indicating,induction 1.0 0.000143348623853 0 1 -1
hours,between 1.0 0.000286697247706 0 2 -2
out,decreased 1.0 0.000143348623853 0 1 -1
receiving,known 1.0 0.000143348623853 1 0 1
state,on 1.0 0.000143348623853 0 1 -1
response,was 1.0 0.000286697247706 0 2 -2
any,unexpected 1.0 0.000143348623853 0 1 -1
but,generally 1.0 0.000143348623853 0 1 -1
examines,the 1.0 0.000143348623853 0 1 -1
capacity,should 1.0 0.000143348623853 0 1 -1
a4,cyp3a4 1.0 0.000143348623853 0 1 -1
after,intravenous 1.0 0.000143348623853 0 1 -1
lapatinib,inhibits 1.0 0.000286697247706 0 2 -2
functional,integrity 1.0 0.000143348623853 0 1 -1
the,maintenance 0.0 0.0 1 1 0
various,pesticides 1.0 0.000143348623853 0 1 -1
h,antagonists 0.0 0.0 1 1 0
induration,skin 1.0 0.000143348623853 0 1 -1
thus,there 1.0 0.000143348623853 0 1 -1
vacuolation,were 1.0 0.000143348623853 0 1 -1
not,related 1.0 0.000143348623853 0 1 -1
phosphohydrolase,becomes 1.0 0.000143348623853 0 1 -1
hmgcoa,reductase 1.0 0.000286697247706 0 2 -2
can,attenuate 1.0 0.000286697247706 2 0 2
high,maintenance 1.0 0.000143348623853 1 0 1
anti-arrhythmic,agents 1.0 0.000143348623853 0 1 -1
of,more 0.6 0.00043004587156 1 4 -3
of,neurological 1.0 0.00043004587156 0 3 -3
community,or 1.0 0.000143348623853 0 1 -1
dl,dose 1.0 0.000143348623853 1 0 1
av,nodes 1.0 0.000143348623853 0 1 -1
normal,tissue 1.0 0.000143348623853 0 1 -1
inomax,on 1.0 0.000143348623853 1 0 1
severe,rhabdomyolysis 1.0 0.000143348623853 1 0 1
c19,e1 1.0 0.000143348623853 0 1 -1
well,concurrent 1.0 0.000143348623853 1 0 1
examine,the 1.0 0.000573394495413 0 4 -4
ergocalcitriol,will 1.0 0.00043004587156 0 3 -3
compounds,for 1.0 0.000143348623853 0 1 -1
be,interrupted 1.0 0.000286697247706 0 2 -2
complications,in 1.0 0.000143348623853 0 1 -1
of,noradrenaline 1.0 0.000143348623853 0 1 -1
maintain,inhibition 1.0 0.000143348623853 0 1 -1
well-controlled,studies 1.0 0.000573394495413 0 4 -4
system,of 1.0 0.000143348623853 0 1 -1
increases,extracellular 1.0 0.000143348623853 0 1 -1
auc0-12,and 1.0 0.000143348623853 1 0 1
or,compete 1.0 0.000143348623853 0 1 -1
potent,inhibitory 1.0 0.000143348623853 0 1 -1
of,beta-adrenergic 0.333333333333 0.000143348623853 2 1 1
adl-8,is 1.0 0.000143348623853 1 0 1
colazal,however 1.0 0.000143348623853 0 1 -1
d3,exhibit 1.0 0.000143348623853 0 1 -1
and,identifies 1.0 0.000143348623853 0 1 -1
of,only 1.0 0.000286697247706 2 0 2
times,day 1.0 0.000143348623853 0 1 -1
document,no 1.0 0.000143348623853 0 1 -1
as,channel-blockers 1.0 0.000143348623853 0 1 -1
recommended,and 0.333333333333 0.000143348623853 2 1 1
for,mania 1.0 0.000143348623853 0 1 -1
and,regulates 1.0 0.000143348623853 0 1 -1
reserved,for 1.0 0.000143348623853 0 1 -1
are,so 1.0 0.00043004587156 0 3 -3
theophylline,decreased 1.0 0.000143348623853 1 0 1
new,therapeutic 1.0 0.000143348623853 0 1 -1
d,is 1.0 0.000143348623853 0 1 -1
to,fivefold 1.0 0.000143348623853 0 1 -1
can,either 1.0 0.000143348623853 0 1 -1
this,activity 1.0 0.000143348623853 0 1 -1
warfarin,eszopiclone 1.0 0.000143348623853 0 1 -1
coronary,insufficiency 1.0 0.000286697247706 0 2 -2
rate-limiting,step 1.0 0.000143348623853 0 1 -1
an,enteric 1.0 0.000143348623853 0 1 -1
to,survive 1.0 0.000143348623853 0 1 -1
in,low-density 1.0 0.000143348623853 0 1 -1
may,affect 0.857142857143 0.00172018348624 1 13 -12
cause,severe 0.2 0.000143348623853 3 2 1
toxicity,see 1.0 0.000143348623853 0 1 -1
be,obtained 1.0 0.00043004587156 0 3 -3
mtx,nsaids 1.0 0.000286697247706 0 2 -2
both,invirase 1.0 0.000143348623853 0 1 -1
containing,sequential 1.0 0.000143348623853 1 0 1
include,optimal 1.0 0.000143348623853 0 1 -1
false-positive,reaction 1.0 0.00200688073394 0 14 -14
made,of 0.0 0.0 1 1 0
from,intravenous 1.0 0.000286697247706 0 2 -2
time,course 1.0 0.000143348623853 0 1 -1
agents,dynamic 1.0 0.000143348623853 0 1 -1
increased,indicating 1.0 0.000143348623853 0 1 -1
taking,this 1.0 0.000286697247706 0 2 -2
interactions,how 1.0 0.000143348623853 0 1 -1
acetate,l-histidine 1.0 0.000143348623853 1 0 1
behavior,in 1.0 0.000286697247706 0 2 -2
these,disturbances 1.0 0.000143348623853 1 0 1
enantiomer,pharmacokinetics 1.0 0.000143348623853 0 1 -1
of,many 1.0 0.000143348623853 1 0 1
plasma,hdl 1.0 0.000286697247706 0 2 -2
cholestyramine,has 1.0 0.00043004587156 3 0 3
calcidiol,cholestyramine 1.0 0.00043004587156 3 0 3
and,resistant 1.0 0.000143348623853 0 1 -1
of,antimicrobial 1.0 0.000143348623853 0 1 -1
be,dispersed 1.0 0.000143348623853 0 1 -1
high,temperature 1.0 0.000143348623853 1 0 1
linear,regression 1.0 0.000143348623853 0 1 -1
pronounced,though 1.0 0.000143348623853 1 0 1
not,performed 1.0 0.000286697247706 0 2 -2
anti-platelet,activity 1.0 0.000143348623853 0 1 -1
year,controlled 1.0 0.000143348623853 0 1 -1
using,more 1.0 0.000143348623853 0 1 -1
symptoms,that 1.0 0.000143348623853 1 0 1
reaction,is 1.0 0.000286697247706 0 2 -2
alternate-day,administration 1.0 0.000143348623853 1 0 1
the,tca 1.0 0.000143348623853 1 0 1
and,socioeconomic 1.0 0.000143348623853 0 1 -1
therefore,potential 1.0 0.000143348623853 0 1 -1
professional,know 1.0 0.000143348623853 1 0 1
lesions,actually 1.0 0.000143348623853 0 1 -1
from,amevive 1.0 0.000143348623853 0 1 -1
the,affinity 1.0 0.000143348623853 0 1 -1
the,pharmacologically 1.0 0.000143348623853 1 0 1
weather,prolonged 1.0 0.000143348623853 1 0 1
added,to 0.111111111111 0.000286697247706 10 8 2
mefloquine,have 1.0 0.000143348623853 0 1 -1
min,before 0.333333333333 0.000143348623853 1 2 -1
other,has 0.333333333333 0.000143348623853 1 2 -1
cyp2d6,may 1.0 0.000143348623853 0 1 -1
mg,clo-4 1.0 0.000143348623853 0 1 -1
similar,mechanism 0.0 0.0 1 1 0
activity,effects 0.2 0.000143348623853 2 3 -1
cavity,or 1.0 0.000143348623853 0 1 -1
total,bilirubin 1.0 0.00043004587156 0 3 -3
csf,primarily 1.0 0.000143348623853 0 1 -1
patients,concomitant 1.0 0.000143348623853 0 1 -1
chronotropic,effects 1.0 0.000143348623853 0 1 -1
a,substitute 1.0 0.000573394495413 0 4 -4
bovine,lung 1.0 0.000143348623853 0 1 -1
of,hormone 1.0 0.000286697247706 0 2 -2
distinctive,effects 1.0 0.000143348623853 0 1 -1
cause,weakness 0.333333333333 0.000143348623853 2 1 1
challenge,and 1.0 0.000143348623853 0 1 -1
max,is 1.0 0.000143348623853 1 0 1
formal,clinical 1.0 0.000573394495413 0 4 -4
or,without 0.111111111111 0.000143348623853 5 4 1
that,chronic 1.0 0.000143348623853 1 0 1
no,influence 1.0 0.00043004587156 0 3 -3
daily,before 1.0 0.000286697247706 0 2 -2
requirements,in 0.0 0.0 1 1 0
treatment,discontinuation 1.0 0.000143348623853 0 1 -1
erythromycin,and 0.0 0.0 1 1 0
prolongs,and 1.0 0.000143348623853 0 1 -1
when,contrast 1.0 0.000286697247706 0 2 -2
musculoskeletal,adverse 1.0 0.000143348623853 0 1 -1
other,hypotensive 1.0 0.000143348623853 1 0 1
mediated,via 1.0 0.000286697247706 0 2 -2
diagnostic,serum 1.0 0.000143348623853 0 1 -1
varied,from 1.0 0.000143348623853 0 1 -1
below,a 1.0 0.000143348623853 0 1 -1
any,changes 1.0 0.000573394495413 0 4 -4
with,several 1.0 0.000143348623853 0 1 -1
clearance,may 1.0 0.000143348623853 0 1 -1
resemblance,of 1.0 0.000143348623853 1 0 1
in,dmpge2 1.0 0.000143348623853 0 1 -1
activity,can 1.0 0.000143348623853 1 0 1
the,possibility 0.0285714285714 0.000143348623853 18 17 1
behavioral,mechanisms 1.0 0.000143348623853 0 1 -1
since,interactions 0.333333333333 0.000143348623853 2 1 1
of,functionally 1.0 0.000143348623853 0 1 -1
demonstrates,the 1.0 0.000143348623853 0 1 -1
in,elucidating 1.0 0.000143348623853 0 1 -1
milk,on 1.0 0.000143348623853 0 1 -1
study,cynomolgus 1.0 0.000143348623853 0 1 -1
either,oral 1.0 0.000143348623853 1 0 1
the,longterm 1.0 0.000143348623853 0 1 -1
trials,currently 1.0 0.000143348623853 0 1 -1
bradycardia,and 0.333333333333 0.000143348623853 1 2 -1
cause,clinically 1.0 0.000143348623853 0 1 -1
q4h,and 1.0 0.000143348623853 0 1 -1
prinivil,is 1.0 0.000143348623853 1 0 1
already,responded 1.0 0.000143348623853 0 1 -1
intermittent,hemodialysis 1.0 0.000143348623853 0 1 -1
or,led 1.0 0.000143348623853 1 0 1
or,effect 0.0 0.0 1 1 0
concentrations,decreased 1.0 0.000143348623853 0 1 -1
reaction,of 1.0 0.000286697247706 2 0 2
oral,including 1.0 0.000143348623853 1 0 1
fluvoxamine,is 1.0 0.000286697247706 0 2 -2
concentrations,decreases 1.0 0.000143348623853 1 0 1
lesions,or 1.0 0.000143348623853 0 1 -1
its,epoxide 1.0 0.000143348623853 0 1 -1
rash,peripheral 1.0 0.000143348623853 0 1 -1
frequently,in 1.0 0.000143348623853 0 1 -1
volunteers,has 0.333333333333 0.000286697247706 4 2 2
frequently,if 1.0 0.00043004587156 3 0 3
occur,due 1.0 0.000143348623853 0 1 -1
volunteers,had 1.0 0.000143348623853 1 0 1
m1,cmax 1.0 0.000143348623853 0 1 -1
extensive,intake 1.0 0.000143348623853 0 1 -1
or,metabolic 1.0 0.000143348623853 0 1 -1
acids,such 1.0 0.000143348623853 1 0 1
from,what 1.0 0.000143348623853 0 1 -1
rate,compared 1.0 0.000143348623853 1 0 1
of,dynacirc 1.0 0.000286697247706 0 2 -2
simultaneous,administration 0.142857142857 0.000143348623853 4 3 1
because,increases 1.0 0.000143348623853 1 0 1
cite,primary 1.0 0.000143348623853 0 1 -1
dextrorotatory,isomer 1.0 0.000143348623853 0 1 -1
been,analysed 1.0 0.000143348623853 0 1 -1
beta-adrenergic,neuroeffector 1.0 0.000143348623853 0 1 -1
synkayvite,use 1.0 0.000143348623853 0 1 -1
anticoagulants,predispose 1.0 0.000143348623853 0 1 -1
that,intracellular 1.0 0.000143348623853 0 1 -1
that,homocysteine 1.0 0.000143348623853 0 1 -1
therapy,to 1.0 0.000286697247706 2 0 2
for,drug-drug 1.0 0.000143348623853 0 1 -1
extended,a 1.0 0.000143348623853 1 0 1
hypotension,occurs 1.0 0.000143348623853 0 1 -1
volunteers,resulting 1.0 0.000143348623853 0 1 -1
scale,were 1.0 0.000143348623853 1 0 1
sustiva,are 1.0 0.000143348623853 0 1 -1
route,and 1.0 0.000143348623853 1 0 1
norvir,viracept 1.0 0.000143348623853 1 0 1
displacement,from 1.0 0.000143348623853 0 1 -1
approximately,a 1.0 0.000143348623853 1 0 1
sometimes,been 1.0 0.000143348623853 0 1 -1
reservoir,function 1.0 0.000143348623853 0 1 -1
dose,on 1.0 0.000716743119266 0 5 -5
period,after 1.0 0.00043004587156 0 3 -3
with,hepatotoxicity 1.0 0.000143348623853 1 0 1
thus,requiring 1.0 0.000143348623853 1 0 1
problems,with 1.0 0.000143348623853 0 1 -1
higher,occurrence 1.0 0.000286697247706 2 0 2
the,recommended 0.384615384615 0.000716743119266 4 9 -5
co,administration 1.0 0.000143348623853 1 0 1
leucovorin,may 1.0 0.000143348623853 1 0 1
their,selective 1.0 0.000143348623853 0 1 -1
a,the 1.0 0.000286697247706 0 2 -2
antioxidative,gallates 1.0 0.000143348623853 0 1 -1
above,cmax 1.0 0.000143348623853 0 1 -1
bleeding,parameters 1.0 0.000143348623853 1 0 1
survanta,on 1.0 0.000143348623853 0 1 -1
dose,of 0.2 0.0045871559633 64 96 -32
initial,dosage 1.0 0.000143348623853 1 0 1
theophylline,following 1.0 0.000143348623853 0 1 -1
products,may 1.0 0.000143348623853 1 0 1
hivid,and 1.0 0.000143348623853 0 1 -1
with,b-blocking 1.0 0.000716743119266 5 0 5
c,g 1.0 0.000143348623853 1 0 1
drinking,may 1.0 0.000143348623853 1 0 1
and,should 0.529411764706 0.00258027522936 26 8 18
enablex,is 1.0 0.000143348623853 1 0 1
not,when 1.0 0.000143348623853 1 0 1
retard,the 1.0 0.000143348623853 0 1 -1
to,beta-lactam 1.0 0.000143348623853 1 0 1
c,p 0.6 0.00043004587156 1 4 -3
be,useful 0.5 0.000286697247706 1 3 -2
experiencing,severe 1.0 0.000143348623853 0 1 -1
patients,take 0.0 0.0 1 1 0
when,either 0.6 0.00043004587156 4 1 3
these,changes 1.0 0.00043004587156 0 3 -3
on,activity 1.0 0.000143348623853 1 0 1
unbound,free 1.0 0.000143348623853 0 1 -1
recovery,following 1.0 0.000143348623853 1 0 1
to,lead 1.0 0.00043004587156 3 0 3
serious,ventricular 0.0 0.0 1 1 0
fulvestrant,caused 1.0 0.000143348623853 0 1 -1
inspra,to 0.0 0.0 1 1 0
hours,most 1.0 0.000143348623853 0 1 -1
concentrations,appeared 1.0 0.000143348623853 0 1 -1
anti-inflammatory,action 1.0 0.000143348623853 1 0 1
tmax,of 1.0 0.000143348623853 0 1 -1
whether,has 1.0 0.000143348623853 0 1 -1
and,all 1.0 0.000143348623853 0 1 -1
antiminth,taking 1.0 0.000143348623853 1 0 1
elemental,as 1.0 0.000143348623853 1 0 1
least,a 1.0 0.000143348623853 1 0 1
receiving,azopt 1.0 0.000143348623853 0 1 -1
solution,may 1.0 0.000573394495413 4 0 4
in,interaction 1.0 0.000286697247706 0 2 -2
unmodified,nacmc 1.0 0.000143348623853 0 1 -1
to,confirm 1.0 0.000286697247706 0 2 -2
before,a 0.0 0.0 1 1 0
studies,are 1.0 0.000286697247706 0 2 -2
regimen,plus 1.0 0.000143348623853 0 1 -1
chop-like,regimen 1.0 0.000143348623853 0 1 -1
with,monurol 1.0 0.000143348623853 1 0 1
the,formation 0.333333333333 0.000143348623853 1 2 -1
therapeutic,value 1.0 0.000143348623853 0 1 -1
anticholinesterase,poisoning 1.0 0.000143348623853 1 0 1
critically,important 1.0 0.000143348623853 0 1 -1
circulating,metabolite 1.0 0.000143348623853 0 1 -1
ph,h2-receptor 1.0 0.000143348623853 1 0 1
cases,occurred 1.0 0.000143348623853 0 1 -1
cause,ventricular 1.0 0.000143348623853 1 0 1
administered,intravenously 1.0 0.000286697247706 2 0 2
tract,obstruction 1.0 0.000143348623853 0 1 -1
safely,used 1.0 0.000573394495413 0 4 -4
major,subtype 1.0 0.000143348623853 0 1 -1
with,another 0.777777777778 0.00100344036697 1 8 -7
of,vistide 1.0 0.000143348623853 1 0 1
of,or 0.272727272727 0.00172018348624 16 28 -12
of,safety 1.0 0.000143348623853 0 1 -1
of,on 0.611111111111 0.00630733944954 14 58 -44
some,attenuation 1.0 0.000143348623853 0 1 -1
person,based 1.0 0.000143348623853 0 1 -1
additive,effects 0.185185185185 0.000716743119266 16 11 5
mm3,for 1.0 0.000143348623853 0 1 -1
follow-up,blood 1.0 0.000143348623853 0 1 -1
concomitantly,given 1.0 0.000143348623853 0 1 -1
deaths,induced 1.0 0.000143348623853 0 1 -1
resemble,the 1.0 0.000143348623853 0 1 -1
the,prolonged 1.0 0.000143348623853 0 1 -1
tablets,for 1.0 0.000143348623853 0 1 -1
multiple,in 1.0 0.000143348623853 0 1 -1
time,with 1.0 0.000286697247706 2 0 2
reflex,tachycardia 1.0 0.000143348623853 1 0 1
system,maybe 1.0 0.000143348623853 0 1 -1
a,hmgcoa 1.0 0.000143348623853 0 1 -1
most,instances 1.0 0.000143348623853 1 0 1
given,concurrently 0.0909090909091 0.000143348623853 6 5 1
when,tracleer 0.0 0.0 1 1 0
bleeding,tendency 1.0 0.000143348623853 1 0 1
levels,was 1.0 0.000286697247706 2 0 2
qt0,on 1.0 0.000143348623853 0 1 -1
inducers,and 0.5 0.000286697247706 3 1 2
such,treatment 1.0 0.000143348623853 0 1 -1
m,of 1.0 0.000143348623853 0 1 -1
equivalent,amount 1.0 0.000143348623853 0 1 -1
dose,bioavailability 1.0 0.000143348623853 0 1 -1
addiction,after 1.0 0.000143348623853 0 1 -1
poor,metabolizers 0.666666666667 0.00114678899083 2 10 -8
least,weeks 0.142857142857 0.000143348623853 3 4 -1
m,or 1.0 0.000286697247706 2 0 2
halogenated,hydrocarbon 1.0 0.000286697247706 2 0 2
acetaminophen,diminished 1.0 0.000143348623853 1 0 1
calcitriol,and 1.0 0.00043004587156 3 0 3
is,however 0.0 0.0 1 1 0
was,for 1.0 0.000143348623853 1 0 1
zdv,and 1.0 0.000143348623853 0 1 -1
polyfuranoses,with 1.0 0.000143348623853 0 1 -1
dosed,simultaneously 1.0 0.000143348623853 1 0 1
then,be 1.0 0.000143348623853 0 1 -1
an,additional 1.0 0.000143348623853 1 0 1
enhanced,the 0.333333333333 0.000143348623853 1 2 -1
and,prolong 0.2 0.000143348623853 2 3 -1
dosage,may 0.666666666667 0.000573394495413 1 5 -4
excitement,depression 1.0 0.000143348623853 0 1 -1
proliferating,cell 1.0 0.000143348623853 0 1 -1
a,multicenter 1.0 0.000143348623853 0 1 -1
bronchospasm,in 1.0 0.000143348623853 1 0 1
expected,since 1.0 0.000143348623853 0 1 -1
initiating,replacement 1.0 0.000143348623853 0 1 -1
the,different 1.0 0.000143348623853 0 1 -1
when,viracept 1.0 0.000143348623853 0 1 -1
since,photic 1.0 0.000143348623853 0 1 -1
the,remaining 1.0 0.000286697247706 0 2 -2
theophylline,a 1.0 0.000143348623853 0 1 -1
nonsteroidal,antiinflammatories 1.0 0.000143348623853 0 1 -1
have,any 1.0 0.000860091743119 0 6 -6
exceeded,of 1.0 0.000143348623853 0 1 -1
when,atromid-s 1.0 0.000143348623853 1 0 1
abilify,to 1.0 0.000143348623853 0 1 -1
true,interaction 1.0 0.000143348623853 1 0 1
fertility,have 1.0 0.000286697247706 0 2 -2
induction,potential 1.0 0.00043004587156 0 3 -3
hyperkalemia,may 1.0 0.000143348623853 1 0 1
and,titrated 1.0 0.000286697247706 0 2 -2
to,generate 1.0 0.000286697247706 0 2 -2
the,nervous 0.0 0.0 1 1 0
pk,properties 1.0 0.000143348623853 0 1 -1
concentrations,should 0.636363636364 0.00100344036697 9 2 7
was,comparable 1.0 0.000143348623853 0 1 -1
discriminates,among 1.0 0.000143348623853 0 1 -1
proper,monitoring 1.0 0.000143348623853 0 1 -1
increased,stability 1.0 0.000286697247706 0 2 -2
interruption,of 1.0 0.000143348623853 0 1 -1
mc,and 1.0 0.00043004587156 0 3 -3
induced,significant 1.0 0.000143348623853 0 1 -1
disease,congestive 1.0 0.000143348623853 1 0 1
cyp3a4,major 1.0 0.000143348623853 0 1 -1
laboratory,parameters 1.0 0.000143348623853 0 1 -1
pressure,has 1.0 0.00043004587156 0 3 -3
blockers,and 0.333333333333 0.000286697247706 4 2 2
digitalis,glycosides 0.333333333333 0.000143348623853 1 2 -1
s,influence 1.0 0.000143348623853 1 0 1
and,distribution 1.0 0.000143348623853 0 1 -1
motility,dysfunction 1.0 0.000143348623853 0 1 -1
possessing,nephrotoxic 1.0 0.000143348623853 1 0 1
additive,use 1.0 0.000286697247706 2 0 2
benefits,against 1.0 0.000143348623853 0 1 -1
level,has 0.333333333333 0.000143348623853 2 1 1
proscar,mg 1.0 0.000143348623853 0 1 -1
fold,and 0.75 0.000860091743119 7 1 6
alleles,cyp2c9 1.0 0.000143348623853 0 1 -1
to,onset 1.0 0.000143348623853 1 0 1
if,at 0.0 0.0 1 1 0
polyene,many 1.0 0.000143348623853 0 1 -1
n-methylthiotetrazole,or 1.0 0.000143348623853 0 1 -1
hypertensive,patients 1.0 0.000286697247706 0 2 -2
of,normal 0.0 0.0 1 1 0
h,ml 1.0 0.000286697247706 2 0 2
addiction,is 1.0 0.000143348623853 0 1 -1
unless,there 1.0 0.000143348623853 0 1 -1
aeds,and 1.0 0.000286697247706 0 2 -2
and,theasinensin 1.0 0.000143348623853 0 1 -1
coadministration,were 1.0 0.000143348623853 1 0 1
mean,auc 0.0 0.0 5 5 0
across,a 1.0 0.000143348623853 0 1 -1
slightly,about 1.0 0.000143348623853 1 0 1
failing,heart 1.0 0.000143348623853 0 1 -1
is,unusual 1.0 0.000143348623853 0 1 -1
users,the 1.0 0.000143348623853 0 1 -1
discussion,clarithromycin 1.0 0.000143348623853 1 0 1
uptake,is 1.0 0.000573394495413 0 4 -4
mellitus,the 1.0 0.000143348623853 0 1 -1
given,tot 1.0 0.000143348623853 0 1 -1
intravenous,in 1.0 0.000143348623853 0 1 -1
responses,were 1.0 0.000286697247706 0 2 -2
the,two-hour 1.0 0.000143348623853 0 1 -1
nodes,however 1.0 0.000143348623853 0 1 -1
clinically,warranted 1.0 0.000573394495413 4 0 4
to,peak 1.0 0.000143348623853 0 1 -1
studies,performed 1.0 0.000286697247706 0 2 -2
volunteers,suggests 1.0 0.000143348623853 1 0 1
the,cellular 1.0 0.00043004587156 0 3 -3
test,have 1.0 0.000143348623853 0 1 -1
presented,with 1.0 0.000143348623853 0 1 -1
concentrations,within 1.0 0.000143348623853 0 1 -1
levels,or 0.142857142857 0.000143348623853 3 4 -1
causes,increase 1.0 0.000143348623853 1 0 1
oral,nicotinic 1.0 0.000573394495413 0 4 -4
nnrtis,appears 1.0 0.000143348623853 0 1 -1
cyp,enzymes 0.714285714286 0.000716743119266 1 6 -5
a,level 1.0 0.00043004587156 0 3 -3
to,premature 1.0 0.000143348623853 0 1 -1
or,potent 1.0 0.000143348623853 1 0 1
can,continue 1.0 0.000143348623853 0 1 -1
decreased,clearance 1.0 0.000573394495413 4 0 4
ml,in 1.0 0.000143348623853 0 1 -1
non-gastrointestinal,bleedings 1.0 0.000143348623853 0 1 -1
our,laboratory 1.0 0.000143348623853 0 1 -1
of,cyclic 1.0 0.000143348623853 0 1 -1
are,involved 1.0 0.000143348623853 0 1 -1
arimidex,as 1.0 0.000143348623853 1 0 1
epa,dose 1.0 0.000143348623853 0 1 -1
a,result 0.777777777778 0.00100344036697 1 8 -7
mg,and 0.037037037037 0.000143348623853 13 14 -1
myelotoxicity,it 1.0 0.000143348623853 0 1 -1
arthralgia,limb 1.0 0.000143348623853 0 1 -1
effects,potentially 1.0 0.000143348623853 0 1 -1
this,regimen 1.0 0.000143348623853 1 0 1
monkeys,treated 1.0 0.000143348623853 0 1 -1
chronically,receiving 1.0 0.000286697247706 0 2 -2
p-450,for 1.0 0.000143348623853 1 0 1
tambocor,and 0.0 0.0 2 2 0
curve,at 1.0 0.000143348623853 1 0 1
has,increased 1.0 0.000143348623853 0 1 -1
a,pharmacological 1.0 0.000286697247706 0 2 -2
therefore,positive 1.0 0.000143348623853 0 1 -1
immediately,if 1.0 0.000143348623853 0 1 -1
aim,and 1.0 0.000143348623853 0 1 -1
rapid,and 1.0 0.000286697247706 2 0 2
to,health 0.0 0.0 1 1 0
photic,evoked 1.0 0.000286697247706 0 2 -2
infusion,to 1.0 0.000143348623853 0 1 -1
increase,steadystate 1.0 0.000143348623853 1 0 1
some,form 1.0 0.000286697247706 0 2 -2
ze,patients 1.0 0.000143348623853 0 1 -1
factrel,may 1.0 0.000143348623853 1 0 1
a,h 1.0 0.000143348623853 0 1 -1
complications,which 1.0 0.000143348623853 0 1 -1
c,min 1.0 0.000143348623853 0 1 -1
use,especially 1.0 0.000143348623853 0 1 -1
if,vioxx 1.0 0.000143348623853 1 0 1
with,must 1.0 0.000143348623853 1 0 1
development,was 1.0 0.000143348623853 0 1 -1
program,of 1.0 0.000143348623853 0 1 -1
dissolving,dosage 1.0 0.000143348623853 1 0 1
polymorphic,p450 1.0 0.000143348623853 0 1 -1
physician,to 1.0 0.000143348623853 0 1 -1
however,total 1.0 0.000143348623853 0 1 -1
diagnosed,during 1.0 0.000286697247706 0 2 -2
from,grapefruit 1.0 0.000143348623853 0 1 -1
and,genitourinary 1.0 0.000143348623853 0 1 -1
daily,dosing 1.0 0.000143348623853 0 1 -1
response,against 1.0 0.000143348623853 0 1 -1
male,subjects 0.0 0.0 2 2 0
time,lst 1.0 0.000143348623853 0 1 -1
approximately,given 1.0 0.000143348623853 1 0 1
the,sedative 1.0 0.000143348623853 1 0 1
the,natriuresis 1.0 0.000143348623853 1 0 1
experiment,male 1.0 0.000143348623853 0 1 -1
the,pharmacological 1.0 0.000573394495413 0 4 -4
interaction,when 1.0 0.000573394495413 0 4 -4
diuresis,natriuresis 1.0 0.000143348623853 0 1 -1
of,camp-mediated 1.0 0.000143348623853 0 1 -1
concomitant,use 0.0862068965517 0.00143348623853 63 53 10
may,color 1.0 0.000143348623853 0 1 -1
tablets,administered 1.0 0.000143348623853 0 1 -1
and,abuse 1.0 0.000143348623853 0 1 -1
induce,bleeding 1.0 0.000143348623853 1 0 1
cyp2c19,or 1.0 0.000143348623853 0 1 -1
agents,particularly 1.0 0.000143348623853 1 0 1
that,iga 1.0 0.000143348623853 0 1 -1
diphenhydramine,hydrochloride 1.0 0.000143348623853 1 0 1
component,in 1.0 0.000143348623853 0 1 -1
sgpt,or 1.0 0.000143348623853 0 1 -1
plasma,glucose 1.0 0.000286697247706 0 2 -2
q-t,interval 1.0 0.000143348623853 0 1 -1
explain,the 0.0 0.0 1 1 0
or,inhibitors 0.2 0.000143348623853 2 3 -1
potentially,hepatotoxic 1.0 0.000143348623853 1 0 1
of,escherichia 1.0 0.000286697247706 0 2 -2
more,possibly 1.0 0.000143348623853 1 0 1
effects,can 0.5 0.000286697247706 1 3 -2
six,clinical 1.0 0.000143348623853 0 1 -1
menstrual,period 1.0 0.000143348623853 0 1 -1
and,consequently 1.0 0.000143348623853 0 1 -1
indeed,agents 1.0 0.000143348623853 0 1 -1
may,prolong 0.272727272727 0.00043004587156 7 4 3
baboons,given 1.0 0.000143348623853 0 1 -1
rat,bone 1.0 0.000143348623853 0 1 -1
sulfate,and 1.0 0.000143348623853 1 0 1
ions,are 1.0 0.000143348623853 0 1 -1
saline,g 1.0 0.000143348623853 0 1 -1
eszopiclone,mg 1.0 0.000143348623853 0 1 -1
for,ketones 1.0 0.00043004587156 0 3 -3
availability,of 1.0 0.00043004587156 0 3 -3
until,further 1.0 0.000286697247706 0 2 -2
relatively,unexplored 1.0 0.000143348623853 0 1 -1
be,carried 1.0 0.000143348623853 0 1 -1
total,of 1.0 0.000143348623853 0 1 -1
identification,of 1.0 0.000286697247706 0 2 -2
no,additional 1.0 0.000286697247706 2 0 2
marked,bradycardia 0.0 0.0 3 3 0
pi-based,regimens 1.0 0.000143348623853 0 1 -1
of,phosphatases 1.0 0.000143348623853 0 1 -1
any,from 1.0 0.000143348623853 0 1 -1
pipracil,produces 1.0 0.000143348623853 1 0 1
capacity,for 1.0 0.000143348623853 0 1 -1
pancreatitis,may 1.0 0.000143348623853 0 1 -1
the,doses 0.5 0.000286697247706 3 1 2
from,interaction 1.0 0.000143348623853 0 1 -1
for,heart 1.0 0.000143348623853 0 1 -1
crisis,may 1.0 0.000143348623853 0 1 -1
pharmacokinetics,but 1.0 0.000143348623853 1 0 1
metabolite,metabolite 1.0 0.000143348623853 0 1 -1
immobilised,cmc-cys7 1.0 0.000143348623853 0 1 -1
keflex,a 1.0 0.000143348623853 0 1 -1
a,neutralizing 1.0 0.000143348623853 1 0 1
the,specific 0.666666666667 0.000573394495413 1 5 -4
a,min 1.0 0.000143348623853 1 0 1
lean,animals 1.0 0.000143348623853 0 1 -1
potential,risk 0.333333333333 0.000143348623853 1 2 -1
allegra,should 0.0 0.0 1 1 0
other,on 1.0 0.000286697247706 0 2 -2
urinary,tract 1.0 0.00043004587156 0 3 -3
human,milk 1.0 0.000286697247706 0 2 -2
other,or 0.0 0.0 2 2 0
postnatal,immune 1.0 0.000143348623853 0 1 -1
during,a 1.0 0.000286697247706 0 2 -2
of,benign 1.0 0.000143348623853 0 1 -1
steady-state,were 1.0 0.000143348623853 0 1 -1
severe,myelosuppression 1.0 0.000143348623853 0 1 -1
degenerative,changes 1.0 0.000143348623853 0 1 -1
clear,that 1.0 0.000143348623853 0 1 -1
metabolism,causing 1.0 0.000143348623853 1 0 1
and,periodically 1.0 0.000143348623853 0 1 -1
with,copegus 1.0 0.00043004587156 0 3 -3
the,potentiation 1.0 0.000286697247706 0 2 -2
subjects,received 1.0 0.00100344036697 0 7 -7
transcriptional,regulation 1.0 0.000143348623853 0 1 -1
excretion,as 1.0 0.000143348623853 0 1 -1
cardiovascular,safety 1.0 0.000143348623853 0 1 -1
valproate,felbatol 1.0 0.000143348623853 1 0 1
cortisol,concentration 1.0 0.000143348623853 0 1 -1
the,righting 1.0 0.000286697247706 0 2 -2
values,were 1.0 0.000573394495413 0 4 -4
times,when 0.0 0.0 1 1 0
increased,circulating 1.0 0.00043004587156 0 3 -3
the,ability 0.5 0.000286697247706 1 3 -2
may,help 1.0 0.000286697247706 0 2 -2
extrarenal,mechanisms 1.0 0.000143348623853 0 1 -1
the,half- 1.0 0.00043004587156 0 3 -3
the,assay 1.0 0.000573394495413 0 4 -4
weekly,human 1.0 0.000143348623853 0 1 -1
when,taxol 1.0 0.000286697247706 2 0 2
whose,metabolism 1.0 0.000143348623853 0 1 -1
oral,anticoagulants 0.0 0.0 2 2 0
organ,transplants 1.0 0.000143348623853 0 1 -1
transient,increases 0.333333333333 0.000143348623853 1 2 -1
the,patient 0.392857142857 0.00315366972477 17 39 -22
in,coffee 1.0 0.000143348623853 0 1 -1
toward,a 1.0 0.000143348623853 0 1 -1
live,or 1.0 0.000143348623853 1 0 1
cardiotoxicity,associated 1.0 0.000143348623853 0 1 -1
iodide,i 1.0 0.000143348623853 0 1 -1
double-blind,randomized 1.0 0.000143348623853 0 1 -1
lowering,effects 1.0 0.000143348623853 1 0 1
daily,maintenance 1.0 0.000143348623853 1 0 1
increase,to 1.0 0.000143348623853 0 1 -1
as,minimal 1.0 0.000143348623853 0 1 -1
to,predict 1.0 0.000573394495413 0 4 -4
evidence,to 1.0 0.000286697247706 0 2 -2
in,fertility 1.0 0.000143348623853 0 1 -1
were,mainly 1.0 0.000143348623853 0 1 -1
distribution,or 1.0 0.000143348623853 0 1 -1
the-curve,after 1.0 0.000143348623853 1 0 1
baseline,phenytoin 1.0 0.000143348623853 1 0 1
used,the 0.333333333333 0.000143348623853 1 2 -1
at,lower 0.0 0.0 1 1 0
therefore,should 0.333333333333 0.000286697247706 4 2 2
of,rocaltrol 1.0 0.00043004587156 0 3 -3
insufficiency,was 1.0 0.000143348623853 0 1 -1
epidural,injection 1.0 0.000143348623853 1 0 1
strong,evidence 1.0 0.000286697247706 0 2 -2
a,routine 1.0 0.000143348623853 0 1 -1
this,cluster 1.0 0.000143348623853 0 1 -1
also,concurrent 1.0 0.000143348623853 0 1 -1
avoid,potential 1.0 0.000143348623853 0 1 -1
m,at 1.0 0.000143348623853 0 1 -1
evaluation,of 1.0 0.000860091743119 0 6 -6
with,for 0.5 0.000286697247706 3 1 2
anti-coagulant,effect 1.0 0.000143348623853 0 1 -1
of,magnitude 1.0 0.000143348623853 0 1 -1
hypoglycemics,diclofenac 1.0 0.000143348623853 0 1 -1
the,tubular 1.0 0.000573394495413 4 0 4
a,digitalized 1.0 0.000143348623853 1 0 1
subutex,or 1.0 0.000143348623853 0 1 -1
enzyme-inducing,such 1.0 0.000143348623853 1 0 1
daily,the 1.0 0.000286697247706 2 0 2
female,subjects 1.0 0.000286697247706 0 2 -2
patients,be 1.0 0.000143348623853 0 1 -1
agents,co-administration 1.0 0.000143348623853 0 1 -1
isomer,had 1.0 0.000143348623853 0 1 -1
to,raise 1.0 0.000143348623853 1 0 1
respectively,after 0.0 0.0 1 1 0
administered,enter 1.0 0.000143348623853 0 1 -1
task,it 1.0 0.000143348623853 0 1 -1
isoenzymes,and 1.0 0.000286697247706 0 2 -2
foscavir,should 1.0 0.000143348623853 1 0 1
dependent,labelling 1.0 0.000143348623853 0 1 -1
patients,by 0.0 0.0 1 1 0
the,anorectic 1.0 0.000286697247706 2 0 2
testicular,atrophy 1.0 0.000143348623853 0 1 -1
a,thorough 1.0 0.000143348623853 0 1 -1
p450,a 1.0 0.00043004587156 0 3 -3
qtc,intervals 1.0 0.000286697247706 0 2 -2
p450,c 1.0 0.000143348623853 0 1 -1
and,overuse 1.0 0.000143348623853 0 1 -1
profile,between 1.0 0.000143348623853 0 1 -1
a,psychotic 1.0 0.000143348623853 0 1 -1
of,suggested 1.0 0.000143348623853 0 1 -1
activity,patients 1.0 0.000286697247706 2 0 2
of,escalating 1.0 0.000143348623853 0 1 -1
plasma,indicate 1.0 0.000143348623853 0 1 -1
concentrations,auc 0.2 0.000143348623853 3 2 1
deficit,i 1.0 0.000143348623853 0 1 -1
diabetes,have 1.0 0.000286697247706 0 2 -2
the,extremities 1.0 0.000286697247706 0 2 -2
av,conduction 0.5 0.000286697247706 3 1 2
new,rashes 1.0 0.000143348623853 0 1 -1
inhibitor,class 1.0 0.000286697247706 2 0 2
types,of 0.714285714286 0.000716743119266 1 6 -5
present,study 1.0 0.000573394495413 0 4 -4
single-dose,study 1.0 0.000143348623853 0 1 -1
the,stimulant 1.0 0.000143348623853 0 1 -1
placebo,was 1.0 0.000143348623853 0 1 -1
in,cyclosporine-induced 1.0 0.000286697247706 2 0 2
extremely,acidic 1.0 0.000143348623853 0 1 -1
confirmation,test 1.0 0.000143348623853 0 1 -1
to,situate 1.0 0.000143348623853 0 1 -1
more,during 1.0 0.000143348623853 0 1 -1
was,as 1.0 0.000143348623853 0 1 -1
macrolide,immunosuppressant 1.0 0.000143348623853 0 1 -1
isozyme,cytochrome 1.0 0.000716743119266 0 5 -5
were,completely 1.0 0.000143348623853 1 0 1
third,hour 1.0 0.000143348623853 0 1 -1
parameters,the 1.0 0.000143348623853 0 1 -1
cited,in 1.0 0.000143348623853 0 1 -1
one-half,depending 1.0 0.000143348623853 0 1 -1
which,patients 1.0 0.000286697247706 2 0 2
many,without 1.0 0.000143348623853 0 1 -1
however,at 1.0 0.000286697247706 0 2 -2
however,as 1.0 0.000143348623853 1 0 1
travelers,receiving 1.0 0.000143348623853 1 0 1
was,an 1.0 0.000143348623853 0 1 -1
marked,and 1.0 0.000143348623853 1 0 1
erection,disorder 1.0 0.000143348623853 0 1 -1
when,ponstel 1.0 0.000143348623853 0 1 -1
administered,neonatally 1.0 0.000143348623853 0 1 -1
design,with 1.0 0.000143348623853 0 1 -1
no,experience 1.0 0.000286697247706 0 2 -2
on,how 1.0 0.000143348623853 0 1 -1
encouraged,to 1.0 0.000143348623853 0 1 -1
in,fatal 1.0 0.000143348623853 1 0 1
improved,the 1.0 0.000143348623853 0 1 -1
vitro,antiviral 1.0 0.000143348623853 1 0 1
contraindications,indications 1.0 0.000143348623853 0 1 -1
backwards,displacement 1.0 0.000143348623853 0 1 -1
hearing,impairment 1.0 0.000143348623853 1 0 1
use,when 1.0 0.000143348623853 0 1 -1
hormones,complex 1.0 0.000143348623853 0 1 -1
in,heart 0.333333333333 0.000143348623853 2 1 1
serious,resedation 1.0 0.000143348623853 0 1 -1
plus,a 1.0 0.000286697247706 0 2 -2
however,co 1.0 0.000143348623853 1 0 1
increasing,metal 1.0 0.000143348623853 0 1 -1
concentrations,considerably 1.0 0.000143348623853 1 0 1
small,to 1.0 0.000143348623853 0 1 -1
of,angina 0.0 0.0 1 1 0
prescribed,foradil 1.0 0.000143348623853 0 1 -1
mouth,sores 1.0 0.000143348623853 0 1 -1
apparent,pharmacokinetic 1.0 0.000573394495413 0 4 -4
of,phenolic 1.0 0.000143348623853 0 1 -1
effect,agents 1.0 0.000143348623853 0 1 -1
was,generally 0.0 0.0 1 1 0
and,mixed 1.0 0.000286697247706 0 2 -2
however,when 0.333333333333 0.000143348623853 1 2 -1
the,maximum 0.0909090909091 0.000143348623853 5 6 -1
some,associated 1.0 0.000286697247706 0 2 -2
a,five-fold 1.0 0.000143348623853 1 0 1
warfarin,administration 1.0 0.000143348623853 0 1 -1
prescribed,to 0.0 0.0 1 1 0
this,review 1.0 0.000286697247706 0 2 -2
since,hydrochloride 1.0 0.000143348623853 0 1 -1
n1,and 1.0 0.000143348623853 0 1 -1
standard,monitoring 0.0 0.0 1 1 0
warning,signs 1.0 0.000143348623853 0 1 -1
determinants,of 1.0 0.000143348623853 0 1 -1
like,may 1.0 0.000143348623853 1 0 1
a,drugs 1.0 0.000286697247706 0 2 -2
diclofenac,increases 1.0 0.000143348623853 0 1 -1
chemically,modify 1.0 0.000143348623853 0 1 -1
in,ci 1.0 0.000143348623853 0 1 -1
with,should 0.333333333333 0.00043004587156 6 3 3
modify,acth 1.0 0.000143348623853 0 1 -1
be,temporarily 0.0 0.0 1 1 0
reduced,to 0.428571428571 0.00043004587156 5 2 3
steady-state,pharmacokinetic 1.0 0.000286697247706 0 2 -2
of,prostatic 1.0 0.000143348623853 1 0 1
were,well 1.0 0.000143348623853 0 1 -1
killed,at 1.0 0.000143348623853 0 1 -1
dosage,is 0.333333333333 0.000143348623853 1 2 -1
and,be 1.0 0.000143348623853 0 1 -1
than,seven 1.0 0.000143348623853 0 1 -1
ranitidine,also 1.0 0.000143348623853 0 1 -1
weak,inhibitor 0.333333333333 0.000143348623853 1 2 -1
adenosine,cyclic 1.0 0.000143348623853 0 1 -1
in,tmax 1.0 0.000143348623853 0 1 -1
not,normally 1.0 0.000143348623853 0 1 -1
basis,and 1.0 0.000143348623853 0 1 -1
produced,by 0.272727272727 0.00043004587156 7 4 3
safely,without 1.0 0.000143348623853 0 1 -1
for,preparation 1.0 0.000143348623853 0 1 -1
most,cases 1.0 0.000143348623853 0 1 -1
cardiac,patients 1.0 0.000143348623853 0 1 -1
angiotensin,on 1.0 0.000143348623853 0 1 -1
these,problems 1.0 0.000143348623853 0 1 -1
if,plasma 1.0 0.000143348623853 0 1 -1
avoided,and 1.0 0.000143348623853 1 0 1
as,muscle 1.0 0.000143348623853 0 1 -1
k,deficiency 1.0 0.000143348623853 0 1 -1
remained,stable 1.0 0.000143348623853 0 1 -1
increases,inrifabutin 1.0 0.000143348623853 0 1 -1
acid,in 0.333333333333 0.000143348623853 1 2 -1
for,response 1.0 0.000143348623853 0 1 -1
their,efficacy 1.0 0.000143348623853 0 1 -1
multiple,enzyme 1.0 0.000143348623853 0 1 -1
of,hypertriglyceridemia 1.0 0.000286697247706 0 2 -2
administration,at 1.0 0.000143348623853 0 1 -1
single,case 1.0 0.000143348623853 1 0 1
are,potentially 1.0 0.000143348623853 0 1 -1
group,is 1.0 0.000143348623853 0 1 -1
the,synthesis 1.0 0.000286697247706 0 2 -2
coadministration,up 1.0 0.000143348623853 1 0 1
the,parameters 1.0 0.000143348623853 0 1 -1
against,cercariae 1.0 0.000143348623853 0 1 -1
prothrombin,response 1.0 0.00043004587156 3 0 3
increases,the 0.578947368421 0.00157683486239 15 4 11
nondepolarizing,relaxants 1.0 0.000286697247706 0 2 -2
alfenta,is 1.0 0.000143348623853 1 0 1
is,the 0.538461538462 0.00100344036697 3 10 -7
hydroxylase,is 1.0 0.000716743119266 0 5 -5
nucleolin,c23 1.0 0.000286697247706 0 2 -2
exposure,auc 1.0 0.000860091743119 6 0 6
share,or 1.0 0.000143348623853 0 1 -1
significantly,when 0.0 0.0 1 1 0
for,migraines 1.0 0.000143348623853 0 1 -1
coincide,duloxetine 1.0 0.000143348623853 0 1 -1
required,since 1.0 0.000286697247706 0 2 -2
use,were 1.0 0.000143348623853 0 1 -1
urine,as 1.0 0.000143348623853 0 1 -1
cumulative,doses 1.0 0.000143348623853 1 0 1
lower,than 0.6 0.000860091743119 2 8 -6
levels,usually 1.0 0.000143348623853 0 1 -1
the,ca 1.0 0.000286697247706 0 2 -2
studies,translates 1.0 0.000143348623853 0 1 -1
both,or 1.0 0.000143348623853 0 1 -1
on,severe 1.0 0.000143348623853 1 0 1
determinants,downstream 1.0 0.000143348623853 0 1 -1
systems,at 1.0 0.000143348623853 0 1 -1
aluminum-,and 1.0 0.000143348623853 0 1 -1
general,are 1.0 0.000143348623853 0 1 -1
agents,protease 1.0 0.000143348623853 1 0 1
day,before 1.0 0.000143348623853 0 1 -1
enzymatic,test 1.0 0.000143348623853 0 1 -1
cancidas,may 1.0 0.000143348623853 1 0 1
discontinue,the 1.0 0.000286697247706 0 2 -2
proprietary,cold 1.0 0.000143348623853 1 0 1
or,affect 1.0 0.000286697247706 0 2 -2
potent,against 1.0 0.000143348623853 0 1 -1
level,however 1.0 0.000143348623853 1 0 1
conclusively,establish 1.0 0.000143348623853 0 1 -1
method,and 1.0 0.00043004587156 0 3 -3
cardiac,arrest 1.0 0.000286697247706 0 2 -2
conclusions,the 1.0 0.000143348623853 0 1 -1
to,double 1.0 0.000143348623853 1 0 1
concomitant,beta-1a 1.0 0.000143348623853 0 1 -1
no,differential 1.0 0.000286697247706 0 2 -2
in,six 0.5 0.000286697247706 3 1 2
orlistat-orlistat,may 1.0 0.000143348623853 1 0 1
several,human 1.0 0.000143348623853 0 1 -1
experiment,non-diabetic 1.0 0.000143348623853 0 1 -1
infusion,reactions 1.0 0.000143348623853 0 1 -1
ordinarily,should 1.0 0.000143348623853 0 1 -1
to,additive 1.0 0.000143348623853 0 1 -1
additive,negative 1.0 0.000143348623853 1 0 1
and,confirmed 1.0 0.000143348623853 0 1 -1
simulect,use 1.0 0.000143348623853 0 1 -1
an,increase 0.5 0.00372706422018 39 13 26
of,hydrochloride 0.333333333333 0.00043004587156 6 3 3
cases,therefore 1.0 0.000143348623853 0 1 -1
a,first-line 1.0 0.000143348623853 0 1 -1
receiving,growth 1.0 0.000143348623853 0 1 -1
cytoprotective,properties 1.0 0.000143348623853 0 1 -1
only,one 1.0 0.000143348623853 0 1 -1
potassium,kinetics 1.0 0.000143348623853 1 0 1
state,following 1.0 0.000143348623853 0 1 -1
implantable,insertable 1.0 0.000143348623853 0 1 -1
now,difficult 1.0 0.000143348623853 0 1 -1
cmin,decreased 1.0 0.000143348623853 1 0 1
chlorprothixene,may 1.0 0.000143348623853 1 0 1
show,potential 1.0 0.000143348623853 0 1 -1
with,particularly 1.0 0.000143348623853 1 0 1
oral,who 1.0 0.000143348623853 1 0 1
across,all 1.0 0.000143348623853 0 1 -1
with,nonselective 1.0 0.000143348623853 1 0 1
dosage,when 1.0 0.000143348623853 1 0 1
table,established 1.0 0.000143348623853 0 1 -1
they,relate 1.0 0.000143348623853 0 1 -1
interact,significantly 1.0 0.000143348623853 0 1 -1
a,more 1.0 0.000716743119266 0 5 -5
or,citrate 1.0 0.000143348623853 0 1 -1
oxidase,or 1.0 0.000286697247706 0 2 -2
controlled,crossover 1.0 0.000143348623853 0 1 -1
of,animal 1.0 0.000143348623853 0 1 -1
slower,absorption 1.0 0.000143348623853 1 0 1
following,situations 1.0 0.000143348623853 0 1 -1
receiving,starlix 1.0 0.000143348623853 0 1 -1
concomitant,may 1.0 0.000143348623853 1 0 1
of,whether 0.0 0.0 1 1 0
plasma,maximum 1.0 0.000143348623853 0 1 -1
in,additive 1.0 0.000573394495413 4 0 4
taking,celebrex 0.0 0.0 1 1 0
drawn,at 1.0 0.000143348623853 0 1 -1
hydroxide,and 0.333333333333 0.000143348623853 2 1 1
monitoring,particularly 1.0 0.000143348623853 0 1 -1
chloride,in 1.0 0.000143348623853 1 0 1
disease,clinical 1.0 0.000143348623853 0 1 -1
in,male 1.0 0.000716743119266 0 5 -5
and,animal 1.0 0.000286697247706 2 0 2
was,usually 0.0 0.0 1 1 0
those,concomitant 1.0 0.000143348623853 0 1 -1
a,tolerance 1.0 0.000143348623853 1 0 1
weak,inhibitory 1.0 0.000143348623853 0 1 -1
methotrexate,concomitant 1.0 0.000143348623853 1 0 1
were,obtained 1.0 0.00043004587156 0 3 -3
a,dosing 1.0 0.000143348623853 0 1 -1
weak,inhibitors 1.0 0.000143348623853 0 1 -1
horses,from 1.0 0.000143348623853 0 1 -1
pegasys,in 1.0 0.00043004587156 0 3 -3
degraded,by 1.0 0.000143348623853 0 1 -1
naflu,and 1.0 0.000286697247706 0 2 -2
required,to 0.0 0.0 3 3 0
it,increased 1.0 0.000143348623853 0 1 -1
were,administered 0.733333333333 0.00157683486239 2 13 -11
which,indicate 1.0 0.000143348623853 0 1 -1
ptx,have 1.0 0.000143348623853 0 1 -1
after,or 0.5 0.000286697247706 3 1 2
stimulation,study 1.0 0.000143348623853 0 1 -1
of,unchanged 0.5 0.000286697247706 1 3 -2
for,chronic 1.0 0.000143348623853 0 1 -1
receiving,for 1.0 0.000286697247706 0 2 -2
resolution,of 1.0 0.000143348623853 1 0 1
by,dose 1.0 0.000143348623853 1 0 1
producing,of 1.0 0.000143348623853 0 1 -1
of,dizziness 1.0 0.000143348623853 0 1 -1
these,concurrently 1.0 0.000143348623853 0 1 -1
its,efficacy 1.0 0.00043004587156 0 3 -3
pi,over 1.0 0.000143348623853 0 1 -1
protein,involved 1.0 0.000143348623853 0 1 -1
drugs,possessing 0.0 0.0 1 1 0
hormonal,causing 1.0 0.000143348623853 1 0 1
pain,vomiting 1.0 0.000143348623853 0 1 -1
screening,in 1.0 0.000143348623853 0 1 -1
or,divalent 1.0 0.000143348623853 0 1 -1
approximate,the 1.0 0.000143348623853 0 1 -1
liter,potentiated 1.0 0.000143348623853 1 0 1
physicians,needing 1.0 0.000143348623853 0 1 -1
decreased,core 1.0 0.000143348623853 0 1 -1
lacking,cyp3a4 1.0 0.000143348623853 0 1 -1
gastrointestinal,alkalinizing 1.0 0.000143348623853 1 0 1
those,achieved 1.0 0.000143348623853 1 0 1
when,cime-tidine 1.0 0.000143348623853 1 0 1
in,how 1.0 0.000143348623853 0 1 -1
influence,in 1.0 0.000143348623853 0 1 -1
either,class 1.0 0.000286697247706 0 2 -2
together,even 1.0 0.000143348623853 0 1 -1
stimulated,gastric 1.0 0.000143348623853 0 1 -1
permeation,however 1.0 0.000143348623853 0 1 -1
outweigh,the 1.0 0.000573394495413 4 0 4
certain,types 1.0 0.000143348623853 1 0 1
inhibitors,in 0.428571428571 0.00043004587156 5 2 3
could,lead 0.0 0.0 1 1 0
once,monthly 1.0 0.000143348623853 0 1 -1
estradiol,and 0.0 0.0 4 4 0
the,prescription 0.0 0.0 1 1 0
on,pupil 1.0 0.000143348623853 1 0 1
applied,to 0.6 0.00043004587156 1 4 -3
inhibitors,it 1.0 0.000143348623853 0 1 -1
inconsistent,reports 1.0 0.000143348623853 0 1 -1
studied,two 1.0 0.000143348623853 1 0 1
this,risk 1.0 0.000143348623853 0 1 -1
complications,that 1.0 0.000143348623853 0 1 -1
concentrations,it 1.0 0.000143348623853 0 1 -1
narrow,serum 1.0 0.000143348623853 0 1 -1
hepatic,enzyme-inducing 1.0 0.000143348623853 1 0 1
ml,whereas 1.0 0.000143348623853 0 1 -1
little,experience 1.0 0.000286697247706 0 2 -2
concentrations,in 0.0 0.0 5 5 0
plasma,m1 1.0 0.000143348623853 1 0 1
dosing,was 1.0 0.000143348623853 1 0 1
level,serum 1.0 0.000143348623853 0 1 -1
at,greater 1.0 0.000143348623853 0 1 -1
lamivudine,in 1.0 0.000143348623853 1 0 1
for,its 1.0 0.00043004587156 0 3 -3
test,must 1.0 0.000143348623853 0 1 -1
misused,by 1.0 0.000143348623853 0 1 -1
thereof,are 1.0 0.000143348623853 0 1 -1
metabolism,pharmacokinetics 1.0 0.000143348623853 0 1 -1
with,elspar 1.0 0.000143348623853 1 0 1
however,pharmacokinetic 1.0 0.000143348623853 0 1 -1
coagulation,parameters 0.333333333333 0.000143348623853 2 1 1
reach,toxic 1.0 0.000143348623853 0 1 -1
were,done 1.0 0.000143348623853 0 1 -1
androgens,male 1.0 0.000143348623853 0 1 -1
following,are 0.666666666667 0.000573394495413 1 5 -4
of,deoxy 1.0 0.000143348623853 0 1 -1
evaluated,as 1.0 0.000143348623853 0 1 -1
although,has 1.0 0.000143348623853 1 0 1
coagulation,system 1.0 0.000143348623853 0 1 -1
or,clinically 1.0 0.000286697247706 0 2 -2
pre-,and 1.0 0.000143348623853 0 1 -1
maximize,the 1.0 0.000286697247706 0 2 -2
and,fetal 1.0 0.000143348623853 0 1 -1
potassium-sparing,or 0.0 0.0 1 1 0
lead,tml 1.0 0.000143348623853 0 1 -1
patient,interferes 1.0 0.000143348623853 0 1 -1
responding,under 1.0 0.000143348623853 0 1 -1
of,your 1.0 0.000143348623853 0 1 -1
with,auc 1.0 0.000143348623853 0 1 -1
and,coadministration 1.0 0.00043004587156 3 0 3
the,peritoneal 1.0 0.000143348623853 0 1 -1
the,classes 1.0 0.000143348623853 0 1 -1
that,a 0.454545454545 0.00143348623853 6 16 -10
n,x 1.0 0.000143348623853 0 1 -1
and,possibly 0.25 0.000286697247706 5 3 2
of,q12h 1.0 0.000143348623853 1 0 1
and,possible 0.666666666667 0.000573394495413 1 5 -4
for,vitamin 1.0 0.000573394495413 4 0 4
blockers,requires 1.0 0.000143348623853 1 0 1
that,s 1.0 0.000143348623853 0 1 -1
n,n 1.0 0.000143348623853 0 1 -1
mg,tid 0.0 0.0 3 3 0
assist,the 1.0 0.000143348623853 0 1 -1
prolonged,or 0.333333333333 0.000143348623853 1 2 -1
after,day 1.0 0.000143348623853 0 1 -1
the,majority 1.0 0.000573394495413 0 4 -4
of,fold 1.0 0.000143348623853 1 0 1
concurrent,enbrel 1.0 0.000143348623853 1 0 1
death,in 1.0 0.000143348623853 0 1 -1
interactions,associated 1.0 0.000143348623853 0 1 -1
causes,an 1.0 0.000716743119266 5 0 5
class,i 1.0 0.000143348623853 0 1 -1
exposure,and 0.333333333333 0.000143348623853 1 2 -1
escherichia,coli 1.0 0.00043004587156 0 3 -3
class,a 1.0 0.000143348623853 0 1 -1
of,hydroxytolbutamide 1.0 0.000143348623853 0 1 -1
hemorrhages,edema 1.0 0.000143348623853 0 1 -1
starting,daily 1.0 0.000143348623853 0 1 -1
normal,renal 1.0 0.000286697247706 0 2 -2
no,other 1.0 0.00043004587156 0 3 -3
intrathecal,injection 1.0 0.000143348623853 1 0 1
suggest,comparable 1.0 0.000143348623853 0 1 -1
the,present 1.0 0.000716743119266 0 5 -5
addition,fondaparinux 1.0 0.000143348623853 0 1 -1
all,care 1.0 0.000143348623853 0 1 -1
induce,a 1.0 0.000573394495413 0 4 -4
permeation,enhancing 1.0 0.000143348623853 0 1 -1
present,for 1.0 0.000143348623853 0 1 -1
lng,were 1.0 0.000143348623853 0 1 -1
reviews,the 1.0 0.000286697247706 0 2 -2
monitoring,for 0.2 0.000143348623853 3 2 1
vioxx,and 0.2 0.000143348623853 3 2 1
cyp2d6,metabolizers 1.0 0.000143348623853 0 1 -1
study,there 1.0 0.000286697247706 0 2 -2
digitalis,thyroid 1.0 0.000143348623853 1 0 1
other,metal 1.0 0.000143348623853 1 0 1
mean,elimination 0.333333333333 0.000143348623853 2 1 1
drug,level 1.0 0.000143348623853 0 1 -1
using,induced 1.0 0.000143348623853 0 1 -1
virtually,complete 1.0 0.000143348623853 0 1 -1
hospital,for 1.0 0.000143348623853 0 1 -1
kinase,c 1.0 0.000143348623853 0 1 -1
is,frequently 1.0 0.000143348623853 0 1 -1
with,hormonal 0.333333333333 0.000143348623853 1 2 -1
powder,x-ray 1.0 0.000143348623853 0 1 -1
non-steroidal,agent 1.0 0.000143348623853 1 0 1
while,on 0.333333333333 0.000143348623853 2 1 1
groups,but 1.0 0.000143348623853 0 1 -1
in,cytochrome 1.0 0.000143348623853 0 1 -1
study,volunteers 1.0 0.000143348623853 0 1 -1
in,psychopathology 1.0 0.000143348623853 0 1 -1
expensive,or 1.0 0.000143348623853 0 1 -1
together,these 1.0 0.000286697247706 0 2 -2
depressants,and 1.0 0.000143348623853 1 0 1
judged,from 1.0 0.000143348623853 0 1 -1
adolescent,with 1.0 0.000143348623853 1 0 1
in,serum-deprived 1.0 0.000286697247706 0 2 -2
increased,free 1.0 0.000143348623853 0 1 -1
novel,iboga 1.0 0.000143348623853 0 1 -1
pre-gentamycin,strength 1.0 0.000143348623853 0 1 -1
placebo,oral 1.0 0.000143348623853 0 1 -1
contrast,acute 1.0 0.000143348623853 0 1 -1
these,medicines 0.5 0.000573394495413 2 6 -4
of,auc 1.0 0.000143348623853 1 0 1
inhibitors,within 1.0 0.000143348623853 1 0 1
intravenous,unless 1.0 0.000143348623853 1 0 1
have,elevated 1.0 0.000143348623853 1 0 1
other,carbonic 1.0 0.000143348623853 0 1 -1
rats,responding 1.0 0.000143348623853 1 0 1
individual,compounds 1.0 0.000143348623853 0 1 -1
and,induced 1.0 0.000143348623853 0 1 -1
qt,interval 0.666666666667 0.00114678899083 10 2 8
the,e-strain 1.0 0.000143348623853 0 1 -1
be,decided 1.0 0.000143348623853 1 0 1
each,would 1.0 0.000143348623853 0 1 -1
doxorubicin,doxorubicin 1.0 0.000143348623853 1 0 1
clinician,responsible 1.0 0.000143348623853 0 1 -1
one-half,of 1.0 0.000286697247706 2 0 2
miu,ml 1.0 0.000143348623853 0 1 -1
kilometers,of 1.0 0.000143348623853 0 1 -1
ria,kit 1.0 0.000286697247706 0 2 -2
oxidized,metabolites 1.0 0.000143348623853 0 1 -1
clearance,value 1.0 0.000143348623853 0 1 -1
other,produce 1.0 0.000143348623853 0 1 -1
by,aom 1.0 0.000143348623853 0 1 -1
activity,may 0.555555555556 0.000716743119266 2 7 -5
experience,indicates 1.0 0.000286697247706 2 0 2
potent,inducers 0.0 0.0 1 1 0
decreased,efficacy 0.333333333333 0.000143348623853 2 1 1
cytokines,have 1.0 0.000143348623853 0 1 -1
for,converting 1.0 0.000143348623853 1 0 1
colitis,a 1.0 0.000143348623853 1 0 1
probenecid,concomitant 1.0 0.000143348623853 1 0 1
average,higher 1.0 0.000143348623853 0 1 -1
of,osteoarthritis 1.0 0.000143348623853 0 1 -1
target,added 1.0 0.000143348623853 0 1 -1
of,doses 1.0 0.000286697247706 0 2 -2
between,prostin 1.0 0.000143348623853 0 1 -1
dramatic,effect 1.0 0.000286697247706 0 2 -2
known,property 1.0 0.000143348623853 1 0 1
important,when 1.0 0.000143348623853 0 1 -1
studies,suggest 0.2 0.000143348623853 2 3 -1
site,of 1.0 0.00043004587156 0 3 -3
clearance,was 1.0 0.00043004587156 0 3 -3
which,effectiveness 1.0 0.000143348623853 0 1 -1
diminished,urinary 1.0 0.000143348623853 1 0 1
clinical,or 1.0 0.000143348623853 0 1 -1
time,measured 1.0 0.000286697247706 2 0 2
time,the 1.0 0.000143348623853 0 1 -1
can,progress 1.0 0.000143348623853 0 1 -1
are,required 0.333333333333 0.000286697247706 4 2 2
at,very 1.0 0.000143348623853 0 1 -1
injection,lorazepam 1.0 0.000143348623853 1 0 1
levorotatory,isomer 1.0 0.000143348623853 0 1 -1
of,qtc 1.0 0.000286697247706 0 2 -2
proper,interval 1.0 0.000143348623853 0 1 -1
drugs,these 1.0 0.000143348623853 0 1 -1
diabetics,who 1.0 0.000286697247706 0 2 -2
common,distilled 1.0 0.000143348623853 0 1 -1
not,seen 1.0 0.000143348623853 0 1 -1
interact,altered 1.0 0.000143348623853 0 1 -1
not,seem 1.0 0.000143348623853 0 1 -1
cyp2d6,pathway 1.0 0.000143348623853 0 1 -1
moderate,inhibitor 1.0 0.000716743119266 0 5 -5
infusions,must 1.0 0.000143348623853 0 1 -1
beta-naltrexol,were 1.0 0.000143348623853 0 1 -1
administration,hour 1.0 0.000143348623853 0 1 -1
or,daily 1.0 0.000143348623853 0 1 -1
induced,lower 1.0 0.000143348623853 0 1 -1
capsules,or 1.0 0.000143348623853 1 0 1
necessitate,an 1.0 0.000143348623853 0 1 -1
trisphosphate,the 1.0 0.000143348623853 0 1 -1
nimodipine,had 1.0 0.000143348623853 0 1 -1
that,if 1.0 0.000143348623853 1 0 1
with,those 0.428571428571 0.00043004587156 5 2 3
time,pt 0.0 0.0 1 1 0
alcohol-related,deaths 1.0 0.000143348623853 0 1 -1
increase,cardiac 1.0 0.000143348623853 1 0 1
amprenavir,plus 0.0 0.0 1 1 0
in,hyperthyroidism 1.0 0.000143348623853 0 1 -1
advil,nuprin 1.0 0.000143348623853 0 1 -1
north,american 1.0 0.000286697247706 0 2 -2
is,higher 0.0 0.0 1 1 0
buprenorphine,is 1.0 0.000143348623853 0 1 -1
if,oral 1.0 0.000143348623853 0 1 -1
modulates,in 1.0 0.000143348623853 1 0 1
is,only 0.333333333333 0.000143348623853 1 2 -1
to,orders 1.0 0.000143348623853 0 1 -1
recommended,doses 1.0 0.000143348623853 1 0 1
used,clinically 1.0 0.000143348623853 0 1 -1
rural,health 1.0 0.000143348623853 0 1 -1
women,who 1.0 0.00043004587156 0 3 -3
toradol,iv 1.0 0.000143348623853 1 0 1
ht1,agonists 0.333333333333 0.000143348623853 2 1 1
synergy,was 1.0 0.000143348623853 0 1 -1
morphine-induced,increases 1.0 0.000143348623853 1 0 1
situate,the 1.0 0.000143348623853 0 1 -1
of,predisposing 1.0 0.000143348623853 0 1 -1
hyperlactatemia,lactic 1.0 0.000143348623853 0 1 -1
in,table 1.0 0.000286697247706 0 2 -2
symbol,substitution 1.0 0.000143348623853 1 0 1
were,similar 1.0 0.000573394495413 0 4 -4
enlargement,buffalo 1.0 0.000143348623853 0 1 -1
following,immunosuppressives 1.0 0.000143348623853 0 1 -1
free,concentration 1.0 0.000286697247706 0 2 -2
effects,did 1.0 0.000143348623853 0 1 -1
such,cases 1.0 0.000573394495413 0 4 -4
responses,with 1.0 0.000143348623853 0 1 -1
asthma,therapy 1.0 0.000143348623853 0 1 -1
vasodilator,properties 1.0 0.000143348623853 0 1 -1
vitro,glucuronidation 1.0 0.000143348623853 0 1 -1
cyp2e1,cyp4a9 1.0 0.000143348623853 0 1 -1
concomitantly,there 1.0 0.000143348623853 1 0 1
effects,would 1.0 0.000143348623853 0 1 -1
inhibitors,without 1.0 0.000143348623853 0 1 -1
stadol,ns 0.111111111111 0.000143348623853 4 5 -1
when,toradol 1.0 0.000143348623853 1 0 1
seminiferous,tubules 1.0 0.000143348623853 0 1 -1
free,fractions 1.0 0.000143348623853 0 1 -1
of,metabolite 1.0 0.000143348623853 0 1 -1
h,following 1.0 0.000143348623853 1 0 1
these,blocking 1.0 0.000143348623853 0 1 -1
dose-dependently,inhibits 1.0 0.000143348623853 1 0 1
release,and 1.0 0.00043004587156 0 3 -3
primarily,as 1.0 0.000143348623853 0 1 -1
sleep,than 1.0 0.000143348623853 0 1 -1
encountered,during 1.0 0.000143348623853 0 1 -1
co-administered,drug 1.0 0.000143348623853 0 1 -1
unaffected,following 1.0 0.000143348623853 0 1 -1
regarding,protease 1.0 0.000143348623853 0 1 -1
average,for 1.0 0.000143348623853 0 1 -1
obtain,serum 1.0 0.000143348623853 1 0 1
platelet,activation 1.0 0.000286697247706 0 2 -2
